PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ying, M; Zhang, L; Zhou, Q; Shao, X; Cao, J; Zhang, N; Li, W; Zhu, H; Yang, B; He, Q				Ying, M.; Zhang, L.; Zhou, Q.; Shao, X.; Cao, J.; Zhang, N.; Li, W.; Zhu, H.; Yang, B.; He, Q.			The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RAR alpha	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; MYELOID-LEUKEMIA CELLS; GENE AMPLIFICATION; RECEPTOR-ALPHA; CANCER-THERAPY; HUMAN SARCOMAS; P53; PHOSPHORYLATION; STABILIZATION; ACTIVATION	Retinoic acid receptor alpha (RAR alpha) has a critical role in the differentiation process of osteosarcoma cells induced by all-trans retinoic acid (ATRA). However, degradation of RAR alpha through ubiquitin proteasome pathway weakens the differentiation efficiency of osteosarcoma cells. In this study, we discover that murine double minute-2 (MDM2) acts as an E3 ubiquitin ligase to target RAR alpha for degradation. We observe that MDM2 is required for RAR alpha polyubiquitination and proteasomal degradation because downregulation of MDM2 by short hairpin RNA results in the accumulation of RAR alpha, and MDM2 overexpression promotes the degradation of RAR alpha. We also demonstrate that the N-terminal domain of MDM2 (amino acids 1-109) is the major RAR alpha-binding site. Importantly, endogenous MDM2 levels are not only upregulated in human primary osteosarcoma blasts but are also inversely correlated with the level of osteopontin, which is a marker of bone differentiation. Moreover, MDM2 impairs the ATRA-induced osteoblastic differentiation of osteosarcoma cells, whereas an inhibitor of the MDM2 ubiquitin ligase synergizes with ATRA to enhance the differentiation of osteosarcoma cells and primary osteosarcoma blasts. Therefore, our study indicates that MDM2 serves as an E3 ubiquitin ligase to regulate the degradation of RARa and suggests that MDM2 is a novel therapeutic target for ATRA-based differentiation therapeutic approaches in osteosarcoma.	[Ying, M.; Zhang, L.; Zhou, Q.; Shao, X.; Cao, J.; Zhu, H.; Yang, B.; He, Q.] Zhejiang Univ, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou, Zhejiang, Peoples R China; [Zhang, N.; Li, W.] Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Yang, B; He, Q (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmacol & Toxicol, Room 113,866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.	yang924@zju.edu.cn; qiaojunhe@zju.edu.cn		Zhou, Qiong/0000-0002-8240-0440; Zhu, Hong/0000-0002-2575-4031	National Natural Science Foundation of China [81473227, 91029745, 81273536]; Zhejiang Provincial Program for Qianjiang Talents [2013R10025]; Zhejiang Provincial Natural Science Foundation of China [Y14H160124]; Fundamental Research Funds for Central Universities; NATIONAL CANCER INSTITUTE [P30CA046934, R01CA047135] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Program for Qianjiang Talents; Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81473227, 91029745 and 81273536), Zhejiang Provincial Program for Qianjiang Talents (2013R10025), Zhejiang Provincial Natural Science Foundation of China (No. Y14H160124) and the Fundamental Research Funds for the Central Universities.	BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Chai Z, 2009, IUBMB LIFE, V61, P670, DOI 10.1002/iub.212; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dingwall M, 2011, DIFFERENTIATION, V82, P57, DOI 10.1016/j.diff.2011.05.003; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Gianni M, 2009, CANCER RES, V69, P1016, DOI 10.1158/0008-5472.CAN-08-2603; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c; He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078-0432.CCR-09-2499; Hisada K, 2013, J BONE MINER METAB, V31, P53, DOI 10.1007/s00774-012-0385-x; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; LADANYI M, 1993, CANCER RES, V53, P16; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; McCoy MA, 2003, P NATL ACAD SCI USA, V100, P1645, DOI 10.1073/pnas.0334477100; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moumen A, 2007, DEVELOPMENT, V134, P1443, DOI 10.1242/dev.02820; Niederreither K, 2008, NAT REV GENET, V9, P541, DOI 10.1038/nrg2340; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Poyurovsky MV, 2010, NAT STRUCT MOL BIOL, V17, P982, DOI 10.1038/nsmb.1872; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wang WS, 2012, MED RES REV, V32, P1159, DOI 10.1002/med.20236; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Xiong L, 2007, J CELL BIOL, V178, P995, DOI 10.1083/jcb.200703044; Ying MD, 2013, MOL CANCER THER, V12, P195, DOI 10.1158/1535-7163.MCT-12-0433; Zhan CY, 2012, J AM CHEM SOC, V134, P6855, DOI 10.1021/ja301255n; Zhang L, 2014, CELL CYCLE, V13, P1277, DOI 10.4161/cc.28190; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618; Zhou Q, 2014, FEBS J, V281, P3032, DOI 10.1111/febs.12840; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	39	44	45	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4358	4367		10.1038/onc.2015.503	http://dx.doi.org/10.1038/onc.2015.503			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26776160				2022-12-28	WOS:000382152100007
J	Bigi, A; Beltrami, E; Trinei, M; Stendardo, M; Pelicci, PG; Giorgio, M				Bigi, A.; Beltrami, E.; Trinei, M.; Stendardo, M.; Pelicci, P. G.; Giorgio, M.			Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis	ONCOGENE			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; MANGANESE SUPEROXIDE-DISMUTASE; BREAST-CANCER; CELL-DEATH; K-RAS; ONCOGENIC RAS; LUNG-CANCER; IN-VIVO; P53; CYCLOSPORINE	Mitochondrial alterations induced by oncogenes are known to be crucial for tumorigenesis. Ras oncogene leads to proliferative signals through a Raf-1/MEK/ERK kinase cascade, whose components have been found to be also associated with mitochondria. The mitochondrial pepdidyl-prolyl isomerase cyclophilin D (CypD) is an important regulator of the mitochondrial permeability transition and a key player in mitochondria physiology; however, its role in cancer is still unclear. Using cellular and in vivo mouse models, we demonstrated that CypD protein upregulation induced by oncogenic Ras through the Raf-1/MEK/ERK pathway has a deterministic role in tumor progression. In fact, targeting CypD gene expression clearly affected RasV12-induced transformation, as showed by in vitro data on murine NIH3T3 and human MCF10A mammary epithelial cells. In addition, studies in xenograft and K-Ras lung cancer mouse models demonstrated that genetic deletion or pharmacological suppression of CypD efficiently prevented Ras-dependent tumor formation. Furthermore, Erbb2-mediated breast tumorigenesis was similarly prevented by targeting CypD. From a mechanistic point of view, CypD expression was associated with a reduced induction of p21(WAF1/CIP1) and p53 functions, unraveling an antagonistic function of CypD on p21-p53-mediated growth suppression. CypD activity is p53 dependent. Interestingly, a physical association between p53 and CypD was detected in mitochondria of MCF10A cells; furthermore, both in vitro and in vivo studies proved that CypD inhibitor-based treatment was able to efficiently impair this interaction, leading to a tumor formation reduction. All together, these findings indicate that the countering effect of CypD on the p53-p21 pathway participates in oncogene-dependent transformation.	[Bigi, A.; Beltrami, E.; Trinei, M.; Stendardo, M.; Pelicci, P. G.; Giorgio, M.] European Inst Oncol, Dept Expt Oncol, Milan, Italy	IRCCS European Institute of Oncology (IEO)	Giorgio, M (corresponding author), European Inst Oncol, Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	marco.giorgio@ieo.eu	Pelicci, Pier Giuseppe/AAL-6572-2020; Giorgio, Marco/I-9425-2012; beltrami, elena/AAE-9937-2021	Giorgio, Marco/0000-0002-5842-6042; 	Italian Association for Cancer Research (AIRC); Fondazione Umberto Veronesi (FUV)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi (FUV)(Fondazione Umberto Veronesi)	This work was supported by the Italian Association for Cancer Research (AIRC) and the Fondazione Umberto Veronesi (FUV) grants awarded to MG. We thank Michael Forte and Paolo Bernardi for helpful discussion and for providing CypDKO mice, Mariano Barbacid for K-Ras/RERT mice, Jacob Tropmair for MEK-1 mutants and Novartis (Basel-Switzerland) for Deb025.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Beltrami E, 2013, AGING CELL, V12, P177, DOI 10.1111/acel.12036; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Chen G, 2009, ANTIOXID REDOX SIGN, V11, P1083, DOI [10.1089/ars.2008.2321, 10.1089/ARS.2008.2321]; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Elrod JW, 2013, CIRC J, V77, P1111, DOI 10.1253/circj.CJ-13-0321; Galluzzi L, 2011, ANTIOXID REDOX SIGN, V15, P1691, DOI 10.1089/ars.2010.3504; Gambino V, 2013, AGING CELL, V12, P435, DOI 10.1111/acel.12060; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hogan B, 1994, MANIPULATING MOUSE E; Holley AK, 2010, ANN NY ACAD SCI, V1201, P72, DOI 10.1111/j.1749-6632.2010.05612.x; Holley AK, 2009, FUTURE ONCOL, V5, P117, DOI 10.2217/14796694.5.1.117; Hursting SD, 2002, MOL CARCINOGEN, V33, P16, DOI 10.1002/mc.10020; Jiang K, 2012, INT J MOL MED, V30, P302, DOI 10.3892/ijmm.2012.989; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kumar P, 2001, BIOCHEM BIOPH RES CO, V284, P219, DOI 10.1006/bbrc.2001.4952; Li B, 2012, BBA-BIOENERGETICS, V1817, P1628, DOI 10.1016/j.bbabio.2012.05.011; Longo Valter D, 2004, Sci Aging Knowledge Environ, V2004, ppe36, DOI 10.1126/sageke.2004.39.pe36; Luvisetto S, 2008, NEUROSCIENCE, V155, P585, DOI 10.1016/j.neuroscience.2008.06.030; Machida K, 2006, J BIOL CHEM, V281, P14314, DOI 10.1074/jbc.M513297200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marcu R, 2012, BIOELECTROCHEMISTRY, V85, P21, DOI 10.1016/j.bioelechem.2011.11.005; Masuo T, 2009, CANCER LETT, V285, P66, DOI 10.1016/j.canlet.2009.05.001; Murphy ME, 2004, CELL CYCLE, V3, P836; Neuzil J, 2012, CELL RES, V22, P285, DOI 10.1038/cr.2011.160; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Rapino S, 2015, ELECTROCHIM ACTA, V179, P65, DOI 10.1016/j.electacta.2015.04.053; Rasola A, 2010, P NATL ACAD SCI USA, V107, P726, DOI 10.1073/pnas.0912742107; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sperka T, 2012, NAT REV MOL CELL BIO, V13, P579, DOI 10.1038/nrm3420; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tsumura H, 2006, ONCOGENE, V25, P7673, DOI 10.1038/sj.onc.1209749; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Zhao LP, 2013, NEUROCHEM RES, V38, P705, DOI 10.1007/s11064-013-0968-5; Zhao YF, 2002, ONCOGENE, V21, P3836, DOI 10.1038/sj.onc.1205477; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493; Zupanska A, 2005, NEUROCHEM INT, V47, P430, DOI 10.1016/j.neuint.2005.05.010	54	18	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5132	5143		10.1038/onc.2016.42	http://dx.doi.org/10.1038/onc.2016.42			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26973251				2022-12-28	WOS:000384433000005
J	Grassilli, E; Pisano, F; Cialdella, A; Bonomo, S; Missaglia, C; Cerrito, MG; Masiero, L; Ianzano, L; Giordano, F; Cicirelli, V; Narloch, R; D'Amato, F; Noli, B; Ferri, GL; Leone, BE; Stanta, G; Bonin, S; Helin, K; Giovannoni, R; Lavitrano, M				Grassilli, E.; Pisano, F.; Cialdella, A.; Bonomo, S.; Missaglia, C.; Cerrito, M. G.; Masiero, L.; Ianzano, L.; Giordano, F.; Cicirelli, V.; Narloch, R.; D'Amato, F.; Noli, B.; Ferri, G. L.; Leone, B. E.; Stanta, G.; Bonin, S.; Helin, K.; Giovannoni, R.; Lavitrano, M.			A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation	ONCOGENE			English	Article							BRUTONS TYROSINE KINASE; SIGNALING PATHWAYS; POINT MUTATION; HNRNP-K; TRANSLATION; ACTIVATION; INHIBITION; DEFICIENCY; REGION; GENE	Bruton's tyrosine kinase (BTK) is essential for B-cell proliferation/differentiation and it is generally believed that its expression and function are limited to bone marrow-derived cells. Here, we report the identification and characterization of p65BTK, a novel isoform abundantly expressed in colon carcinoma cell lines and tumour tissue samples. p65BTK protein is expressed, through heterogeneous nuclear ribonucleoprotein K (hnRNPK)-dependent and internal ribosome entry site-driven translation, from a transcript containing an alternative first exon in the 5'-untranslated region, and is post-transcriptionally regulated, via hnRNPK, by the mitogen-activated protein kinase (MAPK) pathway. p65BTK is endowed with strong transforming activity that depends on active signal-regulated protein kinases-1/2 (ERK1/2) and its inhibition abolishes RAS transforming activity. Accordingly, p65BTK overexpression in colon cancer tissues correlates with ERK1/2 activation. Moreover, p65BTK inhibition affects growth and survival of colon cancer cells. Our data reveal that BTK, via p65BTK expression, is a novel and powerful oncogene acting downstream of the RAS/MAPK pathway and suggest that its targeting may be a promising therapeutic approach.	[Grassilli, E.; Pisano, F.; Cialdella, A.; Bonomo, S.; Missaglia, C.; Cerrito, M. G.; Masiero, L.; Ianzano, L.; Giordano, F.; Cicirelli, V.; Narloch, R.; Leone, B. E.; Giovannoni, R.; Lavitrano, M.] Univ Milano Bicocca, Sch Med & Surg, Via Cadore 48, I-20900 Monza, MB, Italy; [Grassilli, E.; Pisano, F.; Cialdella, A.] BiOnSil Srl, Monza, Italy; [D'Amato, F.; Noli, B.; Ferri, G. L.] Univ Cagliari, Dept Biomed Sci, NEF Lab, Monserrato, Italy; [Stanta, G.; Bonin, S.] Univ Trieste, Cattinara Hosp, Dept Med Sci, Trieste, Italy; [Helin, K.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Helin, K.] Univ Copenhagen, Ctr Epigenet, Copenhagen, Denmark; [Helin, K.] Univ Copenhagen, Danish Stem Cell Ctr Danstem, Copenhagen, Denmark	University of Milano-Bicocca; University of Cagliari; University of Trieste; University of Copenhagen; University of Copenhagen; University of Copenhagen	Grassilli, E; Lavitrano, M (corresponding author), Univ Milano Bicocca, Sch Med & Surg, Via Cadore 48, I-20900 Monza, MB, Italy.	emanuela.grassilli@unimib.it; marialuisa.lavitrano@unimib.it	Ferri, Luca Angelo/AAC-5890-2022; Bonin, Serena/C-9332-2015; Giovannoni, Roberto/A-1413-2009; grassilli, emanuela/ABB-7845-2020; Helin, Kristian/K-2526-2019; Grassilli, Emanuela/L-7296-2013; Helin, Kristian/HDM-8306-2022; Cerrito, Maria Grazia/AAA-1190-2019; LEONE, BIAGIO EUGENIO/J-8803-2018	Ferri, Luca Angelo/0000-0001-9031-6284; Bonin, Serena/0000-0002-7349-0296; Giovannoni, Roberto/0000-0002-7706-0672; grassilli, emanuela/0000-0001-5387-5925; Grassilli, Emanuela/0000-0001-5387-5925; Helin, Kristian/0000-0003-1975-6097; Cerrito, Maria Grazia/0000-0002-3347-5817; cicirelli, vincenzo/0000-0003-2792-8848; STANTA, GIORGIO/0000-0002-3261-4272; LEONE, BIAGIO EUGENIO/0000-0002-6978-2405; FERRI, Gian-Luca/0000-0003-2768-349X; Lavitrano, Marialuisa/0000-0003-4852-1318	MIUR [PON01_02782]; Ministry of Health [RF-2010-2305526]; University of Milano-Bicocca, FAR grants; Novo Nordisk Foundation Section for Basic Stem Cell Biology [Helin group NNF] Funding Source: researchfish	MIUR(Ministry of Education, Universities and Research (MIUR)); Ministry of Health; University of Milano-Bicocca, FAR grants; Novo Nordisk Foundation Section for Basic Stem Cell Biology	We thank BiOnSil, srl, spin-off of the University of Milano-Bicocca, for making available BN49 anti-p65BTK antibody in the frame of the Scientific agreement with the University of Cagliari, and Dr Elena Sacco and Dr Luca Mologni from the University of Milano-Bicocca for the gift of the RAS-DN and pS-shRAS plasmids. This work was funded by MIUR, PON01_02782, by Ministry of Health, RF-2010-2305526 and by University of Milano-Bicocca, FAR grants to ML.	Barbosa C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003529; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Burger JA, 2014, CURR HEMATOL MALIG R, V9, P44, DOI 10.1007/s11899-013-0188-8; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Didiot MC, 2013, J BIOMOL SCREEN, V18, P407, DOI 10.1177/1087057112466698; Dingjan GM, 1998, EMBO J, V17, P5309, DOI 10.1093/emboj/17.18.5309; Eifert C, 2013, GENE CHROMOSOME CANC, V52, P961, DOI 10.1002/gcc.22091; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Feldhahn N, 2005, P NATL ACAD SCI USA, V102, P13266, DOI 10.1073/pnas.0505196102; Gao B, 2014, BIOCHIM BIOPHYS ACTA, V1849, P753; Guha M, 2014, NAT BIOTECHNOL, V32, P113, DOI 10.1038/nbt0214-113; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Komar AA, 2012, GENE, V502, P75, DOI 10.1016/j.gene.2012.04.039; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Liu WM, 2001, NAT IMMUNOL, V2, P939, DOI 10.1038/ni1001-939; Marash L, 2008, MOL CELL, V30, P447, DOI 10.1016/j.molcel.2008.03.018; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; Novero A, 2014, EXP HEMATOL ONCOL, V3, DOI 10.1186/2162-3619-3-4; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; POW DV, 1993, J NEUROSCI METH, V48, P51, DOI 10.1016/S0165-0270(05)80007-X; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Smith L, 2008, BIOCHEM SOC T, V36, P708, DOI 10.1042/BST0360708; Spatuzza C, 2008, NUCLEIC ACIDS RES, V36, P4402, DOI 10.1093/nar/gkn413; Spriggs KA, 2008, BIOL CELL, V100, P27, DOI 10.1042/BC20070098; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Wurth L, 2015, BBA-GENE REGUL MECH, V1849, P881, DOI 10.1016/j.bbagrm.2014.10.001; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yu L, 2006, J BIOL CHEM, V281, P18201, DOI 10.1074/jbc.M603090200	37	41	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4368	4378		10.1038/onc.2015.504	http://dx.doi.org/10.1038/onc.2015.504			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26804170	hybrid, Green Published			2022-12-28	WOS:000382152100008
J	King, MA; Ganley, IG; Flemington, V				King, M. A.; Ganley, I. G.; Flemington, V.			Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells	ONCOGENE			English	Article							MEMBRANE PERMEABILIZATION; SELECTIVE INHIBITOR; AUTOPHAGY; APOPTOSIS; POTENT; RESISTANCE; DISCOVERY; COMPLEX; DEATH; EXPRESSION	Mutations to fibroblast growth factor receptor 3 (FGFR3) and phosphatase and tensin homologue (PTEN) signalling pathway components (for example, PTEN loss, PIK3CA, AKT1, TSC1/2) are common in bladder cancer, yet small-molecule inhibitors of these nodes (FGFR/PTENi) show only modest activity in preclinical models. As activation of autophagy is proposed to promote survival under FGFR/PTENi, we have investigated this relationship in a panel of 18 genetically diverse bladder cell lines. We found that autophagy inhibition does not sensitise bladder cell lines to FGFR/PTENi, but newly identify an autophagy-independent cell death synergy in FGFR3-mutant cell lines between mTOR (mammalian target of rapamycin) pathway inhibitors and chloroquine (CQ)-an anti-malarial drug used as a cancer therapy adjuvant in over 30 clinical trials. The mechanism of synergy is consistent with lysosomal cell death (LCD), including cathepsin-driven caspase activation, and correlates with suppression of cSREBP1 and cholesterol biosynthesis in sensitive cell lines. Remarkably, loss of viability can be rescued by saturating cellular membranes with cholesterol or recapitulated by statin-mediated inhibition, or small interfering RNA knockdown, of enzymes regulating cholesterol metabolism. Modulation of CQ-induced cell death by atorvastatin and cholesterol is reproduced across numerous cell lines, confirming a novel and fundamental role for cholesterol biosynthesis in regulating LCD. Thus, we have catalogued the molecular events underlying cell death induced by CQ in combination with an anticancer therapeutic. Moreover, by revealing a hitherto unknown aspect of lysosomal biology under stress, we propose that suppression of cholesterol metabolism in cancer cells should elicit synergy with CQ and define a novel approach to future cancer treatments.	[King, M. A.] AstraZeneca Oncol, Alderley Pk, Macclesfield, Cheshire, England; [Ganley, I. G.] Univ Dundee, MRC Prot Phosphorylat & Ubiquitylat Unit, Dundee, Scotland; [Flemington, V.] AstraZeneca Oncol, CRUK Cambridge Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England	AstraZeneca; University of Dundee; AstraZeneca; CRUK Cambridge Institute	King, MA; Flemington, V (corresponding author), AstraZeneca, Oncol IMED, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	matthew.king@astrazeneca.com; vikki.flemington@astrazeneca.com		Ganley, Ian/0000-0003-1481-9407	Medical Research Council [MC_UU_12016/4, MC_UP_A500_1019] Funding Source: Medline; MRC [MC_UU_12016/4] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aits S, 2015, METHOD CELL BIOL, V126, P261, DOI 10.1016/bs.mcb.2014.10.032; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Appelqvist H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050262; Barlaam B, 2015, J MED CHEM, V58, P943, DOI 10.1021/jm501629p; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Ch'ng JH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.265; Christian AE, 1997, J LIPID RES, V38, P2264; Cufi S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02469; Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; Dickstein RJ, 2012, CANCER BIOL THER, V13, P1325, DOI 10.4161/cbt.21793; Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053; Du XN, 2012, CANCER RES, V72, P5843, DOI 10.1158/0008-5472.CAN-12-1329; Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Graham RM, 2014, ONCOTARGET, V5, P1162, DOI 10.18632/oncotarget.1699; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hao SJ, 2008, GEN PHYSIOL BIOPHYS, V27, P278; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Laforge M, 2007, J VIROL, V81, P11426, DOI 10.1128/JVI.00597-07; Lamoureux F, 2013, CLIN CANCER RES, V19, P833, DOI 10.1158/1078-0432.CCR-12-3114; Lee CM, 2006, BRIT J CANCER, V94, P863, DOI 10.1038/sj.bjc.6603010; Li S, 2016, ONCOGENE, V35, P642, DOI 10.1038/onc.2015.123; MCGOWAN EB, 1989, BIOCHEM BIOPH RES CO, V158, P432, DOI 10.1016/S0006-291X(89)80065-8; Medina MW, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003058; Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147; Pike KG, 2013, BIOORG MED CHEM LETT, V23, P1212, DOI 10.1016/j.bmcl.2013.01.019; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Roth BD, 2002, PROGR MED CHEM, V40, P1, DOI 10.1016/S0079-6468(08)70080-8; Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757; Seitz C, 2013, INT J CANCER, V132, P2682, DOI 10.1002/ijc.27935; SHOJIKASAI Y, 1988, P NATL ACAD SCI USA, V85, P146, DOI 10.1073/pnas.85.1.146; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Sun CH, 2011, HISTOPATHOLOGY, V58, P1054, DOI 10.1111/j.1365-2559.2011.03856.x; von Schwarzenberg K, 2013, J BIOL CHEM, V288, P1385, DOI 10.1074/jbc.M112.412007; Wang BT, 2011, P NATL ACAD SCI USA, V108, P15201, DOI 10.1073/pnas.1103746108; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486; Wu XR, 2009, CANCER METAST REV, V28, P281, DOI 10.1007/s10555-009-9189-4; Xu CX, 2011, CANCER BIOL THER, V12, P549, DOI 10.4161/cbt.12.6.16397; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ye J RA, 2011, COLD SPRING HARBOR P, V3; Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158; Zou YY, 2013, J THORAC ONCOL, V8, P693, DOI 10.1097/JTO.0b013e31828c7210	57	39	41	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4518	4528		10.1038/onc.2015.511	http://dx.doi.org/10.1038/onc.2015.511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26853465	Green Published, hybrid			2022-12-28	WOS:000382153100009
J	Kramer, K; Wu, J; Crowe, DL				Kramer, K.; Wu, J.; Crowe, D. L.			Tumor suppressor control of the cancer stem cell niche	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST-CANCER; PPAR-GAMMA; MAMMARY-GLAND; NUCLEAR-ENVELOPE; PROGENITOR CELLS; ANGIOGENESIS; EXPRESSION; VEGF; MOUSE	Mammary stem cells (MSCs) expansion is associated with aggressive human breast cancer. The nuclear receptor peroxisome proliferator activated receptor. (PPAR gamma) is a breast cancer tumor suppressor, but the mechanisms of this suppression are not completely characterized. To determine whether PPAR gamma regulates MSC expansion in mammary cancer, we deleted PPAR gamma expression in the mammary epithelium of an in vivo model of basal breast cancer. Loss of PPAR gamma expression reduced tumor latency, and expanded the CD24+/CD49f(hi) MSC population. PPAR gamma-null mammary tumors exhibited increased angiogenesis, which was detected in human breast cancer. In vivo inhibition of a PPAR gamma-regulated miR-15a/angiopoietin-1 pathway blocked increased angiogenesis and MSC expansion. PPAR gamma bound and activated a canonical response element in the miR-15a gene. PPAR gamma-null tumors were sensitive to the targeted anti-angiogenic drug sunitinib but resistant to cytotoxic chemotherapy. Normalization of tumor vasculature with sunitinib resulted in objective response to cytotoxic chemotherapy. Chemotherapy-treated PPAR gamma-null mammary tumors exhibited luminal phenotype and expansion of unipotent CD61+ luminal progenitor cells. Transplantation of chemotherapy-treated luminal progenitor cells recapitulated the luminal phenotype. These results have important implications for anti-angiogenic therapy in breast cancer patients.	[Kramer, K.; Wu, J.; Crowe, D. L.] Univ Illinois, Ctr Canc, 801 S Paulina St, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Crowe, DL (corresponding author), Univ Illinois, Ctr Canc, 801 S Paulina St, Chicago, IL 60612 USA.	dlcrowe@uic.edu	Wu, Jianchun/AAX-3533-2020	Wu, Jianchun/0000-0002-8473-9368	NIH National Research Service award [DE18381]; Department of Defense Breast Cancer Research Program award [W81XWH-10-1-0081]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE018381, T32DE007057] Funding Source: NIH RePORTER	NIH National Research Service award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program award; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Ke Ma and Jewell Graves (University of Illinois Research Resources Center) for assistance with microscopy and flow cytometry. KK was supported by NIH National Research Service award DE18381. This study was supported by Department of Defense Breast Cancer Research Program award W81XWH-10-1-0081.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asano A, 2001, MOL CELL ENDOCRINOL, V174, P71, DOI 10.1016/S0303-7207(00)00450-0; Bensinger SJ, 2008, NATURE, V454, P470, DOI 10.1038/nature07202; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Caine GJ, 2004, ANN MED, V36, P273, DOI 10.1080/07853890410026098; Chekhonin VP, 2013, CURR CANCER DRUG TAR, V13, P423, DOI 10.2174/15680096113139990074; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Crowe DL, 2004, HISTOL HISTOPATHOL, V19, P505, DOI 10.14670/HH-19.505; Danza K, 2013, EUR J HUM GENET, V21, P824, DOI 10.1038/ejhg.2012.273; Fantozzi A, 2014, CANCER RES, V74, P1566, DOI 10.1158/0008-5472.CAN-13-1641; Fauconnet S, 2002, J BIOL CHEM, V277, P23534, DOI 10.1074/jbc.M200172200; Golembesky AK, 2008, CARCINOGENESIS, V29, P1944, DOI 10.1093/carcin/bgn154; Harfouche R, 2011, J STEROID BIOCHEM, V123, P17, DOI 10.1016/j.jsbmb.2010.09.005; He T, 2014, J PATHOL, V232, P499, DOI 10.1002/path.4324; Heessen S, 2007, EMBO REP, V8, P914, DOI 10.1038/sj.embor.7401075; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636; Lacroix L, 2005, AM J PATHOL, V167, P223, DOI 10.1016/S0002-9440(10)62967-7; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu Yu-hua, 2011, Zhonghua Zhong Liu Za Zhi, V33, P827; Luo QF, 2013, INT J ONCOL, V43, P1212, DOI 10.3892/ijo.2013.2034; Nielsen R, 2008, GENE DEV, V22, P2953, DOI 10.1101/gad.501108; Nieto Y, 2007, BRIT J CANCER, V97, P391, DOI 10.1038/sj.bjc.6603875; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Reddi HV, 2013, CANCER GENE THER, V20, P267, DOI 10.1038/cgt.2013.16; Reiss Y, 2009, J PATHOL, V217, P571, DOI 10.1002/path.2484; Roth C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2766; Saez E, 2004, GENE DEV, V18, P528, DOI 10.1101/gad.1167804; Schmidt SF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-152; Siragam V, 2012, ONCOTARGET, V3, P1370, DOI 10.18632/oncotarget.717; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Steglich B, 2013, NUCLEUS-PHILA, V4, P379, DOI 10.4161/nucl.26394; Tian LF, 2009, CANCER RES, V69, P9236, DOI 10.1158/0008-5472.CAN-09-2067; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Watkins G, 2004, ONCOL REP, V12, P483; Yu J, 2011, J BIOMED RES, V25, P170, DOI 10.1016/S1674-8301(11)60022-5; Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7; Zou C, 2012, CELL CYCLE, V11, P2137, DOI 10.4161/cc.20598	50	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4165	4178		10.1038/onc.2015.475	http://dx.doi.org/10.1038/onc.2015.475			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26686086	Green Accepted			2022-12-28	WOS:000382149800002
J	Zhao, JC; Fong, KW; Jin, HJ; Yang, YA; Kim, J; Yu, J				Zhao, J. C.; Fong, K-W; Jin, H-J; Yang, Y. A.; Kim, J.; Yu, J.			FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression	ONCOGENE			English	Article							TRANSCRIPTION FACTOR GATA-1; RESISTANT PROSTATE-CANCER; ANDROGEN RECEPTOR; BINDING; DIFFERENTIATION; RECRUITMENT; PROGRESSION; ENHANCERS; CHROMATIN; POLYCOMB	Hormonal regulation of gene expression by androgen receptor (AR) is tightly controlled by many transcriptional cofactors, including pioneer factors FOXA1 and GATA2, which, however, exhibit distinct expression patterns and functional roles in prostate cancer. Here, we examined how FOXA1, GATA2 and AR crosstalk and regulate hormone-dependent gene expression in prostate cancer cells. Chromatin immunoprecipitation sequencing analysis revealed that FOXA1 reprograms both AR and GATA2 cistrome by preferably recruiting them to FKHD-containing genomic sites. By contrast, GATA2 is unable to shift AR or FOXA1 to GATA motifs. Rather, GATA2 co-occupancy enhances AR and FOXA1 binding to nearby ARE and FKHD sites, respectively. Similarly, AR increases, but not reprograms, GATA2 and FOXA1 cistromes. Concordantly, GATA2 and AR strongly enhance the transcriptional program of each other, whereas FOXA1 regulates GATA2- and AR-mediated gene expression in a context-dependent manner due to its reprogramming effects. Taken together, our data delineated for the first time the distinct mechanisms by which GATA2 and FOXA1 regulate AR cistrome and suggest that FOXA1 acts upstream of GATA2 and AR in determining hormone-dependent gene expression in prostate cancer.	[Zhao, J. C.; Fong, K-W; Jin, H-J; Yang, Y. A.; Kim, J.; Yu, J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Yu, J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	Kim, Jung/Q-7801-2016	Kim, Jung/0000-0001-6274-2841; Jin, Hongjian/0000-0003-3833-7170; Yang, Angela/0000-0002-9868-7431; Fong, Ka-wing/0000-0001-6995-0264	Robert H Lurie Comprehensive Cancer Center [P30CA060553]; SPORE in Prostate Cancer [P50CA180995]; Research Scholar Award from American Cancer Society [RSG-12-085-01]; NIH Training Program in Oncogenesis and Developmental Biology [T32CA080621]; NIH/NCI training grant [T32CA009560]; Office of the Provost; Office for Research; Northwestern University Information Technology; NATIONAL CANCER INSTITUTE [T32CA080621, P50CA180995, P30CA060553, T32CA009560] Funding Source: NIH RePORTER	Robert H Lurie Comprehensive Cancer Center; SPORE in Prostate Cancer; Research Scholar Award from American Cancer Society; NIH Training Program in Oncogenesis and Developmental Biology; NIH/NCI training grant; Office of the Provost; Office for Research; Northwestern University Information Technology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr John Crispino (Northwestern University) for critical reading of the manuscript. The project described was supported by the Robert H Lurie Comprehensive Cancer Center (P30CA060553), SPORE in Prostate Cancer (P50CA180995), and the Research Scholar Award RSG-12-085-01 (to JY) from the American Cancer Society. JK was supported in part by the NIH Training Program in Oncogenesis and Developmental Biology (T32CA080621), and YAY was supported in part by the NIH/NCI training grant T32CA009560. Computational analysis was supported by the computational resources and staff contributions provided for the Quest high performance computing facility at Northwestern University which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. Accession Numbers: New high-throughput data generated in this study has been deposited in GEO database under accession number GSE69045.	Andreu-Vieyra C, 2011, MOL CELL BIOL, V31, P4648, DOI 10.1128/MCB.05934-11; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bossard P, 1998, DEVELOPMENT, V125, P4909; Boyes J, 1998, J MOL BIOL, V279, P529, DOI 10.1006/jmbi.1998.1783; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gerhardt J, 2012, AM J PATHOL, V180, P848, DOI 10.1016/j.ajpath.2011.10.021; Godoy P, 2014, BREAST CANCER-TOKYO, V21, P491, DOI 10.1007/s12282-012-0404-8; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Jin HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4972; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Sekiya T, 2009, GENE DEV, V23, P804, DOI 10.1101/gad.1775509; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Vidal SJ, 2015, CANCER CELL, V27, P223, DOI 10.1016/j.ccell.2014.11.013; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wu DY, 2014, NUCLEIC ACIDS RES, V42, P3607, DOI 10.1093/nar/gkt1382; Wu L, 2014, ONCOGENE, V33, P504, DOI 10.1038/onc.2012.602; Wu Q, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-3; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Zhang CP, 2011, CANCER RES, V71, P6738, DOI 10.1158/0008-5472.CAN-11-1882; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111	29	36	38	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4335	4344		10.1038/onc.2015.496	http://dx.doi.org/10.1038/onc.2015.496			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26751772	Green Accepted			2022-12-28	WOS:000382152100005
J	Zhang, S; Matsunaga, S; Lin, YF; Sishc, B; Shang, Z; Sui, J; Shih, HY; Zhao, Y; Foreman, O; Story, MD; Chen, DJ; Chen, BPC				Zhang, S.; Matsunaga, S.; Lin, Y-F; Sishc, B.; Shang, Z.; Sui, J.; Shih, H-Y; Zhao, Y.; Foreman, O.; Story, M. D.; Chen, D. J.; Chen, B. P. C.			Spontaneous tumor development in bone marrow-rescued DNA-PKcs(3A/3A) mice due to dysfunction of telomere leading strand deprotection	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; HUMAN SOMATIC-CELLS; DNA-PKCS; CATALYTIC SUBUNIT; BREAK REPAIR; DYSKERATOSIS-CONGENITA; CANCER-CELLS; AUTOPHOSPHORYLATION; OVERHANG; DAMAGE	Phosphorylation of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) at the Thr2609 cluster is essential for its complete function in DNA repair and tissue stem cell homeostasis. This phenomenon is demonstrated by congenital bone marrow failure occurring in DNA-PKcs(3A/3A) mutant mice, which require bone marrow transplantation (BMT) to prevent early mortality. Surprisingly, an increased incidence of spontaneous tumors, especially skin cancer, was observed in adult BMT-rescued DNA-PKcs(3A/3A) mice. Upon further investigation, we found that spontaneous yH2AX foci occurred in DNA-PKcs(3A/3A) skin biopsies and primary keratinocytes and that these foci overlapped with telomeres during mitosis, indicating impairment of telomere replication and maturation. Consistently, we observed significantly elevated frequencies of telomere fusion events in DNA-PKcs3A/3A cells as compared with wild-type and DNA-PKcs-knockout cells. In addition, a previously identified DNA-PKcs Thr2609Pro mutation, found in breast cancer, also induces a similar impairment of telomere leading-end maturation. Taken together, our current analyses indicate that the functional DNA-PKcs T2609 cluster is required to facilitate telomere leading strand maturation and prevention of genomic instability and cancer development.	[Zhang, S.; Matsunaga, S.; Lin, Y-F; Sishc, B.; Shang, Z.; Sui, J.; Shih, H-Y; Story, M. D.; Chen, D. J.; Chen, B. P. C.] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, 2201 Inwood Rd,Room NC7-206, Dallas, TX 75390 USA; [Zhang, S.] Sichuan Canc Hosp, Dept Radiat Oncol, Chengdu 610041, Peoples R China; [Matsunaga, S.] Tottori Univ, Dept Pathophysiol & Therapeut Sci, Div Mol Pharmacol, Yonago, Tottori, Japan; [Zhao, Y.] Sun Yat Sen Univ, Sch Life Sci, Cooperat Innovat Ctr High Performance Comp, Key Lab Gene Engn,Minist Educ, Guangzhou, Guangdong, Peoples R China; [Foreman, O.] Jackson Lab, Sacramento, CA USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Tottori University; Sun Yat Sen University; Jackson Laboratory	Zhang, S; Chen, BPC (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, 2201 Inwood Rd,Room NC7-206, Dallas, TX 75390 USA.; Zhang, S (corresponding author), Sichuan Canc Hosp, Dept Radiat Oncol, Chengdu 610041, Peoples R China.	zhangsc65@hotmail.com; benjamin.chen@utsouthwestern.edu	Story, Michael/AAX-2864-2021; Sishc, Brock James/ABE-4487-2021; Sui, Jiang-Dong/AAU-6005-2021	Story, Michael/0000-0001-6522-4169; 	National Institutes of Health [CA166677]; Cancer Prevention Research Institute of Texas [RP110465]; NATIONAL CANCER INSTITUTE [R01CA166677] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health (CA166677) and the Cancer Prevention Research Institute of Texas (RP110465) to BPC. We thank Dr Titia de Lange for kindly providing anti-TRF1 antibody, and Dr Damiana Chiavolini for critical reading and editing of the manuscript.	Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bombarde O, 2010, EMBO J, V29, P1573, DOI 10.1038/emboj.2010.49; Chai WH, 2006, MOL CELL, V21, P427, DOI 10.1016/j.molcel.2005.12.004; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200; Chow TT, 2012, GENE DEV, V26, P1167, DOI 10.1101/gad.187211.112; Convery E, 2005, P NATL ACAD SCI USA, V102, P1345, DOI 10.1073/pnas.0406466102; Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Giunta S, 2010, J CELL BIOL, V190, P197, DOI 10.1083/jcb.200911156; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Hammel M, 2010, J BIOL CHEM, V285, P1414, DOI 10.1074/jbc.M109.065615; Hayashi MT, 2012, NAT STRUCT MOL BIOL, V19, P387, DOI 10.1038/nsmb.2245; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Heijink AM, 2013, MUTAT RES-FUND MOL M, V750, P45, DOI 10.1016/j.mrfmmm.2013.07.003; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Hsu FM, 2012, TRANSL CANCER RES, V1, P22, DOI 10.3978/j.issn.2218-676X.2012.04.01; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Ishii-Ohba H, 2007, MUTAT RES-FUND MOL M, V619, P124, DOI 10.1016/j.mrfmmm.2007.02.028; Jiang WX, 2015, MOL CELL, V58, P172, DOI 10.1016/j.molcel.2015.02.024; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Khadka P, 2014, BIOCHEM J, V463, P19, DOI 10.1042/BJ20131395; Kirwan M, 2008, CLIN GENET, V73, P103, DOI 10.1111/j.1399-0004.2007.00923.x; Laud PR, 2005, GENE DEV, V19, P2560, DOI 10.1101/gad.1321305; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Meek K, 2007, MOL CELL BIOL, V27, P3881, DOI 10.1128/MCB.02366-06; Mikkola HKA, 2006, DEVELOPMENT, V133, P3733, DOI 10.1242/dev.02568; Mirchandani KD, 2006, EXP CELL RES, V312, P2647, DOI 10.1016/j.yexcr.2006.06.014; Nishio N, 2010, INT J HEMATOL, V92, P419, DOI 10.1007/s12185-010-0695-5; Orthwein A, 2014, SCIENCE, V344, P189, DOI 10.1126/science.1248024; Poon Steven S S, 2001, Curr Protoc Cell Biol, VChapter 18, DOI 10.1002/0471143030.cb1804s12; Potts PR, 2007, NAT STRUCT MOL BIOL, V14, P581, DOI 10.1038/nsmb1259; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Ruis BL, 2008, MOL CELL BIOL, V28, P6182, DOI 10.1128/MCB.00355-08; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Sui JD, 2015, NUCLEIC ACIDS RES, V43, P5971, DOI 10.1093/nar/gkv539; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Wang XS, 2008, CANCER RES, V68, P971, DOI 10.1158/0008-5472.CAN-07-6272; Wang YB, 2009, P NATL ACAD SCI USA, V106, P12430, DOI 10.1073/pnas.0903362106; Williams ES, 2009, CANCER RES, V69, P2100, DOI 10.1158/0008-5472.CAN-08-2854; Wu P, 2010, MOL CELL, V39, P606, DOI 10.1016/j.molcel.2010.06.031; Yajima H, 2006, MOL CELL BIOL, V26, P7520, DOI 10.1128/MCB.00048-06; YU H, 1993, BLOOD, V81, P373; Zhang SC, 2011, J CELL BIOL, V193, P295, DOI 10.1083/jcb.201009074; Zhao Y, 2009, CELL, V138, P463, DOI 10.1016/j.cell.2009.05.026	49	13	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3909	3918		10.1038/onc.2015.459	http://dx.doi.org/10.1038/onc.2015.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616856	Green Accepted			2022-12-28	WOS:000381013100003
J	Radogna, F; Cerella, C; Gaigneaux, A; Christov, C; Dicato, M; Diederich, M				Radogna, F.; Cerella, C.; Gaigneaux, A.; Christov, C.; Dicato, M.; Diederich, M.			Cell type-dependent ROS and mitophagy response leads to apoptosis or necroptosis in neuroblastoma	ONCOGENE			English	Article							OXIDATIVE STRESS; CANCER-CELLS; CARDIAC-GLYCOSIDES; CALOTROPIS-PROCERA; JNK ACTIVATION; AUTOPHAGY; DEATH; UNBS1450; TARGET; CROSSTALK	A limiting factor in the therapeutic outcome of children with high-risk neuroblastoma is the intrinsic and acquired resistance to common chemotherapeutic treatments. Here we investigated the molecular mechanisms by which the hemisynthetic cardiac glycoside UNBS1450 overcomes this limitation and induces differential cell death modalities in both neuroblastic and stromal neuroblastoma through stimulation of a cell-type-specific autophagic response eventually leading to apoptosis or necroptosis. In neuroblastic SH-SY5Y cells, we observed a time-dependent production of reactive oxygen species that affects lysosomal integrity inducing lysosome-associated membrane protein 2 degradation and cathepsin B and L activation. Subsequent mitochondrial membrane depolarization and accumulation of mitochondria in phagophores occurred after 8h of UNBS1450 treatment. Results were confirmed by mitochondrial mass analysis, electron microscopy and co-localization of mitochondria with GFP-LC3, suggesting the impaired clearance of damaged mitochondria. Thus, a stress-induced defective autophagic flux and the subsequent lack of clearance of damaged mitochondria sensitized SH-SY5Y cells to UNBS1450-induced apoptosis. Inhibition of autophagy with small inhibitory RNAs against ATG5, ATG7 and Beclin-1 protected SH-SY5Y cells against the cytotoxic effect of UNBS1450 by inhibiting apoptosis. In contrast, autophagy progression towards the catabolic state was observed in stromal SK-N-AS cells: here reactive oxygen species (ROS) generation remained undetectable preserving intact lysosomes and engulfing damaged mitochondria after UNBS1450 treatment. Moreover, autophagy inhibition determined sensitization of SK-N-AS to apoptosis. We identified efficient mitophagy as the key mechanism leading to failure of activation of the apoptotic pathway that increased resistance of SK-N-AS to UNBS1450, triggering rather necroptosis at higher doses. Altogether we characterize here the differential modulation of ROS and mitophagy as a main determinant of neuroblastoma resistance with potential relevance for personalized anticancer therapeutic approaches.	[Radogna, F.; Cerella, C.; Gaigneaux, A.; Dicato, M.] Hop Kirchberg, Lab Biol Mol & Cellulaire Canc, Luxembourg, Luxembourg; [Christov, C.] Univ Lorraine Vandoeuvre Les Nancy, Med Nancy, Nancy, France; [Diederich, M.] Seoul Natl Univ, Coll Pharm, Seoul, South Korea	Universite de Lorraine; Seoul National University (SNU)	Diederich, M (corresponding author), Seoul Natl Univ, Coll Pharm, Dept Pharm, Seoul 151742, South Korea.	marcdiederich@snu.ac.kr	Diederich, Marc/O-7335-2015; Radogna, Flavia/AAL-5698-2020	Diederich, Marc/0000-0003-0115-4725; Radogna, Flavia/0000-0003-0385-3335; Cerella, Claudia/0000-0001-9308-8176	ThinkPinkLux; Europadonna Luxembourg; Televie grant (Fonds National de la Recherche Scientifique, Belgium); 'Waxweiler grant for cancer prevention research' from the Action LIONS 'Vaincre le Cancer'; Fondation de Recherche Cancer et Sang; Recherches Scientifiques Luxembourg association; 'Een Haerz fir kriibskrank Kanner' association; Action LIONS 'Vaincre le Cancer' association; Televie Luxembourg; National Research Foundation (NRF) by the MEST of Korea for Tumor Microenvironment Global Core Research Center (GCRC) grant [2012-0001184]; Brain Korea (BK21) PLUS program	ThinkPinkLux; Europadonna Luxembourg; Televie grant (Fonds National de la Recherche Scientifique, Belgium); 'Waxweiler grant for cancer prevention research' from the Action LIONS 'Vaincre le Cancer'; Fondation de Recherche Cancer et Sang; Recherches Scientifiques Luxembourg association; 'Een Haerz fir kriibskrank Kanner' association; Action LIONS 'Vaincre le Cancer' association; Televie Luxembourg; National Research Foundation (NRF) by the MEST of Korea for Tumor Microenvironment Global Core Research Center (GCRC) grant; Brain Korea (BK21) PLUS program	FR thanks 'Een Haerz fir kriibskrank Kanner' association for initial support. This manuscript is dedicated to the memory of Marian Aldred. The authors are very thankful to ThinkPinkLux and Europadonna Luxembourg for their generous support. FR and AG are supported by a Televie grant (Fonds National de la Recherche Scientifique, Belgium). CC is supported by a 'Waxweiler grant for cancer prevention research' from the Action LIONS 'Vaincre le Cancer'. Research at LBMCC is financially supported by the Fondation de Recherche Cancer et Sang, the Recherches Scientifiques Luxembourg association, the 'Een Haerz fir kriibskrank Kanner' association, the Action LIONS 'Vaincre le Cancer' association and the Televie Luxembourg. Research at SNU is supported by the National Research Foundation (NRF) by the MEST of Korea for Tumor Microenvironment Global Core Research Center (GCRC) grant (grant number 2012-0001184) and by Brain Korea (BK21) PLUS program. The authors thank Justine Paoli for technical assistance with electron microscopy.	Abhari BA, 2013, ONCOGENE, V32, P3263, DOI 10.1038/onc.2012.337; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Castino R, 2011, TOXICOL SCI, V123, P523, DOI 10.1093/toxsci/kfr179; Cerella C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.134; Cerella C, 2015, CANCER LETT, V356, P251, DOI 10.1016/j.canlet.2014.02.008; Cerella C, 2014, BIOTECHNOL ADV, V32, P1111, DOI 10.1016/j.biotechadv.2014.03.006; Cerella Claudia, 2013, Int J Cell Biol, V2013, P639401, DOI 10.1155/2013/639401; Cerella C, 2013, MITOCHONDRION, V13, P225, DOI 10.1016/j.mito.2012.06.003; Cerella C, 2009, APOPTOSIS, V14, P641, DOI 10.1007/s10495-009-0328-8; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hashem SI, 2015, STEM CELLS, V33, P2343, DOI 10.1002/stem.2015; Hu FL, 2014, APOPTOSIS, V19, P210, DOI 10.1007/s10495-013-0914-7; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Juncker T, 2011, BIOCHEM PHARMACOL, V81, P13, DOI 10.1016/j.bcp.2010.08.025; Juncker T, 2009, BIOCHEM PHARMACOL, V78, P1, DOI 10.1016/j.bcp.2009.01.018; Klose J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095970; Lang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129196; Lefranc F, 2008, NEUROSURGERY, V62, P211, DOI 10.1227/01.NEU.0000311080.43024.0E; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li L, 2013, CELL SIGNAL, V25, P50, DOI 10.1016/j.cellsig.2012.09.020; Li Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093928; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Menger L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003807; Mijatovic T, 2006, MOL CANCER THER, V5, P391, DOI 10.1158/1535-7163.MCT-05-0367; Mora J, 2001, CANCER RES, V61, P6892; Muller F, 2015, CURR MED CHEM, V22, P3447, DOI 10.2174/0929867322666150716115435; Newman RA, 2006, J EXP THER ONCOL, V5, P167; Olenych SG., 2007, CURR PROTOC CELL BIO, V33; Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774; Parganlija D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095288; Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243; Radogna F, 2015, MITOCHONDRION, V21, P113, DOI 10.1016/j.mito.2015.02.003; Radogna F, 2009, TOXICOL APPL PHARM, V238, P170, DOI 10.1016/j.taap.2009.05.011; Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018; Radogna F, 2009, TOXICOL APPL PHARM, V239, P37, DOI 10.1016/j.taap.2009.05.012; Salcher S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-224; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schnekenburger M, 2011, BIOCHEM PHARMACOL, V81, P364, DOI 10.1016/j.bcp.2010.10.013; Sengupta A, 2011, J BIOL CHEM, V286, P7468, DOI 10.1074/jbc.M110.179242; Slingerland M, 2013, INVEST NEW DRUG, V31, P1087, DOI 10.1007/s10637-013-9984-1; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Van Quaquebeke E, 2005, J MED CHEM, V48, P849, DOI 10.1021/jm049405a; Vucicevic L, 2014, AUTOPHAGY, V10, P2362, DOI 10.4161/15548627.2014.984270; Wang Y, 2015, MOL CARCINOGEN, V54, pE26, DOI 10.1002/mc.22147; Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016; Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867	51	54	59	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3839	3853		10.1038/onc.2015.455	http://dx.doi.org/10.1038/onc.2015.455			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26640148				2022-12-28	WOS:000380753200009
J	Ruscetti, M; Dadashian, EL; Guo, W; Quach, B; Mulholland, DJ; Park, JW; Tran, LM; Kobayashi, N; Bianchi-Frias, D; Xing, Y; Nelson, PS; Wu, H				Ruscetti, M.; Dadashian, E. L.; Guo, W.; Quach, B.; Mulholland, D. J.; Park, J. W.; Tran, L. M.; Kobayashi, N.; Bianchi-Frias, D.; Xing, Y.; Nelson, P. S.; Wu, H.			HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer	ONCOGENE			English	Article							ANDROGEN RECEPTOR; DNA-BINDING; INCREASED SURVIVAL; HMGI-C; ACETYLATION; ACTIVATION; CELLS; P53; SENSITIVITY; TRANSITION	PI3K (phosphoinositide 3-kinase)/AKT and RAS/MAPK (mitogen-activated protein kinase) pathway coactivation in the prostate epithelium promotes both epithelial-mesenchymal transition (EMT) and metastatic castration-resistant prostate cancer (mCRPC), which is currently incurable. To study the dynamic regulation of the EMT process, we developed novel genetically defined cellular and in vivo model systems from which epithelial, EMT and mesenchymal-like tumor cells with Pten deletion and Kras activation can be isolated. When cultured individually, each population has the capacity to regenerate all three tumor cell populations, indicative of epithelial-mesenchymal plasticity. Despite harboring the same genetic alterations, mesenchymal-like tumor cells are resistant to PI3K and MAPK pathway inhibitors, suggesting that epigenetic mechanisms may regulate the EMT process, as well as dictate the heterogeneous responses of cancer cells to therapy. Among differentially expressed epigenetic regulators, the chromatin remodeling protein HMGA2 is significantly upregulated in EMT and mesenchymal-like tumors cells, as well as in human mCRPC. Knockdown of HMGA2, or suppressing HMGA2 expression with the histone deacetylase inhibitor LBH589, inhibits epithelial-mesenchymal plasticity and stemness activities in vitro and markedly reduces tumor growth and metastasis in vivo through successful targeting of EMT and mesenchymal-like tumor cells. Importantly, LBH589 treatment in combination with castration prevents mCRPC development and significantly prolongs survival following castration by enhancing p53 and androgen receptor acetylation and in turn sensitizing castration-resistant mesenchymal-like tumor cells to androgen deprivation therapy. Taken together, these findings demonstrate that cellular plasticity is regulated epigenetically, and that mesenchymal-like tumor cell populations in mCRPC that are resistant to conventional and targeted therapies can be effectively treated with the epigenetic inhibitor LBH589.	[Ruscetti, M.; Wu, H.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; [Ruscetti, M.; Dadashian, E. L.; Quach, B.; Mulholland, D. J.; Tran, L. M.; Kobayashi, N.; Wu, H.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA; [Guo, W.; Wu, H.] Peking Univ, Sch Life Sci, Room 106,Jin Guang Life Sci Bldg,5 Yiheyuan Rd, Beijing 100871, Peoples R China; [Park, J. W.; Xing, Y.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA; [Bianchi-Frias, D.; Nelson, P. S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA; [Bianchi-Frias, D.; Nelson, P. S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Ruscetti, M.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; [Mulholland, D. J.] Mt Sinai Hosp, Icahn Sch Med, Div Hematol & Med Oncol, New York, NY 10029 USA; [Park, J. W.] Univ Louisville, KBRIN Bioinformat Core, Comp Engn & Comp Sci, Louisville, KY 40292 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Peking University; University of California System; University of California Los Angeles; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; University of Louisville	Wu, H (corresponding author), Peking Univ, Sch Life Sci, Room 106,Jin Guang Life Sci Bldg,5 Yiheyuan Rd, Beijing 100871, Peoples R China.	hongwu@pku.edu.cn	Guo, Weilong/AAP-2880-2021	Guo, Weilong/0000-0001-5199-1359; Ruscetti, Marcus/0000-0002-4394-2087	NIH [T32 CA009056, F32 CA112988-01, P50 CA097186, P01 CA163227, P50 CA092131, R01 CA107166, RO1 CA121110, U01 CA164188]; General Financial Grant from the China Postdoctoral Science Foundation [2015M570010]; Peking-Tsinghua Center for Life Sciences; CIRM [TG2-01169]; Prostate Cancer Foundation Young Investigator Award; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA107166, F32CA112988, U01CA164188, P50CA097186, P01CA163227, P50CA092131, T32CA009056, R01CA121110] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); General Financial Grant from the China Postdoctoral Science Foundation; Peking-Tsinghua Center for Life Sciences; CIRM(California Institute for Regenerative Medicine); Prostate Cancer Foundation Young Investigator Award; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Hong Wu lab for their critical comments and suggestions. We also thank Drs Yang Zong and Owen Witte for generously supplying us with HMGA2 antibodies, and Dr Shumin Wu for supplying protein lysates from mouse ES cells. MR was supported by NIH T32 CA009056. WG was supported by a General Financial Grant from the China Postdoctoral Science Foundation (2015M570010), and in part by the Postdoctoral Fellowship of Peking-Tsinghua Center for Life Sciences. DJM was supported by NIH F32 CA112988-01, CIRM TG2-01169 and a Prostate Cancer Foundation Young Investigator Award. This work has been supported, in part, by awards from the Prostate Cancer Foundation (to HW), and grants from the NIH (P50 CA097186 and P01 CA163227 to PSN, P50 CA092131 to YX and HW, and R01 CA107166, RO1 CA121110 and U01 CA164188 to HW).	Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490; Attard G, 2011, CLIN CANCER RES, V17, P3867, DOI 10.1158/1078-0432.CCR-11-0943; Baca Sylvan C, 2012, Front Endocrinol (Lausanne), V3, P69, DOI 10.3389/fendo.2012.00069; Bitting RL, 2014, CANCER METAST REV, V33, P441, DOI 10.1007/s10555-013-9483-z; Bradley D, 2009, CANCER-AM CANCER SOC, V115, P5541, DOI 10.1002/cncr.24597; Brannon AR, 2013, J CLIN INVEST, V123, P4568, DOI 10.1172/JCI70935; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haelens A, 2007, CANCER RES, V67, P4514, DOI 10.1158/0008-5472.CAN-06-1701; Haffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Langelotz C, 2003, BRIT J CANCER, V88, P1406, DOI 10.1038/sj.bjc.6600935; Lee S, 2011, CELL MOL LIFE SCI, V68, P325, DOI 10.1007/s00018-010-0457-9; Lei QY, 2006, CANCER CELL, V9, P367, DOI 10.1016/j.ccr.2006.03.031; Li O, 2006, GENESIS, V44, P523, DOI 10.1002/dvg.20242; Liu XM, 2010, PROSTATE, V70, P179, DOI 10.1002/pros.21051; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Luo YZ, 2013, ONCOL LETT, V5, P1353, DOI 10.3892/ol.2013.1193; Marin-Aguilera M, 2014, MOL CANCER THER, V13, P1270, DOI 10.1158/1535-7163.MCT-13-0775; Molife LR, 2010, ANN ONCOL, V21, P109, DOI 10.1093/annonc/mdp270; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2009, CANCER RES, V69, P8555, DOI 10.1158/0008-5472.CAN-08-4673; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017; Rathkopf D, 2010, CANCER CHEMOTH PHARM, V66, P181, DOI 10.1007/s00280-010-1289-x; Rathkopf DE, 2013, CANCER CHEMOTH PHARM, V72, P537, DOI 10.1007/s00280-013-2224-8; Rescigno P, 2012, CURR DRUG TARGETS, V13, P1676, DOI 10.2174/138945012803529956; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; Ruscetti M, 2015, CANCER RES, V75, P2149; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Watanabe S, 2009, AM J PATHOL, V174, P854, DOI 10.2353/ajpath.2009.080523; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Zha L, 2012, MOL CELL BIOCHEM, V364, P243, DOI 10.1007/s11010-012-1224-z; Zong Y, 2012, P NATL ACAD SCI USA, V109, pE3395, DOI 10.1073/pnas.1217982109	50	85	86	2	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3781	3795		10.1038/onc.2015.444	http://dx.doi.org/10.1038/onc.2015.444			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26640144	Green Accepted			2022-12-28	WOS:000380753200004
J	Heltemes-Harris, LM; Larson, JD; Starr, TK; Hubbard, GK; Sarver, AL; Largaespada, DA; Farrar, MA				Heltemes-Harris, L. M.; Larson, J. D.; Starr, T. K.; Hubbard, G. K.; Sarver, A. L.; Largaespada, D. A.; Farrar, M. A.			Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; PROTEIN-KINASE PATHWAYS; CANCER GENE DISCOVERY; NF-KAPPA-B; LYSINE METHYLATION; REGULATED KINASE; BCR-ABL; SENESCENCE; SELECTION; IKAROS	Signal transducer and activator of transcription 5 (STAT5) activation occurs frequently in human progenitor B-cell acute lymphoblastic leukemia (B-ALL). To identify gene alterations that cooperate with STAT5 activation to initiate leukemia, we crossed mice expressing a constitutively active form of STAT5 (Stat5b-CA) with mice in which a mutagenic Sleeping Beauty transposon (T2/Onc) was mobilized only in B cells. Stat5b-CA mice typically do not develop B-ALL (<2% penetrance); in contrast, 89% of Stat5b-CA mice in which the T2/Onc transposon had been mobilized died of B-ALL by 3 months of age. High-throughput sequencing approaches were used to identify genes frequently targeted by the T2/Onc transposon; these included Sos1 (74%), Kdm2a (35%), Jak1 (26%), Bmi1 (19%), Prdm14 or Ncoa2 (13%), Cdkn2a (10%), Ikzf1 (8%), Caap1 (6%) and Klf3 (6%). Collectively, these mutations target three major cellular processes: (i) the Janus kinase/STAT5 pathway (ii) progenitor B-cell differentiation and (iii) the CDKN2A tumor-suppressor pathway. Transposon insertions typically resulted in altered expression of these genes, as well as downstream pathways including STAT5, extracellular signal-regulated kinase (Erk) and p38. Importantly, expression of Sos1 and Kdm2a, and activation of p38, correlated with survival, further underscoring the role these genes and associated pathways have in B-ALL.	[Heltemes-Harris, L. M.; Hubbard, G. K.; Farrar, M. A.] Univ Minnesota, Ctr Immunol, Minneapolis, MN USA; [Heltemes-Harris, L. M.; Hubbard, G. K.; Farrar, M. A.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Heltemes-Harris, L. M.; Larson, J. D.; Starr, T. K.; Hubbard, G. K.; Sarver, A. L.; Largaespada, D. A.; Farrar, M. A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Larson, J. D.; Starr, T. K.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; [Starr, T. K.] Univ Minnesota, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN USA; [Starr, T. K.; Largaespada, D. A.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN USA; [Largaespada, D. A.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Farrar, MA (corresponding author), Univ Minnesota, Ctr Immunol, Minneapolis, MN USA.; Farrar, MA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.; Farrar, MA (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.; Farrar, MA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Ctr Immunol, Masonic Canc Ctr, 2101 6th St SE,2-116 WMBB, Minneapolis, MN 55455 USA.	farra005@umn.edu	Starr, Tim/AAX-9342-2021; Farrar, Michael A/M-7802-2013	Farrar, Michael/0000-0002-5569-0366; Starr, Timothy/0000-0002-6308-3451; Heltemes Harris, Lynn/0000-0002-2668-8005	University of Minnesota Masonic Cancer Center; NIH [R01 CA154998, CA151845, 5R00CA151672-04, R01 CA113636]; NIH Institutional Shared Resource grant [P30-CA77598]; NATIONAL CANCER INSTITUTE [R01CA151845, R00CA151672, R01CA154998, U01CA084221, R01CA113636, P30CA077598] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000114] Funding Source: NIH RePORTER	University of Minnesota Masonic Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Institutional Shared Resource grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Peter Schoettler, Chris Reis, Alyssa Kne, Amy Mack and Emilea Sykes for assistance with animal husbandry, Maya Raghunandan for technical assistance, Paul Champoux for assistance with Flow cytometry and Dr Richard Williams for helpful comments. This work was supported by a Brainstorm grant from the University of Minnesota Masonic Cancer Center (MAF and DAL), NIH grants R01 CA154998 and CA151845 to MAF, NIH grant 5R00CA151672-04 to TKS, NIH R01 CA113636 to DAL, an NIH Institutional Shared Resource grant to the Masonic Cancer Center P30-CA77598 and a Leukemia and Lymphoma Society Scholar award (MAF).	Abbott KL, 2015, NUCLEIC ACIDS RES, V43, pD844, DOI 10.1093/nar/gku770; Arranz L, 2012, CELL CYCLE, V11, P65, DOI 10.4161/cc.11.1.18097; Berquam-Vrieze KE, 2011, BLOOD, V118, P4646, DOI 10.1182/blood-2011-03-343947; Brett BT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024668; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Burchill MA, 2003, J IMMUNOL, V171, P5853, DOI 10.4049/jimmunol.171.11.5853; Chen ZS, 2015, NATURE, V521, P357, DOI 10.1038/nature14231; Cheng ZJ, 2014, GENE DEV, V28, P1758, DOI 10.1101/gad.246561.114; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; Dupuy AJ, 2009, CANCER RES, V69, P8150, DOI 10.1158/0008-5472.CAN-09-1135; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Evelyn CR, 2014, CHEM BIOL, V21, P1618, DOI 10.1016/j.chembiol.2014.09.018; Heltemes-Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4; Irving J, 2014, BLOOD, V124, P3420, DOI 10.1182/blood-2014-04-531871; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jun JE, 2013, MOL CELL BIOL, V33, P2470, DOI 10.1128/MCB.01593-12; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li Q, 2013, NATURE, V504, P143, DOI 10.1038/nature12830; Lu T, 2013, P NATL ACAD SCI USA, V110, P13510, DOI 10.1073/pnas.1311770110; Lu T, 2010, P NATL ACAD SCI USA, V107, P46, DOI 10.1073/pnas.0912493107; Mandal M, 2009, NAT IMMUNOL, V10, P1110, DOI 10.1038/ni.1785; Mullighan CG, 2008, GENE DEV, V22, P1411, DOI 10.1101/gad.1673908; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2013, SEMIN HEMATOL, V50, P314, DOI 10.1053/j.seminhematol.2013.10.001; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Nakayama J, 2009, BLOOD, V113, P1483, DOI 10.1182/blood-2008-07-166355; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Roberts KG, 2015, NAT REV CLIN ONCOL, V12, P344, DOI 10.1038/nrclinonc.2015.38; Sarver AL, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-154; Schwickert TA, 2014, NAT IMMUNOL, V15, P283, DOI 10.1038/ni.2828; Shojaee S, 2015, CANCER CELL, V28, P1; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Starr TK, 2005, CELL CYCLE, V4, P1744, DOI 10.4161/cc.4.12.2223; Vu TT, 2011, J IMMUNOL, V187, P5032, DOI 10.4049/jimmunol.1101450; Vougioukalaki M, 2011, CANCER LETT, V304, P80, DOI 10.1016/j.canlet.2011.02.004; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Williams RT, 2008, COLD SH Q B, V73, P461, DOI 10.1101/sqb.2008.73.039; Xu H, 2013, JNCI-J NATL CANCER I, V105, P733, DOI 10.1093/jnci/djt042; Zhang JH, 2011, BLOOD, V118, P3080, DOI 10.1182/blood-2011-03-341412	46	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3454	3464		10.1038/onc.2015.405	http://dx.doi.org/10.1038/onc.2015.405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26500062	Green Accepted			2022-12-28	WOS:000379270100010
J	Gordon, DJ; Motwani, M; Pellman, D				Gordon, D. J.; Motwani, M.; Pellman, D.			Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; ENRICHMENT ANALYSIS; GENOMIC LANDSCAPE; GENE; EXPRESSION; CANCER; GROWTH; FAMILY; EWS/FLI; PHENOTYPE	Oncogenic transformation in Ewing sarcoma tumors is driven by the fusion oncogene EWS-FLI1. However, despite the well-established role of EWS-FLI1 in tumor initiation, the development of models of Ewing sarcoma in human cells with defined genetic elements has been challenging. Here, we report a novel approach to model the initiation of Ewing sarcoma tumorigenesis that exploits the developmental and pluripotent potential of human embryonic stem cells. The inducible expression of EWS-FLI1 in embryoid bodies, or collections of differentiating stem cells, generates cells with properties of Ewing sarcoma tumors, including characteristics of transformation. These cell lines exhibit anchorage-independent growth, a lack of contact inhibition and a strong Ewing sarcoma gene expression signature. Furthermore, these cells also demonstrate a requirement for the persistent expression of EWS-FLI1 for cell survival and growth, which is a hallmark of Ewing sarcoma tumors.	[Gordon, D. J.; Motwani, M.; Pellman, D.] Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA; [Pellman, D.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Pellman, D.] Howard Hughes Med Inst, Boston, MA 02115 USA; [Gordon, D. J.] Univ Iowa, Div Pediat Hematol Oncol, Dept Pediat, 25S Grand Ave, Iowa City, IA 52242 USA; [Motwani, M.] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Worcester, MA 01655 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Iowa; University of Massachusetts System; University of Massachusetts Worcester	Pellman, D (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA.; Gordon, DJ (corresponding author), Univ Iowa, Div Pediat Hematol Oncol, Dept Pediat, 25S Grand Ave, Iowa City, IA 52242 USA.	david-j-gordon@uiowa.edu; david_pellman@dfci.harvard.edu	Motwani, Mona/AAV-8162-2020	Motwani, Mona/0000-0003-0912-5478; Gordon, David/0000-0003-1830-4371	NCI K08 award [5K08 CA160346-03]; CureSearch Award; Sarcoma Foundation of America Award; NIH [GM083299]; NATIONAL CANCER INSTITUTE [K08CA160346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083299] Funding Source: NIH RePORTER	NCI K08 award; CureSearch Award; Sarcoma Foundation of America Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Hubo Li for helpful discussions and Kelli Goss for assistance with the drug dose-response experiments. DJG is supported by a NCI K08 award (5K08 CA160346-03), a CureSearch Award and a Sarcoma Foundation of America Award. DP is a HHMI investigator and supported by NIH grant GM083299.	Amaral AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083645; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Benini S, 2004, INT J CANCER, V108, P358, DOI 10.1002/ijc.11576; Brenner JC, 2012, CANCER RES, V72, P1608, DOI 10.1158/0008-5472.CAN-11-3648; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; Chansky HA, 2004, J ORTHOPAED RES, V22, P910, DOI 10.1016/j.orthres.2003.12.008; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; De Vito C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023592; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Ganem NJ, 2014, CELL, V158, P833, DOI 10.1016/j.cell.2014.06.029; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156; Grunewald TGP, 2012, MOL CANCER RES, V10, P52, DOI 10.1158/1541-7786.MCR-11-0524; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kobayashi E, 2010, MOL CANCER THER, V9, P535, DOI 10.1158/1535-7163.MCT-09-0774; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kowalewski Ashley A., 2011, Sarcoma, V2011, P598704, DOI 10.1155/2011/598704; KOWALVERN A, 1992, MODERN PATHOL, V5, P56; Ladanyi M, 2002, CANCER BIOL THER, V1, P330; Lawlor ER, 1998, CANCER RES, V58, P2469; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Leacock SW, 2012, DIS MODEL MECH, V5, P95, DOI 10.1242/dmm.007401; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Lessnick SL, 2012, ANNU REV PATHOL-MECH, V7, P145, DOI 10.1146/annurev-pathol-011110-130237; Maire G, 2008, CANCER GENET CYTOGEN, V181, P81, DOI 10.1016/j.cancergencyto.2007.11.002; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Navarro S, 2007, ANTICANCER RES, V27, P2457; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Potikyan G, 2008, LAB INVEST, V88, P1291, DOI 10.1038/labinvest.2008.99; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2014, CANCER CELL, V26, P1; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Roberts P, 2008, GENE CHROMOSOME CANC, V47, P207, DOI 10.1002/gcc.20523; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Sanchez G, 2008, P NATL ACAD SCI USA, V105, P6004, DOI 10.1073/pnas.0710748105; Scotlandi K, 2003, J CLIN ONCOL, V21, P1952, DOI 10.1200/JCO.2003.11.111; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tilan JU, 2013, ONCOTARGET, V4, P2487, DOI 10.18632/oncotarget.1604; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; Wiles ET, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059369; Williams SA, 2013, LAB INVEST, V93, P970, DOI 10.1038/labinvest.2013.92; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	59	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3092	3102		10.1038/onc.2015.368	http://dx.doi.org/10.1038/onc.2015.368			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26455317	Green Submitted, Green Accepted			2022-12-28	WOS:000378092700002
J	Fan, SJ; Snell, C; Turley, H; Li, JL; McCormick, R; Perera, SMW; Heublein, S; Kazi, S; Azad, A; Wilson, C; Harris, AL; Goberdhan, DCI				Fan, S-J; Snell, C.; Turley, H.; Li, J-L; McCormick, R.; Perera, S. M. W.; Heublein, S.; Kazi, S.; Azad, A.; Wilson, C.; Harris, A. L.; Goberdhan, D. C. I.			PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer	ONCOGENE			English	Article							PHOSPHOLIPASE-D; PHOSPHORYLATION; TRANSPORTER; METABOLISM; INITIATION; MECHANISM; GROWTH; 4E-BP1; PROLIFERATION; TRANSLATION	Tumour cells can use strategies that make them resistant to nutrient deprivation to outcompete their neighbours. A key integrator of the cell's responses to starvation and other stresses is amino-acid-dependent mechanistic target of rapamycin complex 1 (mTORC1). Activation of mTORC1 on late endosomes and lysosomes is facilitated by amino-acid transporters within the solute-linked carrier 36 (SLC36) and SLC38 families. Here, we analyse the functions of SLC36 family member, SLC36A4, otherwise known as proton-assisted amino-acid transporter 4 (PAT4), in colorectal cancer. We show that independent of other major pathological factors, high PAT4 expression is associated with reduced relapse-free survival after colorectal cancer surgery. Consistent with this, PAT4 promotes HCT116 human colorectal cancer cell proliferation in culture and tumour growth in xenograft models. Inducible knockdown in HCT116 cells reveals that PAT4 regulates a form of mTORC1 with two distinct properties: first, it preferentially targets eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and second, it is resistant to rapamycin treatment. Furthermore, in HCT116 cells two non-essential amino acids, glutamine and serine, which are often rapidly metabolised by tumour cells, regulate rapamycin-resistant mTORC1 in a PAT4-dependent manner. Overexpressed PAT4 is also able to promote rapamycin resistance in human embryonic kidney-293 cells. PAT4 is predominantly associated with the Golgi apparatus in a range of cell types, and in situ proximity ligation analysis shows that PAT4 interacts with both mTORC1 and its regulator Rab1A on the Golgi. These findings, together with other studies, suggest that differentially localised intracellular amino-acid transporters contribute to the activation of alternate forms of mTORC1. Furthermore, our data predict that colorectal cancer cells with high PAT4 expression will be more resistant to depletion of serine and glutamine, allowing them to survive and outgrow neighbouring normal and tumorigenic cells, and potentially providing a new route for pharmacological intervention.	[Fan, S-J; Perera, S. M. W.; Heublein, S.; Kazi, S.; Azad, A.; Wilson, C.; Goberdhan, D. C. I.] Univ Oxford, Dept Physiol Anat & Genet, Le Gros Clark Bldg,South Parks Rd, Oxford OX1 3QX, England; [Snell, C.; Turley, H.; Li, J-L; McCormick, R.; Harris, A. L.] Univ Oxford, Weatherall Inst Mol Med, Mol Oncol Unit, Oxford, England	University of Oxford; University of Oxford	Goberdhan, DCI (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Le Gros Clark Bldg,South Parks Rd, Oxford OX1 3QX, England.	deborah.goberdhan@dpag.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Snell, Cameron/M-7413-2015	Harris, Adrian L/0000-0003-1376-8409; Perera, Sumeth/0000-0003-3385-0063; Snell, Cameron/0000-0001-7847-3041	Cancer Research UK [C191591/A6181, C19591/A9093, C7713/A6174]; Cancer Research UK Oxford Centre Development Fund [C38302/A12278]; Wellcome Trust [WT093326MA]; BBSRC [BB/L007096/1]; Nuffield Medical Fellowship; Studienstiftung des deutschen Volkes; Max Weber Programm Bayern; British Province of the Society of Jesus [626791]; Biotechnology and Biological Sciences Research Council [BB/L007096/1] Funding Source: researchfish; Cancer Research UK [11359, 18974] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK Oxford Centre Development Fund; Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Nuffield Medical Fellowship; Studienstiftung des deutschen Volkes; Max Weber Programm Bayern; British Province of the Society of Jesus; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK)	We thank Alan McIntyre, Elena Favaro, Thomas Roberts, Aaron Leiblich and Margret Ogmundsdottir for advice and technical help during this study, Katharine Carr, Kristie McCormick and Dan Stevens for critical reading of the manuscript and are especially grateful to Richard Boyd for facilitating key collaborative interactions. This work was supported by Cancer Research UK (C191591/A6181, C19591/A9093, C7713/A6174) and C38302/A12278 grants through the Cancer Research UK Oxford Centre Development Fund, the Wellcome Trust (WT093326MA), the BBSRC (BB/L007096/1), a Nuffield Medical Fellowship to CS, funding from the Studienstiftung des deutschen Volkes and the Max Weber Programm Bayern to SH, and a studentship from The British Province of the Society of Jesus (626791) to SMWP.	Bar-Peled L, 2014, TRENDS CELL BIOL, V24, P400, DOI 10.1016/j.tcb.2014.03.003; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92; Goberdhan DCI, 2005, DEVELOPMENT, V132, P2365, DOI 10.1242/dev.01821; Goberdhan DCI, 2010, CURR OPIN INVEST DR, V11, P1360; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Heublein S, 2010, ONCOGENE, V29, P4068, DOI 10.1038/onc.2010.177; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CLIN CANCER RES, V16, P4914, DOI 10.1158/1078-0432.CCR-10-0433; Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472; Jewell JL, 2013, TRENDS BIOCHEM SCI, V38, P233, DOI 10.1016/j.tibs.2013.01.004; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Kang SA, 2013, SCIENCE, V341, P364, DOI 10.1126/science.1236566; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kim DD, 2012, EXPERT OPIN INV DRUG, V21, P1775, DOI 10.1517/13543784.2012.721353; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704; Li L, 2010, J BIOL CHEM, V285, P19705, DOI 10.1074/jbc.C110.102483; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Malik AR, 2012, BIOCHIM BIOPHYS ACTA, V1834, P1434; Matsui T, 2013, EMBO REP, V14, P450, DOI 10.1038/embor.2013.32; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Ogmundsdottir MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036616; Pillai SM, 2011, J BIOL CHEM, V286, P2455, DOI 10.1074/jbc.M110.172403; Rath A, 2009, P NATL ACAD SCI USA, V106, P1760, DOI 10.1073/pnas.0813167106; Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Thomas JD, 2014, CANCER CELL, V26, P754, DOI 10.1016/j.ccell.2014.09.008; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thwaites DT, 2011, BRIT J PHARMACOL, V164, P1802, DOI 10.1111/j.1476-5381.2011.01438.x; Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132; Wreden CC, 2003, J NEUROSCI, V23, P1265, DOI 10.1523/JNEUROSCI.23-04-01265.2003; Xu LM, 2011, J BIOL CHEM, V286, P25477, DOI 10.1074/jbc.M111.249631; Yoon MS, 2011, J CELL BIOL, V195, P435, DOI 10.1083/jcb.201107033; Zaytseva YY, 2012, CANCER LETT, V319, P1, DOI 10.1016/j.canlet.2012.01.005; Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056	43	39	40	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3004	3015		10.1038/onc.2015.363	http://dx.doi.org/10.1038/onc.2015.363			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434594	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000377474500006
J	De Donatis, GM; Le Pape, E; Pierron, A; Cheli, Y; Hofman, V; Hofman, P; Allegra, M; Zahaf, K; Bahadoran, P; Rocchi, S; Bertolotto, C; Ballotti, R; Passeron, T				De Donatis, G. M.; Le Pape, E.; Pierron, A.; Cheli, Y.; Hofman, V.; Hofman, P.; Allegra, M.; Zahaf, K.; Bahadoran, P.; Rocchi, S.; Bertolotto, C.; Ballotti, R.; Passeron, T.			NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2	ONCOGENE			English	Article							POLYCOMB GROUP PROTEIN; KAPPA-B ACTIVITY; NEOPLASTIC TRANSFORMATION; CELLULAR SENESCENCE; SIGNALING PATHWAY; EPITHELIAL-CELLS; EXPRESSION; CANCER; GROWTH; DIFFERENTIATION	Enhancer of Zeste homologue 2 (EZH2) belongs to the polycomb repressive complex 2 and catalyzes the methylation of histone H3 lysine 27. These pivotal epigenetic marks are altered in many cancers, including melanoma, as a result of EZH2 overexpression. Here, we show that the non-canonical-NF-kB pathway accounts for most of the NF-kB activity in melanoma cells, in contrast to non-cancer cells. We identify the non-canonical-NF-kB pathway as a key regulator of EZH2 expression in melanoma. We show a striking correlation between NF-kB2 and EZH2 expression in human melanoma metastases. We demonstrate that inhibition of the non-canonical NF-kB pathway by targeting NF-kB2/p52 or the upstream kinase NIK restores the senescence program in melanoma cells through the decrease of EZH2. On the contrary, the overexpression of NF-kB2/p52 in normal human melanocytes prevents stress- and oncogene-induced senescence. Finally, we show in mouse models that the inhibition of the non-canonical NF-kB pathway restores senescence and induces a dramatic reduction in tumor growth compared with controls, thus providing potential drug targets for the re-induction of senescence in melanoma and other cancers where EZH2 is overexpressed.	[De Donatis, G. M.; Le Pape, E.; Pierron, A.; Passeron, T.] C3M, INSERM, U1065, Team 12, Nice, France; [Cheli, Y.; Allegra, M.; Bahadoran, P.; Rocchi, S.; Bertolotto, C.; Ballotti, R.] C3M, INSERM, U1065, Team 1, Nice, France; [Hofman, V.; Hofman, P.; Zahaf, K.] CHU Nice, Human Biobank, F-06202 Nice, France; [Hofman, V.; Hofman, P.; Zahaf, K.] IRCAN CNRS, Inst Res Canc & Aging, Nice, France; [Bahadoran, P.; Ballotti, R.; Passeron, T.] Univ Hosp Nice, Dept Dermatol, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Passeron, T (corresponding author), Univ Hosp Nice, Dept Dermatol, U1065, Archet Hosp 2, 150 Route Ginestiere,Batiment Archimed, F-06200 Nice, France.	passeron@unice.fr	Rocchi, Stephane/O-4152-2016; Hofman, Paul/P-7654-2018; Cheli, Yann/O-5783-2016; Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013	Rocchi, Stephane/0000-0002-0943-1304; Hofman, Paul/0000-0003-0431-9353; Cheli, Yann/0000-0001-9839-4332; Bertolotto, Corine/0000-0001-6971-7753; Passeron, Thierry/0000-0002-0797-6570; BALLOTTI, Robert/0000-0002-7322-4908; veronique, HOFMAN/0000-0003-0943-1627; Bahadoran, Philippe/0000-0002-2481-0556	Institut National de la Sante et de la Recherche Medicale (INSERM); Fondation ARC; Societe Francaise de Recherche en Dermatologie (SRD)	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation ARC; Societe Francaise de Recherche en Dermatologie (SRD)	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM), the Fondation ARC, and the Societe Francaise de Recherche en Dermatologie (SRD). The authors would like to thank Professor Robert Weinberg from the MIT Ludiwig Center for Molecular Biology for kindly providing the Mel-ST cells.	Arisan S, 2005, UROL INT, V75, P252, DOI 10.1159/000087804; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Boisvert M, 2008, VIROLOGY, V380, P1, DOI 10.1016/j.virol.2008.07.023; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chandra T, 2012, MOL CELL, V47, P203, DOI 10.1016/j.molcel.2012.06.010; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3; Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Dukers DF, 2004, AM J PATHOL, V164, P873, DOI 10.1016/S0002-9440(10)63175-6; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kia SK, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-16; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Li KX, 2013, BIOORG MED CHEM LETT, V23, P1238, DOI 10.1016/j.bmcl.2013.01.012; McHugh JB, 2007, J CUTAN PATHOL, V34, P597, DOI 10.1111/j.1600-0560.2006.00678.x; Razani B, 2011, IMMUNOL REV, V244, P44, DOI 10.1111/j.1600-065X.2011.01059.x; Rovillain E, 2011, ONCOGENE, V30, P2356, DOI 10.1038/onc.2010.611; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746; Su J, 2015, ONCOL REP, V34, P235, DOI 10.3892/or.2015.3944; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Thu YM, 2012, ONCOGENE, V31, P2580, DOI 10.1038/onc.2011.427; Thu YM, 2010, CYTOKINE GROWTH F R, V21, P213, DOI 10.1016/j.cytogfr.2010.06.002; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wharry CE, 2009, CANCER BIOL THER, V8, P1567, DOI 10.4161/cbt.8.16.8961; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	45	29	29	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2735	2745		10.1038/onc.2015.331	http://dx.doi.org/10.1038/onc.2015.331			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364600				2022-12-28	WOS:000377472700007
J	Hagenbuchner, J; Kiechl-Kohlendorfer, U; Obexer, P; Ausserlechner, MJ				Hagenbuchner, J.; Kiechl-Kohlendorfer, U.; Obexer, P.; Ausserlechner, M. J.			BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma	ONCOGENE			English	Article							SURVIVIN SUPPRESSANT; PANCREATIC-CANCER; PROTEIN SURVIVIN; OXIDATIVE STRESS; DRUG-RESISTANCE; CELL-CYCLE; IN-VITRO; BECLIN 1; APOPTOSIS; AUTOPHAGY	Adverse forms of neuroblastoma (NB), a childhood malignancy that develops from immature neuronal progenitor cells frequently carry a gain of chromosome 17q, which leads to overexpression of the antiapoptotic protein BIRC5/Survivin. We have recently shown that high Survivin expression shuts down mitochondrial complex I activity and shifts NB cells from oxidative phosphorylation to aerobic glycolysis, which further increases resistance to cell death induction. This increased glucose consumption sensitized tumor cells to glycolysis inhibitors. Interestingly, in Survivin-overexpressing cells 2-deoxy-D-glucose (2DG) treatment induces re-fusion of mitochondrial networks after 4 h, which coincides with Survivin repression. 2DG selectively acts on Survivin-expressing NB cells and induces autophagic degradation of Survivin via activation of the E3-ubiquitin ligase Parkin, a downstream target of PINK1. Survivin degradation further releases bound Beclin-1, which enhances autophagy and cell death induction. Knockdown of Parkin, however, reduces the sensitivity of Survivin-expressing NB cells to glycolysis inhibition. The selective activity of 2DG treatment on Survivin-overexpressing tumor cells was also confirmed in a xenograft mouse model, which further supports our hypothesis that glycolysis inhibitors might be useful drugs in the treatment of NB.	[Hagenbuchner, J.; Kiechl-Kohlendorfer, U.; Obexer, P.] Med Univ Innsbruck, Dept Pediat 2, Innrain 66, A-6020 Innsbruck, Austria; [Obexer, P.] Tyrolean Canc Res Inst, Innsbruck, Austria; [Ausserlechner, M. J.] Med Univ Innsbruck, Dept Pediat 1, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Hagenbuchner, J (corresponding author), Med Univ Innsbruck, Dept Pediat 2, Innrain 66, A-6020 Innsbruck, Austria.	judith.hagenbuchner@i-med.ac.at		Hagenbuchner, Judith/0000-0003-1396-3407; Ausserlechner, Michael/0000-0002-1015-2302	Medical University Innsbruck for young scientists MUI-START [P2012032014]; Provita Kinderleukamie Stiftung; Medizinische Forschungsfond Tirol; SVP-Frauen-Initiative; Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK); Tyrolean Cancer Society	Medical University Innsbruck for young scientists MUI-START; Provita Kinderleukamie Stiftung; Medizinische Forschungsfond Tirol; SVP-Frauen-Initiative; Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK); Tyrolean Cancer Society	We thank Dr Hermann Dietrich and his team for the animal care. This work was supported by the intramural funding program of the Medical University Innsbruck for young scientists MUI-START (P2012032014) and by grants from the 'Provita Kinderleukamie Stiftung', the 'Medizinische Forschungsfond Tirol' and 'SVP-Frauen-Initiative'. This study is supported by the 'Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK)' and the 'Tyrolean Cancer Society'.	Abe A, 2012, ONCOL REP, V29, P1333; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ausserlechner MJ, 2006, MOL CANCER THER, V5, P1927, DOI 10.1158/1535-7163.MCT-05-0500; Bean JF, 2014, J PEDIATR SURG, V49, P981, DOI 10.1016/j.jpedsurg.2014.01.037; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Caldas H, 2006, J MED GENET, V43, P119, DOI 10.1136/jmg.2005.034686; Chang CC, 2004, P NATL ACAD SCI USA, V101, P13239, DOI 10.1073/pnas.0405407101; Cheng Y, 2013, INT J MED SCI, V10, P634, DOI 10.7150/ijms.5547; Chuang JH, 2013, INT J BIOCHEM CELL B, V45, P944, DOI 10.1016/j.biocel.2013.01.019; De Lena M, 2001, EUR J CANCER, V37, P364, DOI 10.1016/S0959-8049(00)00400-7; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Denton D, 2015, IMMUNOL CELL BIOL, V93, P35, DOI 10.1038/icb.2014.85; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Geiger K, 2012, MOL BIOL CELL, V23, P2226, DOI 10.1091/mbc.E11-06-0535; Grignani F, 1998, CANCER RES, V58, P14; Groner B, 2014, BIODRUGS, V28, P27, DOI 10.1007/s40259-013-0058-x; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; Hagenbuchner J, 2013, ONCOGENE, V32, P4748, DOI 10.1038/onc.2012.500; Hagenbuchner J, 2013, ONCOTARGET, V4, P1241, DOI 10.18632/oncotarget.1147; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Hagenbuchner J, 2010, J BIOL CHEM, V285, P6904, DOI 10.1074/jbc.M109.038331; Hoepken HH, 2007, NEUROBIOL DIS, V25, P401, DOI 10.1016/j.nbd.2006.10.007; Huang CY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.149; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kang BH, 2006, J BIOL CHEM, V281, P24721, DOI 10.1074/jbc.M603175200; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Niu TK, 2010, FEBS LETT, V584, P3519, DOI 10.1016/j.febslet.2010.07.018; Novak I, 2012, ANTIOXID REDOX SIGN, V17, P794, DOI 10.1089/ars.2011.4407; Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Park E, 2011, BLOOD, V118, P2191, DOI 10.1182/blood-2011-04-351239; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Ramirez-Peinado S, 2013, J BIOL CHEM, V288, P30387, DOI 10.1074/jbc.M113.490581; Ramirez-Peinado S, 2011, CANCER RES, V71, P6796, DOI 10.1158/0008-5472.CAN-11-0759; Rodel F, 2008, INT J RADIAT ONCOL, V71, P247, DOI 10.1016/j.ijrobp.2008.02.011; Sachita K, 2015, J ORAL PATHOL MED, V44, P785, DOI 10.1111/jop.12299; Saita S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2400; Sandebring A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005701; Satoh T, 2009, CLIN CANCER RES, V15, P3872, DOI 10.1158/1078-0432.CCR-08-1946; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Shutt DC, 2010, CANCER BIOL THER, V9, P853, DOI 10.4161/cbt.9.11.11632; Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004; Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; Stock C, 2008, AM J PATHOL, V172, P203, DOI 10.2353/ajpath.2008.061263; Tolcher AW, 2012, ANN ONCOL, V23, P968, DOI 10.1093/annonc/mdr353; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Uchida H, 2004, MOL THER, V10, P162, DOI 10.1016/j.ymthe.2004.05.006; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Wang X, 2007, BRAIN RES, V1132, P1, DOI 10.1016/j.brainres.2006.11.032; Wobser M, 2006, CANCER IMMUNOL IMMUN, V55, P1294, DOI 10.1007/s00262-005-0102-x; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yamamoto A, 2005, J BIOL CHEM, V280, P3390, DOI 10.1074/jbc.M407724200; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013	67	44	48	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2052	2061		10.1038/onc.2015.264	http://dx.doi.org/10.1038/onc.2015.264			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26148234				2022-12-28	WOS:000374505600005
J	Stoll, SW; Stuart, PE; Swindell, WR; Tsoi, LC; Li, B; Gandarillas, A; Lambert, S; Johnston, A; Nair, RP; Elder, JT				Stoll, S. W.; Stuart, P. E.; Swindell, W. R.; Tsoi, L. C.; Li, B.; Gandarillas, A.; Lambert, S.; Johnston, A.; Nair, R. P.; Elder, J. T.			The EGF receptor ligand amphiregulin controls cell division via FoxM1	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CONFIDENCE-INTERVALS; GENE-EXPRESSION; HUMAN KERATINOCYTES; SQUAMOUS-CELL; MICE LACKING; DIFFERENTIATION; CANCER; KINASE; ACTIVATION	Epidermal growth factor receptor (EGFR) is central to epithelial cell physiology, and deregulated EGFR signaling has an important role in a variety of human carcinomas. Here we show that silencing of the EGF-related factor amphiregulin (AREG) markedly inhibits the expansion of human keratinocytes through mitotic failure and accumulation of cells with >= 4n DNA content. RNA-sequencing-based transcriptome analysis revealed that tetracycline-mediated AREG silencing significantly altered the expression of 2331 genes, 623 of which were not normalized by treatment with EGF. Interestingly, genes irreversibly upregulated by suppression of AREG overlapped with genes involved in keratinocyte differentiation. Moreover, a significant proportion of the irreversibly downregulated genes featured upstream binding sites recognized by forkhead box protein M1 (FoxM1), a key transcription factor in the control of mitosis that is widely dysregulated in cancer. The downregulation of FoxM1 and its target genes preceded mitotic arrest. Constitutive expression of FoxM1 in AREG knockdown cells normalized cell proliferation, reduced the number of cells with >= 4n DNA content and rescued expression of FoxM1 target genes. These results demonstrate that AREG controls G2/M progression and cytokinesis in keratinocytes via activation of a FoxM1-dependent transcriptional program, suggesting new avenues for treatment of epithelial cancer.	[Stoll, S. W.; Stuart, P. E.; Swindell, W. R.; Lambert, S.; Johnston, A.; Nair, R. P.; Elder, J. T.] Univ Michigan, Dept Dermatol, 7415 Med Sci Bldg 1,1301 East Catherine, Ann Arbor, MI 48109 USA; [Tsoi, L. C.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Li, B.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Gandarillas, A.] Fdn Inst Invest Marques de Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab, Santander, Spain; [Elder, J. T.] Ann Arbor Vet Affairs Hlth Syst, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Vanderbilt University; Hospital Universitario Marques de Valdecilla (HUMV)	Stoll, SW (corresponding author), Univ Michigan, Dept Dermatol, 7415 Med Sci Bldg 1,1301 East Catherine, Ann Arbor, MI 48109 USA.	sstoll@umich.edu		Tsoi, Lam Cheung/0000-0003-1627-5722	National Institute for Arthritis, Musculoskeletal and Skin Disease (NIAMS), National Institutes of Health (NIH) [K01 AR050462, R03 AR049420, K01 AR064765, R01 AR052889]; Instituto de Salud Carlos III (Spain, ISCIII-FIS/FEDER) [PI11/02070]; Babcock Foundation Endowment; Ann Arbor Veterans Affairs Hospital; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052889, R03AR049420, K01AR050462] Funding Source: NIH RePORTER	National Institute for Arthritis, Musculoskeletal and Skin Disease (NIAMS), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Instituto de Salud Carlos III (Spain, ISCIII-FIS/FEDER); Babcock Foundation Endowment; Ann Arbor Veterans Affairs Hospital; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Mahdu Prasad for assistance with RNA-seq assays and Dr James Rheinwald (Harvard Medical School, Boston, MA) for providing the N/TERT-2G keratinocyte cell line. This work was in part supported by the National Institute for Arthritis, Musculoskeletal and Skin Disease (NIAMS), National Institutes of Health (NIH award K01 AR050462 and R03 AR049420 to SWS, K01 AR064765 to AJ and R01 AR052889 to JTE) and Instituto de Salud Carlos III (Spain, ISCIII-FIS/FEDER, PI11/02070, to AG). AJ is supported by a Babcock Foundation Endowment. JTE is supported by the Ann Arbor Veterans Affairs Hospital.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; BOONSTRA J, 1985, EXP CELL RES, V161, P421, DOI 10.1016/0014-4827(85)90098-9; Busser B, 2011, BBA-REV CANCER, V1816, P119, DOI 10.1016/j.bbcan.2011.05.003; Chandler H, 2013, CURR OPIN CELL BIOL, V25, P765, DOI 10.1016/j.ceb.2013.07.005; Chen LF, 2010, CLIN CANCER RES, V16, P2489, DOI 10.1158/1078-0432.CCR-09-2318; Cousineau D, 2005, TUTOR QUANT METHODS, V1, P42, DOI 10.20982/tqmp.01.1.p042; Cumming G, 2007, J CELL BIOL, V177, P7, DOI 10.1083/jcb.200611141; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Fontijn RD, 2001, MOL CELL BIOL, V21, P2944, DOI 10.1128/MCB.21.8.2944-2955.2001; Gandarillas A, 2014, EXP DERMATOL, V23, P87, DOI 10.1111/exd.12287; Garber M, 2011, NAT METHODS, V8, P469, DOI [10.1038/nmeth.1613, 10.1038/NMETH.1613]; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Jean GW, 2008, PHARMACOTHERAPY, V28, P742, DOI 10.1592/phco.28.6.742; Johnston A, 2011, J INVEST DERMATOL, V131, P329, DOI 10.1038/jid.2010.313; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Kansra S, 2005, MOL PHARMACOL, V67, P1145, DOI 10.1124/mol.104.004689; Kong XY, 2013, CANCER RES, V73, P3987, DOI 10.1158/0008-5472.CAN-12-3859; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Lazic SE, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-5; Lens SMA, 2003, CELL CYCLE, V2, P507, DOI 10.4161/cc.2.6.559; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Lichtenberger BM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005886; Liu BG, 2008, CANCER CELL, V14, P212, DOI 10.1016/j.ccr.2008.07.017; LOFTUS GR, 1994, PSYCHON B REV, V1, P476, DOI 10.3758/BF03210951; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Mascia F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005773; Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863; Maxwell SE, 2004, DESIGNING EXPT ANAL, P868; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Morey RD, 2008, TUTOR QUANT METHODS, V4, P61, DOI 10.20982/tqmp.04.2.p061; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Okabe H, 2001, CANCER RES, V61, P2129; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Peus D, 1997, J INVEST DERMATOL, V109, P751, DOI 10.1111/1523-1747.ep12340759; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rittie L, 2007, AM J PATHOL, V170, P2089, DOI 10.2353/ajpath.2007.060537; Robertson ED, 2012, J CELL SCI, V125, P3320, DOI 10.1242/jcs.095125; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sanderson MP, 2006, GROWTH FACTORS, V24, P121, DOI 10.1080/08977190600634373; Schelfhout VRJ, 2002, J PATHOL, V198, P523, DOI 10.1002/path.1240; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Sternlicht MD, 2008, J MAMMARY GLAND BIOL, V13, P181, DOI 10.1007/s10911-008-9084-6; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; Stoll SW, 2010, J INVEST DERMATOL, V130, P2031, DOI 10.1038/jid.2010.98; Stoll SW, 2010, J INVEST DERMATOL, V130, P295, DOI 10.1038/jid.2009.211; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Stoll SW, 2015, J INVEST DERMA UNPUB; Swindell WR, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-27; Swindell WR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079253; Swindell WR, 2013, SCI REP-UK, V3, DOI 10.1038/srep01215; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; Teh MT, 2002, CANCER RES, V62, P4773; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tinhofer I, 2011, CLIN CANCER RES, V17, P5197, DOI 10.1158/1078-0432.CCR-10-3338; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Wang HX, 2010, CARCINOGENESIS, V31, P1132, DOI 10.1093/carcin/bgq058; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xie Z, 2010, BIOINFORMATICS, V26, P287, DOI 10.1093/bioinformatics/btp631; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yoshida T, 2010, BIOCHEM PHARMACOL, V80, P613, DOI 10.1016/j.bcp.2010.05.014; Yu G, 2015, R PACKAGE VERSION 1	80	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2075	2086		10.1038/onc.2015.269	http://dx.doi.org/10.1038/onc.2015.269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26234682	Green Accepted			2022-12-28	WOS:000374505600007
J	Tsai, WB; Long, Y; Park, JR; Chang, JT; Liu, H; Rodriguez-Canales, J; Savaraj, N; Feun, LG; Davies, MA; Wistuba, II; Kuo, MT				Tsai, W-B; Long, Y.; Park, J-R; Chang, J. T.; Liu, H.; Rodriguez-Canales, J.; Savaraj, N.; Feun, L. G.; Davies, M. A.; Wistuba, I. I.; Kuo, M. T.			Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; CHRONIC MYELOID-LEUKEMIA; QUALITY-OF-LIFE; AXL KINASE; ARGININOSUCCINATE SYNTHETASE; BREAST-CANCER; PROTEIN-S; TRANSLATION INITIATION; DEIMINASE RESISTANCE; DEGRADING ENZYMES	Many human malignancies lack de novo biosynthesis of arginine (Arg) as the key enzyme argininosuccinate synthetase 1 (ASS1) is silenced. These tumors acquire ectopic Arg for survival, and depleting this source by Arg-depleting recombinant enzyme ADI-PEG20 results in cell death. Mechanisms underlying Arg auxotrophy in these tumors and how they respond to Arg-auxotrophic stress are poorly understood. Here, we report that an immediate-early event of Arg-auxotrophic response involves reactive oxygen species-mediated secretion of Gas6, which interacts with its receptor Axl and activates the downstream Ras/PI3K/Akt growth signal leading to accumulation of c-Myc by protein stabilization. Arg-auxotrophic challenge also transcriptionally upregulates c-Myc expression, which provides a feedback mechanism to enhance Axl expression. c-Myc is a positive regulator of ASS1, but elevated ASS1 provides a feedback mechanism to suppress c-Myc and Axl. Our results revealed multiple inter-regulatory pathways in Arg-auxotrophic response, consisting of Axl, c-Myc and ASS1, which regulate Arg homeostasis and ADI-PEG20 sensitivity. These pathways provide potential targets for improving the efficacy of treating Arg-auxotrophic tumors using Arg-deprivation strategies.	[Tsai, W-B; Long, Y.; Liu, H.; Rodriguez-Canales, J.; Wistuba, I. I.; Kuo, M. T.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd,Life Sci Plaza LSP9,4206, Houston, TX 77030 USA; [Park, J-R] Kangwon Natl Univ, Dept Thorac & Cardiovasc Surg, Gangwon, South Korea; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Savaraj, N.] Univ Miami, Sylvester Comprehens Canc Ctr, VA Med Ctr, Miami, FL USA; [Feun, L. G.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Kangwon National University; University of Texas System; University of Texas Health Science Center Houston; University of Miami; University of Miami; University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd,Life Sci Plaza LSP9,4206, Houston, TX 77030 USA.	tkuo@mdanderson.org	Liu, Hui/AAJ-4339-2020	Liu, Hui/0000-0002-7669-9386	NIH/NCI Grant [R01 CA149260, P30CA16672]; NATIONAL CANCER INSTITUTE [R01CA152197, P30CA016672, R01CA149260] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003328] Funding Source: NIH RePORTER	NIH/NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Drs Bor-Wen Wu and John S Bomalaski (Polaris Pharmacologies) for ADI-PEG20 and anti-ASS1 antibody, Drs RM Melillo, S Jakob and WB Ou for recombinant DNAs. This research was supported in part by the NIH/NCI Grants R01 CA149260 (to MTK) and P30CA16672 (MD Anderson Core).	AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BEAUDET AL, 1986, ADV HUM GENET, V15, P291; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Cirone P, 2014, CANCER CHEMOTH PHARM, V73, P525, DOI 10.1007/s00280-014-2376-1; Conacci-Sorrell Maralice, 2014, Cold Spring Harb Perspect Med, V4, pa014357, DOI 10.1101/cshperspect.a014357; Ekman C, 2010, J THROMB HAEMOST, V8, P838, DOI 10.1111/j.1538-7836.2010.03752.x; Erez A, 2013, GENET MED, V15, P251, DOI 10.1038/gim.2012.166; Erez A, 2011, NAT MED, V17, P1619, DOI 10.1038/nm.2544; Feneyrolles C, 2014, MOL CANCER THER, V13, P2141, DOI 10.1158/1535-7163.MCT-13-1083; Feun LG, 2012, BRIT J CANCER, V106, P1481, DOI 10.1038/bjc.2012.106; Feun Lynn, 2006, Expert Opin Investig Drugs, V15, P815, DOI 10.1517/13543784.15.7.815; Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goodwin BL, 2008, BIOCHEM BIOPH RES CO, V370, P254, DOI 10.1016/j.bbrc.2008.03.089; Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847; GRIFFIN JH, 1992, BLOOD, V79, P3203; Haines RJ, 2012, J BIOL CHEM, V287, P26168, DOI 10.1074/jbc.M112.378794; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Holbrook AM, 2005, ARCH INTERN MED, V165, P1095, DOI 10.1001/archinte.165.10.1095; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Huang Z, 2014, MOL CELL ENDOCRINOL, V388, P20, DOI 10.1016/j.mce.2014.02.005; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Khoury HJ, 2012, BLOOD, V119, P3403, DOI 10.1182/blood-2011-11-390120; Kilberg MS, 2012, ADV NUTR, V3, P295, DOI 10.3945/an.112.001891; Kimball SR, 2010, J BIOL CHEM, V285, P29027, DOI 10.1074/jbc.R110.137208; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kodigepalli KM, 2015, FEBS LETT, V589, P3, DOI 10.1016/j.febslet.2014.11.036; Konishi A, 2004, J BIOL CHEM, V279, P28766, DOI 10.1074/jbc.M401977200; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Kuo MT, 2010, ONCOTARGET, V1, P246, DOI 10.18632/oncotarget.135; Laurance S, 2012, ADV NUTR, V3, P196, DOI 10.3945/an.111.001826; Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076; Long Y, 2013, MOL CANCER THER, V12, P2581, DOI 10.1158/1535-7163.MCT-13-0302; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nickel W, 2010, CURR OPIN BIOTECH, V21, P621, DOI 10.1016/j.copbio.2010.06.004; Paccez JD, 2014, INT J CANCER, V134, P1024, DOI 10.1002/ijc.28246; Phillips MM, 2013, CANCER RES TREAT, V45, P251, DOI 10.4143/crt.2013.45.4.251; Qiu FM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004761; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rochlitz C, 1999, LEUKEMIA, V13, P1352, DOI 10.1038/sj.leu.2401484; Saenz JB, 2009, NAT CHEM BIOL, V5, P157, DOI 10.1038/nchembio.144; Sasaki T, 2006, EMBO J, V25, P80, DOI 10.1038/sj.emboj.7600912; Sasaki T, 2002, J BIOL CHEM, V277, P44164, DOI 10.1074/jbc.M207340200; Segawa K, 2014, CELL CYCLE, V13, P2990, DOI 10.4161/15384101.2014.962865; Shan JX, 2012, J BIOL CHEM, V287, P36393, DOI 10.1074/jbc.M112.399600; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Suh CH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3088; Suzuki J, 2014, METHOD ENZYMOL, V544, P381, DOI 10.1016/B978-0-12-417158-9.00015-7; Syed N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.197; Trask PC, 2013, LEUKEMIA RES, V37, P9, DOI 10.1016/j.leukres.2012.09.013; Trask PC, 2012, LEUKEMIA RES, V36, P438, DOI 10.1016/j.leukres.2011.10.011; Tsai WB, 2012, CANCER RES, V72, P2622, DOI 10.1158/0008-5472.CAN-11-3605; Tsai WB, 2009, MOL CANCER THER, V8, P3223, DOI 10.1158/1535-7163.MCT-09-0794; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wiese KE, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014290; Wu XL, 2014, ONCOTARGET, V5, P9546, DOI 10.18632/oncotarget.2542; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	63	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1632	1642		10.1038/onc.2015.237	http://dx.doi.org/10.1038/onc.2015.237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096933	Green Accepted			2022-12-28	WOS:000373064200003
J	Li, H; Zhao, X; Yan, X; Jessen, WJ; Kim, MO; Dombi, E; Liu, PP; Huang, G; Wu, J				Li, H.; Zhao, X.; Yan, X.; Jessen, W. J.; Kim, M-O; Dombi, E.; Liu, P. P.; Huang, G.; Wu, J.			Runx1 contributes to neurofibromatosis type 1 neurofibroma formation	ONCOGENE			English	Article							SCHWANN-CELLS; NF1; DIFFERENTIATION; PROLIFERATION; MICROENVIRONMENT; EXPRESSION; MATURATION; PROGENITOR; INHIBITOR; ORIGIN	Neurofibromatosis type 1 (NF1) patients are predisposed to neurofibromas but the driver(s) that contribute to neurofibroma formation are not fully understood. By cross comparison of microarray gene lists on human neurofibroma-initiating cells and developed neurofibroma Schwann cells (SCs) we identified RUNX1 overexpression in human neurofibroma initiation cells, suggesting RUNX1 might relate to neurofibroma formation. Immunostaining confirmed RUNX1 protein overexpression in human plexiform neurofibromas. Runx1 overexpression was confirmed in mouse Schwann cell progenitors (SCPs) and mouse neurofibromas at the messenger RNA and protein levels. Genetic inhibition of Runx1 expression by small hairpin RNA or pharmacological inhibition of Runx1 function by a Runx1/Cbf beta interaction inhibitor, Ro5-3335, decreased mouse neurofibroma sphere number in vitro. Targeted genetic deletion of Runx1 in SCs and SCPs delayed mouse neurofibroma formation in vivo. Mechanistically, loss of Nf1 increased embryonic day 12.5 Runx1(+)/Blbp(+) progenitors that enable tumor formation. These results suggest that Runx1 has an important role in Nf1 neurofibroma initiation, and inhibition of RUNX1 function might provide a novel potential therapeutic treatment strategy for neurofibroma patients.	[Li, H.; Zhao, X.; Yan, X.; Jessen, W. J.; Huang, G.; Wu, J.] Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol,Canc & Blood Dis Ins, Cincinnati, OH 45229 USA; [Kim, M-O] Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Dombi, E.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; [Liu, P. P.] NHGRI, NIH, Bethesda, MD 20892 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Wu, J (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol,Canc & Blood Dis Ins, Cincinnati, OH 45229 USA.	Jianqiang.wu@cchmc.org		Jessen, Walter/0000-0003-3840-4337; Kim, Mi-Ok/0000-0002-7712-3653	Cincinnati Children's Hospital Trustee Grant;  [NS28840]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000030, ZIAHG000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER	Cincinnati Children's Hospital Trustee Grant; ; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Nancy Ratner for providing the microarray data (supported by NS28840 to NR) and critical review and helpful discussions of the manuscript. This work was supported by a Cincinnati Children's Hospital Trustee Grant to JW.	Aldskogius H, 2009, STEM CELLS, V27, P1592, DOI 10.1002/stem.77; BLATT J, 1986, CANCER, V57, P1225, DOI 10.1002/1097-0142(19860315)57:6<1225::AID-CNCR2820570627>3.0.CO;2-P; Bushweller JH, 2000, SEMIN CELL DEV BIOL, V11, P377, DOI 10.1006/scdb.2000.0182; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Cunningham L, 2012, P NATL ACAD SCI USA, V109, P14592, DOI 10.1073/pnas.1200037109; Friedman JM, 1999, AM J MED GENET, V89, P1; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Inoue KI, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-20; Jaegle M, 2003, GENE DEV, V17, P1380, DOI 10.1101/gad.258203; Jouhilahti EM, 2011, AM J PATHOL, V178, P500, DOI 10.1016/j.ajpath.2010.10.041; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Le LQ, 2009, CELL STEM CELL, V4, P453, DOI 10.1016/j.stem.2009.03.017; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Mayes DA, 2011, CANCER RES, V71, P4675, DOI 10.1158/0008-5472.CAN-10-4558; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Murthy M, 2014, GENE, V540, P191, DOI 10.1016/j.gene.2014.02.038; Nagamachi A, 2010, DEV BIOL, V345, P226, DOI 10.1016/j.ydbio.2010.07.015; Planaguma J, 2004, CANCER RES, V64, P8846, DOI 10.1158/0008-5472.CAN-04-2066; Scheitz CJF, 2013, J CELL BIOCHEM, V114, P985, DOI 10.1002/jcb.24453; Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Theriault FM, 2005, J NEUROSCI, V25, P2050, DOI 10.1523/JNEUROSCI.5108-04.2005; Williams JP, 2008, CELL STEM CELL, V3, P658, DOI 10.1016/j.stem.2008.10.003; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Zheng H, 2008, CANCER CELL, V13, P117, DOI 10.1016/j.ccr.2008.01.002; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	30	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1468	1474		10.1038/onc.2015.207	http://dx.doi.org/10.1038/onc.2015.207			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26073082	Green Accepted			2022-12-28	WOS:000372196400013
J	Castro-Vega, LJ; Lepoutre-Lussey, C; Gimenez-Roqueplo, AP; Favier, J				Castro-Vega, L. J.; Lepoutre-Lussey, C.; Gimenez-Roqueplo, A-P; Favier, J.			Rethinking pheochromocytomas and paragangliomas from a genomic perspective	ONCOGENE			English	Review							ISLAND METHYLATOR PHENOTYPE; GERMLINE SDHB MUTATIONS; TUMOR-SUPPRESSOR GENE; HIPPEL-LINDAU DISEASE; SPORADIC PHEOCHROMOCYTOMA; MALIGNANT PHEOCHROMOCYTOMAS; SUCCINATE-DEHYDROGENASE; SOMATIC MUTATIONS; ABDOMINAL PARAGANGLIOMAS; INTEGRATIVE ANALYSIS	Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors of neural crest origin. These tumors are caused by germline or somatic mutations in known susceptibility genes in up to 70% of cases. Over the past few years, the emergence of high-throughput technologies has enabled the unprecedented characterization of genomic alterations in PCC/PGL, and has improved our understanding of the molecular mechanisms that distinguish the different tumor subtypes. Integrated genomic analyses have shown that the mutation status of PCC/PGL susceptibility genes strongly correlates with multi-omics data. These observations not only emphasize the role of the long-standing susceptibility genes as the main drivers of PCC/PGL tumorigenesis, but also illustrate the functional interdependence between genomic and epigenomic alterations. In this review, we discuss the genomic landscape underlying PCC/PGL, its functional consequences for tumorigenesis and tumor progression, and the potential clinical relevance of this knowledge for the application of precision medicine for patients with PCC/PGL.	[Castro-Vega, L. J.; Lepoutre-Lussey, C.; Gimenez-Roqueplo, A-P; Favier, J.] Paris Cardiovasc Res Ctr, INSERM, UMR970, F-75015 Paris, France; [Castro-Vega, L. J.; Lepoutre-Lussey, C.; Gimenez-Roqueplo, A-P; Favier, J.] Univ Paris 05, Sorbonne Paris Cite, Fac Med, Paris, France; [Gimenez-Roqueplo, A-P] Hop Europeen Georges Pompidou, AP HP, Dept Genet, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Favier, J (corresponding author), Paris Cardiovasc Res Ctr, INSERM, UMR970, F-75015 Paris, France.	judith.favier@inserm.fr	Favier, Judith/M-7601-2017; Lussey-Lepoutre, Charlotte/AAO-7653-2020; Castro-Vega, Luis Jaime/L-5587-2019; Castro-Vega, Luis Jaime/AAO-9988-2021; GIMENEZ-ROQUEPLO, Anne-Paule/T-6752-2018	Favier, Judith/0000-0001-8190-5853; Lussey-Lepoutre, Charlotte/0000-0003-2228-0106; Castro-Vega, Luis Jaime/0000-0002-7232-9871; GIMENEZ-ROQUEPLO, Anne-Paule/0000-0002-4816-670X	Agence Nationale de la Recherche [ANR-2011-JCJC-00701 MODEO-MAPP]; European Union [259735]; Programme Hospitalier de Recherche Clinique [COMETE 3 AOM 06 179]; Plan Cancer Action (AAP Epigenetique et Cancer) [3.2 2009-2013, U970-C13089KS-INSERM PLAN CANCER]; Cancer Research for Personalized Medicine - CARPEM project (Site de Recherche Integre sur le Cancer - SIRIC)	Agence Nationale de la Recherche(French National Research Agency (ANR)); European Union(European Commission); Programme Hospitalier de Recherche Clinique; Plan Cancer Action (AAP Epigenetique et Cancer); Cancer Research for Personalized Medicine - CARPEM project (Site de Recherche Integre sur le Cancer - SIRIC)	We thank the Agence Nationale de la Recherche (ANR-2011-JCJC-00701 MODEO-MAPP), the European Union Seventh Framework Program FP7/2007-2013 (grant agreement no. 259735), the Programme Hospitalier de Recherche Clinique (COMETE 3 AOM 06 179) and the Plan Cancer Action no 3.2 2009-2013 (AAP Epigenetique et Cancer 2013, U970-C13089KS-INSERM PLAN CANCER) for financial support. CL-L received funding from the Cancer Research for Personalized Medicine - CARPEM project (Site de Recherche Integre sur le Cancer - SIRIC). We apologize to researchers in the field whose contributions were not cited because of space limitations.	Aarts M, 2006, GENE CHROMOSOME CANC, V45, P83, DOI 10.1002/gcc.20268; Abe M, 2005, CANCER RES, V65, P828; Abe M, 2007, CANCER LETT, V247, P253, DOI 10.1016/j.canlet.2006.05.001; Agrawal R, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-686; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Amar L, 2007, J CLIN ENDOCR METAB, V92, P3822, DOI 10.1210/jc.2007-0709; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Astuti D, 2005, BRIT J CANCER, V92, P1574, DOI 10.1038/sj.bjc.6602478; August C, 2004, MODERN PATHOL, V17, P1119, DOI 10.1038/modpathol.3800160; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bayley JP, 2010, LANCET ONCOL, V11, P366, DOI 10.1016/S1470-2045(10)70007-3; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Blumenschein GR, 2012, J CLIN ONCOL, V30, P3287, DOI 10.1200/JCO.2011.40.3774; Brouwers FM, 2006, J CLIN ENDOCR METAB, V91, P4505, DOI 10.1210/jc.2006-0423; Burnichon N, 2012, HUM MOL GENET, V21, P5397, DOI 10.1093/hmg/dds374; Burnichon N, 2012, CLIN CANCER RES, V18, P2828, DOI 10.1158/1078-0432.CCR-12-0160; Burnichon N, 2011, HUM MOL GENET, V20, P3974, DOI 10.1093/hmg/ddr324; Burnichon N, 2011, EUR J ENDOCRINOL, V164, P141, DOI 10.1530/EJE-10-0758; Burnichon N, 2010, HUM MOL GENET, V19, P3011, DOI 10.1093/hmg/ddq206; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Cascon A, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv053; Castro-Vega LJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7044; Castro-Vega LJ, 2014, HUM MOL GENET, V23, P2440, DOI 10.1093/hmg/ddt639; Clark GR, 2014, J CLIN ENDOCR METAB; Comino-Mendez I, 2013, HUM MOL GENET, V22, P2169, DOI 10.1093/hmg/ddt069; Comino-Mendez I, 2011, NAT GENET, V43, P663, DOI 10.1038/ng.861; Crona J, 2013, J CLIN ENDOCR METAB, V98, pE1266, DOI 10.1210/jc.2012-4257; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Dannenberg H, 2001, AM J PATHOL, V158, P1937, DOI 10.1016/S0002-9440(10)64662-7; de Cubas AA, 2013, ENDOCR-RELAT CANCER, V20, P477, DOI 10.1530/ERC-12-0183; DEANGELIS LM, 1987, NEUROLOGY, V37, P129, DOI 10.1212/WNL.37.1.129; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Edstrom E, 2000, AM J PATHOL, V156, P651, DOI 10.1016/S0002-9440(10)64769-4; Eisenhofer G, 2004, ENDOCR-RELAT CANCER, V11, P897, DOI 10.1677/erc.1.00838; Eisenhofer G, 2012, EUR J CANCER, V48, P1739, DOI 10.1016/j.ejca.2011.07.016; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Favier J, 2015, NAT REV ENDOCRINOL, V11, P101, DOI 10.1038/nrendo.2014.188; Favier J, 2012, NEW ENGL J MED, V367, P2161, DOI 10.1056/NEJMc1211953; Favier J, 2010, BEST PRACT RES CL EN, V24, P957, DOI 10.1016/j.beem.2010.10.004; Favier J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007094; Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fishbein L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7140; Flynn A, 2015, J PATHOL, V236, P78, DOI 10.1002/path.4503; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Geli J, 2008, CLIN CANCER RES, V14, P2551, DOI 10.1158/1078-0432.CCR-07-1867; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; GRIFFITHS DFR, 1987, Q J MED, V64, P769; Hadoux J, 2014, INT J CANCER, V135, P2711, DOI 10.1002/ijc.28913; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V20, P24, DOI 10.1002/(SICI)1098-2264(199709)20:1<24::AID-GCC4>3.3.CO;2-V; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Huether R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4630; Igaz P, 2015, CELL MOL LIFE SCI, V72, P417, DOI 10.1007/s00018-014-1752-7; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Jarbo C, 2006, INT J CANCER, V118, P1159, DOI 10.1002/ijc.21385; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; KALFF V, 1982, ARCH INTERN MED, V142, P2092, DOI 10.1001/archinte.142.12.2092; Karpathakis A, 2013, ENDOCR-RELAT CANCER, V20, pR65, DOI 10.1530/ERC-12-0338; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; Killian JK, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009961; Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092; Klein RD, 2008, DIAGN MOL PATHOL, V17, P94, DOI 10.1097/PDM.0b013e318150d67c; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kupka S, 2008, J CANCER RES CLIN, V134, P463, DOI 10.1007/s00432-007-0307-9; Laddha SV, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-10; Ladroue C, 2008, NEW ENGL J MED, V359, P2685, DOI 10.1056/NEJMoa0806277; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lenders JWM, 2014, J CLIN ENDOCR METAB, V99, P1915, DOI 10.1210/jc.2014-1498; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Liu TT, 2014, ENDOCR-RELAT CANCER, V21, P427, DOI 10.1530/ERC-14-0016; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; Loriot C, 2012, J CLIN ENDOCR METAB, V97, pE954, DOI 10.1210/jc.2011-3437; Luca R, 2013, EMBO MOL MED, V5, P1523, DOI 10.1002/emmm.201302847; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; Meyer-Rochow GY, 2010, ENDOCR-RELAT CANCER, V17, P835, DOI 10.1677/ERC-10-0142; Milunsky JM, 2001, AM J MED GENET, V100, P311, DOI 10.1002/ajmg.1270; Modali SD, 2015, MOL ENDOCRINOL; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Noushmehr Houtan, 2010, Cancer Cell, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Oudijk L, 2014, J CLIN ENDOCR METAB, V99, pE1376, DOI 10.1210/jc.2013-3879; Papathomas TG, 2014, ENDOCR-RELAT CANCER, V21, P653, DOI 10.1530/ERC-13-0429; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Patterson E, 2012, ENDOCR-RELAT CANCER, V19, P157, DOI 10.1530/ERC-11-0308; Petri BJ, 2008, MODERN PATHOL, V21, P407, DOI 10.1038/modpathol.3801013; Powers JF, 2005, CANCER GENET CYTOGEN, V159, P27, DOI 10.1016/j.cancergencyto.2004.09.018; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Qin Q, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-50; Qin YJ, 2010, NAT GENET, V42, P229, DOI 10.1038/ng.533; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Robinson CM, 2014, FEBS LETT, V588, P2704, DOI 10.1016/j.febslet.2014.02.026; SALDANA MJ, 1973, HUM PATHOL, V4, P251, DOI 10.1016/S0046-8177(73)80012-7; Sandgren J, 2010, ENDOCR-RELAT CANCER, V17, P561, DOI 10.1677/ERC-09-0310; Schlisio S, 2008, GENE DEV, V22, P884, DOI 10.1101/gad.1648608; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Szabo PM, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-48; Tombol Z, 2010, MODERN PATHOL, V23, P1583, DOI 10.1038/modpathol.2010.164; van Nederveen FH, 2009, ENDOCR-RELAT CANCER, V16, P505, DOI 10.1677/ERC-08-0241; Vargas MP, 1997, HUM PATHOL, V28, P411, DOI 10.1016/S0046-8177(97)90028-9; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weeraratne SD, 2012, ACTA NEUROPATHOL, V123, P539, DOI 10.1007/s00401-012-0969-5; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Welander J, 2012, HUM MOL GENET, V21, P5406, DOI 10.1093/hmg/dds402; Wheeler DA, 2013, GENOME RES, V23, P1054, DOI 10.1101/gr.157602.113; Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang CZ, 2015, J MOL MED, V93, P93, DOI 10.1007/s00109-014-1205-7; Yao L, 2010, JAMA-J AM MED ASSOC, V304, P2611, DOI 10.1001/jama.2010.1830; Yeh IT, 2008, HUM GENET, V124, P279, DOI 10.1007/s00439-008-0553-1; Zhang QH, 2013, GENE, V527, P26, DOI 10.1016/j.gene.2013.06.006; Zhuang ZP, 2012, NEW ENGL J MED, V367, P922, DOI 10.1056/NEJMoa1205119	124	34	37	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1080	1089		10.1038/onc.2015.172	http://dx.doi.org/10.1038/onc.2015.172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26028031				2022-12-28	WOS:000371351700002
J	Mancini, F; Pieroni, L; Monteleone, V; Luca, R; Fici, L; Luca, E; Urbani, A; Xiong, S; Soddu, S; Masetti, R; Lozano, G; Pontecorvi, A; Moretti, F				Mancini, F.; Pieroni, L.; Monteleone, V.; Luca, R.; Fici, L.; Luca, E.; Urbani, A.; Xiong, S.; Soddu, S.; Masetti, R.; Lozano, G.; Pontecorvi, A.; Moretti, F.			MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response	ONCOGENE			English	Article							CELL-CYCLE ARREST; MDM4 MDMX; GROWTH ARREST; P53 ACTIVITY; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL PROGRAM; DOWN-REGULATION; PROTEIN; PHOSPHORYLATION; HIPK2	The p53 inhibitor, MDM4 (MDMX) is a cytoplasmic protein with p53-activating function under DNA damage conditions. Particularly, MDM4 promotes phosphorylation of p53 at Ser46, a modification that precedes different p53 activities. We investigated the mechanism by which MDM4 promotes this p53 modification and its consequences in untransformed mammary epithelial cells and tissues. In response to severe DNA damage, MDM4 stimulates p53Ser46P by binding and stabilizing serine-threonine kinase HIPK2. Under these conditions, the p53-inhibitory complex, MDM4/MDM2, dissociates and this allows MDM4 to promote p53/HIPK2 functional interaction. Comparative proteomic analysis of DNA damage-treated cells versus - untreated cells evidenced a diffuse downregulation of proteins with anti-apoptotic activity, some of which were targets of p53Ser46P/HIPK2 repressive activity. Importantly, MDM4 depletion abolishes the downregulation of these proteins indicating the requirement of MDM4 to promote p53-mediated transcriptional repression. Consistently, MDM4-mediated HIPK2/p53 activation precedes HIPK2/p53 nuclear translocation and activity. Noteworthy, repression of these proteins was evident also in mammary glands of mice subjected to.-irradiation and was significantly enhanced in transgenic mice overexpressing MDM4. This study evidences the flexibility of MDM2/MDM4 heterodimer, which allows the development of a positive activity of cytoplasmic MDM4 towards p53-mediated transcriptional function. Noteworthy, this activity uncovers coordinated repression of molecules with shared anti-apoptotic function which precedes active cell apoptosis and that are frequently overexpressed and/or markers of tumour phenotype in human cancer.	[Mancini, F.; Monteleone, V.; Luca, R.; Fici, L.; Luca, E.; Moretti, F.] Natl Res Council Italy CNR, Inst Cell Biol & Neurobiol, I-00143 Rome, Italy; [Mancini, F.; Luca, E.; Pontecorvi, A.] Univ Cattolica Sacro Cuore, Dept Endocrinol & Metab, Rome, Italy; [Pieroni, L.; Urbani, A.] Fdn Santa Lucia, Prote & Metabol Lab, Rome, Italy; [Pieroni, L.; Urbani, A.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy; [Fici, L.; Masetti, R.] Univ Cattolica Sacro Cuore, Dept Obstet & Gynaecol, Rome, Italy; [Xiong, S.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Soddu, S.] Regina Elena Inst Canc Res, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Santa Lucia; University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Texas System; UTMD Anderson Cancer Center; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Mancini, F (corresponding author), Natl Res Council Italy CNR, Inst Cell Biol & Neurobiol, I-00143 Rome, Italy.	francesca.mancini@ibcn.cnr.it; fabiola.moretti@cnr.it	Luca, Emilia/K-6983-2019; Moretti, Fabiola/I-5647-2013; Urbani, Andrea/AAD-1675-2022; Soddu, Silvia/K-2467-2018; Mancini, Francesca/AAZ-1672-2021; mancini, francesca/K-6062-2016; Pieroni, Luisa/Q-6315-2019; Xiong, Shunbin/AAR-5823-2021; Urbani, Andrea/B-2953-2012; Soddu, Silvia/ABH-6774-2020; Lucà, Rossella/J-5921-2018; Pieroni, Luisa/J-8651-2018	Moretti, Fabiola/0000-0002-2691-1254; Soddu, Silvia/0000-0001-8526-0044; Mancini, Francesca/0000-0002-2459-8815; mancini, francesca/0000-0002-2459-8815; Pieroni, Luisa/0000-0001-7141-1817; Soddu, Silvia/0000-0001-8526-0044; Lucà, Rossella/0000-0003-2495-7803; Pieroni, Luisa/0000-0001-7141-1817; MASETTI, Riccardo/0000-0002-7520-9111; Luca, Emilia/0000-0002-8279-067X	Associazione Italiana Ricerca sul Cancro (AIRC) [IG-8825, IG-12767]; Italian Ministry of Economy and Finance; FIRB [RBAP1153LS_007, RBAP11WCRZ_003]; Susan Komen Italia Fellowship; NATIONAL CANCER INSTITUTE [R01CA047296] Funding Source: NIH RePORTER	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Economy and Finance; FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Susan Komen Italia Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported by research grants from Associazione Italiana Ricerca sul Cancro (AIRC; IG-8825, IG-12767) and from the Italian Ministry of Economy and Finance to the CNR for the Project 'FaReBio di Qualita' to FM; by FIRB RBAP1153LS_007 to AP; by FIRB: RBAP11WCRZ_003 to AU. LP and LF were supported by Susan Komen Italia Fellowship. We are grateful to Dr JC Marine for Mdm4<SUP>-/--</SUP>p53<SUP>-/-</SUP> MEFs and lentiviral vectors, Dr L Schmith for polyclonal aHIPK2 antibody and Dr Cinzia Rinaldo for pSuper.retro-ip53 plasmid.	Barboza JA, 2008, MOL CANCER RES, V6, P947, DOI 10.1158/1541-7786.MCR-07-2079; Biderman Lynn, 2012, Genes Cancer, V3, P264, DOI 10.1177/1947601912455331; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chiu CG, 2010, AM J PATHOL, V176, P2067, DOI 10.2353/ajpath.2010.090353; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Conza G, 2012, CELL CYCLE, V11, P749, DOI 10.4161/cc.11.4.19208; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Giglio S, 2010, ONCOGENE, V29, P5935, DOI 10.1038/onc.2010.324; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Iacovelli S, 2009, CELL PROLIFERAT, V42, P373, DOI 10.1111/j.1365-2184.2009.00601.x; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kracikova M, 2013, CELL DEATH DIFFER, V20, P576, DOI 10.1038/cdd.2012.155; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Lecona E, 2008, MOL CELL BIOL, V28, P4665, DOI 10.1128/MCB.00650-07; Lenos K, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-111; Leventaki V, 2012, BRIT J HAEMATOL, V158, P763, DOI 10.1111/j.1365-2141.2012.09243.x; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Lipscomb EA, 2005, CANCER RES, V65, P10970, DOI 10.1158/0008-5472.CAN-05-2327; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mancini F, 2004, J BIOL CHEM, V279, P8169, DOI 10.1074/jbc.M311793200; Mancini F, 2010, INT J BIOCHEM CELL B, V42, P1080, DOI 10.1016/j.biocel.2010.04.010; Mancini F, 2009, CELL CYCLE, V8, P3854, DOI 10.4161/cc.8.23.10089; Mancini F, 2009, EMBO J, V28, P1926, DOI 10.1038/emboj.2009.154; Marchenko ND, 2010, CELL DEATH DIFFER, V17, P255, DOI 10.1038/cdd.2009.173; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Moller A, 2003, CANCER RES, V63, P4310; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Nardinocchi L, 2011, AGING-US, V3, P33, DOI 10.18632/aging.100254; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pieroni L, 2011, MOL BIOSYST, V7, P630, DOI 10.1039/c0mb00135j; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rinaldo C, 2012, MOL CELL, V47, P87, DOI 10.1016/j.molcel.2012.04.029; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Silva JC, 2005, ANAL CHEM, V77, P2187, DOI 10.1021/ac048455k; Sorrentino G, 2013, CELL DEATH DIFFER, V20, P198, DOI 10.1038/cdd.2012.112; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Tsvetkov P, 2009, J BIOL CHEM, V284, P26234, DOI 10.1074/jbc.M109.040493; Wang CL, 2014, CARCINOGENESIS, V35, P1500, DOI 10.1093/carcin/bgu015; Wang XJ, 2011, J BIOL CHEM, V286, P23725, DOI 10.1074/jbc.M110.213868; Werner ME, 2007, J BIOL CHEM, V282, P5560, DOI 10.1074/jbc.M603669200; Xiong SB, 2010, CANCER RES, V70, P7148, DOI 10.1158/0008-5472.CAN-10-1457; Zhu Y, 2013, GENE DEV, V27, P1739, DOI 10.1101/gad.212258.112	65	30	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					228	240		10.1038/onc.2015.76	http://dx.doi.org/10.1038/onc.2015.76			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25961923	Green Published, hybrid			2022-12-28	WOS:000368193900009
J	Wright, HJ; Arulmoli, J; Motazedi, M; Nelson, LJ; Heinemann, FS; Flanagan, LA; Razorenova, OV				Wright, H. J.; Arulmoli, J.; Motazedi, M.; Nelson, L. J.; Heinemann, F. S.; Flanagan, L. A.; Razorenova, O. V.			CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; CUB-DOMAIN; CELL CARCINOMA; TYROSINE PHOSPHORYLATION; TARGET GENE; PKC-DELTA; SURVIVAL; SRC; ADHESION; IDENTIFICATION	Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic form of breast cancer that lacks the estrogen, progesterone and HER2 receptors and is resistant to targeted and hormone therapies. TNBCs express high levels of the transmembrane glycoprotein, complement C1r/C1s, Uegf, Bmp1 (CUB)-domain containing protein 1 (CDCP1), which has been correlated with the aggressiveness and poor prognosis of multiple carcinomas. Full-length CDCP1 (flCDCP1) can be proteolytically cleaved, resulting in a cleaved membrane-bound isoform (cCDCP1). CDCP1 is phosphorylated by Src family kinases in its full-length and cleaved states, which is important for its pro-metastatic signaling. We observed that cCDCP1, compared with flCDCP1, induced a dramatic increase in phosphorylation of the migration-associated proteins: PKCd, ERK1/2 and p38 mitogen-activated protein kinase in HEK 293T. In addition, only cCDCP1 induced migration of HEK 293T cells and rescued migration of the TNBC cell lines expressing short hairpin RNA against CDCP1. Importantly, we found that only cCDCP1 is capable of dimerization, which can be blocked by expression of the extracellular portion of cCDCP1 (ECC), indicating that dimerization occurs through CDCP1's ectodomain. We found that ECC inhibited phosphorylation of PKCd and migration of TNBC cells in two-dimensional culture. Furthermore, ECC decreased cell invasiveness, inhibited proliferation and stimulated apoptosis of TNBC cells in three-dimensional culture, indicating that the cCDCP1 dimer is an important contributor to TNBC aggressiveness. These studies have important implications for the development of a therapeutic to block CDCP1 activity and TNBC metastasis.	[Wright, H. J.; Motazedi, M.; Nelson, L. J.; Razorenova, O. V.] Univ Calif Irvine, Dept Mol Biol & Biochem, 845 Hlth Sci Rd,Gross Hall,Room 3010, Irvine, CA 92697 USA; [Arulmoli, J.; Flanagan, L. A.] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA USA; [Heinemann, F. S.] Hoag Mem Hosp, Dept Pathol, 301 Newport Blvd, Newport Beach, CA 92663 USA; [Flanagan, L. A.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Razorenova, OV (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 845 Hlth Sci Rd,Gross Hall,Room 3010, Irvine, CA 92697 USA.	olgar@uci.edu		Motazedi, Maryam/0000-0002-9856-4933	NIH [F31CA196226]; NATIONAL CANCER INSTITUTE [T32CA121940, F31CA196226] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001414, TL1TR001415] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by NIH Award F31CA196226 to HJW. We thank Drs Alice Police and Erin Lin for providing primary TNBC tissue, Dr Peter Kaiser for MDA-MB-231 and MDA-MB-468 cell lines, Dr Dan Mercola for MDA-MB-453 cell line, Dr Xing Dai for MCF10A cell line, Dr Albert Koong for split-luciferase vectors, Dr Inder Verma for pVSVG and Delta R8.2 lentivirus packaging plasmids, Dr Jae-Won Soh for pHACE-PKC delta construct, Dr Sanford Shattil for pRC-CMV-Src construct, Dr Peter Chumakov for pLM-CMV lentiviral vector, Miranda Paley from Dr Jennifer Prescher lab and Linan Liu from Dr Weian Zhao's lab for help with IVIS Lumina Imager, and Dr David Fruman and Dr Hung Fan for critical reading of the manuscript.	Adams MN, 2015, ONCOGENE, V34, P1375, DOI 10.1038/onc.2014.88; Alajati A, 2015, CELL REP, V11, P564, DOI 10.1016/j.celrep.2015.03.044; Arora R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098370; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chaudary Naz, 2006, Breast Dis, V26, P55; Choi CYH, 2008, MOL IMAGING, V7, P139, DOI 10.2310/7290.2008.00017; Cvetkovic D, 2014, JOVE-J VIS EXP, DOI 10.3791/51341; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Gandji LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123472; Guiro K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118724; He Y, 2016, ONCOGENE, V35, P468, DOI 10.1038/onc.2015.101; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Kim KH, 2010, J LIPID RES, V51, P3425, DOI 10.1194/jlr.M007989; Kim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119473; Kollmorgen G, 2013, MOL ONCOL, V7, P1142, DOI 10.1016/j.molonc.2013.08.009; Kollmorgen G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053050; Law ME, 2013, ONCOGENE, V32, P1316, DOI 10.1038/onc.2012.138; Lee HX, 2009, GENE DEV, V23, P2551, DOI 10.1101/gad.1839309; Leroy C, 2015, ONCOGENE, V34, P5593, DOI 10.1038/onc.2015.19; Lin CY, 2014, CANCER RES, V74, P5229, DOI 10.1158/0008-5472.CAN-13-2995; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Maller O, 2013, J CELL SCI, V126, P4108, DOI 10.1242/jcs.121590; Mamat S, 2010, ONCOL REP, V23, P1221, DOI 10.3892/or_00000753; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Miroshnikova YA, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/2/026013; Miyazawa Y, 2013, MOL CANCER RES, V11, P628, DOI 10.1158/1541-7786.MCR-12-0544; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Ng D, 2009, PLOS BIOL, V7, P278, DOI 10.1371/journal.pbio.1000041; Nieva C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046456; Qiu B, 2015, CANCER DISCOV, V5, P652, DOI 10.1158/2159-8290.CD-14-1507; Razorenova OV, 2014, MOL CELL BIOL, V34, P739, DOI 10.1128/MCB.00644-12; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Razorenova OV, 2005, GENE, V350, P89, DOI 10.1016/j.gene.2005.02.006; Romero A, 1996, FEBS LETT, V382, P15, DOI 10.1016/0014-5793(96)00133-0; Sandercock AM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0415-0; Seidel J, 2011, BIOCHEM BIOPH RES CO, V414, P226, DOI 10.1016/j.bbrc.2011.09.062; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Sowter HM, 2003, CANCER RES, V63, P6130; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Tu YF, 2011, BBA-BIOENERGETICS, V1807, P1125, DOI 10.1016/j.bbabio.2011.04.015; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Uekita T, 2014, MOL CANCER RES, V12, P1449, DOI 10.1158/1541-7786.MCR-13-0587; Uekita T, 2013, CANCER SCI, V104, P865, DOI 10.1111/cas.12154; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Zhau HYE, 2011, CLIN CANCER RES, V17, P2159, DOI 10.1158/1078-0432.CCR-10-2523	54	26	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4762	4772		10.1038/onc.2016.7	http://dx.doi.org/10.1038/onc.2016.7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876198	Green Accepted, Green Submitted			2022-12-28	WOS:000383324700009
J	Kanu, N; Zhang, T; Burrell, RA; Chakraborty, A; Cronshaw, J; DaCosta, C; Gronroos, E; Pemberton, HN; Anderton, E; Gonzalez, L; Sabbioneda, S; Ulrich, HD; Swanton, C; Behrens, A				Kanu, N.; Zhang, T.; Burrell, R. A.; Chakraborty, A.; Cronshaw, J.; DaCosta, C.; Gronroos, E.; Pemberton, H. N.; Anderton, E.; Gonzalez, L.; Sabbioneda, S.; Ulrich, H. D.; Swanton, C.; Behrens, A.			RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; CELL NUCLEAR ANTIGEN; DNA-DAMAGE; MONOUBIQUITINATED PCNA; ANAPHASE BRIDGES; MAMMALIAN-CELLS; FOCUS FORMATION; ACTIVATION; FORKS; CHECKPOINT	The DNA replication machinery invariably encounters obstacles that slow replication fork progression, and threaten to prevent complete replication and faithful segregation of sister chromatids. The resulting replication stress activates ATR, the major kinase involved in resolving impaired DNA replication. In addition, replication stress also activates the related kinase ATM, which is required to prevent mitotic segregation errors. However, the molecular mechanism of ATM activation by replication stress is not defined. Here, we show that monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA), a marker of stalled replication forks, interacts with the ATM cofactor ATMIN via WRN-interacting protein 1 (WRNIP1). ATMIN, WRNIP1 and RAD18, the E3 ligase responsible for PCNA monoubiquitination, are specifically required for ATM signalling and 53BP1 focus formation induced by replication stress, not ionising radiation. Thus, WRNIP1 connects PCNA monoubiquitination with ATMIN/ATM to activate ATM signalling in response to replication stress and contribute to the maintenance of genomic stability.	[Kanu, N.; Zhang, T.; Chakraborty, A.; Cronshaw, J.; DaCosta, C.; Behrens, A.] Francis Crick Inst, Mammalian Genet Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England; [Burrell, R. A.; Gronroos, E.; Swanton, C.] Francis Crick Inst, Translat Canc Therapeut Lab, London, England; [Pemberton, H. N.; Anderton, E.] Francis Crick Inst, Mol Oncol Lab, London, England; [Gonzalez, L.; Ulrich, H. D.] Francis Crick Inst, DNA Damage Tolerance Lab, London, England; [Sabbioneda, S.] CNR, Ist Genet Mol, Pavia, Italy; [Swanton, C.] UCL Canc Inst, London, England; [Behrens, A.] Kings Coll London, Sch Med, Guys Campus, London, England; [Kanu, N.] UCL Canc Inst, Translat Canc Therapeut Lab, 72 Huntley St, London WC1E 6BT, England; [Zhang, T.] Inst Med Biol, 8 A Biomed Grove,06-06 Immunos, Singapore 138648, Singapore; [Gonzalez, L.; Ulrich, H. D.] Inst Mol Biol, Ackermannweg 4, D-55122 Mainz, Germany; [Chakraborty, A.] AstraZeneca, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England	Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of London; University College London; University of London; King's College London; University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Institute of Molecular Biology (IMB); AstraZeneca; CRUK Cambridge Institute	Behrens, A (corresponding author), Francis Crick Inst, Mammalian Genet Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	axel.behrens@crick.ac.uk	Sabbioneda, Simone/N-7017-2015	Sabbioneda, Simone/0000-0001-8551-5465; Ulrich, Helle D./0000-0003-0431-2223; Gronroos, Eva/0000-0001-8303-5409; Swanton, Charles/0000-0002-4299-3018; Behrens, Axel/0000-0002-1557-1143; Da Costa, Clive/0000-0002-0435-6747	Francis Crick Institute; Breast Cancer Research Foundation; A*STAR NSS-PhD scholarship (Singapore); ERC [281661 ATMINDDR]; Cancer Research UK [15679] Funding Source: researchfish; The Francis Crick Institute [10039, 10040] Funding Source: researchfish	Francis Crick Institute; Breast Cancer Research Foundation; A*STAR NSS-PhD scholarship (Singapore)(Agency for Science Technology & Research (A*STAR)); ERC(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK); The Francis Crick Institute	Support was given from Mass Spectrometry, Bioinformatics and Biostatistics and the Equipment Park in the Cancer Research UK London Research Institute (now part of the Francis Crick Institute). We are grateful to JL Parker in the Ulrich laboratory for preparing ubiquitinated PCNA. R Bish, I Dikic, M Myers, E Soutoglou and A Lehmann kindly provided experimental materials. NK is funded by the Breast Cancer Research Foundation. TZ was financially supported by an A*STAR NSS-PhD scholarship (Singapore). This work was supported by an ERC grant (281661 ATMINDDR) to AB.	Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baumann C, 2007, CELL, V128, P101, DOI 10.1016/j.cell.2006.11.041; Bish RA, 2008, J PROTEOME RES, V7, P3481, DOI 10.1021/pr800217q; Bish RA, 2007, J BIOL CHEM, V282, P23184, DOI 10.1074/jbc.M701042200; Blackford AN, 2012, HUM MOL GENET, V21, P2005, DOI 10.1093/hmg/dds013; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Chan KL, 2011, SEMIN CELL DEV BIOL, V22, P906, DOI 10.1016/j.semcdb.2011.07.001; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chan KL, 2007, EMBO J, V26, P3397, DOI 10.1038/sj.emboj.7601777; Crosetto N, 2008, J BIOL CHEM, V283, P35173, DOI 10.1074/jbc.M803219200; Davalos AR, 2004, CELL CYCLE, V3, P1579, DOI 10.4161/cc.3.12.1286; Derheimer FA, 2010, FEBS LETT, V584, P3675, DOI 10.1016/j.febslet.2010.05.031; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Fugger K, 2015, CELL REP; Gamper AM, 2012, J BIOL CHEM, V287, P12445, DOI 10.1074/jbc.M112.352310; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kanu N, 2008, CELL CYCLE, V7, P3483, DOI 10.4161/cc.7.22.7044; Kanu N, 2007, EMBO J, V26, P2933, DOI 10.1038/sj.emboj.7601733; Kawabe Y, 2001, J BIOL CHEM, V276, P20364, DOI 10.1074/jbc.C100035200; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lilley CE, 2010, EMBO J, V29, P943, DOI 10.1038/emboj.2009.400; Loizou JI, 2011, CANCER CELL, V19, P587, DOI 10.1016/j.ccr.2011.03.022; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; McNees CJ, 2005, EMBO J, V24, P2447, DOI 10.1038/sj.emboj.7600704; Niimi A, 2008, P NATL ACAD SCI USA, V105, P16125, DOI 10.1073/pnas.0802727105; Olcina MM, 2013, MOL CELL, V52, P758, DOI 10.1016/j.molcel.2013.10.019; Parker Joanne L, 2012, Methods Mol Biol, V920, P569, DOI 10.1007/978-1-61779-998-3_37; Payne BTI, 2006, NUCLEIC ACIDS RES, V34, P5194, DOI 10.1093/nar/gkl682; Saugar I, 2012, NUCLEIC ACIDS RES, V40, P245, DOI 10.1093/nar/gkr738; Schmidt L, 2014, DNA REPAIR, V24, P122, DOI 10.1016/j.dnarep.2014.09.001; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; Ulrich HD, 2009, DNA REPAIR, V8, P461, DOI 10.1016/j.dnarep.2009.01.006; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773; Yoshimura A, 2009, GENES GENET SYST, V84, P171, DOI 10.1266/ggs.84.171; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang ZT, 2012, CELL CYCLE, V11, P2128, DOI 10.4161/cc.20595	48	24	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					4009	4019		10.1038/onc.2015.427	http://dx.doi.org/10.1038/onc.2015.427			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26549024	Green Accepted, Green Submitted			2022-12-28	WOS:000381013100012
J	Diersch, S; Wirth, M; Schneeweis, C; Jors, S; Geisler, F; Siveke, JT; Rad, R; Schmid, RM; Saur, D; Rustgi, AK; Reichert, M; Schneider, G				Diersch, S.; Wirth, M.; Schneeweis, C.; Joers, S.; Geisler, F.; Siveke, J. T.; Rad, R.; Schmid, R. M.; Saur, D.; Rustgi, A. K.; Reichert, M.; Schneider, G.			Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells	ONCOGENE			English	Article							C-MYC; FAMILY PROTEINS; BETA-CELLS; CANCER; MOUSE; KRAS; ADENOCARCINOMA; RECEPTOR; CARCINOGENESIS; TRANSCRIPTION	Epidermal growth factor receptor (EGFR) signaling has a critical role in oncogenic Kras-driven pancreatic carcinogenesis. However, the downstream targets of this signaling network are largely unknown. We developed a novel model system utilizing murine primary pancreatic ductal epithelial cells (PDECs), genetically engineered to allow time-specific expression of oncogenic Kras(G12D) from the endogenous promoter. We show that primary PDECs are susceptible to Kras(G12D)-driven transformation and form pancreatic ductal adenocarcinomas in vivo after Cdkn2a inactivation. In addition, we demonstrate that activation of Kras(G12D) induces an EGFR signaling loop to drive proliferation. Interestingly, pharmacological inhibition of EGFR fails to decrease Kras(G12D)-activated ERK or PI3K signaling. Instead our data provide novel evidence that EGFR signaling is needed to activate the oncogenic and pro-proliferative transcription factor c-MYC. EGFR and c-MYC have been shown to be essential for pancreatic carcinogenesis. Importantly, our data link both pathways and thereby explain the crucial role of EGFR for Kras(G12D)-driven carcinogenesis in the pancreas.	[Diersch, S.; Wirth, M.; Schneeweis, C.; Joers, S.; Geisler, F.; Siveke, J. T.; Rad, R.; Schmid, R. M.; Saur, D.; Reichert, M.; Schneider, G.] Tech Univ Munich, Med Klin 2, Munich, Germany; [Siveke, J. T.] German Canc Consortium DKTK, Div Translat Solid Tumor Oncol, Partner Site Essen & German Canc Res Ctr DKFZ, Heidelberg, Germany; [Rustgi, A. K.; Reichert, M.] Univ Penn, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Rustgi, A. K.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Rustgi, A. K.] Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA; [Rustgi, A. K.; Reichert, M.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA	Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Schneider, G (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, Ismaninger Str 22, D-81675 Munich, Germany.	guenter.schneider@tum.de	Siveke, Jens/AAQ-6170-2021; Wirth, Matthias/AEG-6333-2022; Reichert, Maximilian/GOH-1246-2022; Saur, Dieter/O-8355-2015	Saur, Dieter/0000-0001-5874-0210; Wirth, Matthias/0000-0002-8340-0872	Wilhelm-Sander Foundation [2012.084.1]; Deutsche Forschungsgemeinschaft (DFG) [SCHN 959/1-2, SCHN 959/2-1, GE2289/1, SI 1549/2-1, SFB824]; Deutsche Krebshilfe [110908, 111273, 109992]; NIH [NIHP30 DK050306, NIH R01DK060694]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060694, P30DK050306] Funding Source: NIH RePORTER	Wilhelm-Sander Foundation; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs S. Hingorani, I. Verma, D. Tuveson, H. Zeng, F. Costantini, T. Jacks, R. DePhino, J. Ferrer, I. de Alboran and F. Alt for generating or providing mouse lines/plasmids. This work was supported by the Wilhelm-Sander Foundation (2012.084.1 to GS), Deutsche Forschungsgemeinschaft (DFG) (SCHN 959/1-2, SCHN 959/2-1 to GS, GE2289/1 to FG, SI 1549/2-1 to JTS and SFB824 to GS and DS), Deutsche Krebshilfe (110908 to GS, 111273 (Max-Eder Program) to MR and 109992 to JTS) and NIH (NIHP30 DK050306 Center for Molecular Studies in Digestive and Liver Diseases (Molecular Pathology and Imaging, Molecular Biology/Gene Expression, Cell Culture, and Transgenic and Chimeric Mouse Cores) to MR and AKR and the NIH R01DK060694 to MR and AKR).	Appleman VA, 2012, MOL CANCER RES, V10, P1228, DOI 10.1158/1541-7786.MCR-12-0340-T; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bonal C, 2009, GASTROENTEROLOGY, V136, P309, DOI 10.1053/j.gastro.2008.10.015; Conradt L, 2011, NEOPLASIA, V13, P1026, DOI 10.1593/neo.111016; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Grippo PJ, 2012, INT J CANCER, V131, P1243, DOI 10.1002/ijc.27322; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hessmann E, 2016, ONCOGENE, V35, P1609, DOI 10.1038/onc.2015.216; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Ischenko I, 2014, P NATL ACAD SCI USA, V111, P3466, DOI 10.1073/pnas.1319911111; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Jors S, 2015, J CLIN INVEST, V125, P2445, DOI 10.1172/JCI78585; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee KE, 2010, CANCER CELL, V18, P448, DOI 10.1016/j.ccr.2010.10.020; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; Lin WC, 2013, CANCER RES, V73, P1821, DOI 10.1158/0008-5472.CAN-12-2067; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Nakhai H, 2008, DEVELOPMENT, V135, P3191, DOI 10.1242/dev.017137; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Perera RM, 2012, CANCER CELL, V22, P281, DOI 10.1016/j.ccr.2012.08.019; Pinho AV, 2011, CELL CYCLE, V10, P1312, DOI 10.4161/cc.10.8.15363; Pinho AV, 2011, GUT, V60, P958, DOI 10.1136/gut.2010.225920; Puri S, 2015, CELL STEM CELL, V16, P18, DOI 10.1016/j.stem.2014.11.001; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Reichert M, 2013, GENE DEV, V27, P288, DOI 10.1101/gad.204453.112; Reichert M, 2011, J CLIN INVEST, V121, P4572, DOI 10.1172/JCI57131; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Sancho R, 2014, CELL STEM CELL, V15, P139, DOI 10.1016/j.stem.2014.06.019; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Schild C, 2009, MOL CARCINOGEN, V48, P1149, DOI 10.1002/mc.20569; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Skoudy Anouchka, 2011, J Gastrointest Cancer, V42, P76, DOI 10.1007/s12029-011-9258-0; Solar M, 2009, DEV CELL, V17, P849, DOI 10.1016/j.devcel.2009.11.003; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; von Burstin J, 2015, MOL CANCER RES, V13, P863, DOI 10.1158/1541-7786.MCR-14-0709; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhou Q, 2007, DEV CELL, V13, P103, DOI 10.1016/j.devcel.2007.06.001	53	29	29	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3880	3886		10.1038/onc.2015.437	http://dx.doi.org/10.1038/onc.2015.437			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26592448	Green Accepted			2022-12-28	WOS:000380753200013
J	Zhang, Q; Wei, T; Shim, K; Wright, K; Xu, K; Palka-Hamblin, HL; Jurkevich, A; Khare, S				Zhang, Q.; Wei, T.; Shim, K.; Wright, K.; Xu, K.; Palka-Hamblin, H. L.; Jurkevich, A.; Khare, S.			Atypical role of sprouty in colorectal cancer: sprouty repression inhibits epithelial-mesenchymal transition	ONCOGENE			English	Article							COLON-CANCER; CELL-MIGRATION; TARGET GENE; EXPRESSION; AKT2; MOUSE; DIFFERENTIATION; ESTABLISHMENT; METASTASIS; ANTAGONIST	Sprouty (SPRY) appears to act as a tumor suppressor in cancer, whereas we demonstrated that SPRY2 functions as a putative oncogene in colorectal cancer (CRC) (Oncogene, 2010, 29: 5241-5253). We investigated the mechanisms by which SPRY regulates epithelial-mesenchymal transition (EMT) in CRC. SPRY1 and SPRY2 mRNA transcripts were significantly upregulated in human CRC. Suppression of SPRY2 repressed AKT2 and EMT-inducing transcription factors and significantly increased E-cadherin expression. Concurrent downregulation of SPRY1 and SPRY2 also increased E-cadherin and suppressed mesenchymal markers in colon cancer cells. An inverse expression pattern between AKT2 and E-cadherin was established in a human CRC tissue microarray. SPRY2 negatively regulated miR-194-5p that interacts with AKT2 3' untranslated region. Mir-194 mimics increased E-cadherin expression and suppressed cancer cell migration and invasion. By confocal microscopy, we demonstrated redistribution of E-cadherin to plasma membrane in colon cancer cells transfected with miR-194. Spry1(-/-) and Spry2(-/-) double mutant mouse embryonic fibroblasts exhibited decreased cell migration while acquiring several epithelial markers. In CRC, SPRY drive EMT and may serve as a biomarker of poor prognosis.	[Zhang, Q.; Wei, T.; Xu, K.; Khare, S.] Univ Missouri, Dept Internal Med, Sect Gastroenterol & Hepatol, Columbia, MO 65212 USA; [Shim, K.; Wright, K.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Palka-Hamblin, H. L.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; [Jurkevich, A.] Univ Missouri, Mol Cytol Core, Columbia, MO 65212 USA; [Khare, S.] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA	University of Missouri System; University of Missouri Columbia; Medical College of Wisconsin; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital	Khare, S (corresponding author), Univ Missouri, Dept Internal Med, 1 Hosp Dr, Columbia, MO 65212 USA.	khares@health.missouri.edu		Jurkevich, Alexander/0000-0002-1161-0918; Wei, Tao/0000-0002-9510-5512	VA Merit Award [1171590]; RO3 Award [CA150081]; University of Missouri Research Board Award; School of Medicine Bridge Funding; RO1 Award [DC010387]; NATIONAL CANCER INSTITUTE [R03CA150081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010387] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000824] Funding Source: NIH RePORTER	VA Merit Award(US Department of Veterans Affairs); RO3 Award; University of Missouri Research Board Award; School of Medicine Bridge Funding; RO1 Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Veterans Affairs(US Department of Veterans Affairs)	Thanks to Yuanxi Xu and Tammy Strawn for providing help in IHC data collection and analysis. Renilla luciferase control vector (pRL-null Vector) is a kind gift from Dr Guifa Xi at Northwestern University, Chicago, IL, USA. pmiR-GLO-AKT2-3'UTR and pmiR-GLO-AKT2-3'UTR mutant is a kind gift from Dr Jie Hong at School of Medicine, Shanghai Jiao Tong University, Shanghi, China. This work was supported by VA Merit Award (Project1171590), RO3 Award (CA150081), University of Missouri Research Board Award and School of Medicine Bridge Funding to SK and an RO1 Award (DC010387) to KS.	Acunzo M, 2013, P NATL ACAD SCI USA, V110, P8573, DOI 10.1073/pnas.1302107110; Agarwal E, 2013, CELL SIGNAL, V25, P1711, DOI 10.1016/j.cellsig.2013.03.025; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Buchan JR, 2007, SCIENCE, V318, P1877, DOI 10.1126/science.1152623; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chi LJ, 2006, ENDOCRINOLOGY, V147, P3777, DOI 10.1210/en.2006-0299; Chiang YP, 2012, EXP THER MED, V3, P560, DOI 10.3892/etm.2011.436; Diaz-Lopez A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156; Feng YH, 2011, CANCER BIOL THER, V11, P111, DOI 10.4161/cbt.11.1.13965; Grille Sylvia, 2004, Journal de la Societe de Biologie, V198, P375; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hick AC, 2013, DEV BIOL, V381, P227, DOI 10.1016/j.ydbio.2013.04.022; Hino K, 2008, RNA, V14, P1433, DOI 10.1261/rna.810208; Hino Kimihiro, 2007, Nucleic Acids Symp Ser (Oxf), P415, DOI 10.1093/nass/nrm208; Holgren C, 2010, ONCOGENE, V29, P5241, DOI 10.1038/onc.2010.264; Khare S, 1999, AM J PHYSIOL-GASTR L, V276, pG1005; Khare S, 2006, AM J PHYSIOL-GASTR L, V291, pG1100, DOI 10.1152/ajpgi.00008.2006; Kroepil F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046665; Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154; Leeksma OC, 2002, EUR J BIOCHEM, V269, P2546, DOI 10.1046/j.1432-1033.2002.02921.x; Li XY, 2011, J CELL BIOL, V195, P729, DOI 10.1083/jcb.201105103; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Masoumi-Moghaddam S, 2014, CANCER METAST REV, V33, P695, DOI 10.1007/s10555-014-9497-1; Natalwala A, 2008, WORLD J GASTROENTERO, V14, P3792, DOI 10.3748/wjg.14.3792; Ordonez-Moran P, 2014, ONCOGENE, V33, P1975, DOI 10.1038/onc.2013.140; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tazawa H, 2011, EXPERT OPIN BIOL TH, V11, P145, DOI 10.1517/14712598.2011.542749; Tsanou E, 2008, ANTICANCER RES, V28, P3815; Villagrasa P, 2012, ONCOGENE, V31, P4022, DOI 10.1038/onc.2011.562; Watanabe T, 2011, EUR J CANCER, V47, P1946, DOI 10.1016/j.ejca.2011.03.029; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Zhao HJ, 2014, THERANOSTICS, V4, P1193, DOI 10.7150/thno.8712	42	26	27	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3151	3162		10.1038/onc.2015.365	http://dx.doi.org/10.1038/onc.2015.365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26434583	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000378092700007
J	Mandal, R; Becker, S; Strebhardt, K				Mandal, R.; Becker, S.; Strebhardt, K.			Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy	ONCOGENE			English	Review							RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASES; I DOSE-ESCALATION; PHASE-I; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; B-RAF; FEEDBACK PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; PI3K/MTOR INHIBITORS	The RAS-RAF-MEK1/2-ERK1/2 pathway is a key signal transduction pathway in the cells. Critically, it remains constitutively active in approximately 30% of human cancers, having key roles in cancer development, maintenance and progression, while being responsible for poorer prognosis and drug resistance. Consequently, the inhibition of this pathway has been the subject of intense research for >25 years. The advent of better patient screening techniques has increasingly shown that upstream regulators like RAS and RAF remain persistently mutated in many cancer types. These gain-of-function mutations, such as KRAS-4BG(12V/G13D/Q61K), NRAS(Q61L/Q61R) or BRAF(V600E), lead to tremendous increase in their activities, resulting in constitutively active extracellular signalregulated kinase 1/2 (ERK1/2). They were not efficiently targeted by the first-generation inhibitors such as Lonafarnib or Sorafenib, which were essentially broad spectrum inhibitors targeting pan-RAS and pan-RAF, respectively. This triggered the development of the second-generation inhibitors selective against the mutated proteins. Second generation inhibitors such as Vemurafenib (Zelboraf) and Dabrafenib (Tafinlar) targeting BRAF(V600E), Trametinib (Mekinist) targeting MEK1/2 and the first generation pan-RAF inhibitor Sorafenib (Nexavar) have already been approved for treating renal, hepatocellular, thyroid cancers and BRAF(V600E/K) harboring metastatic melanoma. Others against RAF and MEK1/2 are presently undergoing clinical trials. Their success would depend on the better understanding of the acquired resistance mechanisms to these drugs in the cancer cells and the identification of predictive biomarkers for the proper administration of suitable inhibitor(s).	[Mandal, R.; Becker, S.; Strebhardt, K.] German Canc Consortium DKTK, Heidelberg, Germany; [Mandal, R.; Strebhardt, K.] Goethe Univ Frankfurt, Dept Obstet & Gynaecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany; [Mandal, R.; Strebhardt, K.] German Canc Res Ctr, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Dept Obstet & Gynaecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Mandal, Ranadip/0000-0003-2861-9545; Strebhardt, Klaus/0000-0003-2173-9763				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Adjei AA, 2013, ASCO M ABSTR S15, V31, P2528; Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-27; Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Ascierto PA, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-38; Azijli K, 2014, ANTICANCER RES, V34, P1493; Baker NM, 2013, NATURE, V497, P577, DOI 10.1038/nature12248; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Britten C, 2012, EUR J CANCER, V48, P109, DOI 10.1016/S0959-8049(12)72156-1; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Caponigro G, 2013, CANC RES S8, V73, P2337; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chintala L, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3593; Cohen RB, 2013, EUR J CANCER, V49, P1521, DOI 10.1016/j.ejca.2013.01.013; Collins S, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3738; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Corcoran RB, 2011, ONCOTARGET, V2, P336; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Cox AD, 2010, CANCER CELL, V17, P221, DOI 10.1016/j.ccr.2010.02.029; Dai BJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1404; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Descot A, 2009, MOL CELL, V35, P291, DOI 10.1016/j.molcel.2009.07.015; Dickson MA, 2015, INVEST NEW DRUG, V33, P349, DOI 10.1007/s10637-014-0191-5; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Fabrey R, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3739; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Finn RS, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.4_suppl.220; Fisher Rosalie, 2012, Cancer Manag Res, V4, P243, DOI 10.2147/CMAR.S25284; Fremin C, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-8; Friday BB, 2008, CLIN CANCER RES, V14, P342, DOI 10.1158/1078-0432.CCR-07-4790; Geest CR, 2009, J LEUKOCYTE BIOL, V86, P237, DOI 10.1189/jlb.0209097; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Gollob JA, 2007, J CLIN ONCOL, V25, P3288, DOI 10.1200/JCO.2007.10.8613; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hocker HJ, 2013, P NATL ACAD SCI USA, V110, P10201, DOI 10.1073/pnas.1300016110; Hoeflich KP, 2009, CANCER RES, V69, P3042, DOI 10.1158/0008-5472.CAN-08-3563; Hoh C, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3591; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Honda K, 2013, CANCER CHEMOTH PHARM, V72, P577, DOI 10.1007/s00280-013-2228-4; Hong D, 2007, P AN M AM SOC CLIN, V25, P3549; Huang TG, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-30; Jing JP, 2012, MOL CANCER THER, V11, P720, DOI 10.1158/1535-7163.MCT-11-0505; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johansson CH, 2014, PHARMACOL THERAPEUT, V142, P176, DOI 10.1016/j.pharmthera.2013.11.011; Juric D, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9051; Khazak V, 2007, EXPERT OPIN THER TAR, V11, P1587, DOI 10.1517/14728222.11.12.1587; Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078-0432.CCR-11-1491; Lam ET, 2010, J CLIN ONCOL, V28, P2323, DOI 10.1200/JCO.2009.25.0068; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Leijen S, 2012, CLIN CANCER RES, V18, P4794, DOI 10.1158/1078-0432.CCR-12-0868; Leow CCY, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.1; Lim HY, 2012, ASCO MEETING ABSTRAC, V30, P4103; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Little AS, 2012, BIOCHEM SOC T, V40, P73, DOI 10.1042/BST20110647; Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Lo RS, 2012, CELL RES, V22, P945, DOI 10.1038/cr.2012.78; Long GV, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9011; Luke JJ, 2012, CLIN CANCER RES, V18, P9, DOI 10.1158/1078-0432.CCR-11-2197; Mandal R, 2014, MOL ONCOL, V8, P232, DOI 10.1016/j.molonc.2013.11.003; Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236; Martinez-Garcia M, 2012, CLIN CANCER RES, V18, P4806, DOI 10.1158/1078-0432.CCR-12-0742; Maurer T, 2012, P NATL ACAD SCI USA, V109, P5299, DOI 10.1073/pnas.1116510109; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Menzies AM, 2014, CLIN CANCER RES, V20, P2035, DOI 10.1158/1078-0432.CCR-13-2054; Menzies AM, 2012, DRUG DES DEV THER, V6, P391, DOI 10.2147/DDDT.S38998; Narita Y, 2014, MOL CANCER THER, V13, P823, DOI 10.1158/1535-7163.MCT-13-0667; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pucci B, 2009, J CELL BIOCHEM, V108, P1166, DOI 10.1002/jcb.22345; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Riess H, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.4129; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rudd CE, 2005, NAT IMMUNOL, V6, P368, DOI 10.1038/ni0405-368; Sale MJ, 2014, BIOCHEM SOC T, V42, P776, DOI 10.1042/BST20140129; Sanada M, 2007, CARCINOGENESIS, V28, P2657, DOI 10.1093/carcin/bgm188; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schneider H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001718; Schwartz GK, 2009, J CLIN ONCOL, V27; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394; Stuart D., 2008, AACR M, V68, P4876; Stuart DD, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3790; Su YJ, 2012, CLIN CANCER RES, V18, P2184, DOI 10.1158/1078-0432.CCR-11-1122; Tentler JJ, 2010, MOL CANCER THER, V9, P3351, DOI 10.1158/1535-7163.MCT-10-0376; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Van Laethem J-L., 2014, J CLIN ONCOL, V32, P4025; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2011, CANCER RES, V71, P7137, DOI 10.1158/0008-5472.CAN-11-1243; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Xiao Z, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.213; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	119	65	67	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2547	2561		10.1038/onc.2015.329	http://dx.doi.org/10.1038/onc.2015.329			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364606				2022-12-28	WOS:000376165700001
J	Chen, J; Bai, M; Ning, C; Xie, B; Zhang, J; Liao, H; Xiong, J; Tao, X; Yan, D; Xi, X; Chen, X; Yu, Y; Bast, RC; Zhang, Z; Feng, Y; Zheng, W				Chen, J.; Bai, M.; Ning, C.; Xie, B.; Zhang, J.; Liao, H.; Xiong, J.; Tao, X.; Yan, D.; Xi, X.; Chen, X.; Yu, Y.; Bast, R. C.; Zhang, Z.; Feng, Y.; Zheng, W.			Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1 alpha/cyclin D1 pathway	ONCOGENE			English	Article							CYCLIN D1; GROWTH-FACTOR; RETINOBLASTOMA PROTEIN; SURVIVIN EXPRESSION; ENDOMETRIAL-CANCER; SURFACE EPITHELIUM; COLORECTAL-CANCER; SIGNALING PATHWAY; RISK REDUCTION; FALLOPIAN-TUBE	Gankyrin is a regulatory subunit of the 26kD proteasome complex. As a novel oncoprotein, gankyrin is expressed aberrantly in cancers from several different sites and has been shown to contribute to oncogenesis in endometrial and cervical carcinomas. Neither gankyrin's contribution to the development of epithelial ovarian cancer nor its interaction with follicle-stimulating hormone (FSH)-driven proliferation in ovarian cancer has been studied. Here we have found that gankyrin is overexpressed in ovarian cancers compared with benign ovarian cystadenomas and that gankyrin regulates FSH upregulation of cyclin D1. Importantly, gankyrin regulates PI3K/AKT signaling by downregulating PTEN. Prolonged AKT activation by FSH stimulation of the FSH receptor (FSHR) promotes gankyrin expression, which, in turn, enhances AKT activation by inhibiting PTEN. Overexpression of gankyrin decreases hypoxia inducible factor-1 alpha (HIF-1 alpha) protein levels, but has little effect on HIF-1 alpha mRNA levels, which could be attributed to gankyrin mediating HIF-1 alpha protein stability via the ubiquitin-proteasome pathway. Reduction in HIF-1 alpha protein stability led to attenuation of the binding with cyclin D1 promoter, resulted in abolishment of the negative regulation of cyclin D1 by HIF-1 alpha, which promotes proliferation of ovarian cancer cells. Our results document that gankyrin regulates HIF-1 alpha protein stability and cyclin D1 expression, ultimately mediating FSH-driven ovarian cancer cell proliferation.	[Chen, J.; Bai, M.; Xie, B.; Zhang, J.; Yan, D.; Xi, X.; Zhang, Z.; Feng, Y.] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Obstet & Gynecol, 100 Haining Rd, Shanghai 200080, Peoples R China; [Ning, C.; Chen, X.; Yu, Y.] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200433, Peoples R China; [Liao, H.] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Clin & Translat Res Ctr, Shanghai 200092, Peoples R China; [Xiong, J.] Fudan Univ, Huashan Hosp, Dept Neuropathol, Shanghai 200433, Peoples R China; [Xiong, J.] Fudan Univ, Obstet & Gynecol Hosp, Dept Pathol, Shanghai 200433, Peoples R China; [Yu, Y.; Bast, R. C.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Zheng, W.] Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA; [Zheng, W.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	Shanghai Jiao Tong University; Fudan University; Tongji University; Fudan University; Fudan University; University of Texas System; UTMD Anderson Cancer Center; University of Arizona; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhang, Z; Feng, Y (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Obstet & Gynecol, 100 Haining Rd, Shanghai 200080, Peoples R China.	zhangzhenbozzb@aliyun.com; Fengyj4806@sohu.com	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462; Bai, Mingzhu/0000-0001-6210-4890	National Natural Science Foundation of China [81272883, 81202044, 81370074, 81172478]; Science and Technology Commission of Shanghai Municipality [12ZR1447600]; Shanghai Municipal Public Health Bureau [XYQ2013119]; 'Chenxing Project' from Shanghai Jiao Tong University; National Foundation for Cancer Research; Stuart; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Public Health Bureau; 'Chenxing Project' from Shanghai Jiao Tong University; National Foundation for Cancer Research; Stuart; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81272883, 81202044, 81370074 and 81172478), the Science and Technology Commission of Shanghai Municipality (grant number 12ZR1447600), the Shanghai Municipal Public Health Bureau (grant number XYQ2013119) and the 'Chenxing Project' from Shanghai Jiao Tong University to ZZ. The role of YY in this project was partially supported by The National Foundation for Cancer Research and contributions from Stuart and Gaye Lynn Zarrow.	Bai ZF, 2013, CANCER RES, V73, P4548, DOI 10.1158/0008-5472.CAN-12-4586; Bose CK, 2008, ONCOL RES, V17, P231, DOI 10.3727/096504008786111383; Brekelmans CTM, 2003, CURR OPIN OBSTET GYN, V15, P63, DOI 10.1097/00001703-200302000-00010; Callahan MJ, 2007, J CLIN ONCOL, V25, P3985, DOI 10.1200/JCO.2007.12.2622; Chen XJ, 2009, MODERN PATHOL, V22, P699, DOI 10.1038/modpathol.2009.25; Chen Y, 2007, CELL RES, V17, P1020, DOI 10.1038/cr.2007.99; Choi JH, 2004, J CLIN ENDOCR METAB, V89, P5508, DOI 10.1210/jc.2004-0044; Choi JH, 2007, ENDOCR REV, V28, P440, DOI 10.1210/er.2006-0036; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; Crum CP, 2009, MOL ONCOL, V3, P165, DOI 10.1016/j.molonc.2009.01.004; Dawson S, 2006, TRENDS CELL BIOL, V16, P229, DOI 10.1016/j.tcb.2006.03.001; Dong LW, 2011, CELL RES, V21, P1248, DOI 10.1038/cr.2011.103; Elsheikh S, 2008, BREAST CANCER RES TR, V109, P325, DOI 10.1007/s10549-007-9659-8; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Huang Y, 2008, CELL RES, V18, P780, DOI 10.1038/cr.2008.70; Huang Y, 2011, ENDOCR-RELAT CANCER, V18, P13, DOI 10.1677/ERC-09-0308; Hung WC, 1996, HUM PATHOL, V27, P1324, DOI 10.1016/S0046-8177(96)90345-7; Jia L, 2011, NEOPLASMA, V58, P104, DOI 10.4149/neo_2011_02_104; Konishi I, 2006, INT J GYNECOL CANCER, V16, P16, DOI 10.1111/j.1525-1438.2006.00425.x; Lai YL, 2013, INT J ONCOL, V42, P776, DOI 10.3892/ijo.2012.1743; Li J, 2011, MODERN PATHOL, V24, P1488, DOI 10.1038/modpathol.2011.106; Li Q, 2013, MOL ENDOCRINOL, V27, P1468, DOI 10.1210/me.2013-1082; Li Y, 2007, MOL CELL ENDOCRINOL, V267, P26, DOI 10.1016/j.mce.2006.11.010; Liao H, 2012, ONCOL REP, V27, P1918, DOI 10.3892/or.2012.1700; Liu Yu-Qiang, 2014, J Anal Methods Chem, V2014, P617367, DOI 10.1155/2014/617367; Ludwig AH, 2009, ENDOCR-RELAT CANCER, V16, P1005, DOI 10.1677/ERC-08-0135; Lukanova A, 2005, CANCER EPIDEM BIOMAR, V14, P98; Man JH, 2010, J CLIN INVEST, V120, P2829, DOI 10.1172/JCI42542; Meng Y, 2010, CANCER LETT, V297, P9, DOI 10.1016/j.canlet.2010.04.019; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; Nichols GE, 1996, MODERN PATHOL, V9, P418; Ohtani K, 2001, CANCER LETT, V166, P207, DOI 10.1016/S0304-3835(00)00713-8; Ortiz CM, 2008, INT J CANCER, V122, P325, DOI 10.1002/ijc.23106; Qian YW, 2012, GASTROENTEROLOGY, V142, P1547, DOI 10.1053/j.gastro.2012.02.042; Qiu W, 2008, ONCOGENE, V27, P4034, DOI 10.1038/onc.2008.43; Riman T, 1998, CLIN ENDOCRINOL, V49, P695, DOI 10.1046/j.1365-2265.1998.00577.x; Semczuk A, 2004, CANCER LETT, V203, P1, DOI 10.1016/j.canlet.2003.09.012; Song X, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-114; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; Tang SH, 2010, CANCER BIOL THER, V9, P88, DOI 10.4161/cbt.9.2.10283; Tao X, 2013, ENDOCR-RELAT CANCER, V20, P415, DOI 10.1530/ERC-12-0005; Udhayakumar G, 2007, MOL CARCINOGEN, V46, P807, DOI 10.1002/mc.20311; Umekita Y, 2002, INT J CANCER, V98, P415, DOI 10.1002/ijc.10151; Wang J, 2003, INT J CANCER, V103, P328, DOI 10.1002/ijc.10848; Wen W, 2010, CANCER RES, V70, P2010, DOI 10.1158/0008-5472.CAN-08-4910; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Zhang JW, 2013, CANCER LETT, V339, P279, DOI 10.1016/j.canlet.2012.10.037; Zhang ZB, 2013, INT J ONCOL, V43, P1194, DOI 10.3892/ijo.2013.2054; Zhang ZB, 2013, ONCOL REP, V29, P1429, DOI 10.3892/or.2013.2278; Zhang ZB, 2012, CANCER LETT, V319, P89, DOI 10.1016/j.canlet.2011.12.033; Zhang ZB, 2009, CANCER LETT, V278, P56, DOI 10.1016/j.canlet.2008.12.024; Zheng TS, 2014, HEPATOLOGY, V59, P935, DOI 10.1002/hep.26705; Zheng WX, 1996, AM J PATHOL, V148, P47	54	68	74	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2506	2517		10.1038/onc.2015.316	http://dx.doi.org/10.1038/onc.2015.316			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26364616				2022-12-28	WOS:000376165500009
J	Nanos-Webb, A; Bui, T; Karakas, C; Zhang, D; Carey, JPW; Mills, GB; Hunt, KK; Keyomarsi, K				Nanos-Webb, A.; Bui, T.; Karakas, C.; Zhang, D.; Carey, J. P. W.; Mills, G. B.; Hunt, K. K.; Keyomarsi, K.			PKCiota promotes ovarian tumor progression through deregulation of cyclin E	ONCOGENE			English	Article							KINASE-C-IOTA; BREAST-CANCER; PKC-IOTA; E OVEREXPRESSION; POOR-PROGNOSIS; ATYPICAL PKC; CELL-CYCLE; EXPRESSION; ACTIVATION; CARCINOMA	The high frequency of relapse of epithelial ovarian tumors treated with standard chemotherapy has highlighted the necessity to identify targeted therapies that can improve patient outcomes. The dynamic relationship between cyclin E and PKCiota frequent overexpression in high-grade ovarian tumors poses a novel pathway for therapeutic investigation. We hypothesized that a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway activating PKCiota perpetuates cyclin E deregulation during ovarian tumorigenesis. We observed a positive correlation between PKCiota and cyclin E in a panel of 19 ovarian cancer cell lines. Modulation of cyclin E had no effect on PKCiota knockdown/overexpression; however, PKCiota differentially regulated cyclin E expression. In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCiota decreased proliferation, caused a G1 arrest and significantly prolonged overall survival in xenograft mouse models. In vitro, shPKCiota decreased the ability of IGROV cells to grow under anchorage-independent conditions and form aberrant acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression. Reverse-phase protein array analysis of PKCiota wild-type, catalytic active, dominant-negative protein isoforms strengthened the association between phospho-PKCiota levels and PI3K pathway activation. Inhibitors of PI3K coordinately decreased phospho-PKCiota and cyclin E protein levels. In conclusion, we have identified a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis.	[Nanos-Webb, A.; Bui, T.; Karakas, C.; Carey, J. P. W.; Keyomarsi, K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 6565 MD Anderson Blvd,Unit 1052, Houston, TX 77030 USA; [Zhang, D.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Hunt, K. K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 6565 MD Anderson Blvd,Unit 1052, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Carey, Jason PW/0000-0002-9729-1742	NIH [CA87458, CA1522228]; NCI CCSG [CA16672]; NATIONAL CANCER INSTITUTE [P50CA116199, R01CA152228, P30CA016672, P50CA083639, R01CA087548] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by NIH grants CA87458 and CA1522228 to KK and by NCI CCSG grant CA16672 to MD Anderson Cancer Center.	Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Akli S, 2004, BREAST CANCER RES, V6, P188, DOI 10.1186/bcr905; Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; Akli S, 2011, CANCER RES, V71, P3377, DOI 10.1158/0008-5472.CAN-10-4086; Awadelkarim KD, 2012, INT J CANCER, V131, P2852, DOI 10.1002/ijc.27600; Bagheri-Yarmand R, 2010, CANCER RES, V70, P5074, DOI 10.1158/0008-5472.CAN-09-4094; Bagheri-Yarmand R, 2010, CANCER RES, V70, P5085, DOI 10.1158/0008-5472.CAN-09-4095; Baldwin RM, 2006, ONCOGENE, V25, P2909, DOI 10.1038/sj.onc.1209312; Bales E, 2005, CANCER RES, V65, P692; Bedrosian I, 2004, ONCOGENE, V23, P2648, DOI 10.1038/sj.onc.1207408; Bedrosian I, 2007, CLIN CANCER RES, V13, P4800, DOI 10.1158/1078-0432.CCR-07-0142; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Courjal F, 1996, INT J CANCER, V69, P247; Duong MT, 2013, CANCER RES, V73, P5556, DOI 10.1158/0008-5472.CAN-13-0013; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Erdogan E, 2009, CLIN CANCER RES, V15, P1527, DOI 10.1158/1078-0432.CCR-08-2459; Evans JD, 2003, AM J CLIN PATHOL, V119, P392, DOI 10.1309/BKPC9DX98R781B87; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Farley J, 2003, CANCER RES, V63, P1235; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kanoh Y, 2003, ENDOCRINOLOGY, V144, P947, DOI 10.1210/en.2002-221017; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lakhani SR, 2004, CLIN CANCER RES, V10, P2473, DOI 10.1158/1078-0432.CCR-1029-3; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Nanos-Webb A, 2012, BREAST CANCER RES TR, V132, P575, DOI 10.1007/s10549-011-1638-4; Paget JA, 2012, ONCOGENE, V31, P3584, DOI 10.1038/onc.2011.524; Rath SL, 2014, BIOCHEMISTRY-US, V53, P4612, DOI 10.1021/bi5004052; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Rosse C, 2014, P NATL ACAD SCI USA, V111, pE1872, DOI 10.1073/pnas.1400749111; Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074; Tan DSP, 2008, J CLIN ONCOL, V26, P5530, DOI 10.1200/JCO.2008.16.1703; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Weichert W, 2003, INT J ONCOL, V23, P633; Wingate H, 2003, CELL CYCLE, V2, P461, DOI 10.4161/cc.2.5.464; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	41	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2428	2440		10.1038/onc.2015.301	http://dx.doi.org/10.1038/onc.2015.301			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279297	Green Accepted			2022-12-28	WOS:000376165500002
J	Gopalakrishnan, R; Matta, H; Tolani, B; Triche, T; Chaudhary, PM				Gopalakrishnan, R.; Matta, H.; Tolani, B.; Triche, T., Jr.; Chaudhary, P. M.			Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors	ONCOGENE			English	Article							KAPOSIS-SARCOMA; KAPPA-B; GENE-EXPRESSION; HSP90 INHIBITOR; IN-VITRO; LENALIDOMIDE; THALIDOMIDE; VFLIP; POMALIDOMIDE; ACTIVATION	Primary effusion lymphoma (PEL) is an aggressive type of non-Hodgkin lymphoma localized predominantly in body cavities. Kaposi's sarcoma-associated herpes virus (KSHV) is the causative agent of PEL. PEL is an incurable malignancy and has extremely poor prognosis when treated with conventional chemotherapy. Immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are Food and Drug Administration-approved drugs for the treatment of various ailments. IMiDs display pronounced antiproliferative effect against majority of PEL cell lines within their clinically achievable concentrations, by arresting cells at G(0)/G(1) phase of cell cycle and without any induction of KSHV lytic cycle reactivation. Although microarray examination of PEL cells treated with lenalidomide revealed activation of interferon (IFN) signaling, blocking the IFN pathway did not block the anti-PEL activity of IMiDs. The anti-PEL effects of IMiDs involved cereblon-dependent suppression of IRF4 and rapid degradation of IKZF1, but not IKZF3. Small hairpin RNA-mediated knockdown of MYC enhanced the cytotoxicity of IMiDs. Bromodomain (BRD) and extra-terminal domain (BET) proteins are epigenetic readers, which perform a vital role in chromatin remodeling and transcriptional regulation. BRD4, a widely expressed transcriptional coactivator, belongs to the BET family of proteins, which has been shown to co-occupy the super enhancers associated with MYC. Specific BRD4 inhibitors were developed, which suppress MYC transcriptionally. Lenalidomide displayed synergistic cytotoxicity with several structurally distinct BRD4 inhibitors (JQ-1, IBET151 and PFI-1). Furthermore, combined administration of lenalidomide and BRD4 inhibitor JQ-1 significantly increased the survival of PEL bearing NOD-SCID mice in an orthotopic xenograft model as compared with either agent alone. These results provide compelling evidence for clinical testing of IMiDs alone and in combination with BRD4 inhibitors for PEL.	[Gopalakrishnan, R.; Matta, H.; Tolani, B.; Triche, T., Jr.; Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90033 USA; [Gopalakrishnan, R.; Matta, H.; Tolani, B.; Triche, T., Jr.; Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Ctr Study Blood Dis, Los Angeles, CA 90033 USA; [Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Med, 1441 Eastlake Ave,NOR 3468, Los Angeles, CA 90033 USA; [Tolani, B.] Univ Calif San Francisco, Sch Med, Dept Surg, San Francisco, CA 94143 USA	University of Southern California; University of Southern California; University of Southern California; University of California System; University of California San Francisco	Chaudhary, PM (corresponding author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Med, 1441 Eastlake Ave,NOR 3468, Los Angeles, CA 90033 USA.	preet.chaudhary@med.usc.edu	Chaudhary, Preet/E-1970-2018; Gopalakrishnan, Ramakrishnan/N-3454-2015	Gopalakrishnan, Ramakrishnan/0000-0002-5068-6886; Triche, Tim/0000-0001-5665-946X; Tolani, Bhairavi/0000-0001-9076-866X	National Institutes of Health [CA139119, DE019811, SC CTSI UL1TR000130, P30CA014089]; Stop Cancer Foundation; National Cancer Institute Cancer Center Shared Grant [P30CA014089]; USC Provost Office Dean's Development Funds; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019811] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stop Cancer Foundation; National Cancer Institute Cancer Center Shared Grant; USC Provost Office Dean's Development Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank the following investigators for their generous gift of cell lines: Dr Jae Jung (BC-3, BCBL-1, JSC-1, BC-1, BCP-1, VG-1 and APK-1); Drs Izidore Lossos and Juan Ramos (UMPEL-1 and UMPEL-3); Dr Art Shaffer (TMD8, U-2932, HBL-1, OCI-Ly7, OCI-Ly8 and OCI-Ly19); Dr Alan Epstein (DG-75); Randall Rossi (SUDHL-4, SUDHL-6, Granta, Toledo, KG-1 and MV-4-11); Dr Markus Mapara (L428, L540, L1236 and KM-H2); Dr Irene Ghobrial (BCWM.1 and WMCL-1); and Dr Alan Lichenstein (MM.1S and RPMI8226). We are grateful to Dr William Kaelin Jr for providing the shRNA constructs (CRBN, IKZF1-1 and IKZF1-2), Dr James Bradner for his generous contribution of (+) and (-) JQ-1, Dr Peter Howley for BRD4 antibody and Dr Gary Hayward for KSHV replication and transcription activator antibody. This work was supported by grants from the National Institutes of Health (CA139119, DE019811, SC CTSI UL1TR000130 and P30CA014089) and Stop Cancer Foundation. Flow Cytometry was analyzed in the USC Flow Cytometry Core Facility that is supported in part by the National Cancer Institute Cancer Center Shared Grant award P30CA014089 and the USC Provost Office Dean's Development Funds.	Antar A, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.6; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Bhatt S, 2013, BLOOD, V122, P1233, DOI 10.1182/blood-2013-01-481713; Cannon JS, 2000, J VIROL, V74, P10187, DOI 10.1128/JVI.74.21.10187-10193.2000; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chen N, 2007, J CLIN PHARMACOL, V47, P1466, DOI 10.1177/0091270007309563; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dimopoulos MA, 2013, CRIT REV ONCOL HEMAT, V88, pS23, DOI 10.1016/j.critrevonc.2013.05.013; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gopalakrishnan R, 2013, CLIN CANCER RES, V19, P5016, DOI 10.1158/1078-0432.CCR-12-3510; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; John LB, 2011, MOL IMMUNOL, V48, P1272, DOI 10.1016/j.molimm.2011.03.006; Jones D, 1998, NEW ENGL J MED, V339, P444, DOI 10.1056/NEJM199808133390705; Kasserra C, 2015, J CLIN PHARMACOL, V55, P168, DOI 10.1002/jcph.384; Keller SA, 2000, BLOOD, V96, P2537; Klein U, 2003, BLOOD, V101, P4115, DOI 10.1182/blood-2002-10-3090; Kobayashi Y, 2007, ACTA HAEMATOL-BASEL, V117, P132, DOI 10.1159/000097460; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Lee BS, 2003, J VIROL, V77, P8072, DOI 10.1128/JVI.77.14.8072-8086.2003; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Li XD, 2010, J VIROL, V84, P8945, DOI 10.1128/JVI.00244-10; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Lopez-Girona A, 2011, BRIT J HAEMATOL, V154, P325, DOI 10.1111/j.1365-2141.2011.08689.x; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036601; Matta H, 2011, J BIOL CHEM, V286, P21555, DOI 10.1074/jbc.M111.224048; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Patel S, 2013, ARCH PATHOL LAB MED, V137, P1152, DOI 10.5858/arpa.2012-0294-RS; Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292; Qin ZQ, 2014, MOL CANCER THER, V13, P154, DOI 10.1158/1535-7163.MCT-13-0466; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Richardson PG, 2013, CRIT REV ONCOL HEMAT, V88, pS36, DOI 10.1016/j.critrevonc.2013.02.001; Sarosiek KA, 2010, P NATL ACAD SCI USA, V107, P13069, DOI 10.1073/pnas.1002985107; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shaffer AL, 2009, CLIN CANCER RES, V15, P2954, DOI 10.1158/1078-0432.CCR-08-1845; Shortt J, 2013, ONCOGENE, V32, P4191, DOI 10.1038/onc.2012.599; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Tolani B, 2014, ONCOGENE, V33, P2928, DOI 10.1038/onc.2013.242; Tolani B, 2014, J VIROL, V88, P6345, DOI 10.1128/JVI.00028-14; Yang YQ, 2011, J BIOL CHEM, V286, P27988, DOI 10.1074/jbc.M110.213363; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Zhang H, 2010, INT J CANCER, V126, P1226, DOI 10.1002/ijc.24825; Zhang LH, 2013, BRIT J HAEMATOL, V160, P487, DOI 10.1111/bjh.12172; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067; Zhu YX, 2013, LEUKEMIA LYMPHOMA, V54, P683, DOI 10.3109/10428194.2012.728597; Zhu YX, 2011, BLOOD, V118, P4771, DOI 10.1182/blood-2011-05-356063	60	73	75	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1797	1810		10.1038/onc.2015.245	http://dx.doi.org/10.1038/onc.2015.245			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119939	Green Accepted			2022-12-28	WOS:000373610400006
J	Wiel, C; Gras, B; Vindrieux, D; Warnier, M; Gitenay, D; Le Calve, B; Ferrand, M; Augert, A; Bernard, D				Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.			Multidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; TRANSPORT; CANCER; SUPPRESSION; MRP3; MICE	Oncogenic-stress-induced senescence (OIS) is a stress response allowing normal cells, when receiving oncogenic signals, to stably arrest their proliferation. OIS thus acts to prevent aberrant cell proliferation and tumor formation. To identify novel tumor suppressive pathways, we have recently completed a loss-of-function genetic screen to identify novel genes promoting escape from OIS and thus, potentially, tumor formation when their functions are lost. Using this approach, we unexpectedly found that loss of function of the multidrug resistance protein 3 (MRP3 or ABCC3) promotes escape from OIS in human epithelial cells. Importantly, ABCC3 expression is reduced in human skin tumors, and ABCC3-knockout mice display increased sensitivity to RAS-induced skin carcinogenesis, concomitantly with decreased OIS. ABCC3 participates in resistance to chemotherapy via its transporter activity. Our data show that this transporter activity is involved in ABCC3-induced senescence, demonstrating that this protein has a complex role in cancer, since its loss of function may promote escape from OIS and tumor formation whereas its gain of function promotes resistance to chemotherapy.	[Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.] Ctr Rech Cancerol Lyon, INSERM, U1052, Senescence Escape Mech Lab Tumoral Escape Dept, Lyon, France; [Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.] CNRS, UMR5286, Lyon, France; [Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.] Ctr Leon Berard, F-69373 Lyon, France; [Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.] Univ Lyon, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard	Bernard, D (corresponding author), Ctr Leon Berard, INSERM, CRCL, U1052,CNRS,UMR 5286, 28 Rue Laennec, F-69373 Lyon 08, France.	david.bernard@lyon.unicancer.fr	; Bernard, David/D-6265-2018	Gitenay, Delphine/0000-0002-6043-4519; Vindrieux, David/0000-0002-4713-5768; Bernard, David/0000-0002-1557-2074	French National Cancer Institute [plbio 2010-181]; Ligue contre le Cancer, comite de la Savoie; Fondation ARC; RTRS Fondation Synergie Lyon Cancer; Ligue Nationale contre le Cancer; Fondation pour la Recherche Medicale	French National Cancer Institute(Institut National du Cancer (INCA) France); Ligue contre le Cancer, comite de la Savoie; Fondation ARC; RTRS Fondation Synergie Lyon Cancer; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	We thank Lea Payen for advice and Sarah Kabani for critical reading of the manuscript. This work was carried out with the support of the French National Cancer Institute (grants plbio 2010-181), the 'Ligue contre le Cancer, comite de la Savoie', the 'Fondation ARC', and the 'RTRS Fondation Synergie Lyon Cancer'. CW is supported by the 'Ligue Nationale contre le Cancer' and the 'Fondation pour la Recherche Medicale'.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Bianchi-Smiraglia A, 2012, CELL CYCLE, V11, P4147, DOI 10.4161/cc.22589; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; Chen ZS, 2011, FEBS J, V278, P3226, DOI 10.1111/j.1742-4658.2011.08235.x; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Gitenay D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.63; Gitenay D, 2014, ONCOTARGET, V5, P5845, DOI 10.18632/oncotarget.2286; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henderson MJ, 2011, J NATL CANCER I, V103, P1236, DOI 10.1093/jnci/djr256; Humbert N, 2010, EMBO J, V29, P376, DOI 10.1038/emboj.2009.342; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Lallet-Daher H, 2013, CANCER RES, V73, P5253, DOI 10.1158/0008-5472.CAN-12-3690; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Nelson DM, 2014, AGE, V36, P1049, DOI 10.1007/s11357-014-9637-0; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Van De Wetering K, 2009, GASTROENTEROLOGY, V137, P1725, DOI 10.1053/j.gastro.2009.06.052; Vindrieux D, 2013, CANCER RES, V73, P6334, DOI 10.1158/0008-5472.CAN-13-0318; Wiel C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.382; Wiel C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4792; Zelcer N, 2006, J HEPATOL, V44, P768, DOI 10.1016/j.jhep.2005.07.022; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	34	3	3	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1596	1601		10.1038/onc.2015.218	http://dx.doi.org/10.1038/onc.2015.218			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073088				2022-12-28	WOS:000373063600012
J	Berbegall, AP; Villamon, E; Piqueras, M; Tadeo, I; Djos, A; Ambros, PF; Martinsson, T; Ambros, IM; Canete, A; Castel, V; Navarro, S; Noguera, R				Berbegall, A. P.; Villamon, E.; Piqueras, M.; Tadeo, I.; Djos, A.; Ambros, P. F.; Martinsson, T.; Ambros, I. M.; Canete, A.; Castel, V.; Navarro, S.; Noguera, R.			Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors	ONCOGENE			English	Article							COPY-NUMBER; METASTATIC NEUROBLASTOMA; INTEGRATIVE GENOMICS; 17Q GAIN; AMPLIFICATION; SURVIVAL; RISK; IDENTIFICATION; EXPRESSION; PHENOTYPE	Intratumoral heterogeneous MYCN amplification (hetMNA) is an unusual event in neuroblastoma with unascertained biological and clinical implications. Diagnosis is based on the detection of MYCN amplification surrounded by non-amplified tumor cells by fluorescence in situ hybridization (FISH). To better define the genetic features of hetMNA tumors, we studied the Spanish cohort of neuroblastic tumors by FISH and single nucleotide polymorphism arrays. We compared hetMNA tumors with homogeneous MNA (homMNA) and nonMNA tumors with 11q deletion (nonMNA w11q-). Of 1091 primary tumors, 28 were hetMNA by FISH. Intratumoral heterogeneity of 1p, 2p, 11q and 17q was closely associated with hetMNA tumors when analyzing different pieces for each case. For chromosome 2, 16 cases showed 2p intact, 4 focal gain at 2p24.3 and 8 MNA. The lengths of the smallest regions of overlap (SROs) for 2p gains and 1p deletions were between the SRO lengths observed in homMNA and nonMNA w11q- tumors. Co-occurrence of 11q- and +17q was frequently found with the largest SROs for both aberrations. The evidence for and frequency of different genetic subpopulations representing a hallmark of the hetMNA subgroup of NB indicates, on one hand, the presence of a considerable genetic instability with different SRO of either gains and losses compared with those of the other NB groups and highlights and, on the other hand, the need for multiple sampling from distant and macroscopically and microscopically distinct tumor areas. Narrowing down the different SRO for both deletions and gains in NB groups would be crucial to pinpointing the candidate gene(s) and the critical gene dosage with prognostic and therapeutic significance. This complexity of segmental chromosomal aberration patterns reinforces the necessity for a larger cohort study using FISH and pangenomic techniques to develop a suitable therapeutic strategy for these patients.	[Berbegall, A. P.; Villamon, E.; Piqueras, M.; Tadeo, I.; Navarro, S.; Noguera, R.] Univ Valencia, Med Res Fdn, INCLIVA, Pathol Dept,Med Sch, Valencia, Spain; [Djos, A.; Martinsson, T.] Univ Gothenburg, Sahlgrenska Acad, Dept Med & Clin Genet, Gothenburg, Sweden; [Ambros, P. F.; Ambros, I. M.] St Anna Kinderkrebsforschung, Childrens Canc Res Inst, Vienna, Austria; [Ambros, P. F.; Canete, A.; Castel, V.] Hosp Univ & Politecn La Fe, Pediat Oncol Unit, Valencia, Spain	University of Valencia; University of Gothenburg; Saint Anna Children's Hospital; Hospital Universitari i Politecnic La Fe	Noguera, R (corresponding author), Univ Valencia, Sch Med, Dept Pathol, INCLIVA, Avda Blasco Ibanez 15, Valencia 46010, Spain.	rosa.noguera@uv.es	Tadeo, Irene/M-1639-2016; Piqueras, Marta/ABH-1866-2020; Ambros, Peter/AAA-1266-2021; Berbegall, Ana/AAB-2258-2020; canete, adela/G-5903-2016; Navarro, Samuel/AAD-2021-2020; Martinsson, Tommy/J-4140-2013; Cañete, Adela/ABG-7558-2020	Tadeo, Irene/0000-0003-3690-5007; Piqueras, Marta/0000-0002-3748-7444; Ambros, Peter/0000-0002-5507-7211; Berbegall, Ana/0000-0002-8798-3286; canete, adela/0000-0002-5669-5097; Navarro, Samuel/0000-0001-5016-5653; Martinsson, Tommy/0000-0002-9403-3123; Djos, Anna/0000-0002-5250-2163; Castel, Victoria/0000-0002-3792-0615; Villamon, Eva/0000-0003-0636-3358	FIS [PI10/15]; RTICC, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation & European Regional Development Fund [RD12/36/20, RD06/20/102]	FIS(Instituto de Salud Carlos III); RTICC, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation & European Regional Development Fund	Spanish Society of Hematology and Pediatric Oncology and Desiree Ramal (Pediatric Oncology Unit, Hospital Universitario y Politecnico La Fe, Valencia, Spain) are gratefully acknowledged for patient data management. We thank members of the International Society of Pediatric Oncology Europe Neuroblastoma Biology Group for validation of the genetic diagnosis. We also thank David Harrison for English language editing. This work was supported by FIS (contract PI10/15) and RTICC (contracts RD12/36/20 and RD06/20/102), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation & European Regional Development Fund.	Ambros IM, 2003, J CLIN ONCOL, V21, P2077, DOI 10.1200/JCO.2003.03.025; Ambros IM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00202; Ambros IM, 2011, CLIN CANCER RES, V17, P792, DOI 10.1158/1078-0432.CCR-10-0830; Ambros PF, 2009, BRIT J CANCER, V100, P1471, DOI 10.1038/sj.bjc.6605014; Ambros PF, 2001, MED PEDIATR ONCOL, V36, P1; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Barone G, 2013, CLIN CANCER RES, V19, P5814, DOI 10.1158/1078-0432.CCR-13-0680; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bishop MW, 2014, J PEDIAT HEMATOL ONC, V36, pE31, DOI 10.1097/MPH.0b013e3182847376; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2002, MED PEDIATR ONCOL, V38, P112, DOI 10.1002/mpo.1282.abs; Brodeur GM, 2002, J PEDIAT HEMATOL ONC, V24, P608, DOI 10.1097/00043426-200211000-00002; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Canete A, 2009, J CLIN ONCOL, V27, P1014, DOI 10.1200/JCO.2007.14.5839; Capasso M, 2010, CANCER TREAT RES, V155, P65, DOI 10.1007/978-1-4419-6033-7_4; Caren H, 2010, P NATL ACAD SCI USA, V107, P4323, DOI 10.1073/pnas.0910684107; Cetinkaya C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-231; Coco S, 2012, INT J CANCER, V131, P1591, DOI 10.1002/ijc.27432; Fix A, 2004, GENE CHROMOSOME CANC, V40, P266, DOI 10.1002/gcc.20041; Fix A, 2008, GENE CHROMOSOME CANC, V47, P819, DOI 10.1002/gcc.20583; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; Guimier A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101990; Kerbl R, 2002, MED PEDIATR ONCOL, V38, P109, DOI 10.1002/mpo.1281.abs; Kumps C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052321; Lastowska M, 2007, ONCOGENE, V26, P7432, DOI 10.1038/sj.onc.1210552; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lundberg G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059268; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Matthay KK, 2003, J CLIN ONCOL, V21, P2486, DOI 10.1200/JCO.2003.09.122; Morowitz M, 2003, MODERN PATHOL, V16, P1248, DOI 10.1097/01.MP.0000097364.64566.81; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; Piqueras M, 2011, BRIT J CANCER, V105, P89, DOI 10.1038/bjc.2011.188; Santo EE, 2012, ONCOGENE, V31, P1571, DOI 10.1038/onc.2011.344; Schleiermacher G, 2007, BRIT J CANCER, V97, P238, DOI 10.1038/sj.bjc.6603820; Schleiermacher G, 2012, BRIT J CANCER, V107, P1418, DOI 10.1038/bjc.2012.375; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Speleman F, 2011, SEMIN CANCER BIOL, V21, P238, DOI 10.1016/j.semcancer.2011.07.003; Spitz R, 2004, EUR J CANCER, V40, P2753, DOI 10.1016/j.ejca.2004.05.002; Squire, 1996, Mol Diagn, V1, P281, DOI 10.1016/S1084-8592(96)70010-3; Theissen J, 2014, GENE CHROMOSOME CANC, V53, P639, DOI 10.1002/gcc.22174; Theissen J, 2009, CLIN CANCER RES, V15, P2085, DOI 10.1158/1078-0432.CCR-08-1648; Thorner PS, 2006, AM J SURG PATHOL, V30, P635, DOI 10.1097/01.pas.0000202163.82525.5c; Valent A, 2004, CANCER GENET CYTOGEN, V153, P10, DOI 10.1016/j.cancergencyto.2003.12.007; Vandesompele J, 2008, INT J CANCER, V122, P1177, DOI 10.1002/ijc.23156; Villamon E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053740; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Westermark UK, 2011, SEMIN CANCER BIOL, V21, P256, DOI 10.1016/j.semcancer.2011.08.001; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306	50	20	20	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1423	1432		10.1038/onc.2015.200	http://dx.doi.org/10.1038/onc.2015.200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26119945				2022-12-28	WOS:000372196400008
J	Hawkins, ED; Oliaro, J; Ramsbottom, KM; Newbold, A; Humbert, PO; Johnstone, RW; Russell, SM				Hawkins, E. D.; Oliaro, J.; Ramsbottom, K. M.; Newbold, A.; Humbert, P. O.; Johnstone, R. W.; Russell, S. M.			Scribble acts as an oncogene in E mu-myc-driven lymphoma	ONCOGENE			English	Article							ASYMMETRIC CELL-DIVISION; PROMOTES MAMMARY TUMORIGENESIS; POLARITY PROTEIN SCRIBBLE; TRANSGENIC MICE; SELF-RENEWAL; C-MYC; DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; BREAST-CANCER; PAR COMPLEX	Scribble complex proteins maintain apicobasal polarity, regulate cell fate determination and function as tumour suppressors in epithelial tissue. Despite evidence that the function of Scribble is maintained in the lymphocyte lineage, we still understand little about its role as a tumour suppressor in haematological malignancies. Using the E mu-myc model of Burkitt's lymphoma we investigated the role of Scribble in lymphomagenesis. We found that contrary to its well-documented tumour suppressor role in epithelial tissue, loss of Scribble expression delayed the expansion of peripheral B cells and delayed the onset of E mu-myc-driven lymphoma. This was despite upregulated ERK phosphorylation levels in Scribble-deficient tumours, which are associated with loss of Scribble expression and the development of more aggressive Burkitt's lymphoma. Interestingly, the developmental stage of lymphoma was unaffected by Scribble expression challenging any role for Scribble in fate determination in the haematopoetic lineage. These data provide evidence for oncogenic properties of Scribble in Myc-driven B-cell lymphomagenesis, reinforcing recent findings that overexpression of a mutant form of Scribble can act as an oncogene in epithelial cells. Our results support the growing appreciation that the tumour regulatory functions of Scribble, and other polarity protein family members, are context dependent.	[Hawkins, E. D.; Oliaro, J.; Ramsbottom, K. M.; Newbold, A.; Johnstone, R. W.; Russell, S. M.] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia; [Hawkins, E. D.; Oliaro, J.; Ramsbottom, K. M.; Newbold, A.; Humbert, P. O.; Johnstone, R. W.; Russell, S. M.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Newbold, A.; Johnstone, R. W.] Peter MacCallum Canc Ctr, Canc Therapeut Programs, Melbourne, Vic, Australia; [Humbert, P. O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic, Australia; [Humbert, P. O.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Humbert, P. O.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Humbert, P. O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic, Australia; [Russell, S. M.] Swinburne Univ Technol, Ctr Microphoton, Hawthorn, Vic 3122, Australia; [Hawkins, E. D.] Univ London Imperial Coll Sci Technol & Med, Sir Alexander Fleming Bldg, London SW7 2AZ, England	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Peter Maccallum Cancer Center; Swinburne University of Technology; Imperial College London	Hawkins, ED (corresponding author), Univ London Imperial Coll Sci Technol & Med, Cell & Mol Biol, Sir Alexander Fleming Bldg,Imperial Coll Rd, London SW7 2AZ, England.; Russell, SM (corresponding author), Peter MacCallum Canc Ctr, Immune Signalling Lab, Canc Immunol, St Andrews Pl, East Melbourne, Vic 3002, Australia.	e.hawkins@imperial.ac.uk; Sarah.Russell@petermac.org	Russell, Sarah M/B-9341-2009; Johnstone, Ricky w/H-3748-2014; Humbert, Patrick O/L-4264-2016	Russell, Sarah M/0000-0001-5826-9641; Johnstone, Ricky w/0000-0001-7053-9237; Humbert, Patrick O/0000-0002-1366-6691; Oliaro, Jane/0000-0002-2097-6428; Hawkins, Edwin/0000-0002-3686-8261	Australian National Health and Medical Research Council (NHRMC); Human Frontiers Science Program; Australian Research Council (ARC); Australian Cancer Research Foundation (ACRF, ACRF Cell Biology Program)	Australian National Health and Medical Research Council (NHRMC)(National Health and Medical Research Council (NHMRC) of Australia); Human Frontiers Science Program(Human Frontier Science Program); Australian Research Council (ARC)(Australian Research Council); Australian Cancer Research Foundation (ACRF, ACRF Cell Biology Program)	This work was funded by the Australian National Health and Medical Research Council (NHRMC, project grants and fellowships to EDH, JO, SMR, POH, RWJ), the Human Frontiers Science Program, the Australian Research Council (ARC, fellowship to SMR) and the Australian Cancer Research Foundation (ACRF, ACRF Cell Biology Program).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; ALEXANDER WS, 1989, ONCOGENE, V4, P575; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Ellenbroek SIJ, 2012, SEMIN CANCER BIOL, V22, P208, DOI 10.1016/j.semcancer.2012.02.012; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Feigin ME, 2014, CANCER RES, V74, P3180, DOI 10.1158/0008-5472.CAN-13-3415; Florian MC, 2010, STEM CELLS, V28, P1623, DOI 10.1002/stem.481; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Godde NJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004323; Gramling MW, 2012, CELL DEATH DIFFER, V19, P1220, DOI 10.1038/cdd.2012.1; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hawkins ED, 2008, ONCOGENE, V27, P7003, DOI 10.1038/onc.2008.350; Hawkins ED, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087376; Hawkins ED, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2796; Humphries LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045276; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Oliaro J, 2010, J IMMUNOL, V185, P367, DOI 10.4049/jimmunol.0903627; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Pike KA, 2011, P NATL ACAD SCI USA, V108, P1116, DOI 10.1073/pnas.1018224108; Powell AE, 2010, STEM CELL RES, V4, P3, DOI 10.1016/j.scr.2009.09.005; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Sandoval GJ, 2013, CANCER IMMUNOL RES, V1, P426, DOI 10.1158/2326-6066.CIR-13-0065; Ting SB, 2012, BLOOD, V119, P2510, DOI 10.1182/blood-2011-11-393272; Vaira V, 2012, ONCOGENE, V31, P27, DOI 10.1038/onc.2011.209; Wirtz-Peitz F, 2008, CELL, V135, P161, DOI 10.1016/j.cell.2008.07.049; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Young LC, 2013, MOL CELL, V52, P679, DOI 10.1016/j.molcel.2013.10.004; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	48	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1193	1197		10.1038/onc.2015.167	http://dx.doi.org/10.1038/onc.2015.167			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982280				2022-12-28	WOS:000371351700013
J	Song, CL; Tang, H; Ran, LK; Ko, BCB; Zhang, ZZ; Chen, X; Ren, JH; Tao, NN; Li, WY; Huang, AL; Chen, J				Song, C-L; Tang, H.; Ran, L-K; Ko, B. C. B.; Zhang, Z-Z; Chen, X.; Ren, J-H; Tao, N-N; Li, W-Y; Huang, A-L; Chen, J.			Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3 beta/BCL2-associated X protein-dependent apoptotic pathway	ONCOGENE			English	Article							PROMOTES DNA-REPAIR; OXIDATIVE STRESS; CELL-DEATH; MITOCHONDRIAL-DNA; BREAST-CANCER; EXPRESSION; METABOLISM; ACTIVATION; BAX; DEACETYLATION	SIRT3 is a class III histone deacetylase that has been implicated in a variety of cancers. The role of SIRT3 in hepatocellular carcinoma (HCC) remains elusive. In this study, we found that SIRT3 expression was frequently repressed in HCC and its downregulation was closely associated with tumor grade and size. Ectopic expression of SIRT3 inhibited cell growth and induced apoptosis in HCC cells, whereas depletion of SIRT3 in immortalized hepatocyte promoted cell growth and decreased epirubicin-induced apoptosis. Mechanistic studies revealed that SIRT3 deacetylated and activated glycogen synthase kinase-3 beta (GSK-3 beta), which subsequently induced expression and mitochondrial translocation of the pro-apoptotic protein BCL2-associated X protein (Bax) to promote apoptosis. GSK-3 beta inhibitor or gene silencing of BAX reversed SIRT3-induced growth inhibition and apoptosis. Furthermore, SIRT3 overexpression also suppressed tumor growth in vivo. Together, this study reveals a role of SIRT3/GSK-3 beta/Bax signaling pathway in the suppression of HCC growth, and also suggests that targeting this pathway may represent a potential therapeutic approach for HCC treatment.	[Song, C-L; Tang, H.; Ran, L-K; Chen, X.; Ren, J-H; Tao, N-N; Li, W-Y; Huang, A-L; Chen, J.] Chongqing Med Univ, Chinese Minist Educ, Affiliated Hosp 2, Chongqing 400016, Peoples R China; [Song, C-L; Tang, H.; Ran, L-K; Chen, X.; Ren, J-H; Tao, N-N; Li, W-Y; Huang, A-L; Chen, J.] Chongqing Med Univ, Chinese Minist Educ, Key Lab Mol Biol Infect Dis Designated, Chongqing 400016, Peoples R China; [Ko, B. C. B.] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; [Ko, B. C. B.] Hong Kong Polytech Univ, State Key Lab Chirosci, Hong Kong, Hong Kong, Peoples R China; [Zhang, Z-Z] Chongqing Med Univ, Childrens Hosp, Dept Infect Dis, Chongqing, Peoples R China; [Huang, A-L] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China	Chongqing Medical University; Chongqing Medical University; Hong Kong Polytechnic University; Hong Kong Polytechnic University; Chongqing Medical University; Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases; Zhejiang University	Huang, AL; Chen, J (corresponding author), Chongqing Med Univ, Chinese Minist Educ, Affiliated Hosp 2, Chongqing 400016, Peoples R China.; Huang, AL; Chen, J (corresponding author), Chongqing Med Univ, Chinese Minist Educ, Key Lab Mol Biol Infect Dis Designated, Chongqing 400016, Peoples R China.	yixin_xinyuan@163.com; ahuang1964@163.com	Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899	National Natural Science Foundation of China [81201282]; National Science and Technology Major Project [2013ZX10002002]; Chongqing Natural Science Foundation [cstc2012jjA10047]; Ministry of Education of China [20125503120004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project; Chongqing Natural Science Foundation(Natural Science Foundation of Chongqing); Ministry of Education of China(Ministry of Education, China)	This study was supported by the National Natural Science Foundation of China (81201282), the National Science and Technology Major Project (2013ZX10002002), the Chongqing Natural Science Foundation (cstc2012jjA10047) and the PhD program through the Ministry of Education of China (Program 20125503120004).	Alhazzazi TY, 2011, BBA-REV CANCER, V1816, P80, DOI 10.1016/j.bbcan.2011.04.004; Alhazzazi TY, 2011, CANCER-AM CANCER SOC, V117, P1670, DOI 10.1002/cncr.25676; Allison SJ, 2007, CELL CYCLE, V6, P2669, DOI 10.4161/cc.6.21.4866; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Byun HO, 2012, EXP CELL RES, V318, P1808, DOI 10.1016/j.yexcr.2012.04.012; Chen J, 2013, HEPATOLOGY, V57, P2287, DOI 10.1002/hep.26278; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.254; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; D'Aquila P, 2012, GENE, V497, P323, DOI 10.1016/j.gene.2012.01.042; Ding J, 2014, CANCER LETT, V346, P17, DOI 10.1016/j.canlet.2013.12.024; Elangovan S, 2011, CANCER RES, V71, P6654, DOI 10.1158/0008-5472.CAN-11-1446; Fabregat I, 2007, LIVER INT, V27, P155, DOI 10.1111/j.1478-3231.2006.01409.x; Fabregat I, 2009, WORLD J GASTROENTERO, V15, P513, DOI 10.3748/wjg.15.513; Giralt A, 2012, BIOCHEM J, V444, P1, DOI 10.1042/BJ20120030; Hall JA, 2013, J CLIN INVEST, V123, P973, DOI 10.1172/JCI64094; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Hori YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073875; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Knight JRP, 2012, CURR OPIN ONCOL, V24, P68, DOI 10.1097/CCO.0b013e32834d813b; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Marfe G, 2009, J CELL BIOCHEM, V106, P643, DOI 10.1002/jcb.22044; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Monteserin-Garcia J, 2013, FASEB J, V27, P1561, DOI 10.1096/fj.12-220129; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Sundaresan NR, 2008, MOL CELL BIOL, V28, P6384, DOI 10.1128/MCB.00426-08; Wang JX, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-297; Westphal D, 2011, BBA-MOL CELL RES, V1813, P521, DOI 10.1016/j.bbamcr.2010.12.019; Zhang CZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051703; Zhang LL, 2010, J CELL PHYSIOL, V224, P218, DOI 10.1002/jcp.22123; Zhao Y, 2013, ANN DIAGN PATHOL, V17, P483, DOI 10.1016/j.anndiagpath.2013.06.001	38	32	34	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					631	641		10.1038/onc.2015.121	http://dx.doi.org/10.1038/onc.2015.121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915842				2022-12-28	WOS:000369548800010
J	Elabd, S; Meroni, G; Blattner, C				Elabd, S.; Meroni, G.; Blattner, C.			TRIMming p53's anticancer activity	ONCOGENE			English	Review							PROMYELOCYTIC LEUKEMIA PROTEIN; RESPONSIVE FINGER PROTEIN; TELANGIECTASIA GROUP-D; BREAST-CANCER CELLS; UBIQUITIN LIGASE; TRIPARTITE-MOTIF; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; PREMATURE SENESCENCE; E3-UBIQUITIN LIGASE	Several TRIM proteins control abundance and activity of p53. Along this route, TRIM proteins have a serious impact on carcinogenesis and prognosis for cancer patients. In the past years, a significant increase has been made in our understanding of how the TRIM protein family controls p53 activity.	[Elabd, S.; Blattner, C.] Karlsruhe Inst Technol, Inst Toxicol & Genet, Karlsruhe, Germany; [Elabd, S.] Univ Alexandria, Med Res Inst, Dept Human Physiol, Alexandria, Egypt; [Meroni, G.] Univ Trieste, Dept Life Sci, Trieste, Italy	Helmholtz Association; Karlsruhe Institute of Technology; Egyptian Knowledge Bank (EKB); Alexandria University; University of Trieste	Blattner, C (corresponding author), Karlsruhe Inst Technol, Inst Toxicol & Genet, POB 3640, CH-76021 Baden, Switzerland.	christine.blattner@kit.edu	Blattner, Christine/ABI-2152-2020; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273	FIRB-MIUR [RBAP11Z4Z9]; AFM-TELETHON [17746];  [COST-BM1307]	FIRB-MIUR(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); AFM-TELETHON(Association Francaise contre les Myopathies); 	CB and GM are supported by COST-BM1307. The work in GM's laboratory is funded by FIRB-MIUR Grant RBAP11Z4Z9 and AFM-TELETHON Grant 17746.	Addison JB, 2015, CANCER RES, V75, P344, DOI 10.1158/0008-5472.CAN-14-1561; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Alsheich-Bartok O, 2008, ONCOGENE, V27, P3653, DOI 10.1038/sj.onc.1211036; Battivelli E, 2011, J VIROL, V85, P7828, DOI 10.1128/JVI.00648-11; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Boehme KA, 2009, CRIT REV BIOCHEM MOL, V44, P367, DOI 10.3109/10409230903401507; Cambiaghi V, 2012, ADV EXP MED BIOL, V770, P77; Caratozzolo MF, 2014, ONCOTARGET, V5, P7446, DOI 10.18632/oncotarget.2081; Chen Y, 2015, ONCOTARGET, V6, P23708, DOI 10.18632/oncotarget.4291; Chu Y, 2011, ONCOGENE, V30, P1108, DOI 10.1038/onc.2010.462; Cui ZB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063887; Dahm-Daphi J, 2005, ONCOGENE, V24, P1663, DOI 10.1038/sj.onc.1208396; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Faesen AC, 2011, MOL CELL, V44, P147, DOI 10.1016/j.molcel.2011.06.034; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Ho J, 2009, J PROTEOME RES, V8, P583, DOI 10.1021/pr8007368; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Horn EJ, 2004, CARCINOGENESIS, V25, P157, DOI 10.1093/carcin/bgh003; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Jain AK, 2014, MOL CELL BIOL, V34, P2695, DOI 10.1128/MCB.01705-12; Joo HM, 2011, EUR J CELL BIOL, V90, P420, DOI 10.1016/j.ejcb.2010.12.001; Kano S, 2008, CANCER RES, V68, P5572, DOI 10.1158/0008-5472.CAN-07-6231; Kapanadze B, 1998, FEBS LETT, V426, P266, DOI 10.1016/S0014-5793(98)00357-3; KAPP LN, 1992, AM J HUM GENET, V51, P45; Kuboshima M, 2006, CANCER SCI, V97, P380, DOI 10.1111/j.1349-7006.2006.00192.x; Kung CP, 2015, MOL CANCER RES, V13, P250, DOI 10.1158/1541-7786.MCR-14-0385; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lerner M, 2007, MOL BIOL CELL, V18, P1670, DOI 10.1091/mbc.E06-03-0248; Li Q, 2011, ONCOGENE, V30, P1194, DOI 10.1038/onc.2010.499; Liu J, 2014, CELL DEATH DIFFER, V21, P1792, DOI 10.1038/cdd.2014.121; Liu L, 2013, CANCER EPIDEMIOL, V37, P71, DOI 10.1016/j.canep.2012.08.005; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Masuda Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8299; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nisole S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00125; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413; Qin Y., 2015, TECHNOL CANC RES TRE; Reddy BA, 2014, MOL CELL, V53, P458, DOI 10.1016/j.molcel.2013.12.017; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rokudai S, 2013, P NATL ACAD SCI USA, V110, P3895, DOI 10.1073/pnas.1300490110; Sakuma M, 2005, GYNECOL ONCOL, V99, P664, DOI 10.1016/j.ygyno.2005.07.103; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Sho T, 2011, BBA-MOL CELL RES, V1813, P1245, DOI 10.1016/j.bbamcr.2011.03.018; Short KM, 2006, J BIOL CHEM, V281, P8970, DOI 10.1074/jbc.M512755200; Sun Y, 2013, BIOCHEM BIOPH RES CO, V441, P600, DOI 10.1016/j.bbrc.2013.10.110; Suzuki T, 2005, CLIN CANCER RES, V11, P6148, DOI 10.1158/1078-0432.CCR-05-0040; Tanaka M, 2010, HISTOCHEM CELL BIOL, V133, P273, DOI 10.1007/s00418-009-0669-y; Tang ZP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063676; Tebaldi T, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1643-9; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vaseva AV, 2009, CELL CYCLE, V8, P1711, DOI 10.4161/cc.8.11.8596; Vincent SR, 2000, BIOCHEM BIOPH RES CO, V279, P482, DOI 10.1006/bbrc.2000.3984; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wittmann S, 2008, GENE CHROMOSOME CANC, V47, P386, DOI 10.1002/gcc.20544; Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478; Yang HB, 2015, J BIOL CHEM, V290, P27146, DOI 10.1074/jbc.M115.665489; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yuan ZG, 2010, MOL CELL BIOL, V30, P3004, DOI 10.1128/MCB.01023-09; Zhang LG, 2012, P NATL ACAD SCI USA, V109, P20931, DOI 10.1073/pnas.1212047110; Zhang P, 2015, ONCOGENE, V34, P5729, DOI 10.1038/onc.2015.21; Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	77	29	29	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5577	5584		10.1038/onc.2016.33	http://dx.doi.org/10.1038/onc.2016.33			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	26898759	Green Submitted			2022-12-28	WOS:000386998300001
J	O'Connor, C; Lohan, F; Campos, J; Ohlsson, E; Salome, M; Forde, C; Artschwager, R; Liskamp, RM; Cahill, MR; Kiely, PA; Porse, B; Keeshan, K				O'Connor, C.; Lohan, F.; Campos, J.; Ohlsson, E.; Salome, Mara; Forde, C.; Artschwager, R.; Liskamp, R. M.; Cahill, M. R.; Kiely, P. A.; Porse, B.; Keeshan, K.			The presence of C/EBP alpha and its degradation are both required for TRIB2-mediated leukaemia	ONCOGENE			English	Article							BINDING-PROTEIN-ALPHA; CEBPA; MUTATIONS; TRIB2; EXPRESSION; C/EBP-ALPHA-P-30; PROTEASOME; COOPERATE; ABSENCE; COP1	C/EBP alpha (p42 and p30 isoforms) is commonly dysregulated in cancer via the action of oncogenes, and specifically in acute myeloid leukaemia (AML) by mutation. Elevated TRIB2 leads to the degradation of C/EBP alpha p42, leaving p30 intact in AML. Whether this relationship is a cooperative event in AML transformation is not known and the molecular mechanism involved remains elusive. Using mouse genetics, our data reveal that in the complete absence of C/EBP alpha, TRIB2 was unable to induce AML. Only in the presence of C/EBP alpha p42 and p30, were TRIB2 and p30 able to cooperate to decrease the latency of disease. We demonstrate that the molecular mechanism involved in the degradation of C/EBP alpha p42 requires site-specific direct interaction between TRIB2 and C/EBP alpha p42 for the K48-specific ubiquitin-dependent proteasomal degradation of C/EBP alpha p42. This interaction and ubiquitination is dependent on a critical C terminal lysine residue on C/EBP alpha. We show effective targeting of this pathway pharmacologically using proteasome inhibitors in TRIB2-positive AML cells. Together, our data show that excess p30 cooperated with TRIB2 only in the presence of p42 to accelerate AML, and the direct interaction and degradation of C/EBP alpha p42 is required for TRIB2-mediated AML.	[O'Connor, C.; Lohan, F.; Campos, J.; Salome, Mara; Keeshan, K.] Univ Glasgow, Inst Canc Sci, Paul OGorman Leukaemia Res Ctr, 21 Shelley Rd, Glasgow G12 0XB, Lanark, Scotland; [Ohlsson, E.; Porse, B.] Univ Copenhagen, Fac Hlth Sci, Rigshosp, Finsen Lab, Copenhagen, Denmark; [Ohlsson, E.; Porse, B.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Ohlsson, E.; Porse, B.] Univ Copenhagen, Fac Hlth Sci, Danish Stem Cell Ctr DanStem, Copenhagen, Denmark; [Forde, C.] Univ Coll Cork, Cork, Ireland; [Artschwager, R.; Liskamp, R. M.] Univ Glasgow, Sch Chem, Glasgow, Lanark, Scotland; [Cahill, M. R.] Cork Univ Hosp, Dept Haematol, Cork, Ireland; [Kiely, P. A.] Univ Limerick, Dept Life Sci, Mat & Surface Sci Inst, Limerick, Ireland; [Kiely, P. A.] Univ Limerick, Stokes Inst, Limerick, Ireland	University of Glasgow; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; University College Cork; University of Glasgow; University College Cork; University of Limerick; University of Limerick	Keeshan, K (corresponding author), Univ Glasgow, Inst Canc Sci, Paul OGorman Leukaemia Res Ctr, 21 Shelley Rd, Glasgow G12 0XB, Lanark, Scotland.	Karen.keeshan@glasgow.ac.uk	Keeshan, Karen/L-5615-2013; Salomé, Mara/I-9423-2018; Liskamp, Rob M/I-5889-2012	Keeshan, Karen/0000-0001-7266-0890; Salomé, Mara/0000-0003-3267-650X; Liskamp, Rob M/0000-0001-8897-8975; Porse, Bo/0000-0001-6043-0844; Cahill, Mary R/0000-0002-1655-3078; O'Connor, Caitriona/0000-0002-7638-9804	Kay Kendall foundation [KKL501]; Howat foundation; Cancer UK; Childrens Leukaemia Research Project grant; Science Foundation Ireland Infrastructure award; Mid-Western Cancer Foundation; centre grant from the NovoNordisk Foundation (The Novo Nordisk Foundation Section for Stem Cell Biology in Human Disease); Novo Nordisk Foundation Section for Basic Stem Cell Biology [Porse group] Funding Source: researchfish	Kay Kendall foundation; Howat foundation; Cancer UK; Childrens Leukaemia Research Project grant; Science Foundation Ireland Infrastructure award(Science Foundation Ireland); Mid-Western Cancer Foundation; centre grant from the NovoNordisk Foundation (The Novo Nordisk Foundation Section for Stem Cell Biology in Human Disease); Novo Nordisk Foundation Section for Basic Stem Cell Biology	We thank all the technical staff at the Paul O'Gorman Leukaemia Research Centre. We thank the Cancer Research UK Glasgow Centre (C596/A18076) and the Biological Service Unit facilities at the Cancer Research UK Beatson Institute (C596/A17196) and the Biological Services at the University of Glasgow. We thank Ruaidhri Carmody for reagents and critical review of the work. We thank the Kay Kendall foundation (KKL501) and the Howat foundation for Flow cytometry facility funding. Work in the Keeshan lab was supported by the Howat Foundation and Children with Cancer UK. CO'C was supported by Childrens Leukaemia Research Project grant. PK was supported by Science Foundation Ireland Infrastructure award and the Mid-Western Cancer Foundation. Work in the Porse lab was supported by a centre grant from the NovoNordisk Foundation (The Novo Nordisk Foundation Section for Stem Cell Biology in Human Disease).	Andreu-Vieyra C, 2014, EXPERT OPIN BIOL TH, V14, P1685, DOI 10.1517/14712598.2014.953050; Annamaneni S, 2014, HEMATOLOGY, V19, P42, DOI 10.1179/1607845413Y.0000000081; Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Bereshchenko O, 2009, CANCER CELL, V16, P390, DOI 10.1016/j.ccr.2009.09.036; Brouwer AJ, 2012, J MED CHEM, V55, P10995, DOI 10.1021/jm301443r; Carnicer MJ, 2008, ANN HEMATOL, V87, P819, DOI 10.1007/s00277-008-0528-2; Colleran A, 2013, P NATL ACAD SCI USA, V110, P618, DOI 10.1073/pnas.1208446110; Collins C, 2014, P NATL ACAD SCI USA, V111, P9899, DOI 10.1073/pnas.1402238111; Fasan A, 2014, LEUKEMIA, V28, P794, DOI 10.1038/leu.2013.273; Fasan A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054365; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Friedman AD, 2015, INT J HEMATOL, V101, P330, DOI 10.1007/s12185-015-1764-6; Geletu M, 2007, BLOOD, V110, P3301, DOI 10.1182/blood-2007-01-071035; Grandinetti KB, 2011, ONCOGENE, V14, P1; Hasemann MS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004079; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; Keeshan K, 2008, BLOOD CELL MOL DIS, V40, P119, DOI 10.1016/j.bcmd.2007.06.005; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Keeshan K, 2010, BLOOD, V116, P4948, DOI 10.1182/blood-2009-10-247361; Kirstetter P, 2008, CANCER CELL, V13, P299, DOI 10.1016/j.ccr.2008.02.008; Leroy H, 2005, LEUKEMIA, V19, P329, DOI 10.1038/sj.leu.2403614; Mancini E, 2011, EMBO J, V8, P1; Ohlsson E, 2014, J EXP MED, V211, P5, DOI 10.1084/jem.20130932; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2008, J CLIN ONCOL, V26, P5088, DOI 10.1200/JCO.2008.16.5563; Paz-Priel Ido, 2011, Critical Reviews in Oncogenesis, V16, P93; Pulikkan JA, 2010, LEUKEMIA, V24, P914, DOI 10.1038/leu.2010.37; Quintana-Bustamante O, 2012, LEUKEMIA, V26, P1537, DOI 10.1038/leu.2012.38; Rishi L, 2014, BLOOD, V123, P2389, DOI 10.1182/blood-2013-07-511683; Taskesen E, 2011, BLOOD, V117, P2469, DOI 10.1182/blood-2010-09-307280; Trivedi AK, 2007, ONCOGENE, V26, P1789, DOI 10.1038/sj.onc.1209964; Wagner K, 2006, P NATL ACAD SCI USA, V103, P6338, DOI 10.1073/pnas.0508143103; Wouters BJ, 2007, BLOOD, V110, P3706, DOI 10.1182/blood-2007-02-073486; Xu SS, 2014, FEBS LETT, V588, P4334, DOI 10.1016/j.febslet.2014.09.042; Ye M, 2013, NAT CELL BIOL, V15, P385, DOI 10.1038/ncb2698; Yokoyama T, 2012, BLOOD, V119, P2608, DOI 10.1182/blood-2010-12-324806; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006	38	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5272	5281		10.1038/onc.2016.66	http://dx.doi.org/10.1038/onc.2016.66			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26996668	Green Submitted, Green Accepted			2022-12-28	WOS:000386053000006
J	Jubierre, L; Soriano, A; Planells-Ferrer, L; Paris-Coderch, L; Tenbaum, SP; Romero, OA; Moubarak, RS; Almazan-Moga, A; Molist, C; Roma, J; Navarro, S; Noguera, R; Sanchez-Cespedes, M; Comella, JX; Palmer, HG; de Toledo, JS; Gallego, S; Segura, MF				Jubierre, L.; Soriano, A.; Planells-Ferrer, L.; Paris-Coderch, L.; Tenbaum, S. P.; Romero, O. A.; Moubarak, R. S.; Almazan-Moga, A.; Molist, C.; Roma, J.; Navarro, S.; Noguera, R.; Sanchez-Cespedes, M.; Comella, J. X.; Palmer, H. G.; Sanchez de Toledo, J.; Gallego, S.; Segura, M. F.			BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways	ONCOGENE			English	Article							SWI/SNF COMPLEX; DNA METHYLATION; BRG1 EXPRESSION; INHIBITION; VORINOSTAT; TRIAL; WIDE; PROLIFERATION; CHEMOTHERAPY; TARGETS	Neuroblastoma (NB) is a neoplasm of the sympathetic nervous system, and is the most common solid tumor of infancy. NBs are very heterogeneous, with a clinical course ranging from spontaneous regression to resistance to all current forms of treatment. High-risk patients need intense chemotherapy, and only 30-40% will be cured. Relapsed or metastatic tumors acquire multi-drug resistance, raising the need for alternative treatments. Owing to the diverse mechanisms that are responsible of NB chemoresistance, we aimed to target epigenetic factors that control multiple pathways to bypass therapy resistance. We found that the SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 (SMARCA4/BRG1) was consistently upregulated in advanced stages of NB, with high BRG1 levels being indicative of poor outcome. Loss-of-function experiments in vitro and in vivo showed that BRG1 is essential for the proliferation of NB cells. Furthermore, whole-genome transcriptome analysis revealed that BRG1 controls the expression of key elements of oncogenic pathways such as PI3K/AKT and BCL2, which offers a promising new combination therapy for high-risk NB.	[Jubierre, L.; Soriano, A.; Paris-Coderch, L.; Almazan-Moga, A.; Molist, C.; Roma, J.; Sanchez de Toledo, J.; Gallego, S.; Segura, M. F.] UAB, Lab Translat Res Child & Adolescent Canc, VHIR, Passeig Vall dHebron 119-129, Barcelona 08035, Spain; [Planells-Ferrer, L.; Moubarak, R. S.; Sanchez-Cespedes, M.; Comella, J. X.] UAB, Cell Signaling & Apoptosis Grp, VHIR, Barcelona, Spain; [Tenbaum, S. P.; Palmer, H. G.] VHIO, Stem Cell & Canc Lab, Barcelona, Spain; [Romero, O. A.] Bellvitge Biomed Res Inst IDIBELL Barcelona, Epigenet & Canc Biol Program PEBC, Barcelona, Spain; [Navarro, S.; Noguera, R.] Univ Valencia, Sch Med, Valencia, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Valencia	Segura, MF (corresponding author), UAB, Lab Translat Res Child & Adolescent Canc, VHIR, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	miguel.segura@vhir.org	Gallego, Soledad/ABI-1334-2020; Palmer, Héctor G./AAG-8332-2019; Segura, Miguel F/J-4749-2013; Soriano, Aroa/J-9105-2016; Jubierre Zapater, Luz/ABD-7848-2021; Comella, Joan/GQA-4279-2022; Romero, Octavio A./AAA-8078-2020; Navarro, Samuel/AAD-2021-2020	Segura, Miguel F/0000-0003-0916-3618; Soriano, Aroa/0000-0001-9659-1471; Jubierre Zapater, Luz/0000-0001-9934-1590; Romero, Octavio A./0000-0003-0229-6530; Navarro, Samuel/0000-0001-5016-5653; Palmer, Hector/0000-0002-9823-5638; Roma, Josep/0000-0001-7692-6123; Gallego, Soledad/0000-0002-4712-9624; Paris Coderch, Laia/0000-0003-2145-5752; Moubarak, Rana/0000-0003-2096-1258	Instituto de Salud Carlos III [CP11/00052, RD12/0036/0016, RD12/0036/0020, RD12/0036/0045, RD12/0036/0012]; European Regional Development Fund (ERDF); Generalitat de Catalunya [2014-SGR-660]; Marie Curie Career Integration Grants	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund (ERDF)(European Commission); Generalitat de Catalunya(Generalitat de Catalunya); Marie Curie Career Integration Grants	We thank members of the Genomics Facility, Statitstics and Bioinformatic Unit, Pathology Laboratory and the Animal Core Facilities of the Vall d'Hebron Research Institute. We thank Dr Mireia Dunac, Dr Jose R Bayascas and Dr Diego Arango for precious advice. We thank Ms Christine O'Hara for text correction. This work was supported by the Instituto de Salud Carlos III (CP11/00052, RD12/0036/0016, RD12/0036/0020, RD12/0036/0045, RD12/0036/0012) co-financed by the European Regional Development Fund (ERDF), Generalitat de Catalunya 2014-SGR-660 and Marie Curie Career Integration Grants.	Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Bai J, 2012, J CANCER RES CLIN, V138, P991, DOI 10.1007/s00432-012-1172-8; Bender A, 2011, ONCOGENE, V30, P494, DOI 10.1038/onc.2010.429; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; Buckley PG, 2011, INT J CANCER, V128, P2296, DOI 10.1002/ijc.25584; Burke MJ, 2014, AM J HEMATOL, V89, P889, DOI 10.1002/ajh.23778; Buscarlet M, 2014, BLOOD, V123, P1720, DOI 10.1182/blood-2013-02-483495; Charlet J, 2012, BIOCHEM PHARMACOL, V83, P858, DOI 10.1016/j.bcp.2012.01.009; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Fouladi M, 2010, J CLIN ONCOL, V28, P3623, DOI 10.1200/JCO.2009.25.9119; Grau E, 2010, J CANCER RES CLIN, V136, P1415, DOI 10.1007/s00432-010-0796-9; Hummel TR, 2013, PEDIATR BLOOD CANCER, V60, P1452, DOI 10.1002/pbc.24541; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irwin MS, 2015, PEDIATR CLIN N AM, V62, P225, DOI 10.1016/j.pcl.2014.09.015; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Keshelava N, 1998, CANCER RES, V58, P5396; Kumar HR, 2008, PEDIATR SURG INT, V24, P1229, DOI 10.1007/s00383-008-2245-2; Lamers F, 2012, EUR J CANCER, V48, P3093, DOI 10.1016/j.ejca.2012.01.037; Li Yan, 2006, Zhonghua Nan Ke Xue, V12, P629; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Liu XR, 2014, EUR J CANCER, V50, P2251, DOI 10.1016/j.ejca.2014.05.017; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Numata M, 2013, INT J ONCOL, V42, P403, DOI 10.3892/ijo.2012.1723; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Opel D, 2011, CLIN CANCER RES, V17, P3233, DOI 10.1158/1078-0432.CCR-10-2530; Popovic R, 2012, CANCER DISCOV, V2, P405, DOI 10.1158/2159-8290.CD-12-0076; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Romero OA, 2012, EMBO MOL MED, V4, P603, DOI 10.1002/emmm.201200236; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Su JM, 2011, CLIN CANCER RES, V17, P589, DOI 10.1158/1078-0432.CCR-10-0738; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Watanabe T, 2011, BRIT J CANCER, V104, P146, DOI 10.1038/sj.bjc.6606018; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Wyce A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072967; Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Yuste VJ, 2001, J BIOL CHEM, V276, P22323, DOI 10.1074/jbc.M100072200; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	55	49	51	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5179	5190		10.1038/onc.2016.50	http://dx.doi.org/10.1038/onc.2016.50			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26996667				2022-12-28	WOS:000384433000009
J	Sakurai, T; Isogaya, K; Sakai, S; Morikawa, M; Morishita, Y; Ehata, S; Miyazono, K; Koinuma, D				Sakurai, T.; Isogaya, K.; Sakai, S.; Morikawa, M.; Morishita, Y.; Ehata, S.; Miyazono, K.; Koinuma, D.			RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma	ONCOGENE			English	Article							FACTOR-BETA; MESENCHYMAL TRANSITION; EXPRESSION; DEGRADATION; LIGASE; RBM47	RNA-binding proteins provide a new layer of posttranscriptional regulation of RNA during cancer progression. We identified RNA-binding motif protein 47 (RBM47) as a target gene of transforming growth factor (TGF)-beta in mammary gland epithelial cells (NMuMG cells) that have undergone the epithelial-to-mesenchymal transition. TGF-beta repressed RBM47 expression in NMuMG cells and lung cancer cell lines. Expression of RBM47 correlated with good prognosis in patients with lung, breast and gastric cancer. RBM47 suppressed the expression of cell metabolism-related genes, which were the direct targets of nuclear factor erythroid 2-related factor 2 (Nrf2; also known as NFE2L2). RBM47 bound to KEAP1 and Cullin 3 mRNAs, and knockdown of RBM47 inhibited their protein expression, which led to enhanced binding of Nrf2 to target genomic regions. Knockdown of RBM47 also enhanced the expression of some Nrf2 activators, p21/CDKN1A and MafK induced by TGF-beta. Both mitochondrial respiration rates and the side population cells in lung cancer cells increased in the absence of RBM47. Our findings, together with the enhanced tumor formation and metastasis of xenografted mice by knockdown of the RBM47 expression, suggested tumor-suppressive roles for RBM47 through the inhibition of Nrf2 activity.	[Sakurai, T.; Isogaya, K.; Sakai, S.; Morishita, Y.; Ehata, S.; Miyazono, K.; Koinuma, D.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; [Morikawa, M.] Uppsala Univ, Ludwig Inst Canc Res, Sci Life Lab, Uppsala, Sweden	University of Tokyo; Ludwig Institute for Cancer Research; Uppsala University	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Koinuma, Daizo/Y-8716-2018; Morikawa, Masato/D-1932-2011	Koinuma, Daizo/0000-0001-5611-2122; Morikawa, Masato/0000-0002-6191-7176; Ehata, Shogo/0000-0002-6740-9391	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [22112002, 15K06831, 15H05774, 24890039]; Japan Agency for Medical Research and Development (AMED) [15ak0101001h0005]; Kanae Foundation for Research Abroad; Japan Society for the Promotion of Science (JSPS); ITO Genboku and SAGARA Chian Memorial Scholarship; Grants-in-Aid for Scientific Research [15K08393, 15H05774, 22112002] Funding Source: KAKEN	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Kanae Foundation for Research Abroad; Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); ITO Genboku and SAGARA Chian Memorial Scholarship; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr Hiroyuki Aburatani, Shuichi Tsutsumi and Aya Nonaka (The University of Tokyo) for the ChIP-seq data and advice regarding RIP-seq analysis, and to Dr Hiroyuki Suzuki (Tsukuba University) for discussion and advice. We also thank Akiyoshi Komuro for a lentiviral luciferase expression plasmid and Keiko Yuki for technical assistance, and members of the Miyazono laboratory for discussion and advice. This work was supported by KAKENHI grants-in-aid for scientific research in Innovative Area (Integrative Research on Cancer Microenvironment Network, (22112002) to KM), Scientific Research (C) ((15K06831) to DK) and (S) ((15H05774) to KM), a Research Activity Start-up grant ((24890039), KI) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); and a grant from the Japan Agency for Medical Research and Development (AMED) (15ak0101001h0005 to DK). This study was performed as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), AMED; MM is supported by the Kanae Foundation for Research Abroad and the ITO Genboku and SAGARA Chian Memorial Scholarship; TS is supported by a grant from the Japan Society for the Promotion of Science (JSPS).	Arase M, 2014, CANCER SCI, V105, P974, DOI 10.1111/cas.12454; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Fossat N, 2014, EMBO REP, V15, P903, DOI 10.15252/embr.201438450; Guan R, 2013, DEV DYNAM, V242, P1395, DOI 10.1002/dvdy.24039; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hast BE, 2014, CANCER RES, V74, P808, DOI 10.1158/0008-5472.CAN-13-1655; Hayes JD, 2012, CELL METAB, V16, P139, DOI 10.1016/j.cmet.2012.07.009; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Isogaya K, 2014, CELL RES, V24, P994, DOI 10.1038/cr.2014.97; Katayama R, 2009, CANCER SCI, V100, P2060, DOI 10.1111/j.1349-7006.2009.01288.x; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Koinuma D, 2011, J BIOL CHEM, V286, P32502, DOI 10.1074/jbc.M111.227561; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Mizutani A, 2011, J BIOL CHEM, V286, P29848, DOI 10.1074/jbc.M110.217745; Morikawa M, 2013, ONCOGENE, V32, P1609, DOI 10.1038/onc.2012.191; Okita Y, 2013, J BIOL CHEM, V288, P20658, DOI 10.1074/jbc.M113.450478; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Petit V, 2009, J MOL BIOL, V385, P65, DOI 10.1016/j.jmb.2008.10.043; Ray D, 2013, NATURE, V499, P172, DOI 10.1038/nature12311; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Saito RA, 2009, CANCER RES, V69, P2783, DOI 10.1158/0008-5472.CAN-08-3490; Shirai Y, 2011, AM J PATHOL, V179, P2920, DOI 10.1016/j.ajpath.2011.08.022; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Singh A, 2006, AM J RESP CELL MOL, V35, P639, DOI 10.1165/rcmb.2005-0325OC; Singh A, 2009, FREE RADICAL BIO MED, V46, P376, DOI 10.1016/j.freeradbiomed.2008.10.026; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sung JM, 2008, BIOCHEM BIOPH RES CO, V371, P163, DOI 10.1016/j.bbrc.2008.04.038; Valdmanis PN, 2015, ONCOGENE, V34, P94, DOI 10.1038/onc.2013.523; Vanharanta S, 2014, ELIFE, V3, DOI 10.7554/eLife.02734; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Yeganeh M, 2013, MOL BIOL REP, V40, P4391, DOI 10.1007/s11033-013-2528-0; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589	39	41	41	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5000	5009		10.1038/onc.2016.35	http://dx.doi.org/10.1038/onc.2016.35			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26923328	hybrid, Green Published			2022-12-28	WOS:000383965300004
J	Anadon, C; Guil, S; Simo-Riudalbas, L; Moutinho, C; Setien, F; Martinez-Cardus, A; Moran, S; Villanueva, A; Calaf, M; Vidal, A; Lazo, PA; Zondervan, I; Savola, S; Kohno, T; Yokota, J; de Pouplana, LR; Esteller, M				Anadon, C.; Guil, S.; Simo-Riudalbas, L.; Moutinho, C.; Setien, F.; Martinez-Cardus, A.; Moran, S.; Villanueva, A.; Calaf, M.; Vidal, A.; Lazo, P. A.; Zondervan, I.; Savola, S.; Kohno, T.; Yokota, J.; Ribas de Pouplana, L.; Esteller, M.			Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CANCER; TRANSCRIPTOME; SITES; CELLS	The introduction of new therapies against particular genetic mutations in non-small-cell lung cancer is a promising avenue for improving patient survival, but the target population is small. There is a need to discover new potential actionable genetic lesions, to which end, non-conventional cancer pathways, such as RNA editing, are worth exploring. Herein we show that the adenosine-to-inosine editing enzyme ADAR1 undergoes gene amplification in non-small cancer cell lines and primary tumors in association with higher levels of the corresponding mRNA and protein. From a growth and invasion standpoint, the depletion of ADAR1 expression in amplified cells reduces their tumorigenic potential in cell culture and mouse models, whereas its overexpression has the opposite effects. From a functional perspective, ADAR1 overexpression enhances the editing frequencies of target transcripts such as NEIL1 and miR-381. In the clinical setting, patients with early-stage lung cancer, but harboring ADAR1 gene amplification, have poor outcomes. Overall, our results indicate a role for ADAR1 as a lung cancer oncogene undergoing gene amplification-associated activation that affects downstream RNA editing patterns and patient prognosis.	[Anadon, C.; Guil, S.; Simo-Riudalbas, L.; Moutinho, C.; Setien, F.; Martinez-Cardus, A.; Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain; [Villanueva, A.; Calaf, M.] IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona, Catalonia, Spain; [Vidal, A.] Bellvitge Unvivers Hosp, Dept Pathol Anat, Barcelona, Catalonia, Spain; [Lazo, P. A.] Univ Salamanca, Expt Therapeut & Translat Oncol Program, Inst Biol Mol & Celular Canc, CSIC, Salamanca, Spain; [Lazo, P. A.] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Zondervan, I.; Savola, S.] MRC Holland, Amsterdam, Netherlands; [Kohno, T.; Yokota, J.] Natl Canc Ctr, Res Inst, Div Genome Biol, Tokyo, Japan; [Yokota, J.] Inst Predict & Personalized Med Canc IMPPC, Genom & Epigen Canc Predict Program, Badalona, Catalonia, Spain; [Ribas de Pouplana, L.; Esteller, M.] IRB, C Baldiri Reixac 10, Barcelona 08028, Catalonia, Spain; [Ribas de Pouplana, L.] ICREA, Barcelona, Catalonia, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); National Cancer Center - Japan; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; University of Barcelona	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via Km 2-7, Barcelona 08908, Spain.	mesteller@idibell.cat	Guil, Sonia/M-8036-2015; Moran, Sebastian/G-5293-2013; Esteller, Manel/L-5956-2014; Lazo, Pedro A./M-6435-2014; Vidal, August/N-4662-2016; Martinez, Anna/AAA-4939-2020	Guil, Sonia/0000-0002-2257-3331; Moran, Sebastian/0000-0003-4192-8983; Esteller, Manel/0000-0003-4490-6093; Lazo, Pedro A./0000-0001-8997-3025; Vidal, August/0000-0001-5727-2099; Savola, Suvi/0000-0002-6221-8617; Anadon Galindo, Carmen Maria/0000-0002-8851-4545	European Research Council under the European Community's Seventh Framework Programme (FP7)/ERC [268626-EPINORC, HEALTH-F2-2010-258677-CURELUNG]; Spanish Ministry of Economy and Competitiveness (MINECO) [SAF2011-22803, PI13-01339, SAF2014-55000-R]; Institute of Health Carlos III (ISCIII) [PI10/02992]; Ministerio de Educacion, Ciencia e Innovacion [SAF2010-14935]; Cellex Foundation; National Cancer Center Research and Development Fund (NCC Biobank) [23 A-1]; Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR [2009SGR1315, 2014SGR633]; ICREA Funding Source: Custom	European Research Council under the European Community's Seventh Framework Programme (FP7)/ERC(European Research Council (ERC)); Spanish Ministry of Economy and Competitiveness (MINECO); Institute of Health Carlos III (ISCIII); Ministerio de Educacion, Ciencia e Innovacion; Cellex Foundation(Foundation CELLEX); National Cancer Center Research and Development Fund (NCC Biobank); Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR; ICREA(ICREA)	This work was supported by the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 268626-EPINORC project, the Grant agreement number HEALTH-F2-2010-258677-CURELUNG project, the Spanish Ministry of Economy and Competitiveness (MINECO Projects no. SAF2011-22803, PI13-01339 and SAF2014-55000-R), the Institute of Health Carlos III (ISCIII)-PI10/02992, Ministerio de Educacion, Ciencia e Innovacion Grant SAF2010-14935, the Cellex Foundation, the National Cancer Center Research and Development Fund (NCC Biobank: 23 A-1) and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR-project no. 2009SGR1315 and 2014SGR633. We thank the staff of the Animal Core Facility of IDIBELL for mouse care and maintenance. LRdP and ME are ICREA Research Professors.	Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Avesson L, 2014, BBA-REV CANCER, V1845, P308, DOI 10.1016/j.bbcan.2014.03.001; Bazak L, 2014, GENOME RES, V24, P365, DOI 10.1101/gr.164749.113; Buettner R, 2013, J CLIN ONCOL, V31, P1858, DOI 10.1200/JCO.2012.45.9867; Chan THM, 2014, GUT, V63, P832, DOI 10.1136/gutjnl-2012-304037; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; Daniel C, 2012, NUCLEIC ACIDS RES, V40, P9876, DOI 10.1093/nar/gks691; Desterro JMP, 2003, J CELL SCI, V116, P1805, DOI 10.1242/jcs.00371; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Jiang QF, 2013, P NATL ACAD SCI USA, V110, P1041, DOI 10.1073/pnas.1213021110; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Liu MM, 2013, MUTAT RES-FUND MOL M, V743, P4, DOI 10.1016/j.mrfmmm.2012.12.003; Peng ZY, 2012, NAT BIOTECHNOL, V30, P253, DOI 10.1038/nbt.2122; Qin YR, 2014, CANCER RES, V74, P840, DOI 10.1158/0008-5472.CAN-13-2545; Rommel PC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069208; Sakurai M, 2014, GENOME RES, V24, P522, DOI 10.1101/gr.162537.113; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Shoshan E, 2015, NAT CELL BIOL, V17, P311, DOI 10.1038/ncb3110; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Skalsky RL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024248; Wang ZY, 2015, ONCOTARGET, V6, P3147, DOI 10.18632/oncotarget.3061; Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530; Yeo JC, 2010, P NATL ACAD SCI USA, V107, P20715, DOI 10.1073/pnas.1009231107	23	59	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4407	4413		10.1038/onc.2015.469	http://dx.doi.org/10.1038/onc.2015.469			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26640150	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000382152100012
J	Grun, D; Adhikary, G; Eckert, RL				Grun, D.; Adhikary, G.; Eckert, R. L.			VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR NEUROPILIN-1; SKIN-CANCER; ANGIOGENESIS; EXPRESSION; OVEREXPRESSION; PROMOTE; PROGRESSION; ACTIVATION; INDUCTION	We identify a limited subpopulation of epidermal cancer stem cells (ECS cells), in squamous cell carcinoma, that form rapidly growing, invasive and highly vascularized tumors, as compared with non-stem cancer cells. These ECS cells grow as non-attached spheroids, and display enhanced migration and invasion. We show that ECS cell-produced vascular endothelial growth factor (VEGF)-A is required for the maintenance of this phenotype, as knockdown of VEGF-A gene expression or treatment with VEGF-A-inactivating antibody reduces these responses. In addition, treatment with bevacizumab reduces tumor vascularity and growth. Surprisingly, the classical mechanism of VEGF-A action via interaction with VEGF receptors does not mediate these events, as these cells lack VEGFR1 and VEGFR2. Instead, VEGF-A acts via the neuropilin-1 (NRP-1) co-receptor. Knockdown of NRP-1 inhibits ECS cell spheroid formation, invasion and migration, and attenuates tumor formation. These studies suggest that VEGF-A acts via interaction with NRP-1 to trigger intracellular events leading to ECS cell survival and formation of aggressive, invasive and highly vascularized tumors.	[Grun, D.; Adhikary, G.; Eckert, R. L.] Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA; [Grun, D.; Adhikary, G.; Eckert, R. L.] Univ Maryland, Sch Med, Dept Mol Biol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Reprod Biol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Marlene, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Stewart Greenebaum Canc, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Eckert, RL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 North Greene St,Rm 103, Baltimore, MD 21201 USA.	reckert@umaryland.edu		Grun, Daniel/0000-0003-4261-7765	Maryland Stem Cell Research Foundation; National Institutes of Health [CA131074, CA184027]; pilot grant from Greenebaum Cancer Center [P30 CA134274]; NATIONAL CANCER INSTITUTE [P30CA134274, R01CA131074, R01CA211909, R01CA184027] Funding Source: NIH RePORTER	Maryland Stem Cell Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); pilot grant from Greenebaum Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Maryland Stem Cell Research Foundation (RLE) and the National Institutes of Health (RLE - CA131074, CA184027) and a pilot grant from the Greenebaum Cancer Center (P30 CA134274).	Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Bachelder RE, 2001, CANCER RES, V61, P5736; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bickers DR, 2006, J AM ACAD DERMATOL, V55, P490, DOI 10.1016/j.jaad.2006.05.048; Borriello L, 2014, CANCER LETT, V349, P120, DOI 10.1016/j.canlet.2014.04.004; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Casanova ML, 2002, CANCER RES, V62, P3402; Chew YC, 2013, J BIOL CHEM, V288, P17759, DOI 10.1074/jbc.M113.477133; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013; Eckert RL, 2013, BBA-GEN SUBJECTS, V1830, P2427, DOI 10.1016/j.bbagen.2012.07.002; Folkman J, 1992, Semin Cancer Biol, V3, P65; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Gray MJ, 2005, CANCER RES, V65, P3664, DOI 10.1158/0008-5472.CAN-04-2229; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Jarvis A, 2010, J MED CHEM, V53, P2215, DOI 10.1021/jm901755g; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Johnson KE, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/483439; Kawakami T, 2002, CANCER, V95, P2196, DOI 10.1002/cncr.10936; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Lampropoulou A, 2014, BIOCHEM SOC T, V42, P1623, DOI 10.1042/BST20140244; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Li M, 2004, CANCER-AM CANCER SOC, V101, P2341, DOI 10.1002/cncr.20634; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Linde N, 2012, J PATHOL, V227, P17, DOI 10.1002/path.3989; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Man XY, 2006, MOL MED, V12, P127, DOI 10.2119/2006-00024.Man; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; Nissen JC, 2013, J NEUROCHEM, V127, P394, DOI 10.1111/jnc.12404; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560; Pincelli C, 2010, J CELL PHYSIOL, V225, P310, DOI 10.1002/jcp.22275; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Rogers HW, 2010, ARCH DERMATOL, V146, P283, DOI 10.1001/archdermatol.2010.19; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; Vanveldhuizen PJ, 2003, ONCOL REP, V10, P1067; Wilgus TA, 2005, AM J PATHOL, V167, P1257, DOI 10.1016/S0002-9440(10)61213-8; Yang XH, 2006, BIOCHEM BIOPH RES CO, V349, P31, DOI 10.1016/j.bbrc.2006.07.213; Zhao Y, 2011, INT J DEV BIOL, V55, P477, DOI 10.1387/ijdb.103225yz; Zhu JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055463; Zhu JW, 2012, INT J BIOCHEM CELL B, V44, P246, DOI 10.1016/j.biocel.2011.10.022	56	52	55	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4379	4387		10.1038/onc.2015.507	http://dx.doi.org/10.1038/onc.2015.507			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26804163	Green Accepted			2022-12-28	WOS:000382152100009
J	Kawatsuki, A; Yasunaga, J; Mitobe, Y; Green, PL; Matsuoka, M				Kawatsuki, A.; Yasunaga, J-i; Mitobe, Y.; Green, P. L.; Matsuoka, M.			HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4(+) T cells	ONCOGENE			English	Article							RETINOBLASTOMA PROTEIN; MOLECULAR-MECHANISMS; TAX; P53; DEGRADATION; GENE; RNA; HBZ; E2F; REPLICATION	Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus that induces a fatal T-cell malignancy, adult T-cell leukemia (ATL). Among several regulatory/accessory genes in HTLV-1, HTLV-1 bZIP factor (HBZ) is the only viral gene constitutively expressed in infected cells. Our previous study showed that HBZ functions in two different molecular forms, HBZ protein and HBZ RNA. In this study, we show that HBZ protein targets retinoblastoma protein (Rb), which is a critical tumor suppressor in many types of cancers. HBZ protein interacts with the Rb/E2F-1 complex and activates the transcription of E2F-target genes associated with cell cycle progression and apoptosis. Mouse primary CD4(+) T cells transduced with HBZ show accelerated G1/S transition and apoptosis, and importantly, T cells from HBZ transgenic (HBZ-Tg) mice also demonstrate enhanced cell proliferation and apoptosis. To evaluate the functions of HBZ protein alone in vivo, we generated a new transgenic mouse strain that expresses HBZ mRNA altered by silent mutations but encoding intact protein. In these mice, the numbers of effector/memory and Foxp3(+) T cells were increased, and genes associated with proliferation and apoptosis were upregulated. This study shows that HBZ protein promotes cell proliferation and apoptosis in primary CD4(+) T cells through activation of the Rb/E2F pathway, and that HBZ protein also confers onto CD4(+) T-cell immunophenotype similar to those of ATL cells, suggesting that HBZ protein has important roles in dysregulation of CD4(+) T cells infected with HTLV-1.	[Kawatsuki, A.; Yasunaga, J-i; Mitobe, Y.; Matsuoka, M.] Kyoto Univ, Inst Virus Res, Lab Virus Control, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan; [Green, P. L.] Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; [Green, P. L.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Green, P. L.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Kyoto University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Yasunaga, J (corresponding author), Kyoto Univ, Inst Virus Res, Lab Virus Control, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	jyasunag@virus.kyoto-u.ac.jp		Matsuoka, Masao/0000-0002-0473-754X; Mitobe, Yuichi/0000-0001-5200-5362	Ministry of Education, Science, Sports and Culture of Japan [22114003, 26460554]; Takeda Science Foundation; National Institutes of Health [CA100730]; JSPS Core-to-Core Program A, Advanced Research Networks; NATIONAL CANCER INSTITUTE [P01CA100730] Funding Source: NIH RePORTER	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JSPS Core-to-Core Program A, Advanced Research Networks(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Linda Kingsbury and Kathleen Hayes-Ozello for editorial comments and proofreading. This study was supported by grants from the Ministry of Education, Science, Sports and Culture of Japan to MM (22114003) and JY (26460554) and a grant from the Takeda Science Foundation (JY) and a grant from the National Institutes of Health (CA100730) to PLG. This study was performed as a research program of the Platform for Dynamic Approaches to Living System from the Ministry of Education, Culture, Sports, Science and Technology, Japan (AK), and also supported in part by the JSPS Core-to-Core Program A, Advanced Research Networks.	Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286; Arpin-Andre C, 2014, PLASMID, V74, P45, DOI 10.1016/j.plasmid.2014.06.001; Borchert S, 2014, J VIROL, V88, P3144, DOI 10.1128/JVI.02916-13; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Boyer SN, 1996, CANCER RES, V56, P4620; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Davidson W, 2008, CELL CYCLE, V7, P1224, DOI 10.4161/cc.7.9.5786; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fan J, 2010, J VIROL, V84, P7278, DOI 10.1128/JVI.02239-09; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Gillet NA, 2011, BLOOD, V117, P3113, DOI 10.1182/blood-2010-10-312926; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; KATOH T, 1986, INT J CANCER, V38, P265, DOI 10.1002/ijc.2910380218; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Knight JS, 2005, P NATL ACAD SCI USA, V102, P18562, DOI 10.1073/pnas.0503886102; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Matsuoka M, 2013, CURR OPIN VIROL, V3, P684, DOI 10.1016/j.coviro.2013.08.010; Melamed A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003271; Mitobe Y, 2015, CANCER RES, V75, P4143, DOI 10.1158/0008-5472.CAN-15-0942; Munakata T, 2007, PLOS PATHOG, V3, P1335, DOI 10.1371/journal.ppat.0030139; Peloponese JM, 2009, J VIROL, V83, P3238, DOI 10.1128/JVI.01824-08; Philip S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004040; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Satou Yorifumi, 2012, Leuk Res Treatment, V2012, P213653, DOI 10.1155/2012/213653; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Sawada S, 1998, J EXP MED, V187, P1439, DOI 10.1084/jem.187.9.1439; Swaims AY, 2010, BLOOD, V116, P2994, DOI 10.1182/blood-2009-07-231050; Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vernin C, 2014, CANCER RES, V74, P6082, DOI 10.1158/0008-5472.CAN-13-3564; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamamoto-Taguchi N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003630; Yasunaga J, 2011, INT J HEMATOL, V94, P435, DOI 10.1007/s12185-011-0937-1; Yoshida M, 2008, J VIROL, V82, P9359, DOI 10.1128/JVI.00242-08; Zhao TJ, 2011, BLOOD, V118, P1865, DOI 10.1182/blood-2010-12-326199; Zhao T, 2009, BLOOD, V113, P2755, DOI 10.1182/blood-2008-06-161729	40	18	19	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4509	4517		10.1038/onc.2015.510	http://dx.doi.org/10.1038/onc.2015.510			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804169	Green Accepted			2022-12-28	WOS:000382153100008
J	Peixoto, P; Blomme, A; Costanza, B; Ronca, R; Rezzola, S; Palacios, AP; Schoysman, L; Boutry, S; Goffart, N; Peulen, O; Maris, P; Di Valentin, E; Hennequiere, V; Bianchi, E; Henry, A; Meunier, P; Rogister, B; Muller, RN; Delvenne, P; Bellahcene, A; Castronovo, V; Turtoi, A				Peixoto, P.; Blomme, A.; Costanza, B.; Ronca, R.; Rezzola, S.; Palacios, A. P.; Schoysman, L.; Boutry, S.; Goffart, N.; Peulen, O.; Maris, P.; Di Valentin, E.; Hennequiere, V.; Bianchi, E.; Henry, A.; Meunier, P.; Rogister, B.; Muller, R. N.; Delvenne, P.; Bellahcene, A.; Castronovo, V.; Turtoi, A.			HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE GENES; NF-KAPPA-B; INTRATUMORAL HETEROGENEITY; TUMOR; CANCER; BRAIN; AMPLIFICATION; ANGIOGENESIS	To date, the mutational status of EGFR and PTEN has been shown as relevant for favoring pro-or anti-tumor functions of STAT3 in human glioblastoma multiforme (GBM). We have screened genomic data from 154 patients and have identified a strong positive correlation between STAT3 and HDAC7 expression. In the current work we show the existence of a subpopulation of patients overexpressing HDAC7 and STAT3 that has particularly poor clinical outcome. Surprisingly, the somatic mutation rate of both STAT3 and HDAC7 was insignificant in GBM comparing with EGFR, PTEN or TP53. Depletion of HDAC7 in a range of GBM cells induced the expression of tyrosine kinase JAK1 and the tumor suppressor AKAP12. Both proteins synergistically sustained the activity of STAT3 by inducing its phosphorylation (JAK1) and protein expression (AKAP12). In absence of HDAC7, activated STAT3 was responsible for significant imbalance of secreted pro-/anti-angiogenic factors. This inhibited the migration and sprouting of endothelial cells in paracrine fashion in vitro as well as angiogenesis in vivo. In a murine model of GBM, induced HDAC7-silencing decreased the tumor burden by threefold. The current data show for the first time that silencing HDAC7 can reset the tumor suppressor activity of STAT3, independently of the EGFR/PTEN/TP53 background of the GBM. This effect could be exploited to overcome tumor heterogeneity and provide a new rationale behind the development of specific HDAC7 inhibitors for clinical use.	[Peixoto, P.; Blomme, A.; Costanza, B.; Palacios, A. P.; Peulen, O.; Maris, P.; Hennequiere, V.; Henry, A.; Bellahcene, A.; Castronovo, V.; Turtoi, A.] Univ Liege, GIGA Canc, Metastasis Res Lab, Ave Hop 3,Tour Patho 4, B-4000 Liege, Belgium; [Ronca, R.; Rezzola, S.] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Schoysman, L.; Meunier, P.] Univ Hosp Liege, Dept Radiol, Liege, Belgium; [Boutry, S.; Muller, R. N.] Univ Mons, Dept Gen Organ & Biomed Chem, NMR & Mol Imaging Lab, Mons, Belgium; [Boutry, S.; Muller, R. N.] Ctr Microscopy & Mol Imaging, Charleroi, Belgium; [Goffart, N.; Rogister, B.] Univ Liege, GIGA Neurosci, Liege, Belgium; [Di Valentin, E.] Univ Liege, GIGA Viral Vectors Platform, Liege, Belgium; [Bianchi, E.; Delvenne, P.] Univ Hosp Liege, Dept Pathol, Liege, Belgium	University of Liege; University of Brescia; University of Liege; University of Mons; University of Liege; University of Liege; University of Liege	Turtoi, A (corresponding author), Univ Liege, GIGA Canc, Metastasis Res Lab, Ave Hop 3,Tour Patho 4, B-4000 Liege, Belgium.	a.turtoi@ulg.ac.be	Maris, Pamela/ABG-2488-2021; Rogister, Bernard/AAJ-9591-2020; Rezzola, Sara/AAA-2745-2019; Ronca, Roberto/AAC-6470-2022; Turtoi, Andrei/ABD-1271-2021; Blomme, Arnaud/AAM-1440-2020; Blomme, Arnaud/AGO-7915-2022; Rezzola, Sara/AAE-8980-2020; Peulen, Olivier/C-1250-2018	Rezzola, Sara/0000-0003-1193-8929; Ronca, Roberto/0000-0001-8979-7068; Turtoi, Andrei/0000-0003-3813-6635; Blomme, Arnaud/0000-0003-4183-8726; Peulen, Olivier/0000-0002-6933-0134; Costanza, Brunella/0000-0001-8279-805X; Di Valentin, Emmanuel/0000-0002-5287-7950; Maris, Pamela/0000-0002-4471-9717; Peixoto, Paul/0000-0001-6302-7823	University of Liege (Concerted Research Action Program (IDEA project)); National Fund for Scientific Research (FNRS/TELEVIE); European Regional Development Fund and Wallonia	University of Liege (Concerted Research Action Program (IDEA project)); National Fund for Scientific Research (FNRS/TELEVIE)(Fonds de la Recherche Scientifique - FNRS); European Regional Development Fund and Wallonia	The authors acknowledge the experimental support of Dr Chantal Humblet and Ms Alice Marquet (GIGA-histology platform, ULg), Dr Sandra Ormenese (GIGA-imaging platform, ULg) as well as of Evgenia Turtoi (Metastasis Research Laboratory) for the immunohistochemistry analysis and of Naima Maloujahmoum (Metastasis Research Laboratory) for the cell culture. The authors are also thankful to Dr Stephanie Gofflot from the institutional Biobank of the University Hospital Liege for providing GBM fresh tissues and to Dr Gilles Doumont (group of Prof Serge Goldman, Universite libre de Bruxelles) for help with animal experiments. The authors are grateful to Ms. Ana Turtoi for proofreading the manuscript. The results shown in this work are in part based on data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This work was supported with grants from the University of Liege (Concerted Research Action Program (IDEA project)) and from the National Fund for Scientific Research (FNRS/TELEVIE). Andrei Turtoi is a post-doctoral research fellow (FNRS/TELEVIE) and Akeila Bellahcene is a senior research associate (FNRS). Arnaud Blomme is a post-doctoral research fellow (FNRS/TELEVIE). The Center for Microscopy and Molecular Imaging (CMMI) is supported by the European Regional Development Fund and Wallonia. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atkinson GP, 2010, EXPERT REV NEUROTHER, V10, P575, DOI [10.1586/ern.10.21, 10.1586/ERN.10.21]; Bezecny P, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0985-5; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; de la Iglesia N, 2008, J NEUROSCI, V28, P5870, DOI 10.1523/JNEUROSCI.5385-07.2008; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gelman IH, 2012, CANCER METAST REV, V31, P493, DOI 10.1007/s10555-012-9360-1; Goeppert B, 2013, J NEUROPATH EXP NEUR, V72, P933, DOI 10.1097/NEN.0b013e3182a59a88; Hamer PCDW, 2010, NEURO-ONCOLOGY, V12, P304, DOI 10.1093/neuonc/nop068; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Inda MD, 2014, CANCERS, V6, P226, DOI 10.3390/cancers6010226; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Little SE, 2012, CANCER RES, V72, P1614, DOI 10.1158/0008-5472.CAN-11-4069; Lokker NA, 2002, CANCER RES, V62, P3729; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Schneller D, 2011, HEPATOLOGY, V54, P164, DOI 10.1002/hep.24329; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Su B, 2013, ONCOGENE, V32, P2016, DOI 10.1038/onc.2012.218; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Talasila KM, 2013, ACTA NEUROPATHOL, V125, P683, DOI 10.1007/s00401-013-1101-1; Turtoi Andrei, 2015, Critical Reviews in Oncogenesis, V20, P119; Turtoi A, 2015, B CANCER, V102, P17, DOI 10.1016/j.bulcan.2014.12.006; Turtoi A, 2012, ANGIOGENESIS, V15, P543, DOI 10.1007/s10456-012-9279-8; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wheeler SE, 2010, ONCOGENE, V29, P5135, DOI 10.1038/onc.2009.279; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166	47	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4481	4494		10.1038/onc.2015.506	http://dx.doi.org/10.1038/onc.2015.506			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26853466				2022-12-28	WOS:000382153100006
J	Wang, YC; Wang, SA; Chen, PH; Hsu, TI; Yang, WB; Chuang, YP; Su, WC; Liaw, HJ; Chang, WC; Hung, JJ				Wang, Y-C; Wang, S-A; Chen, P-H; Hsu, T-I; Yang, W-B; Chuang, Y-P; Su, W-C; Liaw, H-J; Chang, W-C; Hung, J-J			Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy	ONCOGENE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; RNA; METASTASIS; USP24; MDM2; STABILITY; SUV39H1; DISEASE	Ubiquitin is a critical modifier regulating the degradation and function of its target proteins during posttranslational modification. Here we found that ubiquitin-specific peptidase 24 (USP24) is highly expressed in cell lines with enhanced malignancy and in late-stage lung cancer clinical samples. Studying single-nucleotide polymorphisms (SNPs) of USP24 using genomic DNA of lung cancer patients revealed an increase in SNP 7656C/T. When using RNA specimens instead of the genomic DNA of lung cancer patients, we found significant increases in the ratios of variants 930C/T and 7656T/C, suggesting that variants at these two sites are not only caused by the SNP of DNA but also by the RNA editing. USP24-930T and USP24-7656C increase USP24 expression levels by increasing RNA stability. Knocking down USP24 increased Suv39h1 level through a decrease in mouse double-minute 2 homolog levels, thus enhancing lysine-9 methylation of histone H3, and resulting in the prevention of lung cancer malignancy. In conclusion, as USP24 variant analysis revealed a higher ratio of variants in blood specimens of lung cancer patients than that in normal individuals, USP24-930T and USP24-7656C might be useful as diagnostic markers for cancer detection.	[Wang, Y-C; Hung, J-J] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan, Taiwan; [Wang, S-A; Hsu, T-I; Yang, W-B; Hung, J-J] Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan, Taiwan; [Chen, P-H; Chuang, Y-P] Natl Cheng Kung Univ, Dept Pharmacol, Tainan, Taiwan; [Hsu, T-I; Hung, J-J] Natl Cheng Kung Univ, Ctr Infect Dis & Signal Transduct, Tainan, Taiwan; [Hsu, T-I] Taipei Med Univ, PhD Program Neural Regenerat Med, Taipei, Taiwan; [Su, W-C] Natl Cheng Kung Univ, Dept Internal Med, Coll Med & Hosp, Tainan, Taiwan; [Liaw, H-J] Natl Cheng Kung Univ, Dept Life Sci, Coll Biosci Biotechnol, Tainan, Taiwan; [Chang, W-C; Hung, J-J] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, 1 Univ Rd, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw	Hsu, Tsung-I/AAK-9942-2020; Yang, Wen-Bin/AAO-3593-2021; Liaw, Hungjiun/G-7034-2014	Hsu, Tsung-I/0000-0002-7524-7740; Yang, Wen-Bin/0000-0002-6497-4176; Liaw, Hungjiun/0000-0002-3481-709X; Wang, Yi-Chang/0000-0001-9346-5234; Su, Wu-Chou/0000-0003-2953-4105; Wang, Shao-an/0000-0002-5473-4195	National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; Ministry of Science and Technology, Taiwan [MOST 103-2320-B-006-035-MY3, MOST 103-2321-B-006-023-MY3]; National Research Program for Biopharmaceuticals of National Science Council, Taiwan	National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Research Program for Biopharmaceuticals of National Science Council, Taiwan	This work was supported by the National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers, together with grants MOST 103-2320-B-006-035-MY3 and MOST 103-2321-B-006-023-MY3 obtained from the Ministry of Science and Technology, Taiwan. In addition, we thank the Taiwan Lung Cancer Tissue/Specimen and Information Resource Center at National Health Research Institute (NHRI), Taiwan for blood samples' support. This Center was supported by grants from National Research Program for Biopharmaceuticals of National Science Council, Taiwan.	Avesson L, 2014, BBA-REV CANCER, V1845, P308, DOI 10.1016/j.bbcan.2014.03.001; Blanc V, 2010, WIRES SYST BIOL MED, V2, P594, DOI 10.1002/wsbm.82; Blons H, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-25; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; Chiba T, 2015, INT J CANCER, V136, P289, DOI 10.1002/ijc.28985; Das TK, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.34; Dominissini D, 2011, CARCINOGENESIS, V32, P1569, DOI 10.1093/carcin/bgr124; Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169; Torres AG, 2014, FEBS LETT, V588, P4279, DOI 10.1016/j.febslet.2014.09.025; Garg AV, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003699; Guo WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117075; Heideker J, 2015, BIOCHEM J, V467, P191, DOI 10.1042/bj4670191; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Katono K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121460; Khanal P, 2013, FASEB J, V27, P4606, DOI 10.1096/fj.13-236851; Kramer K, 2014, TISSUE ANTIGENS, V84, P370, DOI 10.1111/tan.12411; Li SM, 2014, J BIOL CHEM, V289, P34152, DOI 10.1074/jbc.M113.546077; Li YH, 2006, HUM MUTAT, V27, P1017, DOI 10.1002/humu.20382; Liu CC, 2014, NUCLEIC ACIDS RES, V42, P9543, DOI 10.1093/nar/gku675; Nagahara A, 2010, BIOCHEM BIOPH RES CO, V391, P1641, DOI 10.1016/j.bbrc.2009.12.105; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Ranaweera RS, 2013, J BIOL CHEM, V288, P18939, DOI 10.1074/jbc.M113.454470; Rebbani K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0340-2; Schmid F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-49; Sharma S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7881; Shi Dingding, 2012, Genes Cancer, V3, P240, DOI 10.1177/1947601912455199; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Tomaselli S, 2014, CELL TISSUE RES, V356, P527, DOI 10.1007/s00441-014-1863-3; Vage J, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-10; Villegas J, 2002, NUCLEIC ACIDS RES, V30, P1895, DOI 10.1093/nar/30.9.1895; Wang YQ, 2015, AUTOPHAGY, V11, P595, DOI 10.1080/15548627.2015.1034408; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Wu PC, 2014, CANCER RES, V74, P7333, DOI 10.1158/0008-5472.CAN-13-3572; Wu YR, 2010, CLIN CHIM ACTA, V411, P955, DOI 10.1016/j.cca.2010.03.013; Xu C, 2015, ONCOGENE, V34, P342, DOI 10.1038/onc.2013.557; Yanagisawa T, 2003, THEOR APPL GENET, V107, P84, DOI 10.1007/s00122-003-1235-y; Yang Y, 2015, ONCOGENE, V34, P104, DOI 10.1038/onc.2013.522; Zhang L, 2015, CELL REP, V10, P140, DOI 10.1016/j.celrep.2014.12.024; Zhang L, 2012, CELL CYCLE, V11, P4378, DOI 10.4161/cc.22688; Zhao B, 2012, EUR NEUROL, V68, P181, DOI 10.1159/000339641; Zhao GY, 2015, TUMOR BIOL, V36, P1721, DOI 10.1007/s13277-014-2773-4; Zou Q, 2014, NAT IMMUNOL, V15, P562, DOI 10.1038/ni.2885	42	11	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3669	3680		10.1038/onc.2015.432	http://dx.doi.org/10.1038/onc.2015.432			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26568301				2022-12-28	WOS:000379622800006
J	Alayev, A; Salamon, RS; Berger, SM; Schwartz, NS; Cuesta, R; Snyder, RB; Holz, MK				Alayev, A.; Salamon, R. S.; Berger, S. M.; Schwartz, N. S.; Cuesta, R.; Snyder, R. B.; Holz, M. K.			mTORC1 directly phosphorylates and activates ER alpha upon estrogen stimulation	ONCOGENE			English	Article							BREAST-CANCER; RECEPTOR-ALPHA; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOCRINE-THERAPY; RAPAMYCIN TOR; CELL-GROWTH; EVEROLIMUS; RAPTOR	Breast cancer is the leading cause of cancer-related deaths among women. Approximately 75% of breast cancers are estrogen receptor-alpha (ER alpha) positive, underscoring the dependence of cancer cells on estrogen for growth and survival. Patients treated with endocrine therapy often develop resistance, either de novo or acquired, which in some cases is caused by aberrations within the growth factor signaling pathways. The mechanistic target of rapamycin complex 1 (mTORC1) has emerged as a critical node in estrogenic signaling. We have previously shown that mTORC1 can phosphorylate and activate ER alpha on S167 via its effector-the 40S ribosomal S6 kinase 1 (S6K1). Presently, we have uncovered a direct link between mTORC1 and ER alpha. We found that ERa binds to regulatory-associated protein of mTOR (Raptor) and causes it to translocate to the nucleus upon estrogen stimulation. In addition, we identified mTOR as the kinase that phosphorylates ERa on S104/106 and activates transcription of ER target genes. Our findings show a direct link between mTORC1 and ER alpha, which further implicates mTORC1 signaling in the pathogenesis of ER-positive breast cancer and provides rationale for FDA-approved use of mTORC1 inhibitors in combination with endocrine agents for treatment of this disease.	[Alayev, A.; Salamon, R. S.; Berger, S. M.; Schwartz, N. S.; Cuesta, R.; Snyder, R. B.; Holz, M. K.] Yeshiva Univ, Dept Biol, 245 Lexington Ave Bio 341, New York, NY 10016 USA; [Holz, M. K.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; [Holz, M. K.] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA	Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Holz, MK (corresponding author), Yeshiva Univ, Dept Biol, 245 Lexington Ave Bio 341, New York, NY 10016 USA.	mholz@yu.edu			NIH [CA151112]; Atol Charitable Trust; LAM Foundation [098P0113]; American Cancer Society [RSG-13-287-01-TBE]; National Cancer Center; NATIONAL CANCER INSTITUTE [R15CA151112] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Atol Charitable Trust; LAM Foundation; American Cancer Society(American Cancer Society); National Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Jonathan M Backer (Albert Einstein College of Medicine) for his help with the kinase assay and Adi Berman for excellent technical assistance. This work was supported by the NIH-CA151112; Atol Charitable Trust; LAM Foundation-098P0113; American Cancer Society-RSG-13-287-01-TBE ( all to MKH) and National Cancer Center-no grant number (to AA).	Alayev A, 2013, J CELL PHYSIOL, V228, P1658, DOI 10.1002/jcp.24351; Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chambliss KL, 2010, J CLIN INVEST, V120, P2319, DOI 10.1172/JCI38291; Chaveroux C, 2013, CELL METAB, V17, P586, DOI 10.1016/j.cmet.2013.03.003; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; Ellis M, 2004, ONCOLOGIST, V9, P20, DOI 10.1634/theoncologist.9-suppl_3-20; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fonseca BD, 2015, J BIOL CHEM, V290, P15996, DOI 10.1074/jbc.M114.621730; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Generali D, 2008, CLIN CANCER RES, V14, P2673, DOI 10.1158/1078-0432.CCR-07-1046; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; James MJ, 2004, J BIOL CHEM, V279, P8911, DOI 10.1074/jbc.M307735200; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Madak-Erdogan Z, 2014, MOL CANCER RES, V12, P714, DOI 10.1158/1541-7786.MCR-13-0588; Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; Maruani DM, 2012, ONCOGENE, V31, P5073, DOI 10.1038/onc.2011.657; Miller TW, 2011, J CLIN ONCOL, V29, P4452, DOI 10.1200/JCO.2010.34.4879; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Miller WR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2931; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023; Paplomata E, 2013, BREAST CANCER RES TR, V140, P453, DOI 10.1007/s10549-013-2630-y; Paplomata E, 2013, THER CLIN RISK MANAG, V9, P27, DOI 10.2147/TCRM.S30349; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Piccart M, 2014, ANN ONCOL, V25, P2357, DOI 10.1093/annonc/mdu456; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Yamashita H, 2005, BREAST CANCER RES, V7, pR753, DOI 10.1186/bcr1285; Yamashita H, 2008, ENDOCR-RELAT CANCER, V15, P755, DOI 10.1677/ERC-08-0078; Yamnik RL, 2010, FEBS LETT, V584, P124, DOI 10.1016/j.febslet.2009.11.041; Yamnik RL, 2009, J BIOL CHEM, V284, P6361, DOI 10.1074/jbc.M807532200; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yu J, 2006, CANCER RES, V66, P9461, DOI 10.1158/0008-5472.CAN-06-1895; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	56	47	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3535	3543		10.1038/onc.2015.414	http://dx.doi.org/10.1038/onc.2015.414			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522726	Green Accepted			2022-12-28	WOS:000379621500006
J	Thomas, LR; Foshage, AM; Weissmiller, AM; Popay, TM; Grieb, BC; Qualls, SJ; Ng, V; Carboneau, B; Lorey, S; Eischen, CM; Tansey, WP				Thomas, L. R.; Foshage, A. M.; Weissmiller, A. M.; Popay, T. M.; Grieb, B. C.; Qualls, S. J.; Ng, V.; Carboneau, B.; Lorey, S.; Eischen, C. M.; Tansey, W. P.			Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif	ONCOGENE			English	Article							DNA-BINDING; C-MYC; PROTEIN; VP16; COMPLEX; HCF; ASSOCIATION; RECRUITMENT; FORMS	The MYC family of oncogenes encodes a set of three related transcription factors that are overexpressed in many human tumors and contribute to the cancer-related deaths of more than 70,000 Americans every year. MYC proteins drive tumorigenesis by interacting with co-factors that enable them to regulate the expression of thousands of genes linked to cell growth, proliferation, metabolism and genome stability. One effective way to identify critical co-factors required for MYC function has been to focus on sequence motifs within MYC that are conserved throughout evolution, on the assumption that their conservation is driven by protein-protein interactions that are vital for MYC activity. In addition to their DNA-binding domains, MYC proteins carry five regions of high sequence conservation known as Myc boxes (Mb). To date, four of the Mb motifs (MbI, MbII, MbIIIa and MbIIIb) have had a molecular function assigned to them, but the precise role of the remaining Mb, MbIV, and the reason for its preservation in vertebrate Myc proteins, is unknown. Here, we show that MbIV is required for the association of MYC with the abundant transcriptional coregulator host cell factor-1 (HCF-1). We show that the invariant core of MbIV resembles the tetrapeptide HCF-binding motif (HBM) found in many HCF-interaction partners, and demonstrate that MYC interacts with HCF-1 in a manner indistinguishable from the prototypical HBM-containing protein VP16. Finally, we show that rationalized point mutations in MYC that disrupt interaction with HCF-1 attenuate the ability of MYC to drive tumorigenesis in mice. Together, these data expose a molecular function for MbIV and indicate that HCF-1 is an important co-factor for MYC.	[Thomas, L. R.; Foshage, A. M.; Weissmiller, A. M.; Popay, T. M.; Qualls, S. J.; Ng, V.; Lorey, S.; Tansey, W. P.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, 465 21st Ave S 4140 MRB 3, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Int Scholar Program, 221 Kirkland Hall, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Sch Med, 221 Kirkland Hall, Nashville, TN 37235 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Tansey, WP (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, 465 21st Ave S 4140 MRB 3, Nashville, TN 37232 USA.	william.p.tansey@vanderbilt.edu		Popay, Tessa/0000-0002-4694-8804; Ng, Victoria/0000-0003-2344-8468; Grieb, Brian/0000-0003-3980-8050; Weissmiller, April/0000-0003-4505-0530	Edward P. Evans Foundation; Melanoma Research Foundation; Vanderbilt Ingram Cancer Center Support grant [NIH: CA68485]; NCI SPORE in Breast Cancer [P50 CA098131]; Cellular, Biochemical, and Molecular Sciences Training Program [T32 GM008554]; Integrated Biological Systems Training in Oncology Program [T32 CA119925]; National Center for Advancing Translational Sciences [UL1 TR000445]; Vanderbilt International Scholar Program; National Institutes of Health [R01CA148950, F30AG039164]; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA119925, P50CA098131, R01CA148950, R01CA200709] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F30AG039164] Funding Source: NIH RePORTER	Edward P. Evans Foundation; Melanoma Research Foundation; Vanderbilt Ingram Cancer Center Support grant; NCI SPORE in Breast Cancer; Cellular, Biochemical, and Molecular Sciences Training Program; Integrated Biological Systems Training in Oncology Program; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Vanderbilt International Scholar Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank S Dey, S Hiebert, H McDonald, L Neitzel and A Wilson for reagents, experimental assistance and advice. This work was supported by the Edward P. Evans Foundation (to WPT), the Melanoma Research Foundation (to WPT), the Vanderbilt Ingram Cancer Center Support grant (NIH: CA68485), the NCI SPORE in Breast Cancer (P50 CA098131), the Cellular, Biochemical, and Molecular Sciences Training Program (T32 GM008554), the Integrated Biological Systems Training in Oncology Program (T32 CA119925), the National Center for Advancing Translational Sciences (UL1 TR000445), the Vanderbilt International Scholar Program and grants R01CA148950 (to CME) and F30AG039164 (to BCG) from the National Institutes of Health.	BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dingar D, 2015, J PROTEOMICS, V118, P95, DOI 10.1016/j.jprot.2014.09.029; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Furrer M, 2010, J BIOL CHEM, V285, P39623, DOI 10.1074/jbc.M110.140467; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Kurland JF, 2008, CANCER RES, V68, P3624, DOI 10.1158/0008-5472.CAN-07-6552; Luciano RL, 2003, J BIOL CHEM, V278, P51116, DOI 10.1074/jbc.M303470200; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Tansey W.P., 2014, NEW J SCI, V2014, P1; Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028; Thomas LR, 2015, J SCI TECHNOL, V3; Vogel JL, 2013, VIRUSES-BASEL, V5, P1272, DOI 10.3390/v5051272; Wang YL, 2008, J BIOL CHEM, V283, P33808, DOI 10.1074/jbc.M806936200; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zargar ZU, 2012, TRANSCR-AUSTIN, V3, P187, DOI 10.4161/trns.20711	23	19	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3613	3618		10.1038/onc.2015.416	http://dx.doi.org/10.1038/onc.2015.416			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522729	Green Accepted			2022-12-28	WOS:000379621500014
J	Chen, X; Kamranvar, SA; Masucci, MG				Chen, X.; Kamranvar, S. A.; Masucci, M. G.			Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors	ONCOGENE			English	Article							MEMBRANE-PROTEIN 1; SIGNAL-BINDING-PROTEIN; NF-KAPPA-B; DNA-DAMAGE; NUCLEAR ANTIGEN; GENOMIC INSTABILITY; TYROSINE KINASES; ACTIVATION; EXPRESSION; INDUCTION	Infection of human B lymphocytes by Epstein-Barr virus (EBV) leads to the establishment of immortalized lymphoblastoid cell lines (LCLs) that are widely used as a model of viral oncogenesis. An early consequence of infection is the induction of DNA damage and activation of the DNA damage response, which limits the efficiency of growth transformation. The cause of the DNA damage remains poorly understood. We have addressed this question by comparing the response of B lymphocytes infected with EBV or stimulated with a potent B-cell mitogen. We found that although the two stimuli induce comparable proliferation during the first 10 days of culture, the EBV-infected blasts showed significantly higher levels of DNA damage, which correlated with stronger and sustained accumulation of reactive oxygen species (ROS). Treatment with ROS scavengers decreased DNA damage in both mitogen-stimulated and EBV-infected cells. However, while mitogen-induced proliferation was slightly improved, the proliferation of EBV-infected cells and the establishment of LCLs were severely impaired. Quenching of ROS did not affect the kinetics and magnitude of viral gene expression but was associated with selective downregulation of the viral LMP1 and phosphorylated cellular transcription factor STAT3 that have key roles in transformation. Analysis of the mechanism by which high levels of ROS support LMP1 expression revealed selective inhibition of viral microRNAs that target the LMP1 transcript. Our study provides novel insights into the role of EBV-induced oxidative stress in promoting B-cell immortalization and malignant transformation.	[Chen, X.; Kamranvar, S. A.; Masucci, M. G.] Karolinska Inst, Dept Cell & Mol Biol, Berzelius Vag 35, S-17177 Stockholm, Sweden; [Kamranvar, S. A.] Uppsala Univ, Biomed Ctr BMC, Med Biochem & Microbiol IMBIM, Uppsala, Sweden	Karolinska Institutet; Uppsala University	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Berzelius Vag 35, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809; Chen, Xinsong/0000-0002-3214-9075	Swedish Cancer Society; Swedish Medical Research Council; Karolinska Institutet, Stockholm, Sweden; China Scholarship Council	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet, Stockholm, Sweden; China Scholarship Council(China Scholarship Council)	This study was supported by grants awarded by the Swedish Cancer Society, the Swedish Medical Research Council and the Karolinska Institutet, Stockholm, Sweden. XC was partly supported by a fellowship awarded by the China Scholarship Council. We are grateful to Dr Glenn Goldstein (David Pharmaceuticals, NY, USA), Dr Svante Norgren (Karolinska University Hospital, Stockholm, Sweden) and Dr Jaap Middeldorp (Vrije Universiteit, Amsterdam, The Netherlands) for providing chemicals and antibodies. The contribution of the master student Iris Valent is gratefully acknowledged.	Altmann M, 2006, P NATL ACAD SCI USA, V103, P14188, DOI 10.1073/pnas.0605985103; Ates B, 2008, FREE RADICAL RES, V42, P372, DOI 10.1080/10715760801998638; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bottero V, 2013, J VIROL, V87, P1733, DOI 10.1128/JVI.02958-12; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Dando I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/425708; Davy C, 2007, VIROLOGY, V368, P219, DOI 10.1016/j.virol.2007.05.043; DIEHL V, 1968, J VIROL, V2, P663, DOI 10.1128/JVI.2.7.663-669.1968; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Gargouri B, 2011, BIOL TRACE ELEM RES, V144, P1449, DOI 10.1007/s12011-011-9135-5; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Grand RJA, 1998, VIROLOGY, V244, P330, DOI 10.1006/viro.1998.9102; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; Gruhne B, 2009, ONCOGENE, V28, P3997, DOI 10.1038/onc.2009.258; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HU LF, 1993, ONCOGENE, V8, P1575; HUEN DS, 1995, ONCOGENE, V10, P549; Ingham RJ, 2005, J BIOL CHEM, V280, P34133, DOI 10.1074/jbc.M507831200; Jochum S, 2012, P NATL ACAD SCI USA, V109, pE1396, DOI 10.1073/pnas.1115906109; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Kinjo T, 2010, J VIROL, V84, P5431, DOI 10.1128/JVI.02460-09; Knight JS, 2003, J VIROL, V77, P4261, DOI 10.1128/JVI.77.7.4261-4272.2003; Koganti S, 2014, P NATL ACAD SCI USA, V111, P4946, DOI 10.1073/pnas.1400683111; Koganti S, 2014, J VIROL, V88, P516, DOI 10.1128/JVI.02601-13; Koopal S, 2007, PLOS PATHOG, V3, P1348, DOI 10.1371/journal.ppat.0030140; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Le Clorennec C, 2008, J VIROL, V82, P6721, DOI 10.1128/JVI.02250-07; Lee YJ, 2007, AM J PHYSIOL-RENAL, V293, pF1036, DOI 10.1152/ajprenal.00034.2007; LEIBOLD W, 1975, J NATL CANCER I, V54, P65, DOI 10.1093/jnci/54.1.65; Liu TS, 2004, J BIOL CHEM, V279, P2461, DOI 10.1074/jbc.M307251200; Lo AKF, 2007, P NATL ACAD SCI USA, V104, P16164, DOI 10.1073/pnas.0702896104; Ma Q, 2013, ANTIOXID REDOX SIGN, V18, P80, DOI 10.1089/ars.2012.4584; Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NALESNIK MA, 1988, AM J PATHOL, V133, P173; Nikitin PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087299; Nikitin PA, 2010, CELL HOST MICROBE, V8, P510, DOI 10.1016/j.chom.2010.11.004; Portal D, 2013, P NATL ACAD SCI USA, V110, P18537, DOI 10.1073/pnas.1317608110; Price AM, 2014, ADV VIRUS RES, V88, P279, DOI 10.1016/B978-0-12-800098-4.00006-4; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; Rickinson A, 2002, VIRUS RES, V82, P109; Rickinson AB, 1996, VIROLOGY, P2397; Riley KJ, 2012, EMBO J, V31, P2207, DOI 10.1038/emboj.2012.63; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; Skalsky RL, 2014, J VIROL, V88, P1617, DOI 10.1128/JVI.02071-13; Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484; Sompallae R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012052; Souza V, 2009, TOXICOL LETT, V187, P180, DOI 10.1016/j.toxlet.2009.02.021; Sunitha K, 2013, FREE RADICAL RES, V47, P357, DOI 10.3109/10715762.2013.781595; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Weitzman MD, 2014, CELL HOST MICROBE, V15, P283, DOI 10.1016/j.chom.2014.02.010; White RE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013979; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; Zhao B, 2011, P NATL ACAD SCI USA, V108, P14902, DOI 10.1073/pnas.1108892108	61	30	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3807	3816		10.1038/onc.2015.450	http://dx.doi.org/10.1038/onc.2015.450			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26592445	Bronze			2022-12-28	WOS:000380753200006
J	Obermeier, K; Sachsenweger, J; Friedl, TWP; Pospiech, H; Winqvist, R; Wiesmuller, L				Obermeier, K.; Sachsenweger, J.; Friedl, T. W. P.; Pospiech, H.; Winqvist, R.; Wiesmueller, L.			Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients	ONCOGENE			English	Article							FANCONI-ANEMIA PATHWAY; REPLICATION FORKS; BRCA2; SUSCEPTIBILITY; RISK; RECOMBINATION; MECHANISM; PARTNER; PROTEIN; GENES	Hereditary heterozygous mutations in a variety of DNA double-strand break (DSB) repair genes have been associated with increased breast cancer risk. In the Finnish population, PALB2 (partner and localizer of BRCA2) represents a major susceptibility gene for female breast cancer, and so far, only one mutation has been described, c.1592delT, which leads to a sixfold increased disease risk. PALB2 is thought to participate in homologous recombination (HR). However, the effect of the Finnish founder mutation on DSB repair has not been investigated. In the current study, we used a panel of lymphoblastoid cell lines (LCLs) derived from seven heterozygous female PALB2 c.1592delT mutation carriers with variable health status and six wild-type matched controls. The results of our DSB repair analysis showed that the PALB2 mutation causes specific changes in pathway usage, namely increases in error-prone single-strand annealing (SSA) and microhomology-mediated end-joining (MMEJ) compared with wild-type LCLs. These data indicated haploinsufficiency regarding the suppression of error-prone DSB repair in PALB2 mutation carriers. To the contrary, neither reduced HR activities, nor impaired RAD51 filament assembly, nor sensitization to PARP inhibition were consistently observed. Expression of truncated mutant versus wild-type PALB2 verified a causal role of PALB2 c.1592delT in the shift to error-prone repair. Discrimination between healthy and malignancy-presenting PALB2 mutation carriers revealed a pathway shift particularly in the breast cancer patients, suggesting interaction of PALB2 c.1592delT with additional genomic lesions. Interestingly, the studied PALB2 mutation was associated with 53BP1 accumulation in the healthy mutation carriers but not the patients, and 53BP1 was limiting for error-prone MMEJ in patients but not in healthy carriers. Our study identified a rise in error-prone DSB repair as a potential threat to genomic integrity in heterozygous PALB2 mutation carriers. The used phenotypic marker system has the capacity to capture dysfunction caused by polygenic mechanisms and therefore offers new strategies of cancer risk prediction.	[Obermeier, K.; Sachsenweger, J.; Friedl, T. W. P.; Wiesmueller, L.] Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany; [Pospiech, H.] Univ Oulu, Fac Biochem & Mol Med, Oulu, Finland; [Pospiech, H.] Leibniz Inst Age Res, Fritz Lipmann Inst, Res Grp Biochem, Jena, Germany; [Winqvist, R.] Univ Oulu, Lab Canc Genet & Tumor Biol, Canc & Translat Med Res Unit, Aapistie 5A, SF-90220 Oulu, Finland; [Winqvist, R.] Univ Oulu, Bioctr Oulu, Aapistie 5A, SF-90220 Oulu, Finland; [Winqvist, R.] Northern Finland Lab Ctr NordLab, Oulu, Finland	Ulm University; University of Oulu; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); University of Oulu; University of Oulu	Wiesmuller, L (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany.; Winqvist, R (corresponding author), Univ Oulu, Lab Canc Genet & Tumor Biol, Canc & Translat Med Res Unit, Aapistie 5A, SF-90220 Oulu, Finland.; Winqvist, R (corresponding author), Univ Oulu, Bioctr Oulu, Aapistie 5A, SF-90220 Oulu, Finland.	robert.winqvist@oulu.fi; lisa.wiesmueller@uni-ulm.de	Friedl, Thomas W.P./K-5305-2013	Friedl, Thomas W.P./0000-0002-4773-8067; Wiesmuller, Lisa/0000-0002-2397-5041; Winqvist, Robert/0000-0003-0932-9104	International Graduate School in Molecular Medicine Ulm, Germany; University of Oulu; Finnish Cancer Foundation; Sigrid Juselius Foundation; Academy of Finland Center of Excellence [251314]; Biocenter Oulu; Cancer Foundation Finland sr [150147] Funding Source: researchfish	International Graduate School in Molecular Medicine Ulm, Germany; University of Oulu; Finnish Cancer Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland Center of Excellence(Academy of Finland); Biocenter Oulu; Cancer Foundation Finland sr	We cordially thank Leena Keskitalo, Annika Vantanen and Meeri Otsukka for the initial preparation and culturing of the Northern Finnish PALB2 mutation carrier and the matched wild-type healthy control LCLs as well as their shipment to Ulm for the current study. We are grateful to Daniela Salles, Ulm, for experimental help during the initial phase of the project, and Jeremy M Stark, Department of Cancer Biology, Division of Radiation Biology, Beckmann Research Institute of the City of Hope, Duarte, CA, USA, for the NHEJ reporter EJ5SceGFP. This project was supported by the International Graduate School in Molecular Medicine Ulm, Germany (to LW). KO was and JS is a member of the International Graduate School in Molecular Medicine Ulm. RW was supported by the University of Oulu and Biocenter Oulu, the Finnish Cancer Foundation, Sigrid Juselius Foundation and the Academy of Finland Center of Excellence funding (grant 251314). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Antoniou AC, 2014, NEW ENGL J MED, V371, P497, DOI [10.1056/NEJMoa1400382, 10.1056/NEJMc1410673]; Bennardo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000683; Bohringer M, 2013, ONCOGENE, V32, P5458, DOI 10.1038/onc.2013.38; Bouwman P, 2013, CANCER DISCOV, V3, P1142, DOI 10.1158/2159-8290.CD-13-0094; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, MOL CELL, V39, P164, DOI 10.1016/j.molcel.2010.07.016; Burkovics P, 2014, NUCLEIC ACIDS RES, V42, P1711, DOI 10.1093/nar/gkt1040; Byrnes GB, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2099; Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958; Costantino L, 2014, SCIENCE, V343, P88, DOI 10.1126/science.1243211; Currall Benjamin B, 2013, Curr Genet Med Rep, V1, P81; De Vos M, 2012, BIOCHEM PHARMACOL, V84, P137, DOI 10.1016/j.bcp.2012.03.018; Deng XY, 2009, BIOCHEMISTRY-US, V48, P6633, DOI 10.1021/bi900564k; Do K, 2013, CLIN CANCER RES, V19, P977, DOI 10.1158/1078-0432.CCR-12-0163; Dray E, 2010, NAT STRUCT MOL BIOL, V17, P1255, DOI 10.1038/nsmb.1916; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Erkko H, 2008, CLIN CANCER RES, V14, P4667, DOI 10.1158/1078-0432.CCR-08-0210; Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609; Francis R, 2007, GENE DEV, V21, P1064, DOI 10.1101/gad.1522807; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Guidugli L, 2014, HUM MUTAT, V35, P151, DOI 10.1002/humu.22478; Haanpaa M, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-82; Heikkinen K, 2006, CARCINOGENESIS, V27, P1593, DOI 10.1093/carcin/bgi360; Ho TV, 2002, ENVIRON MOL MUTAGEN, V51, P552; Hucl T, 2011, PHYSIOL RES, V60, P453, DOI 10.33549/physiolres.932115; Huertas P, 2010, NAT STRUCT MOL BIOL, V17, P11, DOI 10.1038/nsmb.1710; Ireno IC, 2014, CARCINOGENESIS, V35, P2273, DOI 10.1093/carcin/bgu160; Keimling M, 2012, FASEB J, V26, P2094, DOI 10.1096/fj.11-200790; Keimling M, 2011, FASEB J, V25, P3849, DOI 10.1096/fj.11-185546; Keka IS, 2015, NUCLEIC ACIDS RES, V43, P6359, DOI 10.1093/nar/gkv621; Lok BH, 2013, ONCOGENE, V32, P3552, DOI 10.1038/onc.2012.391; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; McKinnon PJ, 2007, ANNU REV GENOM HUM G, V8, P37, DOI 10.1146/annurev.genom.7.080505.115648; Meindl A, 2011, DTSCH ARZTEBL INT, V108, P323, DOI 10.3238/arztebl.2011.0323; Murphy AK, 2014, J CELL BIOL, V206, P493, DOI 10.1083/jcb.201404111; Nikkila J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3578; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Park JY, 2014, ONCOGENE, V33, P4803, DOI 10.1038/onc.2013.421; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Ribeiro E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066243; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shahid T, 2014, NAT STRUCT MOL BIOL, V21, P962, DOI 10.1038/nsmb.2899; Siaud N, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002409; Sy SMH, 2009, J BIOL CHEM, V284, P21127, DOI 10.1074/jbc.C109.023937; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Thompson LH, 2009, MUTAT RES-FUND MOL M, V668, P54, DOI 10.1016/j.mrfmmm.2009.02.003; Tischkowitz M, 2010, CANCER RES, V70, P7353, DOI 10.1158/0008-5472.CAN-10-1012; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Walsh T, 2010, P NATL ACAD SCI USA, V107, P12629, DOI 10.1073/pnas.1007983107; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Zhang F, 2009, FERROALLOYS, V1, P1, DOI DOI 10.1155/2009/514306; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018	59	24	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3796	3806		10.1038/onc.2015.448	http://dx.doi.org/10.1038/onc.2015.448			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26640152	Green Published, hybrid			2022-12-28	WOS:000380753200005
J	Kim, SB; Bozeman, RG; Kaisani, A; Kim, W; Zhang, L; Richardson, JA; Wright, WE; Shay, JW				Kim, S. B.; Bozeman, R. G.; Kaisani, A.; Kim, W.; Zhang, L.; Richardson, J. A.; Wright, W. E.; Shay, J. W.			Radiation promotes colorectal cancer initiation and progression by inducing senescence-associated inflammatory responses	ONCOGENE			English	Article							SOLAR PARTICLE EVENT; PROTON-BEAM THERAPY; CDDO-METHYL ESTER; EPITHELIAL-CELLS; MOUSE MODEL; DNA-DAMAGE; SPACE RADIATION; LUNG-CANCER; AUGUST 1972; TRITERPENOIDS	Proton radiotherapy is becoming more common as protons induce more precise DNA damage at the tumor site with reduced side effects to adjacent normal tissues. However, the long-term biological effects of proton irradiation in cancer initiation compared with conventional photon irradiation are poorly characterized. In this study, using a human familial adenomatous polyposis syndrome susceptible mouse model, we show that whole-body irradiation with protons are more effective in inducing senescence-associated inflammatory responses (SIRs), which are involved in colon cancer initiation and progression. After proton irradiation, a subset of SIR genes (Troy, Sox17, Opg, Faim2, Lpo, Tlr2 and Ptges) and a gene known to be involved in invasiveness (Plat), along with the senescence-associated gene (P19Arf), are markedly increased. Following these changes, loss of Casein kinase I alpha and induction of chronic DNA damage and TP53 mutations are increased compared with X-ray irradiation. Proton irradiation also increases the number of colonic polyps, carcinomas and invasive adenocarcinomas. Pretreatment with the non-steroidal anti-inflammatory drug, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid-ethyl amide (CDDO-EA), reduces proton irradiation-associated SIR and tumorigenesis. Thus exposure to proton irradiation elicits significant changes in colorectal cancer initiation and progression that can be mitigated using CDDO-EA.	[Kim, S. B.; Bozeman, R. G.; Kaisani, A.; Kim, W.; Zhang, L.; Wright, W. E.; Shay, J. W.] Univ Texas Southwestern Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd,MC9039, Dallas, TX 75390 USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Pathol, Dallas, TX USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Mol Biol, Dallas, TX USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Plast Surg, Dallas, TX USA; [Shay, J. W.] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah, Saudi Arabia	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; King Abdulaziz University	Shay, JW (corresponding author), Univ Texas Southwestern Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd,MC9039, Dallas, TX 75390 USA.	jerry.shay@utsouthwestern.edu		Kim, Sang Bum/0000-0001-5965-3354	NIH grant [C06 RR30414]; NASA Grant [NNX15AI21G, NNX11AC15G, NNJ05HD36G, NNX09AU95G]; NATIONAL CANCER INSTITUTE [P50CA070907, T32CA124334] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR030414] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NASA Grant(National Aeronautics & Space Administration (NASA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank the support team at Brookhaven National Laboratory (BNL) and NASA Space Radiation Laboratory (NSRL) (Upton, NY, USA) for helping with the Proton and HZE particles delivery to animals. We thank Dr Michael Sporn (Hanover, NH, USA) and Reata Pharmaceuticals (Irving, TX, USA) for providing CDDO-EA reagent, Summer Barron (UT Southwestern, Dallas, TX, USA) for mouse colony maintenance and Gail Fasciani (UT Southwestern, Dallas, TX, USA) for histological processing. This work was performed in laboratories constructed with support from NIH grant C06 RR30414. This work was supported by NASA Grant nos. NNX15AI21G, NNX11AC15G, NNJ05HD36G and NNX09AU95G to JWS.	Ahn PH, 2014, CANCER J, V20, P421, DOI 10.1097/PPO.0000000000000077; Arnold CN, 2005, CANCER-AM CANCER SOC, V104, P2035, DOI 10.1002/cncr.21462; Bahnassy AA, 2004, BMC GASTROENTEROL, V4, DOI 10.1186/1471-230X-4-22; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Breuer H, 2013, PROTON THERAPY RADIO; Collis SJ, 2004, J BIOL CHEM, V279, P49624, DOI 10.1074/jbc.M409600200; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; DANGIO GJ, 1963, NUCLEONICS, V21, P56; Delgado O, 2014, CLIN CANCER RES, V20, P1610, DOI 10.1158/1078-0432.CCR-13-2589; Dicello JF, 2002, J RADIAT RES, V43, pS1; Eaton BR, 2014, CANCER J, V20, P403, DOI 10.1097/PPO.0000000000000079; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Eskiocak U, 2010, RADIAT RES, V174, P27, DOI 10.1667/RR2155.1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; George K, 2003, RADIAT RES, V160, P425, DOI 10.1667/RR3064; Hall EJ, 2006, RADIOBIOLOGY RADIOLO, V6th; Hellweg CE, 2007, NATURWISSENSCHAFTEN, V94, P517, DOI 10.1007/s00114-006-0204-0; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Keole S, 2014, CANCER J, V20, P409, DOI 10.1097/PPO.0000000000000084; Kim SB, 2014, LIFE SCI SPACE RES, V1, P67, DOI 10.1016/j.lssr.2014.02.001; Kim SB, 2013, RADIAT RES, V180, P259, DOI 10.1667/RR3371.1; Kim SB, 2012, P NATL ACAD SCI USA, V109, pE2949, DOI 10.1073/pnas.1207718109; Kim SB, 2014, GRAVIT SPACE RES, V2, P32; KUDO S, 1993, ENDOSCOPY, V25, P455, DOI 10.1055/s-2007-1010367; Lawrence J H, 1964, Trans Am Clin Climatol Assoc, V75, P111; Liby K, 2007, CANCER RES, V67, P2414, DOI 10.1158/0008-5472.CAN-06-4534; Ludlow AT, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku439; Miyaoka Y, 2014, NAT METHODS, V11, P291, DOI 10.1038/nmeth.2840; Moravek Z, 2009, Z MED PHYS, V19, P174, DOI 10.1016/j.zemedi.2009.04.006; Neymotin A, 2011, FREE RADICAL BIO MED, V51, P88, DOI 10.1016/j.freeradbiomed.2011.03.027; Parsons JL, 2000, RADIAT RES, V153, P729, DOI 10.1667/0033-7587(2000)153[0729:ICDRFT]2.0.CO;2; Petronelli A, 2009, ANTI-CANCER DRUG, V20, P880, DOI 10.1097/CAD.0b013e328330fd90; Pribluda A, 2013, CANCER CELL, V24, P242, DOI 10.1016/j.ccr.2013.06.005; Pugh TJ, 2014, CANCER J, V20, P415, DOI 10.1097/PPO.0000000000000083; Reisman SA, 2014, RADIAT RES, V181, P512, DOI 10.1667/RR13578.1; Rithidech KN, 2013, MUTAT RES-GEN TOX EN, V756, P127, DOI 10.1016/j.mrgentox.2013.06.001; Rutter MD, 2010, FRONTLINE GASTROENTE, V1, P126, DOI 10.1136/fg.2010.001438; Simone CB, 2014, CANCER J, V20, P427, DOI 10.1097/PPO.0000000000000080; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUIT HD, 1975, CANCER-AM CANCER SOC, V35, P1646, DOI 10.1002/1097-0142(197506)35:6<1646::AID-CNCR2820350626>3.0.CO;2-1; Thimmulappa RK, 2007, ANTIOXID REDOX SIGN, V9, P1963, DOI 10.1089/ars.2007.1745; TOWNSEND LW, 1991, RADIAT RES, V126, P108, DOI 10.2307/3578178; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Vannini N, 2007, MOL CANCER THER, V6, P3139, DOI 10.1158/1535-7163.MCT-07-0451; VERHEY LJ, 1982, ANNU REV BIOPHYS BIO, V11, P331, DOI 10.1146/annurev.bb.11.060182.001555; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Williams JR, 1999, MUTAT RES-FUND MOL M, V430, P255, DOI 10.1016/S0027-5107(99)00137-2; Wilson JW, 1999, RADIAT MEAS, V30, P361, DOI 10.1016/S1350-4487(99)00063-3	50	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3365	3375		10.1038/onc.2015.395	http://dx.doi.org/10.1038/onc.2015.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26477319	Green Accepted			2022-12-28	WOS:000379270100002
J	Gan, L; Xiu, R; Ren, P; Yue, M; Su, H; Guo, G; Xiao, D; Yu, J; Jiang, H; Liu, H; Hu, G; Qing, G				Gan, L.; Xiu, R.; Ren, P.; Yue, M.; Su, H.; Guo, G.; Xiao, D.; Yu, J.; Jiang, H.; Liu, H.; Hu, G.; Qing, G.			Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters	ONCOGENE			English	Article							SLC16 GENE FAMILY; GLUTAMINE-METABOLISM; ANTITUMOR-ACTIVITY; N-MYC; INHIBITION; CANCER; NEUROBLASTOMA; CELLS; MCT1; 3-BROMOPYRUVATE	Deregulation of the MYC oncogene produces Myc protein that regulates multiple aspects of cancer cell metabolism, contributing to the acquisition of building blocks essential for cancer cell growth and proliferation. Therefore, disabling Myc function represents an attractive therapeutic option for cancer treatment. However, pharmacological strategies capable of directly targeting Myc remain elusive. Here, we identified that 3-bromopyruvate (3-BrPA), a drug candidate that primarily inhibits glycolysis, preferentially induced massive cell death in human cancer cells overexpressing the MYC oncogene, in vitro and in vivo, without appreciable effects on those exhibiting low MYC levels. Importantly, pharmacological inhibition of glutamine metabolism synergistically potentiated the synthetic lethal targeting of MYC by 3-BrPA due in part to the metabolic disturbance caused by this combination. Mechanistically, we identified that the proton-coupled monocarboxylate transporter 1 (MCT1) and MCT2, which enable efficient 3-BrPA uptake by cancer cells, were selectively activated by Myc. Two regulatory mechanisms were involved: first, Myc directly activated MCT1 and MCT2 transcription by binding to specific recognition sites of both genes; second, Myc transcriptionally repressed miR29a and miR29c, resulting in enhanced expression of their target protein MCT1. Of note, expressions of MCT1 and MCT2 were each significantly elevated in MYCN-amplified neuroblastomas and C-MYC-overexpressing lymphomas than in tumors without MYC overexpression, correlating with poor prognosis and unfavorable patient survival. These results identify a novel mechanism by which Myc sensitizes cells to metabolic inhibitors and validate 3-BrPA as potential Myc-selective cancer therapeutics.	[Gan, L.; Hu, G.] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China; [Gan, L.; Xiu, R.; Ren, P.; Yue, M.; Xiao, D.; Qing, G.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Wuhan 430030, Peoples R China; [Su, H.; Guo, G.; Liu, H.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan 430030, Peoples R China; [Yu, J.; Jiang, H.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Syst Biol, Shanghai, Peoples R China; [Qing, G.] Wuhan Univ, Med Res Inst, 185 Donghu Rd, Wuhan 430071, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Wuhan University	Hu, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.; Qing, G (corresponding author), Wuhan Univ, Med Res Inst, 185 Donghu Rd, Wuhan 430071, Peoples R China.	gqhu@tjh.tjmu.edu.cn; qingguoliang@whu.edu.cn			National Natural Science Foundation of China [81171928, 81372205, 81272491, 81200381]; Huazhong University of Science and Technology [2014ZHYX002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Huazhong University of Science and Technology	We thank members of Qing and Liu laboratories for helpful suggestions. This study was supported by the National Natural Science Foundation of China (Grants 81171928 and 81372205 to GQ, 81272491 to GH and 81200381 to HL) and Huazhong University of Science and Technology (Grant 2014ZHYX002 to GQ).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cardaci S, 2012, CANCER RES, V72, P4526, DOI 10.1158/0008-5472.CAN-12-1741; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chapiro J, 2014, CLIN CANCER RES, V20, P6406, DOI 10.1158/1078-0432.CCR-14-1271; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Doherty JR, 2014, CANCER RES, V74, P908, DOI 10.1158/0008-5472.CAN-13-2034; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Geschwind Jean-Francois, 2004, Expert Rev Anticancer Ther, V4, P449, DOI 10.1586/14737140.4.3.449; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Ko YH, 2012, J BIOENERG BIOMEMBR, V44, P163, DOI 10.1007/s10863-012-9417-4; Ko YH, 2001, CANCER LETT, V173, P83, DOI 10.1016/S0304-3835(01)00667-X; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Nilsson LM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002573; Ota S, 2013, TARGET ONCOL, V8, P145, DOI 10.1007/s11523-013-0273-x; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Qing GL, 2010, CANCER RES, V70, P10351, DOI 10.1158/0008-5472.CAN-10-0740; Queiros O, 2012, J BIOENERG BIOMEMBR, V44, P141, DOI 10.1007/s10863-012-9418-3; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thangaraju M, 2009, CANCER, V115, P4655, DOI 10.1002/cncr.24532; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiang Y, 2015, J CLIN INVEST, V125, P2293, DOI 10.1172/JCI75836; Xu RH, 2005, CANCER RES, V65, P613; Yang D, 2010, P NATL ACAD SCI USA, V107, P13836, DOI 10.1073/pnas.1008366107; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003	56	32	36	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3037	3048		10.1038/onc.2015.360	http://dx.doi.org/10.1038/onc.2015.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434591				2022-12-28	WOS:000377474500009
J	Coarfa, C; Fiskus, W; Eedunuri, VK; Rajapakshe, K; Foley, C; Chew, SA; Shah, SS; Geng, C; Shou, J; Mohamed, JS; O'Malley, BW; Mitsiades, N				Coarfa, C.; Fiskus, W.; Eedunuri, V. K.; Rajapakshe, K.; Foley, C.; Chew, S. A.; Shah, S. S.; Geng, C.; Shou, J.; Mohamed, J. S.; O'Malley, B. W.; Mitsiades, N.			Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; DOWN-REGULATION; FOCAL ADHESION; EXPRESSION; TRANSCRIPTION; RECURRENCE; GENE; PROLIFERATION; AMPLIFICATION; COACTIVATOR	MicroRNAs are important epigenetic regulators of protein expression by triggering degradation of target mRNAs and/or inhibiting their translation. Dysregulation of microRNA expression has been reported in several cancers, including prostate cancer (PC). We comprehensively characterized the proteomic footprint of a panel of 12 microRNAs that are potently suppressed in metastatic PC (SiM-miRNAs: miR-1, miR-133a, miR-133b, miR-135a, miR-143-3p, miR-145-3p, miR-205, miR-221-3p, miR-221-5p, miR-222-3p, miR-24-1-5p, and miR-31) using reverse-phase proteomic arrays. Re-expression of these SiM-miRNAs in PC cells suppressed cell proliferation and targeted key oncogenic pathways, including cell cycle, apoptosis, Akt/mammalian target of rapamycin signaling, metastasis and the androgen receptor (AR) axis. However, only 12%, at most, of these observed protein expression changes could be explained by predicted direct binding of miRNAs to corresponding mRNAs, suggesting that the majority of these proteomic effects result indirectly. AR and its steroid receptor coactivators (SRCs; SRC-1, -2 and -3) were recurrently affected by these SiMmiRNAs. In agreement, we identified inverse correlations between expression of these SiM-miRNAs and early clinical recurrence, as well as with AR transcriptional activity in human PC tissues. We also identified robust induction of miR-135a by androgen and strong direct binding of AR to the miR-135a locus. As miR-135a potently suppresses AR expression, this results in a negative feedback loop that suppresses AR protein expression in an androgen-dependent manner, while de-repressing AR expression upon androgen deprivation. Our results demonstrate that epigenetic silencing of these SiM-miRNAs can result in increased AR axis activity and cell proliferation, thus contributing to disease progression. We further demonstrate that a negative feedback loop involving miR-135a can restore AR expression under androgen-deprivation conditions, thus contributing to the upregulation of AR protein expression in castration-resistant PC. Finally, our unbiased proteomic profiling demonstrates that the majority of actual protein expression changes induced by SiM-miRNAs cannot be explained based on predicted direct interactions.	[Coarfa, C.; Fiskus, W.; Rajapakshe, K.; Foley, C.; Chew, S. A.; Shah, S. S.; Geng, C.; O'Malley, B. W.; Mitsiades, N.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,Suite R407,MS BCM187, Houston, TX 77030 USA; [Coarfa, C.; Mitsiades, N.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Fiskus, W.; Foley, C.; Chew, S. A.; Shah, S. S.; Geng, C.; Shou, J.; Mohamed, J. S.; Mitsiades, N.] Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407,MS BCM187, Houston, TX 77030 USA; [Eedunuri, V. K.] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mitsiades, N (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,Suite R407,MS BCM187, Houston, TX 77030 USA.; Mitsiades, N (corresponding author), Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407,MS BCM187, Houston, TX 77030 USA.	mitsiade@bcm.edu	Mohamed, Junaith/AAC-4050-2020; Eedunuri, VIJAY KUMAR/L-2213-2015		American Cancer Society [RSG-14-218-01-TBG]; Prostate Cancer Foundation; Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards; NICHD [8818]; Department of Defense Breast Cancer Research Program Innovator Award; Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center at Baylor College of Medicine [P30-DK079638]; Alkek Foundation for Molecular Discovery Pilot grant; NCI Cancer Center Support [P30CA125123]; Center for Drug Discovery at Baylor College of Medicine; Functional Proteomics RPPA Core Facility (The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD008188] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079638] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Prostate Cancer Foundation; Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards; NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Department of Defense Breast Cancer Research Program Innovator Award; Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center at Baylor College of Medicine; Alkek Foundation for Molecular Discovery Pilot grant; NCI Cancer Center Support(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Drug Discovery at Baylor College of Medicine; Functional Proteomics RPPA Core Facility (The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge the joint participation by Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine. This work was also supported by the American Cancer Society RSG-14-218-01-TBG (to NM), the Prostate Cancer Foundation (to BWO and NM), the Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards (both to NM), NICHD 8818 and Department of Defense Breast Cancer Research Program Innovator Award (to BWO), the Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center (P30-DK079638) at Baylor College of Medicine (to NM), and an Alkek Foundation for Molecular Discovery Pilot grant (to CC). NM is a Dan L. Duncan Scholar, a Caroline Wiess Law Scholar and a member of the Dan L. Duncan Cancer Center (supported by the NCI Cancer Center Support grant P30CA125123) and the Center for Drug Discovery at Baylor College of Medicine. We thank the assistance of the Shared Resources of the Dan L. Duncan Cancer Center (supported by the NCI Cancer Center Support grant P30CA125123) and the Functional Proteomics RPPA Core Facility (The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA).	Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023; Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Aryee MJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005211; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Casanova-Salas I, 2014, J UROLOGY, V192, P252, DOI 10.1016/j.juro.2014.01.107; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Demichelis F, 2009, GENE CHROMOSOME CANC, V48, P366, DOI 10.1002/gcc.20647; Erhard F, 2014, GENOME RES, V24, P906, DOI 10.1101/gr.166702.113; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Fang YX, 2014, ONCOGENE, V33, P135, DOI 10.1038/onc.2013.54; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Formosa A, 2013, ONCOGENE, V32, P127, DOI 10.1038/onc.2012.14; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Gottwein E, 2011, CELL HOST MICROBE, V10, P515, DOI 10.1016/j.chom.2011.09.012; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gregory CW, 2001, CANCER RES, V61, P2892; Gregory CW, 2001, CANCER RES, V61, P4315; Haecker I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002884; Hart M, 2014, MOL CANCER RES, V12, P250, DOI 10.1158/1541-7786.MCR-13-0230; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Hulf T, 2013, ONCOGENE, V32, P2891, DOI 10.1038/onc.2012.300; Kishore S, 2011, NAT METHODS, V8, P559, DOI [10.1038/NMETH.1608, 10.1038/nmeth.1608]; Koivisto P, 1997, CANCER RES, V57, P314; Kroiss A, 2015, ONCOGENE, V34, P2846, DOI 10.1038/onc.2014.222; Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968; Linja MJ, 2001, CANCER RES, V61, P3550; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mitsiades N, 2013, CANCER RES, V73, P4599, DOI 10.1158/0008-5472.CAN-12-4414; Mitsiades N, 2012, CANCER RES, V72, P6142, DOI 10.1158/0008-5472.CAN-12-1335; Nelson PS, 2012, J CLIN ONCOL, V30, P644, DOI 10.1200/JCO.2011.39.1300; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Reyes-Herrera Paula H., 2012, Genomics Proteomics & Bioinformatics, V10, P254, DOI 10.1016/j.gpb.2012.10.001; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540; Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484; Sun T, 2014, ONCOGENE, V33, P2790, DOI 10.1038/onc.2013.230; Sun T, 2012, PROSTATE, V72, P1093, DOI 10.1002/pros.22456; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Taipaleenmaki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008-5472.CAN-14-1026; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Therneau TM, 2000, MODELING SURVIVAL DA; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; Vidigal JA, 2015, TRENDS CELL BIOL, V25, P137, DOI 10.1016/j.tcb.2014.11.004; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Witkos TM, 2011, CURR MOL MED, V11, P93; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yue D, 2009, CURR GENOMICS, V10, P478, DOI 10.2174/138920209789208219; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	59	54	54	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2345	2356		10.1038/onc.2015.295	http://dx.doi.org/10.1038/onc.2015.295			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26364608	Green Accepted			2022-12-28	WOS:000376165000007
J	Kitatani, K; Usui, T; Sriraman, SK; Toyoshima, M; Ishibashi, M; Shigeta, S; Nagase, S; Sakamoto, M; Ogiso, H; Okazaki, T; Hannun, YA; Torchilin, VP; Yaegashi, N				Kitatani, K.; Usui, T.; Sriraman, S. K.; Toyoshima, M.; Ishibashi, M.; Shigeta, S.; Nagase, S.; Sakamoto, M.; Ogiso, H.; Okazaki, T.; Hannun, Y. A.; Torchilin, V. P.; Yaegashi, N.			Ceramide limits phosphatidylinositol-3-kinase C2 beta-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; SHORT-CHAIN CERAMIDE; ACTIVATED PROTEIN-KINASE; LIPOSOMAL DELIVERY; INDUCED APOPTOSIS; ARACHIDONIC-ACID; EPITHELIAL-CELLS; FACTOR RECEPTOR; OKADAIC ACID; C2 DOMAIN	Targeting cell motility, which is required for dissemination and metastasis, has therapeutic potential for ovarian cancer metastasis, and regulatory mechanisms of cell motility need to be uncovered for developing novel therapeutics. Invasive ovarian cancer cells spontaneously formed protrusions, such as lamellipodia, which are required for generating locomotive force in cell motility. Short interfering RNA screening identified class II phosphatidylinositol 3-kinase C2 beta (PI3KC2 beta) as the predominant isoform of PI3K involved in lamellipodia formation of ovarian cancer cells. The bioactive sphingolipid ceramide has emerged as an antitumorigenic lipid, and treatment with short-chain C-6-ceramide decreased the number of ovarian cancer cells with PI3KC2 beta-driven lamellipodia. Pharmacological analysis demonstrated that long-chain ceramide regenerated from C-6-ceramide through the salvage/recycling pathway, at least in part, mediated the action of C-6-ceramide. Mechanistically, ceramide was revealed to interact with the PIK-catalytic domain of PI3KC2 beta and affect its compartmentalization, thereby suppressing PI3KC2 beta activation and its driven cell motility. Ceramide treatment also suppressed cell motility promoted by epithelial growth factor, which is a prometastatic factor. To examine the role of ceramide in ovarian cancer metastasis, ceramide liposomes were employed and confirmed to suppress cell motility in vitro. Ceramide liposomes had an inhibitory effect on peritoneal metastasis in a murine xenograft model of human ovarian cancer. Metastasis of PI3KC2 beta knocked-down cells was insensitive to treatment with ceramide liposomes, suggesting specific involvement of ceramide interaction with PI3KC2 beta in metastasis suppression. Our study identified ceramide as a bioactive lipid that limits PI3KC2 beta-governed cell motility, and ceramide is proposed to serve as a metastasis-suppressor lipid in ovarian cancer. These findings could be translated into developing ceramide-based therapy for metastatic diseases.	[Kitatani, K.; Usui, T.; Yaegashi, N.] Tohoku Univ, Grad Sch Med, Tohoku Med Megabank Org, Sendai, Miyagi 980, Japan; [Kitatani, K.; Toyoshima, M.; Ishibashi, M.; Shigeta, S.; Sakamoto, M.; Yaegashi, N.] Tohoku Univ, Grad Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi 980, Japan; [Sriraman, S. K.; Torchilin, V. P.] Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Dept Pharmaceut Sci, Boston, MA 02115 USA; [Nagase, S.] Yamagata Univ, Dept Obstet & Gynecol, Yamagata 990, Japan; [Ogiso, H.; Okazaki, T.] Kanazawa Med Univ, Dept Life Sci, Med Res Inst, Uchinada, Ishikawa 92002, Japan; [Okazaki, T.] Kanazawa Med Univ, Dept Med, Div Hematol Immunol, Uchinada, Ishikawa 92002, Japan; [Hannun, Y. A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Hannun, Y. A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	Tohoku University; Tohoku University; Northeastern University; Yamagata University; Kanazawa Medical University; Kanazawa Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kitatani, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Obstet & Gynecol, Tohoku Med Megabank Org,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9800873, Japan.	kitatani@med.tohoku.ac.jp	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; Ogiso, Hideo/0000-0002-8241-3006; Nagase, Satoru/0000-0001-5212-1128; xing zhi, shi zhi/0000-0003-3289-5681	JSPS KAKENHI [40539235, 24390375, 23791801]; Health Labour Sciences Research Grant [201221019A]; National Institutes of Health [U54 CA151881, CA087584]; Grants-in-Aid for Scientific Research [26462509, 26670710] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [P01CA097132, R01CA087584, R01CA172517, U54CA151881] Funding Source: NIH RePORTER	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Health Labour Sciences Research Grant(Ministry of Health, Labour and Welfare, Japan); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by JSPS KAKENHI Grants (40539235 to KK, 24390375 to NY and 23791801 to MT), a Health Labour Sciences Research Grant (201221019A to NY), and National Institutes of Health grants (U54 CA151881 to VPT and CA087584 to YAH). We also thank the laboratory members of the Departments of Microbiology and Immunology, and Obstetrics and Gynecology (Tohoku University, Sendai) for critical discussion.	Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Aschrafi A, 2003, BBA-MOL CELL BIOL L, V1634, P30, DOI 10.1016/j.bbalip.2003.08.004; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Bartlett JMS, 1996, BRIT J CANCER, V73, P301, DOI 10.1038/bjc.1996.53; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boddapati SV, 2008, NANO LETT, V8, P2559, DOI 10.1021/nl801908y; Boller D, 2012, ANTICANCER RES, V32, P3015; Calzolari A, 2007, BLOOD CELL MOL DIS, V39, P82, DOI 10.1016/j.bcmd.2007.02.003; Chalfant CE, 2004, J LIPID RES, V45, P496, DOI 10.1194/jlr.M300347-JLR200; Clarke CJ, 2007, J BIOL CHEM, V282, P1384, DOI 10.1074/jbc.M609216200; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Edmond V, 2015, ONCOGENE, V34, P996, DOI 10.1038/onc.2014.55; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Garzotto M, 1998, CANCER RES, V58, P2260; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Huwiler A, 2001, FASEB J, V15, P7; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Ip CKM, 2011, ONCOGENE, V30, P2420, DOI 10.1038/onc.2010.615; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Karahatay S, 2007, CANCER LETT, V256, P101, DOI 10.1016/j.canlet.2007.06.003; Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006; Kitatani K, 2007, J BIOL CHEM, V282, P20647, DOI 10.1074/jbc.M609162200; Kitatani K, 2006, J BIOL CHEM, V281, P36793, DOI 10.1074/jbc.M608137200; Kitatani K, 2009, J BIOL CHEM, V284, P12979, DOI 10.1074/jbc.M809500200; Koshkaryev A, 2012, CANCER BIOL THER, V13, P50, DOI 10.4161/cbt.13.1.18871; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maffucci T, 2005, J CELL BIOL, V169, P789, DOI 10.1083/jcb.200408005; Meyer AS, 2012, J CELL BIOL, V197, P721, DOI 10.1083/jcb.201201003; Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398; Mukhopadhyay A, 2009, FASEB J, V23, P751, DOI 10.1096/fj.08-120550; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; Nitta M, 2001, GYNECOL ONCOL, V81, P10, DOI 10.1006/gyno.2000.6084; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Ogiso H, 2014, METABOLITES, V4, P98, DOI 10.3390/metabo4010098; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Park JW, 2014, BBA-MOL CELL BIOL L, V1841, P671, DOI 10.1016/j.bbalip.2013.08.019; Pua TL, 2009, FUTURE ONCOL, V5, P1659, DOI 10.2217/FON.09.120; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stover T, 2003, J PHARMACOL EXP THER, V307, P468, DOI 10.1124/jpet.103.054056; Stover TC, 2005, CLIN CANCER RES, V11, P3465, DOI 10.1158/1078-0432.CCR-04-1770; Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200; Sun Y, 2008, J LEUKOCYTE BIOL, V83, P1512, DOI 10.1189/jlb.0108076; Takeda S, 2006, J BIOCHEM, V139, P255, DOI 10.1093/jb/mvj026; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Tran MA, 2008, CLIN CANCER RES, V14, P3571, DOI 10.1158/1078-0432.CCR-07-4881; van Vlerken LE, 2007, CANCER RES, V67, P4843, DOI 10.1158/0008-5472.CAN-06-1648; WANG E, 1991, J BIOL CHEM, V266, P14486; Wells A, 2013, TRENDS PHARMACOL SCI, V34, P283, DOI 10.1016/j.tips.2013.03.001; Wijesinghe DS, 2005, J LIPID RES, V46, P2706, DOI 10.1194/jlr.M500313-JLR200; Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yin XL, 2009, CELL PHYSIOL BIOCHEM, V24, P219, DOI 10.1159/000233248; Yoshizaki H, 2007, MOL BIOL CELL, V18, P119, DOI 10.1091/mbc.E06-05-0467; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zhou HY, 2007, ENDOCRINOLOGY, V148, P5195, DOI 10.1210/en.2007-0361	70	40	40	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2801	2812		10.1038/onc.2015.330	http://dx.doi.org/10.1038/onc.2015.330			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364609	Green Accepted			2022-12-28	WOS:000377472700013
J	Navab, R; Strumpf, D; To, C; Pasko, E; Kim, KS; Park, CJ; Hai, J; Liu, J; Jonkman, J; Barczyk, M; Bandarchi, B; Wang, YH; Venkat, K; Ibrahimov, E; Pham, NA; Ng, C; Radulovich, N; Zhu, CQ; Pintilie, M; Wang, D; Lu, A; Jurisica, I; Walker, GC; Gullberg, D; Tsao, MS				Navab, R.; Strumpf, D.; To, C.; Pasko, E.; Kim, K. S.; Park, C. J.; Hai, J.; Liu, J.; Jonkman, J.; Barczyk, M.; Bandarchi, B.; Wang, Y. H.; Venkat, K.; Ibrahimov, E.; Pham, N-A; Ng, C.; Radulovich, N.; Zhu, C-Q; Pintilie, M.; Wang, D.; Lu, A.; Jurisica, I.; Walker, G. C.; Gullberg, D.; Tsao, M-S			Integrin alpha 11 beta 1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer	ONCOGENE			English	Article							FOCAL ADHESION KINASE; COLLAGEN-BINDING; LYSYL OXIDASE; FIBROBLASTS; RECEPTOR; GROWTH; ALPHA-2-BETA-1; REORGANIZATION; MACROPHAGES; EXPRESSION	Integrin alpha 11 beta 1 is a stromal cell-specific receptor for fibrillar collagens and is overexpressed in carcinoma-associated fibroblasts (CAFs). We have investigated its direct role in cancer progression by generating severe combined immune deficient (SCID) mice deficient in integrin alpha 11 (alpha 11) expression. The growth of A549 lung adenocarcinoma cells and two patient-derived non-small cell lung carcinoma (NSCLC) xenografts in these alpha 11 knockout (alpha 11(-/-)) mice was significantly impeded, as compared with wild-type (alpha 11(+/+)) SCID mice. Orthotopic implantation of a spontaneously metastatic NCI-H460SM cell line into the lungs of alpha 11(-/-) and alpha 11(+/+) mice showed significant reduction in the metastatic potential of these cells in the alpha 11(-/-) mice. We identified that collagen cross-linking is associated with stromal alpha 11 expression, and the loss of tumor stromal alpha 11 expression was correlated with decreased collagen reorganization and stiffness. This study shows the role of integrin alpha 11 beta 1, a receptor for fibrillar collagen in differentiation of fibroblasts into CAFs. Furthermore, our data support an important role for alpha 11 signaling pathway in CAFs, promoting tumor growth and metastatic potential of NSCLC cells and being closely associated with collagen cross-linking and the organization and stiffness of fibrillar collagen matrices.	[Navab, R.; Strumpf, D.; To, C.; Pasko, E.; Park, C. J.; Hai, J.; Liu, J.; Jonkman, J.; Bandarchi, B.; Wang, Y. H.; Venkat, K.; Ibrahimov, E.; Pham, N-A; Ng, C.; Radulovich, N.; Zhu, C-Q; Pintilie, M.; Wang, D.; Lu, A.; Jurisica, I.; Tsao, M-S] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2C4, Canada; [Navab, R.; Strumpf, D.; To, C.; Pasko, E.; Park, C. J.; Hai, J.; Liu, J.; Jonkman, J.; Bandarchi, B.; Wang, Y. H.; Venkat, K.; Ibrahimov, E.; Pham, N-A; Ng, C.; Radulovich, N.; Zhu, C-Q; Pintilie, M.; Wang, D.; Lu, A.; Jurisica, I.; Tsao, M-S] Univ Hlth Network, Campbell Family Inst Canc Res, Toronto, ON M5G 2C4, Canada; [Pasko, E.; Tsao, M-S] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Kim, K. S.; Walker, G. C.] Univ Toronto, Dept Chem, 80 St George St, Toronto, ON M5S 1A1, Canada; [Barczyk, M.; Gullberg, D.] Univ Bergen, Dept Biomed, Bergen, Norway; [Barczyk, M.; Gullberg, D.] Univ Bergen, Ctr Canc Biomarkers, Bergen, Norway; [Jurisica, I.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; [Jurisica, I.; Tsao, M-S] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Bergen; University of Bergen; University of Toronto; University of Toronto	Tsao, MS (corresponding author), Univ Hlth Network, Dept Med Biophys & Lab Med & Pathobiol, 200 Elizabeth St,11th Floor, Toronto, ON M5G 2C4, Canada.	ming.tsao@uhn.on.ca	Hai, Josephine/AAO-9919-2020; Gullberg, Donald/H-2495-2016; Tsao, Ming-Sound/M-3503-2017; Navab, Roya/AGD-7380-2022; Tsao, Ming Sound/AFQ-7332-2022	Gullberg, Donald/0000-0002-7245-4437; Tsao, Ming Sound/0000-0002-9160-5405; Wang, Dennis/0000-0003-0068-1005; Hai, Josephine/0000-0002-5842-7686; Zhu, ChangQi/0000-0002-9992-0258; Pham, Nhu-An/0000-0003-3063-0292; Kim, Kris/0000-0002-8912-520X	Canadian Cancer Society [019293, 020527]; Canadian Institutes of Health Research [MOP-115174]; Terry Fox Foundation STIHR; CIHR [TGT-53912]; Norwegian Centre of Excellence; Research Council of Norway [223250]; Ontario Ministry of Health and Long Term Care	Canadian Cancer Society(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Terry Fox Foundation STIHR; CIHR(Canadian Institutes of Health Research (CIHR)); Norwegian Centre of Excellence; Research Council of Norway(Research Council of Norway); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	This work was supported by grants from the Canadian Cancer Society (# 019293 and # 020527), Canadian Institutes of Health Research grant MOP-115174, Terry Fox Foundation STIHR, CIHR grant TGT-53912 (BB), Norwegian Centre of Excellence grant, The Research Council of Norway grants 223250 (DG) and the Ontario Ministry of Health and Long Term Care. Dr Tsao is the M. Qasim Choksi chair in Lung Cancer Translational research. Dr Jurisica is the Canada Research Chair in Integrative Computational Biology. The data reported in this paper have been deposited into the Gene Expression Omnibus (GEO) database, http://ncbi.nlm.nih.gov/geo/(accession no. GSE51722).	Barczyk MM, 2009, J DENT RES, V88, P621, DOI 10.1177/0022034509339291; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Blumbach K, 2012, J BIOL CHEM, V287, P6431, DOI 10.1074/jbc.M111.283119; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Campagnola PJ, 2003, NAT BIOTECHNOL, V21, P1356, DOI 10.1038/nbt894; Carracedo S, 2010, J BIOL CHEM, V285, P10434, DOI 10.1074/jbc.M109.078766; Cheng T, 2014, J MOL CELL BIOL, V6, P506, DOI 10.1093/jmcb/mju039; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Egeblad M, 2008, DIS MODEL MECH, V1, P155, DOI 10.1242/dmm.000596; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314; Hertz H., 1882, J ANGEW MATH, V92, P156, DOI [10.1515/9783112342404-004, DOI 10.1515/CRLL.1882.92.156, 10.1515/crll.1882.92.156]; John T, 2011, CLIN CANCER RES, V17, P134, DOI 10.1158/1078-0432.CCR-10-2224; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Littell RC, 1998, J ANIM SCI, V76, P1216; Liu J, 2004, ONCOGENE, V23, P6316, DOI 10.1038/sj.onc.1207795; Lu N, 2010, MATRIX BIOL, V29, P166, DOI 10.1016/j.matbio.2009.11.003; Malkoski SP, 2012, CLIN CANCER RES, V18, P2173, DOI 10.1158/1078-0432.CCR-11-2557; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Navab R, 2009, NEOPLASIA, V11, P1292, DOI 10.1593/neo.09622; Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003; Owen KA, 2007, J CELL BIOL, V179, P1275, DOI 10.1083/jcb.200708093; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Popova SN, 2007, ACTA PHYSIOL, V190, P179, DOI 10.1111/j.1748-1716.2007.01718.x; Popova SN, 2004, DEV BIOL, V270, P427, DOI 10.1016/j.ydbio.2004.03.006; Popova SN, 2007, MOL CELL BIOL, V27, P4306, DOI 10.1128/MCB.00041-07; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Schulz JN, 2015, J INVEST DERMATOL, V135, P1435, DOI 10.1038/jid.2015.24; Sneddon IN., 1965, INT J ENG SCI, V3, P47, DOI [10.1016/0020-7225(65)90019-4, DOI 10.1016/0020-7225(65)90019-4, 10.1016/0020-7225(65)90019-4.477, DOI 10.1016/0020-7225(65)90019-4.477]; Svendsen OS, 2009, ARTERIOSCL THROM VAS, V29, P1864, DOI 10.1161/ATVBAHA.109.194308; Talior-Volodarsky I, 2012, CARDIOVASC RES, V96, P265, DOI 10.1093/cvr/cvs259; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Wilgus ML, 2011, CANCER-AM CANCER SOC, V117, P2186, DOI 10.1002/cncr.25768; Williams RM, 2005, BIOPHYS J, V88, P1377, DOI 10.1529/biophysj.104.047308; Xiao Q, 2012, CANCER MICROENVIRON, V5, P261, DOI 10.1007/s12307-012-0105-z; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yamauchi Mitsuo, 2008, V446, P95, DOI 10.1007/978-1-60327-084-7_7; Zeltz C, 2014, ADV EXP MED BIOL, V819, P73, DOI 10.1007/978-94-017-9153-3_5; Zeltz C, 2014, BBA-GEN SUBJECTS, V1840, P2533, DOI 10.1016/j.bbagen.2013.12.022; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200; Zhu CQ, 2007, P NATL ACAD SCI USA, V104, P11754, DOI 10.1073/pnas.0703040104; Zweers MC, 2007, J INVEST DERMATOL, V127, P467, DOI 10.1038/sj.jid.5700546	57	101	102	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1899	1908		10.1038/onc.2015.254	http://dx.doi.org/10.1038/onc.2015.254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148229	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000374010300003
J	Ciamporcero, E; Shen, H; Ramakrishnan, S; Ku, SY; Chintala, S; Shen, L; Adelaiye, R; Miles, KM; Ullio, C; Pizzimenti, S; Daga, M; Azabdaftari, G; Attwood, K; Johnson, C; Zhang, J; Barrera, G; Pili, R				Ciamporcero, E.; Shen, H.; Ramakrishnan, S.; Ku, S. Yu; Chintala, S.; Shen, L.; Adelaiye, R.; Miles, K. M.; Ullio, C.; Pizzimenti, S.; Daga, M.; Azabdaftari, G.; Attwood, K.; Johnson, C.; Zhang, J.; Barrera, G.; Pili, R.			YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; INVASIVE BLADDER-CANCER; INDEPENDENT PROGNOSTIC MARKER; BREAST-CANCER; HIPPO PATHWAY; CONFERS RESISTANCE; RADICAL CYSTECTOMY; UP-REGULATION; CISPLATIN; APOPTOSIS	Current standard of care for muscle-invasive urothelial cell carcinoma (UCC) is surgery along with perioperative platinum-based chemotherapy. UCC is sensitive to cisplatin-based regimens, but acquired resistance eventually occurs, and a subset of tumors is intrinsically resistant. Thus, there is an unmet need for new therapeutic approaches to target chemotherapy-resistant UCC. Yes-associated protein (YAP) is a transcriptional co-activator that has been associated with bladder cancer progression and cisplatin resistance in ovarian cancer. In contrast, YAP has been shown to induce DNA damage associated apoptosis in non-small cell lung carcinoma. However, no data have been reported on the YAP role in UCC chemo-resistance. Thus, we have investigated the potential dichotomous role of YAP in UCC response to chemotherapy utilizing two patient-derived xenograft models recently established. Constitutive expression and activation of YAP inversely correlated with in vitro and in vivo cisplatin sensitivity. YAP overexpression protected while YAP knockdown sensitized UCC cells to chemotherapy and radiation effects via increased accumulation of DNA damage and apoptosis. Furthermore, pharmacological YAP inhibition with verteporfin inhibited tumor cell proliferation and restored sensitivity to cisplatin. In addition, nuclear YAP expression was associated with poor outcome in UCC patients who received perioperative chemotherapy. In conclusion, these results suggest that YAP activation exerts a protective role and represents a pharmacological target to enhance the anti-tumor effects of DNA damaging modalities in the treatment of UCC.	[Ciamporcero, E.; Ramakrishnan, S.; Ku, S. Yu; Chintala, S.; Shen, L.; Adelaiye, R.; Miles, K. M.; Johnson, C.; Pili, R.] Roswell Pk Canc Inst, Dept Med, Genitourinary Program, Buffalo, NY 14263 USA; [Ciamporcero, E.; Ullio, C.; Pizzimenti, S.; Daga, M.; Barrera, G.] Univ Turin, Dept Clin & Biol Sci, Turin, Italy; [Shen, H.; Zhang, J.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; [Ramakrishnan, S.; Ku, S. Yu; Adelaiye, R.] Roswell Pk Canc Inst, Dept Canc Pathol & Prevent, Buffalo, NY 14263 USA; [Chintala, S.; Johnson, C.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; [Azabdaftari, G.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Attwood, K.] Roswell Pk Canc Inst, Dept Biostat & Bioinformat, Buffalo, NY 14263 USA; [Pili, R.] Indiana Univ, Dept Med, Indianapolis, IN USA	Roswell Park Cancer Institute; University of Turin; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Barrera, G (corresponding author), Univ Turin, Dept Clin & Biol Sci, Turin, Italy.; Pili, R (corresponding author), Indiana Univ, Dept Med, Simon Canc Ctr, Indianapolis, IN USA.; Pili, R (corresponding author), Roswell Pk Canc Inst, Elm&Carlton St, Buffalo, NY 14263 USA.	giuseppina.barrera@unito.it; rpili@iu.edu	Ciamporcero, Eric/M-6580-2017; Ramakrishnan, Swathi/O-5054-2019; Zhang, Jianmin/AAN-2931-2020; Pizzimenti, Stefania/AAB-8250-2022	Ciamporcero, Eric/0000-0002-3856-6435; Pizzimenti, Stefania/0000-0001-6937-8632	National Cancer Institute [P30 CA016056, R21 CA179693]; American Cancer Society [127226-RSG-14-214-01-TBE]; NATIONAL CANCER INSTITUTE [P30CA016056, R21CA179693] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was in part supported by the National Cancer Institute P30 CA016056 (RP), R21 CA179693 (JZ), the American Cancer Society 127226-RSG-14-214-01-TBE (JZ) and a research donation from Richard Di Vita and family (RP). We thank the MTMR and Pathology Core Facilities at Roswell Park Cancer Institute for processing the tissue samples.	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Belyanskaya LL, 2005, INT J CANCER, V117, P755, DOI 10.1002/ijc.21242; Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Ciamporcero E, 2015, MOL CANCER THER, V14, P101, DOI 10.1158/1535-7163.MCT-14-0094; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Ehsanian R, 2010, ONCOGENE, V29, P6160, DOI 10.1038/onc.2010.339; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Huang JM, 2013, ONCOGENE, V32, P2220, DOI 10.1038/onc.2012.231; Imanaka Y, 2011, J HUM GENET, V56, P270, DOI 10.1038/jhg.2011.1; Jiang N, 2015, ONCOGENE, V34, P2764, DOI 10.1038/onc.2014.206; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Liao WJ, 2009, METHODS, V48, P46, DOI 10.1016/j.ymeth.2009.02.016; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Liu JY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-349; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Madersbacher S, 2003, J CLIN ONCOL, V21, P690, DOI 10.1200/JCO.2003.05.101; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pollack A, 1997, CLIN CANCER RES, V3, P1823; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Reichert S, 2011, RADIOTHER ONCOL, V101, P51, DOI 10.1016/j.radonc.2011.06.037; Roos WP, 2013, CANCER LETT, V332, P237, DOI 10.1016/j.canlet.2012.01.007; Shah JB, 2011, CLIN CANCER RES, V17, P2608, DOI 10.1158/1078-0432.CCR-10-2770; Sheen-Chen SM, 2012, ANTICANCER RES, V32, P3321; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Sun XP, 2014, FEBS J, V281, P115, DOI 10.1111/febs.12577; Todorovic V, 2005, J CELL BIOL, V171, P559, DOI 10.1083/jcb.200504015; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Tsai HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090159; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wang MY, 2009, CANCER RES, V69, P3482, DOI 10.1158/0008-5472.CAN-08-2524; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao YL, 2014, CANCER RES, V74, P4493, DOI 10.1158/0008-5472.CAN-13-2712; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	53	83	83	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1541	1553		10.1038/onc.2015.219	http://dx.doi.org/10.1038/onc.2015.219			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26119935	Green Accepted			2022-12-28	WOS:000373063600007
J	Alesi, GN; Jin, L; Li, D; Magliocca, K; Kang, Y; Chen, ZG; Shin, DM; Khuri, FR; Kang, S				Alesi, G. N.; Jin, L.; Li, D.; Magliocca, K. R.; Kang, Y.; Chen, Z. G.; Shin, D. M.; Khuri, F. R.; Kang, S.			RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis	ONCOGENE			English	Article							CANCER METASTASIS; MAP KINASE; TYROSINE PHOSPHORYLATION; PROTEOMIC ANALYSIS; POTENTIAL TARGET; CELL-MIGRATION; PROTEIN; IDENTIFICATION; PATHWAY; EXPRESSION	Metastasis is responsible for 490% of cancer-related deaths. Complex signaling in cancer cells orchestrates the progression from a primary to a metastatic cancer. However, the mechanisms of these cellular changes remain elusive. We previously demonstrated that p90 ribosomal S6 kinase 2 (RSK2) promotes tumor metastasis. Here we investigated the role of RSK2 in the regulation of microtubule dynamics and its potential implication in cancer cell invasion and tumor metastasis. Stable knockdown of RSK2 disrupted microtubule stability and decreased phosphorylation of stathmin, a microtubule-destabilizing protein, at serine 16 in metastatic human cancer cells. We found that RSK2 directly binds and phosphorylates stathmin at the leading edge of cancer cells. Phosphorylation of stathmin by RSK2 reduced stathmin-mediated microtubule depolymerization. Moreover, overexpression of phospho-mimetic mutant stathmin S16D significantly rescued the decreased invasive and metastatic potential mediated by RSK2 knockdown in vitro and in vivo. Furthermore, stathmin phosphorylation positively correlated with RSK2 expression and metastatic cancer progression in primary patient tumor samples. Our finding demonstrates that RSK2 directly phosphorylates stathmin and regulates microtubule polymerization to provide a pro-invasive and pro-metastatic advantage to cancer cells. Therefore, the RSK2-stathmin pathway represents a promising therapeutic target and a prognostic marker for metastatic human cancers.	[Alesi, G. N.; Jin, L.; Li, D.; Chen, Z. G.; Shin, D. M.; Khuri, F. R.; Kang, S.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3006, Atlanta, GA 30322 USA; [Magliocca, K. R.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Emory University; Emory University; Princeton University	Kang, S (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3006, Atlanta, GA 30322 USA.	smkang@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Kang, Yibin/0000-0002-1626-6730	NIH [R01 CA175316, F31 CA183365]; ACS grant [RSG-11-081-01]; NATIONAL CANCER INSTITUTE [R01CA175316, F31CA183365] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Anthea Hammond for editorial assistance. We thank the shared resources facilities of the Winship Cancer Institute and the Integrated Cellular Imaging Core of Emory University. We also acknowledge and thank Dr Shi-Yong Sun for his insightful scientific input in the development of this work. This work was supported in part by NIH grants R01 CA175316 (to SK), F31 CA183365 (to GNA) and ACS grant RSG-11-081-01 (to SK). GNA is an NIH predoctoral fellow. FRK and SK are Georgia Cancer Coalition Scholars. SK is a Robbins Scholar and an American Cancer Society Basic Research Scholar.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Belletti B, 2011, EXPERT OPIN THER TAR, V15, P1249, DOI 10.1517/14728222.2011.620951; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Cheng AL, 2008, CLIN CANCER RES, V14, P435, DOI 10.1158/1078-0432.CCR-07-1215; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Holmfeldt P, 2006, MOL BIOL CELL, V17, P2921, DOI 10.1091/mbc.e06-02-0165; Hsieh SY, 2010, MOL CARCINOGEN, V49, P476, DOI 10.1002/mc.20627; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Jin LT, 2013, MOL CELL BIOL, V33, P2574, DOI 10.1128/MCB.01677-12; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Kang SM, 2010, J CLIN INVEST, V120, P1165, DOI 10.1172/JCI40582; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; Li D, 2013, J BIOL CHEM, V288, P32528, DOI 10.1074/jbc.M113.500561; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li Y, 2010, ENDOCRINOLOGY, V151, P5146, DOI 10.1210/en.2009-1506; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; Misek DE, 2002, CANCER CELL, V2, P217, DOI 10.1016/S1535-6108(02)00124-1; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; Mizumura K, 2006, J CELL PHYSIOL, V206, P363, DOI 10.1002/jcp.20465; Morrison KC, 2012, ANAL BIOCHEM, V420, P26, DOI 10.1016/j.ab.2011.08.020; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Polzin RG, 2004, GENE, V341, P209, DOI 10.1016/j.gene.2004.06.052; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; San-Marina S, 2012, BBA-GENE REGUL MECH, V1819, P1164, DOI 10.1016/j.bbagrm.2012.09.004; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Tan HT, 2012, J PROTEOME RES, V11, P1433, DOI 10.1021/pr2010956; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537	46	17	19	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5412	5421		10.1038/onc.2016.79	http://dx.doi.org/10.1038/onc.2016.79			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041561	Green Accepted			2022-12-28	WOS:000386677800007
J	Lee, T; Paquet, M; Larsson, O; Pelletier, J				Lee, T.; Paquet, M.; Larsson, O.; Pelletier, J.			Tumor cell survival dependence on the DHX9 DExH-box helicase	ONCOGENE			English	Article							BREAST-CANCER CELLS; RNA-POLYMERASE-II; TRANSLATION INITIATION; MESSENGER-RNAS; A INTERACTS; MUTANT P53; DNA; PROTEIN; PROLIFERATION; INHIBITOR	The NTP-dependent DExH/D-box helicase DHX9 is a key participant in a number of gene regulatory steps, including transcriptional, translational, and microRNA-mediated control, DNA replication and maintenance of genomic stability. DHX9 has also been implicated in tumor cell maintenance and drug response. Here we report that inhibition of DHX9 expression is lethal to human cancer cell lines and murine E mu-Myc lymphomas. Using a novel conditional shDHX9 mouse model, we demonstrate that sustained and prolonged (6 months) suppression of DHX9 does not result in any deleterious effects at the organismal level. Body weight, blood biochemistry and histology of various tissues were comparable to control mice. Global gene expression profiling revealed that, although reduction of DHX9 expression resulted in multiple transcriptome changes, these were relatively benign and did not lead to any discernible phenotype. Our results demonstrate a robust tolerance for systemic DHX9 suppression in vivo and support the targeting of DHX9 as an effective and specific chemotherapeutic approach.	[Lee, T.; Pelletier, J.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Paquet, M.] Univ Montreal, Fac Med Vet, Dept Pathol & Microbiol, St Hyacinthe, PQ, Canada; [Larsson, O.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Pelletier, J.] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Pelletier, J.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ, Canada	McGill University; Universite de Montreal; Karolinska Institutet; McGill University; McGill University	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.	jerry.pelletier@mcgill.ca	Paquet, Marilene/L-3414-2019	Paquet, Marilene/0000-0002-3562-4636; Larsson, Ola/0000-0003-1412-1308	CIHR; Canadian Cancer Society Research Institute [701362]; National Institutes of Health [CA163291]; Swedish Research Council; Swedish Cancer Society; NATIONAL CANCER INSTITUTE [R01CA163291] Funding Source: NIH RePORTER	CIHR(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Francis Robert for performing tail-vein injections of lymphoma cells into mice. TL was supported by a Maysie MacSporran graduate studentship and fellowships from the CIHR-sponsored Chemical Biology and Systems Biology Training Programs. This work is supported by grants from the Canadian Cancer Society Research Institute (no. 701362) and National Institutes of Health (CA163291) to JP and grants from the Swedish Research Council and the Swedish Cancer Society to OL.	Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Barde I., 2010, CURR PROTOC NEUROSCI; Calcabrini A, 2006, CARCINOGENESIS, V27, P1699, DOI 10.1093/carcin/bgl044; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chakraborty P, 2011, DNA REPAIR, V10, P654, DOI 10.1016/j.dnarep.2011.04.013; Dardenne E, 2012, NAT STRUCT MOL BIOL, V19, P1139, DOI 10.1038/nsmb.2390; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Gartel AL, 2002, MOL CANCER THER, V1, P639; HARPER JW, 1993, CELL, V75, P805; Hartman TR, 2006, NAT STRUCT MOL BIOL, V13, P509, DOI 10.1038/nsmb1092; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; Hui L, 2006, ONCOGENE, V25, P7305, DOI 10.1038/sj.onc.1209735; Huo LF, 2010, P NATL ACAD SCI USA, V107, P16125, DOI 10.1073/pnas.1000743107; Jain A, 2013, NUCLEIC ACIDS RES, V41, P10345, DOI 10.1093/nar/gkt804; Jain A, 2010, BIOCHEMISTRY-US, V49, P6992, DOI 10.1021/bi100795m; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; LEE CG, 1992, J BIOL CHEM, V267, P4398; Lee T, 2014, J BIOL CHEM, V289, P22798, DOI 10.1074/jbc.M114.568535; Lin CJ, 2012, CELL REPORTS, V1, P325, DOI 10.1016/j.celrep.2012.02.010; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Manojlovic Z, 2012, RNA, V18, P321, DOI 10.1261/rna.030288.111; Mazurek A, 2014, CELL REP, V7, P1887, DOI 10.1016/j.celrep.2014.05.019; McJunkin K, 2011, P NATL ACAD SCI USA, V108, P7113, DOI 10.1073/pnas.1104097108; Mills JR, 2013, BLOOD, V121, P3402, DOI 10.1182/blood-2012-06-434365; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Parsyan A, 2009, P NATL ACAD SCI USA, V106, P22217, DOI 10.1073/pnas.0909773106; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Robb GB, 2007, MOL CELL, V26, P523, DOI 10.1016/j.molcel.2007.04.016; Robert F, 2014, P NATL ACAD SCI USA, V111, P13421, DOI 10.1073/pnas.1402650111; Saporita AJ, 2011, CANCER RES, V71, P6708, DOI 10.1158/0008-5472.CAN-11-1472; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tetsuka T, 2004, EUR J BIOCHEM, V271, P3741, DOI 10.1111/j.1432-1033.2004.04314.x; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Trudel S, 2007, CLIN CANCER RES, V13, P621, DOI 10.1158/1078-0432.CCR-06-1526; Walstrom KM, 2005, MECH DEVELOP, V122, P707, DOI 10.1016/j.mod.2004.12.002; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; Zhang SS, 1997, J BIOL CHEM, V272, P11487; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	47	33	33	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5093	5105		10.1038/onc.2016.52	http://dx.doi.org/10.1038/onc.2016.52			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26973242	Green Accepted, Bronze			2022-12-28	WOS:000384433000002
J	Lindblad, O; Cordero, E; Puissant, A; Macaulay, L; Ramos, A; Kabir, NN; Sun, J; Vallon-Christersson, J; Haraldsson, K; Hemann, MT; Borg, A; Levander, F; Stegmaier, K; Pietras, K; Ronnstrand, L; Kazi, JU				Lindblad, O.; Cordero, E.; Puissant, A.; Macaulay, L.; Ramos, A.; Kabir, N. N.; Sun, J.; Vallon-Christersson, J.; Haraldsson, K.; Hemann, M. T.; Borg, A.; Levander, F.; Stegmaier, K.; Pietras, K.; Ronnstrand, L.; Kazi, J. U.			Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; FLT3; MUTATIONS; INHIBITORS; KINASE; PKI-587; PKC412; TARGET; PI3K/AKT/MTOR; CYTOGENETICS	Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient. To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib. Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors. Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells. Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer FLT3 dependent. Gene expression analysis of sensitive and resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway in the resistant phenotype, which was further supported by next-generation sequencing and phospho-specific-antibody array analysis. Furthermore, a selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation, and induced apoptosis in resistant cell lines. Gedatolisib significantly extended survival of mice in a sorafenib-resistant AML patient-derived xenograft model. Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway in FLT3-ITD-dependent AML results in resistance to drugs targeting FLT3.	[Lindblad, O.; Cordero, E.; Macaulay, L.; Sun, J.; Pietras, K.; Ronnstrand, L.; Kazi, J. U.] Lund Univ, Dept Lab Med, Div Translat Canc Res, Medicon Village 404 C3, S-22363 Lund, Skane, Sweden; [Lindblad, O.; Macaulay, L.; Sun, J.; Ronnstrand, L.; Kazi, J. U.] Lund Univ, Dept Lab Med, Lund Stem Cell Ctr, Lund, Sweden; [Lindblad, O.] Skane Univ Hosp, Dept Hematol & Vasc Disorders, Lund, Sweden; [Puissant, A.; Stegmaier, K.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA; [Puissant, A.; Stegmaier, K.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA; [Ramos, A.; Hemann, M. T.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Kabir, N. N.; Kazi, J. U.] KN Biomed Res Inst, Lab Computat Biochem, Barisal, Bangladesh; [Vallon-Christersson, J.; Haraldsson, K.; Borg, A.] Lund Univ, Dept Oncol & Pathol, Lund, Sweden; [Levander, F.] Lund Univ, Dept Immunotechnol, BILS, Lund, Sweden	Lund University; Lund University; Lund University; Skane University Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT); Lund University; Lund University	Kazi, JU (corresponding author), Lund Univ, Dept Lab Med, Div Translat Canc Res, Medicon Village 404 C3, S-22363 Lund, Skane, Sweden.	kazi.uddin@med.lu.se	Pietras, Kristian/ABG-2097-2021; Pietras, Kristian/ABE-8727-2020; Kazi, Julhash/D-9190-2011	Pietras, Kristian/0000-0001-6738-4705; Vallon-Christersson, Johan/0000-0002-2195-0385; Levander, Fredrik/0000-0002-0710-9792; Ronnstrand, Lars/0000-0003-1275-5809; Kazi, Julhash/0000-0002-0719-5336	Kungliga Fysiografiska Sallskapet i Lund; Ollie and Elof Ericssons Stiftelse; Ake-Wiberg Stiftelse; Lars Hiertas Minne Stiftelse; Stiftelsen Olle Engkvist Byggmastare; Harald Jeanssons Stiftelse and Harald och Greta Jeanssons Stiftelse; Swedish Childhood Cancer Foundation; Crafoord foundation; Stiftelsen Clas Groschinskys Minnesfond; Swedish Cancer Foundation; Swedish Research Council; Region Skane; Research Funds at Skane University Hospital; Gunnar Nilssons Cancer Foundation; NIH [R01CA140292]; NATIONAL CANCER INSTITUTE [R01CA140292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007287] Funding Source: NIH RePORTER	Kungliga Fysiografiska Sallskapet i Lund; Ollie and Elof Ericssons Stiftelse; Ake-Wiberg Stiftelse; Lars Hiertas Minne Stiftelse; Stiftelsen Olle Engkvist Byggmastare(Swedish Research Council); Harald Jeanssons Stiftelse and Harald och Greta Jeanssons Stiftelse; Swedish Childhood Cancer Foundation(European Commission); Crafoord foundation; Stiftelsen Clas Groschinskys Minnesfond; Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Region Skane; Research Funds at Skane University Hospital; Gunnar Nilssons Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Peter J Valk at Erasmus University Medical Center for help with AML patient data and Dr David Weinstock for leading the development of a bank of patient-derived xenograft models of leukemia at the DFCI. This research was funded by Kungliga Fysiografiska Sallskapet i Lund (JUK), Ollie and Elof Ericssons Stiftelse (JUK), Ake-Wiberg Stiftelse (JUK), Lars Hiertas Minne Stiftelse (JUK), Stiftelsen Olle Engkvist Byggmastare (JUK), Harald Jeanssons Stiftelse and Harald och Greta Jeanssons Stiftelse (JUK), the Swedish Childhood Cancer Foundation (JUK), the Crafoord foundation (JUK), Stiftelsen Clas Groschinskys Minnesfond (JUK), Swedish Cancer Foundation (LR), Swedish Research Council (LR), Region Skane (LR), the Research Funds at Skane University Hospital (LR), Gunnar Nilssons Cancer Foundation (LR) and the NIH R01CA140292 (KS). JUK is a recipient of Assistant Professorship (forskarassistenttjanst) grant from the Swedish Childhood Cancer Foundation. KP is the Goran & Birgitta Grosskopf Professor of Molecular Medicine at Lund University.	Albers C, 2013, LEUKEMIA, V27, P1416, DOI 10.1038/leu.2013.14; Barrett D, 2012, PEDIATR DRUGS, V14, P299, DOI 10.2165/11594740-000000000-00000; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Breitenbuecher F, 2009, BLOOD, V113, P4063, DOI 10.1182/blood-2007-11-126664; Cui J, 2006, CLIN CHIM ACTA, V368, P155, DOI 10.1016/j.cca.2005.12.043; D'Amato V, 2014, BRIT J CANCER, V110, P2887, DOI 10.1038/bjc.2014.241; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Gedaly R, 2012, J SURG RES, V176, P542, DOI 10.1016/j.jss.2011.10.045; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Hakkinen J, 2009, J PROTEOME RES, V8, P3037, DOI 10.1021/pr900189c; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Juliusson G, 2009, BLOOD, V113, P4179, DOI 10.1182/blood-2008-07-172007; Kiyoi H, 2005, INT J HEMATOL, V82, P85, DOI 10.1532/IJH97.05066; Knapper S, 2006, BLOOD, V108, P3494, DOI 10.1182/blood-2006-04-015487; Kutok JL, 2011, J CELL MOL MED, V15, P86, DOI 10.1111/j.1582-4934.2009.00925.x; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Leung AYH, 2013, LEUKEMIA, V27, P260, DOI 10.1038/leu.2012.195; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Mallon R, 2011, CLIN CANCER RES, V17, P3193, DOI 10.1158/1078-0432.CCR-10-1694; Man CH, 2014, BLOOD, V123, P2530, DOI 10.1182/blood-2013-07-512194; Man CH, 2012, BLOOD, V119, P5133, DOI 10.1182/blood-2011-06-363960; Martelli AM, 2011, LEUKEMIA, V25, P1064, DOI 10.1038/leu.2011.46; Masson K, 2009, CELL SIGNAL, V21, P1717, DOI 10.1016/j.cellsig.2009.06.002; Meshinchi S, 2008, BLOOD, V111, P4930, DOI 10.1182/blood-2008-01-117770; Nogami A, 2015, ONCOTARGET, V6, P9189, DOI 10.18632/oncotarget.3279; Puissant A, 2014, CANCER CELL, V25, P226, DOI 10.1016/j.ccr.2014.01.022; Razumovskaya E, 2009, EXP HEMATOL, V37, P979, DOI 10.1016/j.exphem.2009.05.008; Sandhofer N, 2015, LEUKEMIA, V29, P828, DOI 10.1038/leu.2014.305; Sandin M, 2013, MOL CELL PROTEOMICS, V12, P1407, DOI 10.1074/mcp.O112.021907; Sasore T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105280; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Sheikhha Mohammad Hasan, 2003, Hematol J, V4, P41, DOI 10.1038/sj.thj.6200224; Smith CC, 2013, BLOOD, V121, P3165, DOI 10.1182/blood-2012-07-442871; Smith CC, 2012, NATURE, V485, P260, DOI 10.1038/nature11016; Stolzel F, 2010, ANN HEMATOL, V89, P653, DOI 10.1007/s00277-009-0889-1; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Stone RM, 2015, ASH ANN M, V126, P6, DOI DOI 10.1182/blood.V126.23.6.6; Sun J, 2014, ONCOGENE, V33, P5360, DOI 10.1038/onc.2013.479; Venkatesan AM, 2010, J MED CHEM, V53, P2636, DOI 10.1021/jm901830p; von Bubnoff N, 2009, CANCER RES, V69, P3032, DOI 10.1158/0008-5472.CAN-08-2923; Wang W, 2010, BLOOD, V116, P254, DOI 10.1182/blood-2009-11-254664; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299	45	71	72	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5119	5131		10.1038/onc.2016.41	http://dx.doi.org/10.1038/onc.2016.41			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26999641	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000384433000004
J	Jones, KB; Barrott, JJ; Xie, M; Haldar, M; Jin, H; Zhu, JF; Monument, MJ; Mosbruger, TL; Langer, EM; Randall, RL; Wilson, RK; Cairns, BR; Ding, L; Capecchi, MR				Jones, K. B.; Barrott, J. J.; Xie, M.; Haldar, M.; Jin, H.; Zhu, J-F; Monument, M. J.; Mosbruger, T. L.; Langer, E. M.; Randall, R. L.; Wilson, R. K.; Cairns, B. R.; Ding, L.; Capecchi, M. R.			The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; RETROSPECTIVE ANALYSIS; PROGNOSTIC IMPLICATION; MULTIGENE FAMILY; GENE-EXPRESSION; MOUSE MODEL; RT-PCR; SSX; SYT; TRANSCRIPTS	Synovial sarcomas are aggressive soft-tissue malignancies that express chromosomal translocation-generated fusion genes, SS18-SSX1 or SS18-SSX2 in most cases. Here, we report a mouse sarcoma model expressing SS18-SSX1, complementing our prior model expressing SS18-SSX2. Exome sequencing identified no recurrent secondary mutations in tumors of either genotype. Most of the few mutations identified in single tumors were present in genes that were minimally or not expressed in any of the tumors. Chromosome 6, either entirely or around the fusion gene expression locus, demonstrated a copy number gain in a majority of tumors of both genotypes. Thus, by fusion oncogene coding sequence alone, SS18-SSX1 and SS18-SSX2 can each drive comparable synovial sarcomagenesis, independent from other genetic drivers. SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences overall. In direct tumorigenesis comparisons, SS18-SSX2 was slightly more sarcomagenic than SS18-SSX1, but equivalent in its generation of biphasic histologic features. Meta-analysis of human synovial sarcoma patient series identified two tumor-gentoype-phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18-SSX2 tumors. Re-analysis of human SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences, but highlighted increased native SSX2 expression in SS18-SSX1 tumors. This suggests that the translocated locus may drive genotypephenotype differences more than the coding sequence of the fusion gene created. Two possible roles for native SSX2 in synovial sarcomagenesis are explored. Thus, even specific partial failures of mouse genetic modeling can be instructive to human tumor biology.	[Jones, K. B.; Barrott, J. J.; Jin, H.; Zhu, J-F; Monument, M. J.; Randall, R. L.] Univ Utah, Dept Orthopaed, 2000 Circle Hope Dr,Room 4263, Salt Lake City, UT 84112 USA; [Jones, K. B.; Barrott, J. J.; Jin, H.; Zhu, J-F; Cairns, B. R.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT USA; [Jones, K. B.; Barrott, J. J.; Jin, H.; Zhu, J-F; Monument, M. J.; Mosbruger, T. L.; Randall, R. L.; Cairns, B. R.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Xie, M.; Wilson, R. K.; Ding, L.] Washington Univ, Dept Med, St Louis, MO USA; [Haldar, M.; Langer, E. M.; Capecchi, M. R.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA; [Mosbruger, T. L.] Univ Utah, Dept Bioinformat, Salt Lake City, UT USA; [Wilson, R. K.; Ding, L.] Washington Univ, McDonnell Genome Inst, St Louis, MO USA; [Wilson, R. K.; Ding, L.] Washington Univ, Dept Genet, St Louis, MO 63110 USA; [Wilson, R. K.; Ding, L.] Washington Univ, Siteman Canc Ctr, St Louis, MO USA; [Cairns, B. R.] Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Washington University (WUSTL); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Jones, KB (corresponding author), Univ Utah, Dept Orthopaed, 2000 Circle Hope Dr,Room 4263, Salt Lake City, UT 84112 USA.; Jones, KB (corresponding author), Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, 2000 Circle Hope Dr,Room 4263, Salt Lake City, UT 84112 USA.	kevin.jones@hci.utah.edu	Wilson, Richard K./AAF-4139-2019	Wilson, Richard K./0000-0002-1992-1358; Barrott, Jared/0000-0001-6059-9009	Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research; Damon Runyon Cancer Research Foundation; National Cancer Institute/National Institutes of Health (NCI/NIH) [R01CA180006]; National Human Genome Research Institute/NIH [U01HG006517, U54HG003079]; NCI/NIH [K08CA138764]; National Cancer Institute [P30CA042014]; Huntsman Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA210165, P30CA042014, K08CA138764, R01CA180006] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG006517, U54HG003079] Funding Source: NIH RePORTER	Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research; Damon Runyon Cancer Research Foundation; National Cancer Institute/National Institutes of Health (NCI/NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Human Genome Research Institute/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Huntsman Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Matt Hockin for provision of the TATCre and Marc Ladanyi, Louis Guillo, Jean- Michel Coindre, Fernanda Amary, Alessandro Gronchi, Ira Kokovic, Satoshi Takenaka and Takafumi Ueda for sharing raw data from their previously published patient series. This work was directly supported by the Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research and the Damon Runyon Cancer Research Foundation to KBJ, National Cancer Institute/National Institutes of Health (NCI/NIH) grant R01CA180006 to LD and National Human Genome Research Institute/NIH grants U01HG006517 to LD and U54HG003079 to RKW. KBJ received additional career development support from NCI/NIH K08CA138764. This work was also partly supported by P30CA042014 from the National Cancer Institute and the Huntsman Cancer Foundation.	Amary MFC, 2007, MODERN PATHOL, V20, P482, DOI 10.1038/modpathol.3800761; Badea TC, 2003, J NEUROSCI, V23, P2314; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Barrott JJ, 2015, ONCOTARGET, V6, P22758, DOI 10.18632/oncotarget.4283; Begueret H, 2005, AM J SURG PATHOL, V29, P339; Bijwaard KE, 2002, J MOL DIAGN, V4, P59, DOI 10.1016/S1525-1578(10)60681-2; Billings SD, 2004, MODERN PATHOL, V17, P141, DOI 10.1038/modpathol.3800042; Breslin A, 2007, BIOCHEM BIOPH RES CO, V363, P462, DOI 10.1016/j.bbrc.2007.09.052; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; Chen L, 2012, INT J ONCOL, V40, P1986, DOI 10.3892/ijo.2012.1369; Chen YT, 2003, GENOMICS, V82, P628, DOI 10.1016/S0888-7543(03)00183-6; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; D'Arcy P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095136; de Bruijn DRH, 2002, GENE CHROMOSOME CANC, V34, P285, DOI 10.1002/gcc.10073; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; Fernebro J, 2006, INT J CANCER, V118, P1165, DOI 10.1002/ijc.21475; Francis JC, 2015, J PATHOL, V236, P186, DOI 10.1002/path.4517; Goodwin ML, 2014, CANCER CELL, V26, P851, DOI 10.1016/j.ccell.2014.10.003; Guillou L, 2004, J CLIN ONCOL, V22, P4040, DOI 10.1200/JCO.2004.11.093; Gure AO, 2002, INT J CANCER, V101, P448, DOI 10.1002/ijc.10634; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Haldar M, 2009, CANCER RES, V69, P3657, DOI 10.1158/0008-5472.CAN-08-4127; Herzog CE, 2005, J PEDIAT HEMATOL ONC, V27, P215, DOI 10.1097/01.mph.0000161762.53175.e4; Hori A, 2015, MOL BIOL CELL, V26, P2005, DOI 10.1091/mbc.E14-11-1561; Hur K, 2014, GUT, V63, P635, DOI 10.1136/gutjnl-2012-304219; Inagaki H, 2000, MODERN PATHOL, V13, P482, DOI 10.1038/modpathol.3880083; Joseph CG, 2014, GENE CHROMOSOME CANC, V53, P15, DOI 10.1002/gcc.22114; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kim SK, 2014, INT J CANCER, V134, P1067, DOI 10.1002/ijc.28445; Kokovic I, 2004, CANCER DETECT PREV, V28, P294, DOI 10.1016/j.cdp.2004.06.002; Kubo T, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1168-3; Ladanyi M, 2002, CANCER RES, V62, P135; LEROY H, 1993, GENE CHROMOSOME CANC, V6, P156; Li C, 2001, GENOME BIOL, V2, DOI DOI 10.1186/GB-2001-2-8-RESEARCH0032; McFadden DG, 2014, CELL, V156, P1298, DOI 10.1016/j.cell.2014.02.031; Mezzelani A, 2001, BRIT J CANCER, V85, P1535, DOI 10.1054/bjoc.2001.2088; Nakayama R, 2010, AM J SURG PATHOL, V34, P1599, DOI 10.1097/PAS.0b013e3181f7ce2c; Ogawa K, 1999, CARCINOGENESIS, V20, P2083, DOI 10.1093/carcin/20.11.2083; Perani M, 2003, ONCOGENE, V22, P8156, DOI 10.1038/sj.onc.1207031; Przybyl J, 2014, INT J BIOCHEM CELL B, V53, P505, DOI 10.1016/j.biocel.2014.05.006; Ren T, 2013, BRIT J CANCER, V109, P2279, DOI 10.1038/bjc.2013.547; Sandberg AA, 2002, CANCER GENET CYTOGEN, V133, P1, DOI 10.1016/S0165-4608(01)00626-4; Straessler KM, 2013, CANCER CELL, V23, P215, DOI 10.1016/j.ccr.2012.12.019; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Sun Y, 2009, CANCER SCI, V100, P1018, DOI 10.1111/j.1349-7006.2009.01134.x; Takenaka S, 2008, ONCOL REP, V19, P467; Tang SHE, 2002, GENESIS, V32, P199, DOI 10.1002/gene.10030; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; Tvrdik D, 2005, MED SCI MONITOR, V11, pMT1; Varela I, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r100; Wartman LD, 2011, J CLIN INVEST, V121, P1445, DOI 10.1172/JCI45284; Wei YK, 2002, CHINESE MED J-PEKING, V115, P1043; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Xu Z, 2001, Zhonghua Bing Li Xue Za Zhi, V30, P431; Yuan W, 2013, ONCOGENE, V32, P318, DOI 10.1038/onc.2012.53	58	23	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5021	5032		10.1038/onc.2016.38	http://dx.doi.org/10.1038/onc.2016.38			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26947017	Green Submitted, Green Accepted			2022-12-28	WOS:000383965300006
J	Conley, SJ; Bosco, EE; Tice, DA; Hollingsworth, RE; Herbst, R; Xiao, Z				Conley, S. J.; Bosco, E. E.; Tice, D. A.; Hollingsworth, R. E.; Herbst, R.; Xiao, Z.			HER2 drives Mucin-like 1 to control proliferation in breast cancer cells	ONCOGENE			English	Article							FOCAL ADHESION KINASE; EPITHELIAL-SPECIFIC DISRUPTION; CYCLE PROGRESSION; EXPRESSION; IDENTIFICATION; AMPLIFICATION; ACTIVATION	Mucin-like 1 (MUCL1) was first identified as a breast-specific gene over a decade ago. Based on its highly restricted mRNA expression in breast tissue and continued expression during breast tumorigenesis and progression, MUCL1 is an attractive tumor-associated antigen and a potential therapeutic target. However, very little is known about the cellular location, biological functions and regulation of the MUCL1 protein, which will have a major impact on its druggability. Here we describe our efforts to fully characterize the cellular localization of MUCL1, investigate its regulation by key breast cancer oncogenes such as human epidermal growth factor receptor 2 (HER2) and discover its functional roles in breast cancer. Although some mucins are membrane bound, our data indicate that MUCL1 is secreted by some breast cancer cells, whereas others only express high levels of intracellular MUCL1. MUCL1 expression is highest in HER2-amplified breast tumors and inhibiting HER2 activity in tumor cells resulted in a decreased MUCL1 expression. In-depth investigation demonstrated that phosphoinositide3-kinase/Akt pathway, but not Ras/MEK pathway, controls MUCL1 expression downstream of HER2. Phenotypic assays revealed a strong dependence of HER2-positive cells on MUCL1 for cell proliferation. We further identified the mechanism by which MUCL1 regulates cell growth. Knockdown of MUCL1 induced a G1/S phase arrest concomitant with decreased cyclin D and increased p21 and p27 levels. Finally, we investigated the impact of MUCL1 loss on kinase signaling pathways in breast cancer cells through phospho-kinase array profiling. MUCL1 silencing abrogated phospho-focal adhesion kinase (FAK), Jun NH2-terminal kinase (JNK) and c-Jun signals, but not extracellular signal-regulated kinase or Akt pathway activities, thereby pointing to FAK/JNK pathway as the downstream effector of MUCL1 signaling. We are the first to identify an important role for MUCL1 in the proliferation of breast cancer cells, probably mediated via the FAK/JNK signaling pathway. Taken together, these data suggest a potential utility for therapeutic targeting of this protein in breast cancer.	[Conley, S. J.; Bosco, E. E.; Tice, D. A.; Hollingsworth, R. E.; Herbst, R.; Xiao, Z.] MedImmune LLC, Oncol Res, One MedImmune Way, Gaithersburg, MD 20878 USA	AstraZeneca; Medimmune	Conley, SJ; Xiao, Z (corresponding author), MedImmune LLC, Oncol Res, One MedImmune Way, Gaithersburg, MD 20878 USA.	conleys@medimmune.com; xiaoz@medimmune.com			MedImmune	MedImmune(AstraZenecaMedimmune)	Funding for research was provided by MedImmune. We thank John Meekin and Rosa Carrasco for the RNA library, and Terry O'Day and Xin Cao for statistical analysis.	Ayerbes MV, 2008, ADV EXP MED BIOL, V617, P331, DOI 10.1007/978-0-387-69080-3_31; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Colpitts TL, 2002, TUMOR BIOL, V23, P263, DOI 10.1159/000068566; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Houghton RL, 2001, MOL DIAGN, V6, P79, DOI 10.2165/00066982-200106020-00003; Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Lambert Arthur W, 2012, ISRN Oncol, V2012, P493283, DOI 10.5402/2012/493283; Liu L, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-71; Liu ZZ, 2010, CLIN EXP METASTAS, V27, P251, DOI 10.1007/s10585-010-9323-2; Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; Miksicek RJ, 2002, CANCER RES, V62, P2736; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Skliris GP, 2008, HISTOPATHOLOGY, V52, P355, DOI 10.1111/j.1365-2559.2007.02955.x; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TIWARI RK, 1992, ANTICANCER RES, V12, P419; Valladares-Ayerbes M, 2009, J CANCER RES CLIN, V135, P1185, DOI 10.1007/s00432-009-0559-7; Wadle A, 2005, INT J CANCER, V117, P104, DOI 10.1002/ijc.21147; Weigelt B, 2004, BRIT J CANCER, V90, P1531, DOI 10.1038/sj.bjc.6601659; Yang Hua-Wei, 2005, Ai Zheng, V24, P842; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	25	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4225	4234		10.1038/onc.2015.487	http://dx.doi.org/10.1038/onc.2015.487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26725324	hybrid, Green Published			2022-12-28	WOS:000382149800007
J	Yang, W; Du, WW; Li, X; Yee, AJ; Yang, BB				Yang, W.; Du, W. W.; Li, X.; Yee, A. J.; Yang, B. B.			Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis	ONCOGENE			English	Article							GENE-EXPRESSION; TRANSCRIPTION FACTORS; MICRORNA SPONGES; CANCER; METASTASIS; SURVIVAL; TUMORIGENESIS; INVASION; DIFFERENTIATION; PROTEINS	It has recently been shown that the upregulation of a pseudogene specific to a protein-coding gene could function as a sponge to bind multiple potential targeting microRNAs (miRNAs), resulting in increased gene expression. Similarly, it was recently demonstrated that circular RNAs can function as sponges for miRNAs, and could upregulate expression of mRNAs containing an identical sequence. Furthermore, some mRNAs are now known to not only translate protein, but also function to sponge miRNA binding, facilitating gene expression. Collectively, these appear to be effective mechanisms to ensure gene expression and protein activity. Here we show that expression of a member of the forkhead family of transcription factors, Foxo3, is regulated by the Foxo3 pseudogene (Foxo3P), and Foxo3 circular RNA, both of which bind to eight miRNAs. We found that the ectopic expression of the Foxo3P, Foxo3 circular RNA and Foxo3 mRNA could all suppress tumor growth and cancer cell proliferation and survival. Our results showed that at least three mechanisms are used to ensure protein translation of Foxo3, which reflects an essential role of Foxo3 and its corresponding non-coding RNAs.	[Yang, W.; Du, W. W.; Li, X.; Yee, A. J.; Yang, B. B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Yang, W.; Du, W. W.; Li, X.; Yang, B. B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Li, X.] Guangdong Inst Microbiol, State Key Lab Appl Microbiol Southern China, Guangzhou, Guangdong, Peoples R China; [Yang, B. B.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Guangdong Academy of Sciences; Institute of Microbiology, Guangdong Academy of Sciences; University of Toronto	Yee, AJ; Yang, BB (corresponding author), Univ Toronto, Sunnybrook Res Inst, S Wing Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	albert.yee@sunnybrook.ca; byang@sri.utoronto.ca		Yang, Burton B/0000-0002-2892-7209	Natural Sciences and Engineering Research Council of Canada (NSERC) [227937-2012]; Heart and Stroke Foundation of Ontario [CI 7418]; Canadian Institutes of Health Research; Breast Cancer Foundation of Ontario	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Breast Cancer Foundation of Ontario	This work was supported by a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC; 227937-2012) to BBY, who is the recipient of a Career Investigator Award (CI 7418) from the Heart and Stroke Foundation of Ontario. WY is supported by a Graduate Scholarship from Canadian Institutes of Health Research. WWD is supported by a Postdoctoral Fellowship from the Breast Cancer Foundation of Ontario.	AbouHaidar MG, 2014, P NATL ACAD SCI USA, V111, P14542, DOI 10.1073/pnas.1402814111; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773; Bella L, 2014, CURR DRUG TARGETS, V15, P1; Boulias K, 2012, CELL METAB, V15, P439, DOI 10.1016/j.cmet.2012.02.014; Bowman A, 2011, CANCER CELL, V20, P415, DOI 10.1016/j.ccr.2011.10.003; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen QH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015288; Cho EC, 2014, ONCOTARGET, V5, P4834, DOI 10.18632/oncotarget.2044; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Du WW, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.305; Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110; Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670; Haeusler RA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6190; Haimovich G, 2013, CELL, V153, P1000, DOI 10.1016/j.cell.2013.05.012; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hentze MW, 2013, EMBO J, V32, P923, DOI 10.1038/emboj.2013.53; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jeyapalan Z, 2011, NUCLEIC ACIDS RES, V39, P3026, DOI 10.1093/nar/gkq1003; Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113; Kloet DEA, 2011, BBA-MOL CELL RES, V1813, P1926, DOI 10.1016/j.bbamcr.2011.04.003; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; LaPierre DP, 2007, CANCER RES, V67, P4742, DOI 10.1158/0008-5472.CAN-06-3610; Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104; Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527; Li J, 2015, TUMOR BIOL, V36, P685, DOI 10.1007/s13277-014-2698-y; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Moriishi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086629; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nam Y, 2011, CELL, V147, P1080, DOI 10.1016/j.cell.2011.10.020; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Rutnam ZJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3914; Rutnam ZJ, 2012, J CELL SCI, V125, P2075, DOI 10.1242/jcs100818; Salazar M, 2015, CELL DEATH DIFFER, V22, P131, DOI 10.1038/cdd.2014.133; Bilbao PS, 2013, BBA-GEN SUBJECTS, V1830, P4456, DOI 10.1016/j.bbagen.2013.05.034; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Shatseva T, 2011, J CELL SCI, V124, P2826, DOI 10.1242/jcs.077529; Siragam V, 2012, ONCOTARGET, V3, P1370, DOI 10.18632/oncotarget.717; Sykes SM, 2011, CELL, V146, P697, DOI 10.1016/j.cell.2011.07.032; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang CH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002420; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang XL, 2013, NUCLEIC ACIDS RES, V41, P9688, DOI 10.1093/nar/gkt680	51	242	256	3	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3919	3931		10.1038/onc.2015.460	http://dx.doi.org/10.1038/onc.2015.460			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26657152				2022-12-28	WOS:000381013100004
J	D'Abramo, M; Besker, N; Desideri, A; Levine, AJ; Melino, G; Chillemi, G				D'Abramo, M.; Besker, N.; Desideri, A.; Levine, A. J.; Melino, G.; Chillemi, G.			The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; MUTANT P53; CELL-DEATH; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; LUNG-CANCER; TRANSCRIPTIONAL ACTIVATION; ENZYME SPECIFICITY; LYSINE METHYLATION; STRUCTURAL BASIS	The Trp53 gene is the most frequently mutated gene in all human cancers. Its protein product p53 is a very powerful transcription factor that can activate different biochemical pathways and affect the regulation of metabolism, senescence, DNA damage response, cell cycle and cell death. The understanding of its function at the molecular level could be of pivotal relevance for therapy. Investigation of long-range intra- and interdomain communications in the p53 tetramer-DNA complex was performed by means of an atomistic model that included the tetramerization helices in the C-terminal domain, the DNA-binding domains and a consensus DNA-binding site of 18 base pairs. Nonsymmetric dynamics are illustrated in the four DNA-binding domains, with loop L1 switching from inward to outward conformations with respect to the DNA major groove. Direct intra- and intermonomeric longrange communications between the tetramerization and DNA-binding domains are noted. These long-distance conformational changes link the C terminus with the DNA-binding domain and provide a biophysical rationale for the reported functional regulation of the p53 C-terminal region. A fine characterization of the DNA deformation caused by p53 binding is obtained, with `static' deformations always present and measured by the slide parameter in the central thymine-adenine base pairs; we also detect `dynamic' deformations switched on and off by particular p53 tetrameric conformations and measured by the roll and twist parameters in the same base pairs. These different conformations can indeed modulate the electrostatic potential isosurfaces of the whole p53-DNA complex. These results provide a molecular/biophysical understanding of the evident role of the C terminus in post-translational modification that regulates the transcriptional function of p53. Furthermore, the unstructured C terminus is able to facilitate contacts between the core DNA-binding domains of the tetramer.	[D'Abramo, M.] Univ Roma La Sapienza, Dipartimento Chim, Via Tizii 6, I-00185 Rome, Italy; [Besker, N.; Chillemi, G.] CINECA, SCAI SuperComp Applicat & Innovat Dept, Via Tizii 6, I-00185 Rome, Italy; [Desideri, A.] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy; [Levine, A. J.] Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA; [Levine, A. J.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA; [Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy; [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	Sapienza University Rome; CINECA, Italy; University of Rome Tor Vergata; Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Rome Tor Vergata; University of Leicester	Chillemi, G (corresponding author), CINECA, SCAI SuperComp Applicat & Innovat Dept, Via Tizii 6, I-00185 Rome, Italy.	giochillemi@gmail.com	Chillemi, Giovanni/O-2825-2019; D'Abramo, Marco/B-7035-2008; Chillemi, Giovanni/E-5201-2010; Deri, Desi/K-1086-2018	Chillemi, Giovanni/0000-0003-3901-6926; D'Abramo, Marco/0000-0001-6020-8581; Chillemi, Giovanni/0000-0003-3901-6926; desideri, alessandro/0000-0003-1541-4217; Besker, Neva/0000-0002-7024-7178	MIUR-FIRB grant [RBFR12BGHO]; 'Rita Levi Montalcini' research program; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	MIUR-FIRB grant(Ministry of Education, Universities and Research (MIUR)); 'Rita Levi Montalcini' research program; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by a MIUR-FIRB grant (no. RBFR12BGHO) and 'Rita Levi Montalcini' research program. We acknowledge the Cineca Supercomputing centre for computational resources.	AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Amelio I, 2014, ONCOGENE, V33, P5039, DOI 10.1038/onc.2013.456; Antonov AV, 2014, ONCOGENE, V33, P1621, DOI 10.1038/onc.2013.119; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Balatti V, 2015, P NATL ACAD SCI USA, V112, P2169, DOI 10.1073/pnas.1500010112; Bochkareva E, 2005, P NATL ACAD SCI USA, V102, P15412, DOI 10.1073/pnas.0504614102; Brune M, 2013, ONCOGENE, V32, P1460, DOI 10.1038/onc.2012.150; Buckley NE, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.31; Burns DM, 2011, NATURE, V473, P105, DOI 10.1038/nature09908; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Carr SM, 2012, ESSAYS BIOCHEM, V52, P79, DOI [10.1042/bse0520079, 10.1042/BSE0520079]; Chari NS, 2009, APOPTOSIS, V14, P336, DOI 10.1007/s10495-009-0327-9; Chen YH, 2010, STRUCTURE, V18, P246, DOI 10.1016/j.str.2009.11.011; Chillemi G, 2013, CELL CYCLE, V12, P3098, DOI 10.4161/cc.26162; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Ci Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.506; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dashzeveg N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.176; Demir O, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002238; Drosten M, 2014, P NATL ACAD SCI USA, V111, P15155, DOI 10.1073/pnas.1417549111; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Emamzadah S, 2014, J MOL BIOL, V426, P936, DOI 10.1016/j.jmb.2013.12.020; Emerling BM, 2013, CELL, V155, P844, DOI 10.1016/j.cell.2013.09.057; Evstafieva AG, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.469; Fan YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.400; Fatt MP, 2014, CELL DEATH DIFFER, V21, P1546, DOI 10.1038/cdd.2014.61; Feng HQ, 2009, STRUCTURE, V17, P202, DOI 10.1016/j.str.2008.12.009; Fiori ME, 2014, CELL DEATH DIFFER, V21, P774, DOI 10.1038/cdd.2014.6; Foijer F, 2014, P NATL ACAD SCI USA, V111, P13427, DOI 10.1073/pnas.1400892111; Fortunato O, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.507; Garufi A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.217; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Gomes LR, 2015, ONCOGENE, V34, P5329, DOI 10.1038/onc.2014.461; Gorrini C, 2014, P NATL ACAD SCI USA, V111, P11576, DOI 10.1073/pnas.1405580111; Han F, 2015, ONCOGENE, V34, P4391, DOI 10.1038/onc.2014.370; He Z, 2013, CELL DEATH DIFFER, V20, P1415, DOI 10.1038/cdd.2013.104; Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522; Hoffman Y, 2014, CELL DEATH DIFFER, V21, P302, DOI 10.1038/cdd.2013.146; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Johnson KA, 2008, J BIOL CHEM, V283, P26297, DOI 10.1074/jbc.R800034200; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Kim J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.87; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; Lange OF, 2008, PROTEINS, V70, P1294, DOI 10.1002/prot.21618; Laptenko O, 2015, MOL CELL, V57, P1034, DOI 10.1016/j.molcel.2015.02.015; Lavery R, 2009, NUCLEIC ACIDS RES, V37, P5917, DOI 10.1093/nar/gkp608; Leroy B, 2013, NUCLEIC ACIDS RES, V41, pD962, DOI 10.1093/nar/gks1033; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Lezina L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.483; Li D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.158; Li H, 2014, CELL DEATH DIFFER, V21, P1493, DOI 10.1038/cdd.2014.69; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Link N, 2013, GENE DEV, V27, P2433, DOI 10.1101/gad.225565.113; Lu Q, 2007, J PHYS CHEM B, V111, P11538, DOI 10.1021/jp0742261; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; Lubin DJ, 2010, J MOL BIOL, V395, P705, DOI 10.1016/j.jmb.2009.11.013; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Malatesta M, 2013, ONCOGENE, V32, P4721, DOI 10.1038/onc.2012.463; Manzl C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.470; Marcel V, 2014, CELL DEATH DIFFER, V21, P1377, DOI 10.1038/cdd.2014.73; McCammon JA, 1988, DYNAMICS PROTEINS NU, P289; Melero R, 2011, P NATL ACAD SCI USA, V108, P557, DOI [10.1073/pnas.1015520107, 10.1073/pnas.101S520107]; Mello SS, 2013, CELL DEATH DIFFER, V20, P855, DOI 10.1038/cdd.2013.53; Meniel V, 2015, ONCOGENE, V34, P4118, DOI 10.1038/onc.2014.342; Merlo P, 2014, P NATL ACAD SCI USA, V111, P18055, DOI 10.1073/pnas.1419083111; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Nair BC, 2014, CELL DEATH DIFFER, V21, P1409, DOI 10.1038/cdd.2014.55; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Oldfield CJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-S1-S1; Pan YP, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000878; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Petty TJ, 2011, EMBO J, V30, P2167, DOI 10.1038/emboj.2011.127; Peuget S, 2014, CELL DEATH DIFFER, V21, P1107, DOI 10.1038/cdd.2014.28; Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15; Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055; Ren ZJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.327; Rossi M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.113; Rowell JP, 2012, STRUCTURE, V20, P2014, DOI 10.1016/j.str.2012.09.004; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Rufini A, 2012, GENE DEV, V26, P2009, DOI 10.1101/gad.197640.112; Saldana-Meyer R, 2014, GENE DEV, V28, P723, DOI 10.1101/gad.236869.113; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Shetzer Y, 2014, CELL DEATH DIFFER, V21, P1419, DOI 10.1038/cdd.2014.57; Shi Y, 2014, CELL DEATH DIFFER, V21, P612, DOI 10.1038/cdd.2013.186; Simon HU, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.308; Solomon H, 2014, CELL DEATH DIFFER, V21, P1347, DOI 10.1038/cdd.2014.99; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Tan EH, 2014, ONCOGENE, V33, P3325, DOI 10.1038/onc.2013.287; Tang ZY, 2013, CELL, V154, P297, DOI 10.1016/j.cell.2013.06.027; Terrinoni A, 2011, ONCOGENE, V30, P3096, DOI 10.1038/onc.2011.31; Tidow H, 2007, P NATL ACAD SCI USA, V104, P12324, DOI 10.1073/pnas.0705069104; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Van Nostrand JL, 2014, NATURE, V514, P228, DOI 10.1038/nature13585; VanAalten DMF, 1997, J COMPUT CHEM, V18, P169, DOI 10.1002/(SICI)1096-987X(19970130)18:2<169::AID-JCC3>3.0.CO;2-T; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Venkatanarayan A, 2015, NATURE, V517, P626, DOI 10.1038/nature13910; Wang GZ, 2015, P NATL ACAD SCI USA, V112, P2437, DOI 10.1073/pnas.1500243112; Wang GZ, 2015, P NATL ACAD SCI USA, V112, P2443, DOI 10.1073/pnas.1500262112; Wassman CD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2361; Weilbacher A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.284; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Xu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.75; Yang-Hartwich Y, 2015, ONCOGENE, V34, P3605, DOI 10.1038/onc.2014.296; Yoshida K, 2010, CANCER SCI, V101, P831, DOI 10.1111/j.1349-7006.2010.01488.x; Zaccara S, 2014, CELL DEATH DIFFER, V21, P1522, DOI 10.1038/cdd.2014.79; Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201; Zhang HH, 2014, CELL DEATH DIFFER, V21, P1656, DOI 10.1038/cdd.2014.78; Zhu L, 2015, ONCOGENE, V34, P4547, DOI 10.1038/onc.2014.399	120	33	33	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3272	3281		10.1038/onc.2015.388	http://dx.doi.org/10.1038/onc.2015.388			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477317	Green Published, hybrid			2022-12-28	WOS:000378306400006
J	Subbaiah, VK; Zhang, Y; Rajagopalan, D; Abdullah, LN; Yeo-Teh, NSL; Tomaic, V; Banks, L; Myers, MP; Chow, EK; Jha, S				Subbaiah, V. K.; Zhang, Y.; Rajagopalan, D.; Abdullah, L. N.; Yeo-Teh, N. S. L.; Tomaic, V.; Banks, L.; Myers, M. P.; Chow, E. K.; Jha, S.			E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; HISTONE ACETYLTRANSFERASE; EDD; ACETYLATION; PROTEIN; GENE; DEGRADATION; INHIBITION; CHROMATIN; COMPLEX	Tat-interacting protein of 60 kDa (TIP60) is an essential lysine acetyltransferase implicated in transcription, DNA damage response and apoptosis. TIP60 protein expression is reduced in cancers. In cervical cancers, human papillomavirus (HPV) E6 oncogene targets cellular p53, Bak and some of the PDZ domain-containing proteins for proteasome-mediated degradation through E6AP ligase. Recently, E6 oncogene from high-risk and low-risk categories was also shown to target TIP60. However, the molecular mechanisms and whether destabilization of TIP60 contributes to HPV E6-mediated transformation remain unanswered. Our proteomic analyses revealed EDD1 (E3 identified by differential display), an E3 ligase generally overexpressed in cancers as a novel interacting partner of TIP60. By investigating protein turnover and ubiquitination assays, we show that EDD1 negatively regulates TIP60's stability through the proteasome pathway. Strikingly, HPV E6 uses this function of EDD1 to destabilize TIP60. Colony-formation assays and soft agar assays show that gain of function of TIP60 or depletion of EDD1 in HPV-positive cervical cancer cells significantly inhibits cell growth in vitro. This phenotype is strongly supported by the in-vivo studies where re-activation of TIP60 in cervical cancer cells dramatically reduces tumor formation. In summary, we have discovered a novel ligase through which E6 destabilizes TIP60. Currently, in the absence of an effective therapeutic vaccine for malignant cervical cancers, cervical cancer still remains to be a major disease burden. Hence, our studies implying a distinct tumor suppressor role for TIP60 in cervical cancers show that reactivation of TIP60 could be of therapeutic value.	[Subbaiah, V. K.; Zhang, Y.; Rajagopalan, D.; Abdullah, L. N.; Yeo-Teh, N. S. L.; Chow, E. K.; Jha, S.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Rajagopalan, D.; Jha, S.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Yeo-Teh, N. S. L.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; [Tomaic, V.; Banks, L.; Myers, M. P.] Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy; [Chow, E. K.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117595, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; International Center for Genetic Engineering & Biotechnology (ICGEB); National University of Singapore	Jha, S (corresponding author), Ctr Translat Med, 14 Med Dr,MD6-13-02J, Singapore 117599, Singapore.	csisjha@nus.edu.sg	, Subbaiah/AAB-9747-2021; Jha, Sudhakar/B-2308-2009; Jha, Sudhakar/S-3550-2019	Jha, Sudhakar/0000-0002-5093-4843; Yeo-Teh, Nicole/0000-0002-9153-9663; Krishna, Vanitha/0000-0002-0444-531X; Chow, Edward/0000-0002-3075-1898	National Research Foundation Singapore; Singapore Ministry of Education under its Research Centers of Excellence initiative to the Cancer Science Institute of Singapore [R-713-006-014-271]; National Medical Research Council (NMRC) [CBRG-NIG BNIG11nov001]; Ministry of Education Academic Research Fund (MOE AcRF); National Research Foundation Cancer Science Institute of Singapore RCE Main Grant; National Medical Research Council (NMRC CBRG-NIG) [BNIG12nov017]	National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centers of Excellence initiative to the Cancer Science Institute of Singapore(Ministry of Education, Singapore); National Medical Research Council (NMRC)(National Medical Research Council, Singapore); Ministry of Education Academic Research Fund (MOE AcRF); National Research Foundation Cancer Science Institute of Singapore RCE Main Grant(National Research Foundation, Singapore); National Medical Research Council (NMRC CBRG-NIG)(National Medical Research Council, Singapore)	We thank the members of the Jha laboratory for helpful discussion and comments. We thank Drs Neerja Karnani (Singapore Institute for Clinical Science, A*STAR), Daniel G Tenen (Cancer Science Institute of Singapore) and Yoshiaki Ito (Cancer Science Institute of Singapore) for their comments on the manuscript. We thank Drs Shojiro Kitajima for soft agar assays, Amit Kumar Pandey for real-time PCR and Tan Boon Toh for tumor quantification analysis. SJ was supported by grants from the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiative to the Cancer Science Institute of Singapore (R-713-006-014-271), National Medical Research Council (NMRC CBRG-NIG BNIG11nov001) and Ministry of Education Academic Research Fund (MOE AcRF Tier 1 T1-2012 Oct-04). EKC was supported by grants from the National Research Foundation Cancer Science Institute of Singapore RCE Main Grant, National Medical Research Council (NMRC CBRG-NIG BNIG12nov017) and Ministry of Education Academic Research Fund (MOE AcRF Tier 1 T1-2012 Oct-11).	Alpsoy A, 2014, BIOMED PHARMACOTHER, V68, P351, DOI 10.1016/j.biopha.2013.09.007; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; Bradley A, 2014, CARCINOGENESIS, V35, P1100, DOI 10.1093/carcin/bgt489; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Chou SW, 2009, ANTIMICROB AGENTS CH, V53, P81, DOI 10.1128/AAC.01177-08; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; Eblen ST, 2003, J BIOL CHEM, V278, P14926, DOI 10.1074/jbc.M300485200; Fazzio TG, 2008, CELL, V134, P162, DOI 10.1016/j.cell.2008.05.031; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Gupta A, 2013, ONCOGENE, V32, P5017, DOI 10.1038/onc.2012.534; Hay-Koren A, 2011, MOL BIOL CELL, V22, P399, DOI 10.1091/mbc.E10-05-0440; Henderson MJ, 2006, J BIOL CHEM, V281, P39990, DOI 10.1074/jbc.M602818200; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; Hu YF, 2009, DEV DYNAM, V238, P2912, DOI 10.1002/dvdy.22110; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jha S, 2008, MOL CELL BIOL, V28, P2690, DOI 10.1128/MCB.01983-07; Jha S, 2010, MOL CELL, V38, P700, DOI 10.1016/j.molcel.2010.05.020; Jha S, 2009, MOL CELL, V34, P521, DOI 10.1016/j.molcel.2009.05.016; Kaidi A, 2013, NATURE, V498, DOI 10.1038/nature12201; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lee MT, 2013, J BIOL CHEM, V288, P25038, DOI 10.1074/jbc.M113.476952; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Li RF, 2011, CELL HOST MICROBE, V10, P390, DOI 10.1016/j.chom.2011.08.013; Mahajan MA, 2014, MOL CELL ENDOCRINOL, V382, P159, DOI 10.1016/j.mce.2013.09.021; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Mori Y, 2002, CANCER RES, V62, P3641; Ohshima R, 2007, GENES CELLS, V12, P1339, DOI 10.1111/j.1365-2443.2007.01138.x; Reitsma JM, 2011, CELL HOST MICROBE, V9, P103, DOI 10.1016/j.chom.2011.01.006; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Sho T, 2011, BBA-MOL CELL RES, V1813, P1245, DOI 10.1016/j.bbamcr.2011.03.018; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Subbaiah VK, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002543; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Sun YL, 2010, CELL CYCLE, V9, P930, DOI 10.4161/cc.9.5.10931; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Tomaic V, 2011, J VIROL, V85, P3120, DOI 10.1128/JVI.02004-10; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Zheng H, 2013, MOL CELL, V50, P699, DOI 10.1016/j.molcel.2013.04.013	46	37	40	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2062	2074		10.1038/onc.2015.268	http://dx.doi.org/10.1038/onc.2015.268			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26234678				2022-12-28	WOS:000374505600006
J	Humtsoe, JO; Pham, E; Louie, RJ; Chan, DA; Kramer, RH				Humtsoe, J. O.; Pham, E.; Louie, R. J.; Chan, D. A.; Kramer, R. H.			ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth	ONCOGENE			English	Article							MULTICELLULAR TUMOR SPHEROIDS; HYPOXIA-INDUCIBLE FACTORS; TYROSINE KINASE; CARCINOMA-CELLS; NECK-CANCER; MESENCHYMAL TRANSITION; BREAST-CANCER; EXPRESSION; RECEPTOR; THERAPY	Head and neck squamous carcinomas (HNSCC) present as dense epithelioid three-dimensional (3D) tumor nests that can mediate signals via the human epidermal growth factor receptor (ErbB) tyrosine kinase family to promote intratumoral survival and growth. We examined the role of the tumor microenvironment on ErbB receptor family expression and found that the status of intercellular organization altered the receptor profile. We showed that HNSCC cells forced into tumor island-like 3D aggregates strongly upregulated ErbB3 at the level of transcription. Not only was the elevated ErbB3 responsive to HRG-beta 1-induced enhanced signaling mechanism, but also analysis by siRNA-knockdown and kinase inhibitor strategies revealed that the ErbB3/AKT signaling pathway was sufficient to enhance tumor cell survival and growth potential. Elevated ErbB3 expression in the high-density 3D culture system was strongly associated with hypoxia-induced HIF-1 alpha. Hypoxia-regulated ErbB3 expression was mediated by the HIF-1 alpha-binding consensus sequence in the ErbB3 proximal promoter. The findings show that the local 3D tumor microenvironment can trigger reprograming and switching of ErbB family members and thereby influence ErbB3-driven tumor growth.	[Humtsoe, J. O.; Pham, E.; Kramer, R. H.] Univ Calif San Francisco, Dept Cell & Tissue Biol, 521 Parnassus Ave, San Francisco, CA 94143 USA; [Louie, R. J.; Chan, D. A.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Cell & Tissue Biol, 521 Parnassus Ave, San Francisco, CA 94143 USA.	randall.kramer@ucsf.edu			UCSF REAC Award; Cancer Research Coordinating Committee; National Institutes of Health [R01 DE022565]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022565] Funding Source: NIH RePORTER	UCSF REAC Award; Cancer Research Coordinating Committee; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Colleen Sweeney (University of California at Davis) for the kind gift of the ErbB3-promoter constructs and Dr Fan Yang (University of California San Francisco) for providing samples of xenograft specimens. This research was supported by grants from UCSF REAC Award (to RHK), Cancer Research Coordinating Committee (to RHK), and National Institutes of Health, R01 DE022565 (to RHK).	Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a; Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003; Amin DN, 2012, BIOCHEM J, V447, P417, DOI 10.1042/BJ20120724; Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007; Bates RC, 2000, CRIT REV ONCOL HEMAT, V36, P61, DOI 10.1016/S1040-8428(00)00077-9; Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003; Cavalot A, 2007, HEAD NECK-J SCI SPEC, V29, P655, DOI 10.1002/hed.20574; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chen QM, 2004, BIOCHEM BIOPH RES CO, V315, P850, DOI 10.1016/j.bbrc.2004.01.143; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Cohen RB, 2014, CANCER TREAT REV, V40, P567, DOI 10.1016/j.ctrv.2013.10.002; Del Sordo R, J ORAL PATHOL MED, V39, P79; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Dubessy C, 2000, CRIT REV ONCOL HEMAT, V36, P179, DOI 10.1016/S1040-8428(00)00085-8; Friedrich J, 2007, INT J RADIAT BIOL, V83, P849, DOI 10.1080/09553000701727531; Funayama T, 1998, ONCOLOGY-BASEL, V55, P161, DOI 10.1159/000011851; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; He J, 2012, EMBO REP, V13, P1116, DOI 10.1038/embor.2012.162; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Humtsoe JO, 2010, ONCOGENE, V29, P1214, DOI 10.1038/onc.2009.419; Humtsoe JO, 2012, EXP CELL RES, V318, P379, DOI 10.1016/j.yexcr.2011.11.011; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Jain A, 2010, CANCER RES, V70, P1989, DOI 10.1158/0008-5472.CAN-09-3326; Jathal Maitreyee K., 2011, Immunology Endocrine & Metabolic Agents in Medicinal Chemistry, V11, P131; Krig SR, 2010, ONCOGENE, V29, P5500, DOI 10.1038/onc.2010.289; Krig SR, ONCOGENE, V29, P5500; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Luca AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059689; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; Paatero I, 2014, J BIOL CHEM, V289, P22459, DOI 10.1074/jbc.M113.533497; Page H, 2013, CELL TISSUE RES, V352, P123, DOI 10.1007/s00441-012-1441-5; Perez-Sayans M, 2011, CANCER LETT, V313, P1, DOI 10.1016/j.canlet.2011.08.017; Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394; Rabinowits G, 2012, ORAL ONCOL, V48, P1085, DOI 10.1016/j.oraloncology.2012.06.016; Rogers SJ, 2005, CANCER METAST REV, V24, P47, DOI 10.1007/s10555-005-5047-1; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0; Sasabe E, 2010, FREE RADICAL BIO MED, V48, P1321, DOI 10.1016/j.freeradbiomed.2010.02.013; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, ONCOGENE, V29, P625; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shames DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056765; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; SHINTANI S, 1995, CANCER LETT, V95, P79, DOI 10.1016/0304-3835(95)03866-U; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Takikita M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-126; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783; Xia WY, 1997, CLIN CANCER RES, V3, P3; Xia WY, 1999, CLIN CANCER RES, V5, P4164; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; Ziober BL, 2001, CRIT REV ORAL BIOL M, V12, P499, DOI 10.1177/10454411010120060401; Zou YF, 2010, J RADIAT RES, V51, P47, DOI 10.1269/jrr.09070; Zuo JH, 2010, MOL CANCER RES, V8, P170, DOI 10.1158/1541-7786.MCR-09-0354	59	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1554	1564		10.1038/onc.2015.220	http://dx.doi.org/10.1038/onc.2015.220			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073080				2022-12-28	WOS:000373063600008
J	Katara, GK; Kulshrestha, A; Jaiswal, MK; Pamarthy, S; Gilman-Sachs, A; Beaman, KD				Katara, G. K.; Kulshrestha, A.; Jaiswal, M. K.; Pamarthy, S.; Gilman-Sachs, A.; Beaman, K. D.			Inhibition of vacuolar ATPase subunit in tumor cells delays tumor growth by decreasing the essential macrophage population in the tumor microenvironment	ONCOGENE			English	Article							BREAST-CANCER CELLS; H+-ATPASE; IN-VITRO; V-ATPASE; DIFFERENTIATION; POLARIZATION; METASTASIS; EXPRESSION; ISOFORM	In cancer cells, vacuolar ATPase (V-ATPase), a multi-subunit enzyme, is expressed on the plasma as well as vesicular membranes and critically influences metastatic behavior. The soluble, cleaved N-terminal domain of V-ATPase a2 isoform is associated with in vitro induction of tumorigenic characteristics in macrophages. This activity led us to further investigate its in vivo role in cancer progression by inhibition of a2 isoform (a2V) in tumor cells and the concomitant effect on tumor microenvironment in the mouse 4T-1 breast cancer model. Results showed that macrophages cocultivated with a2V knockdown (sh-a2) 4T-1 cells produce lower amounts of tumorigenic factors in vitro and have reduced ability to suppress T-cell activation and proliferation compared with control 4T-1 cells. Data analysis showed a delayed mammary tumor growth in Balb/c mice inoculated with sh-a2 4T-1 cells compared with control. The purified CD11b(+) macrophages from sh-a2 tumors showed a reduced expression of mannose receptor-1 (CD206), interleukin-10, transforming growth factor-beta, arginase-1, matrix metalloproteinase and vascular endothelial growth factor. Flow cytometric analysis of tumor-infiltrated macrophages showed a significantly low number of F4/80(+) CD11c(+) CD206(+) macrophages in sh-a2 tumors compared with control. In sh-a2 tumors, most of the macrophages were F4/80(+) CD11c(+) (antitumor M1 macrophages) suggesting it to be the reason behind delayed tumor growth. Additionally, tumor-infiltrating macrophages from sh-a2 tumors showed a reduced expression of CD206 compared with control whereas CD11c expression was unaffected. These findings demonstrate that in the absence of a2V in tumor cells, the resident macrophage population in the tumor microenvironment is altered which affects in vivo tumor growth. We suggest that by involving the host immune system, tumor growth can be controlled through targeting of a2V on tumor cells.	[Katara, G. K.; Kulshrestha, A.; Jaiswal, M. K.; Pamarthy, S.; Gilman-Sachs, A.; Beaman, K. D.] Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA	Rosalind Franklin University Medical & Science	Beaman, KD (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	kenneth.beaman@rosalindfranklin.edu		Pamarthy, Sahithi/0000-0003-2692-4829	Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA	Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA	We thank Robert Dickinson for technical assistance and the Rosalind Franklin University of Medicine and Science Flow Cytometry Core Facility. This work was supported by the grants from the Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.	Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; Feng SM, 2013, INT J BIOL SCI, V9, P853, DOI 10.7150/ijbs.6030; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Granata F, 2010, J IMMUNOL, V184, P5232, DOI 10.4049/jimmunol.0902501; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Jaiswal MK, 2013, J IMMUNOL, V191, P5702, DOI 10.4049/jimmunol.1301604; Jaiswal MK, 2012, REPRODUCTION, V143, P713, DOI 10.1530/REP-12-0036; Katara GK, 2014, ONCOGENE, V33, P5649, DOI 10.1038/onc.2013.532; Kwong C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22978; Kwong C, 2011, J IMMUNOL, V186, P1781, DOI 10.4049/jimmunol.1002998; Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Motz GT, 2013, IMMUNITY, V39, P61, DOI 10.1016/j.immuni.2013.07.005; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541-7786.MCR-10-0449; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ntrivalas E, 2007, AM J REPROD IMMUNOL, V57, P201, DOI 10.1111/j.1600-0897.2006.00463.x; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Sennoune SR, 2004, CELL BIOCHEM BIOPHYS, V40, P185, DOI 10.1385/CBB:40:2:185; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Umemura N, 2008, J LEUKOCYTE BIOL, V83, P1136, DOI 10.1189/jlb.0907611; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357	28	23	24	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1058	1065		10.1038/onc.2015.159	http://dx.doi.org/10.1038/onc.2015.159			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961933				2022-12-28	WOS:000370823300011
J	Ma, X; Chen, Y; Zhang, S; Xu, W; Shao, Y; Yang, Y; Li, W; Li, M; Xue, L				Ma, X.; Chen, Y.; Zhang, S.; Xu, W.; Shao, Y.; Yang, Y.; Li, W.; Li, M.; Xue, L.			Rho1-Wnd signaling regulates loss-of-cell polarity-induced cell invasion in Drosophila	ONCOGENE			English	Article							MAP KINASE; TUMOR-SUPPRESSOR; JNK ACTIVATION; APOPTOTIC CELLS; ONCOGENIC RAS; RHO-GTPASES; CANCER; DEATH; PATHWAY; MIGRATION	Both cell polarity and c-Jun N-terminal kinase (JNK) activity are essential to the maintenance of tissue homeostasis, and disruption of either is commonly seen in cancer progression. Despite the established connection between loss-of-cell polarity and JNK activation, much less is known about the molecular mechanism by which aberrant cell polarity induces JNK-mediated cell migration and tumor invasion. Here we show results from a genetic screen using an in vivo invasion model via knocking down cell polarity gene in Drosophila wing discs, and identify Rho1-Wnd signaling as an important molecular link that mediates loss-of-cell polarity-triggered JNK activation and cell invasion. We show that Wallenda (Wnd), a protein kinase of the mitogen-activated protein kinase kinase kinase family, by forming a complex with the GTPase Rho1, is both necessary and sufficient for Rho1-induced JNK-dependent cell invasion, MMP1 activation and epithelial-mesenchymal transition. Furthermore, Wnd promotes cell proliferation and tissue growth through wingless production when apoptosis is inhibited by p35. Finally, Wnd shows oncogenic cooperation with Ras(V12) to trigger tumor growth in eye discs and causes invasion into the ventral nerve cord. Together, our data not only provides a novel mechanistic insight on how cell polarity loss contributes to cell invasion, but also highlights the value of the Drosophila model system to explore human cancer biology.	[Ma, X.; Chen, Y.; Zhang, S.; Shao, Y.; Yang, Y.; Li, W.; Li, M.; Xue, L.] Tongji Univ, Inst Intervent Vessel, Shanghai Peoples Hosp 10, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, 1239 Siping Rd, Shanghai 200092, Peoples R China; [Ma, X.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA; [Xu, W.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Tongji University; Howard Hughes Medical Institute; Johns Hopkins University; Tongji University	Li, M; Xue, L (corresponding author), Tongji Univ, Inst Intervent Vessel, Shanghai Peoples Hosp 10, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, 1239 Siping Rd, Shanghai 200092, Peoples R China.; Ma, X (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA.	XianjueMa@jhmi.eduor; cjr.limaoquan@vip.163.com; lei.xue@tongji.edu.cn		Ma, Xianjue/0000-0003-4360-3947	National Basic Research Program of China (973 Program) [2011CB943903]; National Natural Science Foundation of China [31071294, 31171413, 31371490]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20120072110023, 20120072120030]; Shanghai Committee of Science and Technology [09DZ2260100, 14JC1406000]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee)	We thank Drs Duojia Pan, Tian Xu, Helena Richardson, Aaron DiAntonio, Bloomington, VDRC and NIG stock centers for fly stocks and reagents, Dr Margaret Ho and members of Xue lab for discussion and comments, Dr Jonathan Phillips for critically reading the manuscript. This research was supported by the National Basic Research Program of China (973 Program) (2011CB943903), National Natural Science Foundation of China (31071294, 31171413, 31371490), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20120072110023, 20120072120030), and Shanghai Committee of Science and Technology (09DZ2260100, 14JC1406000). Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).	Baek SH, 2010, BIOCHEM BIOPH RES CO, V394, P488, DOI 10.1016/j.bbrc.2010.02.124; Bergstralh DT, 2012, ESSAYS BIOCHEM, V53, P129, DOI [10.1042/BSE0530129, 10.1042/bse0530129]; Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Collins CA, 2006, NEURON, V51, P57, DOI 10.1016/j.neuron.2006.05.026; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409; Ebelt Nancy D, 2013, Genes Cancer, V4, P378, DOI 10.1177/1947601913485413; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/bse0530141, 10.1042/BSE0530141]; Fernandez BG, 2014, ONCOGENE, V33, P2027, DOI 10.1038/onc.2013.155; Gaspar P, 2014, CURR OPIN CELL BIOL, V31, P74, DOI 10.1016/j.ceb.2014.09.003; Geuking P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007709; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Gonzalez C, 2013, NAT REV CANCER, V13, P172, DOI 10.1038/nrc3461; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Hammarlund M, 2009, SCIENCE, V323, P802, DOI 10.1126/science.1165527; Hirai S, 2006, J NEUROSCI, V26, P11992, DOI 10.1523/JNEUROSCI.2272-06.2006; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Itoh A, 2011, J NEUROSCI, V31, P7223, DOI 10.1523/JNEUROSCI.5947-10.2011; Khoo P, 2013, DIS MODEL MECH, V6, P661, DOI 10.1242/dmm.010066; Kulshammer E, 2013, J CELL SCI, V126, P927, DOI 10.1242/jcs.114462; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lesch C, 2010, GENETICS, V186, P943, DOI 10.1534/genetics.110.121822; Lewcock JW, 2007, NEURON, V56, P604, DOI 10.1016/j.neuron.2007.09.009; Ma X, 2014, CELL DEATH DIFFER, V21, P407, DOI 10.1038/cdd.2013.154; Ma X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.392; Ma XJ, 2014, AIMS GENET, V1, P20, DOI 10.3934/genet.2014.1.20; Ma XJ, 2015, P NATL ACAD SCI USA, V112, P1065, DOI 10.1073/pnas.1415020112; Ma XJ, 2013, DEV BIOL, V380, P211, DOI 10.1016/j.ydbio.2013.05.013; Ma XJ, 2012, CELL RES, V22, P425, DOI 10.1038/cr.2011.135; Macara IG, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0012; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Miles WO, 2011, DIS MODEL MECH, V4, P753, DOI 10.1242/dmm.006908; Morata G, 2011, DEV GROWTH DIFFER, V53, P168, DOI 10.1111/j.1440-169X.2010.01225.x; Muthuswamy SK, 2012, ANNU REV CELL DEV BI, V28, P599, DOI 10.1146/annurev-cellbio-092910-154244; Neisch AL, 2010, J CELL BIOL, V189, P311, DOI 10.1083/jcb.200912010; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rauskolb C, 2014, CELL, V158, P143, DOI 10.1016/j.cell.2014.05.035; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Rudrapatna VA, 2014, ONCOGENE, V33, P2801, DOI 10.1038/onc.2013.232; Rudrapatna VA, 2013, EMBO REP, V14, P172, DOI 10.1038/embor.2012.217; Rudrapatna VA, 2012, DEV DYNAM, V241, P107, DOI 10.1002/dvdy.22771; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Tedeschi A, 2013, EMBO REP, V14, P605, DOI 10.1038/embor.2013.64; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vaira V, 2011, AM J PATHOL, V178, P2478, DOI 10.1016/j.ajpath.2011.02.028; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Xiong X, 2012, J NEUROSCI, V32, P610, DOI 10.1523/JNEUROSCI.3586-11.2012; Xue L, 2007, DEV CELL, V13, P446, DOI 10.1016/j.devcel.2007.07.012; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	62	23	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					846	855		10.1038/onc.2015.137	http://dx.doi.org/10.1038/onc.2015.137			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961917				2022-12-28	WOS:000370332200005
J	Kale, S; Raja, R; Thorat, D; Soundararajan, G; Patil, TV; Kundu, GC				Kale, S.; Raja, R.; Thorat, D.; Soundararajan, G.; Patil, T. V.; Kundu, G. C.			Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha 9 beta 1 integrin (vol 33, pg 2295, 2014)	ONCOGENE			English	Correction													Kundu, Gopal C./ABA-9897-2020; Raja, Remya/GXM-8598-2022	Raja, Remya/0000-0002-7576-6778				Kale S, 2014, ONCOGENE, V33, P2295, DOI 10.1038/onc.2013.184	1	14	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5408	5410		10.1038/onc.2015.315	http://dx.doi.org/10.1038/onc.2015.315			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	26473949	Bronze			2022-12-28	WOS:000363479200012
J	Carmona, G; Perera, U; Gillett, C; Naba, A; Law, AL; Sharma, VP; Wang, J; Wyckoff, J; Balsamo, M; Mosis, F; De Piano, M; Monypenny, J; Woodman, N; McConnell, RE; Mouneimne, G; Van Hemelrijck, M; Cao, Y; Condeelis, J; Hynes, RO; Gertler, FB; Krause, M				Carmona, G.; Perera, U.; Gillett, C.; Naba, A.; Law, A-L; Sharma, V. P.; Wang, J.; Wyckoff, J.; Balsamo, M.; Mosis, F.; De Piano, M.; Monypenny, J.; Woodman, N.; McConnell, R. E.; Mouneimne, G.; Van Hemelrijck, M.; Cao, Y.; Condeelis, J.; Hynes, R. O.; Gertler, F. B.; Krause, M.			Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE	ONCOGENE			English	Article							ACTIN-FILAMENT ELONGATION; BREAST-CARCINOMA CELLS; ABL-FAMILY KINASES; LEADING-EDGE; INVADOPODIUM FORMATION; EXPRESSION SIGNATURE; FIBROBLAST MOTILITY; MAMMARY-TUMORS; BARBED ENDS; METASTASIS	Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. How deregulation of actin regulators promotes cancer cell invasion is still enigmatic. We report that increased expression and membrane localization of the actin regulator Lamellipodin correlate with reduced metastasis-free survival and poor prognosis in breast cancer patients. In agreement, we find that Lamellipodin depletion reduced lung metastasis in an orthotopic mouse breast cancer model. Invasive 3D cancer cell migration as well as invadopodia formation and matrix degradation was impaired upon Lamellipodin depletion. Mechanistically, we show that Lamellipodin promotes invasive 3D cancer cell migration via both actin-elongating Ena/VASP proteins and the Scar/WAVE complex, which stimulates actin branching. In contrast, Lamellipodin interaction with Scar/WAVE but not with Ena/VASP is required for random 2D cell migration. We identified a phosphorylation-dependent mechanism that regulates selective recruitment of these effectors to Lamellipodin: Abl-mediated Lamellipodin phosphorylation promotes its association with both Scar/WAVE and Ena/VASP, whereas Src-dependent phosphorylation enhances binding to Scar/WAVE but not to Ena/VASP. Through these selective, regulated interactions Lamellipodin mediates directional sensing of epidermal growth factor (EGF) gradients and invasive 3D migration of breast cancer cells. Our findings imply that increased Lamellipodin levels enhance Ena/VASP and Scar/WAVE activities at the plasma membrane to promote 3D invasion and metastasis.	[Carmona, G.; Naba, A.; Wyckoff, J.; Balsamo, M.; McConnell, R. E.; Hynes, R. O.; Gertler, F. B.] MIT, Koch Inst Integrat Canc Res, BLDG 76-361,77 Massachusetts Ave, Cambridge, MA 02139 USA; [Perera, U.; Law, A-L; Mosis, F.; Monypenny, J.; Krause, M.] Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England; [Gillett, C.; Monypenny, J.; Woodman, N.] Kings Coll London, Res Oncol, Div Canc Studies, Fac Life Sci & Med, London, England; [Sharma, V. P.; Condeelis, J.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10467 USA; [Sharma, V. P.; Condeelis, J.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10467 USA; [Wang, J.; Cao, Y.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [De Piano, M.; Van Hemelrijck, M.] Kings Coll London, Div Canc Studies, Canc Epidemiol Grp, London, England; [Monypenny, J.] Kings Coll London, Div Canc Studies, Richard Dimbleby Dept Canc Res, London, England; [Mouneimne, G.] Univ Arizona, Ctr Canc, Tucson, AZ USA; [Hynes, R. O.] MIT, Howard Hughes Med Inst, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); University of London; King's College London; University of London; King's College London; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; University of London; King's College London; University of London; King's College London; University of Arizona; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Gertler, FB (corresponding author), MIT, Koch Inst Integrat Canc Res, BLDG 76-361,77 Massachusetts Ave, Cambridge, MA 02139 USA.; Krause, M (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	fgertler@mit.edu; Matthias.Krause@kcl.ac.uk	Naba, Alexandra/E-6867-2010; Balsamo, Michele/AAJ-3247-2020; Krause, Matthias/D-9814-2013	Naba, Alexandra/0000-0002-4796-5614; Balsamo, Michele/0000-0002-2315-4761; Krause, Matthias/0000-0002-3200-3199; Van Hemelrijck, Mieke/0000-0002-7317-0858	Experimental Cancer Medicine Centre at King's College London; Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award; Ludwig Fund for Cancer Research; King's College Overseas Research PhD Studentship (KORS); National Cancer Institute [U54-CA112967, U54-CA163109]; Ludwig Center for Metastasis Research at MIT; Koch Institute Support Grant from the National Cancer Institute [P30-CA14051]; Biotechnology and Biological Science Research Council, UK [BB/F011431/1, BB/J000590/1, BB/N000226/1]; Wellcome Trust [082907/Z/07/Z]; NATIONAL CANCER INSTITUTE [U54CA163109, P30CA014051, U54CA112967, R01CA150344, P01CA100324] Funding Source: NIH RePORTER; BBSRC [BB/N000226/1, BB/F011431/1, BB/J000590/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/J000590/1, BB/F011431/1, BB/N000226/1] Funding Source: researchfish; Medical Research Council [1522273] Funding Source: researchfish	Experimental Cancer Medicine Centre at King's College London; Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award; Ludwig Fund for Cancer Research; King's College Overseas Research PhD Studentship (KORS); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ludwig Center for Metastasis Research at MIT; Koch Institute Support Grant from the National Cancer Institute; Biotechnology and Biological Science Research Council, UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome Trust); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank members of the Gertler and Krause laboratories for helpful discussions and technical assistance; R Weinberg for his helpful discussions; J Lamar, S Hansen, D Mullins, M Way, C Cepko, D Sabatini, T Koleske and M Hemann for reagents; the Koch Institute Swanson Biotechnology Center - specifically M Griffin (Flow Cytometry Core Facility), E Vasile (Microscopy Core Facility) and K Cormier (Hope Babette Tang Histology Facility) for technical support. D Barry and M Way (LRI, CRICK, UK) for adapting the Image J plugin ADAPT for us to V1.33. Patient samples and data were provided by King's Health Partners Cancer Biobank, London, UK, which is supported by the Experimental Cancer Medicine Centre at King's College London and the Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award. GC received a postdoctoral fellowship from the Ludwig Fund for Cancer Research and UP received a King's College Overseas Research PhD Studentship (KORS). This work was supported by grants from the National Cancer Institute (U54-CA112967 and U54-CA163109), funds from the Ludwig Center for Metastasis Research at MIT (FBG, GC, AN and ROH), the Koch Institute Support Grant P30-CA14051 from the National Cancer Institute, the Biotechnology and Biological Science Research Council, UK (BB/F011431/1; BB/J000590/1; BB/N000226/1) and the Wellcome Trust (082907/Z/07/Z) (MK).	Arjonen A, 2014, J CLIN INVEST, V124, P1069, DOI 10.1172/JCI67280; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Barry DJ, 2015, J CELL BIOL, V209, P163, DOI 10.1083/jcb.201501081; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Beaty BT, 2014, EUR J CELL BIOL, V93, P438, DOI 10.1016/j.ejcb.2014.07.003; Bisi S, 2013, CURR OPIN CELL BIOL, V25, P565, DOI 10.1016/j.ceb.2013.04.001; Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859; Breitsprecher D, 2008, EMBO J, V27, P2943, DOI 10.1038/emboj.2008.211; Breitsprecher D, 2011, EMBO J, V30, P456, DOI 10.1038/emboj.2010.348; Chereau D, 2006, J STRUCT BIOL, V155, P195, DOI 10.1016/j.jsb.2006.01.012; Derivery E, 2009, CELL MOTIL CYTOSKEL, V66, P777, DOI 10.1002/cm.20342; Di Modugno F, 2006, CLIN CANCER RES, V12, P1470, DOI 10.1158/1078-0432.CCR-05-2027; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Hansen SD, 2010, J CELL BIOL, V191, P571, DOI 10.1083/jcb.201003014; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Iglesias PA, 2008, CURR OPIN CELL BIOL, V20, P35, DOI 10.1016/j.ceb.2007.11.011; Ignatoski KMW, 1999, BREAST CANCER RES TR, V54, P173, DOI 10.1023/A:1006135331912; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Janetopoulos C, 2008, FEBS LETT, V582, P2075, DOI 10.1016/j.febslet.2008.04.035; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Krause M, 2014, NAT REV MOL CELL BIO, V15, P577, DOI 10.1038/nrm3861; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Law AL, 2013, J CELL BIOL, V203, P673, DOI 10.1083/jcb.201304051; Lebrand C, 2004, NEURON, V42, P37, DOI 10.1016/S0896-6273(04)00108-4; Lee SLC, 2009, P NATL ACAD SCI USA, V106, P19485, DOI 10.1073/pnas.0909228106; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Lyulcheva E, 2008, DEV CELL, V15, P680, DOI 10.1016/j.devcel.2008.09.020; Michael M, 2010, CURR BIOL, V20, P783, DOI 10.1016/j.cub.2010.03.048; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Mouneimne G, 2006, CURR BIOL, V16, P2193, DOI 10.1016/j.cub.2006.09.016; Newsome TP, 2006, CELL MICROBIOL, V8, P233, DOI 10.1111/j.1462-5822.2005.00613.x; Pasic L, 2008, J BIOL CHEM, V283, P9814, DOI 10.1074/jbc.M710475200; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Roussos ET, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2784; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vehlow A, 2013, EMBO J, V32, P2722, DOI 10.1038/emboj.2013.212; Youssef G, 2014, MODERN PATHOL, V27, P361, DOI 10.1038/modpathol.2013.129	58	46	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5155	5169		10.1038/onc.2016.47	http://dx.doi.org/10.1038/onc.2016.47			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26996666	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000384433000007
J	Tumiati, M; Munne, PM; Edgren, H; Eldfors, S; Hemmes, A; Kuznetsov, SG				Tumiati, M.; Munne, P. M.; Edgren, H.; Eldfors, S.; Hemmes, A.; Kuznetsov, S. G.			Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers	ONCOGENE			English	Article							MAMMARY-TUMORS; P53; GENE; BRCA1; REPAIR; CELLS; IDENTIFICATION; TUMORIGENESIS; RESISTANCE; SYNERGIZES	Almost half of all hereditary breast cancers (BCs) are associated with germ-line mutations in homologous recombination (HR) genes. However, the tumor phenotypes associated with different HR genes vary, making it difficult to define the role of HR in BC predisposition. To distinguish between HR-dependent and -independent features of BCs, we generated a mouse model in which an essential HR gene, Rad51c, is knocked-out specifically in epidermal tissues. Rad51c is one of the key mediators of HR and a well-known BC predisposition gene. Here, we demonstrate that deletion of Rad51c invariably requires inactivation of the Trp53 tumor suppressor (TP53 in humans) to produce mammary carcinomas in 63% of female mice. Nonetheless, loss of Rad51c shortens the latency of Trp53-deficient mouse tumors from 11 to 6 months. Remarkably, the histopathological features of Rad51c-deficient mammary carcinomas, such as expression of hormone receptors and luminal epithelial markers, faithfully recapitulate the histopathology of human RAD51C-mutated BCs. Similar to other BC models, Rad51c/p53 double-mutant mouse mammary tumors also reveal a propensity for genomic instability, but lack the focal amplification of the Met locus or distinct mutational signatures reported for other HR genes. Using the human mammary epithelial cell line MCF10A, we show that deletion of TP53 can rescue RAD51C-deficient cells from radiation-induced cellular senescence, whereas it exacerbates their centrosome amplification and nuclear abnormalities. Altogether, our data indicate that a trend for genomic instability and inactivation of Trp53 are common features of HR-mediated BCs, whereas histopathology and somatic mutation patterns are specific for different HR genes.	[Tumiati, M.; Munne, P. M.; Edgren, H.; Eldfors, S.; Hemmes, A.; Kuznetsov, S. G.] Univ Helsinki, Inst Mol Med Finland FIMM, Biomed Helsinki 2U,Room E303b,Tukholmankatu 8, FIN-00290 Helsinki, Finland; [Edgren, H.] MediSapiens Ltd, Erottajankatu 19B, Helsinki, Finland	University of Helsinki	Kuznetsov, SG (corresponding author), Univ Helsinki, Inst Mol Med Finland FIMM, Biomed Helsinki 2U,Room E303b,Tukholmankatu 8, FIN-00290 Helsinki, Finland.	sergey.kuznetsov@helsinki.fi	Munne, Pauliina/M-8629-2015; Eldfors, Samuli/AAB-3029-2019	Munne, Pauliina/0000-0002-9720-9964; Eldfors, Samuli/0000-0001-5056-4750; Kuznetsov, Sergey/0000-0002-5662-9700; Tumiati, Manuela/0000-0003-4889-3445	Academy of Finland; Finnish Medical Foundation; Sigrid Juselius Foundation; Cancer Society of Finland; Biocenter Finland; Helsinki Doctoral Program in Biomedicine (DPBM)	Academy of Finland(Academy of Finland); Finnish Medical Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Society of Finland; Biocenter Finland; Helsinki Doctoral Program in Biomedicine (DPBM)	We thank Pekka Ellonen, Maija Lepisto, Sonja Lagstrom, and the rest of the FIMM sequencing unit for advice and sequencing of tumor samples, the pathology unit of the Haartman Institute for histology services, Sami Blom and Dr Johan Lundin for scanning histological slides. We are grateful to Dr Shyam Sharan and Dr Madalena Tarsounas for providing critical comments on the manuscript. Financial support for the project was provided to SGK by the Academy of Finland, Finnish Medical Foundation, Sigrid Juselius Foundation, Cancer Society of Finland, and Biocenter Finland. MT was supported by a fellowship from the Helsinki Doctoral Program in Biomedicine (DPBM), and the Academy of Finland.	Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064; Badie S, 2010, NAT STRUCT MOL BIOL, V17, P1461, DOI 10.1038/nsmb.1943; Badie S, 2009, J CELL BIOL, V185, P587, DOI 10.1083/jcb.200811079; Bogliolo M, 2013, AM J HUM GENET, V92, P800, DOI 10.1016/j.ajhg.2013.04.002; Bowman-Colin C, 2013, P NATL ACAD SCI USA, V110, P8632, DOI 10.1073/pnas.1305362110; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chun J, 2013, MOL CELL BIOL, V33, P387, DOI 10.1128/MCB.00465-12; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Fenech M, 2011, MUTAGENESIS, V26, P125, DOI 10.1093/mutage/geq052; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Francis JC, 2015, J PATHOL, V236, P186, DOI 10.1002/path.4517; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gevensleben H, 2014, VIRCHOWS ARCH, V465, P365, DOI 10.1007/s00428-014-1619-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Katsura M, 2009, NUCLEIC ACIDS RES, V37, P3959, DOI 10.1093/nar/gkp262; Kee Y, 2012, J CLIN INVEST, V122, P3799, DOI 10.1172/JCI58321; Kee Y, 2010, GENE DEV, V24, P1680, DOI 10.1101/gad.1955310; Knight JF, 2013, P NATL ACAD SCI USA, V110, pE1301, DOI 10.1073/pnas.1210353110; Kuznetsov S, 2007, J CELL BIOL, V176, P581, DOI 10.1083/jcb.200608130; Kuznetsov SG, 2009, CANCER RES, V69, P863, DOI 10.1158/0008-5472.CAN-08-3057; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lin ZG, 2006, P NATL ACAD SCI USA, V103, P10328, DOI 10.1073/pnas.0604232103; Lindh AR, 2007, CYTOGENET GENOME RES, V116, P38, DOI 10.1159/000097416; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Munne PM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04663; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Olivares-Illana V, 2010, ONCOGENE, V29, P5113, DOI 10.1038/onc.2010.266; Olopade OI, 2008, CLIN CANCER RES, V14, P7988, DOI 10.1158/1078-0432.CCR-08-1211; Oplustilova L, 2012, CELL CYCLE, V11, P3837, DOI 10.4161/cc.22026; Osorio A, 2012, HUM MOL GENET, V21, P2889, DOI 10.1093/hmg/dds115; Rodrigue A, 2013, J CELL SCI, V126, P348, DOI 10.1242/jcs.114595; Smolen GA, 2006, CANCER RES, V66, P3452, DOI 10.1158/0008-5472.CAN-05-4181; Somyajit K, 2012, J BIOL CHEM, V287, P3366, DOI 10.1074/jbc.M111.311241; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53; Tacconi EMC, 2015, CHROMOSOMA, V124, P119, DOI 10.1007/s00412-014-0497-2; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tumiati M, 2015, J PATHOL, V235, P136, DOI 10.1002/path.4455; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018	49	4	4	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4601	4610		10.1038/onc.2015.528	http://dx.doi.org/10.1038/onc.2015.528			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26820992				2022-12-28	WOS:000382336300006
J	Ande, SR; Nguyen, KH; Padilla-Meier, GP; Nyomba, BLG; Mishra, S				Ande, S. R.; Nguyen, K. H.; Padilla-Meier, G. P.; Nyomba, B. L. G.; Mishra, S.			Expression of a mutant prohibitin from the aP2 gene promoter leads to obesity-linked tumor development in insulin resistance-dependent manner	ONCOGENE			English	Article							DENDRITIC CELLS; BREAST-CANCER; MOUSE MODEL; IGF-AXIS; GHRELIN; INFLAMMATION; IMMUNITY; PROTEIN; DRIVEN; IMMUNOMETABOLISM	A critical unmet need for the study of obesity-linked cancer is the lack of preclinical models that spontaneously develop obesity and cancer sequentially. Prohibitin (PHB) is a pleiotropic protein that has a role in adipose and immune functions. We capitalized on this attribute of PHB to develop a mouse model for obesity-linked tumor. We achieved this by expressing Y114F-PHB (m-PHB) from the aP2 gene promoter for simultaneous manipulation of adipogenic and immune signaling functions. The m-PHB mice develop obesity in a sex-neutral manner, but only male mice develop impaired glucose homeostasis and hyperinsulinemia similar to transgenic mice expressing PHB. Interestingly, only male m-PHB mice develop histiocytosis with lymphadenopathy, suggesting that metabolic dysregulation or m-PHB alone is not sufficient for the tumor development and that both are required for tumorigenesis. Moreover, ovariectomy in female m-PHB mice resulted in impaired glucose homeostasis, hyperinsulinemia and consequently tumor development similar to male m-PHB mice. These changes were not observed in sham-operated control m-Mito-Ob mice, further confirming the role of obesity-related metabolic dysregulation in tumor development in m-PHB mice. Our data provide a proof-of-concept that obesity-associated hyperinsulinemia promotes tumor development by facilitating dormant mutant to manifest and reveals a sex-dimorphic role of PHB in adipose-immune interaction or immunometabolism. Targeting PHB may provide a unique opportunity for the modulation of immunometabolism in obesity, cancer and in immune diseases.	[Ande, S. R.; Nguyen, K. H.; Padilla-Meier, G. P.; Nyomba, B. L. G.; Mishra, S.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada; [Mishra, S.] Univ Manitoba, Dept Physiol & Pathophysiol, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Mishra, S (corresponding author), Univ Manitoba, Dept Internal Med, John Buhler Res Ctr, Room 843,715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	suresh.mishra@umanitoba.ca	Ande, Sudharsana Rao/AAU-6950-2021; Mishra, Suresh/W-1633-2019	Ande, Sudharsana Rao/0000-0001-8194-2902; Nyomba, B. L. Gregoire/0000-0001-9472-607X	Natural Sciences and Engineering Research Council of Canada; Canadian Breast Cancer Foundation; Manitoba Health Research Council (MHRC); Canada Foundation for Innovation; MHRC Postdoctoral Fellowship Award	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Manitoba Health Research Council (MHRC); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); MHRC Postdoctoral Fellowship Award	We thank Anamarija Perry, Department of Pathology, University of Manitoba, Canada for help with tumor characterization and Nivida Mishra for proofreading the manuscript. We were supported by the Natural Sciences and Engineering Research Council of Canada, Canadian Breast Cancer Foundation, Manitoba Health Research Council (MHRC) and Canada Foundation for Innovation. GPP-M is a recipient of an MHRC Postdoctoral Fellowship Award.	Ande SR, 2014, DIABETES, V63, P3734, DOI 10.2337/db13-1807; Ande SR, 2009, BIOCHEM BIOPH RES CO, V390, P1023, DOI 10.1016/j.bbrc.2009.10.101; Ande SR, 2009, BBA-MOL CELL RES, V1793, P1372, DOI 10.1016/j.bbamcr.2009.05.008; Artal-Sanz M, 2009, NATURE, V461, P793, DOI 10.1038/nature08466; de Gruijl TD, 2006, J IMMUNOL, V176, P7232, DOI 10.4049/jimmunol.176.12.7232; DeCensi A, 2014, BREAST CANCER RES TR, V148, P81, DOI 10.1007/s10549-014-3141-1; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; DIXIT VD, 2006, BRAIN BEHAV IMMUN, V20, P14; Dixit VD, 2008, J LEUKOCYTE BIOL, V84, P882, DOI 10.1189/jlb.0108028; Fu YC, 2006, ATHEROSCLEROSIS, V188, P102, DOI 10.1016/j.atherosclerosis.2005.10.041; Gahete MD, 2014, CARCINOGENESIS, V35, P2467, DOI 10.1093/carcin/bgu161; Gallagher EJ, 2013, DIABETES, V62, P3553, DOI 10.2337/db13-0249; Gonzalez-Rey E, 2006, GASTROENTEROLOGY, V130, P1707, DOI 10.1053/j.gastro.2006.01.041; Haabeth OAW, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1239; Hernandez BY, 2015, CANCER MED-US, V4, P354, DOI 10.1002/cam4.375; Hvid H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079710; Kim DK, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004098; Kusminski CM, 2012, NAT MED, V18, P1539, DOI 10.1038/nm.2899; Leenen PJM, 2010, J LEUKOCYTE BIOL, V87, P949, DOI 10.1189/jlb.0609432; Li WG, 2004, CIRCULATION, V109, P2221, DOI 10.1161/01.CIR.0000127956.43874.F2; Madeddu C, 2014, J CELL MOL MED, V18, P2519, DOI 10.1111/jcmm.12413; Makarem N, 2008, CANCER CAUSE CONTROL, V26, P277; Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006; Mathis D, 2011, NAT REV IMMUNOL, V11, P81, DOI 10.1038/nri2922; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nikolic T, 2005, HISTIOCYTIC DISORDERS OF CHILDREN AND ADULTS, P40; Pileri SA, 2002, HISTOPATHOLOGY, V41, P1, DOI 10.1046/j.1365-2559.2002.01418.x; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006; Richter-Dennerlein R, 2014, CELL METAB, V20, P158, DOI 10.1016/j.cmet.2014.04.016; Roding S, 2013, DIAGNOSTIC HISTOPATH; Rose D P, 2004, Obes Rev, V5, P153, DOI 10.1111/j.1467-789X.2004.00142.x; Rutkowski MR, 2015, CANCER CELL, V27, P27, DOI 10.1016/j.ccell.2014.11.009; Schipper HS, 2012, TRENDS ENDOCRIN MET, V23, P407, DOI 10.1016/j.tem.2012.05.011; Sell H, 2012, NAT REV ENDOCRINOL, V8, P709, DOI 10.1038/nrendo.2012.114; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; Takahashi S, 2011, BIOCHEM BIOPH RES CO, V405, P462, DOI 10.1016/j.bbrc.2011.01.054; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Venkan K, 2013, J HEPATOL, V60, P175; Wiedmer P, 2007, NAT CLIN PRACT ENDOC, V3, P705, DOI 10.1038/ncpendmet0625; Wolin KY, 2010, ONCOLOGIST, V15, P556, DOI 10.1634/theoncologist.2009-0285; Zhang Y, 2009, CANCER RES, V69, P5259, DOI 10.1158/0008-5472.CAN-08-3444; Zhao M, 2014, WORLD J CLIN ONCOL, V5, P248, DOI 10.5306/wjco.v5.i3.248	46	17	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4459	4470		10.1038/onc.2015.501	http://dx.doi.org/10.1038/onc.2015.501			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26751773				2022-12-28	WOS:000382153100004
J	Zhu, B; Zhang, M; Williams, EM; Keller, C; Mansoor, A; Davie, JK				Zhu, B.; Zhang, M.; Williams, E. M.; Keller, C.; Mansoor, A.; Davie, J. K.			TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle	ONCOGENE			English	Article							CELL-CYCLE ARREST; EGR-1 TRANSCRIPTION FACTOR; BREAST-CANCER; MYOGENIC DIFFERENTIATION; SIGNALING PATHWAY; TUMOR SUPPRESSION; MUTANT MICE; KINASE-B; IN-VIVO; EXPRESSION	Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children that shares many features of developing skeletal muscle. TBX2, a T-box family member, is highly upregulated in tumor cells of both major RMS subtypes where it functions as an oncogene. TBX2 is a repressor that is often overexpressed in cancer cells and functions in bypassing cell growth control, including the repression of the cell cycle regulators p14 and p21. We have found that TBX2 directly represses the tumor-suppressor phosphatase and tensin homolog (PTEN) in both RMS and normal muscle. Exogenous expression of TBX2 in normal muscle cells downregulates PTEN, and depletion or interference with TBX2 in RMS cells upregulates PTEN. Human RMS tumors show high levels of TBX2 and correspondingly low levels of PTEN. The expression of PTEN in clinical RMS samples is relatively uncharacterized, and we establish that suppression of PTEN is a frequent event in both subtypes of RMS. TBX2 represses PTEN by directly binding to the promoter and recruiting the histone deacetylase, HDAC1. RMS cells have high levels of activated AKT owing to the deregulation of phosphoinositide-3 kinase (PI3K) signaling, and depletion or interference with TBX2, which upregulates PTEN, results in a reduction of phospho-AKT. We have also found that the highly related T-box family member TBX3 does not repress PTEN in the muscle lineage. This work suggests that TBX2 is a central component of the PTEN/PI3K/AKT signaling pathway deregulation in RMS cells and that targeting TBX2 in RMS tumors may offer a novel therapeutic approach for RMS.	[Zhu, B.; Zhang, M.; Davie, J. K.] Southern Illinois Univ, Sch Med, Dept Biochem & Mol Biol, 229 Neckers Bldg,1245 Lincoln Dr, Carbondale, IL 62901 USA; [Zhu, B.; Zhang, M.; Davie, J. K.] Southern Illinois Univ, Sch Med, Simmons Canc Inst, 229 Neckers Bldg,1245 Lincoln Dr, Carbondale, IL 62901 USA; [Williams, E. M.; Mansoor, A.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA; [Keller, C.] Childrens Canc Therapy Dev Inst, Ft Collins, CO USA; [Zhu, B.] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; [Zhang, M.] Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Oregon Health & Science University; Yale University; Yale University	Davie, JK (corresponding author), Southern Illinois Univ, Sch Med, Dept Biochem & Mol Biol, 229 Neckers Bldg,1245 Lincoln Dr, Carbondale, IL 62901 USA.; Davie, JK (corresponding author), Southern Illinois Univ, Sch Med, Simmons Canc Inst, 229 Neckers Bldg,1245 Lincoln Dr, Carbondale, IL 62901 USA.	jdavie@siumed.edu		Keller, Charles/0000-0003-2505-7487	American Cancer Society, Illinois Division [159609]; National Institute of Health, NIAMS division [RAR 060017A]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R15AR060017, R15AR068622] Funding Source: NIH RePORTER	American Cancer Society, Illinois Division(American Cancer Society); National Institute of Health, NIAMS division; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Terry Morgan, MD, PhD, Oregon Health and Sciences University for help with the statistical analysis of the archival RMS tumor samples. We thank Steven Verhulst, PhD, Southern Illinois University School of Medicine for help with the statistical analysis of the primary RMS tumor samples. This work was supported by grant 159609 from the American Cancer Society, Illinois Division to JD and by grant RAR 060017A from the National Institute of Health, NIAMS division.	Burgucu D, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-481; Carlson H, 2002, ONCOGENE, V21, P3827, DOI 10.1038/sj.onc.1205476; Castellino RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010849; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Ciccarelli C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-41; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Douglas NC, 2013, J MAMMARY GLAND BIOL, V18, P143, DOI 10.1007/s10911-013-9282-8; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Huang W, 2007, ONCOGENE, V26, P2471, DOI 10.1038/sj.onc.1210033; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jonsson G, 2007, ONCOGENE, V26, P4738, DOI 10.1038/sj.onc.1210252; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li HG, 2007, CANCER LETT, V253, P215, DOI 10.1016/j.canlet.2007.01.020; Li J, 2014, J BIOL CHEM, V289, P35633, DOI 10.1074/jbc.M114.596411; Liu F, 2013, PIGM CELL MELANOMA R, V26, P67, DOI 10.1111/pcmr.12029; Lomnytska M, 2006, INT J CANCER, V118, P412, DOI 10.1002/ijc.21332; Londhe P, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-14; Londhe P, 2011, MOL CELL BIOL, V31, P2854, DOI 10.1128/MCB.05397-11; Lyng H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-268; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Mandl A, 2007, MOL CELL BIOL, V27, P8098, DOI 10.1128/MCB.00756-07; Okamura H, 2005, J CELL BIOCHEM, V94, P117, DOI 10.1002/jcb.20283; Peres J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-117; Peres Jade, 2010, Genes Cancer, V1, P272, DOI 10.1177/1947601910365160; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Redmond KL, 2010, ONCOGENE, V29, P3252, DOI 10.1038/onc.2010.84; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Renshaw J, 2013, CLIN CANCER RES, V19, P5940, DOI 10.1158/1078-0432.CCR-13-0850; Rodriguez M, 2008, CANCER RES, V68, P7872, DOI 10.1158/0008-5472.CAN-08-0301; Ross AH, 2009, P NATL ACAD SCI USA, V106, P1297, DOI 10.1073/pnas.0812473106; Rowley M, 2004, J MAMMARY GLAND BIOL, V9, P109, DOI 10.1023/B:JOMG.0000037156.64331.3f; Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074; Shao J, 2007, CARCINOGENESIS, V28, P2476, DOI 10.1093/carcin/bgm186; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Sinclair CS, 2002, CANCER RES, V62, P3587; Singh S, 2010, AM J PATHOL, V177, P2055, DOI 10.2353/ajpath.2010.091195; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wan XL, 2003, ONCOGENE, V22, P8205, DOI 10.1038/sj.onc.1206878; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Zhu B, 2014, INT J CANCER, V135, P785, DOI 10.1002/ijc.28721; Zhu XY, 2001, CANCER RES, V61, P4569; 2005, SCIENCE, V307, P1098, DOI DOI 10.1126/SCIENCE.1106148	55	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4212	4224		10.1038/onc.2015.486	http://dx.doi.org/10.1038/onc.2015.486			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26686089	Green Accepted, Green Submitted			2022-12-28	WOS:000382149800006
J	Debruyne, DN; Bhatnagar, N; Sharma, B; Luther, W; Moore, NF; Cheung, K; Gray, NS; George, RE				Debruyne, D. N.; Bhatnagar, N.; Sharma, B.; Luther, W.; Moore, N. F.; Cheung, K.; Gray, N. S.; George, R. E.			ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURE; CANCER-CELLS; THERAPEUTIC TARGET; KINASE INHIBITOR; LUNG-CANCER; RECEPTOR; MUTATIONS; GROWTH; EGFR; MYCN	The crizotinib-resistant ALK(F1174L) mutation arises de novo in neuroblastoma (NB) and is acquired in ALK translocation-driven cancers, lending impetus to the development of novel anaplastic lymphoma kinase (ALK) inhibitors with different modes of action. The diaminopyrimidine TAE684 and its derivative ceritinib (LDK378), which are structurally distinct from crizotinib, are active against NB cells expressing ALK(F1174L). Here we demonstrate acquired resistance to TAE684 and LDK378 in ALK(F1174L)-driven human NB cells that is linked to overexpression and activation of the AXL tyrosine kinase and epithelial-to-mesenchymal transition (EMT). AXL phosphorylation conferred TAE684 resistance to NB cells through upregulated extracellular signal-regulated kinase (ERK) signaling. Inhibition of AXL partly rescued TAE684 resistance, resensitizing these cells to this compound. AXL activation in resistant cells was mediated through increased expression of the active form of its ligand, GAS6, that also served to stabilize the AXL protein. Although ectopic expression of AXL and TWIST2 individually in TAE684-sensitive parental cells led to the elevated expression of mesenchymal markers and invasive capacity, only AXL overexpression induced resistance to TAE684 as well. TAE684-resistant cells showed greater sensitivity to HSP90 inhibition than did their parental counterparts, with downregulation of AXL and AXL-mediated ERK signaling. Our studies indicate that aberrant AXL signaling and development of an EMT phenotype underlie resistance of ALK(F1174L)-driven NB cells to TAE684 and its derivatives. We suggest that the combination of ALK and AXL or HSP90 inhibitors be considered to delay the emergence of such resistance.	[Debruyne, D. N.; Bhatnagar, N.; Sharma, B.; Luther, W.; Moore, N. F.; George, R. E.] Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; [Debruyne, D. N.; Bhatnagar, N.; Sharma, B.; Luther, W.; Moore, N. F.; George, R. E.] Boston Childrens Hosp, Boston, MA USA; [Cheung, K.] Mem Sloan Kettering Canc Ctr, Dept Pediat Oncol, 1275 York Ave, New York, NY 10021 USA; [Gray, N. S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Gray, N. S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [George, R. E.] Harvard Med Sch, Dept Pediat, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	George, RE (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Dana 640E,450 Brookline Ave, Boston, MA 02215 USA.	rani_george@dfci.harvard.edu	George, Rani/AAG-7635-2019		NIH/NCI [R01 CA148688]; Friends for Life Neuroblastoma Fellowship; Ruth L Kirschstein NRSA [F32CA183566]; NATIONAL CANCER INSTITUTE [R01CA148688, P30CA008748] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Friends for Life Neuroblastoma Fellowship; Ruth L Kirschstein NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH/NCI R01 CA148688 (to REG), Friends for Life Neuroblastoma Fellowship (to DND) and a Ruth L Kirschstein NRSA F32CA183566 (to NFM).	Anastassiou D, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-529; Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Bresler SC, 2014, CANCER CELL, V26, P682, DOI 10.1016/j.ccell.2014.09.019; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chen JY, 2013, J MED CHEM, V56, P5673, DOI 10.1021/jm401005u; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Duijkers FAM, 2013, GENE, V521, P62, DOI 10.1016/j.gene.2013.03.029; Eleveld TF, 2015, NAT GENET, V47, P864, DOI 10.1038/ng.3333; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; Gainor JF, 2013, J CLIN ONCOL, V31, P3987, DOI 10.1200/JCO.2012.45.2029; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goruppi S, 1997, FEBS LETT, V415, P59, DOI 10.1016/S0014-5793(97)01093-4; GRECO WR, 1995, PHARMACOL REV, V47, P331; Heuckmann JM, 2011, CLIN CANCER RES, V17, P7394, DOI 10.1158/1078-0432.CCR-11-1648; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hong J, 2013, CANCER RES, V73, P331, DOI 10.1158/0008-5472.CAN-12-3151; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Kim HR, 2013, MOL ONCOL, V7, P1093, DOI 10.1016/j.molonc.2013.08.001; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Korshunov VA, 2012, CLIN SCI, V122, P361, DOI 10.1042/CS20110411; Krishnamoorthy GP, 2013, J BIOL CHEM, V288, P17481, DOI 10.1074/jbc.M112.439422; Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mudduluru G, 2011, ONCOGENE, V30, P2888, DOI 10.1038/onc.2011.13; Mudduluru G, 2008, BIOSCIENCE REP, V28, P161, DOI 10.1042/BSR20080046; Normant E, 2011, ONCOGENE, V30, P2581, DOI 10.1038/onc.2010.625; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Sakamoto H, 2011, CANCER CELL, V19, P679, DOI 10.1016/j.ccr.2011.04.004; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wilson C, 2014, CANCER RES, V74, P5878, DOI 10.1158/0008-5472.CAN-14-1009; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wu ZX, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.016675; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	47	69	73	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3681	3691		10.1038/onc.2015.434	http://dx.doi.org/10.1038/onc.2015.434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26616860	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000379622800007
J	Hong, SM; Park, CW; Kim, SW; Nam, YJ; Yu, JH; Shin, JH; Yun, CH; Im, SH; Kim, KT; Sung, YC; Choi, KY				Hong, S. M.; Park, C. W.; Kim, S. W.; Nam, Y. J.; Yu, J. H.; Shin, J. H.; Yun, C. H.; Im, S-H; Kim, K-T; Sung, Y. C.; Choi, K. Y.			NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer	ONCOGENE			English	Article							NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE NAMPT; TUMOR-CELL SURVIVAL; METABOLISM; INHIBITION; AUTOPHAGY; ENZYME; BIOSYNTHESIS; HOMEOSTASIS; GLYCOGEN; DEATH	Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme involved in NAD+ biosynthesis. Although NAMPT has emerged as a critical regulator of metabolic stress, the underlying mechanisms by which it regulates metabolic stress in cancer cells have not been completely elucidated. In this study, we determined that breast cancer cells expressing a high level of NAMPT were resistant to cell death induced by glucose depletion. Furthermore, NAMPT inhibition suppressed tumor growth in vivo in a xenograft model. Under glucose deprivation conditions, NAMPT inhibition was found to increase the mitochondrial reactive oxygen species (ROS) level, leading to cell death. This cell death was rescued by treatment with antioxidants or NAD+. Finally, we showed that NAMPT increased the pool of NAD+ that could be converted to NADPH through the pentose phosphate pathway and inhibited the depletion of reduced glutathione under glucose deprivation. Collectively, our results suggest a novel mechanism by which tumor cells protect themselves against glucose deprivation-induced oxidative stress by utilizing NAMPT to maintain NADPH levels.	[Hong, S. M.; Park, C. W.; Kim, S. W.; Nam, Y. J.; Yu, J. H.; Shin, J. H.; Im, S-H; Kim, K-T; Sung, Y. C.; Choi, K. Y.] Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang, South Korea; [Park, C. W.] Biokogen Inc, POSTECH Biotech Ctr 226, Pohang, South Korea; [Yun, C. H.; Im, S-H] AIM, IBS, Pohang, South Korea	Pohang University of Science & Technology (POSTECH); Institute for Basic Science - Korea (IBS)	Choi, KY (corresponding author), Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, PBC, Room 327, Pohang 790784, South Korea.	kchoi@postech.ac.kr	Im, Sin-Hyeog/AAM-9586-2021; Im, Sin-Hyeog/E-6811-2013	Im, Sin-Hyeog/0000-0002-3173-1856; Im, Sin-Hyeog/0000-0002-3173-1856; KIM, KYONG-TAI/0000-0001-7292-2627	National R&D Program for Cancer Control, Ministry for Health and Welfare, Korea [1320240]; National Research Foundation of Korea (NRF) grant - Korea government (MEST) [NRF-2014R1A2A2A01002931]; Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea [PJ01121601]; BK21 Plus - Ministry of Education, Korea [10Z20130012243]	National R&D Program for Cancer Control, Ministry for Health and Welfare, Korea; National Research Foundation of Korea (NRF) grant - Korea government (MEST); Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea; BK21 Plus - Ministry of Education, Korea	This research was supported by the National R&D Program for Cancer Control, Ministry for Health and Welfare, Korea (1320240), by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2014R1A2A2A01002931), by the Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea (PJ01121601) and by BK21 Plus funded by the Ministry of Education, Korea (10Z20130012243). We thank Kwan-Suk Lee at the POSTECH animal facility for assistance with animal experiments. Slide scanning images were obtained using Virtual Microscope in UNIST-Olympus Biomed Imaging Center (UOBC). We are grateful to Jin-Hoe Hur and UNIST-Olympus Biomed Imaging Center (UOBC) for providing the data of slide scanning images.	Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Bajrami I, 2012, EMBO MOL MED, V4, P1087, DOI 10.1002/emmm.201201250; Bi TQ, 2010, CANCER BIOL THER, V10, P119, DOI 10.4161/cbt.10.2.12581; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cerna D, 2012, J BIOL CHEM, V287, P22408, DOI 10.1074/jbc.M112.357301; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Chiarugi A, 2012, NAT REV CANCER, V12, P741, DOI 10.1038/nrc3340; Choi YJ, 2014, HORM METAB RES, V46, P233, DOI 10.1055/s-0034-1370907; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Favaro E, 2012, CELL METAB, V16, P751, DOI 10.1016/j.cmet.2012.10.017; Galli U, 2013, J MED CHEM, V56, P6279, DOI 10.1021/jm4001049; Garten A, 2009, TRENDS ENDOCRIN MET, V20, P130, DOI 10.1016/j.tem.2008.10.004; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hsu CP, 2009, CIRC RES, V105, P481, DOI 10.1161/CIRCRESAHA.109.203703; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47; Li L, 2012, FREE RADICAL BIO MED, V53, P1399, DOI 10.1016/j.freeradbiomed.2012.07.011; Liang HL, 2009, AM J PHYSIOL-RENAL, V296, pF266, DOI 10.1152/ajprenal.90533.2008; Madhok BM, 2011, AM J CLIN ONCOL-CANC, V34, P628, DOI 10.1097/COC.0b013e3181e84dec; Magni G, 2006, MINI-REV MED CHEM, V6, P739, DOI 10.2174/138955706777698688; Park CW, 2013, AUTOPHAGY, V9, P345, DOI 10.4161/auto.23072; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Romero-Garcia S, 2011, CANCER BIOL THER, V12, P939, DOI 10.4161/cbt.12.11.18140; ROUSSET M, 1981, CANCER RES, V41, P1165; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Simons AL, 2009, J CANCER RES THER, V5, P2, DOI 10.4103/0973-1482.55133; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Stanton RC, 2012, IUBMB LIFE, V64, P362, DOI 10.1002/iub.1017; Tan B, 2013, J BIOL CHEM, V288, P3500, DOI 10.1074/jbc.M112.394510; Tew KD, 2012, ANTIOXID REDOX SIGN, V17, P1728, DOI 10.1089/ars.2012.4640; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wang B, 2011, ONCOGENE, V30, P907, DOI 10.1038/onc.2010.468; Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224; Xiao Y, 2013, NEOPLASIA, V15, P1137, DOI 10.1593/neo.131304; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672	38	39	43	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3544	3554		10.1038/onc.2015.415	http://dx.doi.org/10.1038/onc.2015.415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26568303				2022-12-28	WOS:000379621500007
J	Parsel, SM; Grandis, JR; Thomas, SM				Parsel, S. M.; Grandis, J. R.; Thomas, S. M.			Nucleic acid targeting: towards personalized therapy for head and neck cancer	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; HERPES-SIMPLEX-VIRUS; P53 GENE-TRANSFER; SMALL INTERFERING RNA; MULTICENTER PHASE-II; FACTOR-KAPPA-B; IN-VIVO; RECURRENT HEAD; GLUCOSYLATED POLYETHYLENIMINE	In light of a detailed characterization of genetic aberrations in cancer, nucleic acid targeting represents an attractive therapeutic approach with significant translational potential. Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer deaths worldwide with stagnant 5-year survival rates. Advances in conventional treatment have done little to improve survival and combined chemoradiation is associated with significant adverse effects. Recent reports have characterized the genetic alterations in HNSCC and demonstrated that mutations confer resistance to conventional and molecular targeted therapies. The ability to use specific nucleic acid sequences to inhibit cancer-associated genes including non-druggable targets facilitates personalized medicine approaches with less adverse effects. Additionally, advances in drug delivery mechanisms have increased the transfection efficiency aiding in greater therapeutic responses. Given these advances, the stage has been set to translate the information garnered from genomic studies into personalized treatment strategies. Genes involved in the tumor protein 53 and epidermal growth factor receptor pathways have been extensively investigated and many promising preclinical studies have shown tumor inhibition through genetic modulation. We, and others, have demonstrated that targeting oncogene expression with gene therapy approaches is feasible in patients. Other methods such as RNA interference have proven to be effective and are potential candidates for clinical studies. This review summarizes the major advances in sequence-specific gene modulation in the preclinical setting and in clinical trials in head and neck cancer patients.	[Parsel, S. M.; Thomas, S. M.] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Thomas, S. M.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA; [Thomas, S. M.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Thomas, SM (corresponding author), Univ Kansas, Med Ctr, 3901 Rainbow Blvd,3020A Wahl Hall East, Kansas City, KS 66160 USA.	sthomas7@kumc.edu	Thomas, Sufi/O-1487-2018; Thomas, Sufi Mary/AFR-1642-2022; Parsel, Sean Michael/G-1228-2013; Parsel, Sean Michael/AAZ-4251-2020	Thomas, Sufi/0000-0001-5370-0842; Thomas, Sufi Mary/0000-0001-5370-0842; Parsel, Sean Michael/0000-0003-0821-7784; Parsel, Sean Michael/0000-0003-0821-7784	Department of Otolaryngology, University of Kansas Medical Center; University of Kansas Cancer Center's CCSG [1-P30-CA168524-02]; Kansas Intellectual and Developmental Disabilities Center [NICHD HD00258]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002528] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA168524, P50CA097190] Funding Source: NIH RePORTER	Department of Otolaryngology, University of Kansas Medical Center; University of Kansas Cancer Center's CCSG; Kansas Intellectual and Developmental Disabilities Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hinrich Staecker, Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS and Dr Stefan Rothenberg, K-State University, Manhattan, KS for critical review of the manuscript. We also thank Mr Phil Shafer for the artwork. We apologize to authors whose work was not cited due to space constraints. Department of Otolaryngology, University of Kansas Medical Center and University of Kansas Cancer Center's CCSG (1-P30-CA168524-02), and the Kansas Intellectual and Developmental Disabilities Center (NICHD HD00258) were the funding sources.	Accardi R, 2008, WORLD CANC REPORT 20, P30; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blackwell JL, 1999, ARCH OTOLARYNGOL, V125, P856, DOI 10.1001/archotol.125.8.856; Boehm AL, 2008, MOL PHARMACOL, V73, P1632, DOI 10.1124/mol.107.044636; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Carson AR, 2012, CANCER RES, V72, P6191, DOI 10.1158/0008-5472.CAN-11-4079; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; Chen SM, 2008, CANCER BIOL THER, V7, P734, DOI 10.4161/cbt.7.5.5722; Chen WH, 2015, CANCER LETT, V359, P65, DOI 10.1016/j.canlet.2014.12.052; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Cohen EEW, 2004, J CLIN ONCOL, V22, P1743, DOI 10.1200/JCO.2004.06.147; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; Deng Y, 2014, GENE, V538, P217, DOI 10.1016/j.gene.2013.12.019; Dobrossy L, 2005, CANCER METAST REV, V24, P9, DOI 10.1007/s10555-005-5044-4; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dolivet G, 2002, CANCER GENE THER, V9, P708, DOI 10.1038/sj.cgt.7700485; Duan JM, 2007, MOL CANCER THER, V6, P37, DOI 10.1158/1535-7163.MCT-05-0285; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Ferris RL, 2007, CLIN CANCER RES, V13, P5663, DOI 10.1158/1078-0432.CCR-07-1544; Fujimoto Y, 2006, ACTA OTO-LARYNGOL, V126, P1115, DOI 10.1080/00016480600702100; Ganly I, 2000, CLIN CANCER RES, V6, P798; Garber K, 2006, J NATL CANCER I, V98, P298, DOI 10.1093/jnci/djj111; Gleich LL, 1998, ARCH OTOLARYNGOL, V124, P1097, DOI 10.1001/archotol.124.10.1097; Gleich LL, 2001, ARCH OTOLARYNGOL, V127, P775; Graff JR, 2007, J CLIN INVEST, V117, P2638, DOI 10.1172/JCI32044; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Guttmann DM, 2013, INT J RADIAT ONCOL, V87, P168, DOI 10.1016/j.ijrobp.2013.05.028; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; Hazar-Rethinam M, 2015, CLIN CANCER RES, V21, P417, DOI 10.1158/1078-0432.CCR-14-1962; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; Heise CC, 1999, CANCER RES, V59, P2623; Hong DS, 2011, CLIN CANCER RES, V17, P6582, DOI 10.1158/1078-0432.CCR-11-0430; Hsin CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113129; Hu JCC, 2006, CLIN CANCER RES, V12, P6737, DOI 10.1158/1078-0432.CCR-06-0759; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jing NJ, 2006, MOL CANCER THER, V5, P279, DOI 10.1158/1535-7163.MCT-05-0302; Kanazawa T, 2003, GENE THER, V10, P51, DOI 10.1038/sj.gt.3301837; Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6; Kawakami K, 2001, CANCER RES, V61, P6194; Kedmi R, 2010, BIOMATERIALS, V31, P6867, DOI 10.1016/j.biomaterials.2010.05.027; Kindt N, 2014, J CANCER RES CLIN, V140, P937, DOI 10.1007/s00432-014-1648-9; Klein JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081819; Konopka K, 2006, CELL MOL BIOL LETT, V11, P171, DOI 10.2478/s11658-006-0015-5; Kothari V, 2012, ANTICANCER RES, V32, P121; Lai SY, 2009, J CLIN ONCOL, V27, P1235, DOI 10.1200/JCO.2008.17.8251; Lalonde ES, 2002, HEAD NECK-J SCI SPEC, V24, P1038, DOI 10.1002/hed.10148; Lamont JP, 2000, ANN SURG ONCOL, V7, P588, DOI 10.1007/BF02725338; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Li DQ, 1999, CLIN CANCER RES, V5, P1551; Li MF, 2002, CLIN CANCER RES, V8, P3570; Li Y, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-16; Liu Dan, 2006, Ai Zheng, V25, P11; LIU TJ, 1995, CANCER RES, V55, P3117; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Lun MY, 2005, ANN CLIN LAB SCI, V35, P251; Mace ATM, 2007, ACTA OTO-LARYNGOL, V127, P880, DOI 10.1080/00016480601075381; Mace ATM, 2008, HEAD NECK-J SCI SPEC, V30, P1045, DOI 10.1002/hed.20840; Mansoori B, 2014, ADV PHARM BULL, V4, P313, DOI 10.5681/apb.2014.046; Masuelli L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-122; Matsui M, 2009, CANCER RES, V69, P2523, DOI 10.1158/0008-5472.CAN-08-2793; Mazumdar A, 2009, HEAD NECK-J SCI SPEC, V31, P625, DOI 10.1002/hed.21007; Michaluart P, 2008, CANCER GENE THER, V15, P676, DOI 10.1038/cgt.2008.35; Morris JC, 2000, MOL THER, V1, P56, DOI 10.1006/mthe.1999.0014; Ndoye A, 2004, INT J ONCOL, V25, P1575; Nemunaitis J, 2009, CLIN CANCER RES, V15, P7719, DOI 10.1158/1078-0432.CCR-09-1044; Nozawa H, 2006, CANCER SCI, V97, P1115, DOI 10.1111/j.1349-7006.2006.00287.x; Okunaga S, 2015, CANCER GENE THER, V22, P163, DOI 10.1038/cgt.2015.3; OMALLEY BW, 1995, CANCER RES, V55, P1080; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Park IK, 2005, ARCH PHARM RES, V28, P1302, DOI 10.1007/BF02978216; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Rahman MA, 2012, J CONTROL RELEASE, V159, P384, DOI 10.1016/j.jconrel.2012.01.045; Rao DD, 2009, ADV DRUG DELIVER REV, V61, P746, DOI 10.1016/j.addr.2009.04.004; Ren H, 2015, MED ONCOL, V32, P1; Saba NF, 2015, ORAL ONCOL, V51, P112, DOI 10.1016/j.oraloncology.2014.11.002; Sahu B, 2009, J ORG CHEM, V74, P1509, DOI 10.1021/jo802211n; Seiwert TY, 2013, ANN ONCOL, V24, P769, DOI 10.1093/annonc/mds523; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675; Shimizu S, 2008, INT J CANCER, V123, P1816, DOI 10.1002/ijc.23710; Shin EJ, 2007, LARYNGOSCOPE, V117, P210, DOI 10.1097/01.mlg.0000246194.66295.d8; Skinner HD, 2012, CLIN CANCER RES, V18, P290, DOI 10.1158/1078-0432.CCR-11-2260; Smith NB, 2003, ULTRASOUND MED BIOL, V29, P311, DOI 10.1016/S0301-5629(02)00706-8; Sobral LM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-32; Sok JC, 2006, CLIN CANCER RES, V12, P5064, DOI 10.1158/1078-0432.CCR-06-0913; Sorace AG, 2014, ULTRASOUND MED BIOL, V40, P755, DOI 10.1016/j.ultrasmedbio.2013.11.002; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sugano M, 2012, INT J PHARMACEUT, V422, P332, DOI 10.1016/j.ijpharm.2011.11.001; Suzuki R, 2007, J CONTROL RELEASE, V117, P130, DOI 10.1016/j.jconrel.2006.09.008; Tassone P, 2013, ORAL ONCOL, V49, P733, DOI 10.1016/j.oraloncology.2013.03.447; Thomas SM, 2003, CANCER GENE THER, V10, P518, DOI 10.1038/sj.cgt.7700567; Thomas SM, 2013, ACS CHEM BIOL, V8, P345, DOI 10.1021/cb3003946; Thomas SM, 2008, MOL PHARMACOL, V73, P627, DOI 10.1124/mol.107.041160; Tousignant JD, 2000, HUM GENE THER, V11, P2493, DOI 10.1089/10430340050207984; van den Broek GB, 2007, CLIN CANCER RES, V13, P4386, DOI 10.1158/1078-0432.CCR-06-2817; Vannucci L, 2013, NEW MICROBIOL, V36, P1; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Villaret D, 2002, HEAD NECK-J SCI SPEC, V24, P661, DOI 10.1002/hed.10107; Wang Y, 2008, CANCER BIOL THER, V7, P896, DOI 10.4161/cbt.7.6.5910; Wang YD, 2013, TECHNOL CANCER RES T, V12, P525, DOI 10.7785/tcrt.2012.500343; Xu L, 2002, MOL CANCER THER, V1, P337; Xu L, 2001, MOL MED, V7, P723, DOI 10.1007/BF03401962; Xu LA, 1999, HUM GENE THER, V10, P2941, DOI 10.1089/10430349950016357; Yoo GH, 2009, ARCH OTOLARYNGOL, V135, P869, DOI 10.1001/archoto.2009.122; Yuen AR, 1999, CLIN CANCER RES, V5, P3357; Zaoui K, 2012, CANCER GENE THER, V19, P181, DOI 10.1038/cgt.2011.75; Zeng Qing, 2002, J Exp Ther Oncol, V2, P174, DOI 10.1046/j.1359-4117.2002.01033.x; Zhang QZ, 2004, INT J CANCER, V111, P849, DOI 10.1002/ijc.20334	114	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3217	3226		10.1038/onc.2015.424	http://dx.doi.org/10.1038/onc.2015.424			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26592450	Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000378306400001
J	Silginer, M; Burghardt, I; Gramatzki, D; Bunse, L; Leske, H; Rushing, EJ; Hao, N; Platten, M; Weller, M; Roth, P				Silginer, M.; Burghardt, I.; Gramatzki, D.; Bunse, L.; Leske, H.; Rushing, E. J.; Hao, N.; Platten, M.; Weller, M.; Roth, P.			The aryl hydrocarbon receptor links integrin signaling to the TGF-beta pathway	ONCOGENE			English	Article							TRANSFORMING GROWTH FACTOR-BETA(1); CELL-CELL CONTACT; DIOXIN RECEPTOR; MEDIATED INDUCTION; EPITHELIAL-CELLS; DOWN-REGULATION; LIGAND-BINDING; GLIOMA-CELLS; IN-VITRO; EXPRESSION	Glioblastoma is the most common and aggressive form of intrinsic brain tumor. Transforming growth factor (TGF)-beta represents a central mediator of the malignant phenotype of these tumors by promoting invasiveness and angiogenesis, maintaining tumor cell stemness and inducing profound immunosuppression. Integrins, which are highly expressed in glioma cells, interact with the TGF-beta pathway. Furthermore, a link has been described between activity of the transcription factor aryl hydrocarbon receptor (AhR) and TGF-beta expression. Here we demonstrate that integrin inhibition, using alpha v, beta 3 or beta 5 neutralizing antibodies, RNA interference-mediated integrin gene silencing or pharmacological inhibition by the cyclic RGD peptide EMD 121974 (cilengitide) or the non-peptidic molecule GLPG0187, inhibits AhR activity. These effects are independent of cell detachment or cell density. While AhR mRNA expression was not affected by integrin inhibition, AhR total and nuclear protein levels were reduced, suggesting that integrin inhibition-mediated regulation of AhR may occur at a post-transcriptional level. AhR-null astrocytes, AhR-null hepatocytes or glioblastoma cells with a transiently silenced AhR gene showed reduced sensitivity to integrin inhibition-mediated alterations in TGF-beta signaling, indicating that AhR mediates integrin control of the TGF-beta pathway. Accordingly, there was a significant correlation of av integrin levels with nuclear AhR and pSmad2 levels as determined by immunohistochemistry in human glioblastoma in vivo. In summary, this study identifies a signaling network comprising integrins, AhR and TGF-beta and validates integrin inhibition as a promising strategy not only to inhibit angiogenesis, but also to block AhR-and TGF-beta-controlled features of malignancy in human glioblastoma.	[Silginer, M.; Burghardt, I.; Gramatzki, D.; Weller, M.; Roth, P.] Univ Zurich, Univ Zurich Hosp, Dept Neurol, Lab Mol Neurooncol, Zurich, Switzerland; [Bunse, L.; Platten, M.] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Neurol, Heidelberg, Germany; [Bunse, L.; Platten, M.] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Leske, H.; Rushing, E. J.] Univ Zurich, Univ Zurich Hosp, Inst Neuropathol, Zurich, Switzerland; [Hao, N.] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia	University of Zurich; University Zurich Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Zurich; University Zurich Hospital; University of Adelaide	Roth, P (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklinikstr 26, CH-8091 Zurich, Switzerland.	patrick.roth@usz.ch	Bunse, Lukas/L-2975-2016; Roth, Patrick/R-6671-2018; Hao, Nan/H-2129-2016; Platten, Michael/F-2902-2013	Bunse, Lukas/0000-0002-4490-7574; Roth, Patrick/0000-0003-3897-214X; Hao, Nan/0000-0001-5836-3507; Platten, Michael/0000-0002-4746-887X; Weller, Michael/0000-0002-1748-174X; Silginer, Manuela/0000-0003-2538-1244	Novartis Foundation for medical-biological research; Kurt und Senta Herrmann Foundation; Heidelberg University Innovation Fund FRONTIER	Novartis Foundation for medical-biological research; Kurt und Senta Herrmann Foundation; Heidelberg University Innovation Fund FRONTIER	This study was supported by grants from the Novartis Foundation for medical-biological research and the Kurt und Senta Herrmann Foundation to PR and the Heidelberg University Innovation Fund FRONTIER to MP.	Abe Y, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-27; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Carraro G, 2005, MOL CELL PROBE, V19, P181, DOI 10.1016/j.mcp.2004.11.004; Cho YC, 2004, TOXICOL APPL PHARM, V199, P220, DOI 10.1016/j.taap.2003.12.025; Codo P, 2014, ONCOTARGET, V5, P7651, DOI 10.18632/oncotarget.2287; Corchero J, 2004, INT J EXP PATHOL, V85, P295, DOI 10.1111/j.0959-9673.2004.00397.x; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Denison MS, 2002, CURR PROTOC TOXICOL; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dietrich C, 2010, CARCINOGENESIS, V31, P1319, DOI 10.1093/carcin/bgq028; Dohr O, 1997, MOL PHARMACOL, V51, P703, DOI 10.1124/mol.51.5.703; Feng SL, 2013, BBA-REV CANCER, V1836, P197, DOI 10.1016/j.bbcan.2013.05.001; GAIDO KW, 1992, J BIOL CHEM, V267, P24591; Goodman SL, 2012, BIOL OPEN, V1, P329, DOI 10.1242/bio.2012364; Gramatzki D, 2009, ONCOGENE, V28, P2593, DOI 10.1038/onc.2009.104; Hao N, 2012, MOL PHARMACOL, V82, P1082, DOI 10.1124/mol.112.078873; Ikuta T, 2004, J BIOL CHEM, V279, P19209, DOI 10.1074/jbc.M310492200; Joseph JV, 2013, BIOCHEM PHARMACOL, V85, P478, DOI 10.1016/j.bcp.2012.11.005; Juan SH, 2006, EUR J PHARMACOL, V530, P1, DOI 10.1016/j.ejphar.2005.11.023; KINSEL LB, 1989, CANCER RES, V49, P1052; Kraus JA, 2012, MODERN PATHOL, V25, P869, DOI 10.1038/modpathol.2011.219; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Kung T, 2009, BIOCHEM PHARMACOL, V77, P536, DOI 10.1016/j.bcp.2008.09.031; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Maurer GD, 2009, NEURO-ONCOLOGY, V11, P747, DOI 10.1215/15228517-2009-012; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Monteiro P, 2007, BIOCHEM BIOPH RES CO, V358, P442, DOI 10.1016/j.bbrc.2007.04.111; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; Murray IA, 2005, ARCH BIOCHEM BIOPHYS, V442, P59, DOI 10.1016/j.abb.2005.07.014; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Prell RA, 1997, J IMMUNOL, V158, P2695; Riecke K, 2003, ARCH TOXICOL, V77, P358, DOI 10.1007/s00204-003-0445-z; Rodon J, 2015, INVEST NEW DRUG, V33, P357, DOI 10.1007/s10637-014-0192-4; Roth P, 2013, BRAIN, V136, P564, DOI 10.1093/brain/aws351; SADEK CM, 1994, J BIOL CHEM, V269, P16067; SADEK CM, 1994, J BIOL CHEM, V269, P31505; Safe S, 2013, TOXICOL SCI, V135, P1, DOI 10.1093/toxsci/kft128; Santiago-Josefat B, 2004, J CELL SCI, V117, P849, DOI 10.1242/jcs.00932; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Silginer M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.543; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; TOWNSEND D, 1981, J EXP ZOOL, V216, P113, DOI 10.1002/jez.1402160112; VOGEL C, 1995, ARCH TOXICOL, V69, P259, DOI 10.1007/s002040050168; Wirsching HG, 2014, BRAIN, V137, P433, DOI 10.1093/brain/awt333; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716	47	40	42	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3260	3271		10.1038/onc.2015.387	http://dx.doi.org/10.1038/onc.2015.387			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26500056	Green Accepted			2022-12-28	WOS:000378306400005
J	de la Cruz-Herrera, CF; Baz-Martinez, M; Lang, V; El Motiam, A; Barbazan, J; Couceiro, R; Abal, M; Vidal, A; Esteban, M; Munoz-Fontela, C; Nieto, A; Rodriguez, MS; Collado, M; Rivas, C				de la Cruz-Herrera, C. F.; Baz-Martinez, M.; Lang, V.; El Motiam, A.; Barbazan, J.; Couceiro, R.; Abal, M.; Vidal, A.; Esteban, M.; Munoz-Fontela, C.; Nieto, A.; Rodriguez, M. S.; Collado, M.; Rivas, C.			Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CATALYTIC SUBUNIT; TARGET PROTEINS; PTEN; SUMOYLATION; ACTIVATION; P85-BETA; PROLIFERATION; TUMORIGENESIS	Class IA phosphatidylinositol 3-kinases (PI3Ks) are composed of p110 catalytic and p85 regulatory subunits. How regulatory subunits modulate PI3K activity remains only partially understood. Here we identified SUMO (small ubiquitin-related modifier) as a new player modulating this regulation. We demonstrate that both p85 beta and p85 alpha are conjugated to SUMO1 and SUMO2. We identified two lysine residues located at the inter-SH2 domain on p85 beta, a critical region required for inhibition of p110, as being required for SUMO conjugation. A SUMOylation-defective mutant p85 beta shows higher activation of the PI3K pathway, and increased cell migration and transformation. Moreover, the cancer-related KS459del mutant in p85 alpha was less efficiently SUMOylated compared with the wild-type protein. Finally, our results show that SUMO modulates p85 tyrosine phosphorylation, a modification correlating with PI3K pathway activation. Thus, SUMO reduces the levels of tyrosine-phosphorylated-p85 while loss of SUMOylation results in increased tyrosine phosphorylation of p85. In summary, we identify SUMO as a new important player in the regulation of the PI3K pathway through modulation of p85.	[de la Cruz-Herrera, C. F.; Esteban, M.; Nieto, A.; Rivas, C.] CSIC, Ctr Nacl Biotecnol, Dept Biol Mol & Celular, Darwin 3, Madrid, Spain; [Baz-Martinez, M.; El Motiam, A.; Vidal, A.; Rivas, C.] Univ Santiago de Compostela, Inst Invest Sanitarias IDIS, Ctr Invest Med Mol & Enfermedades Cron CIMUS, Santiago De Compostela, Spain; [Lang, V.; Rodriguez, M. S.] Inbiomed, Ubiquitylat & Canc Mol Biol Lab, San Sebastian, Gipuzkoa, Spain; [Barbazan, J.; Couceiro, R.; Abal, M.; Collado, M.] Complexo Hosp Univ Santiago de Compostela CHUS, Inst Invest Sanitaria Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Munoz-Fontela, C.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany; [Nieto, A.] CIBER Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Heinrich Pette Institute; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Rivas, C (corresponding author), Campus Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Mol & Cellular Biol, Darwin 3, Madrid 28049, Spain.	crivas@cnb.csic.es	elmotiam, ahmed/AAB-6287-2019; Baz-Martínez, Maite/L-4626-2017; Rivas, Carmen/L-3162-2017; Vidal, Anxo/B-5010-2015; Barbazán, Jorge/AAM-3263-2020; RODRIGUEZ, Manuel S./D-5439-2018; Collado, Manuel/K-8140-2014; Rivas, Carmen/AAB-6278-2019	elmotiam, ahmed/0000-0003-2855-1368; Baz-Martínez, Maite/0000-0001-9160-7833; Rivas, Carmen/0000-0002-0518-7199; Vidal, Anxo/0000-0002-0866-4202; Barbazán, Jorge/0000-0002-7165-8497; Collado, Manuel/0000-0002-0330-0880; Rivas, Carmen/0000-0002-0518-7199; de la Cruz-Herrera, Carlos/0000-0002-7493-5154; Abal Posada, Miguel/0000-0003-3533-7781; Munoz-Fontela, Cesar/0000-0002-7725-2586; ESTEBAN, MARIANO/0000-0003-0846-2827	La Caixa fellowship; CONACYT; ISCIII [PI14/00554];  [BFU2014-58530]	La Caixa fellowship(La Caixa Foundation); CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); ISCIII(Instituto de Salud Carlos III); 	We thank Drs Lewis Cantley and Lynda Chin who deposited p85 plasmids at Addgene. Funding at the laboratory of CR is provided by BFU2014-58530. CFC-H is supported by La Caixa fellowship and CONACYT. Work in the laboratory of MC is funded by ISCIII (PI14/00554). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cariaga-Martinez AE, 2014, BIOL OPEN, V3, P924, DOI 10.1242/bio.20148185; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; Cortes I, 2012, P NATL ACAD SCI USA, V109, P11318, DOI 10.1073/pnas.1118138109; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; de la Cruz-Herrera CF, 2015, ONCOGENE, V34, P1442, DOI 10.1038/onc.2014.48; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gonzalez-Santamaria J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.135; Hale BG, 2006, P NATL ACAD SCI USA, V103, P14194, DOI 10.1073/pnas.0606109103; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Ito Y, 2014, P NATL ACAD SCI USA, V111, P16826, DOI 10.1073/pnas.1420281111; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Marcos-Villar L, 2009, J VIROL, V83, P8849, DOI 10.1128/JVI.00339-09; Martinez-Lorenzo MJ, 2000, INT J BIOCHEM CELL B, V32, P435, DOI 10.1016/S1357-2725(99)00142-9; Philp AJ, 2001, CANCER RES, V61, P7426; Quayle SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049466; Risso G, 2013, CELL CYCLE, V12, P3165, DOI 10.4161/cc.26183; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Shekar SC, 2005, J BIOL CHEM, V280, P27850, DOI 10.1074/jbc.M506005200; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Sun MH, 2010, P NATL ACAD SCI USA, V107, P15547, DOI 10.1073/pnas.1009652107; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vertegaal ACO, 2006, MOL CELL PROTEOMICS, V5, P2298, DOI 10.1074/mcp.M600212-MCP200; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	29	14	14	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2873	2880		10.1038/onc.2015.356	http://dx.doi.org/10.1038/onc.2015.356			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26411363				2022-12-28	WOS:000377473700007
J	Blanco, FF; Jimbo, M; Wulfkuhle, J; Gallagher, I; Deng, J; Enyenihi, L; Meisner-Kober, N; Londin, E; Rigoutsos, I; Sawicki, JA; Risbud, MV; Witkiewicz, AK; Mccue, PA; Jiang, W; Rui, H; Yeo, CJ; Petricoin, E; Winter, JM; Brody, JR				Blanco, F. F.; Jimbo, M.; Wulfkuhle, J.; Gallagher, I.; Deng, J.; Enyenihi, L.; Meisner-Kober, N.; Londin, E.; Rigoutsos, I.; Sawicki, J. A.; Risbud, M. V.; Witkiewicz, A. K.; Mccue, P. A.; Jiang, W.; Rui, H.; Yeo, C. J.; Petricoin, E.; Winter, J. M.; Brody, J. R.			The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells	ONCOGENE			English	Article							PATHWAY ACTIVATION; STABILITY FACTOR; GENE-EXPRESSION; TUMOR HYPOXIA; KINASE PIM-1; C-MYC; GROWTH; GEMCITABINE; LEUKEMIA; TARGET	Previously, it has been shown that pancreatic ductal adenocarcinoma (PDA) tumors exhibit high levels of hypoxia, characterized by low oxygen pressure (pO(2)) and decreased O-2 intracellular perfusion. Chronic hypoxia is strongly associated with resistance to cytotoxic chemotherapy and chemoradiation in an understudied phenomenon known as hypoxia-induced chemoresistance. The hypoxia-inducible, pro-oncogenic, serine-threonine kinase PIM1 (Proviral Integration site for Moloney murine leukemia virus 1) has emerged as a key regulator of hypoxia-induced chemoresistance in PDA and other cancers. Although its role in therapeutic resistance has been described previously, the molecular mechanism behind PIM1 overexpression in PDA is unknown. Here, we demonstrate that cis-acting AU-rich elements (ARE) present within a 38-base pair region of the PIM1 mRNA 3'-untranslated region mediate a regulatory interaction with the mRNA stability factor HuR (Hu antigen R) in the context of tumor hypoxia. Predominantly expressed in the nucleus in PDA cells, HuR translocates to the cytoplasm in response to hypoxic stress and stabilizes the PIM1 mRNA transcript, resulting in PIM1 protein overexpression. A reverse-phase protein array revealed that HuR-mediated regulation of PIM1 protects cells from hypoxic stress through phosphorylation and inactivation of the apoptotic effector BAD and activation of MEK1/2. Importantly, pharmacological inhibition of HuR by MS-444 inhibits HuR homodimerization and its cytoplasmic translocation, abrogates hypoxia-induced PIM1 overexpression and markedly enhances PDA cell sensitivity to oxaliplatin and 5-fluorouracil under physiologic low oxygen conditions. Taken together, these results support the notion that HuR has prosurvival properties in PDA cells by enabling them with growth advantages in stressful tumor microenvironment niches. Accordingly, these studies provide evidence that therapeutic disruption of HuR's regulation of PIM1 may be a key strategy in breaking an elusive chemotherapeutic resistance mechanism acquired by PDA cells that reside in hypoxic PDA microenvironments.	[Blanco, F. F.] Thomas Jefferson Univ, Div Clin Pharmacol, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA; [Blanco, F. F.; Jimbo, M.; Enyenihi, L.; Yeo, C. J.; Winter, J. M.; Brody, J. R.] Thomas Jefferson Univ, Dept Surg, 1015 Walnut St,Suite 618,Curtis Bldg, Philadelphia, PA 19107 USA; [Wulfkuhle, J.; Gallagher, I.; Deng, J.; Petricoin, E.] George Mason Univ, Ctr Appl Prote & Mol Med, Sch Syst Biol, Manassas, VA USA; [Meisner-Kober, N.] Novartis, Novartis Inst Biomed Res, Basel, Switzerland; [Londin, E.; Rigoutsos, I.] Thomas Jefferson Univ, Ctr Computat Med, Philadelphia, PA 19107 USA; [Sawicki, J. A.] Lankenau Inst Med Res, Philadelphia, PA USA; [Risbud, M. V.] Thomas Jefferson Univ, Dept Orthoped Surg, Philadelphia, PA 19107 USA; [Witkiewicz, A. K.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Mccue, P. A.; Jiang, W.] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Rui, H.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; George Mason University; Novartis; Jefferson University; Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Jefferson University; Jefferson University	Brody, JR (corresponding author), Thomas Jefferson Univ, Dept Surg, 1015 Walnut St,Suite 618,Curtis Bldg, Philadelphia, PA 19107 USA.	jonathan.brody@jefferson.edu	Meisner-Kober, Nicole/AFL-9351-2022; Meisner-Kober, Nicole/AAH-1412-2022; Rigoutsos, Isidore/C-5381-2012	Rigoutsos, Isidore/0000-0003-1529-8631; Londin, Eric/0000-0003-4331-6366; Meisner-Kober, Nicole/0000-0003-0912-5902; Enyenihi, Liz/0000-0001-6952-1515	NIH-NIGMS [T32 GM008562 20]; NIH-NCI [R21 CA182692 01A1]; American Cancer Society [MRSG-14-019-01-CDD]; Mary Halinski Pancreatic Cancer Research Fund; Hirshberg Foundation; NATIONAL CANCER INSTITUTE [R21CA182692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008562] Funding Source: NIH RePORTER	NIH-NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Mary Halinski Pancreatic Cancer Research Fund; Hirshberg Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the TJU's Bioimaging core for their assistance with confocal image acquisition and analysis. We also acknowledge Zachary Schoepflin at the TJU Department of Orthopedic Surgery for his assistance with hypoxia chambers. This work was supported by NIH-NIGMS T32 GM008562 20 (to FFB), NIH-NCI R21 CA182692 01A1 (to JRB), American Cancer Society MRSG-14-019-01-CDD (to JMW), the Mary Halinski Pancreatic Cancer Research Fund (to JRB) and the Hirshberg Foundation (to JRB, JW).	ACS, 2014, CANC FACTS FIG 2013; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042; Ayala GE, 2004, CANCER RES, V64, P6082, DOI 10.1158/0008-5472.CAN-04-0838; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Bermudez O, 2011, J CELL PHYSIOL, V226, P276, DOI 10.1002/jcp.22339; Blanco FF, 2014, MOL CELL BIOL, V34, P180, DOI 10.1128/MCB.01020-13; Block KM, 2012, PANCREAS, V41, P773, DOI 10.1097/MPA.0b013e31823cdd10; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brody JR, 2011, WIRES RNA, V2, P435, DOI 10.1002/wrna.62; Buchler P, 2004, J SURG RES, V120, P295, DOI 10.1016/j.jss.2004.02.014; Burkhart RA, 2013, RNA BIOL, V10, P1312, DOI 10.4161/rna.25274; Calaluce R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-126; Chang Q, 2011, CANCER RES, V71, P3110, DOI 10.1158/0008-5472.CAN-10-4049; Chen J, 2009, ONCOGENE, V28, P2581, DOI 10.1038/onc.2009.124; Chen J, 2009, AM J PATHOL, V175, P400, DOI 10.2353/ajpath.2009.080972; Chen LS, 2009, BLOOD, V114, P4150, DOI 10.1182/blood-2009-03-212852; Chou CW, 2012, NEURO-ONCOLOGY, V14, P1227, DOI 10.1093/neuonc/nos195; Cohen AM, 2004, LEUKEMIA LYMPHOMA, V45, P951, DOI 10.1080/10428190310001641251; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Costantino CL, 2009, CANCER RES, V69, P4567, DOI 10.1158/0008-5472.CAN-09-0371; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Federici G, 2013, MOL CANCER RES, V11, P676, DOI 10.1158/1541-7786.MCR-12-0690; Flamant L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-391; Ghosh M, 2009, J CLIN INVEST, V119, P3530, DOI 10.1172/JCI38263; Harrison LB, 2002, ONCOLOGIST, V7, P492, DOI 10.1634/theoncologist.7-6-492; Hsi ED, 2008, LEUKEMIA LYMPHOMA, V49, P2081, DOI 10.1080/10428190802419640; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Improta G, 2011, J PROTEOME RES, V10, P3089, DOI 10.1021/pr200065t; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kishore S, 2011, NAT METHODS, V8, P559, DOI [10.1038/NMETH.1608, 10.1038/nmeth.1608]; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; Kurosu T, 2011, BRIT J CANCER, V104, P819, DOI 10.1038/bjc.2011.20; Lal S, 2014, CANCER RES, V74, P1128, DOI 10.1158/0008-5472.CAN-13-1915; Lara PC, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-29; Liao WL, 2011, J BIOL CHEM, V286, P35499, DOI 10.1074/jbc.M111.263582; Liu L, 2014, MOL BIOL CELL, V25, P3308, DOI 10.1091/mbc.E14-03-0853; Magnuson NS, 2010, FUTURE ONCOL, V6, P1461, DOI 10.2217/FON.10.106; Martelli M, 2008, CRIT REV ONCOL HEMAT, V68, P256, DOI 10.1016/j.critrevonc.2008.07.020; Meisner NC, 2007, NAT CHEM BIOL, V3, P508, DOI 10.1038/nchembio.2007.14; Miyata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059095; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Nabors LB, 2001, CANCER RES, V61, P2154; Pineda DM, 2012, CANCER BIOL THER, V13, P946, DOI 10.4161/cbt.20952; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reiser-Erkan C, 2008, CANCER BIOL THER, V7, P1352, DOI 10.4161/cbt.7.9.6418; Richards NG, 2010, ANN SURG, V252, P499, DOI 10.1097/SLA.0b013e3181f1fd44; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Shay KP, 2005, MOL CANCER RES, V3, P170; Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198; Tamburini J, 2009, BLOOD, V114, P1618, DOI 10.1182/blood-2008-10-184515; Tholey RM, 2015, MOL CANCER RES, V13, P439, DOI 10.1158/1541-7786.MCR-14-0199; Tu ML, 2011, LIFE SCI, V88, P233, DOI 10.1016/j.lfs.2010.12.001; Vineis P, 2010, CARCINOGENESIS, V31, P1703, DOI 10.1093/carcin/bgq087; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang J, 2010, ONCOGENE, V29, P2477, DOI 10.1038/onc.2010.10; Wang PY, 2010, BIOCHEM J, V426, P293, DOI 10.1042/BJ20091459; Wu XQ, 2015, ACS CHEM BIOL, V10, P1476, DOI 10.1021/cb500851u; Xu DP, 2011, CARCINOGENESIS, V32, P488, DOI 10.1093/carcin/bgr007; Yiakouvaki A, 2012, J CLIN INVEST, V122, P48, DOI 10.1172/JCI45021; Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337; Young LE, 2010, CURR COLORECT CANC R, V6, P60, DOI 10.1007/s11888-010-0044-3; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010; Zhu HF, 2015, MOL CANCER RES, V13, P809, DOI 10.1158/1541-7786.MCR-14-0241; Zhu Y, 2002, BRIT J HAEMATOL, V119, P905, DOI 10.1046/j.1365-2141.2002.03931.x; Zou J, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-3	69	70	74	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2529	2541		10.1038/onc.2015.325	http://dx.doi.org/10.1038/onc.2015.325			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26387536	Green Accepted			2022-12-28	WOS:000376165500011
J	Morrison, MM; Williams, MM; Vaught, DB; Hicks, D; Lim, J; McKernan, C; Aurisicchio, L; Ciliberto, G; Simion, C; Sweeney, C; Cook, RS				Morrison, M. M.; Williams, M. M.; Vaught, D. B.; Hicks, D.; Lim, J.; McKernan, C.; Aurisicchio, L.; Ciliberto, G.; Simion, C.; Sweeney, C.; Cook, R. S.			Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth	ONCOGENE			English	Article							FACTOR RECEPTOR FAMILY; ANTI-ERBB3 MONOCLONAL-ANTIBODIES; LEUCINE-RICH REPEAT; NEGATIVE REGULATOR; DOWN-REGULATION; RESISTANCE; OVEREXPRESSION; DEGRADATION; INHIBITION; ACTIVATION	ErbB3, a member of the ErbB family of receptor tyrosine kinases, is a potent activator of phosphatidyl inositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling, driving tumor cell survival and therapeutic resistance in breast cancers. In luminal breast cancers, ErbB3 upregulation following treatment with the antiestrogen fulvestrant enhances PI3K/mTOR-mediated cell survival. However, the mechanism by which ErbB3 is upregulated in fulvestrant-treated cells is unknown. We found that ErbB3 protein levels and cell surface presentation were increased following fulvestrant treatment, focusing our attention on proteins that regulate ErbB3 at the cell surface, including Nrdp1, NEDD4 and LRIG1. Among these, only LRIG1 correlated positively with ER alpha, but inversely with ErbB3 in clinical breast cancer data sets. LRIG1, an estrogen-inducible ErbB downregulator, was decreased in a panel of fulvestrant-treated luminal breast cancer cells. Ectopic LRIG1 expression from an estrogen-independent promoter uncoupled LRIG1 from estrogen regulation, thus sustaining LRIG1 and maintaining low ErbB3 levels in fulvestrant-treated cells. An LRIG1 mutant lacking the ErbB3 interaction motif was insufficient to downregulate ErbB3. Importantly, LRIG1 overexpression improved fulvestrant-mediated growth inhibition, whereas cells expressing the LRIG1 mutant were poorly sensitive to fulvestrant, despite effective ER alpha downregulation. Consistent with these results, LRIG1 expression correlated positively with increased disease-free survival in antiestrogen-treated breast cancer patients. These data suggest that ER alpha-dependent expression of LRIG1 dampens ErbB3 signaling in luminal breast cancer cells, and by blocking ER alpha activity with fulvestrant, LRIG1 is decreased thus permitting ErbB3 accumulation, enhanced ErbB3 signaling to cell survival pathways and blunting therapeutic response to fulvestrant.	[Morrison, M. M.; Williams, M. M.; Vaught, D. B.; Hicks, D.; Lim, J.; McKernan, C.; Cook, R. S.] Vanderbilt Univ, Sch Med, Dept Canc Biol, 2220 Pierce Ave,759 PRB, Nashville, TN USA; [Aurisicchio, L.] Takis Biotech, Via Castel Romano 100, I-00128 Rome, Italy; [Ciliberto, G.] IRCCS Natl Canc Inst G Pascale, Via Mariano Semmola, I-83131 Naples, Italy; [Simion, C.; Sweeney, C.] Univ Calif Davis, Ctr Canc, Basic Sci, Sacramento, CA 95817 USA; [Cook, R. S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA	Vanderbilt University; IRCCS Fondazione Pascale; University of California System; University of California Davis; Vanderbilt University	Cook, RS (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, 2220 Pierce Ave,759 PRB, Nashville, TN 37232 USA.	rebecca.cook@vanderbilt.edu	Williams, Michelle/AAI-2839-2020; Ciliberto, Gennaro/J-4131-2017	Williams, Michelle/0000-0002-7063-9147; Ciliberto, Gennaro/0000-0003-2851-8605; Aurisicchio, Luigi/0000-0003-3110-4534	National Institutes of Health [R01CA143126]; Susan G. Komen for the Cure grant [KG100677]; NATIONAL CANCER INSTITUTE [R01CA118384, R01CA143126] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen for the Cure grant(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health R01CA143126 (RSC) and Susan G. Komen for the Cure grant KG100677 (RSC).	ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Aurisicchio L, 2012, J CELL PHYSIOL, V227, P3381, DOI 10.1002/jcp.24037; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Belleudi F, 2012, CELL CYCLE, V11, P1455, DOI 10.4161/cc.19861; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cook RS, 2011, CANCER RES, V71, P3941, DOI 10.1158/0008-5472.CAN-10-3775; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Fattore L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-180; Ghasimi S, 2012, J NEURO-ONCOL, V108, P435, DOI 10.1007/s11060-012-0856-x; Hamburger AW, 2008, J MAMMARY GLAND BIOL, V13, P225, DOI 10.1007/s10911-008-9077-5; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Huang Z, 2015, ONCOGENE, V34, P1105, DOI 10.1038/onc.2014.56; Hutcheson IR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2848; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Krig SR, 2011, MOL CANCER RES, V9, P1406, DOI 10.1158/1541-7786.MCR-11-0227; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Miller JK, 2008, CANCER RES, V68, P8286, DOI 10.1158/0008-5472.CAN-07-6316; Morrison MM, 2013, J CLIN INVEST, V123, P4329, DOI 10.1172/JCI66764; Noto A, 2013, ONCOTARGET, V4, P1253, DOI 10.18632/oncotarget.1141; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Rafidi H, 2013, J BIOL CHEM, V288, P21593, DOI 10.1074/jbc.M113.486050; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Stern DF, 2008, J MAMMARY GLAND BIOL, V13, P215, DOI 10.1007/s10911-008-9083-7; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Sutherland RL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2878; Tovey S, 2005, CLIN CANCER RES, V11, P4835, DOI 10.1158/1078-0432.CCR-05-0196; Wiseman SM, 2005, CANCER-AM CANCER SOC, V103, P1770, DOI 10.1002/cncr.20970; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464	36	9	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1143	1152		10.1038/onc.2015.169	http://dx.doi.org/10.1038/onc.2015.169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26148232	Green Accepted			2022-12-28	WOS:000371351700008
J	Yonesaka, K; Hirotani, K; Kawakami, H; Takeda, M; Kaneda, H; Sakai, K; Okamoto, I; Nishio, K; Janne, PA; Nakagawa, K				Yonesaka, K.; Hirotani, K.; Kawakami, H.; Takeda, M.; Kaneda, H.; Sakai, K.; Okamoto, I.; Nishio, K.; Jaenne, P. A.; Nakagawa, K.			Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib	ONCOGENE			English	Article							ADVANCED SOLID TUMORS; KINASE DOMAIN; INACTIVE HER3; EGFR; GEFITINIB; AMPLIFICATION; RESISTANCE; THERAPY; ERBB3; ACTIVATION	Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a monoclonal antibody against HER3 that has shown promising results in early-phase clinical trials, but an optimal target population for the drug has yet to be identified. In the present study, we examined whether heregulin, a HER3 ligand that is also overexpressed in a subset of NSCLC, can be used as a biomarker to predict the antitumorigenic efficacy of patritumab and whether the drug can overcome the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistance induced by heregulin. Patritumab sensitivity was associated with heregulin expression, which, when abolished, resulted in the loss of HER3 and AKT activation and growth arrest. Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. Sustained HER3-AKT activation was blocked by combining erlotinib with either anti-HER2 or anti-HER3 antibody. Notably, heregulin was upregulated in tissue samples from an NSCLC patient who had an activating EGFR mutation but was resistant to the TKI gefitinib. These results indicate that patritumab can overcome heregulin-dependent EGFR inhibitor resistance in NSCLC in vitro and in vivo and suggest that it can be used in combination with EGFR TKIs to treat a subset of heregulin-overexpressing NSCLC patients.	[Yonesaka, K.; Kawakami, H.; Takeda, M.; Kaneda, H.; Nakagawa, K.] Kinki Univ, Sch Med, Dept Med Oncol, 377-2 Ohnohigashi Osaka Sayamashi, Osaka 5898511, Japan; [Kawakami, H.] Daiichi Sankyo Pharmaceut Dev, Tokyo, Japan; [Sakai, K.; Nishio, K.] Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan; [Okamoto, I.] Kyushu Univ, Ctr Clin & Translat Res, Fukuoka 812, Japan; [Jaenne, P. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA; [Jaenne, P. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Jaenne, P. A.] Harvard Univ, Sch Med, Brigham Womens Hosp, Dept Med, Boston, MA 02115 USA	Kindai University (Kinki University); Daiichi Sankyo Company Limited; Kindai University (Kinki University); Kyushu University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Yonesaka, K (corresponding author), Kinki Univ, Sch Med, Dept Med Oncol, 377-2 Ohnohigashi Osaka Sayamashi, Osaka 5898511, Japan.; Janne, PA (corresponding author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,HIM223, Boston, MA 02215 USA.	yonesaka@sakai.med.kindai.ac.jp; pjanne@partners.org	Kawakami, Hisato/L-6845-2019	Kawakami, Hisato/0000-0002-3280-4850	Daiichi-Sankyo Pharmaceutical Development	Daiichi-Sankyo Pharmaceutical Development	We thank Haruka Yamaguchi, Yume Shinkai, Michiko Kitano and Mami Kitano for technical support. This work was financially funded in part by Daiichi-Sankyo Pharmaceutical Development.	Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Cappuzzo F, 2005, BRIT J CANCER, V93, P1334, DOI 10.1038/sj.bjc.6602865; Cho BC, 2007, J CLIN ONCOL, V25, P2528, DOI 10.1200/JCO.2006.10.4166; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Garner AP, 2013, CANCER RES, V73, P6024, DOI 10.1158/0008-5472.CAN-13-1198; Guerra-Vladusic FK, 2001, ONCOL REP, V8, P1203; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; LoRusso P, 2013, CLIN CANCER RES, V19, P3078, DOI 10.1158/1078-0432.CCR-12-3051; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mirschberger C, 2013, CANCER RES, V73, P5183, DOI 10.1158/0008-5472.CAN-13-0099; Murakami H, 2013, ANN ONCOL S9, V24; Noto A, 2013, ONCOTARGET, V4, P1253, DOI 10.18632/oncotarget.1141; Ohsaki Y, 2000, ONCOL REP, V7, P603; Okabe T, 2007, CANCER RES, V67, P2046, DOI 10.1158/0008-5472.CAN-06-3339; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Takezawa K, 2009, CANCER RES, V69, P6515, DOI 10.1158/0008-5472.CAN-09-1076; Von Pawel J, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8045; Wakui H, 2014, CANCER CHEMOTH PHARM, V73, P511, DOI 10.1007/s00280-014-2375-2; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Yi ES, 1997, MODERN PATHOL, V10, P142; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442; Zhang Q, 2012, P NATL ACAD SCI USA, V109, P13237, DOI 10.1073/pnas.1200105109; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	37	58	65	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					878	886		10.1038/onc.2015.142	http://dx.doi.org/10.1038/onc.2015.142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961915				2022-12-28	WOS:000370332200008
J	Zane, M; Scavo, E; Catalano, V; Bonanno, M; Todaro, M; De Maria, R; Stassi, G				Zane, M.; Scavo, E.; Catalano, V.; Bonanno, M.; Todaro, M.; De Maria, R.; Stassi, G.			Normal vs cancer thyroid stem cells: the road to transformation	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; ULTIMOBRANCHIAL BODY CYST; GENE-EXPRESSION; SIDE POPULATION; IMMUNOHISTOCHEMICAL DETECTION; TRANSCRIPTION FACTORS; BETA-CATENIN; DIFFERENTIATION; GENERATION; CARCINOMA	Recent investigations in thyroid carcinogenesis have led to the isolation and characterisation of a subpopulation of stem-like cells, responsible for tumour initiation, progression and metastasis. Nevertheless, the cellular origin of thyroid cancer stem cells (SCs) remains unknown and it is still necessary to define the process and the target population that sustain malignant transformation of tissue-resident SCs or the reprogramming of a more differentiated cell. Here, we will critically discuss new insights into thyroid SCs as a potential source of cancer formation in light of the available information on the oncogenic role of genetic modifications that occur during thyroid cancer development. Understanding the fine mechanisms that regulate tumour transformation may provide new ground for clinical intervention in terms of prevention, diagnosis and therapy.	[Zane, M.; Scavo, E.; Catalano, V.; Bonanno, M.; Todaro, M.; Stassi, G.] Univ Palermo, Dept Surg & Oncol Sci, Via Vespro 131, I-90127 Palermo, Italy; [Zane, M.] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy; [De Maria, R.] Regina Elena Inst Canc Res, Rome, Italy	University of Palermo; University of Padua; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Stassi, G (corresponding author), Univ Palermo, Dept Surg & Oncol Sci, Via Vespro 131, I-90127 Palermo, Italy.; De Maria, R (corresponding author), Regina Elena Inst Canc Res, Rome, Italy.	demaria@ifo.it; giorgio.stassi@unipa.it	Todaro, Matilde/K-9523-2016; todaro, matilde/AAC-1003-2022; De Maria, Ruggero/S-6385-2019; Stassi, Giorgio/AAC-1175-2022	todaro, matilde/0000-0001-8686-8043; De Maria, Ruggero/0000-0003-2255-0583; Zane, Mariangela/0000-0001-6766-4686	Italian Association for Cancer Research (AIRC) [IG 12819]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Italian Association for Cancer Research (AIRC) to GS (AIRC IG 12819). We thank Tatiana Terranova for her editorial assistance and all the colleagues who actively contributed to the completion of this review.	Ahn SH, 2014, J CLIN ENDOCR METAB, V99, P536, DOI 10.1210/jc.2013-2558; Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Antonica Francesco, 2012, Nature, V491, P66, DOI 10.1038/nature11525; Arufe MC, 2009, BIOCHEM BIOPH RES CO, V381, P264, DOI 10.1016/j.bbrc.2009.02.035; Brafman DA, 2013, STEM CELL REP, V1, P464, DOI 10.1016/j.stemcr.2013.09.005; Buehler D, 2013, MODERN PATHOL, V26, P54, DOI 10.1038/modpathol.2012.137; Burstein DE, 2004, HUM PATHOL, V35, P465, DOI 10.1016/j.humpath.2003.10.027; Cameselle-Teijeiro J, 2005, HUM PATHOL, V36, P590, DOI 10.1016/j.humpath.2005.02.010; Carina V, 2013, THYROID, V23, P829, DOI 10.1089/thy.2012.0372; Cassinelli G, 2009, NEOPLASIA, V11, P10, DOI 10.1593/neo.08916; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Ciarrocchi A, 2011, EUR J CANCER, V47, P934, DOI 10.1016/j.ejca.2010.11.009; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; Davies TF, 2011, J CLIN ENDOCR METAB, V96, P2692, DOI 10.1210/jc.2011-1047; De Felice M, 2004, ENDOCR REV, V25, P722, DOI 10.1210/er.2003-0028; Deleu S, 2002, EXP CELL RES, V279, P62, DOI 10.1006/excr.2002.5589; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Fagman H, 2011, J MOL ENDOCRINOL, V46, pR33, DOI 10.1677/JME-10-0084; Fierabracci A, 2008, J ENDOCRINOL, V198, P471, DOI 10.1677/JOE-07-0552; Friedman S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005395; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Gibelli B, 2009, ACTA OTORHINOLARYNGO, V29, P290; Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007; Green MD, 2011, NAT BIOTECHNOL, V29, P267, DOI 10.1038/nbt.1788; Hannan NRF, 2013, STEM CELL REP, V1, P293, DOI 10.1016/j.stemcr.2013.09.003; Hardin H, 2013, HUM PATHOL, V44, P1707, DOI 10.1016/j.humpath.2013.01.009; Hardy RG, 2007, AM J PATHOL, V171, P1037, DOI 10.2353/ajpath.2007.061211; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hoshi N, 2007, ENDOCRINOLOGY, V148, P4251, DOI 10.1210/en.2006-0490; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Inaba M, 2012, CELL STEM CELL, V11, P461, DOI 10.1016/j.stem.2012.09.003; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Ke CC, 2013, EUR J NUCL MED MOL I, V40, P61, DOI 10.1007/s00259-012-2242-5; Kebebew E, 2004, J CLIN ENDOCR METAB, V89, P6105, DOI 10.1210/jc.2004-1234; Klonisch T, 2009, THYROID, V19, P1303, DOI 10.1089/thy.2009.1604; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kusakabe T, 2006, DEV DYNAM, V235, P1300, DOI 10.1002/dvdy.20655; Lan L, 2007, J CLIN ENDOCR METAB, V92, P3681, DOI 10.1210/jc.2007-0281; Lan L, 2013, INT J ONCOL, V43, P113, DOI 10.3892/ijo.2013.1913; LEDOUARIN N, 1974, HISTOCHEMISTRY, V38, P297, DOI 10.1007/BF00496718; Li W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065095; Lin RY, 2011, NAT REV ENDOCRINOL, V7, P609, DOI 10.1038/nrendo.2011.127; Lin RY, 2003, ENDOCRINOLOGY, V144, P2644, DOI 10.1210/en.2002-0122; Liu J, 2010, INT J CLIN EXP PATHO, V3, P755; Longmire TA, 2012, CELL STEM CELL, V10, P398, DOI 10.1016/j.stem.2012.01.019; Ma RS, 2013, THYROID, V23, P385, DOI 10.1089/thy.2012.0644; Malaguarnera R, 2011, J CLIN ENDOCR METAB, V96, P766, DOI 10.1210/jc.2010-1255; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Mitsutake N, 2007, ENDOCRINOLOGY, V148, P1797, DOI 10.1210/en.2006-1553; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Nikiforova MN, 2009, THYROID, V19, P1351, DOI 10.1089/thy.2009.0240; Nikiforova MN, 2004, CANCER LETT, V209, P1, DOI 10.1016/j.canlet.2003.12.004; Okamoto M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080801; Onyshchenko MI, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/634914; Ozaki T, 2012, ENDOCRINOLOGY, V153, P2514, DOI 10.1210/en.2011-1365; Ozaki T, 2011, LAB INVEST, V91, P138, DOI 10.1038/labinvest.2010.137; Paez D, 2012, CLIN CANCER RES, V18, P645, DOI 10.1158/1078-0432.CCR-11-2186; Preto A, 2004, MODERN PATHOL, V17, P819, DOI 10.1038/modpathol.3800124; Quiros RM, 2005, CANCER-AM CANCER SOC, V103, P2261, DOI 10.1002/cncr.21073; Raimondi C, 2010, CURR CANCER DRUG TAR, V10, P496, DOI 10.2174/156800910791517154; Reis JS, 2003, MODERN PATHOL, V16, P43, DOI 10.1097/01.MP.0000047306.72278.39; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Moreno MJR, 2011, ENDOCR PATHOL, V22, P35, DOI 10.1007/s12022-010-9145-4; Rivera M, 2008, CANCER-AM CANCER SOC, V113, P48, DOI 10.1002/cncr.23515; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sastre-Perona Ana, 2012, Front Endocrinol (Lausanne), V3, P31, DOI 10.3389/fendo.2012.00031; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Shahriyari L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076195; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Sun YR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005498; Takano T, 2005, THYROID, V15, P432, DOI 10.1089/thy.2005.15.432; Takano T, 2007, SEMIN CANCER BIOL, V17, P233, DOI 10.1016/j.semcancer.2006.02.001; Thomas D, 2008, ENDOCR-RELAT CANCER, V15, P51, DOI 10.1677/ERC-07-0210; Thomas T, 2006, THYROID, V16, P537, DOI 10.1089/thy.2006.16.537; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Tseng LM, 2012, J PHARMACOL EXP THER, V341, P410, DOI 10.1124/jpet.111.188730; Van Vliet G, 2003, CLIN GENET, V63, P445; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Visvader JE, 2010, MOL ONCOL, V4, P369, DOI 10.1016/j.molonc.2010.07.001; Yamashita YM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001313; Zeuner A, 2011, CELL STEM CELL, V9, P289, DOI 10.1016/j.stem.2011.09.006; Zhang P, 2006, PATHOL INT, V56, P240, DOI 10.1111/j.1440-1827.2006.01959.x; Zheng XQ, 2010, INT J ONCOL, V37, P307, DOI 10.3892/ijo_00000679; Zito G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003544	95	18	18	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					805	815		10.1038/onc.2015.138	http://dx.doi.org/10.1038/onc.2015.138			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961919	Green Published			2022-12-28	WOS:000370332200001
J	Sanchez-Tillo, E; de Barrios, O; Valls, E; Darling, DS; Castells, A; Postigo, A				Sanchez-Tillo, E.; de Barrios, O.; Valls, E.; Darling, D. S.; Castells, A.; Postigo, A.			ZEB1 and TCF4 reciprocally modulate their transcriptional activities to regulate Wnt target gene expression	ONCOGENE			English	Article							APC TUMOR-SUPPRESSOR; VITAMIN-D-RECEPTOR; BETA-CATENIN; MESENCHYMAL TRANSITION; COLORECTAL-CANCER; COREPRESSOR CTBP; E-CADHERIN; REPRESSION; ACTIVATION; INVASIVENESS	The canonical Wnt pathway (TCF4/beta-catenin) has important roles during normal differentiation and in disease. Some Wnt functions depend on signaling gradients requiring the pathway to be tightly regulated. A key Wnt target is the transcription factor ZEB1 whose expression by cancer cells promotes tumor invasiveness by repressing the expression of epithelial specification markers and activating mesenchymal genes, including a number of Wnt targets such as LAMC2 and uPA. The ability of ZEB1 to activate/repress its target genes depends on its recruitment of corepressors (CtBP, BRG1) or coactivators (p300) although conditions under which ZEB1 binds these cofactors are not elucidated. Here, we show that TCF4 and ZEB1 reciprocally modulate each other's transcriptional activity: ZEB1 enhances TCF4/beta-catenin-mediated transcription and, in turn, Wnt signaling switches ZEB1 from a repressor into an activator. In colorectal cancer (CRC) cells with active Wnt signaling, ZEB1 enhances transcriptional activation of LAMC2 and uPA by TCF4/beta-catenin. However, in CRC cells with inactive Wnt, ZEB1 represses both genes. Reciprocal modulation of ZEB1 and TCF4 activities involves their binding to DNA and mutual interaction. Wnt signaling turns ZEB1 into an activator by replacing binding of CtBP/BRG1 in favor of p300. Using a mouse model of Wnt-induced intestinal tumorigenesis, we found that downregulation of ZEB1 reduces the expression of LAMC2 in vivo. These results identify a mechanism through which Wnt and ZEB1 transcriptional activities are modulated, offering new approaches in cancer therapy.	[Sanchez-Tillo, E.; de Barrios, O.; Valls, E.; Postigo, A.] IDIBAPS, Dept Hematol & Oncol, Grp Transcript Regulat Gene Express, Barcelona, Spain; [Darling, D. S.] Univ Louisville, Dept Oral Immunol & Infect Dis, Louisville, KY 40292 USA; [Darling, D. S.] Univ Louisville, Ctr Genet & Mol Med, Louisville, KY 40292 USA; [Castells, A.] Hosp Clin Barcelona, Inst Metab & Digest Dis, Barcelona, Spain; [Castells, A.; Postigo, A.] Carlos III Hlth Inst ISCIII, Biomed Res Networking Ctr Hepat & Digest Dis CIBE, Gastrointestinal & Pancreat Oncol Team, Barcelona, Spain; [Postigo, A.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; [Postigo, A.] ICREA, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Louisville; University of Louisville; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Louisville; ICREA	Postigo, A (corresponding author), Univ Barcelona, Sch Med, Dept Hematol & Oncol, IDIBAPS,Grp Transcript Regulat Gene Express, Cellex 1B,Casanova 143, E-08036 Barcelona, Spain.	idib412@clinic.ub.es	Darling, Douglas S/D-4573-2009; de Barrios, Oriol/AAO-6319-2021; Castells, Antoni/ABC-1002-2021	Castells, Antoni/0000-0001-8431-2033; de Barrios, Oriol/0000-0001-5076-1455; Darling, Douglas/0000-0002-9039-1169; Postigo, Antonio/0000-0003-4605-2634	Fundacio La Marato de TV3 [201330.10]; Ministry of Economy and Competitiveness [BFU2010-15163, SAF2014-52874-R]; Leukemia Research Foundation; Academy of Medical and Health Sciences of Catalonia; Balearic Islands, Avon Cosmetics S.A.U. (ACSAU); Catalan Agency for Management of University and Research Grants [AGAUR, 2014-SGR-475]; European Commission of the European Union; Olga Torres Foundation; La Caixa Foundation (LCF); Spanish Association Against Cancer; LCF; CIBERehd; ACSAU; Miguel Servet contract from Instituto de Salud Carlos III [MS13/00200]; Ministry of Education, Culture and Sports (FPU Program) [AP2010-5489]; ICREA Funding Source: Custom	Fundacio La Marato de TV3; Ministry of Economy and Competitiveness; Leukemia Research Foundation; Academy of Medical and Health Sciences of Catalonia; Balearic Islands, Avon Cosmetics S.A.U. (ACSAU); Catalan Agency for Management of University and Research Grants; European Commission of the European Union; Olga Torres Foundation; La Caixa Foundation (LCF); Spanish Association Against Cancer; LCF; CIBERehd; ACSAU; Miguel Servet contract from Instituto de Salud Carlos III(Instituto de Salud Carlos III); Ministry of Education, Culture and Sports (FPU Program); ICREA(ICREA)	We are grateful to all researchers who provided us with reagents (see Materials and Methods and Supplementary Materials and Methods) and apologize to those whose work was cited indirectly through reviews owing to space limitations. This work was developed in the Centre de Recerca Biomedica Cellex at IDIBAPS. The different parts of this study were independently funded by grants to AP from Fundacio La Marato de TV3 (201330.10), Ministry of Economy and Competitiveness (BFU2010-15163 and SAF2014-52874-R), Leukemia Research Foundation, Academy of Medical and Health Sciences of Catalonia and the Balearic Islands, Avon Cosmetics S.A.U. (ACSAU), Catalan Agency for Management of University and Research Grants (AGAUR, 2014-SGR-475), European Commission of the European Union, Olga Torres Foundation, La Caixa Foundation (LCF), Spanish Association Against Cancer. EST's salary was subsequently funded by grants from LCF, CIBERehd, ACSAU, and a Miguel Servet contract (MS13/00200) from Instituto de Salud Carlos III. OdB is recipient of a PhD scholarship from the Ministry of Education, Culture and Sports (FPU Program, AP2010-5489).	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; Gilles C, 2003, CANCER RES, V63, P2658; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hiendlmeyer E, 2004, CANCER RES, V64, P1209, DOI 10.1158/0008-5472.CAN-3627-2; Hlubek F, 2001, CANCER RES, V61, P8089; Hlubek F, 2007, INT J CANCER, V121, P1941, DOI 10.1002/ijc.22916; Hu MC, 2005, DEVELOPMENT, V132, P215, DOI 10.1242/dev.01573; Kiecker C, 2001, DEVELOPMENT, V128, P4189; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Leclerc D, 2004, J CELL BIOCHEM, V93, P1242, DOI 10.1002/jcb.20236; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Memezawa A, 2007, ONCOGENE, V26, P5038, DOI 10.1038/sj.onc.1210320; Moore AC, 2008, MOL CELL BIOL, V28, P977, DOI 10.1128/MCB.01242-07; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Palmer HG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001483; Pena C, 2006, INT J CANCER, V119, P2098, DOI 10.1002/ijc.22083; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Sanchez-Tillo E, 2013, CLIN CANCER RES, V19, P1071, DOI 10.1158/1078-0432.CCR-12-2675; Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Siles L, 2013, MOL CELL BIOL, V33, P1368, DOI 10.1128/MCB.01259-12; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Takagi T, 1998, DEVELOPMENT, V125, P21; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Verzi MP, 2010, P NATL ACAD SCI USA, V107, P15157, DOI 10.1073/pnas.1003822107; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Yuan Y, 2014, BIORESOURCE TECHNOL, V174, P1, DOI 10.1016/j.biortech.2014.07.104; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X	49	31	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5760	5770		10.1038/onc.2015.352	http://dx.doi.org/10.1038/onc.2015.352			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	26387539				2022-12-28	WOS:000364594600008
J	Lopez-Bertoni, H; Lal, B; Michelson, N; Guerrero-Cazares, H; Quinones-Hinojosa, A; Li, Y; Laterra, J				Lopez-Bertoni, H.; Lal, B.; Michelson, N.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; Li, Y.; Laterra, J.			Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells	ONCOGENE			English	Article							HMGA PROTEINS; CANCER; PROLIFERATION; MICRORNAS; MIR-296; TRANSCRIPTION; MOBILITY; RENEWAL; PATHWAY; TARGETS	Solid malignancies contain subsets of multipotent cells that grow as spheres and efficiently propagate tumors in xenograft models, reflecting a stem-like, self-renewing and tumor-propagating phenotype. These cancer 'stem cells (SCs)' have been shown to maintain tumor growth, contribute to resistance and drive tumor recurrence. Cancer cell stemness is dynamically influenced by epigenetic mechanisms and differentially regulated coding and noncoding RNAs. How these mechanisms specifically contribute to the generation and/or maintenance of cancer SCs remains unclear. This study identifies a novel epigenetically regulated circuit that integrates microRNA, chromatin remodeling and the reprogramming transcription factor Sox2 to regulate glioblastoma (GBM)-propagating SCs. We show that miR-296-5p expression is repressed in a DNA methylation-dependent manner under conditions that promote GBM cell stemness and that miR-296-5p inhibits GBM cell stemness and their capacity to self-renew as spheres and propagate glioma xenografts in vivo. We show that the chromatin remodeling protein HMGA1 functions as a downstream effector of these biological responses to miR-296-5p and regulates Sox2 expression, a master driver of cell stemness, by modifying chromatin architecture at the Sox2 promoter. These results show for the first time that miR-296-5p inhibits transcriptional mechanisms that support GBM SCs and identify a miR-296-5p: HMGA1: Sox2 axis as a novel regulator of GBM SCs and candidate pathway for targeting therapies directed at depleting tumors of their tumor-propagating stem cell subsets.	[Lopez-Bertoni, H.; Lal, B.; Michelson, N.; Li, Y.; Laterra, J.] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD USA; [Lopez-Bertoni, H.; Lal, B.; Li, Y.; Laterra, J.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Guerrero-Cazares, H.; Quinones-Hinojosa, A.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA; [Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA; [Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Laterra, J (corresponding author), Johns Hopkins Sch Med, Kennedy Krieger Inst, Dept Neurol, 707 North Broadway, Baltimore, MD 21205 USA.	Laterra@kennedykrieger.org	Lopez, Hernando/AAY-7655-2020	Lopez, Hernando/0000-0001-6618-1092; Guerrero-Cazares, Hugo/0000-0003-1307-719X	American Brain Tumor Association; United States NIH [R01NS073611, R01NS070024]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070024, R01NS073611] Funding Source: NIH RePORTER	American Brain Tumor Association; United States NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the American Brain Tumor Association (to HL-B), and the United States NIH Grants R01NS073611 (to JL) and R01NS070024 (to AQ-H).	Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Belton A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030034; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Catez F, 2006, NAT STRUCT MOL BIOL, V13, P305, DOI 10.1038/nsmb1077; Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164; Cleynen I, 2008, INT J ONCOL, V32, P289; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fanelli M, 2008, ONCOGENE, V27, P358, DOI 10.1038/sj.onc.1210642; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Glas M, 2010, ANN NEUROL, V68, P264, DOI 10.1002/ana.22036; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Gohel PH, 2012, INT J PHARM RES ALLI, V1, P1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Lee KH, 2014, BBA-MOL CELL RES, V1843, P2055, DOI 10.1016/j.bbamcr.2014.06.001; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li YQ, 2005, CANCER RES, V65, P9355, DOI 10.1158/0008-5472.CAN-05-1946; Li YQ, 2012, CANCER RES, V72, P576, DOI 10.1158/0008-5472.CAN-11-3070; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Lin SL, 2011, NUCLEIC ACIDS RES, V39, P1054, DOI 10.1093/nar/gkq850; Lopez-Bertoni H, 2015, ONCOGENE, V34, P3994, DOI 10.1038/onc.2014.334; LUND T, 1983, FEBS LETT, V152, P163, DOI 10.1016/0014-5793(83)80370-6; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; Pardal R, 2005, COLD SH Q B, V70, P177, DOI 10.1101/sqb.2005.70.057; Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Robson JE, 2012, RNA, V18, P135, DOI 10.1261/rna.029561.111; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Shivapurkar N, 2013, INT J COLORECTAL DIS, V28, P887, DOI 10.1007/s00384-012-1560-1; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Singh RP, 2009, CELL TRANSPLANT, V18, P1197, DOI 10.3727/096368909X12483162197204; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wei JJ, 2011, CLIN CANCER RES, V17, P1297, DOI 10.1158/1078-0432.CCR-10-0993; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627; Xu Y, 2004, CANCER RES, V64, P3371, DOI 10.1158/0008-5472.CAN-04-0044	46	43	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4903	4913		10.1038/onc.2016.22	http://dx.doi.org/10.1038/onc.2016.22			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26898758	Green Accepted			2022-12-28	WOS:000383330700008
J	Fluckiger, A; Dumont, A; Derangere, V; Rebe, C; de Rosny, C; Causse, S; Thomas, C; Apetoh, L; Hichami, A; Ghiringhelli, F; Rialland, M				Fluckiger, A.; Dumont, A.; Derangere, V.; Rebe, C.; de Rosny, C.; Causse, S.; Thomas, C.; Apetoh, L.; Hichami, A.; Ghiringhelli, F.; Rialland, M.			Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNF alpha	ONCOGENE			English	Article							POLYUNSATURATED FATTY-ACIDS; TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; PREVENTS BREAST-CANCER; CELL-PROLIFERATION; TUMORICIDAL ACTION; LIPID-METABOLISM; GENE-EXPRESSION; RIP1 KINASE; NF-KAPPAB	The omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) has anti-inflammatory and anti-cancer properties. Among pro-inflammatory mediators, tumor necrosis factor a (TNF alpha) plays a paradoxical role in cancer biology with induction of cancer cell death or survival depending on the cellular context. The objective of the study was to evaluate the role of TNFa in DHA-mediated tumor growth inhibition and colon cancer cell death. The treatment of human colorectal cancer cells, HCT-116 and HCT-8 cells, with DHA triggered apoptosis in autocrine TNF alpha-dependent manner. We demonstrated that DHA-induced increased content of TNF alpha mRNA occurred through a post-transcriptional regulation via the down-regulation of microRNA-21 (miR-21) expression. Treatment with DHA led to nuclear accumulation of Foxo3a that bounds to the miR-21 promoter triggering its transcriptional repression. Moreover, inhibition of RIP1 kinase and AMP-activated protein kinase a reduced Foxo3a nuclear-cytoplasmic shuttling and subsequent increase of TNFa expression through a decrease of miR-21 expression in DHA-treated colon cancer cells. Finally, we were able to show in HCT-116 xenograft tumor-bearing nude mice that a DHA-enriched diet induced a decrease of human miR-21 expression and an increase of human TNF alpha mRNA expression limiting tumor growth in a cancer cell-derived TNF alpha dependent manner. Altogether, the present work highlights a novel mechanism for anti-cancer action of DHA involving colon cancer cell death mediated through autocrine action of TNF alpha.	[Fluckiger, A.; Dumont, A.; Derangere, V.; Rebe, C.; de Rosny, C.; Causse, S.; Thomas, C.; Apetoh, L.; Hichami, A.; Ghiringhelli, F.; Rialland, M.] INSERM, UMR 866, Dijon, France; [Fluckiger, A.; Dumont, A.; de Rosny, C.; Thomas, C.; Hichami, A.; Rialland, M.] Univ Bourgogne, UFR Sci Vie Terre & Environm, Dijon, France; [Derangere, V.; Causse, S.; Apetoh, L.; Ghiringhelli, F.] Univ Bourgogne, UFR Sci Sante, Dijon, France; [Rebe, C.; Apetoh, L.; Ghiringhelli, F.] Ctr Georges Francois Leclerc, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc	Rialland, M (corresponding author), Univ Bourgogne, INSERM, UMR 866, 6 Bd Gabriel, F-21000 Dijon, Bourgogne, France.	mickael.rialland@u-bourgogne.fr	Thomas, charles/C-7130-2019; Causse, Sebastien Zwe/AAZ-7365-2021; REBE, Cédric/AAD-4316-2019; Apetoh, Lionel/AIC-2384-2022	Thomas, charles/0000-0001-9998-6698; REBE, Cédric/0000-0001-8831-145X; Apetoh, Lionel/0000-0002-2774-438X; Causse, Sebastien/0000-0003-3246-3491; ghiringhelli, francois/0000-0002-5465-8305; Rialland, Mickael/0000-0001-9693-9351	Ligue contre le cancer comite Grand-Est; French Government grant [ANR-11-LABX-0021]	Ligue contre le cancer comite Grand-Est; French Government grant	The authors would like to thank the lipidomic plateform and the flow cytometry plateform facilities of Universite de Bourgogne. The present work was supported by Ligue contre le cancer comite Grand-Est and by a French Government grant managed by the French National Research Agency under the program 'Investissements d'Avenir' with reference ANR-11-LABX-0021 (Lipstic Labex).	Al-Zoubi M, 2013, CELL CYCLE, V12, P480, DOI 10.4161/cc.23370; ANTI M, 1992, GASTROENTEROLOGY, V103, P883, DOI 10.1016/0016-5085(92)90021-P; ANTI M, 1994, GASTROENTEROLOGY, V107, P1709, DOI 10.1016/0016-5085(94)90811-7; BALKWILL FR, 1986, CANCER RES, V46, P3990; Bansal T, 2010, P NATL ACAD SCI USA, V107, P228, DOI 10.1073/pnas.0906112107; BARTOLI GM, 1993, MOL ASPECTS MED, V14, P247, DOI 10.1016/0098-2997(93)90011-2; Bartoli R, 2000, GUT, V46, P191, DOI 10.1136/gut.46.2.191; Bathen TF, 2008, ANTICANCER RES, V28, P3717; Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718; BEGIN ME, 1986, JNCI-J NATL CANCER I, V77, P1053; BEGIN ME, 1986, PROG LIPID RES, V25, P573, DOI 10.1016/0163-7827(86)90116-5; BEGIN ME, 1985, PROSTA LEUKOTR MED, V19, P177, DOI 10.1016/0262-1746(85)90084-8; Berger H, 2013, CANCER RES, V73, P3578, DOI 10.1158/0008-5472.CAN-12-4018; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Calviello G, 2004, CARCINOGENESIS, V25, P2303, DOI 10.1093/carcin/bgh265; Calviello G, 2007, CARCINOGENESIS, V28, P1202, DOI 10.1093/carcin/bgl254; Cardaci S, 2012, J CELL SCI, V125, P2115, DOI 10.1242/jcs.095216; Chen Z, 2014, ONCOGENE, V33, P4548, DOI 10.1038/onc.2013.402; Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035; Chou CC, 2014, CANCER RES, V74, P4783, DOI 10.1158/0008-5472.CAN-14-0135; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Chung H, 2015, ONCOGENE, V34, P3504, DOI 10.1038/onc.2014.283; Cianchi F, 2008, CLIN CANCER RES, V14, P7691, DOI 10.1158/1078-0432.CCR-08-0799; Cockbain AJ, 2012, GUT, V61, P135, DOI 10.1136/gut.2010.233718; DAS UN, 1991, CANCER LETT, V56, P235, DOI 10.1016/0304-3835(91)90008-6; Ding WQ, 2007, MOL CANCER THER, V6, P1467, DOI 10.1158/1535-7163.MCT-06-0608; Else PL, 2015, BBA-BIOMEMBRANES, V1848, P417, DOI 10.1016/j.bbamem.2014.10.039; Farago N, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-173; Gattolliat CH, 2015, EUR J CANCER, V51, P409, DOI 10.1016/j.ejca.2014.12.007; Gil-Zamorano J, 2014, J NUTR, V144, P575, DOI 10.3945/jn.113.189050; Giros A, 2009, CANCER PREV RES, V2, P732, DOI 10.1158/1940-6207.CAPR-08-0197; Gravaghi C, 2011, J NUTR BIOCHEM, V22, P360, DOI 10.1016/j.jnutbio.2010.03.003; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Gu ZN, 2013, CARCINOGENESIS, V34, P1968, DOI 10.1093/carcin/bgt147; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kreeger PK, 2009, CANCER RES, V69, P8191, DOI 10.1158/0008-5472.CAN-09-1921; Krzystek-Korpacka M, 2013, CANCER LETT, V337, P107, DOI 10.1016/j.canlet.2013.05.033; Bin L, 2008, WORLD J GASTROENTERO, V14, P2434, DOI 10.3748/wjg.14.2434; Maihofner C, 2003, CARCINOGENESIS, V24, P665, DOI 10.1093/carcin/bgg006; Martinasso G, 2007, PPAR RES, V2007, DOI 10.1155/2007/93416; Monjazeb AM, 2006, CARCINOGENESIS, V27, P1950, DOI 10.1093/carcin/bgl023; NAYLOR MS, 1990, CANCER RES, V50, P4436; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Pierre AS, 2013, BBA-MOL CELL BIOL L, V1831, P759, DOI 10.1016/j.bbalip.2013.01.005; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Schetter AJ, 2009, CLIN CANCER RES, V15, P5878, DOI 10.1158/1078-0432.CCR-09-0627; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216; Shime H, 2012, P NATL ACAD SCI USA, V109, P2066, DOI 10.1073/pnas.1113099109; Sun H, 2008, CANCER RES, V68, P2912, DOI 10.1158/0008-5472.CAN-07-2305; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Varga T, 2011, BBA-MOL BASIS DIS, V1812, P1007, DOI 10.1016/j.bbadis.2011.02.014; Verbeke H, 2010, HUM PATHOL, V41, P990, DOI 10.1016/j.humpath.2009.09.021; Wang K, 2010, J BIOL CHEM, V285, P16958, DOI 10.1074/jbc.M109.093005; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Yao L, 2015, CANCER RES, V75, P1388, DOI 10.1158/0008-5472.CAN-14-2561; Yu HN, 2015, ARCH MED SCI, V11, P282, DOI 10.5114/aoms.2015.50962; Yu XF, 2015, ONCOTARGET, V6, P1995, DOI 10.18632/oncotarget.3038; Zhang XM, 2012, CANCER RES, V72, P4707, DOI 10.1158/0008-5472.CAN-12-0639; Zhou R, 2010, NUCLEIC ACIDS RES, V38, P3222, DOI 10.1093/nar/gkq056; Zins K, 2007, CANCER RES, V67, P1038, DOI 10.1158/0008-5472.CAN-06-2295; Zou ZQ, 2013, J LIPID RES, V54, P3453, DOI 10.1194/jlr.M042754	67	31	33	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4611	4622		10.1038/onc.2015.523	http://dx.doi.org/10.1038/onc.2015.523			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26853468				2022-12-28	WOS:000382336300007
J	Li, L; Fang, R; Liu, B; Shi, H; Wang, Y; Zhang, W; Zhang, X; Ye, L				Li, L.; Fang, R.; Liu, B.; Shi, H.; Wang, Y.; Zhang, W.; Zhang, X.; Ye, L.			Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth	ONCOGENE			English	Article							CHAPERONE-MEDIATED AUTOPHAGY; PROGNOSTIC-SIGNIFICANCE; ACETYLATION TARGETS; BINDING-PROTEIN; YAP PATHWAY; CELLS; KINASE; PROLIFERATION; EXPRESSION; RECEPTOR	Reduction or loss of tumor-suppressor mammalian STE20-like kinase 1 (MST1) in Hippo pathway contributes to the tumorigenesis. However, the mechanism leading to reduction of MST1 in cancers remains poorly understood. In this study, we explored the hypothesis that the oncoprotein hepatitis B X-interacting protein (HBXIP) is involved in the reduction of MST1 in breast cancer. Immunohistochemical analysis of tissue microarrays revealed that the expression of HBXIP was negatively associated with that of MST1 in 98 clinical breast tissue samples. Then we found that HBXIP could posttranslationally downregulate MST1 in breast cancer cells. Mechanistically, we identified that MST1 could be acetylated on its lysine 35 residue in the cells. Strikingly, the treatment with trichostatin A, an inhibitor of histone deacetylases (HDACs), markedly increased the levels of MST1 acetylation and protein in the cells. Interestingly, the oncoprotein HBXIP could significantly inhibit acetylation of MST1, resulting in the reduction of MST1 protein. Notably, we revealed that the HDAC6 could reduce the protein levels of MST1 through deacetylation modification of MST1 in the cells. Moreover, our data revealed that HBXIP upregulated HDAC6 at the levels of mRNA and protein by activating transcription factor nuclear factor-kappa B. Deacetylation of MST1 promoted the interaction of MST1 with HSC70 in the cells, resulting in a lysosome-dependent degradation of MST1 via chaperone-mediated autophagy (CMA). Functionally, the reduction of tumor-suppressor MST1 mediated by HBXIP promoted the growth of breast cancer cells in vitro and in vivo. Thus we conclude that the deacetylation of MST1 mediated by HBXIP-enhanced HDAC6 results in MST1 degradation in a CMA manner in promotion of breast cancer growth. Our finding provides new insights into the mechanism of tumor-suppressor MST1 reduction in breast cancer.	[Li, L.; Fang, R.; Liu, B.; Shi, H.; Wang, Y.; Zhang, W.; Ye, L.] Nankai Univ, Coll Life Sci, Dept Biochem, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China; [Zhang, X.] Nankai Univ, Coll Life Sci, Dept Canc Res, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Ye, L (corresponding author), Nankai Univ, Coll Life Sci, Dept Biochem, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China.; Zhang, X (corresponding author), Nankai Univ, Coll Life Sci, Dept Canc Res, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China.	zhangxd@nankai.edu.cn; yelihong@nankai.edu.cn	Fang, Runping/AAF-6835-2020		National Basic Research Program of China (973 Program) [2015CB553905]; National Natural Scientific Foundation of China [81372186, 81272218, 31470756]; Tianjin Natural Scientific Foundation [14JCZDJC32800]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Natural Scientific Foundation	This work was supported by grants from the National Basic Research Program of China (973 Program, No. 2015CB553905), the National Natural Scientific Foundation of China (Nos. 81372186, 81272218, 31470756) and Tianjin Natural Scientific Foundation (No. 14JCZDJC32800).	Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824; Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Cinar B, 2007, EMBO J, V26, P4523, DOI 10.1038/sj.emboj.7601872; Cinar B, 2011, CANCER RES, V71, P4303, DOI 10.1158/0008-5472.CAN-10-4532; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Ding G, 2013, FEBS LETT, V587, P880, DOI 10.1016/j.febslet.2013.02.001; Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hong WJ, 2012, SEMIN CELL DEV BIOL, V23, P785, DOI 10.1016/j.semcdb.2012.05.004; Hsu YL, 2015, ONCOGENE, V34, P4056, DOI 10.1038/onc.2014.333; Hu N, 2011, J BIOL CHEM, V286, P13714, DOI 10.1074/jbc.M110.204131; Jeong H, 2009, CELL, V137, P60, DOI 10.1016/j.cell.2009.03.018; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Kang R, 2014, ONCOGENE, V33, P567, DOI 10.1038/onc.2012.631; Kuser-Abali G, 2014, EPIGENETICS-US, V9, P634, DOI 10.4161/epi.27957; Li H, 2015, J BIOL CHEM, V290, P22649, DOI 10.1074/jbc.M115.658468; Li H, 2012, LIVER INT, V32, P38, DOI 10.1111/j.1478-3231.2011.02646.x; Li K, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012286, 10.1371/journal.pone.0010341]; Li SS, 2013, BIOCHEM J, V452, P281, DOI 10.1042/BJ20120680; Lin CW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2876; Lin XY, 2013, TUMOR BIOL, V34, P3239, DOI 10.1007/s13277-013-0895-8; Liu FB, 2014, CARCINOGENESIS, V35, P1144, DOI 10.1093/carcin/bgu021; Liu Q, 2013, INT J CANCER, V133, P1310, DOI 10.1002/ijc.28154; Liu SP, 2012, J BIOL CHEM, V287, P30228, DOI 10.1074/jbc.M112.343947; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Madonna R, 2014, J BIOL CHEM, V289, P19585, DOI 10.1074/jbc.M113.540559; Majeski AE, 2004, INT J BIOCHEM CELL B, V36, P2435, DOI 10.1016/j.biocel.2004.02.013; Melegari M, 1998, J VIROL, V72, P1737, DOI 10.1128/JVI.72.3.1737-1743.1998; Minoo P, 2007, MODERN PATHOL, V20, P331, DOI 10.1038/modpathol.3800740; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Park SJ, 2014, CANCER LETT, V354, P97, DOI 10.1016/j.canlet.2014.07.041; Perez-Mancera PA, 2012, NATURE, V486, P266, DOI 10.1038/nature11114; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Rausa FM, 2004, J BIOL CHEM, V279, P43070, DOI 10.1074/jbc.M407472200; Ren AX, 2008, CANCER RES, V68, P2266, DOI 10.1158/0008-5472.CAN-07-6248; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Salah Z, 2011, CANCER RES, V71, P2010, DOI 10.1158/0008-5472.CAN-10-3516; Seidel C, 2007, MOL CARCINOGEN, V46, P865, DOI 10.1002/mc.20317; Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596; Wang FZ, 2007, ACTA PHARMACOL SIN, V28, P431, DOI 10.1111/j.1745-7254.2007.00531.x; Wang P, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0435-8; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yue L, 2013, CARCINOGENESIS, V34, P927, DOI 10.1093/carcin/bgs399; Zhang KJ, 2014, PROTEIN CELL, V5, P48, DOI 10.1007/s13238-013-0011-2; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005	52	51	55	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4048	4057		10.1038/onc.2015.476	http://dx.doi.org/10.1038/onc.2015.476			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26657153				2022-12-28	WOS:000381020900003
J	Rai, R; Zhang, F; Colavita, K; Leu, NA; Kurosaka, S; Kumar, A; Birnbaum, MD; Gyorffy, B; Dong, DW; Shtutman, M; Kashina, A				Rai, R.; Zhang, F.; Colavita, K.; Leu, N. A.; Kurosaka, S.; Kumar, A.; Birnbaum, M. D.; Gyorffy, B.; Dong, D. W.; Shtutman, M.; Kashina, A.			Arginyltransferase suppresses cell tumorigenic potential and inversely correlates with metastases in human cancers	ONCOGENE			English	Article							RNA-PROTEIN TRANSFERASE; END RULE PATHWAY; IN-VIVO; ARGINYLATION; EXPRESSION; FORMS; ATE1	Arginylation is an emerging post-translational modification mediated by arginyltransferase (ATE1) that is essential for mammalian embryogenesis and regulation of the cytoskeleton. Here, we discovered that Ate1-knockout (KO) embryonic fibroblasts exhibit tumorigenic properties, including abnormally rapid contact-independent growth, reduced ability to form cell-cell contacts and chromosomal aberrations. Ate1-KO fibroblasts can form large colonies in Matrigel and exhibit invasive behavior, unlike wild-type fibroblasts. Furthermore, Ate1-KO cells form tumors in subcutaneous xenograft assays in immunocompromised mice. Abnormal growth in these cells can be partially rescued by reintroduction of stably expressed specific Ate1 isoforms, which also reduce the ability of these cells to form tumors. Tumor array studies and bioinformatics analysis show that Ate1 is downregulated in several types of human cancer samples at the protein level, and that its transcription level inversely correlates with metastatic progression and patient survival. We conclude that Ate1-KO results in carcinogenic transformation of cultured fibroblasts, suggesting that in addition to its previously known activities Ate1 gene is essential for tumor suppression and also likely participates in suppression of metastatic growth.	[Rai, R.; Zhang, F.; Colavita, K.; Leu, N. A.; Kurosaka, S.; Kashina, A.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; [Zhang, F.; Kumar, A.; Birnbaum, M. D.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Gyorffy, B.] MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary; [Gyorffy, B.] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary; [Dong, D. W.] Univ Penn, Perelman Sch Med, Inst Biomed Informat, Philadelphia, PA 19104 USA; [Shtutman, M.] Univ South Carolina, Columbia, SC 29208 USA	University of Pennsylvania; University of Miami; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University; University of Pennsylvania; Pennsylvania Medicine; University of South Carolina System; University of South Carolina Columbia	Kashina, A (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	akashina@vet.upenn.edu	Gyorffy, Balazs/AAA-9135-2021; Shtutman, Michael/AAB-8391-2020	Gyorffy, Balazs/0000-0002-5772-3766; Shtutman, Michael/0000-0002-2458-3226	NIH [GM104003, GM117984, GM109091]; Pilot Grant from the Mari Lowe Center for Comparative Oncology; OTKA grant [K108655]; Developmental Grant from Sylvester Comprehensive Cancer Center; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM109091, R01GM104003, R01GM108744] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pilot Grant from the Mari Lowe Center for Comparative Oncology; OTKA grant(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Developmental Grant from Sylvester Comprehensive Cancer Center; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants GM104003 and GM117984 and the Pilot Grant from the Mari Lowe Center for Comparative Oncology to AK. BG was supported by the OTKA K108655 grant. MS was supported by NIH grant GM109091. FZ, MDB and A Kumar were partly supported by a Developmental Grant from Sylvester Comprehensive Cancer Center.	BALZI E, 1990, J BIOL CHEM, V265, P7464; Eisenach PA, 2014, J BIOL CHEM, V289, P35376, DOI 10.1074/jbc.M114.578674; Gyorffy B, 2015, ONCOTARGET, V6, P13334; KAJI H, 1963, BIOCHIM BIOPHYS ACTA, V76, P477; Karakozova M, 2006, SCIENCE, V313, P192, DOI 10.1126/science.1129344; Kurosaka S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000878; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Piatkov KI, 2012, P NATL ACAD SCI USA, V109, pE1839, DOI 10.1073/pnas.1207786109; Rai R, 2005, P NATL ACAD SCI USA, V102, P10123, DOI 10.1073/pnas.0504500102; Rai R, 2006, EMBO REP, V7, P800, DOI 10.1038/sj.embor.7400747; Saha S, 2011, CHEM BIOL, V18, P1369, DOI 10.1016/j.chembiol.2011.08.019; Saha S, 2011, DEV BIOL, V358, P1, DOI 10.1016/j.ydbio.2011.06.043; Wang JL, 2014, CHEM BIOL, V21, P331, DOI 10.1016/j.chembiol.2013.12.017; Wang JL, 2011, CHEM BIOL, V18, P121, DOI 10.1016/j.chembiol.2010.10.016; Wong CCL, 2007, PLOS BIOL, V5, P2231, DOI 10.1371/journal.pbio.0050258; Zhang FL, 2012, J CELL BIOL, V197, P819, DOI 10.1083/jcb.201112129	18	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4058	4068		10.1038/onc.2015.473	http://dx.doi.org/10.1038/onc.2015.473			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686093	Green Accepted, Green Submitted			2022-12-28	WOS:000381020900004
J	Han, XR; Zha, Z; Yuan, HX; Feng, X; Xia, YK; Lei, QY; Guan, KL; Xiong, Y				Han, X-R; Zha, Z.; Yuan, H-X; Feng, X.; Xia, Y-K; Lei, Q-Y; Guan, K-L; Xiong, Y.			KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation	ONCOGENE			English	Article							UBIQUITIN-LIGASE COMPLEX; F-BOX; CPG ISLANDS; CELL; TRANSCRIPTION; PHOSPHORYLATION; DOMAIN; PROTEINS; KINASE; FAMILY	KDM2B (also known as FBXL10) controls stem cell self-renewal, somatic cell reprogramming and senescence, and tumorigenesis. KDM2B contains multiple functional domains, including a JmjC domain that catalyzes H3K36 demethylation and a CxxC zinc-finger that recognizes CpG islands and recruits the polycomb repressive complex 1. Here, we report that KDM2B, via its F-box domain, functions as a subunit of the CUL1-RING ubiquitin ligase (CRL1/SCFKDM2B) complex. KDM2B targets c-Fos for polyubiquitylation and regulates c-Fos protein levels. Unlike the phosphorylation of other SCF (SKP1-CUL1-F-box)/CRL1 substrates that promotes substrates binding to F-box, epidermal growth factor (EGF)-induced c-Fos S374 phosphorylation dissociates c-Fos from KDM2B and stabilizes c-Fos protein. Non-phosphorylatable and phosphomimetic mutations at S374 result in c-Fos protein which cannot be induced by EGF or accumulates constitutively and lead to decreased or increased cell proliferation, respectively. Multiple tumor-derived KDM2B mutations impaired the function of KDM2B to target c-Fos degradation and to suppress cell proliferation. These results reveal a novel function of KDM2B in the negative regulation of cell proliferation by assembling an E3 ligase to targeting c-Fos protein degradation that is antagonized by mitogenic stimulations.	[Han, X-R; Zha, Z.; Yuan, H-X; Feng, X.; Xia, Y-K; Lei, Q-Y; Guan, K-L; Xiong, Y.] Fudan Univ, Minist Educ, Key Lab Mol Med, Shanghai, Peoples R China; [Han, X-R; Zha, Z.; Yuan, H-X; Feng, X.; Xia, Y-K; Guan, K-L; Xiong, Y.] Fudan Univ, Inst Biomed Sci, Mol & Cell Biol Lab, Shanghai, Peoples R China; [Han, X-R; Zha, Z.; Feng, X.; Xia, Y-K; Xiong, Y.] Fudan Univ, Sch Life Sci, Shanghai, Peoples R China; [Lei, Q-Y; Guan, K-L] Fudan Univ, Shanghai Med Coll, Dept Biochem & Mol Biol, Shanghai, Peoples R China; [Guan, K-L] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Guan, K-L] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Xiong, Y.] Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC USA	Fudan University; Fudan University; Fudan University; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego	Lei, QY; Guan, KL; Xiong, Y (corresponding author), Univ N Carolina, Lineberger Canc Ctr 22 012, Campus Box 7295, Chapel Hill, NC 27599 USA.	qlei@fudan.edu.cn; kuguan@ucsd.edu; yxiong@email.unc.edu	Xia, Yukun/HGT-9369-2022; Guan, Kun-Liang/ADK-7088-2022; Lei, Qun-Ying/J-1390-2017	Xia, Yukun/0000-0002-8728-9745; Lei, Qun-Ying/0000-0002-8547-8518; Han, Xiaoran/0000-0002-2435-4191	Chinese Ministry of Sciences and Technology 973 [2015CB910401]; NSFC [81225016, 81430057]; Shanghai Key basic research program [12JC1401100]; Shanghai Outstanding Academic Leader [13XD1400600]; Youth Science and Technology Leading Talent by MOST; NIH [EY022611, CA132809, GM067113]; NATIONAL CANCER INSTITUTE [R01CA132809, R01CA068377] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY022611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067113] Funding Source: NIH RePORTER	Chinese Ministry of Sciences and Technology 973; NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Key basic research program; Shanghai Outstanding Academic Leader; Youth Science and Technology Leading Talent by MOST; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of the Fudan MCB laboratory for discussions and support throughout this study and Michele Pagano of NYU for providing plasmids expressing full-length human KDM2B cDNA. This work was supported by Chinese Ministry of Sciences and Technology 973 (Grant No. 2015CB910401), NSFC (Grant No. 81225016, 81430057), Shanghai Key basic research program (12JC1401100), Shanghai Outstanding Academic Leader (Grant No. 13XD1400600) and the Youth Science and Technology Leading Talent by MOST (to Q-YL), NIH Grants EY022611 and CA132809 (to K-LG) and GM067113 (to YX).	Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bakiri L, 2011, ONCOGENE, V30, P1506, DOI 10.1038/onc.2010.542; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Farcas AM, 2012, ELIFE, V1, DOI 10.7554/eLife.00205; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furukawa Manabu, 2005, V301, P37; Gearhart MD, 2006, MOL CELL BIOL, V26, P6880, DOI 10.1128/MCB.00630-06; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gilley R, 2009, CELL SIGNAL, V21, P969, DOI 10.1016/j.cellsig.2009.02.006; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; He J, 2013, NAT CELL BIOL, V15, P373, DOI 10.1038/ncb2702; He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736; Kottakis F, 2014, CANCER RES, V74, P3935, DOI 10.1158/0008-5472.CAN-13-2733; Koyama-Nasu R, 2007, NAT CELL BIOL, V9, P1074, DOI 10.1038/ncb1628; Liang GY, 2012, NAT CELL BIOL, V14, P457, DOI 10.1038/ncb2483; Maher VM, 1981, NATL CANCER I MONOGR, V58, P217; Nakakuki T, 2010, CELL, V141, P884, DOI 10.1016/j.cell.2010.03.054; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Pfau R, 2008, P NATL ACAD SCI USA, V105, P1907, DOI 10.1073/pnas.0711865105; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535; Wu XD, 2013, MOL CELL, V49, P1134, DOI 10.1016/j.molcel.2013.01.016; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	35	24	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4179	4190		10.1038/onc.2015.482	http://dx.doi.org/10.1038/onc.2015.482			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26725323	Green Accepted, Green Submitted			2022-12-28	WOS:000382149800003
J	Yang, CF; Yang, GD; Huang, TJ; Li, R; Chu, QQ; Xu, L; Wang, MS; Cai, MD; Zhong, L; Wei, HJ; Huang, HB; Huang, JL; Qian, CN; Huang, BJ				Yang, C-F; Yang, G-D; Huang, T-J; Li, R.; Chu, Q-Q; Xu, L.; Wang, M-S; Cai, M-D; Zhong, L.; Wei, H-J; Huang, H-B; Huang, J-L; Qian, C-N; Huang, B-J			EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; CANCER CELLS; MICRORNA-21; EXPRESSION; IDENTIFICATION; PTEN; MEMBRANE-PROTEIN-1; HEAD	Our previous study reported that Epstein-Barr virus(EBV)-encoded latent membrane protein 1 (LMP1) could induce development of CD44(+/High) stem-like cells in nasopharyngeal carcinoma (NPC). However, the molecular mechanisms that underlie modulation of cancer stem cells (CSCs) in NPC remain unclear. Here, we show that LMP1 induced CSC-like properties through promotion of the expression of epithelial-mesenchymal transition-like cellular markers and through alterations in differentiation markers. Furthermore, LMP1 activated and triggered phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway, which subsequently stimulated expression of CSC markers, development of side population and tumor sphere formation. This suggests that PI3K/AKT pathway has an important role in the induction and maintenance of CSC properties in NPC. Similarly, PI3K/AKT pathway was also activated by phosphorylase in LMP1-induced CD44(+/High) cells. In addition, LMP1 greatly increased expression of miR-21 and downregulated expression of the miR-21 target, PTEN. Overexpression of miR-21 by transfection of miR-21 mimics into LMP1-transformed cells led to phosphorylase-mediated activation of the PI3K/AKT pathway and induction of CSCs. On the contrary, phosphorylation of the PI3K/AKT pathway and the expression of CSC were reversed by an miR-21 inhibitor. The specific inhibitor (Ly294002) of PI3K/AKT pathway significantly decreased expression of miR-21 and CSC markers and upregulated the expression of PTEN, which indicates that miR-21 and PTEN are the downstream effectors of PI3K/AKT and that expression of these two effectors are related to the development of NPC CSCs. Taken together, our novel findings indicate that LMP1, PI3K/AKT, miR-21 and PTEN constitute a positive feedback loop and have a key role in LMP1-induced CSCs in NPC.	[Yang, C-F; Xu, L.; Qian, C-N; Huang, B-J] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Expt Res,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Yang, C-F; Wang, M-S; Cai, M-D; Zhong, L.; Wei, H-J] Gaozhou Peoples Hosp, Dept Canc Chemotherapy, Gaozhou, Peoples R China; [Yang, G-D] Sun Yat Sen Univ, BoJi Affiliated Hosp, Zengcheng Peoples Hosp, Dept Canc Chemotherapy, Zengcheng, Peoples R China; [Huang, T-J] Second Peoples Hosp Shenzhen, Dept Nucl Med, Shenzhen, Peoples R China; [Li, R.] Soothern Med Univ, Coll Clin Med 2, Guangzhou, Guangdong, Peoples R China; [Chu, Q-Q] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China; [Huang, H-B] Sun Yat Sen Univ, Ctr Canc, Dept Pharm, Guangzhou, Guangdong, Peoples R China; [Huang, J-L] St Barnabas Hosp, Dept Pathol, Livingston, NJ USA; [Qian, C-N] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Second People's Hospital of Shenzhen; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Qian, CN; Huang, BJ (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Dept Expt Res, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	qianchn@sysucc.org.cn; huangbj@sysucc.org.cn	Huang, Bi-Jun/GSD-2430-2022; Huang, Huang/AAN-5671-2020		National Natural Science Foundation of China [81572901, 31170151, 81272340, 30770108, 81030043]; Science and Technology Planning Project of Guangdong Province, China [2014B020212017, 2014A020209024, 2009A030331005]; Guangzhou Key Program of Science and Technology [2012Y2-00026]; Shenzhen Basic Research Program of Science and Technology RD [JC201105170709A, JCYJ20150330102720115]; Guangdong Natural Science Foundation [2014A030310029]; National High Technology Research and Development Program of China (863 Program) [2012AA02A501]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province, China; Guangzhou Key Program of Science and Technology; Shenzhen Basic Research Program of Science and Technology RD; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China)	This work was supported by grants from the National Natural Science Foundation of China (grant no. 81572901, 31170151, 81272340, 30770108 and 81030043), the Science and Technology Planning Project of Guangdong Province, China (grant no. 2014B020212017, 2014A020209024 and 2009A030331005), the Guangzhou Key Program of Science and Technology (grant no. 2012Y2-00026), the Shenzhen Basic Research Program of Science and Technology R&D (grant no. JC201105170709A and JCYJ20150330102720115), the Guangdong Natural Science Foundation (grant no. 2014A030310029) and the National High Technology Research and Development Program of China (863 Program; No. 2012AA02A501).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Asuthkar S, 2012, ONCOTARGET, V3, P1439; Bao B, 2012, BBA-REV CANCER, V1826, P272, DOI 10.1016/j.bbcan.2012.04.008; Bao LL, 2013, CANCER LETT, V337, P226, DOI 10.1016/j.canlet.2013.05.007; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Castellino RC, 2007, NAT CLIN PRACT NEURO, V3, P682, DOI 10.1038/ncpneuro0661; Chen CC, 2010, CELL SIGNAL, V22, P1132, DOI 10.1016/j.cellsig.2010.03.008; Chen Jiezhong, 2012, World J Virol, V1, P154, DOI 10.5501/wjv.v1.i6.154; Chen YR, 2008, J VIROL, V82, P8124, DOI 10.1128/JVI.00430-08; Chew MMS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-574; Chung WM, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt247; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dubrovska A, 2010, CLIN CANCER RES, V16, P5692, DOI 10.1158/1078-0432.CCR-10-1601; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Han M, 2012, CANCER SCI, V4, P1058; Hannigan A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-184; Kondo S, 2011, J VIROL, V85, P11255, DOI 10.1128/JVI.00188-11; Kutz H, 2008, VIROLOGY, V371, P246, DOI 10.1016/j.virol.2007.09.044; Lambert SL, 2007, J IMMUNOL, V179, P8225, DOI 10.4049/jimmunol.179.12.8225; Lavorgna A, 2012, P NATL ACAD SCI USA, V109, P2188, DOI 10.1073/pnas.1121357109; Lee JW, 2009, CANCER LETT, V279, P193, DOI 10.1016/j.canlet.2009.01.037; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Mainou BA, 2005, ONCOGENE, V24, P6917, DOI 10.1038/sj.onc.1208846; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Prince MEP, 2008, J CLIN ONCOL, V26, P2871, DOI 10.1200/JCO.2007.15.1613; Qian CN, 2009, CANCER RES, V69, P8256, DOI 10.1158/0008-5472.CAN-09-1689; Sayed D, 2010, J BIOL CHEM, V285, P20281, DOI 10.1074/jbc.M110.109207; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Singh SK, 2003, CANCER RES, V63, P5821; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yamamoto C, 2010, CANCER RES, V70, P8715, DOI 10.1158/0008-5472.CAN-10-0043; Yang CF, 2014, CANCER LETT, V344, P260, DOI 10.1016/j.canlet.2013.11.006; Yang GW, 2013, DISCRETE DYN NAT SOC, V2013, DOI 10.1155/2013/507828; Yang SM, 2013, TOXICOLOGY, V306, P162, DOI 10.1016/j.tox.2013.02.014; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu XS, 2013, CANCER IMMUNOL IMMUN, V62, P689, DOI 10.1007/s00262-012-1367-5	51	43	45	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3419	3431		10.1038/onc.2015.402	http://dx.doi.org/10.1038/onc.2015.402			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26568302				2022-12-28	WOS:000379270100007
J	Godin-Heymann, N; Brabetz, S; Murillo, MM; Saponaro, M; Santos, CR; Lobley, A; East, P; Chakravarty, P; Matthews, N; Kelly, G; Jordan, S; Castellano, E; Downward, J				Godin-Heymann, N.; Brabetz, S.; Murillo, M. M.; Saponaro, M.; Santos, C. R.; Lobley, A.; East, P.; Chakravarty, P.; Matthews, N.; Kelly, G.; Jordan, S.; Castellano, E.; Downward, J.			Tumour-suppression function of KLF12 through regulation of anoikis	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; KRUPPEL-LIKE-FACTORS; MESENCHYMAL TRANSITION; CANCER-CELLS; EXTRACELLULAR-MATRIX; DOWN-REGULATION; BREAST-CANCER; UP-REGULATION; CYCLE ARREST; RAS	Suppression of detachment-induced cell death, known as anoikis, is an essential step for cancer metastasis to occur. We report here that expression of KLF12, a member of the Kruppel-like family of transcription factors, is downregulated in lung cancer cell lines that have been selected to grow in the absence of cell adhesion. Knockdown of KLF12 in parental cells results in decreased apoptosis following cell detachment from matrix. KLF12 regulates anoikis by promoting the cell cycle transition through S phase and therefore cell proliferation. Reduced expression levels of KLF12 results in increased ability of lung cancer cells to form tumours in vivo and is associated with poorer survival in lung cancer patients. We therefore identify KLF12 as a novel metastasis-suppressor gene whose loss of function is associated with anoikis resistance through control of the cell cycle.	[Godin-Heymann, N.; Brabetz, S.; Murillo, M. M.; Jordan, S.; Castellano, E.; Downward, J.] Canc Res UK London Res Inst, Signal Transduct, London WC2A 3PX, England; [Murillo, M. M.; Downward, J.] Inst Canc Res, London SW3 6JB, England; [Saponaro, M.] Canc Res UK London Res Inst, Clare Hall Labs, Mechanisms Gene Transcript Lab, London WC2A 3PX, England; [Santos, C. R.] Canc Res UK London Res Inst, Translat Canc Therapeut, London WC2A 3PX, England; [Lobley, A.; East, P.; Chakravarty, P.; Kelly, G.] Canc Res UK London Res Inst, Bioinformat & Biostat Labs, London WC2A 3PX, England; [Matthews, N.] Canc Res UK London Res Inst, Adv Sequencing Facil, London WC2A 3PX, England; [Castellano, E.] Univ London, Ctr Canc & Inflammat, Barts Canc Inst, Charterhouse Sq, London EC1M 6BP, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; Cancer Research UK; Cancer Research UK; Cancer Research UK; University of London; Queen Mary University London	Downward, J (corresponding author), Signal Transduct Lab Canc Res UK, 44 Lincolns Inn Fields, London WC2A 3LY, England.	downward@cancer.org.uk	Sánchez, Esther Castellano/AAA-8087-2020; Saponaro, Marco/M-1854-2015; Kelly, Gavin/ABG-2715-2021	Sánchez, Esther Castellano/0000-0002-8449-4081; Saponaro, Marco/0000-0002-9302-2553; Kelly, Gavin/0000-0001-7219-560X; chakravarty, probir/0000-0003-1146-8824; Downward, Julian/0000-0002-2331-4729	Cancer Research UK, from the European Commission [259770]; European Research Council Advanced Grant RASTARGET; Cancer Research UK [15680] Funding Source: researchfish; The Francis Crick Institute [10071, 10002, 10070, 10074] Funding Source: researchfish	Cancer Research UK, from the European Commission; European Research Council Advanced Grant RASTARGET; Cancer Research UK(Cancer Research UK); The Francis Crick Institute	We thank Elza de Bruin and Clare Sheridan for advice. We also thank Mike Howell and LRI Core Technology Facilities, including Equipment Park, FACS lab and Cell Services. This work was funded by Cancer Research UK, funding from the European Commission's Seventh Framework Programme (FP7/2007-2013) under the grant agreement LUNGTARGET (project 259770) and from the European Research Council Advanced Grant RASTARGET.	Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Bretland AJ, 2001, CELL PROLIFERAT, V34, P199, DOI 10.1046/j.1365-2184.2001.00198.x; Buchheit CL, 2012, SEMIN CELL DEV BIOL, V23, P402, DOI 10.1016/j.semcdb.2012.04.007; Bureau C, 2009, CURR GENOMICS, V10, P353, DOI 10.2174/138920209788921010; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Chen CS, 2001, GENE CHROMOSOME CANC, V31, P333, DOI 10.1002/gcc.1152; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Derouet M, 2007, NEOPLASIA, V9, P536, DOI 10.1593/neo.07217; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2013, J CELL SCI, V126, P21, DOI 10.1242/jcs.120907; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Giefing M, 2008, NEOPLASMA, V55, P55; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Imhof A, 1999, MOL CELL BIOL, V19, P194; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim HRC, 1999, CANCER RES, V59, P4148; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Lahiri SK, 2012, AM J TRANSL RES, V4, P357; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Nakamura Y, 2009, INT J CANCER, V125, P1859, DOI 10.1002/ijc.24538; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Petersen GM, 2010, NAT GENET, V42, P224, DOI 10.1038/ng.522; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Rabien A, 2012, CANCER SCI, V103, P169, DOI 10.1111/j.1349-7006.2011.02140.x; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Steckel M, 2012, CELL RES, V22, P1227, DOI 10.1038/cr.2012.82; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Wei L, 2004, ONCOGENE, V23, P9052, DOI 10.1038/sj.onc.1208091; Yang YZ, 2012, CELL CYCLE, V11, P4033, DOI 10.4161/cc.22265; Yoo BH, 2011, J BIOL CHEM, V286, P38894, DOI 10.1074/jbc.M111.290692; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhong XL, 2012, CELL SIGNAL, V24, P393, DOI 10.1016/j.cellsig.2011.10.005	48	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3324	3334		10.1038/onc.2015.394	http://dx.doi.org/10.1038/onc.2015.394			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26455320	hybrid, Green Published			2022-12-28	WOS:000378306400011
J	Palazzo, E; Kellett, M; Cataisson, C; Gormley, A; Bible, PW; Pietroni, V; Radoja, N; Hwang, J; Blumenberg, M; Yuspa, SH; Morasso, MI				Palazzo, E.; Kellett, M.; Cataisson, C.; Gormley, A.; Bible, P. W.; Pietroni, V.; Radoja, N.; Hwang, J.; Blumenberg, M.; Yuspa, S. H.; Morasso, M. I.			The homeoprotein DLX3 and tumor suppressor p53 co-regulate cell cycle progression and squamous tumor growth	ONCOGENE			English	Article							HOMEOBOX GENE; HUMAN KERATINOCYTES; BINDING-SITES; P63; DIFFERENTIATION; SKIN; EXPRESSION; CANCER; TAP63; TUMORIGENESIS	Epidermal homeostasis depends on the coordinated control of keratinocyte cell cycle. Differentiation and the alteration of this balance can result in neoplastic development. Here we report on a novel DLX3-dependent network that constrains epidermal hyperplasia and squamous tumorigenesis. By integrating genetic and transcriptomic approaches, we demonstrate that DLX3 operates through a p53-regulated network. DLX3 and p53 physically interact on the p21 promoter to enhance p21 expression. Elevating DLX3 in keratinocytes produces a G1-S blockade associated with p53 signature transcriptional profiles. In contrast, DLX3 loss promotes a mitogenic phenotype associated with constitutive activation of ERK. DLX3 expression is lost in human skin cancers and is extinguished during progression of experimentally induced mouse squamous cell carcinoma (SCC). Reinstatement of DLX3 function is sufficient to attenuate the migration of SCC cells, leading to decreased wound closure. Our data establish the DLX3-p53 interplay as a major regulatory axis in epidermal differentiation and suggest that DLX3 is a modulator of skin carcinogenesis.	[Palazzo, E.; Kellett, M.; Gormley, A.; Bible, P. W.; Pietroni, V.; Radoja, N.; Hwang, J.; Morasso, M. I.] NIAMS, Skin Biol Lab, NIH, Bldg 50,Room 1523, Bethesda, MD 20892 USA; [Cataisson, C.; Yuspa, S. H.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Blumenberg, M.] NYU, Dept Dermatol, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York University	Morasso, MI (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 50,Room 1523, Bethesda, MD 20892 USA.	morasso@nih.gov	Palazzo, Elisabetta/J-5287-2016	Palazzo, Elisabetta/0000-0002-0812-5524; McCarter, Anna/0000-0003-3828-9797; Blumenberg, Miroslav/0000-0002-8672-7774	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [ZIA AR041124-14]; NATIONAL CANCER INSTITUTE [ZIABC004504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZICAR041186, ZIAAR041124] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank current and past members of the Laboratory of Skin Biology and members of the Laboratory of Cancer Biology and Genetics, and Dr Mark Udey for helpful discussions. We also thank Andrew Ryscavage (LCBG), Gustavo Gutierrez-Cruz (NIAMS Genome Analysis Core Facility), Dr Hong-Wei Sun (Biodata Mining and Discovery Section, NIAMS) and Kristina Zaal of the NIAMS Light Imaging Core Facility. This work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (M.I.M. ZIA AR041124-14).	Aasen T, 2010, NAT PROTOC, V5, P371, DOI 10.1038/nprot.2009.241; Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Botchkarev VA, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015248; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Cai BH, 2012, J BIOCHEM, V152, P99, DOI 10.1093/jb/mvs053; Candi E, 2007, P NATL ACAD SCI USA, V104, P11999, DOI 10.1073/pnas.0703458104; Candi E, 2014, HUM MUTAT, V35, P702, DOI 10.1002/humu.22523; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; Cataisson C, 2009, CANCER RES, V69, P319, DOI 10.1158/0008-5472.CAN-08-2490; Chakravarti D, 2014, P NATL ACAD SCI USA, V111, pE572, DOI 10.1073/pnas.1319743111; Crum CP, 2010, ANNU REV PATHOL-MECH, V5, P349, DOI 10.1146/annurev-pathol-121808-102117; Darwiche N, 2007, ONCOGENE, V26, P6885, DOI 10.1038/sj.onc.1210491; Di Costanzo A, 2009, CELL CYCLE, V8, P1185, DOI 10.4161/cc.8.8.8202; Dotto JE, 2006, J CUTAN PATHOL, V33, P413, DOI 10.1111/j.0303-6987.2006.00477.x; Duverger O, 2008, J CELL PHYSIOL, V216, P337, DOI 10.1002/jcp.21491; Duverger O, 2008, J BIOL CHEM, V283, P20198, DOI 10.1074/jbc.M709562200; Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793; Gandarillas A, 2012, CELL CYCLE, V11, P4507, DOI 10.4161/cc.22529; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Ha LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021877; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hwang J, 2008, DEVELOPMENT, V135, P3149, DOI 10.1242/dev.022202; Hwang J, 2011, P NATL ACAD SCI USA, V108, P11566, DOI 10.1073/pnas.1019658108; Karia PS, 2013, J AM ACAD DERMATOL, V68, P957, DOI 10.1016/j.jaad.2012.11.037; Kelder T, 2012, NUCLEIC ACIDS RES, V40, pD1301, DOI 10.1093/nar/gkr1074; King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337; King KE, 2013, J SKIN CANCER, V2013, DOI 10.1155/2013/632028; Koh LF, 2015, EXP DERMATOL, V24, P754, DOI 10.1111/exd.12764; Koster MI, 2004, DIFFERENTIATION, V72, P364, DOI 10.1111/j.1432-0436.2004.07208002.x; Lessard JC, 2015, EXP DERMATOL, V24, P55, DOI 10.1111/exd.12568; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masse I, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.62; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morasso Maria I., 2005, Birth Defects Research, V75, P163, DOI 10.1002/bdrc.20047; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Priolo M, 2001, J MED GENET, V38, P579, DOI 10.1136/jmg.38.9.579; Radoja N, 2006, PHYSIOL GENOMICS, V27, P65, DOI 10.1152/physiolgenomics.00031.2006; Radoja N, 2007, DEVELOPMENT, V134, P13, DOI 10.1242/dev.02703; Ratushny V, 2012, J CLIN INVEST, V122, P464, DOI 10.1172/JCI57415; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Saramaki A, 2006, NUCLEIC ACIDS RES, V34, P543, DOI 10.1093/nar/gkj460; Schavolt KL, 2007, ONCOGENE, V26, P6125, DOI 10.1038/sj.onc.1210441; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tu Zhigang, 2012, Small GTPases, V3, P163, DOI 10.4161/sgtp.19884; Vanbokhoven H, 2011, J INVEST DERMATOL, V131, P1196, DOI 10.1038/jid.2011.84; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043	61	19	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3114	3124		10.1038/onc.2015.380	http://dx.doi.org/10.1038/onc.2015.380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26522723	Bronze, Green Accepted			2022-12-28	WOS:000378092700004
J	Cheng, H; Liu, P; Ohlson, C; Xu, E; Symonds, L; Isabella, A; Muller, WJ; Lin, NU; Krop, IE; Roberts, TM; Winer, EP; Arteaga, CL; Zhao, JJ				Cheng, H.; Liu, P.; Ohlson, C.; Xu, E.; Symonds, L.; Isabella, A.; Muller, W. J.; Lin, N. U.; Krop, I. E.; Roberts, T. M.; Winer, E. P.; Arteaga, C. L.; Zhao, J. J.			PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling	ONCOGENE			English	Article							HUMAN BREAST-CANCER; PIK3CA MUTATIONS; TRASTUZUMAB RESISTANCE; ADJUVANT CHEMOTHERAPY; METABOLIC-REGULATION; UP-REGULATION; INHIBITION; EXPRESSION; PATHWAY; IMPACT	Human breast cancers that have HER2 amplification/overexpression frequently carry PIK3CA mutations, and are often associated with a worse prognosis. However, the role of PIK3CA mutations in the initiation and maintenance of these breast cancers remains elusive. In the present study, we generated a compound mouse model that genetically mimics HER2-positive breast cancer with coexisting PIK3CA(H1047R). Induction of PIK3CA(H1047R) expression in mouse mammary glands with constitutive expression of activated Her2/Neu resulted in accelerated mammary tumorigenesis with enhanced metastatic potential. Interestingly, inducible expression of mutant PIK3CA resulted in a robust activation of phosphatidylinositol-3-kinase (PI3K)/AKT signaling but attenuation of Her2/Her3 signaling, and this can be reversed by deinduction of PIK3CA(H1047R) expression. Strikingly, although these Her2(+) PIK3CA(H1047R) initiated primary mammary tumors are refractory to HER2-targeted therapy, all tumors responded to inactivation of the oncogenic PIK3CA(H1047R), a situation closely mimicking the use of a highly effective inhibitor specifically targeting the mutant PIK3CA/p110a. Notably, these tumors eventually resumed growth, and a fraction of them escaped PI3K dependence by compensatory ERK activation, which can be blocked by combined inhibition of Her2 and MEK. Together, these results suggest that PIK3CA-specific inhibition as a monotherapy followed by combination therapy targeting MAPK and HER2 in a timely manner may be an effective treatment approach against HER2-positive cancers with coexisting PIK3CA-activating mutations.	[Cheng, H.] Dalian Med Univ, Hosp 2, Inst Canc, Dalian 116023, Peoples R China; [Cheng, H.; Liu, P.; Ohlson, C.; Xu, E.; Symonds, L.; Isabella, A.; Roberts, T. M.; Zhao, J. J.] Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA; [Muller, W. J.] McGill Univ, Goodman Canc Res Ctr, Dept Biochem, Montreal, PQ, Canada; [Lin, N. U.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; [Krop, I. E.; Winer, E. P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Arteaga, C. L.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Med, 221 Kirkland Hall, Nashville, TN 37235 USA	Dalian Medical University; Harvard University; Dana-Farber Cancer Institute; McGill University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Vanderbilt University	Cheng, H (corresponding author), Dalian Med Univ, Hosp 2, Inst Canc, Dalian 116023, Peoples R China.; Zhao, JJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA.	hailingcheng_dmu@163.com; jean_zhao@dfci.harvard.edu			Susan G. Komen Breast Cancer Foundation [CCR12225834]; Susan G. Komen Breast Cancer Foundation; Breast Cancer Research Foundation; ACS [CRP-07-234-06-COUN]; NIH [CA187918, CA172461-01, 1P50CA168504]; NATIONAL CANCER INSTITUTE [R01CA187918, P50CA168504, R01CA172461] Funding Source: NIH RePORTER	Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; ACS(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Roderick Bronson and the Dana-Farber/Harvard Cancer Center Rodent Histoplathology Core for histopathological analyses. We thank L. Chodosh (University of Pennsylvania School of Medicine) for providing MMTVrtTAmice. This work was supported by the Susan G. Komen Breast Cancer Foundation CCR12225834 (HC), Susan G. Komen Breast Cancer Foundation (IEK), Breast Cancer Research Foundation (NUL, EPW and JJZ), ACS grant CRP-07-234-06-COUN (CLA), NIH grants CA187918 (TMR and JJZ), CA172461-01 (JJZ) and 1P50CA168504 (TMR, IEK, EPW, NUL and JJZ).	Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Baselga J, 2013, P 104 ANN M AM ASS C; Baselga J, 2013, 27 SEPT 1 OCT 2013 E; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cizkova M, 2013, BRIT J CANCER, V108, P1807, DOI 10.1038/bjc.2013.164; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694; Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Ghosh R, 2011, CANCER RES, V71, P1871, DOI 10.1158/0008-5472.CAN-10-1872; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hynes NE, 2009, CANCER CELL, V15, P353, DOI 10.1016/j.ccr.2009.04.004; Jensen JD, 2012, ANN ONCOL, V23, P2034, DOI 10.1093/annonc/mdr546; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lerma E, 2008, VIRCHOWS ARCH, V453, P133, DOI 10.1007/s00428-008-0643-4; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Miron A, 2010, CANCER RES, V70, P5674, DOI 10.1158/0008-5472.CAN-08-2660; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Perez EA, 2013, J CLIN ONCOL, V31, P2115, DOI 10.1200/JCO.2012.42.2642; Perez EA, 2012, JNCI-J NATL CANCER I, V104, P159, DOI 10.1093/jnci/djr490; Perez EA, 2011, J CLIN ONCOL, V29, P4491, DOI 10.1200/JCO.2011.36.7045; Razis E, 2011, BREAST CANCER RES TR, V128, P447, DOI 10.1007/s10549-011-1572-5; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Sopasakis VR, 2010, CELL METAB, V11, P220, DOI 10.1016/j.cmet.2010.02.002; Stachler MD, 2015, APPL IMMUNOHISTOCHEM; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Yuan TL, 2008, P NATL ACAD SCI USA, V105, P9739, DOI 10.1073/pnas.0804123105	36	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2961	2970		10.1038/onc.2015.377	http://dx.doi.org/10.1038/onc.2015.377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26640141	Green Accepted			2022-12-28	WOS:000377474500002
J	Koch, A; Maia, A; Janssen, A; Medema, RH				Koch, A.; Maia, A.; Janssen, A.; Medema, R. H.			Molecular basis underlying resistance to Mps1/TTK inhibitors	ONCOGENE			English	Article							SPINDLE-ASSEMBLY CHECKPOINT; PROTEIN-KINASES; MITOTIC CHECKPOINT; MYELOID-LEUKEMIA; DRUG-RESISTANCE; AURORA KINASES; CANCER-THERAPY; BCR-ABL; CELLS; KINETOCHORES	Mps1/TTK is a dual-specificity kinase, with an essential role in mitotic checkpoint signaling, which has emerged as a potential target in cancer therapy. Several Mps1/TTK small-molecule inhibitors have been described that exhibit promising activity in cell culture and xenograft models. Here, we investigated whether cancer cells can develop resistance to these drugs. To this end, we treated various cancer cell lines with sublethal concentrations of a potent Mps1/TTK inhibitor in order to isolate inhibitor-resistant monoclonal cell lines. We identified four point mutations in the catalytic domain of Mps1/TTK that gave rise to inhibitor resistance but retained wildtype catalytic activity. Interestingly, cross-resistance of the identified mutations to other Mps1/TTK inhibitors is limited. Our studies predict that Mps1/TTK inhibitor-resistant tumor cells can arise through the acquisition of mutations in the adenosine triphosphate-binding pocket of the kinase that prevent stable binding of the inhibitors. In addition, our results suggest that combinations of inhibitors could be used to prevent acquisition of drug resistance. Interestingly, cross-resistance seems nonspecific for inhibitor scaffolds, a notion that can be exploited in future drug design to evict possible resistance mutations during clinical treatment.	[Koch, A.; Maia, A.; Janssen, A.; Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Janssen, A.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Dept Genome Dynam, Berkeley, CA 94720 USA	Netherlands Cancer Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Medema, RH (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.medema@nki.nl		Maia, Ana/0000-0003-1261-7211; Janssen, Aniek/0000-0001-6731-6657; Koch, Andre/0000-0003-3502-382X; Medema, Rene/0000-0002-6754-0381	NWO Gravitation Program (Cancer Genomics Center, CGC.nl); EMBO long-term fellowship [ALTF-425-2013]	NWO Gravitation Program (Cancer Genomics Center, CGC.nl); EMBO long-term fellowship(European Molecular Biology Organization (EMBO))	We thank Geert Kops (UMC Utrecht, The Netherlands) Susanne Lens (UMC Utrecht, The Netherlands) and Anastassis Perrakis (NKI, Amsterdam, The Netherlands) for reagents. Roos Klop, Yoshitaka Hiruma and Mathijs Vleugel for technical help. Bram van den Broek (NKI, Amsterdam, The Netherlands) for providing the ImageJ analysis macro for mitotic index analysis. We thank our colleagues for support and helpful suggestions. The research was funded by the NWO Gravitation Program (Cancer Genomics Center, CGC.nl). AK was supported by an EMBO long-term fellowship (ALTF-425-2013).	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Barouch-Bentov R, 2011, EXPERT OPIN INV DRUG, V20, P153, DOI 10.1517/13543784.2011.546344; Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Chu MLH, 2010, BIOCHEMISTRY-US, V49, P1689, DOI 10.1021/bi901970c; Colombo R, 2010, CANCER RES, V70, P10255, DOI 10.1158/0008-5472.CAN-10-2101; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; D'Alise AM, 2008, MOL CANCER THER, V7, P1140, DOI 10.1158/1535-7163.MCT-07-2051; Daniel J, 2011, P NATL ACAD SCI USA, V108, P5384, DOI 10.1073/pnas.1007645108; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Eyers PA, 2005, CELL CYCLE, V4, P784, DOI 10.4161/cc.4.6.1693; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Girdler F, 2008, CHEM BIOL, V15, P552, DOI 10.1016/j.chembiol.2008.04.013; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hewitt L, 2010, J CELL BIOL, V190, P25, DOI 10.1083/jcb.201002133; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jemaa M, 2013, CELL DEATH DIFFER, V20, P1532, DOI 10.1038/cdd.2013.105; Kornev AP, 2008, P NATL ACAD SCI USA, V105, P14377, DOI 10.1073/pnas.0807988105; Kumar DV, 2012, BIOORG MED CHEM LETT, V22, P4377, DOI 10.1016/j.bmcl.2012.04.131; Kwiatkowski N, 2010, NAT CHEM BIOL, V6, P359, DOI 10.1038/nchembio.345; Lan WJ, 2010, J CELL BIOL, V190, P21, DOI 10.1083/jcb.201006080; Liu XD, 2012, ANNU REV BIOCHEM, V81, P561, DOI 10.1146/annurev-biochem-061611-090435; Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799; London N, 2012, CURR BIOL, V22, P900, DOI 10.1016/j.cub.2012.03.052; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Marina Caldarelli MA, 2009, Pyrazolo-quinazolines, Patent No. [WO 2009156315 A1, 2009156315]; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Naud S, 2013, J MED CHEM, V56, P10045, DOI 10.1021/jm401395s; Nijenhuis W, 2014, NAT CELL BIOL, V16, P1257, DOI 10.1038/ncb3065; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Schmidt M, 2005, EMBO REP, V6, P866, DOI 10.1038/sj.embor.7400483; Scutt PJ, 2009, J BIOL CHEM, V284, P15880, DOI 10.1074/jbc.M109.005694; Shepperd LA, 2012, CURR BIOL, V22, P891, DOI 10.1016/j.cub.2012.03.051; Sloane DA, 2010, ACS CHEM BIOL, V5, P563, DOI 10.1021/cb100053q; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Tannous BA, 2013, JNCI-J NATL CANCER I, V105, P1322, DOI 10.1093/jnci/djt168; Tardif KD, 2011, MOL CANCER THER, V10, P2267, DOI 10.1158/1535-7163.MCT-11-0453; Vleugel M, 2013, J CELL BIOL, V203, P943, DOI 10.1083/jcb.201307016; Wacker SA, 2012, NAT CHEM BIOL, V8, P235, DOI [10.1038/NCHEMBIO.779, 10.1038/nchembio.779]; Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126; Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515	43	32	33	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2518	2528		10.1038/onc.2015.319	http://dx.doi.org/10.1038/onc.2015.319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26364596	hybrid, Green Published			2022-12-28	WOS:000376165500010
J	Puhr, M; Hoefer, J; Eigentler, A; Dietrich, D; van Leenders, G; Uhl, B; Hoogland, M; Handle, F; Schlick, B; Neuwirt, H; Sailer, V; Kristiansen, G; Klocker, H; Culig, Z				Puhr, M.; Hoefer, J.; Eigentler, A.; Dietrich, D.; van Leenders, G.; Uhl, B.; Hoogland, M.; Handle, F.; Schlick, B.; Neuwirt, H.; Sailer, V.; Kristiansen, G.; Klocker, H.; Culig, Z.			PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer	ONCOGENE			English	Article							ANDROGEN RECEPTOR; SPLICE VARIANTS; SUMOYLATION; DOCETAXEL; ENZALUTAMIDE; ABIRATERONE; RESISTANCE; PATHWAY; PROLIFERATION; MITOXANTRONE	Novel drugs like Abiraterone or Enzalutamide, which target androgen receptor (AR) signaling to improve androgen deprivation therapy (ADT), have been developed during the past years. However, the application of these drugs is limited because of occurrence of inherent or acquired therapy resistances during the treatment. Thus, identification of new molecular targets is urgently required to improve current therapeutic prostate cancer (PCa) treatment strategies. PIAS1 (protein inhibitor of activated STAT1 (signal transducer and activator of transcription-1)) is known to be an important cell cycle regulator and PIAS1-mediated SUMOylation is essential for DNA repair. In this context, elevated PIAS1 expression has already been associated with cancer initiation. Thus, in the present study, we addressed the question of whether PIAS1 targeting can be used as a basis for an improved PCa therapy in combination with anti-androgens. We show that PIAS1 significantly correlates with AR expression in PCa tissue and in cell lines and demonstrate that high PIAS1 levels predict shorter relapse-free survival. Our patient data are complemented by mechanistic and functional in vitro experiments that identify PIAS1 as an androgen-responsive gene and a crucial factor for AR signaling via prevention of AR degradation. Furthermore, PIAS1 knockdown is sufficient to decrease cell proliferation as well as cell viability. Strikingly, Abiraterone or Enzalutamide treatment in combination with PIAS1 depletion is even more effective than singledrug treatment in multiple PCa cell models, rendering PIAS1 as a promising target protein for a combined treatment approach to improve future PCa therapies.	[Puhr, M.; Hoefer, J.; Eigentler, A.; Handle, F.; Schlick, B.; Klocker, H.; Culig, Z.] Med Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria; [Dietrich, D.; Uhl, B.; Sailer, V.; Kristiansen, G.] Univ Hosp Bonn, Inst Pathol, Bonn, Germany; [van Leenders, G.; Hoogland, M.] Erasmus MC, Inst Pathol, Rotterdam, Netherlands; [Neuwirt, H.] Med Univ Innsbruck, Dept Internal Med Nephrol & Hypertens 4, A-6020 Innsbruck, Austria	Medical University of Innsbruck; University of Bonn; Erasmus University Rotterdam; Erasmus MC; Medical University of Innsbruck	Puhr, M (corresponding author), Med Univ Innsbruck, Dept Urol, Expt Urol, Anichstr 35, A-6020 Innsbruck, Austria.	martin.puhr@i-med.ac.at	Handle, Florian/S-5447-2019; Neuwirt, Hannes/AAF-1090-2019; Klocker, Helmut/AAI-7130-2020	Handle, Florian/0000-0002-7558-5635; Neuwirt, Hannes/0000-0003-1064-0098; Hoefer, Julia/0000-0003-1138-3134	Austrian Cancer Society/Tirol; intramural funding program of the Medical University of Innsbruck for young scientists MUI-START [2010012007]; Austrian Science Fund (FWF) [P 25639-B19, W1101-B18]; Anniversary Fund Austrian National Bank (ONB) Grant [15374]; Austrian Science Fund (FWF) [P 25639] Funding Source: researchfish	Austrian Cancer Society/Tirol; intramural funding program of the Medical University of Innsbruck for young scientists MUI-START; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Anniversary Fund Austrian National Bank (ONB) Grant; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Irma Sottsas for TMA preparation, paraffin embedding and immunohistochemistry (IHC) stainings, Mag Eberhard Steiner for patient selection and statistical analysis, Dr Walter Parson for cell line authentication and Dr Yaron Galanty (University of Cambridge) for generously sharing PIAS1 constructs. This work was supported by the Austrian Cancer Society/Tirol, the intramural funding program of the Medical University of Innsbruck for young scientists MUI-START, Project 2010012007, Austrian Science Fund (FWF) Grants P 25639-B19 (to MP) and W1101-B18 (to ZC) and Anniversary Fund Austrian National Bank (ONB) Grant 15374 (to ZC).	Bu H, 2013, FEBS J, V280, P1249, DOI 10.1111/febs.12118; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Driscoll JJ, 2010, BLOOD, V115, P2827, DOI 10.1182/blood-2009-03-211045; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Geney R, 2002, CLIN CHEM LAB MED, V40, P918, DOI 10.1515/CCLM.2002.161; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Heemers HV, 2009, MOL ENDOCRINOL, V23, P572, DOI 10.1210/me.2008-0363; Heidegger I, 2014, ANTICANCER RES, V34, P307; Hobisch A, 2006, PROSTATE, V66, P413, DOI 10.1002/pros.20365; Hobisch A, 2001, CLIN CANCER RES, V7, P2941; Hoefer J, 2012, AM J PATHOL, V180, P2097, DOI 10.1016/j.ajpath.2012.01.026; Hoogland AM, 2012, MODERN PATHOL, V25, P471, DOI 10.1038/modpathol.2011.176; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089464; Mikolcevic P, 2012, MOL CELL BIOL, V32, P868, DOI 10.1128/MCB.06261-11; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nadal R, 2014, PROSTATE, V74, P1560, DOI 10.1002/pros.22874; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Puhr M, 2014, ONCOTARGET, V5, P12043, DOI 10.18632/oncotarget.2658; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Puhr M, 2009, CANCER RES, V69, P7375, DOI 10.1158/0008-5472.CAN-09-0806; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Rytinki M, 2012, MOL CELL BIOL, V32, P4195, DOI 10.1128/MCB.00753-12; Rytinki MM, 2009, CELL MOL LIFE SCI, V66, P3029, DOI 10.1007/s00018-009-0061-z; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Sharrocks AD, 2006, GENE DEV, V20, P754, DOI 10.1101/gad.1421006; Shima H, 2013, J CELL SCI, V126, P5284, DOI 10.1242/jcs.133744; Sutinen P, 2014, NUCLEIC ACIDS RES, V42, P8310, DOI 10.1093/nar/gku543; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Toropainen S, 2015, NUCLEIC ACIDS RES, V43, P848, DOI 10.1093/nar/gku1375; van der Steen T, 2013, INT J MOL SCI, V14, P14833, DOI 10.3390/ijms140714833; van Soest RJ, 2013, EUR J CANCER, V49, P3821, DOI 10.1016/j.ejca.2013.09.026	39	29	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2322	2332		10.1038/onc.2015.292	http://dx.doi.org/10.1038/onc.2015.292			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26257066	Green Published, hybrid			2022-12-28	WOS:000376165000005
J	Lee, S; Axelsen, TV; Andersen, AP; Vahl, P; Pedersen, SF; Boedtkjer, E				Lee, S.; Axelsen, T. V.; Andersen, A. P.; Vahl, P.; Pedersen, S. F.; Boedtkjer, E.			Disrupting Na+, HCO3--cotransporter NBCn1 (Slc4a7) delays murine breast cancer development	ONCOGENE			English	Article							INTRACELLULAR PH; SUSCEPTIBILITY LOCI; COTRANSPORTER NBCN1; NHE1; METABOLISM; EXCHANGER; SKELETAL; CELLS; PROLIFERATION; GLYCOLYSIS	Increased metabolism and insufficient blood supply cause acidic waste product accumulation in solid cancers. During carcinogenesis, cellular acid extrusion is upregulated but the underlying molecular mechanisms and their consequences for cancer growth and progression have not been established. Genome-wide association studies have indicated a possible link between the Na+, HCO3--cotransporter NBCn1 (SLC4A7) and breast cancer. We tested the functional consequences of NBCn1 knockout (KO) for breast cancer development. NBCn1 protein expression increased 2.5-fold during breast carcinogenesis and was responsible for the increased net acid extrusion and alkaline intracellular pH of breast cancer compared with normal breast tissue. Genetic disruption of NBCn1 delayed breast cancer development: tumor latency was similar to 50% increased while tumor growth rate was similar to 65% reduced in NBCn1 KO compared with wild-type (WT) mice. Breast cancer histopathology in NBCn1 KO mice differed from that in WT mice and included less aggressive tumor types. The extracellular tumor microenvironment in NBCn1 KO mice contained higher concentrations of glucose and lower concentrations of lactate than that in WT mice. Independently of NBCn1 genotype, the cleaved fraction of poly(ADP-ribose) polymerase (PARP)-1 and expression of monocarboxylate transporter (MCT) 1 increased while phosphorylation of Akt and ERK1 decreased as functions of tumor volume. Cell proliferation, evaluated from Ki-67 and phosphohistone H-3 staining, was similar to 60% lower in breast cancer of NBCn1 KO than that of WT mice when corrected for variations in tumor size. We conclude that NBCn1 facilitates acid extrusion from breast cancer tissue, maintains the alkaline intracellular environment and promotes aggressive cancer development and growth.	[Lee, S.; Axelsen, T. V.; Boedtkjer, E.] Aarhus Univ, Dept Biomed, Ole Worms Alle 3,Bldg 1170, DK-8000 Aarhus C, Denmark; [Andersen, A. P.; Pedersen, S. F.] Univ Copenhagen, Dept Biol, Copenhagen, Denmark; [Vahl, P.] Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus, Denmark	Aarhus University; University of Copenhagen; Aarhus University	Boedtkjer, E (corresponding author), Aarhus Univ, Dept Biomed, Ole Worms Alle 3,Bldg 1170, DK-8000 Aarhus C, Denmark.	eb@biomed.au.dk	Pedersen, Stine Falsig/O-1133-2019; Boedtkjer, Ebbe/O-8449-2019; Boedtkjer, Ebbe/B-7315-2008	Pedersen, Stine Falsig/0000-0002-3044-7714; Boedtkjer, Ebbe/0000-0002-5078-9279; Boedtkjer, Ebbe/0000-0002-5078-9279; Andersen, Anne Poder/0000-0002-6693-1524	Danish Council for Independent Research [10-094816, 12-127290]; Novo Nordisk Foundation [2131, 7393]; Danish Cancer Society [R72-A4273-13-S2]; MEMBRANES at Aarhus University; Novo Nordisk Fonden [NNF13OC0007393] Funding Source: researchfish; The Danish Cancer Society [R72-A4273] Funding Source: researchfish	Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Cancer Society(Danish Cancer Society); MEMBRANES at Aarhus University; Novo Nordisk Fonden(Novo Nordisk Foundation); The Danish Cancer Society(Danish Cancer Society)	Financial support was provided from the Danish Council for Independent Research (10-094816 to EB and 12-127290 to SFP), Novo Nordisk Foundation (2131 and 7393 to EB), Danish Cancer Society (R72-A4273-13-S2 to EB) and MEMBRANES at Aarhus University. We thank Dr. Christian Aalkjaer (Aarhus University) for valuable discussions, Drs Frauke Alves and Roser Ufartes (Max Planck Institute for Experimental Medicine) for advice on chemical breast cancer induction and Dr Vibeke Dam, Jane Ronn and Ida Tvilling for expert technical assistance.	Aalkjaer C, 2014, COMPR PHYSIOL, V4, P1605, DOI 10.1002/cphy.c130005; Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354; Andersen AP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0098; Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549; Boedtkjer E, 2006, CIRC RES, V98, P515, DOI 10.1161/01.RES.0000204750.04971.76; Boedtkjer E, 2012, CURR PHARM DESIGN, V18, P1345, DOI 10.2174/138161212799504830; Boedtkjer E, 2013, INT J CANCER, V132, P1288, DOI 10.1002/ijc.27782; Boedtkjer E, 2011, CIRCULATION, V124, P1819, DOI 10.1161/CIRCULATIONAHA.110.015974; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Brunner A, 2012, BRIT J CANCER, V107, P84, DOI 10.1038/bjc.2012.198; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chen W, 2012, BREAST CANCER RES TR, V136, P847, DOI 10.1007/s10549-012-2309-9; Chiche J, 2012, INT J CANCER, V130, P1511, DOI 10.1002/ijc.26125; Currier N, 2005, TOXICOL PATHOL, V33, P726, DOI 10.1080/01926230500352226; Damkier HH, 2006, AM J PHYSIOL-HEART C, V290, pH172, DOI 10.1152/ajpheart.00713.2005; De Milito A, 2012, CURR PHARM DESIGN, V18, P1395, DOI 10.2174/138161212799504911; Eigenbrodt E, 1998, ANTICANCER RES, V18, P3267; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FIDELMAN ML, 1982, AM J PHYSIOL, V242, pC87, DOI 10.1152/ajpcell.1982.242.1.C87; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Gorbatenko A, 2014, FASEB J, V28, P350, DOI 10.1096/fj.13-233288; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Han W, 2011, CANCER EPIDEM BIOMAR, V20, P793, DOI 10.1158/1055-9965.EPI-10-1282; Hulikova A, 2013, J CELL PHYSIOL, V228, P743, DOI 10.1002/jcp.24221; Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8; Jenkins CM, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.203661; Landis MD, 2006, ONCOGENE, V25, P3325, DOI 10.1038/sj.onc.1209365; Lauritzen G, 2010, EXP CELL RES, V316, P2538, DOI 10.1016/j.yexcr.2010.06.005; Lauritzen G, 2012, CANCER LETT, V317, P172, DOI 10.1016/j.canlet.2011.11.023; Lee S, 2015, PFLUG ARCH EUR J PHY, V467, P367, DOI 10.1007/s00424-014-1524-0; Long JR, 2010, CANCER EPIDEM BIOMAR, V19, P2357, DOI 10.1158/1055-9965.EPI-10-0054; Loo SY, 2012, CURR PHARM DESIGN, V18, P1372; Mortensen B, 2013, AM J PHYSIOL-ENDOC M, V304, pE1379, DOI 10.1152/ajpendo.00295.2012; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Pedersen SF, 2007, CELL PHYSIOL BIOCHEM, V20, P735, DOI 10.1159/000110434; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Robertson N, 2004, CANCER RES, V64, P6160, DOI 10.1158/0008-5472.CAN-03-2224; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Silva AS, 2009, CANCER RES, V69, P2677, DOI 10.1158/0008-5472.CAN-08-2394; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Sueta A, 2012, BREAST CANCER RES TR, V132, P711, DOI 10.1007/s10549-011-1904-5; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; VAUPEL P, 1989, CANCER RES, V49, P6449; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003	50	52	53	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2112	2122		10.1038/onc.2015.273	http://dx.doi.org/10.1038/onc.2015.273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26212013				2022-12-28	WOS:000374505600010
J	Marchesini, M; Matocci, R; Tasselli, L; Cambiaghi, V; Orleth, A; Furia, L; Marinelli, C; Lombardi, S; Sammarelli, G; Aversa, F; Minucci, S; Faretta, M; Pelicci, PG; Grignani, F				Marchesini, M.; Matocci, R.; Tasselli, L.; Cambiaghi, V.; Orleth, A.; Furia, L.; Marinelli, C.; Lombardi, S.; Sammarelli, G.; Aversa, F.; Minucci, S.; Faretta, M.; Pelicci, P. G.; Grignani, F.			PML is required for telomere stability in non-neoplastic human cells	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN HEMATOPOIETIC PROGENITORS; QUADRUPLEX LIGAND RHPS4; DNA-DAMAGE; RAR-ALPHA; T(15-17) TRANSLOCATION; COMPUTATIONAL PLATFORM; HISTONE DEACETYLASE; HUMAN FIBROBLASTS; NUCLEAR-BODIES	Telomeres interact with numerous proteins, including components of the shelterin complex, whose alteration, similarly to proliferation-induced telomere shortening, initiates cellular senescence. In tumors, telomere length is maintained by Telomerase activity or by the Alternative Lengthening of Telomeres mechanism, whose hallmark is the telomeric localization of the promyelocytic leukemia (PML) protein. Whether PML contributes to telomeres maintenance in normal cells is unknown. We show that in normal human fibroblasts the PML protein associates with few telomeres, preferentially when they are damaged. Proliferation-induced telomere attrition or their damage due to alteration of the shelterin complex enhances the telomeric localization of PML, which is increased in human T-lymphocytes derived from patients genetically deficient in telomerase. In normal fibroblasts, PML depletion induces telomere damage, nuclear and chromosomal abnormalities, and senescence. Expression of the leukemia protein PML/RAR alpha in hematopoietic progenitors displaces PML from telomeres and induces telomere shortening in the bone marrow of pre-leukemic mice. Our work provides a novel view of the physiologic function of PML, which participates in telomeres surveillance in normal cells. Our data further imply that a diminished PML function may contribute to cell senescence, genomic instability, and tumorigenesis.	[Marchesini, M.; Matocci, R.; Tasselli, L.; Marinelli, C.; Grignani, F.] Univ Perugia, Dept Expt Med, Gen Pathol Sect, I-06100 Perugia, Italy; [Marchesini, M.; Tasselli, L.; Cambiaghi, V.; Orleth, A.; Furia, L.; Marinelli, C.; Lombardi, S.; Minucci, S.; Faretta, M.; Pelicci, P. G.] European Inst Oncol, Dept Expt Oncol, Via Giuseppe Ripamonti 435, I-20141 Milan, Italy; [Sammarelli, G.; Aversa, F.] Univ Parma, Dept Clin & Expt Med, Hematol & Bone Marrow Transplantat Unit, I-43100 Parma, Italy; [Minucci, S.] Univ Milan, Dept Biosci, Milan, Italy; [Pelicci, P. G.] Univ Milan, Dipartimento Med Chirurgia & Odontoiatria, Milan, Italy; [Marchesini, M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA; [Tasselli, L.] Stanford Univ, Sch Med, Dept Med, Div Endocrinol Gerontol & Metab, Stanford, CA 94305 USA; [Tasselli, L.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA	University of Perugia; IRCCS European Institute of Oncology (IEO); University of Parma; University Hospital of Parma; University of Milan; University of Milan; University of Texas System; UTMD Anderson Cancer Center; Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Giuseppe Ripamonti 435, I-20141 Milan, Italy.; Grignani, F (corresponding author), Dept Expt Med, Gen Pathol Sect, Piazza Lucio Severi 1, I-06132 Perugia, Italy.	piergiuseppe.pelicci@ieo.eu; francesco.grignani@unipg.it	Faretta, Mario/H-8946-2012; Tasselli, Luisa/L-8979-2016; Marchesini, Matteo/AAC-4629-2022; Tasselli, Luisa/AAM-6781-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022	Faretta, Mario/0000-0003-1678-5781; Tasselli, Luisa/0000-0003-3349-1371; Tasselli, Luisa/0000-0003-3349-1371; Aversa, Franco/0000-0002-8871-6817; Marchesini, Matteo/0000-0001-9489-7899	AIRC IG grant; Fondazione Cassa di Risparmio di Perugia	AIRC IG grant(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Perugia(Fondazione Cassa Risparmio Perugia)	This work was supported by AIRC IG grant to FG, and SM, and by a grant from the Fondazione Cassa di Risparmio di Perugia to FG. We thank Lucilla Luzi and Alessandro Brozzi (European Institute of Oncology, Milan) for their help in statistical analysis and Annamaria Biroccio (Istituto Nazionale Tumori Regina Elena, Roma) for kindly providing us the RHPS4 compound. We are grateful to Simona Colla (MD Anderson Cancer Center) for encouragement and critical reading of the manuscript, to Giulio Draetta and Luigi Nezi (MD Anderson Cancer Center) for their encouragement and support. This work was supported by AIRC IG grant to FG, and SM, and by a grant from the Fondazione Cassa di Risparmio di Perugia to FG.	Akbar AN, 2007, J IMMUNOL, V178, P6689, DOI 10.4049/jimmunol.178.11.6689; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Armanios M, 2013, J CLIN INVEST, V123, P996, DOI 10.1172/JCI66370; Armanios M, 2012, NAT REV GENET, V13, P693, DOI 10.1038/nrg3246; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Berardinelli F, 2010, RADIAT RES, V174, P539, DOI 10.1667/RR2127.1; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Chang FTM, 2013, NUCLEIC ACIDS RES, V41, P4447, DOI 10.1093/nar/gkt114; D'Alcontres MS, 2007, J CELL BIOL, V179, P855, DOI 10.1083/jcb.200703020; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; de The H, 2012, J CELL BIOL, V198, P11, DOI 10.1083/jcb.201112044; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6; Flores I, 2006, CURR OPIN CELL BIOL, V18, P254, DOI 10.1016/j.ceb.2006.03.003; Furia L, 2013, CYTOM PART A, V83A, P333, DOI 10.1002/cyto.a.22266; Furia L, 2013, CYTOM PART A, V83A, P344, DOI 10.1002/cyto.a.22265; Ghaffari SH, 2008, ANN ONCOL, V19, P1927, DOI 10.1093/annonc/mdn394; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gunes C, 2013, CELL, V152, P390, DOI 10.1016/j.cell.2013.01.010; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiorns LR, 1997, BRIT J HAEMATOL, V96, P314, DOI 10.1046/j.1365-2141.1997.d01-2037.x; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Leonetti C, 2004, MOL PHARMACOL, V66, P1138, DOI 10.1124/mol.104.001537; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mazza M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00174; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; Nandakumar J, 2013, NAT REV MOL CELL BIO, V14, P71, DOI 10.1038/nrm3505; Newgard CB, 2013, J CLIN INVEST, V123, P946, DOI 10.1172/JCI68833; O'Sullivan RJ, 2014, NAT STRUCT MOL BIOL, V21, P167, DOI 10.1038/nsmb.2754; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pantic M, 2000, MED ONCOL, V17, P307, DOI 10.1007/BF02782196; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Racanicchi S, 2005, EMBO J, V24, P1232, DOI 10.1038/sj.emboj.7600593; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salvati E, 2007, J CLIN INVEST, V117, P3236, DOI 10.1172/JCI32461; Slatter T, 2010, AM J PATHOL, V177, P2694, DOI 10.2353/ajpath.2010.100468; Slatter TL, 2012, J PATHOL, V226, P509, DOI 10.1002/path.2981; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Vian L, 2014, CELL DEATH DIFFER, V21, P290, DOI 10.1038/cdd.2013.145; Yeager TR, 1999, CANCER RES, V59, P4175	62	19	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1811	1821		10.1038/onc.2015.246	http://dx.doi.org/10.1038/onc.2015.246			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119943	Green Published, hybrid			2022-12-28	WOS:000373610400007
J	Ordonez-Navadijo, A; Fuertes-Yebra, E; Acosta-Iborra, B; Balsa, E; Elorza, A; Aragones, J; Landazuri, MO				Ordonez-Navadijo, A.; Fuertes-Yebra, E.; Acosta-Iborra, B.; Balsa, E.; Elorza, A.; Aragones, J.; Landazuri, M. O.			Mutant versions of von Hippel-Lindau (VHL) can protect HIF1 alpha from SART1-mediated degradation in clear-cell renal cell carcinoma	ONCOGENE			English	Article							HIF-ALPHA; HYPOXIA; HIF-1-ALPHA; EXPRESSION; FACTOR-1-ALPHA; DESTRUCTION; MUTATIONS; PATTERNS; BINDING	Inactivation of the von Hippel-Lindau (VHL) tumor suppressor drives the development of clear-cell renal cell carcinoma (ccRCC) through hypoxia-inducible factors (HIFs). Although ccRCC cells exhibit constitutive normoxic HIF signaling, the potential role of hypoxia in this setting is not fully understood. We show here that the ccRCC cell lines RCC4 and RCC10, which express mutant versions of VHL, have reduced HIF1 alpha expression in hypoxia, whereas HIF2 alpha expression is increased or not affected. Similar findings were observed in normoxia after abrogation of prolyl hydroxylase activity by siRNA or pharmacological inhibition, and by siRNA inhibition of mutant VHL. This reduction of HIF1 alpha protein is due to proteasome-dependent degradation and is mediated by the E3 ubiquitin ligase SART1. HIF1 alpha degradation favors ccRCC proliferation, in line with the previously recognized tumor suppressor capability of HIF1 alpha. Our data indicate that mutant VHL can protect HIF1 alpha from SART1-dependent degradation in normoxic conditions, but this protection is lost in hypoxic settings, favoring hypoxia-dependent ccRCC proliferation. This mechanism of HIF1 alpha degradation might operate in some VHL-related clear-cell renal carcinomas in which the deletion of HIF1 alpha locus does not occur.	[Ordonez-Navadijo, A.; Fuertes-Yebra, E.; Acosta-Iborra, B.; Balsa, E.; Elorza, A.; Aragones, J.; Landazuri, M. O.] Univ Autonoma Madrid, Hosp Univ Princesa, Hosp Univ Santa Cristina, Inst Invest Sanitaria,Unidad Invest, C Maestro Amadeo Vives 2-3,Edificio B,5a Plant, Madrid 28009, Spain; [Landazuri, M. O.] Univ Cent Ecuador, Quito, Ecuador	Autonomous University of Madrid; Universidad Central del Ecuador	Landazuri, MO (corresponding author), Univ Autonoma Madrid, Hosp Univ Princesa, Hosp Univ Santa Cristina, Inst Invest Sanitaria,Unidad Invest, C Maestro Amadeo Vives 2-3,Edificio B,5a Plant, Madrid 28009, Spain.	manuel.ortiz@salud.madrid.org	Elorza, Ainara/I-1642-2015; Acosta-Iborra, M Bárbara/L-5570-2013	Acosta-Iborra, M Bárbara/0000-0002-1517-114X	MINECO [SAF 2010-14851, SAF 2013-48130]; Recava Network [RD12/0042/0065]; Metoxia Project-Health [F2 2009-222741]; Consepoc [S2014/BMD-2542 consepoc-CM]; MICINN [SAF 2011-29716]; Programa Prometeo Government of Ecuador	MINECO(Spanish Government); Recava Network(Instituto de Salud Carlos III); Metoxia Project-Health; Consepoc; MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Programa Prometeo Government of Ecuador	This work was supported by MINECO (SAF 2010-14851), MINECO (SAF 2013-48130), Recava Network (RD12/0042/0065), Programa Prometeo Government of Ecuador and Metoxia Project-Health (F2 2009-222741) to MOL; Consepoc (S2014/BMD-2542 consepoc-CM) and MICINN (SAF 2011-29716) to JA. We thank M. Ohh (Laboratory Medicine & Pathobiology University of Toronto) for providing the RCC10 cell line.	Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; De Bock K, 2011, CURR OPIN GENET DEV, V21, P73, DOI 10.1016/j.gde.2010.10.008; Elorza A, 2012, MOL CELL, V48, P681, DOI 10.1016/j.molcel.2012.09.017; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lawrentschuk N, 2011, UROL ONCOL-SEMIN ORI, V29, P411, DOI 10.1016/j.urolonc.2009.03.028; Lidgren A, 2005, CLIN CANCER RES, V11, P1129; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Miller F, 2005, J BIOL CHEM, V280, P7985, DOI 10.1074/jbc.M413160200; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	31	7	9	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					587	594		10.1038/onc.2015.113	http://dx.doi.org/10.1038/onc.2015.113			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915846				2022-12-28	WOS:000369548800006
J	Urtasun, R; Elizalde, M; Azkona, M; Latasa, MU; Garcia-Irigoyen, O; Uriarte, I; Fernandez-Barrena, MG; Vicent, S; Alonso, MM; Muntane, J; Prieto, J; Avila, MA; Berasain, C				Urtasun, R.; Elizalde, M.; Azkona, M.; Latasa, M. U.; Garcia-Irigoyen, O.; Uriarte, I.; Fernandez-Barrena, M. G.; Vicent, S.; Alonso, M. M.; Muntane, J.; Prieto, J.; Avila, M. A.; Berasain, C.			Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression	ONCOGENE			English	Article							MICRORNA CLUSTER; CYCLE ARREST; AUTOPHAGY; MYC; APOPTOSIS; GROWTH; ROLES; AMPHIREGULIN; INHIBITION; METABOLISM	Resisting death is a central hallmark of cancer cells. Tumors rely on a number of genetic mechanisms to avoid apoptosis, and alterations in mRNA alternative splicing are increasingly recognized to have a role in tumorigenesis. In this study, we identify the splicing regulator SLU7 as an essential factor for the preservation of hepatocellular carcinoma (HCC) cells viability. Compared with hepatocytes, SLU7 expression is reduced in HCC cells; however, further SLU7 depletion triggered autophagy-related cellular apoptosis in association with the overproduction of reactive oxygen species. Remarkably, these responses were not observed in primary human hepatocytes or in the well-differentiated HepaRG cell line. Mechanistically, we demonstrate that SLU7 binds the C13orf25 primary transcript in which the polycistronic oncomir miR-17-92 cluster is encompassed, and is necessary for its processing and expression. SLU7 knockdown altered the splicing of the C13orf25 primary transcript, and markedly reduced the expression of its miR-17, miR-20 and miR-92a constituents. This led to the upregulation of CDKN1A (P21) and BCL2L11 (BIM) expression, two bona fide targets of the miR-17-92 cluster and recognized mediators of its pro-survival and tumorigenic activity. Interestingly, altered splicing of miR-17-92 and downregulation of miR-17 and miR-20 were not observed upon SLU7 knockdown in non-transformed hepatocytes, but was found in other (HeLa, H358) but not in all (Caco2) non-hepatic tumor cells. The functional relevance of miR-17-92 dysregulation upon SLU7 knockdown was established when oxidative stress, autophagy and apoptosis were reversed by co-transfection of HCC cells with a miR-17 mimic. Together, these findings indicate that SLU7 is co-opted by HCC cells and other tumor cell types to maintain survival, and identify this splicing regulator as a new determinant for the expression of the oncogenic miR-17-92 cluster. This novel mechanism may be exploited for the development of antitumoral strategies in cancers displaying such SLU7-miR-17-92 crosstalk.	[Urtasun, R.; Elizalde, M.; Azkona, M.; Latasa, M. U.; Garcia-Irigoyen, O.; Fernandez-Barrena, M. G.; Prieto, J.; Avila, M. A.; Berasain, C.] Univ Navarra, CIMA, Div Hepatol, Avda Pio 12,N55, Pamplona 31008, Spain; [Urtasun, R.; Latasa, M. U.; Fernandez-Barrena, M. G.; Vicent, S.; Alonso, M. M.; Avila, M. A.; Berasain, C.] Navarra Inst Hlth Res, IDISNA, Pamplona, Spain; [Uriarte, I.; Muntane, J.; Prieto, J.; Avila, M. A.; Berasain, C.] Inst Salud Carlos III, CIBERehd, Madrid, Spain; [Vicent, S.; Alonso, M. M.] Univ Navarra, CIMA, Div Oncol, Pamplona, Spain; [Alonso, M. M.] Univ Navarra Clin, Div Oncol, Pamplona, Spain; [Muntane, J.] Univ Seville, Dept Gen Surg, Virgen del Rocio Virgen Macarena Univ Hosp, IBiS,CSIC, Seville, Spain	University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Instituto de Salud Carlos III; University of Navarra; University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS)	Avila, MA; Berasain, C (corresponding author), Univ Navarra, CIMA, Div Hepatol, Avda Pio 12,N55, Pamplona 31008, Spain.	maavila@unav.es; cberasain@unav.es	Sharma, Ashwani/AAK-3879-2020; Garcia-Irigoyen, Oihane/HDM-3461-2022; Uriarte, Iker/AFP-1513-2022; Avila, Matias A/Y-6342-2019; Vicent, Silvestre/K-4261-2017; Uriarte, Iker/AFP-1514-2022; Berasain, Carmen/E-4139-2016; Azkona, Maria/Z-2273-2019; Fernandez-Barrena, Maite G/J-8040-2014; URIARTE, IKER/Z-2161-2019; URTASUN, RAQUEL/AAD-1590-2021; M., Elizalde/Z-2691-2019; Alonso, Marta M/AAI-9457-2020; Latasa, Maria Ujue/Z-2178-2019	Sharma, Ashwani/0000-0001-9835-1973; Garcia-Irigoyen, Oihane/0000-0002-9964-3940; Avila, Matias A/0000-0001-6570-3557; Vicent, Silvestre/0000-0002-9457-6881; Berasain, Carmen/0000-0001-7075-2476; Azkona, Maria/0000-0003-4044-8427; Fernandez-Barrena, Maite G/0000-0003-0375-6236; URIARTE, IKER/0000-0001-5237-7799; M., Elizalde/0000-0002-7636-1836; Alonso, Marta M/0000-0002-7520-7351; Latasa, Maria Ujue/0000-0002-0878-1337; Prieto, Jesus/0000-0002-1091-9593; URTASUN, RAQUEL/0000-0003-2332-5361	Instituto de Salud Carlos III (ISCIII) - 'Fondo Europeo de Desarrollo Regional' (FEDER) 'Una manera de hacer Europa' [FIS PI10/02642, PI13/00359, PI10/00038, PI13/00385]; PFIS fellowship from ISCIII; FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Gobierno de Navarra; Ministerio de Educacion; Fundaciones Mario Losantos, MTorres, Eugenio Rodriguez Pascual; Agustina Damboriena Support	Instituto de Salud Carlos III (ISCIII) - 'Fondo Europeo de Desarrollo Regional' (FEDER) 'Una manera de hacer Europa'; PFIS fellowship from ISCIII; FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Gobierno de Navarra; Ministerio de Educacion; Fundaciones Mario Losantos, MTorres, Eugenio Rodriguez Pascual; Agustina Damboriena Support	FIMA and the 'UTE project CIMA'; RTICC-RD06 00200061; CIBERehd; Grant numbers: FIS PI10/02642, PI13/00359, PI10/00038, PI13/00385 from Instituto de Salud Carlos III (ISCIII) co-financed by 'Fondo Europeo de Desarrollo Regional' (FEDER) 'Una manera de hacer Europa'; Gobierno de Navarra; 'Torres Quevedo' and 'Ramon y Cajal' contracts from Ministerio de Educacion; PFIS fellowship from ISCIII; FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Fundaciones Mario Losantos, MTorres, Eugenio Rodriguez Pascual; Agustina Damboriena Support.	Alberstein M, 2007, RNA, V13, P1988, DOI 10.1261/rna.492907; Bellot GL, 2013, MITOCHONDRION, V13, P155, DOI 10.1016/j.mito.2012.06.007; Berasain C, 2005, J BIOL CHEM, V280, P19012, DOI 10.1074/jbc.M413344200; Berasain C, 2014, HEPAT ONCOL, V1, P241, DOI [10.2217/hep.13.17, 10.2217/HEP.13.17]; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Castillo J, 2006, CANCER RES, V66, P6129, DOI 10.1158/0008-5472.CAN-06-0404; Castillo J, 2009, GASTROENTEROLOGY, V137, P1805, DOI 10.1053/j.gastro.2009.07.065; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; Chettouh H, 2013, CANCER RES, V73, P3974, DOI 10.1158/0008-5472.CAN-12-3824; Comincini S, 2013, CANCER BIOL THER, V14, P574, DOI 10.4161/cbt.24597; Concepcion CP, 2012, CANCER J, V18, P262, DOI 10.1097/PPO.0b013e318258b60a; Czaja MJ, 2013, AUTOPHAGY, V9, P1131, DOI 10.4161/auto.25063; Das S, 2014, MOL CANCER RES, V12, P1195, DOI 10.1158/1541-7786.MCR-14-0131; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Ebi H, 2009, ONCOGENE, V28, P3371, DOI 10.1038/onc.2009.201; Elizalde M, 2014, J CLIN INVEST, V124, P2909, DOI 10.1172/JCI74382; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Ghigna C, 1998, CANCER RES, V58, P5818; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hsu TYT, 2015, NATURE, V525, P384, DOI 10.1038/nature14985; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Janas MM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002330; Ji M, 2011, AM J PATHOL, V179, P1645, DOI 10.1016/j.ajpath.2011.06.008; Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942; Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401; Koh CM, 2015, NATURE, V523, P96, DOI 10.1038/nature14351; Kurokawa K, 2014, ONCOGENE, V33, P1407, DOI 10.1038/onc.2013.86; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Olive V, 2013, IMMUNOL REV, V253, P158, DOI 10.1111/imr.12054; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Osada H, 2011, CANCER SCI, V102, P9, DOI 10.1111/j.1349-7006.2010.01707.x; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Paglin S, 2001, CANCER RES, V61, P439; Perugorria MJ, 2009, CANCER RES, V69, P1358, DOI 10.1158/0008-5472.CAN-08-2545; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pichard Lydiane, 2006, Methods Mol Biol, V320, P283; Shomron N, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/594678; Singh RK, 2012, TRENDS MOL MED, V18, P472, DOI 10.1016/j.molmed.2012.06.006; Tan WQ, 2014, WORLD J GASTROENTERO, V20, P5962, DOI 10.3748/wjg.v20.i20.5962; Thomas M, 2013, INT J MOL SCI, V14, P12273, DOI 10.3390/ijms140612273; Urtasun R, 2011, HEPATOLOGY, V54, P2149, DOI 10.1002/hep.24587; Yang H, 2015, BRIT J CANCER, V112, P112, DOI 10.1038/bjc.2014.547; Ying SY, 2006, J BIOMED SCI, V13, P5, DOI 10.1007/s11373-005-9036-8; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhu HQ, 2014, AM J PATHOL, V184, P2828, DOI 10.1016/j.ajpath.2014.06.024	56	17	18	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4719	4729		10.1038/onc.2015.517	http://dx.doi.org/10.1038/onc.2015.517			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26804174				2022-12-28	WOS:000383324700005
J	Shi, Z; Jiao, S; Zhou, Z				Shi, Z.; Jiao, S.; Zhou, Z.			STRIPAK complexes in cell signaling and cancer	ONCOGENE			English	Review							PROTEIN PHOSPHATASE 2A; 8P11 MYELOPROLIFERATIVE SYNDROME; MEMBRANE-ASSOCIATED PROTEIN; CALMODULIN-BINDING PROTEIN; ORGAN SIZE CONTROL; STRIATIN-INTERACTING PHOSPHATASE; SARCOLEMMAL-ASSOCIATED PROTEINS; STE20-LIKE KINASE MST3; MALFORMATION 3 CCM3; TUMOR-SUPPRESSOR	Striatin-interacting phosphatase and kinase (STRIPAK) complexes are striatin-centered multicomponent supramolecular structures containing both kinases and phosphatases. STRIPAK complexes are evolutionarily conserved and have critical roles in protein (de) phosphorylation. Recent studies indicate that STRIPAK complexes are emerging mediators and regulators of multiple vital signaling pathways including Hippo, MAPK (mitogen-activated protein kinase), nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are extensively involved in a variety of fundamental biological processes ranging from cell growth, differentiation, proliferation and apoptosis to metabolism, immune regulation and tumorigenesis. Growing evidence correlates dysregulation of STRIPAK complexes with human diseases including cancer. In this review, we summarize the current understanding of the assembly and functions of STRIPAK complexes, with a special focus on cell signaling and cancer.	[Shi, Z.; Jiao, S.; Zhou, Z.] Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,State Key Lab Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China; [Shi, Z.] Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China; [Zhou, Z.] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Tongji University; ShanghaiTech University	Zhou, Z (corresponding author), Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,State Key Lab Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zczhou@sibcb.ac.cn	Shi, Zhubing/F-9490-2010	Shi, Zhubing/0000-0002-9624-4960	973 Program of the Ministry of Science and Technology of China [2012CB910204]; National Natural Science Foundation of China [31270808, 31300734, 31470736, 31470868, 91442125, 91542125]; Science and Technology Commission of Shanghai Municipality [13ZR1446400]; 'Cross and Cooperation in Science and Technology Innovation Team' project of the Chinese Academy of Sciences; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences [2014KIP202]	973 Program of the Ministry of Science and Technology of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); 'Cross and Cooperation in Science and Technology Innovation Team' project of the Chinese Academy of Sciences; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences(Knowledge Innovation Program of the Chinese Academy of SciencesChinese Academy of Sciences)	This work was supported by the 973 Program of the Ministry of Science and Technology of China (2012CB910204), the National Natural Science Foundation of China (31270808, 31300734, 31470736, 31470868, 91442125, 91542125), the Science and Technology Commission of Shanghai Municipality (13ZR1446400) and the 'Cross and Cooperation in Science and Technology Innovation Team' project of the Chinese Academy of Sciences, and the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (2014KIP202).	AL Zeyadi M, 2015, BIOTECHNOL BIOTEC EQ, V29, P111, DOI 10.1080/13102818.2014.989179; Andreazza S, 2015, CELL REP, V11, P1266, DOI 10.1016/j.celrep.2015.04.033; Ashton-Beaucage D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001809; Bai SW, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-54; Baillat G, 2002, J BIOL CHEM, V277, P18961, DOI 10.1074/jbc.M108818200; Baillat G, 2001, MOL BIOL CELL, V12, P663, DOI 10.1091/mbc.12.3.663; Bailly YJR, 2007, CEREBELLUM, V6, P344, DOI [10.1080/14734220701225912, 10.1080/147342207012259120]; Bartoli M, 1999, J NEUROBIOL, V40, P234, DOI 10.1002/(SICI)1097-4695(199908)40:2<234::AID-NEU9>3.3.CO;2-K; Bartoli M, 1998, J BIOL CHEM, V273, P22248, DOI 10.1074/jbc.273.35.22248; Beck AH, 2010, ONCOGENE, V29, P845, DOI 10.1038/onc.2009.381; Bergametti F, 2005, AM J HUM GENET, V76, P42, DOI 10.1086/426952; Blanchoin L, 2014, PHYSIOL REV, V94, P235, DOI 10.1152/physrev.00018.2013; Boada-Romero E, 2013, EMBO J, V32, P566, DOI 10.1038/emboj.2013.8; Breitman M, 2008, BBA-MOL CELL RES, V1783, P1792, DOI 10.1016/j.bbamcr.2008.04.017; Byers JT, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-48; Castets F, 2000, J BIOL CHEM, V275, P19970, DOI 10.1074/jbc.M909782199; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; Ceccarelli DF, 2011, J BIOL CHEM, V286, P25056, DOI 10.1074/jbc.M110.213777; Cha JD, 2011, ORAL SURG ORAL MED O, V111, P594, DOI 10.1016/j.tripleo.2010.11.020; Chen CB, 2009, BIOSCIENCE REP, V29, P405, DOI 10.1042/BSR20090096; Chen CC, 2014, J BIOL CHEM, V289, P9651, DOI 10.1074/jbc.M113.529297; Chen HW, 2002, MOL CELL BIOL, V22, P1792, DOI 10.1128/MCB.22.6.1792-1803.2002; Chen YK, 2012, MOL BIOL CELL, V23, P4383, DOI 10.1091/mbc.E12-05-0365; Chen YK, 2012, J NEUROSCI, V32, P1043, DOI 10.1523/JNEUROSCI.4405-11.2012; Cheung J, 2001, GENOMICS, V78, P7, DOI 10.1006/geno.2001.6651; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Cooper WN, 2009, ONCOGENE, V28, P2988, DOI 10.1038/onc.2009.152; Cornils H, 2011, MOL CELL BIOL, V31, P1382, DOI 10.1128/MCB.01216-10; Coutinho P, 2014, ENDOCRINOLOGY, V155, P2233, DOI 10.1210/en.2013-1834; Couzens AL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004712; Crawley SW, 2014, J CELL BIOL, V207, P441, DOI 10.1083/jcb.201407015; Dadgostar H, 2003, FEBS LETT, V553, P403, DOI 10.1016/S0014-5793(03)01072-X; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Fidalgo M, 2012, J BIOL CHEM, V287, P11556, DOI 10.1074/jbc.M111.320259; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Frost A, 2012, CELL, V149, P1339, DOI 10.1016/j.cell.2012.04.028; Gaillard S, 2001, FEBS LETT, V508, P49, DOI 10.1016/S0014-5793(01)03020-4; Glatter T, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.75; Gloerich M, 2012, NAT CELL BIOL, V14, P793, DOI 10.1038/ncb2537; Gordon J, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-54; Goudreault M, 2009, MOL CELL PROTEOMICS, V8, P157, DOI 10.1074/mcp.M800266-MCP200; Grand EK, 2004, GENE CHROMOSOME CANC, V40, P78, DOI 10.1002/gcc.20023; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Guo C, 2011, J BIOL CHEM, V286, P6253, DOI 10.1074/jbc.M110.178210; Guo T, 2013, CELL RES, V23, P1201, DOI 10.1038/cr.2013.120; Guzzo RM, 2005, AM J PHYSIOL-HEART C, V288, pH1810, DOI 10.1152/ajpheart.01015.2004; Guzzo RM, 2004, BIOCHEM J, V381, P599, DOI 10.1042/BJ20031723; Guzzo RM, 2004, J CELL SCI, V117, P2271, DOI 10.1242/jcs.01079; Haeberle AM, 2006, J COMP NEUROL, V495, P336, DOI 10.1002/cne.20895; Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005; Hao Q, 2014, J STRUCT BIOL, V186, P224, DOI 10.1016/j.jsb.2014.04.005; Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103; Hata Y, 2013, MAR DRUGS, V11, P896, DOI 10.3390/md11030896; Hauri S, 2013, MOL SYST BIOL, V9, DOI 10.1002/msb.201304750; Henderson JL, 2015, J MED CHEM, V58, P419, DOI 10.1021/jm5014055; Hergovich A, 2011, CELL SIGNAL, V23, P1433, DOI 10.1016/j.cellsig.2011.04.007; Horn T, 2011, NAT METHODS, V8, P341, DOI 10.1038/NMETH.1581; Hsieh JY, 2013, NUCLEIC ACIDS RES, V41, P9753, DOI 10.1093/nar/gkt666; Huang J, 2005, EMBO J, V24, P4018, DOI 10.1038/sj.emboj.7600863; Hwang JY, 2014, INT J BIOCHEM CELL B, V47, P118, DOI 10.1016/j.biocel.2013.11.021; Hyodo T, 2012, J BIOL CHEM, V287, P25019, DOI 10.1074/jbc.M112.372342; Ikeda M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000300; Ishikawa T, 2012, CIRC-ARRHYTHMIA ELEC, V5, P1098, DOI 10.1161/CIRCEP.111.969972; Ito M, 2010, J INNATE IMMUN, V2, P607, DOI 10.1159/000317690; Jackson CC, 2010, HUM PATHOL, V41, P461, DOI 10.1016/j.humpath.2009.11.003; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kachidian P, 1998, NEUROSCIENCE, V85, P111, DOI 10.1016/S0306-4522(97)00593-9; Kazmierczak-Baranska J, 2015, FEBS LETT, V589, P222, DOI 10.1016/j.febslet.2014.12.003; Kean MJ, 2011, J BIOL CHEM, V286, P25065, DOI 10.1074/jbc.M110.214486; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042734; Koontz LM, 2013, DEV CELL, V25, P388, DOI 10.1016/j.devcel.2013.04.021; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lant B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7449; Li XF, 2011, J BIOL CHEM, V286, P26138, DOI 10.1074/jbc.M110.211250; Lin A, 2010, AM J PATHOL, V176, P108, DOI 10.2353/ajpath.2010.090256; Lin JL, 2001, ONCOGENE, V20, P6559, DOI 10.1038/sj.onc.1204818; Lin ZH, 2014, INT J ONCOL, V45, P629, DOI 10.3892/ijo.2014.2455; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Ma X, 2007, LIFE SCI, V81, P1141, DOI 10.1016/j.lfs.2007.08.006; Ma X, 2007, MOL BIOL CELL, V18, P1965, DOI 10.1091/mbc.E06-07-0608; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; Madsen CD, 2015, NAT CELL BIOL, V17, P68, DOI 10.1038/ncb3083; Marion JD, 2013, J BIOL CHEM, V288, P18612, DOI 10.1074/jbc.M112.440859; Mills AM, 2011, AM J SURG PATHOL, V35, P583, DOI 10.1097/PAS.0b013e318211abd6; Moens SJB, 2012, CIRCULATION, V126, P1993, DOI 10.1161/CIRCULATIONAHA.112.124529; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moqrich A, 1998, GENOMICS, V51, P136, DOI 10.1006/geno.1998.5342; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Moreno CS, 2001, J BIOL CHEM, V276, P24253, DOI 10.1074/jbc.M102398200; MURO Y, 1995, BIOCHEM BIOPH RES CO, V207, P1029, DOI 10.1006/bbrc.1995.1288; Nelson S, 2013, J CELL SCI, V126, P873, DOI 10.1242/jcs.100479; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Ohoka Y, 1998, GENES CELLS, V3, P603, DOI 10.1046/j.1365-2443.1998.00216.x; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Peng S, 2015, CLIN EXP IMMUNOL, V182, P57, DOI 10.1111/cei.12658; Pojoga LH, 2012, AM J HYPERTENS, V25, P243, DOI 10.1038/ajh.2011.197; Polesello C, 2006, CURR BIOL, V16, P2459, DOI 10.1016/j.cub.2006.10.060; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Record CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011905; Ribeiro PS, 2010, MOL CELL, V39, P521, DOI 10.1016/j.molcel.2010.08.002; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Rorth P, 2009, ANNU REV CELL DEV BI, V25, P407, DOI 10.1146/annurev.cellbio.042308.113231; Sakuma C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6180; Salin P, 1998, J COMP NEUROL, V397, P41; Schmitt DC, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.116; Schulte J, 2010, J NEUROSCI, V30, P5189, DOI 10.1523/JNEUROSCI.5823-09.2010; Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shi ZB, 2015, ACTA BIOCH BIOPH SIN, V47, P29, DOI 10.1093/abbs/gmu107; Shi ZB, 2013, STRUCTURE, V21, P449, DOI 10.1016/j.str.2013.01.007; Shih PY, 2014, J CELL SCI, V127, P3521, DOI 10.1242/jcs.149476; Song H, 2010, BIOCHEM BIOPH RES CO, V391, P969, DOI 10.1016/j.bbrc.2009.11.175; Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Stirnimann CU, 2010, TRENDS BIOCHEM SCI, V35, P565, DOI 10.1016/j.tibs.2010.04.003; Sugden PH, 2013, BIOCHEM J, V454, P13, DOI 10.1042/BJ20130219; Sukotjo C, 2003, J BIOL CHEM, V278, P51527, DOI 10.1074/jbc.M309616200; Sukotjo C, 2002, J DENT RES, V81, P229, DOI 10.1177/154405910208100402; Sung V, 2003, CANCER RES, V63, P3356; Suwanwela J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016204; ten Klooster JP, 2009, DEV CELL, V16, P551, DOI 10.1016/j.devcel.2009.01.016; Trammell MA, 2008, J CELL SCI, V121, P1284, DOI 10.1242/jcs.017210; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041; Wagh V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.273; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; Wang YG, 1999, SCI CHINA SER C, V42, P323, DOI 10.1007/BF03183610; Wielowieyski PA, 2000, J BIOL CHEM, V275, P38474, DOI 10.1074/jbc.M007682200; Wigle JT, 1997, J BIOL CHEM, V272, P32384, DOI 10.1074/jbc.272.51.32384; Xiao S, 2000, BLOOD, V96, P699; Xiong WP, 2015, MOL ENDOCRINOL, V29, P460, DOI 10.1210/me.2014-1332; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang M, 2013, STRUCTURE, V21, P680, DOI 10.1016/j.str.2013.02.015; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zheng XJ, 2010, J CLIN INVEST, V120, P2795, DOI 10.1172/JCI39679; Zou Q, 2015, J EXP MED, V212, P1323, DOI 10.1084/jem.20150110	143	50	51	4	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4549	4557		10.1038/onc.2016.9	http://dx.doi.org/10.1038/onc.2016.9			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26876214				2022-12-28	WOS:000382336300001
J	Fleskens, V; Mokry, M; van der Leun, AM; Huppelschoten, S; Pals, CEM; Peeters, J; Coenen, S; Cardoso, BA; Barata, JT; van Loosdregt, J; Coffer, PJ				Fleskens, V.; Mokry, M.; van der Leun, A. M.; Huppelschoten, S.; Pals, C. E. G. M.; Peeters, J.; Coenen, S.; Cardoso, B. A.; Barata, J. T.; van Loosdregt, J.; Coffer, P. J.			FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; REGULATORY T-CELLS; GENE-EXPRESSION; TUMOR-SUPPRESSOR; TRANSGENIC MICE; PROTEIN LMO2; CANCER-CELLS; COMPLEX; DIFFERENTIATION; SCL	T-cell acute lymphoblastic leukemia (T-ALL) frequently involves aberrant expression of TAL1 (T-cell acute lymphocytic leukemia 1) and LMO2, oncogenic members of the TAL1 transcriptional complex. Transcriptional activity of the TAL1-complex is thought to have a pivotal role in the transformation of thymocytes and is associated with a differentiation block and self-renewal. The transcription factor Forkhead Box P3 (FOXP3) was recently described to be expressed in a variety of malignancies including T-ALL. Here we show that increased FOXP3 levels negatively correlate with expression of genes regulated by the oncogenic TAL1-complex in human T-ALL patient samples as well as a T-ALL cell line ectopically expressing FOXP3. In these cells, FOXP3 expression results in altered regulation of cell cycle progression and reduced cell viability. Finally, we demonstrate that FOXP3 binds LMO2 in vitro, resulting in decreased interaction between LMO2 and TAL1, providing a molecular mechanism for FOXP3-mediated transcriptional modulation in T-ALL. Collectively, our findings provide initial evidence for a novel role of FOXP3 as a tumor suppressor in T-ALL through modulation of TAL1 transcriptional activity.	[Fleskens, V.; van der Leun, A. M.; Huppelschoten, S.; Pals, C. E. G. M.; Peeters, J.; Coenen, S.; van Loosdregt, J.; Coffer, P. J.] Univ Med Ctr Utrecht, Ctr Mol Med, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [Mokry, M.; van Loosdregt, J.; Coffer, P. J.] Wilhelmina Childrens Hosp, Div Pediat, Utrecht, Netherlands; [Cardoso, B. A.; Barata, J. T.] Univ Lisbon, Fac Med, Inst Mol Med, Lisbon, Portugal	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Universidade de Lisboa	Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Ctr Mol Med, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	p.j.coffer@umcutrecht.nl	Barata, João T./D-9181-2015; Mokry, Michal/AAN-3809-2021; Coffer, Paul/AAF-7970-2020	Barata, João T./0000-0002-4826-8976; Mokry, Michal/0000-0002-5298-4852; Cardoso, Bruno/0000-0002-6521-7257; Peeters, Janneke/0000-0002-5777-4352	Dutch Arthritis Foundation (Rheumafonds); Fundacao para a Ciencia e a Tecnologia	Dutch Arthritis Foundation (Rheumafonds); Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission)	We thank S Sakaguchi and T Mutis for providing us with plasmids and T Radstake for providing us with cells. VF and JvL were supported by a grant from the Dutch Arthritis Foundation (Rheumafonds), and BAC was supported by a fellowship from Fundacao para a Ciencia e a Tecnologia. This work was supported by grant from the Dutch Arthritis Foundation (Rheumafonds), and a fellowship from Fundacao para a Ciencia e a Tecnologia.	Aarts-Riemens T, 2008, EUR J IMMUNOL, V38, P1381, DOI 10.1002/eji.200737590; Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Atak ZK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003997; Barata JT, 2004, BLOOD, V103, P1891, DOI 10.1182/blood-2002-12-3861; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Cardoso BA, 2011, LEUKEMIA, V25, P1578, DOI 10.1038/leu.2011.140; Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163; Condorelli GL, 1996, CANCER RES, V56, P5113; Correia NC, 2013, LEUKEMIA, V27, P1603, DOI 10.1038/leu.2013.63; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fleskens V, 2014, INT REV IMMUNOL, V33, P94, DOI 10.3109/08830185.2013.816698; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hansson A, 2003, BIOCHEM BIOPH RES CO, V312, P1073, DOI 10.1016/j.bbrc.2003.11.030; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Karanikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Luo XD, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-34; Ma GF, 2013, BIOCHEM BIOPH RES CO, V430, P804, DOI 10.1016/j.bbrc.2012.11.065; Mansour MR, 2013, J EXP MED, V210, P1545, DOI 10.1084/jem.20122516; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Martin F, 2010, ONCOGENE, V29, P4121, DOI 10.1038/onc.2010.174; Matsubara Y, 2005, LEUKEMIA, V19, P482, DOI 10.1038/sj.leu.2403628; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; McMurchy AN, 2013, BLOOD, V121, P1265, DOI 10.1182/blood-2012-05-431023; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Roncador G, 2005, LEUKEMIA, V19, P2247, DOI 10.1038/sj.leu.2403965; Rudra D, 2012, NAT IMMUNOL, V13, P1010, DOI 10.1038/ni.2402; Samon JB, 2008, BLOOD, V112, P1813, DOI 10.1182/blood-2008-03-144980; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Shi XZ, 2010, STEM CELLS, V28, P462, DOI 10.1002/stem.274; Tremblay M, 2003, J BIOL CHEM, V278, P12680, DOI 10.1074/jbc.M209870200; Tremblay M, 2010, GENE DEV, V24, P1093, DOI 10.1101/gad.1897910; Tuovinen H, 2008, IMMUNOL CELL BIOL, V86, P523, DOI 10.1038/icb.2008.36; van Loosdregt J, 2013, IMMUNITY, V39, P259, DOI 10.1016/j.immuni.2013.05.018; van Loosdregt J, 2013, IMMUNITY, V39, P298, DOI 10.1016/j.immuni.2013.07.019; van Loosdregt J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019047; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	57	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4141	4148		10.1038/onc.2015.481	http://dx.doi.org/10.1038/onc.2015.481			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686090				2022-12-28	WOS:000381020900012
J	Lin, KY; Ye, H; Han, BW; Wang, WT; Wei, PP; He, B; Li, XJ; Chen, YQ				Lin, K-Y; Ye, H.; Han, B-W; Wang, W-T; Wei, P-P; He, B.; Li, X-J; Chen, Y-Q			Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; NECROSIS-FACTOR-ALPHA; CELL-DIFFERENTIATION; SIGNAL TRANSDUCER; IN-VITRO; CANCER; STAT3; GROWTH; EXPRESSION; INTERLEUKIN-6	Cholangiocarcinoma (CCA), which is a poor prognosis malignancy that arises from the malignant transformation of cholangiocytes, is associated with chronic inflammation of the biliary epithelium. Thus far, the molecular mechanisms of the origin and neoplastic processes of CCA that are promoted by inflammation are still unclear and need to be fully elucidated. Here using small RNA sequencing to determine the microRNA (miRNA) expression profiles in CCA, we found that let-7c, miR-99a and miR-125b, which are three miRNAs of the same cluster, were downregulated in CCA and targeted interleukin 6 (IL-6), IL-6R and type 1 insulin-like growth factor, which are important cytokines and receptors of the IL-6/signal transducer and activator 3 (STAT3) pathway and have key roles in inflammation and CCA initiation. We also found that enforced expression of let-7c, miR-99a or miR-125b could reduce the activity of STAT3 and further suppress CCA tumorigenicity in vivo and inhibit the migration and invasion of CCA cells in vitro. Surprisingly, let-7c/miR-99a/miR-125b cluster also significantly decreased the ability of CCA cells for cancer stem cell-like mammosphere generation by downregulating CD133 and CD44, which suggests the pivotal roles of let-7c, miR-99a and miR-125b in CCA by regulating both inflammation and stem-like properties. Our findings showed potential links between miRNAs and inflammation, and provide a potential treatment strategy for developing an miRNA-based therapy via IL-6/STAT3 targeting for CCA.	[Lin, K-Y; Han, B-W; Wang, W-T; Wei, P-P; Li, X-J; Chen, Y-Q] Sun Yat Sen Univ, State Key Lab Biocontrol, Sch Life Sci, Key Lab Gene Engn,Minist Engn, Guangzhou, Guangdong, Peoples R China; [Ye, H.; He, B.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary, Guangzhou, Guangdong, Peoples R China; [Ye, H.; He, B.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Chen, YQ (corresponding author), Sun Yat Sen Univ, Biotechnol Res Ctr, Minist Educ, Key Lab Gene Engn, Guangzhou 510275, Guangdong, Peoples R China.	lsscyq@mail.sysu.edu.cn	Lin, Kangyu/I-8050-2016	Lin, Kangyu/0000-0003-0140-2557; Wang, Wen-Tao/0000-0003-3913-4455	National Science and Technology Department [973, 2011CB8113015, 2011CBA0110]; National Science Foundation of China [81270629]; Guangdong Province Key Laboratory of Computational Science; Guangdong Province Computational Science Innovative Research Team; National Science Foundation of Guangdong [2014A020212135]	National Science and Technology Department; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Key Laboratory of Computational Science; Guangdong Province Computational Science Innovative Research Team; National Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province)	This work was supported by the funds from National Science and Technology Department (973, 2011CB8113015 and 2011CBA0110), National Science Foundation of China (no. 81270629) and Guangdong (2014A020212135). This work is also supported in part by the Guangdong Province Key Laboratory of Computational Science and the Guangdong Province Computational Science Innovative Research Team.	Akiyama T, 1998, HEPATO-GASTROENTEROL, V45, P665; Alvaro D, 2006, AM J PATHOL, V169, P877, DOI 10.2353/ajpath.2006.050464; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Barton BE, 2004, MOL CANCER THER, V3, P1183; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benckert C, 2003, CANCER RES, V63, P1083; Boonyanugomol W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077358; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Falamarzian A, 2014, J BIOMED MATER RES A, V102, P3216, DOI 10.1002/jbm.a.34992; Fava G, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/630543; Furqan M, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-90; Gores GJ, 2003, HEPATOLOGY, V37, P961, DOI 10.1053/jhep.2003.50200; Groner B, 2008, SEMIN CELL DEV BIOL, V19, P341, DOI 10.1016/j.semcdb.2008.06.005; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Isomoto H, 2005, HEPATOLOGY, V42, P1329, DOI 10.1002/hep.20966; Isomoto H, 2007, GASTROENTEROLOGY, V132, P384, DOI 10.1053/j.gastro.2006.10.037; Isomoto H, 2009, DIGESTION, V79, P2, DOI 10.1159/000167859; Johnson Christopher, 2012, Transl Gastrointest Cancer, V1, P58; Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7; Kimura F, 1999, HEPATO-GASTROENTEROL, V46, P1613; Kokuryo T, 2012, J HEPATO-BIL-PAN SCI, V19, P606, DOI 10.1007/s00534-012-0542-6; Landi S, 2003, CANCER RES, V63, P3560; Lazaridis KN, 2005, GASTROENTEROLOGY, V128, P1655, DOI 10.1053/j.gastro.2005.03.040; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Li S, 2012, CANCER RES, V72, P865, DOI 10.1158/0008-5472.CAN-11-1357; Li XJ, 2013, BRIT J CANCER, V109, P2189, DOI 10.1038/bjc.2013.562; Li Z, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-17; Lin KY, 2011, J BIOL CHEM, V286, P38253, DOI 10.1074/jbc.M111.269670; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Munoz-Garrido P, 2012, WORLD J GASTROENTERO, V18, P6189, DOI 10.3748/wjg.v18.i43.6189; Park J, 1999, HEPATOLOGY, V29, P1037, DOI 10.1002/hep.510290423; Rojas A, 2011, ONCOGENE, V30, P2345, DOI 10.1038/onc.2010.605; Rosen HR, 1997, DIGEST DIS SCI, V42, P1290, DOI 10.1023/A:1018822628096; Scotte M, 1991, Eur Cytokine Netw, V2, P177; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Sirica AE, 2005, HEPATOLOGY, V41, P5, DOI 10.1002/hep.20537; Smith AD, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0070-8; Sun D, 2014, ONCOGENE, V33, P1448, DOI 10.1038/onc.2013.77; Sun YM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-6; Sun Z, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-14; Thanan R, 2013, FREE RADICAL BIO MED, V65, P1464, DOI 10.1016/j.freeradbiomed.2013.07.034; Wang WT, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0086-0; Wang WT, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-6; Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674; Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056; Yazumi S, 2000, INT J CANCER, V86, P782; Zen Y, 2005, LAB INVEST, V85, P572, DOI 10.1038/labinvest.3700236; Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006849; Zhang KZ, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-28; Zheng TS, 2014, HEPATOLOGY, V59, P935, DOI 10.1002/hep.26705; Zheng YS, 2012, ONCOGENE, V31, P80, DOI 10.1038/onc.2011.208; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	57	52	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3376	3386		10.1038/onc.2015.396	http://dx.doi.org/10.1038/onc.2015.396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26455324	Green Published, hybrid			2022-12-28	WOS:000379270100003
J	Jen, J; Lin, LL; Chen, HT; Liao, SY; Lo, FY; Tang, YA; Su, WC; Salgia, R; Hsu, CL; Huang, HC; Juan, HF; Wang, YC				Jen, J.; Lin, L-L; Chen, H-T; Liao, S-Y; Lo, F-Y; Tang, Y-A; Su, W-C; Salgia, R.; Hsu, C-L; Huang, H-C; Juan, H-F; Wang, Y-C			Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer	ONCOGENE			English	Article							ZINC-FINGER PROTEIN; MARCKS-RELATED DOMAIN; KINASE-C; GASTRIC-CANCER; CELL-GROWTH; SPECTRIN; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; PROGRESSION	ZNF322A encoding a classical Cys2His2 zinc finger transcription factor was previously revealed as a potential oncogene in lung cancer patients. However, the oncogenic role of ZNF322A and its underlying mechanism in lung tumorigenesis remain elusive. Here we show ZNF322A protein overexpression in 123 Asian and 74 Caucasian lung cancer patients. Multivariate Cox regression analysis indicated that ZNF322A was an independent risk factor for a poor outcome in lung cancer, corroborating the Kaplan-Meier results that patients with ZNF322A protein overexpression had significantly poorer overall survival than other patients. Overexpression of ZNF322A promoted cell proliferation and soft agar growth by prolonging cell cycle in S phase in multiple lung cell lines, including the immortalized lung cell BEAS-2B. In addition, ZNF322A overexpression enhanced cell migration and invasion, whereas knockdown of ZNF322A reduced cell growth, invasion and metastasis abilities in vitro and in vivo. Quantitative proteomic analysis revealed potential ZNF322A-regulated downstream targets, including alpha-adducin (ADD1), cyclin D1 (CCND1), and p53. Using luciferase promoter activity assay combined with site-directed mutagenesis and sequential chromatin immunoprecipitation-PCR assay, we found that ZNF322A could form a complex with c-Jun and cooperatively activate ADD1 and CCND1 but repress p53 gene transcription by recruiting differential chromatin modifiers, such as histone deacetylase 3, in an AP-1 element dependent manner. Reconstitution experiments indicated that CCND1 and p53 were important to ZNF322A-mediated promotion of cell proliferation, whereas ADD1 was necessary for ZNF322A-mediated cell migration and invasion. Our results provide compelling evidence that ZNF322A overexpression transcriptionally dysregulates genes involved in cell growth and motility therefore contributes to lung tumorigenesis and poor prognosis.	[Jen, J.; Liao, S-Y; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 701, Taiwan; [Lin, L-L; Hsu, C-L; Juan, H-F] Natl Taiwan Univ, Dept Life Sci, Inst Mol & Cellular Biol, Grad Inst Biomed Elect & Bioinformat, 1,Sec 4,Roosevelt Rd, Taipei 116, Taiwan; [Chen, H-T; Lo, F-Y; Tang, Y-A; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; [Su, W-C] Natl Cheng Kung Univ, Dept Internal Med, Coll Med, Tainan 701, Taiwan; [Salgia, R.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; [Huang, H-C] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan; [Huang, H-C] Natl Yang Ming Univ, Ctr Syst & Synthet Biol, Taipei 112, Taiwan	National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Cheng Kung University; University of Chicago; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 701, Taiwan.; Juan, HF (corresponding author), Natl Taiwan Univ, Dept Life Sci, Inst Mol & Cellular Biol, Grad Inst Biomed Elect & Bioinformat, 1,Sec 4,Roosevelt Rd, Taipei 116, Taiwan.	yukijuan@ntu.edu.tw; ycw5798@mail.ncku.edu.tw	Huang, Hsuan-Cheng/C-7266-2011; Wang, Yi-Ching/J-8702-2019; Hsu, Chia-Lang/O-1458-2013	Huang, Hsuan-Cheng/0000-0002-3386-0934; Wang, Yi-Ching/0000-0002-7694-2067; Hsu, Chia-Lang/0000-0002-7447-8045; JUAN, HSUEH-FEN/0000-0003-4876-3309; Su, Wu-Chou/0000-0003-2953-4105	Taiwan Ministry of Science and Technology Grant [103-2627-B-006-007, 103-2627-B-002-002]; Taiwan Ministry of Health and Welfare Grant [MOHW103-TD-B-111-06]; Aim for the Top University Project Grant; Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital	Taiwan Ministry of Science and Technology Grant; Taiwan Ministry of Health and Welfare Grant; Aim for the Top University Project Grant; Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital	This work was supported by the Taiwan Ministry of Science and Technology Grant (103-2627-B-006-007; 103-2627-B-002-002), Taiwan Ministry of Health and Welfare Grant (MOHW103-TD-B-111-06) and the Aim for the Top University Project Grant. We are grateful for the support from the Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. Accession numbers: Data from proteomics was deposited in the ProteomeXchange Consortium with accession number PXD001123.	Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; BENNETT V, 1988, J BIOL CHEM, V263, P5860; Chauhan S, 2013, MOL CELL, V50, P16, DOI 10.1016/j.molcel.2013.01.024; Chen CL, 2007, J CELL SCI, V120, P1157, DOI 10.1242/jcs.03408; Cheng YD, 2012, MOL CANCER RES, V10, P925, DOI 10.1158/1541-7786.MCR-11-0594; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Frietze S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015082; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; Gocke CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003255; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Jeon BN, 2014, NUCLEIC ACIDS RES, V42, P11447, DOI 10.1093/nar/gku857; Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim MK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004864; Lai KP, 2014, INT J CANCER, V135, P1790, DOI 10.1002/ijc.28819; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; Li YQ, 2004, BIOCHEM BIOPH RES CO, V325, P1383, DOI 10.1016/j.bbrc.2004.10.183; Lo FY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-235; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Meruvu S, 2011, J BIOL CHEM, V286, P26516, DOI 10.1074/jbc.M110.212506; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Tian C, 2009, NAT CELL BIOL, V11, P580, DOI 10.1038/ncb1864; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Wagner S, 2000, J BIOL CHEM, V275, P15685, DOI 10.1074/jbc.M910152199; Wei Z, 2009, STEM CELLS, V27, P2969, DOI 10.1002/stem.231; Yang GL, 2014, ONCOL REP, V31, P1877, DOI 10.3892/or.2014.2997; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Zhang L, 2014, ONCOGENE, V33, P5491, DOI 10.1038/onc.2013.495	38	33	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2357	2369		10.1038/onc.2015.296	http://dx.doi.org/10.1038/onc.2015.296			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26279304	hybrid, Green Published			2022-12-28	WOS:000376165000008
J	Mahajan, K				Mahajan, K.			hPso4/hPrp19: a critical component of DNA repair and DNA damage checkpoint complexes	ONCOGENE			English	Review							PRE-MESSENGER-RNA; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; DOUBLE-STRAND BREAKS; DEPENDENT PROTEIN-KINASE; HEMATOPOIETIC STEM-CELLS; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; U-BOX; BIOCHEMICAL-CHARACTERIZATION; HOMOLOGOUS-RECOMBINATION	Genome integrity is vital to cellular homeostasis and its forfeiture is linked to deleterious consequences-cancer, immunodeficiency, genetic disorders and premature aging. The human ubiquitin ligase Pso4/Prp19 has emerged as a critical component of multiple DNA damage response (DDR) signaling networks. It not only senses DNA damage, binds double-stranded DNA in a sequence-independent manner, facilitates processing of damaged DNA, promotes DNA end joining, regulates replication protein A (RPA2) phosphorylation and ubiquitination at damaged DNA, but also regulates RNA splicing and mitotic spindle formation in its integral capacity as a scaffold for a multimeric core complex. Accordingly, by virtue of its regulatory and structural interactions with key proteins critical for genome integrity-DNA double-strand break (DSB) repair, DNA interstrand crosslink repair, repair of stalled replication forks and DNA end joining-it fills a unique niche in restoring genomic integrity after multiple types of DNA damage and thus has a vital role in maintaining chromatin integrity and cellular functions. These properties may underlie its ability to thwart replicative senescence and, not surprisingly, have been linked to the self-renewal and colony-forming ability of murine hematopoietic stem cells. This review highlights recent advances in hPso4 research that provides a fascinating glimpse into the pleiotropic activities of a ubiquitously expressed multifunctional E3 ubiquitin ligase.	[Mahajan, K.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL 33682 USA; [Mahajan, K.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Oncol Sci, 12902 Magnolia Dr, Tampa, FL 33682 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Mahajan, K (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL 33682 USA.; Mahajan, K (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Dept Oncol Sci, 12902 Magnolia Dr, Tampa, FL 33682 USA.	kiran.mahajan@moffitt.org	Mahajan, Kiran/ABA-3013-2020	Mahajan, Kiran/0000-0001-7192-396X	Department of Defense [W81XWH-12-1-0248, W81XWH-14-1-0251, W81XWH-15-1-0059]	Department of Defense(United States Department of Defense)	I thank Dr Nupam Mahajan and Professor William Kaufmann (UNC Chapel Hill) for critical reading of the manuscript and suggestions. I appreciate Urvashi Mahajan for help with the illustrations. This work is supported in part by Department of Defense Awards W81XWH-12-1-0248, W81XWH-14-1-0251 and W81XWH-15-1-0059 to KM.	Abbas M, 2014, J BIOL CHEM, V289, P14009, DOI 10.1074/jbc.M113.520056; Alvarez-Quilon A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4347; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beck BD, 2008, J BIOL CHEM, V283, P9023, DOI 10.1074/jbc.M800150200; Beck BD, 2011, BIOCHEMISTRY-US, V50, P4360, DOI 10.1021/bi200333k; Beck BD, 2010, ARCH BIOCHEM BIOPHYS, V498, P89, DOI 10.1016/j.abb.2010.04.011; Benjamin AB, 2014, BIOMED PHARMACOTHER, V68, P463, DOI 10.1016/j.biopha.2014.03.006; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan SP, 2005, J BIOL CHEM, V280, P31190, DOI 10.1074/jbc.M505060200; Chan SP, 2003, SCIENCE, V302, P279, DOI 10.1126/science.1086602; Chan YA, 2014, TRENDS GENET, V30, P245, DOI 10.1016/j.tig.2014.03.005; Cordaux R, 2006, P NATL ACAD SCI USA, V103, P8101, DOI 10.1073/pnas.0601161103; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; DASILVA KVCL, 1995, CURR GENET, V27, P207, DOI 10.1007/BF00326150; David CJ, 2011, GENE DEV, V25, P972, DOI 10.1101/gad.2038011; DEANDRADE HHR, 1989, MOL GEN GENET, V217, P419; Dellago H, 2012, AGING-US, V4, P290, DOI 10.18632/aging.100452; Dellago H, 2011, BIOCHEM J, V438, P81, DOI 10.1042/BJ20110183; Fortschegger K, 2007, MOL CELL BIOL, V27, P3123, DOI 10.1128/MCB.01188-06; Gangi-Peterson L, 1999, J CLIN INVEST, V103, P833, DOI 10.1172/JCI4320; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241; Gotzmann J, 2000, EXP CELL RES, V261, P166, DOI 10.1006/excr.2000.5025; Grey M, 1996, NUCLEIC ACIDS RES, V24, P4009, DOI 10.1093/nar/24.20.4009; Grillari J, 2005, NUCLEIC ACIDS RES, V33, P6868, DOI 10.1093/nar/gki986; Grillari J, 2009, J BIOL CHEM, V284, P29193, DOI 10.1074/jbc.M109.036632; Grote M, 2010, MOL CELL BIOL, V30, P2105, DOI 10.1128/MCB.01505-09; Gupta GP, 2013, MOL CELL, V52, P353, DOI 10.1016/j.molcel.2013.09.001; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HENRIQUES JAP, 1989, MUTAT RES, V218, P111, DOI 10.1016/0921-8777(89)90017-7; Hofmann JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074851; Howard SM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004943; Iyama T, 2015, NUCLEIC ACIDS RES, V43, P247, DOI 10.1093/nar/gku1279; Jaehnig EJ, 2013, CELL REP, V4, P174, DOI 10.1016/j.celrep.2013.05.041; Jiang GC, 2013, J BIOL CHEM, V288, P8966, DOI 10.1074/jbc.M112.412650; Kakarougkas A, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130685; Kaufmann WK, 2010, CARCINOGENESIS, V31, P751, DOI 10.1093/carcin/bgp230; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kleinridders A, 2009, MOL CELL BIOL, V29, P3173, DOI 10.1128/MCB.01807-08; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuo PC, 2009, CANCER RES, V69, P8877, DOI 10.1158/0008-5472.CAN-09-2023; Kuraoka I, 2008, J BIOL CHEM, V283, P940, DOI 10.1074/jbc.M706647200; Lammens K, 2011, CELL, V145, P54, DOI 10.1016/j.cell.2011.02.038; Lee BS, 2013, MOL CELL BIOL, V33, P3568, DOI 10.1128/MCB.00308-13; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Legerski RJ, 2009, CELL CYCLE, V8, P3448, DOI 10.4161/cc.8.21.9760; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu DX, 2007, MOL CELL BIOL, V27, P1125, DOI 10.1128/MCB.01899-06; Loscher M, 2005, BIOCHEM J, V388, P593, DOI 10.1042/BJ20041517; Lu XY, 2007, BIOCHEM BIOPH RES CO, V354, P968, DOI 10.1016/j.bbrc.2007.01.097; Mahajan KN, 1999, P NATL ACAD SCI USA, V96, P13926, DOI 10.1073/pnas.96.24.13926; Mahajan KN, 2003, P NATL ACAD SCI USA, V100, P10746, DOI 10.1073/pnas.1631060100; Makarova OV, 2004, EMBO J, V23, P2381, DOI 10.1038/sj.emboj.7600241; Marechal A, 2014, MOL CELL, V53, P235, DOI 10.1016/j.molcel.2013.11.002; Marin I, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-331; Mateos-Gomez PA, 2015, NATURE, V518, P254, DOI 10.1038/nature14157; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Myung K, 2002, P NATL ACAD SCI USA, V99, P4500, DOI 10.1073/pnas.062702199; Ohi MD, 2005, MOL CELL BIOL, V25, P451, DOI 10.1128/MCB.25.1.451-460.2005; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Paull TT, 2015, ANNU REV BIOCHEM, V84, P711, DOI 10.1146/annurev-biochem-060614-034335; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Purugganan MM, 2001, NUCLEIC ACIDS RES, V29, P1638, DOI 10.1093/nar/29.7.1638; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Roman Y, 2007, BIOCHEMISTRY-US, V46, P11369, DOI 10.1021/bi7005477; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Schraml E, 2008, STEM CELLS DEV, V17, P355, DOI 10.1089/scd.2007.0107; Smolka MB, 2007, P NATL ACAD SCI USA, V104, P10364, DOI 10.1073/pnas.0701622104; Song EJ, 2010, GENE DEV, V24, P1434, DOI 10.1101/gad.1925010; Sykora P, 2015, NUCLEIC ACIDS RES, V43, P943, DOI 10.1093/nar/gku1356; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; Tobin LA, 2013, ONCOGENE, V32, P1784, DOI 10.1038/onc.2012.203; Tresini M, 2015, NATURE, V523, P53, DOI 10.1038/nature14512; Vander Kooi CW, 2010, STRUCTURE, V18, P584, DOI 10.1016/j.str.2010.02.015; Vander Kooi CW, 2006, BIOCHEMISTRY-US, V45, P121, DOI 10.1021/bi051787e; Vermeij WP, 2014, CURR OPIN GENET DEV, V26, P124, DOI 10.1016/j.gde.2014.06.006; von Zglinicki T, 2005, MECH AGEING DEV, V126, P111, DOI 10.1016/j.mad.2004.09.034; Wan L, 2014, J BIOL CHEM, V289, P6619, DOI 10.1074/jbc.M113.543439; Williamson EA, 2008, NUCLEIC ACIDS RES, V36, P5822, DOI 10.1093/nar/gkn560; Woods NT, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002255; Wray J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005323; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zha S, 2011, P NATL ACAD SCI USA, V108, P2028, DOI 10.1073/pnas.1019293108; Zha S, 2011, NATURE, V469, P250, DOI 10.1038/nature09604; Zhang JQ, 2015, NAT STRUCT MOL BIOL, V22, P242, DOI 10.1038/nsmb.2956; Zhang NX, 2009, EMBO REP, V10, P1029, DOI 10.1038/embor.2009.122; Zhang NX, 2005, J BIOL CHEM, V280, P40559, DOI 10.1074/jbc.M508453200	94	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2279	2286		10.1038/onc.2015.321	http://dx.doi.org/10.1038/onc.2015.321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26364595				2022-12-28	WOS:000376165000001
J	Li, T; Xie, J; Shen, C; Cheng, D; Shi, Y; Wu, Z; Deng, X; Chen, H; Shen, B; Peng, C; Li, H; Zhan, Q; Zhu, Z				Li, T.; Xie, J.; Shen, C.; Cheng, D.; Shi, Y.; Wu, Z.; Deng, X.; Chen, H.; Shen, B.; Peng, C.; Li, H.; Zhan, Q.; Zhu, Z.			RETRACTED: Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma (Retracted article. See vol. 41, pg. 4839, 2022)	ONCOGENE			English	Article; Retracted Publication							GENE; EXPRESSION; SEQUENCE; TRANSCRIPTION; PROGRESSION; CHROMATIN; MALAT1; ROLES; HULC; EMT	Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Despite progress in diagnostics and treatment of HCC, its prognosis remains poor. Emerging studies showed that long noncoding RNAs (lncRNAs) have crucial regulatory roles in cancer biology. In the current study, differentially expressed lncRNAs between HCC and paired non-tumor tissues were identified using microarrays. The effects of a specific differentially expressed lncRNA (termed ZEB1-AS1) on tumor progression were investigated in vitro and in vivo. We found that ZEB1-AS1 is frequently upregulated in HCC samples, especially in metastatic tumor tissues. DNA methylation analysis shows a tumor-specific ZEB1-AS1 promoter hypomethylation. Aberrant methylation is tightly correlated with overexpression of ZEB1-AS1 in HCC. Patients with ZEB1-AS1 hypomethylation or with high ZEB1-AS1 expression have poor recurrence-free survival. Functionally, ZEB1-AS1 promotes tumor growth and metastasis, acts as an oncogene in HCC. The ZEB1-AS1 gene is located in physical contiguity with ZEB1 and positively regulates the ZEB1 expression. ZEB1 inhibition partially abrogates ZEB1-AS1-induced epithelial to mesenchymal transition (EMT) and cancer metastasis. Our results provide novel insights into the function of lncRNA-driven hepatocarcinogenesis, highlight the important role of ZEB1-AS1 and ZEB1 in HCC progression, and indicate that ZEB1-AS1 may be served as a valuable prognostic biomarker for HCC.	[Li, T.; Xie, J.; Shen, C.; Cheng, D.; Shi, Y.; Wu, Z.; Deng, X.; Chen, H.; Shen, B.; Peng, C.; Li, H.; Zhan, Q.; Zhu, Z.] Shanghai Jiao Tong Univ, Dept Hepatobiliopancreat Surg, Shanghai Inst Digest Surg, Rui Jin Hosp, Ruijin Er Rd 197, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University	Zhu, Z (corresponding author), Shanghai Jiao Tong Univ, Dept Hepatobiliopancreat Surg, Shanghai Inst Digest Surg, Rui Jin Hosp, Ruijin Er Rd 197, Shanghai 200025, Peoples R China.	zhuzhecheng@126.com		WU, Zhichong/0000-0002-6166-755X; Peng, Chenghong/0000-0002-5573-7873				Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054; Babajko S, 2009, CELLS TISSUES ORGANS, V189, P115, DOI 10.1159/000151748; Befeler AS, 2002, GASTROENTEROLOGY, V122, P1609, DOI 10.1053/gast.2002.33411; Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Guo F, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-19; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Hammerle M, 2013, HEPATOLOGY, V58, P1703, DOI 10.1002/hep.26537; Hasuwa H, 2013, SCIENCE, V341, P71, DOI 10.1126/science.1237999; He Y, 2014, CANCER LETT, V344, P20, DOI 10.1016/j.canlet.2013.10.021; Ho MY, 2013, CANCER RES, V73, P439, DOI 10.1158/0008-5472.CAN-12-2220; Huang JL, 2014, CARCINOGENESIS, V35, P507, DOI 10.1093/carcin/bgt405; Khaitan D, 2011, CANCER RES, V71, P3852, DOI 10.1158/0008-5472.CAN-10-4460; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kurihara M, 2014, J MOL BIOL, V426, P3069, DOI 10.1016/j.jmb.2014.06.018; Lepoivre C, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-914; Majid S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067686; Malkowski Piotr, 2006, Przegl Epidemiol, V60, P731; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Quagliata L, 2014, HEPATOLOGY, V59, P911, DOI 10.1002/hep.26740; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Shah PP, 2015, ONCOGENE, V34, P1709, DOI 10.1038/onc.2014.97; Soini Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-73; Sun L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt646; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang WJ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-49; Wei W, 2011, TRENDS GENET, V27, P267, DOI 10.1016/j.tig.2011.04.002; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wu WJ, 2013, GASTROENTEROLOGY, V144, P956, DOI 10.1053/j.gastro.2013.01.019; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yang WT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088827; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y	45	234	249	3	75	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1575	1584		10.1038/onc.2015.223	http://dx.doi.org/10.1038/onc.2015.223			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073087				2022-12-28	WOS:000373063600010
J	Liang, L; Fang, JY; Xu, J				Liang, L.; Fang, J-Y; Xu, J.			Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; MITOCHONDRIAL-DNA; MET AMPLIFICATION; POOR-PROGNOSIS; AURORA-KINASE; CLINICOPATHOLOGICAL FEATURES; HELICOBACTER-PYLORI; INTEGRATED ANALYSIS	Gastric cancer (GC) is among the most common malignancy in the world with poor prognosis and limited treatment options. It has been established that gastric carcinogenesis is caused by a complex interaction between host and environmental factors. Copy number variation (CNV) refers to a form of genomic structural variation that results in abnormal gene copy numbers, including gene amplification, gain, loss and deletion. DNA CNV is an important influential factor for the expression of both protein-coding and non-coding genes, affecting the activity of various signaling pathways. CNV arises as a result of preferential selection that favors cancer development, and thus, targeting the amplified 'driver genes' in GC may provide novel opportunities for personalized therapy. The detection of CNVs in chromosomal or mitochondrial DNA from tissue or blood samples may assist the diagnosis, prognosis and targeted therapy of GC. In this review, we discuss the recent CNV discoveries that shed light on the molecular pathogenesis of GC, with a specific emphasis on CNVs that display diagnostic, prognostic or therapeutic significances in GC.	[Fang, J-Y; Xu, J.] State Key Lab Oncogenes & Related Genes, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Fang, J-Y; Xu, J.] Minist Hlth, Key Lab Gastroenterol & Hepatol, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Fang, J-Y; Xu, J.] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Renji Hosp, Sch Med, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Fang, J-Y; Xu, J.] Shanghai Inst Digest Dis, Shanghai Canc Inst, Mid Shandong Rd 145, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Fang, JY; Xu, J (corresponding author), State Key Lab Oncogenes & Related Genes, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Fang, JY; Xu, J (corresponding author), Minist Hlth, Key Lab Gastroenterol & Hepatol, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Fang, JY; Xu, J (corresponding author), Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Renji Hosp, Sch Med, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Fang, JY; Xu, J (corresponding author), Shanghai Inst Digest Dis, Shanghai Canc Inst, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.	jingyuanfang@yahoo.com; xujieletter@gmail.com	Xu, Jie/K-3712-2019; Xu, Jie/C-4283-2016	Xu, Jie/0000-0001-9163-3898; Xu, Jie/0000-0001-9163-3898; liang, lunxi/0000-0003-4178-9055	National Natural Science Foundation of China [30971330, 31371420, 81320108024, 81000861, 81322036, 81272383]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81421001]; Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project; Shanghai Science and Technology Commission 'Pujiang Project' [13PJ1405900]; Shanghai Natural Science Foundation [12ZR1417900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project; Shanghai Science and Technology Commission 'Pujiang Project'; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai)	This project was supported by grants from National Natural Science Foundation of China (30971330, 31371420, 81320108024, 81000861, 81322036 and 81272383); Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81421001), the Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project (2013XJ); Shanghai Science and Technology Commission 'Pujiang Project' (13PJ1405900) and Shanghai Natural Science Foundation (12ZR1417900). The sponsors of this study had no role in the analysis and interpretation of the literatures, the decision to submit the manuscript for publication or the writing of the manuscript.	An J, 2013, J CELL BIOCHEM, V114, P2160, DOI 10.1002/jcb.24565; An X, 2014, CANCER-AM CANCER SOC, V120, P675, DOI 10.1002/cncr.28454; Ang TL, 2014, SINGAP MED J, V55, P621, DOI 10.11622/smedj.2014174; Bang YJ, 2010, LANCET, V376, P1302; Bellini MF, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/891961; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bi R, 2011, MUTAT RES-FUND MOL M, V709-10, P15, DOI 10.1016/j.mrfmmm.2011.02.016; Bonberg N, 2014, BMC CANCER, V14, P11; Bornschein J, 2010, DIGEST DIS, V28, P609, DOI 10.1159/000320061; Bria E, 2013, ANN ONCOL, V24, P693, DOI 10.1093/annonc/mds506; Buffart TE, 2012, ONCOLOGIST, V17, P653, DOI 10.1634/theoncologist.2010-0379; Calcagno DQ, 2010, CANCER GENET CYTOGEN, V202, P63, DOI 10.1016/j.cancergencyto.2010.05.020; Chang JJ, 2015, ONCOTARGET, V6, P2009, DOI 10.18632/oncotarget.2987; Chang VY, 2013, PEDIATR BLOOD CANCER, V60, P570, DOI 10.1002/pbc.24316; Chen KX, 2015, P NATL ACAD SCI USA, V112, P1107, DOI 10.1073/pnas.1422640112; Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05; Cheng L, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-14; Chiodo J, 2012, ASSEMBLY AUTOM, V32, P8, DOI 10.1108/01445151211198683; Dar AA, 2008, CANCER-AM CANCER SOC, V112, P1688, DOI 10.1002/cncr.23371; Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765; Das K, 2014, CANCER LETT, V353, P167, DOI 10.1016/j.canlet.2014.07.021; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Despierre E, 2014, GYNECOL ONCOL, V135, P415, DOI 10.1016/j.ygyno.2014.09.014; Fan BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029824; Fang ZY, 2012, CLIN TRANSL ONCOL, V14, P60, DOI 10.1007/s12094-012-0762-x; Fang ZY, 2011, MED ONCOL, V28, P1017, DOI 10.1007/s12032-010-9602-4; Fassan M, 2014, GASTRIC CANCER, V17, P442, DOI 10.1007/s10120-013-0315-1; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fernandes J, 2014, CANCER EPIDEM BIOMAR, V23, P2430, DOI 10.1158/1055-9965.EPI-14-0471; da Costa JDFB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021988; Ferreira RM, 2014, BEST PRACT RES CL GA, V28, P1003, DOI 10.1016/j.bpg.2014.09.004; Figueiredo C, 2013, HELICOBACTER, V18, P28, DOI 10.1111/hel.12083; Fox SB, 2012, AM J SURG PATHOL, V36, P577, DOI 10.1097/PAS.0b013e318244adbb; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Fuse N, GASTRIC CANC; Garcia-Garcia E, 2011, HISTOPATHOLOGY, V59, P8, DOI 10.1111/j.1365-2559.2011.03894.x; Gavine PR, 2015, MOL ONCOL, V9, P323, DOI 10.1016/j.molonc.2014.08.015; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gray SE, 2011, CANCER GENOM PROTEOM, P8; Graziano F, 2011, J CLIN ONCOL, V29, P4789, DOI 10.1200/JCO.2011.36.7706; Guo X, 2010, ONCOGENE, V29, P3908, DOI 10.1038/onc.2010.143; Ha SY, 2013, MODERN PATHOL, V26, P1632, DOI 10.1038/modpathol.2013.108; Hatakeyama M, 2014, CELL HOST MICROBE, V15, P306, DOI 10.1016/j.chom.2014.02.008; Hayashi H, 2015, ONCOGENE, V34, P199, DOI 10.1038/onc.2013.547; He C, 2013, WORLD J GASTROENTERO, V19, P2171, DOI 10.3748/wjg.v19.i14.2171; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Higaki E, GASTRIC CANC; Hong L, 2014, EXPERT REV GASTROENT, V8, P111, DOI 10.1586/17474124.2014.844648; Hong L, 2013, GENE, V529, P69, DOI 10.1016/j.gene.2013.07.106; Horpaopan S, 2015, INT J CANCER, V136, pE578, DOI 10.1002/ijc.29215; Hou JP, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0056-8; Hu LW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0123-z; Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686; Hudler P, 2012, SCI WORLD J, DOI 10.1100/2012/761909; Hung WY, 2010, BBA-GEN SUBJECTS, V1800, P264, DOI 10.1016/j.bbagen.2009.06.006; Hwang-Verslues WW, 2013, P NATL ACAD SCI USA, V110, P12331, DOI 10.1073/pnas.1222684110; Janjigian YY, 2011, CANCER EPIDEM BIOMAR, V20, P1021, DOI 10.1158/1055-9965.EPI-10-1080; Jin GF, 2009, CARCINOGENESIS, V30, P987, DOI 10.1093/carcin/bgp090; Jung KH, 2012, ARCH PHARM RES, V35, P595, DOI 10.1007/s12272-012-0402-6; Kang JU, 2012, INT J MOL MED, V29, P81, DOI 10.3892/ijmm.2011.811; Kang JU, 2010, INT J ONCOL, V36, P1429, DOI 10.3892/ijo_00000628; Karaman A, 2010, GENET COUNSEL, V21, P439; Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444; Katsha A, 2014, MOL ONCOL, V8, P1419, DOI 10.1016/j.molonc.2014.05.012; Katsha A, 2013, GASTROENTEROLOGY, V145, P1312, DOI 10.1053/j.gastro.2013.08.050; Kawakami H, 2013, ONCOTARGET, V4, P9, DOI 10.18632/oncotarget.718; Kim HK, 2012, PHARMACOGENOMICS J, V12, P119, DOI 10.1038/tpj.2010.87; Kim O, GASTRIC CANC; Kiyose S, 2012, PATHOL INT, V62, P728, DOI 10.1111/j.1440-1827.2012.02862.x; Kuo WH, 2014, ANTICANCER RES, V34, P4963; Labots M, 2014, CELL ONCOL, V37, P41, DOI 10.1007/s13402-013-0162-4; Leal MF, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/631268; Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105; Lee H, BIOINFORMATICS; Lee HE, 2013, EUR J CANCER, V49, P1448, DOI 10.1016/j.ejca.2012.10.018; Lee HC, 2014, WORLD J GASTROENTERO, V20, P3950, DOI 10.3748/wjg.v20.i14.3950; Lee J, 2011, ONCOL REP, V25, P1517, DOI 10.3892/or.2011.1219; Lee JW, 2012, EURASIP J IMAGE VIDE, DOI 10.1186/1687-5281-2012-7; Lee MC, 2010, J BIOL CHEM, V285, P9041, DOI 10.1074/jbc.M109.075358; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Li Z, 2012, ONCOGENE, V31, P1475, DOI 10.1038/onc.2011.351; Liao LM, 2011, CANCER EPIDEM BIOMAR, V20, P1944, DOI 10.1158/1055-9965.EPI-11-0379; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; Liu YY, 2012, WORLD J GASTROENTERO, V18, P4522, DOI 10.3748/wjg.v18.i33.4522; Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5; Maddox J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003048; Matsumoto K, 2012, BRIT J CANCER, V106, P727, DOI 10.1038/bjc.2011.603; Matsuoka T, 2015, WORLD J CLIN CASES, V3, P42, DOI 10.12998/wjcc.v3.i1.42; Mauro JA, 2015, GENE, V554, P50, DOI 10.1016/j.gene.2014.10.021; Nakamura Y, 2009, J HUM GENET, V54, P1, DOI 10.1038/jhg.2008.6; Niels TF, 2013, EXPERT REV MOL DIAGN, V13, P10; Oh HS, 2014, GASTRIC CANCER, V17, P402, DOI 10.1007/s10120-013-0288-0; Okamoto W, 2012, MOL CANCER THER, V11, P1557, DOI 10.1158/1535-7163.MCT-11-0934; Okines AFC, 2010, EUR J CANCER, V46, P1949, DOI 10.1016/j.ejca.2010.05.003; Oshima T, 2012, SURG TODAY, V42, P313, DOI 10.1007/s00595-011-0065-9; Ozaki T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/603925; Ozdemir M, 2014, TURK J MED SCI, V44, P461, DOI 10.3906/sag-1303-139; Park CH, 2010, J SURG ONCOL, V102, P454, DOI 10.1002/jso.21585; Park YS, 2012, HUM PATHOL, V43, P413, DOI 10.1016/j.humpath.2011.05.019; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parmar NR, 2014, J MOL MICROB BIOTECH, V24, P249, DOI 10.1159/000365054; Patel R, 2012, CURR PHARM DESIGN, V18, P2672, DOI 10.2174/138161212800626148; Piazuelo MB, 2013, COLOMB MEDICA, V44, P192; Qian J, 2014, GUT, V64, P12; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Silva TCR, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-85; Ribeiro HF, 2010, BRAZ J MED BIOL RES, V43, P717, DOI 10.1590/S0100-879X2010007500068; Rossi E, 2011, REV ESP ENFERM DIG, V103, P632, DOI 10.4321/s1130-01082011001200005; Samuels Y, 2004, SCIENCE, P304; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, P16; Sheng WQ, 2013, ANN ONCOL, V24, P2360, DOI 10.1093/annonc/mdt232; Shi J, 2014, WORLD J GASTROENTERO, P20; Shi J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-50; Shi ZQ, 2014, CRIT REV EUKAR GENE, V24, P14; Shim JH, 2014, GENE, V546, P288, DOI 10.1016/j.gene.2014.05.064; Shinmura K, 2014, J SURG ONCOL, V109, P189, DOI 10.1002/jso.23482; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Silveira SM, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0181-x; Smalley SR, 2012, J CLIN ONCOL, V30, P2327, DOI 10.1200/JCO.2011.36.7136; Sonoda A, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-25; Stahl P, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0231-4; Stenzinger A, 2012, J MOL DIAGN, V14, P199, DOI 10.1016/j.jmoldx.2012.01.012; Sun KY, 2014, J CANCER RES CLIN, V140, P1537, DOI 10.1007/s00432-014-1714-3; Suzuki Kazufumi, 2011, J Biomed Biotechnol, V2011, P978312, DOI 10.1155/2011/978312; Takahashi Naoki, 2014, BMC Res Notes, V7, P271, DOI 10.1186/1756-0500-7-271; Takeshima H, 2015, CANCER LETT, V357, P328, DOI 10.1016/j.canlet.2014.11.038; de Souza CRT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064420; Teng LS, 2013, INT J MOL MED, V32, P1247, DOI 10.3892/ijmm.2013.1531; Tsai PC, 2014, PLOS ONE, P9; Krepischi ACV, 2012, FUTURE ONCOL, V8, P441, DOI [10.2217/FON.12.34, 10.2217/fon.12.34]; Waddell T, 2013, LANCET ONCOL, V14, P9; Wang JL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5735; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang X, GASTRIC CANC; Wang YK, 2011, MOL CYTOGENET, V4, DOI 10.1186/1755-8166-4-14; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wen SL, 2013, ONCOL LETT, V6, P1098, DOI 10.3892/ol.2013.1492; Xia JZ, 2014, J CANCER RES CLIN, V140, P1451, DOI 10.1007/s00432-014-1649-8; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Xu HT, 2015, J CANCER, V6, P247, DOI 10.7150/jca.10747; Xu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.75; Yang Q, 2014, CLIN BIOCHEM, V47, P111, DOI 10.1016/j.clinbiochem.2013.10.014; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yen CC, 2012, ANN SURG ONCOL, V19, P3491, DOI 10.1245/s10434-012-2389-0; Yoda Y, 2015, GASTRIC CANCER, V18, P65, DOI 10.1007/s10120-014-0348-0; Yoon JH, 2011, J PATHOL, V223, P618, DOI 10.1002/path.2838; Yoshida S, 2013, ANTICANCER RES, V33, P469; Zhang D, 2011, J SURG ONCOL, V103, P124, DOI 10.1002/jso.21792; Zhang L, 2014, J PATHOL, V233, P103, DOI 10.1002/path.4351; Zhang L, 2010, MOL CELL BIOCHEM, V344, P125, DOI 10.1007/s11010-010-0536-0; Zhao SD, 2011, J PATHOL, V223, P672, DOI 10.1002/path.2827; Zhu GJ, 2014, EXP THER MED, V8, P1501, DOI 10.3892/etm.2014.1982	153	87	88	1	48	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1475	1482		10.1038/onc.2015.209	http://dx.doi.org/10.1038/onc.2015.209			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073079				2022-12-28	WOS:000373063600001
J	Yin, N; Qi, X; Tsai, S; Lu, Y; Basir, Z; Oshima, K; Thomas, JP; Myers, CR; Stoner, G; Chen, G				Yin, N.; Qi, X.; Tsai, S.; Lu, Y.; Basir, Z.; Oshima, K.; Thomas, J. P.; Myers, C. R.; Stoner, G.; Chen, G.			p38 gamma MAPK is required for inflammation-associated colon tumorigenesis	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; RAS TRANSFORMATION; ESTROGEN-RECEPTOR; BETA-CATENIN; CANCER; STRESS; CARCINOGENESIS; PIRFENIDONE; EXPRESSION; PATHWAY	Chronic inflammation has long been considered to causatively link to colon cancer development. However, signal transduction pathways involved remain largely unidentified. Here, we report that p38 gamma mitogen-activated protein kinase mediates inflammatory signaling to promote colon tumorigenesis. Inflammation activates p38 gamma in mouse colon tissues and intestinal epithelial cell-specific p38 gamma knockout (KO) attenuates colitis and inhibits pro-inflammatory cytokine expression. Significantly, p38 gamma KO inhibits tumorigenesis in a colitis-associated mouse model. The specific p38 gamma pharmacological inhibitor pirfenidone also suppresses pro-inflammatory cytokine expression and colon tumorigenesis. The tumor-promoting activity of epithelial p38 gamma was further demonstrated by xenograft studies. In addition, p38 gamma is required for beta-catenin/Wnt activities and p38 gamma stimulates Wnt transcription by phosphorylating beta-catenin at Ser605. These results show that p38 gamma activation links inflammation and colon tumorigenesis. Targeting p38 gamma may be a novel strategy for colon cancer prevention and treatment.	[Yin, N.; Qi, X.; Myers, C. R.; Chen, G.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd,BSB 660, Milwaukee, WI 53226 USA; [Tsai, S.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Lu, Y.] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Basir, Z.; Oshima, K.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Thomas, J. P.; Stoner, G.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; [Chen, G.] Med Coll Wisconsin, Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Chen, G (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd,BSB 660, Milwaukee, WI 53226 USA.	gchen@mcw.edu	Yin, Ning/AAA-7617-2020; Oshima, Kiyoko/CAF-1543-2022	Myers, Charles/0000-0001-7956-3217	Department of Veterans Affairs Merit Review [I01BX002883]; Cancer Center of Medical College of Wisconsin (the State of Wisconsin Tax Check-Off Program); Clinical & Translational Science Institute (CTSI) of Southeast Wisconsin; Veterans Affairs [I01BX002883] Funding Source: NIH RePORTER	Department of Veterans Affairs Merit Review(US Department of Veterans Affairs); Cancer Center of Medical College of Wisconsin (the State of Wisconsin Tax Check-Off Program); Clinical & Translational Science Institute (CTSI) of Southeast Wisconsin; Veterans Affairs(US Department of Veterans Affairs)	We thank Boehringer Ingelheim Pharmaceuticals Inc. and Dr Zhen Yan (University of Virginia) for providing the floxed p38 gamma mice. We also thank former lab members Drs PS Suresh for maintaining mice and conducting some preliminary experiments, and S Hou for generating the p38 gamma-depleted HCT116 cell lines. In addition, we express our gratitude to Drs D Wang (Blood Institute of Wisconsin), A Chan, R Li and J Tichelaar (Medical College of Wisconsin) for useful discussions. We also thank Drs J Han (The Scripps Research Institute), A Cuenda (National Center for Biotechnology-CSIC), NK Tonks (Cold Spring Harbor) and H Howe (South Carolina University) for providing various reagents. This work was in part supported by the grants from the Department of Veterans Affairs Merit Review (I01BX002883), the Cancer Center of Medical College of Wisconsin (the State of Wisconsin Tax Check-Off Program), and Clinical & Translational Science Institute (CTSI) of Southeast Wisconsin (to GC).	Abdollahi T, 2005, APOPTOSIS, V10, P1383, DOI 10.1007/s10495-005-2139-x; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; del Reino P, 2014, CANCER RES, V74, P6150, DOI 10.1158/0008-5472.CAN-14-0870; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Gillespie MA, 2009, J CELL BIOL, V187, P991, DOI 10.1083/jcb.200907037; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gupta J, 2014, CANCER CELL, V25, P484, DOI 10.1016/j.ccr.2014.02.019; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Hou SW, 2012, J BIOL CHEM, V287, P27895, DOI 10.1074/jbc.M111.335794; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Kim C, 2008, NAT IMMUNOL, V9, P1019, DOI 10.1038/ni.1640; Korb A, 2006, ARTHRITIS RHEUM, V54, P2745, DOI 10.1002/art.22080; Kozono S, 2013, CANCER RES, V73, P2345, DOI 10.1158/0008-5472.CAN-12-3180; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lee MH, 2009, FASEB J, V23, P3874, DOI 10.1096/fj.08-117804; Liu LX, 2003, WORLD J GASTROENTERO, V9, P683, DOI 10.3748/wjg.v9.i4.683; Loesch M, 2010, J BIOL CHEM, V285, P15149, DOI 10.1074/jbc.M110.105429; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Meng FY, 2011, NEOPLASIA, V13, P472, DOI 10.1593/neo.101748; Moran N, 2011, NAT BIOTECHNOL, V29, P301, DOI 10.1038/nbt0411-301; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4; Oku H, 2002, EUR J PHARMACOL, V446, P167, DOI 10.1016/S0014-2999(02)01757-0; Otsuka M, 2010, GASTROENTEROLOGY, V138, P1255, DOI 10.1053/j.gastro.2010.01.005; Ozes O, 2008, United States Patent-US, P1, Patent No. [7,407,973, 7407973, US7407973B2]; Pogozelski AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007934; Qi XM, 2007, J BIOL CHEM, V282, P31398, DOI 10.1074/jbc.M703857200; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Qi XM, 2014, ONCOTARGET, V5, P4269, DOI 10.18632/oncotarget.2001; Qi XM, 2012, J BIOL CHEM, V287, P14681, DOI 10.1074/jbc.M112.349357; Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Risco A, 2012, P NATL ACAD SCI USA, V109, P11200, DOI 10.1073/pnas.1207290109; Rosenthal DT, 2011, CANCER RES, V71, P6338, DOI 10.1158/0008-5472.CAN-11-1291; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schreiber S, 2006, CLIN GASTROENTEROL H, V4, P325, DOI 10.1016/j.cgh.2005.11.013; Seril DN, 2003, CARCINOGENESIS, V24, P353, DOI 10.1093/carcin/24.3.353; Suzuki R, 2006, CARCINOGENESIS, V27, P162, DOI 10.1093/carcin/bgi205; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tang J, 2005, J BIOL CHEM, V280, P23910, DOI 10.1074/jbc.M500699200; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tian Y, 2013, AM J PATHOL, V182, P2310, DOI 10.1016/j.ajpath.2013.02.037; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wakeman D, 2012, SURGERY, V152, P286, DOI 10.1016/j.surg.2012.05.009; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yang K, 2013, SCI REP-UK, V3, DOI 10.1038/srep03021	49	24	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1039	1048		10.1038/onc.2015.158	http://dx.doi.org/10.1038/onc.2015.158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961922				2022-12-28	WOS:000370823300009
J	Schreck, I; Grico, N; Hansjosten, I; Marquardt, C; Bormann, S; Seidel, A; Kvietkova, DL; Pieniazek, D; Segerback, D; Diabate, S; van der Horst, GTJ; Oesch-Bartlomowicz, B; Oesch, F; Weiss, C				Schreck, I.; Grico, N.; Hansjosten, I.; Marquardt, C.; Bormann, S.; Seidel, A.; Kvietkova, D. L.; Pieniazek, D.; Segerback, D.; Diabate, S.; van der Horst, G. T. J.; Oesch-Bartlomowicz, B.; Oesch, F.; Weiss, C.			The nucleotide excision repair protein XPC is essential for bulky DNA adducts to promote interleukin-6 expression via the activation of p38-SAPK	ONCOGENE			English	Article							XERODERMA-PIGMENTOSUM; HUMAN-LUNG; 7,8-DIOL 9,10-EPOXIDES; ULTRAVIOLET-RADIATION; INDUCED APOPTOSIS; AH RECEPTOR; P38; KINASE; CELLS; GENE	Polycyclic aromatic hydrocarbons (PAHs) are environmental pollutants, and many are potent carcinogens. Benzo[a]pyrene (B[a]P), one of the best-studied PAHs, is metabolized ultimately to the genotoxin anti-B[a]P-7,8-dihydrodiol-9,10-epoxide (BPDE). BPDE triggers stress responses linked to gene expression, cell death and survival. So far, the underlying mechanisms that initiate these signal transduction cascades are unknown. Here we show that BPDE-induced DNA damage is recognized by DNA damage sensor proteins to induce activation of the stress-activated protein kinase (SAPK) p38. Surprisingly, the classical DNA damage response, which involves the kinases ATM and ATR, is not involved in p38-SAPK activation by BPDE. Moreover, the induction of p38-SAPK phosphorylation also occurs in the absence of DNA strand breaks. Instead, increased phosphorylation of p38-SAPK requires the nucleotide excision repair (NER) and DNA damage sensor proteins XPC and mHR23B. Interestingly, other genotoxins such as cisplatin (CDDP), hydrogen peroxide and ultraviolet radiation also enhance XPC-dependent p38-SAPK phosphorylation. In contrast, anti-benzo[c]phenanthrene-3,4-dihydrodiol-1,2-epoxide, the DNA adducts of which are not properly recognized by NER, does not trigger p38-SAPK activation. As a downstream consequence, expression and secretion of the pro-inflammatory cytokine interleukin-6 is induced by BPDE and CDDP in vitro and by CDDP in the murine lung, and depends on XPC. In conclusion, we describe a novel pathway in which DNA damage recognition by NER proteins specifically leads to activation of p38-SAPK to promote inflammatory gene expression.	[Schreck, I.; Grico, N.; Hansjosten, I.; Marquardt, C.; Bormann, S.; Diabate, S.; Weiss, C.] Inst Toxicol & Genet, KIT Campus North,Hermann von Helmholtzpl 1, D-76344 Eggenstein Leopoldshafen, Germany; [Grico, N.; Oesch-Bartlomowicz, B.; Oesch, F.] Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55122 Mainz, Germany; [Seidel, A.] Biochem Inst Environm Carcinogens, Lurup 4, Grosshansdorf, Germany; [Kvietkova, D. L.; Pieniazek, D.; Segerback, D.] Novum, Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden; [van der Horst, G. T. J.] Erasmus Univ, Med Ctr, Dept Genet, MGC, Rotterdam, Netherlands	Helmholtz Association; Karlsruhe Institute of Technology; Johannes Gutenberg University of Mainz; Karolinska Institutet; Erasmus University Rotterdam; Erasmus MC	Weiss, C (corresponding author), Inst Toxicol & Genet, KIT Campus North,Hermann von Helmholtzpl 1, D-76344 Eggenstein Leopoldshafen, Germany.	carsten.weiss@kit.edu	Oesch, Franz/AAA-8746-2020; van der Horst, Gijsbertus TJ/E-3661-2015; Weiss, Carsten/I-1811-2013	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Weiss, Carsten/0000-0002-5380-3208; Marquardt, Clarissa/0000-0001-5872-0164	ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5: 'Food Quality and Safety' [513943]	ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5: 'Food Quality and Safety'	This work was supported by ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5: 'Food Quality and Safety' (Contract No 513943). We thank Dorit Mattern for technical assistance; Jonathan Sleeman for critical reading and editing, Selma Huber, Simone Maier, Tobias Stoger and Barbel Ritter for supervision and performance of the animal experiments. Heinz Frank is greatly acknowledged for his contribution to the synthesis of PAHs and sadly passed away.	[Anonymous], 1985, BIOACTIVATION FOREIG; Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Boehme KA, 2008, P NATL ACAD SCI USA, V105, P7785, DOI 10.1073/pnas.0703423105; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; BROUGHTON BC, 1995, AM J HUM GENET, V56, P167; Brown RH, 1999, J APPL PHYSIOL, V87, P2362, DOI 10.1152/jappl.1999.87.6.2362; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Buterin T, 2000, CANCER RES, V60, P1849; Callizot N, 2008, CANCER CHEMOTH PHARM, V62, P995, DOI 10.1007/s00280-008-0689-7; Chen SJ, 2003, J BIOL CHEM, V278, P19526, DOI 10.1074/jbc.M300780200; Chen WS, 2012, CARCINOGENESIS, V33, P1368, DOI 10.1093/carcin/bgs159; Chen YM, 1996, JPN J CLIN ONCOL, V26, P18, DOI 10.1093/oxfordjournals.jjco.a023173; Cheo DL, 1997, MUTAT RES-FUND MOL M, V374, P1, DOI 10.1016/S0027-5107(97)00046-8; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; DIPPLE A, 1987, NATURE, V327, P535, DOI 10.1038/327535a0; Donauer J, 2012, ARCH TOXICOL, V86, P329, DOI 10.1007/s00204-011-0757-3; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Gaestel M, 2009, NAT REV DRUG DISCOV, V8, P480, DOI 10.1038/nrd2829; Gehrke H, 2013, NANOTOXICOLOGY, V7, P274, DOI 10.3109/17435390.2011.652207; Graham JM, 2001, AM J HUM GENET, V69, P291, DOI 10.1086/321295; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herrlich P, 2008, MOL CELL, V29, P279, DOI 10.1016/j.molcel.2008.01.001; Hollander MC, 2005, P NATL ACAD SCI USA, V102, P13200, DOI 10.1073/pnas.0503133102; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; Kumar S, 1997, J ORG CHEM, V62, P8535, DOI 10.1021/jo9712355; Lagerqvist A, 2008, DNA REPAIR, V7, P1202, DOI 10.1016/j.dnarep.2008.03.022; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Lloyd DR, 2000, CANCER RES, V60, P517; Lubin A, 2014, INT J MOL SCI, V15, P141, DOI 10.3390/ijms15010141; Maillard O, 2008, MUTAT RES-REV MUTAT, V658, P271, DOI 10.1016/j.mrrev.2008.01.007; Maillard O, 2007, PLOS BIOL, V5, P717, DOI 10.1371/journal.pbio.0050079; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MCCAUSTLAND DJ, 1975, TETRAHEDRON LETT, P2549; Mitazaki S, 2009, TOXICOLOGY, V265, P115, DOI 10.1016/j.tox.2009.10.005; Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Oh KS, 2006, HUM MUTAT, V27, P1092, DOI 10.1002/humu.20392; PELKONEN O, 1982, PHARMACOL REV, V34, P189; Pereira L, 2013, EMBO MOL MED, V5, P1759, DOI 10.1002/emmm.201302732; Petit-Frere C, 1998, J INVEST DERMATOL, V111, P354, DOI 10.1038/sj.jid.5602962; Phillips DH, 1999, MUTAGENESIS, V14, P301, DOI 10.1093/mutage/14.3.301; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668; RANDERATH K, 1989, CARCINOGENESIS, V10, P1231, DOI 10.1093/carcin/10.7.1231; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; SAYER JM, 1981, J AM CHEM SOC, V103, P4970, DOI 10.1021/ja00406a063; Schafer ZT, 2007, J CLIN INVEST, V117, P3660, DOI 10.1172/JCI34237; Schreck I, 2009, TOXICOLOGY, V259, P91, DOI 10.1016/j.tox.2009.02.006; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stoeger T, 2004, INTERPRETATIONS MOL, P75; Straif K, 2005, LANCET ONCOL, V6, P931, DOI 10.1016/S1470-2045(05)70458-7; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Ulrich-Pur H, 2000, ONCOLOGY-BASEL, V59, P187, DOI 10.1159/000012159; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; YAGI H, 1977, J AM CHEM SOC, V99, P1604, DOI 10.1021/ja00447a053; Zhao Q, 2008, J BIOL CHEM, V283, P32553, DOI 10.1074/jbc.M803963200	67	8	8	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					908	918		10.1038/onc.2015.145	http://dx.doi.org/10.1038/onc.2015.145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25982271				2022-12-28	WOS:000370332200011
J	Ohno, S; Naito, Y; Mukai, S; Yabuta, N; Nojima, H				Ohno, S.; Naito, Y.; Mukai, S.; Yabuta, N.; Nojima, H.			ELAS1-mediated inhibition of the cyclin G1-B 'gamma interaction promotes cancer cell apoptosis via stabilization and activation of p53	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; DNA-DAMAGE; PHOSPHOINOSITIDE 3-KINASE; COLORECTAL-CANCER; MEDIATED TRANSFER; G2 EXPRESSION; TUMOR-GROWTH; G1; ARREST; PHOSPHORYLATION	Radiation therapy (RT) is useful for selectively killing cancer cells. However, because high levels of ionizing radiation (IR) are toxic to normal cells, RT cannot be applied repeatedly to cancer patients. Therefore, novel chemicals that enhance the efficacy of chemoradiotherapy (CRT) would be valuable. Here, we report that ELAS1, a peptide corresponding to the protein phosphatase 2A (PP2A) association domain of cyclin G1 (CycG1), can enhance the efficacy of CRT. ELAS1 interacts with the PP2A B'gamma-subunit and competitively inhibits association with CycG1, thereby preventing the PP2A holoenzyme from dephosphorylating target proteins, Mdm2 (pT218) and p53 (pS46), following DNA double-strand break (DSB) insults. Doxycycline (Dox)-induced overexpression of Myc-ELAS1 caused.-irradiation to induce apoptosis in human osteosarcoma (U2OS) cells, at 1/10th the effective dosage of.-irradiation required for apoptosis in Myc-vector-expressing cells; ELAS1 peptide incorporation into U2OS cells also showed similar apoptotic effects. Moreover, administration of DSB-inducing chemicals, camptothecin (CPT) or irinotecan, to Myc-ELAS1-expressing U2OS cells also induced efficient apoptosis with only 1/100th (CPT) or 1/5th (irinotecan) of the amounts of drugs required for this effect in Myc-vector-expressing cells. Taken together, ELAS1 may be important for the design of ELAS1-mimetic compounds to improve CRT efficacy.	[Ohno, S.; Naito, Y.; Mukai, S.; Yabuta, N.; Nojima, H.] Osaka Univ, Microbial Dis Res Inst, Dept Mol Genet, Suita, Osaka 5650871, Japan	Osaka University	Nojima, H (corresponding author), Osaka Univ, Reasearch Inst Microbial Dis, Dept Mol Genet, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	snj-0212@biken.osaka-u.ac.jp			Osaka University; Ministry of Education, Culture, Sports, Science and Technology of Japan [23370086]	Osaka University; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Patrick Hughes for critically reading the manuscript and Ms Yuki Ozaki for technical assistance. This work was supported by the Drug Discovery Gap Fund from Osaka University (to HN) and Grants-in-aid for Scientific Research (to HN) (No. 23370086) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Baek WK, 2003, AM J OBSTET GYNECOL, V188, P634, DOI 10.1067/mob.2003.140; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Chen DS, 1997, HUM GENE THER, V8, P1667, DOI 10.1089/hum.1997.8.14-1667; Chen WB, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/675429; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055; Fu G, 2011, ONCOGENE, V30, P3953, DOI 10.1038/onc.2011.127; Gordon EM, 2000, CANCER RES, V60, P3343; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Ito Y, 2003, ANTICANCER RES, V23, P2335; Jensen MR, 2003, HEPATOLOGY, V37, P862, DOI 10.1053/jhep.2003.50137; Kalev P, 2011, ANTI-CANCER AGENT ME, V11, P38, DOI 10.2174/187152011794941172; Kampmeier J, 2000, HUM GENE THER, V11, P1, DOI 10.1089/10430340050016102; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Le XF, 2007, MOL CANCER THER, V6, P2843, DOI 10.1158/1535-7163.MCT-07-0109; Liu C, 2014, NUCLEIC ACIDS RES, V42, P6106, DOI 10.1093/nar/gku284; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; Mi J, 2009, MOL CANCER THER, V8, P135, DOI 10.1158/1535-7163.MCT-08-0457; Naito Y, 2013, CELL CYCLE, V12, P1773, DOI 10.4161/cc.24878; Naito Y, 2012, CELL CYCLE, V11, P604, DOI 10.4161/cc.11.3.19114; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Park IJ, 2014, WORLD J GASTROENTERO, V20, P2023, DOI 10.3748/wjg.v20.i8.2023; Peng A, 2010, ONCOGENE, V29, P5977, DOI 10.1038/onc.2010.371; Perez R, 2003, J GASTROINTEST SURG, V7, P884, DOI 10.1016/j.gassur.2003.08.001; Piscopo DM, 2008, CANCER RES, V68, P5581, DOI 10.1158/0008-5472.CAN-07-6346; Ragel BT, 2007, NEUROSURG REV, V30, P181, DOI 10.1007/s10143-007-0070-z; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Seo HR, 2006, CELL DEATH DIFFER, V13, P1475, DOI 10.1038/sj.cdd.4401822; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; SKOTZKO M, 1995, CANCER RES, V55, P5493; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; TAMURA K, 1993, ONCOGENE, V8, P2113; Todo T, 2001, P NATL ACAD SCI USA, V98, P6396, DOI 10.1073/pnas.101136398; Tomicic MT, 2013, BBA-REV CANCER, V1835, P11, DOI 10.1016/j.bbcan.2012.09.002; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wen W, 2012, HEPATOLOGY, V55, P1787, DOI 10.1002/hep.25596; Xu GX, 2008, MOL BIOL CELL, V19, P4968, DOI 10.1091/mbc.E08-03-0259; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yang J, 2010, LIFE SCI, V87, P659, DOI 10.1016/j.lfs.2010.10.003; Zhang Qingxiu, 2012, Enzyme Res, V2012, P659649, DOI 10.1155/2012/659649; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhao L, 2003, MOL CANCER RES, V1, P195; Zimmermann M, 2012, J BIOL CHEM, V287, P22838, DOI 10.1074/jbc.M112.376855	48	6	6	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5983	5996		10.1038/onc.2015.47	http://dx.doi.org/10.1038/onc.2015.47			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25915850				2022-12-28	WOS:000366113500005
J	Castillo-Lluva, S; Hontecillas-Prieto, L; Blanco-Gomez, A; Saez-Freire, MD; Garcia-Cenador, B; Garcia-Criado, J; Perez-Andres, M; Orfao, A; Canamero, M; Mao, JH; Gridley, T; Castellanos-Martin, A; Perez-Losada, J				Castillo-Lluva, S.; Hontecillas-Prieto, L.; Blanco-Gomez, A.; del Mar Saez-Freire, M.; Garcia-Cenador, B.; Garcia-Criado, J.; Perez-Andres, M.; Orfao, A.; Canamero, M.; Mao, J. H.; Gridley, T.; Castellanos-Martin, A.; Perez-Losada, J.			A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; PROGENITOR CELLS; MESENCHYMAL TRANSITION; KINASE-ACTIVITY; PROTO-ONCOGENE; SELF-RENEWAL; SLUG GENE; STEM; EXPRESSION; CYCLIN	Breast cancer is a major cause of mortality in women. The transcription factor SNAI2 has been implicated in the pathogenesis of several types of cancer, including breast cancer of basal origin. Here we show that SNAI2 is also important in the development of breast cancer of luminal origin in MMTV-ErbB2 mice. SNAI2 deficiency leads to longer latency and fewer luminal tumors, both of these being characteristics of pretumoral origin. These effects were associated with reduced proliferation and a decreased ability to generate mammospheres in normal mammary glands. However, the capacity to metastasize was not modified. Under conditions of increased ERBB2 oncogenic activity after pregnancy plus SNAI2 deficiency, both pretumoral defects-latency and tumor load-were compensated. However, the incidence of lung metastases was dramatically reduced. Furthermore, SNAI2 was required for proper postlactational involution of the breast. At 3 days post lactational involution, the mammary glands of Snai2-deficient mice exhibited lower levels of pSTAT3 and higher levels of pAKT1, resulting in decreased apoptosis. Abundant noninvoluted ducts were still present at 30 days post lactation, with a greater number of residual ERBB2+ cells. These results suggest that this defect in involution leads to an increase in the number of susceptible target cells for transformation, to the recovery of the capacity to generate mammospheres and to an increase in the number of tumors. Our work demonstrates the participation of SNAI2 in the pathogenesis of luminal breast cancer, and reveals an unexpected connection between the processes of postlactational involution and breast tumorigenesis in Snai2-null mutant mice.	[Castillo-Lluva, S.; Hontecillas-Prieto, L.; Blanco-Gomez, A.; del Mar Saez-Freire, M.; Perez-Andres, M.; Orfao, A.; Castellanos-Martin, A.; Perez-Losada, J.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc IBMCC, Salamanca 37007, Spain; [Castillo-Lluva, S.; Hontecillas-Prieto, L.; Blanco-Gomez, A.; del Mar Saez-Freire, M.; Garcia-Cenador, B.; Garcia-Criado, J.; Perez-Andres, M.; Orfao, A.; Castellanos-Martin, A.; Perez-Losada, J.] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Garcia-Cenador, B.; Garcia-Criado, J.] Univ Salamanca, Dept Cirugia, Salamanca 37007, Spain; [Perez-Andres, M.; Orfao, A.] Univ Salamanca, IBSAL, Unidad Citometria Flujo, Salamanca, Spain; [Canamero, M.] Ctr Nacl Invest Oncol CNIO, Madrid, Spain; [Mao, J. H.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Life Sci Div, Berkeley, CA 94720 USA; [Gridley, T.] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Maine Medical Center	Castellanos-Martin, A (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel de Unamuno Sn, Salamanca 37007, Spain.	andres.castellanos@irbbarcelona.org; jperezlosada@usal.es	/AAI-3238-2021; Blanco-Gomez, Adrian/GPK-8337-2022; Mao, Jian-Hua/EIZ-8595-2022; Cenador, Begoña García/Q-9417-2018; Cenador, María Begoña García/CAI-2603-2022; CASTILLO-LLUVA, SONIA/AAA-1776-2020; Perez-Andres, Martin/B-3692-2019; Pérez-Losada, Jesús/A-5883-2019; Castellanos, Andres/F-3302-2016; Orfao, Alberto/B-5801-2017	Mao, Jian-Hua/0000-0001-9320-6021; Cenador, Begoña García/0000-0002-8950-8542; Cenador, María Begoña García/0000-0002-8950-8542; Perez-Andres, Martin/0000-0003-4599-0776; Pérez-Losada, Jesús/0000-0003-2400-624X; Castellanos, Andres/0000-0003-2864-7271; Blanco Gomez, Adrian/0000-0002-1956-088X; Castillo-LLuva, Sonia/0000-0001-5357-7178	FEDER; MICINN [PLE2009-119, SAF2014-56989-R]; Instituto de Salud Carlos III [PI07/0057, PI10/00328, PIE14/00066]; Junta de Castilla y Leon [SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13]; Fundacion Eugenio Rodriguez Pascual; 'Fundacion Inbiomed' (Instituto Oncologico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa); Fundacion Sandra Ibarra de Solidaridad frente al Cancer; FIS [PI07/0057]; JAEdoc Fellowship (CSIC)/FSE; Junta de Castilla y Leon; National Institutes of Health; National Cancer Institute [R01 CA116481]; Low-Dose Scientific Focus Area, Office of Biological and Environmental Research, US Department of Energy [DE-AC02-05CH11231]; NATIONAL CANCER INSTITUTE [R01CA116481] Funding Source: NIH RePORTER	FEDER(European Commission); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Junta de Castilla y Leon(Junta de Castilla y Leon); Fundacion Eugenio Rodriguez Pascual; 'Fundacion Inbiomed' (Instituto Oncologico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa); Fundacion Sandra Ibarra de Solidaridad frente al Cancer; FIS(Instituto de Salud Carlos III); JAEdoc Fellowship (CSIC)/FSE; Junta de Castilla y Leon(Junta de Castilla y Leon); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Low-Dose Scientific Focus Area, Office of Biological and Environmental Research, US Department of Energy(United States Department of Energy (DOE)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JP-L was partially supported by FEDER and MICINN (PLE2009-119, SAF2014-56989-R), Instituto de Salud Carlos III (PI07/0057, PI10/00328, PIE14/00066), Junta de Castilla y Leon (SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13), the 'Fundacion Eugenio Rodriguez Pascual', the 'Fundacion Inbiomed' (Instituto Oncologico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa) and the 'Fundacion Sandra Ibarra de Solidaridad frente al Cancer'. AC-M was supported by FIS (PI07/0057) and MICINN (PLE2009-119). SC-L was funded by a JAEdoc Fellowship (CSIC)/FSE. MMS-F and AB-G are funded by fellowships from the Junta de Castilla y Leon. J-HM was supported by the National Institutes of Health, a National Cancer Institute Grant (R01 CA116481) and the Low-Dose Scientific Focus Area, Office of Biological and Environmental Research, US Department of Energy (DE-AC02-05CH11231). We thank Dr Montoliu for HC11 cells, Dr Garcia Macias and the Comparative Pathology Core Facility of the 'Centro de Investigacion del Cancer (CIC) de la Universidad de Salamanca' for Pathology support, Maria Luz Hernandez Mulas and Isabel Ramos for technical assistance, Dr Sanchez-Garcia and Dr Martin-Zanca for useful comments along this project, Dr Balmain and Dr Lazo for comments about the manuscript and Nicholas Skinner for his useful help in English editing.	Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bowe DB, 2002, ONCOGENE, V21, P291, DOI 10.1038/sj/onc/1205025; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Carpenter RL, 2014, ONCOGENE, V34, P546; Castellanos-Martin A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0599-z; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; Deugnier MA, 2006, DEV BIOL, V293, P414, DOI 10.1016/j.ydbio.2006.02.007; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hajra KM, 2002, CANCER RES, V62, P1613; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hinohara K, 2012, P NATL ACAD SCI USA, V109, P6584, DOI 10.1073/pnas.1113271109; Hudson LG, 2007, MOL CARCINOGEN, V46, P257, DOI 10.1002/mc.20257; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; KNIGHT CH, 1982, J REPROD FERTIL, V65, P521, DOI 10.1530/jrf.0.0650521; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Landis MD, 2006, ONCOGENE, V25, P3325, DOI 10.1038/sj.onc.1209365; Little JL, 2014, ONCOGENE, V33, P411, DOI 10.1038/onc.2012.607; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Mittal MK, 2011, J BIOL CHEM, V286, P469, DOI 10.1074/jbc.M110.164384; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Nassour M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053498; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Prater MD, 2014, NAT CELL BIOL, V16, P942, DOI 10.1038/ncb3025; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rowse GJ, 1998, CANCER RES, V58, P2675; Sanchez-Garcia I, 2009, NEW ENGL J MED, V360, P297, DOI 10.1056/NEJMcibr0808031; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; VANDUUREN BL, 1975, CANCER RES, V35, P502; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Villarejo A, 2015, CARCINOGENESIS, V36, P585, DOI 10.1093/carcin/bgv021; Wang GH, 2014, MOL CANCER THER, V13, P1837, DOI 10.1158/1535-7163.MCT-14-0049; Watson CJ, 2011, INT J DEV BIOL, V55, P757, DOI 10.1387/ijdb.113414cw; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Zhang WZ, 2013, CANCER CELL, V23, P647, DOI 10.1016/j.ccr.2013.03.012	67	8	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4777	4790		10.1038/onc.2015.224	http://dx.doi.org/10.1038/onc.2015.224			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	26096931	Green Accepted, Green Submitted			2022-12-28	WOS:000360931500011
J	Vellinga, TT; den Uil, S; Rinkes, IHB; Marvin, D; Ponsioen, B; Alvarez-Varela, A; Fatrai, S; Scheele, C; Zwijnenburg, DA; Snippert, H; Vermeulen, L; Medema, JP; Stockmann, HB; Koster, J; Fijneman, RJA; de Rooij, J; Kranenburg, O				Vellinga, T. T.; den Uil, S.; Rinkes, I. H. B.; Marvin, D.; Ponsioen, B.; Alvarez-Varela, A.; Fatrai, S.; Scheele, C.; Zwijnenburg, D. A.; Snippert, H.; Vermeulen, L.; Medema, J. P.; Stockmann, H. B.; Koster, J.; Fijneman, R. J. A.; de Rooij, J.; Kranenburg, O.			Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; HUMAN COLORECTAL-CANCER; MOLECULAR SUBTYPES; UP-REGULATION; TGF-BETA; TRANSITION; METASTASIS; SURVIVAL; PROGRAM; MATRIX	Gene expression-based classification systems have identified an aggressive colon cancer subtype with mesenchymal features, possibly reflecting epithelial-to-mesenchymal transition (EMT) of tumor cells. However, stromal fibroblasts contribute extensively to the mesenchymal phenotype of aggressive colon tumors, challenging the notion of tumor EMT. To separately study the neoplastic and stromal compartments of colon tumors, we have generated a stroma gene filter (SGF). Comparative analysis of stroma(high) and stroma(low) tumors shows that the neoplastic cells in stromahigh tumors express specific EMT drivers (ZEB2, TWIST1, TWIST2) and that 98% of differentially expressed genes are strongly correlated with them. Analysis of differential gene expression between mesenchymal and epithelial cancer cell lines revealed that hepatocyte nuclear factor 4 alpha (HNF4 alpha), a transcriptional activator of intestinal (epithelial) differentiation, and its target genes are highly expressed in epithelial cancer cell lines. However, mesenchymal-type cancer cell lines expressed only part of the mesenchymal genes expressed by tumor-derived neoplastic cells, suggesting that external cues were lacking. We found that collagen-I dominates the extracellular matrix in aggressive colon cancer. Mimicking the tumor microenvironment by replacing laminin-rich Matrigel with collagen-I was sufficient to induce tumor-specific mesenchymal gene expression, suppression of HNF4 alpha and its target genes, and collective tumor cell invasion of patient-derived colon tumor organoids. The data connect collagen-rich stroma to mesenchymal gene expression in neoplastic cells and to collective tumor cell invasion. Targeting the tumor-collagen interface may therefore be explored as a novel strategy in the treatment of aggressive colon cancer.	[Vellinga, T. T.; Rinkes, I. H. B.; Marvin, D.; Fatrai, S.; Kranenburg, O.] Univ Med Ctr Utrecht, Ctr Canc, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [den Uil, S.; Fijneman, R. J. A.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands; [den Uil, S.; Stockmann, H. B.; de Rooij, J.] Spaarne Gasthuis, Dept Surg, Haarlem, Netherlands; [Ponsioen, B.; Alvarez-Varela, A.; Scheele, C.; Snippert, H.] Univ Med Ctr Utrecht, Dept Mol Canc Res, Utrecht, Netherlands; [Zwijnenburg, D. A.] Acad Med Ctr Amsterdam, Dept Oncogen, Amsterdam, Netherlands; [Vermeulen, L.; Medema, J. P.; Koster, J.] Acad Med Ctr Amsterdam, Ctr Expt & Mol Med, Amsterdam, Netherlands; [Fijneman, R. J. A.] Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; Spaarne Hospital; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute	Kranenburg, O (corresponding author), Univ Med Ctr Utrecht, Ctr Canc, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	O.kranenburg@umcutrecht.nl	Scheele, Colinda/AAZ-9118-2021; Fijneman, Remond/X-4199-2019; de rooij, johan/C-1325-2019; Vermeulen, Louis/B-7488-2008; Koster, Jan/C-5934-2008	Scheele, Colinda/0000-0001-8999-5451; Fijneman, Remond/0000-0003-2076-5521; Vermeulen, Louis/0000-0002-6066-789X; Koster, Jan/0000-0002-0890-7585; Medema, Jan Paul/0000-0003-3045-2924; Alvarez-Varela, Adrian/0000-0001-5315-3092; Zwijnenburg, Danny/0000-0002-9353-8904				Belt EJT, 2011, EUR J CANCER, V47, P1837, DOI 10.1016/j.ejca.2011.04.025; Boissiere-Michot F, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.29256; Boyd M, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-68; Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212; Caiado F, 2013, CANCER RES, V73, P4233, DOI 10.1158/0008-5472.CAN-13-0085; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Celesti G, 2013, GASTROENTEROLOGY, V145, P647, DOI 10.1053/j.gastro.2013.05.011; Chanrion M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6005; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Emmink BL, 2014, CANCER RES, V74, P6717, DOI 10.1158/0008-5472.CAN-14-1645; Fatrai S, 2015, GASTROENTEROLOGY, V149, P692, DOI 10.1053/j.gastro.2015.05.003; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Hongo K, 2013, J SURG RES, V182, P75, DOI 10.1016/j.jss.2012.08.034; Huang Da Wei, 2009, Curr Protoc Bioinformatics, VChapter 13, DOI 10.1002/0471250953.bi1311s27; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Julien S, 2012, CLIN CANCER RES, V18, P5314, DOI 10.1158/1078-0432.CCR-12-0372; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021; Lussier CR, 2008, AM J PHYSIOL-GASTR L, V294, pG418, DOI 10.1152/ajpgi.00418.2007; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Mesker WE, 2007, CELL ONCOL, V29, P387; Mesker WE, 2009, CELL ONCOL, V31, P169, DOI 10.3233/CLO-2009-0478; Miles FL, 2014, MOL CANCER RES, V12, P297, DOI 10.1158/1541-7786.MCR-13-0535; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; Perez-Villamil B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-260; Phillips SM, 2004, BRIT J SURG, V91, P469, DOI 10.1002/bjs.4472; Roepman P, 2014, INT J CANCER, V134, P552, DOI 10.1002/ijc.28387; Sadanandam A, 2014, CELL CYCLE, V13, P353, DOI 10.4161/cc.27769; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Santangelo L, 2011, HEPATOLOGY, V53, P2063, DOI 10.1002/hep.24280; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schlicker A, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-66; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Stegmann A, 2006, PHYSIOL GENOMICS, V27, P141, DOI 10.1152/physiolgenomics.00314.2005; Tabibzadeh S, 2002, FRONT BIOSCI-LANDMRK, V7, pD1231; Thomson S, 2011, CLIN EXP METASTAS, V28, P137, DOI 10.1007/s10585-010-9367-3; Wei SC, 2015, NAT CELL BIOL, V17, P678, DOI 10.1038/ncb3157; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yao HS, 2015, MOL CARCINOG; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438	49	67	69	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5263	5271		10.1038/onc.2016.60	http://dx.doi.org/10.1038/onc.2016.60			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26996663				2022-12-28	WOS:000386053000005
J	Teng, Y; Pi, W; Wang, Y; Cowell, JK				Teng, Y.; Pi, W.; Wang, Y.; Cowell, J. K.			WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; LAMELLIPODIA FORMATION; PROMOTING PROTEIN; TARGETED THERAPY; GENE; ACTIVATION; EXPRESSION; MIGRATION; WAVE3; HER2	The WASF3 gene is overexpressed in high-grade breast cancer and promotes invasion and metastasis, but does not affect proliferation. The HER2/ERBB2/NEU gene is also frequently overexpressed in breast cancer, and has been shown to promote invasion and metastasis in these tumors. Here, we show that WASF3 is present in the HER2 immunocomplex and suppression of WASF3 function leads to suppression of invasion even in the presence of HER2 expression. Overexpression of both HER2 and WASF3 in non-metastatic MCF7 breast cancer cells promotes invasion and metastasis more significantly than either gene alone. HER2 forms homodimers as well as heterodimers with other HER family members and we now show that the ability of WASF3 to promote invasion is highly dependent on the HER2/HER3 heterodimer. The engagement of WASF3 with the HER2/HER3 complex facilitates its phospho-activation and transcriptional upregulation, which is facilitated by HER2/HER3 activation of JAK/STAT signaling. In breast cancer cells overexpressing HER2, therefore, WASF3 is specifically required to facilitate the invasion/metastasis response. Targeting WASF3, therefore, could be a potential therapeutic approach to suppress metastasis of HER2-overexpressing breast tumors.	[Teng, Y.; Wang, Y.; Cowell, J. K.] Georgia Regents Univ, Ctr Canc, Augusta, GA USA; [Teng, Y.; Pi, W.] Georgia Regents Univ, Dept Biochem & Mol Biol, Augusta, GA USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Teng, Y (corresponding author), Georgia Regents Univ, 1120 15th St, Augusta, GA 30912 USA.	yteng@gru.edu	Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289	National Institutes of Health [CA120510]; NATIONAL CANCER INSTITUTE [R01CA120510] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grant CA120510 from the National Institutes of Health. We would like to thank Yun Mei and Hao Zhang for the technical assistance.	Atalay G, 2003, ANN ONCOL, V14, P1346, DOI 10.1093/annonc/mdg365; Barok M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3621; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Cai Z, 2008, ONCOGENE, V27, P3870, DOI 10.1038/onc.2008.13; Freudenberg JA, 2009, EXP MOL PATHOL, V87, P1, DOI 10.1016/j.yexmp.2009.05.001; Ghoshal P, 2012, INT J CANCER, V131, pE905, DOI 10.1002/ijc.27631; Gomez-Martin C, 2014, CANCER LETT, V351, P30, DOI 10.1016/j.canlet.2014.05.019; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Johnson E, 2010, J BIOL CHEM, V285, P29491, DOI 10.1074/jbc.M110.136770; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Roses RE, 2009, CANCER EPIDEM BIOMAR, V18, P1386, DOI 10.1158/1055-9965.EPI-08-1101; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Shankaran H, 2006, BIOPHYS J, V90, P3993, DOI 10.1529/biophysj.105.080580; Sossey-Alaoui K, 2005, J BIOL CHEM, V280, P21748, DOI 10.1074/jbc.M500503200; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200; Sossey-Alaoui K, 2013, SEMIN CELL DEV BIOL, V24, P287, DOI 10.1016/j.semcdb.2012.10.006; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Taylor MA, 2013, BREAST CANCER RES TR, V142, P341, DOI 10.1007/s10549-013-2753-1; Teng Y, 2016, ONCOGENE, V35, P333, DOI 10.1038/onc.2015.86; Teng Y, 2014, ONCOGENE, V33, P203, DOI 10.1038/onc.2012.565; Teng Y, 2010, BRIT J CANCER, V103, P1066, DOI 10.1038/sj.bjc.6605850; Teng Y, 2015, CANC RES; Teng Yong, 2014, JAKSTAT, V3, pe28086, DOI 10.4161/jkst.28086; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Teng Y, 2013, CARCINOGENESIS, V34, P1994, DOI 10.1093/carcin/bgt167; Teng Y, 2012, J BIOL CHEM, V287, P10051, DOI 10.1074/jbc.M111.335000; Teng Y, 2011, INT J CANCER, V129, P2825, DOI 10.1002/ijc.25964; Tsujioka H, 2010, ANTICANCER RES, V30, P3107; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; Vaught DB, 2012, CANCER RES, V72, P2672, DOI 10.1158/0008-5472.CAN-11-3594; Zhang J, 2013, GYNECOL ONCOL, V130, P354, DOI 10.1016/j.ygyno.2013.05.005	43	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4633	4640		10.1038/onc.2015.527	http://dx.doi.org/10.1038/onc.2015.527			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26804171	Green Accepted			2022-12-28	WOS:000382336300009
J	Chan, JY; LaPara, K; Yee, D				Chan, J. Y.; LaPara, K.; Yee, D.			Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells	ONCOGENE			English	Article							GROWTH-FACTOR-I; ADVANCED SOLID TUMORS; DOWN-REGULATION; MONOCLONAL-ANTIBODIES; CLINICAL-IMPLICATIONS; PHASE-I; EXPRESSION; TAMOXIFEN; ESTROGEN; THERAPY	The insulin-like growth factor (IGF) system is a well-studied growth regulatory pathway implicated in breast cancer biology. Clinical trials testing monoclonal antibodies directed against the type I IGF receptor (IGF1R) in combination with estrogen receptor-a (ER) targeting have been completed, but failed to show benefits in patients with endocrine-resistant tumors compared to ER targeting alone. We have previously shown that the closely related insulin receptor (InsR) is expressed in tamoxifen-resistant (TamR) breast cancer cells. Here we examined if inhibition of InsR affected TamR breast cancer cells. InsR function was inhibited by three different mechanisms: InsR short hairpin RNA, a small InsR-blocking peptide, S961 and an InsR monoclonal antibody (mAb). Suppression of InsR function by these methods in TamR cells successfully blocked insulin-mediated signaling, monolayer proliferation, cell cycle progression and anchorage-independent growth. This strategy was not effective in parental cells likely because of the presence of IGFR/InsR hybrid receptors. Downregulation of IGF1R in conjunction with InsR inhibition was more effective in blocking IGF- and insulin-mediated signaling and growth in parental cells compared with single-receptor targeting alone. Our findings show TamR cells were stimulated by InsR and were not sensitive to IGF1R inhibition, whereas in tamoxifen-sensitive parental cancer cells, the presence of both receptors, especially hybrid receptors, allowed cross-reactivity of ligand-mediated activation and growth. To suppress the IGF system, targeting of both IGF1R and InsR is optimal in endocrine-sensitive and -resistant breast cancer.	[Chan, J. Y.; Yee, D.] Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA; [LaPara, K.; Yee, D.] Univ Minnesota, Mason Canc Ctr, MMC 806,420 Delaware St SE, Minneapolis, MN 55414 USA; [Yee, D.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Yee, D (corresponding author), Univ Minnesota, Mason Canc Ctr, MMC 806,420 Delaware St SE, Minneapolis, MN 55414 USA.	yeexx006@umn.edu		Yee, Douglas/0000-0002-3387-4009	NIH/NCI [2P30-CA077598, P50CA116201]; Komen for the Cure [SAC110039]; NATIONAL CANCER INSTITUTE [P50CA116201, P30CA077598] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the assistance of the University Flow Cytometry Resource at the University of Minnesota; Novo Nordisk for supplying S961 peptides. Funding was provided by NIH/NCI 2P30-CA077598 (JYC, KL and DY), NIH/NCI P50CA116201 (DY), and Komen for the Cure SAC110039 (DY).	Arnedos M, 2014, ANN ONCOL, V25, P605, DOI 10.1093/annonc/mdt575; Arpino G, 2009, ONCOLOGY-BASEL, V77, P23, DOI 10.1159/000258493; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Belfiore A, 2011, ENDOCR-RELAT CANCER, V18, pR125, DOI 10.1530/ERC-11-0074; Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047; Chen HX, 2013, CHIN J CANCER, V32, P242, DOI 10.5732/cjc.012.10263; Dowling RJO, 2012, J MOL ENDOCRINOL, V48, pR31, DOI 10.1530/JME-12-0007; Drury SC, 2011, ENDOCR-RELAT CANCER, V18, P565, DOI 10.1530/ERC-10-0046; Fagan DH, 2012, CANCER RES, V72, P3372, DOI 10.1158/0008-5472.CAN-12-0684; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Fulzele K, 2007, J BIOL CHEM, V282, P25649, DOI 10.1074/jbc.M700651200; Garber K, 2014, SCIENCE, V345, P865, DOI 10.1126/science.345.6199.865; Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078; Giuliano M, 2011, BREAST, V20, pS42, DOI 10.1016/S0960-9776(11)70293-4; Harrington SC, 2012, GROWTH HORM IGF RES, V22, P108, DOI 10.1016/j.ghir.2012.04.001; JAQUES G, 1989, EXP CELL RES, V184, P396, DOI 10.1016/0014-4827(89)90339-X; Jiang LY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-131; Jones HE, 2006, BRIT J CANCER, V95, P172, DOI 10.1038/sj.bjc.6603237; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Josefson D, 2000, BRIT MED J, V320, P1496; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; Knudsen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051972; Lee AV, 1997, J ENDOCRINOL, V152, P39, DOI 10.1677/joe.0.1520039; Macaskill EJ, 2006, ONCOLOGIST, V11, P1081, DOI 10.1634/theoncologist.11-10-1081; MILAZZO G, 1992, CANCER RES, V52, P3924; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; Nadji M, 2005, AM J CLIN PATHOL, V123, P21, DOI 10.1309/4WV79N2GHJ3X1841; OBRIEN RM, 1987, EMBO J, V6, P4003, DOI 10.1002/j.1460-2075.1987.tb02743.x; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Paridaens RJ, 2008, J CLIN ONCOL, V26, P4883, DOI 10.1200/JCO.2007.14.4659; Puzanov I, 2015, CLIN CANCER RES, V21, P701, DOI 10.1158/1078-0432.CCR-14-0303; Ramos RR, 2007, P NATL ACAD SCI USA, V104, P10470, DOI 10.1073/pnas.0701114104; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Rose DP, 2007, ENDOCR REV, V28, P763, DOI 10.1210/er.2006-0019; Rostoker R, 2015, ENDOCR-RELAT CANCER, V22, P145, DOI 10.1530/ERC-14-0490; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Thompson MD, 2015, CANCER PREV RES, V8, P231, DOI 10.1158/1940-6207.CAPR-14-0181-T; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Weinstein D, 2014, ENDOCR CONNECT, V3, P24, DOI 10.1530/EC-13-0086; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Zhang H, 2010, ONCOGENE, V29, P2517, DOI 10.1038/onc.2010.17; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712; Zhang H, 2009, BREAST CANCER RES TR, V114, P277, DOI 10.1007/s10549-008-0014-5	47	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4235	4243		10.1038/onc.2015.488	http://dx.doi.org/10.1038/onc.2015.488			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26876199	Green Accepted			2022-12-28	WOS:000382149800008
J	Bajpai, R; Matulis, SM; Wei, C; Nooka, AK; Von Hollen, HE; Lonial, S; Boise, LH; Shanmugam, M				Bajpai, R.; Matulis, S. M.; Wei, C.; Nooka, A. K.; Von Hollen, H. E.; Lonial, S.; Boise, L. H.; Shanmugam, M.			Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax	ONCOGENE			English	Article							ANTITUMOR-ACTIVITY; CELL-SURVIVAL; MCL-1; INHIBITOR; APOPTOSIS; EXPRESSION; DEPENDENCE; RITONAVIR; ABT-199; POTENT	Multiple myeloma (MM) is a plasma cell malignancy that is largely incurable due to development of resistance to therapy-elicited cell death. Nutrients are intricately connected to maintenance of cellular viability in part by inhibition of apoptosis. We were interested to determine if examination of metabolic regulation of BCL-2 proteins may provide insight on alternative routes to engage apoptosis. MM cells are reliant on glucose and glutamine and withdrawal of either nutrient is associated with varying levels of apoptosis. We and others have demonstrated that glucose maintains levels of key resistance-promoting BCL-2 family member, myeloid cell leukemic factor 1 (MCL-1). Cells continuing to survive in the absence of glucose or glutamine were found to maintain expression of MCL-1 but importantly induce pro-apoptotic BIM expression. One potential mechanism for continued survival despite induction of BIM could be due to binding and sequestration of BIM to alternate pro-survival BCL-2 members. Our investigation revealed that cells surviving glutamine withdrawal in particular, enhance expression and binding of BIM to BCL-2, consequently sensitizing these cells to the BH3 mimetic venetoclax. Glutamine deprivation-driven sensitization to venetoclax can be reversed by metabolic supplementation with TCA cycle intermediate alpha-ketoglutarate. Inhibition of glucose metabolism with the GLUT4 inhibitor ritonavir elicits variable cytotoxicity in MM that is marginally enhanced with venetoclax treatment, however, targeting glutamine metabolism with 6-diazo-5-oxo-L-norleucine uniformly sensitized MM cell lines and relapse/refractory patient samples to venetoclax. Our studies reveal a potent therapeutic strategy of metabolically driven synthetic lethality involving targeting glutamine metabolism for sensitization to venetoclax in MM.	[Bajpai, R.; Matulis, S. M.; Wei, C.; Nooka, A. K.; Von Hollen, H. E.; Lonial, S.; Boise, L. H.; Shanmugam, M.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University	Shanmugam, M (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.	mala.shan@emory.edu	Shanmugam, Mala/M-6491-2019; Boise, Lawrence/AAD-2314-2019; Bajpai, Richa/H-6404-2019	Shanmugam, Mala/0000-0002-4415-8083; Boise, Lawrence/0000-0001-9436-8815	American Cancer Society Research scholar grant [RSG-11-254-01-CSM]; TJ Martell Foundation;  [P30CA138292]; NATIONAL CANCER INSTITUTE [P30CA138292] Funding Source: NIH RePORTER	American Cancer Society Research scholar grant(American Cancer Society); TJ Martell Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the American Cancer Society Research scholar grant (RSG-11-254-01-CSM) to MS. LHB is a Georgia Research Alliance distinguished cancer scientist and also received support from the TJ Martell Foundation and P30CA138292.	Accardi F, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.2067.2067; Barlogie B, 2014, BLOOD, V124, P3043, DOI 10.1182/blood-2014-07-552059; Bartel TB, 2009, BLOOD, V114, P2068, DOI 10.1182/blood-2009-03-213280; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Brown G, 2008, BIOCHEMISTRY-US, V47, P5724, DOI 10.1021/bi800097h; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chonghaile TN, 2008, ONCOGENE, V27, pS149, DOI 10.1038/onc.2009.52; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Coloff JL, 2011, J BIOL CHEM, V286, P5921, DOI 10.1074/jbc.M110.179101; Dalva-Aydemir S, 2015, CLIN CANCER RES, V21, P1161, DOI 10.1158/1078-0432.CCR-14-1088; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Eguchi T, 2009, MOL CANCER THER, V8, P1460, DOI 10.1158/1535-7163.MCT-08-1159; Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Liu ZQ, 2014, BLOOD, V124, P2061, DOI 10.1182/blood-2014-03-557298; McBrayer SK, 2012, BLOOD, V119, P4686, DOI 10.1182/blood-2011-09-377846; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Mishra RK, 2015, J BIOL CHEM, V290, P14441, DOI 10.1074/jbc.M114.628826; Morales AA, 2011, BLOOD, V118, P1329, DOI 10.1182/blood-2011-01-327197; Nakajima W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.6; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Olsen RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116998; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; Podar K, 2008, ONCOGENE, V27, P721, DOI 10.1038/sj.onc.1210679; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Prideaux Steven M, 2014, Adv Hematol, V2014, P864058, DOI 10.1155/2014/864058; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; ROBERTS RS, 1976, J CELL SCI, V21, P609; Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849; Shanmugam M, 2009, J BIOL CHEM, V284, P26816, DOI 10.1074/jbc.M109.000646; SHAPIRO RA, 1979, J BIOL CHEM, V254, P2835; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Vo TT, 2012, CELL, V151, P344, DOI 10.1016/j.cell.2012.08.038; Thomas RL, 2013, GENE DEV, V27, P1365, DOI 10.1101/gad.215871.113; Touzeau C, 2014, LEUKEMIA, V28, P210, DOI 10.1038/leu.2013.216; Tuffy LP, 2010, MOL CELL BIOL, V30, P5484, DOI 10.1128/MCB.00575-10; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vyas AK, 2010, J BIOL CHEM, V285, P36395, DOI 10.1074/jbc.M110.176321; Wensveen FM, 2010, IMMUNITY, V32, P754, DOI 10.1016/j.immuni.2010.06.005; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07	49	58	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3955	3964		10.1038/onc.2015.464	http://dx.doi.org/10.1038/onc.2015.464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26640142	Green Accepted			2022-12-28	WOS:000381013100007
J	Chu, PC; Yang, MC; Kulp, SK; Salunke, SB; Himmel, LE; Fang, CS; Jadhav, AM; Shan, YS; Lee, CT; Lai, MD; Shirley, LA; Bekaii-Saab, T; Chen, CS				Chu, P-C; Yang, M-C; Kulp, S. K.; Salunke, S. B.; Himmel, L. E.; Fang, C-S; Jadhav, A. M.; Shan, Y-S; Lee, C-T; Lai, M-D; Shirley, L. A.; Bekaii-Saab, T.; Chen, C-S			Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; K-RAS; DUCTAL ADENOCARCINOMA; GENE-EXPRESSION; HNRNP A1; EGF RECEPTOR; KINASE; TRANSCRIPTION; PROTEIN; MYC	Integrin-linked kinase (ILK) is a mediator of aggressive phenotype in pancreatic cancer. On the basis of our finding that knockdown of either KRAS or ILK has a reciprocal effect on the other's expression, we hypothesized the presence of an ILK-KRAS regulatory loop that enables pancreatic cancer cells to regulate KRAS expression. This study aimed to elucidate the mechanism by which this regulatory circuitry is regulated and to investigate the translational potential of targeting ILK to suppress oncogenic KRAS signaling in pancreatic cancer. Interplay between KRAS and ILK and the roles of E2F1, c-Myc and heterogeneous nuclear ribonucleoprotein as intermediary effectors in this feedback loop was interrogated by genetic manipulations through small interfering RNA/short hairpin RNA knockdown and ectopic expression, western blotting, PCR, promoter-luciferase reporter assays, chromatin immunoprecipitation and pull-down analyses. In vivo efficacy of ILK inhibition was evaluated in two murine xenograft models. Our data show that KRAS regulated the expression of ILK through E2F1-mediated transcriptional activation, which, in turn, controlled KRAS gene expression via hnRNPA1-mediated destabilization of the G-quadruplex on the KRAS promoter. Moreover, ILK inhibition blocked KRAS-driven epithelial-mesenchymal transition and growth factor-stimulated KRAS expression. The knockdown or pharmacological inhibition of ILK suppressed pancreatic tumor growth, in part, by suppressing KRAS signaling. These studies suggest that this KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes. This regulatory loop provides a mechanistic rationale for targeting ILK to suppress oncogenic KRAS signaling, which might foster new therapeutic strategies for pancreatic cancer.	[Chu, P-C; Yang, M-C; Kulp, S. K.; Salunke, S. B.; Himmel, L. E.; Fang, C-S; Jadhav, A. M.; Chen, C-S] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, 500W 12th Ave, Columbus, OH 43201 USA; [Chu, P-C; Lai, M-D; Chen, C-S] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Chu, P-C; Chen, C-S] Acad Sinica, Inst Biol Chem, Taipei, Taiwan; [Himmel, L. E.] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH USA; [Shan, Y-S] Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan, Taiwan; [Lee, C-T] Natl Cheng Kung Univ, Coll Med, Dept Pathol, Tainan, Taiwan; [Shirley, L. A.] Ohio State Univ, Coll Med, Dept Surg, Columbus, OH USA; [Bekaii-Saab, T.] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH USA	University System of Ohio; Ohio State University; National Cheng Kung University; Academia Sinica - Taiwan; University System of Ohio; Ohio State University; National Cheng Kung University; National Cheng Kung University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Chen, CS (corresponding author), Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, 500W 12th Ave, Columbus, OH 43201 USA.	chen.844@osu.edu	Lai, Ming-Derg/M-8028-2014; Jadhav, Appaso/ABC-8338-2020	Jadhav, Appaso/0000-0002-4892-0792; Bekaii-Saab, Tanios/0000-0001-7721-1699	Lucius A Wing Endowed Chair Fund; Ministry of Science and Technology [MOST 103-2320-B-001-017]; National Cheng Kung University College of Medicine; Ohio State University Wexner Medical Center; Comprehensive Cancer Center; National Institutes of Health [P30 CA016058]; Comparative Pathology and Mouse Phenotyping Shared Resource at The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	Lucius A Wing Endowed Chair Fund; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Cheng Kung University College of Medicine; Ohio State University Wexner Medical Center; Comprehensive Cancer Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Comparative Pathology and Mouse Phenotyping Shared Resource at The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Lucius A Wing Endowed Chair Fund (CSC), Ministry of Science and Technology grant MOST 103-2320-B-001-017 (PCC), Bi-institutional Collaborative Pancreatic Cancer Research grants from National Cheng Kung University College of Medicine (CSC) and The Ohio State University Wexner Medical Center and Comprehensive Cancer Center (TBS) and National Institutes of Health grant P30 CA016058, which supports, in part, the Comparative Pathology and Mouse Phenotyping Shared Resource at The Ohio State University Comprehensive Cancer Center.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Bommert KS, 2013, LEUKEMIA, V27, P441, DOI 10.1038/leu.2012.185; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cogoi S, 2006, NUCLEIC ACIDS RES, V34, P2536, DOI 10.1093/nar/gkl286; Cogoi S, 2010, J BIOL CHEM, V285, P22003, DOI 10.1074/jbc.M110.101923; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 2011, ONCOGENE, V30, P4375, DOI 10.1038/onc.2011.177; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hsu EC, 2015, NEOPLASIA, V17, P497, DOI 10.1016/j.neo.2015.06.001; Jean-Philippe J, 2013, INT J MOL SCI, V14, P18999, DOI 10.3390/ijms140918999; Kalra J, 2010, ONCOGENE, V29, P6343, DOI 10.1038/onc.2010.366; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Lee SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067149; Lee SL, 2011, J MED CHEM, V54, P6364, DOI 10.1021/jm2007744; Liu TM, 2015, BLOOD, V125, P284, DOI 10.1182/blood-2014-06-583518; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Meng P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.326; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Paramasivam M, 2009, NUCLEIC ACIDS RES, V37, P2841, DOI 10.1093/nar/gkp138; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Sawai H, 2006, ONCOGENE, V25, P3237, DOI 10.1038/sj.onc.1209356; Schaeffer DF, 2010, VIRCHOWS ARCH, V456, P261, DOI 10.1007/s00428-009-0866-z; Seidler B, 2008, P NATL ACAD SCI USA, V105, P10137, DOI 10.1073/pnas.0800487105; Serrano I, 2013, ONCOGENE, V32, P50, DOI 10.1038/onc.2012.30; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Stolzenberg-Solomon RZ, 2005, JAMA-J AM MED ASSOC, V294, P2872, DOI 10.1001/jama.294.22.2872; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Wang ZW, 2013, J CELL PHYSIOL, V228, P556, DOI 10.1002/jcp.24162; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Young A, 2009, ADV CANCER RES, V102, P1, DOI 10.1016/S0065-230X(09)02001-6; Zhou ZJ, 2013, INT J CANCER, V132, P1080, DOI 10.1002/ijc.27742	47	28	29	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3897	3908		10.1038/onc.2015.458	http://dx.doi.org/10.1038/onc.2015.458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616862				2022-12-28	WOS:000381013100002
J	Kotani, H; Ebi, H; Kitai, H; Nanjo, S; Kita, K; Huynh, TG; Ooi, A; Faber, AC; Mino-Kenudson, M; Yano, S				Kotani, H.; Ebi, H.; Kitai, H.; Nanjo, S.; Kita, K.; Huynh, T. G.; Ooi, A.; Faber, A. C.; Mino-Kenudson, M.; Yano, S.			Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression	ONCOGENE			English	Article							IN-SITU HYBRIDIZATION; ACQUIRED-RESISTANCE; GENE AMPLIFICATION; TARGETED THERAPIES; BREAST-CANCER; GROWTH; SENSITIVITY; ACTIVATION; GENOMICS; AZD4547	Targeted therapies are effective in subsets of lung cancers with EGFR mutations and anaplastic lymphoma kinase (ALK) translocations. Large-scale genomics have recently expanded the lung cancer landscape with FGFR1 amplification found in 10-20% of squamous cell carcinomas (SCCs). However, the response rates have been low for biomarker-directed fibroblast growth factor receptor (FGFR) inhibitor therapy in SCC, which contrasts to the relatively high rates of response seen in EGFR mutant and ALK-translocated lung cancers treated with epidermal growth factor receptor (EGFR) inhibitors and ALK inhibitors, respectively. In order to better understand the low response rates of FGFR1-amplified lung cancers to FGFR inhibitors, relationships between gene copy number, mRNA expression and protein expression of FGFR1 were assessed in cell lines, tumor specimens and data from The Cancer Genome Atlas. The importance of these factors for the sensitivity to FGFR inhibitors was determined by analyzing drug screen data and conducting in vitro and in vivo experiments. We report that there was a discrepancy between FGFR1 amplification level and FGFR1 protein expression in a number of these cell lines, and the cancers with unexpectedly low FGFR1 expression were uniformly resistant to the different FGFR inhibitors. Further interrogation of the receptor tyrosine kinase activity in these discordant cell lines revealed co-activation of HER2 and platelet-derived growth factor receptor-a (PDGFRa) caused by gene amplification or ligand overexpression maintained phosphoinositide 3-kinase (PI3K) and MEK/ERK signaling even in the presence of FGFR inhibitor. Accordingly, co-inhibition of FGFR1 and HER2 or PDGFRa led to enhanced drug responses. In contrast, FGFR1-amplified high FGFR1 protein-expressing lung cancers are sensitive to FGFR inhibitor monotherapy by downregulating ERK signaling. Addition of a PI3K inhibitor to these high FGFR1 protein-expressing cancers further sensitized them to FGFR inhibitor. These data reveal that biomarker-directed trials for FGFR1-amplified SCC require assessment of FGFR1 protein expression and uncover novel therapeutic strategies for FGFR1-amplified SCC with low FGFR1 protein expression.	[Kotani, H.; Ebi, H.; Kitai, H.; Nanjo, S.; Kita, K.; Yano, S.] Kanazawa Univ, Canc Res Inst, Div Med Oncol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan; [Huynh, T. G.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Ooi, A.] Kanazawa Univ, Grad Sch Med Sci, Dept Mol & Cellular Pathol, Kanazawa, Ishikawa, Japan; [Faber, A. C.] Virginia Commonwealth Univ, Sch Dent, VCU Philips Inst Oral Hlth Res, Richmond, VA USA; [Faber, A. C.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA	Kanazawa University; Harvard University; Massachusetts General Hospital; Kanazawa University; Virginia Commonwealth University; Virginia Commonwealth University	Ebi, H; Yano, S (corresponding author), Kanazawa Univ, Canc Res Inst, Div Med Oncol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	hebi@staff.kanazawa-u.ac.jp; syano@staff.kanazawa-u.ac.jp	Ebi, Hiromichi/AAA-7358-2019; Kitai, Hidenori/AAD-4168-2022; KITA, Kenji/D-8437-2015	Ebi, Hiromichi/0000-0003-3155-7576; KITA, Kenji/0000-0002-4622-6633; Kotani, Hiroshi/0000-0002-6001-0636; KITAI, HIDENORI/0000-0001-6372-846X	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [26830105, 22112010A01]	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Shuta Tomida at Okayama University for his assistance with the statistics. This work was supported by Grants-in-Aid for Scientific Research (H Ebi, 26830105 and S Yano, 21390256), Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' (H Ebi and S Yano, 22112010A01) and Grant-in-Aid for Project for Development of Innovative Research on Cancer Therapeutics (P-Direct) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; Dienstmann R, 2014, ANN ONCOL, V25, P552, DOI 10.1093/annonc/mdt419; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Gandara DR, 2015, CLIN CANCER RES, V21, P2236, DOI 10.1158/1078-0432.CCR-14-3039; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Heist RS, 2012, J THORAC ONCOL, V7, P1775, DOI 10.1097/JTO.0b013e31826aed28; Helsten T, 2015, CLIN CANC RES; Herbst RS, 2015, CLIN CANCER RES, V21, P1514, DOI 10.1158/1078-0432.CCR-13-3473; Kim HR, 2013, J CLIN ONCOL, V31, P731, DOI 10.1200/JCO.2012.43.8622; Kohler LH, 2012, VIRCHOWS ARCH, V461, P49, DOI 10.1007/s00428-012-1250-y; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malchers F, 2014, CANCER DISCOV, V4, P246, DOI 10.1158/2159-8290.CD-13-0323; McDermott U, 2009, CANCER RES, V69, P3937, DOI 10.1158/0008-5472.CAN-08-4327; Meador CB, 2014, CLIN CANCER RES, V20, P2264, DOI 10.1158/1078-0432.CCR-13-1591; Montenegro MF, 2015, ONCOGENE, V34, P135, DOI 10.1038/onc.2013.605; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Nogova L, 2014, ASCO M, V32, P8034; O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028; Ooi A, 2012, J PATHOL, V227, P8, DOI 10.1002/path.3974; Paik PK, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8035; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Pros E, 2013, INT J CANCER, V133, P898, DOI 10.1002/ijc.28090; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Schildhaus HU, 2012, MODERN PATHOL, V25, P1473, DOI 10.1038/modpathol.2012.102; Seo AN, 2014, VIRCHOWS ARCH, V465, P547, DOI 10.1007/s00428-014-1634-2; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Terai H, 2013, MOL CANCER RES, V11, P759, DOI 10.1158/1541-7786.MCR-12-0652; Tran TN, 2013, LUNG CANCER, V81, P462, DOI 10.1016/j.lungcan.2013.05.015; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wang J, 2015, ONCOGENE, V34, P2167, DOI 10.1038/onc.2014.161; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wynes MW, 2014, CLIN CANCER RES, V20, P3299, DOI 10.1158/1078-0432.CCR-13-3060; Zhang JC, 2012, CLIN CANCER RES, V18, P6658, DOI 10.1158/1078-0432.CCR-12-2694	49	29	30	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3587	3597		10.1038/onc.2015.426	http://dx.doi.org/10.1038/onc.2015.426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26549034	Green Submitted			2022-12-28	WOS:000379621500011
J	Wang, Z; Kim, J; Teng, Y; Ding, HF; Zhang, J; Hai, T; Cowell, JK; Yan, C				Wang, Z.; Kim, J.; Teng, Y.; Ding, H-F; Zhang, J.; Hai, T.; Cowell, J. K.; Yan, C.			Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5(+)CK8(+) epithelial cells	ONCOGENE			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; TO-LUMINAL DIFFERENTIATION; ADAPTIVE-RESPONSE; CANCER; ESTROGEN; BASAL; PTEN; GROWTH; BETA; INFLAMMATION	Steroid sex hormones can induce prostate carcinogenesis, and are thought to contribute to the development of prostate cancer during aging. However, the mechanism for hormone-induced prostate carcinogenesis remains elusive. Here, we report that activating transcription factor 3 (ATF3)-a broad stress sensor-suppressed hormone-induced prostate carcinogenesis in mice. Although implantation of testosterone and estradiol (T+E-2) pellets for 2 months in wild-type mice rarely induced prostatic intraepithelial neoplasia (PIN) in dorsal prostates (one out of eight mice), the loss of ATF3 led to the appearance of not only PIN but also invasive lesions in almost all examined animals. The enhanced carcinogenic effects of hormones on ATF3-deficient prostates did not appear to be caused by a change in estrogen signaling, but were more likely a consequence of elevated androgen signaling that stimulated differentiation of prostatic basal cells into transformation-preferable luminal cells. Indeed, we found that hormone-induced lesions in ATF3-knockout mice often contained cells with both basal and luminal characteristics, such as p63(+) cells (a basal-cell marker) showing luminal-like morphology, or cells double-stained with basal (CK5(+)) and luminal (CK8(+)) markers. Consistent with these findings, low ATF3 expression was found to be a poor prognostic marker for prostate cancer in a cohort of 245 patients. Our results thus support that ATF3 is a tumor suppressor in prostate cancer.	[Wang, Z.; Teng, Y.; Ding, H-F; Cowell, J. K.; Yan, C.] Georgia Regents Univ, GRU Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA; [Wang, Z.; Yan, C.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Kim, J.] Sungkyunkwan Univ, Dept Stat, Seoul, South Korea; [Ding, H-F] Georgia Regents Univ, Med Coll Georgia, Dept Pathol, Augusta, GA USA; [Zhang, J.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; [Hai, T.] Ohio State Univ, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA; [Yan, C.] Georgia Regents Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA USA	University System of Georgia; Augusta University; Albany Medical College; Sungkyunkwan University (SKKU); University System of Georgia; Augusta University; Case Western Reserve University; University System of Ohio; Ohio State University; University System of Georgia; Augusta University	Yan, C (corresponding author), Georgia Regents Univ, GRU Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA.	cyan@gru.edu	Hai, Tsonwin/E-3185-2011; Teng, Yong/AAK-4160-2020	Hai, Tsonwin/0000-0003-4510-0315; Teng, Yong/0000-0002-1856-7289; Ding, Han-Fei/0000-0001-5702-3439; Yan, Chunhong/0000-0002-3974-7991	NIH [R01CA139107, R01CA164006]; Department of Defense award [W81XWH-15-1-0049]; NATIONAL CANCER INSTITUTE [R01CA139107, R01CA164006, P30CA016058] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense award(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants R01CA139107 and R01CA164006, and a Department of Defense award W81XWH-15-1-0049 to CY. We thank Dr Ahmed Chadli for providing the PR antibody.	Bennett NC, 2010, INT J BIOCHEM CELL B, V42, P813, DOI 10.1016/j.biocel.2009.11.013; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bonkhoff H, 1996, PROSTATE, V28, P98; Bosland Maarten C, 2005, Rev Urol, V7 Suppl 3, pS4; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gnanapragasam VJ, 2000, BJU INT, V86, P1001, DOI 10.1046/j.1464-410x.2000.00943.x; Goldstein AS, 2013, GENE DEV, V27, P1539, DOI 10.1101/gad.222380.113; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Heemers HW, 2005, ENDOCR REV, V28, P778; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Huang XW, 2008, J BIOL CHEM, V283, P29795, DOI 10.1074/jbc.M802515200; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kwon OJ, 2014, P NATL ACAD SCI USA, V111, pE592, DOI 10.1073/pnas.1318157111; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lau KM, 2000, CANCER RES, V60, P3175; Liu YQ, 2013, CANCER LETT, V337, P66, DOI 10.1016/j.canlet.2013.05.022; Lu TL, 2013, AM J PATHOL, V182, P975, DOI 10.1016/j.ajpath.2012.11.025; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; NOBLE RL, 1977, CANCER RES, V37, P1929; Okamoto A, 2006, MOL CELL BIOL, V26, P1087, DOI 10.1128/MCB.26.3.1087-1097.2006; Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ricke WA, 2008, FASEB J, V22, P1512, DOI 10.1096/fj.07-9526com; Ricke WA, 2007, DIFFERENTIATION, V75, P871, DOI 10.1111/j.1432-0436.2007.00224.x; Risbridger G, 2001, DEV BIOL, V229, P432, DOI 10.1006/dbio.2000.9994; Risbridger GP, 2001, ENDOCRINOLOGY, V142, P2443, DOI 10.1210/en.142.6.2443; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Wang HB, 2012, MOL CELL BIOL, V32, P3190, DOI 10.1128/MCB.00159-12; Wang JJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4415; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Wang Z, 2015, ONCOGENE, V34, P4975, DOI 10.1038/onc.2014.426; Wang Z, MOL CELL ON IN PRESS; Wang ZA, 2014, CELL REP, V8, P1339, DOI 10.1016/j.celrep.2014.08.002; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2006, CELL CYCLE, V5, P926, DOI 10.4161/cc.5.9.2714	43	14	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3555	3564		10.1038/onc.2015.417	http://dx.doi.org/10.1038/onc.2015.417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522727	Green Accepted			2022-12-28	WOS:000379621500008
J	Fahraeus, R; Marin, M; Olivares-Illana, V				Fahraeus, R.; Marin, M.; Olivares-Illana, V.			Whisper mutations: cryptic messages within the genetic code	ONCOGENE			English	Review							ASH1 MESSENGER-RNA; SYNONYMOUS MUTATIONS; ESCHERICHIA-COLI; SILENT MUTATIONS; IN-VIVO; TRANSLATION RATES; DNA-DAMAGE; YEAST BUD; PROTEIN; P53	Recent years have seen a great expansion in our understandings of how silent mutations can drive a disease and that mRNAs are not only mere messengers between the genome and the encoded proteins but also encompass regulatory activities. This review focuses on how silent mutations within open reading frames can affect the functional properties of the encoded protein. We describe how mRNAs exert control of cell biological processes governed by the encoded proteins via translation kinetics, protein folding, mRNA stability, spatio-temporal protein expression and by direct interactions with cellular factors. These examples illustrate how additional levels of information lie within the coding sequences and that the degenerative genetic code is not redundant and have co-evolved with the encoded proteins. Hence, so called synonymous mutations are not always silent but 'whisper'.	[Fahraeus, R.] Univ Paris 07, IUH Hop St Louis, Inst Genet Mol, Equipe Labellisee Ligue Canc,INSERM UMRS1162, F-75010 Paris, France; [Fahraeus, R.] Masaryk Mem Canc Inst, RECAMO, Zluty Kopec 7, Brno, Czech Republic; [Marin, M.] Univ Republica, Fac Ciencias, Inst Biol, Secc Biquim, Montevideo, Uruguay; [Olivares-Illana, V.] Univ Autonoma San Luis Potosi, Inst Fis, San Luis Potosi 78290, Mexico	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Masaryk Memorial Cancer Institute; Universidad de la Republica, Uruguay; Universidad Autonoma de San Luis Potosi	Fahraeus, R (corresponding author), Univ Paris 07, IUH Hop St Louis, Inst Genet Mol, Equipe Labellisee Ligue Canc,INSERM UMRS1162, F-75010 Paris, France.; Marin, M (corresponding author), Univ Republica, Fac Ciencias, Inst Biol, Secc Biquim, Montevideo, Uruguay.; Olivares-Illana, V (corresponding author), Univ Autonoma San Luis Potosi, Inst Fis, San Luis Potosi 78290, Mexico.	robin.fahraeus@inserm.fr; marin@fcien.edu.uy; vanesa@ifisica.uaslp.mx	Olivares-Illana, Vanesa/AAF-9710-2021; fahraeus, robin/K-8726-2014	Olivares-Illana, Vanesa/0000-0001-6949-5986	 [MEYS-NPS I-LO1413]		Equipe Labellisee La ligue contre le cancer, ECOS-Sud Program Cooperation France-Uruguay, ECOS-Nord Program Cooperation France-Mexico, Inserm and the project MEYS-NPS I-LO1413.	Aguirre B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021035; Aretz S, 2004, HUM MUTAT, V24, P370, DOI 10.1002/humu.20087; Barrick JE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r239; Bartoszewski RA, 2010, J BIOL CHEM, V285, P28741, DOI 10.1074/jbc.M110.154575; Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Breaker RR, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a003566; Breaker RR, 2011, MOL CELL, V43, P867, DOI 10.1016/j.molcel.2011.08.024; Buchan JR, 2007, BIOL CELL, V99, P475, DOI 10.1042/BC20070037; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Chartrand P, 1999, CURR BIOL, V9, P333, DOI 10.1016/S0960-9822(99)80144-4; Cortazzo P, 2002, BIOCHEM BIOPH RES CO, V293, P537, DOI 10.1016/S0006-291X(02)00226-7; Di Liegro CM, 2014, INT J MOL MED, V33, P747, DOI 10.3892/ijmm.2014.1629; Du TG, 2008, EMBO REP, V9, P781, DOI 10.1038/embor.2008.112; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Frieda KL, 2012, SCIENCE, V338, P397, DOI 10.1126/science.1225722; Fung KL, 2014, CANCER RES, V74, P598, DOI 10.1158/0008-5472.CAN-13-2064; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Gartner JJ, 2013, P NATL ACAD SCI USA, V110, P13481, DOI 10.1073/pnas.1304227110; Gingold H, 2014, CELL, V158, P1281, DOI 10.1016/j.cell.2014.08.011; Gonsalvez Graydon B, 2012, F1000 Biol Rep, V4, P16, DOI 10.3410/B4-16; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hasegawa Y, 2008, RNA, V14, P2333, DOI 10.1261/rna.1016508; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Jansen RP, 2012, CURR PROTEIN PEPT SC, V13, P284, DOI 10.2174/138920312801619493; Kim SJ, 2015, SCIENCE, V348, P444, DOI 10.1126/science.aaa3974; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Komar AA, 2007, PHARMACOGENOMICS, V8, P1075, DOI 10.2217/14622416.8.8.1075; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lamolle G, 2006, MUTAT RES-FUND MOL M, V600, P102, DOI 10.1016/j.mrfmmm.2006.03.004; Lazrak A, 2013, FASEB J, V27, P4630, DOI 10.1096/fj.13-227330; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Malbert-Colas L, 2014, MOL CELL, V54, P500, DOI 10.1016/j.molcel.2014.02.035; Mandal M, 2003, CELL, V113, P577, DOI 10.1016/S0092-8674(03)00391-X; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; Mlynarczyk C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6067; Montange RK, 2008, ANNU REV BIOPHYS, V37, P117, DOI 10.1146/annurev.biophys.37.032807.130000; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Nedialkova DD, 2015, CELL, V161, P1606, DOI 10.1016/j.cell.2015.05.022; Nissley DA, 2014, J AM CHEM SOC, V136, P17892, DOI 10.1021/ja510082j; Noubissi Felicite K, 2010, Genes Cancer, V1, P1074, DOI 10.1177/1947601910395581; O'Connor PBF, 2013, BIOINFORMATICS, V29, P1488, DOI 10.1093/bioinformatics/btt184; Olivier C, 2005, MOL CELL BIOL, V25, P4752, DOI 10.1128/MCB.25.11.4752-4766.2005; Pagani F, 2005, P NATL ACAD SCI USA, V102, P6368, DOI 10.1073/pnas.0502288102; Paquin N, 2007, MOL CELL, V26, P795, DOI 10.1016/j.molcel.2007.05.016; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pechmann S, 2014, NAT STRUCT MOL BIOL, V21, P1100, DOI 10.1038/nsmb.2919; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Pizzo L, 2015, MUTAT RES-FUND MOL M, V775, P19, DOI 10.1016/j.mrfmmm.2015.03.005; Presnyak V, 2015, CELL, V160, P1111, DOI 10.1016/j.cell.2015.02.029; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Rosano GL, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-41; Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051; Saunders R, 2010, NUCLEIC ACIDS RES, V38, P6719, DOI 10.1093/nar/gkq495; Shen ZF, 2010, GENE DEV, V24, P1914, DOI 10.1101/gad.1937510; Shepard KA, 2003, P NATL ACAD SCI USA, V100, P11429, DOI 10.1073/pnas.2033246100; Stergachis AB, 2013, SCIENCE, V342, P1367, DOI 10.1126/science.1243490; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Tafech A, 2007, BBA-GENE STRUCT EXPR, V1769, P49, DOI 10.1016/j.bbaexp.2006.11.009; Takizawa PA, 2000, P NATL ACAD SCI USA, V97, P5273, DOI 10.1073/pnas.080585897; Thanaraj TA, 1996, PROTEIN SCI, V5, P1594, DOI 10.1002/pro.5560050814; Tribouillard-Tanvier D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002174; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899; Zalucki YM, 2011, BIOTECHNOL J, V6, P660, DOI 10.1002/biot.201000334; Zhang G, 2009, NAT STRUCT MOL BIOL, V16, P274, DOI 10.1038/nsmb.1554	69	18	18	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3753	3759		10.1038/onc.2015.454	http://dx.doi.org/10.1038/onc.2015.454			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26657150				2022-12-28	WOS:000380753200001
J	Valente, LJ; Grabow, S; Vandenberg, CJ; Strasser, A; Janic, A				Valente, L. J.; Grabow, S.; Vandenberg, C. J.; Strasser, A.; Janic, A.			Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53	ONCOGENE			English	Article							CELL-CYCLE ARREST; TUMOR SUPPRESSION; TRANSGENIC MICE; P21(WAF1/CIP1); GENE; MUTATIONS; P27(KIP1); ABSENCE; CANCER; DELAYS	The tumor suppressor p53 is mutated in similar to 50% of human cancers. P53 is activated by a range of stimuli and regulates several cellular processes, including apoptotic cell death, cell cycle arrest, senescence and DNA repair. P53 induces apoptosis via transcriptional induction of the BH3-only proteins PUMA (p53-upregulated modulator of apoptosis) and NOXA, and cell cycle arrest via p21. Induction of these processes was proposed to be critical for p53-mediated tumor suppression. It is therefore surprising that mice lacking PUMA, NOXA and p21, as well as mice bearing mutations in p53 that impair the transcriptional activation of these genes, are not tumor prone, unlike mice lacking p53 function, which spontaneously develop tumors with 100% incidence. These p53 target genes and the processes they regulate may, however, impact differently on tumor development depending on the oncogenic drivers. For example, loss of PUMA enhances c-MYC-driven lymphoma development in mice, but, interestingly, the acceleration was less impressive compared with that caused by the loss of even a single p53 allele. Different studies have reported that loss of p21 can accelerate, delay or have no impact on tumorigenesis. In an attempt to resolve this controversy, we examined whether loss of p21-mediated cell cycle arrest cooperates with PUMA deficiency in accelerating lymphoma development in E mu-Myc mice (overexpressing c-MYC in B-lymphoid cells). We found that E mu-Myc mice lacking both p21 and PUMA (E mu-Myc; Puma(-/-); p21(-/-)) developed lymphoma at a rate comparable to E mu-Myc; Puma(-/-) animals, notably with considerably longer latency than E mu-Myc; p53(+/-) mice. Loss of p21 had no impact on the numbers, cycling or survival of pre-leukemic E mu-Myc B-lymphoid cells, even when PUMA was lost concomitantly. These results demonstrate that even in the context of deregulated c-MYC expression, p53 must suppress tumor development by activating processes apart from, or in addition to, PUMA-mediated apoptosis and p21-induced cell cycle arrest.	[Valente, L. J.; Grabow, S.; Vandenberg, C. J.; Strasser, A.; Janic, A.] Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, 1G Royal Parade, Melbourne, Vic 3052, Australia; [Valente, L. J.; Grabow, S.; Vandenberg, C. J.; Strasser, A.; Janic, A.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Valente, L. J.] Stanford Univ, Dept Radiat Oncol, Sch Med, Div Radiat & Canc Biol, Stanford, CA 94305 USA	University of Melbourne; Stanford University	Strasser, A; Janic, A (corresponding author), Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, 1G Royal Parade, Melbourne, Vic 3052, Australia.	strasser@wehi.edu.au; janic@wehi.edu.au	Janic, Ana/AAR-4783-2020; Strasser, Andreas/C-7581-2013	Janic, Ana/0000-0002-4200-2560; Strasser, Andreas/0000-0002-5020-4891; Valente, Liz J/0000-0002-5591-7700; Grabow, Stephanie/0000-0003-0467-7871	Cancer Council of Victoria; Leukaemia Foundation Australia; Lady Tata Memorial Trust Research Award; Leukemia & Lymphoma Society of America; Beatriu de Pinos Foundation; Cancer Australia; Cure Cancer Australia Foundation [1067571]; National Health and Medical Research Council (NHMRC) [1016701, 1020363]; Leukemia & Lymphoma Society of America (Specialized Center of Research (SCOR)) [7001-13]; Australian Government Independent Medical Research Institutes Infrastructure Support Scheme (IRIISS); Victorian State Government Operational Infrastructure Support (OIS)	Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Leukaemia Foundation Australia; Lady Tata Memorial Trust Research Award; Leukemia & Lymphoma Society of America(Leukemia and Lymphoma Society); Beatriu de Pinos Foundation; Cancer Australia; Cure Cancer Australia Foundation; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Leukemia & Lymphoma Society of America (Specialized Center of Research (SCOR)); Australian Government Independent Medical Research Institutes Infrastructure Support Scheme (IRIISS)(Australian Government); Victorian State Government Operational Infrastructure Support (OIS)	The authors thank Drs GL Kelly, ARD Delbridge, BJ Aubrey, S Cory and JM Adams for discussions and gifts of mice; K Walker, J Mansheim, C Gatt, G Siciliano and S O'Connor for expert animal care; B Helbert, H Ierino, K Mackwell and C Young for help with genotyping; J Corbin and J McManus for automated blood cell analysis. This work was supported by a PhD scholarship and Postdoctoral Fellowships from the Cancer Council of Victoria to SG and LV, by Postdoctoral Fellowships from the Leukaemia Foundation Australia to SG, from the Lady Tata Memorial Trust Research Award to AJ and SG, from the Leukemia & Lymphoma Society of America and the Beatriu de Pinos Foundation to AJ and by grants from Cancer Australia and Cure Cancer Australia Foundation (grant no. 1067571), the National Health and Medical Research Council (NHMRC; program grant no. 1016701, NHMRC Senior Principal Research Fellow (SPRF) Fellowship 1020363 to AS) and the Leukemia & Lymphoma Society of America (Specialized Center of Research (SCOR) grant no. 7001-13). This work was made possible by operational infrastructure grants through the Australian Government Independent Medical Research Institutes Infrastructure Support Scheme (IRIISS) and the Victorian State Government Operational Infrastructure Support (OIS).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Bearss DJ, 2002, CANCER RES, V62, P2077; Bieging KT, 2012, TRENDS CELL BIOL, V22, P97, DOI 10.1016/j.tcb.2011.10.006; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jiang DD, 2011, P NATL ACAD SCI USA, V108, P17123, DOI 10.1073/pnas.1111245108; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; McKenzie KE, 1997, CLIN CANCER RES, V3, P1669; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Newbold A, 2014, ONCOGENE, V33, P5415, DOI 10.1038/onc.2013.482; Patino-Garcia A, 1998, PEDIATR RES, V43, P393, DOI 10.1203/00006450-199803000-00014; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Post SM, 2010, ONCOGENE, V29, P1260, DOI 10.1038/onc.2009.423; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Yang WC, 2001, CANCER RES, V61, P565; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	24	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3866	3871		10.1038/onc.2015.457	http://dx.doi.org/10.1038/onc.2015.457			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26640149				2022-12-28	WOS:000380753200011
J	Hunter, JE; Butterworth, JA; Zhao, B; Sellier, H; Campbell, KJ; Thomas, HD; Bacon, CM; Cockell, SJ; Gewurz, BE; Perkins, ND				Hunter, J. E.; Butterworth, J. A.; Zhao, B.; Sellier, H.; Campbell, K. J.; Thomas, H. D.; Bacon, C. M.; Cockell, S. J.; Gewurz, B. E.; Perkins, N. D.			The NF-kappa B subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma	ONCOGENE			English	Article							CLASSICAL HODGKIN LYMPHOMA; MYC-INDUCED LYMPHOMAGENESIS; REPRESSOR BACH2; SURVIVAL; GENE; ACTIVATION; MUTATIONS; ROLES; ONCOPROTEIN; ASSOCIATION	The REL gene, encoding the NF-kappa B subunit c-Rel, is frequently amplified in B-cell lymphoma and functions as a tumour-promoting transcription factor. Here we report the surprising result that c-rel-/- mice display significantly earlier lymphomagenesis in the c-Myc driven, E mu-Myc model of B-cell lymphoma. c-Rel loss also led to earlier onset of disease in a separate TCL1-Tg-driven lymphoma model. Tumour reimplantation experiments indicated that this is an effect intrinsic to the E mu-Myc lymphoma cells but, counterintuitively, c-rel-/- E mu-Myc lymphoma cells were more sensitive to apoptotic stimuli. To learn more about why loss of c-Rel led to earlier onset of disease, microarray gene expression analysis was performed on B cells from 4-week-old, wild-type and c-rel-/E mu- Myc mice. Extensive changes in gene expression were not seen at this age, but among those transcripts significantly downregulated by the loss of c-Rel was the B-cell tumour suppressor BTB and CNC homology 2 ( Bach2). Quantitative PCR and western blot analysis confirmed loss of Bach2 in c-Rel mutant E mu-Myc tumours at both 4 weeks and the terminal stages of disease. Moreover, Bach2 expression was also downregulated in c-rel-/- TCL1-Tg mice and RelA Thr505Ala mutant E mu-Myc mice. Analysis of wild-type E mu-Myc mice demonstrated that the population expressing low levels of Bach2 exhibited the earlier onset of lymphoma seen in c-rel-/- mice. Confirming the relevance of these findings to human disease, analysis of chromatin immunoprecipitation sequencing data revealed that Bach2 is a c-Rel and NF-kappa B target gene in transformed human B cells, whereas treatment of Burkitt's lymphoma cells with inhibitors of the NF-kappa B/I kappa B kinase pathway or deletion of c-Rel or RelA resulted in loss of Bach2 expression. These data reveal a surprising tumour suppressor role for c-Rel in lymphoma development explained by regulation of Bach2 expression, underlining the context-dependent complexity of NF-kappa B signalling in cancer.	[Hunter, J. E.; Butterworth, J. A.; Sellier, H.; Perkins, N. D.] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci ICaMB, Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Zhao, B.; Gewurz, B. E.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Campbell, K. J.] Beatson Inst Canc Res, Glasgow, Lanark, Scotland; [Thomas, H. D.; Bacon, C. M.] Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Cockell, S. J.] Newcastle Univ, Fac Med Sci, Bioinformat Support Unit, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Harvard University; Brigham & Women's Hospital; Beatson Institute; Newcastle University - UK; Newcastle University - UK	Perkins, ND (corresponding author), Newcastle Univ, Sch Med, Inst Cell & Mol Biosci ICaMB, Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	neil.perkins@ncl.ac.uk		Cockell, Simon/0000-0002-6831-9806; Bacon, Chris/0000-0002-8268-2812	Leukemia Lymphoma Research [11022]; Wellcome Trust [094409]; NDP lab from Cancer Research UK [C1443/A12750]; Welcome Trust Equipment grant [087961]; US National Institutes of Health [K08 CA140780, RO1 CA12850]; Burroughs Wellcome Medical Scientist career award; NATIONAL CANCER INSTITUTE [K08CA140780, R01CA085180] Funding Source: NIH RePORTER; Cancer Research UK [22095, 22311, 12750] Funding Source: researchfish	Leukemia Lymphoma Research; Wellcome Trust(Wellcome TrustEuropean Commission); NDP lab from Cancer Research UK; Welcome Trust Equipment grant; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Medical Scientist career award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK)	We thank Fiona Oakley, Sonia Rocha, Derek Mann, Claire Richardson, Saimir Luli, Elaine Willmore and all members of the NDP laboratory for their helpful advice and assistance. We are very grateful to Michael J. Walsh for assistance with generation of CRISPR/Cas9 knock-out cell lines. JEH is funded by Leukemia Lymphoma Research grant 11022, JAB and HS are funded by the Wellcome Trust grant 094409, further funding from the NDP lab was obtained from Cancer Research UK grant C1443/A12750. The IVIS Spectrum was funded by Welcome Trust Equipment grant 087961. BZ and BEG are funded by US National Institutes of Health (grants K08 CA140780 and RO1 CA12850) and by a Burroughs Wellcome Medical Scientist career award.	Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Casolari DA, 2013, LEUKEMIA, V27, P409, DOI 10.1038/leu.2012.220; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Chin M, 2009, ONCOGENE, V28, P2100, DOI 10.1038/onc.2009.74; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Curry Choladda V, 2009, J Hematop, V2, P20, DOI 10.1007/s12308-009-0021-4; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Enciso-Mora V, 2010, NAT GENET, V42, P1126, DOI 10.1038/ng.696; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Fan YJ, 2008, ADV EXP MED BIOL, V615, P223, DOI 10.1007/978-1-4020-6554-5_11; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Fullard N, 2012, INT J BIOCHEM CELL B, V44, P851, DOI 10.1016/j.biocel.2012.02.017; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Greenfeld H, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004890; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Ichikawa S, 2014, CANCER SCI, V105, P437, DOI 10.1111/cas.12361; Jing H, 2011, GENE DEV, V25, P2137, DOI 10.1101/gad.17620611; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Keller U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-348; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kuppers R, 2009, NAT REV CANCER, V9, P15, DOI 10.1038/nrc2542; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Msaki A, 2011, MOL BIOL CELL, V22, P3032, DOI 10.1091/mbc.E11-04-0280; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Naito Y, 2015, BIOINFORMATICS, V31, P1120, DOI 10.1093/bioinformatics/btu743; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pham LV, 2005, BLOOD, V106, P3940, DOI 10.1182/blood-2005-03-1167; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sasaki S, 2000, ONCOGENE, V19, P3739, DOI 10.1038/sj.onc.1203716; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Swaminathan S, 2013, NAT MED, V19, P1014, DOI 10.1038/nm.3247; Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y; Tumang JR, 2002, CELL IMMUNOL, V217, P47, DOI 10.1016/S0008-8749(02)00513-0; WEIH F, 1994, ONCOGENE, V9, P3289; Zhao B, 2014, CELL REP, V8, P1595, DOI 10.1016/j.celrep.2014.07.037	52	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3476	3484		10.1038/onc.2015.399	http://dx.doi.org/10.1038/onc.2015.399			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26522720	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000379270100012
J	Yang, YC; Cheng, TY; Huang, SM; Su, CY; Yang, PW; Lee, JM; Chen, CK; Hsiao, M; Hua, KT; Kuo, ML				Yang, Y-C; Cheng, T-Y; Huang, S-M; Su, C-Y; Yang, P-W; Lee, J-M; Chen, C-K; Hsiao, M.; Hua, K-T; Kuo, M-L			Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association	ONCOGENE			English	Article							PYRUVATE-KINASE M2; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; GENE-TRANSCRIPTION; MUTATIONS; GEFITINIB; PROMOTES; ISOFORM; ACTIVATION; ADENOCARCINOMAS	Secondary mutation of epidermal growth factor receptor (EGFR) resulting in drug resistance is one of the most critical issues in lung cancer therapy. Several drugs are being developed to overcome EGFR tyrosine kinase inhibitor (TKI) resistance. Here, we report that pyruvate kinase M2 (PKM2) stabilized mutant EGFR protein by direct interaction and sustained cell survival signaling in lung cancer cells. PKM2 silencing resulted in markedly reduced mutant EGFR expression in TKI-sensitive or-resistant human lung cancer cells, and in inhibition of tumor growth in their xenografts, concomitant with downregulation of EGFR-related signaling. Mechanistically, PKM2 directly interacted with mutant EGFR and heat-shock protein 90 (HSP90), and thus stabilized EGFR by maintaining its binding with HSP90 and co-chaperones. Stabilization of EGFR relied on dimeric PKM2, and the protein half-life of mutant EGFR decreased when PKM2 was forced into its tetramer form. Clinical levels of PKM2 positively correlated with mutant EGFR expression and with patient outcome. These results reveal a previously undescribed non-glycolysis function of PKM2 in the cytoplasm, which contribute to EGFR-dependent tumorigenesis and provide a novel strategy to overcome drug resistance to EGFR TKIs.	[Yang, Y-C] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan; [Cheng, T-Y] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Huang, S-M; Chen, C-K; Hua, K-T; Kuo, M-L] Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, 1,Sect 1,Jen Ai Rd, Taipei 10055, Taiwan; [Su, C-Y; Chen, C-K; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Yang, P-W; Lee, J-M] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Kuo, M-L] Natl Taiwan Univ, Coll Life Sci Sci, Inst Biochem Sci, 1,Roosevelt Rd,Sect 4, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hua, KT (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, 1,Sect 1,Jen Ai Rd, Taipei 10055, Taiwan.; Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Life Sci Sci, Inst Biochem Sci, 1,Roosevelt Rd,Sect 4, Taipei, Taiwan.	kthua@ntu.edu.tw; kuominliang@ntu.edu.tw	Hsiao, Michael/U-6238-2019; Su, Chia-Yi/L-5378-2016; Yang, Yi-Chieh/D-6248-2019; Cheng, TY/X-1695-2019	Hsiao, Michael/0000-0001-8529-9213; Su, Chia-Yi/0000-0002-9483-4510; LEE, JANG-MING/0000-0001-9727-227X; CHENG, TSU-YAO/0000-0002-7370-5605; Hua, Kuo-Tai/0000-0002-8468-4977	National Science Council, Taiwan [NSC 104-2321-B-002-006, NSC-104-2911-I-002-302, NSC 104-2923-B-002-003]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr Zhimin Lu for the Flag-tagged K367M, K433E and wild-type PKM2, Dr Zhi-Ren Liu for HA-tagged R399E and wild-type PKM2, Dr Mien-Chie Hung for myc-tagged EGFR-ECM and -ICM, Dr Ann-Lii Cheng and Dr James Chih-Hsin Yang for helpful discussion, Integrated Core Facility for Functional Genomics of the National Core Facility Program for Biotechnology, the Microarray Core Facility of the National Taiwan University Center of Genomic Medicine and Dr Sung-Liang Yu for technical support. This study was supported by grants from National Science Council, Taiwan (NSC 104-2321-B-002-006, NSC-104-2911-I-002-302 and NSC 104-2923-B-002-003).	Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Arcila ME, 2011, CLIN CANCER RES, V17, P1169, DOI 10.1158/1078-0432.CCR-10-2277; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chiosis G, 2013, NAT STRUCT MOL BIOL, V20, P1, DOI 10.1038/nsmb.2481; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Chung BM, 2009, ONCOGENE, V28, P1821, DOI 10.1038/onc.2009.31; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cortes-Cros M, 2013, P NATL ACAD SCI USA, V110, P489, DOI 10.1073/pnas.1212780110; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Haspinger ER, 2014, J CLIN ONCOL, V32, P859, DOI 10.1200/JCO.2013.52.8794; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Keller KE, 2014, MOL CELL, V53, P700, DOI 10.1016/j.molcel.2014.02.015; Kobayashi N, 2012, LUNG CANCER, V75, P161, DOI 10.1016/j.lungcan.2011.04.022; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kobayashi S, 2006, CANCER RES, V66, P11389, DOI 10.1158/0008-5472.CAN-06-2318; Le Mellay V, 2002, ADV ENZYME REGUL, V42, P317, DOI 10.1016/S0065-2571(01)00036-X; Li J, 2014, CLIN TRANSL ONCOL, V16, P200, DOI 10.1007/s12094-013-1063-8; Lim JY, 2012, WORLD J GASTROENTERO, V18, P4037, DOI 10.3748/wjg.v18.i30.4037; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/507103; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Nyati MK, 2006, NAT REV CANCER, V6, P876, DOI 10.1038/nrc1953; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Parnell KM, 2013, MOL CANCER THER, V12, P1453, DOI 10.1158/1535-7163.MCT-13-0026; Pirazzoli V, 2014, CELL REP, V7, P999, DOI 10.1016/j.celrep.2014.04.014; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; VOLLMER SH, 1994, J BIOL CHEM, V269, P8082; Walter AO, 2013, CANCER DISCOV, V3, P1404, DOI 10.1158/2159-8290.CD-13-0314; Wang P, 2015, PROTEIN CELL, V6, P275, DOI 10.1007/s13238-015-0132-x; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yang JCH, 2013, J CLIN ONCOL, V31, P3342, DOI 10.1200/JCO.2012.46.1764; Yang SC, 2006, CANCER RES, V66, P6990, DOI 10.1158/0008-5472.CAN-06-1042; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yuan SS, 2011, J CLIN ONCOL, V29, P3435, DOI 10.1200/JCO.2011.35.3979	50	33	34	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3387	3398		10.1038/onc.2015.397	http://dx.doi.org/10.1038/onc.2015.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26500058				2022-12-28	WOS:000379270100004
J	Das, S; Rachagani, S; Sheinin, Y; Smith, LM; Gurumurthy, CB; Roy, HK; Batra, SK				Das, S.; Rachagani, S.; Sheinin, Y.; Smith, L. M.; Gurumurthy, C. B.; Roy, H. K.; Batra, S. K.			Mice deficient in Muc4 are resistant to experimental colitis and colitis-associated colorectal cancer	ONCOGENE			English	Article							CELL-SURFACE MUCIN; GENE-EXPRESSION; PROGNOSTIC-FACTOR; INTESTINAL INFLAMMATION; BARRIER; CARCINOMA; DIAGNOSIS; PROTECTS; PATHWAY	MUC4, a large transmembrane mucin normally expressed in the small and large intestine, is differentially expressed during inflammatory and malignant conditions of the colon. However, the expression pattern and the role of MUC4 in colitis and colorectal cancer (CRC) are inconclusive. Therefore, the aim of this study was to understand the role of Muc4 during inflammatory and malignant conditions of the colon. Here, we generated Muc4(-/-) mice and addressed its role in colitis and colitis-associated CRC using dextran sodium sulfate (DSS) and azoxymethane (AOM)-DSS experimental models, respectively. Muc4(-/-) mice were viable, fertile with no apparent defects. Muc4(-/-) mice displayed increased resistance to DSS-induced colitis compared with wild-type (WT) littermates that was evaluated by survival rate, body weight loss, diarrhea and fecal blood score, and histological score. Reduced infiltration of inflammatory cells, that is, CD3(+) lymphocytes and F4/80(+) macrophages was observed in the inflamed mucosa along with reduction in the mRNA levels of inflammatory cytokines interleukin (IL)-1 beta and tumor necrosis factor (TNF)-alpha and anti-microbial genes Lysozyme M and SLPI in the colon of Muc4(-/-) mice compared with WT littermates. Compensatory upregulation of Muc2 and Muc3 mucins under basal and DSS treatment conditions partly explains the resistance observed in Muc4(-/-) mice. Accordingly, Muc4(-/-) mice exhibited significantly reduced tumor burden compared with WT mice assessed in a colitis-induced tumor model using AOM/DSS. An increased percentage of Ki67(+) nuclei was observed in the tumors from WT compared with Muc4(-/-) mice suggesting Muc4 to be critical in intestinal cell proliferation during tumorigenesis. Taken together, we conclusively demonstrate for the first time the role of Muc4 in driving intestinal inflammation and inflammation-associated tumorigenesis using a novel Muc4(-/-) mouse model.	[Das, S.; Rachagani, S.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Sheinin, Y.] Univ Nebraska Med Ctr, Dept Pathol, Omaha, NE 68198 USA; [Smith, L. M.] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA; [Gurumurthy, C. B.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Mouse Genome Engn Core Facil, Omaha, NE 68198 USA; [Roy, H. K.] Boston Univ, Sch Med, Ctr Digest Disorders, Boston, MA 02118 USA; [Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Buffett Canc Ctr, Omaha, NE 68198 USA; [Das, S.] Karolinska Univ Sjukhuset, Dept Med, S-17176 Stockholm, Sweden	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Boston University; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Buffett Canc Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	Gurumurthy, Channabasavaiah B/H-8268-2016; Das, Srustidhar/GVU-1044-2022; Roy, Hemant/AAC-9096-2020; Gurumurthy, Channabasavaiah B/E-7205-2011	Gurumurthy, Channabasavaiah B/0000-0002-8022-4033; 	National Institutes of Health [RO1 CA 78590, RO1 CA183459, UO1CA111294, SPORE P50CA127297, TMEN U54CA163120, R03 CA167342]; NATIONAL CANCER INSTITUTE [R03CA167342, U54CA163120, U01CA111294, R01CA183459, R01CA078590, P50CA127297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM110768] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Don Harms and Rolen Quadros of the mouse genome-engineering core at the University of Nebraska Medical Center (UNMC) for the electroporation, microinjection and generation of chimera for Muc4 knockout mice. We thank UNMC tissue sciences facility for processing of tissues used in the study. We also thank Dr Imayavaramban Lakshmanan and Kavita Mallya for technical assistance. The work in the manuscript, in parts, was supported by the grants from the National Institutes of Health (RO1 CA 78590, RO1 CA183459, UO1CA111294, SPORE P50CA127297, TMEN U54CA163120 and R03 CA167342).	Araki A, 2005, J GASTROENTEROL, V40, P16, DOI 10.1007/s00535-004-1492-9; Biemer-Huttmann AE, 1999, J HISTOCHEM CYTOCHEM, V47, P1039, DOI 10.1177/002215549904700808; Biemer-Huttmann AE, 2000, CLIN CANCER RES, V6, P1909; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boltin D, 2013, J CLIN GASTROENTEROL, V47, P106, DOI 10.1097/MCG.0b013e3182688e73; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Buisine MP, 1999, INFLAMM BOWEL DIS, V5, P24, DOI 10.1097/00054725-199902000-00004; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chauhan SC, 2006, MODERN PATHOL, V19, P1386, DOI 10.1038/modpathol.3800646; Dharmani P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025058; Enss ML, 2000, INFLAMM RES, V49, P162, DOI 10.1007/s000110050576; Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44; Ho SB, 2010, BBA-GEN SUBJECTS, V1800, P629, DOI 10.1016/j.bbagen.2010.03.010; Hoebler C, 2006, DIGEST DIS SCI, V51, P381, DOI 10.1007/s10620-006-3142-y; Iwashita J, 2003, IMMUNOL CELL BIOL, V81, P275, DOI 10.1046/j.1440-1711.2003.t01-1-01163.x; Kim YD, 2002, J KOREAN MED SCI, V17, P765, DOI 10.3346/jkms.2002.17.6.765; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Longman RJ, 2006, J HISTOCHEM CYTOCHEM, V54, P1335, DOI 10.1369/jhc.5A6904.2006; Luu Y, 2010, INT J BIOCHEM CELL B, V42, P996, DOI 10.1016/j.biocel.2010.03.001; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; McGuckin MA, 2011, NAT REV MICROBIOL, V9, P265, DOI 10.1038/nrmicro2538; Miyahara N, 2008, EUR J CANCER, V44, P1048, DOI 10.1016/j.ejca.2008.03.007; Mukhopadhyay P, 2011, BBA-REV CANCER, V1815, P224, DOI 10.1016/j.bbcan.2011.01.001; Myerscough N, 1995, BIOCHEM SOC T, V23, pS536, DOI 10.1042/bst023536s; OGATA S, 1992, CANCER RES, V52, P5971; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Petersson J, 2011, AM J PHYSIOL-GASTR L, V300, pG327, DOI 10.1152/ajpgi.00422.2010; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Ponnusamy MP, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-7; Resta-Lenert S, 2011, AM J PHYSIOL-GASTR L, V300, pG1144, DOI 10.1152/ajpgi.00138.2010; Saitou M, 2005, J CLIN PATHOL, V58, P845, DOI 10.1136/jcp.2004.023572; Senapati S, 2008, BRIT J CANCER, V99, P949, DOI 10.1038/sj.bjc.6604632; Senapati S, 2010, TRENDS BIOCHEM SCI, V35, P236, DOI 10.1016/j.tibs.2009.10.003; Shanmugam C, 2010, CANCER-AM CANCER SOC, V116, P3577, DOI 10.1002/cncr.25095; Shekels LL, 2003, BBA-GENE STRUCT EXPR, V1627, P90, DOI 10.1016/S0167-4781(03)00081-2; Sheng YH, 2012, J GASTROEN HEPATOL, V27, P28, DOI 10.1111/j.1440-1746.2011.06909.x; Sheng YH, 2011, GUT, V60, P1661, DOI 10.1136/gut.2011.239194; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh AP, 2008, LANCET ONCOL, V9, P1076, DOI 10.1016/S1470-2045(08)70277-8; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Tamada S, 2006, CLIN CANCER RES, V12, P4257, DOI 10.1158/1078-0432.CCR-05-2814; Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020; VanKlinken BJW, 1995, BIOCHEM SOC T, V23, P814, DOI 10.1042/bst0230814; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Zhang J, 2006, TISSUE CELL, V38, P271, DOI 10.1016/j.tice.2006.06.004	51	45	48	0	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2645	2654		10.1038/onc.2015.327	http://dx.doi.org/10.1038/onc.2015.327			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364605	Green Accepted			2022-12-28	WOS:000376165700011
J	Li, HJ; Yu, PN; Huang, KY; Su, HY; Hsiao, TH; Chang, CP; Yu, MH; Lin, YW				Li, H-J; Yu, P-N; Huang, K-Y; Su, H-Y; Hsiao, T-H; Chang, C-P; Yu, M-H; Lin, Y-W			NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition	ONCOGENE			English	Article							PANCREATIC BETA-CELLS; E-CADHERIN REPRESSION; VENTRAL NEURAL-TUBE; CANCER STEM-CELLS; CERVICAL-CANCER; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; NEURONAL FATE; COMPLEX	The transcription factor NKX6.1 (NK6 homeobox 1) is important in the development of pancreatic beta-cells and neurons. Although recent publications show that NKX6.1 is hypermethylated and downregulated during tumorigenesis, the function of NKX6.1 in carcinogenesis remains elusive. Here, we address the metastasis suppressor function of human NKX6.1 using cell, animal and clinical analyses. Our data show that NKX6.1 represses tumor formation and metastatic ability both in vitro and in vivo. Mechanistically, NKX6.1 suppresses cell invasion by inhibiting the epithelial-to-mesenchymal transition (EMT). NKX6.1 directly enhances the mRNA level of E-cadherin by recruiting BAF155 coactivator and represses that of vimentin and N-cadherin by recruiting RBBP7 (retinoblastoma binding protein 7) corepressor. Clinical cancer tumors with metastasis show low NKX6.1 protein expression coinciding with low E-cadherin and high vimentin expression. Our results demonstrate that NKX6.1 functions as an EMT suppressor by interacting with different epigenetic modifiers, making it a potential novel therapeutic option.	[Li, H-J; Huang, K-Y; Lin, Y-W] Natl Def Med Ctr, Grad Inst Life Sci, 161,Sect 6,Min Chuan East Rd, Taipei, Taiwan; [Yu, P-N; Chang, C-P; Lin, Y-W] Natl Def Med Ctr, Dept & Grad Inst Microbiol & Immunol, 161,Sect 6,Min Chuan East Rd, Taipei, Taiwan; [Su, H-Y; Yu, M-H] Natl Def Med Ctr, Dept Obstet & Gynecol, Triserv Gen Hosp, Taipei, Taiwan; [Hsiao, T-H] Taichung Vet Gen Hosp, Dept Med Res, Taipei, Taiwan	National Defense Medical Center; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; Taichung Veterans General Hospital	Lin, YW (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, 161,Sect 6,Min Chuan East Rd, Taipei, Taiwan.; Lin, YW (corresponding author), Natl Def Med Ctr, Dept & Grad Inst Microbiol & Immunol, 161,Sect 6,Min Chuan East Rd, Taipei, Taiwan.	ndmc.yawen@msa.hinet.net	Huang, Kuo-Yen/AAC-9247-2019		National Research Program for Genomic Medicine Grants of NSC [NSC 97-3112-B-001-016]; Ministry of Science and Technology, Taiwan, Republic of China [NSC 100-2314-B-016-021, NSC 102-2320-B-016-016-MY3, MOST 103-2314-B-016-008, MOST 103-2321-B-016-007]; Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China	National Research Program for Genomic Medicine Grants of NSC; Ministry of Science and Technology, Taiwan, Republic of China; Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China	We thank Yong-Jang Chen for technical assistance. RNA interference reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 97-3112-B-001-016). This work was supported by the following grants: NSC 100-2314-B-016-021, NSC 102-2320-B-016-016-MY3, MOST 103-2314-B-016-008 and MOST 103-2321-B-016-007 from the Ministry of Science and Technology, Taiwan, Republic of China, and the Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China.	Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; DelBove J, 2011, EPIGENETICS-US, V6, P1444, DOI 10.4161/epi.6.12.18492; Donelan W, 2010, J BIOL CHEM, V285, P12181, DOI 10.1074/jbc.M109.064238; Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Duffield JS, 2013, ANNU REV PATHOL-MECH, V8, P241, DOI 10.1146/annurev-pathol-020712-163930; Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gao DC, 2012, CANCER RES, V72, P4883, DOI 10.1158/0008-5472.CAN-12-1223; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Hsu TI, 2012, ONCOGENE, V31, P3973, DOI 10.1038/onc.2011.568; Iype T, 2004, MOL ENDOCRINOL, V18, P1363, DOI 10.1210/me.2004-0006; Jorgensen MC, 1999, FEBS LETT, V461, P287, DOI 10.1016/S0014-5793(99)01436-2; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lai HC, 2008, INT J CANCER, V123, P161, DOI 10.1002/ijc.23519; Lai HC, 2010, CANCER-AM CANCER SOC, V116, P4266, DOI 10.1002/cncr.25252; Lin WC, 2013, BBA-MOL CELL RES, V1833, P3206, DOI 10.1016/j.bbamcr.2013.08.020; Lin YW, 2013, GYNECOL ONCOL, V131, P174, DOI 10.1016/j.ygyno.2013.07.111; Liu CY, 2009, J PATHOL, V219, P222, DOI 10.1002/path.2589; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Matsuno Y, 2012, INT J BIOCHEM CELL B, V44, P776, DOI 10.1016/j.biocel.2012.01.021; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Micalizzi DS, 2009, FUTURE ONCOL, V5, P1129, DOI 10.2217/FON.09.94; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Ohta H, 2009, BRIT J CANCER, V100, P389, DOI 10.1038/sj.bjc.6604846; PECORARO G, 1991, AM J PATHOL, V138, P1; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083; Syu LJ, 2009, BRAIN RES, V1266, P8, DOI 10.1016/j.brainres.2009.01.068; Taylor KH, 2007, CANCER RES, V67, P2617, DOI 10.1158/0008-5472.CAN-06-3993; Tsao CM, 2012, HEPATOLOGY, V56, P2277, DOI 10.1002/hep.25933; Wang YT, 2008, J MOL BIOL, V380, P869, DOI 10.1016/j.jmb.2008.05.043; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108	43	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2266	2278		10.1038/onc.2015.289	http://dx.doi.org/10.1038/onc.2015.289			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26257059	Green Published, hybrid			2022-12-28	WOS:000374986000011
J	Tervonen, TA; Belitskin, D; Pant, SM; Englund, JI; Marques, E; Ala-Hongisto, H; Nevalaita, L; Sihto, H; Heikkila, P; Leidenius, M; Hewitson, K; Ramachandra, M; Moilanen, A; Joensuu, H; Kovanen, PE; Poso, A; Klefstrom, J				Tervonen, T. A.; Belitskin, D.; Pant, S. M.; Englund, J. I.; Marques, E.; Ala-Hongisto, H.; Nevalaita, L.; Sihto, H.; Heikkila, P.; Leidenius, M.; Hewitson, K.; Ramachandra, M.; Moilanen, A.; Joensuu, H.; Kovanen, P. E.; Poso, A.; Klefstrom, J.			Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR ACTIVATOR INHIBITOR-1; BREAST-CANCER; MATRIPTASE ACTIVATION; IN-VITRO; PROSTATE; IDENTIFICATION; PROGRESSION; SUBSTRATE; CELLS	Hepsin belongs to a family of cell-surface serine proteases, which have sparked interest as therapeutic targets because of the accessibility of extracellular protease domain for inhibitors. Hepsin is frequently amplified and/or overexpressed in epithelial cancers, but it is not clear how enhanced hepsin expression confers a potential for oncogenicity. We show that hepsin is consistently overexpressed in more than 40% of examined breast cancers, including all major biological subtypes. The effects of doxycycline-induced hepsin overexpression were examined in mammary epithelial organoids, and we found that induced hepsin acutely downmodulates its cognate inhibitor, hepatocyte growth factor (HGF) activator inhibitor type 1 (HAI-1). Hepsin-induced depletion of cellular HAI-1 led to a sharp increase in pericellular serine protease activity. The derepressed hepsin proteolytically activated downstream serine proteases, augmented HGF/MET signalling and caused deterioration of desmosomes and hemidesmosomes; structures important for cell cohesion and cell-basement membrane interaction. Moreover, chronic induction of hepsin considerably shortened the latency of Myc-dependent tumourigenesis in the mouse mammary gland. The serine protease and uPA system inhibitor WX-UK1, identified as a micromolar range hepsin inhibitor, prevented hepsin from augmenting HGF/MET signalling and disrupting desmosomes and hemidesmosomes. The findings suggest that the oncogenic activity of hepsin arises not only from elevated expression level but also from depletion of HAI-1, events which together trigger gain-of-function activity impacting HGF/MET signalling and epithelial cohesion. Thus, hepsin overexpression is a major oncogenic conferrer to a serine protease activity involved in breast cancer dissemination.	[Tervonen, T. A.; Belitskin, D.; Pant, S. M.; Englund, J. I.; Marques, E.; Ala-Hongisto, H.; Nevalaita, L.; Klefstrom, J.] Univ Helsinki, Translat Canc Biol & Inst Biomed, Res Programs Unit, Canc Cell Circuitry Lab, FIN-00014 Helsinki, Finland; [Sihto, H.; Joensuu, H.] Univ Helsinki, Dept Oncol, FIN-00014 Helsinki, Finland; [Sihto, H.; Joensuu, H.] Helsinki Univ Cent Hosp, Helsinki, Finland; [Heikkila, P.; Kovanen, P. E.] Helsinki Univ Cent Hosp, HUSLAB, Dept Pathol, Helsinki, Finland; [Heikkila, P.; Kovanen, P. E.] Helsinki Univ Cent Hosp, Haartman Inst, Helsinki, Finland; [Heikkila, P.; Kovanen, P. E.] Univ Helsinki, FIN-00014 Helsinki, Finland; [Leidenius, M.] Helsinki Univ Cent Hosp, Breast Surg Unit, Helsinki, Finland; [Hewitson, K.] Helsinki Innovat Serv Ltd, Tukholmankatu 8A, Helsinki 00290, Finland; [Ramachandra, M.] Aurigene Discovery Technol Ltd, 39-40 KIADB Ind Area,Elect City Phase 2, Bangalore, Karnataka, India; [Moilanen, A.] Orion Pharma, Orion Corp, Turku, Finland; [Poso, A.] Univ Eastern Finland, Sch Pharm, Kuopio, Finland; [Poso, A.] Finnish Inst Mol Med, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aurigene Discovery Technologies Limited; Orion Corporation; University of Eastern Finland	Klefstrom, J (corresponding author), Univ Helsinki, Canc Cell Circuitry Lab, Translat Canc Biol Res Program, Haartmaninkatu 8,Room B507,POB 63, FIN-00014 Helsinki, Finland.	Juha.Klefstrom@helsinki.fi	Englund, Johanna/GYJ-7086-2022; Sihto, Harri J/B-3432-2015; Englund, Johanna/ABG-6420-2021	Sihto, Harri J/0000-0001-5265-5509; Englund, Johanna/0000-0001-9637-6843; Poso, Antti/0000-0003-4196-4204; Belitskin, Denis/0000-0002-0032-2769; Ramachandra, Murali/0000-0003-4039-1491; Joensuu, Heikki/0000-0003-0281-2507	Academy of Finland; Sigrid Juselius Foundation; Finnish Cancer Society; Research Funds of the Helsinki University Central Hospital; Jane and Aatos Erkko Foundation; Helsinki Graduate Program in Biotechnology and Molecular Biology and Innovative Medicines Initiative Joint Undertaking [115188]	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Society; Research Funds of the Helsinki University Central Hospital; Jane and Aatos Erkko Foundation; Helsinki Graduate Program in Biotechnology and Molecular Biology and Innovative Medicines Initiative Joint Undertaking	We thank all the members of Klefstrom laboratory for discussions and critical comments on the manuscript. T Raatikainen and T Valimaki are thanked for technical assistance. Biomedicum Imaging Unit and Biomedicum Functional Genomics Unit are acknowledged for core services and technical support. This study was funded by the Academy of Finland, Sigrid Juselius Foundation, the Finnish Cancer Society, the Research Funds of the Helsinki University Central Hospital, Jane and Aatos Erkko Foundation, and Helsinki Graduate Program in Biotechnology and Molecular Biology and Innovative Medicines Initiative Joint Undertaking under grant agreement no 115188.	Antalis TM, 2010, BIOCHEM J, V428, P325, DOI 10.1042/BJ20100046; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Buzza MS, 2013, J BIOL CHEM, V288, P10328, DOI 10.1074/jbc.M112.443432; Chen MQ, 2010, MOL CELL BIOCHEM, V337, P259, DOI 10.1007/s11010-009-0307-y; Chen YW, 2010, J BIOL CHEM, V285, P31755, DOI 10.1074/jbc.M110.150367; Chevillet JR, 2008, MOL CANCER THER, V7, P3343, DOI 10.1158/1535-7163.MCT-08-0446; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Domoto T, 2012, CANCER SCI, V103, P448, DOI 10.1111/j.1349-7006.2011.02162.x; Fan B, 2005, J BIOL CHEM, V280, P34513, DOI 10.1074/jbc.M502119200; Friis S, 2013, J BIOL CHEM, V288, P19028, DOI 10.1074/jbc.M113.469932; Ganesan R, 2012, PROTEIN ENG DES SEL, V25, P127, DOI 10.1093/protein/gzr067; Ganesan R, 2011, MOL CANCER RES, V9, P1175, DOI 10.1158/1541-7786.MCR-11-0004; Gastaldi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2617; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Godiksen S, 2008, BIOCHEM J, V413, P251, DOI 10.1042/BJ20071496; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Goswami R, 2013, ACS MED CHEM LETT, V4, P1152, DOI 10.1021/ml400213v; Guerin-Dubiard C, 2006, J AGR FOOD CHEM, V54, P3901, DOI 10.1021/jf0529969; Heinemann V, 2013, BRIT J CANCER, V108, P766, DOI 10.1038/bjc.2013.62; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Kaipparettu BA, 2008, BIOTECHNIQUES, V45, P165, DOI 10.2144/000112883; Kiyomiya KI, 2006, AM J PHYSIOL-CELL PH, V291, pC40, DOI 10.1152/ajpcell.00351.2005; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Koschubs T, 2012, BIOCHEM J, V442, P483, DOI 10.1042/BJ20111317; Li W, 2009, CANCER RES, V69, P8395, DOI 10.1158/0008-5472.CAN-09-1995; Li Y, 2005, BBA-GENE STRUCT EXPR, V1681, P157, DOI 10.1016/j.bbaexp.2004.11.003; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Miao JY, 2008, INT J CANCER, V123, P2041, DOI 10.1002/ijc.23726; Moran P, 2006, J BIOL CHEM, V281, P30439, DOI 10.1074/jbc.M605440200; Nandana S, 2010, PROSTATE, V70, P591, DOI 10.1002/pros.21093; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Partanen JI, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0111; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Peters DE, 2014, J BIOL CHEM, V289, P14740, DOI 10.1074/jbc.M113.541318; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Szabo R, 2008, INT J BIOCHEM CELL B, V40, P1297, DOI 10.1016/j.biocel.2007.11.013; Tang X, 2014, ONCOTARGET, V5, P1352, DOI 10.18632/oncotarget.1817; Tripathi M, 2008, J BIOL CHEM, V283, P30576, DOI 10.1074/jbc.M802312200; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Xing P, 2011, J INVEST MED, V59, P803, DOI 10.2310/JIM.0b013e31821451a1; Xuan JA, 2006, CANCER RES, V66, P3611, DOI 10.1158/0008-5472.CAN-05-2983; Yue J, 2012, CANCER MICROENVIRON, V5, P275, DOI 10.1007/s12307-012-0101-3	46	30	30	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1832	1846		10.1038/onc.2015.248	http://dx.doi.org/10.1038/onc.2015.248			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26165838				2022-12-28	WOS:000373610400009
J	Poria, DK; Guha, A; Nandi, I; Ray, PS				Poria, D. K.; Guha, A.; Nandi, I.; Ray, P. S.			RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4	ONCOGENE			English	Article							MESSENGER-RNA; EXPRESSION; PDCD4; MECHANISMS; STRESS; MIR-21; TARGET; SWITCH; VEGFA; DECOY	Translation control of proinflammatory genes has a crucial role in regulating the inflammatory response and preventing chronic inflammation, including a transition to cancer. The proinflammatory tumor suppressor protein programmed cell death 4 (PDCD4) is important for maintaining the balance between inflammation and tumorigenesis. PDCD4 messenger RNA translation is inhibited by the oncogenic microRNA, miR-21. AU-rich element-binding protein HuR was found to interact with the PDCD4 3'-untranslated region (UTR) and prevent miR-21-mediated repression of PDCD4 translation. Cells stably expressing miR-21 showed higher proliferation and reduced apoptosis, which was reversed by HuR expression. Inflammatory stimulus caused nuclear-cytoplasmic relocalization of HuR, reversing the translation repression of PDCD4. Unprecedentedly, HuR was also found to bind to miR-21 directly, preventing its interaction with the PDCD4 3'-UTR, thereby preventing the translation repression of PDCD4. This suggests that HuR might act as a 'miRNA sponge' to regulate miRNA-mediated translation regulation under conditions of stress-induced nuclear-cytoplasmic translocation of HuR, which would allow fine-tuned gene expression in complex regulatory environments.	[Poria, D. K.; Guha, A.; Nandi, I.; Ray, P. S.] Indian Inst Sci Educ & Res, Dept Biol Sci, Kolkata, India	Indian Institute of Science Education & Research (IISER) - Kolkata	Ray, PS (corresponding author), Indian Inst Sci Educ & Res, Dept Biol Sci, Mohanpur Campus, Nadia 741246, W Bengal, India.	psray@iiserkol.ac.in	Ray, Partho Sarothi/H-3020-2019; Poria, Dipak Kumar/AAM-2084-2021	Ray, Partho Sarothi/0000-0002-8795-3060; Poria, Dipak Kumar/0000-0002-6935-4160; Nandi, Ipsita/0000-0002-4502-2559; Guha, Abhishek/0000-0003-2767-9941	Wellcome Trust-DBT India Alliance intermediate fellowship [WT500139/Z/09/Z]; CSIR senior research fellowship; IISER PBIP fellowship	Wellcome Trust-DBT India Alliance intermediate fellowship(Wellcome Trust DBT India Alliance); CSIR senior research fellowship(Council of Scientific & Industrial Research (CSIR) - India); IISER PBIP fellowship	We acknowledge P L Fox (Cleveland Clinic), S Das (IISc Bangalore), S N Bhattacharyya (IICB, Kolkata), D Chattopadhyay (University of Calcutta) and S Sengupta (University of Calcutta) for providing reagents and laboratory facilities. We are thankful to LRI Molecular Biotechnology Core for services provided. This work was supported by a Wellcome Trust-DBT India Alliance intermediate fellowship (WT500139/Z/09/Z) to PSR, a CSIR senior research fellowship to DKP and IISER PBIP fellowship to AG.	Abdelmohsen K, 2008, BIOL CHEM, V389, P243, DOI 10.1515/BC.2008.022; Abdelmohsen K, 2009, EMBO J, V28, P1271, DOI 10.1038/emboj.2009.67; Anderson P, 2010, NAT REV IMMUNOL, V10, P24, DOI 10.1038/nri2685; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Balkhi MY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004177; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Biyanee A, 2015, ONCOGENE, V34, P1384, DOI 10.1038/onc.2014.83; Dormoy-Raclet V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3388; Ebert MS, 2010, CURR BIOL, V20, pR858, DOI 10.1016/j.cub.2010.08.052; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Epis MR, 2011, J BIOL CHEM, V286, P41442, DOI 10.1074/jbc.M111.301481; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6; Jafarifar F, 2011, EMBO J, V30, P1324, DOI 10.1038/emboj.2011.38; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; Lankat-Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Ray PS, 2009, NATURE, V457, P915, DOI 10.1038/nature07598; Ray PS, 2002, NUCLEIC ACIDS RES, V30, P4500, DOI 10.1093/nar/gkf583; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Srikantan S, 2012, CURR PROTEIN PEPT SC, V13, P372, DOI 10.2174/138920312801619394; Srikantan S, 2011, MOL CELL BIOL, V31, P3790, DOI 10.1128/MCB.05639-11; Tominaga K, 2011, MOL CELL BIOL, V31, P4219, DOI 10.1128/MCB.05955-11; Uren PJ, 2011, J BIOL CHEM, V286, P37063, DOI 10.1074/jbc.C111.266882; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Yao P, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001635; Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337	35	70	74	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1703	1715		10.1038/onc.2015.235	http://dx.doi.org/10.1038/onc.2015.235			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26189797	Green Published, hybrid			2022-12-28	WOS:000373064200009
J	Stacer, AC; Fenner, J; Cavnar, SP; Xiao, A; Zhao, S; Chang, SL; Salomonnson, A; Luker, KE; Luker, GD				Stacer, A. C.; Fenner, J.; Cavnar, S. P.; Xiao, A.; Zhao, S.; Chang, S. L.; Salomonnson, A.; Luker, K. E.; Luker, G. D.			Endothelial CXCR7 regulates breast cancer metastasis	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; CXCL12 ISOFORMS; TUMOR-GROWTH; IN-VIVO; EXPRESSION; CELLS; INHIBITION; MIGRATION; LUNG; PROGNOSIS	Atypical chemokine receptor CXCR7 (ACKR3) functions as a scavenger receptor for chemokine CXCL12, a molecule that promotes multiple steps in tumor growth and metastasis in breast cancer and multiple other malignancies. Although normal vascular endothelium expresses low levels of CXCR7, marked upregulation of CXCR7 occurs in tumor vasculature in breast cancer and other tumors. To investigate effects of endothelial CXCR7 in breast cancer, we conditionally deleted this receptor from vascular endothelium of adult mice, generating CXCR7(Delta END/Delta END) animals. CXCR7(Delta END/Delta END) mice appeared phenotypically normal, although these animals exhibited a modest 35 +/- 3% increase in plasma CXCL12 as compared with control. Using two different syngeneic, orthotopic tumor implant models of breast cancer, we discovered that CXCR7(Delta END/Delta END) mice had significantly greater local recurrence of cancer following resection, elevated numbers of circulating tumor cells and more spontaneous metastases. CXCR7(Delta END/Delta END) mice also showed greater experimental metastases following intracardiac injection of cancer cells. These results establish that endothelial CXCR7 limits breast cancer metastasis at multiple steps in the metastatic cascade, advancing understanding of CXCL12 pathways in tumor environments and informing ongoing drug development targeting CXCR7 in cancer.	[Stacer, A. C.; Fenner, J.; Xiao, A.; Salomonnson, A.; Luker, K. E.; Luker, G. D.] Univ Michigan, Sch Med, Dept Radiol, Ctr Mol Imaging, Ann Arbor, MI USA; [Stacer, A. C.; Fenner, J.; Cavnar, S. P.; Xiao, A.; Zhao, S.; Chang, S. L.; Salomonnson, A.; Luker, K. E.; Luker, G. D.] Univ Michigan, Coll Engn, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA; [Cavnar, S. P.; Luker, G. D.] Univ Michigan, Sch Med, Dept Biomed Engn, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA; [Zhao, S.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI USA; [Chang, S. L.] Univ Michigan, Sch Med, Dept Chem Engn, Ann Arbor, MI USA; [Luker, G. D.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Coll Engn, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Sch Med, Dept Biomed Engn, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Sch Med, Dept Radiol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu	zhao, shuangling/HCI-6255-2022	luker, gary/0000-0001-6832-2581	United States National Institute of Health [R21CA182333, R01CA136553, R01CA142750, R01CA170198, P50CA093990]; NATIONAL CANCER INSTITUTE [R01CA170198, R01CA136553, P01CA085878, P50CA093990, R21CA182333, R01CA142750] Funding Source: NIH RePORTER	United States National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Mark Penfold and ChemoCentryx for CXCR7 loxP mice and antibody 11G8. Dr Jun-Lin Guan provided SCL Cre<SUP>ERT</SUP> through courteous permission of Dr Glenn Begley. We thank Dr Aaron Robida from the University of Michigan Flow Cytometry Core for assistance. Research was supported by United States National Institute of Health grants R21CA182333, R01CA136553, R01CA142750, R01CA170198 and P50CA093990.	Akashi T, 2008, CANCER SCI, V99, P539, DOI 10.1111/j.1349-7006.2007.00712.x; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Berahovich RD, 2014, IMMUNOLOGY, V141, P111, DOI 10.1111/imm.12176; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Cavnar SP, 2014, INTEGR BIOL-UK, V6, P564, DOI 10.1039/c4ib00015c; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Cruz-Orengo L, 2011, J EXP MED, V208, P327, DOI 10.1084/jem.20102010; Cullen M, 2009, CANCER RES, V69, P6021, DOI 10.1158/0008-5472.CAN-09-1086; D'Alterio C, 2010, CURR CANCER DRUG TAR, V10, P772, DOI 10.2174/156800910793605839; D'Alterio C, 2014, INT J CANCER, V135, P379, DOI 10.1002/ijc.28689; Dang SP, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/712561; Ding BS, 2014, NATURE, V505, P97, DOI 10.1038/nature12681; Dona E, 2013, NATURE, V503, P285, DOI 10.1038/nature12635; Ewens A, 2005, ANTICANCER RES, V25, P3905; Fenner J, 2014, SCI REP-UK, V4, DOI 10.1038/srep05512; Gerrits H, 2008, GENESIS, V46, P235, DOI 10.1002/dvg.20387; Goguet-Surmenian E, 2013, BRIT J CANCER, V109, P1579, DOI 10.1038/bjc.2013.482; Gothert JR, 2005, BLOOD, V105, P2724, DOI 10.1182/blood-2004-08-3037; Guillemot E, 2012, BRIT J CANCER, V107, P1944, DOI 10.1038/bjc.2012.503; Hoellenriegel J, 2014, BLOOD, V123, P1032, DOI 10.1182/blood-2013-03-493924; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190; Liao Y, 2001, P NATL ACAD SCI USA, V98, P9989, DOI 10.1073/pnas.171305298; Liberman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043665; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luker K, 2012, ONCOGENE, V31, P4570, DOI DOI 10.1038/0NC.2011.633; Luker KE, 2010, ONCOGENE, V29, P4599, DOI 10.1038/onc.2010.212; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; Maishi N, 2012, PATHOL INT, V62, P309, DOI 10.1111/j.1440-1827.2012.02792.x; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Potter SM, 2009, BREAST CANCER RES TR, V115, P279, DOI 10.1007/s10549-008-0078-2; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Ray P, 2012, INT J BIOCHEM CELL B, V44, P669, DOI 10.1016/j.biocel.2012.01.007; Salomonnson E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051500; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Singh S, 2010, BRIT J CANCER, V103, P1671, DOI 10.1038/sj.bjc.6605968; Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun YN, 2014, TUMOR BIOL, V35, P7765, DOI 10.1007/s13277-014-1816-1; Tachezy M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-238; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Totonchy JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069828; Venkiteswaran G, 2013, CELL, V155, P674, DOI 10.1016/j.cell.2013.09.046; Wald O, 2013, THERANOSTICS, V3, P26, DOI 10.7150/thno.4922; Walters MJ, 2014, BRIT J CANCER, V110, P1179, DOI 10.1038/bjc.2013.830; Walters MJ, 2013, IMMUNOL LETT, V151, P44, DOI 10.1016/j.imlet.2013.01.006; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Wang YL, 2011, NEURON, V69, P61, DOI 10.1016/j.neuron.2010.12.005; Xu TP, 2013, CANCER EPIDEMIOL, V37, P725, DOI 10.1016/j.canep.2013.04.017; Xue TC, 2012, EXP THER MED, V3, P117, DOI 10.3892/etm.2011.358; Yao X, 2011, J INT MED RES, V39, P1253, DOI 10.1177/147323001103900413; Yokoyama K, 2008, BIOORGAN MED CHEM, V16, P7021, DOI 10.1016/j.bmc.2008.05.036; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zhao S, 2014, TRANSL ONCOL, V7, P429, DOI 10.1016/j.tranon.2014.04.001	63	31	32	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1716	1724		10.1038/onc.2015.236	http://dx.doi.org/10.1038/onc.2015.236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26119946	Green Accepted			2022-12-28	WOS:000373064200010
J	Lee, YS; Bae, SC				Lee, Y-S; Bae, S-C			How do K-RAS-activated cells evade cellular defense mechanisms?	ONCOGENE			English	Review							LUNG-CANCER; TRANSFORMING GENE; STEM-CELLS; RESTRICTION POINT; P53; CARCINOMA; ONCOGENE; ORIGIN; DIFFERENTIATION; ADENOCARCINOMA	Lung adenocarcinomas, like other cancers, develop through the accumulation of epigenetic and genetic alterations. Numerous studies have shown that K-RAS mutation is among the most important early events in carcinogenesis of the lung. However, it is also well established that growth-stimulating signals feed back into growth-suppressing pathways, and any imbalance in these signaling networks will cause the cell to exit the cell cycle, thereby preventing uncontrolled cell growth. How, then, do K-RAS-activated cells evade cellular defense mechanisms? To answer this question, it is necessary to identify the molecular event(s) responsible for the development of early dysplastic lesions that are unable to defend against aberrant oncogene activation. Lineage-determining transcriptional regulators govern differentiation status during normal lung development, as well as in lung adenocarcinoma. Among the genes involved in K-RAS-induced lung tumorigenesis, RUNX3 is unique: inactivation of Runx3 in mouse lung induces lung adenoma and abrogates the ARF-p53 pathway. This observation raises the possibility of intimate cross-talk between the differentiation program and oncogene surveillance. In this review, we summarized evidences suggesting that K-RAS-activated cells do not evade cellular defense mechanisms per se; instead, cells with K-RAS mutations are selected only if they occur in cells in which defense mechanism is abrogated.	[Lee, Y-S; Bae, S-C] Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea; [Lee, Y-S; Bae, S-C] Chungbuk Natl Univ, Inst Tumor Res, Cheongju, South Korea	Chungbuk National University; Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea.; Bae, SC (corresponding author), Chungbuk Natl Univ, Inst Tumor Res, Cheongju, South Korea.	scbae@chungbuk.ac.kr		Bae, Sang-Cheol/0000-0003-4658-1093	Creative Research Grant [2014R1A3A2030690]; Basic Science Research Program through National Research Foundation (NRF) - Ministry of Education of Korea [2013R1A1A2057659]	Creative Research Grant; Basic Science Research Program through National Research Foundation (NRF) - Ministry of Education of Korea	S-CB is supported by a Creative Research Grant (2014R1A3A2030690) and Y-SL is supported by Basic Science Research Program (2013R1A1A2057659) through the National Research Foundation (NRF) funded by the Ministry of Education of Korea.	Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Bishop AE, 2004, CELL PROLIFERAT, V37, P89, DOI 10.1111/j.1365-2184.2004.00302.x; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Blanpain C, 2013, NAT CELL BIOL, V15, P126, DOI 10.1038/ncb2657; Cho HC, 2011, CANCER RES, V71, P7250, DOI 10.1158/0008-5472.CAN-11-0903; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Keijzer R, 2001, DEVELOPMENT, V128, P503; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim WJ, 2011, J UROLOGY, V185, P2366, DOI 10.1016/j.juro.2011.02.017; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lee KS, 2010, ONCOGENE, V29, P3349, DOI 10.1038/onc.2010.79; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Marchetti A, 1996, J PATHOL, V179, P254, DOI 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Park SY, 2012, J CELL PHYSIOL, V227, P899, DOI 10.1002/jcp.22799; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; Rauen KA, 2007, CLIN GENET, V71, P101, DOI 10.1111/j.1399-0004.2007.00743.x; Reddy R, 2004, AM J PHYSIOL-LUNG C, V286, pL658, DOI 10.1152/ajplung.00159.2003; Rock JR, 2011, ANNU REV CELL DEV BI, V27, P493, DOI 10.1146/annurev-cellbio-100109-104040; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; SUGIO K, 1994, CANCER RES, V54, P5811; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Sutherland KD, 2010, MOL ONCOL, V4, P397, DOI 10.1016/j.molonc.2010.05.002; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Travis WD., 2004, TRAVIS WB WHO CLASSI; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weinberg RA, 2007, BIOL CANC; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wistuba II, 2006, ANNU REV PATHOL-MECH, V1, P331, DOI 10.1146/annurev.pathol.1.110304.100103; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yin Z, 2006, AM J PHYSIOL-LUNG C, V291, pL191, DOI 10.1152/ajplung.00385.2005; Zhang YZ, 2007, DEVELOPMENT, V134, P189, DOI 10.1242/dev.02720	68	20	20	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					827	832		10.1038/onc.2015.153	http://dx.doi.org/10.1038/onc.2015.153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961920	Green Published, hybrid			2022-12-28	WOS:000370332200003
J	Jin, L; Alesi, GN; Kang, S				Jin, L.; Alesi, G. N.; Kang, S.			Glutaminolysis as a target for cancer therapy	ONCOGENE			English	Review							KIDNEY-TYPE GLUTAMINASE; GLUTAMATE-DEHYDROGENASE; OXIDATIVE STRESS; REDUCTIVE CARBOXYLATION; CELL-PROLIFERATION; BREAST-CANCER; METABOLISM; GROWTH; GLUCOSE; GLYCOLYSIS	Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in these metabolic processes could provide novel approaches to improve cancer treatment. This review summarizes current findings on the role of glutaminolytic enzymes in human cancers and provides an update on the development of small molecule inhibitors to target glutaminolysis for cancer therapy.	[Jin, L.; Alesi, G. N.; Kang, S.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA	Emory University	Jin, L; Kang, S (corresponding author), Emory Univ, Sch Med, Winship Canc Inst Emory, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Room C3006, Atlanta, GA 30322 USA.	LJIN4@emory.edu; smkang@emory.edu			ACS grant [RSG-11-081-01]; NIH [R01 CA175316, F31 CA183365]; NATIONAL CANCER INSTITUTE [R01CA175316] Funding Source: NIH RePORTER	ACS grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Anthea Hammond for editorial assistance. We apologize to authors whose contributions were not directly cited in this review due to space limitations. This study is supported in part by ACS grant RSG-11-081-01 and NIH grants R01 CA175316 (S.K.) and F31 CA183365 (G.A.). S.K. is a Georgia Cancer Coalition Scholar, Robbins Scholar, and an American Cancer Society Basic Research Scholar.	Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006; AHLUWALIA GS, 1990, PHARMACOL THERAPEUT, V46, P243, DOI 10.1016/0163-7258(90)90094-I; Bhutia YD, 2015, CANCER RES, V75, P1782, DOI 10.1158/0008-5472.CAN-14-3745; Chen RH, 2014, P NATL ACAD SCI USA, V111, P14217, DOI 10.1073/pnas.1409653111; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Colombo SL, 2011, P NATL ACAD SCI USA, V108, P21069, DOI 10.1073/pnas.1117500108; Csibi A, 2013, CELL, V153, P840, DOI 10.1016/j.cell.2013.04.023; Csibi A, 2014, CURR BIOL, V24, P2274, DOI 10.1016/j.cub.2014.08.007; Dang CV, 2010, CELL CYCLE, V9, P3884, DOI 10.4161/cc.9.19.13302; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeLaBarre B, 2014, CHEM BIOL, V21, P1143, DOI 10.1016/j.chembiol.2014.08.007; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Elhammali A, 2014, CANCER DISCOV, V4, P828, DOI 10.1158/2159-8290.CD-13-0572; Elorza A, 2012, MOL CELL, V48, P681, DOI 10.1016/j.molcel.2012.09.017; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; Frezza C, 2009, SEMIN CANCER BIOL, V19, P4, DOI 10.1016/j.semcancer.2008.11.008; Friday E, 2011, J CELL PHYSIOL, V226, P511, DOI 10.1002/jcp.22360; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Ghesquiere B, 2014, NATURE, V511, P167, DOI 10.1038/nature13312; Giacobbe A, 2013, CELL CYCLE, V12, P1395, DOI 10.4161/cc.24478; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hassanein M, 2015, INT J CANCER, V137, P1587, DOI 10.1002/ijc.29535; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Herranz D, 2015, NAT MED, V21, P1182, DOI 10.1038/nm.3955; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Katt WP, 2014, DRUG DISCOV TODAY, V19, P450, DOI 10.1016/j.drudis.2013.10.008; Katt WP, 2012, MOL CANCER THER, V11, P1269, DOI 10.1158/1535-7163.MCT-11-0942; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Korangath P, 2015, CLIN CANCER RES, V21, P3263, DOI 10.1158/1078-0432.CCR-14-1200; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; LACEY JM, 1990, NUTR REV, V48, P297, DOI 10.1111/j.1753-4887.1990.tb02967.x; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Li CH, 2006, J BIOL CHEM, V281, P10214, DOI 10.1074/jbc.M512792200; Li J, 2015, P NATL ACAD SCI USA, V112, pE21, DOI 10.1073/pnas.1417015112; Lorin S, 2013, AUTOPHAGY, V9, P850, DOI 10.4161/auto.24083; Lu WQ, 2010, CANCER CELL, V18, P199, DOI 10.1016/j.ccr.2010.08.017; Martin-Rufian M, 2014, J MOL MED, V92, P277, DOI 10.1007/s00109-013-1105-2; Mates JM, 2013, CURR MOL MED, V13, P514; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; MEDINA MA, 1990, INT J BIOCHEM, V22, P681, DOI 10.1016/0020-711X(90)90001-J; MEDINA MA, 1992, MOL CELL BIOCHEM, V113, P1; Medina MA, 2001, J NUTR, V131, p2539S, DOI 10.1093/jn/131.9.2539S; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Moncada S, 2012, BIOCHEM J, V446, P1, DOI 10.1042/BJ20120427; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; Mullen AR, 2014, CELL REP, V7, P1679, DOI 10.1016/j.celrep.2014.04.037; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Murphy TA, 2013, METAB ENG, V15, P206, DOI 10.1016/j.ymben.2012.07.008; NEWSHOLME EA, 1985, Q J EXP PHYSIOL CMS, V70, P473, DOI 10.1113/expphysiol.1985.sp002935; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Ooi A, 2011, CANCER CELL, V20, P511, DOI 10.1016/j.ccr.2011.08.024; Plaitakis A, 2011, NEUROCHEM INT, V59, P495, DOI 10.1016/j.neuint.2011.03.015; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Shroff EH, 2015, P NATL ACAD SCI USA, V112, P6539, DOI 10.1073/pnas.1507228112; Shukla K, 2012, J MED CHEM, V55, P10551, DOI 10.1021/jm301191p; Smith TJ, 2008, TRENDS BIOCHEM SCI, V33, P557, DOI 10.1016/j.tibs.2008.07.007; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; SOUBA WW, 1993, ANN SURG, V218, P715, DOI 10.1097/00000658-199312000-00004; Stalnecker CA, 2015, P NATL ACAD SCI USA, V112, P394, DOI 10.1073/pnas.1414056112; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Tanaka K, 2015, J CLIN INVEST, V125, P1591, DOI 10.1172/JCI78239; Thangavelu K, 2012, P NATL ACAD SCI USA, V109, P7705, DOI 10.1073/pnas.1116573109; Thornburg JM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2154; Ulanet DB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115144; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wang Q, 2014, INT J CANCER, V135, P1060, DOI 10.1002/ijc.28749; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Willems L, 2013, BLOOD, V122, P3521, DOI 10.1182/blood-2013-03-493163; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiang LS, 2013, BBA-MOL CELL RES, V1833, P2996, DOI 10.1016/j.bbamcr.2013.08.003; Xiang Y, 2015, J CLIN INVEST, V125, P2293, DOI 10.1172/JCI75836; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yang H, 2015, EMBO J, V34, P1110, DOI 10.15252/embj.201591041; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang J, 2014, MOL CELL, V56, P205, DOI 10.1016/j.molcel.2014.08.018	90	231	234	4	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3619	3625		10.1038/onc.2015.447	http://dx.doi.org/10.1038/onc.2015.447			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26592449	Green Accepted			2022-12-28	WOS:000379622800001
J	Mizutani, R; Imamachi, N; Suzuki, Y; Yoshida, H; Tochigi, N; Oonishi, T; Suzuki, Y; Akimitsu, N				Mizutani, R.; Imamachi, N.; Suzuki, Y.; Yoshida, H.; Tochigi, N.; Oonishi, T.; Suzuki, Y.; Akimitsu, N.			Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA	ONCOGENE			English	Article							BINDING PROTEINS; TRANSLATIONAL CONTROL; CANCER; GROWTH; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; ACTIVATION; STABILITY; REGULONS	RNA-binding proteins (RBPs) have important roles in tumorigenesis. Although IGF2BP3, an evolutionally conserved RBP, has been reported as a useful diagnostic marker for various cancers and has been considered a regulator of tumorigenesis, little is known of the function of IGF2BP3 because of lack of information regarding IGF2BP3 target mRNAs. Here, we report the identification of IGF2BP3 target mRNAs and IGF2BP3 function in cancer proliferation. We identified mRNAs with altered expression in IGF2BP3-depleted cells by massive sequencing analysis and IGF2BP3-binding RNAs by immunoprecipitation of IGF2BP3 followed by massive sequencing analysis, resulting in the identification of 110 candidates that are negatively regulated by IGF2BP3. We found that IGF2BP3 destabilized EIF4E-BP2 and MEIS3 mRNAs. Co-immunoprecipitation analysis revealed the interaction between IGF2BP3 and ribonucleases such as XRN2 and exosome component. The retarded proliferation of IGF2BP3-depleted cells was partially rescued by the depletion of EIF4E-BP2, which negatively regulates eukaryotic translation initiation factor 4E (eIF4E), an activator of translation and a well-known proto-oncogene. Consistent with this observation, IGF2BP3 depletion reduced phosphorylated eIF4E, the active form, and translational efficiency of eIF4E target transcripts. Reduction of phosphorylated eIF4E by IGF2BP3 depletion was rescued by EIF4E-BP2 depletion. At last, we found an inverse correlation between the expression level of IGF2BP3 and EIF4E-BP2 in human lung adenocarcinoma tissues. Together, these results suggest that IGF2BP3 promotes eIF4E-mediated translational activation through the reduction of EIF4E-BP2 via mRNA degradation, leading to enhanced cell proliferation. This is the first report demonstrating that IGF2BP3 is an RNA-destabilizing factor. Notably, here we provide the first evidence for the functional linkage between two previously well-known cancer biomarkers, IGF2BP3 and eIF4E.	[Mizutani, R.; Imamachi, N.; Akimitsu, N.] Univ Tokyo, Isotope Sci Ctr, Tokyo, Japan; [Suzuki, Y.; Yoshida, H.; Tochigi, N.] Asahi Gen Hosp, Dept Pathol, Chiba, Japan; [Oonishi, T.] Med Consultat Off Inc, Yokohama, Kanagawa, Japan; [Suzuki, Y.] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol, Kashiwa, Chiba, Japan	University of Tokyo; University of Tokyo	Akimitsu, N (corresponding author), Univ Tokyo, Radioisotope Ctr, Bunkyo Ku, 2-11-16 Yayoi, Tokyo 1130032, Japan.	akimitsu@ric.u-tokyo.ac.jp		Imamachi, Naoto/0000-0002-3503-7589	Research Fellowship of the Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology of Japan; Funding Program for World-Leading Innovative R&D on Science and Technology of the Japan Society for the Promotion of Science	Research Fellowship of the Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Funding Program for World-Leading Innovative R&D on Science and Technology of the Japan Society for the Promotion of Science	We thank Dr Hiroki Kurihara, Dr Yukiko Kurihara, Dr Hiro-oki Iwakawa and Dr Yukihide Tomari (The University of Tokyo) for helpful supports and fruitful discussions. This work was financially supported by the Research Fellowship of the Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research on Innovative Areas 'Functional machinery for noncoding RNAs' and 'Genome science' from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and The Funding Program for World-Leading Innovative R&D on Science and Technology of the Japan Society for the Promotion of Science.	Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bhardwaj A, 2013, NUCLEIC ACIDS RES, V41, P5062, DOI 10.1093/nar/gkt189; Bitterman PB, 2014, BIOCHIM BIOPHYS ACTA, V1849, P774; Blackinton JG, 2014, SEMIN CELL DEV BIOL, V34, P44, DOI 10.1016/j.semcdb.2014.05.014; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Cook KB, 2011, NUCLEIC ACIDS RES, V39, pD301, DOI 10.1093/nar/gkq1069; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003; Fedele M, 2010, MOL CELL ENDOCRINOL, V326, P19, DOI 10.1016/j.mce.2010.03.019; Findeis-Hosey JJ, 2010, HUM PATHOL, V41, P477, DOI 10.1016/j.humpath.2009.10.004; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Hammerle M, 2013, HEPATOLOGY, V58, P1703, DOI 10.1002/hep.26537; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Hwang YS, 2012, CARCINOGENESIS, V33, P2135, DOI 10.1093/carcin/bgs258; Imamachi N, 2014, METHODS, V67, P55, DOI 10.1016/j.ymeth.2013.07.014; Jeng YM, 2008, HEPATOLOGY, V48, P1118, DOI 10.1002/hep.22459; Jonson L, 2014, CELL REP, V7, P539, DOI 10.1016/j.celrep.2014.03.015; Kanematsu S, 2014, GENE, V533, P520, DOI 10.1016/j.gene.2013.08.005; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kim YY, 2009, CANCER RES, V69, P8455, DOI 10.1158/0008-5472.CAN-09-1923; Liao BS, 2005, J BIOL CHEM, V280, P18517, DOI 10.1074/jbc.M500270200; Lukong KE, 2008, TRENDS GENET, V24, P416, DOI 10.1016/j.tig.2008.05.004; Martineau Y, 2013, ONCOGENE, V32, P671, DOI 10.1038/onc.2012.116; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Muller D, 2013, TRANSLATION, V1, DOI 10.4161/trla.25819; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Musunuru K, 2003, TRENDS CARDIOVAS MED, V13, P188, DOI 10.1016/S1050-1738(03)00075-6; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Sonenberg N, 2007, MOL CELL, V28, P721, DOI 10.1016/j.molcel.2007.11.018; Stohr N, 2006, J CELL BIOL, V175, P527, DOI 10.1083/jcb.200608071; Sutandy FX, 2015, CRIT REV BIOTECHNOL, V20, P1; Suvasini R, 2011, J BIOL CHEM, V286, P25882, DOI 10.1074/jbc.M110.178012; Tani H, 2012, GENOME RES, V22, P947, DOI 10.1101/gr.130559.111; Topisirovic I, 2011, COLD SH Q B, V76, P355, DOI 10.1101/sqb.2011.76.010785; Vargas TR, 2014, ONCOGENE, V33, P2866, DOI 10.1038/onc.2013.252; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wagner M, 2003, GASTROENTEROLOGY, V124, P1901, DOI 10.1016/S0016-5085(03)00402-5; Wei QZ, 2014, HUM PATHOL, V45, P2218, DOI 10.1016/j.humpath.2014.07.006; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Yuan RH, 2009, ANN SURG ONCOL, V16, P1711, DOI 10.1245/s10434-009-0446-0; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011	49	36	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3495	3502		10.1038/onc.2015.410	http://dx.doi.org/10.1038/onc.2015.410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522719				2022-12-28	WOS:000379621500002
J	Auvergne, R; Wu, C; Connell, A; Au, S; Cornwell, A; Osipovitch, M; Benraiss, A; Dangelmajer, S; Guerrero-Cazares, H; Quinones-Hinojosa, A; Goldman, SA				Auvergne, R.; Wu, C.; Connell, A.; Au, S.; Cornwell, A.; Osipovitch, M.; Benraiss, A.; Dangelmajer, S.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; Goldman, S. A.			PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo	ONCOGENE			English	Article							PROTEASE-ACTIVATED RECEPTOR-1; SMALL-MOLECULE ANTAGONISTS; CANCER STEM-CELLS; HUMAN GLIOBLASTOMA; GENE-EXPRESSION; HUMAN BRAIN; THROMBIN; IDENTIFICATION; EGFR; ANGIOGENESIS	Glioblastoma (GBM) remains the most common and lethal intracranial tumor. In a comparison of gene expression by A2B5-defined tumor-initiating progenitor cells (TPCs) to glial progenitor cells derived from normal adult human brain, we found that the F2R gene encoding PAR1 was differentially overexpressed by A2B5-sorted TPCs isolated from gliomas at all stages of malignant development. In this study, we asked if PAR1 is causally associated with glioma progression. Lentiviral knockdown of PAR1 inhibited the expansion and self-renewal of human GBM-derived A2B5(+) TPCs in vitro, while pharmacological inhibition of PAR 1 similarly slowed both the growth and migration of A2B5(+) TPCs in culture. In addition, PAR1 silencing potently suppressed tumor expansion in vivo, and significantly prolonged the survival of mice following intracranial transplantation of human TPCs. These data strongly suggest the importance of PAR1 to the self-renewal and tumorigenicity of A2B5-defined glioma TPCs; as such, the abrogation of PAR1-dependent signaling pathways may prove a promising strategy for gliomas.	[Auvergne, R.; Wu, C.; Connell, A.; Au, S.; Cornwell, A.; Osipovitch, M.; Benraiss, A.; Goldman, S. A.] Neurol Univ Rochester, Med Ctr, Ctr Translat Neuromed, Dept Neurol, Rochester, NY USA; [Auvergne, R.; Wu, C.; Connell, A.; Au, S.; Cornwell, A.; Osipovitch, M.; Benraiss, A.; Goldman, S. A.] Neurol Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Dangelmajer, S.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Goldman, S. A.] Univ Copenhagen, Ctr Basic & Translat Neurosci, Copenhagen, Denmark	University of Rochester; University of Rochester; Johns Hopkins University; University of Copenhagen	Auvergne, R; Goldman, SA (corresponding author), Neurol Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA.; Auvergne, R; Goldman, SA (corresponding author), Neurol Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.	romane_auvergne@urmc.rochester.edu; steven_goldman@urmc.rochester.edu	Auvergne, Romane M/N-2624-2016; Benraiss, Abdellatif/AAI-8584-2021	Auvergne, Romane M/0000-0002-9497-0184; Benraiss, Abdellatif/0000-0002-0325-6234; Guerrero-Cazares, Hugo/0000-0003-1307-719X; Goldman, Steven/0000-0002-5498-4303; Au, Sandra/0000-0002-7924-3982; Cornwell, Adam/0000-0002-0572-3107	Dr Miriam and Sheldon G Adelson Medical Research Foundation; New York State Stem Cell Research Program; NIH [R01NS070024]; Novo Nordisk Fonden [NNF13OC0004260] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH104701, R01MH099578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075345] Funding Source: NIH RePORTER	Dr Miriam and Sheldon G Adelson Medical Research Foundation; New York State Stem Cell Research Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novo Nordisk Fonden(Novo Nordisk Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Mahlon Johnson for the histopathological validation of tumor stage, Dr Kevin Walter for arranging tissue donation and Shengtao Qu and Eric Franklin for technical assistance. This work was supported by the Dr Miriam and Sheldon G Adelson Medical Research Foundation, and by the New York State Stem Cell Research Program. Tissue collection, processing and studies on human tissue derived from Johns Hopkins University were supported by NIH R01NS070024.	Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Arora P, 2008, ONCOGENE, V27, P4434, DOI 10.1038/onc.2008.84; Auvergne RM, 2013, CELL REP, V3, P2127, DOI 10.1016/j.celrep.2013.04.035; Baumer N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094993; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar-Shavit R, 2011, IUBMB LIFE, V63, P397, DOI 10.1002/iub.452; Bergmann S, 2006, ONCOL REP, V15, P889; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Brat DJ, 2004, LAB INVEST, V84, P397, DOI 10.1038/labinvest.3700070; Carneiro-Lobo TC, 2014, ONCOL REP, V31, P679, DOI 10.3892/or.2013.2880; Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Defeo K, 2010, CANCER BIOL THER, V10, P1001, DOI 10.4161/cbt.10.10.13236; Du XL, 2011, JPN J CLIN ONCOL, V41, P1086, DOI 10.1093/jjco/hyr108; Elste AP, 2010, J MOL HISTOL, V41, P89, DOI 10.1007/s10735-010-9274-6; Eroglu A, 2012, ANN SURG ONCOL, V19, P1365, DOI 10.1245/s10434-011-1969-8; Feve M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091519; Fujimoto D, 2008, ANTICANCER RES, V28, P847; Garcia-Lopez MT, 2010, CURR MED CHEM, V17, P109, DOI 10.2174/092986710790112639; Garnier D, 2010, THROMB RES, V125, pS44, DOI 10.1016/S0049-3848(10)70012-8; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghio P, 2006, CLIN LUNG CANCER, V7, P395, DOI 10.3816/CLC.2006.n.023; Gibson E, 2012, CURR OPIN ONCOL, V24, P672, DOI 10.1097/CCO.0b013e3283571a8e; Gieseler F, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-86; Guo H, 2013, J NEUROSCI, V33, P6181, DOI 10.1523/JNEUROSCI.4491-12.2013; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Kaufmann R, 1998, NEUROREPORT, V9, P709, DOI 10.1097/00001756-199803090-00027; Kaufmann R, 2012, ADV EXP MED BIOL, V740, P979, DOI 10.1007/978-94-007-2888-2_45; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kuhn SA, 2014, NEUROL RES, V36, P709, DOI 10.1179/1743132813Y.0000000303; Lee CJ, 2011, BRIT J CLIN PHARMACO, V72, P581, DOI 10.1111/j.1365-2125.2011.03916.x; Lin N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094871; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Magnus N, 2013, J THROMB HAEMOST, V11, P1197, DOI 10.1111/jth.12242; Massi D, 2005, HUM PATHOL, V36, P676, DOI 10.1016/j.humpath.2005.04.008; Milsom C, 2009, ARTERIOSCL THROM VAS, V29, P2005, DOI 10.1161/ATVBAHA.108.177444; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Perry JR, 2012, NEURO-ONCOLOGY, V14, P73, DOI 10.1093/neuonc/nos197; Persson AI, 2010, CANCER CELL, V18, P669, DOI 10.1016/j.ccr.2010.10.033; Queiroz KCS, 2014, INT J CANCER, V135, P2294, DOI 10.1002/ijc.28726; Ramachandran R, 2012, NAT REV DRUG DISCOV, V11, P69, DOI 10.1038/nrd3615; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soh UJK, 2010, BRIT J PHARMACOL, V160, P191, DOI 10.1111/j.1476-5381.2010.00705.x; Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Talloen W, 2007, BIOINFORMATICS, V23, P2897, DOI 10.1093/bioinformatics/btm478; Tchoghandjian A, 2010, BRAIN PATHOL, V20, P211, DOI 10.1111/j.1750-3639.2009.00269.x; Tsopanoglou NE, 2007, SEMIN THROMB HEMOST, V33, P680, DOI 10.1055/s-2007-991535; Venere M, 2011, GLIA, V59, P1148, DOI 10.1002/glia.21185; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Villares GJ, 2011, ONCOTARGET, V2, P8; Zania P, 2006, J PHARMACOL EXP THER, V318, P246, DOI 10.1124/jpet.105.099069; Zhang Y, 2011, PATHOL RES PRACT, V207, P24, DOI 10.1016/j.prp.2010.10.003; Zhao PS, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00067; Zigler M, 2011, CANCER RES, V71, P6561, DOI 10.1158/0008-5472.CAN-11-1432	60	33	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3817	3828		10.1038/onc.2015.452	http://dx.doi.org/10.1038/onc.2015.452			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26616854	Green Accepted			2022-12-28	WOS:000380753200007
J	Metzig, MO; Fuchs, D; Tagscherer, KE; Grone, HJ; Schirmacher, P; Roth, W				Metzig, M. Oliver; Fuchs, D.; Tagscherer, K. E.; Groene, H-J; Schirmacher, P.; Roth, W.			Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-alpha-dependent necroptosis driven by RIP1 kinase and NF-kappa B	ONCOGENE			English	Article							APOPTOSIS RESISTANCE; DRUG-RESISTANCE; DEATH; ACTIVATION; INDUCTION; CLEAVAGE; NECROSIS; IDENTIFICATION; RIPOPTOSOME; IAPS	Resistance towards the drug 5-fluorouracil (5-FU) is a key challenge in the adjuvant chemotherapy of colorectal cancer (CRC), and novel targeted approaches are required to improve the therapeutic outcome. Necroptosis is a recently discovered form of programmed cell death, which depends on receptor interacting protein 1 (RIP1) and particularly occurs under caspase-deficient conditions. The targeted induction of necroptosis represents a promising strategy to overcome apoptosis resistance in cancer. The aim of this study was to systematically explore the usage of pan-caspase inhibitors to sensitize resistant CRC cells for 5-FU. We found that pan-caspase inhibitors facilitated 5-FU-induced necroptosis, which was mediated by autocrine secretion of tumor necrosis factor alpha (TNF-alpha). TNF-alpha production was driven by nuclear factor kappa B (NF-kappa B) and required RIP1 kinase. In vivo xenograft experiments showed that the novel pan-caspase inhibitor IDN-7314 in combination with 5-FU synergistically blocked tumor growth. Ex vivo experiments with fresh human CRC tissue specimens further indicated that a subgroup of patients could benefit from combinatory treatment. Thereby, elevated levels of secreted TNF-alpha and expression of components of the necroptotic pathway might help to predict the sensitivity to pro-necroptotic therapies. Together, our results shed new light on the molecular regulation of necroptosis by NF-kappa B and RIP1. Moreover, we identify necroptotic cell death as an important effector mechanism of 5-FU-mediated anti-tumoral activity. On the basis of this study, we propose pan-caspase inhibitors as a novel approach in the adjuvant chemotherapy of CRC.	[Metzig, M. Oliver; Fuchs, D.; Schirmacher, P.; Roth, W.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany; [Metzig, M. Oliver; Fuchs, D.; Tagscherer, K. E.; Roth, W.] German Canc Res Ctr, Mol Tumor Pathol, Heidelberg, Germany; [Groene, H-J] German Canc Res Ctr, Cellular & Mol Pathol, Heidelberg, Germany; [Roth, W.] Univ Med Ctr Mainz, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Johannes Gutenberg University of Mainz	Roth, W (corresponding author), Univ Med Ctr Mainz, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany.	Wilfried.Roth@unimedizin-mainz.de	Tagscherer, Katrin/AAS-3809-2021	Tagscherer, Katrin/0000-0002-0657-6399	Manfred-Stolte-Foundation; Rahel Goitein-Straus Program of the Medical Faculty of Heidelberg	Manfred-Stolte-Foundation; Rahel Goitein-Straus Program of the Medical Faculty of Heidelberg	We are grateful to Marina Gernold, Martina Keith, Katarina Duglova and Scott Oliver for excellent technical assistance. We thank Sylvia Kaden for technical assistance during electron microscopy. We thank the tissue bank of the Center for National Tumor Disease (NCT, Heidelberg, Germany) for providing CRC tissues, and Sarah MeBnard and David Jansen for technical assistance during immunohistochemistry. This study was supported by a grant from the Manfred-Stolte-Foundation to WR, and by the Rahel Goitein-Straus Program of the Medical Faculty of Heidelberg (fellowship to MOM).	Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Christofferson DE, 2014, ANNU REV PHYSIOL, V76, P129, DOI 10.1146/annurev-physiol-021113-170259; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Darding M, 2012, CELL DEATH DIFFER, V19, P58, DOI 10.1038/cdd.2011.163; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Douillard JY, 2003, ANN ONCOL, V14, P7, DOI 10.1093/annonc/mdg723; Dunai ZA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041945; Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Fuchs D, 2015, ONCOGENE, V34, P2753, DOI 10.1038/onc.2014.213; Fulda S, 2014, SEMIN CELL DEV BIOL, V35, P51, DOI 10.1016/j.semcdb.2014.07.002; Grassilli E, 2013, CLIN CANCER RES, V19, P3820, DOI 10.1158/1078-0432.CCR-12-3289; Hagan Suzanne, 2013, EPMA J, V4, P3, DOI 10.1186/1878-5085-4-3; Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Jouan-Lanhouet S, 2014, SEMIN CELL DEV BIOL, V35, P2, DOI 10.1016/j.semcdb.2014.08.010; Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lamkanfi M, 2006, J CELL BIOL, V173, P165, DOI 10.1083/jcb.200509092; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Linton SD, 2005, J MED CHEM, V48, P6779, DOI 10.1021/jm050307e; Marshall John L, 2007, Gastrointest Cancer Res, V1, P146; McComb S, 2014, J IMMUNOL, V192, P5671, DOI 10.4049/jimmunol.1303380; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moretti L, 2009, MOL CANCER THER, V8, P1270, DOI 10.1158/1535-7163.MCT-08-0893; Probst BL, 2010, CELL DEATH DIFFER, V17, P1645, DOI 10.1038/cdd.2010.44; Shiffman ML, 2010, ALIMENT PHARM THER, V31, P969, DOI 10.1111/j.1365-2036.2010.04264.x; Shikama Y, 2003, EUR J IMMUNOL, V33, P1998, DOI 10.1002/eji.200324013; Staal J, 2011, CELL RES, V21, P40, DOI 10.1038/cr.2010.168; Steinhart L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.320; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Vanden Berghe T, 2013, METHODS, V61, P117, DOI 10.1016/j.ymeth.2013.02.011; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Wang WG, 2004, CANCER RES, V64, P8167, DOI 10.1158/0008-5472.CAN-04-0970; Wilson P. M., 2007, CANCER RES, V1, P237; Zhang LQ, 2015, MOL CELL BIOL, V35, P3324, DOI 10.1128/MCB.00692-15; Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013	47	66	66	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3399	3409		10.1038/onc.2015.398	http://dx.doi.org/10.1038/onc.2015.398			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26522725				2022-12-28	WOS:000379270100005
J	Wang, H; Liu, B; Al-Aidaroos, AQO; Shi, H; Li, L; Guo, K; Li, J; Tan, BCP; Loo, JM; Tang, JP; Thura, M; Zeng, Q				Wang, H.; Liu, B.; Al-Aidaroos, A. Q. O.; Shi, H.; Li, L.; Guo, K.; Li, J.; Tan, B. C. P.; Loo, J. M.; Tang, J. P.; Thura, M.; Zeng, Q.			Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans	ONCOGENE			English	Article							C-SRC; PROTEIN; CANCER; KINASES; FAMILY; IDENTIFICATION; METASTASIS; TARGETS; FAK; ACTIVATION	Despite abundant data supporting c-Src as a metastasis-promoting oncogene, activating mutations of c-Src are rare. This suggests that trans-interacting proteins may have a critical role in regulating c-Src activation. Here, we first report the discovery of Src homology 3 (SH3) domain-binding glutamic acid-rich-like protein (SH3BGRL), a novel c-Src activator in mice. Ectopic expression of murine SH3BGRL (mSH3BGRL) strongly promoted both tumor cell invasion and lung metastasis. Molecularly, mSH3BGRL specifically bound the inactive form of c-Src phosphorylated at Tyr527, promoting Tyr416 phosphorylation of c-Src and subsequent FAK-mediated activation of ERK and AKT signaling pathways. Targeting endogenous c-Src alone was sufficient to abolish mSH3BGRL-induced cancer metastasis in vivo. Unexpectedly, human SH3BGRL (hSH3BGRL) in turn suppressed tumorigenesis and metastasis in nature. We attempted site-specific reversion of hSH3BGRL amino-acid sequence to mSH3BGRL and found V108A substitution sufficient to restore SH3BGRL function as a c-Src activator and metastasis promoter. Notably, the somatic mutation R76C of hSH3BGRL can similarly act as hSH3BGRL-V108A and mSH3BGRL in tumorigenesis and metastasis. Our results uncover an evolutionarily controversial role of SH3BGRL in driving tumor metastasis through c-Src activation, and suggests that hSH3BGRL mutation status could be relevant to cancer diagnosis and therapy.	[Wang, H.; Liu, B.; Shi, H.; Li, L.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, 74 Second Zhonshan Rd, Guangzhou 510080, Guangdong, Peoples R China; [Wang, H.; Liu, B.; Shi, H.; Li, L.] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Guangzhou 510275, Guangdong, Peoples R China; [Al-Aidaroos, A. Q. O.; Guo, K.; Li, J.; Tan, B. C. P.; Tang, J. P.; Thura, M.; Zeng, Q.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Loo, J. M.] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA; [Zeng, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117548, Singapore	Sun Yat Sen University; Sun Yat Sen University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Rockefeller University; National University of Singapore	Wang, H (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, 74 Second Zhonshan Rd, Guangzhou 510080, Guangdong, Peoples R China.; Zeng, Q (corresponding author), 61 Biopolis Dr,Room 3-02, Singapore 138673, Singapore.	wanghaih@mail.sysu.edu.cn; mcbzengq@imcb.astar.edu.sg	Haihe, Wang/AAD-4036-2021	Loo, Jia Min/0000-0002-6605-4031; LIU, BIN/0000-0003-0467-3678	National Natural Science Foundation of China [81171947]; Project of International Collaboration in Science and Technology, Guangdong Province [2014A050503030]; Agency of Science, Technology and Research (A* STAR), Singapore	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of International Collaboration in Science and Technology, Guangdong Province; Agency of Science, Technology and Research (A* STAR), Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by research grants from the National Natural Science Foundation of China (WH; No. 81171947), Project of International Collaboration in Science and Technology, Guangdong Province (WH; No. 2014A050503030) and The Agency of Science, Technology and Research (A* STAR), Singapore. We are also thankful to Professor Wanjin Hong, Professor Shulan Yang and Mr Mingming Zhang in our group for critical reading of the manuscript.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Arcaro A, 2007, CELL SIGNAL, V19, P1081, DOI 10.1016/j.cellsig.2006.12.003; Berleth ES, 2000, INT J IMMUNOPHARMACO, V22, P1137, DOI 10.1016/S0192-0561(00)00071-0; Berleth ES, 1999, CANCER RES, V59, P5497; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BRATTAIN MG, 1980, CANCER RES, V40, P2142; Egeo A, 1998, BIOCHEM BIOPH RES CO, V247, P302, DOI 10.1006/bbrc.1998.8763; Elkin Michael, 2001, Curr Protoc Cell Biol, VChapter 19, DOI 10.1002/0471143030.cb1902s12; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Garritano S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.15; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Henn AD, 2001, FASEB J, V15, P1315, DOI 10.1096/fj.00-0543fje; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson FM, 2007, ANTI-CANCER AGENT ME, V7, P651, DOI 10.2174/187152007784111278; Liu WS, 2015, ONCOTARGET, V6, P8851, DOI 10.18632/oncotarget.3316; Majid SM, 2006, ONCOGENE, V25, P756, DOI 10.1038/sj.onc.1209107; Mazzocco M, 2002, GENE, V291, P233, DOI 10.1016/S0378-1119(02)00602-9; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Nilbert M, 2000, CANCER GENET CYTOGEN, V121, P94, DOI 10.1016/S0165-4608(00)00226-0; Piguet AC, 2011, J HEPATOL, V54, P1317, DOI 10.1016/j.jhep.2010.12.013; Rao S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117215; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sen Banibrata, 2011, J Signal Transduct, V2011, P865819, DOI 10.1155/2011/865819; Sigal A, 2000, CANCER RES, V60, P6788; Tan YX, 2005, WORLD J GASTROENTERO, V11, P2351, DOI 10.3748/wjg.v11.i15.2351; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Warmuth M, 2003, CURR PHARM DESIGN, V9, P2043, DOI 10.2174/1381612033454126; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zeng Q, 2003, CANCER RES, V63, P2716	35	15	15	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3303	3313		10.1038/onc.2015.391	http://dx.doi.org/10.1038/onc.2015.391			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26455318	Green Published, hybrid			2022-12-28	WOS:000378306400009
J	Ferreira, HJ; Heyn, H; Vizoso, M; Moutinho, C; Vidal, E; Gomez, A; Martinez-Cardus, A; Simo-Riudalbas, L; Moran, S; Jost, E; Esteller, M				Ferreira, H. J.; Heyn, H.; Vizoso, M.; Moutinho, C.; Vidal, E.; Gomez, A.; Martinez-Cardus, A.; Simo-Riudalbas, L.; Moran, S.; Jost, E.; Esteller, M.			DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia	ONCOGENE			English	Article							AML; GENES; CELL; HOX; METHYLATION; EXPRESSION; TARGETS	Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of the DNA methylation setting and the presence of mutations in epigenetic modifier genes can also be molecular drivers of the disease. In recent years, somatic missense mutations of the DNA methyltransferase 3A (DNMT3A) have been reported in similar to 20% of AML patients; however, no obvious critical downstream gene has been identified that could explain the role of DNMT3A in the natural history of AML. Herein, using whole-genome bisulfite sequencing and DNA methylation microarrays, we have identified a key gene undergoing promoter hypomethylation-associated transcriptional reactivation in DNMT3 mutant patients, the leukemogenic HOX cofactor MEIS1. Our results indicate that, in the absence of mixed lineage leukemia fusions, an alternative pathway for engaging an oncogenic MEIS1-dependent transcriptional program can be mediated by DNMT3A mutations.	[Ferreira, H. J.; Heyn, H.; Vizoso, M.; Moutinho, C.; Vidal, E.; Gomez, A.; Martinez-Cardus, A.; Simo-Riudalbas, L.; Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, PEBC, Barcelona, Catalonia, Spain; [Jost, E.] Rhein Westfal TH Aachen, Fac Med, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); RWTH Aachen University; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, PEBC, 3rd Floor,Avda Gran Via Km 2-7, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Esteller, Manel/L-5956-2014; Moran, Sebastian/G-5293-2013; Martinez, Anna/AAA-4939-2020; Vidal, Enrique/R-5593-2019; Gomez Moruno, Antonio/H-7574-2015	Esteller, Manel/0000-0003-4490-6093; Moran, Sebastian/0000-0003-4192-8983; Vidal, Enrique/0000-0002-4217-1807; Heyn, Holger/0000-0002-3276-1889; Ferreira, Humberto/0000-0003-0834-2956; Gomez Moruno, Antonio/0000-0001-5308-981X; Martinez Cardus, Anna/0000-0002-3937-8794; Vizoso, Miguel/0000-0002-9992-2851	European Community [HEALTH-F5-011-282510-BLUEPRINT]; Cellex Foundation; MINECO Project [SAF2011-22803]; AGAUR [2014SGR633]; Health and Science Departments of the Catalan government (Generalitat de Catalunya); Program in Experimental Biology and Biomedicine, University of Coimbra, Portugal; ERC [268626-EPINORC]; ICREA Funding Source: Custom	European Community(European Commission); Cellex Foundation(Foundation CELLEX); MINECO Project(Spanish Government); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Health and Science Departments of the Catalan government (Generalitat de Catalunya); Program in Experimental Biology and Biomedicine, University of Coimbra, Portugal; ERC(European Research Council (ERC)European Commission); ICREA(ICREA)	This work was supported by the European Community's Seventh Framework Program (FP7/2007-2013) under grant agreements HEALTH-F5-011-282510-BLUEPRINT and ERC no. 268626-EPINORC project; the Cellex Foundation; the MINECO Project no. SAF2011-22803 and AGAUR 2014SGR633 grants; and the Health and Science Departments of the Catalan government (Generalitat de Catalunya). HJF was supported by the Program in Experimental Biology and Biomedicine, University of Coimbra, Portugal and ME is an ICREA Research Professor.	Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Hajkova H, 2012, LEUKEMIA RES, V36, P1128, DOI 10.1016/j.leukres.2012.05.012; Heuser M, 2011, CANCER CELL, V20, P39, DOI 10.1016/j.ccr.2011.06.020; Hollink IHIM, 2012, LEUKEMIA, V26, P371, DOI 10.1038/leu.2011.210; Im AP, 2014, LEUKEMIA, V28, P1774, DOI 10.1038/leu.2014.124; Kohlmann A, 2005, LEUKEMIA, V19, P953, DOI 10.1038/sj.leu.2403746; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Qu Y, 2014, EPIGENETICS-US, V9, P1108, DOI 10.4161/epi.29315; Roller A, 2013, LEUKEMIA, V27, P1573, DOI 10.1038/leu.2013.65; Russler-Germain DA, 2014, CANCER CELL, V25, P442, DOI 10.1016/j.ccr.2014.02.010; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004	15	37	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3079	3082		10.1038/onc.2015.359	http://dx.doi.org/10.1038/onc.2015.359			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434589	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000377474500013
J	Chalermrujinanant, C; Michowski, W; Sittithumcharee, G; Esashi, F; Jirawatnotai, S				Chalermrujinanant, C.; Michowski, W.; Sittithumcharee, G.; Esashi, F.; Jirawatnotai, S.			Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation	ONCOGENE			English	Article							STRAND BREAK REPAIR; DNA-END RESECTION; HOMOLOGY-DIRECTED REPAIR; MANTLE CELL LYMPHOMA; GENOMIC STABILITY; DAMAGE REPAIR; CANCER; PROTEIN; GENE; RECOMBINATION	BRCA2 has an important role in the maintenance of genome stability by interacting with RAD51 recombinase through its C-terminal domain. This interaction is abrogated by cyclin A-CDK2-mediated phosphorylation of BRCA2 at serine 3291 (Ser3291). Recently, we showed that cyclin D1 facilitates RAD51 recruitment to BRCA2-containing DNA repair foci, and that downregulation of cyclin D1 leads to inefficient homologous-mediated DNA repair. Here, we demonstrate that cyclin D1, via amino acids 20-90, interacts with the C-terminal domain of BRCA2, and that this interaction is increased in response to DNA damage. Interestingly, CDK4-cyclin D1 does not phosphorylate Ser3291. Instead, cyclin D1 bars cyclin A from the C-terminus of BRCA2, prevents cyclin A-CDK2-dependent Ser3291 phosphorylation and facilitates RAD51 binding to the C-terminal domain of BRCA2. These findings indicate that the interplay between cyclin D1 and other cyclins such as cyclin A regulates DNA integrity through RAD51 interaction with the BRCA2 C-terminal domain.	[Chalermrujinanant, C.; Sittithumcharee, G.; Jirawatnotai, S.] Mahidol Univ, Siriraj Hosp, Fac Med, Lab Syst Pharmacol,Dept Pharmacol, 2 Prannok Rd,12th Floor Srisawarin Bldg, Bangkok 10700, Thailand; [Michowski, W.; Jirawatnotai, S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Esashi, F.] Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England; [Jirawatnotai, S.] Mahidol Univ, Inst Mol Biosci, Bangkok 10700, Thailand	Mahidol University; Harvard University; Dana-Farber Cancer Institute; University of Oxford; Mahidol University	Jirawatnotai, S (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Lab Syst Pharmacol,Dept Pharmacol, 2 Prannok Rd,12th Floor Srisawarin Bldg, Bangkok 10700, Thailand.	siwanon.jir@mahidol.ac.th		Esashi, Fumiko/0000-0003-0902-2364	Thailand Research Fund [RSA5580018]; Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University; Advanced Research on Pharmacology Fund, Siriraj Foundation [D003421]; Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University	Thailand Research Fund(Thailand Research Fund (TRF)); Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University; Advanced Research on Pharmacology Fund, Siriraj Foundation; Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University	We thank Dr Piotr Sicinski, Dana-Farber Cancer Institute, in whose laboratory this work was initiated. This study was supported by Thailand Research Fund RSA5580018, Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University, and the Advanced Research on Pharmacology Fund, Siriraj Foundation D003421. SJ was supported by the Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University.	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1995, ONCOGENE, V10, P775; BATES S, 1994, ONCOGENE, V9, P1633; Berman DB, 1996, CANCER RES, V56, P3409; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; BOSCH F, 1994, BLOOD, V84, P2726; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies OR, 2007, NAT STRUCT MOL BIOL, V14, P475, DOI 10.1038/nsmb1251; DEBOER CJ, 1995, BLOOD, V86, P2715, DOI 10.1182/blood.V86.7.2715.bloodjournal8672715; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Esashi F, 2007, NAT STRUCT MOL BIOL, V14, P468, DOI 10.1038/nsmb1245; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2012, EMBO REP, V13, P561, DOI 10.1038/embor.2012.58; GILLETT C, 1994, CANCER RES, V54, P1812; Goggins M, 1996, CANCER RES, V56, P5360; Gretarsdottir S, 1998, CANCER RES, V58, P859; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; Huertas P, 2008, NATURE, V455, P689, DOI 10.1038/nature07215; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; JARES P, 1994, CANCER RES, V54, P4813; Jasin M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012740; JavanMoghadam-Kamrani S, 2008, CELL CYCLE, V7, P2434, DOI 10.4161/cc.6364; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; JIANG W, 1992, CANCER RES, V52, P2980; Jirawatnotai S, 2012, CANCER RES, V72, P4289, DOI 10.1158/0008-5472.CAN-11-3549; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; KOMATSU H, 1993, BRIT J HAEMATOL, V85, P427, DOI 10.1111/j.1365-2141.1993.tb03194.x; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Li ZP, 2014, CANCER RES, V74, P3959, DOI 10.1158/0008-5472.CAN-13-3137; Li ZP, 2010, CANCER RES, V70, P8802, DOI 10.1158/0008-5472.CAN-10-0312; Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Lu G, 2013, SCI WORLD J, DOI 10.1155/2013/424617; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pefani DE, 2014, NAT CELL BIOL, V16, P962, DOI 10.1038/ncb3035; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shimura T, 2013, CELL CYCLE, V12, P2738, DOI 10.4161/cc.25746; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Thorslund T, 2007, EMBO J, V26, P2915, DOI 10.1038/sj.emboj.7601739; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yata K, 2014, CELL REP, V7, P1547, DOI 10.1016/j.celrep.2014.04.023; Yata K, 2012, MOL CELL, V45, P371, DOI 10.1016/j.molcel.2011.12.028; Yu VPCC, 2000, GENE DEV, V14, P1400; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	60	12	12	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2815	2823		10.1038/onc.2015.354	http://dx.doi.org/10.1038/onc.2015.354			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387543	Green Accepted			2022-12-28	WOS:000377473700001
J	Meng, Z; Jia, LF; Gan, YH				Meng, Z.; Jia, L-F; Gan, Y-H			PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; TRICHOSTATIN-A; MEMBRANE ASSOCIATION; PHOSPHATASE-ACTIVITY; SUPPRESSOR PTEN; PROSTATE-CANCER; PLASMA-MEMBRANE; CELL-MIGRATION; BINDING MOTIF; BREAST-CANCER	Phosphatase and tensin homologue deleted on chromosome 10 (PTEN), an important tumour-suppressor gene, is mutated, downregulated or dysfunctional in many tumours. The phosphatase activity of PTEN depends on membrane translocation (activation). As promising anti-cancer agents, histone deacetylase (HDAC) inhibitors, particularly trichostatin A (TSA), can promote PTEN membrane translocation, but the underlying mechanism remains unknown. In this study, we revealed that non-selective HDAC inhibitors, namely, TSA or suberoylanilide hydroxamic acid (SAHA), induced PTEN membrane translocation through PTEN acetylation at K163 by inhibiting HDAC6. K163 acetylation inhibited the interaction of the PTEN C-tail with the remaining part of PTEN, resulting in PTEN membrane translocation. Overexpression of wild-type PTEN, but not K163-mutated PTEN, facilitated the inhibition of cell proliferation, migration and invasion, as well as xenograft tumour growth, induced by SAHA or tubastatin A, an HDAC6-specific inhibitor. These results indicated that PTEN activation by inhibiting HDAC6 significantly contributed to tumour inhibition. Therefore, non-selective HDAC or HDAC6-specific inhibitors may be more clinically suitable to treat tumours without PTEN mutations or deletions.	[Meng, Z.; Jia, L-F; Gan, Y-H] Peking Univ, Cent Lab, Sch & Hosp Stomatol, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China; [Meng, Z.; Gan, Y-H] Peking Univ, Dept Oral & Maxillofacial Surg, Sch & Hosp Stomatol, Beijing 100081, Peoples R China	Peking University; Peking University	Gan, YH (corresponding author), Peking Univ, Cent Lab, Sch & Hosp Stomatol, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China.	kqyehuagan@bjmu.edu.cn			National Natural Science Foundation of China [81472764, 81271173]; China International Science and Technology Cooperation [2013DFB30360]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China International Science and Technology Cooperation	This work was supported by the National Natural Science Foundation of China (Grant No. 81472764 and 81271173) and China International Science and Technology Cooperation (Grant No. 2013DFB30360).	Altonsy MO, 2012, NUTR CANCER, V64, P1251, DOI 10.1080/01635581.2012.721156; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Butler LM, 2000, CANCER RES, V60, P5165; Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200; Dallavalle S, 2012, BIOCHEM PHARMACOL, V84, P756, DOI 10.1016/j.bcp.2012.06.014; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Dekker FJ, 2009, DRUG DISCOV TODAY, V14, P942, DOI 10.1016/j.drudis.2009.06.008; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Donadelli M, 2003, MOL CARCINOGEN, V38, P59, DOI 10.1002/mc.10145; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Gan YH, 2009, ORAL ONCOL, V45, pE150, DOI 10.1016/j.oraloncology.2009.05.563; Georgescu MM, 2000, CANCER RES, V60, P7033; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Herold C, 2002, J HEPATOL, V36, P233, DOI 10.1016/S0168-8278(01)00257-4; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Kim HR, 2006, EXP MOL MED, V38, P616, DOI 10.1038/emm.2006.73; Kou XX, 2013, CARCINOGENESIS, V34, P58, DOI 10.1093/carcin/bgs336; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Leslie NR, 2005, BIOCHEM SOC T, V33, P1507, DOI 10.1042/BST0331507; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lumb CN, 2013, BIOPHYS J, V104, P613, DOI 10.1016/j.bpj.2012.12.002; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Mei SP, 2004, INT J ONCOL, V25, P1509; Meuillet EJ, 2004, ARCH BIOCHEM BIOPHYS, V429, P123, DOI 10.1016/j.abb.2004.04.020; Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Squarize CH, 2013, NEOPLASIA, V15, P461, DOI 10.1593/neo.121024; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tashiro H, 1997, CANCER RES, V57, P3935; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06	48	47	48	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2333	2344		10.1038/onc.2015.293	http://dx.doi.org/10.1038/onc.2015.293			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26279303				2022-12-28	WOS:000376165000006
J	Schnerch, D; Nigg, EA				Schnerch, D.; Nigg, E. A.			Structural centrosome aberrations favor proliferation by abrogating microtubule-dependent tissue integrity of breast epithelial mammospheres	ONCOGENE			English	Article							PROMOTES MAMMARY TUMORIGENESIS; NINEIN-LIKE PROTEIN; CELL POLARITY; CENTRIOLE BIOGENESIS; CANCER; NLP; ORGANIZATION; DUPLICATION; EXPRESSION; CARCINOMA	Structural centrosome aberrations are frequently observed in early stage carcinomas, but their role in malignant transformation is poorly understood. Here, we examined the impact of overexpression of Ninein-like protein (Nlp) on the architecture of polarized epithelia in three-dimensional mammospheres. When Nlp was overexpressed to levels resembling those seen in human tumors, it formed striking centrosome-related bodies (CRBs), which sequestered Ninein and affected the kinetics of microtubule (MT) nucleation and release. In turn, the profound reorganization of the MT cytoskeleton resulted in mislocalization of several adhesion and junction proteins as well as the tumor suppressor Scribble, resulting in the disruption of epithelial polarity, cell-cell interactions and mammosphere architecture. Remarkably, cells harboring Nlp-CRBs displayed an enhanced proliferative response to epidermal growth factor. These results demonstrate that structural centrosome aberrations cause not only the disruption of epithelial polarity but also favor overproliferation, two phenotypes typically associated with human carcinomas.	[Schnerch, D.; Nigg, E. A.] Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland	University of Basel	Nigg, EA (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	erich.nigg@unibas.ch		nigg, erich/0000-0003-4835-5719	University of Basel; Swiss National Science Foundation [310030B_149641]; Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)	University of Basel; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)	We thank Tilman Brummer (University of Freiburg), Stefan Zimmermann and Ralph Wasch (University Medical Center Freiburg) as well as Heike Brinkhaus and Mohamed Bentires-Alj (FMI Basel) for cell lines and technical advice, and Cheuk Leung (University of Minnesota) as well as Yi-Ren Hong (Kaohsiung Medical University, Taiwan) for viral vectors. We also thank Alexia Loynton-Ferrand and other members of the Imaging Core Facility (IMCF) for help and Elena Nigg-Martignoni for technical assistance. Finally, we are grateful to Felix B. Engel and the 'Emerging fields Initiative' (EFI) for 'Cell Cycle in Disease and Regeneration (CYDER)' from the Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU) for constructive comments and support, as well as to all members of the Nigg lab for helpful discussions. This work was supported by the University of Basel and the Swiss National Science Foundation (310030B_149641).	Abal M, 2002, J CELL BIOL, V159, P731, DOI 10.1083/jcb.200207076; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Azimzadeh J, 2007, J CELL SCI, V120, P2139, DOI 10.1242/jcs.005231; Bartolini F, 2006, J CELL SCI, V119, P4155, DOI 10.1242/jcs.03227; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bettencourt-Dias M, 2011, TRENDS GENET, V27, P307, DOI 10.1016/j.tig.2011.05.004; Brito DA, 2012, CURR OPIN CELL BIOL, V24, P4, DOI 10.1016/j.ceb.2012.01.003; Carraway Coralie A Carothers, 2007, Sci STKE, V2007, pre3, DOI 10.1126/stke.3812007re3; Casenghi M, 2005, J CELL SCI, V118, P5101, DOI 10.1242/jcs.02622; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Delgehyr N, 2005, J CELL SCI, V118, P1565, DOI 10.1242/jcs.02302; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Feigin ME, 2014, CANCER RES, V74, P3180, DOI 10.1158/0008-5472.CAN-13-3415; Fogeron ML, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2517; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fujita Y, 2011, CANCER SCI, V102, P1749, DOI 10.1111/j.1349-7006.2011.02011.x; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Godinho SA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0467; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Gonczy P, 2012, NAT REV MOL CELL BIO, V13, P425, DOI 10.1038/nrm3373; Guo HQ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1752; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Harris H, 2008, J CELL SCI, V121, P3, DOI 10.1242/jcs.025742; Hernandez P, 2010, DIS MODEL MECH, V3, P304, DOI 10.1242/dmm.004507; Hogan C, 2012, CELL MOL LIFE SCI, V69, P203, DOI 10.1007/s00018-011-0806-3; Hotta A, 2010, J CELL BIOL, V189, P901, DOI 10.1083/jcb.200910095; Jakobsen L, 2011, EMBO J, V30, P1520, DOI 10.1038/emboj.2011.63; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jiang F, 2003, INT J CANCER, V106, P661, DOI 10.1002/ijc.11251; Kayser G, 2005, VIRCHOWS ARCH, V447, P61, DOI 10.1007/s00428-004-1191-1; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Kollman JM, 2011, NAT REV MOL CELL BIO, V12, P709, DOI 10.1038/nrm3209; Kronenwett U, 2005, BRIT J CANCER, V92, P389, DOI 10.1038/sj.bjc.6602246; Lechler T, 2007, J CELL BIOL, V176, P147, DOI 10.1083/jcb.200609109; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Li J, 2011, BRIT J CANCER, V104, P1523, DOI 10.1038/bjc.2011.130; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; Meng W, 2008, CELL, V135, P948, DOI 10.1016/j.cell.2008.09.040; Mogensen MM, 2000, J CELL SCI, V113, P3013; MOGENSEN MM, 2004, CENTROSOMES DEV DIS, P299; Moss DK, 2007, J CELL SCI, V120, P3064, DOI 10.1242/jcs.010322; Musch A, 2004, TRAFFIC, V5, P1, DOI 10.1046/j.1600-0854.2003.00149.x; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pihan GA, 2003, CANCER RES, V63, P1398; Qu D, 2008, GYNECOL ONCOL, V110, P230, DOI 10.1016/j.ygyno.2008.04.015; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Rodriguez-Boulan E, 2014, NAT REV MOL CELL BIO, V15, P225, DOI 10.1038/nrm3775; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Salisbury JL, 1999, J HISTOCHEM CYTOCHEM, V47, P1265, DOI 10.1177/002215549904701006; Sato N, 1999, CLIN CANCER RES, V5, P963; Schmidt TI, 2009, CURR BIOL, V19, P1005, DOI 10.1016/j.cub.2009.05.016; Segat D, 2010, HISTOL HISTOPATHOL, V25, P551, DOI 10.14670/HH-25.551; Shao SJ, 2010, J CLIN INVEST, V120, P498, DOI 10.1172/JCI39447; Simpson DR, 2011, CANCER RES, V71, P3822, DOI 10.1158/0008-5472.CAN-10-3782; Thein KH, 2007, J CELL BIOL, V178, P345, DOI 10.1083/jcb.200701163; Wang Y, 2007, J BIOL CHEM, V282, P17712, DOI 10.1074/jbc.M701350200; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Xiang B, 2006, METHOD ENZYMOL, V406, P692, DOI 10.1016/S0076-6879(06)06054-X; Yamauchi H, 2012, CELL RES, V22, P1527, DOI 10.1038/cr.2012.69; Yan J, 2010, J BIOL CHEM, V285, P40230, DOI 10.1074/jbc.M110.140541; Yan XM, 2006, MOL BIOL CELL, V17, P634, DOI 10.1091/mbc.E05-08-0810; Yu LL, 2009, ONCOL REP, V22, P789, DOI 10.3892/or_00000501; Yvon AMC, 2002, MOL BIOL CELL, V13, P1871, DOI 10.1091/mbc.01-11-0539; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhao WH, 2012, CANCER BIOL THER, V13, P156, DOI 10.4161/cbt.13.3.18697; Zhao XL, 2010, CANCER BIOL THER, V10, P949, DOI 10.4161/cbt.10.9.13368; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zyss D, 2009, TRENDS CELL BIOL, V19, P334, DOI 10.1016/j.tcb.2009.04.001	85	18	19	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2711	2722		10.1038/onc.2015.332	http://dx.doi.org/10.1038/onc.2015.332			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364601	Green Published, hybrid			2022-12-28	WOS:000377472700005
J	Timsah, Z; Ahmed, Z; Ivan, C; Berrout, J; Gagea, M; Zhou, Y; Pena, GNA; Hu, X; Vallien, C; Kingsley, CV; Lu, Y; Hancock, JF; Liu, J; Gladden, AB; Mills, GB; Lopez-Berestein, G; Hung, MC; Sood, AK; Bogdanov, M; Ladbury, JE				Timsah, Z.; Ahmed, Z.; Ivan, C.; Berrout, J.; Gagea, M.; Zhou, Y.; Pena, G. N. A.; Hu, X.; Vallien, C.; Kingsley, C. V.; Lu, Y.; Hancock, J. F.; Liu, J.; Gladden, A. B.; Mills, G. B.; Lopez-Berestein, G.; Hung, M-C; Sood, A. K.; Bogdanov, M.; Ladbury, J. E.			Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer	ONCOGENE			English	Article							PI3K/AKT/MTOR INHIBITORS; SIGNALING PATHWAY; PHOSPHORYLATION; FGFR2; PHOSPHATASE; ACTIVATION; QUANTIFICATION; MUTATIONS; KINASE; RAS	In the absence of extracellular stimulation the adaptor protein growth factor receptor-bound protein (Grb2) and the phospholipase Plc gamma 1 compete for the same binding site on fibroblast growth factor receptor 2 (FGFR2). Reducing cellular Grb2 results in upregulation of Plc gamma 1 and depletion of the phospholipid PI(4,5)P-2. The functional consequences of this event on signaling pathways are unknown. We show that the decrease in PI(4,5)P-2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. This results in excessive cell proliferation and tumor progression in a xenograft mouse model. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plc gamma 1 and Grb2 correlate with patient survival. Oncogenesis through fluctuation in the expression levels of these proteins negates extracellular stimulation or mutation and defines them as novel prognostic markers in ovarian cancer.	[Timsah, Z.; Ahmed, Z.; Ladbury, J. E.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, Houston, TX 77030 USA; [Timsah, Z.; Berrout, J.; Ladbury, J. E.] Univ Leeds, Sch Mol & Cellular Biol, Miall Bldg, Leeds LS2 9JT, W Yorkshire, England; [Ahmed, Z.; Ladbury, J. E.] Univ Texas MD Anderson Canc Ctr, Ctr Biomol Struct & Funct, Unit 1000, Houston, TX 77030 USA; [Ivan, C.; Pena, G. N. A.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Ivan, C.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNAi & Noncoding RNA, Houston, TX 77030 USA; [Berrout, J.] Baylor Coll Med, Ctr Cell & Gene Therapy, Stem Cells & Regenerat Med Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Gagea, M.; Vallien, C.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Unit 63, Houston, TX 77030 USA; [Zhou, Y.; Hancock, J. F.] Univ Texas Hlth Sci Ctr Houston, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Hu, X.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Kingsley, C. V.] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Unit 1472, Houston, TX 77030 USA; [Lu, Y.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Liu, J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol Lab Med, Div Pathol Lab Med, Houston, TX 77030 USA; [Gladden, A. B.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Unit 1010, Houston, TX 77030 USA; [Lopez-Berestein, G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Bogdanov, M.] Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, Sch Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Leeds; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Ladbury, JE (corresponding author), Univ Leeds, Sch Mol & Cellular Biol, Miall Bldg, Leeds LS2 9JT, W Yorkshire, England.	J.E.Ladbury@leeds.ac.uk	Hung, Mien-Chie/ABD-5911-2021; Bogdanov, Mikhail/J-3695-2017; Sood, Anoop Kumar/A-7344-2013	Hung, Mien-Chie/0000-0003-4317-4740; Sood, Anoop Kumar/0000-0001-5702-4108; Ladbury, John/0000-0002-6328-7200; Hancock, John/0000-0003-0542-4710; Zhou, Yong/0000-0002-0214-8151; Ivan, Cristina/0000-0002-4848-0168; Armaiz-Pena, Guillermo N/0000-0002-9081-5339	G. Harold and Leila Y. Mathers Charitable Foundation; NIH [U54CA151668, P50 CA083639, P50 CA098258]; RGK Foundation; Gilder Foundation; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA098258, U54CA151668, P50CA083639] Funding Source: NIH RePORTER	G. Harold and Leila Y. Mathers Charitable Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RGK Foundation; Gilder Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the G. Harold and Leila Y. Mathers Charitable Foundation. This work was supported by NIH grants U54CA151668, P50 CA083639, P50 CA098258 and by the RGK Foundation and the Gilder Foundation.	Ahmed Z, 2013, J CELL BIOL, V200, P493, DOI 10.1083/jcb.201204106; Ahmed Z, 2010, CELL SIGNAL, V22, P23, DOI 10.1016/j.cellsig.2009.08.011; Ahmed Z, 2008, BIOCHEM J, V413, P37, DOI 10.1042/BJ20071594; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Byron SA, 2009, FUTURE ONCOL, V5, P27, DOI 10.2217/14796694.5.1.27; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Ching JK, 2010, AM J PHYSIOL-CELL PH, V299, pC1171, DOI 10.1152/ajpcell.00514.2009; Clark J, 2011, NAT METHODS, V8, P267, DOI 10.1038/NMETH.1564; Cole C, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12585; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fry Michael J., 2009, V462, P345, DOI 10.1007/978-1-60327-115-8_22; Gauglhofer C, 2011, HEPATOLOGY, V53, P854, DOI 10.1002/hep.24099; Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196; Katoh Y, 2009, INT J MOL MED, V23, P307, DOI 10.3892/ijmm_00000132; Khan KH, 2013, CHIN J CANCER, V32, P253, DOI 10.5732/cjc.013.10057; Konig S, 2008, ANAL BIOCHEM, V378, P197, DOI 10.1016/j.ab.2008.03.052; Lin CC, 2012, CELL, V149, P1514, DOI 10.1016/j.cell.2012.04.033; Matsuda Yoko, 2012, Patholog Res Int, V2012, P574768, DOI 10.1155/2012/574768; Mazzoletti M, 2010, CURR MED CHEM, V17, P4433, DOI 10.2174/092986710794182999; Ooms Lisa M., 2009, V462, P223, DOI 10.1007/978-1-60327-115-8_15; Pan JJ, 2010, CHEM RES TOXICOL, V23, P568, DOI 10.1021/tx9003193; Pirkmajer S, 2011, AM J PHYSIOL-CELL PH, V301, pC272, DOI 10.1152/ajpcell.00091.2011; Redfern RE, 2008, BIOCHEMISTRY-US, V47, P2162, DOI 10.1021/bi702114w; Risbud MV, 2005, SPINE, V30, P2503, DOI 10.1097/01.brs.0000186326.82747.13; Rodriguez EF, 2011, ACTA NEUROPATHOL, V121, P407, DOI 10.1007/s00401-010-0784-9; Rotblat B, 2004, MOL CELL BIOL, V24, P6799, DOI 10.1128/MCB.24.15.6799-6810.2004; Sato K., 2012, J SIGNAL TRANSDUCT, V2012; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Thapa N, 2012, DEV CELL, V22, P116, DOI 10.1016/j.devcel.2011.10.030; Timsah Z, 2014, NAT STRUCT MOL BIOL, V21, P180, DOI 10.1038/nsmb.2752; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Troncoso R, 2012, CARDIOVASC RES, V93, P320, DOI 10.1093/cvr/cvr321; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yamamoto N, 2006, J CELL SCI, V119, P4623, DOI 10.1242/jcs.03236; Yang K, 2011, METABOLITES, V1, P21, DOI 10.3390/metabo1010021; Zhou Y, 2014, MOL CELL BIOL, V34, P862, DOI 10.1128/MCB.01227-13	45	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2186	2196		10.1038/onc.2015.279	http://dx.doi.org/10.1038/onc.2015.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26212011	Green Accepted, Green Published			2022-12-28	WOS:000374986000005
J	Wang, J; Ding, S; Duan, Z; Xie, Q; Zhang, T; Zhang, X; Wang, Y; Chen, X; Zhuang, H; Lu, F				Wang, J.; Ding, S.; Duan, Z.; Xie, Q.; Zhang, T.; Zhang, X.; Wang, Y.; Chen, X.; Zhuang, H.; Lu, F.			Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression	ONCOGENE			English	Article							NUCLEOLAR-LOCALIZATION; NUCLEOPHOSMIN B23; DOWN-REGULATION; NUCLEAR EXPORT; P53 PROTEIN; ARF; SOX6; MDM2; HDM2; UBIQUITINATION	Sex-determining region Y box 6 (SOX6) has been described as a tumor-suppressor gene in several cancers. Our previous work has suggested that SOX6 upregulated p21(Waf1/Cip1)(p21) expression in a p53-dependent manner; however, the underlying mechanism has remained elusive. In this study, we confirmed that SOX6 can suppress cell proliferation in vitro and in vivo by stabilizing p53 protein and subsequently upregulating p21. Co-immunoprecipitation and immunocytofluorescence assays demonstrated that SOX6 can promote formation of the p14ARF-HDM2-p53 ternary complex by promoting translocation of p14ARF (p14 alternate reading frame tumor suppressor) to the nucleoplasm, thereby inhibiting HDM2-mediated p53 nuclear export and degradation. Chromatin immunoprecipitation combined with PCR assay proved that SOX6 can bind to a potential binding site in the regulatory region of the c-Myc gene. Furthermore, we confirmed that SOX6 can downregulate the expression of c-Myc, as well as its direct target gene nucleophosmin 1 (NPM1), and that the SOX6-induced downregulation of NPM1 is linked to translocation of p14ARF to the nucleoplasm. Finally, we showed that the highly conserved high-mobility group (HMG) domain of SOX6 is required for SOX6-mediated p53 stabilization and tumor inhibitory activity. Collectively, these results reveal a new mechanism of SOX6-mediated tumor suppression involving p21 upregulation via the p14ARF-HDM2-p53 axis in an HMG domain-dependent manner.	Peking Univ, Dept Microbiol, Sch Basic Med, Hlth Sci Ctr, Beijing 100871, Peoples R China; Peking Univ, Ctr Infect Dis, Sch Basic Med, Hlth Sci Ctr, Beijing 100871, Peoples R China	Peking University; Peking University	Chen, X; Lu, F (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Microbiol, 38 Xueyuan Rd, Beijing 100191, Peoples R China.; Chen, X; Lu, F (corresponding author), Peking Univ, Hlth Sci Ctr, Ctr Infect Dis, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	xm_chen6176@bjmu.edu.cn; lu.fengmin@hsc.pku.edu.cn		Wang, Jie/0000-0001-6518-948X	973 Program [2015CB554000]; National S & T Major Project for Infectious Diseases [2012ZX10004-904]; Ministry of Education of China [20110001120017]; National Natural Science Foundation of China [81372603]; 111 Project [B07001]	973 Program(National Basic Research Program of China); National S & T Major Project for Infectious Diseases; Ministry of Education of China(Ministry of Education, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 111 Project(Ministry of Education, China - 111 Project)	This work was supported by grants from the 973 Program (2015CB554000), the National S & T Major Project for Infectious Diseases (2012ZX10004-904), the Doctoral Fund and of the Ministry of Education of China (20110001120017), the National Natural Science Foundation of China (81372603) and the 111 Project (B07001).	Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Cantu C, 2011, BLOOD, V117, P3669, DOI 10.1182/blood-2010-04-282350; Cantu' C, 2011, NUCLEIC ACIDS RES, V39, P486, DOI 10.1093/nar/gkq819; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Gu JJ, 2001, CANCER RES, V61, P6703; Guo XD, 2013, CANCER EPIDEMIOL, V37, P732, DOI 10.1016/j.canep.2013.05.002; Hagiwara N, 2011, DEV DYNAM, V240, P1311, DOI 10.1002/dvdy.22639; Hamilton G, 2014, ONCOTARGET, V5, P6142, DOI 10.18632/oncotarget.2178; Huang YH, 2003, CANCER RES, V63, P3646; Iguchi H, 2007, J BIOL CHEM, V282, P19052, DOI 10.1074/jbc.M700460200; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qin YR, 2011, CLIN CANCER RES, V17, P46, DOI 10.1158/1078-0432.CCR-10-1155; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Wang SS, 2012, J HEPATOL, V57, P322, DOI 10.1016/j.jhep.2012.03.029; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Xie Q, 2012, CANCER-AM CANCER SOC, V118, P2431, DOI 10.1002/cncr.26566; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zhang X, 2014, J VIRAL HEPATITIS, V21, P264, DOI 10.1111/jvh.12137; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	36	45	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1692	1702		10.1038/onc.2015.234	http://dx.doi.org/10.1038/onc.2015.234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26119940	Green Published, hybrid			2022-12-28	WOS:000373064200008
J	Fedorenko, IV; Abel, EV; Koomen, JM; Fang, B; Wood, ER; Chen, YA; Fisher, KJ; Iyengar, S; Dahlman, KB; Wargo, JA; Flaherty, KT; Sosman, JA; Sondak, VK; Messina, JL; Gibney, GT; Smalley, KSM				Fedorenko, I. V.; Abel, E. V.; Koomen, J. M.; Fang, B.; Wood, E. R.; Chen, Y. A.; Fisher, K. J.; Iyengar, S.; Dahlman, K. B.; Wargo, J. A.; Flaherty, K. T.; Sosman, J. A.; Sondak, V. K.; Messina, J. L.; Gibney, G. T.; Smalley, K. S. M.			Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells	ONCOGENE			English	Article							E-CADHERIN; EXTRACELLULAR-MATRIX; ADAPTIVE RESISTANCE; DRUG-RESISTANCE; RAF INHIBITORS; B-RAF; BRAF(V600E); ACTIVATION; GROWTH; PHOSPHORYLATION	The mechanisms by which some melanoma cells adapt to Serine/threonine-protein kinase B-Raf (BRAF) inhibitor therapy are incompletely understood. In the present study, we used mass spectrometry-based phosphoproteomics to determine how BRAF inhibition remodeled the signaling network of melanoma cell lines that were BRAF mutant and PTEN null. Short-term BRAF inhibition was associated with marked changes in fibronectin-based adhesion signaling that were PTEN dependent. These effects were recapitulated through BRAF siRNA knockdown and following treatment with chemotherapeutic drugs. Increased fibronectin expression was also observed in mouse xenograft models as well as specimens from melanoma patients undergoing BRAF inhibitor treatment. Analysis of a melanoma tissue microarray showed loss of PTEN expression to predict for a lower overall survival, with a trend for even lower survival being seen when loss of fibronectin was included in the analysis. Mechanistically, the induction of fibronectin limited the responses of these PTEN-null melanoma cell lines to vemurafenib, with enhanced cytotoxicity observed following the knockdown of either fibronectin or its receptor alpha(5)beta(1) integrin. This in turn abrogated the cytotoxic response to BRAF inhibition via increased AKT signaling, which prevented the induction of cell death by maintaining the expression of the pro-survival protein Mcl-1. The protection conveyed by the induction of FN expression could be overcome through combined treatment with a BRAF and PI3K inhibitor.	[Fedorenko, I. V.; Koomen, J. M.; Wood, E. R.; Smalley, K. S. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Abel, E. V.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Fang, B.; Wood, E. R.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Prote, Tampa, FL 33612 USA; [Chen, Y. A.; Fisher, K. J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL 33612 USA; [Iyengar, S.; Sondak, V. K.; Messina, J. L.; Gibney, G. T.; Smalley, K. S. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL 33612 USA; [Dahlman, K. B.; Sosman, J. A.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Wargo, J. A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Flaherty, K. T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Jefferson University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Vanderbilt University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Smalley, KSM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	keiran.smalley@moffitt.org	Smalley, Inna/AAR-8638-2021; Smalley, Inna/G-9016-2015	Smalley, Inna/0000-0002-6796-9145; Smalley, Inna/0000-0002-6796-9145; Smalley, Keiran/0000-0003-1089-9307; Chen, yian/0000-0003-1468-3490	National Institutes of Health [R01 CA161107]; NATIONAL CANCER INSTITUTE [P30CA076292, R01CA161107, P50CA168536] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Gideon Bollag (Plexxikon) for providing vemurafenib and the PLX4720 chow; Noel Clark, Ashley Troutman, Kelli Noyd, Jayme O'Neal and Holly Crandell for assistance with IHC staining; Marta Perez and Monica Torres for assistance with xenograft studies; Agnieszka Kasprazak and Joseph Johnson for assistance with microscopy; and Laura Hall for assistance with qRT-PCR. The work in the Smalley laboratory is supported by R01 CA161107 from the National Institutes of Health.	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Boyd SC, 2013, J INVEST DERMATOL, V133, P1269, DOI 10.1038/jid.2012.421; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Fedorenko IV, 2011, BIOCHEM PHARMACOL, V82, P201, DOI 10.1016/j.bcp.2011.05.015; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Muro AF, 2008, AM J RESP CRIT CARE, V177, P638, DOI 10.1164/rccm.200708-1291OC; Nathanson KL, 2013, CLIN CANCER RES, V19, P4868, DOI 10.1158/1078-0432.CCR-13-0827; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Remily-Wood ER, 2011, PROTEOM CLIN APPL, V5, P383, DOI 10.1002/prca.201000115; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang JM, 1999, MOL CELL BIOL, V19, P6195; White ES, 2006, AM J RESP CRIT CARE, V173, P112, DOI 10.1164/rccm.200507-1058OC; Xiang Y, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005520; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522	50	49	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1225	1235		10.1038/onc.2015.188	http://dx.doi.org/10.1038/onc.2015.188			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26073081	Green Accepted			2022-12-28	WOS:000371763100003
J	Guo, F; Wang, Y; Liu, J; Mok, SC; Xue, F; Zhang, W				Guo, F.; Wang, Y.; Liu, J.; Mok, S. C.; Xue, F.; Zhang, W.			CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks	ONCOGENE			English	Review							CHEMOKINE RECEPTOR CXCR4; EPITHELIAL-MESENCHYMAL TRANSITION; CHRONIC LYMPHOCYTIC-LEUKEMIA; LYMPH-NODE METASTASIS; OVARIAN-CANCER; COLORECTAL-CANCER; CXCR4/CXCL12 AXIS; TUMOR-SUPPRESSOR; PROSTATE-CANCER; CARCINOMA-CELLS	Increasing evidence indicates that the tumor microenvironment has critical roles in all aspects of cancer biology, including growth, angiogenesis, metastasis and progression. Although chemokines and their receptors were originally identified as mediators of inflammatory diseases, it is being increasingly recognized that they serve as critical communication bridges between tumor cells and stromal cells to create a permissive microenvironment for tumor growth and metastasis. Thus, an important therapeutic strategy for cancer is to break this communication channel and isolate tumor cells for long-term elimination. Cytokine CXCL12 (also known as stromal-derived factor 1a) and its receptor CXCR4 represent the most promising actionable targets for this strategy. Both are overexpressed in various cancer types, and this aberrant expression strongly promotes proliferation, migration and invasion through multiple signal pathways. Several molecules that target CXCL12 or CXCR4 have been developed to interfere with tumor growth and metastasis. In this article, we review our current understanding of the CXCL12/CXCR4 axis in cancer tumorigenesis and progression and discuss its therapeutic implications.	[Guo, F.; Wang, Y.; Xue, F.] Tianjin Med Univ, Dept Gynecol & Obstet, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Guo, F.; Liu, J.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd Unit 85, Houston, TX 77030 USA; [Mok, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA	Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xue, F (corresponding author), Tianjin Med Univ, Dept Gynecol & Obstet, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.; Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd Unit 85, Houston, TX 77030 USA.	fengxiaxue1962@163.com; wzhang@mdanderson.org			Tianjin Municipal Science and Technology Commission International Cooperation Foundation [15RCGFSY00108]; Natural Science Fund of Tianjin Municipal Science and Technology Commission [12JCYBJC17900]; Tianjin Medical University Science Foundation [2014KYQ03]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Tianjin Municipal Science and Technology Commission International Cooperation Foundation; Natural Science Fund of Tianjin Municipal Science and Technology Commission; Tianjin Medical University Science Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ann Sutton from the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for editing this manuscript. This work was partially supported by funds from the Tianjin Municipal Science and Technology Commission International Cooperation Foundation (No. 15RCGFSY00108), the Natural Science Fund of Tianjin Municipal Science and Technology Commission (No. 12JCYBJC17900), and the Tianjin Medical University Science Foundation (No. 2014KYQ03).	Agarwal A, 2014, LEUKEMIA RES, V38, P1097, DOI 10.1016/j.leukres.2014.05.017; Archibald KM, 2012, ONCOGENE, V31, P4987, DOI 10.1038/onc.2011.653; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Barbero S, 2003, CANCER RES, V63, P1969; Barbieri F, 2010, J ONCOL, V2010, DOI 10.1155/2010/426956; Barbolina MV, 2010, MOL CANCER RES, V8, P653, DOI 10.1158/1541-7786.MCR-09-0463; Bartolome RA, 2009, AM J PATHOL, V174, P602, DOI 10.2353/ajpath.2009.080636; Beider K, 2014, ONCOTARGET, V5, P11283, DOI 10.18632/oncotarget.2207; Bignotti E, 2007, AM J OBSTET GYNECOL, V196, P245, DOI 10.1016/j.ajog.2006.10.874; Boudot A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020898; Buechli ME, 2013, STEM CELLS DEV, V22, P1288, DOI 10.1089/scd.2012.0411; Byrne SN, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27562; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978-0-12-411638-2.00002-1; Chen L, 2010, ACTA BIOCH BIOPH SIN, V42, P1, DOI 10.1093/abbs/gmp108; Chu CY, 2009, CARCINOGENESIS, V30, P205, DOI 10.1093/carcin/bgn228; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Conley-LaComb MK, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-85; Crowther-Swanepoel D, 2009, BLOOD, V114, P4843, DOI 10.1182/blood-2009-07-235184; Cui X. Y., 2014, CHINESE GEN PRACTICE, V21, P1929, DOI [10.3969/j.issn.1674-4748.2014.21.005, DOI 10.3969/J.ISSN.1674-4748.2014.21.005, DOI 10.1002/HEP.27665]; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; de Nigris F, 2012, RECENT PAT ANTI-CANC, V7, P251, DOI 10.2174/157489212801820039; Deutsch AJA, 2013, MODERN PATHOL, V26, P182, DOI 10.1038/modpathol.2012.134; Domanska UM, 2012, NEOPLASIA, V14, P709, DOI 10.1593/neo.12324; Douglass S, 2014, J PATHOL, V234, P74, DOI 10.1002/path.4381; Duan FT, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-164; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Durr C, 2010, CANCER RES, V70, P10170, DOI 10.1158/0008-5472.CAN-10-1943; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Forde S, 2007, BLOOD, V109, P1825, DOI 10.1182/blood-2006-05-023028; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Ganzfried BF, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat013; Gelmini S, 2009, CLIN EXP METASTAS, V26, P261, DOI 10.1007/s10585-009-9240-4; Ghanem I, 2014, AM J TRANSL RES, V6, P340; Gil M, 2014, J IMMUNOL, V193, P5327, DOI 10.4049/jimmunol.1400201; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Guo Li, 2011, Chin J Cancer, V30, P336; Guo Qing, 2013, Zhonghua Yi Xue Za Zhi, V93, P1677; Guyon A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00065; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; Heckmann D, 2014, CLIN CANCER RES, V20, P604, DOI 10.1158/1078-0432.CCR-13-0582; Heinrich EL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-68; Hoellenriegel J, 2014, BLOOD, V123, P1032, DOI 10.1182/blood-2013-03-493924; Hsieh JY, 2013, NUCLEIC ACIDS RES, V41, P9753, DOI 10.1093/nar/gkt666; Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012; Huang AF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-115; Huang Z, 2014, GUT, V63, P1247, DOI 10.1136/gutjnl-2012-304213; Ierano C, 2009, CELL CYCLE, V8, P1228, DOI 10.4161/cc.8.8.8250; Infantino S, 2006, J IMMUNOL, V176, P2197, DOI 10.4049/jimmunol.176.4.2197; Iwasa S, 2009, ANTICANCER RES, V29, P4751; Jaszczynska-Nowinka K, 2014, ONCOL LETT, V7, P1618, DOI 10.3892/ol.2014.1897; Jee SH, 2004, J INVEST DERMATOL, V123, P1169, DOI 10.1111/j.0022-202X.2004.23497.x; Jeon ES, 2008, STEM CELLS, V26, P789, DOI 10.1634/stemcells.2007-0742; Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036; Jiang Yu-Ping, 2007, Zhonghua Fu Chan Ke Za Zhi, V42, P403; Kajiyama H, 2008, INT J CANCER, V122, P91, DOI 10.1002/ijc.23083; Kajiyama H, 2007, CELL TISSUE RES, V330, P221, DOI 10.1007/s00441-007-0455-x; Kang KS, 2013, BIOCHEM BIOPH RES CO, V432, P333, DOI 10.1016/j.bbrc.2013.01.102; Karin N, 2010, J LEUKOCYTE BIOL, V88, P463, DOI 10.1189/jlb.0909602; Kawaguchi A, 2009, BLOOD, V114, P2961, DOI 10.1182/blood-2008-11-189308; Kim J, 2006, ANN SURG, V244, P113, DOI 10.1097/01.sla.0000217690.65909.9c; Ko SY, 2012, J CLIN INVEST, V122, P3603, DOI 10.1172/JCI62229; Kojima K, 2011, BLOOD, V118, P4431, DOI 10.1182/blood-2011-02-334136; Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904; Kryczek I, 2005, CANCER RES, V65, P465; Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006; Kulbe H, 2005, CANCER RES, V65, P10355, DOI 10.1158/0008-5472.CAN-05-0957; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kwong J, 2009, MOL CANCER THER, V8, P1893, DOI 10.1158/1535-7163.MCT-08-0966; Lee YH, 2010, CLIN ENDOCRINOL, V72, P209, DOI 10.1111/j.1365-2265.2009.03629.x; Leone V, 2011, J CLIN ENDOCR METAB, V96, pE1388, DOI 10.1210/jc.2011-0345; Li XQ, 2014, MOL CELL BIOCHEM, V392, P77, DOI 10.1007/s11010-014-2020-8; Li XQ, 2012, CANCER LETT, V322, P169, DOI 10.1016/j.canlet.2012.02.035; Liang JJ, 2010, CANCER EPIDEM BIOMAR, V19, P2598, DOI 10.1158/1055-9965.EPI-10-0405; Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182; Liao AY, 2016, MOL NEUROBIOL, V53, P210, DOI 10.1007/s12035-014-9006-0; Lim JB, 2015, CYTOKINE, V73, P16, DOI 10.1016/j.cyto.2015.01.010; Limon-Flores AY, 2009, TOXICOL SCI, V112, P144, DOI 10.1093/toxsci/kfp181; Lin L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.392; Lin SY, 2013, INT J ONCOL, V43, P1817, DOI 10.3892/ijo.2013.2109; Liu FF, 2009, HISTOPATHOLOGY, V54, P741, DOI 10.1111/j.1365-2559.2009.03289.x; Liu SC, 2014, NEURO-ONCOLOGY, V16, P21, DOI 10.1093/neuonc/not149; Liu YL, 2014, INT J ONCOL, V44, P203, DOI 10.3892/ijo.2013.2168; Liu Yu-Qiang, 2014, J Anal Methods Chem, V2014, P617367, DOI 10.1155/2014/617367; Liu Z, 2015, CIRC-CARDIOVASC GENE, V8, P11, DOI 10.1161/CIRCGENETICS.114.000598; Lu J, 2014, CARCINOGENESIS, V35, P554, DOI 10.1093/carcin/bgt354; Lu ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065719; Luo HN, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0789-z; Machelon V, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-97; Madden SF, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-241; Martin SK, 2010, HAEMATOL-HEMATOL J, V95, P776, DOI 10.3324/haematol.2009.015628; Monteagudo C, 2012, CLIN EXP METASTAS, V29, P625, DOI 10.1007/s10585-012-9476-2; Monterrubio M, 2009, BIOCHEM BIOPH RES CO, V388, P199, DOI 10.1016/j.bbrc.2009.07.153; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood-2008-06-162123; Niedermeier M, 2009, BLOOD, V113, P5549, DOI 10.1182/blood-2008-06-165068; Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008-5472.CAN-11-2449; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Perim AD, 2013, MOL BIOL REP, V40, P4591, DOI 10.1007/s11033-013-2551-1; Pietkiewicz PP, 2010, BIOMED PHARMACOTHER, V64, P54, DOI 10.1016/j.biopha.2009.04.041; Pillai MM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014304; Ping YF, 2011, J PATHOL, V224, P344, DOI 10.1002/path.2908; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Popple A, 2012, BRIT J CANCER, V106, P1306, DOI 10.1038/bjc.2012.49; Porcile C, 2004, ANN NY ACAD SCI, V1030, P162, DOI 10.1196/annals.1329.021; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Qu QX, 2012, ONCOL RES, V20, P383, DOI 10.3727/096504013X13657689382653; Quattrocchi L, 2013, J OBSTET GYNAECOL RE, V39, P297, DOI 10.1111/j.1447-0756.2012.01949.x; Ramakrishnan M, 2013, CANCER RES, V73, P5360, DOI 10.1158/0008-5472.CAN-13-0896; Ramos EAS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029461; Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23; Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357; Ratajczak MZ, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-95; Ray P, 2011, NEOPLASIA, V13, P1152, DOI 10.1593/neo.111076; Redjal N, 2006, CLIN CANCER RES, V12, P6765, DOI 10.1158/1078-0432.CCR-06-1372; Rehman AO, 2009, INT J ORAL SCI, V1, P105, DOI 10.4248/IJOS.09059; Righi E, 2011, CANCER RES, V71, P5522, DOI 10.1158/0008-5472.CAN-10-3143; Rigo A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-273; Roccaro AM, 2014, CELL REP, V9, P118, DOI 10.1016/j.celrep.2014.08.042; Romain B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-58; Salomonnson E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051500; Sanchez-Martin L, 2013, TRENDS MOL MED, V19, P12, DOI 10.1016/j.molmed.2012.10.004; Sanz-Pamplona R, 2012, MOL BIOSYST, V8, P2085, DOI 10.1039/c2mb25104c; Sarchio SNE, 2014, J INVEST DERMATOL, V134, P1091, DOI 10.1038/jid.2013.424; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shen PF, 2014, PROSTATE, V74, P756, DOI 10.1002/pros.22795; Shen XY, 2009, J HUAZHONG U SCI-MED, V29, P363, DOI 10.1007/s11596-009-0320-0; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Spinello I, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.24; Staton AA, 2011, NAT GENET, V43, P204, DOI 10.1038/ng.758; Su YC, 2006, BREAST, V15, P533, DOI 10.1016/j.breast.2005.08.034; Tang JQ, 2012, CANCER INVEST, V30, P380, DOI 10.3109/07357907.2012.666692; Taverna S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-169; Thiele S, 2014, BRIT J PHARMACOL, V171, P5313, DOI 10.1111/bph.12842; Thomas RM, 2008, GUT, V57, P1555, DOI 10.1136/gut.2007.143941; Toritsuka M, 2013, P NATL ACAD SCI USA, V110, P17552, DOI 10.1073/pnas.1312661110; Tsukamoto H, 2007, CLIN EXP METASTAS, V24, P423, DOI 10.1007/s10585-007-9079-5; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Uygur B, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-139; Vater A, 2013, CLIN PHARMACOL THER, V94, P150, DOI 10.1038/clpt.2013.58; Wagner PL, 2009, J THORAC CARDIOV SUR, V137, P615, DOI 10.1016/j.jtcvs.2008.07.039; Wang H, 2014, ONCOL LETT, V7, P1581, DOI 10.3892/ol.2014.1926; Wang JH, 2005, CELL SIGNAL, V17, P1578, DOI 10.1016/j.cellsig.2005.03.022; Wang JH, 2007, CANCER RES, V67, P149, DOI 10.1158/0008-5472.CAN-06-2971; Wang Z, 2008, BRIT J CANCER, V99, P1695, DOI 10.1038/sj.bjc.6604745; Wei S, 2007, CANCER RES, V67, P7487, DOI 10.1158/0008-5472.CAN-07-0565; Welschinger R, 2013, EXP HEMATOL, V41, P293, DOI 10.1016/j.exphem.2012.11.004; Wertel I, 2011, GINEKOL POL, V82, P414; Wu MH, 2008, J CELL BIOCHEM, V103, P245, DOI 10.1002/jcb.21400; Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099; Xu M, 2010, J ORAL PATHOL MED, V39, P63, DOI 10.1111/j.1600-0714.2009.00801.x; Xue BY, 2013, MOL CELL BIOCHEM, V380, P177, DOI 10.1007/s11010-013-1671-1; Yang BG, 2007, J IMMUNOL, V179, P4376, DOI 10.4049/jimmunol.179.7.4376; Yang P, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0377-x; Yang-Hartwich Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06116; Yoon Y, 2007, CANCER RES, V67, P7518, DOI 10.1158/0008-5472.CAN-06-2263; Yu T, 2014, ONCOGENE, V33, P5017, DOI 10.1038/onc.2013.448; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Yu YC, 2007, EUR J CANCER PREV, V16, P430, DOI 10.1097/01.cej.0000236259.88146.a4; Yu YC, 2013, ONCOL RES, V21, P217, DOI 10.3727/096504014X13907540404879; Yu YC, 2014, DNA CELL BIOL, V33, P543, DOI 10.1089/dna.2013.2289; Zannettino ACW, 1998, BLOOD, V92, P2613, DOI 10.1182/blood.V92.8.2613.420k15_2613_2628; Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood-2008-05-158311; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690; Zhao ED, 2012, ONCOIMMUNOLOGY, V1, P152, DOI 10.4161/onci.1.2.18480; Zhi Y, 2012, DIGEST DIS SCI, V57, P650, DOI 10.1007/s10620-011-1922-5; Zhou JD, 2014, INT J CLIN EXP PATHO, V7, P7182; Zhou W, 2009, J CANCER RES CLIN, V135, P91, DOI 10.1007/s00432-008-0435-x; Zhu S, 2010, ONCOGENE, V29, P1763, DOI 10.1038/onc.2009.459	176	298	312	7	99	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					816	826		10.1038/onc.2015.139	http://dx.doi.org/10.1038/onc.2015.139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961926	Bronze			2022-12-28	WOS:000370332200002
J	Whang, YM; Park, SI; Trenary, IA; Egnatchik, RA; Fessel, JP; Kaufman, JM; Carbone, DP; Young, JD				Whang, Y. M.; Park, S. I.; Trenary, I. A.; Egnatchik, R. A.; Fessel, J. P.; Kaufman, J. M.; Carbone, D. P.; Young, J. D.			LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR MUTATIONS; GENE-MUTATIONS; GROWTH; AMPK; APOPTOSIS; CHEMOTHERAPY; METABOLISM; INHIBITION; GEFITINIB	The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK) signaling confers sensitivity to metabolic inhibition or stress-induced mitochondrial insults. We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. LKB1-deficient cells exhibited enhanced sensitivity to erlotinib in vitro and in vivo that was associated with alterations in energy metabolism and mitochondrial dysfunction. Loss of LKB1 expression altered the cellular response to erlotinib treatment, resulting in impaired ATP homeostasis and an increase in reactive oxygen species. Furthermore, erlotinib selectively blocked mammalian target of rapamycin signaling, inhibited cell growth and activated apoptosis in LKB1-deficient cells. Erlotinib treatment also induced AMPK activation despite loss of LKB1 expression, which was partially reduced by the application of a calcium/calmodulin-dependent protein kinase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM). These findings may have significant implications for the design of novel NSCLC treatments that target dysregulated metabolic and signaling pathways in LKB1-deficient tumors.	[Whang, Y. M.; Trenary, I. A.; Egnatchik, R. A.; Young, J. D.] Vanderbilt Univ, Dept Biomol & Chem Engn, PMB 351604, Nashville, TN 37235 USA; [Park, S. I.] Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Ctr Bone Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Fessel, J. P.] Vanderbilt Univ, Dept Med, Div Allergy Pulm & Crit Care Med, 221 Kirkland Hall, Nashville, TN 37235 USA; [Kaufman, J. M.] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Carbone, D. P.] Ohio State Univ, Med Ctr, Dept Internal Med, Columbus, OH 43210 USA; [Young, J. D.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University System of Ohio; Ohio State University; Vanderbilt University	Young, JD (corresponding author), Vanderbilt Univ, Dept Biomol & Chem Engn, PMB 351604, Nashville, TN 37235 USA.	j.d.young@vanderbilt.edu	Park, Serk In/D-2840-2011; Young, Jamey/A-5857-2012	Park, Serk In/0000-0001-8643-5096; Fessel, Joshua/0000-0003-0797-7693	NIH [P50 CA090949, K08 HL121174]; DOD [W81XWH-12-1-0383]; NSF [CBET-1105991]; Uniting Against Lung Cancer; NATIONAL CANCER INSTITUTE [P50CA090949, U10CA180850] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL121174] Funding Source: NIH RePORTER; Div Of Chem, Bioeng, Env, & Transp Sys [1105991] Funding Source: National Science Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); NSF(National Science Foundation (NSF)); Uniting Against Lung Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Div Of Chem, Bioeng, Env, & Transp Sys(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This work was supported by NIH P50 CA090949, DOD W81XWH-12-1-0383, NSF CBET-1105991, and by an award from Uniting Against Lung Cancer. Dr Joshua P. Fessel was also supported by NIH K08 HL121174. The authors thank Dr Changki Lee for his assistance with the animal experiments.	Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961; Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111; Garassino MC, 2011, J CLIN ONCOL, V29, P3835, DOI 10.1200/JCO.2011.36.7847; Gowans GJ, 2013, CELL METAB, V18, P556, DOI 10.1016/j.cmet.2013.08.019; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kaufman JM, 2014, J THORAC ONCOL, V9, P794, DOI 10.1097/JTO.0000000000000173; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Ling YH, 2008, MOL PHARMACOL, V74, P793, DOI 10.1124/mol.107.044396; Liu Y, 2013, CANCER DISCOV, V3, P870, DOI 10.1158/2159-8290.CD-13-0015; Mahoney CL, 2009, BRIT J CANCER, V100, P370, DOI 10.1038/sj.bjc.6604886; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Murphy TA, 2013, BIOTECHNOL BIOENG, V110, P1748, DOI 10.1002/bit.24836; Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Oakhill JS, 2010, P NATL ACAD SCI USA, V107, P19237, DOI 10.1073/pnas.1009705107; Onozato R, 2007, CANCER SCI, V98, P1747, DOI 10.1111/j.1349-7006.2007.00585.x; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Park SI, 2013, CANCER RES, V73, P6574, DOI 10.1158/0008-5472.CAN-12-4692; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Van Schaeybroeck S, 2006, MOL CANCER THER, V5, P1154, DOI 10.1158/1535-7163.MCT-05-0446; West L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031906; Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zannetti A, 2008, CLIN CANCER RES, V14, P5209, DOI 10.1158/1078-0432.CCR-08-0374	44	37	38	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					856	866		10.1038/onc.2015.140	http://dx.doi.org/10.1038/onc.2015.140			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	26119936	Green Accepted			2022-12-28	WOS:000370332200006
J	Helmke, C; Becker, S; Strebhardt, K				Helmke, C.; Becker, S.; Strebhardt, K.			The role of Plk3 in oncogenesis	ONCOGENE			English	Review							POLO-LIKE-KINASE; SPINDLE ASSEMBLY CHECKPOINT; CELL-CYCLE PROGRESSION; BOX DOMAIN; DNA-DAMAGE; C-JUN; GENE-EXPRESSION; SERINE/THREONINE KINASE; TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE	The polo-like kinases (Plks) encompass a family of five serine/threonine protein kinases that play essential roles in many cellular processes involved in the control of the cell cycle, including entry into mitosis, DNA replication and the response to different types of stress. Plk1, which has been validated as a cancer target, came into the focus of many pharmaceutical companies for the development of small-molecule inhibitors as anticancer agents. Recently, FDA (Food and Drug Administration) has granted a breakthrough therapy designation to the Plk inhibitor BI 6727 (volasertib), which provided a survival benefit for patients suffering from acute myeloid leukemia. However, the various ATP-competitive inhibitors of Plk1 that are currently in clinical development also inhibit the activities of Plk2 and Plk3, which are considered as tumor suppressors. Plk3 contributes to the control and progression of the cell cycle while acting as a mediator of apoptosis and various types of cellular stress. The aberrant expression of Plk3 was found in different types of tumors. Recent progress has improved our understanding of Plk3 in regulating stress signaling and tumorigenesis. When using ATP-competitive Plk1 inhibitors, the biological roles of Plk1-related family members like Plk3 in cancer cells need to be considered carefully to improve treatment strategies against cancer.	[Helmke, C.; Becker, S.; Strebhardt, K.] Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, D-60590 Frankfurt, Hessen, Germany; [Strebhardt, K.] German Canc Consortium DKTK, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, Theodor Stern Kai 7-9, D-60590 Frankfurt, Hessen, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763	German Cancer Consortium (DKTK) (Heidelberg); Sander-Stiftung; Carls-Stiftung; Deutsche Krebshilfe; BANSS Stiftung	German Cancer Consortium (DKTK) (Heidelberg); Sander-Stiftung; Carls-Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); BANSS Stiftung	This work was supported by grants from the German Cancer Consortium (DKTK) (Heidelberg), Sander-Stiftung, Carls-Stiftung, Deutsche Krebshilfe and BANSS Stiftung.	Alberts GF, 2004, CELL CYCLE, V3, P678; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Archambault V, 2008, GENE DEV, V22, P2707, DOI 10.1101/gad.486808; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Bahassi El Mustapha, 2002, Oncogene, V21, P6633; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Bai Y, 2012, CANCER RES, V72, P2501, DOI 10.1158/0008-5472.CAN-11-3015; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Berg T, 2012, EXPERT OPIN INV DRUG, V21, P1069, DOI 10.1517/13543784.2012.691163; Bergeron M, 2014, NEUROSCIENCE, V256, P72, DOI 10.1016/j.neuroscience.2013.09.061; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bieche I, 1998, ONCOL REP, V5, P267; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Bruinsma W, 2014, J CELL SCI, V127, P801, DOI 10.1242/jcs.137216; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cholewa BD, 2013, CANCER RES, V73, P6848, DOI 10.1158/0008-5472.CAN-13-2197; Conn CW, 2000, CANCER RES, V60, P6826; Craig SN, 2014, EXPERT OPIN DRUG DIS, V9, P773, DOI 10.1517/17460441.2014.918100; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; De Franceschi L, 2011, BLOOD, V118, P5652, DOI 10.1182/blood-2011-05-355339; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gauci S, 2009, ANAL CHEM, V81, P4493, DOI 10.1021/ac9004309; Gilmartin AG, 2009, CANCER RES, V69, P6969, DOI 10.1158/0008-5472.CAN-09-0945; Gjertsen BT, 2014, LEUKEMIA OFFICIAL J; Han ES, 2008, PHYSIOL GENOMICS, V34, P112, DOI 10.1152/physiolgenomics.00239.2007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Horner TJ, 2009, MOL CELL BIOL, V29, P1999, DOI 10.1128/MCB.00982-08; Iida M, 2008, BIOCHEM J, V411, P27, DOI 10.1042/BJ20071394; Inglis KJ, 2009, J BIOL CHEM, V284, P2598, DOI 10.1074/jbc.C800206200; Iuchi T, 2002, GENE CHROMOSOME CANC, V35, P170, DOI 10.1002/gcc.10080; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Jen KY, 2005, CANCER RES, V65, P7666, DOI 10.1158/0008-5472.CAN-05-1039; Jiang N, 2006, J BIOL CHEM, V281, P10577, DOI 10.1074/jbc.M513156200; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; Kis E, 2006, INT J RADIAT ONCOL, V66, P1506, DOI 10.1016/j.ijrobp.2006.08.004; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Larsson E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.89; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee KS, 2008, CELL CYCLE, V7, P141, DOI 10.4161/cc.7.2.5272; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Li H, 2009, MOL CELL PROTEOMICS, V8, P1839, DOI 10.1074/mcp.M900030-MCP200; Li MJ, 2011, MED SCI MONITOR, V17, pBR290, DOI 10.12659/MSM.881976; Li ZG, 2014, MOL CELL BIOL, V34, P3642, DOI 10.1128/MCB.00814-14; Li ZK, 2005, J BIOL CHEM, V280, P16843, DOI 10.1074/jbc.M410119200; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lopez-Sanchez I, 2009, MOL CELL BIOL, V29, P1189, DOI 10.1128/MCB.01341-08; Lu JW, 2010, INVEST OPHTH VIS SCI, V51, P5034, DOI 10.1167/iovs.10-5501; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mamrosh JL, 2014, ELIFE, V3, DOI 10.7554/eLife.01694; Mbefo MK, 2010, J BIOL CHEM, V285, P2807, DOI 10.1074/jbc.M109.081950; McInnes C, 2005, CURR TOP MED CHEM, V5, P181, DOI 10.2174/1568026053507660; McInnes C, 2012, MOL CANCER THER, V11, P1683, DOI 10.1158/1535-7163.MCT-12-0006-T; McInnes C, 2011, DRUG DISCOV TODAY, V16, P619, DOI 10.1016/j.drudis.2011.05.002; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Myer DL, 2011, MUTAT RES-FUND MOL M, V714, P1, DOI 10.1016/j.mrfmmm.2011.02.006; Myer DL, 2005, ONCOGENE, V24, P299, DOI 10.1038/sj.onc.1208278; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Pellegrino R, 2010, HEPATOLOGY, V51, P857, DOI 10.1002/hep.23467; Petronczki M, 2008, DEV CELL, V14, P646, DOI 10.1016/j.devcel.2008.04.014; Qian WJ, 2013, CHEM BIOL, V20, P1255, DOI 10.1016/j.chembiol.2013.09.005; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Raab M, 2014, CELL RES, V24, P1141, DOI 10.1038/cr.2014.86; Raab M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1395; Reindl WG, 2008, CHEM BIOL, V15, P459, DOI 10.1016/j.chembiol.2008.03.013; Reindl W, 2009, CHEMBIOCHEM, V10, P1145, DOI 10.1002/cbic.200900059; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Salvi M, 2012, BBA-PROTEINS PROTEOM, V1824, P1366, DOI 10.1016/j.bbapap.2012.07.003; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shan HM, 2015, BIOCHEM BIOPH RES CO, V456, P780, DOI 10.1016/j.bbrc.2014.11.125; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Srinivasrao G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107432; Staib F, 2005, CANCER RES, V65, P10255, DOI 10.1158/0008-5472.CAN-05-1714; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; SUNKEL CE, 1988, J CELL SCI, V89, P25; Utada Y, 2000, CLIN CANCER RES, V6, P3193; Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765; van de Weerdt BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/cc.5.8.2692; van de Weerdt BCM, 2005, MOL CELL BIOL, V25, P2031, DOI 10.1128/MCB.25.5.2031-2044.2005; Wang JF, 2011, CELL SIGNAL, V23, P2030, DOI 10.1016/j.cellsig.2011.07.017; Wang L, 2008, J BIOL CHEM, V283, P25928, DOI 10.1074/jbc.M801326200; Wang L, 2007, J BIOL CHEM, V282, P32121, DOI 10.1074/jbc.M702791200; Wang L, 2011, INVEST OPHTH VIS SCI, V52, P3200, DOI 10.1167/iovs.10-6485; Wang L, 2011, J BIOL CHEM, V286, P1951, DOI 10.1074/jbc.M110.166009; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Weichert W, 2005, VIRCHOWS ARCH, V446, P442, DOI 10.1007/s00428-005-1212-8; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu DZ, 2010, J BIOL CHEM, V285, P39935, DOI 10.1074/jbc.M110.166462; Xu DZ, 2010, J BIOL CHEM, V285, P38944, DOI 10.1074/jbc.M110.160325; Xu J, 2013, NAT STRUCT MOL BIOL, V20, P1047, DOI 10.1038/nsmb.2623; Yang YL, 2008, CANCER RES, V68, P4077, DOI 10.1158/0008-5472.CAN-07-6182; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016/j.ajpath.2011.06.031; Zhang H, 2004, J BIOL CHEM, V279, P35726, DOI 10.1074/jbc.M403264200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou JX, 2013, CNS NEUROSCI THER, V19, P688, DOI 10.1111/cns.12124; Zhou T, 2006, ENVIRON HEALTH PERSP, V114, P553, DOI 10.1289/ehp.8026; Zimmerman WC, 2007, CELL CYCLE, V6, P1314, DOI 10.4161/cc.6.11.4275; Zimmerman WC, 2007, P NATL ACAD SCI USA, V104, P1847, DOI 10.1073/pnas.0610856104; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	144	57	61	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					135	147		10.1038/onc.2015.105	http://dx.doi.org/10.1038/onc.2015.105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25915845				2022-12-28	WOS:000368193900001
J	Huang, B; Song, JH; Cheng, Y; Abraham, JM; Ibrahim, S; Sun, Z; Ke, X; Meltzer, SJ				Huang, B.; Song, J. H.; Cheng, Y.; Abraham, J. M.; Ibrahim, S.; Sun, Z.; Ke, X.; Meltzer, S. J.			Long non-coding antisense RNA KRT7-AS is activated in gastric cancers and supports cancer cell progression by increasing KRT7 expression	ONCOGENE			English	Article							NATURAL ANTISENSE; ESOPHAGEAL ADENOCARCINOMA; COLORECTAL-CANCER; GENE-EXPRESSION; MESSENGER-RNA; TRANSCRIPT; H19; OVEREXPRESSION; PROLIFERATION; EVOLUTION	Alterations in long non-coding RNAs (lncRNAs) are associated with human carcinogenesis. One group of lncRNAs, which are antisense in orientation to coding mRNAs (ASs), have been recently described in cancers but are poorly understood. We sought to identify ASs involved in human gastric cancer (GC) and to elucidate their mechanisms of action in carcinogenesis. We performed massively parallel RNA sequencing in GCs and matched normal tissues, as well as in GC-derived and normal gastric epithelial cell lines. One AS, designated Homo sapiens keratin 7 (KRT7-AS), was selected due to its marked upregulation and concordant expression with its cognate sense counterpart, KRT7, in GC tissues and cell lines. KRT7-AS formed an RNA-RNA hybrid with KRT7 and controlled KRT7 expression at both the mRNA and the post-transcriptional levels. Moreover, forced overexpression of the KRT7-overlapping region (OL) of KRT7-AS (but not its non-KRT7-OL portions) increased keratin 7 protein levels in cells. Finally, forced overexpression of full-length KRT7-AS or OL KRT7-AS (but not its non-KRT7-OL regions) promoted GC cell proliferation and migration. We conclude that lncRNA KRT7-AS promotes GC, at least in part, by increasing KRT7 expression.	[Huang, B.] Tongji Univ, Sch Med, Tongji Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Huang, B.; Song, J. H.; Cheng, Y.; Abraham, J. M.; Ibrahim, S.; Sun, Z.; Ke, X.; Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA; [Huang, B.; Song, J. H.; Cheng, Y.; Abraham, J. M.; Ibrahim, S.; Sun, Z.; Ke, X.; Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Dept Oncol, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA; [Huang, B.; Song, J. H.; Cheng, Y.; Abraham, J. M.; Ibrahim, S.; Sun, Z.; Ke, X.; Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA	Tongji University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA.; Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA.; Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA.	smeltzer@jhmi.edu			NIH [CA190040, CA85069, DK087454, CA133012, CA173390]; China Scholarship Council (CSC); Joint Johns Hopkins University-Tongji University of China student scholarship; NATIONAL CANCER INSTITUTE [R01CA190040, R01CA146799, U01CA085069, R21CA173390, R01CA133012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087454] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council (CSC)(China Scholarship Council); Joint Johns Hopkins University-Tongji University of China student scholarship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	SJM, the Harry and Betty Myerberg/Thomas R Hendrix Professor of Gastroenterology, is also an American Cancer Society Clinical Research Professor and was supported by NIH grants CA190040, CA85069, DK087454, CA133012, CA173390, and Sidney Kimmel Comprehensive Cancer Center Core facilities. BH was supported by an Exchange Scholarship from the China Scholarship Council (CSC). BH is a recipient of a Joint Johns Hopkins University-Tongji University of China student scholarship. BH was supported by an Exchange Scholarship from the China Scholarship Council (CSC).	Alam T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109443; Balbin OA, 2015, GENOME RES, V25, P1068, DOI 10.1101/gr.180596.114; Byun HM, 2007, CANCER RES, V67, P10753, DOI 10.1158/0008-5472.CAN-07-0329; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Cayre A, 2003, BREAST CANCER RES, V5, pR223, DOI 10.1186/bcr652; Cunnington MS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000899; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784; Faghihi MA, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r56; Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Harbaum L, 2011, HISTOPATHOLOGY, V59, P225, DOI 10.1111/j.1365-2559.2011.03694.x; Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037; Iacobucci I, 2011, LEUKEMIA RES, V35, P1052, DOI 10.1016/j.leukres.2011.02.020; Kanduc D, 2002, J VIROL, V76, P7040, DOI 10.1128/JVI.76.14.7040-7048.2002; Karantza V, 2011, ONCOGENE, V30, P127, DOI 10.1038/onc.2010.456; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Kimura T, 2013, CELL MOL LIFE SCI, V70, P1451, DOI 10.1007/s00018-012-1216-x; Lambaudie E, 2014, ANTICANCER RES, V34, P177; Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154; Medrzycki M, 2014, CANCER RES, V74, P6463, DOI 10.1158/0008-5472.CAN-13-2922; Michael DR, 2011, J BIOL CHEM, V286, P19523, DOI 10.1074/jbc.M111.233916; Munroe SH, 2006, CELL MOL LIFE SCI, V63, P2102, DOI 10.1007/s00018-006-6070-2; Nishizawa M, 2015, FRONT BIOSCI-LANDMRK, V20, P1, DOI 10.2741/4297; Oue N, 2012, ANN SURG ONCOL, V19, P1902, DOI 10.1245/s10434-011-2175-4; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Pujal J, 2009, FASEB J, V23, P1366, DOI 10.1096/fj.08-115576; Salameh A, 2015, P NATL ACAD SCI USA, V112, P8403, DOI 10.1073/pnas.1507882112; Sandilands A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064404; Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103; Schmid M, 2015, CELL REP, V12, P128, DOI 10.1016/j.celrep.2015.06.008; Span PN, 2011, ENDOCR-RELAT CANCER, V18, P323, DOI 10.1530/ERC-10-0184; Su WY, 2012, CELL RES, V22, P1374, DOI 10.1038/cr.2012.57; Tan JY, 2015, GENOME RES, V25, P655, DOI 10.1101/gr.181974.114; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Villegas VE, 2015, INT J MOL SCI, V16, P3251, DOI 10.3390/ijms16023251; Wahlestedt C, 2006, DRUG DISCOV TODAY, V11, P503, DOI 10.1016/j.drudis.2006.04.013; Wight M, 2013, ESSAYS BIOCHEM, V54, P91, DOI [10.1042/BSE0540091, 10.1042/bse0540091]; Wu WJ, 2013, GASTROENTEROLOGY, V144, P956, DOI 10.1053/j.gastro.2013.01.019; Xi QL, 2014, INT J BIOCHEM CELL B, V55, P242, DOI 10.1016/j.biocel.2014.09.012; Yamaguchi N, 2001, LANCET ONCOL, V2, P88, DOI 10.1016/S1470-2045(00)00225-4; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yang X, 2014, GUT, V63, P881, DOI 10.1136/gutjnl-2013-305266; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhou XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11516	45	104	107	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4927	4936		10.1038/onc.2016.25	http://dx.doi.org/10.1038/onc.2016.25			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876208	Green Accepted			2022-12-28	WOS:000383330700010
J	Xie, X; Lozano, G; Siddik, ZH				Xie, X.; Lozano, G.; Siddik, Z. H.			Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53	ONCOGENE			English	Article							WILD-TYPE P53; DNA-DAMAGE; DEGRADATION; ACTIVATION; PHOSPHORYLATION; PROTEIN; CANCER; SENSITIVITY; APOPTOSIS; IMPACT	Cisplatin is an important antitumor agent, but its clinical utility is often limited by multifactorial mechanism of resistance. Loss of tumor suppressor p53 function is a major mechanism that is affected by either mutation in the DNA-binding domain or dysregulation by overexpression of p53 inhibitors MDM2 and MDM4, which destabilize p53 by increasing its proteosomal degradation. In the present study, cisplatin-resistant 2780CP/Cl-16 ovarian tumor cells expressed a heterozygous, temperature-sensitive p53(V172F) mutation, which reduced p53 half-life by two-to threefold compared with homozygous wild-type (wt) p53 in parental A2780 cells. Although reduced p53 stability in 2780CP/Cl-16 cells was associated with moderate cellular overexpression of MDM2 or MDM4 (o1.5-fold), their binding to p53 was substantially enhanced (five-to eightfold). The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53V172F mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. The inference that p53 was unstable as a heteromeric p53wt/p53(V172F) complex was confirmed in 2780CP/Cl-24 cells transfected with wt p53 or multimer-inhibiting p53(L344P) mutant, and further supported by normalization of p53 stability in both resistant cell lines grown at the permissive temperature of 32.5 degrees C. Surprisingly, in 2780CP/Cl-16 and 2780CP/Cl-24 models, cisplatin-induced transactivity of p53 was attenuated at 37 degrees C, and this correlated with cisplatin resistance. However, downregulation of MDM2 or MDM4 by small interfering RNA in either resistant cell line induced p53 and restored p21 transactivation at 37 degrees C, as did cisplatin-induced DNA damage at 32.5 degrees C that coincided with reduced p53-MDM4 binding and cisplatin resistance. These results demonstrate that cisplatin-mediated p53(V172F) mutation regulates p53 stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53(V172F) complex that inhibits p53-dependent transactivation. This represents a novel cellular mechanism of p53 inhibition, and, thereby, induction of cisplatin resistance.	[Xie, X.; Siddik, Z. H.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA; [Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Siddik, ZH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA.	zsiddik@mdanderson.org			US Public Health Service - National Cancer Institute [CA160687, CA16672]; Megan McBride Franz Endowed Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA160687] Funding Source: NIH RePORTER	US Public Health Service - National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)United States Public Health Service); Megan McBride Franz Endowed Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The research support from the US Public Health Service Grants CA160687 to ZHS and Support Grant CA16672 to MD Anderson Cancer Center, awarded by the National Cancer Institute, and in part from the Megan McBride Franz Endowed Research Fund, is gratefully acknowledged. We thank Dr Shiaw-Yih Lin (MD Anderson Cancer Center) for the His-Ubiquitin plasmid, and also Dr Guangan He and Michelle Martinez for helpful discussions.	Brachova P, 2013, INT J MOL SCI, V14, P19257, DOI 10.3390/ijms140919257; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Cocker HA, 2001, BRIT J CANCER, V85, P1746, DOI 10.1054/bjoc.2001.2145; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Gaglia G, 2013, P NATL ACAD SCI USA, V110, P15497, DOI 10.1073/pnas.1311126110; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; He G, 2013, BRIT J CANCER, V109, P2378, DOI 10.1038/bjc.2013.613; He GG, 2011, GYNECOL ONCOL, V122, P402, DOI 10.1016/j.ygyno.2011.04.034; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Komlodi-Pasztor E, 2009, ONCOGENE, V28, P3111, DOI 10.1038/onc.2009.166; KONDO S, 1995, ONCOGENE, V10, P2001; Kuang J, 2001, CLIN CANCER RES, V7, P3629; Lam S, 2010, ONCOGENE, V29, P2415, DOI 10.1038/onc.2009.522; Lenos K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/876173; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Mancini F, 2004, J BIOL CHEM, V279, P8169, DOI 10.1074/jbc.M311793200; Martinez-Rivera M, 2012, BIOCHEM PHARMACOL, V83, P1049, DOI 10.1016/j.bcp.2011.12.026; Mujoo K, 2003, J CANCER RES CLIN, V129, P709, DOI 10.1007/s00432-003-0480-4; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Pei DS, 2012, ONCOTARGET, V3, P228; Perry ME, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000968; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Siddik ZH, 2006, CANC DRUG DISC DEV, P283, DOI 10.1007/978-1-59745-035-5_16; Siddik ZH, 1998, CANCER RES, V58, P698; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Tsvetkov P, 2010, CELL DEATH DIFFER, V17, P103, DOI 10.1038/cdd.2009.67; Wang XJ, 2012, FEBS LETT, V586, P1390, DOI 10.1016/j.febslet.2012.02.049; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yazlovitskaya EM, 2001, BIOCHEM BIOPH RES CO, V283, P732, DOI 10.1006/bbrc.2001.4849	31	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4798	4806		10.1038/onc.2016.12	http://dx.doi.org/10.1038/onc.2016.12			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876197	Green Accepted			2022-12-28	WOS:000383324700012
J	Dey, A; Robitaille, M; Remke, M; Maier, C; Malhotra, A; Gregorieff, A; Wrana, JL; Taylor, MD; Angers, S; Kenney, AM				Dey, A.; Robitaille, M.; Remke, M.; Maier, C.; Malhotra, A.; Gregorieff, A.; Wrana, J. L.; Taylor, M. D.; Angers, S.; Kenney, A. M.			YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells	ONCOGENE			English	Article							BOX-BINDING PROTEIN-1; GROWTH-FACTOR-II; TRANSCRIPTION FACTOR YB-1; NUCLEAR EXPRESSION; GENE-EXPRESSION; BREAST-CANCER; P-GLYCOPROTEIN; CYCLE PROGRESSION; TARGET; ALPHA	Postnatal proliferation of cerebellar granule neuron precursors (CGNPs), proposed cells of origin for the SHH-associated subgroup of medulloblastoma, is driven by Sonic hedgehog (Shh) and insulin-like growth factor (IGF) in the developing cerebellum. Shh induces the oncogene Yes-associated protein (YAP), which drives IGF2 expression in CGNPs and mouse Shh-associated medulloblastomas. To determine how IGF2 expression is regulated downstream of YAP, we carried out an unbiased screen for transcriptional regulators bound to IGF2 promoters. We report that Y-box binding protein-1 (YB-1), an onco-protein regulating transcription and translation, binds to IGF2 promoter P3. We observed that YB-1 is upregulated across human medulloblastoma subclasses as well as in other varieties of pediatric brain tumors. Utilizing the cerebellar progenitor model for the Shh subgroup of medulloblastoma in mice, we show for the first time that YB-1 is induced by Shh in CGNPs. Its expression is YAP-dependent and it is required for IGF2 expression in CGNPs. Finally, both gain-of function and loss-of-function experiments reveal that YB-1 activity is required for sustaining CGNP and medulloblastoma cell (MBC) proliferation. Collectively, our findings describe a novel role for YB-1 in driving proliferation in the developing cerebellum and MBCs and they identify the SHH:YAP:YB1:IGF2 axis as a powerful target for therapeutic intervention in medulloblastomas.	[Dey, A.; Maier, C.; Malhotra, A.; Kenney, A. M.] Emory Univ, Dept Pediat Oncol, 1760 Haygood Dr,Suite E390, Atlanta, GA 30322 USA; [Robitaille, M.; Angers, S.] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON, Canada; [Robitaille, M.; Angers, S.] Univ Toronto, Fac Med, Dept Biochem, Toronto, ON, Canada; [Remke, M.; Taylor, M. D.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON, Canada; [Gregorieff, A.; Wrana, J. L.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Syst Biol, Toronto, ON, Canada	Emory University; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Kenney, AM (corresponding author), Emory Univ, Dept Pediat Oncol, 1760 Haygood Dr,Suite E390, Atlanta, GA 30322 USA.	anna.kenney@emory.edu	Angers, Stephane/E-1432-2014; Robitaille, Melanie/ABA-5861-2020; Wrana, Jeffrey/F-8857-2013	Angers, Stephane/0000-0001-7241-9044; Robitaille, Melanie/0000-0001-9354-5162; Malhotra, Anshu/0000-0002-0255-2680; Dey, Abhinav/0000-0003-0412-6236; Roe, Caroline/0000-0003-4680-9553; Taylor, Michael/0000-0001-7009-3466; Remke, Marc/0000-0002-9404-9993	NIH [NINDS R01 NS061070]; CURE Childhood Cancer Foundation; Winship Cancer Institute (P30 center grant) [CA138292]; Alex Lemonade Stand Foundation; Northwestern Mutual Foundation; Integrated Cellular Imaging (ICI) core at Emory University; NATIONAL CANCER INSTITUTE [P30CA138292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CURE Childhood Cancer Foundation; Winship Cancer Institute (P30 center grant); Alex Lemonade Stand Foundation; Northwestern Mutual Foundation; Integrated Cellular Imaging (ICI) core at Emory University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful for the resources available from the Winship Cancer Institute (WCI)Pathology Core Lab for paraffin embedding of tissues. We acknowledge the assistance provided by Neil Anthony (Integrated Imaging Core, Emory University) during image acquisition and analysis. We thank Tobey Macdonald, Matthew Schniederjan and Megan Hamling from Children's Healthcare of Atlanta (CHOA) for providing human medulloblastoma tissue sections. We also thank Daniel Brat and Carol Tucker-Burden for assistance in slice culture experiments. We greatly appreciate the suggestions and feedback from Nada Jabado, Dan Brat, Sandra Dunn, Tracy Ann-Read, Renee Read and Tamara Caspary. This work has been supported by grants to AMK from the NIH (NINDS R01 NS061070), CURE Childhood Cancer Foundation and Winship Cancer Institute (P30 center grant-CA138292). AD acknowledges Alex Lemonade Stand Foundation and Northwestern Mutual Foundation for Young Investigator Award and Imaging studies were supported by a pilot grant to AD from the Integrated Cellular Imaging (ICI) core at Emory University.	Bai CB, 2002, DEVELOPMENT, V129, P4753; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bhatia B, 2009, CANCER RES, V69, P7224, DOI 10.1158/0008-5472.CAN-09-1299; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Chowdhury RP, 2007, J BACTERIOL, V189, P8973, DOI 10.1128/JB.01222-07; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dolfini D, 2013, CELL DEATH DIFFER, V20, P676, DOI 10.1038/cdd.2013.13; Eberhart CG, 2008, CANCER CELL, V14, P105, DOI 10.1016/j.ccr.2008.07.011; Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049; En-Nia A, 2005, J BIOL CHEM, V280, P7702, DOI 10.1074/jbc.M413353200; Faury D, 2007, J CLIN ONCOL, V25, P1196, DOI 10.1200/JCO.2006.07.8626; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Gu CD, 2001, ANTICANCER RES, V21, P2357; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Homer C, 2005, ONCOGENE, V24, P8314, DOI 10.1038/sj.onc.1208998; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Huang JX, 2005, INT J ONCOL, V26, P607; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jung K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-328; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Lasham A, 2013, BIOCHEM J, V449, P11, DOI 10.1042/BJ20121323; Lee J, 1997, DEVELOPMENT, V124, P2537; LEE JE, 1990, DEVELOPMENT, V110, P151; Lossi L, 2009, PROG NEUROBIOL, V88, P221, DOI 10.1016/j.pneurobio.2009.01.002; Mainwaring LA, 2011, ONCOGENE, V30, P1784, DOI 10.1038/onc.2010.564; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Mill P, 2005, DEV CELL, V9, P293, DOI 10.1016/j.devcel.2005.05.009; Miwa A, 2006, BBA-GEN SUBJECTS, V1760, P1675, DOI 10.1016/j.bbagen.2006.08.027; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Pham NV, 1998, BRAIN RES, V810, P1, DOI 10.1016/S0006-8993(98)00783-5; Pomeroy SL, 2011, FUTURE ONCOL, V7, P327, DOI [10.2217/FON.11.15, 10.2217/fon.11.15]; Reginensi A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003380; Reiss Krzysztof, 2002, Expert Opin Ther Targets, V6, P539, DOI 10.1517/14728222.6.5.539; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; Rubinstein DB, 2002, CANCER RES, V62, P4985; SABATH DE, 1990, J BIOL CHEM, V265, P12671; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; Shih DJH, 2014, J CLIN ONCOL, V32, P886, DOI 10.1200/JCO.2013.50.9539; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Tiberi L, 2014, CANCER CELL, V26, P797, DOI 10.1016/j.ccell.2014.10.021; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Uchiumi T, 2006, J BIOL CHEM, V281, P40440, DOI 10.1074/jbc.M605948200; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wu Joyce, 2007, Transl Oncogenomics, V2, P49; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yahata H, 2002, J CANCER RES CLIN, V128, P621, DOI 10.1007/s00432-002-0386-6; Zhang C, 2003, DEVELOPMENT, V130, P5609, DOI 10.1242/dev.00798	75	22	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4256	4268		10.1038/onc.2015.491	http://dx.doi.org/10.1038/onc.2015.491			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26725322	Green Accepted			2022-12-28	WOS:000382149800010
J	Garcia-Limones, C; Lara-Chica, M; Jimenez-Jimenez, C; Perez, M; Moreno, P; Munoz, E; Calzado, MA				Garcia-Limones, C.; Lara-Chica, M.; Jimenez-Jimenez, C.; Perez, M.; Moreno, P.; Munoz, E.; Calzado, M. A.			CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2	ONCOGENE			English	Article							BETA-CATENIN DEGRADATION; DNA-DAMAGE CHECKPOINT; PROLYL-HYDROXYLASES; APOPTOTIC RESPONSE; MURINE HOMOLOGS; CANCER-THERAPY; STRAND BREAKS; KINASE CHK2; PHOSPHORYLATION; HYPOXIA	The serine threonine checkpoint kinase 2 (CHK2) is a critical protein involved in the DNA damage-response pathway, which is activated by phosphorylation inducing cellular response such as DNA repair, cell-cycle regulation or apoptosis. Although CHK2 activation mechanisms have been amply described, very little is known about degradation control processes. In the present study, we identify the ubiquitin E3 ligase SIAH2 as an interaction partner of CHK2, which mediates its ubiquitination and proteasomal degradation. CHK2 degradation is independent of both its activation and its kinase activity, but also of the phosphorylation in S456. We show that SIAH2-deficient cells present CHK2 accumulation together with lower ubiquitination levels. Accordingly, SIAH2 depletion by siRNA increases CHK2 levels. In response to DNA damage induced by etoposide, interaction between both proteins is disrupted, thus avoiding CHK2 degradation and promoting its stabilization. We also found that CHK2 phosphorylates SIAH2 at three residues (Thr26, Ser28 and Thr119), modifying its ability to regulate certain substrates. Cellular arrest in the G2/M phase induced by DNA damage is reverted by SIAH2 expression through the control of CHK2 levels. We observed that hypoxia decreases CHK2 levels in parallel to SIAH2 induction. Similarly, we provide evidence suggesting that resistance to apoptosis induced by genotoxic agents in cells subjected to hypoxia could be partly explained by the mutual regulation between both proteins. These results indicate that SIAH2 regulates CHK2 basal turnover, with important consequences on cell-cycle control and on the ability of hypoxia to alter the DNA damage-response pathway in cancer cells.	[Garcia-Limones, C.; Lara-Chica, M.; Jimenez-Jimenez, C.; Perez, M.; Moreno, P.; Munoz, E.; Calzado, M. A.] Univ Reina Sofia, Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC Hosp, Dept Cell Biol Physiol & Immunol, Cordoba, Spain	Universidad de Cordoba	Calzado, MA (corresponding author), Inst Maimonides Invest Biomed Cordoba IMIBIC, Dept Biol Celular Fisiol & Inmunol, Avda Menendez Pidal S-N, Cordoba 14004, Spain.	mcalzado@uco.es	Munoz, Eduardo/I-5225-2012; Lara Chica, Maribel/GRF-0887-2022; Calzado, Marco A./S-2295-2019	Munoz, Eduardo/0000-0001-8478-5842; Calzado, Marco A./0000-0002-5338-535X; Lara-Chica, Maribel/0000-0003-2908-9929; MORENO, PAULA/0000-0003-4403-7035	FPU fellowship from Ministerio de Educacion [FPU13/03393]; MICINN [SAF2010-17122]; Consejeria de Salud (Junta de Andalucia) [PI-0650-2010, PI-0246-2013]; Instituto de Salud Carlos III grants [PIE14/00005-FLEXI-MET]	FPU fellowship from Ministerio de Educacion(German Research Foundation (DFG)); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Consejeria de Salud (Junta de Andalucia)(Junta de Andalucia); Instituto de Salud Carlos III grants(Instituto de Salud Carlos III)	We thank David Bowtell, Andreas Moller, ML Schmitz, H Piwnica-Worms, Stephen J Elledge, David F Stern, Frank S Lee, Carol Prives, S-Y Shieh, Laura Zannini and Domenico Delia for providing material. MLC was supported by a FPU fellowship (FPU13/03393) from Ministerio de Educacion. This work was supported by MICINN (SAF2010-17122), Consejeria de Salud (Junta de Andalucia) (PI-0650-2010 and PI-0246-2013) and Instituto de Salud Carlos III (PIE14/00005-FLEXI-MET) grants.	Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Bohgaki M, 2013, CELL DEATH DIFFER, V20, P812, DOI 10.1038/cdd.2013.7; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Carlessi L, 2010, BBA-MOL CELL RES, V1803, P1213, DOI 10.1016/j.bbamcr.2010.06.002; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Choi SY, 2013, NUCLEIC ACIDS RES, V41, P2180, DOI 10.1093/nar/gks1319; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Feng L, 2012, NAT STRUCT MOL BIOL, V19, P201, DOI 10.1038/nsmb.2211; FRANKENBERGSCHWAGER M, 1991, RADIAT RES, V128, P243, DOI 10.2307/3578046; Frasor J, 2005, P NATL ACAD SCI USA, V102, P13153, DOI 10.1073/pnas.0502782102; Freeman AK, 2010, CELL CYCLE, V9, P736, DOI 10.4161/cc.9.4.10613; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gibson SL, 2005, CANCER RES, V65, P10734, DOI 10.1158/0008-5472.CAN-05-1160; Guo X, 2010, J BIOL CHEM, V285, P33348, DOI 10.1074/jbc.M110.149609; Holloway AJ, 1997, GENOMICS, V41, P160, DOI 10.1006/geno.1997.4642; House CM, 2009, CANCER RES, V69, P8835, DOI 10.1158/0008-5472.CAN-09-1676; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Kass EM, 2007, J BIOL CHEM, V282, P30311, DOI 10.1074/jbc.M704642200; Kass EM, 2009, CELL CYCLE, V8, P430, DOI 10.4161/cc.8.3.7624; Khurana A, 2006, J BIOL CHEM, V281, P35316, DOI 10.1074/jbc.M606568200; Kirkin V, 2011, CURR OPIN GENET DEV, V21, P21, DOI 10.1016/j.gde.2010.10.004; Knauer SK, 2015, CYTOKINE GROWTH F R, V26, P405, DOI 10.1016/j.cytogfr.2015.04.002; Le Moan N, 2011, MOL CELL, V44, P476, DOI 10.1016/j.molcel.2011.08.033; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Li SH, 2002, MOL CELL BIOL, V22, P6854, DOI 10.1128/MCB.22.19.6854-6865.2002; Liao YL, 2013, GENES NUTR, V8, P69, DOI 10.1007/s12263-012-0297-3; Liu J, 2014, BIOCHIM BIOPHYS ACTA, V1855, P50; Lovly CM, 2008, MOL CELL BIOL, V28, P5874, DOI 10.1128/MCB.00821-08; Lukas C, 2001, CANCER RES, V61, P4990; Ma B, 2015, NAT CELL BIOL, V17, P95, DOI 10.1038/ncb3073; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Munoz MA, 2007, CELL CYCLE, V6, P3070, DOI 10.4161/cc.6.24.5021; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Overgaard J, 2007, J CLIN ONCOL, V25, P4066, DOI 10.1200/JCO.2007.12.7878; Pereg Y, 2006, MOL CELL BIOL, V26, P6819, DOI 10.1128/MCB.00562-06; Perez M, 2012, J MOL CELL BIOL, V4, P316, DOI 10.1093/jmcb/mjs047; Sarkar TR, 2012, MOL CELL BIOL, V32, P320, DOI 10.1128/MCB.05790-11; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Soler-Torronteras R, 2014, BBA-MOL CELL RES, V1843, P2730, DOI 10.1016/j.bbamcr.2014.07.005; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stracker TH, 2009, DNA REPAIR, V8, P1047, DOI 10.1016/j.dnarep.2009.04.012; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Taira N, 2010, J BIOL CHEM, V285, P4909, DOI 10.1074/jbc.M109.042341; Terris DJ, 2002, ARCH OTOLARYNGOL, V128, P698, DOI 10.1001/archotol.128.6.698; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wong CSF, 2013, CANCER RES, V73, P2400, DOI 10.1158/0008-5472.CAN-12-4348; Xie W, 2009, J CELL MOL MED, V13, P1719, DOI 10.1111/j.1582-4934.2008.00423.x; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zannini L, 2014, J MOL CELL BIOL, V6, P442, DOI 10.1093/jmcb/mju045; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhao HL, 2010, BIOCHEM BIOPH RES CO, V399, P623, DOI 10.1016/j.bbrc.2010.07.127	67	18	20	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4289	4301		10.1038/onc.2015.495	http://dx.doi.org/10.1038/onc.2015.495			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26751770				2022-12-28	WOS:000382152100001
J	Ingthorsson, S; Andersen, K; Hilmarsdottir, B; Maelandsmo, GM; Magnusson, MK; Gudjonsson, T				Ingthorsson, S.; Andersen, K.; Hilmarsdottir, B.; Maelandsmo, G. M.; Magnusson, M. K.; Gudjonsson, T.			HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; MYOEPITHELIAL CELLS; ERBB RECEPTORS; CLAUDIN-LOW; CANCER; DIFFERENTIATION; EXPRESSION; TRANSFORMATION; ENDOCYTOSIS; HIERARCHY	The members of the epidermal growth factor receptor (EGFR) kinase family are important players in breast morphogenesis and cancer. EGFR2/HER2 and EGFR expression have a prognostic value in certain subtypes of breast cancer such as HER2-amplified, basal-like and luminal type B. Many clinically approved small molecular inhibitors and monoclonal antibodies have been designed to target HER2, EGFR or both. There is, however, still limited knowledge on how the two receptors are expressed in normal breast epithelium, what effects they have on cellular differentiation and how they participate in neoplastic transformation. D492 is a breast epithelial cell line with stem cell properties that can undergo epithelial to mesenchyme transition (EMT), generate luminal-and myoepithelial cells and form complex branching structures in three-dimensional (3D) culture. Here, we show that overexpression of HER2 in D492 (D492(HER2)) resulted in EMT, loss of contact growth inhibition and increased oncogenic potential in vivo. HER2 overexpression, furthermore, inhibited endogenous EGFR expression. Re-introducing EGFR in D492(HER2) (D492(HER2/EGFR)) partially reversed the mesenchymal state of the cells, as an epithelial phenotype reappeared both in 3D cultures and in vivo. The D492(HER2/EGFR) xenografts grow slower than the D492HER2 tumors, while overexpression of EGFR alone (D492(EGFR)) was not oncogenic in vivo. Consistent with the EGFR-mediated epithelial phenotype, overexpression of EGFR drove the cells toward a myoepithelial phenotype in 3D culture. The effect of two clinically approved anti-HER2 and EGFR therapies, trastuzumab and cetuximab, was tested alone and in combination on D492HER2 xenografts. While trastuzumab had a growth inhibitory effect compared with untreated control, the effect of cetuximab was limited. When administered in combination, the growth inhibitory effect of trastuzumab was less pronounced. Collectively, our data indicate that in HER2-overexpressing D492 cells, EGFR can behave as a tumor suppressor, by pushing the cells towards epithelial differentiation.	[Ingthorsson, S.; Hilmarsdottir, B.; Magnusson, M. K.; Gudjonsson, T.] Univ Iceland, Biomed Ctr, Stem Cell Res Unit, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Ingthorsson, S.; Hilmarsdottir, B.; Magnusson, M. K.; Gudjonsson, T.] Landspitali Univ Hosp, Dept Haematol Lab, Reykjavik, Iceland; [Andersen, K.; Maelandsmo, G. M.] Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, Oslo, Norway; [Andersen, K.; Maelandsmo, G. M.] Norwegian Radium Hosp, Oslo Univ Hosp, Canc Stem Cell Innovat Ctr, Oslo, Norway; [Maelandsmo, G. M.] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Breast Canc Res, Oslo, Norway; [Magnusson, M. K.] Univ Iceland, Dept Pharmacol & Toxicol, Reykjavik, Iceland	University of Iceland; Landspitali National University Hospital; University of Oslo; University of Oslo; University of Oslo; University of Iceland	Gudjonsson, T (corresponding author), Univ Iceland, Biomed Ctr, Stem Cell Res Unit, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland.	tgudjons@hi.is	Mælandsmo, Gunhild Mari/AFV-4446-2022; Hilmarsdottir, Bylgja/AAV-7406-2020	Gudjonsson, Thorarinn/0000-0001-9645-9665; Hilmarsdottir, Bylgja/0000-0001-8693-5541; Ingthorsson, Saevar/0000-0001-8480-9680	Landspitali University Hospital Science Fund; University of Iceland Research Fund; Science and Technology Policy Council Research Fund; Grant of Excellence, 'Gongum saman'	Landspitali University Hospital Science Fund; University of Iceland Research Fund; Science and Technology Policy Council Research Fund; Grant of Excellence, 'Gongum saman'	This work was supported from Landspitali University Hospital Science Fund, University of Iceland Research Fund, Science and Technology Policy Council Research Fund and Grant of Excellence, 'Gongum saman', a supporting group for breast cancer research in Iceland. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We are grateful to Petros Gebregziabher and Alexandr Kristian for advicing on and performing the in vivo experiments.	Balk-Moller E, 2014, AM J PATHOL, V184, P1198, DOI 10.1016/j.ajpath.2013.12.013; Barsky SH, 2005, J MAMMARY GLAND BIOL, V10, P249, DOI 10.1007/s10911-005-9585-5; Baulida J, 1996, J BIOL CHEM, V271, P5251; Carpenter RL, 2014, ONCOGENE, V34, P546; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Davis NM, 2014, ONCOTARGET, V5, P4603, DOI 10.18632/oncotarget.2209; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Flageng MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074618; Forster N, 2014, DEV CELL, V28, P147, DOI 10.1016/j.devcel.2013.11.019; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Gudjonsson T, 2002, J CELL SCI, V115, P39; Guth U, 2014, BREAST, V23, P26, DOI 10.1016/j.breast.2013.10.007; Gupta P, 2014, MOL ONCOL, V8, P1532, DOI 10.1016/j.molonc.2014.06.006; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartman Z, 2013, ONCOGENE, V32, P4169, DOI 10.1038/onc.2012.418; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hilmarsdottir B, 2015, DEV BIOL, V403, P150, DOI 10.1016/j.ydbio.2015.05.007; Hilmarsdottir B, 2014, GENES-BASEL, V5, P804, DOI 10.3390/genes5030804; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Ingthorsson Saevar, 2010, BMC Res Notes, V3, P184, DOI 10.1186/1756-0500-3-184; Jenndahl LE, 2005, INT J ONCOL, V27, P439; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee K, 2011, EMBO J, V30, P2662, DOI 10.1038/emboj.2011.159; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Moyret-Lalle C, 2014, WORLD J CLIN ONCOL, V5, P311, DOI 10.5306/wjco.v5.i3.311; Nakagawa M, 2012, BREAST CANCER-TOKYO, V19, P54, DOI 10.1007/s12282-011-0265-6; Oakes SR, 2014, CELL MOL LIFE SCI, V71, P4301, DOI 10.1007/s00018-014-1674-4; Ortega-Cava Cesar F, 2011, J Carcinog, V10, P29, DOI 10.4103/1477-3163.90443; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinhel I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3145; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Sabatier R, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-228; Schneider MR, 2016, ONCOGENE, V35, P2949, DOI 10.1038/onc.2015.372; Sigurdsson V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023833; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sobande Folakemi, 2015, Cesk Patol, V51, P80; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081; Zhang MH, 2014, BIOMED REP, V2, P41, DOI 10.3892/br.2013.187; Zwang Yaara, 2009, Traffic, V10, P349, DOI 10.1111/j.1600-0854.2008.00870.x	49	47	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4244	4255		10.1038/onc.2015.489	http://dx.doi.org/10.1038/onc.2015.489			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26686087	hybrid, Green Published			2022-12-28	WOS:000382149800009
J	Melo, CA; Leveille, N; Rooijers, K; Wijchers, PJ; Geeven, G; Tal, A; Melo, SA; de Laat, W; Agami, R				Melo, C. A.; Leveille, N.; Rooijers, K.; Wijchers, P. J.; Geeven, G.; Tal, A.; Melo, S. A.; de Laat, W.; Agami, R.			A p53-bound enhancer region controls a long intergenic noncoding RNA required for p53 stress response	ONCOGENE			English	Article							CHROMATIN INTERACTIONS; GENE-EXPRESSION; HUMAN-CELLS; GENOME; TRANSCRIPTION; CANCER; CONFORMATION; REPRESSION; OCCUPANCY; LNCRNA	Genome-wide chromatin studies identified the tumor suppressor p53 as both a promoter and an enhancer-binding transcription factor. As an enhancer factor, p53 can induce local production of enhancer RNAs, as well as transcriptional activation of distal neighboring genes. Beyond the regulation of protein-coding genes, p53 has the capacity to regulate long intergenic noncoding RNA molecules (lincRNAs); however, their importance to the p53 tumor suppressive function remains poorly characterized. Here, we identified and characterized a novel p53-bound intronic enhancer that controls the expression of its host, the lincRNA00475 (linc-475). We demonstrate the requirement of linc-475 for the proper induction of a p53-dependent cell cycle inhibitory response. We further confirm the functional importance of linc-475 in the maintenance of CDKN1A/p21 levels, a cell cycle inhibitor and a major p53 target gene, following p53 activation. Interestingly, loss of linc-475 reduced the binding of both p53 and RNA polymerase II (RNAPII) to the promoter of p21, attenuating its transcription rate following p53 activation. Altogether, our data suggest a direct role of p53-bound enhancer domains in the activation of lincRNAs required for an efficient p53 transcriptional response.	[Melo, C. A.; Leveille, N.; Rooijers, K.; Tal, A.; Agami, R.] Netherlands Canc Inst, Div Biol Stress Response, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Wijchers, P. J.; Geeven, G.; de Laat, W.] Hubrecht Inst KNAW, Utrecht, Netherlands; [Wijchers, P. J.; Geeven, G.; de Laat, W.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Melo, S. A.] Univ Porto IPATIMUP, Inst Invest & Inovacao Saude, Inst Pathol & Mol Immunol, Univ Porto, Oporto, Portugal; [Agami, R.] Rotterdam Univ, Dept Genet, Erasmus MC, Rotterdam, Netherlands	Netherlands Cancer Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Erasmus University Rotterdam; Erasmus MC	Leveille, N; Agami, R (corresponding author), Netherlands Canc Inst, Div Biol Stress Response, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	n.leveille@nki.nl; r.agami@nki.nl	agami, reuven/GOG-8289-2022; MELO, SONIA/H-8972-2013	Guedes, Carlos/0000-0001-9648-0560; Geeven, Geert/0000-0002-5603-0095; Rooijers, Koos/0000-0002-0412-468X; MELO, SONIA/0000-0002-2291-4263; de Laat, Wouter/0000-0002-6393-595X; Leveille, Nicolas/0000-0002-6086-5984; Agami, Reuven/0000-0002-2848-2473				Abdelmohsen K, 2013, AGING CELL, V12, P890, DOI 10.1111/acel.12115; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; de Leeuw J, 2009, J STAT SOFTW, V32, P1; De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Grossi E, 2016, BBA-GENE REGUL MECH, V1859, P200, DOI 10.1016/j.bbagrm.2015.07.011; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Kumar PP, 2014, ELIFE, V3, DOI 10.7554/eLife.02805; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lazorthes S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6971; Leveille N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7520; Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210; Marin-Bejar O, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r104; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Rippe K, 2001, TRENDS BIOCHEM SCI, V26, P733, DOI 10.1016/S0968-0004(01)01978-8; Sanchez Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6812; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schaukowitch K, 2014, MOL CELL, V56, P29, DOI 10.1016/j.molcel.2014.08.023; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682; Splinter E, 2011, EMBO J, V30, P4345, DOI 10.1038/emboj.2011.344; Splinter E, 2011, GENE DEV, V25, P1371, DOI 10.1101/gad.633311; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Zhou X, 2013, NAT METHODS, V10, P375, DOI 10.1038/nmeth.2440; Zuin J, 2014, P NATL ACAD SCI USA, V111, P996, DOI 10.1073/pnas.1317788111	38	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4399	4406		10.1038/onc.2015.502	http://dx.doi.org/10.1038/onc.2015.502			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26776159				2022-12-28	WOS:000382152100011
J	Heinicke, U; Kupka, J; Fichter, I; Fulda, S				Heinicke, U.; Kupka, J.; Fichter, I.; Fulda, S.			Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; QUISINOSTAT JNJ-26481585; CANCER; VORINOSTAT; LYMPHOMA; CHILDREN; CELLS; CHEMOTHERAPY; FREQUENCY; CASPASE-8	JNJ-26481585 is a second-generation histone deacetylase inhibitor with broad-range efficacy and improved pharmacodynamic properties. In the present study, we investigated the therapeutic potential of JNJ-26481585 and its molecular mechanisms of action in rhabdomyosarcoma (RMS). Here, we report that JNJ-26481585's anticancer activity critically depends on an intact mitochondrial pathway of apoptosis. JNJ-26481585 induces apoptosis and also inhibits long-term clonogenic survival of several RMS cell lines at nanomolar concentrations that cause histone acetylation. Importantly, JNJ-26481585 significantly suppresses tumor growth in vivo in two preclinical RMS models, that is, the chorioallantoic membrane model and a xenograft mouse model. Mechanistically, we identify activation of the mitochondrial pathway of apoptosis as a key event that is critically required for JNJ-26481585-mediated cell death. JNJ-26481585 upregulates expression levels of several BH3-only proteins including Bim, Puma and Noxa, which all contribute to JNJ-26481585-mediated apoptosis, as knockdown of Bim, Puma or Noxa significantly inhibits cell death. This shift toward proapoptotic Bcl-2 proteins promotes activation of Bax and Bak as a critical event, as genetic silencing of Bax or Bak protects against JNJ-26481585-induced apoptosis. Intriguingly, rescue experiments reveal that JNJ-26481585 triggers Bax/Bak activation independently of caspase activation and activates caspase-9 as the initiator caspase in the cascade, as Bcl-2 overexpression, but not the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) blocks JNJ-26481585-induced Bax/Bak activation and caspase-9 cleavage. In conclusion, JNJ-26481585 exerts potent antitumor activity against RMS in vitro and in vivo by engaging mitochondrial apoptosis before caspase activation and represents a promising therapeutic for further investigation in RMS.	[Heinicke, U.; Kupka, J.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany; [Fichter, I.] Expt Pharmacol & Oncol GmbH, Berlin, Germany; [Fulda, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Fulda, S.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	BMBF; Deutsche Kinderkrebsstiftung	BMBF(Federal Ministry of Education & Research (BMBF)); Deutsche Kinderkrebsstiftung	We thank C. Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the BMBF and the Deutsche Kinderkrebsstiftung (to SF).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078-0432.CCR-09-0547; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Carol H, 2014, PEDIATR BLOOD CANCER, V61, P245, DOI 10.1002/pbc.24724; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466; Deleu S, 2009, LEUKEMIA, V23, P1894, DOI 10.1038/leu.2009.121; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; FELIX CA, 1992, CANCER RES, V52, P2243; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Graab U, 2015, ONCOTARGET, V6, P8722, DOI 10.18632/oncotarget.2726; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Happo L, 2012, J CELL SCI, V125, P1081, DOI 10.1242/jcs.090514; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Heinicke U, 2014, CANCER LETT, V351, P50, DOI 10.1016/j.canlet.2014.04.021; Inoue S, 2007, LEUKEMIA, V21, P1773, DOI 10.1038/sj.leu.2404760; Labi V, 2008, J EXP MED, V205, P641, DOI 10.1084/jem.20071658; Matthews GM, 2012, ADV CANCER RES, V116, P165, DOI 10.1016/B978-0-12-394387-3.00005-7; MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W; Sarosiek KA, 2013, MOL CELL, V51, P751, DOI 10.1016/j.molcel.2013.08.048; Stuhmer T, 2010, BRIT J HAEMATOL, V149, P529, DOI 10.1111/j.1365-2141.2010.08126.x; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Venugopal B, 2013, CLIN CANCER RES, V19, P4262, DOI 10.1158/1078-0432.CCR-13-0312; Vogler M, 2009, CANCER RES, V69, P2425, DOI 10.1158/0008-5472.CAN-08-2436; Wiegmans AP, 2011, CANCER RES, V71, P3603, DOI 10.1158/0008-5472.CAN-10-3289; Witt O, 2012, KLIN PADIATR, V224, P398, DOI 10.1055/s-0032-1323692; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Xargay-Torrent S, 2011, CLIN CANCER RES, V17, P3956, DOI 10.1158/1078-0432.CCR-10-3412	35	26	26	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3729	3741		10.1038/onc.2015.440	http://dx.doi.org/10.1038/onc.2015.440			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26616861				2022-12-28	WOS:000379622800011
J	Zhao, X; Li, D; Pu, J; Mei, H; Yang, D; Xiang, X; Qu, H; Huang, K; Zheng, L; Tong, Q				Zhao, X.; Li, D.; Pu, J.; Mei, H.; Yang, D.; Xiang, X.; Qu, H.; Huang, K.; Zheng, L.; Tong, Q.			CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression	ONCOGENE			English	Article							MATRIX-METALLOPROTEINASE 14; GASTRIC-CANCER CELLS; HUMAN P53 GENE; N-MYC; TUMOR-SUPPRESSOR; NEURONAL DIFFERENTIATION; AMPLIFIED NEUROBLASTOMA; CONDITIONAL EXPRESSION; EPIGENETIC REGULATION; TRANSCRIPTION FACTOR	Previous studies have indicated the important roles of MYCN in tumorigenesis and progression of neuroblastoma (NB), the most common extracranial solid tumor derived from neural crest in childhood. However, the regulatory mechanisms of MYCN expression in NB still remain largely unknown. In this study, through mining public microarray databases and analyzing the cis-regulatory elements and chromatin immunoprecipitation data sets, we identified CCCTC-binding factor (CTCF) as a crucial transcription factor facilitating the MYCN expression in NB. RNA immunoprecipitation, RNA electrophoretic mobility shift assay, RNA pull down and in vitro binding assay indicated the physical interaction between CTCF and MYCN opposite strand (MYCNOS), a natural noncoding RNA surrounding the MYNC promoter. Gain- and loss-of-function studies revealed that MYCNOS facilitated the recruitment of CTCF to its binding sites within the MYCN promoter to induce chromatin remodeling, resulting in enhanced MYCN levels and altered downstream gene expression, in cultured NB cell lines. CTCF cooperated with MYCNOS to suppress the differentiation and promote the growth, invasion and metastasis of NB cells in vitro and in vivo. In clinical NB tissues and cell lines, CTCF and MYCNOS were upregulated and positively correlated with MYCN expression. CTCF was an independent prognostic factor for unfavorable outcome of NB, and patients with high MYCNOS expression had lower survival probability. Taken together, these results demonstrate that CTCF cooperates with noncoding RNA MYCNOS to exhibit oncogenic activity that affects the aggressiveness and progression of NB through transcriptional upregulation of MYCN.	[Zhao, X.; Li, D.; Pu, J.; Mei, H.; Yang, D.; Xiang, X.; Qu, H.; Tong, Q.] Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat Surg, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China; [Huang, K.; Zheng, L.; Tong, Q.] Huazhong Univ Sci & Technol, Union Hosp, Clin Ctr Human Genom Res, Tongji Med Coll, Wuhan, Peoples R China; [Huang, K.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China; [Zheng, L.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, Wuhan 430022, Hubei Province, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Tong, Q (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat Surg, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China.; Zheng, L (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, Wuhan 430022, Hubei Province, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com	Tong, Qiangsong/B-4500-2014; Zhao, Xiang/AAL-6578-2020	Tong, Qiangsong/0000-0002-2615-6404; Zhao, Xiang/0000-0002-5332-4602	National Natural Science Foundation of China [81272779, 81372667, 81372401, 81472363, 81402301, 81402408, 81572423]; Fundamental Research Funds for the Central Universities [2012QN224, 2013ZHYX003, 01-18-530112, 01-18-530115]; Natural Science Foundation of Hubei Province [2014CFA012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province)	We are grateful to Drs William L Carroll and Danny Reinberg for providing vectors. This work was supported by the National Natural Science Foundation of China (81272779, 81372667, 81372401, 81472363, 81402301, 81402408, 81572423), Fundamental Research Funds for the Central Universities (2012QN224, 2013ZHYX003, 01-18-530112, 01-18-530115) and Natural Science Foundation of Hubei Province (2014CFA012).	ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; Bell E, 2010, CANCER LETT, V293, P144, DOI 10.1016/j.canlet.2010.01.015; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chernukhin IV, 2000, J BIOL CHEM, V275, P29915, DOI 10.1074/jbc.M001538200; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; De la Rosa-Velazquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024; Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Hasan MK, 2013, SCI REP-UK, V3, DOI 10.1038/srep03450; Henriksen JR, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-1; Huang KM, 2013, J BIOL CHEM, V288, P26067, DOI 10.1074/jbc.M113.486175; Inge TH, 2002, SURGERY, V132, P232, DOI 10.1067/msy.2002.125387; Jacobs JFM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-239; Jiang GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031379; Kaneko Y, 2015, CANCER SCI, V106, P840, DOI 10.1111/cas.12677; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; Li D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0320-6; Li D, 2013, ONCOTARGET, V4, P2021, DOI 10.18632/oncotarget.1579; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Liu PY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju113; Loven J, 2010, P NATL ACAD SCI USA, V107, P1553, DOI 10.1073/pnas.0913517107; Lutz W, 1996, ONCOGENE, V13, P803; Michel AM, 2014, NUCLEIC ACIDS RES, V42, pD859, DOI 10.1093/nar/gkt1035; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Pandey GK, 2014, CANCER CELL, V26, P722, DOI 10.1016/j.ccell.2014.09.014; Pession A, 2005, CURR CANCER DRUG TAR, V5, P273, DOI 10.2174/1568009054064606; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Qu HX, 2015, HUM MOL GENET, V24, P2539, DOI 10.1093/hmg/ddv018; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Saldana-Meyer R, 2014, GENE DEV, V28, P723, DOI 10.1101/gad.236869.113; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Shoji W, 2015, BIOCHEM BIOPH RES CO, V461, P501, DOI 10.1016/j.bbrc.2015.04.050; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509; Suenaga Y, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1003996; Suenaga Y, 2009, BIOCHEM BIOPH RES CO, V390, P21, DOI 10.1016/j.bbrc.2009.09.044; Sun S, 2013, CELL, V153, P1537, DOI 10.1016/j.cell.2013.05.028; Tanaka N, 2008, INT J ONCOL, V33, P815, DOI 10.3892/ijo_00000069; Tee AE, 2014, ONCOTARGET, V5, P1793, DOI 10.18632/oncotarget.1785; Thomas WD, 2004, INT J BIOCHEM CELL B, V36, P771, DOI 10.1016/S1357-2725(03)00254-1; Vance KW, 2014, EMBO J, V33, P296, DOI 10.1002/embj.201386225; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060; Yu M, 2009, INT J ONCOL, V34, P931, DOI 10.3892/ijo_00000219; Zhang H, 2014, ONCOGENE, V33, P387, DOI 10.1038/onc.2012.574; Zhang HY, 2012, MOL CANCER THER, V11, P1454, DOI 10.1158/1535-7163.MCT-12-0001; Zhang XH, 1999, ANTICANCER RES, V19, P1641; Zheng LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055719; Zheng LD, 2013, MOL CANCER RES, V11, P182, DOI 10.1158/1541-7786.MCR-12-0534; Zheng LD, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-74; Zheng LD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-33	56	54	55	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3565	3576		10.1038/onc.2015.422	http://dx.doi.org/10.1038/onc.2015.422			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26549029				2022-12-28	WOS:000379621500009
J	Sanchez-Lopez, E; Flashner-Abramson, E; Shalapour, S; Zhong, Z; Taniguchi, K; Levitzki, A; Karin, M				Sanchez-Lopez, E.; Flashner-Abramson, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Levitzki, A.; Karin, M.			Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling	ONCOGENE			English	Article							FACTOR-I RECEPTOR; COLITIS-ASSOCIATED CANCER; ADENOMATOUS POLYPS; CIRCULATING LEVELS; MOUSE MODEL; GROWTH; TUMORIGENESIS; METASTASIS; ACTIVATION; CELLS	The tumor microenvironment (TME) exerts critical pro-tumorigenic effects through cytokines and growth factors that support cancer cell proliferation, survival, motility and invasion. Insulin-like growth factor-1 (IGF-1) and signal transducer and activator of transcription 3 (STAT3) stimulate colorectal cancer development and progression via cell autonomous and microenvironmental effects. Using a unique inhibitor, NT157, which targets both IGF-1 receptor (IGF-1R) and STAT3, we show that these pathways regulate many TME functions associated with sporadic colonic tumorigenesis in CPC-APC mice, in which cancer development is driven by loss of the Apc tumor suppressor gene. NT157 causes a substantial reduction in tumor burden by affecting cancer cells, cancer-associated fibroblasts (CAF) and myeloid cells. Decreased cancer cell proliferation and increased apoptosis were accompanied by inhibition of CAF activation and decreased inflammation. Furthermore, NT157 inhibited expression of protumorigenic cytokines, chemokines and growth factors, including IL-6, IL-11 and IL-23 as well as CCL2, CCL5, CXCL7, CXCL5, ICAM1 and TGF beta; decreased cancer cell migratory activity and reduced their proliferation in the liver. NT157 represents a new class of anticancer drugs that affect both the malignant cell and its supportive microenvironment.	[Sanchez-Lopez, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Karin, M.] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Sanchez-Lopez, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Karin, M.] Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Flashner-Abramson, E.; Levitzki, A.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel; [Taniguchi, K.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Hebrew University of Jerusalem; Keio University	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.; Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Sanchez-Lopez, Elsa/A-7131-2017	Sanchez-Lopez, Elsa/0000-0002-4236-1985; Zhong, Zhenyu/0000-0002-9441-7645	Sara Borrell fellowship ISCIII/MICINN program; ERC Advanced Grant [249898]; NIH grants [AI043477, CA118165]; NATIONAL CANCER INSTITUTE [R01CA118165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER	Sara Borrell fellowship ISCIII/MICINN program; ERC Advanced Grant(European Research Council (ERC)); NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	ESL was supported by Sara Borrell fellowship ISCIII/MICINN program. SS and ZZ are CRI Irvington postdoctoral fellows. KT is Uehara Memorial Foundation Fellow. AL and EFA were supported by ERC Advanced Grant (249898) to AL. Research was supported by NIH grants (AI043477 and CA118165) to MK, who is an American Cancer Society Research Professor and holds the Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases.	Albanell J, 2001, JNCI-J NATL CANCER I, V93, P1830, DOI 10.1093/jnci/93.24.1830; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chan B, 2008, J MAMMARY GLAND BIOL, V13, P415, DOI 10.1007/s10911-008-9101-9; Chang Q, 2002, CANCER RES, V62, P6035; Esposito DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036190; Feng QY, 2014, WORLD J GASTROENTERO, V20, P4263, DOI 10.3748/wjg.v20.i15.4263; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Huang F, 2012, CLIN CANCER RES, V18, P1156, DOI 10.1158/1078-0432.CCR-11-1135; Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Lee J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103551; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Maeda S, 2009, HEPATOLOGY, V50, P1851, DOI 10.1002/hep.23199; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Ollberding NJ, 2012, CANCER EPIDEM BIOMAR, V21, P810, DOI 10.1158/1055-9965.EPI-11-1105; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Prager GW, 2012, HAMOSTASEOLOGIE, V32, P105, DOI 10.5482/ha-1163; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ramocki NM, 2008, ENDOCRINOLOGY, V149, P261, DOI 10.1210/en.2007-0869; Reuveni H, 2013, CANCER RES, V73, P4383, DOI 10.1158/0008-5472.CAN-12-3385; Rojas A, 2011, ONCOGENE, V30, P2345, DOI 10.1038/onc.2010.605; Ryan PD, 2008, ONCOLOGIST, V13, P16, DOI 10.1634/theoncologist.2007-0199; Schlussel AT, 2014, J GASTROINTEST ONCOL, V5, P326, DOI 10.3978/j.issn.2078-6891.2014.069; Shiratsuchi I, 2011, ANTICANCER RES, V31, P2541; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Soubry A, 2012, INT J CANCER, V131, P512, DOI 10.1002/ijc.26393; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Tang Z, 2008, AM J SURG, V196, P690, DOI 10.1016/j.amjsurg.2008.08.001; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang KP, 2014, IMMUNITY, V41, P1052, DOI 10.1016/j.immuni.2014.11.009; Woodson K, 2004, JNCI-J NATL CANCER I, V96, P407, DOI 10.1093/jnci/djh042; Xiong H, 2014, INT J CANCER, V134, P2030, DOI 10.1002/ijc.28539; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zhou SL, 2014, CARCINOGENESIS, V35, P597, DOI 10.1093/carcin/bgt397; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	50	95	104	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2634	2644		10.1038/onc.2015.326	http://dx.doi.org/10.1038/onc.2015.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364612	Green Submitted, Green Accepted			2022-12-28	WOS:000376165700010
J	Malaterre, J; Pereira, L; Putoczki, T; Millen, R; Paquet-Fifield, S; Germann, M; Liu, J; Cheasley, D; Sampurno, S; Stacker, SA; Achen, MG; Ward, RL; Waring, P; Mantamadiotis, T; Ernst, M; Ramsay, RG				Malaterre, J.; Pereira, L.; Putoczki, T.; Millen, R.; Paquet-Fifield, S.; Germann, M.; Liu, J.; Cheasley, D.; Sampurno, S.; Stacker, S. A.; Achen, M. G.; Ward, R. L.; Waring, P.; Mantamadiotis, T.; Ernst, M.; Ramsay, R. G.			Intestinal-specific activatable Myb initiates colon tumorigenesis in mice	ONCOGENE			English	Article							ADENOID CYSTIC CARCINOMA; C-MYB; COLORECTAL-CANCER; STEM-CELLS; MOUSE MODEL; VASCULAR-PERMEABILITY; EXPRESSION; GROWTH; P27(KIP1); GENES	Transcription factor Myb is overexpressed in most colorectal cancers (CRC). Patients with CRC expressing the highest Myb are more likely to relapse. We previously showed that mono-allelic loss of Myb in an Adenomatous polyposis coli (APC)-driven CRC mouse model (Apc(Min/+)) significantly improves survival. Here we directly investigated the association of Myb with poor prognosis and how Myb co-operates with tumor suppressor genes (TSGs) (Apc) and cell cycle regulator, p27. Here we generated the first intestinal-specific, inducible transgenic model; a MybER transgene encoding a tamoxifen-inducible fusion protein between Myb and the estrogen receptor-a ligand-binding domain driven by the intestinal-specific promoter, Gpa33. This was to mimic human CRC with constitutive Myb activity in a highly tractable mouse model. We confirmed that the transgene was faithfully expressed and inducible in intestinal stem cells (ISCs) before embarking on carcinogenesis studies. Activation of the MybER did not change colon homeostasis unless one p27 allele was lost. We then established that MybER activation during CRC initiation using a pro-carcinogen treatment, azoxymethane (AOM), augmented most measured aspects of ISC gene expression and function and accelerated tumorigenesis in mice. CRC-associated symptoms of patients including intestinal bleeding and anaemia were faithfully mimicked in AOM-treated MybER transgenic mice and implicated hypoxia and vessel leakage identifying an additional pathogenic role for Myb. Collectively, the results suggest that Myb expands the ISC pool within which CRC is initiated while co-operating with TSG loss. Myb further exacerbates CRC pathology partly explaining why high MYB is a predictor of worse patient outcome.	[Malaterre, J.; Pereira, L.; Millen, R.; Paquet-Fifield, S.; Germann, M.; Cheasley, D.; Sampurno, S.; Stacker, S. A.; Achen, M. G.; Ramsay, R. G.] Peter MacCallum Canc Ctr, Differentiat & Transcript Lab, Melbourne, Vic, Australia; [Malaterre, J.; Millen, R.; Cheasley, D.; Stacker, S. A.; Achen, M. G.; Ramsay, R. G.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Putoczki, T.; Cheasley, D.] Walter & Elisa Hall Inst Med Res, Melbourne, Vic, Australia; [Millen, R.; Liu, J.; Ward, R. L.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Waring, P.; Mantamadiotis, T.; Ramsay, R. G.] UNSW Med, Prince Wales Clin Sch, Sydney, NSW, Australia; [Waring, P.; Mantamadiotis, T.; Ramsay, R. G.] UNSW Med, Lowy Canc Res Ctr, Sydney, NSW, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne	Ramsay, RG (corresponding author), Peter MacCallum Canc Ctr, Differentiat & Transcript Lab, East Melbourne, Vic 3002, Australia.	rob.ramsay@petermac.org	Ramsay, Robert G/C-3291-2015; Ernst, Matthias/D-5111-2012; Mantamadiotis, Theo/W-9010-2019; Paquet-Fifield, Sophie/AAL-6410-2021; Mantamadiotis, Theo/AAM-1346-2020; Ward, Robyn/I-2313-2013	Ramsay, Robert G/0000-0001-5003-0433; Ernst, Matthias/0000-0002-6399-1177; Mantamadiotis, Theo/0000-0003-3971-5380; Germann, Markus/0000-0001-8306-6918; Achen, Marc/0000-0002-3791-803X; Ward, Robyn/0000-0002-6877-8906; Stacker, Steven/0000-0003-4096-9273; Cheasley, Dane/0000-0002-1170-4690	NHMRC	NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank the Peter MacCallum Histology and Microscopy departments and animal facility as well as the NHMRC Senior Research Fellowship Scheme (RR, ME) and Program Grant scheme (RGR, JM and ME).	Altemani A, 2013, HISTOPATHOLOGY, V62, P531, DOI 10.1111/j.1365-2559.2013.04352.x; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9; Bell D, 2011, CANCER BIOL THER, V12, P569, DOI 10.4161/cbt.12.7.17008; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; Cheasley D, 2011, STEM CELLS, V29, P2042, DOI 10.1002/stem.761; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Ciznadija D, 2009, CELL DEATH DIFFER, V16, P1530, DOI 10.1038/cdd.2009.94; Coletta PL, 2004, BLOOD, V103, P1050, DOI 10.1182/blood-2003-03-0707; CORBETT TH, 1975, CANCER RES, V35, P2434; Cross RS, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2014.29; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Flentjar N, 2007, GASTROENTEROLOGY, V132, P1410, DOI 10.1053/j.gastro.2007.02.054; Gottschalk AR, 2001, CANCER RES, V61, P2105; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Holstein von SL, 2013, OPHTHALMOLOGY; Hugo H, 2006, GENE CHROMOSOME CANC, V45, P1143, DOI 10.1002/gcc.20378; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kim SY, 2008, ORAL ONCOL, V44, P383, DOI 10.1016/j.oraloncology.2007.05.004; Lin SA, 2011, J GASTROENTEROL, V46, P1039, DOI 10.1007/s00535-011-0424-8; Lutwyche JK, 2006, BIOCHEM BIOPH RES CO, V344, P1300, DOI 10.1016/j.bbrc.2006.04.045; Malaterre J, 2007, P NATL ACAD SCI USA, V104, P3829, DOI 10.1073/pnas.0610055104; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Nagy JA, 2008, ANGIOGENESIS, V11, P109, DOI 10.1007/s10456-008-9099-z; Ouyang DL, 2005, AM J GASTROENTEROL, V100, P1393, DOI 10.1111/j.1572-0241.2005.41427.x; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; POTTEN CS, 1974, CELL TISSUE KINET, V7, P271, DOI 10.1111/j.1365-2184.1974.tb00907.x; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; Ramsay RG, 2005, DNA CELL BIOL, V24, P21, DOI 10.1089/dna.2005.24.21; Ramsay RG, 2003, EXPERT OPIN THER TAR, V7, P235; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Roeb E, 2013, INTERNIST, V54, P242, DOI 10.1007/s00108-012-3184-5; Rothenberg ME, 2012, GASTROENTEROLOGY, V142, P1195, DOI 10.1053/j.gastro.2012.02.006; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Stenman G, 2013, HEAD NECK PATHOL, V7, pS12, DOI 10.1007/s12105-013-0462-z; Stephens PJ, 2013, J CLIN INVEST, V123, P2965, DOI 10.1172/JCI67201; Takeda N, 2011, SCIENCE, V334, P1420, DOI 10.1126/science.1213214; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsutsui S, 2005, CANCER-AM CANCER SOC, V104, P2048, DOI 10.1002/cncr.21471; Umar Shahid, 2010, Curr Gastroenterol Rep, V12, P340, DOI 10.1007/s11894-010-0130-3; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Waldron T, 2012, LEUKEMIA, V26, P644, DOI 10.1038/leu.2011.264; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Williams BB, 2008, CANCER IMMUNOL IMMUN, V57, P1635, DOI 10.1007/s00262-008-0497-2; Xu HL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012112; You SJ, 2006, INT J EXP PATHOL, V87, P227, DOI 10.1111/j.1365-2613.2006.00477.x; Ziskin JL, 2013, GUT, V62, P1012, DOI 10.1136/gutjnl-2011-301195	54	11	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2475	2484		10.1038/onc.2015.305	http://dx.doi.org/10.1038/onc.2015.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26300002	Green Published, hybrid			2022-12-28	WOS:000376165500006
J	Zhang, YW; Nasto, RE; Varghese, R; Jablonski, SA; Serebriiskii, IG; Surana, R; Calvert, VS; Bebu, I; Murray, J; Jin, L; Johnson, M; Riggins, R; Ressom, H; Petricoin, E; Clarke, R; Golemis, EA; Weiner, LM				Zhang, Y-W; Nasto, R. E.; Varghese, R.; Jablonski, S. A.; Serebriiskii, I. G.; Surana, R.; Calvert, V. S.; Bebu, I.; Murray, J.; Jin, L.; Johnson, M.; Riggins, R.; Ressom, H.; Petricoin, E.; Clarke, R.; Golemis, E. A.; Weiner, L. M.			Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation	ONCOGENE			English	Article							INTERACTING PROTEINS; SIGNALING PATHWAYS; RECEPTOR PATHWAY; ER-ALPHA; RESISTANCE; TOB; DATABASE; MUTATIONS; COMPLEXES; APOPTOSIS	Resistance to therapies targeting the estrogen pathway remains a challenge in the treatment of estrogen receptor-positive breast cancer. To address this challenge, a systems biology approach was used. A library of small interfering RNAs targeting an estrogen receptor (ER)- and aromatase-centered network identified 46 genes that are dispensable in estrogen-dependent MCF7 cells, but are selectively required for the survival of estrogen-independent MCF7-derived cells and multiple additional estrogen-independent breast cancer cell lines. Integration of this information identified a tumor suppressor gene TOB1 as a critical determinant of estrogen-independent ER-positive breast cell survival. Depletion of TOB1 selectively promoted G1 phase arrest and sensitivity to AKT and mammalian target of rapmycin (mTOR) inhibitors in estrogen-independent cells but not in estrogen-dependent cells. Phosphoproteomic profiles from reverse-phase protein array analysis supported by mRNA profiling identified a significant signaling network reprogramming by TOB1 that differed in estrogen-sensitive and estrogen-resistant cell lines. These data support a novel function for TOB1 in mediating survival of estrogen-independent breast cancers. These studies also provide evidence for combining TOB1 inhibition and AKT/mTOR inhibition as a therapeutic strategy, with potential translational significance for the management of patients with ER-positive breast cancers.	[Zhang, Y-W; Nasto, R. E.; Varghese, R.; Jablonski, S. A.; Surana, R.; Murray, J.; Jin, L.; Johnson, M.; Riggins, R.; Ressom, H.; Clarke, R.; Weiner, L. M.] Georgetown Univ, Sch Med, Dept Oncol, Georgetown Lombardi Comprehens Canc Ctr, Res Bldg E501,3970 Reservoir Rd NW, Washington, DC 20057 USA; [Nasto, R. E.; Serebriiskii, I. G.; Golemis, E. A.] Fox Chase Canc Ctr, Program Dev Therapeut, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Nasto, R. E.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Serebriiskii, I. G.] Kazan Fed Univ, Kazan, Russia; [Calvert, V. S.; Petricoin, E.] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA; [Bebu, I.] George Washington Univ, Biostat Ctr, Washington, DC USA	Georgetown University; Fox Chase Cancer Center; Drexel University; Kazan Federal University; George Mason University; George Washington University	Weiner, LM (corresponding author), Georgetown Univ, Sch Med, Dept Oncol, Georgetown Lombardi Comprehens Canc Ctr, Res Bldg E501,3970 Reservoir Rd NW, Washington, DC 20057 USA.	weinerl@georgetown.edu	Clarke, Robert/A-6485-2008; Riggins, Rebecca/GQH-4466-2022	Clarke, Robert/0000-0002-9278-0854; Golemis, Erica/0000-0003-3618-3673	NIH/NCI grant [P30-CA051008]; Russian Government;  [R01CA050633];  [CA51880];  [U54 CA149147];  [R01CA63366];  [R21CA181287]; NATIONAL CANCER INSTITUTE [R01CA050633, R21CA181287, R01CA063366, U54CA149147, P30CA006927, U01CA051880, T32CA009686, P30CA051008] Funding Source: NIH RePORTER	NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Russian Government; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the Flow Cytometry and Cell Sorting Shared Resource at the Lombardi Comprehensive Cancer Center, which is partially supported by NIH/NCI grant P30-CA051008. We also thank Wei Xu, Alan Zwart, David Goldstein, Annie Zuo and Yuri Gusev for their technical assistance. This study was supported by R01CA050633, CA51880, U54 CA149147 (to LMW), R01CA63366 and R21CA181287 (to EAG), and by the subsidy of the Russian Government to support the program of competitive growth of Kazan Federal University (to IS).	Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; American Cancer Society, 2013, CANC FACTS FIG 2013; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Bader GD, 2000, BIOINFORMATICS, V16, P465, DOI 10.1093/bioinformatics/16.5.465; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bostner J, 2013, BREAST CANCER RES TR, V137, P397, DOI 10.1007/s10549-012-2376-y; Britton DJ, 2006, BREAST CANCER RES TR, V96, P131, DOI 10.1007/s10549-005-9070-2; Brunner N, 1997, CANCER RES, V57, P3486; Caravatta L, 2008, J CELL PHYSIOL, V214, P192, DOI 10.1002/jcp.21186; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Chitre M, 2014, CLINICOECONOMIC OUTC, V6, P331, DOI 10.2147/CEOR.S57214; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Garcia-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108; Gritsch David, 2011, J Exp Ther Oncol, V9, P37; Helms MW, 2009, CANCER RES, V69, P5049, DOI 10.1158/0008-5472.CAN-08-4154; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Kim B, 2015, ONCOGENE, V34, P1083, DOI 10.1038/onc.2014.51; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; Levin ER, 2009, J PHYSIOL-LONDON, V587, P5019, DOI 10.1113/jphysiol.2009.177097; Licata L, 2012, NUCLEIC ACIDS RES, V40, pD857, DOI 10.1093/nar/gkr930; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; Matsuda S, 1996, ONCOGENE, V12, P705; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Nair BC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2929; Nehra R, 2010, FASEB J, V24, P2040, DOI 10.1096/fj.09-138305; O'Malley S, 2009, INT J CANCER, V125, P1805, DOI 10.1002/ijc.24490; Orchard S, 2014, NUCLEIC ACIDS RES, V42, pD358, DOI 10.1093/nar/gkt1115; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Redon CE, 2010, CLIN CANCER RES, V16, P4532, DOI 10.1158/1078-0432.CCR-10-0523; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Saj A, 2010, DEV CELL, V18, P862, DOI 10.1016/j.devcel.2010.03.013; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Solimini NL, 2012, SCIENCE, V337, P104, DOI 10.1126/science.1219580; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Sun M, 2001, CANCER RES, V61, P5985; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Suzuki T, 2001, GENES CELLS, V6, P131, DOI 10.1046/j.1365-2443.2001.00406.x; Suzuki T, 2012, J BIOL CHEM, V287, P40256, DOI 10.1074/jbc.M112.353805; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Tarcea VG, 2009, NUCLEIC ACIDS RES, V37, pD642, DOI 10.1093/nar/gkn722; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020	54	22	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1643	1656		10.1038/onc.2015.226	http://dx.doi.org/10.1038/onc.2015.226			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26165839	Green Accepted			2022-12-28	WOS:000373064200004
J	Giacobbe, A; Compagnone, M; Bongiorno-Borbone, L; Antonov, A; Markert, EK; Zhou, JH; Annicchiarico-Petruzzelli, M; Melino, G; Peschiaroli, A				Giacobbe, A.; Compagnone, M.; Bongiorno-Borbone, L.; Antonov, A.; Markert, E. K.; Zhou, J. H.; Annicchiarico-Petruzzelli, M.; Melino, G.; Peschiaroli, A.			p63 controls cell migration and invasion by transcriptional regulation of MTSS1	ONCOGENE			English	Article							BREAST-CANCER; P53 HOMOLOG; METASTASIS; CARCINOMA; SUPPRESSOR; TARGET; TUMORIGENESIS; DELTA-NP63; SURVIVAL; PATHWAY	Metastasis is a multistep cell-biological process, which is orchestrated by many factors, including metastasis activators and suppressors. Metastasis Suppressor 1 (MTSS1) was originally identified as a metastasis suppressor protein whose expression is lost in metastatic bladder and prostate carcinomas. However, recent findings indicate that MTSS1 acts as oncogene and pro-migratory factor in melanoma tumors. Here, we identify and characterized a molecular mechanism controlling MTSS1 expression, which impinges on a pro-tumorigenic role of MTSS1 in breast tumors. We found that in normal and in cancer cell lines Delta Np63 is able to drive the expression of MTSS1 by binding to a p63-binding responsive element localized in the MTSS1 locus. We reported that Delta Np63 is able to drive the migration of breast tumor cells by inducing the expression of MTSS1. Notably, in three human breast tumors data sets the MTSS1/p63 co-expression is a negative prognostic factor on patient survival, suggesting that the MTSS1/p63 axis might be functionally important to regulate breast tumor progression.	[Giacobbe, A.; Compagnone, M.; Bongiorno-Borbone, L.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Antonov, A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Markert, E. K.] Inst Adv Study, Simons Ctr Syst Biol, Olden Lane, Princeton, NJ 08540 USA; [Zhou, J. H.] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Annicchiarico-Petruzzelli, M.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Biochem Lab IDI IRCCS, Rome, Italy; [Peschiaroli, A.] CNR, IBCN, Rome, Italy	University of Rome Tor Vergata; University of Leicester; Institute for Advanced Study - USA; Radboud University Nijmegen; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR)	Melino, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.; Peschiaroli, A (corresponding author), CNR, CNR IBCN Inst Cell Biol & Neurobiol, Viale E Ramarini 32, I-00015 Rome, Italy.	melino@uniroma2.it; angelo.peschiaroli@cnr.it	Annicchiarico-Petruzzelli, Margherita/AAG-7746-2020; Zhou, Huiqing/B-1721-2013; Zhou, Jo Huiqing/ADR-5134-2022	Annicchiarico-Petruzzelli, Margherita/0000-0002-4717-4740; Zhou, Huiqing/0000-0002-2434-3986; Zhou, Jo Huiqing/0000-0002-2434-3986; Giacobbe, Arianna/0000-0002-5874-1851; PESCHIAROLI, ANGELO/0000-0001-6311-2382	MFAG AIRC [15523]; Medical Research Council (UK); Ministry of Health [Rc1.1, Rc 1.3]; AIRC [IG-15653, 9979]; 'NCDs Fondazione Roma' grant; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	MFAG AIRC(Fondazione AIRC per la ricerca sul cancro); Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ministry of Health; AIRC(Fondazione AIRC per la ricerca sul cancro); 'NCDs Fondazione Roma' grant; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the laboratory members for helpful discussion. This work has been supported by MFAG AIRC 15523 grant awarded to AP, and by Medical Research Council (UK), Ministry of Health 'Rc1.1' and 'Rc 1.3', AIRC Grant IG-15653, AIRC 5xmille (#9979), 'NCDs Fondazione Roma' grant awarded to GM.	Amelio I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.9; Antonov AV, 2014, ONCOGENE, V33, P1621, DOI 10.1038/onc.2013.119; Barbareschi M, 2001, AM J SURG PATHOL, V25, P1054, DOI 10.1097/00000478-200108000-00010; Bergholz J, 2014, ONCOGENE, V33, P212, DOI 10.1038/onc.2012.564; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Candi E, 2014, HUM MUTAT, V35, P702, DOI 10.1002/humu.22523; Celardo I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.175; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cho MS, 2010, CELL CYCLE, V9, P2434, DOI 10.4161/cc.9.12.12051; Dawson JC, 2012, ONCOGENE, V31, P1781, DOI 10.1038/onc.2011.376; Du ZJ, 2010, CANCER SCI, V101, P2417, DOI 10.1111/j.1349-7006.2010.01700.x; Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411; Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793; Fukushima H, 2009, CANCER RES, V69, P9263, DOI 10.1158/0008-5472.CAN-09-1188; Giacobbe A, 2013, CELL CYCLE, V12, P1395, DOI 10.4161/cc.24478; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Kedmi M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005866; Lee KB, 2014, CANCER LETT, V353, P124, DOI 10.1016/j.canlet.2014.07.016; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Machesky LM, 2007, J MOL MED-JMM, V85, P569, DOI 10.1007/s00109-007-0207-0; Malatesta M, 2013, ONCOGENE, V32, P4721, DOI 10.1038/onc.2012.463; Matin RN, 2013, J EXP MED, V210, P581, DOI 10.1084/jem.20121439; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Mertz KD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4465; Missero C, 2014, EXP DERMATOL, V23, P143, DOI 10.1111/exd.12320; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Peschiaroli A, 2010, BIOCHEM BIOPH RES CO, V402, P425, DOI 10.1016/j.bbrc.2010.10.050; Ramsey MR, 2013, J CLIN INVEST, V123, P3525, DOI 10.1172/JCI68899; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Trink B, 2007, CELL CYCLE, V6, P240, DOI 10.4161/cc.6.3.3803; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Velletri T, 2013, CELL CYCLE, V12, P3564, DOI 10.4161/cc.26771; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Wang Xiaojuan, 2002, Breast Cancer, V9, P216, DOI 10.1007/BF02967592; Xie F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-95; Xie Fei, 2011, Front Biosci (Schol Ed), V3, P621, DOI 10.2741/s175; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang XP, 2011, CANCER RES, V71, P3688, DOI 10.1158/0008-5472.CAN-10-3445	47	32	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1602	1608		10.1038/onc.2015.230	http://dx.doi.org/10.1038/onc.2015.230			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26119942				2022-12-28	WOS:000373063600013
J	Park, SJ; Shim, JW; Park, HS; Eum, DY; Park, MT; Yi, JM; Choi, SH; Kim, SD; Son, TG; Lu, W; Kim, ND; Yang, K; Heo, K				Park, S-J; Shim, J. W.; Park, H. S.; Eum, D-Y; Park, M-T; Yi, J. Mi; Choi, S. H.; Kim, S. D.; Son, T. G.; Lu, W.; Kim, N. D.; Yang, K.; Heo, K.			MacroH2A1 downregulation enhances the stem-like properties of bladder cancer cells by transactivation of Lin28B	ONCOGENE			English	Article							INITIATING CELLS; HISTONE VARIANTS; SIDE POPULATION; LIN-28; EXPRESSION; RADIORESISTANCE; PROLIFERATION; PROGRESSION; REPRESSION; CARCINOMA	The histone variant, macroH2A1, has an important role in embryonic stem cell differentiation and tumor progression in various types of tumors. However, the regulatory roles of macroH2A1 on bladder cancer progression have not been fully elucidated. Here, we show that macroH2A1 knockdown promotes stem-like properties of bladder cancer cells. The knockdown of macroH2A1 in bladder cancer cells increased tumorigenicity, radioresistance, degeneration of reactive oxygen species, increased sphere formation capability and an increase in the proportion of side populations. We found that macroH2A1 is required for the suppression of Lin28B identified as a novel downstream target of macroH2A1 in bladder cancer. Loss of macroH2A1 expression significantly correlated with the elevated levels of Lin28B expression and subsequently inhibited the mature let-7 microRNA expression. Furthermore, the stable overexpression of Lin28B enhances the several phenotypes, including tumorigenicity and sphere-forming ability, which are induced by macroH2A1 depletion. Importantly, Lin28B expression was regulated by macroH2A1-mediated reciprocal binding of p300 and EZH2/SUV39H1. Our results suggest that Lin28B/let-7 pathway is tightly regulated by macroH2A1 and its cofactors, and have a pivotal role in the bladder tumor progression and the regulation of stem-like characteristics of bladder cancer cells.	[Park, S-J; Shim, J. W.; Park, H. S.; Eum, D-Y; Park, M-T; Yi, J. Mi; Choi, S. H.; Kim, S. D.; Son, T. G.; Yang, K.; Heo, K.] Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Jwadong Gil 40, Busan 619953, South Korea; [Park, S-J; Kim, N. D.] Pusan Natl Univ, Dept Pharm, Busan, South Korea; [Lu, W.] Univ So Calif, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Yang, K.] Dongnam Inst Radiol & Med Sci, Dept Radiat Oncol, Busan, South Korea; [Yang, K.] Korea Inst Radiol & Med Sci, Dept Radiat Oncol, Seoul, South Korea	Korea Institute of Radiological & Medical Sciences; Pusan National University; University of Southern California; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences	Yang, K; Heo, K (corresponding author), Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Jwadong Gil 40, Busan 619953, South Korea.	kmyang@dirams.re.kr; khjhk33@gmail.com		Heo, Kyu/0000-0001-8833-4731	National Research Foundation of Korea (DIRAMS) grant - Korea government (MSIP) [50590-2015]; (Basic Science Research Program) through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [NRF-2014 M2A2A 7043665]	National Research Foundation of Korea (DIRAMS) grant - Korea government (MSIP); (Basic Science Research Program) through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning	We thank Peter Jones for the UROtsa and LD611 cell lines. This work was supported by the National Research Foundation of Korea (DIRAMS) grant funded by the Korea government (MSIP) (50590-2015) and the (Basic Science Research Program) through the National Research Foundation of Korea (NRF) (NRF-2014 M2A2A 7043665) funded by the Ministry of Science, ICT & Future Planning.	Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; Banaszynski LA, 2010, DEV CELL, V19, P662, DOI 10.1016/j.devcel.2010.10.014; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barrero MJ, 2013, CELL REP, V3, P1005, DOI 10.1016/j.celrep.2013.02.029; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Cai WY, 2013, J CELL SCI, V126, P2877, DOI 10.1242/jcs.123810; Chan KS, 2010, CURR OPIN UROL, V20, P393, DOI 10.1097/MOU.0b013e32833cc9df; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Cheng SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080053; Copley MR, 2013, NAT CELL BIOL, V15, P916, DOI 10.1038/ncb2783; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Dai B, 2007, STEM CELLS, V25, P2567, DOI 10.1634/stemcells.2007-0131; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Doyen CM, 2006, MOL CELL BIOL, V26, P1156, DOI 10.1128/MCB.26.3.1156-1164.2006; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Gamble MJ, 2010, CELL CYCLE, V9, P2568, DOI 10.4161/cc.9.13.12144; Gaspar-Maia A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2582; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kim JM, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.40; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Lee DF, 2012, CELL STEM CELL, V11, P179, DOI 10.1016/j.stem.2012.05.020; Li XF, 2012, J BIOL CHEM, V287, P23171, DOI 10.1074/jbc.M112.379412; Lu LG, 2012, CARCINOGENESIS, V33, P2119, DOI 10.1093/carcin/bgs243; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Novikov L, 2011, MOL CELL BIOL, V31, P4244, DOI 10.1128/MCB.05244-11; Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091; Pasque V, 2012, J CELL SCI, V125, P6094, DOI 10.1242/jcs.113019; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26; Sporn JC, 2012, AM J PATHOL, V180, P2516, DOI 10.1016/j.ajpath.2012.02.027; Svotelis A, 2010, CELL CYCLE, V9, P364, DOI 10.4161/cc.9.2.10465; Tanasijevic B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021512; Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wang WJ, 2013, CANCER RES, V73, P1219, DOI 10.1158/0008-5472.CAN-12-1408; Wang YC, 2010, CARCINOGENESIS, V31, P1516, DOI 10.1093/carcin/bgq107; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Xia ZB, 2013, MOL CANCER RES, V11, P1101, DOI 10.1158/1541-7786.MCR-13-0044; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	48	28	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1292	1301		10.1038/onc.2015.187	http://dx.doi.org/10.1038/onc.2015.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028027	Green Published, hybrid			2022-12-28	WOS:000371763100009
J	Pytel, D; Majsterek, I; Diehl, JA				Pytel, D.; Majsterek, I.; Diehl, J. A.			Tumor progression and the different faces of the PERK kinase	ONCOGENE			English	Review							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ELEMENT-MEDIATED EXPRESSION; INDUCED GENE-EXPRESSION; CUL3-BASED E3 LIGASE; INDUCED ER STRESS; TRANSCRIPTION FACTOR; PHOSPHATIDIC-ACID; TRANSLATIONAL CONTROL; DEPENDENT REGULATION	The serine/threonine endoplasmic reticulum (ER) kinase, protein kinase R (PKR)-like ER kinase (PERK), is a pro-adaptive protein kinase whose activity is regulated indirectly by protein misfolding within the ER. As the oxidative folding environment in the ER is sensitive to a variety of cellular stresses, many of which occur during neoplastic transformation and in the tumor microenvironment, there has been considerable interest in defining whether PERK positively contributes to tumor progression and whether it represents a significant therapeutic target. Herein, we review the current knowledge of PERK-dependent signaling pathways, the contribution of downstream substrates including recently characterized new PERK substrates transcription factors Forkhead box O protein and diacyglycerol a lipid signaling second messenger, and efforts to develop small molecule PERK inhibitors.	[Pytel, D.; Diehl, J. A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, HO-712F, Charleston, SC 29425 USA; [Majsterek, I.] Med Univ Lodz, Dept Clin Chem & Biochem, Hallera 1, Lodz, Poland	Medical University of South Carolina; Medical University Lodz	Pytel, D; Diehl, JA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, HO-712F, Charleston, SC 29425 USA.	pytel@musc.edu; diehl@musc.edu		Majsterek, Ireneusz/0000-0001-6231-3334	National Institutes of Health [CA104838]; Polish National Science Centre (NCN) 'HARMONIA 5' grant [2013/10/M/N21/00280]; NATIONAL CANCER INSTITUTE [T32CA009140, P01CA104838] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Polish National Science Centre (NCN) 'HARMONIA 5' grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health grant CA104838 (JAD); Polish National Science Centre (NCN) 'HARMONIA 5' grant no. 2013/10/M/N21/00280.	Ackerman D, 2014, TRENDS CELL BIOL, V24, P472, DOI 10.1016/j.tcb.2014.06.001; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109; Axten JM, 2013, ACS MED CHEM LETT, V4, P964, DOI 10.1021/ml400228e; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Bhattacharya S, 2013, ONCOGENE, V32, P4214, DOI 10.1038/onc.2012.439; Bhattacharya S, 2011, BLOOD, V118, P4179, DOI 10.1182/blood-2010-12-325373; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Bobrovnikova-Marjon E, 2012, MOL CELL BIOL, V32, P2268, DOI 10.1128/MCB.00063-12; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Byrd AE, 2012, J CELL BIOL, V196, P689, DOI 10.1083/jcb.201201077; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Carbajo-Pescador S, 2014, CURR MED CHEM, V21, P1231, DOI 10.2174/0929867321666131228205703; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chang RCC, 2002, NEUROREPORT, V13, P2429, DOI 10.1097/00001756-200212200-00011; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chikka MR, 2013, J BIOL CHEM, V288, P4405, DOI 10.1074/jbc.M112.432344; Chitnis N, 2013, TRENDS BIOCHEM SCI, V38, P447, DOI 10.1016/j.tibs.2013.06.012; Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025; Coelho DS, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00076; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018; Del Vecchio CA, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001945; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; DeZwaan-McCabe D, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003937; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dimcheff DE, 2003, J VIROL, V77, P12617, DOI 10.1128/JVI.77.23.12617-12629.2003; Espenshade PJ, 2007, ANNU REV GENET, V41, P401, DOI 10.1146/annurev.genet.41.110306.130315; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Finnie JW, 2000, VET PATHOL, V37, P677, DOI 10.1354/vp.37-6-677; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gao Y, 2012, MOL CELL BIOL, V32, P5129, DOI 10.1128/MCB.01009-12; de la Cadena SC, 2014, APOPTOSIS, V19, P414, DOI 10.1007/s10495-013-0930-7; Garg AD, 2012, TRENDS MOL MED, V18, P589, DOI 10.1016/j.molmed.2012.06.010; Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Gupta S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.74; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hamanaka RB, 2009, ONCOGENE, V28, P910, DOI 10.1038/onc.2008.428; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; Hami LS, 2004, CYTOTHERAPY, V6, P554, DOI 10.1080/14653240410005348; Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hoozemans JJM, 2007, BIOCHEM BIOPH RES CO, V354, P707, DOI 10.1016/j.bbrc.2007.01.043; Hoozemans JJM, 2005, ACTA NEUROPATHOL, V110, P165, DOI 10.1007/s00401-005-1038-0; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Isler JA, 2005, J VIROL, V79, P6890, DOI 10.1128/JVI.79.11.6890-6899.2005; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Kanamori M, 2015, NEURO-ONCOLOGY, V17, P555, DOI 10.1093/neuonc/nou282; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Kim YI, 2014, MOL CELL BIOL, V34, P4368, DOI 10.1128/MCB.00599-14; Kincaid MM, 2007, ANTIOXID REDOX SIGN, V9, P2373, DOI 10.1089/ars.2007.1817; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Kusio-Kobialka M, 2012, CELL CYCLE, V11, P4069, DOI 10.4161/cc.22387; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lees JR, 2007, J CLIN INVEST, V117, P297, DOI 10.1172/JCI31254; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Li W, 2008, BBA-MOL CELL RES, V1783, P1847, DOI 10.1016/j.bbamcr.2008.05.024; Lim HK, 2003, J BIOL CHEM, V278, P45117, DOI 10.1074/jbc.M303789200; Lin WS, 2007, J CLIN INVEST, V117, P448, DOI 10.1172/JCI29571; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Mahadevan NR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051845; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Malhi H, 2008, SEMIN LIVER DIS, V28, P360, DOI 10.1055/s-0028-1091980; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Meares GP, 2014, MOL CELL BIOL, V34, P3911, DOI 10.1128/MCB.00980-14; MILLER PF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P151, DOI 10.1016/0167-4781(90)90157-W; Mohammad MK, 2012, TOXICOL APPL PHARM, V265, P73, DOI 10.1016/j.taap.2012.09.021; Mor A, 2007, NAT CELL BIOL, V9, P713, DOI 10.1038/ncb1592; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Moreno JA, 2012, NATURE, V485, P507, DOI 10.1038/nature11058; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nagata T, 2007, NEUROL RES, V29, P767, DOI 10.1179/016164107X229803; Natalini PM, 2014, EXP EYE RES, V125, P142, DOI 10.1016/j.exer.2014.06.007; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Oda T, 2008, NEUROSCI RES, V60, P29, DOI 10.1016/j.neures.2007.09.005; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Petzer JP, 2003, CHEM RES TOXICOL, V16, P1463, DOI 10.1021/tx034154e; Pineau L, 2009, TRAFFIC, V10, P673, DOI 10.1111/j.1600-0854.2009.00903.x; Poli A, 2014, ONCOTARGET, V5, P11526, DOI 10.18632/oncotarget.2578; Pytel D, 2014, J BIOMOL SCREEN, V19, P1024, DOI 10.1177/1087057114525853; Qian ZK, 2012, J VIROL, V86, P6712, DOI 10.1128/JVI.00200-12; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosalia RA, 2013, CANCER IMMUNOL IMMUN, V62, P1161, DOI 10.1007/s00262-013-1411-0; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Saito S, 2009, CANCER RES, V69, P4225, DOI 10.1158/0008-5472.CAN-08-2689; Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5; Schroder M, 2006, MOL BIOTECHNOL, V34, P279, DOI 10.1385/MB:34:2:279; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shiozaki K, 2015, FASEB J, V29, P2099, DOI 10.1096/fj.14-262543; Spitzer J A, 1989, Prog Clin Biol Res, V308, P575; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Szendroedi J, 2014, P NATL ACAD SCI USA, V111, P9597, DOI 10.1073/pnas.1409229111; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Ulianichl L, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00055; Upton JP, 2012, SCIENCE, V338, P818, DOI 10.1126/science.1226191; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Volkmann K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199737; Volmer R, 2015, CURR OPIN CELL BIOL, V33, P67, DOI 10.1016/j.ceb.2014.12.002; Volmer R, 2013, P NATL ACAD SCI USA, V110, P4628, DOI 10.1073/pnas.1217611110; Wang LJ, 2014, NEUROBIOL DIS, V71, P317, DOI 10.1016/j.nbd.2014.08.010; Wang LJ, 2011, HUM MOL GENET, V20, P1008, DOI 10.1093/hmg/ddq546; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; WATOWICH SS, 1991, J VIROL, V65, P3590, DOI 10.1128/JVI.65.7.3590-3597.1991; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wilhelmus MMM, 2011, BRAIN PATHOL, V21, P130, DOI 10.1111/j.1750-3639.2010.00429.x; Xie LK, 2012, BLOOD, V119, P3503, DOI 10.1182/blood-2011-09-381905; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yan Y, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-445; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002; Zhang W, 2013, GENE DEV, V27, P441, DOI 10.1101/gad.201731.112; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	165	40	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1207	1215		10.1038/onc.2015.178	http://dx.doi.org/10.1038/onc.2015.178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028033	Green Accepted			2022-12-28	WOS:000371763100001
J	Cao, H; Eppinga, RD; Razidlo, GL; Krueger, EW; Chen, J; Qiang, L; McNiven, MA				Cao, H.; Eppinga, R. D.; Razidlo, G. L.; Krueger, E. W.; Chen, J.; Qiang, L.; McNiven, M. A.			Stromal fibroblasts facilitate cancer cell invasion by a novel invadopodia-independent matrix degradation process	ONCOGENE			English	Article							CARCINOMA-ASSOCIATED FIBROBLASTS; CLATHRIN-COATED PITS; MEDIATED ENDOCYTOSIS; PANCREATIC-CANCER; MAMMALIAN-CELLS; TUMOR-GROWTH; DYNAMIN; METASTASIS; EXPRESSION; METALLOPROTEINASE	Metastatic invasion of tumors into peripheral tissues is known to rely upon protease-mediated degradation of the surrounding stroma. This remodeling process uses complex, actin-based, specializations of the plasma membrane termed invadopodia that act both to sequester and release matrix metalloproteinases. Here we report that cells of mesenchymal origin, including tumor-associated fibroblasts, degrade substantial amounts of surrounding matrix by a mechanism independent of conventional invadopodia. These degradative sites lack the punctate shape of conventional invadopodia to spread along the cell base and are reticular and/or fibrous in character. In marked contrast to invadopodia, this degradation does not require the action of Src kinase, Cdc42 or Dyn2. Rather, inhibition of Dyn2 causes a marked upregulation of stromal matrix degradation. Further, expression and activity of matrix metalloproteinases are differentially regulated between tumor cells and stromal fibroblasts. This matrix remodeling by fibroblasts increases the invasive capacity of tumor cells, thereby illustrating how the tumor microenvironment can contribute to metastasis. These findings provide evidence for a novel matrix remodeling process conducted by stromal fibroblasts that is substantially more effective than conventional invadopodia, distinct in structural organization and regulated by disparate molecular mechanisms.	[Cao, H.; Eppinga, R. D.; Razidlo, G. L.; Krueger, E. W.; Chen, J.; McNiven, M. A.] Mayo Clin, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA; [Cao, H.; Razidlo, G. L.; Qiang, L.; McNiven, M. A.] Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA; [Eppinga, R. D.] Dordt Coll, Dept Biol, Sioux Ctr, IA USA	Mayo Clinic; Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.; McNiven, MA (corresponding author), Mayo Clin, Ctr Basic Res Digest Dis, 200 First St SW, Rochester, MN 55905 USA.	mmcniven@mayo.edu		Razidlo, Gina/0000-0002-9042-2738	Mayo Clinic Center for Cell Signaling in Gastroenterology [R01 CA104125, P30DK084567]; Mayo Clinic SPORE in Pancreatic Cancer [P50 CA102701];  [T32 DK007198]; NATIONAL CANCER INSTITUTE [P50CA102701, R01CA104125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007198, P30DK084567] Funding Source: NIH RePORTER	Mayo Clinic Center for Cell Signaling in Gastroenterology; Mayo Clinic SPORE in Pancreatic Cancer; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by R01 CA104125 to MAM, P30DK084567 (Mayo Clinic Center for Cell Signaling in Gastroenterology), T32 DK007198 (to RDE), and P50 CA102701 (Mayo Clinic SPORE in Pancreatic Cancer, to GLR).	Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Baldassarre M, 2003, MOL BIOL CELL, V14, P1074, DOI 10.1091/mbc.E02-05-0308; Boateng LR, 2012, EUR J CELL BIOL, V91, P878, DOI 10.1016/j.ejcb.2012.06.003; Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; De Wever O, 2014, SEMIN CANCER BIOL, V25, P33, DOI 10.1016/j.semcancer.2013.12.009; Destaing O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077956; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Eppinga RD, 2012, ONCOGENE, V31, P1228, DOI 10.1038/onc.2011.329; Ferguson S, 2009, DEV CELL, V17, P811, DOI 10.1016/j.devcel.2009.11.005; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Goicoechea SM, 2014, ONCOGENE, V33, P1265, DOI 10.1038/onc.2013.68; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Luga V, 2013, CANCER RES, V73, P6843, DOI 10.1158/0008-5472.CAN-13-1791; Martinez-Outschoorn UE, 2014, SEMIN CANCER BIOL, V25, P47, DOI 10.1016/j.semcancer.2014.01.005; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mishra P, 2011, J LEUKOCYTE BIOL, V89, P31, DOI 10.1189/jlb.0310182; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nakahara H, 2003, GENES CELLS, V8, P1019, DOI 10.1111/j.1365-2443.2003.00695.x; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Razidlo GL, 2014, CURR BIOL, V24, P86, DOI 10.1016/j.cub.2013.11.013; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood-2006-10-051060; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Waghray M, 2013, CURR OPIN GASTROEN, V29, P537, DOI 10.1097/MOG.0b013e328363affe; Wang Y, 2012, J CELL BIOL, V196, P375, DOI 10.1083/jcb.201105153; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025	37	23	23	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1099	1110		10.1038/onc.2015.163	http://dx.doi.org/10.1038/onc.2015.163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982272	Green Published, Green Accepted			2022-12-28	WOS:000371351700004
J	Wang, L; Yang, H; Lei, Z; Zhao, J; Chen, Y; Chen, P; Li, C; Zeng, Y; Liu, Z; Liu, X; Zhang, HT				Wang, L.; Yang, H.; Lei, Z.; Zhao, J.; Chen, Y.; Chen, P.; Li, C.; Zeng, Y.; Liu, Z.; Liu, X.; Zhang, H-T			Repression of TIF gamma by SOX2 promotes TGF-beta-induced epithelial-mesenchymal transition in non-small-cell lung cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTION FACTORS; MULTIPLE ROLES; GROWTH; METASTASIS; EXPRESSION; TIF1-GAMMA; SMAD4; PROGRESSION; SURVIVAL	TIF1 gamma is a novel regulator of transforming growth factor (TGF)-beta/Smad signaling. Our previous studies show that dysregulated expression of transcriptional intermediary factor 1 gamma (TIF1 gamma) and abnormal TGF-beta/Smad signaling are implicated in non-small-cell lung cancer (NSCLC) separately. However, how TIF1 gamma contributes to NSCLC by controlling TGF-beta/Smad signaling is poorly understood. Here, we investigated the mechanistic role of TIF1 gamma in TGF-beta-induced epithelial-mesenchymal transition (EMT), as well as a link between TIF1 gamma and SOX2 in NSCLC. We show that TIF1 gamma is a downstream target of SOX2 in NSCLC cells. SOX2 overexpression negatively regulated TIF1 gamma promoter activity and thereby attenuated TIF1 gamma mRNA and protein expression levels; SOX2 knockdown significantly enhanced TIF1 gamma promoter activity and augmented TIF1 gamma expression. Moreover, TIF1 gamma mRNA expression was downregulated in human NSCLC tissues and negatively correlated with SOX2 protein, which was upregulated in NSCLC tissues. Importantly, knockdown of TIF1 gamma or SOX2 overexpression augmented SMAD4 (human Mad (mothers against decapentaplegic)-related homologous protein 4)-dependent transcriptional responses, and enhanced TGF-beta-induced EMT and human NSCLC cell invasion; knockdown of SOX2 impaired TGF-beta-induced EMT and NSCLC cell invasion. In an in vivo model of metastasis, knockdown of TIF1 gamma promotes NSCLC cell metastasis. In addition, our data suggested that TIF1 gamma inhibited TGF-beta-induced EMT through competing with SMAD4 in NSCLC cells. Taken together, our findings reveal a new mechanism by which SOX2-mediated transcription repression of TIF1 gamma promotes TGF-beta-induced EMT in NSCLC.	[Wang, L.; Yang, H.; Lei, Z.; Liu, X.; Zhang, H-T] Soochow Univ, Coll Med, Lab Canc Mol Genet, 199 Renai Rd,Sinosingapore Ind Pk, Suzhou 215123, Peoples R China; [Wang, L.; Yang, H.; Lei, Z.; Zhao, J.; Li, C.; Zeng, Y.; Liu, Z.; Liu, X.; Zhang, H-T] Suzhou Key Lab Mol Canc Genet, Suzhou, Peoples R China; [Zhao, J.; Li, C.; Zeng, Y.; Liu, Z.] Soochow Univ, Dept Thorac & Cardiovasc Surg, Affiliated Hosp 1, Coll Med, Suzhou, Peoples R China; [Chen, Y.] Soochow Univ, Coll Med, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, Suzhou, Peoples R China; [Chen, P.] Genome Scale Biol, Res Programs Unit, Syst Biol Lab, Haartmaninkatu 8, Helsinki, Finland; [Chen, P.] Univ Helsinki, Fac Med, Inst Biomed Biochem & Dev Biol, Haartmaninkatu 8, Helsinki, Finland	Soochow University - China; Soochow University - China; Soochow University - China; University of Helsinki	Zhang, HT (corresponding author), Soochow Univ, Coll Med, Lab Canc Mol Genet, 199 Renai Rd,Sinosingapore Ind Pk, Suzhou 215123, Peoples R China.	htzhang@suda.edu.cn	Chen, Ping/AAL-8264-2020; Zhang, Hong-Tao/P-9661-2017; Lei, Zhe/AGZ-4963-2022	Chen, Ping/0000-0002-8068-1891; Zhang, Hong-Tao/0000-0003-4182-421X; 	National Natural Science Foundation of China [81372277, 81171894, 81201575]; Jiangsu Province's Key Provincial Talents Program [RC2011106]; '333' Project of Jiangsu Province Government; Graduate Innovation Project of Jiangsu Province [CXZZ13_0830]; Soochow Scholar Project of Soochow University; Suzhou Key Laboratory for Molecular Cancer Genetics [SZS201209]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province's Key Provincial Talents Program; '333' Project of Jiangsu Province Government; Graduate Innovation Project of Jiangsu Province; Soochow Scholar Project of Soochow University; Suzhou Key Laboratory for Molecular Cancer Genetics; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	We are grateful for participation and cooperation from the patients with NSCLC. This work was supported in part by the grants from National Natural Science Foundation of China (81372277, 81171894 and 81201575), Jiangsu Province's Key Provincial Talents Program (RC2011106), '333' Project of Jiangsu Province Government, Graduate Innovation Project of Jiangsu Province (CXZZ13_0830), Soochow Scholar Project of Soochow University, Suzhou Key Laboratory for Molecular Cancer Genetics (SZS201209) and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; Aucagne R, 2011, J CLIN INVEST, V121, P2361, DOI 10.1172/JCI45213; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Fang WT, 2014, INT J CANCER, V135, P809, DOI 10.1002/ijc.28734; Fattet L, 2013, J CELL SCI, V126, P3713, DOI 10.1242/jcs.126748; Feng J, 2012, AM J CLIN PATHOL, V138, P230, DOI 10.1309/AJCPDHQFNYJZ01YG; Gontan C, 2008, DEV BIOL, V317, P296, DOI 10.1016/j.ydbio.2008.02.035; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Han G, 2005, J CLIN INVEST, V115, P1714, DOI 10.1172/JCI24399; Han X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041335; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Hesling C, 2011, EMBO REP, V12, P665, DOI 10.1038/embor.2011.78; Jeon HS, 2010, J THORAC ONCOL, V5, P417, DOI 10.1097/JTO.0b013e3181ce3afd; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Lei Z, 2014, FASEB J, V28, P2696, DOI 10.1096/fj.13-247288; Lei Z, 2009, CANCER RES, V69, P7046, DOI 10.1158/0008-5472.CAN-08-4602; Li XF, 2013, CANCER LETT, V336, P379, DOI 10.1016/j.canlet.2013.03.027; Liu KC, 2013, CELL SIGNAL, V25, P1264, DOI 10.1016/j.cellsig.2013.02.013; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; Nakatsugawa M, 2011, LAB INVEST, V91, P1796, DOI 10.1038/labinvest.2011.140; Park C, 2002, LUNG CANCER-J IASLC, V38, P143, DOI 10.1016/S0169-5002(02)00182-4; Pirozzi G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021548; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Qian Q, 2014, INT J ONCOL, V44, P874, DOI 10.3892/ijo.2014.2255; Que JW, 2009, DEVELOPMENT, V136, P1899, DOI 10.1242/dev.034629; Szymanowska-Narloch A, 2013, ADV MED SCI-POLAND, V58, P196, DOI 10.2478/ams-2013-0025; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Vincent DF, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000575; Wang Longqiang, 2013, Zhongguo Fei Ai Za Zhi, V16, P227, DOI 10.3779/j.issn.1009-3419.2013.05.02; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Xu Wei, 2013, Zhongguo Fei Ai Za Zhi, V16, P591, DOI 10.3779/j.issn.1009-3419.2013.11.05; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Zhang HT, 2004, CLIN CANCER RES, V10, P2359, DOI 10.1158/1078-0432.CCR-0959-3; Zhao J, 2008, J CANCER RES CLIN, V134, P919, DOI 10.1007/s00432-008-0392-4; Zhou CH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-18	47	51	58	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					867	877		10.1038/onc.2015.141	http://dx.doi.org/10.1038/onc.2015.141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961934				2022-12-28	WOS:000370332200007
J	Mortusewicz, O; Evers, B; Helleday, T				Mortusewicz, O.; Evers, B.; Helleday, T.			PC4 promotes genome stability and DNA repair through binding of ssDNA at DNA damage sites	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; TRANSCRIPTIONAL COACTIVATOR PC4; ONCOGENE-INDUCED SENESCENCE; MAMMALIAN-CELLS; HOMOLOGOUS RECOMBINATION; REPLICATION FORKS; FRAGILE SITES; COFACTOR PC4; RPA; ACTIVATION	The transcriptional cofactor PC4 is an ancient single-strand DNA (ssDNA)-binding protein that has a homologue in bacteriophage TS where it is likely the elusive replicative ssDNA-binding protein. We hypothesize that human PC4 has retained functions in ssDNA binding to stabilize replication forks and prevent genome instability in mammalian cells, Here we demonstrate that PC4 is recruited to hydroxyurea (HU)-stalled replication forks, which is dependent on active transcription and its ssDNA-binding ability. Interestingly, we demonstrate that ssDNA binding by PC4 is critical to suppress spontaneous DNA damage and promote cellular survival. PC4 accumulation co-localizes with replication protein A (RPA) at stalled forks and is increased upon RPA depletion, demonstrating compensatory functions in ssDNA binding. Depletion of PC4 not only results in defective resolution of HU-induced DNA damage but also significantly reduces homologous recombination repair efficiency. Altogether, our results indicate that PC4 has similar functions to RPA in binding ssDNA to promote genome stability, especially at sites of replication transcription collisions,	[Mortusewicz, O.; Evers, B.; Helleday, T.] Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab, Box 1031, S-17121 Stockholm, Sweden; [Evers, B.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands	Karolinska Institutet; Netherlands Cancer Institute	Mortusewicz, O; Helleday, T (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Translat Med & Chem Biol, Sci Life Lab, Box 1031, S-17121 Stockholm, Sweden.	oliver.mortusewicz@scilifelab.se; thomas.helleday@scilifelab.se		Helleday, Thomas/0000-0002-7384-092X	Swedish Research Council; Swedish Cancer Society; EMBO LTF [O.M. 451-2010]; Dutch Cancer Society (BE); Torsten and Ragnar Soderberg Foundation; AXA foundation; Goran Gustafsson Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); EMBO LTF(European Molecular Biology Organization (EMBO)); Dutch Cancer Society (BE); Torsten and Ragnar Soderberg Foundation; AXA foundation; Goran Gustafsson Foundation	We would like to express our gratitude to Annette Medhurst and Songmin Ying for help with the fibre assay, Guy Kingham for assistance on the DR-GFP assay and to Mick Woodcock for support with the FACS analysis. This project was supported by the Swedish Research Council, Swedish Cancer Society, EMBO LTF (O.M. 451-2010), Dutch Cancer Society (BE), the Torsten and Ragnar Soderberg Foundation, AXA foundation and the Goran Gustafsson Foundation.	Alabert C, 2014, NAT CELL BIOL, V16, P281, DOI 10.1038/ncb2918; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Batta K, 2009, J MOL BIOL, V385, P788, DOI 10.1016/j.jmb.2008.11.008; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; Das C, 2006, MOL CELL BIOL, V26, P8303, DOI 10.1128/MCB.00887-06; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Lundin C, 2003, J MOL BIOL, V328, P521, DOI 10.1016/S0022-2836(03)00313-9; Mortusewicz O, 2013, EMBO J, V32, P493, DOI 10.1038/emboj.2013.20; Mortusewicz O, 2008, J CELL BIOL, V183, P769, DOI 10.1083/jcb.200808097; Pan ZQ, 1996, J BIOL CHEM, V271, P22111, DOI 10.1074/jbc.271.36.22111; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Sakaguchi K, 2009, FEBS J, V276, P943, DOI 10.1111/j.1742-4658.2008.06841.x; Steigemann B, 2013, J MOL BIOL, V425, P4125, DOI 10.1016/j.jmb.2013.09.001; Suzuki K, 2011, NAT PROTOC, V6, P134, DOI 10.1038/nprot.2010.183; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Vassin VM, 2009, J CELL SCI, V122, P4070, DOI 10.1242/jcs.053702; Wang JY, 2004, MOL CELL BIOL, V24, P6084, DOI 10.1128/MCB.24.13.6084-6093.2004; Werten S, 2006, NAT STRUCT MOL BIOL, V13, P181, DOI 10.1038/nsmb1044; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Yu LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058015; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	29	31	31	4	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					761	770		10.1038/onc.2015.135	http://dx.doi.org/10.1038/onc.2015.135			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961912				2022-12-28	WOS:000370331300009
J	Naik, RR; Singh, AK; Mali, AM; Khirade, MF; Bapat, SA				Naik, R. R.; Singh, A. K.; Mali, A. M.; Khirade, M. F.; Bapat, S. A.			A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses	ONCOGENE			English	Article							STEM-CELLS; CANCER; HETEROGENEITY; CONTRIBUTE; ANEUPLOIDY	Tumor heterogeneity and the presence of drug-sensitive and refractory populations within the same tumor are almost never assessed in the drug discovery pipeline. Such incomplete assessment of drugs arising from spatial and temporal tumor cell heterogeneity reflects on their failure in the clinic and considerable wasted costs in the drug discovery pipeline. Here we report the derivation of a flow cytometry-based tumor deconstruction platform for resolution of at least 18 discrete tumor cell fractions. This is achieved through concurrent identification, quantification and analysis of components of cancer stem cell hierarchies, genetically instable clones and differentially cycling populations within a tumor. We also demonstrate such resolution of the tumor cytotype to be a potential value addition in drug screening through definitive cell target identification. Additionally, this real-time definition of intra-tumor heterogeneity provides a convenient, incisive and analytical tool for predicting drug efficacies through profiling perturbations within discrete tumor cell subsets in response to different drugs and candidates. Consequently, possible applications in informed therapeutic monitoring and drug repositioning in personalized cancer therapy would complement rational design of new candidates besides achieving a re-evaluation of existing drugs to derive non-obvious combinations that hold better chances of achieving remission.	[Naik, R. R.; Singh, A. K.; Mali, A. M.; Khirade, M. F.; Bapat, S. A.] Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Bapat, SA (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	sabapat@nccs.res.in	Bapat, Sharmila/AGU-4130-2022	Bapat, Sharmila/0000-0002-9557-2233	NCCS	NCCS	We appreciate the efforts of Dr Mrunalini Moghe (Deenanath Mangeshkar Hospital, Pune) and Dr Anjali Kusumbe in karyotyping, Mr Swapnil Kamble in cryosectioning and thank Dr Shona Nag (Jehangir Hospital, Pune) for providing gemcitabine. This research is supported by NCCS intra-mural grants to SAB.	Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bian ML, 2010, SCI CHINA LIFE SCI, V53, P1322, DOI 10.1007/s11427-010-4086-1; Bouchet BP, 2007, BRIT J CANCER, V97, P1218, DOI 10.1038/sj.bjc.6603936; Cavanagh BL, 2011, MOLECULES, V9, P7980; Centenera MM, 2013, NAT REV UROL, V10, P483, DOI 10.1038/nrurol.2013.126; Chiang YP, 1996, BBA-MOL CELL RES, V1313, P295, DOI 10.1016/0167-4889(96)00103-6; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Cree IA, 2010, CURR OPIN PHARMACOL, V10, P375, DOI 10.1016/j.coph.2010.05.001; Diaz-Cano SJ, 2012, INT J MOL SCI, V13, P1951, DOI 10.3390/ijms13021951; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kunos CA, 2011, RADIAT RES, V176, P425, DOI 10.1667/RR2556.1; Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802; Kusumbe AP, 2009, STEM CELLS, V27, P498, DOI 10.1634/stemcells.2008-0868; Li B, 2012, CLIN CANCER RES, V18, P5595, DOI 10.1158/1078-0432.CCR-12-1427; Lin D, 2014, ASIAN J ANDROL, V16, P407, DOI 10.4103/1008-682X.125394; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Natrajan R, 2013, CANCER RES, V73, P3483, DOI 10.1158/0008-5472.CAN-12-4717; Navin NE, 2010, MOL ONCOL, V4, P267, DOI 10.1016/j.molonc.2010.04.010; Niu DD, 2009, PROTEOMICS, V9, P3856, DOI 10.1002/pmic.200900071; Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schoenborn JR, 2013, CLIN CANCER RES, V19, P4058, DOI 10.1158/1078-0432.CCR-12-3606; Shan-Cheng R, 2013, ASIAN J ANDROL, V15, P729; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang B, 2010, EXPERT OPIN DRUG DEL, V7, P1159, DOI 10.1517/17425247.2010.513968; Wani AA, 2006, ONCOGENE, V25, P6336, DOI 10.1038/sj.onc.1209649; Ye Neng-Sheng, 2006, Genomics Proteomics & Bioinformatics, V4, P18, DOI 10.1016/S1672-0229(06)60012-0	33	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					727	737		10.1038/onc.2015.130	http://dx.doi.org/10.1038/onc.2015.130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25915841				2022-12-28	WOS:000370331300006
J	Pang, MF; Georgoudaki, AM; Lambut, L; Johansson, J; Tabor, V; Hagikura, K; Jin, Y; Jansson, M; Alexander, JS; Nelson, CM; Jakobsson, L; Betsholtz, C; Sunds, M; Karlsson, MCI; Fuxe, J				Pang, M-F; Georgoudaki, A-M; Lambut, L.; Johansson, J.; Tabor, V.; Hagikura, K.; Jin, Y.; Jansson, M.; Alexander, J. S.; Nelson, C. M.; Jakobsson, L.; Betsholtz, C.; Sunds, M.; Karlsson, M. C. I.; Fuxe, J.			TGF-beta 1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CHEMOKINE RECEPTOR 7; NF-KAPPA-B; TGF-BETA; ENDOTHELIAL-CELLS; NODE METASTASIS; VESSEL INVASION; STEM-CELLS; INFLAMMATION; EXPRESSION	Tumor cells frequently disseminate through the lymphatic system during metastatic spread of breast cancer and many other types of cancer. Yet it is not clear how tumor cells make their way into the lymphatic system and how they choose between lymphatic and blood vessels for migration. Here we report that mammary tumor cells undergoing epithelial-mesenchymal transition (EMT) in response to transforming growth factor-beta (TGF-beta 1) become activated for targeted migration through the lymphatic system, similar to dendritic cells (DCs) during inflammation. EMT cells preferentially migrated toward lymphatic vessels compared with blood vessels, both in vivo and in 3D cultures. A mechanism of this targeted migration was traced to the capacity of TGF-beta 1 to promote CCR7/CCL21-mediated crosstalk between tumor cells and lymphatic endothelial cells. On one hand, TGF-beta 1 promoted CCR7 expression in EMT cells through p38 MAP kinase-mediated activation of the JunB transcription factor. Blockade of CCR7, or treatment with a p38 MAP kinase inhibitor, reduced lymphatic dissemination of EMT cells in syngeneic mice. On the other hand, TGF-beta 1 promoted CCL21 expression in lymphatic endothelial cells. CCL21 acted in a paracrine fashion to mediate chemotactic migration of EMT cells toward lymphatic endothelial cells. The results identify TGF-beta 1-induced EMT as a mechanism, which activates tumor cells for targeted, DC-like migration through the lymphatic system. Furthermore, it suggests that p38 MAP kinase inhibition may be a useful strategy to inhibit EMT and lymphogenic spread of tumor cells.	[Pang, M-F; Lambut, L.; Johansson, J.; Tabor, V.; Hagikura, K.; Jin, Y.; Jakobsson, L.; Betsholtz, C.; Fuxe, J.] Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, SE-17177 Stockholm, Sweden; [Pang, M-F; Nelson, C. M.] Princeton Univ, Dept Chem & Biol Engn, Princeton, NJ 08544 USA; [Georgoudaki, A-M; Karlsson, M. C. I.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden; [Hagikura, K.] Nihon Univ, Sch Med, Div Cell Regenerat & Transplantat, Dept Funct Morphol, Tokyo, Japan; [Jansson, M.; Sunds, M.] Umea Univ, Dept Surg & Perioperat Sci Surg, Umea, Sweden; [Alexander, J. S.] Louisiana State Univ, Dept Mol & Cellular Physiol, Hlth Sci Ctr, Shreveport, LA 71105 USA	Karolinska Institutet; Princeton University; Karolinska Institutet; Nihon University; Umea University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Fuxe, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, SE-17177 Stockholm, Sweden.	jonas.fuxe@ki.se	Georgoudaki, Anna-Maria/AAM-9829-2020; Fuxe, Jonas/T-4433-2017; Jakobsson, Lars/B-4200-2011; Nelson, Celeste/AAT-7612-2021	Fuxe, Jonas/0000-0003-4576-9377; Jakobsson, Lars/0000-0001-7956-587X; Nelson, Celeste/0000-0001-9973-8870; Jin, Yi/0000-0001-9704-973X	Swedish Research Council; Swedish Cancer Society; Strategic Cancer Programme at Karolinska Institutet; Nordic Cancer Foundation; Swedish Childhood Cancer Foundation; Stockholm County Council/Karolinska Institutet; Nilsson-Ehle donation; Robert Lundberg foundation; Swedish Society for Medical Research (SSMF); Swedish Medical Society; Magnus Bergvall foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Strategic Cancer Programme at Karolinska Institutet; Nordic Cancer Foundation; Swedish Childhood Cancer Foundation(European Commission); Stockholm County Council/Karolinska Institutet(Stockholm County Council); Nilsson-Ehle donation; Robert Lundberg foundation; Swedish Society for Medical Research (SSMF); Swedish Medical Society; Magnus Bergvall foundation	We thank Drs Carl-Henrik Heldin and Marene Landstrom at the Ludwig Institute for Cancer Research (Uppsala, Sweden) and Dr Lars Holmgren at the Karolinska Institutet (Stockholm, Sweden) for valuable input on the results. We thank Dr Lena Claesson-Welsh at Uppsala University and Dr Jonathan S Alexander (Louisiana State University Health Sciences Center, Shreveport, Louisiana) for providing the lymphatic endothelial cells. We also thank Dr Seonghyang SOHN (Department of Microbiology School of Medicine, Suwon, Korea) for providing the CCL21 construct. JF was supported by project grants from the Swedish Research Council, the Swedish Cancer Society, The Strategic Cancer Programme at Karolinska Institutet, the Nordic Cancer Foundation and the Swedish Childhood Cancer Foundation. M-FP was supported by a PhD fellowship (KID-funding) from Stockholm County Council/Karolinska Institutet, by the Nilsson-Ehle donation, The Robert Lundberg foundation and the Swedish Society for Medical Research (SSMF). MCIK was supported by the Swedish Research Council, the Swedish Cancer Society, the Swedish Medical Society and the Magnus Bergvall foundation. VT was supported by the Swedish Cancer Society.	Baluk P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596; Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554; Biswas S, 2014, BREAST CANCER RES TR, V143, P265, DOI 10.1007/s10549-013-2811-8; Chladkova B, 2011, J CELL MOL MED, V15, P938, DOI 10.1111/j.1582-4934.2010.01066.x; Chod J, 2008, EUR J GYNAECOL ONCOL, V29, P613; Choi B, 2013, IMMUNOBIOLOGY, V218, P579, DOI 10.1016/j.imbio.2012.07.003; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cote SC, 2009, MOL IMMUNOL, V46, P2682, DOI 10.1016/j.molimm.2008.08.269; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cunningham HD, 2010, TRANSL ONCOL, V3, P354, DOI 10.1593/tlo.10178; DALAL BI, 1993, AM J PATHOL, V143, P381; Davidson B, 2006, GYNECOL ONCOL, V102, P453, DOI 10.1016/j.ygyno.2006.01.034; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Esteva FJ, 2004, CANCER-AM CANCER SOC, V100, P499, DOI 10.1002/cncr.11940; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; Fuxe J, 2012, SEMIN CANCER BIOL, V22, P455, DOI 10.1016/j.semcancer.2012.05.004; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Issa A, 2009, CANCER RES, V69, P349, DOI 10.1158/0008-5472.CAN-08-1875; Johansson J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00003; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lappin MB, 1999, IMMUNOLOGY, V98, P181; LAURIA R, 1995, CANCER-AM CANCER SOC, V76, P1772, DOI 10.1002/1097-0142(19951115)76:10<1772::AID-CNCR2820761014>3.0.CO;2-O; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Mburu YK, 2012, J BIOL CHEM, V287, P3581, DOI 10.1074/jbc.M111.294876; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Shields JD, 2007, CANCER CELL, V11, P526, DOI 10.1016/j.ccr.2007.04.020; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Van den Eynden GG, 2006, BRIT J CANCER, V94, P1643, DOI 10.1038/sj.bjc.6603152; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Weaver DL, 2011, NEW ENGL J MED, V364, P412, DOI 10.1056/NEJMoa1008108; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5	47	206	212	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					748	760		10.1038/onc.2015.133	http://dx.doi.org/10.1038/onc.2015.133			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961925	Green Published, hybrid			2022-12-28	WOS:000370331300008
J	Wang, G; Fu, Y; Yang, X; Luo, X; Wang, J; Gong, J; Hu, J				Wang, G.; Fu, Y.; Yang, X.; Luo, X.; Wang, J.; Gong, J.; Hu, J.			Brg-1 targeting of novel miR550a-5p/RNF43/Wnt signaling axis regulates colorectal cancer metastasis	ONCOGENE			English	Article							NUCLEOSOME-REMODELING COMPLEXES; SWI/SNF COMPLEX; HEPATOCELLULAR-CARCINOMA; UBIQUITIN LIGASE; CELL; RNF43; EXPRESSION; MUTATIONS; COMPONENT; FAMILY	Metastasis is one of the main causes of death in patients with colorectal cancer (CRC). Brg-1 is a central component of the SWItch/Sucrose NonFermentable chromatin-remodeling complex, which features a bromodomain and helicase/ATPase activity. The gene encoding Brg-1 is frequently mutated or silenced in human cancers. Several reports have proposed Brg-1 as a tumor suppressor; however, little is known about its role in oncogenesis and metastasis. Here we demonstrated that decreased Brg-1 regulates a novel miR-550a-5p/RNF43/Wnt/beta-catenin signaling pathway, to promote CRC metastasis in vitro and in vivo. In particular, we used high-throughput RNA-sequencing analysis to show that Brg-1 negatively regulates miR-550a-5p in CRC cells. We further found that Brg-1 inhibits the transcriptional activity of miR-550a-5p promoter, and that decreased Brg-1 expression increased miR-550a-5p expression. We also identified ring finger 43 (RNF43), an inhibitor of Wnt/beta-catenin signaling, as a target of miR-550a-5p. Knockdown of Brg-1 by small interfering RNA led to decreased RNF43 expression, increased Wnt signaling and increased CRC cell migration and invasion. This novel pathway defines a new function for Brg-1 and provides potential targets for the treatment of Brg-1 mutant and loss-of-function tumors.	[Wang, G.; Fu, Y.; Yang, X.; Luo, X.; Hu, J.] Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Res Inst, 1095 Jiefang Rd, Wuhan 430030, Peoples R China; [Wang, J.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, 1095 Jiefang Rd, Wuhan 430030, Peoples R China; [Gong, J.] Huazhong Univ Sci & Technol, Tongji Hosp, Mol Med Ctr, 1095 Jiefang Rd, Wuhan 430030, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Hu, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Res Inst, 1095 Jiefang Rd, Wuhan 430030, Peoples R China.; Hu, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Canc Res Inst, 1095 Jiefang Rd, Wuhan 430030, Peoples R China.	jbhu@tjh.tjmu.edu.cn	Wang, Guihua/AAX-3130-2021		National Natural Science foundation [81300411, 81372662]; Fundamental Research Funds for the Central Universities [2015QN144]	National Natural Science foundation(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This study was supported by the National Natural Science foundation (Number. 81300411 and Number. 81372662) and the Fundamental Research Funds for the Central Universities (Number 2015QN144).	Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Griffin CT, 2008, DEVELOPMENT, V135, P493, DOI 10.1242/dev.010090; Han D, 2008, DEV BIOL, V315, P136, DOI 10.1016/j.ydbio.2007.12.024; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Koizumi Y, 1997, CLIN CANCER RES, V3, P1067; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; MCNUTT NS, 1981, LAB INVEST, V44, P309; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Shinada K, 2011, BIOCHEM BIOPH RES CO, V404, P143, DOI 10.1016/j.bbrc.2010.11.082; STRAGAND JJ, 1980, CANCER RES, V40, P2846; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sugiura T, 2008, EXP CELL RES, V314, P1519, DOI 10.1016/j.yexcr.2008.01.013; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Tian Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048958; Trotter K., 2008, NUCL RECEPT SIGNAL, V6, P1, DOI DOI 10.1621/NRS.06004; Valdman A, 2003, INT J ONCOL, V22, P1003; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Van Rechem C, 2009, BIOCHEM BIOPH RES CO, V385, P586, DOI 10.1016/j.bbrc.2009.05.115; von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916; Wang G, 2015, ONCOGENE, V34, P912, DOI 10.1038/onc.2014.30; Wang G, 2012, CELL DEATH DIFFER, V19, P1870, DOI 10.1038/cdd.2012.70; Wang GH, 2013, ANGIOGENESIS, V16, P561, DOI 10.1007/s10456-013-9336-y; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wong AKC, 2000, CANCER RES, V60, P6171; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Yen CC, 2003, INT J ONCOL, V23, P871; Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787; Zou Y, 2013, GENE, V531, P112, DOI 10.1016/j.gene.2013.08.054	45	47	48	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					651	661		10.1038/onc.2015.124	http://dx.doi.org/10.1038/onc.2015.124			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25961913				2022-12-28	WOS:000369548800012
J	Mandato, E; Manni, S; Zaffino, F; Semenzato, G; Piazza, F				Mandato, E.; Manni, S.; Zaffino, F.; Semenzato, G.; Piazza, F.			Targeting CK2-driven non-oncogene addiction in B-cell tumors	ONCOGENE			English	Review							PROTEIN-KINASE CK2; LYMPHOBLASTIC-LEUKEMIA CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; LIGAND-INDUCED APOPTOSIS; SELECTIVE INHIBITOR; CASEIN KINASE-2; DNA-DAMAGE; MESENCHYMAL TRANSITION; THERAPEUTIC TARGETS; TYROSINE KINASE	Genetic mutations of oncogenes often underlie deranged cell growth and altered differentiation pathways leading to malignant transformation of B-lymphocytes. However, addiction to oncogenes is not the only drive to lymphoid tumor pathogenesis. Dependence on non-oncogenes, which act by propelling basic mechanisms of cell proliferation and survival, has also been recognized in the pathobiology of lymphoid leukemias, lymphomas and multiple myeloma. Among the growing number of molecules that may uphold non-oncogene addiction, a key place is increasingly being recognized to the serine-threonine kinase CK2. This enzyme is overexpressed and overactive in B-acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphomas, such as mantle cell, follicular, Burkitt's and diffuse large B-cell lymphomas. In these tumors, CK2 may serve the activity of oncogenes, similar to BCR-ABL and c-MYC, control the activation of critical signaling cascades, such as NF-.B (nuclear factor-.B), STAT3 (signal transducer and activator of transcription 3) and PTEN/PI3K/AKT (phosphatase and tensin homolog protein/phosphoinositide 3-kinase/AKR thymoma), and sustain multiple cellular stress-elicited pathways, such as the proteotoxic stress, unfolded protein and DNA-damage responses. CK2 has also been shown to have an essential role in tuning signals derived from the stromal tumor microenvironment. Not surprisingly, targeting CK2 in lymphoid tumor cell lines or mouse xenograft models can boost the cytotoxic effects of both conventional chemotherapeutics and novel agents, similar to heat-shock protein 90, proteasome and tyrosine kinases inhibitors. In this review, we summarize the evidence indicating how CK2 embodies most of the features of a cancer growth-promoting non-oncogene, focusing on lymphoid tumors. We further discuss the preclinical data of the use of small ATP-competitive CK2 inhibitors, which hold the promise to be additional options in novel drug combinations for the therapy of lymphoid and plasmacellular malignancies.	[Mandato, E.; Manni, S.; Zaffino, F.; Semenzato, G.; Piazza, F.] Univ Padua, Hematol Branch, Dept Med, Via Giustiniani 2, I-35128 Padua, Italy; [Mandato, E.; Manni, S.; Zaffino, F.; Semenzato, G.; Piazza, F.] Venetian Inst Mol Med, Padua, Italy	University of Padua; Veneto Institute Molecular Medicine	Piazza, F (corresponding author), Univ Padua, Hematol Branch, Dept Med, Via Giustiniani 2, I-35128 Padua, Italy.	francesco.piazza@unipd.it	SEMENZATO, GIANPIETRO C/J-7727-2016; Manni, Sabrina/AAE-9182-2021; mandato, elisa/AGI-6364-2022; Piazza, Francesco/AAD-1600-2019; Piazza, Francesco/K-6695-2016	SEMENZATO, GIANPIETRO C/0000-0002-6061-4595; mandato, elisa/0000-0002-7443-2821; Piazza, Francesco/0000-0002-2831-623X; Piazza, Francesco/0000-0002-2831-623X; MANNI, SABRINA/0000-0001-6804-0680	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 14481]; Ministero dell'Istruzione, dell'Universita e della Ricerca Scientifica (FIRB-Futuro in Ricerca) [RBFR086EW9_001]; 'Fondazione Umberto Veronesi', Milan, Italy	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, dell'Universita e della Ricerca Scientifica (FIRB-Futuro in Ricerca); 'Fondazione Umberto Veronesi', Milan, Italy(Fondazione Umberto Veronesi)	This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) to FP (IG 14481) and GS and from the Ministero dell'Istruzione, dell'Universita e della Ricerca Scientifica (FIRB-Futuro in Ricerca 2008, no. RBFR086EW9_001). SM is supported by a research fellowship from the 'Fondazione Umberto Veronesi', Milan, Italy.	Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Aparicio-Siegmund S, 2014, ONCOTARGET, V5, P2131, DOI 10.18632/oncotarget.1852; Aronson LI, 2012, HAEMATOL-HEMATOL J, V97, P1119, DOI 10.3324/haematol.2012.064923; Austen B, 2008, BRIT J HAEMATOL, V142, P925, DOI 10.1111/j.1365-2141.2008.07281.x; Balakrishnan K, 2015, LEUKEMIA, V29, P1811, DOI 10.1038/leu.2015.105; Buontempo F, 2016, ONCOTARGET, V7, P1323, DOI 10.18632/oncotarget.6361; Caino MC, 2009, APOPTOSIS, V14, P392, DOI 10.1007/s10495-009-0316-z; Castillo JJ, 2016, CANCER J, V22, P34, DOI 10.1097/PPO.0000000000000170; Cottini F, 2015, CANCER DISCOV, V5, P972, DOI 10.1158/2159-8290.CD-14-0943; Cox ML, 2010, CELL SIGNAL, V22, P564, DOI 10.1016/j.cellsig.2009.11.014; Curran E, 2014, CURR OPIN ONCOL, V26, P469, DOI 10.1097/CCO.0000000000000113; Deshiere A, 2013, ONCOGENE, V32, P1373, DOI 10.1038/onc.2012.165; Deshiere A, 2011, MOL CELL BIOCHEM, V356, P11, DOI 10.1007/s11010-011-0942-y; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Di Maira G, 2009, CELL MOL LIFE SCI, V66, P3363, DOI 10.1007/s00018-009-0108-1; Dixit D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.10; Dovat S, 2011, MOL CELL BIOCHEM, V356, P201, DOI 10.1007/s11010-011-0964-5; Drygin D, 2011, BIOCHEM BIOPH RES CO, V415, P163, DOI 10.1016/j.bbrc.2011.10.046; Duncan JS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001682; Duncan JS, 2010, BBA-PROTEINS PROTEOM, V1804, P505, DOI 10.1016/j.bbapap.2009.11.001; Flinn IW, 2014, BLOOD, V123, P3406, DOI 10.1182/blood-2013-11-538546; Fowler N, 2013, HEMATOL-AM SOC HEMAT, P553, DOI 10.1182/asheducation-2013.1.553; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Galluzzi L, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00001; Giusiano S, 2011, EUR J CANCER, V47, P792, DOI 10.1016/j.ejca.2010.11.028; Guerra B, 2014, CANCER LETT, V345, P115, DOI 10.1016/j.canlet.2013.11.008; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herman SEM, 2013, LEUKEMIA, V27, P1769, DOI 10.1038/leu.2013.37; Hill RJ, 2013, INT REV IMMUNOL, V32, P377, DOI 10.3109/08830185.2013.818141; Izeradjene K, 2005, ONCOGENE, V24, P2050, DOI 10.1038/sj.onc.1208397; Izeradjene K, 2004, CLIN CANCER RES, V10, P6650, DOI 10.1158/1078-0432.CCR-04-0576; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Kalathur M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8227; Kastner P, 2013, AM J BLOOD RES, V3, P1; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; Kuiatse I, 2015, CLIN CANCER RES, V21, P2538, DOI 10.1158/1078-0432.CCR-14-1462; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lu RQ, 2008, TRENDS IMMUNOL, V29, P487, DOI 10.1016/j.it.2008.07.006; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Manni S, 2014, LEUKEMIA, V28, P2094, DOI 10.1038/leu.2014.178; Manni S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075280; Manni S, 2012, CLIN CANCER RES, V18, P1888, DOI 10.1158/1078-0432.CCR-11-1789; Gomes AM, 2014, HAEMATOLOGICA, V99, P1062, DOI 10.3324/haematol.2013.096438; Martins LR, 2014, LEUKEMIA, V28, P179, DOI 10.1038/leu.2013.232; Martins LR, 2010, BLOOD, V116, P2724, DOI 10.1182/blood-2010-04-277947; Maxwell KN, 2012, NAT REV CLIN ONCOL, V9, P520, DOI 10.1038/nrclinonc.2012.123; Melander F, 2008, J CELL BIOL, V181, P213, DOI 10.1083/jcb.200708210; Mishra S, 2007, LEUKEMIA, V21, P178, DOI 10.1038/sj.leu.2404460; Mishra S, 2003, ONCOGENE, V22, P8255, DOI 10.1038/sj.onc.1207156; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; Miyata Y, 2009, CELL MOL LIFE SCI, V66, P1840, DOI 10.1007/s00018-009-9152-0; Montenarh M, 2014, ADV CLIN EXP MED, V23, P153, DOI 10.17219/acem/37040; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268; Olsen BB, 2010, ONCOGENE, V29, P6016, DOI 10.1038/onc.2010.337; Olsen BB, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471-2199-13-7; Peng B, 2015, NUCLEIC ACIDS RES, V43, P5936, DOI 10.1093/nar/gkv528; Piazza F, 2012, LEUKEMIA, V26, P1174, DOI 10.1038/leu.2011.385; Piazza FA, 2006, BLOOD, V108, P1698, DOI 10.1182/blood-2005-11-013672; Pizzi M, 2015, ONCOTARGET, V6, P6544, DOI 10.18632/oncotarget.3446; Plotnikov A, 2011, MOL CELL BIOL, V31, P3515, DOI 10.1128/MCB.05424-11; Popescu M, 2009, J BIOL CHEM, V284, P13869, DOI 10.1074/jbc.M900209200; Pospisilova S, 2004, BIOCHEM J, V378, P939, DOI 10.1042/BJ20030662; Prins RC, 2013, LEUKEMIA, V27, P2094, DOI 10.1038/leu.2013.228; Riabinska A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005814; Ruzzene M, 2011, MOL CELL BIOCHEM, V356, P5, DOI 10.1007/s11010-011-0959-2; Ruzzene M, 2010, BBA-PROTEINS PROTEOM, V1804, P499, DOI 10.1016/j.bbapap.2009.07.018; Sawas A, 2011, CURR OPIN HEMATOL, V18, P280, DOI 10.1097/MOH.0b013e328347786d; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Schevzov G, 2015, MOL BIOL CELL, V26, P2475, DOI 10.1091/mbc.E14-10-1453; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shehata M, 2010, BLOOD, V116, P2513, DOI 10.1182/blood-2009-10-248054; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Song CH, 2015, BLOOD, V126, P1813, DOI 10.1182/blood-2015-06-651505; Song Chunhua, 2011, World J Biol Chem, V2, P126, DOI 10.4331/wjbc.v2.i6.126; St-Denis NA, 2009, CELL MOL LIFE SCI, V66, P1817, DOI 10.1007/s00018-009-9150-2; Strom CE, 2011, DNA REPAIR, V10, P961, DOI 10.1016/j.dnarep.2011.07.004; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trembley JH, 2009, CELL MOL LIFE SCI, V66, P1858, DOI 10.1007/s00018-009-9154-y; Trembley JH, 2010, BIOFACTORS, V36, P187, DOI 10.1002/biof.96; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang GX, 2006, CANCER RES, V66, P2242, DOI 10.1158/0008-5472.CAN-05-2772; Wang S, 2006, CURR BIOL, V16, P2239, DOI 10.1016/j.cub.2006.09.034; Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Young RM, 2015, SEMIN HEMATOL, V52, P77, DOI 10.1053/j.seminhematol.2015.01.008; Zheng Y, 2011, BLOOD, V118, P156, DOI 10.1182/blood-2010-01-266320	96	18	19	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6045	6052		10.1038/onc.2016.86	http://dx.doi.org/10.1038/onc.2016.86			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27041560				2022-12-28	WOS:000388509800001
J	Zhang, W; Hong, S; Maniar, KP; Cheng, S; Jie, C; Rademaker, AW; Krensky, AM; Clayberger, C				Zhang, W.; Hong, S.; Maniar, K. P.; Cheng, S.; Jie, C.; Rademaker, A. W.; Krensky, A. M.; Clayberger, C.			KLF13 regulates the differentiation-dependent human papillomavirus life cycle in keratinocytes through STAT5 and IL-8	ONCOGENE			English	Article							KRUPPEL-LIKE FACTORS; TUMOR-SUPPRESSOR; CLINICAL-IMPLICATIONS; CHEMOKINE RANTES; CERVICAL-CANCER; INTERLEUKIN-8; EXPRESSION; ANGIOGENESIS; GROWTH; TRANSFORMATION	High-risk strains of human papillomavirus (HPV) are the causative agents of cervical and anogenital cancers and are associated with 5% of all human cancers. Although prophylactic vaccines targeting a subset of HPV types are available, they are ineffective in HPV-infected individuals. Elucidation of the mechanisms controlling HPV replication may allow development of novel anti-HPV therapeutics. Infectious HPV virions are produced during terminal differentiation of host cells. The process of viral maturation requires synergistic interactions between viral and cellular proteins that leads to amplification of the viral genome and expression of late viral genes. Here we show that the transcription factor Kruppel-like factor 13 (KLF13) has a critical role in the HPV life cycle. KLF13 is overexpressed in HPV-positive keratinocytes and cervical cancer cell lines. Expression of KLF13 in normal cervical epithelium is low but increases significantly in cervical intraepithelial neoplasia and invasive squamous cervical cancer. After HPV infection, the E7 protein suppresses ubiquitin ligase FBW7 expression leading to an increase in KLF13 expression. Reduction of KLF13 with short hairpin RNA in differentiating HPV-positive cells resulted in diminished levels of viral gene expression and genome amplification. Knockdown of KLF13 also reduced the level of the transcription factor signal transducer and activator of transcription 5, which led to the downregulation of the ataxia-telangiectasia mutated DNA damage pathway and the chemokine interleukin-8 (IL-8). In addition, neutralization of IL-8 diminished viral genome amplification in differentiating HPV-positive cells. Thus, KLF13 is critical for the activation of the HPV productive life cycle and is likely involved in initiation and progression of cervical cancer.	[Zhang, W.; Hong, S.; Cheng, S.; Krensky, A. M.; Clayberger, C.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 300 East Super St, Chicago, IL 60611 USA; [Maniar, K. P.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Jie, C.] Des Moines Univ, Dept Res Biostat, Des Moines, IA USA; [Rademaker, A. W.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Rademaker, A. W.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; [Krensky, A. M.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Clayberger, C (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 300 East Super St, Chicago, IL 60611 USA.	Clayberger@northwestern.edu	zhang, wei/A-7015-2011		H Foundation Cancer Research Fund; Robert H Lurie Comprehensive Cancer Center	H Foundation Cancer Research Fund; Robert H Lurie Comprehensive Cancer Center	This work was supported in part by the H Foundation Cancer Research Fund and Robert H Lurie Comprehensive Cancer Center (to W Zhang). We thank Dr Laimonis A Laimins for helpful discussions.	Ahn YT, 2007, MOL CELL BIOL, V27, P253, DOI 10.1128/MCB.01071-06; Ai WD, 2000, J VIROL, V74, P5198, DOI 10.1128/JVI.74.11.5198-5205.2000; Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376; ANTTILA HSI, 1992, CLIN EXP IMMUNOL, V89, P509; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; Britschgi A, 2012, CANCER CELL, V22, P419; Cao ZX, 2010, BLOOD, V116, P4404, DOI 10.1182/blood-2010-05-285353; Chen JJW, 2003, CLIN CANCER RES, V9, P729; De Larco JE, 2004, CLIN CANCER RES, V10, P4895, DOI 10.1158/1078-0432.CCR-03-0760; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fehrmann Frauke, 2005, Methods Mol Biol, V292, P317; Forte E, 2015, J VIROL, V89, P2333, DOI 10.1128/JVI.03317-14; Fujimoto J, 2000, CANCER RES, V60, P2632; Grone A, 2002, VET IMMUNOL IMMUNOP, V88, P1, DOI 10.1016/S0165-2427(02)00136-8; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Harry BL, 2012, EXPERT OPIN INV DRUG, V21, P637, DOI 10.1517/13543784.2012.677432; Henson B J, 2010, Cytogenet Genome Res, V128, P192, DOI 10.1159/000308303; Hong SM, 2013, J NANOMATER, V2013, DOI [10.1155/2013/246328, 10.1155/2013/790323]; Hong SY, 2013, FUTURE MICROBIOL, V8, P1547, DOI 10.2217/fmb.13.127; Kajitani N, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00152; Kim DS, 2012, BLOOD, V120, P1658, DOI 10.1182/blood-2012-03-415968; Liao W, 2008, NAT IMMUNOL, V9, P1288, DOI 10.1038/ni.1656; Limame R, 2014, ONCOTARGET, V5, P29, DOI 10.18632/oncotarget.1456; Marrero-Rodriguez D, 2014, TUMOR BIOL, V35, P11399, DOI 10.1007/s13277-014-2380-4; Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moody CA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000605; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Ooi AGL, 2010, P NATL ACAD SCI USA, V107, P21505, DOI 10.1073/pnas.1016218107; Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111; Sakakibara N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003321; Simard JC, 2014, FEBS LETT, V588, P2141, DOI 10.1016/j.febslet.2014.04.027; Steenbergen RDM, 2014, NAT REV CANCER, V14, P395, DOI 10.1038/nrc3728; Thierry F, 2009, VIROLOGY, V384, P375, DOI 10.1016/j.virol.2008.11.014; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Walker J, 2011, VIROLOGY, V410, P283, DOI 10.1016/j.virol.2010.11.010; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wu SH, 2013, MOL CELL BIOCHEM, V375, P69, DOI 10.1007/s11010-012-1529-y; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12; Zhao X, 2010, ARTHRITIS RHEUM-US, V62, P3425, DOI 10.1002/art.27632	48	17	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5565	5575		10.1038/onc.2016.97	http://dx.doi.org/10.1038/onc.2016.97			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27041562				2022-12-28	WOS:000386998200010
J	Garcia-Palmero, I; Torres, S; Bartolome, RA; Pelaez-Garcia, A; Larriba, MJ; Lopez-Lucendo, M; Pena, C; Escudero-Paniagua, B; Munoz, A; Casal, JI				Garcia-Palmero, I.; Torres, S.; Bartolome, R. A.; Pelaez-Garcia, A.; Larriba, M. J.; Lopez-Lucendo, M.; Pena, C.; Escudero-Paniagua, B.; Munoz, A.; Casal, J. I.			Twist1-induced activation of human fibroblasts promotes matrix stiffness by upregulating palladin and collagen alpha 1(VI)	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-ASSOCIATED FIBROBLASTS; BUNDLING PROTEIN PALLADIN; RENAL-CELL CARCINOMA; POOR-PROGNOSIS; COLON-CANCER; COLORECTAL-CANCER; TUMOR-METASTASIS; BREAST-CANCER; INVADOPODIA FORMATION	The transcription factor Twist1 is involved in the epithelial-mesenchymal transition and contributes to cancer metastasis through mostly unknown mechanisms. In colorectal cancer, Twist1 expression is mainly restricted to the tumor stroma. We found that human fibroblast cell lines stably transfected with Twist1 acquired characteristics of activated cancer-associated fibroblasts (CAFs), such as hyperproliferation, an increased ability to migrate and an alignment of the actin cytoskeleton. Further, Twist1-activated fibroblasts promoted increased matrix stiffness. Using quantitative proteomics, we identified palladin and collagen alpha 1(VI) as two major mediators of the Twist1 effects in fibroblast cell lines. Co-immunoprecipitation studies indicated that palladin and Twist1 interact within the nucleus, suggesting that palladin could act as a transcription regulator. Palladin was found to be more relevant for the cellular biomechanical properties, orientation and polarity, and collagen alpha 1(VI) for the migration and invasion capacity, of Twist1-activated fibroblasts. Both palladin and collagen alpha 1(VI) were observed to be overexpressed in colorectal CAFs and to be associated with poor colorectal cancer patient survival and relapse prediction. Our results demonstrate that Twist1-expressing fibroblasts mimic the properties of CAFs present at the tumor invasive front, which likely explains the prometastatic activities of Twist1. Twist1 appears to require both palladin and collagen alpha 1(VI) as downstream effectors for its prometastatic effects, which could be future therapeutic targets in cancer metastasis.	[Garcia-Palmero, I.; Torres, S.; Bartolome, R. A.; Pelaez-Garcia, A.; Escudero-Paniagua, B.; Casal, J. I.] CSIC, CIB, Dept Cellular & Mol Med, Ramiro de Maeztu 9, Madrid 28040, Spain; [Larriba, M. J.; Munoz, A.] UAM, CSIC, Inst Invest Biomed Alberto Sols, IdiPAZ, Madrid, Spain; [Lopez-Lucendo, M.] CSIC, CIB, Prote Core Facil, Madrid, Spain; [Pena, C.] Hosp Univ Puerta de Hierro, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Hospital Puerta de Hierro-Majadahonda	Casal, JI (corresponding author), CSIC, CIB, Dept Cellular & Mol Med, Ramiro de Maeztu 9, Madrid 28040, Spain.	icasal@cib.csic.es	Munoz, Alberto/O-6393-2014; LARRIBA, MARIA JESUS/O-4652-2014; Casal, Ignacio/M-2312-2014; Bartolome, Ruben A/M-1873-2014	Munoz, Alberto/0000-0003-3890-4251; LARRIBA, MARIA JESUS/0000-0001-9035-7414; Casal, Ignacio/0000-0003-1085-2840; Pelaez Garcia, Alberto/0000-0002-5401-3216; Bartolome, Ruben A/0000-0002-3292-1491	Comunidad de Madrid [S2010/BMD-2344/Colomics2]; Juan de la Cierva programme; Asociacion Espanola Contra el Cancer (AECC); ProteoRed contract; Ministry of Economy and Competitiveness (MINECO); Comunidad de Madrid, 'Asociacion Espanola Contra el Cancer (AECC) [S2010/BMD-2344/Colomics2]; MINECO [BIO2012-31023]; Instituto de Salud Carlos III-FEDER [PRB2 (IPT13/0001-ISCIII-SGEFI/FEDER), RD12/0036/0041, RD12/0036/0021]	Comunidad de Madrid(Comunidad de Madrid); Juan de la Cierva programme; Asociacion Espanola Contra el Cancer (AECC); ProteoRed contract; Ministry of Economy and Competitiveness (MINECO)(Spanish Government); Comunidad de Madrid, 'Asociacion Espanola Contra el Cancer (AECC)(Comunidad de Madrid); MINECO(Spanish Government); Instituto de Salud Carlos III-FEDER(Instituto de Salud Carlos IIIEuropean Commission)	IG-P was supported by a contract S2010/BMD-2344/Colomics2 from the Comunidad de Madrid. ST was a recipient of a Juan de la Cierva programme. RAB was supported by a grant to established research groups of the Asociacion Espanola Contra el Cancer (AECC). ML-L was a recipient of a ProteoRed contract. AP-G and BE-P were FPI fellows from the Ministry of Economy and Competitiveness (MINECO). This research was supported by grants to established research groups of the S2010/BMD-2344/Colomics2 from the Comunidad de Madrid, 'Asociacion Espanola Contra el Cancer (AECC)', BIO2012-31023 from the MINECO, PRB2 (IPT13/0001-ISCIII-SGEFI/FEDER), RD12/0036/0041 and RD12/0036/0021 from the Instituto de Salud Carlos III-FEDER.	Amatangelo MD, 2005, AM J PATHOL, V167, P475, DOI 10.1016/S0002-9440(10)62991-4; Bartolome RA, 2014, ONCOGENE, V33, P1658, DOI 10.1038/onc.2013.117; Bartolome RA, 2015, CANCER RES, V75, P2434, DOI 10.1158/0008-5472.CAN-14-3650; Bartolome RA, 2014, J BIOL CHEM, V289, P34801, DOI 10.1074/jbc.M114.600502; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cannon AR, 2015, CYTOSKELETON, V72, P402, DOI 10.1002/cm.21239; Chen PW, 2013, TRENDS MOL MED, V19, P410, DOI 10.1016/j.molmed.2013.04.001; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Chin YR, 2010, FEBS LETT, V584, P4769, DOI 10.1016/j.febslet.2010.10.056; Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031; Chiu KH, 2011, J PROTEOME RES, V10, P1110, DOI 10.1021/pr1008724; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Endlich N, 2009, KIDNEY INT, V75, P214, DOI 10.1038/ki.2008.486; Goicoechea SM, 2014, ONCOGENE, V33, P1265, DOI 10.1038/onc.2013.68; Goicoechea SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010347; Gomez I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018023; Groulx JF, 2011, MATRIX BIOL, V30, P195, DOI 10.1016/j.matbio.2011.03.002; Gupta V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021494; Larriba MJ, 2009, CARCINOGENESIS, V30, P1459, DOI 10.1093/carcin/bgp140; Jin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012823; Jin L, 2009, J BIOL CHEM, V284, P2121, DOI 10.1074/jbc.M806095200; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Liu TJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142547; Liu XS, 2007, J CELL BIOCHEM, V100, P1288, DOI 10.1002/jcb.21126; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; McLane JS, 2015, BIOPHYS J, V109, P249, DOI 10.1016/j.bpj.2015.06.033; Ohba K, 2014, INT J CLIN EXP PATHO, V7, P3158; Ou DL, 2008, ANTICANCER RES, V28, P1355; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Riaz M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3317; Ronty MJ, 2006, J INVEST DERMATOL, V126, P2387, DOI 10.1038/sj.jid.5700427; Salaria SN, 2007, CANCER BIOL THER, V6, P324, DOI 10.4161/cbt.6.3.3904; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; Sung CO, 2011, AM J PATHOL, V179, P1827, DOI 10.1016/j.ajpath.2011.06.032; Torres S, 2015, CLIN CANCER RES, V21, P4892, DOI 10.1158/1078-0432.CCR-14-3096; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Valdes-Mora F, 2009, ANN SURG ONCOL, V16, P78, DOI 10.1245/s10434-008-0166-x; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wan FN, 2015, ONCOTARGET, V6, P27378, DOI 10.18632/oncotarget.4860; Watson MA, 2007, CLIN CANCER RES, V13, P5001, DOI 10.1158/1078-0432.CCR-07-0024; Wei SC, 2015, NAT CELL BIOL, V17, P678, DOI 10.1038/ncb3157; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Xie FW, 2009, CLIN EXP METASTAS, V26, P1025, DOI 10.1007/s10585-009-9292-5; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	53	39	40	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5224	5236		10.1038/onc.2016.57	http://dx.doi.org/10.1038/onc.2016.57			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26973246				2022-12-28	WOS:000386053000002
J	Muramatsu, T; Kozaki, KI; Imoto, S; Yamaguchi, R; Tsuda, H; Kawano, T; Fujiwara, N; Morishita, M; Miyano, S; Inazawa, J				Muramatsu, T.; Kozaki, K-I; Imoto, S.; Yamaguchi, R.; Tsuda, H.; Kawano, T.; Fujiwara, N.; Morishita, M.; Miyano, S.; Inazawa, J.			The hypusine cascade promotes cancer progression and metastasis through the regulation of RhoA in squamous cell carcinoma	ONCOGENE			English	Article							TRANSLATION INITIATION-FACTOR; FACTOR 5A EIF5A; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; PROTEOMIC ANALYSIS; COLORECTAL-CANCER; PANCREATIC-CANCER; TUMOR-METASTASIS; LIVER-CANCER; IN-VIVO	Metastasis is a critical factor contributing to poor prognosis in cancer, but the underlying mechanisms of metastasis are still poorly understood. We established a highly metastatic cell subline (HOC313-LM) derived from an oral squamous cell carcinoma cell line (HOC313) for uncovering the mechanisms of metastasis, and identified deoxyhypusine synthase (DHPS) as a metastasis-associated gene within the specific amplification at 19p13.2-p13.13 in HOC313-LM. DHPS-mediated hypusine-modification of eukaryotic translation factor 5A facilitated the translation of RhoA, resulting in the activation of the RhoA signaling pathway and leading to not only increased cell motility, invasion and metastasis of cancer cells in vitro, but also increased tumor growth in vivo. Moreover, the use of N1-Guanyl-1,7-diaminoheptane, a DHPS inhibitor, resulted in a significant decrease in tumor formation in vivo. In patients with esophageal squamous cell carcinoma (ESCC), overexpression of DHPS in ESCC tumors was significantly associated with worse recurrence-free survival, and correlated with distant metastasis. The elucidation of these molecular mechanisms within the hypusine cascade suggests opportunities for novel therapeutic targets in SCC.	[Muramatsu, T.; Kozaki, K-I; Fujiwara, N.; Morishita, M.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; [Muramatsu, T.; Inazawa, J.] Tokyo Med & Dent Univ, Global Ctr Excellence GCOE, Program Frontier Res Mol Destruct & Reconstitut T, Tokyo, Japan; [Muramatsu, T.] Japan Soc Promot Sci, Tokyo, Japan; [Kozaki, K-I; Inazawa, J.] Tokyo Med & Dent Univ, Bioresource Res Ctr, Tokyo, Japan; [Kozaki, K-I] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Dent Pharmacol, Okayama, Japan; [Imoto, S.; Yamaguchi, R.; Miyano, S.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Dept DNA Informat Anal, Tokyo, Japan; [Tsuda, H.] Natl Def Med Coll, Dept Basic Pathol, Saitama, Japan; [Kawano, T.; Fujiwara, N.] Tokyo Med & Dent Univ, Grad Sch, Dept Surg, Tokyo, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Society for the Promotion of Science; Tokyo Medical & Dental University (TMDU); Okayama University; University of Tokyo; National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp		Imoto, Seiya/0000-0002-2989-308X; Miyano, Satoru/0000-0002-1753-6616	Ministry of Education, Culture, Sports, Science and Technology (MEXT) [22134002, 15H05908, 22240090, 25250019, 15K18401, 26890012]; Tailor-Made Medical Treatment; BioBank Japan Project (BBJ); Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development [15Ack0106017h0002]; AMED; Global Center of Excellence (GCOE) Program for International Research Center for Molecular Science in Tooth and Bone Diseases; Ministry of Education, Culture, Sports, Science and Technology, Japan	Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Tailor-Made Medical Treatment; BioBank Japan Project (BBJ); Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development(Japan Agency for Medical Research and Development (AMED)); AMED; Global Center of Excellence (GCOE) Program for International Research Center for Molecular Science in Tooth and Bone Diseases; Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported in part by a Grant-in Aid for Scientific Research (KAKENHI) for Innovative Areas (22134002, 15H05908) (Integrative Systems Understanding of Cancer for Advanced Diagnosis, Therapy and Prevention), Scientific Research (A) (22240090, 25250019), Challenging Exploratory Research (B) (15K18401), Research Activity Start-up (26890012), JSPS Fellows from Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Tailor-Made Medical Treatment with the BioBank Japan Project (BBJ) and the Practical Research for Innovative Cancer Control (15Ack0106017h0002) from Japan Agency for Medical Research and development, AMED and Global Center of Excellence (GCOE) Program for International Research Center for Molecular Science in Tooth and Bone Diseases, from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Balabanov S, 2007, BLOOD, V109, P1701, DOI 10.1182/blood-2005-03-037648; Caraglia M, 2013, AMINO ACIDS, V44, P103, DOI 10.1007/s00726-011-1182-x; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Cipollini G, 1997, INT J CANCER, V73, P297, DOI 10.1002/(SICI)1097-0215(19971009)73:2<297::AID-IJC22>3.0.CO;2-B; Dong ZZ, 2005, MOL CELL PROTEOMICS, V4, P993, DOI 10.1074/mcp.M500044-MCP200; Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965; Fujimura K, 2015, J BIOL CHEM, V290, P29907, DOI 10.1074/jbc.M115.687418; Fujimura K, 2014, CANCER RES, V74, P6671, DOI 10.1158/0008-5472.CAN-14-1031; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Guan XY, 2004, CANCER RES, V64, P4197, DOI 10.1158/0008-5472.CAN-03-3747; Gutierrez E, 2013, MOL CELL, V51, P35, DOI 10.1016/j.molcel.2013.04.021; He XY, 2012, CARCINOGENESIS, V33, P555, DOI 10.1093/carcin/bgs002; Huang YF, 2007, P NATL ACAD SCI USA, V104, P4194, DOI 10.1073/pnas.0611609104; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Jasiulionis MG, 2007, CELL BIOCHEM FUNCT, V25, P109, DOI 10.1002/cbf.1351; Kaiser A, 2012, AMINO ACIDS, V42, P679, DOI 10.1007/s00726-011-1042-8; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Lee NP, 2010, INT J CANCER, V127, P968, DOI 10.1002/ijc.25100; Li YJ, 2012, PROCEEDINGS OF INTERNATIONAL SYMPOSIUM ON EMERGENCY MANAGEMENT 2011, P5; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Lou B, 2013, EXP CELL RES, V319, P2708, DOI 10.1016/j.yexcr.2013.08.010; Lu ZJ, 2014, CELL PHYSIOL BIOCHEM, V33, P859, DOI 10.1159/000358658; Maier B, 2010, J CLIN INVEST, V120, P2156, DOI 10.1172/JCI38924; Mandal A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111800; Memin E, 2014, CANCER RES, V74, P552, DOI 10.1158/0008-5472.CAN-13-0474; Minden MD, 2014, AM J HEMATOL, V89, P363, DOI 10.1002/ajh.23640; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Nakayama K, 2006, P NATL ACAD SCI USA, V103, P18739, DOI 10.1073/pnas.0604083103; Neeb A, 2012, ONCOGENE, V31, P3796, DOI 10.1038/onc.2011.535; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646; Park MH, 2010, AMINO ACIDS, V38, P491, DOI 10.1007/s00726-009-0408-7; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Preukschas M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043468; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Scuoppo C, 2012, NATURE, V487, P244, DOI 10.1038/nature11126; Semenza GL, 2003, NAT REV CANCER, V4, P191; Shih IM, 2011, MODERN PATHOL, V24, P638, DOI 10.1038/modpathol.2010.230; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Straume O, 2012, P NATL ACAD SCI USA, V109, P8699, DOI 10.1073/pnas.1017909109; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tang DJ, 2010, HEPATOLOGY, V51, P1255, DOI 10.1002/hep.23451; Taylor CA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-35; Tunca B, 2013, J CANCER RES CLIN, V139, P691, DOI 10.1007/s00432-013-1372-x; Villalonga P, 2006, GROWTH FACTORS, V24, P159, DOI 10.1080/08977190600560651; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Wang FW, 2013, INT J BIOL SCI, V9, P1013, DOI 10.7150/ijbs.7191; Wei JH, 2014, BRIT J CANCER, V110, P1767, DOI 10.1038/bjc.2014.52; Yap KL, 2012, CANCER RES, V72, P4085, DOI 10.1158/0008-5472.CAN-12-0302; Yasumoto E, 2004, ANTICANCER RES, V24, P755; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255; Zhu W, 2014, GASTROENTEROLOGY, V146	56	24	26	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5304	5316		10.1038/onc.2016.71	http://dx.doi.org/10.1038/onc.2016.71			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041563				2022-12-28	WOS:000386053000009
J	Hung, MH; Chen, YL; Chu, PY; Shih, CT; Yu, HC; Tai, WT; Shiau, CW; Chen, KF				Hung, M-H; Chen, Y-L; Chu, P-Y; Shih, C-T; Yu, H-C; Tai, W-T; Shiau, C-W; Chen, K-F			Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; ACUTE MYELOID-LEUKEMIA; ANTICANCER THERAPY; TUMOR-SUPPRESSOR; CELL-SURVIVAL; OKADAIC ACID; PP2A; INHIBITION; SORAFENIB; CANCER	The SET protein is a potent inhibitor of protein phosphatase 2A (PP2A). Here, we report the oncogenic role of SET in hepatocarcinogenesis, clinical aggressiveness and anti-hepatocellular carcinoma (HCC) therapeutics. By analyzing samples obtained from 147 HCC patients, we found that SET overexpression was detected specifically in 30.6% HCC tumor samples, and was significantly associated with worse clinical features and high p-Akt expression in HCC tumors. Co-expression of SET and Akt predicted shorter post-operative recurrence-free survival in this cohort (P = 0.045). Furthermore, SET was significantly associated with cell growth and hepatosphere formation. To elucidate the anti-HCC potential of targeting SET, we generated a novel SET antagonist, EMQA (N-4-(3-ethynylphenyl)-6,7-dimethoxy-N-2-(4-phenoxyphenyl) quinazoline-2,4-diamine). EMQA enhanced PP2A activity via disrupting SET-PP2Ac (catalytic domain of PP2A) binding in HCC cells, which restored PP2A-mediated p-Akt downregulation and promoted HCC cell death. In HCC cells or recombinant proteins expressing the N- and C-truncated forms of SET, only the C-terminal SET was required for EMQA targeting. Furthermore, combining sorafenib and EMQA showed good synergism in inhibiting HCC survival. Our findings suggested the oncogenic role of SET and the adverse prognostic value of SET overexpression in HCC. This alteration defines a subgroup of HCC patients who could benefit from SET antagonists, such as EMQA.	[Hung, M-H] Taipei Vet Gen Hosp, Dept Oncol, Div Med Oncol, Taipei, Taiwan; [Hung, M-H] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan; [Hung, M-H] Natl Yang Ming Univ, Sch Life Sci, Program Mol Med, Taipei, Taiwan; [Hung, M-H] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chen, Y-L] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan; [Chen, Y-L] Changhua Christian Hosp, Dept Surg, Changhua, Taiwan; [Chu, P-Y] Show Chwan Mem Hosp, Dept Pathol, Changhua, Taiwan; [Chu, P-Y] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan; [Shih, C-T; Yu, H-C; Tai, W-T; Chen, K-F] Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan S Rd, Taipei 100, Taiwan; [Tai, W-T; Chen, K-F] Natl Taiwan Univ Hosp, Natl Ctr Excellence Clin Trial & Res, Taipei, Taiwan; [Shiau, C-W] Natl Yang Ming Univ, Inst Biopharmaceut Sci, 155,Sec 2,Li Nong St, Taipei, Taiwan	Taipei Veterans General Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Kaohsiung Medical University; Changhua Christian Hospital; Show Chwan Memorial Hospital; Fu Jen Catholic University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University	Chen, KF (corresponding author), Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan S Rd, Taipei 100, Taiwan.; Shiau, CW (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, 155,Sec 2,Li Nong St, Taipei, Taiwan.	cwshiau@ym.edu.tw; kfchen1970@ntu.edu.tw		Chu, Pei-Yi/0000-0001-7336-2465	Ministry of Science and Technology [MOST-104-3113-B-076-001]; Taipei Veterans General Hospital [104DHA0100480, V105B-015]; Taiwan Clinical Oncology Research Foundation; Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taipei Veterans General Hospital(Taipei Veterans General Hospital); Taiwan Clinical Oncology Research Foundation; Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program	This study is supported by grant MOST-104-3113-B-076-001 from the Ministry of Science and Technology and grant 104DHA0100480 and V105B-015 from Taipei Veterans General Hospital, and partial support from Taiwan Clinical Oncology Research Foundation, Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program.	Agarwal A, 2014, CLIN CANCER RES, V20, P2092, DOI 10.1158/1078-0432.CCR-13-2575; Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; Arnaud L, 2011, FEBS LETT, V585, P2653, DOI 10.1016/j.febslet.2011.07.020; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bononi A, 2011, ENZYME RES, V2011, DOI [10.4061/2011/329098, DOI 10.4061/2011/329098]; Bruix J, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.4006; Carlson SG, 1998, J AM SOC NEPHROL, V9, P1873; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357; Chen KF, 2012, BIOORGAN MED CHEM, V20, P6144, DOI 10.1016/j.bmc.2012.08.039; Chen KF, 2011, J PHARMACOL EXP THER, V337, P155, DOI 10.1124/jpet.110.175786; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen WB, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/675429; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Cristobal I, 2015, CLIN CANCER RES, V21, P347, DOI 10.1158/1078-0432.CCR-14-0724; Cristobal I, 2012, HAEMATOL-HEMATOL J, V97, P543, DOI 10.3324/haematol.2011.050542; EISENMANN DM, 1994, GENETICS, V137, P647; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Fukukawa C, 2000, CANCER LETT, V161, P89, DOI 10.1016/S0304-3835(00)00598-X; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Issa NP, 2015, NEUROLOGY, V84, P99, DOI 10.1212/WNL.0000000000001109; Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kubota D, 2014, J PROTEOME RES, V13, P2250, DOI 10.1021/pr400929h; Leopoldino AM, 2012, MOL CELL BIOCHEM, V363, P65, DOI 10.1007/s11010-011-1158-x; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Liu GP, 2012, NEUROBIOL AGING, V33, P254, DOI 10.1016/j.neurobiolaging.2010.01.016; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Muto S, 2007, P NATL ACAD SCI USA, V104, P4285, DOI 10.1073/pnas.0603762104; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Neviani P, 2013, J CLIN INVEST, V123, P4144, DOI 10.1172/JCI68951; Patching SG, 2014, BBA-BIOMEMBRANES, V1838, P43, DOI 10.1016/j.bbamem.2013.04.028; Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Pippa R, 2014, LEUKEMIA, V28, P1915, DOI 10.1038/leu.2014.141; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Switzer CH, 2011, ONCOGENE, V30, P2504, DOI 10.1038/onc.2010.622; Tai WT, 2014, HEPATOLOGY, V59, P190, DOI 10.1002/hep.26640; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Yu HC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.325; Yu HC, 2013, BIOCHEM PHARMACOL, V85, P356, DOI 10.1016/j.bcp.2012.11.009; Zhai B, 2014, MOL CANCER THER, V13, P1589, DOI 10.1158/1535-7163.MCT-13-1043	50	27	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4891	4902		10.1038/onc.2016.21	http://dx.doi.org/10.1038/onc.2016.21			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876205				2022-12-28	WOS:000383330700007
J	Sun, Y; Zhu, D; Chen, F; Qian, M; Wei, H; Chen, W; Xu, J				Sun, Y.; Zhu, D.; Chen, F.; Qian, M.; Wei, H.; Chen, W.; Xu, J.			SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment	ONCOGENE			English	Article							SECRETORY PHENOTYPE; DRIVEN RESISTANCE; DRUG-RESISTANCE; SENESCENCE; FIBROBLASTS; EXPRESSION; INHIBITORS; PATHWAYS; PROTEINS; COMPLEX	Most tumors initially respond to cytotoxic treatments, but acquired resistance often follows. The tumor microenvironment (TME) is a major barrier to clinical success by compromising therapeutic efficacy, and pathological relevance of multiple soluble factors released by a therapeutically remodeled TME remains largely unexplored. Here we show that the secreted frizzled-related protein 2 (SFRP2), a Wnt pathway modulator, is produced by human primary fibroblasts after genotoxic treatments. SFRP2 induction is remarkable in tumor stroma, with transcription mainly modulated by the nuclear factor-kappa B (NF-kappa B) complex, a property shared by several effectors of the DNA damage secretory program. Instead of directly altering canonical Wnt signaling, SFRP2 augments beta-catenin activities initiated by WNT16B, another soluble factor from DNA-damaged stroma. WNT16B recognizes cancer cell surface receptors including frizzled (FZD) 3/4/6, a process enhanced by SFRP2, coordinated by the co-receptor LRP6 but subject to abrogation by DKK1. Importantly, we found WNT16B plays a central role in promoting advanced malignancies particularly acquired resistance by counteracting cell death, an effect that can be minimized by a neutralizing antibody co-administered with classical chemotherapy. Furthermore, DNA damage-triggered expression of WNT16B is systemic, imaged by significant induction among diverse solid organs and circulation in peripheral blood, thereby holding promise as not only a TME-derived anticancer target but also a novel biomarker for clinical evaluation of treatment efficacy. Overall, our study substantiates the biological complexity and pathological implication of a therapy-activated TME, and provides the proof of principle of co-targeting tumor and the TME to prevent acquired resistance, with the aim of improving intervention outcome in an era of precision medicine.	[Sun, Y.; Chen, F.; Qian, M.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Sun, Y.; Chen, F.; Qian, M.] Shanghai Jiao Tong Univ, Sch Med SJTUSM, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Sun, Y.] Shanghai Jiao Tong Univ, Sch Med, Collaborat Innovat Ctr Syst Biomed, Shanghai, Peoples R China; [Sun, Y.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Sun, Y.] Univ Washington, VAPSHCS, Seattle, WA 98195 USA; [Zhu, D.; Xu, J.] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Wei, H.; Chen, W.] Second Mil Med Univ, Changzheng Hosp, Dept Pharmacol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fudan University; Naval Medical University	Sun, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	sunyu@sibs.ac.cn		sun, yu/0000-0001-7121-9112	US DoD PCRP Idea Development Award [PC111703]; National Natural Science Foundation of China [81472709, 81272390, 81472228]; National 1000 Youth Elites Research Program of China	US DoD PCRP Idea Development Award; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National 1000 Youth Elites Research Program of China	We thank Dr Peter Nelson (Fred Hutchinson Cancer Research Center) for kindly providing fibroblast cell lines, essential reagents and conferring critical comments. This work was supported by a US DoD PCRP Idea Development Award (PC111703 to YS), the National Natural Science Foundation of China (81472709 to YS, 81272390 and 81472228 to JX) and the National 1000 Youth Elites Research Program of China (to YS).	Alspach E, 2014, CANCER DISCOV, V4, P716, DOI 10.1158/2159-8290.CD-13-0743; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bao J, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003028; Basch E, 2014, J CLIN ONCOL, V32, P3436, DOI 10.1200/JCO.2013.54.8404; Binet R, 2009, CANCER RES, V69, P9183, DOI 10.1158/0008-5472.CAN-09-1016; Borriello L, 2014, M S-MED SCI, V30, P445, DOI 10.1051/medsci/20143004021; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Chen F, 2014, PROTEIN CELL, V5, P816, DOI 10.1007/s13238-014-0097-1; Cheng ZH, 2011, NAT STRUCT MOL BIOL, V18, P1204, DOI 10.1038/nsmb.2139; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Corso S, 2013, CANCER DISCOV, V3, P978, DOI 10.1158/2159-8290.CD-13-0040; Courtwright A, 2009, CANCER RES, V69, P4621, DOI 10.1158/0008-5472.CAN-08-3402; Halabi S, 2013, JNCI-J NATL CANCER I, V105, P1729, DOI 10.1093/jnci/djt280; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Huber RM, 2015, ONCOTARGET, V6, P2134, DOI 10.18632/oncotarget.3040; Kinugasa Y, 2014, STEM CELLS, V32, P145, DOI 10.1002/stem.1556; Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006; Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Laberge RM, 2012, AGING CELL, V11, P569, DOI 10.1111/j.1474-9726.2012.00818.x; Mii Y, 2009, DEVELOPMENT, V136, P4083, DOI 10.1242/dev.032524; O'Hurley G, 2011, HISTOPATHOLOGY, V59, P1240, DOI 10.1111/j.1365-2559.2011.04073.x; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Ostman A, 2012, NAT MED, V18, P1332, DOI 10.1038/nm.2938; PAGET S, 1989, CANCER METAST REV, V8, P98; Pazolli E, 2012, CANCER RES, V72, P2251, DOI 10.1158/0008-5472.CAN-11-3386; Perry AS, 2013, INT J CANCER, V132, P1771, DOI 10.1002/ijc.27798; Ren SY, 2013, P NATL ACAD SCI USA, V110, P1440, DOI 10.1073/pnas.1211179110; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Saini S, 2011, NAT REV UROL, V8, P690, DOI 10.1038/nrurol.2011.146; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Siamakpour-Reihani S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020412; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044; Sun Y, 2015, MED RES REV, V35, P408, DOI 10.1002/med.21338; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Sun Y, 2012, CLIN CANCER RES, V18, P4019, DOI 10.1158/1078-0432.CCR-11-0768; Tsuchimochi K, 2010, J BIOL CHEM, V285, P8395, DOI 10.1074/jbc.M109.038638; Vidal SJ, 2014, ONCOGENE, V33, P4451, DOI 10.1038/onc.2013.411; von Marschall Z, 2010, BIOCHEM BIOPH RES CO, V400, P299, DOI 10.1016/j.bbrc.2010.08.043; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xu J, 2007, ANN SURG, V245, P583, DOI 10.1097/01.sla.0000250453.34507.d3; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Yang Y, 2015, CANCER RES, V75, P594, DOI 10.1158/0008-5472.CAN-14-2362; Zhang Shengting, 2014, Zhonghua Xue Ye Xue Za Zhi, V35, P466, DOI 10.3760/cma.j.issn.0253-2727.2014.05.022	49	64	65	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4321	4334		10.1038/onc.2015.494	http://dx.doi.org/10.1038/onc.2015.494			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26751775	Green Published, hybrid			2022-12-28	WOS:000382152100004
J	Mukhopadhyay, P; Ferguson, B; Muller, HK; Handoko, HY; Walker, GJ				Mukhopadhyay, P.; Ferguson, B.; Muller, H. K.; Handoko, H. Y.; Walker, G. J.			Murine melanomas accelerated by a single UVR exposure carry photoproduct footprints but lack UV signature C > T mutations in critical genes	ONCOGENE			English	Article							ULTRAVIOLET-RADIATION; SOMATIC MUTATIONS; NORMAL SKIN; DNA; REPAIR; MECHANISMS; MUTAGENESIS; DRIVEN; CANCER; RISK	Ultraviolet radiation (UVR) exposure increases malignant melanoma (MM) risk, but in the context of acute, not cumulative exposure. C > T and CC > TT changes make up the overwhelming majority of single base substitutions (SBS) in MM DNA, as both precursor melanocytes and melanocytic lesions have incurred incidental exposures to sunlight. To study the mutagenic mechanisms by which acute sunburn accelerates MM, we sequenced the exomes of spontaneous and neonatal UVB-induced Cdk4-R24C::Tyr-NRASQ61K mouse MMs. UVR-induced MMs carried more SBSs than spontaneous MMs, but the levels of genomic instability, reflected by translocations and copy number changes, were not different. C > T/G > A was the most common SBS in spontaneous and UVR-induced MMs, only modestly increased in the latter. However, they tended to occur at the motif A/GpCpG (reflecting C > T transition due to spontaneous deamination of cytosine at CpG) in spontaneous MMs, and T/CpCpC/T (reflecting the effects of pyrimidine dimers on either side of the mutated C) in UVR-induced MMs. Unlike MMs associated with repetitive exposures, we observed no CC > TT changes. In addition, we also found UVR `footprints' at T > A/A > Ts (at NpTpT) and T > C/A > G (at CpTpC). These footprints are also present in MMs from a chronic UVR mouse model, and in some human MMs, suggesting that they may be minor UVR signature changes. We found few significantly somatically mutated genes (similar to 6 per spontaneous and 15 per UVR-induced melanoma) in addition to the Cdk4 and NRAS mutations already present. Trp53 was the most convincing recurrently mutated gene; however, in the UVR-induced MMs no Trp53 mutations were at C > T/G > A, suggesting that it was probably mutated during tumour progression, not directly induced by UVR photoproducts. The very low load of recurrent mutations convincingly induced by classical UVB-induced dimer photoproducts may support a role for cell extrinsic mechanisms, such as photoimmunosuppression and inflammation in driving MM after acute UVB exposure.	[Mukhopadhyay, P.; Ferguson, B.; Handoko, H. Y.; Walker, G. J.] QIMR Berghofer Med Res Inst, 300 Herston Rd, Herston, Qld 4006, Australia; [Muller, H. K.] Univ Tasmania, Sch Med, Hobart, Tas, Australia	QIMR Berghofer Medical Research Institute; University of Tasmania	Walker, GJ (corresponding author), QIMR Berghofer Med Res Inst, 300 Herston Rd, Herston, Qld 4006, Australia.	Graeme.Walker@qimrberghofer.edu.au	, Herlina/F-4193-2015	, Herlina/0000-0003-3153-2248; Ferguson, Blake/0000-0002-5643-6976	Cancer Council of Queensland; National Health and Medical Research Council of Australia	Cancer Council of Queensland(Cancer Council Queensland); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by The Cancer Council of Queensland, and the National Health and Medical Research Council of Australia. We thank Nick Hayward and Peter Johansson for helpful discussions, and Grant Morahan for prompting us to consider the influence of genetic background on cancer incidence.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Besaratinia A, 2004, BIOCHEMISTRY-US, V43, P8169, DOI 10.1021/bi049761v; Besaratinia A, 2008, FASEB J, V22, P2379, DOI 10.1096/fj.07-105437; Brash DE, 2015, PHOTOCHEM PHOTOBIOL, V91, P15, DOI 10.1111/php.12377; Bryan DS, 2014, GENOME RES, V24, P1534, DOI 10.1101/gr.174052.114; Carstens MJ, 2004, J BIOL CHEM, V279, P35984, DOI 10.1074/jbc.M400408200; Ferguson B, 2015, ONCOGENE, V34, P2879, DOI 10.1038/onc.2014.227; Fulci G, 2002, CANCER RES, V62, P2897; Furney SJ, 2013, J PATHOL, V230, P261, DOI 10.1002/path.4204; Gandini S, 2005, EUR J CANCER, V41, P45, DOI 10.1016/j.ejca.2004.10.016; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Ikehata H, 2013, J INVEST DERMATOL, V133, P1850, DOI 10.1038/jid.2012.504; Ikehata H, 2011, J RADIAT RES, V52, P115, DOI 10.1269/jrr.10175; Jans J, 2006, MOL CELL BIOL, V26, P8515, DOI 10.1128/MCB.00807-06; Jia PL, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-11; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Malcikova J, 2009, BLOOD, V114, P5307, DOI 10.1182/blood-2009-07-234708; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Matin RN, 2013, J EXP MED, V210, P581, DOI 10.1084/jem.20121439; Metz CHD, 2013, CANCER MED-US, V2, P208, DOI 10.1002/cam4.61; Mitchell DL, 2009, PHOTOCHEM PHOTOBIOL, V85, P1384, DOI 10.1111/j.1751-1097.2009.00591.x; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; Otoshi E, 2000, CANCER RES, V60, P1729; Ouhtit A, 1998, J NATL CANCER I, V90, P523, DOI 10.1093/jnci/90.7.523; Pattison DI, 2006, EXP SUPPL, V96, P131; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; Robert C, 1996, J INVEST DERMATOL, V106, P721, DOI 10.1111/1523-1747.ep12345616; SELVANAYAGAM CS, 1995, CANCER RES, V55, P3310; Sheppard KE, 2013, CLIN CANCER RES, V19, P5320, DOI 10.1158/1078-0432.CCR-13-0259; Slovackova J, 2010, CELL CYCLE, V9, P2141, DOI 10.4161/cc.9.11.11808; Song Q, 2014, NUCLEIC ACIDS RES, V42, P13122, DOI 10.1093/nar/gku1049; Su DGT, 2010, CHEM RES TOXICOL, V23, P474, DOI 10.1021/tx9003962; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Wolnicka-Glubisz A, 2006, PHOTOCH PHOTOBIO SCI, V5, P254, DOI 10.1039/b506974b; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666	41	15	15	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3342	3350		10.1038/onc.2015.386	http://dx.doi.org/10.1038/onc.2015.386			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477315				2022-12-28	WOS:000378306400013
J	Qiang, L; Shah, P; Barcellos-Hoff, MH; He, YY				Qiang, L.; Shah, P.; Barcellos-Hoff, M. H.; He, Y. Y.			TGF-beta signaling links E-cadherin loss to suppression of nucleotide excision repair	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CELL CARCINOMA PROGRESSION; GROWTH-FACTOR-BETA; XERODERMA-PIGMENTOSUM; DOWN-REGULATION; ADHESION MOLECULE; DNA-BINDING; C-MYC; SKIN; INDUCTION	E-cadherin is a cell adhesion molecule best known for its function in suppressing tumor progression and metastasis. Here we show that E-cadherin promotes nucleotide excision repair through positively regulating the expression of xeroderma pigmentosum complementation group C (XPC) and DNA damage-binding protein 1 (DDB1). Loss of E-cadherin activates the E2F4 and p130/107 transcription repressor complexes to suppress the transcription of both XPC and DDB1 through activating the transforming growth factor-beta (TGF-beta) pathway. Adding XPC or DDB1, or inhibiting the TGF-beta pathway, increases the repair of ultraviolet (UV)-induced DNA damage in E-cadherin-inhibited cells. In the mouse skin and skin tumors, UVB radiation downregulates E-cadherin. In sunassociated premalignant and malignant skin neoplasia, E-cadherin is downregulated in association with reduced XPC and DDB1 levels. These findings demonstrate a crucial role of E-cadherin in efficient DNA repair of UV-induced DNA damage, identify a new link between epithelial adhesion and DNA repair and suggest a mechanistic link of early E-cadherin loss in tumor initiation.	[Qiang, L.; Shah, P.; He, Y. Y.] Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA; [Barcellos-Hoff, M. H.] NYU, Sch Med, Dept Radiat Oncol & Cell Biol, New York, NY USA	University of Chicago; New York University	He, YY (corresponding author), Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Qiang, Lei/B-2763-2012	Qiang, Lei/0000-0002-7164-3164; Barcellos-Hoff, Mary Helen/0000-0002-5994-9558	NIH/NIEHS [ES016936, ES024373]; American Cancer Society (ACS) [RSG-13-078-01]; University of Chicago Cancer Research Center [P30 CA014599]; CTSA [UL1 TR000430]; University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936, R01ES024373] Funding Source: NIH RePORTER	NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Cancer Society (ACS)(American Cancer Society); University of Chicago Cancer Research Center; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We are grateful to Dr Altaf Wani for his helpful suggestions. We thank Terri Li for immunohistochemistry and Dr Ann Motten for a critical reading of the manuscript. This work was supported by the NIH/NIEHS grants ES016936 and ES024373 (to YYH), the American Cancer Society (ACS) grant RSG-13-078-01 (to YYH), the University of Chicago Cancer Research Center (P30 CA014599), the CTSA (UL1 TR000430) and the University of Chicago Friends of Dermatology Endowment Fund.	Boyle J, 2008, HUM MUTAT, V29, P1194, DOI 10.1002/humu.20768; Bradford PT, 2011, J MED GENET, V48, P168, DOI 10.1136/jmg.2010.083022; Braithwaite E, 1998, CARCINOGENESIS, V19, P1239, DOI 10.1093/carcin/19.7.1239; Brouxhon S, 2007, CANCER RES, V67, P7654, DOI 10.1158/0008-5472.CAN-06-4415; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Cho IJ, 2010, HEPATOLOGY, V52, P2053, DOI 10.1002/hep.23931; Cleaver JE, 2009, NAT REV GENET, V10, P756, DOI 10.1038/nrg2663; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Cui TT, 2015, ONCOTARGET, V6, P10060, DOI 10.18632/oncotarget.3542; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; DiGiovanna JJ, 2012, J INVEST DERMATOL, V132, P785, DOI 10.1038/jid.2011.426; Dominguez-Brauer C, 2009, EMBO REP, V10, P1036, DOI 10.1038/embor.2009.139; Dubrovska A, 2005, ONCOGENE, V24, P2289, DOI 10.1038/sj.onc.1208443; Fei J, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001183; Fleisch MC, 2006, ENDOCR-RELAT CANCER, V13, P379, DOI 10.1677/erc.1.01112; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Glick AB, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/249063; Gu CN, 2006, BIOCHEMISTRY-US, V45, P10739, DOI 10.1021/bi060423z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Imoto K, 2002, J INVEST DERMATOL, V119, P1177, DOI 10.1046/j.1523-1747.2002.19514.x; Jamal S, 2002, J CLIN INVEST, V110, P443, DOI 10.1172/JCI200213729; Jans J, 2005, CURR BIOL, V15, P105, DOI 10.1016/j.cub.2005.01.001; Kad NM, 2010, MOL CELL, V37, P702, DOI 10.1016/j.molcel.2010.02.003; Kao YC, 2010, MOL CELL BIOL, V30, P4767, DOI 10.1128/MCB.01021-09; Katsumi S, 2001, J INVEST DERMATOL, V117, P1156, DOI 10.1046/j.0022-202x.2001.01540.x; Kim I, 2014, GENES DIS, V1, P188, DOI 10.1016/j.gendis.2014.08.005; Kim MR, 2015, MOL CANCER RES, V13, P319, DOI 10.1158/1541-7786.MCR-14-0098-T; Kobayashi N, 2001, PIGM CELL RES, V14, P94, DOI 10.1034/j.1600-0749.2001.140204.x; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; Li JY, 2006, CANCER RES, V66, P8590, DOI 10.1158/0008-5472.CAN-06-1115; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Mitra D, 2013, J INVEST DERMATOL, V133, P2609, DOI 10.1038/jid.2013.213; Nakagawa H, 2014, P NATL ACAD SCI USA, V111, P1090, DOI 10.1073/pnas.1322731111; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nichols AF, 2003, NUCLEIC ACIDS RES, V31, P562, DOI 10.1093/nar/gkg152; NIGGLI HJ, 1988, J INVEST DERMATOL, V91, P579, DOI 10.1111/1523-1747.ep12477095; Oh KS, 2011, PHOTOCHEM PHOTOBIOL, V87, P729, DOI 10.1111/j.1751-1097.2011.00909.x; Orsulic S, 1999, J CELL SCI, V112, P1237; Perez-Lorenzo R, 2010, CARCINOGENESIS, V31, P1116, DOI 10.1093/carcin/bgq041; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Ravindran A, 2014, CARCINOGENESIS, V35, P959, DOI 10.1093/carcin/bgt486; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shah P, 2015, PHOTOCHEM PHOTOBIOL, V91, P254, DOI 10.1111/php.12406; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2005, CELL, V121, P387, DOI 10.1016/j.cell.2005.02.035; Sugasawa K, 2008, CARCINOGENESIS, V29, P455, DOI 10.1093/carcin/bgm282; Sugasawa K, 2009, DNA REPAIR, V8, P969, DOI 10.1016/j.dnarep.2009.05.001; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; VINK AA, 1991, CARCINOGENESIS, V12, P861, DOI 10.1093/carcin/12.5.861; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang HJ, 2005, FREE RADICAL BIO MED, V38, P890, DOI 10.1016/j.freeradbiomed.2004.12.005; Wang QE, 2013, NUCLEIC ACIDS RES, V41, P1722, DOI 10.1093/nar/gks1312; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	64	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3293	3302		10.1038/onc.2015.390	http://dx.doi.org/10.1038/onc.2015.390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477308	Green Accepted, Green Submitted			2022-12-28	WOS:000378306400008
J	Borcherding, DC; Tong, W; Hugo, ER; Barnard, DF; Fox, S; LaSance, K; Shaughnessy, E; Ben-Jonathan, N				Borcherding, D. C.; Tong, W.; Hugo, E. R.; Barnard, D. F.; Fox, S.; LaSance, K.; Shaughnessy, E.; Ben-Jonathan, N.			Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; PERIPHERAL DOPAMINE; GUANYLATE-CYCLASE; NITRIC-OXIDE; TUMOR-GROWTH; AGONIST; CELLS; ANGIOGENESIS; FENOLDOPAM; NEURONS	Patients with advanced breast cancer often fail to respond to treatment, creating a need to develop novel biomarkers and effective therapeutics. Dopamine (DA) is a catecholamine that binds to five G protein-coupled receptors. We discovered expression of DA type-1 receptors (D1Rs) in breast cancer, thereby identifying these receptors as novel therapeutic targets in this disease. Strong to moderate immunoreactive D1R expression was found in 30% of 751 primary breast carcinomas, and was associated with larger tumors, higher tumor grades, node metastasis and shorter patient survival. DA and D1R agonists, signaling through the cGMP/protein kinase G (PKG) pathway, suppressed cell viability, inhibited invasion and induced apoptosis in multiple breast cancer cell lines. Fenoldopam, a peripheral D1R agonist that does not penetrate the brain, dramatically suppressed tumor growth in two mouse models with D1R-expressing xenografts by increasing both necrosis and apoptosis. D1R-expressing primary tumors and metastases in mice were detected by fluorescence imaging. In conclusion, D1R overexpression is associated with advanced breast cancer and poor prognosis. Activation of the D1R/cGMP/PKG pathway induces apoptosis in vitro and causes tumor shrinkage in vivo. Fenoldopam, which is FDA (Food and Drug Administration) approved to treat renal hypertension, could be repurposed as a novel therapeutic agent for patients with D1R-expressing tumors.	[Borcherding, D. C.; Hugo, E. R.; Barnard, D. F.; Fox, S.; Ben-Jonathan, N.] Univ Cincinnati, Dept Canc Biol, Cincinnati, OH 45267 USA; [Tong, W.] Univ Cincinnati, Dept Pathol, Cincinnati, OH 45267 USA; [LaSance, K.] Univ Cincinnati, Dept Radiol, Cincinnati, OH 45267 USA; [Shaughnessy, E.] Univ Cincinnati, Dept Surg, 231 Bethesda Ave, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Ben-Jonathan, N (corresponding author), Univ Cincinnati, Dept Canc Biol, Coll Med, 3125 Eden Ave, Cincinnati, OH 45267 USA.	Nira.Ben-Jonathan@uc.edu	Hugo, Eric/ADA-3523-2022	Borcherding, Dana/0000-0002-8849-2139	NIH [CA096613, ES020909]; DOD [AR110050, BC122992]; University of Cincinnati Center for Clinical and Translational Science and Training (CCTST); Marlene Harris-Ride Cincinnati; NATIONAL CANCER INSTITUTE [R01CA096613, T32CA117846] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES020909, R01ES012212] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); University of Cincinnati Center for Clinical and Translational Science and Training (CCTST); Marlene Harris-Ride Cincinnati; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We dedicate this manuscript to Wilson Tong, M.D., whose untimely death was a major loss to all who knew him. We thank Dean Quaranta for technical assistance, and Drs Susan Waltz and Peter Stambrook for critical reviews of this manuscript. This investigation was funded by NIH grants CA096613 and ES020909, DOD grants AR110050 and BC122992, and pilot grants from Marlene Harris-Ride Cincinnati, and the University of Cincinnati Center for Clinical and Translational Science and Training (CCTST).	Almubarak M, 2009, ONCOLOGY-NY, V23, P255; Amenta F., 2002, Italian Journal of Anatomy and Embryology, V107, P145; Arcangeli S, 2013, J CEREBR BLOOD F MET, V33, P278, DOI 10.1038/jcbfm.2012.167; Azevedo MF, 2014, ENDOCR REV, V35, P195, DOI 10.1210/er.2013-1053; Basu S, 2004, CANCER RES, V64, P5551, DOI 10.1158/0008-5472.CAN-04-1600; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642; Bodei S, 2009, N-S ARCH PHARMACOL, V379, P413, DOI 10.1007/s00210-008-0384-6; Borcherding DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025537; Carlo RD, 1986, ANN NY ACAD SCI, V464, P559, DOI DOI 10.1111/J.1749-6632.1986.TB16068.X; Chakroborty D, 2009, CANCER RES, V69, P3727, DOI 10.1158/0008-5472.CAN-08-4289; Choi BM, 2002, J BIOCHEM MOL BIOL, V35, P116; Conole D, 2013, DRUGS, V73, P1967, DOI 10.1007/s40265-013-0149-5; Contreras F, 2002, J HUM HYPERTENS, V16, pS13, DOI 10.1038/sj.jhh.1001334; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Eisenhofer G, 1999, CLIN EXP PHARMACOL P, V26, pS41; Evgenov OV, 2006, NAT REV DRUG DISCOV, V5, P755, DOI 10.1038/nrd2038; FLAIM KE, 1985, LIFE SCI, V36, P1427, DOI 10.1016/0024-3205(85)90049-9; Ghosh D, 2007, CELL MOL LIFE SCI, V64, P2013, DOI 10.1007/s00018-007-7175-y; Goldstein DS, 1999, J CLIN ENDOCR METAB, V84, P2523, DOI 10.1210/jc.84.7.2523; GRANADOSPRINCIP.S, 2015, BREAST CANCER RES, V17, P527; Hoque KE, 2010, PSYCHOPHARMACOLOGY, V207, P571, DOI 10.1007/s00213-009-1687-0; JOHNSON DE, 1995, ANTI-CANCER DRUG, V6, P471, DOI 10.1097/00001813-199506000-00017; Li ZS, 2006, J NEUROSCI, V26, P2798, DOI 10.1523/JNEUROSCI.4720-05.2006; Lin DTS, 2010, SYNAPSE, V64, P460, DOI 10.1002/syn.20750; Maggio R, 2009, PARKINSONISM RELAT D, V15, pS2, DOI 10.1016/S1353-8020(09)70826-0; Michel MC, 2009, N-S ARCH PHARMACOL, V379, P385, DOI 10.1007/s00210-009-0395-y; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Moreno-Smith M, 2011, CLIN CANCER RES, V17, P3649, DOI 10.1158/1078-0432.CCR-10-2441; Murphy MB, 2001, NEW ENGL J MED, V345, P1548, DOI 10.1056/NEJMra010253; Natarajan A, 2010, J PHARMACOL EXP THER, V332, P640, DOI 10.1124/jpet.109.159871; Ng SSW, 2000, BRIT J PHARMACOL, V129, P853, DOI 10.1038/sj.bjp.0703119; Proskuryakov SY, 2010, CURR PHARM DESIGN, V16, P56, DOI 10.2174/138161210789941793; Rubi B, 2010, ENDOCRINOLOGY, V151, P5570, DOI 10.1210/en.2010-0745; Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049; Sammut S, 2006, NEUROPSYCHOPHARMACOL, V31, P493, DOI 10.1038/sj.npp.1300826; Sarkar C, 2004, AM J PHYSIOL-HEART C, V287, pH1554, DOI 10.1152/ajpheart.00272.2004; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Sharma RK, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00056; Shen LH, J BIOMED BIOTECHNOL; Sidhu A, 2000, INT J DEV NEUROSCI, V18, P669, DOI 10.1016/S0736-5748(00)00033-2; Supuran CT, 2006, CURR PHARM DESIGN, V12, P3459, DOI 10.2174/138161206778343118; Wang PS, 2002, ARCH GEN PSYCHIAT, V59, P1147, DOI 10.1001/archpsyc.59.12.1147; WEBER RR, 1988, BRIT J CLIN PHARMACO, V25, P17, DOI 10.1111/j.1365-2125.1988.tb03276.x; Zaccolo M, 2007, CIRC RES, V100, P1569, DOI 10.1161/CIRCRESAHA.106.144501; Zhang L, 2006, BRAIN RES, V1118, P192, DOI 10.1016/j.brainres.2006.08.028; Zhao DL, 2007, NEUROPHARMACOLOGY, V53, P724, DOI 10.1016/j.neuropharm.2007.07.017; Zhu B, 2007, CURR TOP MED CHEM, V7, P437, DOI 10.2174/156802607779941198	48	57	68	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3103	3113		10.1038/onc.2015.369	http://dx.doi.org/10.1038/onc.2015.369			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26477316	Green Accepted			2022-12-28	WOS:000378092700003
J	Yokdang, N; Hatakeyama, J; Wald, JH; Simion, C; Tellez, JD; Chang, DZ; Swamynathan, MM; Chen, M; Murphy, WJ; Carraway, KL; Sweeney, C				Yokdang, N.; Hatakeyama, J.; Wald, J. H.; Simion, C.; Tellez, J. D.; Chang, D. Z.; Swamynathan, M. M.; Chen, M.; Murphy, W. J.; Carraway, K. L., III; Sweeney, C.			LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; HUMAN-PAPILLOMAVIRUS STATUS; NEGATIVE REGULATOR LRIG1; LEUCINE-RICH REPEAT; MET RECEPTOR; C-MET; CLINICAL-IMPLICATIONS; MASTER REGULATORS; TUMOR-SUPPRESSOR; TIGHT JUNCTIONS	LRIG1 (leucine-rich repeat and immunoglobulin-like domain containing), a member of the LRIG family of transmembrane leucine-rich repeat-containing proteins, is a negative regulator of receptor tyrosine kinase signaling and a tumor suppressor. LRIG1 expression is broadly decreased in human cancer and in breast cancer and low expression of LRIG1 has been linked to decreased relapse-free survival. Recently, low expression of LRIG1 was revealed to be an independent risk factor for breast cancer metastasis and death. These findings suggest that LRIG1 may oppose breast cancer cell motility and invasion, cellular processes that are fundamental to metastasis. However, very little is known of LRIG1 function in this regard. In this study, we demonstrate that LRIG1 is downregulated during epithelial-to-mesenchymal transition (EMT) of human mammary epithelial cells, suggesting that LRIG1 expression may represent a barrier to EMT. Indeed, depletion of endogenous LRIG1 in human mammary epithelial cells expands the stem cell population, augments mammosphere formation and accelerates EMT. Conversely, expression of LRIG1 in highly invasive Basal B breast cancer cells provokes a mesenchymal-to-epithelial transition accompanied by a dramatic suppression of tumorsphere formation and a striking loss of invasive growth in three-dimensional culture. LRIG1 expression perturbs multiple signaling pathways and represses markers and effectors of the mesenchymal state. Furthermore, LRIG1 expression in MDA-MB-231 breast cancer cells significantly slows their growth as tumors, providing the first in vivo evidence that LRIG1 functions as a growth suppressor in breast cancer.	[Yokdang, N.; Hatakeyama, J.; Wald, J. H.; Simion, C.; Chang, D. Z.; Swamynathan, M. M.; Carraway, K. L., III; Sweeney, C.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Tellez, J. D.; Chen, M.] Univ Calif Davis, Dept Pathol & Lab Med, Sacramento, CA 95817 USA; [Murphy, W. J.] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Sweeney, C (corresponding author), Univ Calif, UC Davis Med Ctr, Dept Biochem & Mol Med, Res Bldg 3,4645 2nd Ave, Sacramento, CA 95817 USA.	casweeney@ucdavis.edu		Mosur Swamynathan, Manojit/0000-0003-1156-586X; Hatakeyama, Jason/0000-0001-8690-5107	T32 training grant in Oncogenic Signals and Chromosome Biology [CA108459]; Lawrence Livermore National Labs UC Davis Fitzpatrick Research Fellowship; NIH [CA118384, CA166412]; UC Davis Comprehensive Cancer Center Support Grant (CCSG) - National Cancer Institute [NCI P30CA093373]; NATIONAL CANCER INSTITUTE [T32CA108459, R01CA166412, P30CA093373, R01CA118384] Funding Source: NIH RePORTER	T32 training grant in Oncogenic Signals and Chromosome Biology; Lawrence Livermore National Labs UC Davis Fitzpatrick Research Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UC Davis Comprehensive Cancer Center Support Grant (CCSG) - National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert Weinberg (Whitehead Institute) for the kind gift of the HMLE and HMLE-Twist-ER cells, Dr Paola Marignani (Dalhousie University) for the kind gift of the 293GPG packaging cell line, and Dr Ashley Hodel and Mr Sina Azadi for technical support and advice. Dr Nucharee Yokdang was a trainee on the T32 training grant in Oncogenic Signals and Chromosome Biology (CA108459). Dr Joseph Tellez was supported by a Lawrence Livermore National Labs UC Davis Fitzpatrick Research Fellowship. This work was supported by NIH grants CA118384 (Sweeney) and CA166412 (Carraway). We acknowledge the UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute (NCI P30CA093373) for using the flow cytometer.	Accornero P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044982; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Bai LC, 2012, CANCER RES, V72, P1229, DOI 10.1158/0008-5472.CAN-11-2428; Chang L, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-101; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Chun J, 2013, CHEM-BIOL INTERACT, V205, P212, DOI 10.1016/j.cbi.2013.07.002; Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gastaldi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2617; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hallett RM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00227; Hawkes SP, 2010, METHODS MOL BIOL, V622, P257, DOI 10.1007/978-1-60327-299-5_16; Hedman H, 2007, EUR J CANCER, V43, P676, DOI 10.1016/j.ejca.2006.10.021; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Ho-Yen CM, 2014, CANCER-AM CANCER SOC, V120, P163, DOI 10.1002/cncr.28386; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Jensen KB, 2006, P NATL ACAD SCI USA, V103, P11958, DOI 10.1073/pnas.0601886103; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Jimenez-Salazar JE, 2014, HORM CANCER-US, V5, P161, DOI 10.1007/s12672-014-0180-3; Kim YJ, 2014, INT J CANCER, V134, P2424, DOI 10.1002/ijc.28566; Knopfova L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-15; Krig SR, 2011, MOL CANCER RES, V9, P1406, DOI 10.1158/1541-7786.MCR-11-0227; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Ledda F, 2008, J NEUROSCI, V28, P39, DOI 10.1523/JNEUROSCI.2196-07.2008; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Leidy J, 2014, ARCH PATHOL LAB MED, V138, P37, DOI 10.5858/arpa.2012-0439-RA; Lim YC, 2012, ORAL ONCOL, V48, P1114, DOI 10.1016/j.oraloncology.2012.05.013; Lindquist D, 2014, BRIT J CANCER, V110, P1793, DOI 10.1038/bjc.2014.87; Liu L, 2011, MOL CANCER THER, V10, P518, DOI 10.1158/1535-7163.MCT-10-0698; Lu L, 2013, J PATHOL, V229, P608, DOI 10.1002/path.4148; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marchini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014131; Mehner C, 2014, ONCOTARGET, V5, P2736, DOI 10.18632/oncotarget.1932; Miller JK, 2008, CANCER RES, V68, P8286, DOI 10.1158/0008-5472.CAN-07-6316; Mueller KL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3224; Muller S, 2013, INT J ONCOL, V42, P247, DOI 10.3892/ijo.2012.1702; Munshi N, 2010, MOL CANCER THER, V9, P1544, DOI 10.1158/1535-7163.MCT-09-1173; Nakamura T, 2014, J CLIN INVEST, V124, P385, DOI 10.1172/JCI71488; Nalwoga H, 2010, BRIT J CANCER, V102, P369, DOI 10.1038/sj.bjc.6605488; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ponzo MG, 2010, CELL CYCLE, V9, P1043, DOI 10.4161/cc.9.6.11033; Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Rafidi H, 2013, J BIOL CHEM, V288, P21593, DOI 10.1074/jbc.M113.486050; Rhodes LV, 2014, BREAST CANCER RES TR, V145, P593, DOI 10.1007/s10549-014-2979-6; Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035; Rondahl V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073635; Rouam S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-150; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Sheu JJC, 2014, ONCOGENE, V33, P1375, DOI 10.1038/onc.2013.98; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Tanemura A, 2005, DERMATOL SURG, V31, P423, DOI 10.1097/00042728-200504000-00008; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thompson PA, 2014, CANCER RES, V74, P2928, DOI 10.1158/0008-5472.CAN-13-2112; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsai PC, 2012, TOXICON, V60, P734, DOI 10.1016/j.toxicon.2012.05.019; Valentin MD, 2012, BREAST CANCER RES TR, V134, P21, DOI 10.1007/s10549-011-1934-z; Van Itallie CM, 2014, SEMIN CELL DEV BIOL, V36, P157, DOI 10.1016/j.semcdb.2014.08.011; Wang B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041355; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Wang Y, 2013, BRIT J CANCER, V108, P1765, DOI 10.1038/bjc.2013.138; Wang YS, 2014, CANCER RES, V74, P520, DOI 10.1158/0008-5472.CAN-13-2182; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Xie RF, 2013, ONCOL REP, V29, P177, DOI 10.3892/or.2012.2102; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YOUNG RK, 1974, IN VITRO CELL DEV B, V9, P239	80	29	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2932	2947		10.1038/onc.2015.345	http://dx.doi.org/10.1038/onc.2015.345			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387542	Green Submitted, Green Accepted			2022-12-28	WOS:000377473700013
J	Lee, S; Kim, W; Ko, C; Ryu, WS				Lee, S.; Kim, W.; Ko, C.; Ryu, W-S			Hepatitis B virus X protein enhances Myc stability by inhibiting SCFSkp2 ubiquitin E3 ligase-mediated Myc ubiquitination and contributes to oncogenesis	ONCOGENE			English	Article							BOX RNA HELICASE; C-MYC; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; F-BOX; CANCER-CELLS; HBX GENE; DEGRADATION; SKP2; HEPATOCARCINOGENESIS	The stability of Myc oncoprotein is regulated by Skp/cullin/F-box (SCF) ubiquitin E3 ligase, in particular, via either SCFSkp2 or SCFFbw7 ubiquitin E3 ligases. An earlier study has shown that hepatitis B virus X protein (HBx) augments Myc stability via a mechanism involving the inhibition of Myc ubiquitination. However, the underlying mechanism by which HBx inhibits Myc ubiquitination remained to be elucidated. Moreover, to what extent HBx-mediated Myc stabilization contributes to viral oncogenesis is unknown. First, we corroborated the physiological significance of HBx-mediated Myc stabilization in HBV-replicating cells by demonstrating that (1) the elevation of Myc level in a HBV-replicating HepG2.2.15 cell compared to parental cells; (2) HBx-mediated Myc stabilization in a HBV replicon transfected cells; and (3) the inhibition of Myc ubiquitination by HBx in a HBV replicon transfected cells. Then, the molecular interaction between HBx and Myc protein was revealed via coimmunoprecipitation and immunofluorescence experiments. Subsequent analysis indicated that HBx stabilizes Myc oncoprotein by blocking Skp2, as opposed to Fbw7, -mediated Myc ubiquitination. Next, we defined the Myc-binding region to four residues (VFVL) near the C-terminus of HBx polypeptide. An HBx variant with mutated VFVL consistently failed to not only interact with Myc but also suppress Myc ubiquitination. Importantly, the VFVL mutant lost the ability to transform NIH3T3 cells in concert with Ras, implying that the HBx-Myc interaction is critical for viral oncogenesis. Consistently, immunohistochemistry of liver biopsies revealed that Myc protein is elevated in HBV-infected tissues. We concluded that HBx stabilizes Myc oncoprotein by inhibiting SCFSkp2 ubiquitin E3 ligase-mediated Myc ubiquitination, and the HBx-mediated Myc stabilization greatly contributes to viral oncogenesis.	[Lee, S.; Kim, W.; Ko, C.; Ryu, W-S] Yonsei Univ, Dept Biochem, 50 Yonsei Ro, Seoul 120749, South Korea	Yonsei University	Ryu, WS (corresponding author), Yonsei Univ, Dept Biochem, 50 Yonsei Ro, Seoul 120749, South Korea.	wsryu@yonsei.ac.kr		Ryu, Wang-Shick/0000-0002-0383-5666	National Research Foundation of Korea (NRF) grant - Korean government (MSIP) [NRF-2012R1A2A2A01007811]; BK21 PLUS program	National Research Foundation of Korea (NRF) grant - Korean government (MSIP); BK21 PLUS program	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP; NRF-2012R1A2A2A01007811). SL and WK are fellowship awardee by BK21 PLUS program.	Bajaj BG, 2008, J VIROL, V82, P4082, DOI 10.1128/JVI.02500-07; Baresova P, 2012, J BIOL CHEM, V287, P16199, DOI 10.1074/jbc.M111.335216; Barry Michele, 2006, Sci STKE, V2006, ppe21; Benhenda S, 2009, ADV CANCER RES, V103, P75, DOI 10.1016/S0065-230X(09)03004-8; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Cha MY, 2009, J GEN VIROL, V90, P978, DOI 10.1099/vir.0.009928-0; Cho HS, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2074; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Geng X, 2012, P NATL ACAD SCI USA, V109, P18471, DOI 10.1073/pnas.1204668109; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Kalra N, 2006, FEBS LETT, V580, P431, DOI 10.1016/j.febslet.2005.12.034; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim S, 2010, J VIROL, V84, P52, DOI 10.1128/JVI.01232-09; Kim S, 2007, J VIROL, V81, P1714, DOI 10.1128/JVI.01863-06; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Ko C, 2014, J VIROL, V88, P13689, DOI 10.1128/JVI.02035-14; Kusunoki H, 2014, BIOCHEM BIOPH RES CO, V450, P741, DOI 10.1016/j.bbrc.2014.06.042; Lakhtakia R, 2003, J GASTROEN HEPATOL, V18, P80, DOI 10.1046/j.1440-1746.2003.02902.x; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Li T, 2010, NAT STRUCT MOL BIOL, V17, P105, DOI 10.1038/nsmb.1719; Ma NF, 2008, CLIN CANCER RES, V14, P5061, DOI 10.1158/1078-0432.CCR-07-5082; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Neuveut C, 2010, J HEPATOL, V52, P594, DOI 10.1016/j.jhep.2009.10.033; Ng SA, 2011, J GASTROENTEROL, V46, P974, DOI 10.1007/s00535-011-0415-9; Oishi N, 2007, CANCER SCI, V98, P1540, DOI 10.1111/j.1349-7006.2007.00579.x; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Reifenberg K, 1997, J HEPATOL, V26, P119, DOI 10.1016/S0168-8278(97)80018-9; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Slagle BL, 2015, HEPATOLOGY, V61, P1416, DOI 10.1002/hep.27360; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tu H, 2001, CANCER RES, V61, P7803; Utku Y, 2006, MOL BIOSYST, V2, P312, DOI 10.1039/b603229j; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000986; Wang HF, 2009, J VIROL, V83, P5815, DOI 10.1128/JVI.00011-09; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101	49	33	36	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1857	1867		10.1038/onc.2015.251	http://dx.doi.org/10.1038/onc.2015.251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26165841				2022-12-28	WOS:000373610400011
J	Sin, WC; Aftab, Q; Bechberger, JF; Leung, JH; Chen, H; Naus, CC				Sin, W. C.; Aftab, Q.; Bechberger, J. F.; Leung, J. H.; Chen, H.; Naus, C. C.			Astrocytes promote glioma invasion via the gap junction protein connexin43	ONCOGENE			English	Article							C-TERMINAL REGION; MALIGNANT GLIOMA; MICROENVIRONMENTAL REGULATION; INTERCELLULAR COMMUNICATION; REACTIVE ASTROCYTES; GENE-EXPRESSION; DIRECTED INACTIVATION; GROWTH-FACTOR; MICE LACKING; TUMOR-CELLS	Reactive astrocytes are integral to the glioma microenvironment. Connexin43 (Cx43) is a major gap junction protein in astrocytes and its expression is enhanced significantly in glioma-associated astrocytes, especially at the peri-tumoral region. Although downregulation of Cx43-mediated intercellular communication is associated with increased malignancy in tumor cells, the role of Cx43 in stromal cells in glioma progression is not defined. Using a mouse model consisting of syngeneic intracranial implantation of GL261 glioma cells into Nestin-Cre: Cx43(fl/fl) mice where Cx43 was eliminated in astrocytes, we demonstrate a role of astrocytic Cx43 in the dissemination of glioma cells from the tumor core. To determine whether heterocellular communication between astrocytes and glioma cells is essential for reduced invasion in the absence of astrocytic Cx43, we abolished channel formation between glioma cells and astrocytes by either knocking down Cx43 in glioma cells with short hairpin RNA (shRNA) or overexpressing a dominant-negative channel-defective Cx43-T154A mutant in these cells. Although Cx43shRNA in glioma cells reduced invasion, expression of Cx43-T154A had no effect on glioma invasion, suggesting tumoral Cx43 may influence motility independently from its channel function. Alteration in astrocytic Cx43 function, such as by replacing the wild-type allele with a C-terminal truncated Cx43 mutant exhibiting reduced intercellular coupling, is sufficient to reduce glioma spreading into the brain parenchyma. Our results reveal a novel role of astrocytic Cx43 in the formation of an invasive niche and raise the possibility to control glioma progression by manipulating the microenvironment.	[Sin, W. C.; Aftab, Q.; Bechberger, J. F.; Leung, J. H.; Chen, H.; Naus, C. C.] Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Sin, WC; Naus, CC (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	wcsin@mail.ubc.ca; cnaus@mail.ubc.ca			Canadian Institutes of Health Research [MOP-102489, MOP-93572]; National Sciences and Engineering Research Council of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	We thank Lina Wang, Elodie Montaudon, Kushal Kolar, Xu Qiu Guo, Aishah Tul-Firdaus Binte Abdul Khalid and Jose Luis Vega for providing technical support for this project. We also wish to thank Maxence Le Vasseur for critical review of the manuscript. This study was supported by two operating grants (MOP-102489 and MOP-93572) to WCS and CCN from the Canadian Institutes of Health Research. CCN holds a Canada Research Chair. QA was supported by a postgraduate scholarship from the National Sciences and Engineering Research Council of Canada.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Aronica E, 2001, ACTA NEUROPATHOL, V101, P449; Baklaushev VP, 2011, DRUG DELIV, V18, P331, DOI 10.3109/10717544.2010.549527; Bates DC, 2007, GLIA, V55, P1554, DOI 10.1002/glia.20569; Beahm DL, 2006, J BIOL CHEM, V281, P7994, DOI 10.1074/jbc.M506533200; Behrens J, 2010, EUR J CELL BIOL, V89, P828, DOI 10.1016/j.ejcb.2010.06.003; Berube NG, 2005, J CLIN INVEST, V115, P258, DOI 10.1172/JCI200522329; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Caltabiano R, 2010, ACTA HISTOCHEM, V112, P529, DOI 10.1016/j.acthis.2009.05.008; Candolfi M, 2007, J NEURO-ONCOL, V85, P133, DOI 10.1007/s11060-007-9400-9; Casper KB, 2006, MOL CELL NEUROSCI, V31, P676, DOI 10.1016/j.mcn.2005.12.006; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cina C, 2009, J NEUROSCI, V29, P2009, DOI 10.1523/JNEUROSCI.5025-08.2009; Cotrina ML, 2008, GLIA, V56, P1791, DOI 10.1002/glia.20728; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Crespin S, 2010, J CELL BIOCHEM, V110, P589, DOI 10.1002/jcb.22554; De Bock M, 2014, BBA-MOL CELL RES, V1843, P2211, DOI 10.1016/j.bbamcr.2014.04.016; Dermietzel R, 2000, BRAIN RES REV, V32, P45, DOI 10.1016/S0165-0173(99)00067-3; di Tomaso E, 2011, CANCER RES, V71, P19, DOI 10.1158/0008-5472.CAN-10-2602; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; Dubois NC, 2006, GENESIS, V44, P355, DOI 10.1002/dvg.20226; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Edwards LA, 2011, JNCI-J NATL CANCER I, V103, P1162, DOI 10.1093/jnci/djr224; Elias LAB, 2007, NATURE, V448, P901, DOI 10.1038/nature06063; Fidler IJ, 2010, MOL CELLS, V30, P93, DOI 10.1007/s10059-010-0133-9; Fitzgerald DP, 2008, CLIN EXP METASTAS, V25, P799, DOI 10.1007/s10585-008-9193-z; Fonseca CG, 2002, BRAIN RES, V929, P105, DOI 10.1016/S0006-8993(01)03289-9; Frisch C, 2003, EUR J NEUROSCI, V18, P2313, DOI 10.1046/j.1460-9568.2003.02971.x; Gagliano N, 2009, ONCOL REP, V22, P1349, DOI 10.3892/or_00000574; Giaume C, 2012, METHODS MOL BIOL, V814, P283, DOI 10.1007/978-1-61779-452-0_19; Gielen PR, 2013, NEUROPHARMACOLOGY, V75, P539, DOI 10.1016/j.neuropharm.2013.05.002; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Herculano-Houzel S, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.031.2009; Herve JC, 2004, BBA-BIOMEMBRANES, V1662, P22, DOI 10.1016/j.bbamem.2003.10.022; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; HOLNESS CL, 1993, BLOOD, V81, P1607; Homkajorn B, 2010, NEUROSCI LETT, V486, P197, DOI 10.1016/j.neulet.2010.09.051; HOSSAIN MZ, 1994, BRAIN RES, V652, P311, DOI 10.1016/0006-8993(94)90242-9; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006; Iacobas DA, 2004, NEUROCHEM INT, V45, P243, DOI 10.1016/j.neuint.2003.12.008; Iacobas DA, 2003, PHYSIOL GENOMICS, V15, P177, DOI 10.1152/physiolgenomics.00062.2003; Jacobs VL, 2011, ASN NEURO, V3, DOI 10.1042/AN20110014; Jones TS, 2012, ONCOGENE, V31, P1995, DOI 10.1038/onc.2011.398; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kang J, 2008, J NEUROSCI, V28, P4702, DOI 10.1523/JNEUROSCI.5048-07.2008; Karpuk N, 2011, J NEUROSCI, V31, P414, DOI 10.1523/JNEUROSCI.5247-10.2011; Katz AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032453; Kim SJ, 2011, NEOPLASIA, V13, P286, DOI 10.1593/neo.11112; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kolar K, 2015, J NEUROPATH EXP NEUR, V74, P64, DOI 10.1097/NEN.0000000000000150; Kozoriz MG, 2010, J NEUROPATH EXP NEUR, V69, P196, DOI 10.1097/NEN.0b013e3181cd44df; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Le DM, 2003, J NEUROSCI, V23, P4034; Le HT, 2014, J BIOL CHEM, V289, P1345, DOI 10.1074/jbc.M113.508390; Lee IH, 2005, J COMP NEUROL, V489, P1, DOI 10.1002/cne.20567; Lee J, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-9; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Maass K, 2004, MOL BIOL CELL, V15, P4597, DOI 10.1091/mbc.E04-04-0324; Maass K, 2007, CIRC RES, V101, P1283, DOI 10.1161/CIRCRESAHA.107.162818; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Markovic DS, 2005, J NEUROPATH EXP NEUR, V64, P754, DOI 10.1097/01.jnen.0000178445.33972.a9; Matsuuchi L, 2013, BBA-BIOMEMBRANES, V1828, P94, DOI 10.1016/j.bbamem.2012.05.014; Mesnil M, 2005, BBA-BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004; Moreno AP, 2005, BBA-BIOMEMBRANES, V1711, P164, DOI 10.1016/j.bbamem.2005.02.016; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nagy JI, 1996, BRAIN RES, V717, P173, DOI 10.1016/0006-8993(95)01526-4; Nagy JI, 1999, NEUROSCIENCE, V88, P447, DOI 10.1016/S0306-4522(98)00191-2; Nakase T, 2004, AM J PATHOL, V164, P2067, DOI 10.1016/S0002-9440(10)63765-0; Naus CCG, 1997, J NEUROSCI RES, V49, P528, DOI 10.1002/(SICI)1097-4547(19970901)49:5<528::AID-JNR3>3.0.CO;2-D; Naus CC, 2010, NAT REV CANCER, V10, P435, DOI 10.1038/nrc2841; Newcomb EW, 2009, CNS CANC MODELS MARK, V12, P227, DOI DOI 10.1007/978-1-60327-553-8; O'Carroll SJ, 2013, METHODS MOL BIOL, V1037, P519, DOI 10.1007/978-1-62703-505-7_31; OCHALSKI PAY, 1995, GLIA, V14, P279, DOI 10.1002/glia.440140405; Oliveira R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-7; Olk S, 2010, GLIA, V58, P494, DOI 10.1002/glia.20942; Olk S, 2009, CELL MOTIL CYTOSKEL, V66, P1000, DOI 10.1002/cm.20404; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Ponsaerts R, 2010, FASEB J, V24, P4378, DOI 10.1096/fj.09-153007; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rath BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054752; Rhee DY, 2009, DEVELOPMENT, V136, P3185, DOI 10.1242/dev.032334; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rivera-Zengotita M, 2012, ADV ANAT PATHOL, V19, P239, DOI 10.1097/PAP.0b013e31825c6a04; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Rozental R, 2000, BRAIN RES REV, V32, P11, DOI 10.1016/S0165-0173(99)00095-8; Saez JC, 2005, BBA-BIOMEMBRANES, V1711, P215, DOI 10.1016/j.bbamem.2005.01.014; Sansone P, 2011, CURR OPIN GENET DEV, V21, P80, DOI 10.1016/j.gde.2010.11.001; Scemes E, 1998, GLIA, V24, P65, DOI 10.1002/(SICI)1098-1136(199809)24:1<65::AID-GLIA7>3.0.CO;2-#; Scemes E, 2000, J NEUROSCI, V20, P1435; Schajnovitz A, 2011, NAT IMMUNOL, V12, P391, DOI 10.1038/ni.2017; Schalper KA, 2008, MOL BIOL CELL, V19, P3501, DOI 10.1091/mbc.E07-12-1240; Scheckenbach KEL, 2011, J VASC RES, V48, P91, DOI 10.1159/000316942; Seike T, 2011, CLIN EXP METASTAS, V28, P13, DOI 10.1007/s10585-010-9354-8; Shintani-Ishida K, 2007, AM J PHYSIOL-HEART C, V293, pH1714, DOI 10.1152/ajpheart.00022.2007; Silver DJ, 2013, J NEUROSCI, V33, P15603, DOI 10.1523/JNEUROSCI.3004-12.2013; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Sin WC, 2012, BBA-BIOMEMBRANES, V1818, P2058, DOI 10.1016/j.bbamem.2011.10.022; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Strale PO, 2012, MOL CARCINOGEN, V51, P845, DOI 10.1002/mc.20853; Tafani M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-32; Theis M, 2001, CELL COMMUN ADHES, V8, P383, DOI 10.3109/15419060109080758; Theis M, 2004, GLIA, V46, P130, DOI 10.1002/glia.10350; Theis M, 2003, J NEUROSCI, V23, P766; Theodoric N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047311; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080933; Watters JJ, 2005, J NEUROSCI RES, V81, P447, DOI 10.1002/jnr.20485; Williams SP, 2011, CANCER RES, V71, P5374, DOI 10.1158/0008-5472.CAN-10-3026; Yang CZ, 2012, P NATL ACAD SCI USA, V109, P6963, DOI 10.1073/pnas.1118754109; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zagzag D, 2008, AM J PATHOL, V173, P545, DOI 10.2353/ajpath.2008.071197; Zhang W, 2003, J NEUROSURG, V99, P1039, DOI 10.3171/jns.2003.99.6.1039; Zhang W, 1999, CANCER RES, V59, P1994; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008	125	87	96	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1504	1516		10.1038/onc.2015.210	http://dx.doi.org/10.1038/onc.2015.210			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26165844				2022-12-28	WOS:000373063600004
J	Niu, J; Xue, A; Chi, Y; Xue, J; Wang, W; Zhao, Z; Fan, M; Yang, CH; Shao, ZM; Pfeffer, LM; Wu, J; Wu, ZH				Niu, J.; Xue, A.; Chi, Y.; Xue, J.; Wang, W.; Zhao, Z.; Fan, M.; Yang, C. H.; Shao, Z-M; Pfeffer, L. M.; Wu, J.; Wu, Z-H			Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer	ONCOGENE			English	Article							NF-KAPPA-B; SQUAMOUS-CELL CARCINOMA; DNA-DAMAGE RESPONSE; TARGETING MICRORNAS; UP-REGULATION; EXPRESSION; PATHWAY; PHOSPHORYLATION; CHEMORESISTANCE; ACTIVATION	Acquired therapeutic resistance is the major drawback to effective systemic therapies for cancers. Aggressive triple-negative breast cancers (TNBC) develop resistance to chemotherapies rapidly, whereas the underlying mechanisms are not completely understood. Here we show that genotoxic treatments significantly increased the expression of miR-181a in TNBC cells, which enhanced TNBC cell survival and metastasis upon Doxorubicin treatment. Consistently, high miR-181a level associated with poor disease free survival and overall survival after treatments in breast cancer patients. The upregulation of miR-181a was orchestrated by transcription factor STAT3 whose activation depended on NF-kappa B-mediated IL-6 induction in TNBC cells upon genotoxic treatment. Intriguingly, activated STAT3 not only directly bound to MIR181A1 promoter to drive transcription but also facilitated the recruitment of MSK1 to the same region where MSK1 promoted a local active chromatin state by phosphorylating histone H3. We further identified BAX as a direct functional target of miR-181a, whose suppression decreased apoptosis and increased invasion of TNBC cells upon Dox treatment. These results were further confirmed by evidence that suppression of miR-181a significantly enhanced therapeutic response and reduced lung metastasis in a TNBC orthotopic model. Collectively, our data suggested that miR-181a induction had a critical role in promoting therapeutic resistance and aggressive behavior of TNBC cells upon genotoxic treatment. Antagonizing miR-181a may serve as a promising strategy to sensitize TNBC cells to chemotherapy and mitigate metastasis.	[Niu, J.; Wang, W.; Fan, M.; Yang, C. H.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; [Niu, J.; Chi, Y.; Wang, W.; Fan, M.; Yang, C. H.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Canc Res Ctr, Memphis, TN 38163 USA; [Xue, A.; Zhao, Z.] Fudan Univ, Shanghai Med Coll, Dept Forens Med, Shanghai 200032, Peoples R China; [Chi, Y.; Xue, J.; Shao, Z-M; Wu, J.] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Chi, Y.; Xue, J.; Shao, Z-M; Wu, J.] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Fudan University; Fudan University; Fudan University	Wu, J (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China.; Wu, ZH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 19S Manassas St, Memphis, TN 38163 USA.	wujiong1122@vip.sina.com; zwu6@uthsc.edu		fan, meiyun/0000-0002-0185-5065; Pfeffer, Lawrence/0000-0003-2809-1234	National Cancer Institute [R01 CA149251]; American Cancer Society [RSG-13-186-01-CSM]; National Natural Science Foundation of China (NSFC) [81272924]; NATIONAL CANCER INSTITUTE [R01CA149251, R01CA140346] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Bert Vogelstein (Johns Hopkins University) for wild-type and DICER - / - HCT116 cells. The BAX expression construct was a generous gift from Dr Douglas Green (St Jude Children's Research Hospital). We also thank Dr R. Laribee (UTHSC) for stimulating discussion and critical reading of the manuscript. This work was supported in part by grants from National Cancer Institute (R01 CA149251 to ZW), American Cancer Society (RSG-13-186-01-CSM to ZW), and National Natural Science Foundation of China (NSFC) (81272924 to JW).	Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boldin MP, 2012, IMMUNOL REV, V246, P205, DOI 10.1111/j.1600-065X.2011.01089.x; Bonnay F, 2014, EMBO J, V33, P2349, DOI 10.15252/embj.201488456; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Chaudhry MA, 2010, DNA CELL BIOL, V29, P553, DOI 10.1089/dna.2009.0978; Chen YR, 2014, EXP CELL RES, V320, P12, DOI 10.1016/j.yexcr.2013.10.014; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Fan MY, 2013, J BIOL CHEM, V288, P27480, DOI 10.1074/jbc.M113.491803; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112; Garofalo M, 2013, DRUG RESIST UPDATE, V16, P47, DOI 10.1016/j.drup.2013.05.001; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gehani SS, 2010, MOL CELL, V39, P886, DOI 10.1016/j.molcel.2010.08.020; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hedrich CM, 2014, P NATL ACAD SCI USA, V111, P13457, DOI 10.1073/pnas.1408023111; Hickey CJ, 2013, BLOOD, V121, P159, DOI 10.1182/blood-2012-05-428573; Ji DB, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-86; Jiao XY, 2013, BREAST CANCER RES TR, V139, P717, DOI 10.1007/s10549-013-2607-x; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kato M, 2009, ONCOGENE, V28, P2419, DOI 10.1038/onc.2009.106; Lau PNI, 2011, P NATL ACAD SCI USA, V108, P2801, DOI 10.1073/pnas.1012798108; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu M, 2013, BIOCHEM BIOPH RES CO, V441, P364, DOI 10.1016/j.bbrc.2013.10.051; Llambi F, 2011, MOL CELL, V44, P517, DOI 10.1016/j.molcel.2011.10.001; McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Niu JX, 2013, EMBO J, V32, P3206, DOI 10.1038/emboj.2013.247; Niu JX, 2012, J BIOL CHEM, V287, P21783, DOI 10.1074/jbc.M112.355495; Ouyang M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096228; Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Parikh A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3977; Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415; Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907; Sawicka A, 2014, GENOME RES, V24, P1808, DOI 10.1101/gr.176255.114; Tan GY, 2012, J BIOL CHEM, V287, P33036, DOI 10.1074/jbc.M112.383273; Tartey S, 2014, EMBO J, V33, P2332, DOI 10.15252/embj.201488447; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Wakahara R, 2012, GENES CELLS, V17, P132, DOI 10.1111/j.1365-2443.2011.01575.x; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; Wu ZH, 2007, J MOL MED, V85, P1187, DOI 10.1007/s00109-007-0227-9; Yang CH, 2010, CANCER RES, V70, P8108, DOI 10.1158/0008-5472.CAN-10-2579; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Zhang XN, 2011, MOL CELL, V41, P371, DOI 10.1016/j.molcel.2011.01.020; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	49	98	101	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1302	1313		10.1038/onc.2015.189	http://dx.doi.org/10.1038/onc.2015.189			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028030	Green Accepted			2022-12-28	WOS:000371763100010
J	Bonci, D; Coppola, V; Patrizii, M; Addario, A; Cannistraci, A; Francescangeli, F; Pecci, R; Muto, G; Collura, D; Bedini, R; Zeuner, A; Valtieri, M; Sentinelli, S; Benassi, MS; Gallucci, M; Carlini, P; Piccolo, S; De Maria, R				Bonci, D.; Coppola, V.; Patrizii, M.; Addario, A.; Cannistraci, A.; Francescangeli, F.; Pecci, R.; Muto, G.; Collura, D.; Bedini, R.; Zeuner, A.; Valtieri, M.; Sentinelli, S.; Benassi, M. S.; Gallucci, M.; Carlini, P.; Piccolo, S.; De Maria, R.			A microRNA code for prostate cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; TGF-BETA; BREAST-CANCER; STEM-CELLS; BONE-METASTASIS; SELF-RENEWAL; TUMOR; RAS; PROGRESSION	Although the development of bone metastasis is a major detrimental event in prostate cancer, the molecular mechanisms responsible for bone homing and destruction remain largely unknown. Here we show that loss of miR-15 and miR-16 in cooperation with increased miR-21 expression promote prostate cancer spreading and bone lesions. This combination of microRNA endows bone-metastatic potential to prostate cancer cells. Concomitant loss of miR-15/miR-16 and gain of miR-21 aberrantly activate TGF-beta and Hedgehog signaling, that mediate local invasion, distant bone marrow colonization and osteolysis by prostate cancer cells. These findings establish a new molecular circuitry for prostate cancer metastasis that was validated in patients' cohorts. Our data indicate a network of biomarkers and druggable pathways to improve patient treatment.	[Bonci, D.; Coppola, V.; Patrizii, M.; Addario, A.; Cannistraci, A.; Francescangeli, F.; Zeuner, A.; Valtieri, M.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy; [Bonci, D.; Sentinelli, S.; Gallucci, M.; Carlini, P.; De Maria, R.] Regina Elena Inst Canc Res, Sci Directorate, Rome, Italy; [Pecci, R.; Bedini, R.] Ist Super Sanita, Dept Technol & Hlth, Viale Regina Elena 299, I-00161 Rome, Italy; [Muto, G.; Collura, D.] S Giovanni Bosco Hosp, Dept Urol, Turin, Italy; [Muto, G.] Campus Biomed Univ, Dept Urol, Rome, Italy; [Benassi, M. S.] Ist Ortoped Rizzoli, Lab Expt Oncol, Bologna, Italy; [Piccolo, S.] Univ Padua, Sch Med, Dept Mol Med, Padua, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); University Campus Bio-Medico - Rome Italy; IRCCS Istituto Ortopedico Rizzoli; University of Padua	Bonci, D; De Maria, R (corresponding author), IRE, Regina Elena Canc Inst, Italian Natl Canc Inst Regina Elena, Viale Elio Chianesi 53, I-00144 Rome, Italy.	desiree.bonci@iss.it; demaria@ifo.it	Francescangeli, Federica/K-6500-2016; Bedini, Rossella/B-2465-2013; De Maria, Ruggero/S-6385-2019; Zeuner, Ann/K-8607-2016; Bonci, Desiree/K-6488-2016; Addario, Antonio/AAC-4707-2022; valtieri, mauro/H-1044-2016; Coppola, Valeria/K-5120-2016; Zeuner, Ann/A-8529-2010; Gallucci, Michele/K-9600-2016	Francescangeli, Federica/0000-0002-1086-5265; De Maria, Ruggero/0000-0003-2255-0583; Bonci, Desiree/0000-0002-2472-5140; Addario, Antonio/0000-0001-8527-8738; valtieri, mauro/0000-0002-9139-6754; Coppola, Valeria/0000-0002-5745-2572; collura, devis/0000-0002-8964-5248; Bedini, Rossella/0000-0002-0830-6632; Zeuner, Ann/0000-0002-8295-3715; PICCOLO, STEFANO/0000-0002-2037-0004; Gallucci, Michele/0000-0002-3637-6531; Muto, Giovanni/0000-0003-3593-6450; Pecci, Raffaella/0000-0002-6500-9124	National Ministry of Health; Italy-USA microRNA program; Italian Association for Cancer Research (AIRC); Fondazione Roma	National Ministry of Health; Italy-USA microRNA program; Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma(Fondazione RomaEuropean Commission)	We thank Giuseppe Loreto, Tania Merlino, Laura De Salvo and Roberto Giaconella for their technical support. We thank Michelangelo Cordenonsi, Maria Musumeci and Marcello Maugeri-Sacca for manuscript discussion. This manuscript has been supported by National Ministry of Health, Under-forty researcher and Italy-USA microRNA program to DB and the Italian Association for Cancer Research (AIRC) and Fondazione Roma funding to RDM.	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chan E, 2011, TRENDS MOL MED, V17, P235, DOI 10.1016/j.molmed.2011.01.008; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Coppola V, 2013, ONCOGENE, V32, P1843, DOI 10.1038/onc.2012.194; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76; Das S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034374; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frezzetti D, 2011, ONCOGENE, V30, P275, DOI 10.1038/onc.2010.416; Grusch M, 2010, CURR CANCER DRUG TAR, V10, P849, DOI 10.2174/156800910793357943; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Javelaud D, 2012, FEBS LETT, V586, P2016, DOI 10.1016/j.febslet.2012.05.011; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karaa ZS, 2009, RNA, V15, P249, DOI 10.1261/rna.1301109; Kim C, 2010, NAT REV CLIN ONCOL, V7, P340, DOI 10.1038/nrclinonc.2010.61; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Luo J, 2002, CANCER RES, V62, P2220; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martello G, 2007, NATURE, V449, P183, DOI 10.1038/nature06100; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Perrot CY, 2013, PHARMACOL THERAPEUT, V137, P183, DOI 10.1016/j.pharmthera.2012.10.002; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555-006-9032-0; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sanchez P, 2005, CANCER RES, V65, P2990, DOI 10.1158/0008-5472.CAN-05-0439; Shariat SF, 2004, CLIN CANCER RES, V10, P1992, DOI 10.1158/1078-0432.CCR-0768-03; Shi L, 2014, CANCER RES, V74, P532, DOI 10.1158/0008-5472.CAN-13-2203; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140-6736(11)61226-9; Sorrentino A, 2008, EXP HEMATOL, V36, P1035, DOI 10.1016/j.exphem.2008.03.004; Stinchfield MJ, 2012, DEVELOPMENT, V139, P2721, DOI 10.1242/dev.077206; Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teicher BA, 2001, CANCER METAST REV, V20, P133, DOI 10.1023/A:1013177011767; Valtieri M, 2008, J CELL PHYSIOL, V217, P296, DOI 10.1002/jcp.21521; Vo BT, 2011, PROSTATE, V71, P1084, DOI 10.1002/pros.21326; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246	66	94	100	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1180	1192		10.1038/onc.2015.176	http://dx.doi.org/10.1038/onc.2015.176			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26073083	hybrid, Green Published			2022-12-28	WOS:000371351700012
J	Chua, CY; Liu, Y; Granberg, KJ; Hu, L; Haapasalo, H; Annala, MJ; Cogdell, DE; Verploegen, M; Moore, LM; Fuller, GN; Nykter, M; Cavenee, WK; Zhang, W				Chua, C. Y.; Liu, Y.; Granberg, K. J.; Hu, L.; Haapasalo, H.; Annala, M. J.; Cogdell, D. E.; Verploegen, M.; Moore, L. M.; Fuller, G. N.; Nykter, M.; Cavenee, W. K.; Zhang, W.			IGFBP2 potentiates nuclear EGFR-STAT3 signaling	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; FACTOR-BINDING PROTEIN-2; FACTOR RECEPTOR; EGF RECEPTOR; FACTOR-ALPHA; HUMAN GLIOMAS; GLIOBLASTOMA-MULTIFORME; PROGNOSTIC-SIGNIFICANCE; ASTROCYTIC GLIOMAS; MESSENGER-RNA	Insulin-like growth factor binding protein 2 (IGFBP2) is a pleiotropic oncogenic protein that has both extracellular and intracellular functions. Despite a clear causal role in cancer development, the tumor-promoting mechanisms of IGFBP2 are poorly understood. The contributions of intracellular IGFBP2 to tumor development and progression are also unclear. Here we present evidence that both exogenous IGFBP2 treatment and cellular IGEBP2 overexpression lead to aberrant activation of epidermal growth factor receptor (EGFR), which subsequently activates signal transducer and activator of transcription factor 3 (STAT3) signaling. Furthermore, we demonstrate that IGFBP2 augments the nuclear accumulation of EGFR to potentiate STAT3 transactivation activities, via activation of the nuclear EGFR signaling pathway. Nuclear IGFBP2 directly influences the invasive and migratory capacities of human glioblastoma cells, providing a direct link between intracellular (and particularly nuclear) IGFBP2 and cancer hallmarks. These activities are also consistent with the strong association between IGFBP2 and STAT3-activated genes derived from The Cancer Genome Atlas database for human glioma. A high level of all three proteins (IGFBP2, EGFR and STAT3) was strongly correlated with poorer survival in an independent patient data set. These results identify a novel tumor-promoting function for IGFBP2 of activating EGFR/STAT3 signaling and facilitating EGFR accumulation in the nucleus, thereby deregulating EGFR signaling by two distinct mechanisms. As targeting EGFR in glioma has been relatively unsuccessful, this study suggests that IGFBP2 may be a novel therapeutic target.	[Chua, C. Y.; Liu, Y.; Granberg, K. J.; Hu, L.; Annala, M. J.; Cogdell, D. E.; Verploegen, M.; Moore, L. M.; Fuller, G. N.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Chua, C. Y.; Fuller, G. N.; Zhang, W.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Liu, Y.; Fuller, G. N.; Zhang, W.] ISB MDA Genome Data Anal Ctr, Canc Genome Atlas, Seattle, WA USA; [Liu, Y.; Fuller, G. N.; Zhang, W.] ISB MDA Genome Data Anal Ctr, Canc Genome Atlas, Houston, TX USA; [Granberg, K. J.; Annala, M. J.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Granberg, K. J.; Annala, M. J.; Nykter, M.] Univ Tampere, Inst Biomed Technol, FIN-33101 Tampere, Finland; [Haapasalo, H.] Fimlab Labs, Dept Pathol, Tampere, Finland; [Haapasalo, H.] Univ Tampere, FIN-33101 Tampere, Finland; [Verploegen, M.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands; [Cavenee, W. K.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Tampere University; Tampere University; Radboud University Nijmegen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Unit 85, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org	Verploegen, Maartje/GYA-0516-2022	Chua, Corrine Ying Xuan/0000-0002-5724-8715; Rautajoki, Kirsi Johanna/0000-0001-6549-7810; Nykter, Matti/0000-0001-6956-2843; Fuller, Gregory/0000-0001-9447-2647	US National Institutes of Health [CA098503, CA141432, CA143835, U24 CA143835]; Cancer Systems Informatics Center from the National Foundation for Cancer Research; NIH/NCI grant [P30CA016672]; Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor program; Academy of Finland [259038]; NATIONAL CANCER INSTITUTE [R01CA141432, U24CA143835, P30CA016672, R01CA098503] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Systems Informatics Center from the National Foundation for Cancer Research; NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor program; Academy of Finland(Academy of Finland); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Oliver Bogler, Dr Zhimin Lu, Dr Frederick Lang, Dr Paul Chiao and Dr Tapio Visakorpi for their helpful comments and discussions and Kathryn L Hale, Department of Scientific Publications at MD Anderson Cancer Center, for editing the manuscript. We thank Ville Kytola for contributions to the immunohistochemical association analyses. This work was partially supported by grants from the US National Institutes of Health (CA098503, CA141432 and CA143835 to WZ and GNF and U24 CA143835 to WZ), by funding for the Cancer Systems Informatics Center from the National Foundation for Cancer Research (to WZ), by NIH/NCI grant P30CA016672 to MD Anderson Cancer Center supporting the Flow Cytometry and Cellular Imaging Core Facility and by the Finnish Funding Agency for Technology and Innovation Finland Distinguished Professor program and the Academy of Finland (grant 259038 to KG). WKC is a Fellow of the National Foundation for Cancer Research,	Arese M, 1999, MOL BIOL CELL, V10, P1429, DOI 10.1091/mbc.10.5.1429; Azar WJ, 2014, ONCOGENE, V33, P578, DOI 10.1038/onc.2012.630; Azar WJ, 2011, ENDOCRINOLOGY, V152, P3332, DOI 10.1210/en.2011-1121; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; Baxter RC, 2013, J CELL COMMUN SIGNAL, V7, P179, DOI 10.1007/s12079-013-0203-9; Becher OJ, 2008, J CHILD NEUROL, V23, P1205, DOI 10.1177/0883073808321766; Besnard V, 2001, BBA-MOL CELL RES, V1538, P47, DOI 10.1016/S0167-4889(00)00136-1; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Brand TM, 2011, DISCOV MED, V12, P419; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; CLEMMONS DR, 1990, TRENDS ENDOCRIN MET, V1, P412, DOI 10.1016/1043-2760(90)90102-9; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Demory ML, 2009, J BIOL CHEM, V284, P36592, DOI 10.1074/jbc.M109.000760; Dobrowolski R, 2012, NAT REV MOL CELL BIO, V13, P53, DOI 10.1038/nrm3244; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FERRER I, 1995, NEUROSCIENCE, V66, P189, DOI 10.1016/0306-4522(94)00584-R; Fuller GN, 1999, CANCER RES, V59, P4228; Ganesan A, 2012, PROTEIN SCI, V21, P918, DOI 10.1002/pro.2089; Gerrard DE, 1999, J ANIM SCI, V77, P1431; Giannopoulou E, 2006, IN VIVO, V20, P421; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Haapasalo H, 1996, BRIT J CANCER, V73, P620, DOI 10.1038/bjc.1996.107; Han S, 2014, BRIT J CANCER, V111, P1400, DOI 10.1038/bjc.2014.435; Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0; Haynik DM, 2007, APPL IMMUNOHISTO M M, V15, P56, DOI 10.1097/01.pai.0000213133.09160.da; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Herms JW, 1999, SURG NEUROL, V51, P536, DOI 10.1016/S0090-3019(98)00028-7; Hoeflich A, 2004, BIOCHEM BIOPH RES CO, V324, P705, DOI 10.1016/j.bbrc.2004.09.111; Holmes KM, 2012, P NATL ACAD SCI USA, V109, P3475, DOI 10.1073/pnas.1120375109; Hoshino M, 2007, PATHOBIOLOGY, V74, P15, DOI 10.1159/000101047; Housden BE, 2014, TRENDS BIOCHEM SCI, V39, P457, DOI 10.1016/j.tibs.2014.07.008; Hsieh D, 2010, BIOCHEM BIOPH RES CO, V397, P367, DOI 10.1016/j.bbrc.2010.05.145; Huynh H, 2011, BLOOD, V118, P3236, DOI 10.1182/blood-2011-01-331876; Jaganathan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019605; Jahani-Asl A, 2013, CURR MOL MED, V13, P1241, DOI 10.2174/1566524011313080002; Joki T, 2000, CANCER RES, V60, P4926; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; KASER MR, 1992, MOL BRAIN RES, V16, P316, DOI 10.1016/0169-328X(92)90241-3; Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; LAZAR LM, 1992, J NEUROSCI, V12, P1688; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; Li X, 2015, ONCOGENE, V34, P1619, DOI 10.1038/onc.2014.98; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; McDonald KL, 2007, J NEUROPATH EXP NEUR, V66, P405, DOI 10.1097/nen.0b013e31804567d7; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Miyako K, 2009, MOL ENDOCRINOL, V23, P169, DOI 10.1210/me.2008-0168; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Pennock S, 2003, MOL CELL BIOL, V23, P5803, DOI 10.1128/MCB.23.16.5803-5815.2003; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; Sallinen SL, 2000, CANCER RES, V60, P6617; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Sarfstein R, 2013, ENDOCRINOLOGY, V154, P1672, DOI 10.1210/en.2012-2165; Scharf JG, 1996, HEPATOLOGY, V23, P818, DOI 10.1002/hep.510230424; Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635; Scrideli CA, 2007, J NEURO-ONCOL, V83, P233, DOI 10.1007/s11060-007-9328-0; Shao H, 2003, CANCER RES, V63, P3923; Shono T, 2001, CANCER RES, V61, P4375; Smalheiser NR, 1996, MOL BIOL CELL, V7, P1003, DOI 10.1091/mbc.7.7.1003; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Stachowiak MK, 2003, J CELL BIOCHEM, V90, P662, DOI 10.1002/jcb.10606; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Terrien X, 2005, BIOCHEM J, V392, P457, DOI 10.1042/BJ20050517; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; TORP SH, 1993, EUR J CANCER, V29A, P1604, DOI 10.1016/0959-8049(93)90305-Y; TUZI NL, 1991, BRIT J CANCER, V63, P227, DOI 10.1038/bjc.1991.54; Waage IS, 2013, INT J SURG PATHOL, V21, P573, DOI 10.1177/1066896913492196; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200; Wang H, 2003, CANCER RES, V63, P4315; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; WOOD TL, 1992, DEVELOPMENT, V114, P59; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; Xu KM, 2014, ONCOTARGET, V5, P1241, DOI 10.18632/oncotarget.1370; Yang DI, 2002, ANN NY ACAD SCI, V962, P8, DOI 10.1111/j.1749-6632.2002.tb04052.x; Yazawa T, 2009, AM J PATHOL, V175, P976, DOI 10.2353/ajpath.2009.081004; Zheng XG, 2007, CANCER SCI, V98, P674, DOI 10.1111/j.1349-7006.2007.00440.x; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	96	50	54	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					738	747		10.1038/onc.2015.131	http://dx.doi.org/10.1038/onc.2015.131			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25893308	Green Accepted			2022-12-28	WOS:000370331300007
J	Jin, H; Lee, K; Kim, YH; Oh, HK; Maeng, YI; Kim, TH; Suh, DS; Bae, J				Jin, H.; Lee, K.; Kim, Y-H; Oh, H. K.; Maeng, Y-I; Kim, T-H; Suh, D-S; Bae, J.			Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; UBIQUITIN-PROTEASOME SYSTEM; LIM-ONLY PROTEIN; GENE IEX-1; TRIGGERS APOPTOSIS; IN-VIVO; P53; EXPRESSION; TARGET; IDENTIFICATION	The expression of immediate early response 3 (IER3), a protein with a short half-life, is rapidly induced by various cellular stimuli. We recently reported that IER3 induces the apoptosis of cervical cancer cells and that its expression is downregulated in patients with cervical cancer. However, the molecular mechanism involved in the rapid degradation of IER3 remains unknown. Here, we demonstrate that MDM2 is an E3 ligase that interacts with IER3 and promotes its ubiquitination, followed by proteasomal degradation. Polyubiquitination of the conserved lysine 60 of IER3 is essential for its degradation. In addition, four and a half LIM domains protein 2 (FHL2) binds to both IER3 and MDM2, allowing for efficient MDM2-mediated IER3 degradation by facilitating an association between MDM2 and IER3. Moreover, IER3 induces cell cycle arrest in cervical cancer cells and its activity is further enhanced in cells in which FHL2 or MDM2 was silenced, thereby preventing IER3 degradation. The E6 and E7 oncoproteins of human papilloma virus 18 regulated IER3 expression. FHL2 expression was significantly higher in the squamous epithelium of cervical carcinoma tissues than in non-cancerous cervical tissues, whereas cervical carcinoma expression of IER3 was downregulated in this region. Thus, we determined the molecular mechanism responsible for IER3 degradation, involving a ternary complex of IER3, MDM2 and FHL2, which may contribute to cervical tumor growth. Furthermore, we demonstrated that FHL2 serves as a scaffold for E3 ligase and its substrate during the ubiquitination reaction, a function that has not been previously reported for this protein.	[Jin, H.; Bae, J.] Chung Ang Univ, Sch Pharm, 84 Heukseok Ro, Seoul 156756, South Korea; [Lee, K.] Chung Ang Univ, Dept Life Sci, Seoul, South Korea; [Kim, Y-H] Catholic Univ Daegu, Sch Med, Dept Microbiol, Daegu, South Korea; [Oh, H. K.; Maeng, Y-I] Catholic Univ Daegu, Sch Med, Dept Pathol, Daegu, South Korea; [Kim, T-H] Chosun Univ, Sch Med, Dept Biochem, Gwangju, South Korea; [Suh, D-S] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea	Chung Ang University; Chung Ang University; Catholic University of Daegu; Catholic University of Daegu; Chosun University; University of Ulsan; Asan Medical Center	Bae, J (corresponding author), Chung Ang Univ, Sch Pharm, 84 Heukseok Ro, Seoul 156756, South Korea.	jeehyeon@cau.ac.kr	Park, Sang-Youel/D-5966-2012	Park, Sang-Youel/0000-0003-0575-6045; Jin, Hanyong/0000-0002-5850-0791	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2014R1A2A2A01006839, NRF-2015R1A5A1008958, NRF-2015R1A2A1A15054332]; Next-Generation BioGreen 21 Program, the Rural Development Administration of the Republic of Korea [PJ01117703]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Next-Generation BioGreen 21 Program, the Rural Development Administration of the Republic of Korea	This research was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2014R1A2A2A01006839; NRF-2015R1A5A1008958; NRF-2015R1A2A1A15054332) and by the Next-Generation BioGreen 21 Program (PJ01117703), the Rural Development Administration of the Republic of Korea.	Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Arlt A, 2011, EUR J CELL BIOL, V90, P545, DOI 10.1016/j.ejcb.2010.10.002; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Balsas P, 2012, LEUKEMIA RES, V36, P212, DOI 10.1016/j.leukres.2011.09.011; Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002; Campo-Fernandez B, 2007, J VIROL, V81, P1027, DOI 10.1128/JVI.01699-06; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chen JZ, 2015, REV MED VIROL, V25, P24, DOI 10.1002/rmv.1823; Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692; Ding LH, 2009, J CLIN INVEST, V119, P349, DOI 10.1172/JCI35930; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayashi H, 2009, ARTERIOSCL THROM VAS, V29, P909, DOI 10.1161/ATVBAHA.108.178541; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Jin H, 2015, SCI REP-UK, V5, DOI 10.1038/srep08367; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Jung CR, 2010, J CLIN INVEST, V120, P4493, DOI 10.1172/JCI42674; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Kim JH, 2014, J REPROD DEVELOP, V60, P14, DOI 10.1262/jrd.2013-090; Kim JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3936; Kirkin V, 2011, CURR OPIN GENET DEV, V21, P21, DOI 10.1016/j.gde.2010.10.004; Kleiber K, 2007, ANTICANCER RES, V27, P55; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee MJ, 2013, PROG NEUROBIOL, V105, P49, DOI 10.1016/j.pneurobio.2013.03.001; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Manzo-Merino J, 2015, VIROLOGY, V476, P100, DOI 10.1016/j.virol.2014.11.025; Mille F, 2009, NAT CELL BIOL, V11, P739, DOI 10.1038/ncb1880; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Muerkoster SS, 2008, ONCOGENE, V27, P1122, DOI 10.1038/sj.onc.1210728; Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115; Ng CF, 2011, CANCER LETT, V304, P97, DOI 10.1016/j.canlet.2011.02.001; Pawlikowska P, 2010, CELL DEATH DIFFER, V17, P1739, DOI 10.1038/cdd.2010.56; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Qian Z, 2009, LEUKEMIA, V23, P1650, DOI 10.1038/leu.2009.78; Ryou SM, 2014, J CONTROL RELEASE, V196, P287, DOI 10.1016/j.jconrel.2014.10.021; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Suh DS, 2015, J PROTEOME RES, V14, P2446, DOI 10.1021/pr501230b; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Wu MX, 2013, EXPERT OPIN THER TAR, V17, P593, DOI 10.1517/14728222.2013.768234; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Yoon S, 2009, BIOCHEM BIOPH RES CO, V382, P400, DOI 10.1016/j.bbrc.2009.03.037; Zienert E, 2015, CANCER LETT, V364, P17, DOI 10.1016/j.canlet.2015.04.019	50	22	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5106	5118		10.1038/onc.2016.54	http://dx.doi.org/10.1038/onc.2016.54			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26973248	hybrid, Green Published			2022-12-28	WOS:000384433000003
J	Tandon, M; Chen, Z; Othman, AH; Pratap, J				Tandon, M.; Chen, Z.; Othman, A. H.; Pratap, J.			Role of Runx2 in IGF-1R beta/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR RUNX2; MAMMARY EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; SIGNALING PATHWAYS; ECTOPIC EXPRESSION; PROSTATE-CANCER; DNA-DAMAGE; PROGRESSION; INVASION	The mechanisms underlying reprogramming of growth factor signaling and metabolic pathways during bone metastasis of breast cancer are not clear. The Runt-related transcription factor (Runx2) regulates cell signaling during mammary epithelial morphogenesis and promotes invasion; therefore, we investigated its role in cell growth and metabolic signaling in bone-seeking breast cancer cells. We performed systemic inoculation of control or Runx2 knockdown invasive MDA-MB-231 cells in NOD/SCID mice, and compared parental and bone-derived variants for phenotypic and molecular alterations. The Runx2 knockdown showed early (0-2 weeks) inhibition of metastatic spread but late (4-6 weeks) outgrowth, suggesting Runx2-dependent bi-phasic response and reprogramming of metastatic cells. The late-stage tumor outgrowth of bone-derived Runx2 knockdown cells was associated with increased insulin-like growth factor-1R beta (IGF-1R beta) levels. Interestingly, glucose uptake and glycolysis were reduced in the bone-derived Runx2 knockdown cells that could be further reduced by extracellular-regulated protein kinase (Erk1/2) inhibition. Furthermore, the Runx2 knockdown cells displayed activation of AMP-activated protein kinase (AMPK alpha), the sensor of cellular metabolism. Importantly, the Runx2 knockdown in bone-derived cells resulted in increased sensitivity to both Erk1/2 inhibition and AMPK alpha activation by PD184161 and metformin, respectively, despite increased IGF-1R beta and AMPK alpha levels. Our results reveal that Runx2 promotes metastatic spread of mammary tumor cells. The growth of late-stage tumor cells can be targeted by Runx2 knockdown in combination with Mek-Erk1/2 inhibition and metformin treatment.	[Tandon, M.; Chen, Z.; Othman, A. H.; Pratap, J.] Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL 60612 USA	Rush University	Pratap, J (corresponding author), Rush Univ, Med Ctr, Armour Acad Ctr, Dept Anat & Cell Biol, 600 South Paulina St,Suite 507, Chicago, IL 60612 USA.	jitesh_pratap@rush.edu		Othman, Ahmad/0000-0001-9995-1233	Bears Care Foundation	Bears Care Foundation	We thank Rush University Medical Center investigators; Dr Rick Sumner and his lab members, Dr Ryan Ross and Maleeha Mashiatulla for assistance with mu CT data acquisition and analysis; Dr Amarjit Virdi for help with the ex vivo bone tumor co-culture model. We thank Dr Carl Maki and members of his lab, Dr Lei Duan and Ricardo Perez for helpful discussions throughout this study; Dr Elena Dedkova and Dr Lothar Blatter for assistance with sea horse data acquisition and analysis. This study was supported by the grant from Bears Care Foundation.	Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609; Ali SA, 2012, J CELL SCI, V125, P2732, DOI 10.1242/jcs.100909; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Boumah CE, 2009, MOL ENDOCRINOL, V23, P1255, DOI 10.1210/me.2008-0217; Campbell JP, 2012, JOVE-J VIS EXP, DOI 10.3791/4260; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13; Dowling RJO, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-33; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Dunn SE, 1998, CANCER RES, V58, P3353; Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009; Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747; Ge C, 2016, ONCOGENE, V35, P366, DOI 10.1038/onc.2015.91; Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046; Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980; Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Hatoum D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/548436; Henkels KM, 2015, FASEB J, V29, P1299, DOI 10.1096/fj.14-260992; Hiraga T, 2012, CANCER RES, V72, P4238, DOI 10.1158/0008-5472.CAN-11-3061; Ibrahim T, 2013, ONCOL LETT, V6, P306, DOI 10.3892/ol.2013.1372; Inman CK, 2005, MOL CELL BIOL, V25, P3182, DOI 10.1128/MCB.25.8.3182-3193.2005; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kovacs JJ, 2009, DEV CELL, V17, P443, DOI 10.1016/j.devcel.2009.09.011; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Leong DT, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2762; Lian JB, 2003, CONNECT TISSUE RES, V44, P141, DOI 10.1080/03008200390152232; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579; Lucero CMJ, 2013, J CELL PHYSIOL, V228, P714, DOI 10.1002/jcp.24218; Martin TJ, 2001, TRENDS ENDOCRIN MET, V12, P2, DOI 10.1016/S1043-2760(00)00351-9; McDonald L, 2014, DIS MODEL MECH, V7, P525, DOI 10.1242/dmm.015040; Monami G, 2008, J CELL PHYSIOL, V216, P426, DOI 10.1002/jcp.21405; Morales DR, 2015, ANNU REV MED, V66, P17, DOI 10.1146/annurev-med-062613-093128; MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756-3282(91)90057-P; Oakley RH, 2012, P NATL ACAD SCI USA, V109, P17591, DOI 10.1073/pnas.1209411109; Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229; Onodera Y, 2010, CANCER SCI, V101, P2670, DOI 10.1111/j.1349-7006.2010.01742.x; Ozaki T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.127; Pande S, 2013, J CELL PHYSIOL, V228, P1784, DOI 10.1002/jcp.24339; Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Pratap J, 2003, CANCER RES, V63, P5357; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008-5472.CAN-09-1471; Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280; Robey IF, 2008, NEOPLASIA, V10, P745, DOI 10.1593/neo.07724; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Ross RD, 2014, J BONE MINER RES, V29, P1597, DOI 10.1002/jbmr.2188; Sachdev D, 2010, ONCOGENE, V29, P251, DOI 10.1038/onc.2009.316; Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227; Taipaleenmaki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008-5472.CAN-14-1026; Taliaferro-Smith L, 2009, ONCOGENE, V28, P2621, DOI 10.1038/onc.2009.129; Tandon M, 2014, J CELL BIOCHEM, V115, P2208, DOI 10.1002/jcb.24939; Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611; Tandon M, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-27; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Westendorf JJ, 2006, J CELL BIOCHEM, V98, P54, DOI 10.1002/jcb.20805; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r52; Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18; Zhuang YX, 2011, MOL CANCER RES, V9, P603, DOI 10.1158/1541-7786.MCR-10-0343; Zordoky BNM, 2014, BBA-GEN SUBJECTS, V1840, P1943, DOI 10.1016/j.bbagen.2014.01.023	79	30	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4730	4740		10.1038/onc.2015.518	http://dx.doi.org/10.1038/onc.2015.518			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26804175				2022-12-28	WOS:000383324700006
J	Wang, Q; Liu, P; Spangle, JM; Von, T; Roberts, TM; Lin, NU; Krop, IE; Winer, EP; Zhao, JJ				Wang, Q.; Liu, P.; Spangle, J. M.; Von, T.; Roberts, T. M.; Lin, N. U.; Krop, I. E.; Winer, E. P.; Zhao, J. J.			PI3K-p110 alpha mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers	ONCOGENE			English	Article							P110-ALPHA ISOFORM; PI3K; PIK3CA; TUMORIGENESIS; TRASTUZUMAB; INHIBITION; RECEPTORS; P110-BETA; TUMORS; METASTASIS	Human epidermal growth factor receptor-2 (HER2) amplification/overexpression (HER2+) frequently co-occurs with PI3K pathway activation in breast tumors. PI3K signaling is most often activated by PIK3CA mutation or PTEN loss, which frequently results in sensitivity to p110 alpha or p110 beta inhibitors, respectively. To examine the p110 isoform dependence in HER2+, PTEN-deficient tumors, we generated genetic mouse models of breast tumors driven by concurrent Her2 activation and Pten loss coupled with deletion of p110 alpha or p110 beta. Ablation of p110 alpha, but not p110 beta, significantly impaired the development of Her2+/Pten-null tumors in mice. We further show that p110 alpha primarily mediates oncogenic signaling in HER2+/PTEN-deficient human cancers while p110 beta conditionally mediates PI3K/AKT signaling only upon HER2 inhibition. Combined HER2 and p110 alpha inhibition effectively reduced PI3K/AKT signaling and growth of cancer cells both in vitro and in vivo. Addition of the p110 beta inhibitor to dual HER2 and p110 alpha inhibition induced tumor regression in a xenograft model of HER2+/PTEN-deficient human cancers. Together, our data suggest that combined inhibition of HER2 and p110 alpha/beta may serve as a potent and durable therapeutic regimen for the treatment of HER2+, PTEN-deficient breast tumors.	[Wang, Q.; Liu, P.; Spangle, J. M.; Von, T.; Roberts, T. M.; Zhao, J. J.] Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave,Smith 936B, Boston, MA 02115 USA; [Wang, Q.; Spangle, J. M.; Von, T.; Roberts, T. M.; Zhao, J. J.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Liu, P.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China; [Lin, N. U.; Krop, I. E.; Winer, E. P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Wang, Q.] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Huazhong University of Science & Technology; Harvard University; Dana-Farber Cancer Institute; Medical University of South Carolina	Zhao, JJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave,Smith 936B, Boston, MA 02115 USA.	jean_zhao@dfci.harvard.edu			Department of Pathology and Laboratory Medicine, Medical University of South Carolina; Susan G. Komen Breast Cancer Foundation [CCR 12225834]; Breast Cancer Research Foundation; NIH grants [CA187918, CA172461-01, 1P50CA168504]; NATIONAL CANCER INSTITUTE [R01CA172461, R01CA187918, P50CA168504] Funding Source: NIH RePORTER	Department of Pathology and Laboratory Medicine, Medical University of South Carolina; Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Roderick Bronson and the Dana-Farber/Harvard Cancer Center Rodent Histopathology Core for histopathological analyses. MMTV-NIC mice were provided by W Muller (McGill University). Floxed Pten mice were provided by H Wu (UCLA). This work was supported by start-up fund from Department of Pathology and Laboratory Medicine, Medical University of South Carolina (QW), the Susan G. Komen Breast Cancer Foundation CCR 12225834 (IEK), the Breast Cancer Research Foundation (NUL, EPW, JJZ), NIH grants CA187918 (TMR and JJZ), CA172461-01 (JJZ) and 1P50CA168504 (TMR, IEK, EPW, NUL and JJZ).	Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Guillermet-Guibert J, 2008, P NATL ACAD SCI USA, V105, P8292, DOI 10.1073/pnas.0707761105; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Juric D, 2012, CANCER RES, V72, P1; Juric D, 2013, CANCER RES, V73, P6; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Schade B, 2009, J BIOL CHEM, V284, P19018, DOI 10.1074/jbc.M109.018937; Schmit F, 2014, P NATL ACAD SCI USA, V111, P6395, DOI 10.1073/pnas.1323004111; Schwartz S, 2015, CANCER CELL, V27, P109, DOI 10.1016/j.ccell.2014.11.008; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112; Vanhaesebroeck B, 2014, CANCER CELL, V25, P269, DOI 10.1016/j.ccr.2014.02.012; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103	27	31	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3607	3612		10.1038/onc.2015.406	http://dx.doi.org/10.1038/onc.2015.406			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26500061	Green Accepted			2022-12-28	WOS:000379621500013
J	Perotti, V; Baldassari, P; Molla, A; Vegetti, C; Bersani, I; Maurichi, A; Santinami, M; Anichini, A; Mortarini, R				Perotti, V.; Baldassari, P.; Molla, A.; Vegetti, C.; Bersani, I.; Maurichi, A.; Santinami, M.; Anichini, A.; Mortarini, R.			NFATc2 is an intrinsic regulator of melanoma dedifferentiation	ONCOGENE			English	Article							ACTIVATED T-CELLS; C-MYC EXPRESSION; NUCLEAR FACTOR; METASTATIC MELANOMA; THERAPEUTIC TARGET; MALIGNANT-MELANOMA; SIGNALING PATHWAY; INITIATING CELLS; ONCOGENIC BRAF; DIFFERENTIATION	Melanoma dedifferentiation, characterized by the loss of MITF and MITF regulated genes and by upregulation of stemness markers as CD271, is implicated in resistance to chemotherapy, target therapy and immunotherapy. The identification of intrinsic mechanisms fostering melanoma dedifferentiation may provide actionable therapeutic targets to improve current treatments. Here, we identify NFATc2 transcription factor as an intrinsic regulator of human melanoma dedifferentiation. In panels of melanoma cell lines, NFATc2 expression correlated inversely with MITF at both mRNA and protein levels. NFATc2(+/Hi) melanoma cell lines were CD271(+) and deficient for expression of melanocyte differentiation antigens (MDAs) MART-1, gp100, tyrosinase and of GPNMB, PGC1-alpha and Rab27a, all regulated by MITF. Targeting of NFATc2 by small interfering RNA, short hairpin RNA and by an NFATc2 inhibitor upregulated MITF, MDAs, GPNMB, PGC-1 alpha, tyrosinase activity and pigmentation and suppressed CD271. Mechanistically, we found that NFATc2 controls melanoma dedifferentiation by inducing expression in neoplastic cells of membrane-bound tumor necrosis factor-alpha (mTNF-alpha) and that melanoma-expressed TNF-alpha regulates a c-myc-Brn2 axis. Specifically, NFATc2, mTNF-alpha and expression of TNF receptors were significantly correlated in panels of cell lines. NFATc2 silencing suppressed TNF-alpha expression, and neutralization of melanoma-expressed TNF-alpha promoted melanoma differentiation. Moreover, silencing of NFATc2 and TNF-alpha neutralization downmodulated c-myc and POU3F2/Brn2. Brn2 was strongly expressed in NFATc2(+/Hi) MITFLo cell lines and its silencing upregulated MITF. Targeting of c-myc, by silencing or by a c-myc inhibitor, suppressed Brn2 and upregulated MITF and MART-1 in melanoma cells. The relevance of NFATc2-dependent melanoma dedifferentiation for immune escape was shown by cytolytic T-cell assays. NFATc2(Hi) MITFLo MDA(Lo) HLA-A2.1(+) melanoma cells were poorly recognized by MDA-specific and HLA-A2-restricted CTL lines, but NFATc2 targeting significantly increased CTL-mediated tumor recognition. Taken together, these results suggest that the expression of NFATc2 promotes melanoma dedifferentiation and immune escape.	[Perotti, V.; Baldassari, P.; Molla, A.; Vegetti, C.; Bersani, I.; Anichini, A.; Mortarini, R.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Human Tumors Immunobiol Unit, Via Venezian 1, I-20133 Milan, Italy; [Maurichi, A.; Santinami, M.] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Melanoma & Sarcoma Unit, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Mortarini, R (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Human Tumors Immunobiol Unit, Via Venezian 1, I-20133 Milan, Italy.	roberta.mortarini@istitutotumori.mi.it	Anichini, Andrea/K-1434-2016; Mortarini, Roberta/C-9483-2017; Maurichi, Andrea/AAX-5020-2020; Perotti, Valentina/C-1049-2017; Maurichi, Andrea/E-7030-2017; Santinami, Mario/I-3795-2017	Anichini, Andrea/0000-0001-5096-5538; Mortarini, Roberta/0000-0001-7732-0561; Maurichi, Andrea/0000-0002-6503-5373; Perotti, Valentina/0000-0003-4506-2363; Maurichi, Andrea/0000-0002-6503-5373; Santinami, Mario/0000-0001-8436-4757	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C., Milan) [12020, 15860]	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C., Milan)(Fondazione AIRC per la ricerca sul cancro)	We thank Dr L. De Cecco and Mr. E. Marchesi of the Functional Genomics Facility of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, for qPCR and gene expression analysis, Ms. G. Nicolini for the skillfull technical work. This investigation was supported by grant #12020 #15860 (to RM) from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C., Milan).	Anichini A, 2006, CANCER RES, V66, P6405, DOI 10.1158/0008-5472.CAN-06-0854; Barral AM, 2000, MELANOMA RES, V10, P331, DOI 10.1097/00008390-200008000-00004; Bellei B, 2011, PIGM CELL MELANOMA R, V24, P309, DOI 10.1111/j.1755-148X.2010.00800.x; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bonvin E, 2012, MOL CELL BIOL, V32, P4674, DOI 10.1128/MCB.01067-12; Caballero FJ, 2007, BIOCHEM PHARMACOL, V73, P1013, DOI 10.1016/j.bcp.2006.12.001; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Cheli Y, 2014, ONCOTARGET, V5, P5272, DOI 10.18632/oncotarget.1967; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Flockhart RJ, 2009, BRIT J CANCER, V101, P1448, DOI 10.1038/sj.bjc.6605277; Furuta J, 2014, J INVEST DERMATOL, V134, P1369, DOI 10.1038/jid.2013.490; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Grazia G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.410; Harris RG, 2002, J BIOL CHEM, V277, P34815, DOI 10.1074/jbc.M109609200; Hartman ML, 2015, CELL MOL LIFE SCI, V72, P1249, DOI 10.1007/s00018-014-1791-0; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Kaminuma O, 2008, J IMMUNOL, V180, P319, DOI 10.4049/jimmunol.180.1.319; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Lawrence MC, 2011, J BIOL CHEM, V286, P1025, DOI 10.1074/jbc.M110.158675; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Medyouf H, 2008, CELL CYCLE, V7, P297, DOI 10.4161/cc.7.3.5357; Menon DR, 2015, ONCOGENE, V34, P4448, DOI 10.1038/onc.2014.372; Minematsu H, 2011, CELL SIGNAL, V23, P1785, DOI 10.1016/j.cellsig.2011.06.013; Mognol GP, 2012, CELL CYCLE, V11, P1014, DOI 10.4161/cc.11.5.19518; Mortarini R, 2005, CANCER RES, V65, P3428, DOI 10.1158/0008-5472.CAN-04-3239; Mortarini R, 2003, CANCER RES, V63, P2535; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; NINOMIYATSUJI J, 1993, P NATL ACAD SCI USA, V90, P9611, DOI 10.1073/pnas.90.20.9611; Oliver JL, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12091; Perotti V, 2012, J INVEST DERMATOL, V132, P2652, DOI 10.1038/jid.2012.179; Pouryazdanparast P, 2012, MODERN PATHOL, V25, P1221, DOI 10.1038/modpathol.2012.75; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Romero P, 2006, ADV IMMUNOL, V92, P187, DOI 10.1016/S0065-2776(06)92005-7; Santini MP, 2001, P NATL ACAD SCI USA, V98, P9575, DOI 10.1073/pnas.161299698; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Shou JW, 2015, CANCER LETT, V361, P174, DOI 10.1016/j.canlet.2015.03.005; Singh G, 2010, J BIOL CHEM, V285, P27241, DOI 10.1074/jbc.M110.100438; Takada Y, 2007, ONCOGENE, V26, P1201, DOI 10.1038/sj.onc.1209906; Tam TTP, 2013, BIOCHEM BIOPH RES CO, V430, P722, DOI 10.1016/j.bbrc.2012.11.082; Tassi E, 2012, CLIN CANCER RES, V18, P3316, DOI 10.1158/1078-0432.CCR-11-2232; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zhou YN, 2014, MOL BIOL CELL, V25, P2882, DOI 10.1091/mbc.E14-05-0998	51	28	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2862	2872		10.1038/onc.2015.355	http://dx.doi.org/10.1038/onc.2015.355			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387540				2022-12-28	WOS:000377473700006
J	Sheikh, BN; Bechtel-Walz, W; Lucci, J; Karpiuk, O; Hild, I; Hartleben, B; Vornweg, J; Helmstadter, M; Sahyoun, AH; Bhardwaj, V; Stehle, T; Diehl, S; Kretz, O; Voss, AK; Thomas, T; Manke, T; Huber, TB; Akhtar, A				Sheikh, B. N.; Bechtel-Walz, W.; Lucci, J.; Karpiuk, O.; Hild, I.; Hartleben, B.; Vornweg, J.; Helmstaedter, M.; Sahyoun, A. H.; Bhardwaj, V.; Stehle, T.; Diehl, S.; Kretz, O.; Voss, A. K.; Thomas, T.; Manke, T.; Huber, T. B.; Akhtar, A.			MOF maintains transcriptional programs regulating cellular stress response	ONCOGENE			English	Article							H4 LYSINE 16; HISTONE ACETYLTRANSFERASE; EMBRYONIC-DEVELOPMENT; DOSAGE COMPENSATION; PODOCYTE; AUTOPHAGY; GENE; ACETYLATION; PROTEIN; SENESCENCE	MOF (MYST1, KAT8) is the major H4K16 lysine acetyltransferase (KAT) in Drosophila and mammals and is essential for embryonic development. However, little is known regarding the role of MOF in specific cell lineages. Here we analyze the differential role of MOF in proliferating and terminally differentiated tissues at steady state and under stress conditions. In proliferating cells, MOF directly binds and maintains the expression of genes required for cell cycle progression. In contrast, MOF is dispensable for terminally differentiated, postmitotic glomerular podocytes under physiological conditions. However, in response to injury, MOF is absolutely critical for podocyte maintenance in vivo. Consistently, we detect defective nuclear, endoplasmic reticulum and Golgi structures, as well as presence of multivesicular bodies in vivo in podocytes lacking Mof following injury. Undertaking genome-wide expression analysis of podocytes, we uncover several MOF-regulated pathways required for stress response. We find that MOF, along with the members of the non-specific lethal but not the male-specific lethal complex, directly binds to genes encoding the lysosome, endocytosis and vacuole pathways, which are known regulators of podocyte maintenance. Thus, our work identifies MOF as a key regulator of cellular stress response in glomerular podocytes.	[Sheikh, B. N.; Lucci, J.; Karpiuk, O.; Sahyoun, A. H.; Bhardwaj, V.; Stehle, T.; Diehl, S.; Manke, T.; Akhtar, A.] Max Planck Inst Immunobiol & Epigenet, Dept Chromatin Regulat, Stubeweg 51, D-79108 Freiburg, Baden Wuertenbe, Germany; [Bechtel-Walz, W.; Hild, I.; Hartleben, B.; Vornweg, J.; Helmstaedter, M.; Kretz, O.; Huber, T. B.] Univ Med Ctr, Renal Div, Freiburg, Germany; [Kretz, O.] Univ Freiburg, Neuroanat, Hugstetter Str 55, D-79106 Freiburg, Germany; [Voss, A. K.; Thomas, T.] Walter & Eliza Hall Inst Med Res, Dev & Canc Div, Melbourne, Vic 3050, Australia; [Voss, A. K.; Thomas, T.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Huber, T. B.] Univ Freiburg, BIOSS Ctr Biol Signaling Studies, Hugstetter Str 55, D-79106 Freiburg, Germany	Max Planck Society; University of Freiburg; University of Freiburg; University of Melbourne; University of Freiburg	Akhtar, A (corresponding author), Max Planck Inst Immunobiol & Epigenet, Dept Chromatin Regulat, Stubeweg 51, D-79108 Freiburg, Baden Wuertenbe, Germany.	akhtar@ie-freiburg.mpg.de	Manke, Thomas/L-9075-2019; Voss, Anne K/F-5110-2013	Voss, Anne K/0000-0002-3853-9381; Bechtel-Walz, Wibke/0000-0001-6032-3627; Sahyoun, Abdullah/0000-0002-3333-8599; Thomas, Tim/0000-0002-7623-8344; Bhardwaj, Vivek/0000-0002-5570-9338; Sheikh, Bilal/0000-0002-1970-6236; Keller, Julia/0000-0001-9808-4983; Manke, Thomas/0000-0003-3702-0868; Kretz, Oliver/0000-0003-1152-5956; Huber, Tobias B./0000-0001-7175-5062	Humboldt postdoctoral fellowship; Marie Curie Career Integration Grant; Margarete von Wrangell Habilitations-Stipendium; Australian National Health and Medical Research Council; Australian Federal Government (IRISS); Victorian State Government (OIS); DFG (Heisenberg program) [CRC992, CRC1140]; European Research Council (ERC grant); DGF [CRC992, CRC1140, CRC746]	Humboldt postdoctoral fellowship; Marie Curie Career Integration Grant; Margarete von Wrangell Habilitations-Stipendium; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Federal Government (IRISS)(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government (OIS); DFG (Heisenberg program)(German Research Foundation (DFG)); European Research Council (ERC grant)(European Research Council (ERC)); DGF(German Research Foundation (DFG))	We thank K Lam, M Shvedunova and A Chatterjee for helpful discussions. We are grateful for the assistance provided by P Kindle (MPI-IE, Imaging facility) and B Joch (University Freiburg). BNS is supported by a Humboldt postdoctoral fellowship, WBW by a Marie Curie Career Integration Grant and a Margarete von Wrangell Habilitations-Stipendium. AKV and TT were supported by the Australian National Health and Medical Research Council, operational infrastructure grants from the Australian Federal Government (IRISS) and the Victorian State Government (OIS). TBH was supported by the DFG (Heisenberg program and CRC992 and CRC1140) and the European Research Council (ERC grant). AA is supported by the DGF CRC1140, CRC992 and CRC746. AA and TBH are part of the BIOSS II (Freiburg), the Excellence Initiative of the German Federal and State Governments.	Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; ALLFREY VG, 1964, SCIENCE, V144, P559, DOI 10.1126/science.144.3618.559; Bechtel W, 2013, J AM SOC NEPHROL, V24, P727, DOI 10.1681/ASN.2012070700; Bhadra MP, 2012, CHROMOSOMA, V121, P79, DOI 10.1007/s00412-011-0344-7; Blumenthal A, 2015, AM J PHYSIOL-RENAL, V308, pF602, DOI 10.1152/ajprenal.00190.2014; Boerries M, 2013, KIDNEY INT, V83, P1052, DOI 10.1038/ki.2012.487; Brinkkoetter PT, 2013, NAT REV NEPHROL, V9, P328, DOI 10.1038/nrneph.2013.78; Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981; Campeau PM, 2012, AM J HUM GENET, V90, P282, DOI 10.1016/j.ajhg.2011.11.023; Carson JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099771; Chelmicki T, 2014, ELIFE, V3, DOI 10.7554/eLife.02024; Chung JJ, 2015, J CLIN INVEST, V125, P2307, DOI 10.1172/JCI79641; Cina DP, 2012, J AM SOC NEPHROL, V23, P412, DOI 10.1681/ASN.2011070690; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Endlich N, 2001, J AM SOC NEPHROL, V12, P413, DOI 10.1681/ASN.V123413; Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835; Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07; Gupta A, 2014, CELL REP, V8, P177, DOI 10.1016/j.celrep.2014.05.044; Gupta A, 2013, MUTAGENESIS, V28, P263, DOI 10.1093/mutage/ges080; Hartleben B, 2010, J CLIN INVEST, V120, P1084, DOI 10.1172/JCI39492; Howell GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069520; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huber TB, 2012, AUTOPHAGY, V8, P1009, DOI 10.4161/auto.19821; Jiang M, 2012, KIDNEY INT, V82, P1271, DOI 10.1038/ki.2012.261; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim JY, 2010, TRANSPLANTATION, V89, P215, DOI 10.1097/TP.0b013e3181c353e5; Krishnan V, 2011, P NATL ACAD SCI USA, V108, P12325, DOI 10.1073/pnas.1102789108; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; Kumar R, 2011, P NATL ACAD SCI USA, V108, P3636, DOI 10.1073/pnas.1016524108; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lee VWS, 2011, NEPHROLOGY, V16, P30, DOI 10.1111/j.1440-1797.2010.01383.x; Lenoir O, 2015, AUTOPHAGY, V11, P1130, DOI 10.1080/15548627.2015.1049799; Li XZ, 2012, CELL STEM CELL, V11, P163, DOI 10.1016/j.stem.2012.04.023; Li XZ, 2010, MOL CELL BIOL, V30, P5335, DOI 10.1128/MCB.00350-10; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liapis H, 2013, AM J PATHOL, V183, P1364, DOI 10.1016/j.ajpath.2013.06.033; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Moeller MJ, 2003, GENESIS, V35, P39, DOI 10.1002/gene.10164; Mundel P, 2002, J AM SOC NEPHROL, V13, P3005, DOI 10.1097/01.ASN.0000039661.06947.FD; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Raja SJ, 2010, MOL CELL, V38, P827, DOI 10.1016/j.molcel.2010.05.021; Schell C, 2014, SEMIN CELL DEV BIOL, V36, P39, DOI 10.1016/j.semcdb.2014.07.016; Sharma GG, 2010, MOL CELL BIOL, V30, P3582, DOI 10.1128/MCB.01476-09; Sheikh BN, 2015, ONCOGENE, V34, P5807, DOI 10.1038/onc.2015.33; Sheikh BN, 2015, BLOOD, V125, P1910, DOI 10.1182/blood-2014-08-594655; Sheikh BN, 2014, CELL TISSUE RES, V356, P553, DOI 10.1007/s00441-014-1835-7; Simpson MA, 2012, AM J HUM GENET, V90, P290, DOI 10.1016/j.ajhg.2011.11.024; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Takabatake Y, 2014, NEPHROL DIAL TRANSPL, V29, P1639, DOI 10.1093/ndt/gft535; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; Thomas T, 2000, DEVELOPMENT, V127, P2537; Thomas T, 2008, MOL CELL BIOL, V28, P5093, DOI 10.1128/MCB.02202-07; Voss AK, 2009, BIOESSAYS, V31, P1050, DOI 10.1002/bies.200900051; Weavers H, 2009, NATURE, V457, P322, DOI 10.1038/nature07526; Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401; Xu W, 2006, BLOOD, V107, P4407, DOI 10.1182/blood-2005-08-3263; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zhang FJ, 2013, J AM SOC NEPHROL, V24, P209, DOI 10.1681/ASN.2012080795	67	37	37	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2698	2710		10.1038/onc.2015.335	http://dx.doi.org/10.1038/onc.2015.335			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26387537	Green Published, hybrid			2022-12-28	WOS:000377472700004
J	Jia, L; Zhou, Z; Liang, H; Wu, J; Shi, P; Li, F; Wang, Z; Wang, C; Chen, W; Zhang, H; Wang, Y; Liu, R; Feng, J; Chen, C				Jia, L.; Zhou, Z.; Liang, H.; Wu, J.; Shi, P.; Li, F.; Wang, Z.; Wang, C.; Chen, W.; Zhang, H.; Wang, Y.; Liu, R.; Feng, J.; Chen, C.			KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2	ONCOGENE			English	Article							NECROSIS-FACTOR-ALPHA; PRIMARY RESPONSE GENE; KRUPPEL-LIKE FACTOR-5; CELL-PROLIFERATION; TUNNELING NANOTUBES; EPITHELIAL-CELLS; PROGNOSTIC-FACTOR; BINDING-PROTEIN; ANIMAL-CELLS; RHO-GTPASES	The Kruppel-like factor 5 (KLF5) transcription factor is highly expressed in high-grade and basal-like breast cancers. However, the mechanism by which KLF5 promotes cell migration and invasion is still not completely understood. In this study, we demonstrate that TNFAIP2, a tumor necrosis factor-alpha (TNF alpha)-induced gene, is a direct KLF5 target gene. The expression of TNFAIP2 is highly correlated with the expression of KLF5 in breast cancers. The manipulation of KLF5 expression positively alters TNFAIP2 expression levels. KLF5 directly binds to the TNFAIP2 gene promoter and activates its transcription. Functionally, KLF5 promotes cancer cell proliferation, migration and invasion in part through TNFAIP2. TNFAIP2 interacts with the two small GTPases Rac1 and Cdc42, thereby increasing their activities to change actin cytoskeleton and cell morphology. These findings collectively suggest that TNFAIP2 is a direct KLF5 target gene, and both KLF5 and TNFAIP2 promote breast cancer cell proliferation, migration and invasion through Rac1 and Cdc42.	[Jia, L.; Zhou, Z.; Liang, H.; Wu, J.; Shi, P.; Li, F.; Wang, Z.; Wang, C.; Zhang, H.; Liu, R.; Chen, C.] Chinese Acad Sci, Kunming Inst Zool, Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, 32 Jiaochang East Rd, Kunming 650223, Yunnan, Peoples R China; [Jia, L.] Yuxi Normal Univ, Dept Biol, Yuxi, Peoples R China; [Jia, L.; Wu, J.; Wang, C.] Univ Chinese Acad Sci, Beijing, Peoples R China; [Wu, J.] Kunming Med Univ, Dept Biochem & Mol Biol, Kunming, Peoples R China; [Wang, C.] Kunming Med Univ, Dept Pathol, Affiliated Hosp 1, Kunming, Peoples R China; [Chen, W.; Wang, Y.] Kunming Med Univ, Canc Hosp, Kunming, Peoples R China; [Feng, J.] Southern Med Univ, Affiliated Fengxian Hosp, Dept Lab Med, Shanghai 201499, Peoples R China; [Feng, J.] Southern Med Univ, Affiliated Fengxian Hosp, Cent Lab, Shanghai 201499, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Yuxi Normal University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Kunming Medical University; Kunming Medical University; Kunming Medical University; Southern Medical University - China; Southern Medical University - China	Chen, C (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, 32 Jiaochang East Rd, Kunming 650223, Yunnan, Peoples R China.; Feng, J (corresponding author), Southern Med Univ, Affiliated Fengxian Hosp, Dept Lab Med, Shanghai 201499, Peoples R China.; Feng, J (corresponding author), Southern Med Univ, Affiliated Fengxian Hosp, Cent Lab, Shanghai 201499, Peoples R China.	fengjing8801530@163.com; chenc@mail.kiz.ac.cn	Wang, Zehua/I-6452-2018	Wang, Zehua/0000-0002-0769-8865; wang, zhengbo/0000-0002-4717-5137	Strategic Priority Research Program of the Chinese Academy of Sciences, Stem Cell and Regenerative Medicine Research [XDA01040406]; National Natural Science Foundation of China [81120108019, 81325016, U1132605, 81322038, 81272930]; West Light Foundation of Chinese Academy of Sciences; Shanghai Health System outstanding academic leader training program [XBR2013114]	Strategic Priority Research Program of the Chinese Academy of Sciences, Stem Cell and Regenerative Medicine Research; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); West Light Foundation of Chinese Academy of Sciences(Chinese Academy of Sciences); Shanghai Health System outstanding academic leader training program	We thank Professor Jun Zhou at Nankai University for providing reagents and Professor Ping Wang from Tongji University for bioinformatics analysis. This study was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences, Stem Cell and Regenerative Medicine Research (XDA01040406) and the National Natural Science Foundation of China (81120108019, 81325016, U1132605, 81322038 and 81272930) West Light Foundation of Chinese Academy of Sciences (to RL) and Shanghai Health System outstanding academic leader training program (XBR2013114 to JF).	Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bafford R, 2006, SURGERY, V140, P289, DOI 10.1016/j.surg.2006.04.004; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Chanchevalap S, 2006, NUCLEIC ACIDS RES, V34, P1216, DOI 10.1093/nar/gkl014; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen CS, 2007, INT J CANCER, V121, P80, DOI 10.1002/ijc.22653; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CJ, 2012, PATHOL ONCOL RES, V18, P161, DOI 10.1007/s12253-011-9422-7; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Chen LC, 2011, MODERN PATHOL, V24, P175, DOI 10.1038/modpathol.2010.193; Chevrier N, 2011, CELL, V147, P853, DOI 10.1016/j.cell.2011.10.022; Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dong JT, 2009, CELL MOL LIFE SCI, V66, P2691, DOI 10.1007/s00018-009-0045-z; Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990; He M, 2009, J BIOCHEM, V146, P683, DOI 10.1093/jb/mvp115; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Kimura S, 2012, EXP CELL RES, V318, P1699, DOI 10.1016/j.yexcr.2012.05.013; Kojima S, 1997, J BIOCHEM, V121, P389; Liu R, 2011, MOL ENDOCRINOL, V25, P1137, DOI 10.1210/me.2010-0497; Ma Y, 2003, ONCOGENE, V22, P4924, DOI 10.1038/sj.onc.1206728; Maxmen A, 2012, NATURE, V485, pS50, DOI 10.1038/485S50a; McConnell BB, 2009, CANCER RES, V69, P4125, DOI 10.1158/0008-5472.CAN-08-4402; Mori A, 2009, MOL CANCER RES, V7, P1390, DOI 10.1158/1541-7786.MCR-08-0525; Ohno Hiroshi, 2010, Commun Integr Biol, V3, P231; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; SARMA V, 1992, J IMMUNOL, V148, P3302; Schiller C, 2013, J CELL SCI, V126, P767, DOI 10.1242/jcs.114033; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shi XJ, 2012, CELL CYCLE, V11, P1554, DOI 10.4161/cc.19954; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Sur I, 2002, EUR J CELL BIOL, V81, P323, DOI 10.1078/0171-9335-00257; Suzuki T, 2009, J BIOL CHEM, V284, P9549, DOI 10.1074/jbc.M806230200; Takagi K, 2012, ENDOCR-RELAT CANCER, V19, P741, DOI 10.1530/ERC-12-0017; Tong D, 2006, CLIN CANCER RES, V12, P2442, DOI 10.1158/1078-0432.CCR-05-0964; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang C, 2015, ONCOTARGET; WOLF FW, 1994, J BIOL CHEM, V269, P3633; Xia HJ, 2013, J BIOL CHEM, V288, P26731, DOI 10.1074/jbc.M113.483958; Yang YZ, 2008, J BIOL CHEM, V283, P18812, DOI 10.1074/jbc.M801384200; Zhao D, 2012, CARCINOGENESIS, V33, P59, DOI 10.1093/carcin/bgr242; Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040; Zheng HQ, 2009, ONCOGENE, V28, P3702, DOI 10.1038/onc.2009.235; Zhu NX, 2006, J BIOL CHEM, V281, P14711, DOI 10.1074/jbc.M513810200	50	96	104	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2040	2051		10.1038/onc.2015.263	http://dx.doi.org/10.1038/onc.2015.263			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26189798				2022-12-28	WOS:000374505600004
J	Phatak, P; Byrnes, KA; Mansour, D; Liu, L; Cao, S; Li, R; Rao, JN; Turner, DJ; Wang, JY; Donahue, JM				Phatak, P.; Byrnes, K. A.; Mansour, D.; Liu, L.; Cao, S.; Li, R.; Rao, J. N.; Turner, D. J.; Wang, J-Y; Donahue, J. M.			Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1	ONCOGENE			English	Article							MESSENGER-RNA; DOWN-REGULATION; EXPRESSION; MICRORNAS; APOPTOSIS	Based on its marked overexpression in multiple malignancies and its roles in promoting cell survival and proliferation, survivin is an attractive candidate for targeted therapy. Toward this end, a detailed understanding of the mechanisms regulating survivin expression in different cancer cells will be critical. We have previously shown that the RNA-binding protein (RBP) CUG-BP1 is overexpressed in esophageal cancer cells and post-transcriptionally regulates survivin in these cells. The objective of this study was to investigate the role of microRNAs (miRs) in regulating survivin expression in esophageal cancer cells. Using miR expression profiling analysis, we found that miR-214-3p is one of the most markedly downregulated miRs in two esophageal squamous cancer cell lines compared with esophageal epithelial cells. Interestingly, using miR target prediction programs, both survivin and CUG-BP1 mRNA were found to contain potential binding sites for miR-214-3p. Forced expression of miR-214-3p in esophageal cancer cells leads to a decrease in the mRNA and protein levels of both survivin and CUG-BP1. This effect is due to decreased mRNA stability of both targets. By contrast, silencing miR-214-3p in esophageal epithelial cells leads to an increase in both survivin and CUG-BP1 mRNA and protein. To determine whether the observed effect of miR-214-3p on survivin expression was direct, mediated through CUG-BP1, or both, binding studies utilizing biotin pull-down assays and heterologous luciferase reporter constructs were performed. These demonstrated that the mRNA of survivin and CUG-BP1 each contain two functional miR-214-3p-binding sites as confirmed by mutational analysis. Finally, forced expression of miR-214-3p enhances the sensitivity of esophageal cancer cells to cisplatin-induced apoptosis. This effect is abrogated with rescue expression of survivin or CUG-BP1. These findings suggest that miR-214-3p acts as a tumor suppressor and that its downregulation contributes to chemoresistance in esophageal cancer cells by targeting both survivin and CUG-BP1.	[Phatak, P.; Byrnes, K. A.; Mansour, D.; Liu, L.; Cao, S.; Li, R.; Rao, J. N.; Turner, D. J.; Wang, J-Y; Donahue, J. M.] Univ Maryland, Sch Med, Dept Surg, Cell Biol Grp, 29 South Greene St,Suite 504, Baltimore, MD 21201 USA; [Phatak, P.; Byrnes, K. A.; Mansour, D.; Liu, L.; Cao, S.; Li, R.; Rao, J. N.; Turner, D. J.; Wang, J-Y; Donahue, J. M.] Baltimore Vet Affairs Med Ctr, Baltimore, MD USA; [Wang, J-Y] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore	Donahue, JM (corresponding author), Univ Maryland, Sch Med, Dept Surg, Cell Biol Grp, 29 South Greene St,Suite 504, Baltimore, MD 21201 USA.	jdonahue@smail.umaryland.edu			Department of Veterans Affairs, USA; National Institutes of Health [DK-57819, DK-61972, DK-68491]; Department of Surgery, University of Maryland School of Medicine; NATIONAL CANCER INSTITUTE [T32CA154274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068491, R01DK061972, R01DK057819] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000713, I01BX000113, I01BX000332] Funding Source: NIH RePORTER	Department of Veterans Affairs, USA(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Surgery, University of Maryland School of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Department of Veterans Affairs, USA (Merit Review Grants to JNR, DJT and J-YW; VA Career Development Award to JMD); the National Institutes of Health (grant numbers DK-57819, DK-61972 and DK-68491 to J-YW) and departmental funds from the Department of Surgery, University of Maryland School of Medicine (to JMD). The authors also acknowledge Dr Karthika Natarajan, Dr Xi Yang and Ratnakar Potla for their technical assistance as well as Dr Anne W Hamburger for assistance in preparation of the manuscript.	Audic Y, 2004, BIOL CELL, V96, P479, DOI 10.1016/j.biolcel.2004.05.002; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Cao WG, 2013, TUMOR BIOL, V34, P963, DOI 10.1007/s13277-012-0632-8; Chang E, 2010, J THORAC CARDIOV SUR, V140, P225, DOI 10.1016/j.jtcvs.2009.11.038; Chang ET, 2012, BIOCHEM J, V446, P113, DOI 10.1042/BJ20120112; Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233; Choi YE, 2014, ELIFE, V3, DOI 10.7554/eLife.02445; Ciafre SA, 2013, RNA BIOL, V10, P935, DOI 10.4161/rna.24641; Cui YH, 2012, MOL BIOL CELL, V23, P151, DOI 10.1091/mbc.E11-05-0456; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Donahue JM, 2011, BIOCHEM J, V437, P89, DOI 10.1042/BJ20110028; Duan Q, 2012, PLOS ONE, V7, P1; Gareau C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020254; Huang SD, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-51; Jangpatarapongsa K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045971; Kato J, 2001, INT J CANCER, V95, P92; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Liu L, 2009, MOL BIOL CELL, V20, P4885, DOI 10.1091/mbc.E09-07-0550; Matsushima K, 2010, DIGESTION, V82, P138, DOI 10.1159/000310918; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; Orom UA, 2007, METHODS, V43, P162, DOI 10.1016/j.ymeth.2007.04.007; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Shen ZS, 2012, MED ONCOL, V29, P2473, DOI 10.1007/s12032-011-0156-x; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Talwar S, 2013, RNA BIOL, V10, P277, DOI 10.4161/rna.23315; Vallbohmer D, 2008, PHARMACOGENOMICS, V9, P681, DOI 10.2217/14622416.9.6.681; Wang F, 2013, FEBS LETT, V587, P488, DOI 10.1016/j.febslet.2013.01.016; Wang W, 2013, CELL BIOCHEM FUNCT, V31, P82, DOI 10.1002/cbf.2863; Xu D, 2013, MOL MED REP, V8, P379, DOI 10.3892/mmr.2013.1504; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Zhang ZX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0100416, 10.1371/journal.pone.0089140, 10.1371/journal.pone.0099511]	33	70	76	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2087	2097		10.1038/onc.2015.271	http://dx.doi.org/10.1038/onc.2015.271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26234674	Green Accepted			2022-12-28	WOS:000374505600008
J	Wu, YC; Tang, SJ; Sun, GH; Sun, KH				Wu, Y-C; Tang, S-J; Sun, G-H; Sun, K-H			CXCR7 mediates TGF beta 1-promoted EMT and tumor-initiating features in lung cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TGF-BETA; CHEMOKINE RECEPTOR; STEM-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; BREAST; EXPRESSION; MIGRATION; SURVIVAL; ADHESION	In the tumor microenvironment, chemokine system has a critical role in tumorigenesis and metastasis. The acquisition of stem-like properties by cancer cells is involved in metastasis and drug resistance, which are pivotal problems that result in poor outcomes in patients with lung cancer. Patients with advanced lung cancer present high plasma levels of transforming growth factor-beta 1 (TGF beta 1), which correlate with poor prognostic features. Therefore, TGF beta 1 may be important in the tumor microenvironment, where chemokines are widely expressed. However, the role of chemokines in TGF beta 1-induced tumor progression still remains unclear. In our study, TGF beta 1 upregulated CXC chemokine receptor expression, migration, invasion, epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) formation in lung adenocarcinoma. We found that CXCR7 was the most upregulated chemokine receptor induced by TGF beta 1. CXCR7 knockdown resulted in reduction of migration, invasion and EMT induced by TGF beta 1, whereas CXCR4 knockdown did not reverse TGF beta 1-promoted EMT. CXCR7 silencing significantly decreased cancer sphere-forming capacity, stem-like properties, chemoresistance and TGF beta 1-induced CSC tumor initiation in vivo. In clinical samples, high TGF beta 1 and CXCR7 expression was significantly associated with the late stages of lung adenocarcinoma. Moreover, TGF beta 1 and CXCR7 coexpression was positively correlated with the CSC marker, CD44, which is associated with lymph node metastasis. Besides, patients with high expression of both CXCR7 and TGF beta 1 presented a significantly worse survival rate. These results suggest that the TGF beta 1-CXCR7 axis may be a prognostic marker and may provide novel targets for combinational therapies to be used in the treatment of advanced lung cancer in the future.	[Wu, Y-C; Sun, K-H] Natl Yang Ming Univ, Taipei City Hosp, Dept Educ & Res, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan; [Tang, S-J] Natl Taiwan Ocean Univ, Inst Marine Biotechnol, Keelung, Taiwan; [Sun, G-H] Triserv Gen Hosp, Dept Surg, Div Surg, 325,Sect 2,Chenggong Rd, Taipei 114, Taiwan; [Sun, G-H] Natl Def Med Ctr, 325,Sect 2,Chenggong Rd, Taipei 114, Taiwan	National Yang Ming Chiao Tung University; Taipei City Hospital; National Taiwan Ocean University; Tri-Service General Hospital; National Defense Medical Center	Sun, GH (corresponding author), Triserv Gen Hosp, Dept Surg, Div Surg, 325,Sect 2,Chenggong Rd, Taipei 114, Taiwan.; Sun, GH (corresponding author), Natl Def Med Ctr, 325,Sect 2,Chenggong Rd, Taipei 114, Taiwan.; Sun, KH (corresponding author), Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, 155,Sect 2,Linong St, Taipei 11221, Taiwan.; Sun, KH (corresponding author), Taipei City Hosp, Dept Educ & Res, 155,Sect 2,Linong St, Taipei 11221, Taiwan.	ghsun@ndmctsgh.edu.tw; khsun@ym.edu.tw			Ministry of Science and Technology (MOST) [103-2320-B-010-039-MY3, 103-2321-B-010-029]; Ministry of Education (Aim for the Top University Plan); Tri-Service General Hospital; National Defense Medical Center [TSGHC-C103-062, TSGH-104-507]; Taipei City Hospital, Taiwan	Ministry of Science and Technology (MOST)(Ministry of Science and Technology, China); Ministry of Education (Aim for the Top University Plan)(Ministry of Education, Taiwan); Tri-Service General Hospital; National Defense Medical Center; Taipei City Hospital, Taiwan	This study was supported by the Ministry of Science and Technology (MOST 103-2320-B-010-039-MY3, 103-2321-B-010-029), the Ministry of Education (Aim for the Top University Plan), the Tri-Service General Hospital and the National Defense Medical Center (TSGHC-C103-062, TSGH-104-507) and the Taipei City Hospital, Taiwan.	Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Bareschino Maria Anna, 2011, J Thorac Dis, V3, P122, DOI 10.3978/j.issn.2072-1439.2010.12.08; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bertran E, 2009, CELL SIGNAL, V21, P1595, DOI 10.1016/j.cellsig.2009.06.006; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015; Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x; Guo Y, 2005, STEM CELLS, V23, P1324, DOI 10.1634/stemcells.2005-0085; Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; Hou YL, 2013, CANCER EPIDEMIOL, V37, P750, DOI 10.1016/j.canep.2013.04.013; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang Xiefang, 2010, Zhongguo Fei Ai Za Zhi, V13, P451, DOI 10.3779/j.issn.1009-3419.2010.05.14; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Maksym RB, 2009, EUR J PHARMACOL, V625, P31, DOI 10.1016/j.ejphar.2009.04.071; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Pirozzi G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021548; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Sakaki-Yumoto M, 2013, BBA-GEN SUBJECTS, V1830, P2280, DOI 10.1016/j.bbagen.2012.08.008; Sanchez-Martin L, 2013, TRENDS MOL MED, V19, P12, DOI 10.1016/j.molmed.2012.10.004; Schaeffer D, 2014, MOL CELL BIOL, V34, P3486, DOI 10.1128/MCB.00694-14; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Su LP, 2005, CLIN CANCER RES, V11, P8273, DOI 10.1158/1078-0432.CCR-05-0537; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Suzuki M, 2008, INT J ONCOL, V33, P113; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Xu CC, 2011, MOL MED REP, V4, P1007, DOI 10.3892/mmr.2011.530; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zhao XP, 2010, ACTA PHARMACOL SIN, V31, P347, DOI 10.1038/aps.2009.204; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	41	77	79	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2123	2132		10.1038/onc.2015.274	http://dx.doi.org/10.1038/onc.2015.274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26212008				2022-12-28	WOS:000374505600011
J	Chang, YW; Tseng, CF; Wang, MY; Chang, WC; Lee, CC; Chen, LT; Hung, MC; Su, JL				Chang, Y-W; Tseng, C-F; Wang, M-Y; Chang, W-C; Lee, C-C; Chen, L-T; Hung, M-C; Su, J-L			Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer	ONCOGENE			English	Article							GLUCOSE-REGULATED PROTEIN; MOTILITY-FACTOR-RECEPTOR; HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; PROTEASOME-SYSTEM; PROSTATE-CANCER; CELL-PROLIFERATION; CYP3A4 EXPRESSION; ADP-RIBOSYLATION; DOWN-REGULATION	Heat-shock protein 5 (HSPA5) is a marker for poor prognosis in breast cancer patients and has an important role in cancer progression, including promoting drug resistance and metastasis. In this study, we identify that the specific lysine residue 447 (K447) of HSPA5 could be modified with polyubiquitin for subsequent degradation through the ubiquitin proteasomal system, leading to the suppression of cell migration and invasion of breast cancer. We further found that GP78, an E3 ubiquitin ligase, interacted with the C-terminal region of HSPA5 and mediated HSPA5 ubiquitination and degradation. Knock down of GP78 significantly increased the expression of HSPA5 and enhanced migration/invasive ability of breast cancer cells. Knock down of histone deacetylase-6 (HDAC6) increased the acetylation of HSPA5 at lysine residues 353 (K353) and reduced GP78-mediated ubiquitination of HSPA5 at K447 and then increased cell migration/invasion. In addition, we demonstrate that E3 ubiquitin ligase GP78 preferentially binds to deacetylated HSPA5. Notably, the expression levels of GP78 inversely correlated with HSPA5 levels in breast cancer patients. Patients with low GP78 expression significantly correlated with invasiveness of breast cancer, advanced tumor stages and poor clinical outcome. Taken together, our results provide new mechanistic insights into the understanding that deacetylation of HSPA5 by HDAC6 facilitates GP78-mediated HSPA5 ubiquitination and suggest that post-translational regulation of HSPA5 protein is critical for HSPA5-mediated metastatic properties of breast cancer.	[Chang, Y-W; Tseng, C-F; Chen, L-T; Su, J-L] Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan; [Tseng, C-F] Natl Tsing Hua Univ, Coll Life Sci, Grad Program Biotechnol Med, Hsinchu, Taiwan; [Wang, M-Y] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chang, W-C; Su, J-L] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Lee, C-C] Acad Sinica, Core Facil Prot Struct Anal, Taipei 115, Taiwan; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Su, J-L] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Su, J-L] Asia Univ, Dept Biotechnol, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Tsing Hua University; National Taiwan University; National Taiwan University Hospital; China Medical University Taiwan; Academia Sinica - Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Su, JL (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan.	jlsu@nhri.org.tw	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	National Science Council grant from Taiwan [NSC 99-2314-B-400-006-MY3, NSC 101-2320-B-400-016-MY3, NSC 102-2314-B-038-028-MY3, NSC 103-2314-B-038-059, MOST 103-2628-B-006-003-MY3]; National Health Research Institutes grant from Taiwan [CA-102-PP-41, CA-103-PP-35, CA-104-SP-01, CA-104-PP-12, MOHW104-TDU-B-212-124-008]; Ministry of Health and Welfare, Taiwan [DOH101-TD-PB-111-NSC015, DOH 102-TD-C-111-004]; Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan [103TMU-SHH-26]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Science Council grant from Taiwan; National Health Research Institutes grant from Taiwan; Ministry of Health and Welfare, Taiwan; Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Science Council grant from Taiwan (NSC 99-2314-B-400-006-MY3, NSC 101-2320-B-400-016-MY3, NSC 102-2314-B-038-028-MY3, NSC 103-2314-B-038-059, MOST 103-2628-B-006-003-MY3); National Health Research Institutes grant from Taiwan (CA-102-PP-41, CA-103-PP-35, CA-104-SP-01, CA-104-PP-12, MOHW104-TDU-B-212-124-008); Ministry of Health and Welfare, Taiwan (DOH101-TD-PB-111-NSC015, DOH 102-TD-C-111-004); and Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan (103TMU-SHH-26). We thank Ms Fang-Yu Tsai and Dr I-Shou Chang of Taiwan Bioinformatics Institute Core Facility for assistance on using Oncomine (National Core Facility Program for Biotechnology, NSC-100-2319-B-400-001). We thank Dr Shiu-Feng Huang and Dr Yu-Ting Chiu of National Health Research Institutes pathology core lab for assistance in pathology services.	Bassermann F, 2014, BBA-MOL CELL RES, V1843, P150, DOI 10.1016/j.bbamcr.2013.02.028; Bedford L, 2011, NAT REV DRUG DISCOV, V10, P29, DOI 10.1038/nrd3321; Bertrand J, 2013, PROTEOMICS, V13, P3284, DOI 10.1002/pmic.201300082; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chang YW, 2014, ONCOTARGET, V5, P10558, DOI 10.18632/oncotarget.2510; Chang YJ, 2010, ANN SURG ONCOL, V17, P1703, DOI 10.1245/s10434-010-0912-8; Chen B, 2006, P NATL ACAD SCI USA, V103, P341, DOI 10.1073/pnas.0506618103; Chiu CC, 2008, MOL CANCER THER, V7, P2788, DOI 10.1158/1535-7163.MCT-08-0172; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151; Fairbank M, 2009, MOL BIOSYST, V5, P793, DOI 10.1039/b820820b; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Festing Michael F W, 2002, ILAR J, V43, P244; Floriano-Sanchez E, 2014, ASIAN PAC J CANCER P, V15, P3805, DOI 10.7314/APJCP.2014.15.8.3805; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Fujimura T, 2012, CANCER SCI, V103, P176, DOI 10.1111/j.1349-7006.2011.02143.x; Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439; Haga A, 2006, LEUKEMIA LYMPHOMA, V47, P2234, DOI 10.1080/10428190600773263; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; Hesling C, 2004, J INVEST DERMATOL, V122, P369, DOI 10.1046/j.0022-202X.2004.22212.x; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hirono Y, 1996, BRIT J CANCER, V74, P2003, DOI 10.1038/bjc.1996.667; His M, 2014, EUR J EPIDEMIOL, V29, P119, DOI 10.1007/s10654-014-9884-5; Jo Y, 2010, CRIT REV BIOCHEM MOL, V45, P185, DOI 10.3109/10409238.2010.485605; Joshi B, 2010, J BIOL CHEM, V285, P8830, DOI 10.1074/jbc.M109.074344; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kundrat L, 2010, J MOL BIOL, V395, P587, DOI 10.1016/j.jmb.2009.11.017; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2006, CANCER BIOL THER, V5, P721, DOI 10.4161/cbt.5.7.3120; Li M, 2013, CANCER CELL, V23, P693, DOI 10.1016/j.ccr.2013.03.025; Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200; Lopitz-Otsoa F, 2012, J PROTEOMICS, V75, P2998, DOI 10.1016/j.jprot.2011.12.001; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; McFadyen MCE, 2004, MOL CANCER THER, V3, P363; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Rao R, 2008, BLOOD, V112, P1886, DOI 10.1182/blood-2008-03-143644; Rao R, 2010, MOL CANCER THER, V9, P942, DOI 10.1158/1535-7163.MCT-09-0988; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Sakurai K, 2011, SURG TODAY, V41, P674, DOI 10.1007/s00595-009-4328-7; SATOH M, 1993, EXP CELL RES, V205, P76, DOI 10.1006/excr.1993.1060; Schointuch MN, 2014, GYNECOL ONCOL, V134, P346, DOI 10.1016/j.ygyno.2014.05.015; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Sommer T, 2014, BBA-MOL CELL RES, V1843, P1, DOI 10.1016/j.bbamcr.2013.09.009; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Su JL, 2010, CANCER RES, V70, P5096, DOI 10.1158/0008-5472.CAN-09-4148; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Tsai YC, 2007, NAT MED, V13, P1504, DOI 10.1038/nm1686; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang Q, 2005, CANCER DETECT PREV, V29, P544, DOI 10.1016/j.cdp.2005.09.010; Wang X, 2015, MOL CELL PROTEOMICS, V14, P686, DOI 10.1074/mcp.M114.042697; Wang YL, 2012, SOFT POWER STUDY FROM CULTURE, EDUCATION AND SOCIAL SYSTEM PERSPECTIVE, P478; Wang YQ, 2015, J BIOL CHEM, V290, P3308, DOI 10.1074/jbc.M114.611525; Wong CSF, 2013, CANCER RES, V73, P2400, DOI 10.1158/0008-5472.CAN-12-4348; Xing XM, 2006, CLIN CHIM ACTA, V364, P308, DOI 10.1016/j.cca.2005.07.016; Yang YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644; Ying Z, 2009, HUM MOL GENET, V18, P4268, DOI 10.1093/hmg/ddp380; Zhang J, 2006, CLIN EXP METASTAS, V23, P401, DOI 10.1007/s10585-006-9051-9; Zhang TP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118448; Zia H, 2015, INT J EXP PATHOL, V96, P81, DOI 10.1111/iep.12115	70	45	46	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1517	1528		10.1038/onc.2015.214	http://dx.doi.org/10.1038/onc.2015.214			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26119938				2022-12-28	WOS:000373063600005
J	Slany, RK				Slany, R. K.			The molecular mechanics of mixed lineage leukemia	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; MLL-REARRANGED LEUKEMIA; HOX GENE-EXPRESSION; ACUTE MYELOID-LEUKEMIA; PROTO-ONCOPROTEIN MLL; RNA-POLYMERASE-II; DEPENDENT KINASE INHIBITORS; METHYLTRANSFERASE ACTIVITY; 11Q23 TRANSLOCATIONS; FUSION PROTEINS	Mixed lineage leukemia caused by MLL fusion proteins is still a mostly incurable disease. Research on novel treatment strategies has gained momentum in the last years with the elucidation of the molecular mechanisms underlying the transforming potential of these powerful oncoproteins. This review summarizes the recent developments in this area including new attempts to treat MLL in a rational way by exploiting the biochemical vulnerabilities of the leukemogenic process.	[Slany, R. K.] Univ Erlangen Nurnberg, Dept Genet, Erwin Rommel St 3, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Erwin Rommel St 3, D-91058 Erlangen, Germany.	robert.slany@fau.de			Deutsche Forschungsgemeinschaft; Bavarian Ministry of Sciences, Research and the Arts in the framework of the Bavarian Molecular Biosystems Research Network; Emerging Fields Initiative of the FAU University Erlangen-Nurnberg (CYDER)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bavarian Ministry of Sciences, Research and the Arts in the framework of the Bavarian Molecular Biosystems Research Network; Emerging Fields Initiative of the FAU University Erlangen-Nurnberg (CYDER)	I would like to apologize to all colleagues whose work could not be cited because of space constraints. Research in the lab of the author is funded by: Deutsche Forschungsgemeinschaft, the Bavarian Ministry of Sciences, Research and the Arts in the framework of the Bavarian Molecular Biosystems Research Network and by the Emerging Fields Initiative of the FAU University Erlangen-Nurnberg (CYDER).	Anderson M, 2002, DEV GENES EVOL, V212, P107, DOI 10.1007/s00427-002-0213-8; Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Arai S, 2011, BLOOD, V117, P6304, DOI 10.1182/blood-2009-07-234310; Barretto Nisha N, 2014, J Exp Ther Oncol, V10, P293; Beldjord K, 2014, BLOOD, V123, P3739, DOI 10.1182/blood-2014-01-547695; BERGER R, 1982, LEUKEMIA RES, V6, P17, DOI 10.1016/0145-2126(82)90039-X; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Blachly JS, 2013, LEUKEMIA LYMPHOMA, V54, P2133, DOI 10.3109/10428194.2013.783911; Borkin D, 2015, CANCER CELL, V27, P589, DOI 10.1016/j.ccell.2015.02.016; Brown P, 2013, HEMATOL-AM SOC HEMAT, P596, DOI 10.1182/asheducation-2013.1.596; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001; Caslini C, 2007, CANCER RES, V67, P7275, DOI 10.1158/0008-5472.CAN-06-2369; Chang PY, 2010, J MOL BIOL, V400, P137, DOI 10.1016/j.jmb.2010.05.005; Chen CW, 2015, EXP HEMATOL, V43, P673, DOI 10.1016/j.exphem.2015.05.012; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; Chen J, 2008, CANCER RES, V68, P6199, DOI 10.1158/0008-5472.CAN-07-6514; Chen L, 2013, LEUKEMIA, V27, P813, DOI 10.1038/leu.2012.327; Chessells JM, 2002, LEUKEMIA, V16, P776, DOI 10.1038/sj.leu.2402468; CHILDS C C, 1988, Hematologic Pathology, V2, P145; Cowell IG, 2012, P NATL ACAD SCI USA, V109, P8989, DOI 10.1073/pnas.1204406109; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Dawson MA, 2014, LEUKEMIA, V28, P311, DOI 10.1038/leu.2013.338; Denissov S, 2014, DEVELOPMENT, V141, P526, DOI 10.1242/dev.102681; Deshpande AJ, 2014, CANCER CELL, V26, P896, DOI 10.1016/j.ccell.2014.10.009; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Eskeland R, 2010, MOL CELL, V38, P452, DOI 10.1016/j.molcel.2010.02.032; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Feng Y, 2010, BLOOD, V116, P4483, DOI 10.1182/blood-2010-03-276501; Garcia-Cuellar MP, 2014, LEUKEMIA, V28, P1427, DOI 10.1038/leu.2014.40; Garcia-Cuellar MP, 2015, HAEMATOLOGICA, V100, P905, DOI 10.3324/haematol.2015.124032; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/nchembio.1859, 10.1038/NCHEMBIO.1859]; Grembecka J, 2012, NAT CHEM BIOL, V8, P277, DOI [10.1038/NCHEMBIO.773, 10.1038/nchembio.773]; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guenther MG, 2008, GENE DEV, V22, P3403, DOI 10.1101/gad.1741408; He SH, 2014, J MED CHEM, V57, P1543, DOI 10.1021/jm401868d; Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Hilden JM, 2006, BLOOD, V108, P441, DOI 10.1182/blood-2005-07-3011; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Itzen F, 2014, NUCLEIC ACIDS RES, V42, P7577, DOI 10.1093/nar/gku449; Jo SY, 2011, BLOOD, V117, P4759, DOI 10.1182/blood-2010-12-327668; Jonkers I, 2015, NAT REV MOL CELL BIO, V16, P167, DOI 10.1038/nrm3953; KANEKO Y, 1986, BLOOD, V67, P484; Kanno T, 2014, NAT STRUCT MOL BIOL, V21, P1047, DOI 10.1038/nsmb.2912; Leach BI, 2013, STRUCTURE, V21, P176, DOI 10.1016/j.str.2012.11.011; Li ZJ, 2013, BLOOD, V121, P1422, DOI 10.1182/blood-2012-07-442004; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Liu H, 2014, CANCER CELL, V25, P530, DOI 10.1016/j.ccr.2014.03.008; Llano M, 2006, SCIENCE, V314, P461, DOI 10.1126/science.1132319; Maethner E, 2013, CELL REP, V3, P1553, DOI 10.1016/j.celrep.2013.03.038; McLean CM, 2014, LEUKEMIA, V28, P2131, DOI 10.1038/leu.2014.169; Mereau H, 2013, LEUKEMIA, V27, P1245, DOI 10.1038/leu.2013.10; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Mishra BP, 2014, CELL REP, V7, P1239, DOI 10.1016/j.celrep.2014.04.015; Mohan M, 2010, GENE DEV, V24, P574, DOI 10.1101/gad.1898410; Monroe SC, 2011, EXP HEMATOL, V39, P77, DOI 10.1016/j.exphem.2010.09.003; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Mueller D, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000249; Muntean AG, 2010, CANCER CELL, V17, P609, DOI 10.1016/j.ccr.2010.04.012; Muntean AG, 2008, BLOOD, V112, P4690, DOI 10.1182/blood-2008-01-134056; Murai MJ, 2014, BLOOD, V124, P3730, DOI 10.1182/blood-2014-01-550079; Nguyen AT, 2011, CELL RES, V21, P1370, DOI 10.1038/cr.2011.115; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Okuda H, 2014, NUCLEIC ACIDS RES, V42, P4241, DOI 10.1093/nar/gkt1394; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Paggetti J, 2010, ONCOGENE, V29, P5019, DOI 10.1038/onc.2010.254; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Pigneux A, 2015, LEUKEMIA, V29, P2375, DOI 10.1038/leu.2015.143; Placke T, 2014, BLOOD, V124, P13, DOI 10.1182/blood-2014-02-558114; Pott S, 2015, NAT GENET, V47, P8, DOI 10.1038/ng.3167; Pui CH, 2011, J CLIN ONCOL, V29, P551, DOI 10.1200/JCO.2010.30.7405; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Roderick JE, 2014, BLOOD, V123, P1040, DOI 10.1182/blood-2013-08-522698; ROWLEY JD, 1973, NEW ENGL J MED, V289, P220; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley JD, 2002, GENE CHROMOSOME CANC, V33, P331, DOI 10.1002/gcc.10040; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schwieger M, 2009, BLOOD, V114, P2476, DOI 10.1182/blood-2008-05-158196; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Shi AB, 2012, BLOOD, V120, P4461, DOI 10.1182/blood-2012-05-429274; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Smith E, 2011, GENE DEV, V25, P661, DOI 10.1101/gad.2015411; Spencer DH, 2015, LEUKEMIA, V29, P1279, DOI 10.1038/leu.2015.6; Srinivasan RS, 2004, LEUKEMIA, V18, P1364, DOI 10.1038/sj.leu.2403415; Sroczynska P, 2014, BLOOD, V123, P1870, DOI 10.1182/blood-2013-08-522094; STARK B, 1986, CANCER-AM CANCER SOC, V58, P1265, DOI 10.1002/1097-0142(19860915)58:6<1265::AID-CNCR2820580615>3.0.CO;2-6; Steffen PA, 2014, NAT REV MOL CELL BIO, V15, P340, DOI 10.1038/nrm3789; Stein EM, 2015, CURR OPIN HEMATOL, V22, P92, DOI 10.1097/MOH.0000000000000123; Tan JY, 2011, CANCER CELL, V20, P563, DOI 10.1016/j.ccr.2011.09.008; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tomizawa D, 2007, LEUKEMIA, V21, P2258, DOI 10.1038/sj.leu.2404903; van der Linden MH, 2014, CELL CYCLE, V13, P834, DOI 10.4161/cc.27757; van der Linden MH, 2009, BLOOD, V114, P3764, DOI 10.1182/blood-2009-02-204214; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; VERMAELEN K, 1983, CANCER GENET CYTOGEN, V10, P105, DOI 10.1016/0165-4608(83)90111-5; Wang E, 2013, P NATL ACAD SCI USA, V110, P3901, DOI 10.1073/pnas.1301045110; Wang ES, 2014, HEMATOL-AM SOC HEMAT, P14, DOI 10.1182/asheducation-2014.1.14; Wang QF, 2011, BLOOD, V117, P6895, DOI 10.1182/blood-2010-12-324699; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xu BW, 2015, BLOOD, V125, P346, DOI 10.1182/blood-2014-06-581082; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Yokoyama A, 2008, CANCER CELL, V14, P36, DOI 10.1016/j.ccr.2008.05.003; Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zeisig DT, 2005, ONCOGENE, V24, P5525, DOI 10.1038/sj.onc.1208699; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zhang Y, 2013, BLOOD, V122, P2888, DOI 10.1182/blood-2012-08-453662; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	129	50	52	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5215	5223		10.1038/onc.2016.30	http://dx.doi.org/10.1038/onc.2016.30			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26923329	Green Published			2022-12-28	WOS:000386053000001
J	Ceccon, M; Merlo, MEB; Mologni, L; Poggio, T; Varesio, LM; Menotti, M; Bombelli, S; Rigolio, R; Manazza, AD; Di Giacomo, F; Ambrogio, C; Giudici, G; Casati, C; Mastini, C; Compagno, M; Turner, SD; Gambacorti-Passerini, C; Chiarle, R; Voena, C				Ceccon, M.; Merlo, M. E. Boggio; Mologni, L.; Poggio, T.; Varesio, L. M.; Menotti, M.; Bombelli, S.; Rigolio, R.; Manazza, A. D.; Di Giacomo, F.; Ambrogio, C.; Giudici, G.; Casati, C.; Mastini, C.; Compagno, M.; Turner, S. D.; Gambacorti-Passerini, C.; Chiarle, R.; Voena, C.			Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; LUNG-CANCER; ACQUIRED-RESISTANCE; CONFER RESISTANCE; DNA-REPLICATION; NUCLEAR EXPORT; INHIBITORS; MUTATIONS; SENSITIVITY; CRIZOTINIB	Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(2; 5; p23;q35) that produces the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase). NPM-ALK-deregulated kinase activity drives several pathways that support malignant transformation of lymphoma cells. We found that in ALK-rearranged ALCL cell lines, NPM-ALK was distributed in equal amounts between the cytoplasm and the nucleus. Only the cytoplasmic portion was catalytically active in both cell lines and primary ALCL, whereas the nuclear portion was inactive because of heterodimerization with NPM1. Thus, about 50% of the NPM-ALK is not active and sequestered as NPM-ALK/NPM1 heterodimers in the nucleus. Overexpression or relocalization of NPM-ALK to the cytoplasm by NPM genetic knockout or knockdown caused ERK1/2 (extracellular signal-regulated protein kinases 1 and 2) increased phosphorylation and cell death through the engagement of an ATM/Chk2- and gamma H2AX (phosphorylated H2A histone family member X)-mediated DNA-damage response. Remarkably, human NPM-ALK-amplified cell lines resistant to ALK tyrosine kinase inhibitors (TKIs) underwent apoptosis upon drug withdrawal as a consequence of ERK1/2 hyperactivation. Altogether, these findings indicate that an excess of NPM-ALK activation and signaling induces apoptosis via oncogenic stress responses. A 'drug holiday' where the ALK TKI treatment is suspended could represent a therapeutic option in cells that become resistant by NPM-ALK amplification.	[Ceccon, M.; Mologni, L.; Bombelli, S.; Gambacorti-Passerini, C.] Univ Milano Bicocca, Dept Hlth Sci, Via Cadore 48, I-20900 Monza, Italy; [Merlo, M. E. Boggio; Poggio, T.; Varesio, L. M.; Menotti, M.; Manazza, A. D.; Di Giacomo, F.; Mastini, C.; Compagno, M.; Chiarle, R.; Voena, C.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Merlo, M. E. Boggio; Poggio, T.; Varesio, L. M.; Menotti, M.; Manazza, A. D.; Di Giacomo, F.; Mastini, C.; Compagno, M.; Chiarle, R.; Voena, C.] Citta Salute & Sci, CERMS, Turin, Italy; [Rigolio, R.] Univ Milano Bicocca, Surg & Translat Med Dept, Monza, Italy; [Ambrogio, C.] Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid, Spain; [Giudici, G.] Univ Milano Bicocca, Pediat Clin, Tettamanti Res Ctr, Monza, Italy; [Casati, C.] MetaSystems Slr, Milan, Italy; [Compagno, M.; Chiarle, R.] Childrens Hosp, Dept Pathol, Boston, MA USA; [Compagno, M.; Chiarle, R.] Harvard Med Sch, Enders 1116-1,320 Longwood Ave, Boston, MA 02115 USA; [Turner, S. D.] Addenbrookes Hosp, Div Mol Histopathol, Cambridge, England; [Gambacorti-Passerini, C.] San Gerardo Hosp, Sect Haematol, Monza, Italy	University of Milano-Bicocca; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; University of Milano-Bicocca; University of Milano-Bicocca; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; San Gerardo Hospital	Gambacorti-Passerini, C (corresponding author), Univ Milano Bicocca, Dept Hlth Sci, Via Cadore 48, I-20900 Monza, Italy.; Chiarle, R (corresponding author), Harvard Med Sch, Enders 1116-1,320 Longwood Ave, Boston, MA 02115 USA.; Chiarle, R (corresponding author), Childrens Hosp Boston, Dept Pathol, Enders 1116-1,320 Longwood Ave, Boston, MA 02115 USA.	carlo.gambacorti@unimib.it; roberto.chiarle@childrens.harvard.edu	Menotti, Matteo/AAA-9312-2022; VOENA, Claudia/ADJ-6244-2022; Turner, Suzanne Dawn/K-4405-2013; Mologni, Luca/AAC-1065-2022	Turner, Suzanne Dawn/0000-0002-8439-4507; Mologni, Luca/0000-0002-6365-5149; Boggio Merlo, Maria Elena/0000-0002-1967-7308; Menotti, Matteo/0000-0002-1260-2389; Voena, Claudia/0000-0002-1324-1431; Ambrogio, Chiara/0000-0003-4122-701X; Varesio, Lydia/0000-0001-6394-1607; GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X; Poggio, Teresa/0000-0003-2560-8488	Regione Lombardia [ID14546A]; Fondazione Berlucchi Onlus Grant; FP7 ERC-StG [242965]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-12023]; Koch Institute/DFCC Bridge Project Fund; Ellison Foundation Boston; Worldwide Cancer Research Association [12-0216]; Grant for Oncology Innovation by Merck-Serono;  [R01 CA196703-01]; NATIONAL CANCER INSTITUTE [R01CA196703] Funding Source: NIH RePORTER	Regione Lombardia(Regione Lombardia); Fondazione Berlucchi Onlus Grant; FP7 ERC-StG; Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Koch Institute/DFCC Bridge Project Fund; Ellison Foundation Boston(Lawrence Ellison Foundation); Worldwide Cancer Research Association; Grant for Oncology Innovation by Merck-Serono; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Maria Stella Scalzo for technical support, Dr Emanuela Colombo for kindly providing MEFs that lack NPM1 (MEF NPM<SUP>-/-</SUP>p53<SUP>-/-</SUP>) and control fibroblasts (MEF p53<SUP>-/-</SUP>), Dr Guido Serini for the use of his confocal microscopy unit at the Candiolo Cancer Institute-IRCCS, Torino, Italy. We also thank Ariad Pharmaceutical, Pfizer, Astellas and Novartis that kindly provided all drugs used in this study. This work was supported by the Regione Lombardia (ID14546A) and Fondazione Berlucchi Onlus Grant 2014 (to CGP), and by grants FP7 ERC-2009-StG (Proposal No. 242965-'Lunely'); Associazione Italiana per la Ricerca sul Cancro (AIRC) Grant IG-12023; Koch Institute/DFCC Bridge Project Fund; Ellison Foundation Boston; Worldwide Cancer Research Association (former AICR) grant 12-0216; the Grant for Oncology Innovation by Merck-Serono and R01 CA196703-01 (to RC).	Amin AD, 2015, CANCER RES, V75, P2916, DOI 10.1158/0008-5472.CAN-14-3437; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Ceccon M, 2015, MOL CANCER RES, V13, P775, DOI 10.1158/1541-7786.MCR-14-0157; Ceccon M, 2013, MOL CANCER RES, V11, P122, DOI 10.1158/1541-7786.MCR-12-0569; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Cui YX, 2009, BLOOD, V113, P5217, DOI 10.1182/blood-2008-06-160168; Das A, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0002-5; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Dengler MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025139; Desplat V, 2005, CANCER-AM CANCER SOC, V103, P102, DOI 10.1002/cncr.20758; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; Etchin J, 2013, BRIT J HAEMATOL, V161, P117, DOI 10.1111/bjh.12231; Friboulet L, 2014, CANCER DISCOV, V4, P662, DOI 10.1158/2159-8290.CD-13-0846; Funakoshi Y, 2013, INVEST NEW DRUG, V31, P1158, DOI 10.1007/s10637-013-9959-2; Gambacorti-Passerini C, 2011, NEW ENGL J MED, V364, P775, DOI 10.1056/NEJMc1013224; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Hapgood G, 2015, BLOOD, V126, P17, DOI 10.1182/blood-2014-10-567461; Hills SA, 2014, CURR BIOL, V24, pR435, DOI 10.1016/j.cub.2014.04.012; Ignatius Ou SH, 2014, J THORAC ONCOL, V9, P549, DOI DOI 10.1097/JTO.0000000000000094; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Katayama R, 2015, CLIN CANCER RES, V21, P2227, DOI 10.1158/1078-0432.CCR-14-2791; Katayama R, 2014, CLIN CANCER RES, V20, P5686, DOI 10.1158/1078-0432.CCR-14-1511; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Koop A, 2014, BRIT J DERMATOL, V170, P220, DOI 10.1111/bjd.12615; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Martinengo C, 2014, CANCER RES, V74, P6094, DOI 10.1158/0008-5472.CAN-14-0268; Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; Mologni L, 2015, ONCOTARGET, V6, P5720, DOI 10.18632/oncotarget.3122; Mologni L, 2015, TRANSL LUNG CANCER R, V4, P5, DOI 10.3978/j.issn.2218-6751.2014.07.02; Mologni L, 2012, EXPERT OPIN INV DRUG, V21, P985, DOI 10.1517/13543784.2012.690031; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Pall G, 2015, CURR OPIN ONCOL, V27, P118, DOI 10.1097/CCO.0000000000000165; Passerini CG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt378; Piva R, 2006, BLOOD, V107, P689, DOI 10.1182/blood-2005-05-2125; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Rassidakis GZ, 2005, LEUKEMIA, V19, P1663, DOI 10.1038/sj.leu.2403840; Shaw AT, 2014, NEW ENGL J MED, V370, P2537, DOI 10.1056/NEJMc1404894; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Suda K, 2012, LUNG CANCER, V76, P292, DOI 10.1016/j.lungcan.2011.11.007; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tipping AJ, 2001, BLOOD, V98, P3864, DOI 10.1182/blood.V98.13.3864; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Voena C, 2007, CANCER RES, V67, P4278, DOI 10.1158/0008-5472.CAN-06-4350; Voena C, 2012, EXPERT OPIN INV DRUG, V21, P1751, DOI 10.1517/13543784.2012.717930; Walker CJ, 2013, BLOOD, V122, P3034, DOI 10.1182/blood-2013-04-495374; Wei F, 2011, CURR MED CHEM, V18, P5476, DOI 10.2174/092986711798194388; Zdzalik D, 2014, J CANCER RES CLIN, V140, P589, DOI 10.1007/s00432-014-1589-3	54	28	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3854	3865		10.1038/onc.2015.456	http://dx.doi.org/10.1038/onc.2015.456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26657151	Green Accepted			2022-12-28	WOS:000380753200010
J	Hiratsuka, T; Takei, Y; Ohmori, R; Imai, Y; Ozeki, M; Tamaki, K; Haga, H; Nakamura, T; Tsuruyama, T				Hiratsuka, T.; Takei, Y.; Ohmori, R.; Imai, Y.; Ozeki, M.; Tamaki, K.; Haga, H.; Nakamura, T.; Tsuruyama, T.			ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway	ONCOGENE			English	Article							ZINC-FINGER PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; NF-KAPPA-B; RETROVIRUS INTEGRATION; BONE-MARROW; BCR CHECKPOINT; HEAVY-CHAINS; GENE; BTK; LOCUS	ZFP521 was previously identified as a putative gene involved in induction of B-cell lymphomagenesis. However, the contribution of ZFP521 to lymphomagenesis has not been confirmed. In this study, we sought to elucidate the role of ZFP521 in B-cell lymphomagenesis. To this end, we used a retroviral insertion method to show that ZFP521 was a target of mutagenesis in pre-B-lymphoblastic lymphoma cells. The pre-B-cell receptor (pre-BCR) signaling molecules BLNK, BTK and BANK1 were positively regulated by the ZFP521 gene, leading to enhancement of the pre-BCR signaling pathway. In addition, c-myc and c-jun were upregulated following activation of ZFP521. Stimulation of pre-BCR signaling using anti-Vpreb antibodies caused aberrant upregulation of c-myc and c-jun and of Ccnd3, which encodes cyclin D3, thereby inducing the growth of pre-B cells. Stimulation with Vpreb affected the growth of pre-B cells, and addition of interleukin (IL)-7 receptor exerted competitive effects on pre-B-cell growth. Knockdown of BTK and BANK1, targets of ZFP521, suppressed the effects of Vpreb stimulation on cell growth. Furthermore, in human lymphoblastic lymphoma, analogous to pre-B-cell lymphoma in mice, the expression of ZNF521, the homolog of ZFP521 in humans, was upregulated. In conclusion, our data showed that the ZFP521 gene comprehensively induced pre-B-cell lymphomagenesis by modulating the pre-B-cell receptor signaling pathway.	[Hiratsuka, T.] Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Kyoto, Japan; [Takei, Y.; Haga, H.; Tsuruyama, T.] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 606, Japan; [Ohmori, R.; Tsuruyama, T.] Kyoto Univ, Grad Sch Med, Ctr Anat Pathol & Forens Med Res, Kyoto, Japan; [Imai, Y.; Ozeki, M.; Tamaki, K.] Kyoto Univ, Grad Sch Med, Dept Forens Med, Kyoto, Japan; [Nakamura, T.] Carcinogenesis Lab, Inst Canc, Tokyo, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University	Tsuruyama, T (corresponding author), Kyoto Univ Hosp, Dept Diagnost Pathol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068506, Japan.	tsuruyam@kuhp.kyoto-u.ac.jp		Haga, Hironori/0000-0003-4322-9561				Addison WN, 2014, MOL CELL BIOL, V34, P3076, DOI 10.1128/MCB.00185-14; Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-59; Bernal-Quiros M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059842; Bond HM, 2008, INT J BIOCHEM CELL B, V40, P848, DOI 10.1016/j.biocel.2007.04.006; Bond HM, 2004, BLOOD, V103, P2062, DOI 10.1182/blood-2003-07-2388; Clark MR, 2014, NAT REV IMMUNOL, V14, P69, DOI 10.1038/nri3570; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Dai XZ, 2007, J IMMUNOL, V179, P1068, DOI 10.4049/jimmunol.179.2.1068; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; Fernandez-Vega I, 2015, VIRCHOWS ARCH, V466, P229, DOI 10.1007/s00428-014-1698-z; Flemming A, 2003, NAT IMMUNOL, V4, P38, DOI 10.1038/ni862; Geier JK, 2006, SEMIN IMMUNOL, V18, P31, DOI 10.1016/j.smim.2005.11.001; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hendriks RW, 2004, TRENDS IMMUNOL, V25, P249, DOI 10.1016/j.it.2004.02.011; Hiai H, 2003, CANCER SCI, V94, P847, DOI 10.1111/j.1349-7006.2003.tb01365.x; Hiratsuka T, 2008, LEUKEMIA RES, V32, P309, DOI 10.1016/j.leukres.2007.05.013; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Imamura Y, 2009, J BIOL CHEM, V284, P9804, DOI 10.1074/jbc.M809051200; Jin G, 2003, CANCER SCI, V94, P791, DOI 10.1111/j.1349-7006.2003.tb01520.x; Kamiya D, 2011, NATURE, V470, P503, DOI 10.1038/nature09726; Kaszynski RH, 2010, CANCER SCI, V101, P800, DOI 10.1111/j.1349-7006.2009.01437.x; Kiviranta R, 2013, J EXP MED, V210, P969, DOI 10.1084/jem.20121187; Li LX, 2010, J IMMUNOL, V184, P1728, DOI 10.4049/jimmunol.0903023; Lu LM, 1999, CANCER RES, V59, P2593; Malin S, 2010, NAT IMMUNOL, V11, P171, DOI 10.1038/ni.1827; Mandal M, 2009, NAT IMMUNOL, V10, P1110, DOI 10.1038/ni.1785; Mega T, 2011, CELL CYCLE, V10, P2129, DOI 10.4161/cc.10.13.16045; Melchers F, 2005, NAT REV IMMUNOL, V5, P578, DOI 10.1038/nri1649; Minegishi Y, 2001, IMMUNITY, V14, P631, DOI 10.1016/S1074-7613(01)00131-5; Muschen M, 2015, BLOOD, V125, P3688, DOI 10.1182/blood-2015-01-567842; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Murray MY, 2015, CELL CYCLE, V14, P2367, DOI 10.1080/15384101.2014.998067; Nakayama J, 2009, BLOOD, V113, P1483, DOI 10.1182/blood-2008-07-166355; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Rickert RC, 2013, NAT REV IMMUNOL, V13, P578, DOI 10.1038/nri3487; Rushworth SA, 2013, CELL SIGNAL, V25, P106, DOI 10.1016/j.cellsig.2012.09.008; Stadhouders R, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001791; Tsuruyama T, 2002, P NATL ACAD SCI USA, V99, P8253, DOI 10.1073/pnas.112202899; Tsuruyama T, 2011, AM J PATHOL, V178, P1374, DOI 10.1016/j.ajpath.2010.12.012; Tsuruyama T, 2010, J LEUKOCYTE BIOL, V88, P107, DOI 10.1189/jlb.1109748; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; Wei CJ, 2000, J IMMUNOL, V164, P1961, DOI 10.4049/jimmunol.164.4.1961; Wollscheid B, 1999, CURR TOP MICROBIOL, V246, P283; Yamasaki N, 2010, ONCOGENE, V29, P1963, DOI 10.1038/onc.2009.475; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yokoyama K, 2002, EMBO J, V21, P83, DOI 10.1093/emboj/21.1.83	46	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3227	3238		10.1038/onc.2015.385	http://dx.doi.org/10.1038/onc.2015.385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26522721				2022-12-28	WOS:000378306400002
J	van Geldermalsen, M; Wang, Q; Nagarajah, R; Marshall, AD; Thoeng, A; Gao, D; Ritchie, W; Feng, Y; Bailey, CG; Deng, N; Harvey, K; Beith, JM; Selinger, CI; O'Toole, SA; Rasko, JEJ; Holst, J				van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Marshall, A. D.; Thoeng, A.; Gao, D.; Ritchie, W.; Feng, Y.; Bailey, C. G.; Deng, N.; Harvey, K.; Beith, J. M.; Selinger, C. I.; O'Toole, S. A.; Rasko, J. E. J.; Holst, J.			ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; AMINO-ACID-TRANSPORT; HUMAN HEPATOMA-CELLS; MOLECULAR SUBTYPE; LUNG-CANCER; METABOLISM; EXPRESSION; TARGET; PROGRESSION; SENSITIVITY	Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, a conditionally essential amino acid in rapidly proliferating tumour cells. Uptake of glutamine and subsequent glutaminolysis is critical for activation of the mTORC1 nutrient-sensing pathway, which regulates cell growth and protein translation in cancer cells. This is of particular interest in breast cancer, as glutamine dependence is increased in high-risk breast cancer subtypes. Pharmacological inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast cancer cell lines, leading to the suppression of mTORC1 signalling, cell growth and cell cycle progression. Notably, these effects were subtype-dependent, with ASCT2 transport critical only for triple-negative (TN) basal-like breast cancer cell growth compared with minimal effects in luminal breast cancer cells. Both stable and inducible shRNA-mediated ASCT2 knockdown confirmed that inhibiting ASCT2 function was sufficient to prevent cellular proliferation and induce rapid cell death in TN basal-like breast cancer cells, but not in luminal cells. Using a bioluminescent orthotopic xenograft mouse model, ASCT2 expression was then shown to be necessary for both successful engraftment and growth of HCC1806 TN breast cancer cells in vivo. Lower tumoral expression of ASCT2 conferred a significant survival advantage in xenografted mice. These responses remained intact in primary breast cancers, where gene expression analysis showed high expression of ASCT2 and glutamine metabolism-related genes, including GLUL and GLS, in a cohort of 90 TN breast cancer patients, as well as correlations with the transcriptional regulators, MYC and ATF4. This study provides preclinical evidence for the feasibility of novel therapies exploiting ASCT2 transporter activity in breast cancer, particularly in the high-risk basal-like subgroup of TN breast cancer where there is not only high expression of ASCT2, but also a marked reliance on its activity for sustained cellular proliferation.	[van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Holst, J.] Centenary Inst, Origins Canc Program, Camperdown, NSW, Australia; [van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Marshall, A. D.; Thoeng, A.; Gao, D.; Ritchie, W.; Feng, Y.; Bailey, C. G.; Rasko, J. E. J.; Holst, J.] Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW, Australia; [van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Marshall, A. D.; Thoeng, A.; Gao, D.; Ritchie, W.; Feng, Y.; Bailey, C. G.; Beith, J. M.; O'Toole, S. A.; Rasko, J. E. J.; Holst, J.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Gao, D.; Ritchie, W.] Centenary Inst, Bioinformat Lab, Camperdown, NSW, Australia; [Deng, N.; Harvey, K.; O'Toole, S. A.] St Vincents Hosp, Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia; [Deng, N.; Harvey, K.; O'Toole, S. A.] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Deng, N.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Harvey, K.; Selinger, C. I.; O'Toole, S. A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia; [Beith, J. M.] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia; [Rasko, J. E. J.] Royal Prince Alfred Hosp, Cell & Mol Therapies, Sydney, NSW, Australia	University of Sydney; Centenary Institute; University of Sydney; Centenary Institute; University of Sydney; University of Sydney; Centenary Institute; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney; University of Sydney; University of Sydney; University of Sydney	Holst, J (corresponding author), Centenary Inst, Origins Canc Program, Locked Bag 6, Newtown, NSW 2042, Australia.	j.holst@centenary.org.au	Gao, Dadi/AAW-4359-2020; Holst, Jeff/H-7634-2012	Gao, Dadi/0000-0002-3638-8479; Holst, Jeff/0000-0002-0377-9318; Deng, Niantao/0000-0001-9717-2236; Wang, Qian (Kevin)/0000-0002-6514-3470; rasko, John/0000-0003-2975-807X; Bailey, Charles/0000-0002-4725-7829; Marshall, Amy/0000-0001-5803-3815	National Breast Cancer Foundation [ECF-12-05]; Movember through the Prostate Cancer Foundation of Australia [YI0813, YI0707]; Cancer Institute NSW; Cancer Council NSW [APP1080503]; University of Sydney; Tour de Cure Fellowship; Sydney Breast Cancer Foundation; RT Hall Foundation; Cure the Future and an anonymous foundation; National Breast Cancer Foundation [PRAC-16-006] Funding Source: researchfish	National Breast Cancer Foundation; Movember through the Prostate Cancer Foundation of Australia; Cancer Institute NSW; Cancer Council NSW(Cancer Council New South Wales); University of Sydney(University of Sydney); Tour de Cure Fellowship; Sydney Breast Cancer Foundation; RT Hall Foundation; Cure the Future and an anonymous foundation; National Breast Cancer Foundation	This work was supported by grants from the National Breast Cancer Foundation (ECF-12-05 to JH); Movember through the Prostate Cancer Foundation of Australia (YI0813 to QW; YI0707 to JH); Cancer Institute NSW (WR and MvG); Cancer Council NSW (APP1080503 to JH); University of Sydney (AM); Cure the Future and an anonymous foundation (JEJR); Tour de Cure Fellowship (CGB); Sydney Breast Cancer Foundation and the RT Hall Foundation (SO'T). We thank Michael P Kuligowski from Centenary Imaging Facility for assistance with Volocity image analysis and staff at the Advanced Cytometry Facility, Sydney for FACS assistance.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Chen XS, 2010, TUMORI J, V96, P103, DOI 10.1177/030089161009600117; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Esslinger CS, 2005, BIOORGAN MED CHEM, V13, P1111, DOI 10.1016/j.bmc.2004.11.028; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fuchs BC, 2004, AM J PHYSIOL-GASTR L, V286, pG467, DOI 10.1152/ajpgi.00344.2003; Fuchs BC, 2007, AM J PHYSIOL-CELL PH, V293, pC55, DOI 10.1152/ajpcell.00330.2006; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Hassanein M, 2015, INT J CANCER, V137, P1587, DOI 10.1002/ijc.29535; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Jacque N, 2015, BLOOD, V126, P1346, DOI 10.1182/blood-2015-01-621870; Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006; Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; Kim S, 2013, ENDOCR-RELAT CANCER, V20, P339, DOI 10.1530/ERC-12-0398; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Saqcena M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074157; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Tiffen JC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-299; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Wang Q, 2015, J PATHOL, V236, P278, DOI 10.1002/path.4518; Wang Q, 2014, INT J CANCER, V135, P1060, DOI 10.1002/ijc.28749; Wang Q, 2013, JNCI-J NATL CANCER I, V105, P1463, DOI 10.1093/jnci/djt241; Wang Q, 2011, CANCER RES, V71, P7525, DOI 10.1158/0008-5472.CAN-11-1821; Willems L, 2013, BLOOD, V122, P3521, DOI 10.1182/blood-2013-03-493163; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28	47	309	318	9	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3201	3208		10.1038/onc.2015.381	http://dx.doi.org/10.1038/onc.2015.381			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26455325	hybrid, Green Published			2022-12-28	WOS:000378092700011
J	Patel, B; Patel, J; Cho, JH; Manne, S; Bonala, S; Henske, E; Roegiers, F; Markiewski, M; Karbowniczek, M				Patel, B.; Patel, J.; Cho, J-H; Manne, S.; Bonala, S.; Henske, E.; Roegiers, F.; Markiewski, M.; Karbowniczek, M.			Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex	ONCOGENE			English	Article							RADIAL GLIAL-CELLS; RAPAMYCIN; NOTCH; TSC; ANGIOMYOLIPOMA; MECHANISMS; DIFFERENTIATION; PROGENITORS; ACTIVATION; GROWTH	Functions of extracellular vesicles including exosomes in the pathogenesis of tuberous sclerosis complex (TSC) have not yet been studied. We report that the extracellular vesicles such as exosomes derived from tuberous sclerosis 1 (Tsc1)-null cells transform phenotypes of neighboring wild-type cells in vivo in such manner that they become functionally similar to Tsc1-null cells. The loss of Tsc1 in the mouse neural tube increases the number of the wild-type neuronal progenitors, which is followed by the precocious and transient acceleration of neuronal differentiation of these cells. The mechanisms regulating these changes involve the exosomal delivery of exosomal shuttle Notch1 and Rheb esRNA and component of.-secretase complex presenilin 1 from Tsc1-null cells to wild-type cells leading to the activation of Notch and Rheb signaling in the recipient cells. The exosome-mediated mechanisms may also operate in the cells of angiomyolipoma (AML), which develops as a result of mutations in TSC1/TSC2 genes in TSC patients, because we observed the reactivation of mammalian target of rapamycin and Notch pathways, driven by the delivery of Rheb and Notch1 esRNA, in AML cells depleted of Rheb that were treated with the exosomes purified from AML cells with the constitutively high Rheb levels.	[Patel, B.; Patel, J.; Cho, J-H; Manne, S.; Bonala, S.; Markiewski, M.; Karbowniczek, M.] Texas Tech Univ Hlth Sci Ctr, Sch Pharm, Dept Immunotherapeut & Biotechnol, 1718 Pine St, Abilene, TX 79601 USA; [Henske, E.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Henske, E.] Harvard Univ, Sch Med, Boston, MA USA; [Roegiers, F.] Fox Chase Canc Ctr, Canc Biol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA	Texas Tech University System; Texas Tech University Health Science Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Fox Chase Cancer Center	Karbowniczek, M (corresponding author), Texas Tech Univ Hlth Sci Ctr, Sch Pharm, Dept Immunotherapeut & Biotechnol, 1718 Pine St, Abilene, TX 79601 USA.	Magdalena.karbowniczek@ttuhsc.edu			CPRIT [RP 120168]; DoD grant [BC 111038]	CPRIT; DoD grant	We thank Drs Maureen Murphy and Aristotelis Astreinidis for his invaluable comments. CPRIT grant RP 120168 to M Karbowniczek and the DoD grant BC 111038 to MM Markiewski.	Arbiser JL, 2002, AM J PATHOL, V161, P781, DOI 10.1016/S0002-9440(10)64237-X; Arbiser JL, 2001, AM J PATHOL, V159, P483, DOI 10.1016/S0002-9440(10)61720-8; Au KS, 1999, AM J HUM GENET, V65, P1790, DOI 10.1086/302648; Bakhti M, 2011, J BIOL CHEM, V286, P787, DOI 10.1074/jbc.M110.190009; Baonza A, 2001, DEVELOPMENT, V128, P3889; Baybis M, 2004, ANN NEUROL, V56, P478, DOI 10.1002/ana.20211; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Bonnet CS, 2009, HUM MOL GENET, V18, P2166, DOI 10.1093/hmg/ddp149; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Cepeda C, 2010, EPILEPSIA, V51, P160, DOI 10.1111/j.1528-1167.2010.02633.x; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; Govindarajan B, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-11; Hall DJ, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-10; Hartman TR, 2009, HUM MOL GENET, V18, P151, DOI 10.1093/hmg/ddn325; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; Johnson MW, 1999, BRAIN PATHOL, V9, P45; Karbowniczek M, 2006, J BIOL CHEM, V281, P25447, DOI 10.1074/jbc.M605273200; Karbowniczek M, 2010, J CLIN INVEST, V120, P93, DOI 10.1172/JCI40221; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Knox S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000375; Kornblum HI, 2007, STROKE, V38, P810, DOI 10.1161/01.STR.0000255757.12198.0f; Lasser C, 2012, JOVE-J VIS EXP, DOI 10.3791/3037; Lee C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050501; Lee PS, 2010, AM J RESP CELL MOL, V42, P227, DOI 10.1165/rcmb.2009-0050OC; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Ma DZ, 2010, J BIOL CHEM, V285, P8621, DOI 10.1074/jbc.M109.092353; Malatesta P, 2000, DEVELOPMENT, V127, P5253; Martynoga B, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008359; Marzesco AM, 2005, J CELL SCI, V118, P2849, DOI 10.1242/jcs.02439; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Mineo M, 2012, ANGIOGENESIS, V15, P33, DOI 10.1007/s10456-011-9241-1; Mizuguchi M, 2000, ACTA NEUROPATHOL, V99, P503, DOI 10.1007/s004010051152; Neuman NA, 2011, EMBO MOL MED, V3, P189, DOI 10.1002/emmm.201100131; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Okamura Y, 2008, DEVELOPMENT, V135, P3555, DOI 10.1242/dev.022319; Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E; Pardal R, 2007, CELL, V131, P364, DOI 10.1016/j.cell.2007.07.043; Parker MA, 2005, EXP NEUROL, V194, P320, DOI 10.1016/j.expneurol.2005.04.018; Patch K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007574; Ramesh V, 2003, BIOCHEM SOC T, V31, P579, DOI 10.1042/bst0310579; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733; Walker AS, 2010, NEURAL PLAST, V2010, DOI 10.1155/2010/894374; Weisman R, 2007, GENETICS, V175, P1153, DOI 10.1534/genetics.106.064170; Wilson C, 2006, CANCER RES, V66, P7934, DOI 10.1158/0008-5472.CAN-06-1740; Wong M, 2008, EPILEPSIA, V49, P8, DOI 10.1111/j.1528-1167.2007.01270.x; Yu J, 2004, AM J PHYSIOL-LUNG C, V286, pL694, DOI 10.1152/ajplung.00204.2003; Zhou XM, 2009, P NATL ACAD SCI USA, V106, P8923, DOI 10.1073/pnas.0903621106	52	27	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3027	3036		10.1038/onc.2015.358	http://dx.doi.org/10.1038/onc.2015.358			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434588				2022-12-28	WOS:000377474500008
J	Babaian, A; Romanish, MT; Gagnier, L; Kuo, LY; Karimi, MM; Steidl, C; Mager, DL				Babaian, A.; Romanish, M. T.; Gagnier, L.; Kuo, L. Y.; Karimi, M. M.; Steidl, C.; Mager, D. L.			Onco-exaptation of an endogenous retroviral LTR drives IRF5 expression in Hodgkin lymphoma	ONCOGENE			English	Article							TRANSPOSABLE ELEMENTS; GENES; ISOFORM; TRANSCRIPTS; PROMOTERS; ALIGNMENT; BIOLOGY	The transcription factor interferon regulatory factor 5 (IRF5) is upregulated in Hodgkin lymphoma (HL) and is a key regulator of the aberrant transcriptome characteristic of this disease. Here we show that IRF5 upregulation in HL is driven by transcriptional activation of a normally dormant endogenous retroviral LOR1a long terminal repeat (LTR) upstream of IRF5. Specifically, through screening of RNA-sequencing libraries, we detected LTR-IRF5 chimeric transcripts in multiple HL cell lines but not in normal B-cell controls. In HL, the LTR was in an open and hypomethylated epigenetic state, and we further show the LTR is the site of transcriptional initiation. Among HL cell lines, usage of the LTR promoter strongly correlates with overall levels of IRF5 mRNA and protein, indicating that LTR transcriptional awakening is a major contributor to IRF5 upregulation in HL. Taken together, oncogenic IRF5 overexpression in HL is the result of a specific LTR transcriptional activation. We propose that such LTR derepression is a distinct mechanism of oncogene activation ('onco-exaptation'), and that such a mechanism warrants further investigation in molecular and cancer research.	[Babaian, A.; Romanish, M. T.; Gagnier, L.; Kuo, L. Y.; Mager, D. L.] British Columbia Canc Agcy, Terry Fox Lab, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Babaian, A.; Romanish, M. T.; Gagnier, L.; Karimi, M. M.; Mager, D. L.] Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada; [Karimi, M. M.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC, Canada; [Steidl, C.] British Columbia Canc Agcy, Dept Lymphoid Canc Res, Vancouver, BC V5Z 1L3, Canada; [Steidl, C.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; British Columbia Cancer Agency; University of British Columbia	Mager, DL (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.; Steidl, C (corresponding author), British Columbia Canc Agcy, Ctr Lymphoid Canc, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	CSteidl@bccancer.bc.ca; dmager@bccrc.ca		Mager, Dixie/0000-0002-5955-2550; Karimi, Mohammad Mahdi/0000-0001-5017-1252; Babaian, Artem/0000-0002-4315-6262	Leukemia and Lymphoma Society of Canada; British Columbia Cancer Agency; Natural Sciences and Engineering Research Council of Canada; Michael Smith Foundation for Health Research (MSFHR); MSFHR	Leukemia and Lymphoma Society of Canada; British Columbia Cancer Agency; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); MSFHR(Michael Smith Foundation for Health Research)	This work was supported by a grant from the Leukemia and Lymphoma Society of Canada to DM and CS, with core support provided by the British Columbia Cancer Agency. AB is supported by a studentship award from the Natural Sciences and Engineering Research Council of Canada, MMK is supported by a postdoctoral fellowship from the Michael Smith Foundation for Health Research (MSFHR) and CS is supported by a scholarship award from MSFHR.	Chiaromonte F, 2002, Pac Symp Biocomput, P115; Clark DN, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00360; Davydov EV, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001025; De Smet Charles, 2010, Epigenetics, V5, P206; Faulkner GJ, 2009, NAT GENET, V41, P563, DOI 10.1038/ng.368; Hur K, 2014, GUT, V63, P635, DOI 10.1136/gutjnl-2012-304219; Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979; Kapusta A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003470; Karimi MM, 2011, CELL STEM CELL, V8, P676, DOI 10.1016/j.stem.2011.04.004; Kelley D, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-11-r107; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kreher S, 2014, P NATL ACAD SCI USA, V111, pE4513, DOI 10.1073/pnas.1406985111; Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lazzari E, 2014, CLIN IMMUNOL, V153, P343, DOI 10.1016/j.clim.2014.06.001; Liu Y, 2014, LEUKEMIA, V28, P2248, DOI 10.1038/leu.2014.201; Lock FE, 2014, P NATL ACAD SCI USA, V111, pE3534, DOI 10.1073/pnas.1405507111; Mancl ME, 2005, J BIOL CHEM, V280, P21078, DOI 10.1074/jbc.M500543200; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; PANGANIBAN AT, 1985, CELL, V42, P5, DOI 10.1016/S0092-8674(85)80092-1; Rebollo R, 2012, ANNU REV GENET, V46, P21, DOI 10.1146/annurev-genet-110711-155621; Rebollo R, 2012, MOBILE DNA-UK, V3, DOI 10.1186/1759-8753-3-9; Rebollo R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002301; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Romanish MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005761; Roullet MR, 2007, EXPERT REV MOL DIAGN, V7, P805, DOI 10.1586/14737159.7.6.805; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Slotkin RK, 2007, NAT REV GENET, V8, P272, DOI 10.1038/nrg2072; St Laurent G, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r73; Steidl C, 2012, BLOOD, V120, P3530, DOI 10.1182/blood-2012-06-439570; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Weber B, 2010, ONCOGENE, V29, P5775, DOI 10.1038/onc.2010.227; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917; Xie MC, 2013, NAT GENET, V45, P836, DOI 10.1038/ng.2649	35	44	45	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2542	2546		10.1038/onc.2015.308	http://dx.doi.org/10.1038/onc.2015.308			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279299				2022-12-28	WOS:000376165500012
J	Emmrich, S; Engeland, F; El-Khatib, M; Henke, K; Obulkasim, A; Schoning, J; Katsman-Kuipers, JE; Zwaan, CM; Pich, A; Stary, J; Baruchel, A; de Haas, V; Reinhardt, D; Fornerod, M; van den Heuvel-Eibrink, MM; Klusmann, JH				Emmrich, S.; Engeland, F.; El-Khatib, M.; Henke, K.; Obulkasim, A.; Schoening, J.; Katsman-Kuipers, J. E.; Zwaan, C. Michel; Pich, A.; Stary, J.; Baruchel, A.; de Haas, V.; Reinhardt, D.; Fornerod, M.; van den Heuvel-Eibrink, M. M.; Klusmann, J. H.			miR-139-5p controls translation in myeloid leukemia through EIF4G2	ONCOGENE			English	Article							DOWN-REGULATION; MALIGNANT-TRANSFORMATION; PROTEIN-SYNTHESIS; POOR-PROGNOSIS; UP-REGULATION; EXPRESSION; BTG3; PHOSPHORYLATION; PROLIFERATION; METHYLATION	MicroRNAs (miRNAs) are crucial components of homeostatic and developmental gene regulation. In turn, dysregulation of miRNA expression is a common feature of different types of cancer, which can be harnessed therapeutically. Here we identify miR-139-5p suppression across several cytogenetically defined acute myeloid leukemia (AML) subgroups. The promoter of mir-139 was transcriptionally silenced and could be reactivated by histone deacetylase inhibitors in a dose-dependent manner. Restoration of mir-139 expression in cell lines representing the major AML subgroups (t[8;21], inv[16], mixed lineage leukemia-rearranged and complex karyotype AML) caused cell cycle arrest and apoptosis in vitro and in xenograft mouse models in vivo. During normal hematopoiesis, mir-139 is exclusively expressed in terminally differentiated neutrophils and macrophages. Ectopic expression of mir-139 repressed proliferation of normal CD34(+)-hematopoietic stem and progenitor cells and perturbed myelomonocytic in vitro differentiation. Mechanistically, mir-139 exerts its effects by repressing the translation initiation factor EIF4G2, thereby reducing overall protein synthesis while specifically inducing the translation of cell cycle inhibitor p27(Kip1). Knockdown of EIF4G2 recapitulated the effects of mir-139, whereas restoring EIF4G2 expression rescued the mir-139 phenotype. Moreover, elevated miR-139-5p expression is associated with a favorable outcome in a cohort of 165 pediatric patients with AML. Thus, mir-139 acts as a global tumor suppressor-miR in AML by controlling protein translation. As AML cells are dependent on high protein synthesis rates controlling the expression of mir-139 constitutes a novel path for the treatment of AML.	[Emmrich, S.; Engeland, F.; El-Khatib, M.; Henke, K.; Schoening, J.; Klusmann, J. H.] Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg St 1, D-30625 Hannover, Germany; [Obulkasim, A.; Katsman-Kuipers, J. E.; Zwaan, C. Michel; Fornerod, M.; van den Heuvel-Eibrink, M. M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Pich, A.] Hannover Med Sch, Inst Toxicol, D-30625 Hannover, Germany; [Stary, J.] Charles Univ Prague, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [Baruchel, A.] Hop Univ St Louis, St Louis Hosp, Dept Hematol, Paris, France; [de Haas, V.] Stichting Kinderoncol Nederland SKION, Dutch Childhood Oncol Grp, The Hague, Netherlands; [Reinhardt, D.] Univ Hosp Essen, Clin Pediat 3, Essen, Germany; [Fornerod, M.] Erasmus MC Sophia Childrens Hosp, Dept Biochem, Rotterdam, Netherlands	Hannover Medical School; Erasmus University Rotterdam; Erasmus MC; Hannover Medical School; Charles University Prague; Motol University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Dutch Childhood Oncology Group; University of Duisburg Essen; Erasmus University Rotterdam; Erasmus MC	Klusmann, JH (corresponding author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg St 1, D-30625 Hannover, Germany.	klusmann.jan-henning@mh-hannover.de	Stary, Jan/AAB-9635-2020; Reinhardt, Dirk/N-7003-2016; Klusmann, Jan-Henning/M-9655-2015	Reinhardt, Dirk/0000-0002-7027-4483; Klusmann, Jan-Henning/0000-0002-1070-0727; Fornerod, Maarten/0000-0002-6166-3030	Children Cancer Free Foundation (KIKA) [49, 109]; KIKA project [109]; DFG [KL-2374/2-1]	Children Cancer Free Foundation (KIKA); KIKA project; DFG(German Research Foundation (DFG))	The authors thank Drs K Weber, B Fehse and D Heckl for providing plasmids; Dr M Ballmaier for sorting. SE, FE and KH were supported by the Hannover Biomedical Research School. JEK-K was supported by the Children Cancer Free Foundation (KIKA, project 49). JHK is a fellow of the Emmy Noether-Programme from the German Research Foundation (DFG; KL-2374/2-1). A.O. was supported by KIKA project 109. This work was supported by grants to CMZ and MMvdH-E from the Children Cancer Free Foundation (KIKA, projects 49 and 109) and to JHK from the DFG (KL-2374/2-1).	Alemdehy MF, 2015, BLOOD; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bao W, 2011, GASTROENTEROLOGY, V141, P2076, DOI 10.1053/j.gastro.2011.08.050; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berindan-Neagoe I, 2014, CA-CANCER J CLIN, V64, P311, DOI 10.3322/caac.21244; Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572; Breinbauer R, 2003, CHEMBIOCHEM, V4, P1147, DOI 10.1002/cbic.200300705; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Chen P, 2013, P NATL ACAD SCI USA, V110, P11511, DOI 10.1073/pnas.1310144110; Cheng JJ, 2013, CELL REP, V5, P471, DOI 10.1016/j.celrep.2013.08.050; Cheng YC, 2013, P NATL ACAD SCI USA, V110, P5993, DOI 10.1073/pnas.1220635110; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Creutzig U, 2012, BLOOD, V120, P3187, DOI 10.1182/blood-2012-03-362608; Deng BY, 2013, TUMOR BIOL, V34, P2617, DOI 10.1007/s13277-013-0811-2; Dou L, 2012, ONCOGENE, V31, P507, DOI 10.1038/onc.2011.248; Emmrich S, 2014, LEUKEMIA, V28, P1022, DOI 10.1038/leu.2013.357; Fan Q, 2013, CELL BIOCHEM FUNCT, V31, P319, DOI 10.1002/cbf.2902; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Gu W, 2014, ONCOL REP, V31, P397, DOI 10.3892/or.2013.2831; Hariri F, 2013, LEUKEMIA, V27, P2047, DOI 10.1038/leu.2013.73; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Hinnebusch AG, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011544; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jiang H, 2011, CELL, V144, P513, DOI 10.1016/j.cell.2011.01.020; Kar AN, 2013, J NEUROSCI, V33, P7165, DOI 10.1523/JNEUROSCI.2040-12.2013; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Krishnan K, 2013, RNA, V19, P1767, DOI 10.1261/rna.042143.113; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee DW, 2012, ONCOGENE, V31, P4085, DOI 10.1038/onc.2011.579; Lee SH, 2006, EMBO J, V25, P4008, DOI 10.1038/sj.emboj.7601268; Li RY, 2013, CNS NEUROSCI THER, V19, P477, DOI 10.1111/cns.12089; Li ZJ, 2012, BLOOD, V119, P2314, DOI 10.1182/blood-2011-10-386235; Lin TY, 2012, ONCOGENE, V31, P3287, DOI 10.1038/onc.2011.491; Luo HN, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0789-z; Marash L, 2008, MOL CELL, V30, P447, DOI 10.1016/j.molcel.2008.03.018; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Masaki S, 2007, BIOCHEM BIOPH RES CO, V364, P509, DOI 10.1016/j.bbrc.2007.10.077; Mazan-Mamczarz K, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004105; Nousch M, 2007, RNA, V13, P374, DOI 10.1261/rna.372307; Placke T, 2014, BLOOD, V124, P13, DOI 10.1182/blood-2014-02-558114; Qin H, 2003, J BIOL CHEM, V278, P48570, DOI 10.1074/jbc.M308781200; Sanders MA, 2013, CURR OPIN HEMATOL, V20, P79, DOI 10.1097/MOH.0b013e32835d821c; Scheicher R, 2015, BLOOD, V125, P90, DOI 10.1182/blood-2014-06-584417; Shen K, 2014, FEBS J, V281, P3609, DOI 10.1111/febs.12880; Solh M, 2014, AM J HEMATOL, V89, P1121, DOI 10.1002/ajh.23821; Srivastava T, 2012, J NEUROSCI, V32, P5620, DOI 10.1523/JNEUROSCI.0030-12.2012; Stankov MV, 2014, LEUKEMIA, V28, P577, DOI 10.1038/leu.2013.264; Tamburini J, 2009, CELL CYCLE, V8, P3893, DOI 10.4161/cc.8.23.10091; Tu LX, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-78; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Vinther J, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl590; Virgili G, 2013, STRUCTURE, V21, P517, DOI 10.1016/j.str.2013.01.015; Wang ZY, 2013, MOL CELL BIOCHEM, V383, P59, DOI 10.1007/s11010-013-1754-z; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; YANAGISAWA K, 1991, BLOOD, V78, P451; Yu JW, 2008, GENE EXPRESSION, V14, P173; Zhang LJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-124	60	42	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1822	1831		10.1038/onc.2015.247	http://dx.doi.org/10.1038/onc.2015.247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26165837				2022-12-28	WOS:000373610400008
J	Wang, JY; Chen, SY; Sun, CN; Chien, T; Chern, Y				Wang, J-Y; Chen, S-Y; Sun, C-N; Chien, T.; Chern, Y.			A central role of TRAX in the ATM-mediated DNA repair	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; FACTOR-X TRAX; A(2A) ADENOSINE RECEPTOR; SUPPRESSES TUMOR-GROWTH; KINESIN FAMILY-MEMBER; INDUCED CELL-DEATH; MRN COMPLEX; MRE11-RAD50-NBS1 COMPLEX; SACCHAROMYCES-CEREVISIAE; DAMAGE RESPONSE	DNA repair is critical for the maintenance of genome stability. Upon genotoxic stress, dysregulated DNA repair may induce apoptosis. Translin-associated factor X (TRAX), which was initially identified as a binding partner of Translin, has been implicated in genome stability. However, the exact role of TRAX in DNA repair remains largely unknown. Here, we showed that TRAX participates in the ATM/H2AX-mediated DNA repair machinery by interacting with ATM and stabilizing the MRN complex at double-strand breaks. The exogenous expression of wild-type (WT) TRAX, but not a TRAX variant lacking the nuclear localization signal (NLS), rescued the vulnerability of TRAX-null mouse embryo fibroblasts (MEFs). This finding confirms the importance of the nuclear localization of TRAX in the repair of DNA damage. Compared with WT MEFs, TRAX-null MEFs exhibited impaired DNA repair (for example, reduced phosphorylation of ATM and H2AX) after treatment with ultra violet-C or.-ray irradiation and a higher incidence of p53-mediated apoptosis. Our findings demonstrate that TRAX is required for MRN complex-ATM-H2AX signaling, which optimizes DNA repair by interacting with the activated ATM and protects cells from genotoxic stress-induced apoptosis.	[Wang, J-Y] Kaohsiung Med Univ, Sch Med, Dept Neurol, Coll Med, Kaohsiung, Taiwan; [Wang, J-Y; Chen, S-Y; Sun, C-N; Chern, Y.] Acad Sinica, Inst Biomed Sci, Neurosci Div, N333 IBMS, Taipei 115, Taiwan; [Chien, T.; Chern, Y.] Natl Def Med Ctr, Inst Life Sci, Taipei, Taiwan	Kaohsiung Medical University; Academia Sinica - Taiwan; National Defense Medical Center	Chern, Y (corresponding author), Acad Sinica, Inst Biomed Sci, Neurosci Div, N333 IBMS, Taipei 115, Taiwan.	bmychern@ibms.sinica.edu.tw	chern, yijuang/S-7013-2018	chern, yijuang/0000-0002-5842-5429	Ministrant of Technology and Science of Taiwan [NSC96-2321-B-001-015, NSC97-2321-B-001-012, 100-2320-B-001-0110MY3]; Institute of Biomedical Sciences of Academia Sinica; Kaohsiung Medical University [KMU-Q102011]	Ministrant of Technology and Science of Taiwan; Institute of Biomedical Sciences of Academia Sinica(Academia Sinica - Taiwan); Kaohsiung Medical University	We thank Hsing-Lin Lai and Shuyung Chang for technical support. This work was supported by grants from the Ministrant of Technology and Science of Taiwan (NSC96-2321-B-001-015, NSC97-2321-B-001-012 and 100-2320-B-001-0110MY3 to YC), the Institute of Biomedical Sciences of Academia Sinica (to YC) and the Kaohsiung Medical University (KMU-Q102011 to J-YW).	Aisiku OR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015001; AJIMURA M, 1993, GENETICS, V133, P51; Amano T, 2009, J NEURO-ONCOL, V92, P357, DOI 10.1007/s11060-009-9844-1; Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bray JD, 2004, MOL REPROD DEV, V69, P387, DOI 10.1002/mrd.20171; Bray JD, 2002, GENOMICS, V79, P799, DOI 10.1006/geno.2002.6779; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; Chen SH, 2007, MOL BIOL CELL, V18, P2525, DOI 10.1091/mbc.E07-02-0188; Chen WSV, 2003, METHOD ENZYMOL, V365, P367; Chennathukuzhi VM, 2001, J BIOL CHEM, V276, P13256, DOI 10.1074/jbc.M009707200; Colton SL, 2006, J BIOL CHEM, V281, P27117, DOI 10.1074/jbc.M602826200; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Delmas S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000552; Devon RS, 2000, MAMM GENOME, V11, P395, DOI 10.1007/s003350010074; Dupre A, 2008, NAT CHEM BIOL, V4, P119, DOI 10.1038/nchembio.63; Erdemir T, 2002, MOL MICROBIOL, V46, P947, DOI 10.1046/j.1365-2958.2002.03224.x; Erdemir T, 2002, J CELL SCI, V115, P207; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Hakem R, 2008, EMBO J, V27, P589, DOI 10.1038/emboj.2008.15; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hong SH, 2012, ONCOL REP, V27, P1251, DOI 10.3892/or.2012.1641; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Kaina B, 2003, BIOCHEM PHARMACOL, V66, P1547, DOI 10.1016/S0006-2952(03)00510-0; Kerzendorfer C, 2009, DNA REPAIR, V8, P1139, DOI 10.1016/j.dnarep.2009.04.018; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Lamarche BJ, 2010, FEBS LETT, V584, P3682, DOI 10.1016/j.febslet.2010.07.029; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee JH, 2010, EMBO J, V29, P574, DOI 10.1038/emboj.2009.372; Li Z, 2008, BBA-GENE REGUL MECH, V1779, P479, DOI 10.1016/j.bbagrm.2008.03.008; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Liu Y, 2009, SCIENCE, V325, P750, DOI 10.1126/science.1176325; Malmlof M, 2007, J BIOL CHEM, V282, P2288, DOI 10.1074/jbc.M604953200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meng G, 2000, J HUM GENET, V45, P305, DOI 10.1007/s100380070022; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Mochan TA, 2003, CANCER RES, V63, P8586; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Robison JG, 2007, CELL CYCLE, V6, P2408, DOI 10.4161/cc.6.19.4773; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Schroer U, 2007, EUR J NEUROSCI, V26, P2169, DOI 10.1111/j.1460-9568.2007.05849.x; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sun CN, 2006, MOL PHARMACOL, V70, P454, DOI 10.1124/mol.105.021261; Sun CN, 2010, DEV NEUROBIOL, V70, P604, DOI 10.1002/dneu.20802; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Warmerdam DO, 2010, MUTAT RES-REV MUTAT, V704, P2, DOI 10.1016/j.mrrev.2009.12.001; Wu YC, 2011, J NEUROCHEM, V116, P1112, DOI 10.1111/j.1471-4159.2010.07166.x; Xu M, 2004, INT J HYPERTHER, V20, P157, DOI 10.1080/02656730310001625986; Yajima H, 2009, J MOL BIOL, V385, P800, DOI 10.1016/j.jmb.2008.11.036; Yang L, 2004, WORLD J GASTROENTERO, V10, P155; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Ye XC, 2011, NAT STRUCT MOL BIOL, V18, P650, DOI 10.1038/nsmb.2032; Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021; Zgheib O, 2005, RADIOTHER ONCOL, V76, P119, DOI 10.1016/j.radonc.2005.06.026; Zhao X, 2008, J VIROL, V82, P5316, DOI 10.1128/JVI.02677-07; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	66	15	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1657	1670		10.1038/onc.2015.228	http://dx.doi.org/10.1038/onc.2015.228			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096928				2022-12-28	WOS:000373064200005
J	Karunarathna, U; Kongsema, M; Zona, S; Gong, C; Cabrera, E; Gomes, AR; Man, EPS; Khongkow, P; Tsang, JWH; Khoo, US; Medema, RH; Freire, R; Lam, EWF				Karunarathna, U.; Kongsema, M.; Zona, S.; Gong, C.; Cabrera, E.; Gomes, A. R.; Man, E. P. S.; Khongkow, P.; Tsang, J. W-H; Khoo, U-S; Medema, R. H.; Freire, R.; Lam, E. W-F			OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance	ONCOGENE			English	Article							EXPRESSION; PROTEIN; DOMAIN; BINDING; ENZYME; CELLS; OVEREXPRESSION; SPECIFICITY; DOXORUBICIN; MUTATIONS	The forkhead transcription factor FOXM1 has a key role in DNA damage response, and its deregulated overexpression is associated with genotoxic drug resistance in breast cancer. However, little is known about the posttranslational mechanisms by which FOXM1 expression is regulated by genotoxic agents and how they are deregulated in resistant cells. Initial co-immunoprecipitation studies verified previous proteomic analysis finding that the OTUB1 is a novel FOXM1-interacting protein. Western blot analysis showed that both OTUB1 and FOXM1 expression reduced upon genotoxic agent treatment in MCF-7 cells, but remained relatively constant in resistant cells. FOXM1 expression reduced upon OTUB1 depletion by siRNA and increased with OTUB1 overexpression in MCF-7 cells, arguing that OTUB1 positively regulates FOXM1 expression. In agreement, co-immunoprecipitation experiments demonstrated that FOXM1 expression is associated with OTUB1 binding but inversely correlates with conjugation to the protein degradation-associated Lys-48-linked ubiquitin-chains. Overexpression of wild-type (WT) OTUB1, but not the OTUB1( C91S) mutant, disrupted the formation of Lys48-linked ubiquitin-conjugates on FOXM1. Importantly, knockdown of OTUB1 by siRNA resulted in an increase in turnover of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide, whereas overexpression of WT OTUB1, but not the OTUB1( C91S) mutant, significantly enhances the half-life of FOXM1. In addition, proliferative and clonogenic assays also show that OTUB1 can enhance the proliferative rate and epirubicin resistance through targeting FOXM1, as OTUB1 has little effect on FOXM1-deficient cells. The physiological relevance of the regulation of FOXM1 by OTUB1 is further underscored by the significant correlations between FOXM1 and OTUB1 expression in breast cancer patient samples. Cox-regression survival analysis indicates that OTUB1 overexpression is linked to poorer outcome in particular in patients treated with chemotherapy. Collectively, these data suggest that OTUB1 limits the ubiquitination and degradation of FOXM1 in breast cancer and has a key role in genotoxic agent resistance.	[Karunarathna, U.; Kongsema, M.; Zona, S.; Gong, C.; Gomes, A. R.; Khongkow, P.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus, London, England; [Gong, C.; Man, E. P. S.; Khoo, U-S] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Cabrera, E.; Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, Tenerife, Spain; [Tsang, J. W-H] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	Imperial College London; University of Hong Kong; Universidad de la Laguna; University of Hong Kong; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, ICTEM, Hammersmith Hosp Campus,Room 134,1st Floor, London W12 0NN, England.	eric.lam@imperial.ac.uk	Kongsema, Mesayamas/H-3063-2017; Cabrera, Elisa/GPX-3455-2022; Khoo, Ui Soon/C-4293-2009; Freire, Raimundo/Q-7660-2019; Khoo, Ui Soon/C-1345-2014; Lam, Eric W-F/AAW-8566-2020; Khoo, Ui Soon/K-2041-2019	Khoo, Ui Soon/0000-0003-2200-7505; Freire, Raimundo/0000-0003-4473-8894; Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; Medema, Rene/0000-0002-6754-0381; Khongkow, Pasarat/0000-0003-3068-2412	Cancer Research UK; Breast Cancer Campaign; BBSRC studentship; Royal Thai Government Scholarship; Committee on Research and Conference Grants from the University of Hong Kong (CRCG) [201007176118]; Biotechnology and Biological Sciences Research Council [1243234, BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Breast Cancer Campaign [2012NovPhD016, 2012MayPR070] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; BBSRC studentship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Royal Thai Government Scholarship; Committee on Research and Conference Grants from the University of Hong Kong (CRCG); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Breast Cancer Campaign	EW-F Lam and AR Gomes were supported by grants from Cancer Research UK, EW-F Lam and S Zona by grants from Breast Cancer Campaign. U Karunarathna is the recipient of a BBSRC studentship. P Khongkow and M Kongsema were supported by grants from the Royal Thai Government Scholarship. US Khoo received funding from Committee on Research and Conference Grants from the University of Hong Kong (CRCG) (201007176118). We also thank for help with this work.	CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Cohen MM, 2011, J CELL SCI, V124, P1403, DOI 10.1242/jcs.079293; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Edelmann MJ, 2009, BIOCHEM J, V418, P379, DOI 10.1042/BJ20081318; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Fox EM, 2008, STEROIDS, V73, P1039, DOI 10.1016/j.steroids.2008.04.006; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Iglesias-Gato D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0280-2; Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Li YH, 2014, J BIOL CHEM, V289, P5097, DOI 10.1074/jbc.M113.533109; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Liu X, 2014, PATHOL RES PRACT, V210, P770, DOI 10.1016/j.prp.2014.05.008; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Mevissen TET, 2013, CELL, V154, P169, DOI 10.1016/j.cell.2013.05.046; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Myatt SS, 2014, ONCOGENE, V33, P4316, DOI 10.1038/onc.2013.546; Myatt SS, 2008, NAT REV CANCER, V8, P244, DOI 10.1038/nrc2223-c2; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakada S, 2010, NATURE, V466, P941, DOI 10.1038/nature09297; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Savarese DMF, 1997, J CLIN ONCOL, V15, P2981, DOI 10.1200/JCO.1997.15.8.2981; SINGH S, 1993, HUM GENET, V90, P635; Stanisic V, 2009, J BIOL CHEM, V284, P16135, DOI 10.1074/jbc.M109.007484; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Wang T, 2009, J MOL BIOL, V386, P1011, DOI 10.1016/j.jmb.2008.12.085; Weissman AM, 2011, NAT REV MOL CELL BIO, V12, P605, DOI 10.1038/nrm3173; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Zhou Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-258	37	91	94	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1433	1444		10.1038/onc.2015.208	http://dx.doi.org/10.1038/onc.2015.208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26148240	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000372196400009
J	Kim, J; Liu, Y; Qiu, M; Xu, Y				Kim, J.; Liu, Y.; Qiu, M.; Xu, Y.			Pluripotency factor Nanog is tumorigenic by deregulating DNA damage response in somatic cells	ONCOGENE			English	Article							CYCLE ARREST; P53; ACTIVATION; EXPRESSION; INVASION; ATM	The pluripotency gene Nanog is not expressed in normal adult tissues but is overexpressed in some human cancers. However, the tumorigenic roles of Nanog remain unclear. The ectopic expression of Nanog is not sufficient to induce spontaneous tumors in mice but can promote metastasis of established tumors by activating the expression of metastatic genes. The expression of Nanog in mouse skin activates tumor suppressor p53, leading to the differentiation of epidermal stem cells. In the absence of p53, Nanog induces spontaneous squamous cell carcinoma, identifying a novel role of Nanog in tumorigenesis. Therefore, the induction of p53 and differentiation in Nanog-expressing skin suppresses the tumorigenic activities of Nanog, which include the induction of DNA double-stranded break damage. Notably, Nanog interacts with the KRAB-associated protein 1 (KAP1) and inhibits its sumoylation activity, impairing KAP1-mediated chromatin remodeling, which is important for efficiently activating DNA damage response. In summary, Nanog is an oncogene with multiple roles in promoting tumorigenesis and metastasis.	[Kim, J.; Liu, Y.; Xu, Y.] Southern Med Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China; [Kim, J.; Qiu, M.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA	Southern Medical University - China; University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X	Chinese Ministry of Science and Technology [2012CB966900, 2013ZX10002008002]; CIRM [RC1-00148]	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); CIRM(California Institute for Regenerative Medicine)	We thank Dr Manando Nakasaki for help with skin analysis, Dr Colin Jamora for providing K14-cre transgenic mice, and the UCSD Cancer Center Histology Core for help with the histological analysis. This work was supported by grants from Chinese Ministry of Science and Technology (2012CB966900 and 2013ZX10002008002) and CIRM (RC1-00148).	Badeaux MA, 2013, CELL CYCLE, V12, P2395, DOI 10.4161/cc.25402; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chiu SJ, 2009, CHEM-BIOL INTERACT, V182, P173, DOI 10.1016/j.cbi.2009.08.019; Costa Y, 2013, NATURE, V495, P370, DOI 10.1038/nature11925; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Falk M, 2008, BBA-MOL CELL RES, V1783, P2398, DOI 10.1016/j.bbamcr.2008.07.010; Fischedick G, 2014, STEM CELL RES, V13, P300, DOI 10.1016/j.scr.2014.08.001; Gandarillas A, 2012, CELL CYCLE, V11, P4507, DOI 10.4161/cc.22529; Goodarzi AA, 2011, NAT STRUCT MOL BIOL, V18, P831, DOI 10.1038/nsmb.2077; Han JH, 2012, CANCER LETT, V321, P80, DOI 10.1016/j.canlet.2012.02.021; Ho BT, 2012, J BIOL CHEM, V287, P18656, DOI 10.1074/jbc.M111.322883; Ivanov AV, 2007, MOL CELL, V28, P823, DOI 10.1016/j.molcel.2007.11.012; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kim J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.87; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI200213563; Lin YL, 2011, MOL CELL BIOCHEM, V351, P109, DOI 10.1007/s11010-011-0717-5; Liu DP, 2010, NAT CELL BIOL, V12, P993, DOI 10.1038/ncb2100; Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moretto-Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Noh KH, 2012, J CLIN INVEST, V122, P4077, DOI 10.1172/JCI64057; Piazzolla D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5226; Piestun D, 2006, BIOCHEM BIOPH RES CO, V343, P279, DOI 10.1016/j.bbrc.2006.02.152; Santaliz-Ruiz LEIV, 2014, INT J CANCER, V135, P2741, DOI 10.1002/ijc.28690; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Siu MKY, 2013, ONCOGENE, V32, P3500, DOI 10.1038/onc.2012.363; Sun C, 2013, INT J BIOCHEM CELL B, V45, P1099, DOI 10.1016/j.biocel.2013.02.017; Takata H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075622; Theunissen TW, 2011, PHILOS T R SOC B, V366, P2222, DOI 10.1098/rstb.2011.0003; Thomson JA, 1998, CURR TOP DEV BIOL, V38, P133; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135	36	13	13	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1334	1340		10.1038/onc.2015.205	http://dx.doi.org/10.1038/onc.2015.205			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26073077				2022-12-28	WOS:000371763100014
J	Kuriyama, S; Yoshida, M; Yano, S; Aiba, N; Kohno, T; Minamiya, Y; Goto, A; Tanaka, M				Kuriyama, S.; Yoshida, M.; Yano, S.; Aiba, N.; Kohno, T.; Minamiya, Y.; Goto, A.; Tanaka, M.			LPP inhibits collective cell migration during lung cancer dissemination	ONCOGENE			English	Article							LIPOMA-PREFERRED PARTNER; N-CADHERIN EXPRESSION; MATRIX METALLOPROTEINASES; FOCAL ADHESION; VALPROIC ACID; METASTASIS; INVASION; REQUIRES; DOMAIN; ADENOCARCINOMA	Lipoma preferred partner (LPP) is a LIM domain protein, which has multiple functions as an actin-binding protein and a transcriptional coactivator, and it has been suggested that LPP has some roles in cell migration or invasion, however, its role in cancer cells remains to be elucidated. Here, we showed that LPP degraded N-cadherin in lung cancer, PC14PE6 cells via regulating the expression of matrix metalloproteinase 15 (MMP-15), and loss-of-LPP increases collective cell migration (CCM) and dissemination consequently. Knockdown of LPP and its functional partner, Etv5, markedly restores the full-length N-cadherin and increases cell-cell adhesion. We investigated the common target of LPP and Etv5, and found that MMP-15 is transcribed as their direct transcriptional target. Furthermore, MMP-15 could directly digest the N-cadherin extracellular domain. LPP knockdown in PC14PE6 cells increases N-cadherin-dependent CCM in the three-dimensional collagen gel invasion assays, and promoted the dissemination of cancer cells when they were orthotopically implanted in nude mice. Immunohistochemistry of lung adenocarcinoma specimens revealed the heterogeneity of LPP intensity and complementary expression of LPP and N-cadherin in the primary tumors. These findings suggest that loss-of-LPP, Etv5 or MMP-15 can be a prognostic marker of increasing malignancy.	[Kuriyama, S.; Aiba, N.; Tanaka, M.] Akita Univ, Grad Sch, Dept Mol Med & Biochem, Akita 0108543, Japan; [Kuriyama, S.; Yoshida, M.; Aiba, N.; Goto, A.; Tanaka, M.] Akita Univ, Fac Med, Akita 0108543, Japan; [Yoshida, M.; Goto, A.] Akita Univ, Grad Sch, Dept Cellular & Organ Pathol, Akita 0108543, Japan; [Yano, S.] Kanazawa Univ, Canc Res Inst, Canc Therapeut Dev Program, Div Med Oncol, Kanazawa, Ishikawa 920, Japan; [Kohno, T.] Natl Canc Res Ctr Inst, Div Genome Biol, Grp Dev Mol Diagnost & Individualized Therapy, Chiba, Japan; [Minamiya, Y.] Akita Univ, Dept Thoras Surg, Akita 0108543, Japan	Akita University; Akita University; Akita University; Kanazawa University; Akita University	Tanaka, M (corresponding author), Akita Univ, Dept Mol Med & Biochem, Hondo 1-1-1, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp	Kuriyama, Sei/AAV-2368-2020; Goto, Akiteru/P-5775-2014	Kuriyama, Sei/0000-0002-5502-7177; Goto, Akiteru/0000-0001-8776-9004	NICHD; JST KAKENHI [24700962, 25290042, 26640068]; MEXT KAKENHI [25111702]	NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); JST KAKENHI; MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Yuichiro Hamanaka for kindly providing the melanoma cell lines. The MNCD2 antibody developed by Takeichi and Matsunami was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of NICHD and maintained by Department of Biology, The University of Iowa, Iowa City, IA, USA. This work is supported by JST KAKENHI (grant number 24700962, SK; grant number 25290042, 26640068, MT) and MEXT KAKENHI (grant number 25111702, SK).	Asano K, 2004, J NEURO-ONCOL, V70, P3, DOI 10.1023/B:NEON.0000040811.14908.f2; Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008-5472.CAN-12-3775; Camand E, 2012, J CELL SCI, V125, P844, DOI 10.1242/jcs.087668; Carey MF, 2009, COLD SPRING HARB PRO, V114; Colas E, 2012, ONCOGENE, V31, P4778, DOI 10.1038/onc.2011.632; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Covington MD, 2006, AM J PHYSIOL-RENAL, V290, pF43, DOI 10.1152/ajprenal.00179.2005; Cui Zheng Yun, 2006, Cancer Res Treat, V38, P234, DOI 10.4143/crt.2006.38.4.234; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; de Launoit Y, 2006, BBA-REV CANCER, V1766, P79, DOI 10.1016/j.bbcan.2006.02.002; Doki Y, 1999, BRIT J CANCER, V79, P1121, DOI 10.1038/sj.bjc.6690178; Firlej V, 2008, J CELL SCI, V121, P3393, DOI 10.1242/jcs.027201; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gorenne I, 2003, AM J PHYSIOL-CELL PH, V285, pC674, DOI 10.1152/ajpcell.00608.2002; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grunewald TGP, 2009, TRANSL ONCOL, V2, P107, DOI 10.1593/tlo.09112; Guo BQ, 2006, MOL CELL BIOL, V26, P4529, DOI 10.1128/MCB.01667-05; Haeger A, 2014, BBA-GEN SUBJECTS, V1840, P2386, DOI 10.1016/j.bbagen.2014.03.020; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hegerfeldt Y, 2002, CANCER RES, V62, P2125; Ikebe D, 2007, GENES CELLS, V12, P197, DOI 10.1111/j.1365-2443.2007.01043.x; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kobayashi K, 2004, ONCOGENE, V23, P3089, DOI 10.1038/sj.onc.1207433; Kohutek ZA, 2009, J NEUROSCI, V29, P4605, DOI 10.1523/JNEUROSCI.5126-08.2009; Kuphal S, 2006, ONCOGENE, V25, P248, DOI 10.1038/sj.onc.1209054; Kuriyama S, 2014, J CELL BIOL, V206, P113, DOI 10.1083/jcb.201402093; Lettice LA, 2012, DEV CELL, V22, P459, DOI 10.1016/j.devcel.2011.12.010; Li B, 2003, J CELL SCI, V116, P1359, DOI 10.1242/jcs.00309; Li G, 2001, CANCER RES, V61, P3819; Maret D, 2010, NEOPLASIA, V12, P1066, DOI 10.1593/neo.10954; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Petit MMR, 2008, CIRC RES, V103, P61, DOI 10.1161/CIRCRESAHA.108.177436; Petit MMR, 2003, J BIOL CHEM, V278, P2157, DOI 10.1074/jbc.M206106200; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Shih WT, 2012, J CELL SCI, V125, P3661, DOI 10.1242/jcs.103861; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Tanaka M, 2012, J CELL SCI, V125, P4343, DOI 10.1242/jcs.104083; Theveneau E, 2010, DEV CELL, V19, P39, DOI 10.1016/j.devcel.2010.06.012; Wang Y, 2003, BBA-MOL CELL RES, V1593, P115, DOI 10.1016/S0167-4889(02)00349-X; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Yamaura T, 2000, NEOPLASIA, V2, P315, DOI 10.1038/sj.neo.7900098; Yano S, 1997, ONCOL RES, V9, P573; Zwolinska AK, 2012, ONCOGENE, V31, P3311, DOI 10.1038/onc.2011.507	52	29	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					952	964		10.1038/onc.2015.155	http://dx.doi.org/10.1038/onc.2015.155			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	26028032				2022-12-28	WOS:000370823300002
J	Adamo, P; Ladomery, MR				Adamo, P.; Ladomery, M. R.			The oncogene ERG: a key factor in prostate cancer	ONCOGENE			English	Review							TRANSCRIPTION FACTOR ERG; TMPRSS2-ERG GENE FUSION; ETS-RELATED GENE; DNA-BINDING MOTIF; HEMATOPOIETIC STEM-CELLS; T-LYMPHOBLASTIC LEUKEMIA; HUMAN MYELOID-LEUKEMIA; ANDROGEN RECEPTOR; SERINE-PROTEASE; CHROMOSOMAL TRANSLOCATION	ETS-related gene (ERG) is a member of the E-26 transformation-specific (ETS) family of transcription factors with roles in development that include vasculogenesis, angiogenesis, haematopoiesis and bone development. ERG's oncogenic potential is well known because of its involvement in Ewing's sarcoma and leukaemia. However, in the past decade ERG has become highly associated with prostate cancer development, particularly as a result of a gene fusion with the promoter region of the androgeninduced TMPRRSS2 gene. We review ERG's structure and function, and its role in prostate cancer. We discuss potential new therapies that are based on targeting ERG.	[Adamo, P.] Univ Leicester, Leicester Royal Infirm, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Ladomery, M. R.] Univ W England, Fac Hlth & Appl Sci, Dept Biol Biomed & Analyt Sci, Frenchay Campus,Coldharbour Lane, Bristol BS16 1QY, Avon, England	University of Leicester; University of West England	Ladomery, MR (corresponding author), Univ W England, Fac Hlth & Appl Sci, Dept Biol Biomed & Analyt Sci, Frenchay Campus,Coldharbour Lane, Bristol BS16 1QY, Avon, England.	Michael.Ladomery@uwe.ac.uk			Rotary Club of Bristol; Bristol Urological Institute; Funds for Women Graduates; University of the West of England, Bristol; Bristol Urological Institute [BUI256]	Rotary Club of Bristol; Bristol Urological Institute; Funds for Women Graduates; University of the West of England, Bristol; Bristol Urological Institute	Dr P Adamo was supported by the Rotary Club of Bristol, The Bristol Urological Institute, Funds for Women Graduates and the University of the West of England, Bristol. Dr MR Ladomery was supported by a grant from the Bristol Urological Institute (BUI256). We would also like to thank Dr Ian Wilson for providing constructive feedback.	Abate-Shen C, 2008, DIFFERENTIATION, V76, P717, DOI 10.1111/j.1432-0436.2008.00292.x; Anderson MK, 1999, DEVELOPMENT, V126, P3131; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bastus NC, 2010, CANCER RES, V70, P9544, DOI 10.1158/0008-5472.CAN-10-1638; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Becker-Santos DD, 2012, CARCINOGENESIS, V33, P2558, DOI 10.1093/carcin/bgs285; Berezovska OP, 2006, CELL CYCLE, V5, P1886; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876; Bertram S, 2010, J VIROL, V84, P10016, DOI 10.1128/JVI.00239-10; Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346; Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016; Birdsey GM, 2012, BLOOD, V119, P894, DOI 10.1182/blood-2011-04-350025; Bjorkman M, 2008, INT J CANCER, V123, P2774, DOI 10.1002/ijc.23885; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bottcher-Friebertshauser E, 2010, J VIROL, V84, P5605, DOI 10.1128/JVI.00140-10; Bohne A, 2009, LEUKEMIA RES, V33, P817, DOI 10.1016/j.leukres.2008.11.012; Bosco A, 2013, DEVELOPMENT, V140, P372, DOI 10.1242/dev.089094; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Bowen KA, 2009, ANTICANCER RES, V29, P4439; Brase JC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-507; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Buttice G, 1996, ONCOGENE, V13, P2297; Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328; Camuzeaux B, 2005, BIOCHEM BIOPH RES CO, V332, P1107, DOI 10.1016/j.bbrc.2005.05.057; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Carver BS, 2009, NATURE, V457, pE1, DOI 10.1038/nature07738; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Casey OM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041668; Cerveira N, 2006, NEOPLASIA, V8, P826, DOI 10.1593/neo.06427; Chatterjee P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060408; Chen YW, 2010, AM J PATHOL, V176, P2986, DOI 10.2353/ajpath.2010.090665; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; Cox MK, 2014, EXP CELL RES, V328, P410, DOI 10.1016/j.yexcr.2014.08.015; Coyne HJ, 2012, J MOL BIOL, V421, P67, DOI 10.1016/j.jmb.2012.05.010; Dai Mei-Jie, 2008, Zhonghua Yi Xue Za Zhi, V88, P669; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Deramaudt TB, 2001, GENE, V274, P169, DOI 10.1016/S0378-1119(01)00610-2; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; Fine SW, 2010, MODERN PATHOL, V23, P1325, DOI 10.1038/modpathol.2010.120; Fortson WS, 2011, INT J ONCOL, V39, P111, DOI 10.3892/ijo.2011.1014; Furusato B, 2010, PROSTATE CANCER P D, V13, P228, DOI 10.1038/pcan.2010.23; Furusato B, 2008, MODERN PATHOL, V21, P67, DOI 10.1038/modpathol.3800981; Garrett-Sinha LA, 2013, CELL MOL LIFE SCI, V70, P3375, DOI 10.1007/s00018-012-1243-7; Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Gopalan A, 2009, CANCER RES, V69, P1400, DOI 10.1158/0008-5472.CAN-08-2467; Gordanpour A, 2011, ANTICANCER RES, V31, P403; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Green SM, 2010, J BIOL CHEM, V285, P18496, DOI 10.1074/jbc.M109.096958; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Gutierrez-Hartmann A, 2007, TRENDS ENDOCRIN MET, V18, P150, DOI 10.1016/j.tem.2007.03.002; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hagen RM, 2014, AM J CLIN PATHOL, V142, P533, DOI 10.1309/AJCPH88QHXARISUP; Hagglof C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086824; HART AH, 1995, ONCOGENE, V10, P1423; Hart M, 2013, FEBS J, V280, P2105, DOI 10.1111/febs.12236; Hatesuer B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003774; Hawksworth D, 2010, PROSTATE CANCER P D, V13, P311, DOI 10.1038/pcan.2010.31; Heo SH, 2010, J CELL PHYSIOL, V224, P734, DOI 10.1002/jcp.22175; Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008-5472.CAN-06-1871; Hermans KG, 2009, CLIN CANCER RES, V15, P6398, DOI 10.1158/1078-0432.CCR-09-1176; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Hu Y, 2008, CLIN CANCER RES, V14, P4719, DOI 10.1158/1078-0432.CCR-08-0531; Huang KC, 2014, CLIN TRANSL ONCOL, V16, P973, DOI 10.1007/s12094-014-1182-x; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; Iwamoto M, 2007, DEV BIOL, V305, P40, DOI 10.1016/j.ydbio.2007.01.037; Iwamoto M, 2013, BIRTH DEFECTS RES C, V99, P192, DOI 10.1002/bdrc.21042; Jolma A, 2010, GENOME RES, V20, P861, DOI 10.1101/gr.100552.109; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; Kao CJ, 2014, ONCOGENE, V33, P2495, DOI 10.1038/onc.2013.200; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kim CA, 2003, TRENDS BIOCHEM SCI, V28, P625, DOI 10.1016/j.tibs.2003.11.001; Kim J, 2014, ONCOGENE, V33, P5183, DOI 10.1038/onc.2013.461; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Lapointe J, 2007, MODERN PATHOL, V20, P467, DOI 10.1038/modpathol.3800759; Larroux C, 2006, EVOL DEV, V8, P150, DOI 10.1111/j.1525-142X.2006.00086.x; Lathen C, 2014, CIRCULATION, V130, P1179, DOI 10.1161/CIRCULATIONAHA.113.007822; Lau DKW, 2012, PROTEIN SCI, V21, P1716, DOI 10.1002/pro.2151; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Laxman B, 2006, NEOPLASIA, V8, P885, DOI 10.1593/neo.06625; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Leinonen KA, 2013, CANCER EPIDEM BIOMAR, V22, P2333, DOI 10.1158/1055-9965.EPI-13-0333-T; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Lin BY, 1999, CANCER RES, V59, P4180; Liu WN, 2007, GENE CHROMOSOME CANC, V46, P972, DOI 10.1002/gcc.20482; Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617; Mackereth CD, 2004, J MOL BIOL, V342, P1249, DOI 10.1016/j.jmb.2004.07.094; Mani RS, 2011, CANCER RES, V71, P5387, DOI 10.1158/0008-5472.CAN-11-0876; Mani RS, 2009, SCIENCE, V326, P1230, DOI 10.1126/science.1178124; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; McLaughlin F, 2001, BLOOD, V98, P3332, DOI 10.1182/blood.V98.12.3332; Meadows SM, 2011, SEMIN CELL DEV BIOL, V22, P976, DOI 10.1016/j.semcdb.2011.09.009; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mehra R, 2007, CANCER RES, V67, P7991, DOI 10.1158/0008-5472.CAN-07-2043; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Mohamed AA, 2010, J CANCER, V1, P197; Mosquera JM, 2008, CLIN CANCER RES, V14, P3380, DOI 10.1158/1078-0432.CCR-07-5194; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Netto GJ, 2010, HISTOPATHOLOGY, V57, P633, DOI 10.1111/j.1365-2559.2010.03659.x; Ng AP, 2011, BLOOD, V118, P2454, DOI 10.1182/blood-2011-03-344739; Nhili R, 2013, NUCLEIC ACIDS RES, V41, P125, DOI 10.1093/nar/gks971; Nikolova-Krstevski V, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-72; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Owczarek CM, 2004, GENE, V324, P65, DOI 10.1016/j.gene.2003.09.047; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Pettersson A, 2012, CANCER EPIDEM BIOMAR, V21, P1497, DOI 10.1158/1055-9965.EPI-12-0042; PRASAD DDK, 1994, ONCOGENE, V9, P669; Rahim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019343; Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008-5472.CAN-05-0147; Rajput AB, 2007, J CLIN PATHOL, V60, P1238, DOI 10.1136/jcp.2006.043810; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; Regan MC, 2013, P NATL ACAD SCI USA, V110, P13374, DOI 10.1073/pnas.1301726110; Rickman DS, 2012, P NATL ACAD SCI USA, V109, P9083, DOI 10.1073/pnas.1112570109; Rickman DS, 2010, NEOPLASIA, V12, P1031, DOI 10.1593/neo.10866; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; Robert G, 2013, PROSTATE, V73, P113, DOI 10.1002/pros.22546; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Rouzier C, 2008, CANCER GENET CYTOGEN, V183, P21, DOI 10.1016/j.cancergencyto.2008.01.021; Rubin MA, 2006, LAB INVEST, V86, P1099, DOI 10.1038/labinvest.3700477; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Saramaki OR, 2008, CLIN CANCER RES, V14, P3395, DOI 10.1158/1078-0432.CCR-07-2051; Schachterle W, 2012, DEV BIOL, V361, P439, DOI 10.1016/j.ydbio.2011.10.023; Schwartzman J, 2011, EPIGENETICS-US, V6, P1248, DOI 10.4161/epi.6.10.17727; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Shao L, 2012, CLIN CANCER RES, V18, P6648, DOI 10.1158/1078-0432.CCR-12-2715; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Shwartz A, 2013, DEVELOPMENT, V140, P2746, DOI 10.1242/dev.093138; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Singareddy R, 2013, MOL CANCER RES, V11, P1349, DOI 10.1158/1541-7786.MCR-12-0705; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Soller W, 2006, EUR UROL SUPPL, V5, P789, DOI 10.1016/S1569-9056(06)61261-X; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sperone A, 2010, ATHEROSCLEROSIS, V213, pE17, DOI 10.1016/j.atherosclerosis.2010.08.039; Sreenath Taduru L, 2011, J Carcinog, V10, P37, DOI 10.4103/1477-3163.91122; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Taichman RS, 2002, CANCER RES, V62, P1832; Thangapazham R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-16; Thoms JAI, 2011, BLOOD, V117, P7079, DOI 10.1182/blood-2010-12-317990; Tian TV, 2014, ONCOGENE, V33, P2204, DOI 10.1038/onc.2013.176; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tsourlakis MC, 2014, AM J PATHOL, V184, P609, DOI 10.1016/j.ajpath.2013.11.007; Tsuzuki S, 2011, BLOOD, V117, P3858, DOI 10.1182/blood-2010-11-320515; Vanaja DK, 2003, CANCER RES, V63, P3877; Velaeti S, 2014, TUMOR BIOL, V35, P9597, DOI 10.1007/s13277-014-2250-0; Verger A, 2001, J BIOL CHEM, V276, P17181, DOI 10.1074/jbc.M010208200; Vijayaraj P, 2012, DEVELOPMENT, V139, P3973, DOI 10.1242/dev.081596; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wang S, 2014, P NATL ACAD SCI USA, V111, P4251, DOI 10.1073/pnas.1322198111; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066; Winnes M, 2007, ONCOL REP, V17, P1033; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Wu DY, 2011, TRENDS ENDOCRIN MET, V22, P474, DOI 10.1016/j.tem.2011.07.006; Wu LT, 2013, CANCER RES, V73, P6068, DOI 10.1158/0008-5472.CAN-13-0882; Xiao J, 2012, PROSTATE, V72, P1514, DOI 10.1002/pros.22501; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yang L, 2003, BIOCHEM J, V369, P651, DOI 10.1042/BJ20020854; Yeap LS, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-12; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yuan L, 2012, J BIOL CHEM, V287, P6582, DOI 10.1074/jbc.M111.300236; Yuan L, 2011, BLOOD, V118, P1145, DOI 10.1182/blood-2010-10-315275; Yuan P, 2009, GENE DEV, V23, P2507, DOI 10.1101/gad.1831909; Zammarchi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0049721; Zhang SL, 2010, DIAGN MOL PATHOL, V19, P151, DOI 10.1097/PDM.0b013e3181bb216a; Zhang XP, 2009, MOL CANCER THER, V8, P499, DOI 10.1158/1535-7163.MCT-08-0544; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	205	125	133	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					403	414		10.1038/onc.2015.109	http://dx.doi.org/10.1038/onc.2015.109			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25915839	Bronze			2022-12-28	WOS:000369056700001
J	Schmid, F; Wang, Q; Huska, MR; Andrade-Navarro, MA; Lemm, M; Fichtner, I; Dahlmann, M; Kobelt, D; Walther, W; Smith, J; Schlag, PM; Stein, U				Schmid, F.; Wang, Q.; Huska, M. R.; Andrade-Navarro, M. A.; Lemm, M.; Fichtner, I.; Dahlmann, M.; Kobelt, D.; Walther, W.; Smith, J.; Schlag, P. M.; Stein, U.			SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX PROTEIN; EXPRESSION ANALYSIS; MET; SPONDIN-2; MARKER; HGF	MACC1 (metastasis associated in colon cancer 1) is a prognostic biomarker for tumor progression, metastasis and survival of a variety of solid cancers including colorectal cancer (CRC). Here we aimed to identify the MACC1-induced transcriptome and key players mediating the MACC1-induced effects in CRC. We performed microarray analyses using CRC cells ectopically overexpressing MACC1. We identified more than 1300 genes at least twofold differentially expressed, including the gene SPON2 (Spondin 2) as 90-fold upregulated transcriptional target of MACC1. MACC1-dependent SPON2 expression regulation was validated on mRNA and protein levels in MACC1 high (endogenously or ectopically) and low (endogenously or by knockdown) expressing cells. Chromatin immunoprecipitation analysis demonstrated the binding of MACC1 to the gene promoter of SPON2. In cell culture, ectopic SPON2 overexpression induced cell viability, migration, invasion and colony formation in endogenously MACC1 and SPON2 low expressing cells, whereas SPON2 knockdown reduced proliferative, migratory and invasive abilities in CRC cells with high endogenous MACC1 and SPON2 expression. In intrasplenically transplanted NOD/SCID mice, metastasis induction was analyzed with control or SPON2-overexpressing CRC cells. Tumors with SPON2 overexpression induced liver metastasis (vs control animals without any metastases, P = 0.0036). In CRC patients, SPON2 expression was determined in primary tumors (stages I-III), and survival time was analyzed by Kaplan-Meier method. CRC patients with high SPON2 expressing primary tumors demonstrated 8 months shorter metastasis-free survival (MFS) compared with patients with low SPON2 levels (P = 0.053). Combining high levels of SPON2 and MACC1 improved the identification of high-risk patients with a 20-month shorter MFS vs patients with low biomarker expression. In summary, SPON2 is a transcriptional target of the metastasis gene MACC1. SPON2 induces cell motility in vitro and CRC metastasis in mice. In patients, SPON2 serves as prognostic indicator for CRC metastasis and survival, and might represent a promising target for therapeutic approaches.	[Schmid, F.; Wang, Q.; Dahlmann, M.; Kobelt, D.; Walther, W.; Smith, J.; Stein, U.] Charite, Expt & Clin Res Ctr, Robert Rossle Str 10, D-13125 Berlin, Germany; [Schmid, F.; Wang, Q.; Huska, M. R.; Andrade-Navarro, M. A.; Lemm, M.; Fichtner, I.; Dahlmann, M.; Kobelt, D.; Walther, W.; Smith, J.; Stein, U.] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany; [Schlag, P. M.] Charite Comprehens Canc Ctr, Berlin, Germany; [Stein, U.] German Canc Consortium DKTK, Heidelberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Stein, U (corresponding author), Charite, Expt & Clin Res Ctr, Robert Rossle Str 10, D-13125 Berlin, Germany.; Stein, U (corresponding author), Helmholtz Assoc, Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	ustein@mdc-berlin.de		Stein, Ulrike/0000-0001-7006-282X; Dahlmann, Mathias/0000-0002-0036-5283; Huska, Matthew/0000-0002-0912-745X; Walther, Wolfgang/0000-0003-2360-1370	German Cancer Consortium (DKTK)	German Cancer Consortium (DKTK)	We are thankful to Wolfgang Kemmner and his laboratory for the help with the microarray experiments. We thank Maria Stecklum and Nadine Basler for support with the in vivo bioluminescence imaging, and Jutta Aumann for assistance on expression analyses. We thank Manisha Juneja and Katharina Ilm for help with the combinatorial biomarker analysis in the CRC patients. We are grateful to Markus Niederstrasser for statistical advice. This work was supported by the German Cancer Consortium (DKTK).	Anderson GL, 2010, JNCI-J NATL CANCER I, V102, P26, DOI 10.1093/jnci/djp438; Arlt F, 2009, INT J BIOCHEM CELL B, V41, P2356, DOI 10.1016/j.biocel.2009.08.001; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Burock S, 2015, WORLD J GASTROENTERO, V21, P333, DOI 10.3748/wjg.v21.i1.333; Carvalho B, 2012, CELL ONCOL, V35, P53, DOI 10.1007/s13402-011-0065-1; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Edwards S, 2005, BRIT J CANCER, V92, P376, DOI 10.1038/sj.bjc.6602261; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Galimi F, 2011, CLIN CANCER RES, V17, P3146, DOI 10.1158/1078-0432.CCR-10-3377; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Hagemann C, 2013, NEURO-ONCOLOGY, V15, P1696, DOI 10.1093/neuonc/not136; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Ilm K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0316-2; Jia W, 2005, BLOOD, V106, P3854, DOI 10.1182/blood-2005-04-1658; Juneja M, 2013, MOL ONCOL, V7, P929, DOI 10.1016/j.molonc.2013.05.003; Koelzer VH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1150-z; Li H, 2006, EMBO J, V25, P4097, DOI 10.1038/sj.emboj.7601289; Lucarelli G, 2013, J UROLOGY, V190, P2271, DOI 10.1016/j.juro.2013.05.004; Manda R, 1999, GENOMICS, V61, P5, DOI 10.1006/geno.1999.5939; Neufeld G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006718; Nitsche U, 2012, ANN SURG, V256, P763, DOI 10.1097/SLA.0b013e318272de87; Parry R, 2005, CANCER RES, V65, P8397, DOI 10.1158/0008-5472.CAN-05-1203; Pichorner A, 2012, CLIN EXP METASTAS, V29, P573, DOI 10.1007/s10585-012-9472-6; Qian XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037225; Rajkumar T, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-45; Ridley AJ, 2001, J CELL SCI, V114, P2713; Romanuik TL, 2009, AM J PATHOL, V175, P2264, DOI 10.2353/ajpath.2009.080868; Sakurai A, 2012, CELL RES, V22, P23, DOI 10.1038/cr.2011.198; Schmid F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-49; Simon I, 2007, GYNECOL ONCOL, V106, P112, DOI 10.1016/j.ygyno.2007.03.007; Stein Ulrike, 2007, V176, P61; Stein U, 2013, EXPERT OPIN THER TAR, V17, P1039, DOI 10.1517/14728222.2013.815727; Stein U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049249; Stein U, 2011, NEOPLASIA, V13, P131, DOI 10.1593/neo.101172; Stein U, 2010, J MOL MED, V88, P11, DOI 10.1007/s00109-009-0537-1; Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Wagstaff L, 2011, FRONT BIOSCI-LANDMRK, V16, P1861, DOI 10.2741/3827; Wang Nina, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P312; Zhang Q, 2015, ONCOTARGET, V6, P15095, DOI 10.18632/oncotarget.3822	42	40	43	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5942	5952		10.1038/onc.2015.451	http://dx.doi.org/10.1038/onc.2015.451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	26686083				2022-12-28	WOS:000388509400002
J	Zheng, D; Gui, B; Gray, KP; Tinay, I; Rafiei, S; Huang, Q; Sweeney, CJ; Kibel, AS; Jia, L				Zheng, D.; Gui, B.; Gray, K. P.; Tinay, I.; Rafiei, S.; Huang, Q.; Sweeney, C. J.; Kibel, A. S.; Jia, L.			Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer	ONCOGENE			English	Article							RECEPTOR-MEDIATED TRANSCRIPTION; SERINE PROTEINASE-INHIBITORS; GRANULIN-EPITHELIN PRECURSOR; GROWTH-FACTOR; EXPRESSION; PROGRESSION; GENES; MODEL; OVEREXPRESSION; INFLAMMATION	Androgen receptor (AR)-mediated gene expression continues to have a critical role in promoting castration-resistant prostate cancer (CRPC) survival and growth even after androgen deprivation therapy. AR cistrome analyses in CRPC cells have identified a large number of AR target genes involved in proliferative and cell cycle-related functions, and hold promise for development of novel therapeutic approaches for CRPC. However, there is little understanding of how these genes function in vivo and what the clinical implications are. We previously reported that secretory leukocyte peptidase inhibitor (SLPI) is regulated by the AR in a ligand-independent manner in CRPC cells and required for CRPC cell proliferation under androgen-deprived conditions. SLPI is a secreted serine protease inhibitor, which is overexpressed in a number of cancers, including lung, breast and ovarian cancer, and involved in tumor progression. However, the oncogenic potential of SLPI in prostate cancer remains unknown. Here we provide the first evidence that SLPI is upregulated in a subset of CRPC cell lines and CRPC patient tumors. In addition, serum SLPI levels are significantly elevated in metastatic CRPC patients compared with hormone naive patients, raising the possibility that this could serve as a biomarker. We demonstrated that SLPI expression has functional significance, as it promotes CRPC cell survival and growth after androgen withdrawal in vivo and in vitro. Last, we demonstrated that the oncogenic effect of SLPI may be due to protection of growth factor progranulin from enzymatic cleavage or suppression of CRPC cell apoptosis independent of anti-protease activity of SLPI. These findings implicate SLPI as a potential biomarker of resistance to AR inhibition and therapeutic target for CRPC treatment.	[Zheng, D.; Huang, Q.] Washington Univ, Sch Med, Dept Med, Ctr Pharmacogen, St Louis, MO 63110 USA; [Gui, B.; Tinay, I.; Rafiei, S.; Kibel, A. S.; Jia, L.] Brigham & Womens Hosp, Dept Surg, Div Urol, 45 Francis St,ASB 2-3, Boston, MA 02115 USA; [Gui, B.; Tinay, I.; Rafiei, S.; Sweeney, C. J.; Kibel, A. S.; Jia, L.] Harvard Med Sch, 45 Francis St,ASB 2-3, Boston, MA 02115 USA; [Gray, K. P.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Gray, K. P.] Harvard Sch Publ Hlth, Boston, MA USA; [Sweeney, C. J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute	Jia, L (corresponding author), Brigham & Womens Hosp, Dept Surg, Div Urol, 45 Francis St,ASB 2-3, Boston, MA 02115 USA.; Jia, L (corresponding author), Harvard Med Sch, 45 Francis St,ASB 2-3, Boston, MA 02115 USA.	ljia@bwh.harvard.edu	Zheng, Dali/J-2973-2019	Zheng, Dali/0000-0003-2345-4040	Anthony DiNovi Fund; 'Turkiye Kanserle Savas Vakfi' Scholarship Program	Anthony DiNovi Fund; 'Turkiye Kanserle Savas Vakfi' Scholarship Program	This work was supported by Anthony DiNovi Fund. Ilker Tinay was partially supported by the 'Turkiye Kanserle Savas Vakfi' Scholarship Program.	American Cancer Society, 2015, CANC FACTS FIG 2015; Ameshima S, 2000, CANCER-AM CANCER SOC, V89, P1448, DOI 10.1002/1097-0142(20001001)89:7<1448::AID-CNCR6>3.0.CO;2-Q; Bernard B, 2015, CURR UROL REP, V16, DOI 10.1007/s11934-015-0488-8; Bouchard D, 2006, LANCET ONCOL, V7, P167, DOI 10.1016/S1470-2045(06)70579-4; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Cheng WL, 2008, INT J CANCER, V123, P1787, DOI 10.1002/ijc.23746; Chopra DP, 2004, CANCER LETT, V203, P145, DOI 10.1016/j.canlet.2003.09.016; Davis JS, 2011, MOL ENDOCRINOL, V25, P611, DOI 10.1210/me.2010-0312; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Decker KF, 2012, NUCLEIC ACIDS RES, V40, P10765, DOI 10.1093/nar/gks888; Devoogdt N, 2003, P NATL ACAD SCI USA, V100, P5778, DOI 10.1073/pnas.1037154100; Devoogdt N, 2009, CANCER SCI, V100, P434, DOI 10.1111/j.1349-7006.2009.01076.x; Flavin R, 2014, CLIN CANCER RES, V20, P4904, DOI 10.1158/1078-0432.CCR-13-1341; Gipson TS, 1999, J IMMUNOL, V162, P3653; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; HIGASHIYAMA M, 1995, CANCER-AM CANCER SOC, V76, P1368, DOI 10.1002/1097-0142(19951015)76:8<1368::AID-CNCR2820760812>3.0.CO;2-N; Ho JC, 2008, HEPATOLOGY, V47, P1524, DOI 10.1002/hep.22191; Hoskins E, 2011, GYNECOL ONCOL, V122, P656, DOI 10.1016/j.ygyno.2011.04.052; Hough CD, 2000, CANCER RES, V60, P6281; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jia L, 2006, MOL CELL BIOL, V26, P7331, DOI 10.1128/MCB.00581-06; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kataoka H, 2002, PATHOL INT, V52, P89, DOI 10.1046/j.1440-1827.2002.01320.x; Kluger HM, 2005, CANCER RES, V65, P5578, DOI 10.1158/0008-5472.CAN-05-0108; Kluger HM, 2004, LAB INVEST, V84, P320, DOI 10.1038/labinvest.3700044; Lee ECY, 2003, CELL DEATH DIFFER, V10, P761, DOI 10.1038/sj.cdd.4401228; Lentsch AB, 1999, GASTROENTEROLOGY, V117, P953, DOI 10.1016/S0016-5085(99)70355-0; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lovat F, 2009, CARCINOGENESIS, V30, P861, DOI 10.1093/carcin/bgp050; Lowe AW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000323; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; Monami G, 2009, AM J PATHOL, V174, P1037, DOI 10.2353/ajpath.2009.080735; Nukiwa T, 2008, CANCER SCI, V99, P849, DOI 10.1111/j.1349-7006.2008.00772.x; Pan CX, 2004, CLIN CANCER RES, V10, P1333, DOI 10.1158/1078-0432.CCR-1123-03; Rasool N, 2010, CLIN CANCER RES, V16, P600, DOI 10.1158/1078-0432.CCR-09-1979; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Simpkins FA, 2008, CARCINOGENESIS, V29, P466, DOI 10.1093/carcin/bgm212; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Song XY, 1999, J EXP MED, V190, P535, DOI 10.1084/jem.190.4.535; Taggart CC, 2005, J EXP MED, V202, P1659, DOI 10.1084/jem.20050768; Tangkeangsirisin W, 2004, CANCER RES, V64, P1737, DOI 10.1158/0008-5472.CAN-03-2364; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; THALMANN GN, 1994, CANCER RES, V54, P2577; Thompson M, 2008, PROSTATE, V68, P1248, DOI 10.1002/pros.20792; Tomlins SA, 2008, CANCER CELL, V13, P519, DOI 10.1016/j.ccr.2008.04.016; Treda CJ, 2014, CARCINOGENESIS, V35, P896, DOI 10.1093/carcin/bgt382; Tsukishiro S, 2005, GYNECOL ONCOL, V96, P516, DOI 10.1016/j.ygyno.2004.10.036; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang DP, 2009, CANCER RES, V69, P9448, DOI 10.1158/0008-5472.CAN-09-1903; Zelvyte I, 2004, ANTICANCER RES, V24, P241; Zheng DL, 2013, MOL CANCER RES, V11, P482, DOI 10.1158/1541-7786.MCR-12-0520; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	59	22	23	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4807	4815		10.1038/onc.2016.13	http://dx.doi.org/10.1038/onc.2016.13			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876202				2022-12-28	WOS:000383324700013
J	Levy, P; Bartosch, B				Levy, P.; Bartosch, B.			Metabolic reprogramming: a hallmark of viral oncogenesis	ONCOGENE			English	Review							HUMAN CYTOMEGALOVIRUS-INFECTION; SARCOMA-ASSOCIATED HERPESVIRUS; EPSTEIN-BARR-VIRUS; HPV-16 E7 ONCOPROTEIN; FATTY-ACID SYNTHESIS; ATP CITRATE LYASE; KINASE TYPE M2; HUMAN-PAPILLOMAVIRUS; PYRUVATE-KINASE; KAPOSIS-SARCOMA	More than 1 in 10 cases of cancer in the world are due to chronic viral infections. Viruses induce oncogenesis by targeting the same pathways known to be responsible for neoplasia in tumor cells, such as control of cell cycle progression, cell migration, proliferation and evasion from cell death and the host's immune defense. In addition, metabolic reprogramming has been identified over a century ago as a requirement for growth of transformed cells. Renewed interest in this topic has emerged recently with the discovery that basically all metabolic changes in tumor cells are finely orchestrated by oncogenes and tumor suppressors. Indeed, cancer cells activate biosynthetic pathways in order to provide them with sufficient levels of energy and building blocks to proliferate. Interestingly, viruses introduce into their host cells similar metabolic adaptations, and importantly, it seems that they depend on these changes for their persistence and amplification. The central carbon metabolism, for example, is not only frequently altered in tumor cells but also modulated by human papillomavirus, hepatitis B and C viruses, Epstein-Barr virus and Kaposi's Sarcoma-associated virus. Moreover, adenoviruses (Ad) and human cytomegalovirus, which are not directly oncogenic but present oncomodulatory properties, also divert cellular metabolism in a tumor cell-like mnner. Thus, metabolic reprogramming appears to be a hallmark of viral infection and provides an interesting therapeutic target, in particular, for oncogenic viruses. Therapeutic targeting of metabolic pathways may not only allow to eliminate or control the viral infection but also to prevent virus-induced carcinogenesis.	[Levy, P.; Bartosch, B.] Univ Lyon, Canc Res Ctr Lyon, Inserm U1052, 151 Cours Albert Thomas, F-69434 Lyon, France; [Bartosch, B.] DevWeCan Labs Excellence Network Labex, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Bartosch, B (corresponding author), Univ Lyon, Canc Res Ctr Lyon, Inserm U1052, 151 Cours Albert Thomas, F-69434 Lyon, France.	Birke.Bartosch@inserm.fr	Bartosch, Birke/I-7255-2018; Levy, Pierre/AAR-4370-2020	Bartosch, Birke/0000-0001-6354-4660; Levy, Pierre/0000-0003-3213-0080	French National Agency for AIDS and Viral Hepatitis Research [14370]; Comite de Savoie de la Ligue contre le cancer [RAB12023CCA]; Agence Nationale de Recherche; DevWeCan French Laboratories of Excellence Network (Labex) [ANR-10-LABX-61]; OpeRa IHU program [ANR-10-IBHU-004]; Region Rhone-Alpes	French National Agency for AIDS and Viral Hepatitis Research; Comite de Savoie de la Ligue contre le cancer; Agence Nationale de Recherche(French National Research Agency (ANR)); DevWeCan French Laboratories of Excellence Network (Labex); OpeRa IHU program; Region Rhone-Alpes(Region Auvergne-Rhone-Alpes)	This work was supported by the French National Agency for AIDS and Viral Hepatitis Research (14370), Comite de Savoie de la Ligue contre le cancer (RAB12023CCA), Agence Nationale de Recherche, the Region Rhone-Alpes, DevWeCan French Laboratories of Excellence Network (Labex, Grant ANR-10-LABX-61) and OpeRa IHU program (GRANT ANR-10-IBHU-004).	Amako Y, 2015, J VIROL, V89, P4092, DOI 10.1128/JVI.01653-14; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Bard-Chapeau EA, 2014, NAT GENET, V46, P24, DOI 10.1038/ng.2847; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019; Bhatt AP, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00401; Bhatt AP, 2012, P NATL ACAD SCI USA, V109, P11818, DOI 10.1073/pnas.1205995109; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Birungi G, 2010, J PROTEOME RES, V9, P6523, DOI 10.1021/pr100727m; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Bodily JM, 2011, CANCER RES, V71, P1187, DOI 10.1158/0008-5472.CAN-10-2626; Bugianesi E, 2012, J HEPATOL, V56, pS56, DOI 10.1016/S0168-8278(12)60007-5; Cai QL, 2006, PLOS PATHOG, V2, P1002, DOI 10.1371/journal.ppat.0020116; Cai Q, 2007, J VIROL, V81, P10413, DOI 10.1128/JVI.00611-07; Carroll PA, 2006, J VIROL, V80, P10802, DOI 10.1128/JVI.00673-06; Cavallin LE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004154; Chambers JW, 2010, J VIROL, V84, P1867, DOI 10.1128/JVI.02123-09; Cinati J, 2004, TRENDS MOL MED, V10, P19, DOI 10.1016/j.molmed.2003.11.002; Claus C, 2014, ARCH VIROL, V159, P1267, DOI 10.1007/s00705-013-1841-1; Clippinger AJ, 2011, J VIROL, V85, P9369, DOI 10.1128/JVI.05102-11; Cobbs CS, 2002, CANCER RES, V62, P3347; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Darekar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042072; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; De Clercq E, 2004, NAT REV MICROBIOL, V2, P704, DOI 10.1038/nrmicro975; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Delgado T, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002866; Delgado T, 2010, P NATL ACAD SCI USA, V107, P10696, DOI 10.1073/pnas.1004882107; DeVita VT, 2008, CANCER RES, V68, P8643, DOI 10.1158/0008-5472.CAN-07-6611; Diamond DL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000719; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; El-Bacha T, 2013, INT J BIOCHEM CELL B, V45, P41, DOI 10.1016/j.biocel.2012.09.021; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Fajas L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00004; Fan J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.65; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Fontaine KA, 2014, J VIROL, V88, P4366, DOI 10.1128/JVI.03134-13; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Gameiro PA, 2013, CELL METAB, V17, P372, DOI 10.1016/j.cmet.2013.02.002; Gandhi MK, 2004, LANCET INFECT DIS, V4, P725, DOI 10.1016/S1473-3099(04)01202-2; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; Garcia-Cao I, 2012, CELL, V149, P49, DOI 10.1016/j.cell.2012.02.030; Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388; Graham F.L., 1984, ADENOVIRUSES, P339; Griffiths PD, 2012, LANCET INFECT DIS, V12, P790, DOI 10.1016/S1473-3099(12)70197-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Henken FE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-71; Hollenbaugh JA, 2011, VIROLOGY, V415, P153, DOI 10.1016/j.virol.2011.04.007; Jones JL, 1999, J ACQ IMMUN DEF SYND, V21, pS11; Kaarbo M, 2011, MITOCHONDRION, V11, P935, DOI 10.1016/j.mito.2011.08.008; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Karki R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001331; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kikuchi H, 2009, CANCER RES, V69, P8499, DOI 10.1158/0008-5472.CAN-09-2213; Kim JE, 2004, DIABETES, V53, P2748, DOI 10.2337/diabetes.53.11.2748; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Kong K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004102; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; LANDINI MP, 1984, J GEN VIROL, V65, P1229, DOI 10.1099/0022-1317-65-7-1229; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Lemon SM, 2012, GASTROENTEROLOGY, V142, P1274, DOI 10.1053/j.gastro.2012.01.045; Lenaerts L, 2008, REV MED VIROL, V18, P357, DOI 10.1002/rmv.589; Li HD, 2015, SCI REP-UK, V5, DOI 10.1038/srep08421; Li QS, 2013, NAT MED, V19, P722, DOI 10.1038/nm.3190; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maehama T, 1998, INT J CANCER, V76, P639, DOI 10.1002/(SICI)1097-0215(19980529)76:5<639::AID-IJC5>3.0.CO;2-R; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Matsuoka M, 2011, ONCOGENE, V30, P1379, DOI 10.1038/onc.2010.537; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; McArdle J, 2011, J VIROL, V85, P705, DOI 10.1128/JVI.01557-10; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Michaelis M, 2009, NEOPLASIA, V11, P1, DOI 10.1593/neo.81178; Miller G, 2009, SCIENCE, V323, P30, DOI 10.1126/science.323.5910.30; Molinolo AA, 2012, CLIN CANCER RES, V18, P2558, DOI 10.1158/1078-0432.CCR-11-2824; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Morrish F, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014225; Mukai R, 2014, ONCOGENE, V33, P2317, DOI 10.1038/onc.2013.181; Munger J, 2008, NAT BIOTECHNOL, V26, P1179, DOI 10.1038/nbt.1500; Munger J, 2006, PLOS PATHOG, V2, P1165, DOI 10.1371/journal.ppat.0020132; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Na TY, 2009, HEPATOLOGY, V49, P1122, DOI 10.1002/hep.22740; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; Nasimuzzaman M, 2007, J VIROL, V81, P10249, DOI 10.1128/JVI.00763-07; Negro F, 2014, J HEPATOL, V61, pS69, DOI 10.1016/j.jhep.2014.08.003; Negro F, 2010, GUT, V59, P1279, DOI 10.1136/gut.2009.192732; Nicolay BN, 2013, CURR OPIN CELL BIOL, V25, P735, DOI 10.1016/j.ceb.2013.07.012; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Pim D, 2005, ONCOGENE, V24, P7830, DOI 10.1038/sj.onc.1208935; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Price RL, 2013, CANCER RES, V73, P3441, DOI 10.1158/0008-5472.CAN-12-3846; Prins RM, 2008, NEW ENGL J MED, V359, P539, DOI 10.1056/NEJMc0804818; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; RACKER E, 1972, AM SCI, V60, P56; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Ramiere C, 2014, J VIROL, V88, P3246, DOI 10.1128/JVI.02862-13; Rickinson AB, 2014, SEMIN CANCER BIOL, V26, P99, DOI 10.1016/j.semcancer.2014.04.004; Ripoli M, 2010, J VIROL, V84, P647, DOI 10.1128/JVI.00769-09; Ritter JB, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-61; Rogers PM, 2008, DIABETES, V57, P2321, DOI 10.2337/db07-1311; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Samanta M, 2003, J UROLOGY, V170, P998, DOI 10.1097/01.ju.0000080263.46164.97; Sanchez EL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005052; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shin YC, 2008, CANCER RES, V68, P1751, DOI 10.1158/0008-5472.CAN-07-2766; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10; Spencer CM, 2011, J VIROL, V85, P5814, DOI 10.1128/JVI.02630-10; Sripadi P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012590; Straus S.E., 1984, ADENOVIRUSES, P451, DOI [DOI 10.1007/978-1-4684-7935-5_11, 10.1007/978-1-4684-7935-5_11]; Takahashi M, 2013, ANTIVIR RES, V99, P238, DOI 10.1016/j.antiviral.2013.06.016; TANAKA S, 1975, J VIROL, V15, P297, DOI 10.1128/JVI.15.2.297-304.1975; Tang XD, 2007, CLIN CANCER RES, V13, P2568, DOI 10.1158/1078-0432.CCR-06-2704; Taylor GS, 2011, CANCER LETT, V305, P263, DOI 10.1016/j.canlet.2010.08.019; Teng CF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122373; Teng CF, 2015, J VIROL, V89, P605, DOI 10.1128/JVI.02363-14; Terry LJ, 2012, P NATL ACAD SCI USA, V109, P3071, DOI 10.1073/pnas.1200494109; Thai M, 2014, CELL METAB, V19, P694, DOI 10.1016/j.cmet.2014.03.009; Tommasino M, 2003, HUM MUTAT, V21, P307, DOI 10.1002/humu.10178; Treins C, 2006, BIOCHEM BIOPH RES CO, V342, P1197, DOI 10.1016/j.bbrc.2006.02.088; Uldrick TS, 2011, CANCER LETT, V305, P150, DOI 10.1016/j.canlet.2011.02.006; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Vastag L, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002124; Vazquez A, 2013, CANCER RES, V73, P478, DOI 10.1158/0008-5472.CAN-12-3709; Vogt PK, 2012, NAT REV CANCER, V12, P639, DOI 10.1038/nrc3320; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang ZQ, 2010, INT J OBESITY, V34, P1355, DOI 10.1038/ijo.2010.77; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wu XY, 2008, FEBS LETT, V582, P2155, DOI 10.1016/j.febslet.2008.05.033; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; You XN, 2013, CARCINOGENESIS, V34, P1644, DOI 10.1093/carcin/bgt089; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yu YJ, 2014, P NATL ACAD SCI USA, V111, P1951, DOI 10.1073/pnas.1310779111; Yu YJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003266; Yu YJ, 2012, J VIROL, V86, P2942, DOI 10.1128/JVI.06467-11; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Yurochko AD, 2008, CURR TOP MICROBIOL, V325, P205; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	177	29	33	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4155	4164		10.1038/onc.2015.479	http://dx.doi.org/10.1038/onc.2015.479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26686092	Bronze			2022-12-28	WOS:000382149800001
J	Somarelli, JA; Schaeffer, D; Marengo, MS; Bepler, T; Rouse, D; Ware, KE; Hish, AJ; Zhao, Y; Buckley, AF; Epstein, JI; Armstrong, AJ; Virshup, DM; Garcia-Blanco, MA				Somarelli, J. A.; Schaeffer, D.; Marengo, M. S.; Bepler, T.; Rouse, D.; Ware, K. E.; Hish, A. J.; Zhao, Y.; Buckley, A. F.; Epstein, J. I.; Armstrong, A. J.; Virshup, D. M.; Garcia-Blanco, M. A.			Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ALTERNATIVE SPLICING REPORTERS; E-CADHERIN; IN-VIVO; PROSTATE-CANCER; TRANSGENIC MICE; DOWN-REGULATION; CELL CARCINOMA; BREAST-CANCER; COLONIZATION	The cascade that culminates in macrometastases is thought to be mediated by phenotypic plasticity, including epithelial-mesenchymal and mesenchymal-epithelial transitions (EMT and MET). Although there is substantial support for the role of EMT in driving cancer cell invasion and dissemination, much less is known about the importance of MET in the later steps of metastatic colonization. We created novel reporters, which integrate transcriptional and post-transcriptional regulation, to test whether MET is required for metastasis in multiple in vivo cancer models. In a model of carcinosarcoma, metastasis occurred via an MET-dependent pathway; however, in two prostate carcinoma models, metastatic colonization was MET independent. Our results provide evidence for both MET-dependent and MET-independent metastatic pathways.	[Somarelli, J. A.; Schaeffer, D.; Marengo, M. S.; Bepler, T.; Ware, K. E.; Garcia-Blanco, M. A.] Duke Univ, Med Ctr, Ctr RNA Biol, Durham, NC 27708 USA; [Somarelli, J. A.; Schaeffer, D.; Marengo, M. S.; Bepler, T.; Ware, K. E.; Garcia-Blanco, M. A.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA; [Rouse, D.] Duke Univ, Med Ctr, Dept Lab Anim Resources, Durham, NC USA; [Hish, A. J.; Armstrong, A. J.] Duke Univ, Med Ctr, Dept Med, Duke Canc Inst, Durham, NC 27710 USA; [Zhao, Y.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA; [Buckley, A. F.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Epstein, J. I.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Epstein, J. I.] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA; [Epstein, J. I.] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA; [Armstrong, A. J.] Duke Univ, Med Ctr, Solid Tumor Program, Durham, NC USA; [Armstrong, A. J.] Duke Univ, Med Ctr, Duke Prostate Ctr, Duke Canc Inst, Durham, NC USA; [Virshup, D. M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Garcia-Blanco, M. A.] Duke Univ, Med Ctr, Duke Canc Inst, Program Mol Genet & Genom, Durham, NC USA; [Garcia-Blanco, M. A.] Univ Texas Med Branch, Dept Biochem & Mol Biol, 108 BSB, Galveston, TX 77555 USA; [Marengo, M. S.] Monsanto Co, Trait Delivery Program, Durham Site, Durham, NC USA; [Bepler, T.] MIT, Computat & Syst Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Duke University; National University of Singapore; Duke University; University of Texas System; University of Texas Medical Branch Galveston; Monsanto; Massachusetts Institute of Technology (MIT)	Somarelli, JA (corresponding author), Duke Univ, Med Ctr, Ctr RNA Biol, Durham, NC 27708 USA.; Garcia-Blanco, MA (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 108 BSB, Galveston, TX 77555 USA.	jason.somarelli@duke.edu; maragarc@utmb.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Bepler, Tristan/0000-0001-5595-9954; Buckley, Anne/0000-0003-1209-5791	National Institutes of Health (NIH) grant [R01 5R01-CA127727]; American Cancer Society Post-doctoral Fellowship [PF-11-036-01-DDC]; NIH T32 Training Grant [5T32CA009111]; NIH NRSA postdoctoral fellowship [F32-CA165482]; NIH NRSA Fellowship [1F32CA142095]; Duke Cancer Institute; Department of Orthopedics; Genitourinary Oncology Laboratory; NATIONAL CANCER INSTITUTE [F32CA165482, F32CA142095, T32CA009111, R01CA127727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063090] Funding Source: NIH RePORTER	National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society Post-doctoral Fellowship(American Cancer Society); NIH T32 Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH NRSA postdoctoral fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH NRSA Fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Duke Cancer Institute; Department of Orthopedics; Genitourinary Oncology Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health (NIH) grant R01 5R01-CA127727 to MAGB, American Cancer Society Post-doctoral Fellowship #PF-11-036-01-DDC to JAS, NIH T32 Training Grant #5T32CA009111 and an NIH NRSA postdoctoral fellowship (F32-CA165482) to DS, and NIH NRSA Fellowship 1F32CA142095 to MSM. JAS acknowledges support from the Duke Cancer Institute, The Department of Orthopedics and the Genitourinary Oncology Laboratory. We would like to acknowledge Dr Sebastian Oltean (Bristol University, UK) for his suggestion to develop the lineage-tracing reporter. We would also like to thank Dr Shelton Bradrick for helpful discussions. We acknowledge the Duke University Animal Pathology Core Facility, the Duke University Flow Cytometry Shared Resource and the Duke University Light Microscopy Core Facility.	Bonano VI, 2007, NAT PROTOC, V2, P2166, DOI 10.1038/nprot.2007.292; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; Chao Y, 2012, CANCER MICROENVIRON, V5, P19, DOI 10.1007/s12307-011-0085-4; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; De Gasperi R, 2008, GENESIS, V46, P308, DOI 10.1002/dvg.20400; Gao Y, 2015, ONCOTARGET, V6, P7828, DOI 10.18632/oncotarget.3488; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Han KS, 2015, MOL CANCER THER, V14, P1024, DOI 10.1158/1535-7163.MCT-14-0771; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Khan S, 2015, INT J BIOCHEM CELL B, V58, P1, DOI 10.1016/j.biocel.2014.10.028; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kurahara H, 2012, J SURG ONCOL, V105, P655, DOI 10.1002/jso.23020; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Oltean S, 2008, CLIN EXP METASTAS, V25, P611, DOI 10.1007/s10585-008-9186-y; Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103; Putzke AP, 2011, AM J PATHOL, V179, P400, DOI 10.1016/j.ajpath.2011.03.028; SAUER B, 1990, New Biologist, V2, P441; Schulten HJ, 2008, INT J GYNECOL CANCER, V18, P339, DOI 10.1111/j.1525-1438.2007.01004.x; Somarelli JA, 2013, RNA, V19, P116, DOI 10.1261/rna.035097.112; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wagner Eric J, 2004, Methods Mol Biol, V257, P29, DOI 10.1385/1-59259-750-5:029; Weinberg RA, 2014, CELL, V157, P267, DOI 10.1016/j.cell.2014.03.004; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Yori JL, 2010, J BIOL CHEM, V285, P16854, DOI 10.1074/jbc.M110.114546; Zhu YD, 2015, INTEGR CANCER THER, V14, P271, DOI 10.1177/1534735415572880	30	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4302	4311		10.1038/onc.2015.497	http://dx.doi.org/10.1038/onc.2015.497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26751776	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000382152100002
J	Tesio, M; Trinquand, A; Macintyre, E; Asnafi, V				Tesio, M.; Trinquand, A.; Macintyre, E.; Asnafi, V.			Oncogenic PTEN functions and models in T-cell malignancies	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; TUMOR-SUPPRESSOR PTEN; DEFICIENT MICE; CANCER SUSCEPTIBILITY; PHOSPHATASE-ACTIVITY; INITIATING CELLS; PROSTATE-CANCER; MESSENGER-RNAS; PTEN(+/-) MICE	PTEN is a protein phosphatase that is crucial to prevent the malignant transformation of T-cells. Although a numerous mechanisms regulate its expression and function, they are often altered in T-cell acute lymphoblastic leukaemias and T-cell lymphomas. As such, PTEN inactivation frequently occurs in these malignancies, where it can be associated with chemotherapy resistance and poor prognosis. Different Pten knockout models recapitulated the development of T-cell leukaemia/lymphoma, demonstrating that PTEN loss is at the center of a complex oncogenic network that sustains and drives tumorigenesis via the activation of multiple signalling pathways. These aspects and their therapeutic implications are discussed in this review.	Univ Paris Descartes Sorbonne Cite, INEM, INSERM U1151, Paris, France; Hop Necker Enfants Malad, AP HP, Lab Oncohematol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Asnafi, V (corresponding author), Univ Paris 5 Descartes, Hop Necker Enfants Malad, Hematol Lab, INEM INSERM U1151, 149 Rue Sevres, F-75015 Paris, France.	vahid.asnafi@nck.aphp.fr	Trinquand, Amélie/AAV-7203-2021	Macintyre-Davi, Elizabeth Anne/0000-0003-0520-0493; TESIO, Melania/0000-0001-9291-0797	'Fondation de France' Fellowship; INCa (Institut National du Cancer: 'Soutien a la Recherche Translationnelle')	'Fondation de France' Fellowship; INCa (Institut National du Cancer: 'Soutien a la Recherche Translationnelle')	This work has been supported by a 'Fondation de France' Fellowship to MT and a grant from INCa (Institut National du Cancer: 'Soutien a la Recherche Translationnelle 2012') to AT.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Bandapalli OR, 2013, HAEMATOLOGICA, V98, P928, DOI 10.3324/haematol.2012.073585; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Blackburn JS, 2014, CANCER CELL, V25, P366, DOI 10.1016/j.ccr.2014.01.032; Bonnet M, 2011, BLOOD, V117, P6650, DOI 10.1182/blood-2011-02-336842; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Chiarini F, 2008, LEUKEMIA, V22, P1106, DOI 10.1038/leu.2008.79; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Clappier E, 2011, J EXP MED, V208, P653, DOI 10.1084/jem.20110105; Cristofoletti C, 2013, BLOOD, V122, P3511, DOI 10.1182/blood-2013-06-510578; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dose M, 2014, P NATL ACAD SCI USA, V111, P391, DOI 10.1073/pnas.1315752111; Fala F, 2008, MOL PHARMACOL, V74, P884, DOI 10.1124/mol.108.047639; Finlay DK, 2009, J EXP MED, V206, P2441, DOI 10.1084/jem.20090219; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Gazzola A, 2009, HAEMATOL-HEMATOL J, V94, P1036, DOI 10.3324/haematol.2009.006718; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gothert JR, 2005, BLOOD, V105, P2724, DOI 10.1182/blood-2004-08-3037; Grimaldi C, 2012, LEUKEMIA, V26, P91, DOI 10.1038/leu.2011.269; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Guo W, 2011, P NATL ACAD SCI USA, V108, P1409, DOI 10.1073/pnas.1006937108; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; Hagenbeek TJ, 2008, LEUKEMIA, V22, P608, DOI 10.1038/sj.leu.2405056; Hagenbeek TJ, 2004, J EXP MED, V200, P883, DOI 10.1084/jem.20040495; Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Jenkinson S, 2016, LEUKEMIA, V30, P39, DOI 10.1038/leu.2015.206; Johnsson P, 2013, NAT STRUCT MOL BIOL, V20, P440, DOI 10.1038/nsmb.2516; Jotta PY, 2010, LEUKEMIA, V24, P239, DOI 10.1038/leu.2009.209; Kalaitzidis D, 2012, CELL STEM CELL, V11, P429, DOI 10.1016/j.stem.2012.06.009; Kharas MG, 2010, BLOOD, V115, P1406, DOI 10.1182/blood-2009-06-229443; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; La Starza R, 2014, BLOOD, V124, P3577, DOI 10.1182/blood-2014-06-578856; Lee JY, 2010, CELL STEM CELL, V7, P593, DOI 10.1016/j.stem.2010.09.015; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liang H, 2014, CELL METAB, V19, P836, DOI 10.1016/j.cmet.2014.03.023; Liu XH, 2010, J CLIN INVEST, V120, P2497, DOI 10.1172/JCI42382; Locke FL, 2013, J IMMUNOL, V191, P1677, DOI 10.4049/jimmunol.1202018; Magee JA, 2012, CELL STEM CELL, V11, P415, DOI 10.1016/j.stem.2012.05.026; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037; Medyouf H, 2010, BLOOD, V115, P1175, DOI 10.1182/blood-2009-04-214718; Mendes RD, 2014, BLOOD, V124, P567, DOI 10.1182/blood-2014-03-562751; Miething C, 2014, NATURE, V510, P402, DOI 10.1038/nature13239; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Naguib A, 2015, MOL CELL, V58, P255, DOI 10.1016/j.molcel.2015.03.011; Nakahata S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4393; Newton RH, 2015, BLOOD, V125, P852, DOI 10.1182/blood-2014-04-571372; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Papadavid E, 2014, EXP DERMATOL, V23, P931, DOI 10.1111/exd.12547; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Remke M, 2009, BLOOD, V114, P1053, DOI 10.1182/blood-2008-10-186536; Scarisbrick JJ, 2000, BLOOD, V95, P2937, DOI 10.1182/blood.V95.9.2937.009k15_2937_2942; Schubbert S, 2014, CANCER RES, V74, P7048, DOI 10.1158/0008-5472.CAN-14-1470; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616; Silva A, 2010, HAEMATOL-HEMATOL J, V95, P674, DOI 10.3324/haematol.2009.011999; Soond DR, 2012, J IMMUNOL, V188, P5935, DOI 10.4049/jimmunol.1102116; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Subramaniam PS, 2012, CANCER CELL, V21, P459, DOI 10.1016/j.ccr.2012.02.029; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Svensson RU, 2011, AM J PATHOL, V179, P502, DOI 10.1016/j.ajpath.2011.03.014; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tan YF, 2008, CANCER RES, V68, P1296, DOI 10.1158/0008-5472.CAN-07-3218; Tandon P, 2011, P NATL ACAD SCI USA, V108, P2361, DOI 10.1073/pnas.1013629108; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Tesio M, 2013, J EXP MED, V210, P2337, DOI 10.1084/jem.20122768; Trinquand A, 2013, J CLIN ONCOL, V31, P4333, DOI 10.1200/JCO.2012.48.5292; Uner AH, 2005, LEUKEMIA LYMPHOMA, V46, P1463, DOI 10.1080/10428190500144813; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Xue L, 2008, P NATL ACAD SCI USA, V105, P2022, DOI 10.1073/pnas.0712059105; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; You DW, 2015, CELL REP, V10, P2055, DOI 10.1016/j.celrep.2015.02.056; Zhang J, 2011, LEUKEMIA, V25, P1857, DOI 10.1038/leu.2011.220; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zuurbier L, 2012, HAEMATOL-HEMATOL J, V97, P1405, DOI 10.3324/haematol.2011.059030	94	21	21	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3887	3896		10.1038/onc.2015.462	http://dx.doi.org/10.1038/onc.2015.462			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616857				2022-12-28	WOS:000381013100001
J	Zhao, Y; Masiello, D; McMillian, M; Nguyen, C; Wu, Y; Melendez, E; Smbatyan, G; Kida, A; He, Y; Teo, JL; Kahn, M				Zhao, Y.; Masiello, D.; McMillian, M.; Nguyen, C.; Wu, Y.; Melendez, E.; Smbatyan, G.; Kida, A.; He, Y.; Teo, J-L; Kahn, M.			CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BETA-CATENIN; GENE-EXPRESSION; CANCER-CELLS; DIFFERENTIAL ROLES; KINASE INHIBITION; BINDING PROTEIN	CREB-binding protein (CBP) and p300 are highly homologous transcriptional coactivators with unique, non-redundant roles that bind a wide array of proteins, including catenins-beta and gamma. ICG-001 is a small-molecule inhibitor that specifically inhibits the CBP/catenin interaction. Importantly, ICG-001 does not inhibit the p300/catenin interaction. We demonstrate that specifically inhibiting the interaction between CBP and catenin with ICG-001 results in the differentiation of quiescent drug-resistant chronic myelogenous leukemia-initiating cells (CML LICs), thereby sensitizing them to BCR-ABL tyrosine kinase inhibitors, for example, Imatinib. Using ICG-001 in a NOD/SCID/IL2R gamma(-/-) mouse model of engrafted human chronic myelogenous leukemia, we now demonstrate the complete elimination of engrafted leukemia after only one course of combined chemotherapy. Combination-treated animals live as long as their non-engrafted littermates. Results from these studies demonstrate that specifically antagonizing the CBP/catenin interaction with ICG-001 can eliminate drug-resistant CML LICs without deleterious effects to the normal endogenous hematopoietic stem cell population.	[Zhao, Y.] Univ Southern Calif, Keck Sch Med, Dept Med, Los Angeles, CA USA; [Zhao, Y.; McMillian, M.; Nguyen, C.; Melendez, E.; Smbatyan, G.; Teo, J-L; Kahn, M.] Univ Southern Calif, Norris Comprehens Canc Ctr, 1450 Biggy St,NRT 4501, Los Angeles, CA 90033 USA; [Zhao, Y.; Masiello, D.; McMillian, M.; Nguyen, C.; Wu, Y.; Melendez, E.; Smbatyan, G.; Kida, A.; He, Y.; Teo, J-L; Kahn, M.] Univ Southern Calif, Keck Sch Med, Ctr Mol Pathways & Drug Discovery, Los Angeles, CA USA; [Kahn, M.] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Kahn, M.] Univ Southern Calif, Keck Sch Med, Dept Mol Pharmacol & Toxicol, Los Angeles, CA USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Kahn, M (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, 1450 Biggy St,NRT 4501, Los Angeles, CA 90033 USA.	kahnm@usc.edu			USC Norris Comprehensive Cancer Center Support Grant [P30 CA014089]; NIH [1R01CA166161-01A1, 1R01 HL112638-01]; NATIONAL CANCER INSTITUTE [R01CA166161, P30CA014089] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL112638] Funding Source: NIH RePORTER	USC Norris Comprehensive Cancer Center Support Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Support from USC Norris Comprehensive Cancer Center Support Grant P30 CA014089, NIH 1R01CA166161-01A1 and NIH 1R01 HL112638-01 is gratefully acknowledged.	Banerjee ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033165; Bolton-Gillespie E, 2013, BLOOD, V121, P4175, DOI 10.1182/blood-2012-11-466938; Chan WI, 2011, MOL CELL BIOL, V31, P5046, DOI 10.1128/MCB.05830-11; el-Khoueiry A., 2013, J CLIN ONC ABSTR, V31, P2501, DOI DOI 10.1200/jco.2013.31.15_suppl.2501; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Giles FJ, 2008, SEMIN ONCOL, V35, pS1, DOI 10.1053/j.seminoncol.2007.12.002; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Hao S, 2011, J AM SOC NEPHROL, V22, P1642, DOI 10.1681/ASN.2010101079; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Hasegawa K, 2012, STEM CELL TRANSL MED, V1, P18, DOI 10.5966/sctm.2011-0033; He KJ, 2014, INT J CANCER, V134, P43, DOI 10.1002/ijc.28341; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Heidel FH, 2012, CELL STEM CELL, V10, P412, DOI 10.1016/j.stem.2012.02.017; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Jabbour EJ, 2013, CL LYMPH MYELOM LEUK, V13, P515, DOI 10.1016/j.clml.2013.03.018; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kahn M, 2011, FUTURE MED CHEM, V3, P1745, DOI [10.4155/FMC.11.126, 10.4155/fmc.11.126]; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim YM, 2011, CURR CANCER DRUG TAR, V11, P213, DOI 10.2174/156800911794328420; Konig H, 2008, LEUKEMIA, V22, P748, DOI 10.1038/sj.leu.2405086; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Marson A, 2008, CELL STEM CELL, V3, P132, DOI 10.1016/j.stem.2008.06.019; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Nicholson E, 2009, CLIN LYMPHOMA MYELOM, V9, pS376, DOI 10.3816/CLM.2009.s.037; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; Park E, 2011, BLOOD, V118, P2191, DOI 10.1182/blood-2011-04-351239; Pehlivan M, 2009, LEUKEMIA RES, V33, P1062, DOI 10.1016/j.leukres.2008.11.013; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Ramos YFM, 2010, NUCLEIC ACIDS RES, V38, P5396, DOI 10.1093/nar/gkq184; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rice KN, 2010, INT J HEMATOL, V91, P748, DOI 10.1007/s12185-010-0615-8; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Teo JL, 2005, P NATL ACAD SCI USA, V102, P12171, DOI 10.1073/pnas.0504600102; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Wend P, 2013, EMBO J, V32, P1977, DOI 10.1038/emboj.2013.127; Xia BF, 2012, BIOPHARM DRUG DISPOS, V33, P536, DOI 10.1002/bdd.1821; Yamada T, 2003, CANCER RES, V63, P895; Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032; Zemans RL, 2011, P NATL ACAD SCI USA, V108, P15990, DOI 10.1073/pnas.1110144108; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003	49	36	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3705	3717		10.1038/onc.2015.438	http://dx.doi.org/10.1038/onc.2015.438			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26657156	Green Accepted			2022-12-28	WOS:000379622800009
J	Semprucci, E; Tocci, P; Cianfrocca, R; Sestito, R; Caprara, V; Veglione, M; Di Castro, V; Spadaro, F; Ferrandina, G; Bagnato, A; Rosano, L				Semprucci, E.; Tocci, P.; Cianfrocca, R.; Sestito, R.; Caprara, V.; Veglione, M.; Di Castro, V.; Spadaro, F.; Ferrandina, G.; Bagnato, A.; Rosano, L.			Endothelin A receptor drives invadopodia function and cell motility through the beta-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; CANCER CELLS; EPITHELIAL CARCINOMA; ACTIN REORGANIZATION; PDZ-RHOGEF; N-WASP; MIGRATION; ACTIVATION; RHOC; INVASION	The endothelin-1 (ET-1)/ET A receptor (ETAR) signalling pathway is a well-established driver of epithelial ovarian cancer (EOC) progression. One key process promoted by ET-1 is tumor cell invasion, which requires the scaffolding functions of beta-arrestin-1 (beta-arr1) downstream of the receptor; however, the potential role of ET-1 in inducing invadopodia, which are crucial for cellular invasion and tumor metastasis, is completely unknown. We describe here that ET-1/ETAR, through beta-arr1, activates RhoA and RhoC GTPase and downstream ROCK (Rho-associated coiled coil-forming kinase) kinase activity, promoting actin-based dynamic remodelling and enhanced cell invasion. This is accomplished by the direct interaction of beta-arr1 with PDZ-RhoGEF (postsynaptic density protein 95/disc-large/zonula occludens-RhoGEF). Interestingly, ETAR-mediated invasive properties are related to the regulation of invadopodia, as evaluated by colocalization of actin with cortactin, as well as with TKS5 and MT1-MMP (membrane type 1-matrix metalloproteinase) with areas of matrix degradation, and activation of cofilin pathway, which is crucial for regulating invadopodia activity. Depletion of PDZ-RhoGEF, or beta-arr1, or RhoC, as well as the treatment with the dual ET-1 receptor antagonist macitentan, significantly impairs invadopodia function, MMP activity and invasion, demonstrating that beta-arr1/PDZ-RhoGEF interaction mediates ETAR-driven ROCK-LIMK-cofilin pathway through the control of RhoC activity. In vivo, macitentan is able to inhibit metastatic dissemination and cofilin phosphorylation. Collectively, our data unveil a noncanonical activation of the RhoC/ROCK pathway through the beta-arr1/PDZ-RhoGEF complex as a regulator of ETAR-induced motility and metastasis, establishing ET-1 axis as a novel regulator of invadopodia protrusions through the RhoC/ROCK/LIMK/cofilin pathway during the initial steps of EOC invasion.	[Semprucci, E.; Tocci, P.; Cianfrocca, R.; Sestito, R.; Caprara, V.; Veglione, M.; Di Castro, V.; Bagnato, A.; Rosano, L.] Regina Elena Natl Canc Inst Rome, Via Elio Chianesi 53, I-00144 Rome, Italy; [Spadaro, F.] Ist Super Sanita, Dept Haematol Oncol & Mol Med, Sect Expt Immunotherapy, Rome, Italy; [Ferrandina, G.] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, Rome, Italy	Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Bagnato, A; Rosano, L (corresponding author), Regina Elena Natl Canc Inst Rome, Via Elio Chianesi 53, I-00144 Rome, Italy.	bagnato@ifo.it; rosano@ifo.it	Rosanò, Laura/B-2863-2018; Spadaro, Francesca/M-7512-2017; ROSANO', Laura/AAK-1424-2020; Ferrandina, Gabriella/AAA-9083-2019; Sestito, Rosanna/K-2361-2018; Di Castro, Valeriana/H-8873-2017; Tocci, Piera/AAX-9815-2021; Bagnato, Anna/G-9747-2016; Tocci, Piera/ABH-7630-2020; Rosanò, Laura/AAB-7821-2019	Rosanò, Laura/0000-0002-9962-6411; Spadaro, Francesca/0000-0002-6610-350X; ROSANO', Laura/0000-0002-9962-6411; Sestito, Rosanna/0000-0001-5460-2777; Di Castro, Valeriana/0000-0002-1899-3683; Tocci, Piera/0000-0003-3771-013X; Bagnato, Anna/0000-0002-7269-9522; Rosanò, Laura/0000-0002-3981-8593; FERRANDINA, Maria Gabriella/0000-0003-4672-4197	Associazione Italiana Ricerca sul Cancro (AIRC) [AIRC 14199, AIRC 12852]; Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship(Fondazione AIRC per la ricerca sul cancro)	We gratefully acknowledge Aldo Lupo for excellent technical assistance, Maria Vincenza Sarcone for secretarial assistance. This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC) to AB (AIRC 14199) and LR (AIRC 12852). PT is recipient of Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship.	Aittaleb M, 2009, CELL SIGNAL, V21, P1569, DOI 10.1016/j.cellsig.2009.06.003; Anthony DF, 2011, MOL CELL BIOL, V31, P1066, DOI 10.1128/MCB.00883-10; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; Bravo-Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039; Chen S, 2013, INT J MOL SCI, V14, P24187, DOI 10.3390/ijms141224187; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Cleghorn WM, 2015, MOL BIOL CELL, V26, P622, DOI 10.1091/mbc.E14-02-0740; Coffman L, 2013, CANCER BIOL THER, V14, P184, DOI 10.4161/cbt.22959; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; DeFea KA, 2013, PROG MOL BIOL TRANSL, V118, P205, DOI 10.1016/B978-0-12-394440-5.00008-5; Dunn HA, 2015, MOL PHARMACOL, V88, P624, DOI 10.1124/mol.115.098509; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Gou WF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-477; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Horiuchi A, 2003, LAB INVEST, V83, P861, DOI 10.1097/01.LAB.0000073128.16098.31; Jaiswal M, 2011, J BIOL CHEM, V286, P18202, DOI 10.1074/jbc.M111.226431; Kim SJ, 2015, CLIN CANCER RES, V21, P4630, DOI 10.1158/1078-0432.CCR-14-3195; Kim SJ, 2012, TRANSL ONCOL, V5, P39, DOI 10.1593/tlo.11286; Kim SJ, 2011, NEOPLASIA, V13, P167, DOI 10.1593/neo.10806; Korkina O, 2013, J BIOL CHEM, V288, P5364, DOI 10.1074/jbc.M112.414060; Ma XJ, 2014, J BIOL CHEM, V289, P13638, DOI 10.1074/jbc.M113.511360; Ma XJ, 2012, J BIOL CHEM, V287, P18925, DOI 10.1074/jbc.M112.352260; Martin-Villar E, 2015, ONCOGENE, V34, P4531, DOI 10.1038/onc.2014.388; Mikelis CM, 2013, J BIOL CHEM, V288, P12232, DOI 10.1074/jbc.M112.428599; Min JA, 2011, MOL PHARMACOL, V80, P760, DOI 10.1124/mol.111.072470; Mittal N, 2013, CELL REP, V5, P1010, DOI 10.1016/j.celrep.2013.10.015; Moshfegh Y, 2014, NAT CELL BIOL, V16, P571, DOI 10.1038/ncb2972; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Ogata S, 2009, INT J GYNECOL CANCER, V19, P1473, DOI 10.1111/IGC.0b013e3181c03909; Patel M, 2014, MOL PHARMACOL, V86, P252, DOI 10.1124/mol.114.093914; Pichot CS, 2010, CANCER RES, V70, P8347, DOI 10.1158/0008-5472.CAN-09-4149; Ridley AJ, 2013, J MICROSC-OXFORD, V251, P242, DOI 10.1111/jmi.12025; Roh-Johnson M, 2014, ONCOGENE, V33, P4203, DOI 10.1038/onc.2013.377; Rosano L, 2005, CANCER RES, V65, P11649, DOI 10.1158/0008-5472.CAN-05-2123; Rosano L, 2013, ONCOGENE, V32, P5066, DOI 10.1038/onc.2012.527; Rosano L, 2001, CANCER RES, V61, P8340; Rosano L, 2014, CANCER RES, V74, P7453, DOI 10.1158/0008-5472.CAN-13-3133; Rosano L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546; Rosano L, 2011, CLIN CANCER RES, V17, P2350, DOI 10.1158/1078-0432.CCR-10-2325; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Saykali BA, 2014, CELL COMMUN ADHES, V21, P207, DOI 10.3109/15419061.2014.923845; Shankar H, 2010, J BIOL CHEM, V285, P8316, DOI 10.1074/jbc.M109.062521; Shukla AK, 2011, TRENDS BIOCHEM SCI, V36, P457, DOI 10.1016/j.tibs.2011.06.003; Siehler S, 2009, BRIT J PHARMACOL, V158, P41, DOI 10.1111/j.1476-5381.2009.00121.x; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Spinella F, 2013, J MOL MED, V91, P395, DOI 10.1007/s00109-012-0956-2; Struckhoff AP, 2013, J CELL SCI, V126, P4514, DOI 10.1242/jcs.132381; Ward JD, 2015, CANCER LETT, V356, P382, DOI 10.1016/j.canlet.2014.09.030; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Zhao Y, 2013, GYNECOL ONCOL, V130, P570, DOI 10.1016/j.ygyno.2013.06.004; Zhao Y, 2010, GYNECOL ONCOL, V116, P563, DOI 10.1016/j.ygyno.2009.11.015; Zheng R, 2006, ONCOGENE, V25, P5942, DOI 10.1038/sj.onc.1209586; Zoudilova M, 2010, J BIOL CHEM, V285, P14318, DOI 10.1074/jbc.M109.055806	57	40	40	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3432	3442		10.1038/onc.2015.403	http://dx.doi.org/10.1038/onc.2015.403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26522724				2022-12-28	WOS:000379270100008
J	Luanpitpong, S; Li, J; Manke, A; Brundage, K; Ellis, E; McLaughlin, SL; Angsutararux, P; Chanthra, N; Voronkova, M; Chen, YC; Wang, L; Chanvorachote, P; Pei, M; Issaragrisil, S; Rojanasakul, Y				Luanpitpong, S.; Li, J.; Manke, A.; Brundage, K.; Ellis, E.; McLaughlin, S. L.; Angsutararux, P.; Chanthra, N.; Voronkova, M.; Chen, Y. C.; Wang, L.; Chanvorachote, P.; Pei, M.; Issaragrisil, S.; Rojanasakul, Y.			SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma	ONCOGENE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; BREAST-CANCER; ALDEHYDE DEHYDROGENASE; DEGRADATION; ADENOCARCINOMA; EXPRESSION; GROWTH; IDENTIFICATION	Cancer stem cells (CSCs) are a promising target for cancer therapy, particularly for metastatic lung cancers, but how CSCs are regulated is largely unknown. We identify two proteins, SLUG (encoded by SNAI2 gene) and SOX9, which are associated with advanced stage lung cancers and are implicated in the regulation of CSCs. Inhibition of either SLUG or SOX9 sufficiently inhibits CSCs in human lung cancer cells and attenuates experimental lung metastasis in a xenograft mouse model. Correlation between SLUG and SOX9 levels was observed remarkably, we therefore sought to explore their mechanistic relationship and regulation. SLUG, beyond its known function as an epithelial-mesenchymal transition transcription factor, was found to regulate SOX9 by controlling its stability via a post-translational modification process. SLUG interacts directly with SOX9 and prevents it from ubiquitin-mediated proteasomal degradation. SLUG expression and binding are necessary for SOX9 promotion of lung CSCs and metastasis in a mouse model. Together, our findings provide a novel mechanistic insight into the regulation of CSCs via SLUG-SOX9 regulatory axis, which represents a potential novel target for CSC therapy that may overcome cancer chemoresistance and relapse.	[Angsutararux, P.; Chanthra, N.; Issaragrisil, S.] Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Ctr Excellence Stem Cell Res, Bangkok 10700, Thailand; [Luanpitpong, S.; Manke, A.; Rojanasakul, Y.] W Virginia Univ, Pharmaceut & Pharmacol Sci Program, Morgantwon, WV 26506 USA; [Luanpitpong, S.; Voronkova, M.; Rojanasakul, Y.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantwon, WV 26506 USA; [Li, J.; Pei, M.] W Virginia Univ, Stem Cell & Tissue Engn Lab, Morgantwon, WV 26506 USA; [Brundage, K.] W Virginia Univ, Flow Cytometry Core Facil, Morgantwon, WV 26506 USA; [Ellis, E.; McLaughlin, S. L.] W Virginia Univ, Anim Models & Imaging Facil, Morgantwon, WV 26506 USA; [Chen, Y. C.] Alderson Broaddus Univ, Div Nat Sci, Philippi, WV USA; [Wang, L.] NIOSH, Allergy & Clin Immunol Branch, Morgantown, WV USA; [Chanvorachote, P.] Chulalongkorn Univ, Prod Dev Res Unit, Cell Based Drug & Hlth, Bangkok, Thailand	Mahidol University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Chulalongkorn University	Luanpitpong, S (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Ctr Excellence Stem Cell Res, Bangkok 10700, Thailand.; Luanpitpong, S; Rojanasakul, Y (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantwon, WV 26506 USA.	suidjit@gmail.com; yrojan@hsc.wvu.edu	Li, Jingting/AAA-4598-2020; Luanpitpong, Sudjit/ABF-1962-2021; Pei, Ming/N-8175-2017	Li, Jingting/0000-0002-3576-0320; chanvorachote, pithi/0000-0002-3103-3249; McLaughlin, Sarah/0000-0002-8413-3585; Voronkova, Maria/0000-0001-9778-5032; Luanpitpong, Sudjit/0000-0002-1639-4935	National Institutes of Health (NIH) [R01-ES022968]; National Science Foundation [CBET-1434503]; Mary Babb Randolph Cancer Center (MBRCC) Sara C Allen Lung and James F Allen Comp Lung Cancer Research Fund; NIH [P30 GM103488, P20 RR016440, P30 RR032138/GM103488, S10 RR026378]; MBRCC; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026378, P20RR016440, P30RR032138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES022968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103488] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Mary Babb Randolph Cancer Center (MBRCC) Sara C Allen Lung and James F Allen Comp Lung Cancer Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MBRCC; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Institutes of Health (NIH; R01-ES022968), National Science Foundation (CBET-1434503) and Mary Babb Randolph Cancer Center (MBRCC) Sara C Allen Lung and James F Allen Comp Lung Cancer Research Fund. Flow cytometric analysis was performed in the WVU Flow Cytometry Core Facility, which is supported in part by the NIH Grant P30 GM103488. Animal experiments were performed in the WVU Animal Models and Imaging Facility, which is supported in part by the MBRCC and NIH Grants P20 RR016440, P30 RR032138/GM103488 and S10 RR026378. We would like to acknowledge the WVU Pathology Laboratory for Translational Medicine for tissue sectioning and staining services and Drs Davor Solter and Barbara Knowles for their comments on the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Cates JMM, 2009, PANCREAS, V38, pE1, DOI 10.1097/MPA.0b013e3181878b7f; Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086; Chakravarty G, 2011, CANCER BIOL THER, V11, P71, DOI 10.4161/cbt.11.1.13952; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Crino L, 2010, ANN ONCOL, V21, pv103, DOI 10.1093/annonc/mdq207; Cronin JC, 2013, CANCER RES, V73, P5709, DOI 10.1158/0008-5472.CAN-12-4620; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Ding GX, 2012, PANMINERVA MED, V54, P219; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Esposito L, 2010, CURR GENOMICS, V11, P513, DOI 10.2174/138920210793175903; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hasan MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082846; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Krueger KE, 2006, MOL CELL PROTEOMICS, V5, P1799, DOI 10.1074/mcp.R600009-MCP200; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Levina V, 2010, CANCER RES, V70, P338, DOI 10.1158/0008-5472.CAN-09-1102; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Luanpitpong S, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-22; Luanpitpong S, 2013, MOL BIOL CELL, V24, P858, DOI 10.1091/mbc.E12-10-0747; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nurwidya F, 2012, CANCER RES TREAT, V44, P151, DOI 10.4143/crt.2012.44.3.151; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Riihimaki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020; Rockich BE, 2013, P NATL ACAD SCI USA, V110, pE4456, DOI 10.1073/pnas.1311847110; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tan YX, 2014, MOL CLIN ONCOL, V2, P111, DOI 10.3892/mco.2013.195; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Turcatel G, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-117; Xu Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034327; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zheng YF, 2011, J BIOL CHEM, V286, P17722, DOI 10.1074/jbc.M110.184739	49	77	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2824	2833		10.1038/onc.2015.351	http://dx.doi.org/10.1038/onc.2015.351			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387547	Green Accepted			2022-12-28	WOS:000377473700002
J	Zhu, T; Wang, J; Pei, Y; Wang, Q; Wu, Y; Qiu, G; Zhang, D; Lv, M; Li, W; Zhang, J				Zhu, T.; Wang, J.; Pei, Y.; Wang, Q.; Wu, Y.; Qiu, G.; Zhang, D.; Lv, M.; Li, W.; Zhang, J.			Neddylation controls basal MKK7 kinase activity in breast cancer cells	ONCOGENE			English	Article							PROTEIN-KINASE; NEDD8-ACTIVATING ENZYME; UBIQUITIN LIGASE; ACTIVATION; JNK; NEDD8; APOPTOSIS; IDENTIFICATION; INHIBITOR; STABILITY	The c-Jun NH2-terminal protein kinase (JNK) pathway has been implicated in mammary tumor development. However, the molecular mechanisms regulating JNK activity in breast cancer cells remain unclear. Here, we report that the inhibition of ubiquitination-like post-translational modification neddylation through different strategies results in enhanced basal JNK phosphorylation in human breast cancer cells. The upregulation of basal JNK phosphorylation upon neddylation inhibition is independent of the deneddylation of Cullins, the well-characterized neddylation substrates. Since augmented basal JNK phosphorylation via ectopic MKK7 expression impedes proliferation and the epithelial-to-mesenchymal transition (EMT) phenotype, the neddylation system might contribute to mammary tumor development partially through limiting basal JNK phosphorylation. Further exploration reveals that MKK7, a JNK-specific MAP2K, undergoes neddylation in human breast cancer cells. MKK7 coprecipitates with a fragment of Ran-binding protein 2 (RanBP2), a large multimodular and pleiotropic protein that has been recognized as a SUMO E3 ligase. Knockdown of RanBP2 attenuates MKK7 neddylation and augments basal JNK phosphorylation without affecting the neddylation of Cullins, whereas ectopic expression of a RanBP2 fragment possessing SUMO E3 activity (RanBP2 Delta FG) manifests the opposite effects. In vitro neddylation assays confirm that RanBP2 Delta FG works as the neddylation E3 ligase for MKK7. The basal kinase activity of endogenous MKK7 increases upon RanBP2 knockdown but decreases upon the ectopic expression of RanBP2 Delta FG. Furthermore, purified MKK7 shows reduced basal kinase activity after in vitro neddylation by RanBP2 Delta FG. Consistently, RanBP2 knockdown leads to reduced proliferation and impaired EMT phenotype in human breast cancer cells and the effects of RanBP2 knockdown are reversed by simultaneous MKK7 knockdown. Taken together, our data suggest that MKK7 undergoes neddylation in human breast cancer cells, which limits its basal kinase activity.	[Zhu, T.; Wang, J.; Pei, Y.; Wang, Q.; Wu, Y.; Qiu, G.; Zhang, D.; Lv, M.; Li, W.; Zhang, J.] Inst Basic Med Sci, Dept Mol Immunol, 27 Taiping Rd, Beijing 100850, Peoples R China		Zhang, J (corresponding author), Inst Basic Med Sci, Dept Mol Immunol, 27 Taiping Rd, Beijing 100850, Peoples R China.	zhangjy@nic.bmi.ac.cn	Z, D/AFG-4813-2022	, DALIN/0000-0002-6553-7373; Zhang, Jiyan/0000-0001-8011-8719	National Natural Science Foundation of China [81472736, 31270960]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Professors Ming Shi, Ning Guo, Ailing Li and Xuemin Zhang for providing reagents. This work was supported by grants from National Natural Science Foundation of China (81472736, 31270960).	Aoki I, 2013, ONCOGENE, V32, P3954, DOI 10.1038/onc.2012.428; Broemer M, 2010, MOL CELL, V40, P810, DOI 10.1016/j.molcel.2010.11.011; Cellurale C, 2012, CANCER RES, V72, P472, DOI 10.1158/0008-5472.CAN-11-1628; Cellurale C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012469; Chen PL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010443; Collier-Hyams LS, 2005, J IMMUNOL, V175, P4194, DOI 10.4049/jimmunol.175.7.4194; Cui J, 2009, MOL CANCER THER, V8, P3214, DOI 10.1158/1535-7163.MCT-09-0408; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Godbersen JC, 2014, CLIN CANCER RES, V20, P1576, DOI 10.1158/1078-0432.CCR-13-0987; Guo YY, 2013, HEPATOLOGY, V57, P140, DOI 10.1002/hep.25978; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hjerpe R, 2012, BIOCHEM J, V441, P927, DOI 10.1042/BJ20111671; Hutten S, 2008, MOL BIOL CELL, V19, P2300, DOI 10.1091/mbc.E07-12-1279; Jubelin G, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001128; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Pelham CJ, 2012, CELL METAB, V16, P462, DOI 10.1016/j.cmet.2012.08.011; Schramek D, 2011, NAT GENET, V43, P212, DOI 10.1038/ng.767; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wang J, 2011, MOL BIOL CELL, V22, P117, DOI 10.1091/mbc.E10-06-0492; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang J, 2008, CELL DEATH DIFFER, V15, P1654, DOI 10.1038/cdd.2008.87; Zhang JY, 2010, J IMMUNOL, V185, P3554, DOI 10.4049/jimmunol.1000431; Zhang Z, 2014, ONCOGENE, V33, P3374, DOI 10.1038/onc.2013.337	36	12	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2624	2633		10.1038/onc.2015.323	http://dx.doi.org/10.1038/onc.2015.323			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364603				2022-12-28	WOS:000376165700009
J	Satheesha, S; Manzella, G; Bovay, A; Casanova, EA; Bode, PK; Belle, R; Feuchtgruber, S; Jaaks, P; Dogan, N; Koscielniak, E; Schafer, BW				Satheesha, S.; Manzella, G.; Bovay, A.; Casanova, E. A.; Bode, P. K.; Belle, R.; Feuchtgruber, S.; Jaaks, P.; Dogan, N.; Koscielniak, E.; Schafer, B. W.			Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma	ONCOGENE			English	Article							STEM-CELLS; TUMOR-CELL; PATHWAY; GROWTH; GLI; REQUIREMENT; EXPRESSION; MODEL; RAS	Current treatment regimens for rhabdomyosarcoma (RMS), the most common pediatric soft tissue cancer, rely on conventional chemotherapy, and although they show clinical benefit, there is a significant risk of adverse side effects and secondary tumors later in life. Therefore, identifying and targeting sub-populations with higher tumorigenic potential and self-renewing capacity would offer improved patient management strategies. Hedgehog signaling has been linked to the development of embryonal RMS (ERMS) through mouse genetics and rare human syndromes. However, activating mutations in this pathway in sporadic RMS are rare and therefore the contribution of hedgehog signaling to oncogenesis remains unclear. Here, we show by genetic loss-and gain-of-function experiments and the use of clinically relevant small molecule modulators that hedgehog signaling is important for controlling self-renewal of a subpopulation of RMS cells in vitro and tumor initiation in vivo. In addition, hedgehog activity altered chemoresistance, motility and differentiation status. The core stem cell gene NANOG was determined to be important for ERMS self-renewal, possibly acting downstream of hedgehog signaling. Crucially, evaluating the presence of a subpopulation of tumor-propagating cells in patient biopsies identified by GLI1 and NANOG expression had prognostic significance. Hence, this work identifies novel functional aspects of hedgehog signaling in ERMS, redefines the rationale for its targeting as means to control ERMS self-renewal and underscores the importance of studying functional tumor heterogeneity in pediatric cancers.	[Satheesha, S.; Manzella, G.; Bovay, A.; Casanova, E. A.; Bode, P. K.; Belle, R.; Jaaks, P.; Dogan, N.; Schafer, B. W.] Univ Childrens Hosp, Dept Oncol, Steinwiessstr 75, CH-8032 Zurich, Switzerland; [Satheesha, S.; Manzella, G.; Bovay, A.; Casanova, E. A.; Bode, P. K.; Belle, R.; Jaaks, P.; Dogan, N.; Schafer, B. W.] Univ Childrens Hosp, Childrens Res Ctr, Steinwiessstr 75, CH-8032 Zurich, Switzerland; [Bode, P. K.] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Feuchtgruber, S.; Koscielniak, E.] Klinikum Stuttgart, Olgahosp, Dept Oncol Hematol Immunol, Stuttgart, Germany	University Children's Hospital Zurich; University Children's Hospital Zurich; University of Zurich; University Zurich Hospital; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart	Schafer, BW (corresponding author), Univ Childrens Hosp, Dept Oncol, Steinwiessstr 75, CH-8032 Zurich, Switzerland.; Schafer, BW (corresponding author), Univ Childrens Hosp, Childrens Res Ctr, Steinwiessstr 75, CH-8032 Zurich, Switzerland.	Beat.Schaefer@kispi.uzh.ch		Bode, Peter/0000-0002-9633-4042; Schafer, Beat/0000-0001-5988-2915; Rappaz, Sampoorna/0000-0002-7330-7586; Bovay, Amandine/0000-0001-6947-9812	Swiss National Science Fund [31003A-138460]; Sciex [F-80016-02-01]; Cancer League Canton Zurich	Swiss National Science Fund(Swiss National Science Foundation (SNSF)); Sciex; Cancer League Canton Zurich	We highly appreciate St Jude's Children's Research Hospital for providing the ERMS PDX samples, Swiss Pediatric Oncology Group (SPOG) for providing ERMS patient tumor samples and the German Soft tissue sarcoma study group (CWS) for providing the TMA sections and performing the clinical data analysis. We are also grateful to Silvia Behnke (Sophistolab AG) and the technicians at the Institute of Surgical Pathology (University Hospital Zurich) for their excellent service. The work was supported by grants from Swiss National Science Fund (31003A-138460), Sciex (F-80016-02-01) and Cancer League Canton Zurich.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Annavarapu SR, 2013, LAB INVEST, V93, P1090, DOI 10.1038/labinvest.2013.97; Belyea Brian, 2012, Sarcoma, V2012, P406239, DOI 10.1155/2012/406239; Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Ehnman M, 2013, CANCER RES, V73, P2139, DOI 10.1158/0008-5472.CAN-12-1646; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gage PJ, 2005, INVEST OPHTH VIS SCI, V46, P4200, DOI 10.1167/iovs.05-0691; Hawkins DS, 2014, CURR OPIN PEDIATR, V26, P50, DOI 10.1097/MOP.0000000000000041; Hirotsu M, 2009, BRIT J CANCER, V101, P2030, DOI 10.1038/sj.bjc.6605407; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Kuang S, 2008, CELL STEM CELL, V2, P22, DOI 10.1016/j.stem.2007.12.012; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Liu P, 2010, DEV DYNAM, V239, P2161, DOI 10.1002/dvdy.22347; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Nitzki F, 2011, ONCOGENE, V30, P4428, DOI 10.1038/onc.2011.157; Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Pressey JG, 2013, PEDIATR BLOOD CANCER, V60, P45, DOI 10.1002/pbc.24117; Pressey JG, 2011, PEDIATR BLOOD CANCER, V57, P930, DOI 10.1002/pbc.23174; Raimondi L, 2012, CELL DEATH DIFFER, V19, P871, DOI 10.1038/cdd.2011.171; Rajurkar M, 2014, ONCOGENE, V33, P5370, DOI 10.1038/onc.2013.480; Satheesha S, 2014, STEM CELLS CANC STEM, V11, P111; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Theunissen TW, 2011, PHILOS T R SOC B, V366, P2222, DOI 10.1098/rstb.2011.0003; Vermeulen L, 2012, LANCET ONCOL, V13, pE83, DOI 10.1016/S1470-2045(11)70257-1; Vidal SJ, 2014, ONCOGENE, V33, P4451, DOI 10.1038/onc.2013.411; von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008; Voronova A, 2013, J BIOL CHEM, V288, P4389, DOI 10.1074/jbc.M112.400184; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Walter D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019506; Wang ML, 2013, ONCOTARGETS THER, V6, P1207, DOI 10.2147/OTT.S38114; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368	40	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2020	2030		10.1038/onc.2015.267	http://dx.doi.org/10.1038/onc.2015.267			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26189795	hybrid, Green Published			2022-12-28	WOS:000374505600002
J	Yang, W; Mok, MTS; Li, MSM; Kang, W; Wang, H; Chan, AW; Chou, JL; Chen, J; Ng, EKW; To, KF; Yu, J; Chan, MWY; Chan, FKL; Sung, JJY; Cheng, ASL				Yang, W.; Mok, M. T. S.; Li, M. S. M.; Kang, W.; Wang, H.; Chan, A. W.; Chou, J-L; Chen, J.; Ng, E. K. W.; To, K-F; Yu, J.; Chan, M. W. Y.; Chan, F. K. L.; Sung, J. J. Y.; Cheng, A. S. L.			Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development	ONCOGENE			English	Article							DIFFERENTIATION FACTOR-I; INTESTINAL METAPLASIA; SOMATIC MUTATIONS; TUMOR-SUPPRESSOR; GENE; EXPRESSION; RISK; RECEPTOR; CELLS; FOXD3	Accumulating evidence reveals the effectiveness of epigenetic therapy in gastric cancer. However, the molecular mechanisms and targets underlying such therapeutic responses remain elusive. Herein, we report an aberrant yet therapeutically rectifiable epigenetic signaling in gastric carcinogenesis. Administration of DNA-demethylating drug 5-aza-2'-deoxycytidine (5-aza-dC) reduced gastric cancer incidence by similar to 74% (P<0.05) in N-nitroso-N-methylurea-treated mice. Through genome-wide methylation scanning, novel promoter hypermethylation-silenced and drug-targeted genes were identified in the resected murine stomach tumors and tissues. We uncovered that growth/differentiation factor 1 (Gdf1), a member of the transforming growth factor-beta superfamily, was silenced by promoter hypermethylation in control tumor-bearing mice, but became reactivated in 5-aza-dCtreated mice (P<0.05). In parallel, the downregulated SMAD2/3 phosphorylation in gastric cancer was revived by 5-aza-dC in vivo. Such hypermethylation-dependent silencing and 5-aza-dC-mediated reactivation of GDF1-SMAD2/3 activity was conserved in human gastric cancer cells (Po0.05). Subsequent functional characterization further revealed the antiproliferative activity of GDF1, which was exerted through activation of SMAD2/3/4-mediated signaling, transcriptional controls on p15, p21 and c-Myc cell-cycle regulators and phosphorylation of retinoblastoma protein. Clinically, hypermethylation and loss of GDF1 was significantly associated with reduced phosphorylated-SMAD2/3 and poor survival in stomach cancer patients (Po0.05). Taken together, we demonstrated a causal relationship between DNA methylation and a tumor-suppressive pathway in gastric cancer. Epigenetic silencing of GDF1 abrogates the growth-inhibitory SMAD signaling and renders proliferation advantage to gastric epithelial cells during carcinogenesis. This study lends support to epigenetic therapy for gastric cancer chemoprevention and identifies a potential biomarker for prognosis.	[Yang, W.; Yu, J.; Chan, F. K. L.; Sung, J. J. Y.; Cheng, A. S. L.] Chinese Univ Hong Kong, State Key Lab Digest Dis, Shatin, Hong Kong, Peoples R China; [Yang, W.; Yu, J.; Chan, F. K. L.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Mok, M. T. S.; Li, M. S. M.; Cheng, A. S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China; [Mok, M. T. S.; Cheng, A. S. L.] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Kang, W.; Chan, A. W.; To, K-F] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Wang, H.] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China; [Chou, J-L; Chan, M. W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Chiayi 621, Taiwan; [Chen, J.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China; [Ng, E. K. W.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Chinese University of Hong Kong; Chinese University of Hong Kong; National Chung Cheng University; Sun Yat Sen University; Chinese University of Hong Kong	Cheng, ASL (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Shatin, Hong Kong, Peoples R China.; Cheng, ASL (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.	alfredcheng@cuhk.edu.hk	Chan, Francis K. L./F-4851-2010; KANG, Wei/C-5451-2016; Chan, Anthony W.H./N-6719-2016; Chan, Anthony/U-7768-2019; Cheng, Alfred SL/C-3327-2014; Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015; Mok, Myth/M-2958-2013; Chan, Michael/F-9615-2018; Wang, Maggie Haitian/F-5954-2017; Chan, Anthony Wing Hung/HGB-4311-2022; Ng, Enders Kwok-wai/E-8276-2016	Chan, Francis K. L./0000-0001-7388-2436; KANG, Wei/0000-0002-4651-677X; Chan, Anthony W.H./0000-0002-1771-163X; Chan, Anthony/0000-0002-1771-163X; Cheng, Alfred SL/0000-0003-2345-6951; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153; Mok, Myth/0000-0003-3156-4944; Chan, Michael/0000-0003-1431-322X; Wang, Maggie Haitian/0000-0003-1223-4595; Chan, Anthony Wing Hung/0000-0002-1771-163X; Chan, Michael/0000-0003-0314-2437; Ng, Enders Kwok-wai/0000-0001-7219-5810	Health and Medical Research Fund [08070172]; National Natural Science Foundation of China [373492, 81302167]; Chinese University of Hong Kong;  [1907301]	Health and Medical Research Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese University of Hong Kong(Chinese University of Hong Kong); 	This study was supported by the Health and Medical Research Fund (08070172), National Natural Science Foundation of China (373492, 81302167), Focused Investment Scheme - Scheme B (1907301) and the Direct Grant from the Chinese University of Hong Kong.	Andersson O, 2006, DEV BIOL, V293, P370, DOI 10.1016/j.ydbio.2006.02.002; Asada K, 2015, GUT, V64, P388, DOI 10.1136/gutjnl-2014-307094; Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; Burt David W., 1994, Progress in Growth Factor Research, V5, P99; Cheng ASL, 2013, GASTROENTEROLOGY, V144, P122, DOI 10.1053/j.gastro.2012.10.002; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Cheung KF, 2012, CANCER-AM CANCER SOC, V118, P947, DOI 10.1002/cncr.26189; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Feng H, 2011, J CLIN INVEST, V121, P3159, DOI 10.1172/JCI45967; Fuerer C, 2014, J BIOL CHEM, V289, P17854, DOI 10.1074/jbc.M114.550301; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holbrook JD, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-119; Ivanova T, 2013, GUT, V62, P22, DOI 10.1136/gutjnl-2011-301113; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaasinen E, 2010, HUM MOL GENET, V19, P2747, DOI 10.1093/hmg/ddq164; Kaminskas E, 2005, ONCOLOGIST, V10, P176, DOI 10.1634/theoncologist.10-3-176; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Karkera JD, 2007, AM J HUM GENET, V81, P987, DOI 10.1086/522890; Katsuno Y, 2012, J PATHOL, V228, P391, DOI 10.1002/path.4020; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; Leung WK, 2008, CARCINOGENESIS, V29, P1648, DOI 10.1093/carcin/bgn156; Leung WK, 2004, GUT, V53, P1244, DOI 10.1136/gut.2003.034629; Li X, 2012, ONCOGENE, V31, P3419, DOI 10.1038/onc.2011.511; Liu J, 2012, ONCOL REP, V28, P545, DOI 10.3892/or.2012.1838; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Nagarajan N, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-12-r115; Niwa T, 2013, CANCER PREV RES, V6, P263, DOI 10.1158/1940-6207.CAPR-12-0369; Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x; Rankin CT, 2000, NAT GENET, V24, P262, DOI 10.1038/73472; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Schmid CA, 2013, GASTROENTEROLOGY, V144, P22, DOI 10.1053/j.gastro.2012.11.014; Shin VY, 2011, CARCINOGENESIS, V32, P240, DOI 10.1093/carcin/bgq240; Sun XW, 2013, MOL BIOL REP, V40, P1291, DOI 10.1007/s11033-012-2172-0; Sung JJY, 2000, GASTROENTEROLOGY, V119, P7, DOI 10.1053/gast.2000.8550; Wall NA, 2000, DEV BIOL, V227, P495, DOI 10.1006/dbio.2000.9926; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Yoda Y, 2015, GASTRIC CANCER, V18, P65, DOI 10.1007/s10120-014-0348-0; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang L, 2013, TRENDS BIOCHEM SCI, V38, P612, DOI 10.1016/j.tibs.2013.10.001; Zhang Y, 2014, BBA-MOL BASIS DIS, V1842, P232, DOI 10.1016/j.bbadis.2013.11.018; Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504	50	14	14	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2133	2144		10.1038/onc.2015.276	http://dx.doi.org/10.1038/onc.2015.276			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26212015				2022-12-28	WOS:000374505600012
J	Zhu, J; Zhao, C; Zhuang, T; Jonsson, P; Sinha, I; Williams, C; Stromblad, S; Dahlman-Wright, K				Zhu, J.; Zhao, C.; Zhuang, T.; Jonsson, P.; Sinha, I.; Williams, C.; Stromblad, S.; Dahlman-Wright, K.			RING finger protein 31 promotes p53 degradation in breast cancer cells	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; UBIQUITIN LIGASE ACTIVITY; MDM2 ANTAGONIST NUTLIN-3; TRANSCRIPTIONAL REPRESSION; ONCOPROTEIN MDM2; E3; ACTIVATION; MUTATIONS; IDENTIFICATION; NEUROBLASTOMA	The atypical E3 ubiquitin ligase RNF31 is highly expressed in human breast cancer, the most frequent neoplastic lethality among women. Here, RNF31 depletion in breast cancer cells in combination with global gene expression profiling revealed p53 (TP53) signaling as a potential RNF31 target. Interestingly, RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner. Furthermore, RNF31 associated with the p53/MDM2 complex and facilitated p53 polyubiquitination and degradation by stabilizing MDM2, suggesting a molecular mechanism by which RNF31 regulates cell death. Analysis of publically available clinical data sets displayed a negative correlation between RNF31 and p53 target genes, including IGFBP3 and BTG1, consistent with RNF31 regulating p53 function in vivo as well. Together, our findings suggest RNF31 as a potential therapeutic target to restore p53 function in breast cancer.	[Zhu, J.; Zhao, C.; Zhuang, T.; Sinha, I.; Stromblad, S.; Dahlman-Wright, K.] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Jonsson, P.; Williams, C.] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA; [Williams, C.] Royal Inst Technol KTH, SciLifeLab, Dept Prote & Nanotechnol, Solna, Sweden; [Dahlman-Wright, K.] SciLifeLab, Sci Life Lab, Solna, Sweden	Karolinska Institutet; University of Houston System; University of Houston; Royal Institute of Technology; SciLifeLab; SciLifeLab	Dahlman-Wright, K (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Novum, Halsovagen 7-9, SE-14183 Huddinge, Stockholmm, Sweden.	karin.dahlman-wright@ki.se	Williams, Cecilia/A-6677-2009; zhu, jian/D-7361-2017	Williams, Cecilia/0000-0002-0602-2062; zhu, jian/0000-0003-3596-4339; Zhuang, Ting/0000-0002-6308-1253; Stromblad, Staffan/0000-0002-1236-6339; Sinha, Indranil/0000-0002-2513-5927; Jonsson, Philip/0000-0002-1537-0624; zhu, jian/0000-0003-0171-4251	China Scholarship Council; Karolinska Institutet; Center for Innovative Medicine at Karolinska Institutet, Marie Curie Actions via the VINNOVA programme Mobility for Growth [GROWTH 291795]; Swedish Cancer Society; Swedish Research Council	China Scholarship Council(China Scholarship Council); Karolinska Institutet(Karolinska Institutet); Center for Innovative Medicine at Karolinska Institutet, Marie Curie Actions via the VINNOVA programme Mobility for Growth; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission)	We thank members of the KDW, SS and ET group members for sharing materials and for valuable discussions. We thank Marie Franzen for assisting with manuscript submission and Lars-Arne Haldosen for critical comments. This study was supported by scholarships from the China Scholarship Council, a PhD student grant (KID) from the Karolinska Institutet, funding from the Center for Innovative Medicine at Karolinska Institutet, Marie Curie Actions FP7-PEOPLE-2011-COFUND [GROWTH 291795] via the VINNOVA programme Mobility for Growth, the Swedish Cancer Society, the Swedish Research Council and the Karolinska Institutet.	Barnes DM, 1996, J MAMMARY GLAND BIOL, V1, P163, DOI 10.1007/BF02013640; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Di Leo A, 2007, ANN ONCOL, V18, P997, DOI 10.1093/annonc/mdm075; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Ehrlund A, 2009, MOL CELL BIOL, V29, P2230, DOI 10.1128/MCB.00743-08; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Grumati P, 2014, CANCER DISCOV, V4, P394, DOI 10.1158/2159-8290.CD-14-0177; Gustafsson N, 2010, CANCER RES, V70, P1265, DOI 10.1158/0008-5472.CAN-09-2674; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang BY, 2009, AGING-US, V1, P845, DOI 10.18632/aging.100091; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jiang M, 2007, J BIOL CHEM, V282, P2636, DOI 10.1074/jbc.M606928200; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; MacKay C, 2014, CANCER RES, V74, P2246, DOI 10.1158/0008-5472.CAN-13-2131; Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Peirce SK, 2009, INT J ONCOL, V34, P1395, DOI 10.3892/ijo_00000267; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Smit JJ, 2012, EMBO J, V31, P3833, DOI 10.1038/emboj.2012.217; Tatematsu K, 2008, J BIOL CHEM, V283, P11575, DOI 10.1074/jbc.M706961200; Thompson HGR, 2004, EXP CELL RES, V295, P448, DOI 10.1016/j.yexcr.2004.01.019; Uji K, 2014, CANCER LETT, V342, P19, DOI 10.1016/j.canlet.2013.08.028; Van Maerken T, 2009, JNCI-J NATL CANCER I, V101, P1562, DOI 10.1093/jnci/djp355; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wen W, 2014, ONCOGENE, V33, P421, DOI 10.1038/onc.2012.605; Williams C, 1998, CLIN CHEM, V44, P455; Yang YB, 2014, CANCER DISCOV, V4, P480, DOI 10.1158/2159-8290.CD-13-0915; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573	41	36	38	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1955	1964		10.1038/onc.2015.260	http://dx.doi.org/10.1038/onc.2015.260			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148235	hybrid, Green Published			2022-12-28	WOS:000374010300008
J	Zou, M; Baitei, EY; Al-Rijjal, RA; Parhar, RS; Al-Mohanna, FA; Kimura, S; Pritchard, C; Binessa, HA; Alzahrani, AS; Al-Khalaf, HH; Hawwari, A; Akhtar, M; Assiri, AM; Meyer, BF; Shi, Y				Zou, M.; Baitei, E. Y.; Al-Rijjal, R. A.; Parhar, R. S.; Al-Mohanna, F. A.; Kimura, S.; Pritchard, C.; Binessa, H. A.; Alzahrani, A. S.; Al-Khalaf, H. H.; Hawwari, A.; Akhtar, M.; Assiri, A. M.; Meyer, B. F.; Shi, Y.			TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; SERUM TSH; TRANSGENIC MICE; BRAF MUTATIONS; MOUSE MODEL; IN-VIVO; PTEN; CARCINOMA; CELLS; RAS	The BRAF(V600E) mutation is found in approximately 40% of papillary thyroid cancers (PTC). Mice with thyroid-specific expression of BRAF(V600E) (TPO-BRAF(V600E)) develop PTC rapidly with high levels of serum thyroid-stimulating hormone (TSH). It is unclear to what extent the elevated TSH contributes to tumor progression. To investigate the progression of BRAF(V600E)-induced PTC (BVE-PTC) under normal TSH, we transplanted BVE-PTC tumors subcutaneously into nude and TPO-Braf(WT) mice. Regression of the transplanted tumors was observed in both nude and TPO-Braf(WT) mice. They were surrounded by heavy lymphocyte infiltration and oncogene-induced senescence (OIS) was demonstrated by strong beta-gal staining and absence of Ki-67 expression. In contrast, BVE-PTC transplants continued to grow when transplanted into TPO-BRAF(V600E) mice. The expression of Trp53 was increased in tumor transplants undergoing OIS. Trp53 inactivation reversed OIS and enabled tumor transplants to grow in nude mice with characteristic cell morphology of anaplastic thyroid cancer (ATC). PTC-to-ATC transformation was also observed in primary BVE-PTC tumors. ATC cells derived from Trp53 knockout tumors had increased PI3K/AKT signaling and became resistant to BRAF(V600E) inhibitor PLX4720, which could be overcome by combined treatment of PI3K inhibitor LY294002 and PLX4720. In conclusion, BVE-PTC progression could be contained via p53-dependent OIS and TSH is a major disruptor of this balance. Simultaneous targeting of both MAPK and PI3K/AKT pathways offer a better therapeutic outcome against ATC. The current study reinforces the importance of rigorous control of serum TSH in PTC patients.	[Zou, M.; Baitei, E. Y.; Al-Rijjal, R. A.; Binessa, H. A.; Hawwari, A.; Meyer, B. F.; Shi, Y.] King Faisal Specialist Hosp & Res Ctr, Dept Genet, MBC 3,Takhassusi St,POB 3354, Riyadh 11211, Saudi Arabia; [Parhar, R. S.; Al-Mohanna, F. A.] King Faisal Specialist Hosp & Res Ctr, Dept Cell Biol, Riyadh 11211, Saudi Arabia; [Kimura, S.] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; [Pritchard, C.] Univ Leicester, Dept Biochem, Lancaster Rd, Leicester LE1 7RH, Leics, England; [Alzahrani, A. S.] King Faisal Specialist Hosp & Res Ctr, Dept Med, POB 3354, Riyadh 11211, Saudi Arabia; [Al-Khalaf, H. H.] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh 11211, Saudi Arabia; [Akhtar, M.] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, POB 3354, Riyadh 11211, Saudi Arabia; [Assiri, A. M.] King Faisal Specialist Hosp & Res Ctr, Dept Comparat Med, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Leicester; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Shi, Y (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Genet, MBC 3,Takhassusi St,POB 3354, Riyadh 11211, Saudi Arabia.	yufei@kfshrc.edu.sa	Shi, Yufei/ABG-5228-2020; Alkhalaf, Huda/Z-5701-2019; Hawwari, Abbas/L-1934-2019	Shi, Yufei/0000-0002-6999-0191; Hawwari, Abbas/0000-0001-9643-6500; Pritchard, Catrin/0000-0003-1859-4487; Assiri, Abdullah/0000-0002-2753-5238; Assiri, Abdullah/0000-0002-5605-2876	KACST [11-BIO1434-20]; NATIONAL CANCER INSTITUTE [ZIABC005522] Funding Source: NIH RePORTER; Cancer Research UK [13083] Funding Source: researchfish	KACST; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK)	We would like to thank Mr Wilfredo Antiquera for excellent technical support. This study is supported by KACST grant 11-BIO1434-20.	Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Arciuch VGA, 2011, ONCOTARGET, V2, P1109, DOI 10.18632/oncotarget.380; Boelaert K, 2006, J CLIN ENDOCR METAB, V91, P4295, DOI 10.1210/jc.2006-0527; Boelaert K, 2009, ENDOCR-RELAT CANCER, V16, P1065, DOI 10.1677/ERC-09-0150; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Charles RP, 2014, MOL CANCER RES, V12, P979, DOI 10.1158/1541-7786.MCR-14-0158-T; Charles RP, 2011, CANCER RES, V71, P3863, DOI 10.1158/0008-5472.CAN-10-4463; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng JC, 2011, ONCOGENE, V30, P1020, DOI 10.1038/onc.2010.486; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838; Durante C, 2007, J CLIN ENDOCR METAB, V92, P2840, DOI 10.1210/jc.2006-2707; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fiore E, 2010, ENDOCR-RELAT CANCER, V17, P231, DOI 10.1677/ERC-09-0251; Fiore E, 2009, ENDOCR-RELAT CANCER, V16, P1251, DOI 10.1677/ERC-09-0036; Fiore E, 2012, J CLIN ENDOCR METAB, V97, P1134, DOI 10.1210/jc.2011-2735; Franco AT, 2011, P NATL ACAD SCI USA, V108, P1615, DOI 10.1073/pnas.1015557108; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Fujisawa T, 2012, INT J CANCER, V131, P344, DOI 10.1002/ijc.26366; Hagemann T, 2007, MOL CANCER THER, V6, P1993, DOI 10.1158/1535-7163.MCT-07-0118; Haymart MR, 2009, CLIN ENDOCRINOL, V71, P434, DOI 10.1111/j.1365-2265.2008.03489.x; Hollenbeak CS, 2013, EUR J ENDOCRINOL, V168, P549, DOI 10.1530/EJE-12-0848; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Jonklaas J, 2008, THYROID, V18, P943, DOI 10.1089/thy.2008.0061; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Kollmar O, 2008, J SURG RES, V145, P295, DOI 10.1016/j.jss.2007.02.010; Kusakabe T, 2004, GENESIS, V39, P212, DOI 10.1002/gene.20043; Li XY, 2014, ONCOTARGET, V5, P788, DOI 10.18632/oncotarget.1772; Malaguarnera R, 2007, ENDOCR-RELAT CANCER, V14, P43, DOI 10.1677/erc.1.01223; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mazzaferri EL, 2001, J CLIN ENDOCR METAB, V86, P1447, DOI 10.1210/jc.86.4.1447; McFadden DG, 2014, P NATL ACAD SCI USA, V111, pE1600, DOI 10.1073/pnas.1404357111; Mercer K, 2005, CANCER RES, V65, P11493, DOI 10.1158/0008-5472.CAN-05-2211; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Natori T, 2002, BIOCHEM BIOPH RES CO, V297, P1058, DOI 10.1016/S0006-291X(02)02335-5; Romei C, 2008, ENDOCR-RELAT CANCER, V15, P511, DOI 10.1677/ERC-07-0130; Rosivatz E, 2006, ACS CHEM BIOL, V1, P780, DOI 10.1021/cb600352f; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shimamura M, 2013, ENDOCRINOLOGY, V154, P4423, DOI 10.1210/en.2013-1174; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vizioli MG, 2014, ONCOTARGET, V5, P8270, DOI 10.18632/oncotarget.2013; Vizioli MG, 2011, ENDOCR-RELAT CANCER, V18, P743, DOI 10.1530/ERC-11-0240; Wei S, 1999, CANCER RES, V59, P1539; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524; Yoshimura T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058791; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856; Zou MJ, 2014, THYROID, V24, P1256, DOI 10.1089/thy.2013.0610	59	27	27	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1909	1918		10.1038/onc.2015.253	http://dx.doi.org/10.1038/onc.2015.253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26477313	Green Accepted			2022-12-28	WOS:000374010300004
J	Boudjadi, S; Carrier, JC; Groulx, JF; Beaulieu, JF				Boudjadi, S.; Carrier, J. C.; Groulx, J-F; Beaulieu, J-F			Integrin alpha 1 beta 1 expression is controlled by c-MYC in colorectal cancer cells	ONCOGENE			English	Article							TRANSCRIPTIONAL REGULATION; EPITHELIAL-CELLS; GENE-EXPRESSION; DNA-BINDING; MAX; APOPTOSIS; PROLIFERATION; CARCINOMA; INVASION; SUBUNIT	The alpha 1 beta 1 collagen receptor is only present in a few epithelial cell types. In the intestine, it is specifically expressed in proliferating crypt cells. This integrin has been reported to be involved in various cancers where it mediates the downstream activation of the Ras/ERK proliferative pathway. We have recently shown that integrin alpha 1 beta 1 is present in two-thirds of colon adenocarcinomas, but the mechanism by which ITGA1 expression is regulated is not known. DNA methylation, involved in ITGA1 repression during megakaryocyte differentiation, is not the mechanism of ITGA1 regulation in colorectal cancer cells. Our in silico analysis of the ITGA1 promoter revealed two response elements for MYC, an oncogenic factor known to regulate cancer cell proliferation, invasion and migration. In situ, the expressions of both MYC and ITGA1 are localized in the lower crypt of the normal colon and correlate in 72% of the 65 analyzed colorectal cancers. MYC pharmacological inhibition or downregulation of expression with short hairpin RNA in HT29, T84 and SW480 cells resulted in reduced ITGA1 expression at both the transcript and protein levels. Chromatin immunoprecipitation assays revealed that MYC was bound to the chromatin region of the ITGA1 proximal promoter, whereas MYC overexpression enhanced ITGA1 promoter activity that was reduced with MAD co-transfection or by the disruption of the response elements. We concluded that MYC is a key regulating factor for the control of ITGA1 expression.	[Boudjadi, S.; Carrier, J. C.; Groulx, J-F; Beaulieu, J-F] Univ Sherbrooke, Lab Intestinal Physiopathol, Dept Anat & Cell Biol, Sherbrooke, PQ J1K 2R1, Canada; [Boudjadi, S.; Carrier, J. C.] Univ Sherbrooke, Dept Med, Fac Med & Hlth Sci, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke; University of Sherbrooke	Beaulieu, JF (corresponding author), Fac Med & Sci Sante, Dept Anat & Biol Cellulaire, Aile 4,Local 9425,3001,12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Jean-Francois.Beaulieu@USherbrooke.ca			Canadian Institute of Health Research Grants [MOP-97836, MOP-123415]; Canadian Research Chair in Intestinal Physiopathology; Fonds de la Recherche en Sante du Quebec; Fonds de la Recherche du Quebec-Sante (FRQS)	Canadian Institute of Health Research Grants(Canadian Institutes of Health Research (CIHR)); Canadian Research Chair in Intestinal Physiopathology; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Fonds de la Recherche du Quebec-Sante (FRQS)	We thank Elizabeth Herring for technical support and reviewing the manuscript, Eric Tremblay for virus production, Dr Marie-Pierre Garand of the Biostatistics Facility of the Centre de Recherche du CHUS for assistance in statistical analyses and Dr Andrea Quaroni (Cornell University, Ithaca) for the gift of Caco-2/15 cells. This work was supported by the Canadian Institute of Health Research Grants MOP-97836 and MOP-123415 (to J-FB). J-FB is the recipient of the Canadian Research Chair in Intestinal Physiopathology. JCC is a scholar of the Fonds de la Recherche du Quebec-Sante (FRQS). J-FB and JCC are members of the Fonds de la Recherche en Sante du Quebec-funded Centre de Recherche of the Centre Hospitalier Universitaire de Sherbrooke.	Abair TD, 2008, BLOOD, V112, P3242, DOI 10.1182/blood-2007-12-126433; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Basora N, 1998, INT J CANCER, V75, P738, DOI 10.1002/(SICI)1097-0215(19980302)75:5<738::AID-IJC12>3.0.CO;2-2; Beaulieu Jean-Francois, 2010, World J Gastrointest Pathophysiol, V1, P3, DOI 10.4291/wjgp.v1.i1.3; BEAULIEU JF, 1992, J CELL SCI, V102, P427; Beausejour M, 2012, APOPTOSIS, V17, P566, DOI 10.1007/s10495-012-0713-6; Belaguli NS, 2010, NEOPLASIA, V12, P856, DOI 10.1593/neo.10224; Benoit YD, 2010, BIOCHEM BIOPH RES CO, V399, P434, DOI 10.1016/j.bbrc.2010.07.107; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boudjadi S, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-16; Boudjadi S, 2013, AM J PATHOL, V183, P266, DOI 10.1016/j.ajpath.2013.03.021; Bustin SA, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-74; Cheli Y, 2007, BBA-GENE STRUCT EXPR, V1769, P546, DOI 10.1016/j.bbaexp.2007.06.004; Chen YH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-246; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dydensborg AB, 2006, AM J PHYSIOL-GASTR L, V290, pG1067, DOI 10.1152/ajpgi.00234.2005; Dydensborg AB, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-223; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fujimoto H, 2001, GENES CELLS, V6, P337, DOI 10.1046/j.1365-2443.2001.00428.x; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Groulx JF, 2014, CARCINOGENESIS, V35, P1217, DOI 10.1093/carcin/bgu006; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin CP, 2007, ANTI-CANCER DRUG, V18, P161, DOI 10.1097/CAD.0b013e3280109424; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; Macias-Perez I, 2008, CANCER RES, V68, P6127, DOI 10.1158/0008-5472.CAN-08-1395; Mo H, 2006, P NATL ACAD SCI USA, V103, P6344, DOI 10.1073/pnas.0601418103; Ni HH, 2005, ONCOGENE, V24, P6820, DOI 10.1038/sj.onc.1208848; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; Obata H, 1997, J BIOL CHEM, V272, P26643, DOI 10.1074/jbc.272.42.26643; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park S, 2004, BBA-GEN SUBJECTS, V1670, P217, DOI 10.1016/j.bbagen.2003.12.007; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; Suzuki H, 2010, CARCINOGENESIS, V31, P342, DOI 10.1093/carcin/bgp179; Tanaka N, 2008, INT J ONCOL, V33, P815, DOI 10.3892/ijo_00000069; Vachon Pierre H, 2011, J Signal Transduct, V2011, P738137, DOI 10.1155/2011/738137; van Golen CM, 2003, ONCOGENE, V22, P2664, DOI 10.1038/sj.onc.1206362; Van Slambrouck S, 2007, INT J ONCOL, V31, P1501; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yang CQ, 2003, CANCER RES, V63, P8312; Yang HP, 2009, HEPATOLOGY, V49, P860, DOI 10.1002/hep.22720; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	55	37	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1671	1678		10.1038/onc.2015.231	http://dx.doi.org/10.1038/onc.2015.231			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096932	hybrid, Green Published			2022-12-28	WOS:000373064200006
J	Pantel, K; Speicher, MR				Pantel, K.; Speicher, M. R.			The biology of circulating tumor cells	ONCOGENE			English	Review							BREAST-CANCER PATIENTS; BONE-MARROW; PROGNOSTIC-SIGNIFICANCE; CLONAL EVOLUTION; LIQUID BIOPSY; ARRAY-CGH; METASTASIS; GENOME; DISSEMINATION; DNA	Metastasis is a biologically complex process consisting of numerous stochastic events which may tremendously differ across various cancer types. Circulating tumor cells (CTCs) are cells that are shed from primary tumors and metastatic deposits into the blood stream. CTCs bear a tremendous potential to improve our understanding of steps involved in the metastatic cascade, starting from intravasation of tumor cells into the circulation until the formation of clinically detectable metastasis. These efforts were propelled by novel high-resolution approaches to dissect the genomes and transcriptomes of CTCs. Furthermore, capturing of viable CTCs has paved the way for innovative culturing technologies to study fundamental characteristics of CTCs such as invasiveness, their kinetics and responses to selection barriers, such as given therapies. Hence the study of CTCs is not only instrumental as a basic research tool, but also allows the serial monitoring of tumor genotypes and may therefore provide predictive and prognostic biomarkers for clinicians. Here, we review how CTCs have contributed to significant insights into the metastatic process and how they may be utilized in clinical practice.	[Pantel, K.] Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, Martinistr 52, D-20246 Hamburg, Germany; [Speicher, M. R.] Med Univ Graz, Inst Human Genet, Harrachgasse 21-8, A-8010 Graz, Austria	University of Hamburg; University Medical Center Hamburg-Eppendorf; Medical University of Graz	Pantel, K (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, Martinistr 52, D-20246 Hamburg, Germany.; Speicher, MR (corresponding author), Med Univ Graz, Inst Human Genet, Harrachgasse 21-8, A-8010 Graz, Austria.	pantel@uke.de; michael.speicher@medunigraz.at	Speicher, Michael R/B-5362-2013	Speicher, Michael R/0000-0003-0105-955X	Austrian Science Fund (FWF) [P20338, P23284]; Oesterreichische Nationalbank [15093]; ERC Advanced Investigator Grant DISSECT; Deutsche Forschungsgemeinschaft (DFG) [PA 341/19]; Cancer-ID - Innovative Medicines Joint Undertaking (IMI JU); TRANSCAN ERA-Network: Grant CTC-SCAN	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Oesterreichische Nationalbank; ERC Advanced Investigator Grant DISSECT; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Cancer-ID - Innovative Medicines Joint Undertaking (IMI JU); TRANSCAN ERA-Network: Grant CTC-SCAN	This work was supported in the laboratory of MRS by the Austrian Science Fund (FWF) (grant#: P20338 and P23284), the Oesterreichische Nationalbank (project#: 15093) and in the laboratory of KP by the ERC Advanced Investigator Grant DISSECT, TRANSCAN ERA-Network: Grant CTC-SCAN and Deutsche Forschungsgemeinschaft (DFG) grant PA 341/19. Both authors are supported by Cancer-ID, a project funded by the Innovative Medicines Joint Undertaking (IMI JU).	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Alix-Panabieres C, 2007, CLIN CHEM, V53, P537, DOI 10.1373/clinchem.2006.079509; Alix-Panabieres C, 2014, NAT REV CANCER, V14, P623, DOI 10.1038/nrc3820; Alix-Panabieres C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258; Alix-Panabieres Catherine, 2012, Recent Results Cancer Res, V195, P69, DOI 10.1007/978-3-642-28160-0_6; Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378; Almendro V, 2014, CELL REP, V6, P514, DOI 10.1016/j.celrep.2013.12.041; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Bailey CK, 2012, J BIOL CHEM, V287, P19472, DOI 10.1074/jbc.M112.345728; Bednarz-Knoll N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2940; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Campos M, 2008, J HISTOCHEM CYTOCHEM, V56, P667, DOI 10.1369/jhc.2008.951111; Cayrefourcq L, 2015, CANCER RES, V75, P892, DOI 10.1158/0008-5472.CAN-14-2613; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen HB, 2008, J CLIN ONCOL, V26, P3284, DOI 10.1200/JCO.2008.16.3543; Cho EH, 2012, PHYS BIOL, V9, DOI 10.1088/1478-3975/9/1/016001; Cohen SJ, 2009, ANN ONCOL, V20, P1223, DOI 10.1093/annonc/mdn786; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; Deneve E, 2013, CLIN CHEM, V59, P1384, DOI 10.1373/clinchem.2013.202846; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Fiegler H, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1030; Fischer JC, 2013, P NATL ACAD SCI USA, V110, P16580, DOI 10.1073/pnas.1313594110; Fonkem E, 2011, J CLIN ONCOL, V29, P4594, DOI 10.1200/JCO.2011.39.0187; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933; Guzvic M, 2014, CANCER RES, V74, P7383, DOI 10.1158/0008-5472.CAN-14-0934; Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He W, 2007, P NATL ACAD SCI USA, V104, P11760, DOI 10.1073/pnas.0703875104; Heidary M, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0421-y; Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm477; Heitzer E, 2013, INT J CANCER, V133, P346, DOI 10.1002/ijc.28030; Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140; Hodgkinson CL, 2014, NAT MED, V20, P897, DOI 10.1038/nm.3600; Holen I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3201; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Janni W, 2011, CLIN CANCER RES, V17, P2967, DOI 10.1158/1078-0432.CCR-10-2515; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Kidess E, 2013, GENOME MED, V5, DOI 10.1186/gm474; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253; Krebs MG, 2011, J CLIN ONCOL, V29, P1556, DOI 10.1200/JCO.2010.28.7045; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Labelle M, 2012, CANCER DISCOV, V2, P1091, DOI 10.1158/2159-8290.CD-12-0329; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; LIOTTA LA, 1976, CANCER RES, V36, P889; Lohr JG, 2014, NAT BIOTECHNOL, V32, P479, DOI 10.1038/nbt.2892; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; MANDYBUR TI, 1984, ACTA NEUROPATHOL, V63, P203, DOI 10.1007/BF00685246; Mathiesen RR, 2012, INT J CANCER, V131, pE405, DOI 10.1002/ijc.26444; Meng SD, 2004, CLIN CANCER RES, V10, P8152, DOI 10.1158/1078-0432.CCR-04-1110; Metzker Michael L, 2010, Nat Rev Genet, V11, P31, DOI 10.1038/nrg2626; Muller C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009095; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Navin NE, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0452-9; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ni XH, 2013, P NATL ACAD SCI USA, V110, P21083, DOI 10.1073/pnas.1320659110; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Ozkumur E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005616; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008-5472.CAN-13-2030; Pantel K, 2012, CLIN CHEM, V58, P936, DOI 10.1373/clinchem.2011.175570; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Powell AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033788; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Sandberg R, 2014, NAT METHODS, V11, P22, DOI 10.1038/nmeth.2764; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; SEIDEN MV, 1994, J CLIN ONCOL, V12, P2634, DOI 10.1200/JCO.1994.12.12.2634; Seoane J, 2014, CANCER DISCOV, V4, P1259, DOI 10.1158/2159-8290.CD-14-1178; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Speicher MR, 2014, NAT BIOTECHNOL, V32, P441, DOI 10.1038/nbt.2897; Stott SL, 2010, P NATL ACAD SCI USA, V107, P18392, DOI 10.1073/pnas.1012539107; Stott SL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000403; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Ting DT, 2014, CELL REP, V8, P1905, DOI 10.1016/j.celrep.2014.08.029; Uhra JW, 2011, P NATL ACAD SCI USA, V108, P12396, DOI 10.1073/pnas.1106613108; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Van Loo P, 2014, CURR OPIN GENET DEV, V24, P82, DOI 10.1016/j.gde.2013.12.004; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; Xi L, 2007, CLIN CHEM, V53, P1206, DOI 10.1373/clinchem.2006.081828; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yu M, 2014, SCIENCE, V345, P216, DOI 10.1126/science.1253533; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021; Zhang LX, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005109; Zong CH, 2012, SCIENCE, V338, P1622, DOI 10.1126/science.1229164	119	292	306	7	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1216	1224		10.1038/onc.2015.192	http://dx.doi.org/10.1038/onc.2015.192			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26050619				2022-12-28	WOS:000371763100002
J	Groves, IJ; Knight, ELA; Ang, QY; Scarpini, CG; Coleman, N				Groves, I. J.; Knight, E. L. A.; Ang, Q. Y.; Scarpini, C. G.; Coleman, N.			HPV16 oncogene expression levels during early cervical carcinogenesis are determined by the balance of epigenetic chromatin modifications at the integrated virus genome	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; TRANSCRIPTION FACTOR-BINDING; GENE-EXPRESSION; IN-VITRO; HISTONE MODIFICATIONS; REGULATORY ELEMENTS; CELL-LINE; P-TEFB; KERATINOCYTES; METHYLATION	In cervical squamous cell carcinomas, high-risk human papillomavirus (HRHPV) DNA is usually integrated into host chromosomes. Multiple integration events are thought to be present within the cells of a polyclonal premalignant lesion and the features that underpin clonal selection of one particular integrant remain poorly understood. We previously used the W12 model system to generate a panel of cervical keratinocyte clones, derived from cells of a low-grade premalignant lesion naturally infected with the major HRHPV type, HPV16. The cells were isolated regardless of their selective advantage and differed only by the site of HPV16 integration into the host genome. We used this resource to test the hypothesis that levels of HPV16 E6/E7 oncogene expression in premalignant cells are regulated epigenetically. We performed a comprehensive analysis of the epigenetic landscape of the integrated HPV16 DNA in selected clones, in which levels of virus oncogene expression per DNA template varied similar to 6.6-fold. Across the cells examined, higher levels of virus expression per template were associated with more open chromatin at the HPV16 long control region, together with greater loading of chromatin remodelling enzymes and lower nucleosome occupancy. There were higher levels of histone post-translational modification hallmarks of transcriptionally active chromatin and lower levels of repressive hallmarks. There was greater abundance of the active/elongating form of the RNA polymerase-II enzyme (RNAPII-Ser2P), together with CDK9, the component of positive transcription elongation factor b complex responsible for Ser2 phosphorylation. The changes observed were functionally significant, as cells with higher HPV16 expression per template showed greater sensitivity to depletion and/or inhibition of histone acetyltransferases and CDK9 and less sensitivity to histone deacetylase inhibition. We conclude that virus gene expression per template following HPV16 integration is determined through multiple layers of epigenetic regulation, which are likely to contribute to selection of individual cells during cervical carcinogenesis.	[Groves, I. J.; Knight, E. L. A.; Ang, Q. Y.; Scarpini, C. G.; Coleman, N.] Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England	University of Cambridge	Coleman, N (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	nc109@cam.ac.uk	Groves, Ian John/HGU-5954-2022	Groves, Ian John/0000-0001-8882-6701; Scarpini, Cinzia G./0000-0003-4730-5197; Ang, Qi Yan/0000-0002-9788-1283	Cancer Research UK [A13080]; Medical Research Council; Pathological Society of Great Britain and Ireland; Agency for Science, Technology and Research, Singapore; Cancer Research UK [13080] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Pathological Society of Great Britain and Ireland; Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR)); Cancer Research UK(Cancer Research UK)	This work was supported by Cancer Research UK (Programme Grant A13080); the Medical Research Council; The Pathological Society of Great Britain and Ireland (ELAK); and the Agency for Science, Technology and Research, Singapore (QYA). Funding for open access charge: Cancer Research UK and the Medical Research Council.	Arce JD, 2012, HUM MOL GENET, V21, P1693, DOI 10.1093/hmg/ddr604; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; BEDELL MA, 1991, J VIROL, V65, P2254, DOI 10.1128/JVI.65.5.2254-2260.1991; Bernard HU, 2013, VIROLOGY, V445, P197, DOI 10.1016/j.virol.2013.04.035; Bogdanovic O, 2012, GENOME RES, V22, P2043, DOI 10.1101/gr.134833.111; Carson A, 2006, J VIROL, V80, P4356, DOI 10.1128/JVI.80.9.4356-4362.2006; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; COLEMAN N, 1994, HUM PATHOL, V25, P73, DOI 10.1016/0046-8177(94)90174-0; COLEMAN N, 1993, AM J PATHOL, V143, P355; Dall KL, 2008, CANCER RES, V68, P8249, DOI 10.1158/0008-5472.CAN-08-1741; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Euskirchen GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002008; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Gray E, 2010, CANCER RES, V70, P4081, DOI 10.1158/0008-5472.CAN-09-3335; Groves IJ, 2015, J PATHOL, V235, P527, DOI 10.1002/path.4496; Groves IJ, 2009, J GEN VIROL, V90, P2364, DOI 10.1099/vir.0.012526-0; Hanning JE, 2013, BRIT J CANCER, V108, P450, DOI 10.1038/bjc.2012.564; Hanning JE, 2013, J PATHOL, V231, P354, DOI 10.1002/path.4244; Hanning JE, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-159; Hazzalin CA, 2005, PLOS BIOL, V3, P2111, DOI 10.1371/journal.pbio.0030393; He HP, 2012, CELL CYCLE, V11, P617, DOI 10.4161/cc.11.3.19115; Herdman MT, 2006, CARCINOGENESIS, V27, P2341, DOI 10.1093/carcin/bgl172; Hyland PL, 2011, J VIROL, V85, P10999, DOI 10.1128/JVI.00160-11; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Jha S, 2010, MOL CELL, V38, P700, DOI 10.1016/j.molcel.2010.05.020; Johannsen E, 2013, VIROLOGY, V445, P205, DOI 10.1016/j.virol.2013.07.016; Johansson C, 2015, VIROLOGY, V482, P244, DOI 10.1016/j.virol.2015.02.053; Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112; Kim CH, 2015, BIOSCI BIOTECH BIOCH, V79, P532, DOI 10.1080/09168451.2014.993914; Kruppel U, 2008, VIROLOGY, V377, P151, DOI 10.1016/j.virol.2008.04.006; Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014; McLaughlin-Drubin ME, 2011, P NATL ACAD SCI USA, V108, P2130, DOI 10.1073/pnas.1009933108; Palermo RD, 2008, BIOCHEM SOC T, V36, P625, DOI 10.1042/BST0360625; Pena LD, 2001, J VIROL, V75, P10005, DOI 10.1128/JVI.75.20.10005-10013.2001; Pett M, 2007, J PATHOL, V212, P356, DOI 10.1002/path.2192; Pett MR, 2004, CANCER RES, V64, P1359, DOI 10.1158/0008-5472.CAN-03-3214; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Scarpini CG, 2014, J PATHOL, V233, P281, DOI 10.1002/path.4358; Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444; Smith JA, 2014, VIROLOGY, V468, P311, DOI 10.1016/j.virol.2014.08.022; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Stunkel W, 1999, J VIROL, V73, P1918; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang S, 2008, TRENDS PHARMACOL SCI, V29, P302, DOI 10.1016/j.tips.2008.03.003; Wang WM, 2011, J BIOL CHEM, V286, P40974, DOI 10.1074/jbc.M111.290874; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; Wentzensen N, 2012, JNCI-J NATL CANCER I, V104, P1738, DOI 10.1093/jnci/djs425; Wooldridge TR, 2008, VIROLOGY, V374, P371, DOI 10.1016/j.virol.2007.12.011; Xu M, 2013, VIROLOGY, V446, P17, DOI 10.1016/j.virol.2013.07.014; Yew CW, 2011, CANCER RES, V71, P6696, DOI 10.1158/0008-5472.CAN-11-1271; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	56	16	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4773	4786		10.1038/onc.2016.8	http://dx.doi.org/10.1038/onc.2016.8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876196	Green Published, hybrid			2022-12-28	WOS:000383324700010
J	Zhang, QB; Zhang, BH; Zhang, KZ; Meng, XT; Jia, QA; Zhang, QB; Bu, Y; Zhu, XD; Ma, DN; Ye, BG; Zhang, N; Ren, ZG; Sun, HC; Tang, ZY				Zhang, Q-B; Zhang, B-H; Zhang, K-Z; Meng, X-T; Jia, Q-A; Zhang, Q-B; Bu, Y.; Zhu, X-D; Ma, D-N; Ye, B-G; Zhang, N.; Ren, Z-G; Sun, H-C; Tang, Z-Y			Moderate swimming suppressed the growth and metastasis of the transplanted liver cancer in mice model: with reference to nervous system	ONCOGENE			English	Article							PHYSICAL-ACTIVITY; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; TUMOR-GROWTH; TGF-BETA; EXERCISE INTERVENTION; PREFRONTAL CORTEX; DOWN-REGULATION; GASTRIC-CANCER; T-CELLS	Physical activity has been shown to suppress tumor initiation and progression. The neurotransmitter dopamine (DA) is closely related to movement and exhibits antitumor properties. However, whether the suppressive effects of physical activity on tumors was mediated by the nervous system via increased DA level remains unknowns. Here we show that regular moderate swimming (8 min/day, 9 weeks) raised DA levels in the prefrontal cortex, serum and tumor tissue, suppressed growth, reduced lung metastasis of transplanted liver cancer, and prolonged survival in a C57BL/6 mouse model, while overload swimming (16 and 32 min/day, 9 weeks) had the opposite effect. In nude mice that were orthotopically implanted with human liver cancer cell lines, DA treatment significantly suppressed growth and lung metastasis by acting on the D2 receptor (DR2). Furthermore, DR2 blockade attenuated the suppressive effect of moderate swimming on liver cancer. Both moderate swimming and DA treatment suppressed the transforming growth factor-beta (TGF-beta 1)-induced epithelial-mesenchymal transition of transplanted liver cancer cells. At the molecular level, DR2 signaling inhibited extracellular signal-regulated kinase phosphorylation and expression of TGF-beta 1 in vitro. Together, these findings demonstrated a novel mechanism by which the moderate exercise suppressed liver cancer through boosting DR2 activity, while overload exercise had the opposite effect, highlighting the possible importance of the dopaminergic system in tumor growth and metastasis of liver cancer.	[Zhang, Q-B; Zhang, B-H; Zhang, K-Z; Jia, Q-A; Zhang, Q-B; Bu, Y.; Zhu, X-D; Ma, D-N; Ye, B-G; Zhang, N.; Ren, Z-G; Sun, H-C; Tang, Z-Y] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China; [Zhang, Q-B; Jia, Q-A] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China; [Zhang, K-Z] Fudan Univ, Huashan Hosp, Canc Metastasis Inst, Shanghai, Peoples R China; [Meng, X-T] Peoples Hosp Taizhou City, Dept Gen Surg, Taizhou, Peoples R China; [Zhang, Q-B] Xuzhou Med Coll, Sch Anesthesiol, Xuzhou, Peoples R China; [Zhang, Q-B] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China	Fudan University; Fudan University; Xuzhou Medical University; Shandong University	Tang, ZY (corresponding author), Fudan Univ, Liver Canc Inst, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Tang, ZY (corresponding author), Fudan Univ, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China.	tang.zhaoyou@zs-hospital.sh.cn	Zhu, Xiao-Dong/A-8197-2010	Zhu, Xiao-Dong/0000-0001-9864-6763; Sun, Hui-Chuan/0000-0003-3761-7058	National Natural Science Foundation of China [81372314]; National Key Project for Infectious Diseases of China [2012ZX10002012-004]; Shanghai Natural Science Fund for Youth Scholars [12ZR1442300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Project for Infectious Diseases of China; Shanghai Natural Science Fund for Youth Scholars	This project was supported by the National Natural Science Foundation of China (grant number: 81372314), the National Key Project for Infectious Diseases of China (2012ZX10002012-004) and the Shanghai Natural Science Fund for Youth Scholars (12ZR1442300). The authors appreciate the instruction in writing of the manuscript provided by Professor Hong Tu and Assistant Professor Yu Gan (State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, China).	Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Almeida PWM, 2009, J APPL PHYSIOL, V107, P261, DOI 10.1152/japplphysiol.00249.2009; Ballard-Barbash R, 2012, JNCI-J NATL CANCER I, V104, P815, DOI 10.1093/jnci/djs207; Chakroborty D, 2004, CLIN CANCER RES, V10, P4349, DOI 10.1158/1078-0432.CCR-04-0059; Chakroborty D, 2008, J CLIN INVEST, V118, P1380, DOI 10.1172/JCI33125; Demarzo MMP, 2004, CANCER LETT, V216, P31, DOI 10.1016/j.canlet.2004.06.002; Friedenreich CM, 2010, J CLIN ONCOL, V28, P1458, DOI 10.1200/JCO.2009.24.9557; Ganguly S, 2010, AM J PATHOL, V177, P2701, DOI 10.2353/ajpath.2010.100617; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Giovannucci EL, 2012, JNCI-J NATL CANCER I, V104, P797, DOI 10.1093/jnci/djs229; Goldacre MJ, 2005, BRIT J PSYCHIAT, V187, P334, DOI 10.1192/bjp.187.4.334; Gray JR, 2002, P NATL ACAD SCI USA, V99, P4115, DOI 10.1073/pnas.062381899; He SB, 2012, INT J SPORTS MED, V33, P525, DOI 10.1055/s-0032-1306325; Heinen MM, 2011, AM J CLIN NUTR, V94, P1314, DOI 10.3945/ajcn.110.007542; Herz DM, 2014, NEUROIMAGE, V90, P15, DOI 10.1016/j.neuroimage.2013.11.023; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; ISHIBASHI M, 1994, CANCER RES, V54, P3442; Jia QA, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-89; Klaissle P, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-132; Lee J, 2012, J NUTR BIOCHEM, V23, P1341, DOI 10.1016/j.jnutbio.2011.08.003; Li Y, 2003, J CANCER RES CLIN, V129, P43, DOI 10.1007/s00432-002-0396-4; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Moderate exercise may reduce ovarian cancer risk, 2006, MAYO CLIN WOMENS HLT, V10, P3; Moreno-Smith M, 2011, CLIN CANCER RES, V17, P3649, DOI 10.1158/1078-0432.CCR-10-2441; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Muller HK, 2011, BRAIN RES, V1385, P26, DOI 10.1016/j.brainres.2011.02.048; Murphy EA, 2004, J APPL PHYSIOL, V97, P955, DOI 10.1152/japplphysiol.00252.2004; Pacheco R, 2009, J NEUROIMMUNOL, V216, P8, DOI 10.1016/j.jneuroim.2009.07.018; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Peng H, 2013, HEPATOLOGY, V57, P2299, DOI 10.1002/hep.26258; Pickett M, 2002, CANCER PRACT, V10, P284, DOI 10.1046/j.1523-5394.2002.106006.x; Saez MD, 2007, MOL CELL BIOCHEM, V294, P19, DOI 10.1007/s11010-005-9067-5; Sasvari M, 2011, J SPORT SCI MED, V10, P93; Tang ZY, 2012, CHIN J INTEGR MED, V18, P323, DOI 10.1007/s11655-012-1103-1; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; THOMPSON HJ, 1994, CANCER RES, V54, pS1960; Tian F, 2003, CANCER RES, V63, P8284; Wan DF, 2004, P NATL ACAD SCI USA, V101, P15724, DOI 10.1073/pnas.0404089101; Wang J, 2012, SCAND J MED SCI SPOR, V22, P643, DOI 10.1111/j.1600-0838.2010.01288.x; Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808; World Health Organization, 2010, GLOB REC PHYS ACT HL, P10; Zhang Q, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054250, 10.1371/journal.pone.0059667]; Zhang W, 2012, GASTROENTEROLOGY, V143, P1641, DOI 10.1053/j.gastro.2012.08.032; Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904	45	33	39	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4122	4131		10.1038/onc.2015.484	http://dx.doi.org/10.1038/onc.2015.484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686088				2022-12-28	WOS:000381020900010
J	Bieging-Rolett, KT; Johnson, TM; Brady, CA; Beaudry, VG; Pathak, N; Han, S; Attardi, LD				Bieging-Rolett, K. T.; Johnson, T. M.; Brady, C. A.; Beaudry, V. G.; Pathak, N.; Han, S.; Attardi, L. D.			p19(Arf) is required for the cellular response to chronic DNA damage	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; GENOMIC INSTABILITY; TUMOR SUPPRESSION; LIFE-SPAN; ARF; P53; CELLS; ACTIVATION; ARREST; CHECKPOINT	The p53 tumor suppressor is a stress sensor, driving cell cycle arrest or apoptosis in response to DNA damage or oncogenic signals. p53 activation by oncogenic signals relies on the p19(Arf) tumor suppressor, while p53 activation downstream of acute DNA damage is reported to be p19(Arf)-independent. Accordingly, p19(Arf)-deficient mouse embryo fibroblasts (MEFs) arrest in response to acute DNA damage. However, p19(Arf) is required for replicative senescence, a condition associated with an activated DNA damage response, as p19(Arf) -/- MEFs do not senesce after serial passage. A possible explanation for these seemingly disparate roles for p19(Arf) is that acute and chronic DNA damage responses are mechanistically distinct. Replicative senescence may result from chronic, low-dose DNA damage responses in which p19(Arf) has a specific role. We therefore examined the role of p19(Arf) in cellular responses to chronic, low-dose DNA-damaging agent treatment by maintaining MEFs in low oxygen and administering 0.5 G y gamma-irradiation daily or 150 mu M hydroxyurea, a replication stress inducer. In contrast to their response to acute DNA damage, p19(Arf) -/- MEFs exposed to chronic DNA damage do not senesce, revealing a selective role for p19(Arf) in senescence upon low-level, chronic DNA damage. We show further that p53 pathway activation in p19(Arf) -/- MEFs exposed to chronic DNA damage is attenuated relative to wild-type MEFs, suggesting a role for p19(Arf) in fine-tuning p53 activity. However, combined Nutlin3a and chronic DNA-damaging agent treatment is insufficient to promote senescence in p19(Arf) -/- MEFs, suggesting that the role of p19(Ar)f in the chronic DNA damage response may be partially p53-independent. These data suggest the importance of p19(Arf) for the cellular response to the low-level DNA damage incurred in culture or upon oncogene expression, providing new insight into how p19(Arf) serves as a tumor suppressor. Moreover, our study helps reconcile reports suggesting crucial roles for both p19(Arf) and DNA damage-signaling pathways in tumor suppression.	[Bieging-Rolett, K. T.; Johnson, T. M.; Brady, C. A.; Beaudry, V. G.; Pathak, N.; Han, S.; Attardi, L. D.] Stanford Univ, Dept Radiat Oncol, Sch Med, Div Radiat & Canc Biol, Stanford, CA 94305 USA; [Attardi, L. D.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Attardi, LD (corresponding author), Stanford Univ, Sch Med, Div Radiat & Canc Biol, Dept Radiat Oncol,CCSR South, Room 1255,269 Campus Dr, Stanford, CA 94305 USA.	attardi@stanford.edu		han, shuo/0000-0003-1181-351X	American Cancer Society postdoctoral fellowship [122767-PF-12-195-01-TBG]; American Cancer Society [RSG-06-065-01-MGO]; Leukemia and Lymphoma Society [LLS-1012-09]; National Institutes of Health [CA140875]; NATIONAL CANCER INSTITUTE [R35CA197591, R01CA140875] Funding Source: NIH RePORTER	American Cancer Society postdoctoral fellowship(American Cancer Society); American Cancer Society(American Cancer Society); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Charles Sherr for the kind gift of the p19<SUP>Arf</SUP> antibody and Nitin Raj and Margot Bowen for critical reading of the manuscript. KBR was funded by an American Cancer Society postdoctoral fellowship 122767-PF-12-195-01-TBG. This work was supported by funding from the American Cancer Society (RSG-06-065-01-MGO), the Leukemia and Lymphoma Society (LLS-1012-09), and the National Institutes of Health (CA140875) to LDA.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Borel F, 2002, J CELL SCI, V115, P2829; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Carlos AR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3697; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2008, CELL CYCLE, V7, P3601, DOI 10.4161/cc.7.22.7152; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Evangelou K, 2013, CELL DEATH DIFFER, V20, P1485, DOI 10.1038/cdd.2013.76; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hinkal G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006654; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Kotsinas A, 2014, CELL CYCLE, V13, P1227, DOI 10.4161/cc.28654; Kuo ML, 2008, CELL CYCLE, V7, P3378, DOI 10.4161/cc.7.21.6930; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Monasor A, 2013, CELL CYCLE, V12, P1948, DOI 10.4161/cc.25017; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991	44	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4414	4421		10.1038/onc.2015.490	http://dx.doi.org/10.1038/onc.2015.490			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26725325	Green Accepted			2022-12-28	WOS:000382152100013
J	Yeganeh, M; Gui, Y; Kandhi, R; Bobbala, D; Tobelaim, WS; Saucier, C; Yoshimura, A; Ferbeyre, G; Ramanathan, S; Ilangumaran, S				Yeganeh, M.; Gui, Y.; Kandhi, R.; Bobbala, D.; Tobelaim, W-S; Saucier, C.; Yoshimura, A.; Ferbeyre, G.; Ramanathan, S.; Ilangumaran, S.			Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; SOCS PROTEINS; EGF RECEPTOR; P21; REGENERATION; CANCER; HEPATOCARCINOGENESIS; PHOSPHORYLATION; P21(WAF1/CIP1); PROLIFERATION	The SOCS1 gene coding for suppressor of cytokine signaling 1 is frequently repressed in hepatocellular carcinoma (HCC), and hence SOCS1 is considered a tumor suppressor in the liver. However, the tumor-suppressor mechanisms of SOCS1 are not yet well understood. SOCS1 is known to inhibit pro-inflammatory cytokine production and signaling and to promote activation of the p53 tumor suppressor. However, we observed that SOCS1-deficient mice developed numerous and large liver tumor nodules following treatment with the hepatocarcinogen diethylnitrosamine (DEN) without showing increased interleukin-6 production or activation of p53. On the other hand, the livers of DEN-treated Socs1-null mice showed elevated levels of p21(CIP1/WAF1) protein (p21). Even though p21 generally functions as a tumor suppressor, paradoxically many cancers, including HCC, are known to express elevated levels of p21 that correlate with poor prognosis. We observed elevated p21 expression also in the regenerating livers of SOCS1-deficient mice and in cisplatin-treated Socs1-null hepatocytes, wherein the p21 protein showed increased stability. We show that SOCS1 interacts with p21 and promotes its ubiquitination and proteasomal degradation. Besides, the DEN-treated livers of Socs1-null mice showed increased nuclear and cytosolic p21 staining, and the latter was associated with growth factor-induced, phosphatidylinositol 3-kinase-dependent phosphorylation of p21 in SOCS1-deficient hepatocytes. Cytosolic p21 is often associated with malignancy and chemo-resistance in many cancers. Accordingly, SOCS1-deficient hepatocytes showed increased resistance to apoptosis that was reversed by shRNA-mediated p21 knockdown. In the regenerating livers of Socs1-null mice, increased p21 expression coincided with elevated cyclinD levels. Correspondingly, SOCS1-deficient hepatocytes showed increased proliferation to growth factor stimulation that was reversed by p21 knockdown. Overall, our findings indicate that the tumor-suppressor functions of SOCS1 in the liver could be mediated, at least partly, via regulation of the expression, stability and subcellular distribution of p21 and its paradoxical oncogenic functions, namely, resistance to apoptosis and increased proliferation.	[Yeganeh, M.; Gui, Y.; Kandhi, R.; Bobbala, D.; Ramanathan, S.; Ilangumaran, S.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, Div Immunol, 3001 North 12th Ave, Sherbrooke, PQ J1H 5N4, Canada; [Tobelaim, W-S; Saucier, C.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Anat & Cell Biol, Sherbrooke, PQ, Canada; [Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo, Japan; [Ferbeyre, G.] Univ Montreal, Dept Biochem, Montreal, PQ, Canada	University of Sherbrooke; University of Sherbrooke; Keio University; Universite de Montreal	Ilangumaran, S (corresponding author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, Div Immunol, 3001 North 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	Subburaj.Ilangumaran@Usherbrooke.ca	Saucier, Caroline/Q-9250-2019; Yoshimura, Akihiko/K-5515-2013	Saucier, Caroline/0000-0001-7678-9886; Ilangumaran, Subburaj/0000-0002-7563-576X	FRQNT graduate scholarship; Canadian Liver Foundation; Faculte de medecine et des sciences de la sante, Universite de Sherbrooke; FRQS; Canadian Institutes of Heath research [MOP-84234]; Cancer Research Society, Montreal, Canada [PIN: 17009]	FRQNT graduate scholarship; Canadian Liver Foundation; Faculte de medecine et des sciences de la sante, Universite de Sherbrooke; FRQS; Canadian Institutes of Heath research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society, Montreal, Canada	MY was a recipient of FRQNT graduate scholarship. YG was supported by a graduate scholarship from the Canadian Liver Foundation. RK is supported by a graduate scholarship from the Faculte de medecine et des sciences de la sante, Universite de Sherbrooke. DB is a recipient of a postdoctoral fellowship from FRQS. CR-CHUS is an FRQS-funded research center. This work was supported by operating grants from the Canadian Institutes of Heath research (to SI, MOP-84234) and Cancer Research Society, Montreal, Canada (to SI and GF, PIN: 17009).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Anderson P, 2010, NAT REV IMMUNOL, V10, P24, DOI 10.1038/nri2685; Boylan JM, 2005, BIOCHEM BIOPH RES CO, V330, P722, DOI 10.1016/j.bbrc.2005.03.042; Budhu A, 2006, J LEUKOCYTE BIOL, V80, P1197, DOI 10.1189/jlb.0506297; Buitrago-Molina LE, 2013, HEPATOLOGY, V58, P1143, DOI 10.1002/hep.26412; Calabrese V, 2009, MOL CELL, V36, P754, DOI 10.1016/j.molcel.2009.09.044; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2006, MOL CANCER THER, V5, P1385, DOI 10.1158/1535-7163.MCT-06-0163; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Gui Y, 2015, ONCOGENE, V34, P5718, DOI 10.1038/onc.2015.20; Gui YR, 2011, J HEPATOL, V55, P1300, DOI 10.1016/j.jhep.2011.03.027; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Iwahori K, 2013, INT J CANCER, V132, P459, DOI 10.1002/ijc.27611; Kazi JU, 2014, CELL MOL LIFE SCI, V71, P3297, DOI 10.1007/s00018-014-1619-y; Kong XN, 2012, HEPATOLOGY, V56, P1150, DOI 10.1002/hep.25744; Lachenmayer A, 2010, DIGEST LIVER DIS, V42, pS264, DOI 10.1016/S1590-8658(10)60515-4; Marhenke S, 2014, GUT, V63, P1501, DOI 10.1136/gutjnl-2013-304829; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsuda M, 2005, LAB INVEST, V85, P655, DOI 10.1038/labinvest.3700257; Natarajan A, 2007, P NATL ACAD SCI USA, V104, P17081, DOI 10.1073/pnas.0704126104; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Oh J, 2009, ONCOGENE, V28, P3145, DOI 10.1038/onc.2009.169; Okumura F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00010; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Schneller D, 2011, HEPATOLOGY, V54, P164, DOI 10.1002/hep.24329; Seki E, 2008, J HEPATOL, V48, P237, DOI 10.1016/j.jhep.2007.08.020; Sheng G, 2006, GASTROENTEROLOGY, V131, P153, DOI 10.1053/j.gastro.2006.05.007; Skarpen E, 2005, J CELL PHYSIOL, V202, P707, DOI 10.1002/jcp.20171; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Tanaka K, 2008, J IMMUNOL, V180, P3746, DOI 10.4049/jimmunol.180.6.3746; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Wierod L, 2008, ONCOGENE, V27, P2763, DOI 10.1038/sj.onc.1210937; Woelk T, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-11; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	46	24	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4200	4211		10.1038/onc.2015.485	http://dx.doi.org/10.1038/onc.2015.485			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26725321				2022-12-28	WOS:000382149800005
J	Bharti, R; Dey, G; Ojha, PK; Rajput, S; Jaganathan, SK; Sen, R; Mandal, M				Bharti, R.; Dey, G.; Ojha, P. K.; Rajput, S.; Jaganathan, S. K.; Sen, R.; Mandal, M.			Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer	ONCOGENE			English	Article							MULTIPLE-MYELOMA; PROSTATE-CANCER; CELL-SURVIVAL; INTERLEUKIN-6; PATHWAY; STAT3; IL-6; GP130; PHOSPHORYLATION; GROWTH	Interleukin-6 (IL-6) signaling network has been implicated in oncogenic transformations making it attractive target for the discovery of novel cancer therapeutics. In this study, potent antiproliferative and apoptotic effect of diacerein were observed against breast cancer. In vitro apoptosis was induced by this drug in breast cancer cells as verified by increased sub-G(1) population, LIVE/DEAD assay, cell cytotoxicity and presence of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells, as well as downregulation of antiapoptotic proteins Bcl-2 and Bcl-xL and upregulation of apoptotic protein Bax. In addition, apoptosis induction was found to be caspase dependent. Further molecular investigations indicated that diacerein instigated apoptosis was associated with inhibition of IL-6/IL-6R autocrine signaling axis. Suppression of STAT3, MAPK and Akt pathways were also observed as a consequence of diacerein-mediated upstream inhibition of IL-6/IL-6R. Fluorescence study and western blot analysis revealed cytosolic accumulation of STAT3 in diacerein-treated cells. The docking study showed diacerein/IL-6R interaction that was further validated by competitive binding assay and isothermal titration calorimetry. Most interestingly, it was found that diacerein considerably suppressed tumor growth in MDA-MB-231 xenograft model. The in vivo antitumor effect was correlated with decreased proliferation (Ki-67), increased apoptosis (TUNEL) and inhibition of IL-6/IL-6R-mediated STAT3, MAPK and Akt pathway in tumor remnants. Taken together, diacerein offered a novel blueprint for cancer therapy by hampering IL-6/IL-6R/STAT3/MAPK/Akt network.	[Bharti, R.; Dey, G.; Rajput, S.; Mandal, M.] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India; [Ojha, P. K.] Jadavpur Univ, Dept Pharmaceut Technol, Div Med & Pharmaceut Chem, Drug Theoret & Cheminformat Lab, Kolkata, India; [Jaganathan, S. K.] Univ Teknol, Fac Biosci & Med Engn, IJN UTM Cardiovasc Engn Ctr, Skudai, Johor, Malaysia; [Sen, R.] Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur, W Bengal, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; Jadavpur University; Universiti Teknologi Malaysia; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur	Mandal, M (corresponding author), Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.	mahitosh@smst.iitkgp.ernet.in	Mandal, Mahitosh/Q-7421-2016; Sen, Ramkrishna/C-8772-2014; Jaganathan, Saravana Kumar/N-2385-2017; jain, shashi/AAF-4706-2020; JAIN, SHASHI/N-8877-2017; Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323; Sen, Ramkrishna/0000-0002-6207-3307; Jaganathan, Saravana Kumar/0000-0002-2785-137X; jain, shashi/0000-0001-9428-0135; JAIN, SHASHI/0000-0001-9428-0135; Mandal, Mahitosh/0000-0003-3861-3323; Dey, Goutam/0000-0002-8210-3219; OJHA, PROBIR KUMAR/0000-0003-4796-3915; Bharti, Rashmi/0000-0002-7612-7695	MHRD; CSIR; MoES, India [MoES/16/48/09/RDEAS]	MHRD; CSIR(Council of Scientific & Industrial Research (CSIR) - India); MoES, India	We thank MHRD, CSIR and MoES, India (Grant No: MoES/16/48/09/RDEAS; Date: 15-07-2010).	Andersen JL, 2014, ACTA CRYSTALLOGR D, V70, P451, DOI 10.1107/S1399004713030149; Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; Ataie-Kachoie P, 2013, CYTOKINE GROWTH F R, V24, P163, DOI 10.1016/j.cytogfr.2012.09.001; Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Brinkmann K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.61; Calisto KL, 2012, CRIT CARE, V16, DOI 10.1186/cc11478; Cavarretta IT, 2007, ONCOGENE, V26, P2822, DOI 10.1038/sj.onc.1210097; Chakravarti N, 2006, INT J CANCER, V119, P1268, DOI 10.1002/ijc.21967; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Conze D, 2001, CANCER RES, V61, P8851; Culig Z, 2011, BBA-MOL CELL RES, V1813, P308, DOI 10.1016/j.bbamcr.2010.12.010; Das Subhasis, 2012, J Exp Ther Oncol, V10, P139; Dey G, 2015, SCI REP-UK, V5, DOI 10.1038/srep10316; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Gadotti VM, 2012, PHARMACOL BIOCHEM BE, V102, P549, DOI 10.1016/j.pbb.2012.06.018; Ghofrani HA, 2006, NAT REV DRUG DISCOV, V5, P689, DOI 10.1038/nrd2030; Gibson RM, 2000, J BIOL CHEM, V275, P22574, DOI 10.1074/jbc.M907658199; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Hideshima T, 2001, BLOOD, V98, p639a; Johnson Christopher, 2012, Transl Gastrointest Cancer, V1, P58; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Liu Y, 2011, CANCER PREV RES, V4, P1296, DOI 10.1158/1940-6207.CAPR-10-0317; Liu Y, 2010, J BIOL CHEM, V285, P27429, DOI 10.1074/jbc.M110.142752; Liu YX, 2009, MOL PHARMACOL, V76, P91, DOI 10.1124/mol.109.056085; Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438; Mahata D, 2014, INT J BIOL MACROMOL, V69, P5, DOI 10.1016/j.ijbiomac.2014.05.017; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Michaud-Levesque J, 2012, EXP CELL RES, V318, P925, DOI 10.1016/j.yexcr.2012.02.017; Palumbo A, 2008, BLOOD, V111, P3968, DOI 10.1182/blood-2007-10-117457; Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012; Pooja S, 2012, CYTOKINE, V60, P122, DOI 10.1016/j.cyto.2012.06.241; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Rajput S, 2013, LIFE SCI, V93, P783, DOI 10.1016/j.lfs.2013.09.009; Rajput S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061342; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Rose-John S, 2002, TRENDS BIOTECHNOL, V20, P417, DOI 10.1016/S0167-7799(02)02056-5; Sachdev JC, 2012, CLIN BREAST CANCER, V12, P19, DOI 10.1016/j.clbc.2011.07.001; Sarkar S, 2011, J CELL PHYSIOL, V226, P375, DOI 10.1002/jcp.22343; Sethi G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-66; Shariat SF, 2011, J UROLOGY, V186, P2107, DOI 10.1016/j.juro.2011.06.048; Silver JS, 2010, J LEUKOCYTE BIOL, V88, P1145, DOI 10.1189/jlb.0410217; Su JL, 2005, CANCER RES, V65, P4827, DOI 10.1158/0008-5472.CAN-05-0188; Varghese JN, 2002, P NATL ACAD SCI USA, V99, P15959, DOI 10.1073/pnas.232432399; Venkatesan P, 2011, BIOMATERIALS, V32, P3794, DOI 10.1016/j.biomaterials.2011.01.027; Venkatesan SK, 2010, J COMPUT CHEM, V31, P2463, DOI 10.1002/jcc.21538; Voorhees PM, 2007, CLIN CANCER RES, V13, P6469, DOI 10.1158/1078-0432.CCR-07-1293; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Yosifov DY, 2012, LEUKEMIA RES, V36, P764, DOI 10.1016/j.leukres.2012.02.016	52	46	47	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3965	3975		10.1038/onc.2015.466	http://dx.doi.org/10.1038/onc.2015.466			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616855				2022-12-28	WOS:000381013100008
J	Dayde, D; Guerard, M; Perron, P; Hatat, AS; Barrial, C; Eymin, B; Gazzeri, S				Dayde, D.; Guerard, M.; Perron, P.; Hatat, A-S; Barrial, C.; Eymin, B.; Gazzeri, S.			Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SIGNALING NETWORK; PROGNOSTIC VALUE; P14(ARF) EXPRESSION; IONIZING-RADIATION; PROTEIN EXPRESSION; CANCER; MUTATIONS; MECHANISMS; GEFITINIB	Epidermal growth factor receptor (EGFR) is a cell surface receptor that has an essential role in cell proliferation and survival, and overexpression of EGFR is a common feature of human cancers. In Non-small-cell lung cancer (NSCLC), activating mutations of EGFR have also been described. We recently showed that mutant EGFR-L858R inhibits the expression of the p14ARF tumor-suppressor protein to promote cell survival. In this study, we defined the molecular bases by which EGFR controls Arf expression. Using various lung tumor models, we showed that EGF stimulation inhibits Arf transcription by a mechanism involving the nuclear transport and recruitment of EGFR to the Arf promoter. We unraveled the vesicular trafficking protein Vps34 as a mediator of EGFR nuclear trafficking and showed that its neutralization prevents the accumulation of EGFR to the Arf promoter in response to ligand activation. Finally, in lung tumor cells that carry mutant EGFR-L858R, we demonstrated that inhibition of Vps34 using small interfering RNA restrains nuclear EGFR location and restores Arf expression leading to apoptosis. These findings identify the Arf tumor suppressor as a new transcriptional target of nuclear EGFR and highlight Vps34 as an important regulator of the nuclear EGFR/Arf survival pathway. As a whole, they provide a mechanistic explanation to the inverse correlation between nuclear expression of EGFR and overall survival in NSCLC patients.	[Dayde, D.; Guerard, M.; Perron, P.; Hatat, A-S; Barrial, C.; Eymin, B.; Gazzeri, S.] INSERM, Ctr Rech, Equipe Bases Mol Progress Canc Poumo, U823, Grenoble, France; [Dayde, D.; Guerard, M.; Perron, P.; Hatat, A-S; Barrial, C.; Eymin, B.; Gazzeri, S.] Univ Grenoble 1, Inst Albert Bonniot, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM, Ctr Rech, Equipe Bases Mol Progress Canc Poumon,U823, F-38042 Grenoble, France.	Sylvie.Gazzeri@ujf-grenoble.fr	eymin, beatrice/U-4670-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013	eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839	Institut National de la Sante et de la Recherche Medicale [U823]; Fondation ARC pour la recherche sur le cancer [20131200109]; Fondation de France; Ligue Nationale contre Le Cancer Comite de Savoie; Fond de Dotation pour la Recherche en Sante Respiratoire; Fondation ARC pour la recherche sur le cancer; le Fonds Agir pour les Maladies Chroniques; French Research Ministry	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation ARC pour la recherche sur le cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation de France(Fondation de France); Ligue Nationale contre Le Cancer Comite de Savoie; Fond de Dotation pour la Recherche en Sante Respiratoire; Fondation ARC pour la recherche sur le cancer(Fondation ARC pour la Recherche sur le Cancer); le Fonds Agir pour les Maladies Chroniques; French Research Ministry(Ministry of Research, France)	We thank Professor A Gazdar for providing us with the H1719, HCC827 and H1975 cellular models and Dr MC Hung for the CHO-EGFR and CHO-EGFR-pNLS cells. This work was supported by Institut National de la Sante et de la Recherche Medicale U823, the Fondation ARC pour la recherche sur le cancer (grant no. 20131200109), the Fondation de France and the Ligue Nationale contre Le Cancer Comite de Savoie. DD was supported by the Fond de Dotation pour la Recherche en Sante Respiratoire 2010 and the Fondation ARC pour la recherche sur le cancer. MG was supported by le Fonds Agir pour les Maladies Chroniques. A-SH was supported by the French Research Ministry.	Abhold EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032459; Aggarwal H, 2011, EXP MOL PATHOL, V91, P496, DOI 10.1016/j.yexmp.2011.05.006; Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427; Brand TM, 2011, DISCOV MED, V12, P419; Burda P, 2002, J CELL SCI, V115, P3889, DOI 10.1242/jcs.00090; Carpenter G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008979; Chen DJ, 2007, CLIN CANCER RES, V13, P6555, DOI 10.1158/1078-0432.CCR-07-1610; Cortot AB, 2014, CLIN LUNG CANCER, V15, P124, DOI 10.1016/j.cllc.2013.08.003; Dittmann K, 2010, FEBS LETT, V584, P3878, DOI 10.1016/j.febslet.2010.08.005; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Jaganathan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019605; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Lill NL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003341; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2010, DISCOV MED, V10, P44; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maggi LB, 2014, BBA-MOL BASIS DIS, V1842, P831, DOI 10.1016/j.bbadis.2014.01.016; MAO L, 1995, CANCER RES, V55, P2995; Marsh T, 2015, NAT CELL BIOL, V17, P1, DOI 10.1038/ncb3089; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Meng XX, 2012, LUNG CANCER, V77, P24, DOI 10.1016/j.lungcan.2012.02.015; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mounawar M, 2007, CANCER RES, V67, P5667, DOI 10.1158/0008-5472.CAN-06-4229; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozenne P, 2013, ONCOGENE, V32, P1050, DOI 10.1038/onc.2012.107; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; QUELLE DE, 1995, CELL, V83, P993; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Tao YG, 2005, EXP CELL RES, V303, P240, DOI 10.1016/j.yexcr.2004.09.030; Traynor AM, 2013, LUNG CANCER, V81, P138, DOI 10.1016/j.lungcan.2013.03.020; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang YN, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-13; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhao ZH, 2008, LUNG CANCER, V62, P113, DOI 10.1016/j.lungcan.2008.02.014	54	23	24	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3986	3994		10.1038/onc.2015.480	http://dx.doi.org/10.1038/onc.2015.480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26686095	Green Submitted			2022-12-28	WOS:000381013100010
J	Kimura, T; Wang, L; Tabu, K; Tsuda, M; Tanino, M; Maekawa, A; Nishihara, H; Hiraga, H; Taga, T; Oda, Y; Tanaka, S				Kimura, T.; Wang, L.; Tabu, K.; Tsuda, M.; Tanino, M.; Maekawa, A.; Nishihara, H.; Hiraga, H.; Taga, T.; Oda, Y.; Tanaka, S.			Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; CANCER STEM-CELLS; PROTO-ONCOPROTEIN SYT; BREAST-CANCER; TUMOR-GROWTH; BONE-MARROW; ANTAGONIST CTCE-9908; PROSTATE-CANCER; EXPRESSION; METASTASIS	Synovial sarcoma accounts for almost 10% of all soft tissue sarcomas, and its prognosis is poor with 5-year survival rates at 36%. Thus, new treatments and therapeutic targets for synovial sarcoma are required. Tumor-initiating cells have been defined by the ability for self-renewal and multipotent differentiation, and they exhibit higher tumorigenic capacity, chemoresistance and radiation resistance, expecting to be a new therapeutic target. In synovial sarcoma, the presence of such stemness remains largely unclear; thus, we analyzed whether synovial sarcoma possessed tumor-initiating cells and explored specific markers, and we discovered that synovial sarcoma cell lines possessed heterogeneity by way of containing a sphere-forming subpopulation highly expressing NANOG, OCT4 and SOX2. By expression microarray analysis, CXCR4 was identified to be highly expressed in the sphere subpopulation and correlated with stem-cell-associated markers. Inhibition of CXCR4 suppressed the cell proliferation of synovial sarcoma cell lines in vitro. The tumor-initiating ability of CXCR4-positive cells was demonstrated by xenograft propagation assay. CXCR4-positive cells showed higher tumorigenicity than negative ones and possessed both self-renewal and multipotent differentiation ability. Immunohistochemical analysis of 39 specimens of synovial sarcoma patients revealed that CXCR4 strongly correlated with poor prognosis of synovial sarcoma. Thus, we conclude that CXCR4 is the marker of synovial sarcoma-initiating cells, a new biomarker for prognosis and a new potential therapeutic target.	[Kimura, T.; Wang, L.; Nishihara, H.] Hokkaido Univ, Grad Sch Med, Dept Translat Pathol, Sapporo, Hokkaido, Japan; [Tabu, K.; Taga, T.] Tokyo Med & Dent Univ TMDU, Med Res Inst, Dept Stem Cell Regulat, Bunkyo Ku, Tokyo, Japan; [Tsuda, M.; Tanino, M.; Tanaka, S.] Hokkaido Univ, Grad Sch Med, Dept Canc Pathol, Sapporo, Hokkaido, Japan; [Maekawa, A.; Oda, Y.] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka, Japan; [Hiraga, H.] Natl Hosp Org Hokkaido Canc Ctr, Div Orthoped, Sapporo, Hokkaido, Japan	Hokkaido University; Tokyo Medical & Dental University (TMDU); Hokkaido University; Kyushu University	Kimura, T; Tanaka, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Translat Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.; Kimura, T; Tanaka, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Canc Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	ktaichi@syd.odn.ne.jp; tanaka@med.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Tabu, Kouichi/AAW-1225-2020	Tabu, Kouichi/0000-0002-3524-967X; Taga, Tetsuya/0000-0002-1625-0122	Joint Usage/Research Program of Medical Research Institute, Tokyo Medical and Dental University (TMDU)	Joint Usage/Research Program of Medical Research Institute, Tokyo Medical and Dental University (TMDU)	We thank Dr T Akagi for pCX4bleo vector. This work was supported in part by the Joint Usage/Research Program of Medical Research Institute, Tokyo Medical and Dental University (TMDU).	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Akashi T, 2008, CANCER SCI, V99, P539, DOI 10.1111/j.1349-7006.2007.00712.x; Chapman MR, 2013, INTEGR BIOL-UK, V5, P692, DOI 10.1039/c3ib20290a; De Falco V, 2007, CANCER RES, V67, P11821, DOI 10.1158/0008-5472.CAN-07-0899; Dubrovska A, 2012, BRIT J CANCER, V107, P43, DOI 10.1038/bjc.2012.105; Dubrovska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031226; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Haldar M, 2008, CLIN ORTHOP RELAT R, V466, P2156, DOI 10.1007/s11999-008-0340-2; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665; Hirata K, 2013, BRIT J CANCER, V109, P379, DOI 10.1038/bjc.2013.314; Hirotsu M, 2009, BRIT J CANCER, V101, P2030, DOI 10.1038/sj.bjc.6605407; Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044; Ito T, 2004, LAB INVEST, V84, P1484, DOI 10.1038/labinvest.3700174; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Jung MJ, 2013, ONCOGENE, V32, P209, DOI 10.1038/onc.2012.37; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Kim M, 2010, CANCER RES, V70, P10411, DOI 10.1158/0008-5472.CAN-10-2591; Kim SY, 2008, CLIN EXP METASTAS, V25, P201, DOI 10.1007/s10585-007-9133-3; Kimura T, 2012, CANCER INVEST, V30, P390, DOI 10.3109/07357907.2012.672607; Kimura Y, 2013, ONCOTARGET, V4, P785, DOI 10.18632/oncotarget.1048; Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283; Lee CG, 2012, BRIT J HAEMATOL, V158, P79, DOI 10.1111/j.1365-2141.2012.09123.x; Liu AG, 2013, INT J ONCOL, V42, P1399, DOI 10.3892/ijo.2013.1826; Minami Y, 2014, CANCER SCI, V105, P1152, DOI 10.1111/cas.12479; Mohseny AB, 2011, STEM CELLS, V29, P397, DOI 10.1002/stem.596; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murase M, 2009, BRIT J CANCER, V101, P1425, DOI 10.1038/sj.bjc.6605330; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Oda Y, 2009, INT J CANCER, V124, P1852, DOI 10.1002/ijc.24128; Olsson E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-418; Palmerini E, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-014-0222-5; Perani M, 2005, J BIOL CHEM, V280, P42863, DOI 10.1074/jbc.M502963200; Porvasnik S, 2009, PROSTATE, V69, P1460, DOI 10.1002/pros.21008; Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Saigusa S, 2010, ANN SURG ONCOL, V17, P2051, DOI 10.1245/s10434-010-0970-y; Scala S, 2005, CLIN CANCER RES, V11, P1835, DOI 10.1158/1078-0432.CCR-04-1887; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Suva ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242; Taichman RS, 2002, CANCER RES, V62, P1832; Tan L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023383; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; Tsuda M, 2005, ONCOGENE, V24, P7984, DOI 10.1038/sj.onc.1208942; Watanabe T, 2006, MOL CANCER RES, V4, P499, DOI 10.1158/1541-7786.MCR-05-0141; Watanabe T, 2009, CELL RES, V19, P638, DOI 10.1038/cr.2009.40; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099; Yopp AC, 2012, ANN SURG ONCOL, V19, pS339, DOI 10.1245/s10434-011-1774-4; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zeilstra J, 2014, ONCOGENE, V33, P665, DOI 10.1038/onc.2012.611; Zheng XS, 2011, ONCOL RES, V19, P555, DOI 10.3727/096504012X13340632812631	58	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3932	3943		10.1038/onc.2015.461	http://dx.doi.org/10.1038/onc.2015.461			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26640147				2022-12-28	WOS:000381013100005
J	Min, B; Park, H; Lee, S; Li, Y; Choi, JM; Lee, JY; Kim, J; Choi, YD; Kwon, YG; Lee, HW; Bae, SC; Yun, CO; Chung, KC				Min, B.; Park, H.; Lee, S.; Li, Y.; Choi, J-M; Lee, J. Y.; Kim, J.; Choi, Y. D.; Kwon, Y-G; Lee, H-W; Bae, S-C; Yun, C-O; Chung, K. C.			CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer	ONCOGENE			English	Article							TISSUE TRANSGLUTAMINASE; E3 LIGASE; PROGNOSTIC-SIGNIFICANCE; PROTEIN; EXPRESSION; SUPPRESSOR; ADENOCARCINOMA; CALCIFICATION; SENSITIVITY; METASTASIS	The multifunctional enzyme transglutaminase 2 (TG2) primarily catalyzes cross-linking reactions of proteins via (gamma-glutamyl) lysine bonds. Several recent findings indicate that altered regulation of intracellular TG2 levels affects renal cancer. Elevated TG2 expression is observed in renal cancer. However, the molecular mechanism underlying TG2 degradation is not completely understood. Carboxyl-terminus of Hsp70-interacting protein (CHIP) functions as an ubiquitin E3 ligase. Previous studies reveal that CHIP deficiency mice displayed a reduced life span with accelerated aging in kidney tissues. Here we show that CHIP promotes polyubiquitination of TG2 and its subsequent proteasomal degradation. In addition, TG2 upregulation contributes to enhanced kidney tumorigenesis. Furthermore, CHIP-mediated TG2 downregulation is critical for the suppression of kidney tumor growth and angiogenesis. Notably, our findings are further supported by decreased CHIP expression in human renal cancer tissues and renal cancer cells. The present work reveals that CHIP-mediated TG2 ubiquitination and proteasomal degradation represent a novel regulatory mechanism that controls intracellular TG2 levels. Alterations in this pathway result in TG2 hyperexpression and consequently contribute to renal cancer.	[Min, B.; Chung, K. C.] Yonsei Univ, Dept Syst Biol, Coll Life Sci & Biotechnol, Yonsei Ro 50, Seoul 03722, South Korea; [Park, H.; Lee, S.; Choi, J-M; Kwon, Y-G; Lee, H-W] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul, South Korea; [Li, Y.; Yun, C-O] Hanyang Univ, Dept Bioengn, Coll Engn, Seoul, South Korea; [Lee, J. Y.; Choi, Y. D.] Yonsei Univ, Dept Urol, Coll Med, Seoul, South Korea; [Kim, J.] Catholic Univ Korea, Sch Med, Dept Anat, Seoul, South Korea; [Bae, S-C] Chungbuk Natl Univ, Dept Biochem, Coll Med, Cheongju, South Korea	Yonsei University; Yonsei University; Hanyang University; Yonsei University; Yonsei University Health System; Catholic University of Korea; Chungbuk National University	Chung, KC (corresponding author), Yonsei Univ, Dept Syst Biol, Coll Life Sci & Biotechnol, Yonsei Ro 50, Seoul 03722, South Korea.	kchung@yonsei.ac.kr		Yun, Chae-Ok/0000-0002-9466-4531; Choi, Young Deuk/0000-0002-8545-5797	National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea [2014M3C7A1064545]; Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C0093]; NRF [2015R1A2A2A01003080, 2007-0056092]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea; Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; NRF	We thank SY Kim and DH Lee for providing plasmids and JJ Hwang for providing renal cancer cell line lysates. We also thank KH Chun, IK Chung and J Song for their technical assistances, critical comments and helpful discussions. This research was supported by grants from the National Research Foundation of Korea (NRF; 2014M3C7A1064545 to KCC) funded by the Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea, and from the Korea Healthcare Technology R&D Project (HI14C0093 to KCC) through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea. This work was supported in part by NRF grants (2015R1A2A2A01003080 and 2007-0056092 to KCC).	Ahmed SF, 2012, J BIOL CHEM, V287, P15996, DOI 10.1074/jbc.M111.321083; Ai LB, 2008, CARCINOGENESIS, V29, P510, DOI 10.1093/carcin/bgm280; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bento CF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015062; Boroughs LK, 2011, J BIOL CHEM, V286, P37094, DOI 10.1074/jbc.M111.242438; Chen NX, 2013, AM J NEPHROL, V37, P191, DOI 10.1159/000347031; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dyer LM, 2011, J NEURO-ONCOL, V101, P429, DOI 10.1007/s11060-010-0277-7; ELSASSER HP, 1993, EUR J CELL BIOL, V61, P321; Erdem S, 2015, WORLD J UROL, V33, P1553, DOI 10.1007/s00345-014-1462-7; Filiano AJ, 2008, FASEB J, V22, P2662, DOI 10.1096/fj.07-097709; Fok JY, 2006, MOL CANCER THER, V5, P1493, DOI 10.1158/1535-7163.MCT-06-0083; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hidaka H, 2012, ONCOTARGET, V3, P44; Hwang JY, 2008, CANCER RES, V68, P5849, DOI 10.1158/0008-5472.CAN-07-6130; Jan CI, 2011, J PATHOL, V225, P424, DOI 10.1002/path.2921; Jang KW, 2011, J CELL BIOCHEM, V112, P3612, DOI 10.1002/jcb.23292; Johnson TS, 2007, J AM SOC NEPHROL, V18, P3078, DOI 10.1681/ASN.2006070690; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kim DS, 2011, ONCOGENE, V30, P4780, DOI 10.1038/onc.2011.183; Koleganova N, 2009, NEPHROL DIAL TRANSPL, V24, P2488, DOI 10.1093/ndt/gfp137; Ku BM, 2014, J CANCER RES CLIN, V140, P757, DOI 10.1007/s00432-014-1623-5; Ku BM, 2013, FASEB J, V27, P3487, DOI 10.1096/fj.12-224220; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Min JN, 2008, MOL CELL BIOL, V28, P4018, DOI 10.1128/MCB.00296-08; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Park D, 2010, AMINO ACIDS, V39, P619, DOI 10.1007/s00726-010-0500-z; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Pavlovich CP, 2004, NAT REV CANCER, V4, P381, DOI 10.1038/nrc1364; Sarkar S, 2014, ONCOGENE, V33, P26, DOI 10.1038/onc.2012.561; Su CH, 2011, CELL SIGNAL, V23, P1824, DOI 10.1016/j.cellsig.2011.06.018; Verma A, 2008, CLIN CANCER RES, V14, P1997, DOI 10.1158/1078-0432.CCR-07-1533; Verma A, 2006, CANCER RES, V66, P10525, DOI 10.1158/0008-5472.CAN-06-2387; Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522; Wang YM, 2014, CARCINOGENESIS, V35, P983, DOI 10.1093/carcin/bgt393; Wiesener MS, 2001, CANCER RES, V61, P5215; Xin H, 2005, J BIOL CHEM, V280, P20842, DOI 10.1074/jbc.M412275200; Xu T, 2011, CANCER SCI, V102, P959, DOI 10.1111/j.1349-7006.2011.01888.x; Yakubov B, 2013, NEOPLASIA, V15, P609, DOI 10.1593/neo.121878; Yan S, 2010, EMBO J, V29, P3773, DOI 10.1038/emboj.2010.245; Yang MJ, 2011, J EXP MED, V208, P2099, DOI 10.1084/jem.20102667; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048; Zemskov EA, 2007, J CELL SCI, V120, P3188, DOI 10.1242/jcs.010397	45	14	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3718	3728		10.1038/onc.2015.439	http://dx.doi.org/10.1038/onc.2015.439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26568304				2022-12-28	WOS:000379622800010
J	O'Hayre, M; Inoue, A; Kufareva, I; Wang, Z; Mikelis, CM; Drummond, RA; Avino, S; Finkel, K; Kalim, KW; DiPasquale, G; Guo, F; Aoki, J; Zheng, Y; Lionakis, MS; Molinolo, AA; Gutkind, JS				O'Hayre, M.; Inoue, A.; Kufareva, I.; Wang, Z.; Mikelis, C. M.; Drummond, R. A.; Avino, S.; Finkel, K.; Kalim, K. W.; DiPasquale, G.; Guo, F.; Aoki, J.; Zheng, Y.; Lionakis, M. S.; Molinolo, A. A.; Gutkind, J. S.			Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the G alpha(13)/RhoA axis in B cells	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; SOMATIC MUTATIONS; UVEAL MELANOMA; ALPHA-SUBUNIT; P115 RHOGEF; G12 FAMILY; MIGRATION; GTPASE; ACTIVATION	G proteins and their cognate G protein-coupled receptors (GPCRs) function as critical signal transduction molecules that regulate cell survival, proliferation, motility and differentiation. The aberrant expression and/or function of these molecules have been linked to the growth, progression and metastasis of various cancers. As such, the analysis of mutations in the genes encoding GPCRs, G proteins and their downstream targets provides important clues regarding how these signaling cascades contribute to malignancy. Recent genome-wide sequencing efforts have unveiled the presence of frequent mutations in GNA13, the gene encoding the G protein G alpha(13), in Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL). We found that mutations in the downstream target of G alpha(13), RhoA, are also present in Burkitt's lymphoma and DLBCL. By multiple complementary approaches, we now show that that these cancer-specific GNA13 and RHOA mutations are inhibitory in nature, and that the expression of wild-type G alpha(13) in B-cell lymphoma cells with mutant GNA13 has limited impact in vitro but results in a remarkable growth inhibition in vivo. Thus, although G alpha(13) and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for G alpha(13) and RhoA in Burkitt's lymphoma and DLBCL.	[O'Hayre, M.; Wang, Z.; Avino, S.; Finkel, K.; Molinolo, A. A.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Inoue, A.; Aoki, J.] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi, Japan; [Inoue, A.] Japan Sci & Technol Agcy JST, PRESTO, Kawaguchi, Saitama, Japan; [Kufareva, I.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Mikelis, C. M.] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Biomed Sci, Amarillo, TX USA; [Drummond, R. A.; Lionakis, M. S.] NIAID, Fungal Pathogenesis Unit, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Avino, S.] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, Cs, Italy; [Kalim, K. W.; Guo, F.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [DiPasquale, G.] Natl Inst Dent & Craniofacial Res, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD USA; [Aoki, J.] Japan Agcy Med Res & Dev, Core Res Evolut Sci & Technol AMED CREST, AMED, Chiyoda Ku, Tokyo, Japan; [Gutkind, J. S.] UC San Diego Moores Canc Ctr, Dept Pharmacol, 3855 Hlth Sci Dr,0803, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Tohoku University; Japan Science & Technology Agency (JST); University of California System; University of California San Diego; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Calabria; Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), UC San Diego Moores Canc Ctr, Dept Pharmacol, 3855 Hlth Sci Dr,0803, La Jolla, CA 92093 USA.	sgutkind@ucsd.edu	Lionakis, Michail/J-8840-2017; Gutkind, J. Silvio/J-1201-2016; Drummond, Rebecca/I-3155-2019; Mikelis, Constantinos/AGF-9423-2022	Lionakis, Michail/0000-0003-4994-9500; Gutkind, J. Silvio/0000-0002-5150-4482; Drummond, Rebecca/0000-0001-5424-7074; Aoki, Junken/0000-0001-9435-1896; Kufareva, Irina/0000-0001-9083-7039	National Institute of Dental and Craniofacial Research intramural program at NIH; PRESTO from JST; AMED-CREST from AMED; Division of Intramural Research, NIAID, NIH; NIH [R01 GM071872, R01 AI118985]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118985, ZIAAI001175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071872] Funding Source: NIH RePORTER	National Institute of Dental and Craniofacial Research intramural program at NIH; PRESTO from JST(Japan Science & Technology Agency (JST)); AMED-CREST from AMED; Division of Intramural Research, NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by the National Institute of Dental and Craniofacial Research intramural program at NIH. We thank Maria S Degese for her help with immunohistochemistry. AI was funded by PRESTO from JST. JA was funded by AMED-CREST from AMED. We thank Miho Morikawa for technical assistance with the TGF alpha shedding assay. RAD and MSL are supported by the Division of Intramural Research, NIAID, NIH. IK is supported by NIH grants R01 GM071872 and R01 AI118985.	Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Cattoretti G, 2009, CANCER RES, V69, P8686, DOI 10.1158/0008-5472.CAN-09-1110; Cools J, 2014, NAT GENET, V46, P320, DOI 10.1038/ng.2937; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Garcia-Marcos M, 2015, J BIOL CHEM, V290, P6697, DOI 10.1074/jbc.R114.613414; Green JA, 2011, NAT IMMUNOL, V12, P672, DOI 10.1038/ni.2047; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/nmeth.2172, 10.1038/NMETH.2172]; Inoue A, 2011, EMBO J, V30, P4248, DOI 10.1038/emboj.2011.296; Jaffe ES, 2011, HEMATOL-AM SOC HEMAT, P506, DOI 10.1182/asheducation-2011.1.506; Juneja J, 2009, BRIT J PHARMACOL, V158, P32, DOI 10.1111/j.1476-5381.2009.00180.x; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kufareva I, 2011, STRUCTURE, V19, P1108, DOI 10.1016/j.str.2011.05.012; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Manso R, 2014, BLOOD, V123, P2893, DOI 10.1182/blood-2014-02-555946; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Menon MP, 2012, CANCER J, V18, P411, DOI 10.1097/PPO.0b013e31826aee97; Mikelis CM, 2013, J BIOL CHEM, V288, P12232, DOI 10.1074/jbc.M112.428599; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Qin L, 2015, SCIENCE, V347, P1117, DOI 10.1126/science.1261064; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Rohde M, 2014, GENE CHROMOSOME CANC, V53, P911, DOI 10.1002/gcc.22202; Roschewski M, 2014, NAT REV CLIN ONCOL, V11, P12, DOI 10.1038/nrclinonc.2013.197; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wang ZY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju215; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916	47	48	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3771	3780		10.1038/onc.2015.442	http://dx.doi.org/10.1038/onc.2015.442			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26616858	Green Accepted			2022-12-28	WOS:000380753200003
J	Buczek, ME; Miles, AK; Green, W; Johnson, C; Boocock, DJ; Pockley, AG; Rees, RC; Hulman, G; van Schalkwyk, G; Parkinson, R; Hulman, J; Powe, DG; Regad, T				Buczek, M. E.; Miles, A. K.; Green, W.; Johnson, C.; Boocock, D. J.; Pockley, A. G.; Rees, R. C.; Hulman, G.; van Schalkwyk, G.; Parkinson, R.; Hulman, J.; Powe, D. G.; Regad, T.			Cytoplasmic PML promotes TGF-beta-associated epithelial-mesenchymal transition and invasion in prostate cancer	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA FUSES; MOLECULAR-MECHANISMS; SUPPRESSOR PML; NUCLEAR-BODIES; ALPHA; TRANSLOCATION; INTERFERON; EXPRESSION; T(15-17); TARGETS	Epithelial-mesenchymal transition (EMT) is a key event that is involved in the invasion and dissemination of cancer cells. Although typically considered as having tumour-suppressive properties, transforming growth factor (TGF)-beta signalling is altered during cancer and has been associated with the invasion of cancer cells and metastasis. In this study, we report a previously unknown role for the cytoplasmic promyelocytic leukaemia (cPML) tumour suppressor in TGF-beta signalling-induced regulation of prostate cancer-associated EMT and invasion. We demonstrate that cPML promotes a mesenchymal phenotype and increases the invasiveness of prostate cancer cells. This event is associated with activation of TGF-beta canonical signalling pathway through the induction of Sma and Mad related family 2 and 3 (SMAD2 and SMAD3) phosphorylation. Furthermore, the cytoplasmic localization of promyelocytic leukaemia (PML) is mediated by its nuclear export in a chromosomal maintenance 1 (CRM1)-dependent manner. This was clinically tested in prostate cancer tissue and shown that cytoplasmic PML and CRM1 co-expression correlates with reduced disease-specific survival. In summary, we provide evidence of dysfunctional TGF-beta signalling occurring at an early stage in prostate cancer. We show that this disease pathway is mediated by cPML and CRM1 and results in a more aggressive cancer cell phenotype. We propose that the targeting of this pathway could be therapeutically exploited for clinical benefit.	[Buczek, M. E.; Miles, A. K.; Johnson, C.; Boocock, D. J.; Pockley, A. G.; Rees, R. C.; Powe, D. G.; Regad, T.] Nottingham Trent Univ, John Van Geest Canc Res Ctr, Sch Sci & Technol, Clifton Lane, Nottingham NG11 8NS, England; [Green, W.; Parkinson, R.] City Hosp, Nottingham Univ Hosp NHS Trust, Dept Urol, Nottingham, England; [Hulman, G.; Hulman, J.; Powe, D. G.] Nottingham Univ Hosp Trust, Queens Med Ctr, Dept Cellular Pathol, Nottingham, England; [van Schalkwyk, G.] Royal Derby Hosp, Dept Histopathol, Derby, England	Nottingham Trent University; Nottingham University Hospital NHS Trust; University of Nottingham; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham	Regad, T (corresponding author), Nottingham Trent Univ, John Van Geest Canc Res Ctr, Sch Sci & Technol, Clifton Lane, Nottingham NG11 8NS, England.	tarik.regad@ntu.ac.uk	Regad, Tarik/A-6095-2012; Pockley, Alan G/I-4704-2015; Boocock, David/I-4666-2015	Regad, Tarik/0000-0003-4028-6368; Pockley, Alan G/0000-0001-9593-6431; Boocock, David/0000-0002-7333-3549; Miles, Amanda/0000-0002-5388-938X	John and Lucille van Geest Foundation; Cancer and Polio Research Fund	John and Lucille van Geest Foundation; Cancer and Polio Research Fund	This work was funded by the John and Lucille van Geest Foundation and Cancer and Polio Research Fund. We thank Mrs Anne Schneider, Mr Stephen Reeder, Mr Chris Nolan and Dr Claire Hawkes for their assistance in this study.	Altman DG, 2012, BMC MED, V10, DOI [10.1186/1741-7015-10-51, 10.1371/journal.pmed.1001216]; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CAMP RL, 2004, CLIN CANCER RES, V10, P7252, DOI [10.1158/1078-0432.CCR-04-0713, DOI 10.1158/1078-0432.CCR-04-0713]; Chan JYH, 1998, EUR J CANCER, V34, P1015, DOI 10.1016/S0959-8049(97)10138-1; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Jin GX, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00147; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Kubiczkova L, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-183; Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Mathieu MG, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.29; Mazza M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00174; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; Nisole S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00125; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; TERRIS B, 1995, CANCER RES, V55, P1590; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	33	35	35	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3465	3475		10.1038/onc.2015.409	http://dx.doi.org/10.1038/onc.2015.409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26549027	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000379270100011
J	Nagaraja, AS; Dorniak, PL; Sadaoui, NC; Kang, Y; Lin, T; Armaiz-Pena, G; Wu, SY; Rupaimoole, R; Allen, JK; Gharpure, KM; Pradeep, S; Zand, B; Previs, RA; Hansen, JM; Ivan, C; Rodriguez-Aguayo, C; Yang, P; Lopez-Berestein, G; Lutgendorf, SK; Cole, SW; Sood, AK				Nagaraja, A. S.; Dorniak, P. L.; Sadaoui, N. C.; Kang, Y.; Lin, T.; Armaiz-Pena, G.; Wu, S. Y.; Rupaimoole, R.; Allen, J. K.; Gharpure, K. M.; Pradeep, S.; Zand, B.; Previs, R. A.; Hansen, J. M.; Ivan, C.; Rodriguez-Aguayo, C.; Yang, P.; Lopez-Berestein, G.; Lutgendorf, S. K.; Cole, S. W.; Sood, A. K.			Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis	ONCOGENE			English	Article							BREAST-CANCER; BETA-BLOCKERS; TUMOR-METASTASIS; STRESS; EXPRESSION; CYCLOOXYGENASE-2; NOREPINEPHRINE; CARCINOMA; INVASION; OUTCOMES	Adrenergic stimulation adversely affects tumor growth and metastasis, but the underlying mechanisms are not well understood. Here, we uncovered a novel mechanism by which catecholamines induce inflammation by increasing prostaglandin E2 (PGE2) levels in ovarian cancer cells. Metabolic changes in tumors isolated from patients with depression and mice subjected to restraint stress showed elevated PGE2 levels. Increased metabolites, PTGS2 and PTGES protein levels were found in Skov3-ip1 and HeyA8 cells treated with norepinephrine (NE), and these changes were shown to be mediated by ADRB2 receptor signaling. Silencing PTGS2 resulted in significantly decreased migration and invasion in ovarian cancer cells in the presence of NE and decreased tumor burden and metastasis in restraint stress orthotopic models. In human ovarian cancer samples, concurrent increased ADRB2, PTGS2 and PTGES expression was associated with reduced overall and progression-free patient survival. In conclusion, increased adrenergic stimulation results in increased PGE2 synthesis via ADRB2-Nf-kappa B-PTGS2 axis, which drives tumor growth and metastasis.	[Nagaraja, A. S.; Dorniak, P. L.; Sadaoui, N. C.; Kang, Y.; Armaiz-Pena, G.; Wu, S. Y.; Rupaimoole, R.; Allen, J. K.; Gharpure, K. M.; Pradeep, S.; Zand, B.; Previs, R. A.; Hansen, J. M.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1352,1515 Holcombe Blvd, Houston, TX 77030 USA; [Lin, T.; Yang, P.] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA; [Ivan, C.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNAi & Noncoding RNA, Houston, TX 77030 USA; [Lutgendorf, S. K.] Univ Iowa, Dept Psychol, Obstet & Gynecol, Iowa City, IA 52242 USA; [Lutgendorf, S. K.] Univ Iowa, Urol, Iowa City, IA USA; [Lutgendorf, S. K.] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Cole, S. W.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Mol Biol Inst, Norman Cousins Ctr,Dept Med,Div Hematol Oncol, Los Angeles, CA 90095 USA; [Cole, S. W.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Iowa; University of Iowa; University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of Texas System; UTMD Anderson Cancer Center	Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1352,1515 Holcombe Blvd, Houston, TX 77030 USA.; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Canc Biol, Unit 1352,1515 Holcombe Blvd, Houston, TX 77030 USA.	asood@mdanderson.org	Nagaraja, Archana/AAE-8529-2021; Sood, Anoop Kumar/A-7344-2013; Nagaraja, Archana Sidalaghatta/AAE-2205-2021; Rupaimoole, Rajesha/K-3272-2016	Sood, Anoop Kumar/0000-0001-5702-4108; Rupaimoole, Rajesha/0000-0002-4795-7921; Gharpure, Kshipra/0000-0003-4954-5696; Armaiz-Pena, Guillermo N/0000-0002-9081-5339; Ivan, Cristina/0000-0002-4848-0168; Nagaraja, Archana/0000-0002-2851-9272; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Previs, Rebecca/0000-0001-8087-9120	United States National Institutes of Health [CA116778, CA104825, CA140933, CA109298, CPRIT RP140106, CPRIT RP110595, NIH CA 109298, P50CA083639, P50CA098258, AG017265, AG033590]; NIH [HHSN261200800001E]; Breast Cancer Research Foundation; United States Department of Defense [OC073399, W81XWH-10-1-0158, BC085265]; Marcus Foundation; Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; RGK Foundation; Gilder Foundation; Blanton-Davis Ovarian Cancer Research Program; Betty Anne Asche Murray Distinguished Professorship; CPRIT Graduate Scholar Fellowship; Altman-Goldstein Discovery fellowship; Ovarian Cancer Research Fund, Inc.; Cancer Prevention and Research Institute of Texas [RP101502, RP101489]; NCI-DHHS-NIH T32 training grant [T32 CA101642]; National Cancer Institute Network on Biobehavioral Pathways in Cancer; NATIONAL CANCER INSTITUTE [P50CA083639, R01CA193249, R01CA104825, R01CA109298, R01CA116778, T32CA101642, P50CA098258, R01CA140933, P30CA016672, R01CA177909] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH2TR000943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG017265, R37AG033590] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; United States Department of Defense(United States Department of Defense); Marcus Foundation; Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; RGK Foundation; Gilder Foundation; Blanton-Davis Ovarian Cancer Research Program; Betty Anne Asche Murray Distinguished Professorship; CPRIT Graduate Scholar Fellowship; Altman-Goldstein Discovery fellowship; Ovarian Cancer Research Fund, Inc.; Cancer Prevention and Research Institute of Texas; NCI-DHHS-NIH T32 training grant; National Cancer Institute Network on Biobehavioral Pathways in Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank the following for funding support: the United States National Institutes of Health (CA116778, CA104825, CA140933, CA109298, CPRIT RP140106, CPRIT RP110595, NIH CA 109298, P50CA083639, P50CA098258, AG017265, AG033590), NIH under Contract No. HHSN261200800001E and the Breast Cancer Research Foundation, the United States Department of Defense (OC073399, W81XWH-10-1-0158, and BC085265); the Marcus Foundation; the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; the RGK Foundation; the Gilder Foundation; the Blanton-Davis Ovarian Cancer Research Program and the Betty Anne Asche Murray Distinguished Professorship (AKS). ASN is supported in part by the CPRIT Graduate Scholar Fellowship. KMG is supported by the Altman-Goldstein Discovery fellowship. SYW is supported by the Ovarian Cancer Research Fund, Inc., and by Cancer Prevention and Research Institute of Texas training grants (RP101502 and RP101489). RAP, BZ and JH are supported by the NCI-DHHS-NIH T32 training grant (T32 CA101642). We thank Laila Dahmoush at the University of Iowa for her help analyzing patient tumor slides. This research was supported by the National Cancer Institute Network on Biobehavioral Pathways in Cancer. We also thank Erica Goodoff at MD Anderson for help with scientific editing.	Athanassiadou P, 2008, PATHOL RES PRACT, V204, P241, DOI 10.1016/j.prp.2007.11.004; Benish M, 2008, ANN SURG ONCOL, V15, P2042, DOI 10.1245/s10434-008-9890-5; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Costanzo ES, 2005, CANCER-AM CANCER SOC, V104, P305, DOI 10.1002/cncr.21147; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Gosain A, 2006, J TRAUMA, V60, P736, DOI 10.1097/01.ta.0000196802.91829.cc; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Kruk J, 2004, CANCER DETECT PREV, V28, P399, DOI 10.1016/j.cdp.2004.07.009; Lin Y, 2014, MOL MED REP, V9, P2499, DOI 10.3892/mmr.2014.2131; Lutgendorf SK, 2012, J CLIN ONCOL, V30, P2885, DOI 10.1200/JCO.2011.39.4411; Lutgendorf SK, 2011, BRAIN BEHAV IMMUN, V25, P250, DOI 10.1016/j.bbi.2010.10.012; Lutgendorf SK, 2009, BRAIN BEHAV IMMUN, V23, P176, DOI 10.1016/j.bbi.2008.04.155; Matsumoto Y, 2001, INT J MOL MED, V8, P31; Qiu X, 2014, ENDOCR-RELAT CANCER, V21, P533, DOI 10.1530/ERC-13-0450; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; Sethi J, 2010, METHOD FIND EXP CLIN, V32, P233, DOI 10.1358/mf.2010.32.4.1423889; Shakhar G, 1998, J IMMUNOL, V160, P3251; Sivamani RK, 2009, PLOS MED, V6, P105, DOI 10.1371/journal.pmed.1000012; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang HM, 2013, ANN ONCOL, V24, P1312, DOI 10.1093/annonc/mds616; Weiner J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040221; Yang EV, 2009, BRAIN BEHAV IMMUN, V23, P267, DOI 10.1016/j.bbi.2008.10.005	29	51	51	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2390	2397		10.1038/onc.2015.302	http://dx.doi.org/10.1038/onc.2015.302			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26257064	Green Accepted			2022-12-28	WOS:000376165000011
J	Merino, D; Lok, SW; Visvader, JE; Lindeman, GJ				Merino, D.; Lok, S. W.; Visvader, J. E.; Lindeman, G. J.			Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer	ONCOGENE			English	Review							INDEPENDENT PROGNOSTIC MARKER; MAMMARY-TUMOR DEVELOPMENT; STRUCTURE-GUIDED DESIGN; BH3 MIMETIC ABT-737; RANDOMIZED PHASE-II; CELL LUNG-CANCER; X-L INHIBITOR; PROTEIN EXPRESSION; TRANSGENIC MICE; IN-VIVO	The last three decades have seen significant progress in our understanding of the role of the pro-survival protein BCL-2 and its family members in apoptosis and cancer. BCL-2 and other pro-survival family members including Mcl-1 and BCL-X-L have been shown to have a key role in keeping pro-apoptotic 'effector' proteins BAK and BAX in check. They also neutralize a group of 'sensor' proteins (such as BIM), which are triggered by cytotoxic stimuli such as chemotherapy. BCL-2 proteins therefore have a central role as guardians against apoptosis, helping cancer cells to evade cell death. More recently, an increasing number of BH3 mimetics, which bind and neutralize BCL-2 and/or its pro-survival relatives, have been developed. The utility of targeting BCL-2 in hematological malignancies has become evident in early-phase studies, with remarkable clinical responses seen in heavily pretreated patients. As BCL-2 is overexpressed in similar to 75% of breast cancer, there has been growing interest in determining whether this new class of drug could show similar promise in breast cancer. This review summarizes our current understanding of the role of BCL-2 and its family members in mammary gland development and breast cancer, recent progress in the development of new BH3 mimetics as well as their potential for targeting estrogen receptor-positive breast cancer.	[Merino, D.; Lok, S. W.; Visvader, J. E.; Lindeman, G. J.] Walter & Eliza Hall Inst Med Res, Stem Cells & Canc Div, 1G Royal Parade, Parkville, Vic 3052, Australia; [Merino, D.; Visvader, J. E.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia; [Lok, S. W.; Lindeman, G. J.] Royal Melbourne Hosp, Familial Canc Ctr, Parkville, Vic 3050, Australia; [Lok, S. W.; Lindeman, G. J.] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia; [Lindeman, G. J.] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia	Walter & Eliza Hall Institute; University of Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne	Lindeman, GJ (corresponding author), Walter & Eliza Hall Inst Med Res, Stem Cells & Canc Div, 1G Royal Parade, Parkville, Vic 3052, Australia.; Lindeman, GJ (corresponding author), Royal Melbourne Hosp, Familial Canc Ctr, Parkville, Vic 3050, Australia.; Lindeman, GJ (corresponding author), Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia.; Lindeman, GJ (corresponding author), Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia.	lindeman@wehi.edu.au	Merino, Delphine/L-9159-2017	Merino, Delphine/0000-0002-8075-6275; Lindeman, Geoffrey/0000-0001-9386-2416	NHMRC [1016701, 1040978, 1078730]; National Breast Cancer Foundation [NC-13-21, NT-13-06, ECF-13-06]; Victorian Cancer Agency [TRP13041]; Victorian Government; Australia Fellowship	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation; Victorian Cancer Agency; Victorian Government; Australia Fellowship	We thank P Maltezos for assistance with the figures, G Lessene for advice and F Vaillant for helpful comments on the manuscript. We apologize to authors whose contributions have not been cited due to space limitations. Our research in this area is supported by grants from the NHMRC (1016701, 1040978), National Breast Cancer Foundation (NC-13-21, NT-13-06), the Victorian Cancer Agency (TRP13041) and the Victorian Government. DM is supported by an Early Career Fellowship from the National Breast Cancer Foundation (ECF-13-06), JEV by an Australia Fellowship and GJL by a Research Fellowship from the NHMRC (1078730).	Abdel-Fatah TMA, 2013, ANN ONCOL, V24, P2801, DOI 10.1093/annonc/mdt277; Abdel-Fatah TMA, 2010, J PATHOL, V222, P388, DOI 10.1002/path.2775; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Ali HR, 2012, J PATHOL, V226, P97, DOI 10.1002/path.2976; Anderson MA, 2014, SEMIN HEMATOL, V51, P219, DOI 10.1053/j.seminhematol.2014.05.008; Anderson MA, 2013, BLOOD, V122; Baggstrom MQ, 2011, J THORAC ONCOL, V6, P1757, DOI 10.1097/JTO.0b013e31822e2941; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Binder C, 1995, ANN ONCOL, V6, P1005, DOI 10.1093/oxfordjournals.annonc.a059064; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bozovic-Spasojevic I, 2014, BREAST, V23, P473, DOI 10.1016/j.breast.2014.03.012; Bruncko M, 2015, J MED CHEM, V58, P2180, DOI 10.1021/jm501258m; Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chang J, 2003, CANCER-AM CANCER SOC, V97, P545, DOI 10.1002/cncr.11083; Chen J, 2011, MOL CANCER THER, V10, P2340, DOI 10.1158/1535-7163.MCT-11-0415; Choi JE, 2014, TUMOR BIOL, V35, P12255, DOI 10.1007/s13277-014-2534-4; Cory AH, 2003, ADV ENZYME REGUL, V43, P29, DOI 10.1016/S0065-2571(02)00026-2; Crawford Anatasha, 2011, Current Pharmacogenomics & Personalized Medicine, V9, P184; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Dawson SJ, 2010, BRIT J CANCER, V103, P668, DOI 10.1038/sj.bjc.6605736; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Ermiah E, 2013, TUMOR BIOL, V34, P1569, DOI 10.1007/s13277-013-0687-1; Fang C, 2014, ACS MED CHEM LETT, V5, P1308, DOI 10.1021/ml500388q; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Friberg A, 2013, J MED CHEM, V56, P15, DOI 10.1021/jm301448p; Fu NY, 2015, NAT CELL BIOL, V17, P365, DOI 10.1038/ncb3117; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hwang KT, 2012, INT J CANCER, V131, pE1109, DOI 10.1002/ijc.27539; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jamerson MH, 2004, BRIT J CANCER, V91, P1372, DOI 10.1038/sj.bjc.6602137; JOENSUU H, 1994, AM J PATHOL, V145, P1191; Juin P, 2013, NAT REV CANCER, V13, P455, DOI 10.1038/nrc3538; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Kerr Daniel Alan II, 2011, Hormones & Cancer, V2, P261, DOI 10.1007/s12672-011-0080-8; Kim HS, 2012, J BREAST CANCER, V15, P401, DOI 10.4048/jbc.2012.15.4.401; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kutuk O, 2008, CANCER RES, V68, P7985, DOI 10.1158/0008-5472.CAN-08-1418; Langer CJ, 2014, LUNG CANCER, V85, P420, DOI 10.1016/j.lungcan.2014.05.003; Larsen MS, 2012, ACTA ONCOL, V51, P781, DOI 10.3109/0284186X.2011.653009; Lessene G, 2013, NAT CHEM BIOL, V9, P390, DOI [10.1038/NCHEMBIO.1246, 10.1038/nchembio.1246]; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Li JY, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-102; Lindeman GJ, 2013, BREAST CANCER MANAG, V2, P1; Lipponen P, 1999, ENDOCR-RELAT CANCER, V6, P13, DOI 10.1677/erc.0.0060013; Madjd Zahra, 2009, Cancer Immun, V9, P4; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Merino D, 2015, ONCOGENE, V34, P3926, DOI 10.1038/onc.2014.313; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Moldoveanu T, 2014, TRENDS BIOCHEM SCI, V39, P101, DOI 10.1016/j.tibs.2013.12.006; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Moulder SL, 2008, CLIN CANCER RES, V14, P7909, DOI 10.1158/1078-0432.CCR-08-1104; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nemati F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0080836; Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Perry AM, 2014, BRIT J HAEMATOL, V165, P382, DOI 10.1111/bjh.12763; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Ready N, 2011, J THORAC ONCOL, V6, P781, DOI 10.1097/JTO.0b013e31820a0ea6; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Rolland P, 2007, INT J CANCER, V120, P1311, DOI 10.1002/ijc.22430; Rom J, 2009, ANN ONCOL, V20, P1829, DOI 10.1093/annonc/mdp208; Rooswinkel RW, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.109; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Rucker EB, 2011, GENESIS, V49, P24, DOI 10.1002/dvg.20691; Schorr K, 1999, CANCER RES, V59, P2541; Seveno C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3214; Seymour JF, 2013, BLOOD, V122, p429s; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Sleebs BE, 2013, J MED CHEM, V56, P5514, DOI 10.1021/jm400556w; Smerage JB, 2013, MOL ONCOL, V7, P680, DOI 10.1016/j.molonc.2013.02.013; Sonpavde G, 2012, ANN ONCOL, V23, P1803, DOI 10.1093/annonc/mdr555; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Tanaka Y, 2013, J MED CHEM, V56, P9635, DOI 10.1021/jm401170c; Tao ZF, 2014, ACS MED CHEM LETT, V5, P1088, DOI 10.1021/ml5001867; Tawfik K, 2012, HUM PATHOL, V43, P23, DOI 10.1016/j.humpath.2011.04.011; Trere D, 2007, ANN ONCOL, V18, P1004, DOI 10.1093/annonc/mdm074; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Visco C, 2013, HAEMATOLOGICA, V98, P255, DOI 10.3324/haematol.2012.066209; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Walton KD, 2001, MECH DEVELOP, V109, P281, DOI 10.1016/S0925-4773(01)00549-4; Wang YC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3067; Whittle JR, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0523-1; Williams MM, 2015, ONCOTARGET, V6, P3519, DOI 10.18632/oncotarget.2792; Wong CW, 2001, CANCER RES, V61, P333; Yin ST, 2012, APOPTOSIS, V17, P388, DOI 10.1007/s10495-011-0687-9; Zheng L, 2011, CANCER LETT, V309, P27, DOI 10.1016/j.canlet.2011.05.011	114	93	95	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1877	1887		10.1038/onc.2015.287	http://dx.doi.org/10.1038/onc.2015.287			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26257067				2022-12-28	WOS:000374010300001
J	Fadoukhair, Z; Zardavas, D; Chad, MA; Goulioti, T; Aftimos, P; Piccart, M				Fadoukhair, Z.; Zardavas, D.; Chad, M. A.; Goulioti, T.; Aftimos, P.; Piccart, M.			Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs	ONCOGENE			English	Review							FACTOR RECEPTOR 2; GENETIC-HETEROGENEITY; PROGESTERONE-RECEPTOR; MUTATIONAL EVOLUTION; FUTURE PERSPECTIVES; ESTROGEN-RECEPTOR; TUMOR DNA; METASTASES; EXPRESSION; MANAGEMENT	Breast cancer (BC) has been classified into four intrinsic subtypes through seminal studies employing gene expression profiling analysis of primary tumours, namely the luminal A and B subtypes, the human epidermal growth factor receptor 2-like subtype and the basal-like subtype. More recently, the emergence of high-throughput genomic sequencing techniques, such as next-generation or massive parallel sequencing has expanded our understanding of the complex genomic landscapes of BC, with marked intertumour heterogeneity seen among different patients. In addition, increasing evidence indicates intratumour heterogeneity, with molecular differences observed within one patient, both spatially and longitudinally. These phenomena have an impact on the clinical development of molecularly targeted agents, with the classical paradigm of population-based clinical trials being no longer efficient. In the era of genomically driven oncology, three complementary tools can accelerate the clinical development of targeted agents for advanced BC as follows: (i) the implementation of molecular profiling of metastatic tumour lesions, as exemplified by the AURORA (Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer) programme; (ii) serial assessments of circulating tumour DNA, allowing a more thorough molecular interrogation of metastatic tumour burden; and (iii) new innovative clinical trial designs able to address the challenges of the increasing molecular fragmentation of BC.	[Fadoukhair, Z.] Natl Inst Oncol, Dept Med Oncol, Rabat, Morocco; [Fadoukhair, Z.; Chad, M. A.; Aftimos, P.; Piccart, M.] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, 1 Rrue Heger Bordet, B-1000 Brussels, Belgium; [Zardavas, D.] Breast Int Grp, Aisbl, Brussels, Belgium; [Chad, M. A.] Hassan II Univ Hosp, Dept Med Oncol, Fes, Morocco	Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat; Institut Jules Bordet; Universite Libre de Bruxelles; Breast International Group; Hassan II University Hospital Center of Fez	Piccart, M (corresponding author), Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, 1 Rrue Heger Bordet, B-1000 Brussels, Belgium.	martine.piccart@bordet.be						Ades F, 2014, J CLIN ONCOL, V32, P2794, DOI 10.1200/JCO.2013.54.1870; Ades F, 2014, CURR OPIN ONCOL, V26, P334, DOI 10.1097/CCO.0000000000000076; Andre F, 2014, LANCET ONCOL, V15, P267, DOI 10.1016/S1470-2045(13)70611-9; [Anonymous], 2014, Cancer Discov, V4, pOF2, DOI 10.1158/2159-8290.CD-NB2013-182; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Bjarnadottir O, 2013, BREAST CANCER RES TR, V138, P499, DOI 10.1007/s10549-013-2473-6; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Curigliano G, 2011, ANN ONCOL, V22, P2227, DOI 10.1093/annonc/mdq751; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Curtit E, 2013, ONCOLOGIST, V18, P667, DOI 10.1634/theoncologist.2012-0350; De Mattos-Arruda L, 2014, ANN ONCOL, V25, P1729, DOI 10.1093/annonc/mdu239; De Mattos-Arruda L, 2013, NAT REV CLIN ONCOL, V10, P377, DOI 10.1038/nrclinonc.2013.80; Desmedt C, 2014, UNRAVELING BREAST CA; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Duan NH, 2013, J CLIN EPIDEMIOL, V66, pS21, DOI 10.1016/j.jclinepi.2013.04.006; Duchnowska R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3244; Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Esserman LJ, 2012, J CLIN ONCOL, V30, P3242, DOI 10.1200/JCO.2011.39.2779; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gonzalez-Angulo AM, 2011, MOL CANCER THER, V10, P1093, DOI 10.1158/1535-7163.MCT-10-1089; Hadad S, 2011, BREAST CANCER RES TR, V128, P783, DOI 10.1007/s10549-011-1612-1; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hunsberger S, 2009, CLIN CANCER RES, V15, P5950, DOI 10.1158/1078-0432.CCR-08-3205; Jensen JD, 2011, CLIN CANCER RES, V17, P667, DOI 10.1158/1078-0432.CCR-10-1133; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lindstrom LS, 2012, J CLIN ONCOL, V30, P2601, DOI 10.1200/JCO.2011.37.2482; Louly PG, 2009, CLIN THER, V31, P1007, DOI 10.1016/j.clinthera.2009.05.015; Macfarlane R, 2012, ONCOLOGIST, V17, P172, DOI 10.1634/theoncologist.2011-0127; Martinez de Duenas E, 2014, BREAST CANCER RES TR, V143, P507, DOI 10.1007/s10549-013-2825-2; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; NEDERGAARD L, 1995, APMIS, V103, P20, DOI 10.1111/j.1699-0463.1995.tb01074.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Printz C, 2013, CANCER-AM CANCER SOC, V119, P1925, DOI 10.1002/cncr.28172; Rodon J, 2012, NAT REV CLIN ONCOL, V9, P359, DOI 10.1038/nrclinonc.2012.48; Rothe F, 2014, ANN ONCOL, V25, P1959, DOI 10.1093/annonc/mdu288; Scudeller L, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7653; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Simmons C, 2009, ANN ONCOL, V20, P1499, DOI 10.1093/annonc/mdp028; Sleijfer S, 2013, J CLIN ONCOL, V31, P1834, DOI 10.1200/JCO.2012.45.3639; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Von Hoff DD, 2010, J CLIN ONCOL, V28, P4877, DOI 10.1200/JCO.2009.26.5983; Wilking U, 2011, BREAST CANCER RES TR, V125, P553, DOI 10.1007/s10549-010-1029-2; Yan M, 2014, CANCER TREAT REV, V40, P770, DOI 10.1016/j.ctrv.2014.02.008; Zardavas D, 2014, BRIT J CANCER, V111, P1881, DOI 10.1038/bjc.2014.341; Zardavas D, 2013, AM SOC CLIN ONCOL ED, V2013, P2, DOI DOI 10.1200/EDB00K_; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73; Zardavas D, 2013, FUTURE ONCOL, V9, P1105, DOI [10.2217/fon.13.57, 10.2217/FON.13.57]; Zardavas D, 2013, NAT REV CLIN ONCOL, V10, P191, DOI 10.1038/nrclinonc.2013.29	58	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1743	1749		10.1038/onc.2015.249	http://dx.doi.org/10.1038/onc.2015.249			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119941				2022-12-28	WOS:000373610400001
J	Liu, J; You, P; Chen, G; Fu, X; Zeng, X; Wang, C; Huang, Y; An, L; Wan, X; Navone, N; Wu, CL; McKeehan, WL; Zhang, Z; Zhong, W; Wang, F				Liu, J.; You, P.; Chen, G.; Fu, X.; Zeng, X.; Wang, C.; Huang, Y.; An, L.; Wan, X.; Navone, N.; Wu, C-L; McKeehan, W. L.; Zhang, Z.; Zhong, W.; Wang, F.			Hyperactivated FRS2 alpha-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; FGFR1; PROGRESSION; ACTIVATION; INDUCTION; MOUSE; GENE; ADENOCARCINOMA; AMPLIFICATION	Metastasis of tumors requires angiogenesis, which is comprised of multiple biological processes that are regulated by angiogenic factors. The fibroblast growth factor (FGF) is a potent angiogenic factor and aberrant FGF signaling is a common property of tumors. Yet, how the aberration in cancer cells contributes to angiogenesis in the tumor is not well understood. Most studies of its angiogenic signaling mechanisms have been in endothelial cells. FGF receptor substrate 2 alpha (FRS2 alpha) is an FGF receptor-associated protein required for activation of downstream signaling molecules that include those in the mitogen-activated protein and AKT kinase pathways. Herein, we demonstrated that overactivation and hyperactivity of FRS2 alpha, as well as overexpression of cJUN and HIF1 alpha, were positively correlated with vessel density and progression of human prostate cancer (PCa) toward malignancy. We also demonstrate that FGF upregulated the production of vascular endothelial growth factor A mainly by increasing expression of cJUN and HIF1 alpha. This then promoted recruitment of endothelial cells and vessel formation for the tumor. Tumor angiogenesis in mouse PCa tissues was compromised by tissue-specific ablation of Frs2 alpha in prostate epithelial cells. Depletion of Frs2 alpha expression in human PCa cells and in a preclinical xenograft model, MDA PCa 118b, also significantly suppressed tumor angiogenesis accompanied with decreased tumor growth in the bone. The results underscore the angiogenic role of FRS2 alpha-mediated signaling in tumor epithelial cells in angiogenesis. They provide a rationale for treating PCa with inhibitors of FGF signaling. They also demonstrate the potential of overexpressed FRS2 alpha as a biomarker for PCa diagnosis, prognosis and response to therapies.	[Liu, J.; You, P.; Chen, G.; Fu, X.; Zeng, X.; Wang, C.; Huang, Y.; An, L.; McKeehan, W. L.; Wang, F.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX USA; [Liu, J.; You, P.; Chen, G.; Fu, X.; Zeng, X.; Wang, C.; Huang, Y.; An, L.; McKeehan, W. L.; Wang, F.] Texas A&M Hlth Sci Ctr, Coll Med, Houston, TX USA; [You, P.; Zhang, Z.] Xiamen Univ, Affiliated Zhongshan Hosp, Xiamen, Peoples R China; [Chen, G.; Fu, X.; Zhong, W.] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Guangdong Key Lab Clin Mol Med & Diagnost, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Zeng, X.] Jinan Univ, Inst Tissue Transplantat & Immunol, Guangzhou, Guangdong, Peoples R China; [Wang, C.] Wenzhou Med Univ, Coll Pharm, Wenzhou, Peoples R China; [Wan, X.; Navone, N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Wu, C-L] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Wu, C-L] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA; [Wu, C-L] Harvard Univ, Sch Med, Boston, MA USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Xiamen University; Guangzhou Medical University; Jinan University; Wenzhou Medical University; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Zhang, Z; Zhong, W; Wang, F (corresponding author), Texas A&M Univ, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	zzy11603@163.com; wdezhong@21cn.com; fwang@ibt.tamhsc.edu		Liu, Junchen/0000-0003-2765-9780	National Institutes of Health [CA96824, DE023106, CA140388]; Cancer Prevention and Research Institution of Texas [CPRIT110555]; National Natural Science Foundation of China [81170699, 81272813, 81101712, 81270761, 510180, 81072016]; NATIONAL CANCER INSTITUTE [P50CA083639, R01CA096824, R56CA096824, P50CA140388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R56DE023106] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institution of Texas; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Stefan Siwko and Samantha Del Castillo for critical reading of the manuscript. This work was supported in part by the National Institutes of Health CA96824 and DE023106 to FW, CA140388 to NN, WLM and FW, and The Cancer Prevention and Research Institution of Texas CPRIT110555 to FW and WLM, and the National Natural Science Foundation of China 81170699, 81272813 to CW, 81101712, 81270761 to XL, 510180 to WZ and 81072016 to ZYZ.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Devilard E, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-272; Francescone RA, 2011, JOVE-J VIS EXP, DOI 10.3791/3040; Giri D, 1999, J CELL PHYSIOL, V180, P53, DOI 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P; Giri D, 1999, CLIN CANCER RES, V5, P1063; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Harris AL, 1996, BREAST CANCER RES TR, V38, P97, DOI 10.1007/BF01803788; Huang XQ, 2006, CANCER RES, V66, P1481, DOI 10.1158/0008-5472.CAN-05-2412; Huang YQ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0820-4; Jin CL, 2003, CANCER RES, V63, P8784; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Lin YS, 2007, GENESIS, V45, P554, DOI 10.1002/dvg.20327; McDougall SR, 2006, J THEOR BIOL, V241, P564, DOI 10.1016/j.jtbi.2005.12.022; McKeehan W. L., 2009, HDB CELL SIGNALING; Memarzadeh S, 2007, CANCER CELL, V12, P572, DOI 10.1016/j.ccr.2007.11.002; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Polnaszek N, 2003, CANCER RES, V63, P5754; Song ZG, 2000, CANCER RES, V60, P6730; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teishima J, 2014, ANTICANCER RES, V34, P695; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valencia T, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-484; Valta MP, 2008, INT J CANCER, V123, P22, DOI 10.1002/ijc.23422; Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; Wang JH, 2004, CLIN CANCER RES, V10, P6169, DOI 10.1158/1078-0432.CCR-04-0408; Wang XK, 2011, GENE CHROMOSOME CANC, V50, P849, DOI 10.1002/gcc.20906; WEIDNER N, 1993, AM J PATHOL, V143, P401; Winter SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288; Yang F, 2013, CANCER RES, V73, P3716, DOI 10.1158/0008-5472.CAN-12-3274; Yu EM, 2010, DISCOV MED, V10, P521; Zhang KQ, 2013, CANCER RES, V73, P1298, DOI 10.1158/0008-5472.CAN-12-2086; Zhang YY, 2008, DEVELOPMENT, V135, P775, DOI 10.1242/dev.009910; Zhong WD, 2012, INT J CANCER, V130, P300, DOI 10.1002/ijc.25982	41	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1750	1759		10.1038/onc.2015.239	http://dx.doi.org/10.1038/onc.2015.239			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26096936	Green Accepted			2022-12-28	WOS:000373610400002
J	Marques, E; Englund, JI; Tervonen, TA; Virkunen, E; Laakso, M; Myllynen, M; Makela, A; Ahvenainen, M; Lepikhova, T; Monni, O; Hautaniemi, S; Klefstrom, J				Marques, E.; Englund, J. I.; Tervonen, T. A.; Virkunen, E.; Laakso, M.; Myllynen, M.; Makela, A.; Ahvenainen, M.; Lepikhova, T.; Monni, O.; Hautaniemi, S.; Klefstrom, J.			Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers	ONCOGENE			English	Article							TIGHT JUNCTION FORMATION; MYC-INDUCED APOPTOSIS; C-MYC; POLARITY; LOCALIZATION; DROSOPHILA; GENES; AKT; TUMORIGENESIS; MORPHOGENESIS	Differentiated epithelial structure communicates with individual constituent epithelial cells to suppress their proliferation activity. However, the pathways linking epithelial structure to cessation of the cell proliferation machinery or to unscheduled proliferation in the context of tumorigenesis are not well defined. Here we demonstrate the strong impact of compromised epithelial integrity on normal and oncogenic Myc-driven proliferation in three-dimensional mammary epithelial organoid culture. Systematic silencing of 34 human homologs of Drosophila genes, with previously established functions in control of epithelial integrity, demonstrates a role for human genes of apico-basal polarity, Wnt and Hippo pathways and actin dynamics in regulation of the size, integrity and cell proliferation in organoids. Perturbation of these pathways leads to diverse functional interactions with Myc: manifested as a RhoA-dependent synthetic lethality and Par6-dependent effects on the cell cycle. Furthermore, we show a role for Par6G as a negative regulator of the phosphatidylinositol 3'-kinase/phosphoinositide-dependent protein kinase 1/Akt pathway and epithelial cell proliferation and evidence for frequent inactivation of Par6G gene in epithelial cancers. The findings demonstrate that determinants of epithelial structure regulate the cell proliferation activity via conserved and cancer-relevant regulatory circuitries, which are important for epithelial cell cycle restriction and may provide new targets for therapeutic intervention.	[Marques, E.; Englund, J. I.; Tervonen, T. A.; Virkunen, E.; Myllynen, M.; Makela, A.; Ahvenainen, M.; Klefstrom, J.] Univ Helsinki, Translat Canc Biol, Res Programs Unit, Canc Cell Circuitry Lab, FIN-00014 Helsinki, Finland; [Marques, E.; Englund, J. I.; Tervonen, T. A.; Virkunen, E.; Myllynen, M.; Makela, A.; Ahvenainen, M.; Klefstrom, J.] Univ Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; [Laakso, M.; Hautaniemi, S.] Univ Helsinki, Genome Scale Biol Program, Syst Biol Lab, FIN-00014 Helsinki, Finland; [Laakso, M.; Lepikhova, T.; Monni, O.; Hautaniemi, S.] Univ Helsinki, Inst Biomed, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; [Lepikhova, T.; Monni, O.] Univ Helsinki, Genome Scale Biol Program, FIN-00014 Helsinki, Finland; [Lepikhova, T.] Univ Helsinki, Mol Oncol Lab, FIN-00014 Helsinki, Finland; [Lepikhova, T.] Univ Helsinki, Mol Canc Biol Program, Inst Clin Med, Biomedicum Helsinki, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	Klefstrom, J (corresponding author), Univ Helsinki, Translat Canc Biol Res Program, Canc Cell Circuitry Lab, Haartmaninkatu 8,Room B507,POB 63, FIN-00014 Helsinki, Finland.	Juha.Klefstrom@helsinki.fi	Englund, Johanna/GYJ-7086-2022; Englund, Johanna/ABG-6420-2021; Hautaniemi, Sampsa/A-3122-2009; Hautaniemi, Sampsa/CAG-0362-2022	Englund, Johanna/0000-0001-9637-6843; Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694	Academy of Finland; Center of Excellence in Cancer Genetics Research; TEKES; Sigrid Juselius Foundation; Finnish Cancer Organizations; Helsinki Graduate Program in Biotechnology and Molecular Biology; Innovative Medicines Initiative Joint Undertaking [115188]	Academy of Finland(Academy of Finland); Center of Excellence in Cancer Genetics Research; TEKES(Finnish Funding Agency for Technology & Innovation (TEKES)); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Organizations; Helsinki Graduate Program in Biotechnology and Molecular Biology; Innovative Medicines Initiative Joint Undertaking	We thank all the members of Klefstrom laboratory for discussions and critical comments. We thank Tiina Raatikainen and Tarja Valimaki for technical assistance and Biomedicum Imaging Unit and Biomedicum Functional Genomics Unit for core services and technical support. This study was funded by the Academy of Finland (to JK and SH), Center of Excellence in Cancer Genetics Research (to SH and ML), TEKES, Sigrid Juselius Foundation, Finnish Cancer Organizations (to JK), Helsinki Graduate Program in Biotechnology and Molecular Biology (to EM) and Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115188 (to JK).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Avruch J, 2012, SEMIN CELL DEV BIOL, V23, P770, DOI 10.1016/j.semcdb.2012.07.002; Banks L, 2012, NAT REV CANCER, V12, P876, DOI 10.1038/nrc3400; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Brody T, 1999, TRENDS GENET, V15, P333, DOI 10.1016/S0168-9525(99)01775-8; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Chatterjee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034343; Chen A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-552; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; Clegg NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017449; Cunliffe HE, 2012, AM J CANCER RES, V2, P478; Curto M, 2008, BRIT J CANCER, V98, P256, DOI 10.1038/sj.bjc.6604002; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Fogg VC, 2005, J CELL SCI, V118, P2859, DOI 10.1242/jcs.02412; Gonzalez-Mariscal L, 2012, ANN NY ACAD SCI, V1257, P133, DOI 10.1111/j.1749-6632.2012.06537.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Link W, 2005, J CELL BIOCHEM, V95, P979, DOI 10.1002/jcb.20479; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCrea PD, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002923; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Partanen JI, 2009, CELL CYCLE, V8, P716, DOI 10.4161/cc.8.5.7786; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Sourisseau T, 2006, MOL CELL BIOL, V26, P2387, DOI 10.1128/MCB.26.6.2387-2398.2006; Tervonen TA, 2011, ADV CANCER RES, V111, P97, DOI 10.1016/B978-0-12-385524-4.00003-9; Vleugel M, 2012, DEV CELL, V23, P239, DOI 10.1016/j.devcel.2012.06.013; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weber KL, 2007, J CELL SCI, V120, P3625, DOI 10.1242/jcs.011445; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Weyrich P, 2007, MOL CELL ENDOCRINOL, V268, P30, DOI 10.1016/j.mce.2007.01.011; Whyte J, 2010, J CELL SCI, V123, P3316, DOI 10.1242/jcs.065243; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	54	14	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1386	1398		10.1038/onc.2015.196	http://dx.doi.org/10.1038/onc.2015.196			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26073086	Green Published, hybrid			2022-12-28	WOS:000372196400005
J	Buchert, M; Burns, CJ; Ernst, M				Buchert, M.; Burns, C. J.; Ernst, M.			Targeting JAK kinase in solid tumors: emerging opportunities and challenges	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN HEPATOCELLULAR-CARCINOMA; MULTIPLE SIGNALING PATHWAYS; CLONOGENIC STEM-CELLS; HUMAN PROSTATE-CANCER; BREAST-CANCER; STAT3 ACTIVATION; CONSTITUTIVE ACTIVATION; COLORECTAL-CANCER; GROWTH-FACTOR	Various human malignancies are characterized by excessive activation of the Janus family of cytoplasmic tyrosine kinases (JAK) and their associated transcription factors STAT3 and STAT5. In the majority of solid tumors, this occurs in response to increased abundance of inflammatory cytokines in the tumor microenvironment prominently produced by infiltrating innate immune cells. Many of these cytokines share common receptor subunits and belong to the interleukin (IL)-6/IL-11, IL-10/IL-22 and IL-12/IL-23 families. Therapeutic inhibition of the JAK/STAT3 pathway potentially offers considerable benefit owing to the capacity of JAK/STAT3 signaling to promote cancer hallmarks in the tumor and its environment, including proliferation, survival, angiogenesis, tumor metabolism while suppressing antitumor immunity. This is further emphasized by the current successful clinical applications of JAK-specific small molecule inhibitors for the treatment of inflammatory disorders and hematopoietic malignancies. Here we review current preclinical applications for JAK inhibitors for the treatment of solid cancers in mice, with a focus on the most common malignancies emanating from oncogenic transformation of the epithelial mucosa in the stomach and colon. Emerging data with small molecule JAK-specific adenosine triphosphate-binding analogs corroborate genetic findings and suggest that interference with the JAK/STAT3 pathway may suppress the growth of the most common forms of sporadic colon cancers that arise from mutations of the APC tumor suppressor gene. Likewise inhibition of cytokine-dependent activation of the JAK/STAT3 pathway may also afford orthogonal treatment opportunities for other oncogene-addicted cancer cells that have gained drug resistance.	[Buchert, M.; Burns, C. J.; Ernst, M.] Univ Melbourne, Walter & Eliza Hall Inst, Dept Med Biol, Melbourne, Vic, Australia; [Buchert, M.; Ernst, M.] La Trobe Univ, Austin Hlth, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia; [Buchert, M.; Ernst, M.] La Trobe Univ, Austin Hlth, Sch Canc Med, Heidelberg, Vic, Australia	University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University; Olivia Newton-John Cancer Research Institute; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University	Buchert, M; Ernst, M (corresponding author), ONJCRI, Austin Hlth, 145 Studley Rd, Heidelberg, Vic 3084, Australia.	Michael.Buchert@onjcri.org.au; Matthias.Ernst@onjcri.org.au	Ernst, Matthias/D-5111-2012	Ernst, Matthias/0000-0002-6399-1177; Buchert, Michael/0000-0003-2672-0148; Burns, Christopher/0000-0002-4463-4916	Cancer Council Victoria; National Health and Medical Research Council, Australia [1064987, 1079257]; Ludwig Cancer Research; Operational Infrastructure Support Program by the Victorian Government, Australia	Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Ludwig Cancer Research; Operational Infrastructure Support Program by the Victorian Government, Australia	The work in the authors' laboratories is supported by the Cancer Council Victoria, grants (#1064987 and #1079257) from the National Health and Medical Research Council, Australia, by Ludwig Cancer Research and by funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia.	Andraos R, 2012, CANCER DISCOV, V2, P512, DOI 10.1158/2159-8290.CD-11-0324; Baltgalvis KA, 2008, AM J PHYSIOL-REG I, V294, pR393, DOI 10.1152/ajpregu.00716.2007; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Beebe K, 2010, DEV BIOL, V338, P28, DOI 10.1016/j.ydbio.2009.10.045; Behnsen J, 2014, IMMUNITY, V40, P262, DOI 10.1016/j.immuni.2014.01.003; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biteau B, 2011, DEVELOPMENT, V138, P1045, DOI 10.1242/dev.056671; Blaas L, 2010, HEPATOLOGY, V51, P1319, DOI 10.1002/hep.23469; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buchon N, 2009, CELL HOST MICROBE, V5, P200, DOI 10.1016/j.chom.2009.01.003; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chang HC, 2009, BLOOD, V113, P5887, DOI 10.1182/blood-2008-09-179820; Chang Q, 2014, SEMIN IMMUNOL, V26, P48, DOI 10.1016/j.smim.2014.01.007; Chen PL, 2005, J BIOL CHEM, V280, P5361, DOI 10.1074/jbc.M411974200; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choong ML, 2013, J CELL MOL MED, V17, P1397, DOI 10.1111/jcmm.12156; Chueh FY, 2010, BIOCHEM BIOPH RES CO, V402, P778, DOI 10.1016/j.bbrc.2010.10.112; Cirillo D, 2008, J CELL BIOCHEM, V105, P956, DOI 10.1002/jcb.21911; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Cordero JB, 2012, DEVELOPMENT, V139, P4524, DOI 10.1242/dev.078261; da Rocha LF, 2012, J RHEUMATOL, V39, P1320, DOI 10.3899/jrheum.111027; Dagvadorj A, 2008, CLIN CANCER RES, V14, P1317, DOI 10.1158/1078-0432.CCR-07-2024; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Derenzini E, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.46; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; DU XX, 1994, BLOOD, V83, P33; DU XX, 1994, BLOOD, V83, P2023; Duarte CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029653; DUMMER W, 1995, MELANOMA RES, V5, P67, DOI 10.1097/00008390-199502000-00008; Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213; Durmus S, 2013, PHARMACOL RES, V76, P9, DOI 10.1016/j.phrs.2013.06.009; Emmerich J, 2012, CANCER RES, V72, P3570, DOI 10.1158/0008-5472.CAN-12-0721; Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944; Evrot E, 2013, CLIN CANCER RES, V19, P6230, DOI 10.1158/1078-0432.CCR-13-0905; Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Fiskus W, 2013, MOL CANCER THER, V12, P577, DOI 10.1158/1535-7163.MCT-12-0862; Fiskus W, 2011, CLIN CANCER RES, V17, P7347, DOI 10.1158/1078-0432.CCR-11-1541; Fujitake S, 2004, J GASTROENTEROL, V39, P120, DOI 10.1007/s00535-003-1262-0; Fuke H, 2007, BIOCHEM BIOPH RES CO, V363, P738, DOI 10.1016/j.bbrc.2007.09.049; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Gajewski TF, 2010, CANCER J, V16, P399, DOI 10.1097/PPO.0b013e3181eacbd8; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Ghoreschi K, 2009, IMMUNOL REV, V228, P273, DOI 10.1111/j.1600-065X.2008.00754.x; GOLDSTEIN D, 1988, CA-CANCER J CLIN, V38, P258, DOI 10.3322/canjclin.38.5.258; Gough DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083395; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Greenwood C, 2012, J PROTEOMICS, V75, P3031, DOI 10.1016/j.jprot.2011.11.033; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Haan C, 2011, CHEM BIOL, V18, P314, DOI 10.1016/j.chembiol.2011.01.012; Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harir N, 2007, BLOOD, V109, P1678, DOI 10.1182/blood-2006-01-029918; Hauschild A, 2008, CANCER-AM CANCER SOC, V112, P982, DOI 10.1002/cncr.23251; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hosui A, 2009, J EXP MED, V206, P819, DOI 10.1084/jem.20080003; HUANG M, 1995, CANCER RES, V55, P3847; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Inagaki-Ohara Kyoko, 2013, JAKSTAT, V2, pe24053, DOI 10.4161/jkst.24053; Jarnicki A, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-14; Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320; Joung YH, 2014, INT J ONCOL, V44, P883, DOI 10.3892/ijo.2014.2250; Judd LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095993; Justa S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093279; Kamiya S, 2011, IMMUNOL LETT, V138, P47, DOI 10.1016/j.imlet.2011.02.022; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karpowicz P, 2010, DEVELOPMENT, V137, P4135, DOI 10.1242/dev.060483; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Kershaw NJ, 2013, NAT STRUCT MOL BIOL, V20, P469, DOI 10.1038/nsmb.2519; KIM J, 1995, J IMMUNOL, V155, P2240; Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308; Komazaki T, 2004, JPN J CLIN ONCOL, V34, P191, DOI 10.1093/jjco/hyh035; Koppikar P, 2012, NATURE, V489, P155, DOI 10.1038/nature11303; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lederle W, 2011, INT J CANCER, V128, P2803, DOI 10.1002/ijc.25621; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lee SK, 2005, J DERMATOL SCI, V40, P95, DOI 10.1016/j.jdermsci.2005.06.008; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Leibowitz MS, 2013, CLIN CANCER RES, V19, P798, DOI 10.1158/1078-0432.CCR-12-1517; Leipe J, 2011, ANN RHEUM DIS, V70, P1453, DOI 10.1136/ard.2011.152074; Letellier E, 2014, BRIT J CANCER, V111, P726, DOI 10.1038/bjc.2014.377; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li HZ, 2004, CANCER RES, V64, P4774, DOI 10.1158/0008-5472.CAN-03-3499; Li Y, 2012, CARCINOGENESIS, V33, P1889, DOI 10.1093/carcin/bgs214; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lindemann C, 2011, ACTA NEUROPATHOL, V122, P241, DOI 10.1007/s00401-011-0832-0; Liu SH, 2008, PIGM CELL MELANOMA R, V21, P545, DOI 10.1111/j.1755-148X.2008.00484.x; Lucet IS, 2006, BLOOD, V107, P176, DOI 10.1182/blood-2005-06-2413; Mao YL, 2011, PATHOL ONCOL RES, V17, P333, DOI 10.1007/s12253-010-9321-3; Marini A, 2006, J INVEST DERMATOL, V126, P422, DOI 10.1038/sj.jid.5700073; Marit MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043437; Martini M, 2008, INT J CANCER, V123, P2955, DOI 10.1002/ijc.23805; Masuda M, 2002, CANCER RES, V62, P3351; Mcgee HM, 2013, J INVEST DERMATOL, V133, P1321, DOI 10.1038/jid.2012.463; Melzner I, 2006, INT J CANCER, V118, P1941, DOI 10.1002/ijc.21485; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Mencalha AL, 2010, CANCER CHEMOTH PHARM, V65, P1039, DOI 10.1007/s00280-009-1109-3; Messina NL, 2013, IMMUNOL CELL BIOL, V91, P556, DOI 10.1038/icb.2013.41; Miteva LD, 2014, TUMOR BIOL, V35, P12655, DOI 10.1007/s13277-014-2589-2; Mohan CD, 2014, J BIOL CHEM, V289, P34296, DOI 10.1074/jbc.M114.601104; Monaghan KA, 2011, LEUKEMIA, V25, P1891, DOI 10.1038/leu.2011.175; Mori T, 2006, CANCER RES, V66, P6692, DOI 10.1158/0008-5472.CAN-06-0801; Mumm JB, 2011, CANCER CELL, V20, P781, DOI 10.1016/j.ccr.2011.11.003; Murray PJ, 2006, CURR OPIN PHARMACOL, V6, P379, DOI 10.1016/j.coph.2006.01.010; Musteanu M, 2010, GASTROENTEROLOGY, V138, P1003, DOI 10.1053/j.gastro.2009.11.049; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; Nagai H, 2002, CANCER LETT, V186, P59, DOI 10.1016/S0304-3835(02)00244-6; Nagai H, 2001, J HEPATOL, V34, P416, DOI 10.1016/S0168-8278(00)00038-6; Nagakawa H, 2004, SCAND J IMMUNOL, V60, P449, DOI 10.1111/j.0300-9475.2004.01504.x; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Norman P, 2014, EXPERT OPIN INV DRUG, V23, P1067, DOI 10.1517/13543784.2014.918604; Novotny-Diermayr V, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.14; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Okochi O, 2003, CLIN CANCER RES, V9, P5295; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Onnis B, 2013, J CLIN INVEST, V123, P1615, DOI 10.1172/JCI59623; Orazi A, 1996, LAB INVEST, V75, P33; Oshimo Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521; Pardanani A, 2013, LEUKEMIA, V27, P1322, DOI 10.1038/leu.2013.71; Pecquet C, 2010, BLOOD, V115, P1037, DOI 10.1182/blood-2008-10-183558; Phesse TJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005411; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Pierconti F, 2011, PROSTATE, V71, P318, DOI 10.1002/pros.21245; Pilati C, 2011, J EXP MED, V208, P1359, DOI 10.1084/jem.20110283; PISA P, 1992, P NATL ACAD SCI USA, V89, P7708, DOI 10.1073/pnas.89.16.7708; Plimack ER, 2013, ONCOLOGIST, V18, P819, DOI 10.1634/theoncologist.2013-0198; Potten CS, 1996, STEM CELLS, V14, P452, DOI 10.1002/stem.140452; POTTEN CS, 1995, INT J CANCER, V62, P356, DOI 10.1002/ijc.2910620321; Poussin K, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27090; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Qiu J, 2013, IMMUNITY, V39, P386, DOI 10.1016/j.immuni.2013.08.002; Qiu XY, 2013, MOL CELL BIOCHEM, V378, P99, DOI 10.1007/s11010-013-1599-5; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sasi Walid, 2014, Mol Biol Int, V2014, P630797, DOI 10.1155/2014/630797; Sato T, 1996, CLIN CANCER RES, V2, P1383; Schafer ZT, 2007, J CLIN INVEST, V117, P3660, DOI 10.1172/JCI34237; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schneller D, 2011, HEPATOLOGY, V54, P164, DOI 10.1002/hep.24329; Seavey MM, 2012, MOL CANCER THER, V11, P984, DOI 10.1158/1535-7163.MCT-11-0951; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Silver JS, 2010, J LEUKOCYTE BIOL, V88, P1145, DOI 10.1189/jlb.0410217; Simpson JAD, 2010, GUT, V59, P926, DOI 10.1136/gut.2009.194472; Sobti RC, 2011, CELL ONCOL, V34, P533, DOI 10.1007/s13402-011-0056-2; Sonnenberg GF, 2012, SCIENCE, V336, P1321, DOI 10.1126/science.1222551; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; Steensma DP, 2005, BLOOD, V106, P1207, DOI 10.1182/blood-2005-03-1183; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Stuart E, 2014, MOL CANCER THER, V13, P468, DOI 10.1158/1535-7163.MCT-13-0583-T; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Tan SH, 2008, ENDOCR-RELAT CANCER, V15, P367, DOI 10.1677/ERC-08-0013; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Taylor P, 2014, ANN RHEUM DIS, V73, pA31, DOI 10.1136/annrheumdis-2013-205124.71; Thoma G, 2014, BIOORG MED CHEM LETT, V24, P4617, DOI 10.1016/j.bmcl.2014.08.046; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Tischoff I, 2007, GUT, V56, P1047, DOI 10.1136/gut.2006.111633; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Ueda M, 2003, BRIT J HAEMATOL, V123, P288, DOI 10.1046/j.1365-2141.2003.04601.x; Upadhyay V, 2012, NAT IMMUNOL, V13, P947, DOI 10.1038/ni.2403; Vafaizadeh V, 2010, STEM CELLS, V28, P928, DOI 10.1002/stem.407; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; van Vollenhoven RF, 2012, NEW ENGL J MED, V367, P508, DOI 10.1056/NEJMoa1112072; Venetsanakos E, 1997, BRIT J CANCER, V75, P1826, DOI 10.1038/bjc.1997.311; Walter M, 2009, ONCOGENE, V28, P2745, DOI 10.1038/onc.2009.130; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wang SJ, 2015, ONCOTARGET, V6, P243, DOI 10.18632/oncotarget.2801; Wang YC, 2009, BLOOD, V114, P5024, DOI 10.1182/blood-2009-05-222133; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Will B, 2010, BLOOD, V115, P2901, DOI 10.1182/blood-2009-03-209544; Wolfle SJ, 2011, EUR J IMMUNOL, V41, P413, DOI 10.1002/eji.201040979; Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Xi SC, 2003, CANCER RES, V63, P6763; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Xiong H, 2009, LAB INVEST, V89, P717, DOI 10.1038/labinvest.2009.11; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yang J, 2005, CANCER RES, V65, P939; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yeh YT, 2012, WORLD J SURG, V36, P1128, DOI 10.1007/s00268-012-1505-4; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zenewicz LA, 2013, J IMMUNOL, V190, P5306, DOI 10.4049/jimmunol.1300016; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zhang L, 2014, HEPATOLOGY, V59, P178, DOI 10.1002/hep.26628; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	228	149	157	2	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					939	951		10.1038/onc.2015.150	http://dx.doi.org/10.1038/onc.2015.150			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25982279				2022-12-28	WOS:000370823300001
J	Garant, KA; Shmulevitz, M; Pan, L; Daigle, RM; Ahn, DG; Gujar, SA; Lee, PWK				Garant, K. A.; Shmulevitz, M.; Pan, L.; Daigle, R. M.; Ahn, D-G; Gujar, S. A.; Lee, P. W. K.			Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release	ONCOGENE			English	Article							GOLGI-COMPLEX; H-RAS; FRAGMENTATION; LOCALIZATION; INHIBITION; CANCER; TRAFFICKING; APPARATUS; PROTEINS; REQUIRES	Reovirus is a naturally oncolytic virus that preferentially replicates in Ras-transformed cells and is currently undergoing clinical trials as a cancer therapeutic. Ras transformation promotes reovirus oncolysis by enhancing virion disassembly during entry, viral progeny production, and virus release through apoptosis; however, the mechanism behind the latter is not well understood. Here, we show that reovirus alters the intracellular location of oncogenic Ras to induce apoptosis of H-RasV12-transformed fibroblasts. Reovirus infection decreases Ras palmitoylation levels and causes accumulation of Ras in the Golgi through Golgi fragmentation. With the Golgi being the site of Ras palmitoylation, treatment of target cells with the palmitoylation inhibitor, 2-bromopalmitate (2BP), prompts a greater accumulation of H-RasV12 in the Golgi, and a dose-dependent increase in progeny virus release and subsequent spread. Conversely, tethering H-RasV12 to the plasma membrane (thereby preventing its movement to the Golgi) allows for efficient virus production, but results in basal levels of reovirus-induced cell death. Analysis of Ras downstream signaling reveals that cells expressing cycling H-RasV12 have elevated levels of phosphorylated JNK (c-Jun N-terminal kinase), and that Ras retained at the Golgi body by 28P increases activation of the MEKK1/MKK4/JNK signaling pathway to promote cell death. Collectively, our data suggest that reovirus induces Golgi fragmentation of target cells, and the subsequent accumulation of oncogenic Ras in the Golgi body initiates apoptotic signaling events required for virus release and spread.	[Garant, K. A.; Ahn, D-G; Gujar, S. A.; Lee, P. W. K.] Dalhousie Univ, Dept Microbiol & Immunol, 5850 Coll St,7P Sir Charles Tupper Med Bldg, Halifax, NS B3H 1X5, Canada; [Shmulevitz, M.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada; [Pan, L.] Toronto Western Res Inst, Div Fundamental Neurobiol, Toronto, ON, Canada; [Daigle, R. M.] Dalhousie Univ, Dept Oceanog, Halifax, NS B3H 1X5, Canada; [Gujar, S. A.] IWK Hlth Ctr, Strategy & Org Performance, Halifax, NS, Canada; [Lee, P. W. K.] Dalhousie Univ, Dept Pathol, Halifax, NS B3H 1X5, Canada	Dalhousie University; University of Alberta; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Dalhousie University; Dalhousie University; Dalhousie University	Gujar, SA; Lee, PWK (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, 5850 Coll St,7P Sir Charles Tupper Med Bldg, Halifax, NS B3H 1X5, Canada.	shashi.gujar@dal.ca; patrick.lee@dal.ca	Daigle, Remi M/H-3160-2019; Ahn, Dae-Gyun/L-7106-2015	Daigle, Remi M/0000-0001-8832-4189; Shmulevitz, Maya/0000-0002-8627-068X; Ahn, Dae-Gyun/0000-0001-8251-8820; Gujar, Shashi/0000-0002-5427-0829	Canadian Institutes for Health Research [130574]; Terry Fox Research Institute (TFRI) New Frontiers Program in Cancer Research; National Sciences and Engineering Research Council of Canada; Killam Trusts; Nova Scotia Health Research Foundation; Canadian Institute of Health Research (CIHR)-Cancer Research Training Program; Beatrice Hunter Cancer Research Institute (BHCRI); CIHR postdoctoral fellowship	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Terry Fox Research Institute (TFRI) New Frontiers Program in Cancer Research; National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Killam Trusts; Nova Scotia Health Research Foundation; Canadian Institute of Health Research (CIHR)-Cancer Research Training Program(Canadian Institutes of Health Research (CIHR)); Beatrice Hunter Cancer Research Institute (BHCRI); CIHR postdoctoral fellowship(Canadian Institutes of Health Research (CIHR))	This work was supported by the research grants from the Canadian Institutes for Health Research (Grant FRN # 130574) and the Terry Fox Research Institute (TFRI) New Frontiers Program in Cancer Research (through Canadian Oncolytic Virus Consortium (COVCo)) to PWKL and SAG. Funding for KA Garant was awarded through the National Sciences and Engineering Research Council of Canada, the Killam Trusts and the Nova Scotia Health Research Foundation. Plasma membrane-tethered CD8-H-RasV12xx in pCEFL was a gift from Dr Piero Crespo (University of Cantabria, Cantabria, Spain). D-G Ahn was supported by the Canadian Institute of Health Research (CIHR)-Cancer Research Training Program and the Beatrice Hunter Cancer Research Institute (BHCRI). SG was supported by CIHR postdoctoral fellowship.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Ahearn IM, 2011, MOL CELL, V41, P173, DOI 10.1016/j.molcel.2011.01.001; AVITABILE E, 1995, J VIROL, V69, P7472, DOI 10.1128/JVI.69.12.7472-7482.1995; Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; BOS JL, 1989, CANCER RES, V49, P4682; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clarke P, 2004, J VIROL, V78, P13132, DOI 10.1128/JVI.78.23.13132-13138.2004; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Dekker FJ, 2010, NAT CHEM BIOL, V6, P449, DOI 10.1038/nchembio.362; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; Drisdel RC, 2006, METHODS, V40, P127, DOI 10.1016/j.ymeth.2006.04.015; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Goodwin JS, 2005, J CELL BIOL, V170, P261, DOI 10.1083/jcb.200502063; Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Heinemann L, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-221; Hirasawa K, 2002, CANCER RES, V62, P1696; Ilkow CS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003836; Kominsky DJ, 2002, CELL DEATH DIFFER, V9, P926, DOI 10.1038/sj.cdd.4401045; Kominsky DJ, 2002, J VIROL, V76, P11414, DOI 10.1128/JVI.76.22.11414-11424.2002; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Mendez II, 2000, J VIROL METHODS, V90, P59, DOI 10.1016/S0166-0934(00)00217-2; Mukherjee S, 2007, TRAFFIC, V8, P369, DOI 10.1111/j.1600-0854.2007.00542.x; Norman KL, 2002, HUM GENE THER, V13, P641, DOI 10.1089/10430340252837233; Nozawa K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar422; Parker JSL, 2002, J VIROL, V76, P4483, DOI 10.1128/JVI.76.9.4483-4496.2002; Resh MD, 2006, METHODS, V40, P191, DOI 10.1016/j.ymeth.2006.04.013; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SHARPE AH, 1982, VIROLOGY, V120, P399, DOI 10.1016/0042-6822(82)90040-X; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; Shmulevitz M, 2010, CANCER RES, V70, P4912, DOI 10.1158/0008-5472.CAN-09-4676; Stickney JT, 2001, METHOD ENZYMOL, V332, P64; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Swarthout JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/jbc.M504113200; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261	48	25	25	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					771	782		10.1038/onc.2015.136	http://dx.doi.org/10.1038/onc.2015.136			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961930				2022-12-28	WOS:000370331300010
J	Jeffery, J; Sinha, D; Srihari, S; Kalimutho, M; Khanna, KK				Jeffery, J.; Sinha, D.; Srihari, S.; Kalimutho, M.; Khanna, K. K.			Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis	ONCOGENE			English	Review							GENE-EXPRESSION PROFILES; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; ESCRT-III; PLK1-DEPENDENT PHOSPHORYLATION; INTERCELLULAR BRIDGES; CENTROSOMAL PROTEIN; UP-REGULATION; KINASE 1; MIDBODY	CEP55 was initially identified as a pivotal component of abscission, the final stage of cytokinesis, serving to regulate the physical separation of two daughter cells. Over the past 10 years, several studies have illuminated additional roles for CEP55 including regulating the PI3K/AKT pathway and midbody fate. Concurrently, CEP55 has been studied in the context of cancers including those of the breast, lung, colon and liver. CEP55 overexpression has been found to significantly correlate with tumor stage, aggressiveness, metastasis and poor prognosis across multiple tumor types and therefore has been included as part of several prognostic 'gene signatures' for cancer. Here by discussing in depth the functions of CEP55 across different effector pathways, and also its roles as a biomarker and driver of tumorigenesis, we assemble an exhaustive review, thus commemorating a decade of research on CEP55.	[Jeffery, J.; Sinha, D.; Kalimutho, M.; Khanna, K. K.] QIMR Berghofer Med Res Inst, Signal Transduct Lab, 300 Hcrston Rd, Brisbane, Qld, Australia; [Sinha, D.] Griffith Univ, Sch Nat Sci, Brisbane, Qld 4111, Australia; [Srihari, S.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; Griffith University; University of Queensland	Khanna, KK (corresponding author), QIMR Berghofer Med Res Inst, Signal Transduct Lab, 300 Hcrston Rd, Brisbane, Qld, Australia.	kumkum.khanna@gimrberghofer.edu.au	Kalimutho, Murugan/AAD-1441-2019; Sinha, Debottam/J-5521-2019; Srihari, Sriganesh/H-1740-2013	Sinha, Debottam/0000-0001-7153-856X; Khanna, Kum Kum/0000-0001-8650-5381; Srihari, Sriganesh/0000-0002-0713-6723; Kalimutho, Murugan/0000-0002-0772-8673	Griffith University International and Postgraduate Research Scholarship; Cancer Council Queensland [ID1087363]; National Health & Medical Research Council (NHMRC) [1017028]	Griffith University International and Postgraduate Research Scholarship; Cancer Council Queensland(Cancer Council Queensland); National Health & Medical Research Council (NHMRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)National Health and Medical Research Council (NHMRC) of Australia)	DS is supported by a Griffith University International and Postgraduate Research Scholarship. MK is supported by a project grant from Cancer Council Queensland (ID1087363). This work was supported by a program grant from the National Health & Medical Research Council (NHMRC) to KKK (ID 1017028). KKK is a NHMRC Senior Principal Research Fellow (ID 613638).	Al-Ejeh F, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.14; Anastassiou D, 2012, Biomolecular events in cancer revealed by attractor metagenes. USA, Patent No. [PCT/US2013/037720, 2013037720]; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Bastos RN, 2010, J CELL BIOL, V191, P751, DOI 10.1083/jcb.201008108; Carlton JG, 2008, P NATL ACAD SCI USA, V105, P10541, DOI 10.1073/pnas.0802008105; Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Carter SL, 2005, Prognosis indicators for solid human tumors. USA, Patent No. [PCT/US2006/047662, 2006047662]; Chang YC, 2012, J BIOL CHEM, V287, P4376, DOI 10.1074/jbc.M111.289108; Chang YC, 2010, J CELL BIOCHEM, V109, P1274, DOI 10.1002/jcb.22517; Chen CH, 2007, ONCOGENE, V26, P4272, DOI 10.1038/sj.onc.1210207; Chen CH, 2009, ONCOGENE, V28, P2723, DOI 10.1038/onc.2009.128; Chen CH, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-93; Chen CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005052; Chen DT, 2011, Malignancy-risk signature from histologically normal breast tissue. USA, Patent No. [PCT/US2009/030778, 2009030778]; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920; Cheung M, 2013, CURR CANCER DRUG TAR, V13, P234, DOI 10.2174/1568009611313030002; Colak D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063204; Coutant C, 2011, CLIN CANCER RES, V17, P2591, DOI 10.1158/1078-0432.CCR-10-1045; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Ettinger AW, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1511; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Fournier MV, 2006, CANCER RES, V66, P7095, DOI 10.1158/0008-5472.CAN-06-0515; Fratta E, 2011, MOL ONCOL, V5, P164, DOI 10.1016/j.molonc.2011.02.001; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Green RA, 2012, ANNU REV CELL DEV BI, V28, P29, DOI 10.1146/annurev-cellbio-101011-155718; Greenbaum MP, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005850; Greenbaum MP, 2006, P NATL ACAD SCI USA, V103, P4982, DOI 10.1073/pnas.0505123103; Gromley A, 2005, CELL, V123, P75, DOI 10.1016/j.cell.2005.07.027; Guizetti J, 2011, SCIENCE, V331, P1616, DOI 10.1126/science.1201847; Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189; Hong BS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-556; Hu Y, 2012, P NATL ACAD SCI USA, V109, P3184, DOI 10.1073/pnas.1117872109; Hwang CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084218; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Inoda S, 2011, AM J PATHOL, V178, P1805, DOI 10.1016/j.ajpath.2011.01.004; Inoda S, 2011, EXP MOL PATHOL, V90, P55, DOI 10.1016/j.yexmp.2010.10.001; Inoda S, 2009, J IMMUNOTHER, V32, P474, DOI 10.1097/CJI.0b013e3181a1d109; Iwamori T, 2010, MOL CELL BIOL, V30, P2280, DOI 10.1128/MCB.01392-09; Jeffery J, FASEB J; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kao H, 2001, J EXP MED, V194, P1313, DOI 10.1084/jem.194.9.1313; Kato K, 2005, J CANCER RES CLIN, V131, P340, DOI 10.1007/s00432-004-0654-8; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kruger TE, 2014, CRIT REV ONCOL HEMAT, V89, P330, DOI 10.1016/j.critrevonc.2013.08.013; Kumar A, 2013, PROTOPLASMA, V250, P965, DOI 10.1007/s00709-013-0488-9; Kuo TC, 2011, NAT CELL BIOL, V13, P1214, DOI 10.1038/ncb2332; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Lee HH, 2008, SCIENCE, V322, P576, DOI 10.1126/science.1162042; Lekomtsev S, 2010, J CELL SCI, V123, P1395, DOI 10.1242/jcs.068015; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994; Martin KJ, 2010, Gene expression signature as a predictor of chemotherapeutic response in breast cancer. USA, Patent No. [PCT/US2011/039325, 2011039325]; Martinez-Garay I, 2006, GENOMICS, V87, P243, DOI 10.1016/j.ygeno.2005.11.006; McKenzie L, 2010, CELL CYCLE, V9, P4200, DOI 10.4161/cc.9.20.13532; Mierzwa B, 2014, DEV CELL, V31, P525, DOI 10.1016/j.devcel.2014.11.006; Mondal G, 2012, DEV CELL, V23, P137, DOI 10.1016/j.devcel.2012.05.008; Montero-Conde C, 2008, ONCOGENE, V27, P1554, DOI 10.1038/sj.onc.1210792; Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850; Morita E, 2010, P NATL ACAD SCI USA, V107, P12889, DOI 10.1073/pnas.1005938107; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Naderi A, 2007, ONCOGENE, V26, P1507, DOI 10.1038/sj.onc.1209920; Neto H, 2013, MOL BIOL CELL, V24, P3663, DOI 10.1091/mbc.E13-06-0302; Ochi T, 2009, BLOOD, V113, P66, DOI 10.1182/blood-2008-06-164889; Pandit B, 2009, CELL CYCLE, V8, P3425, DOI 10.4161/cc.8.20.9628; Perou CM, 2008, Gene expression profiles to predict breast cancer outcomes. USA, Patent No. [PCT/US2009/045820, 2009045820]; Perou CM, 2012, Methods of Treating Breast Cancer With Taxane Therapy. USA, Patent No. [PCT/US2012/067317, 2012067317]; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sakai M, 2006, ONCOGENE, V25, P480, DOI 10.1038/sj.onc.1209051; Sauer G, 2005, MOL CELL PROTEOMICS, V4, P35, DOI 10.1074/mcp.M400158-MCP200; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Singh PK, 2015, IMMUNOBIOLOGY, V220, P103, DOI 10.1016/j.imbio.2014.08.014; St-Denis N, 2015, MOL CELL PROTEOMICS, V14, P946, DOI 10.1074/mcp.M114.046086; Stone S, 2010, Gene signatures for cancer diagnosis and prognosis. USA, Patent No. [PCT/US2011/049760, 2011049760]; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Tao JQ, 2014, TUMOR BIOL, V35, P4389, DOI 10.1007/s13277-013-1578-1; Tsai CY, 2015, BIOCHEM PHARMACOL, V93, P34, DOI 10.1016/j.bcp.2014.10.018; van der Horst A, 2009, CELL CYCLE, V8, P3742, DOI 10.4161/cc.8.22.10047; van der Horst A, 2009, CANCER RES, V69, P6651, DOI 10.1158/0008-5472.CAN-09-0825; Wagner S, 2011, Gene signatures for lung cancer prognosis and therapy selection. USA, Patent No. [PCT/US2012/051447, 2012051447]; Waseem A, 2010, ORAL ONCOL, V46, P536, DOI 10.1016/j.oraloncology.2010.03.022; Yanagisawa H, 2009, J CELL COMMUN SIGNAL, V3, P337, DOI 10.1007/s12079-009-0065-3; Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015; Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001	92	81	84	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					683	690		10.1038/onc.2015.128	http://dx.doi.org/10.1038/onc.2015.128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25915844				2022-12-28	WOS:000370331300002
J	Mukherjee, S; Manna, A; Bhattacharjee, P; Mazumdar, M; Saha, S; Chakraborty, S; Guha, D; Adhikary, A; Jana, D; Gorain, M; Mukherjee, SA; Kundu, GC; Sarkar, DK; Das, T				Mukherjee, S.; Manna, A.; Bhattacharjee, P.; Mazumdar, M.; Saha, S.; Chakraborty, S.; Guha, D.; Adhikary, A.; Jana, D.; Gorain, M.; Mukherjee, S. A.; Kundu, G. C.; Sarkar, D. K.; Das, T.			Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4(+) migrating cancer stem cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CHEMOKINE RECEPTOR CXCR4; TUMOR-CELLS; CARCINOMA-CELLS; GROWTH; MICROENVIRONMENT; PERSPECTIVE; PROGRESSION; RESISTANCE; INHIBITION	Although the role of metastatic cancer stem cells (mCSCs) in tumor progression has been well documented, our study reveals a hitherto unidentified role of tumorigenic intrinsic CSCs (iCSCs) in breast cancer metastasis. We show that unlike highly migratory mCSCs residing in the breast tumor disseminating/peripheral regions, iCSCs populate the inner mass of the tumor and are nonmigratory. However iCSCs, via paracrine signaling, induce conversion of non-stem cancer cells to CSCs that (i) are identical to the previously reported mCSCs, and (ii) in contrast to iCSCs, express chemokine receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), which is crucial for their metastatic potential. These mCSCs also demonstrate high in vivo tumorigenicity. Physical non-participation of iCSCs in metastasis is further validated in vivo, where only mCSCs are found to exist in the metastatic sites, lymph nodes and bone marrow, whereas the primary tumor retains both iCSCs and mCSCs. However, iCSCs ensure metastasis since their presence is crucial for deliverance of highly metastatic CXCR4(+) mCSCs to the migrating fraction of cells. Cumulatively, these results unveil a novel role of iCSCs in breast cancer metastasis as parental regulators of CXCR4(+) mCSCs, and highlight the therapeutic requisite of targeting iCSCs, but not CXCR4(+) mCSCs, to restrain breast cancer metastasis from the root by inhibiting the generation of mCSCs from iCSCs. Considering the pivotal role of iCSCs in tumor metastasis, the possibility of metastasis to be a 'stem cell phenomena' is suggested.	[Mukherjee, S.; Manna, A.; Bhattacharjee, P.; Mazumdar, M.; Saha, S.; Chakraborty, S.; Guha, D.; Adhikary, A.; Das, T.] Calcutta Improvement Trust Scheme VII M, Bose Inst, Div Mol Med, P-1-12, Kolkata, W Bengal, India; [Jana, D.; Sarkar, D. K.] SSKM Hosp, Dept Surg, Kolkata, India; [Gorain, M.; Kundu, G. C.] NCCS, Lab Tumor Biol Angiogenesis & Nanomed Res, NCCS Complex, Pune, Maharashtra, India; [Mukherjee, S. A.] Bankura Sammilani Med Coll, Dept Physiol, Kenduadihi, Bankura, India	Department of Science & Technology (India); Bose Institute; Institute of Post Graduate Medical Education & Research (IPGMER), Kolkata; Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Das, T (corresponding author), P 1 12 CIT Scheme VII M, Bose Inst, Div Mol Med, Kolkata 700054, India.	tanya@jcbose.ac.in	Gorain, Mahadeo/AED-4445-2022; Bhattacharjee, Pushpak/AFV-4590-2022; Kundu, Gopal C./ABA-9897-2020; Chakraborty, Samik/Q-1779-2018	Chakraborty, Samik/0000-0002-5232-0474	Council of Scientific and Industrial Research (CSIR), Government of India; Department of Science and Technology (DST), Government of India; Department of Biotechnology (DBT), Government of India	Council of Scientific and Industrial Research (CSIR), Government of India(Council of Scientific & Industrial Research (CSIR) - India); Department of Science and Technology (DST), Government of India(Department of Science & Technology (India)); Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India)	We thank Gaurisankar Sa for his helpful discussions. Authors also acknowledge Uttam K. Ghosh and Ranjan Dutta for technical assistance. This work was supported by research grants from Council of Scientific and Industrial Research (CSIR), Department of Science and Technology (DST) and Department of Biotechnology (DBT), Government of India.	Ablett MP, 2014, ONCOTARGET, V5, P599, DOI 10.18632/oncotarget.1169; Adhikary A, 2014, J BIOL CHEM, V289, P25431, DOI 10.1074/jbc.M113.527267; Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chimal-Ramirez GK, 2013, J ONCOL, V2013, DOI 10.1155/2013/835956; Croker AK, 2008, J CELL MOL MED, V12, P374, DOI 10.1111/j.1582-4934.2007.00211.x; Currier N, 2005, TOXICOL PATHOL, V33, P726, DOI 10.1080/01926230500352226; Dick JE, 2009, NAT BIOTECHNOL, V27, P44, DOI 10.1038/nbt0109-44; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fehm T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2349; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Hallab N, 2000, BIOMATERIALS, V21, P1301, DOI 10.1016/S0142-9612(99)00235-5; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hossain DMS, 2013, IMMUNITY, V39, P1057, DOI 10.1016/j.immuni.2013.11.005; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jinushi M, 2012, AM J CANCER RES, V2, P529; Lebret SC, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1656; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Mukherjee S, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt506; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Park BH, 2013, J BIOL CHEM, V288, P28656, DOI 10.1074/jbc.M113.509505; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Rasanen K, 2012, CANCER DISCOV, V2, P775, DOI 10.1158/2159-8290.CD-12-0312; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang XF, 2013, CANCER EPIDEMIOL, V37, P60, DOI 10.1016/j.canep.2012.07.007; Wei W, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-S1-S6; Wiedswang G, 2004, CLIN CANCER RES, V10, P5342, DOI 10.1158/1078-0432.CCR-04-0245; Yao XH, 2008, J PATHOL, V215, P369, DOI 10.1002/path.2356	45	36	36	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4937	4948		10.1038/onc.2016.26	http://dx.doi.org/10.1038/onc.2016.26			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26923331				2022-12-28	WOS:000383330700011
J	Zhou, J; Luo, J; Wu, K; Yun, EJ; Kapur, P; Pong, RC; Du, Y; Wang, B; Authement, C; Hernandez, E; Yang, J; Xiao, G; Cha, TL; Wu, HC; Wu, D; Margulis, V; Lotan, Y; Brugarolas, J; He, D; Hsieh, JT				Zhou, J.; Luo, J.; Wu, K.; Yun, E-j; Kapur, P.; Pong, R-C; Du, Y.; Wang, B.; Authement, C.; Hernandez, E.; Yang, J.; Xiao, G.; Cha, T-L; Wu, H-C; Wu, D.; Margulis, V.; Lotan, Y.; Brugarolas, J.; He, D.; Hsieh, J-T			Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies	ONCOGENE			English	Article							ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER; BREAST-CANCER; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; RENAL-CARCINOMA; DOWN-REGULATION; ACTIVATION; EXPRESSION	Targeted therapies using small-molecule inhibitors (SMIs) are commonly used in metastatic renal cell cancer (mRCC) patients; patients often develop drug resistance and eventually succumb to disease. Currently, understanding of mechanisms leading to SMIs resistance and any identifiable predictive marker(s) are still lacking. We discovered that DAB2IP, a novel Ras-GTPase-activating protein, was frequently epigenetically silenced in RCC, and DAB2IP loss was correlated with the overall survival of RCC patients. Loss of DAB2IP in RCC cells enhances their sensitivities to growth factor stimulation and resistances to SMI (such as mammalian target of rapamycin (mTOR) inhibitors). Mechanistically, loss of DAB2IP results in the activation of extracellular signal-regulated kinase/RSK1 and phosphoinositide-3 kinase/mTOR pathway, which synergizes the induction of hypoxia-inducible factor (HIF)-2 alpha expression. Consequently, elevated HIF-2 alpha suppresses p21/WAF1 expression that is associated with resistance to mTOR inhibitors. Thus combinatorial targeting both pathways resulted in a synergistic tumor inhibition. DAB2IP appears to be a new prognostic/predictive marker for mRCC patients, and its function provides a new insight into the molecular mechanisms of drug resistance to mTOR inhibitors, which also can be used to develop new strategies to overcome drug-resistant mRCC.	[Zhou, J.; Wu, K.; Du, Y.; Wang, B.; Wu, D.; He, D.] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Urol, 277 Yanta West Rd, Xian 710061, Peoples R China; [Zhou, J.; Yun, E-j; Pong, R-C; Authement, C.; Hernandez, E.; Margulis, V.; Lotan, Y.; Hsieh, J-T] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, J8-134,5323 Harry Hines, Dallas, TX 75390 USA; [Luo, J.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Kapur, P.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Yang, J.; Xiao, G.] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Cha, T-L] Triserv Gen Hosp, Div Urol, Dept Surg, Natl Def Med Ctr, Taipei, Taiwan; [Wu, H-C] China Med Univ Hosp, Dept Urol, Taichung, Taiwan; [Brugarolas, J.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA	Xi'an Jiaotong University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Sun Yat Sen University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Defense Medical Center; Tri-Service General Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Texas System; University of Texas Southwestern Medical Center Dallas	He, D (corresponding author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Urol, 277 Yanta West Rd, Xian 710061, Peoples R China.; Hsieh, JT (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Urol, J8-134,5323 Harry Hines, Dallas, TX 75390 USA.	hedl@mail.xjtu.edu.cn; jt.hsieh@utsouthwestern.edu			National Natural Science Foundation of China [NSFC 81202014]; Fundamental Research Funds for the Central Universities in China; Endowment for Research in Urologic Oncology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities in China; Endowment for Research in Urologic Oncology	We thank John Santoyo for editorial assistance. This work was supported in part by Jean H and John T Walter, Jr, Endowment for Research in Urologic Oncology (to J-TH), the National Natural Science Foundation of China (NSFC 81202014 to KW) and the Fundamental Research Funds for the Central Universities in China (to KW).	Abukhdeir AM, 2008, P NATL ACAD SCI USA, V105, P288, DOI 10.1073/pnas.0710887105; [Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Calvisi DF, 2011, J HEPATOL, V54, P311, DOI 10.1016/j.jhep.2010.06.036; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Das F, 2010, FEBS LETT, V584, P4268, DOI 10.1016/j.febslet.2010.09.010; Di Lorenzo G, 2009, EUR UROL, V56, P959, DOI 10.1016/j.eururo.2009.09.002; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Duggan D, 2007, JNCI-J NATL CANCER I, V99, P1836, DOI 10.1093/jnci/djm250; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; Kroeger N, 2014, EUR UROL, V65, P1086, DOI 10.1016/j.eururo.2013.07.031; Kucejova B, 2011, MOL CANCER RES, V9, P1255, DOI 10.1158/1541-7786.MCR-11-0302; Laptenko O, 2011, P NATL ACAD SCI USA, V108, P10385, DOI 10.1073/pnas.1105680108; Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Omeir RL, 2011, COMPARATIVE MED, V61, P243; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2013, J CLIN INVEST, V123, P2551, DOI 10.1172/JCI66343; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Shinojima T, 2007, CARCINOGENESIS, V28, P529, DOI 10.1093/carcin/bgl143; Smits M, 2012, CLIN CANCER RES, V18, P4048, DOI 10.1158/1078-0432.CCR-12-0399; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wu KJ, 2013, CLIN CANCER RES, V19, P4740, DOI 10.1158/1078-0432.CCR-13-0954; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang XJ, 2012, J GASTROEN HEPATOL, V27, P1117, DOI 10.1111/j.1440-1746.2011.07049.x	50	24	24	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4663	4674		10.1038/onc.2016.4	http://dx.doi.org/10.1038/onc.2016.4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26876207				2022-12-28	WOS:000382336300012
J	Lakshmanan, I; Rachagani, S; Hauke, R; Krishn, SR; Paknikar, S; Seshacharyulu, P; Karmakar, S; Nimmakayala, RK; Kaushik, G; Johansson, SL; Carey, GB; Ponnusamy, MP; Kaur, S; Batra, SK; Ganti, AK				Lakshmanan, I.; Rachagani, S.; Hauke, R.; Krishn, S. R.; Paknikar, S.; Seshacharyulu, P.; Karmakar, S.; Nimmakayala, R. K.; Kaushik, G.; Johansson, S. L.; Carey, G. B.; Ponnusamy, M. P.; Kaur, S.; Batra, S. K.; Ganti, A. K.			MUC5AC interactions with integrin beta 4 enhances the migration of lung cancer cells through FAK signaling	ONCOGENE			English	Article							FOCAL ADHESION KINASE; HUMAN PANCREATIC-CANCER; BREAST-CANCER; GROWTH-FACTOR; EXPRESSION PATTERNS; MUCIN EXPRESSION; REGULATED KINASE; TUMOR-GROWTH; ADENOCARCINOMA; RESISTANCE	MUC5AC is a secretory mucin aberrantly expressed in various cancers. In lung cancer, MUC5AC is overexpressed in both primary and metastatic lesions; however, its functional role is not well understood. The present study was aimed at evaluating mechanistic role of MUC5AC on metastasis of lung cancer cells. Clinically, the overexpression of MUC5AC was observed in lung cancer patient tissues and was associated with poor survival. In addition, the overexpression of Muc5ac was also observed in genetically engineered mouse lung adenocarcinoma tissues (Kras(G12D); Trp53(R172H/+); AdCre) in comparison with normal lung tissues. Our functional studies showed that MUC5AC knockdown resulted in significantly decreased migration in two lung cancer cell lines (A549 and H1437) as compared with scramble cells. Expression of integrins (alpha 5, beta 1, beta 3, beta 4 and beta 5) was decreased in MUC5AC knockdown cells. As both integrins and MUC5AC have a von Willebrand factor domain, we assessed for possible interaction of MUC5AC and integrins in lung cancer cells. MUC5AC strongly interacted only with integrin beta 4. The co-localization of MUC5AC and integrin beta 4 was observed both in A549 lung cancer cells as well as genetically engineered mouse adenocarcinoma tissues. Activated integrins recruit focal adhesion kinase (FAK) that mediates metastatic downstream signaling pathways. Phosphorylation of FAK (Y397) was decreased in MUC5AC knockdown cells. MUC5AC/integrin beta 4/FAK-mediated lung cancer cell migration was confirmed through experiments utilizing a phosphorylation (Y397)specific FAK inhibitor. In conclusion, overexpression of MUC5AC is a poor prognostic marker in lung cancer. MUC5AC interacts with integrin beta 4 that mediates phosphorylation of FAK at Y397 leading to lung cancer cell migration.	[Lakshmanan, I.; Rachagani, S.; Hauke, R.; Krishn, S. R.; Seshacharyulu, P.; Karmakar, S.; Nimmakayala, R. K.; Kaushik, G.; Ponnusamy, M. P.; Kaur, S.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Paknikar, S.; Ganti, A. K.] Univ Nebraska Med Ctr, Dept Internal Med, Div Hematol Oncol, Omaha, NE 68198 USA; [Johansson, S. L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Johansson, S. L.; Ponnusamy, M. P.; Batra, S. K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Carey, G. B.] Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Ganti, A. K.] VA Nebraska Western Iowa Hlth Care Syst, Dept Internal Med, Omaha, NE USA; [Ganti, A. K.] Univ Nebraska Med Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Ganti, AK (corresponding author), Univ Nebraska Med Ctr, Dept Internal Med, Div Hematol Oncol, Omaha, NE 68198 USA.	sbatra@unmc.edu; aganti@unmc.edu	KRISHN, SHIV RAM/K-1949-2019; Ganti, Apar Kishor/D-5498-2015; Kaushik, Garima/AAO-7279-2021; Seshacharyulu, Parthasarathy/AGL-7648-2022; Nimmakayala, Rama Krishna/CAG-5670-2022	KRISHN, SHIV RAM/0000-0002-4770-6671; Ganti, Apar Kishor/0000-0003-3724-2671; Kaushik, Garima/0000-0002-7631-4028; Seshacharyulu, Parthasarathy/0000-0002-2348-3901; Nimmakayala, Rama Krishna/0000-0003-4637-4828; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X; lakshmanan, Imayavaramban/0000-0003-1733-2223	National Institutes of Health [P50 CA127297, U54 CA163120, RO1 CA183459, RO1 CA195586, K22 CA175260, P20 GM103480]; US Department of Veterans' Affairs; UNMC Department of Internal Medicine Summer Undergraduate Research Program and Fred & Pamela Buffett Cancer Center Support Grant [P30CA036727]; NATIONAL CANCER INSTITUTE [R01CA195586, U54CA163120, K22CA175260, P50CA127297, R01CA183459, P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103480] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans' Affairs(US Department of Veterans Affairs); UNMC Department of Internal Medicine Summer Undergraduate Research Program and Fred & Pamela Buffett Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the valuable technical support from Mrs Kavita Mallya and Ms Lynette Smith. We also thank Janice A Tayor and James R Talaska, of the confocal laser scanning microscope core facility at UNMC, for their support. The work is partly supported by grants from the US Department of Veterans' Affairs, UNMC Department of Internal Medicine Summer Undergraduate Research Program and Fred & Pamela Buffett Cancer Center Support Grant (P30CA036727) and National Institutes of Health (P50 CA127297, U54 CA163120, RO1 CA183459, RO1 CA195586, K22 CA175260 and P20 GM103480).	Adsay NV, 2003, AM J SURG PATHOL, V27, P571, DOI 10.1097/00000478-200305000-00002; Andrianifahanana M, 2006, BBA-REV CANCER, V1765, P189, DOI 10.1016/j.bbcan.2006.01.002; Awaya H, 2004, AM J CLIN PATHOL, V121, P644, DOI 10.1039/U4WGE9EBFJN6CM8R; Azim HA, 2006, CANCER TREAT REV, V32, P630, DOI 10.1016/j.ctrv.2006.07.014; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Corfield AP, 2015, BBA-GEN SUBJECTS, V1850, P236, DOI 10.1016/j.bbagen.2014.05.003; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Eberwein P, 2015, BBA-MOL CELL RES, V1853, P2183, DOI 10.1016/j.bbamcr.2015.06.004; Evans CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7281; Evans CM, 2009, CURR OPIN PULM MED, V15, P4, DOI 10.1097/MCP.0b013e32831da8d3; Glavey SV, 2015, BLOOD REV, V29, P269, DOI 10.1016/j.blre.2015.01.003; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Guan JL, 2010, IUBMB LIFE, V62, P268, DOI 10.1002/iub.303; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hata H, 2014, J EUR ACAD DERMATOL, V28, P727, DOI 10.1111/jdv.12156; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jonckheere N, 2014, BBA-REV CANCER, V1846, P142, DOI 10.1016/j.bbcan.2014.04.008; Kang JH, 2015, IMMUNOLOGY, V144, P79, DOI 10.1111/imm.12352; Kharbanda A, 2013, MOL CANCER RES, V11, P714, DOI 10.1158/1541-7786.MCR-12-0668; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lakshmanan I, 2012, ONCOGENE, V31, P805, DOI 10.1038/onc.2011.297; Lakshmanan I, 2015, ONCOTARGET, V6, P21085, DOI 10.18632/oncotarget.3912; Lakshmanan I, 2015, J THORAC ONCOL, V10, P19, DOI 10.1097/JTO.0000000000000404; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; Lopez-Ferrer A, 2001, AM J RESP CELL MOL, V24, P22, DOI 10.1165/ajrcmb.24.1.4294; MacDermed DM, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-16; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; Mariani CR, 1990, CANCER RES, V50, P6107; Mimeault M, 2010, CANCER LETT, V295, P69, DOI 10.1016/j.canlet.2010.02.015; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Nishiumi N, 2003, CLIN CANCER RES, V9, P5616; O'Connor KL, 2012, AM J PHYSIOL-CELL PH, V302, pC605, DOI 10.1152/ajpcell.00095.2011; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Rachagani S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-68; Rossi G, 2012, HISTOPATHOLOGY, V60; Roy MG, 2014, NATURE, V505, P412, DOI 10.1038/nature12807; Roy MG, 2011, AM J RESP CELL MOL, V44, P755, DOI 10.1165/rcmb.2010-0020OC; Sanada Y, 2006, ONCOL REP, V15, P1157; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seshacharyulu P, 2015, ONCOTARGET, V6, P5164, DOI 10.18632/oncotarget.3286; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stewart RL, 2015, LAB INVEST, V95, P976, DOI 10.1038/labinvest.2015.82; Thai P, 2008, ANNU REV PHYSIOL, V70, P405, DOI 10.1146/annurev.physiol.70.113006.100441; Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702; Trehoux S, 2015, BIOCHEM BIOPH RES CO, V456, P757, DOI 10.1016/j.bbrc.2014.12.025; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Yamazoe S, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-53; Yu CJ, 1996, INT J CANCER, V69, P457, DOI 10.1002/(SICI)1097-0215(19961220)69:6<457::AID-IJC7>3.0.CO;2-3; Yu CJ, 2005, LUNG CANCER, V47, P59, DOI 10.1016/j.lungcan.2004.05.018; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	56	53	54	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4112	4121		10.1038/onc.2015.478	http://dx.doi.org/10.1038/onc.2015.478			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26751774	Green Accepted			2022-12-28	WOS:000381020900009
J	Wang, G; Yu, Y; Sun, C; Liu, T; Liang, T; Zhan, L; Lin, X; Feng, XH				Wang, G.; Yu, Y.; Sun, C.; Liu, T.; Liang, T.; Zhan, L.; Lin, X.; Feng, X-H			STAT3 selectively interacts with Smad3 to antagonize TGF-beta signalling	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; CANCER; CELLS; TRANSCRIPTION; ROLES; PHOSPHORYLATION; SUPPRESSION; INHIBITION; EXPRESSION; GENERATION	Smad and STAT proteins are critical signal transducers and transcription factors in controlling cell growth and tumorigenesis. Here we report that the STAT3 signaling pathway attenuates transforming growth factor-beta (TGF-beta)-induced responses through a direct Smad3-STAT3 interplay. Activated STAT3 blunts TGF-beta-mediated signaling. Depletion of STAT3 promotes TGF-beta-mediated transcriptional and physiological responses, including cell cycle arrest, apoptosis and epithelial-to-mesenchymal transition. STAT3 directly interacts with Smad3 in vivo and in vitro, resulting in attenuation of the Smad3-Smad4 complex formation and suppression of DNA-binding ability of Smad3. The N-terminal region of DNA-binding domain of STAT3 is responsible for the STAT3-Smad3 interaction and also indispensable for STAT3-mediated inhibition of TGF-beta signaling. Thus, our finding illustrates a direct crosstalk between the STAT3 and Smad3 signaling pathways that may contribute to tumor development and inflammation.	[Wang, G.; Yu, Y.; Liu, T.; Feng, X-H] Zhejiang Univ, Inst Life Sci, Hangzhou, Zhejiang, Peoples R China; [Wang, G.; Yu, Y.; Liu, T.; Feng, X-H] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou, Zhejiang, Peoples R China; [Wang, G.; Lin, X.; Feng, X-H] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Sun, C.; Feng, X-H] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Liang, T.] Zhejiang Univ, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Liang, T.] Zhejiang Univ, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Zhan, L.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai, Peoples R China; [Feng, X-H] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Sun, C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Zhejiang University; Zhejiang University; Baylor College of Medicine; Baylor College of Medicine; Zhejiang University; Zhejiang University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Feng, XH (corresponding author), Zhejiang Univ, Inst Life Sci, Hangzhou, Zhejiang, Peoples R China.; Feng, XH (corresponding author), Baylor Coll Med, Dept Surg, One Baylor Plaza,Rm R712, Houston, TX 77030 USA.	xhfeng@zju.edu.cn			MOST [2012CB966600]; NSFC [31571447, 31090360]; NIH [R01GM63773, R01 AR053591, R01CA108454, R01DK073932]; Project 985; Fundamental Research Funds for Central Universities; Project 111; NATIONAL CANCER INSTITUTE [R21CA112939, R01CA108454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	MOST; NSFC(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Project 985; Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities); Project 111(Ministry of Education, China - 111 Project); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank David Luskutoff for p800 (PAI-1)-luc, Peter ten Dijke for CAGA-luc, Bert Vogelstein for WWP1 (p21)-luc and SBE-luc and Xiao-Fan Wang for p15-luc. We are grateful to colleagues in our laboratories for helpful discussion and technical assistance. This research was partly supported by grants from MOST (2012CB966600) and NSFC (31571447; 31090360), NIH (R01GM63773, R01 AR053591, R01CA108454 and R01DK073932), Project 111, Project 985 and the Fundamental Research Funds for the Central Universities.	Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Campbell JDM, 2001, J IMMUNOL, V167, P553, DOI 10.4049/jimmunol.167.1.553; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Dai FY, 2009, DEV CELL, V16, P345, DOI 10.1016/j.devcel.2009.01.022; Deheuninck J, 2009, CELL RES, V19, P47, DOI 10.1038/cr.2008.324; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2007, THE TGF BETA FAMILY, P1; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Dunfield LD, 2003, ONCOGENE, V22, P4745, DOI 10.1038/sj.onc.1206617; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Gunaje Jagadambika J., 2000, Molecular Cell Biology Research Communications, V4, P151, DOI 10.1006/mcbr.2001.0272; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirai H, 2001, CANCER CHEMOTH PHARM, V48, pS35, DOI 10.1007/s002800100303; Huang D, 2014, CONNECT TISSUE RES, V55, P391, DOI 10.3109/03008207.2014.959118; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Kim SG, 2005, MOL BIOL CELL, V16, P4672, DOI 10.1091/mbc.E05-01-0054; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Luwor RB, 2013, ONCOGENE, V32, P2433, DOI 10.1038/onc.2012.260; Martinez GJ, 2010, J BIOL CHEM, V285, P29039, DOI 10.1074/jbc.C110.155820; Martinez GJ, 2009, J BIOL CHEM, V284, P35283, DOI 10.1074/jbc.C109.078238; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Okita Keisuke, 2006, Curr Stem Cell Res Ther, V1, P103, DOI 10.2174/157488806775269061; Schmierer B, 2003, J BIOL CHEM, V278, P21197, DOI 10.1074/jbc.M212425200; Ungefroren H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-67; Walia B, 2003, FASEB J, V17, P2130, DOI 10.1096/fj.02-1211fje; Wang DG, 2008, CANCER RES, V68, P783, DOI 10.1158/0008-5472.CAN-07-0008; Wierenga ATJ, 2002, LEUKEMIA, V16, P675, DOI 10.1038/sj.leu.2402425; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zheng R, 2008, CELL BIOCHEM FUNCT, V26, P548, DOI 10.1002/cbf.1464	50	53	55	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4388	4398		10.1038/onc.2015.446	http://dx.doi.org/10.1038/onc.2015.446			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26616859	Green Accepted, Green Submitted			2022-12-28	WOS:000382152100010
J	Du, J; Yang, M; Chen, S; Li, D; Chang, Z; Dong, Z				Du, J.; Yang, M.; Chen, S.; Li, D.; Chang, Z.; Dong, Z.			PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; PHARMACOLOGICAL INHIBITION; SIGNALING PATHWAYS; SUPPRESSOR GENE; PHOSPHORYLATION; IDENTIFICATION; TRANSFORMATION; INACTIVATION; EXPRESSION	Because malignant cells have altered, usually accelerated, energy consumption, targeting metabolic signaling represents a prevailing strategy for tumor therapy. Phosphoinositide-dependent kinase 1 (PDK1) is a proximal signaling molecule of phosphatidylinositol 3-kinase, which is required for metabolic activation. It is still lacking definitive evidence whether inactivation of PDK1 can overwhelm tumorigenesis in vivo. Herein we revealed that mammary-specific ablation of PDK1 could delay tumor initiation, progression and metastasis in a spontaneous mouse tumor model. We also demonstrated that inducible deletion of PDK1 could noticeably shrink the growing breast tumors. However, a small portion of PDK1-deficient tumorigenic cells eventually established tumor lesions, albeit at a relatively later phase, most likely owing to compensatory upregulation of extracellular signalregulated kinase 1/2 (Erk1/2) phosphorylation. Consequently, simultaneous inhibition of PDK1 and Erk1/2 impeded the survival of breast cancer cells. Thus we identify PDK1 as a potential therapeutic target for breast cancer, particularly in combination with an Erk1/2 inhibitor.	[Du, J.; Yang, M.; Chen, S.; Li, D.; Dong, Z.] Tsinghua Univ, Sch Med, Biotech Bldg 4-314,1 Tsinghuayuan, Beijing 100086, Peoples R China; [Chen, S.] Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Beijing 100084, Peoples R China; [Chang, Z.] Tsinghua Univ, Ctr Anim Facil, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University	Dong, Z (corresponding author), Tsinghua Univ, Sch Med, Biotech Bldg 4-314,1 Tsinghuayuan, Beijing 100086, Peoples R China.	dongzj@biomed.tsinghua.edu.cn	Chang, Zhijie/AAH-8109-2019		Natural Science Foundation of China [81322041, 81273198, 81361128016, 81471523]; Beijing Natural Science Foundation [5132018]; Postdoctoral Foundation at Tsinghua-Peking Center for Life Sciences;  [2013CB944901]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Postdoctoral Foundation at Tsinghua-Peking Center for Life Sciences; 	We thank Dr Dario R Alessi (University of Dundee) for sharing the PDK1<SUP>fl/fl</SUP> mice. This work was supported by grants to Dr Zhongjun Dong's laboratory from Natural Science Foundation of China (81322041, 81273198, 81361128016 and 81471523), Minister of Science and Technology of China (2013CB944901) and Beijing Natural Science Foundation (5132018). Juan Du and Meixiang Yang were supported by Postdoctoral Foundation at Tsinghua-Peking Center for Life Sciences.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Cairns P, 1997, CANCER RES, V57, P4997; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cope CL, 2014, J CELL SCI, V127, P788, DOI 10.1242/jcs.137588; Dennis MD, 2013, J BIOL CHEM, V288, P10, DOI 10.1074/jbc.M112.402461; Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Ellwood-Yen K, 2011, CANCER RES, V71, P3052, DOI 10.1158/0008-5472.CAN-10-2282; Emerling BM, 2011, CANCER RES, V71, P7351, DOI 10.1158/0008-5472.CAN-11-1699; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Fyffe Chanse, 2013, Cancer Manag Res, V5, P271, DOI 10.2147/CMAR.S35026; Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Ito K, 2009, P NATL ACAD SCI USA, V106, P8689, DOI 10.1073/pnas.0900064106; Kim MS, 2003, CANCER RES, V63, P5454; Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146; Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862; Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Mikaelian I, 2013, CANCER RES, V73, P6621, DOI 10.1158/0008-5472.CAN-13-0560; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463; O'Neil RG, 2005, MOL IMAGING BIOL, V7, P388, DOI 10.1007/s11307-005-0011-6; Park WS, 2008, MOL CELL, V30, P381, DOI 10.1016/j.molcel.2008.04.008; Pazarentzos E, 2016, ONCOGENE, V35, P1198, DOI 10.1038/onc.2015.173; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242; Raimondi C, 2010, BREAST CANCER RES, V12, pS3, DOI 10.1186/bcr2500; Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Rodriguez-Viciana P, 2006, P NATL ACAD SCI USA, V103, P19290, DOI 10.1073/pnas.0609343103; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xie ZH, 2003, CANCER RES, V63, P5370; Xie ZH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-77; Zeng X, 2002, CANCER RES, V62, P3538; Zhang HY, 2013, ONCOL LETT, V6, P161, DOI 10.3892/ol.2013.1331; Zhang XB, 2013, CURR CANCER DRUG TAR, V13, P175, DOI 10.2174/1568009611313020007	50	41	41	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3314	3323		10.1038/onc.2015.393	http://dx.doi.org/10.1038/onc.2015.393			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26455327				2022-12-28	WOS:000378306400010
J	Flashner-Abramson, E; Klein, S; Mullin, G; Shoshan, E; Song, R; Shir, A; Langut, Y; Bar-Eli, M; Reuveni, H; Levitzki, A				Flashner-Abramson, E.; Klein, S.; Mullin, G.; Shoshan, E.; Song, R.; Shir, A.; Langut, Y.; Bar-Eli, M.; Reuveni, H.; Levitzki, A.			Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling	ONCOGENE			English	Article							MONOCLONAL-ANTIBODIES; OVERCOME RESISTANCE; TUMOR PROGRESSION; CANCER; INHIBITOR; ACTIVATION; THERAPIES	It is well known that specific signal transduction inhibitors rarely suffice as anti-cancer agents. In most cases, tumors possess primary drug resistance due to their inherent heterogeneity, or acquire drug resistance due to genomic instability and acquisition of mutations. Here we expand our previous study of the novel compound, NT157, and show that it acts as a dual-targeting agent that invokes the blockage of two signal transduction pathways that are central to the development and maintenance of multiple human cancers. We show that NT157 targets not only IGF1R-IRS1/2, as previously reported, but also the Stat3 signaling pathway and demonstrates remarkable anti-cancer characteristics in A375 human melanoma cells and in a metastatic melanoma model in mice.	[Flashner-Abramson, E.; Klein, S.; Mullin, G.; Shir, A.; Langut, Y.; Reuveni, H.; Levitzki, A.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel; [Shoshan, E.; Song, R.; Bar-Eli, M.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77030 USA; [Reuveni, H.] NovoTyr Ltd, Tel Hai, Israel	Hebrew University of Jerusalem; University of Texas System; UTMD Anderson Cancer Center	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.; Reuveni, H (corresponding author), TyrNovo Ltd, 8 Abba Eban Ave, IL-4672526 Herzliyya, Israel.	hadas.reuveni@gmail.com; alex.levitzki@mail.huji.ac.il	Mullin, Gerry/H-5294-2019	Mullin, Gerry/0000-0001-5317-6788	ERC Advanced Grant [249898]; NIH Skin Cancer SPORE p50 [CA093459]; Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel; Algen Biopharmaceuticals Ltd; NATIONAL CANCER INSTITUTE [P50CA093459] Funding Source: NIH RePORTER	ERC Advanced Grant; NIH Skin Cancer SPORE p50; Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel; Algen Biopharmaceuticals Ltd; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor Martin Myers (UMMS) for the Jak2 expression plasmids and Professor Scott Weed (WVU) for the GFP-Src expression plasmids. We thank Professor Ruth Halaban (Yale University) and Yale SPORE in Skin Cancer for providing us with the patient-derived melanoma cells (YUMAC and YUSIK), and Dr Michal Lotem (Hadassah Hospital) for providing us the patient-derived melanoma cells (M571 and M2068). We acknowledge Dr Salim Joubran from our laboratory who was instrumental in the chemistry of NT157. This study was supported by an ERC Advanced Grant (No. 249898) to AL by the NIH Skin Cancer SPORE p50 (No. CA093459), by four grants from the Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel to NovoTyr (HR, 2005-2012) and by Algen Biopharmaceuticals Ltd.	Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; DILLMAN RO, 1984, CRC CR REV ONCOL-HEM, V1, P357, DOI 10.1016/S1040-8428(84)80008-6; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Ibuki N, 2014, MOL CANCER THER, V13, P2827, DOI 10.1158/1535-7163.MCT-13-0842; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Levitzki A, 2006, ANNU REV BIOCHEM, V75, P93, DOI 10.1146/annurev.biochem.75.103004.142657; Levitzki A, 2013, ANNU REV PHARMACOL, V53, P161, DOI 10.1146/annurev-pharmtox-011112-140341; Levitzki A, 2010, MOL ASPECTS MED, V31, P287, DOI 10.1016/j.mam.2010.04.001; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Liu F, 2013, J INVEST DERMATOL, V133, P2041, DOI 10.1038/jid.2013.32; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Mano Y, 2013, PATHOBIOLOGY, V80, P146, DOI 10.1159/000346196; OLDHAM RK, 1983, J CLIN ONCOL, V1, P582, DOI 10.1200/JCO.1983.1.9.582; Page BDG, 2011, EXPERT OPIN THER PAT, V21, P65, DOI 10.1517/13543776.2011.539205; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qualls J, 2012, J IMMUNOL, V188, P34; Reuveni H, 2013, CANCER RES, V73, P4383, DOI 10.1158/0008-5472.CAN-12-3385; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Stivarou T, 2015, CANCERS, V7, P238, DOI 10.3390/cancers7010238; WARD HWC, 1973, BMJ-BRIT MED J, V1, P13, DOI 10.1136/bmj.1.5844.13; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	25	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2675	2680		10.1038/onc.2015.229	http://dx.doi.org/10.1038/onc.2015.229			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26119932				2022-12-28	WOS:000376165700014
J	Rampias, T; Favicchio, R; Stebbing, J; Giamas, G				Rampias, T.; Favicchio, R.; Stebbing, J.; Giamas, G.			Targeting tumor-stroma crosstalk: the example of the NT157 inhibitor	ONCOGENE			English	Editorial Material							CANCER; PROGRESSION; INSULIN; STATS; CELLS	Recent clinical research has provided evidence that cancer progression and therapy resistance is driven not only by tumor's genetic profile but also by complex paracrine interactions within the tumor microenvironment (TME). The role of TME in modulating tumor drug sensitivity is increasingly recognized and targeting TME has been the focus of novel therapeutic approaches. Two recent reports show that a new anti-cancer drug, the inhibitor NT157 has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival.	[Rampias, T.; Giamas, G.] Univ Sussex, Dept Biochem & Biomed, Sch Life Sci, Brighton BN1 9QG, E Sussex, England; [Favicchio, R.; Stebbing, J.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus, London, England	University of Sussex; Imperial College London	Rampias, T (corresponding author), Univ Sussex, Dept Biochem & Biomed, Sch Life Sci, Brighton BN1 9QG, E Sussex, England.	rampias@gmail.com	Giamas, Georgios/AAP-3487-2021	Giamas, Georgios/0000-0002-4417-2707; Stebbing, Justin/0000-0002-1117-6947	Department of Health [NIHR-RP-011-053] Funding Source: Medline; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	Department of Health; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))		Castano Z, 2013, CANCER DISCOV, V3, P922, DOI 10.1158/2159-8290.CD-13-0041; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Flashner-Abramson E, 2016, ONCOGENE, V35, P2675, DOI 10.1038/onc.2015.229; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kawada M, 2006, CANCER RES, V66, P4419, DOI 10.1158/0008-5472.CAN-05-4239; Lee C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/502093; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Sanchez-Lopez E, 2016, ONCOGENE, V35, P2634, DOI 10.1038/onc.2015.326; Stebbing J, 2015, MOL CELL PROTEOMICS, V14, P2479, DOI 10.1074/mcp.M115.048090; Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	18	7	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2562	2564		10.1038/onc.2015.392	http://dx.doi.org/10.1038/onc.2015.392			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26477311				2022-12-28	WOS:000376165700002
J	Fan, L; Peng, G; Sahgal, N; Fazli, L; Gleave, M; Zhang, Y; Hussain, A; Qi, J				Fan, L.; Peng, G.; Sahgal, N.; Fazli, L.; Gleave, M.; Zhang, Y.; Hussain, A.; Qi, J.			Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival	ONCOGENE			English	Article							ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; GENE-EXPRESSION; STEM-CELLS; TRANSCRIPTION; PROLIFERATION; JHDM2A; OVEREXPRESSION; PROGRESSION	The histone demethylase JMJD1A, which controls gene expression by epigenetic regulation of H3K9 methylation marks, functions in diverse activities, including spermatogenesis, metabolism and stem cell self-renewal and differentiation. Here, we found that JMJD1A knockdown in prostate cancer cells antagonizes their proliferation and survival. Profiling array analyses revealed that JMJD1A-dependent genes function in cellular growth, proliferation and survival, and implicated that the c-Myc transcriptional network is deregulated following JMJD1A inhibition. Biochemical analyses confirmed that JMJD1A enhances c-Myc transcriptional activity by upregulating c-Myc expression levels. Mechanistically, JMJD1A activity promoted recruitment of androgen receptor (AR) to the c-Myc gene enhancer and induced H3K9 demethylation, increasing AR-dependent transcription of c-Myc mRNA. In parallel, we found that JMJD1A regulated c-Myc stability, likely by inhibiting HUWE1, an E3 ubiquitin ligase known to target degradation of several substrates including c-Myc. JMJD1A (wild type or mutant lacking histone demethylase activity) bound to HUWE1, attenuated HUWE1-dependent ubiquitination and subsequent degradation of c-Myc, increasing c-Myc protein levels. Furthermore, c-Myc knockdown in prostate cancer cells phenocopied effects of JMJD1A knockdown, and c-Myc re-expression in JMJD1A-knockdown cells partially rescued prostate cancer cell growth in vitro and in vivo. c-Myc protein levels were positively correlated with those of JMJD1A in a subset of human prostate cancer specimens. Collectively, our findings identify a critical role for JMJD1A in regulating proliferation and survival of prostate cancer cells by controlling c-Myc expression at transcriptional and post-translational levels.	[Fan, L.; Peng, G.; Zhang, Y.; Hussain, A.; Qi, J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Fan, L.; Peng, G.; Hussain, A.; Qi, J.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Fan, L.; Peng, G.; Hussain, A.; Qi, J.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Sahgal, N.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London, England; [Fazli, L.; Gleave, M.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada; [Zhang, Y.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Hussain, A.] Baltimore VA Med Ctr, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of London; Queen Mary University London; University of British Columbia; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Qi, J (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Marlene & Stewart Greenebaum Canc Ctr, Sch Med, 655W Baltimore St, Baltimore, MD 21201 USA.	jqi@som.umaryland.edu		qi, jianfei/0000-0001-7884-7656; Zhang, Yuji/0000-0002-5429-6762; Gleave, Martin/0000-0003-4235-0167	NCI [CA154888]; Merit Review Award Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R00CA154888, K99CA154888] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Merit Review Award Department of Veterans Affairs; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support by NCI Grant CA154888 (to JQ) and a Merit Review Award Department of Veterans Affairs (to AH) is gratefully acknowledged.	Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen SY, 2006, ONCOGENE, V25, P7212, DOI 10.1038/sj.onc.1209705; Cho HJ, 2014, CANCER DISCOV, V4, P318, DOI 10.1158/2159-8290.CD-13-0346; Civenni G, 2013, CANCER RES, V73, P6816, DOI 10.1158/0008-5472.CAN-13-0615; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Gil J, 2005, CANCER RES, V65, P2179, DOI 10.1158/0008-5472.CAN-03-4030; Goda S, 2013, J BIOL CHEM, V288, P36948, DOI 10.1074/jbc.M113.492595; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hawksworth D, 2010, PROSTATE CANCER P D, V13, P311, DOI 10.1038/pcan.2010.31; Herkert Barbara, 2010, Genes Cancer, V1, P580, DOI 10.1177/1947601910379012; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Kim J, 2012, ONCOGENE, V31, P322, DOI 10.1038/onc.2011.236; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Mimura I, 2012, MOL CELL BIOL, V32, P3018, DOI 10.1128/MCB.06643-11; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Osawa T, 2013, CANCER RES, V73, P3019, DOI 10.1158/0008-5472.CAN-12-3231; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091; Parrish JK, 2015, ONCOGENE, V34, P257, DOI 10.1038/onc.2013.541; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Rye MB, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-50; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sotelo J, 2010, P NATL ACAD SCI USA, V107, P3001, DOI 10.1073/pnas.0906067107; Tao SF, 2014, MOL BIOL REP, V41, P6291, DOI 10.1007/s11033-014-3511-0; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tee AE, 2014, ONCOTARGET, V5, P1793, DOI 10.18632/oncotarget.1785; Vaughan L, 2015, CELL REP, V10, P88, DOI 10.1016/j.celrep.2014.12.012; Wang JQ, 2012, CANCER RES, V72, P4765, DOI 10.1158/0008-5472.CAN-12-0820; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wang XZ, 2014, BIOCHEM BIOPH RES CO, V444, P549, DOI 10.1016/j.bbrc.2014.01.075; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Yu CY, 2011, IN VIVO, V25, P69; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou ZF, 1997, J BIOL CHEM, V272, P8227, DOI 10.1074/jbc.272.13.8227	48	67	69	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2441	2452		10.1038/onc.2015.309	http://dx.doi.org/10.1038/onc.2015.309			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279298	Green Accepted			2022-12-28	WOS:000376165500003
J	Luddecke, S; Ertych, N; Stenzinger, A; Weichert, W; Beissbarth, T; Dyczkowski, J; Gaedcke, J; Valerius, O; Braus, GH; Kschischo, M; Bastians, H				Lueddecke, S.; Ertych, N.; Stenzinger, A.; Weichert, W.; Beissbarth, T.; Dyczkowski, J.; Gaedcke, J.; Valerius, O.; Braus, G. H.; Kschischo, M.; Bastians, H.			The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability	ONCOGENE			English	Article							CENTROSOME AMPLIFICATION; BREAST-CANCER; EXPRESSION; SUSCEPTIBILITY	BRCA1 is a tumor-suppressor gene associated with, but not restricted to, breast and ovarian cancer and implicated in various biological functions. During mitosis, BRCA1 and its positive regulator Chk2 are localized at centrosomes and are required for the regulation of microtubule plus end assembly, thereby ensuring faithful mitosis and numerical chromosome stability. However, the function of BRCA1 during mitosis has not been defined mechanistically. To gain insights into the mitotic role of BRCA1 in regulating microtubule assembly, we systematically identified proteins interacting with BRCA1 during mitosis and found the centrosomal protein Cep72 as a novel BRCA1-interacting protein. CEP72 is frequently upregulated in colorectal cancer tissues and overexpression of CEP72 mirrors the consequences of BRCA1 loss during mitosis. In detail, the overexpression of CEP72 causes an increase in microtubule plus end assembly, abnormal mitotic spindle formation and the induction of chromosomal instability. Moreover, we show that high levels of Cep72 counteract Chk2 as a positive regulator of BRCA1 to ensure proper mitotic microtubule assembly. Thus, CEP72 represents a putative oncogene in colorectal cancer that might negatively regulate the mitotic function of BRCA1 to ensure chromosomal stability.	[Lueddecke, S.; Ertych, N.; Bastians, H.] Univ Gottingen, Sect Cellular Oncol, Gottingen Ctr Mol Biosci GZMB, Grisebachstr 8, D-37073 Gottingen, Germany; [Lueddecke, S.; Ertych, N.; Bastians, H.] Univ Med Ctr Gottingen UMG, Inst Mol Oncol, Grisebachstr 8, D-37073 Gottingen, Germany; [Stenzinger, A.; Weichert, W.] Heidelberg Univ, Inst Pathol, Univ Med Ctr, Neuenheimer Feld 220, Heidelberg, Germany; [Weichert, W.] Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Beissbarth, T.; Dyczkowski, J.] Univ Med Ctr Gottingen UMG, Sect Stat Bioinformat, Inst Med Stat, D-37077 Gottingen, Germany; [Gaedcke, J.] Univ Med Ctr Gottingen UMG, Dept Gen & Visceral Surg, D-37077 Gottingen, Germany; [Valerius, O.; Braus, G. H.] Univ Gottingen, Inst Microbiol & Genet, Dept Mol Microbiol & Genet, D-37073 Gottingen, Germany; [Kschischo, M.] Univ Appl Sci Koblenz, Dept Math & Technol, Remagen, Germany	University of Gottingen; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Gottingen	Bastians, H (corresponding author), Univ Gottingen, Sect Cellular Oncol, Gottingen Ctr Mol Biosci GZMB, Grisebachstr 8, D-37073 Gottingen, Germany.	holger.bastians@uni-goettingen.de	Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626	Deutsche Forschungsgemeinschaft; DFG	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	We thank Linda Wordeman, Sigrid Hoyer-Fender, Bert Vogelstein, Ingrid Hoffmann and Olaf Stemmann for materials and Heike Krebber for microscopy support. We thank Dennis Vollweiter and Eric Schoger for general lab support. We thank the TCGA Research Network (http://cancergenome.nih.gov/) for the open access of gene expression data. This work was supported by the Deutsche Forschungsgemeinschaft (HB and GHB) and by a DFG funded Heisenberg professorship awarded to HB.	Brouhard GJ, 2008, CELL, V132, P79, DOI 10.1016/j.cell.2007.11.043; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Derry WB, 1998, CANCER RES, V58, P1177; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Gregan J, 2011, TRENDS CELL BIOL, V21, P374, DOI 10.1016/j.tcb.2011.01.003; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Kais Z, 2008, CANCER BIOL THER, V7, P1540, DOI 10.4161/cbt.7.10.7053; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Oshimori N, 2006, NAT CELL BIOL, V8, P1095, DOI 10.1038/ncb1474; Oshimori N, 2009, EMBO J, V28, P2066, DOI 10.1038/emboj.2009.161; Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2; Sankaran S, 2007, CANCER RES, V67, P11186, DOI 10.1158/0008-5472.CAN-07-2578; Savage IK, 2014, FEBS J; Silver DP, 2012, CANCER DISCOV, V2, P679, DOI 10.1158/2159-8290.CD-12-0221; Starita LM, 2006, CANCER BIOL THER, V5, P137, DOI 10.4161/cbt.5.2.2479; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Stecklein SR, 2012, P NATL ACAD SCI USA, V109, P13650, DOI 10.1073/pnas.1203326109; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Stowe TR, 2012, MOL BIOL CELL, V23, P3322, DOI 10.1091/mbc.E12-02-0134; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhang PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-14	28	15	16	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2398	2406		10.1038/onc.2015.290	http://dx.doi.org/10.1038/onc.2015.290			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26300001				2022-12-28	WOS:000376165000012
J	Ferrer, I; Verdugo-Sivianes, EM; Castilla, MA; Melendez, R; Marin, JJ; Munoz-Galvan, S; Lopez-Guerra, JL; Vieites, B; Ortiz-Gordillo, MJ; De Leon, JM; Praena-Fernandez, JM; Perez, M; Palacios, J; Carnero, A				Ferrer, I.; Verdugo-Sivianes, E. M.; Castilla, M. A.; Melendez, R.; Marin, J. J.; Munoz-Galvan, S.; Lopez-Guerra, J. L.; Vieites, B.; Ortiz-Gordillo, M. J.; De Leon, J. M.; Praena-Fernandez, J. M.; Perez, M.; Palacios, J.; Carnero, A.			Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors	ONCOGENE			English	Article							GENETIC-LINKAGE ANALYSIS; IN-VITRO PROPAGATION; BINDING-PROTEIN; CHROMOSOME 17Q12-21; DENDRITIC SPINES; FAMILIAL BREAST; POOR-PROGNOSIS; OVARIAN-CANCER; HETEROGENEITY; CARCINOMA	The spinophilin (Spn, PPP1R9B) gene is located at 17q21.33, a region frequently associated with microsatellite instability and loss of heterozygosity, especially in breast tumors. Spn is a regulatory subunit of phosphatase1a (PP1), which targets the catalytic subunit to distinct subcellular locations. Spn downregulation reduces PPP1CA activity against the retinoblastoma protein, pRb, thereby maintaining higher levels of phosphorylated pRb. This effect contributes to an increase in the tumorigenic properties of cells in certain contexts. Here, we explored the mechanism of how Spn downregulation contributes to the malignant phenotype and poor prognosis in breast tumors and found an increase in the stemness phenotype. Analysis of human breast tumors showed that Spn mRNA and protein are reduced or lost in 15% of carcinomas, correlating with a worse prognosis, a more aggressive tumor phenotype and triple-negative tumors, whereas luminal tumors showed high Spn levels. Downregulation of Spn by shRNA increased the stemness properties along with the expression of stem-related genes (Sox2, KLF4, Nanog and OCT4), whereas ectopic overexpression of Spn cDNA reduced these properties. Breast tumor stem cells appeared to have low levels of Spn mRNA, and Spn loss correlated with increased stem-like cell appearance in breast tumors as indicated by an increase in CD44+/CD24- cells. A reduction of the levels of PPP1CA mimicked the cancer stem-like cell phenotype of Spn downregulation, suggesting that the mechanism of Spn involves PP1a. These increased cancer stem cell-like properties with reduced Spn might account for the malignant phenotype observed in Spn-loss tumors and may contribute to a worse patient prognosis.	[Ferrer, I.; Verdugo-Sivianes, E. M.; Castilla, M. A.; Melendez, R.; Marin, J. J.; Munoz-Galvan, S.; Perez, M.; Carnero, A.] Univ Seville, CSIC, HUVR, Inst Biomed Sevilla,IBIS, Campus HUVR,Edificio IBIS,Avda Manuel Siurot S-N, Seville 41013, Spain; [Marin, J. J.] Univ Seville, Dept Prevent Med & Publ Hlth, Seville, Spain; [Lopez-Guerra, J. L.; Ortiz-Gordillo, M. J.] Univ Hosp Virgen Del Rocio, Dept Radiat Oncol, Seville, Spain; [Vieites, B.] Univ Hosp Virgen Del Rocio, Dept Pathol, Seville, Spain; [De Leon, J. M.] Univ Hosp Virgen Del Rocio, Unidad Func Patol Mamaria, Seville, Spain; [Praena-Fernandez, J. M.] Virgen del Rocio Univ Hosp, Methodol Unit, Fdn Publ Andaluza Gest Invest Salud Sevilla, Seville, Spain; [Palacios, J.] Univ Hosp Ramon y Cajal, Dept Pathol, Madrid, Spain; [Carnero, A.] CSIC, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); University of Sevilla; Virgen del Rocio University Hospital; Virgen del Rocio University Hospital; Virgen del Rocio University Hospital; Virgen del Rocio University Hospital; Hospital Universitario Ramon y Cajal; Consejo Superior de Investigaciones Cientificas (CSIC)	Carnero, A (corresponding author), Univ Seville, CSIC, HUVR, Inst Biomed Sevilla,IBIS, Campus HUVR,Edificio IBIS,Avda Manuel Siurot S-N, Seville 41013, Spain.	acarnero-ibis@us.es	IBIS, RADIOBIOLOGIA/H-7452-2016; Muñoz-Galván, Sandra/K-5827-2015; IBIS, CANCER/P-3323-2015; Ferrer, Irene/C-9418-2015; IBIS, BIOMARCADORES/P-3515-2015; PRAENA-FERNANDEZ, J M/GON-7040-2022; Palacios, Jose/AAV-3765-2020; Marin-Lopez, Juan J./G-7123-2012	Ferrer, Irene/0000-0002-2748-2607; PRAENA-FERNANDEZ, J M/0000-0001-5728-1024; Marin-Lopez, Juan J./0000-0001-6072-739X; Carnero, Amancio/0000-0003-4357-3979; VERDUGO SIVIANES, EVA MARIA/0000-0002-0922-0371; Perez, Marco/0000-0001-6997-9593	Spanish Ministry of Economy and Competitivity; Consejeria de Ciencia e Innovacion [CTS-6844, CTS-1848]; Consejeria de Salud of the Junta de Andalucia [PI-0135-2010, PI-0306-2012]; ISCIII [PIE13/0004]; FEDER funds; Sara Borrel Fellowship [CD12/00596]; ISCIII (Fis) - FEDER from Regional Development European Funds (European Union) [PI12/00137, PI15/00045]; ISCIII (RTICC) - FEDER from Regional Development European Funds (European Union) [RD12/0036/0028]	Spanish Ministry of Economy and Competitivity(Spanish Government); Consejeria de Ciencia e Innovacion; Consejeria de Salud of the Junta de Andalucia(Junta de Andalucia); ISCIII(Instituto de Salud Carlos III); FEDER funds(European Commission); Sara Borrel Fellowship; ISCIII (Fis) - FEDER from Regional Development European Funds (European Union); ISCIII (RTICC) - FEDER from Regional Development European Funds (European Union)	AC lab was supported by grants from the Spanish Ministry of Economy and Competitivity, Plan Nacional de I+D+I 2008-2011, Plan Estatal de I+D+I 2013-2016, ISCIII (Fis: PI12/00137, PI15/00045, RTICC: RD12/0036/0028) co-funded by FEDER from Regional Development European Funds (European Union), Consejeria de Ciencia e Innovacion (CTS-6844 and CTS-1848) and Consejeria de Salud of the Junta de Andalucia (PI-0135-2010 and PI-0306-2012). This work has been also possible with the help of the Plan Estatal de I+D+i 2013-2016, Grant PIE13/0004 co-funded by the ISCIII and FEDER funds. We thank the donors and the CNIO tumor bank and HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT13/0010/0056) for the human specimens used in this study. IF was funded by a Sara Borrel Fellowship (CD12/00596).	Abujiang P, 1998, ONCOGENE, V17, P3029, DOI 10.1038/sj.onc.1202230; Aigelsreiter A, 2013, BRIT J CANCER, V108, P1830, DOI 10.1038/bjc.2013.165; Aigelsreiter MM, 2014, HUM PATHOL, V45, P683, DOI 10.1016/j.humpath.2013.11.014; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Allen PB, 2006, NEUROSCIENCE, V140, P897, DOI 10.1016/j.neuroscience.2006.02.067; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Berndt Norbert, 1999, Frontiers in Bioscience, V4, pD22, DOI 10.2741/Berndt; Bielas SL, 2007, CELL, V129, P579, DOI 10.1016/j.cell.2007.03.023; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; Carnero A, 2012, CURR MOL MED, V12, P528, DOI 10.2174/156652412800619987; Castro ME, 2008, CARCINOGENESIS, V29, P491, DOI 10.1093/carcin/bgm246; Chang CC, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1385; COHEN BB, 1993, AM J HUM GENET, V52, P723; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; EASTON DF, 1993, AM J HUM GENET, V52, P678; Estevez-Garcia P, 2013, CLIN CANCER RES, V19, P3925, DOI 10.1158/1078-0432.CCR-13-0057; Ferrer I, 2011, CELL CYCLE, V10, P2751, DOI 10.4161/cc.10.16.16422; Ferrer I, 2011, CELL CYCLE, V10, P1948, DOI 10.4161/cc.10.12.15798; Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736; Ghebeh H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-289; Guijarro MV, 2007, CARCINOGENESIS, V28, P1646, DOI 10.1093/carcin/bgm083; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Kuntziger T, 2011, CELL CYCLE, V10, P1356, DOI 10.4161/cc.10.9.15442; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; Mannello F, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-169; Mannello F, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-344; Molina-Pinelo S, 2011, J PATHOL, V225, P73, DOI 10.1002/path.2905; Ouimet CC, 2004, J COMP NEUROL, V479, P374, DOI 10.1002/cne.20313; Pinto CA, 2013, CANCER LETT, V341, P56, DOI 10.1016/j.canlet.2013.06.003; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; PORTER DE, 1993, BRIT J SURG, V80, P1381, DOI 10.1002/bjs.1800801108; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Querzoli P, 2001, BREAST CANCER RES TR, V66, P135, DOI 10.1023/A:1010643515095; RESNICOFF M, 1987, P NATL ACAD SCI USA, V84, P7295, DOI 10.1073/pnas.84.20.7295; Ress AL, 2014, ONCOTARGET, V5, P8492; Santamaria D, 2011, CELL CYCLE, V10, P2831, DOI 10.4161/cc.10.17.16528; Santra M, 2006, CANCER RES, V66, P11726, DOI 10.1158/0008-5472.CAN-06-1978; Santra M, 2011, CANCER SCI, V102, P1350, DOI 10.1111/j.1349-7006.2011.01952.x; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Setoguchi T, 2004, CELL CYCLE, V3, P414; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; SMITH SA, 1993, AM J HUM GENET, V52, P767; Tseng SL, 1997, GENE CHROMOSOME CANC, V20, P377; Tsukada M, 2003, MECH DEVELOP, V120, P1033, DOI 10.1016/S0925-4773(03)00177-1; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274	52	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2777	2788		10.1038/onc.2015.341	http://dx.doi.org/10.1038/onc.2015.341			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26387546				2022-12-28	WOS:000377472700011
J	Liu, Y; Wang, G; Yang, Y; Mei, Z; Liang, Z; Cui, A; Wu, T; Liu, CY; Cui, L				Liu, Y.; Wang, G.; Yang, Y.; Mei, Z.; Liang, Z.; Cui, A.; Wu, T.; Liu, C-Y; Cui, L.			Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; GASTRIC-CANCER; HIPPO PATHWAY; BETA-CATENIN; E-CADHERIN; ENHANCER; GROWTH; DISRUPTION; COMPLEX; LINEAGE	Dysregulation of the Hippo pathway occurs in a variety of cancers and often correlates with a poor prognosis. To further explore the potential role of Hippo pathway dysregulation in tumor development and progression, we investigated its downstream transcription factor TEAD4 in colorectal cancer (CRC). Increased expression and nuclear localization of TEAD4 were found in a significant portion of CRC tissues, in association with metastasis and a poor prognosis. In CRC cells, TEAD4 knockdown induced the mesenchymal-epithelial transition and decreased cell mobility in vitro and metastasis in vivo. Microarray analysis revealed that TEAD4 promoted cell adhesion and upregulated the epithelial-mesenchymal transition-related transcriptome in CRC cells. Vimentin was identified as a new direct target gene mediating TEAD4 function in CRC cells, whereby forced vimentin expression markedly reversed TEAD4-knockdown-induced cell morphological changes and decreased mobility. Interestingly, rescued expression of both WT TEAD4 and a Y429H mutant can reverse the mesenchymal-epithelial transition and increase vimentin expression, cell mobility and metastatic potential in TEAD4-knockdown CRC cells. The discrepant expression of YAP and TEAD4 in CRC tissues, the rescue ability of TEAD4 mutant defect in YAP binding and no effect on vimentin expression by YAP knockdown in CRC cells, all implicated a YAP-independent manner of TEAD4 function in CRC. Furthermore, vimentin positively correlated and CDH1 reversely correlated with the level of TEAD4 in CRC tissues and xenograft tumors. Our results suggest that TEAD4 nuclear expression can serve as a biomarker for CRC progression and poor prognosis. The transcription factor TEAD4 regulates a pro-metastasis transcription program in a YAP-independent manner in CRC, thus providing a novel mechanism of TEAD4 transcriptional regulation and its oncogenic role in CRC, independently of the Hippo pathway.	[Liu, Y.; Wang, G.; Yang, Y.; Mei, Z.; Liang, Z.; Cui, A.; Wu, T.; Liu, C-Y; Cui, L.] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Colorectal & Anal Surg, Kongjiang Rd 1665, Shanghai 200092, Peoples R China; [Liu, Y.; Wang, G.; Yang, Y.; Mei, Z.; Liang, Z.; Cui, A.; Wu, T.; Liu, C-Y; Cui, L.] Shanghai Colorectal Canc Res Ctr, Shanghai, Peoples R China; [Yang, Y.] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Ctr Med Res, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Liu, CY; Cui, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Colorectal & Anal Surg, Kongjiang Rd 1665, Shanghai 200092, Peoples R China.	cyliu_eric@126.com; longcuidr@126.com	Mei, Zubing/H-7879-2019	cui, long/0000-0003-1838-4471; Liu, Chen-Ying/0000-0002-8930-6182	National Natural Science Foundation of China [81372636, 81302089]; National High Technology Research and Development Program of China (863 Program) [SQ2014SFOZD00314]; Shanghai Excellent Young Teachers Program [ZZjdyx13074]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); Shanghai Excellent Young Teachers Program	This work was supported by National Natural Science Foundation of China (grant no. 81372636 and No. 81302089), the National High Technology Research and Development Program of China (863 Program) (grant no. SQ2014SFOZD00314), the Shanghai Excellent Young Teachers Program (grant no. ZZjdyx13074).	Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Gilles C, 2003, CANCER RES, V63, P2658; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hirate Y, 2012, P NATL ACAD SCI USA, V109, pE3389, DOI 10.1073/pnas.1211810109; Home P, 2012, P NATL ACAD SCI USA, V109, P7362, DOI 10.1073/pnas.1201595109; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hucl T, 2007, CANCER RES, V67, P9055, DOI 10.1158/0008-5472.CAN-07-0474; Jackstadt R, 2013, J EXP MED, V210, P1331, DOI 10.1084/jem.20120812; Kahlert C, 2011, CLIN CANCER RES, V17, P7654, DOI 10.1158/1078-0432.CCR-10-2816; Kaneko KJ, 2007, GENESIS, V45, P577, DOI 10.1002/dvg.20330; Kaneko KJ, 2013, DEVELOPMENT, V140, P3680, DOI 10.1242/dev.093799; Kobayashi H, 2004, CLIN CANCER RES, V10, P572, DOI 10.1158/1078-0432.CCR-1323-03; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; Leung WKC, 2011, ONCOGENE, V30, P4464, DOI 10.1038/onc.2011.161; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Pobbati AV, 2012, STRUCTURE, V20, P1135, DOI 10.1016/j.str.2012.04.004; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang W, 2014, BRIT J CANCER, V110, P450, DOI 10.1038/bjc.2013.724; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yagi R, 2007, DEVELOPMENT, V134, P3827, DOI 10.1242/dev.010223; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhong XY, 2008, HISTOPATHOLOGY, V52, P560, DOI 10.1111/j.1365-2559.2008.02971.x	36	93	95	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2789	2800		10.1038/onc.2015.342	http://dx.doi.org/10.1038/onc.2015.342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26387538				2022-12-28	WOS:000377472700012
J	Latina, A; Viticchie, G; Lena, AM; Piro, MC; Annicchiarico-Petruzzelli, M; Melino, G; Candi, E				Latina, A.; Viticchie, G.; Lena, A. M.; Piro, M. C.; Annicchiarico-Petruzzelli, M.; Melino, G.; Candi, E.			Delta Np63 targets cytoglobin to inhibit oxidative stress-induced apoptosis in keratinocytes and lung cancer	ONCOGENE			English	Article							DOWN-REGULATION; TUMOR-SUPPRESSOR; CELL-SURVIVAL; P53 HOMOLOG; P63; GENE; PROTEIN; EXPRESSION; OVEREXPRESSION; PROLIFERATION	During physiological aerobic metabolism, the epidermis undergoes significant oxidative stress as a result of the production of reactive oxygen species (ROS). To maintain a balanced oxidative state, cells have developed protective antioxidant systems, and preliminary studies suggest that the transcriptional factor p63 is involved in cellular oxidative defence. Supporting this hypothesis, the Delta Np63a isoform of p63 is expressed at high levels in the proliferative basal layer of the epidermis. Here we identify the CYGB gene as a novel transcriptional target of Delta Np63 that is involved in maintaining epidermal oxidative defence. The CYGB gene encodes cytoglobin, a member of the globin protein family, which facilitates the diffusion of oxygen through tissues and acts as a scavenger for nitric oxide or other ROS. By performing promoter activity assays and chromatin immunoprecipitation, reverse transcriptase quantitative PCR and western blotting analyses, we confirm the direct regulation of CYGB by Delta Np63a. We also demonstrate that CYGB has a protective role in proliferating keratinocytes grown under normal conditions, as well as in cells treated with exogenous hydrogen peroxide. These results indicate that Delta Np63, through its target CYGB has an important role in the cellular antioxidant system and protects keratinocytes from oxidative stress-induced apoptosis. The Delta Np63-CYGB axis is also present in lung and breast cancer cell lines, indicating that CYGB-mediated ROS-scavenging activity may also have a role in epithelial tumours. In human lung cancer data sets, the p63-CYGB interaction significantly predicts reduction of patient survival.	[Latina, A.; Viticchie, G.; Lena, A. M.; Piro, M. C.; Melino, G.; Candi, E.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Annicchiarico-Petruzzelli, M.; Candi, E.] IDI IRCCS, Biochem Lab, Rome, Italy; [Melino, G.] Med Res Council Toxicol Unit, Leicester, Leics, England	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Melino, G; Candi, E (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it; candi@uniroma2.it	Annicchiarico-Petruzzelli, Margherita/AAG-7746-2020; Lena, Anna Maria/AAI-5042-2020; PIRO, MARIA CRISTINA/GVT-4380-2022	Annicchiarico-Petruzzelli, Margherita/0000-0002-4717-4740; PIRO, MARIA CRISTINA/0000-0003-3004-367X	AIRC grant [IG13387]; Min. Salute (Ric oncol) [26/07]; IDI-IRCCS [RF08 c.15, RF07 c.57]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC grant(Fondazione AIRC per la ricerca sul cancro); Min. Salute (Ric oncol); IDI-IRCCS; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was mainly supported by the AIRC grant (IG13387) to EC and Min. Salute (Ric oncol 26/07) and IDI-IRCCS (RF08 c.15, RF07 c.57) to GM.	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Agrelo R, 2013, ONCOGENE, V32, P5492, DOI 10.1038/onc.2013.158; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Amelio I, 2014, ONCOGENE, V33, P5039, DOI 10.1038/onc.2013.456; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bause AS, 2013, J BIOL CHEM, V288, P36484, DOI 10.1074/jbc.M113.472324; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Borrelli S, 2010, CELL DEATH DIFFER, V17, P1896, DOI 10.1038/cdd.2010.59; Browne G, 2011, J CELL SCI, V124, P2200, DOI 10.1242/jcs.079327; Budanov AV, 2011, ANTIOXID REDOX SIGN, V15, P1679, DOI 10.1089/ars.2010.3530; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burnley P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.460; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Candi E, 2007, P NATL ACAD SCI USA, V104, P11999, DOI 10.1073/pnas.0703458104; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celardo I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.175; Cervo PRD, 2012, P NATL ACAD SCI USA, V109, P1133, DOI 10.1073/pnas.1112257109; Crum CP, 2010, ANNU REV PATHOL-MECH, V5, P349, DOI 10.1146/annurev-pathol-121808-102117; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dhar SK, 2006, J BIOL CHEM, V281, P21698, DOI 10.1074/jbc.M601083200; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Emara M, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-33; Fordel E, 2004, BIOCHEM BIOPH RES CO, V319, P342, DOI 10.1016/j.bbrc.2004.05.010; Fordel E, 2006, NEUROSCI LETT, V410, P146, DOI 10.1016/j.neulet.2006.09.027; Gao B, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.298; Genin O, 2008, NEOPLASIA, V10, P940, DOI 10.1593/neo.08456; Gorr TA, 2011, ACTA PHYSIOL, V202, P563, DOI 10.1111/j.1748-1716.2010.02205.x; Guo XM, 2006, BBA-GENE STRUCT EXPR, V1759, P208, DOI 10.1016/j.bbaexp.2006.04.002; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Italiano D, 2012, CELL CYCLE, V11, P4589, DOI 10.4161/cc.22853; John R, 2014, DNA REPAIR, V24, P107, DOI 10.1016/j.dnarep.2014.09.003; Katsuyama M, 2012, J CLIN BIOCHEM NUTR, V50, P9, DOI 10.3164/jcbn.11-06SR; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kouwenhoven EN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001065; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Leikam C, 2014, ONCOGENE, V33, P771, DOI 10.1038/onc.2012.641; Lena AM, 2010, BIOCHEM BIOPH RES CO, V401, P568, DOI 10.1016/j.bbrc.2010.09.102; Li C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.468; Liefer KM, 2000, CANCER RES, V60, P4016; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Massion PP, 2003, CANCER RES, V63, P7113; McRonald FE, 2006, HUM MOL GENET, V15, P1271, DOI 10.1093/hmg/ddl042; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakanome A, 2013, ONCOGENE, V32, P3231, DOI 10.1038/onc.2012.336; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Ogawa E, 2008, ONCOGENE, V27, P848, DOI 10.1038/sj.onc.1210682; Oleksiewicz U, 2013, HUM MOL GENET, V22, P3207, DOI 10.1093/hmg/ddt174; Paris M, 2012, CELL DEATH DIFFER, V19, P186, DOI 10.1038/cdd.2011.181; Park Eun-sung, 2003, J Vet Sci, V4, P129; Patel A, 2015, ONCOGENE, V34, P2586, DOI 10.1038/onc.2014.195; Pinton P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Presneau N, 2005, MOL CARCINOGEN, V43, P141, DOI 10.1002/mc.20096; Ramsey MR, 2013, J CLIN INVEST, V123, P3525, DOI 10.1172/JCI68899; Ramsey MR, 2011, CANCER RES, V71, P4373, DOI 10.1158/0008-5472.CAN-11-0046; Rinne T, 2008, HUM MOL GENET, V17, P1968, DOI 10.1093/hmg/ddn094; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Rufini A, 2006, BIOCHEM BIOPH RES CO, V340, P737, DOI 10.1016/j.bbrc.2005.12.065; Rufini A, 2012, GENE DEV, V26, P2009, DOI 10.1101/gad.197640.112; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Schmidt M, 2004, J BIOL CHEM, V279, P8063, DOI 10.1074/jbc.M310540200; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Shalom-Feuerstein R, 2011, CELL DEATH DIFFER, V18, P887, DOI 10.1038/cdd.2010.159; Shaw RJ, 2009, BRIT J CANCER, V101, P139, DOI 10.1038/sj.bjc.6605121; Sommer M, 2006, CELL CYCLE, V5, P2005, DOI 10.4161/cc.5.17.3194; Stagner JI, 2005, TRANSPL P, V37, P3452, DOI 10.1016/j.transproceed.2005.10.001; Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Vanbokhoven H, 2011, J INVEST DERMATOL, V131, P1196, DOI 10.1038/jid.2011.84; Wajcman H, 2009, CR BIOL, V332, P273, DOI 10.1016/j.crvi.2008.07.026; Wansleben S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.365; Wiel C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.382; Wolyniec K, 2013, ONCOGENE, V32, P3510, DOI 10.1038/onc.2012.365; Xinarianos G, 2006, HUM MOL GENET, V15, P2038, DOI 10.1093/hmg/ddl128; Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu XL, 2013, NEURAL REGEN RES, V8, P2198, DOI 10.3969/j.issn.1673-5374.2013.23.010	88	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1493	1503		10.1038/onc.2015.222	http://dx.doi.org/10.1038/onc.2015.222			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26096935				2022-12-28	WOS:000373063600003
J	Dickreuter, E; Eke, I; Krause, M; Borgmann, K; van Vugt, MA; Cordes, N				Dickreuter, E.; Eke, I.; Krause, M.; Borgmann, K.; van Vugt, M. A.; Cordes, N.			Targeting of beta 1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; CONTEXTUAL SYNTHETIC LETHALITY; FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; INHIBITION; INTEGRINS; PATHWAY; KU; PROLIFERATION; FIBRONECTIN	beta 1 Integrin-mediated cell-extracellular matrix interactions allow cancer cell survival and confer therapy resistance. It was shown that inhibition of beta 1 integrins sensitizes cells to radiotherapy. Here, we examined the impact of beta 1 integrin targeting on the repair of radiation-induced DNA double-strand breaks (DSBs). beta 1 Integrin inhibition was accomplished using the monoclonal antibody AIIB2 and experiments were performed in three-dimensional cell cultures and tumor xenografts of human head and neck squamous cell carcinoma (HNSCC) cell lines. AIIB2, X-ray irradiation, small interfering RNA-mediated knockdown and Olaparib treatment were performed and residual DSB number, protein and gene expression, non-homologous end joining (NHEJ) activity as well as clonogenic survival were determined. beta 1 Integrin targeting impaired repair of radiogenic DSB (gamma H2AX/53BP1, pDNA-PKcs T2609 foci) in vitro and in vivo and reduced the protein expression of Ku70, Rad50 and Nbs1. Further, we identified Ku70, Ku80 and DNA-PKcs but not poly(ADP-ribose) polymerase (PARP)-1 to reside in the beta 1 integrin pathway. Intriguingly, combined inhibition of beta 1 integrin and PARP using Olaparib was significantly more effective than either treatment alone in non-irradiated and irradiated HNSCC cells. Here, we support beta 1 integrins as potential cancer targets and highlight a regulatory role for beta 1 integrins in the repair of radiogenic DNA damage via classical NHEJ. Further, the data suggest combined targeting of beta 1 integrin and PARP as promising approach for radiosensitization of HNSCC.	[Dickreuter, E.; Eke, I.; Krause, M.; Cordes, N.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, D-01062 Dresden, Germany; [Dickreuter, E.; Eke, I.; Krause, M.; Cordes, N.] Helmholtz Zentrum Dresden Rossendorf, D-01314 Dresden, Germany; [Eke, I.; Krause, M.; Cordes, N.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Radiat Oncol, D-01062 Dresden, Germany; [Krause, M.; Cordes, N.] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol, D-01314 Dresden, Germany; [Krause, M.; Cordes, N.] German Canc Consortium DKTK, D-01307 Dresden, Germany; [Krause, M.; Cordes, N.] German Canc Res Ctr, Heidelberg, Germany; [Borgmann, K.] Univ Med Ctr Hamburg Eppendorf, Clin Radiotherapy & Radiooncol, Lab Radiobiol & Expt Radiooncol, Hamburg, Germany; [van Vugt, M. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Groningen	Cordes, N (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Fetscherstr 74-PF 41, D-01307 Dresden, Germany.	Nils.Cordes@OncoRay.de	; Eke, Iris/B-9251-2016	Krause, Mechthild/0000-0003-1776-9556; Eke, Iris/0000-0002-3591-019X; Cordes, Nils/0000-0001-5684-629X	Deutsche Krebshilfe e.V. [108976]; EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen [100066308]	Deutsche Krebshilfe e.V.(Deutsche Krebshilfe); EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen	The research and authors were funded in part by the Deutsche Krebshilfe e.V. (108976 to N.C.) and the EFRE Europaische Fonds fur regionale Entwicklung, Europa fordert Sachsen (100066308). We are grateful to R Grenman for providing HNSCC cell lines, DD Schlaepfer for providing mouse FAK cDNA and J Stark for providing NHEJ reporter plasmids. We further thank I Lange for performing real-time PCR experiments, L Stolz-Kieslich and A Zielinski for technical assistance and I Kurth for help with FACS analysis. We appreciate critical reading of the manuscript by E Hammond and A Vehlow.	Albert M, 2012, RADIOTHER ONCOL, V104, P230, DOI 10.1016/j.radonc.2012.06.010; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Borgmann K, 2004, INT J RADIAT ONCOL, V58, P445, DOI 10.1016/j.ijrobp.2003.09.036; Chan N, 2010, CANCER RES, V70, P8045, DOI 10.1158/0008-5472.CAN-10-2352; Chan N, 2010, CLIN CANCER RES, V16, P4553, DOI 10.1158/1078-0432.CCR-10-0527; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Cheng Q, 2011, NUCLEIC ACIDS RES, V39, P9605, DOI 10.1093/nar/gkr656; Couto CAM, 2011, J CELL BIOL, V194, P367, DOI 10.1083/jcb.201012132; Eke I, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju419; Eke I, 2015, SEMIN CANCER BIOL, V31, P65, DOI 10.1016/j.semcancer.2014.07.009; Eke I, 2013, CANCER RES, V73, P5869, DOI 10.1158/0008-5472.CAN-13-0344; Eke I, 2013, CANCER RES, V73, P297, DOI 10.1158/0008-5472.CAN-12-2021; Eke I, 2012, INT J RADIAT ONCOL, V84, pE515, DOI 10.1016/j.ijrobp.2012.06.012; Eke I, 2012, J CLIN INVEST, V122, P1529, DOI 10.1172/JCI61350; Estrugo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000269; Hammel M, 2010, J BIOL CHEM, V285, P1414, DOI 10.1074/jbc.M109.065615; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Hehlgans S, 2012, INT J RADIAT ONCOL, V83, pE669, DOI 10.1016/j.ijrobp.2012.01.065; Hehlgans S, 2009, RADIOTHER ONCOL, V92, P371, DOI 10.1016/j.radonc.2009.08.001; Helleday T, 2005, CELL CYCLE, V4, P1176, DOI 10.4161/cc.4.9.2031; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jean C, 2011, ONCOGENE, V30, P2697, DOI 10.1038/onc.2011.27; Jean C, 2014, J CELL BIOL, V204, P247, DOI 10.1083/jcb.201307067; Jones CB, 2001, MOL PHARMACOL, V59, P69, DOI 10.1124/mol.59.1.69; Klein TJ, 2010, SEMIN RADIAT ONCOL, V20, P282, DOI 10.1016/j.semradonc.2010.05.006; Kotter A, 2014, MOL ONCOL, V8, P1616, DOI 10.1016/j.molonc.2014.06.008; Krajewska M, 2013, ONCOGENE, V32, P3001, DOI 10.1038/onc.2012.296; Krause M, 2007, RADIOTHER ONCOL, V83, P316, DOI 10.1016/j.radonc.2007.04.014; Kumareswaran R, 2012, J CELL SCI, V125, P189, DOI 10.1242/jcs.092262; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Mansour WY, 2013, DNA REPAIR, V12, P1134, DOI 10.1016/j.dnarep.2013.10.005; Mansour WY, 2010, NUCLEIC ACIDS RES, V38, P6065, DOI 10.1093/nar/gkq387; Mladenov E, 2011, MUTAT RES-FUND MOL M, V711, P61, DOI 10.1016/j.mrfmmm.2011.02.005; Park CC, 2008, CANCER RES, V68, P4398, DOI 10.1158/0008-5472.CAN-07-6390; Peng YL, 2002, CANCER RES, V62, P6400; Rose JL, 2007, J PHARMACOL EXP THER, V321, P318, DOI 10.1124/jpet.106.113498; Serrels A, 2012, INT J CANCER, V131, P287, DOI 10.1002/ijc.26351; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013; Storch K, 2010, CANCER RES, V70, P3925, DOI 10.1158/0008-5472.CAN-09-3848; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012; Vandersickel V, 2010, J RADIAT RES, V51, P633, DOI 10.1269/jrr.10033; Williams GJ, 2010, DNA REPAIR, V9, P1299, DOI 10.1016/j.dnarep.2010.10.001; Yan H, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-50	50	48	48	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1353	1362		10.1038/onc.2015.212	http://dx.doi.org/10.1038/onc.2015.212			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26073085				2022-12-28	WOS:000372196400002
J	Tatsumi, N; Hojo, N; Yamada, O; Ogawa, M; Katsura, Y; Kawata, S; Morii, E; Sakamoto, H; Inaba, R; Tsuda, A; Fukuda, I; Moriguchi, N; Hasuwa, H; Okabe, M; Fujiki, F; Nishida, S; Nakajima, H; Tsuboi, A; Oka, Y; Hosen, N; Sugiyama, H; Oji, Y				Tatsumi, N.; Hojo, N.; Yamada, O.; Ogawa, M.; Katsura, Y.; Kawata, S.; Morii, E.; Sakamoto, H.; Inaba, R.; Tsuda, A.; Fukuda, I.; Moriguchi, N.; Hasuwa, H.; Okabe, M.; Fujiki, F.; Nishida, S.; Nakajima, H.; Tsuboi, A.; Oka, Y.; Hosen, N.; Sugiyama, H.; Oji, Y.			Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities	ONCOGENE			English	Article							WILMS-TUMOR GENE; SUPPRESSOR GENE; LEUKEMIC-CELLS; TRANSCRIPTION FACTOR; PROGENITOR CELLS; BINDING-SITES; SOLID TUMORS; WT1 PROTEIN; EXPRESSION; OVEREXPRESSION	The Wilms' tumor gene WT1 is overexpressed in leukemia and solid tumors and has an oncogenic role in leukemogenesis and tumorigenesis. However, precise regulatory mechanisms of WT1 overexpression remain undetermined. In the present study, microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR. MiR-125a knockout mice overexpressed WT1, developed myeloproliferative disorder (MPD) characterized by expansion of myeloid cells in bone marrow (BM), spleen and peripheral blood, and displayed urogenital abnormalities. Silencing of WT1 expression in hematopoietic stem/progenitor cells of miR-125a knockout MPD mice by short-hairpin RNA inhibited myeloid colony formation in vitro. Furthermore, the incidence and severity of MPD were lower in miR-125a (-/-) mice than in miR-125a (+/-) mice, indicating the operation of compensatory mechanisms for the complete loss of miR-125a. To elucidate the compensatory mechanisms, miRNA array was performed. MiR-486 was occasionally induced in compete loss of miR-125a and inhibited WT1 expression instead of miR-125a, resulting in the cancellation of MPD occurrence. These results showed for the first time the post-transcriptional regulatory mechanisms of WT1 by both miR-125a and miR-486 and should contribute to the elucidation of mechanisms of normal hematopoiesis and kidney development.	[Tatsumi, N.; Hojo, N.; Yamada, O.; Ogawa, M.; Katsura, Y.; Kawata, S.; Sakamoto, H.; Inaba, R.; Tsuda, A.; Fukuda, I.; Moriguchi, N.; Sugiyama, H.] Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Yamada Oka 1-7, Suita, Osaka 5650871, Japan; [Morii, E.] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; [Hasuwa, H.; Okabe, M.] Osaka Univ, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; [Fujiki, F.; Nakajima, H.; Oka, Y.] Osaka Univ, Grad Sch Med, Dept Canc Immunol, Suita, Osaka 5650871, Japan; [Nishida, S.] Osaka Univ, Grad Sch Med, Dept Resp Med Immunol & Allergy, Suita, Osaka 5650871, Japan; [Tsuboi, A.] Osaka Univ, Grad Sch Med, Dept Canc Immunotherapy, Suita, Osaka 5650871, Japan; [Hosen, N.; Oji, Y.] Osaka Univ, Grad Sch Med, Dept Canc Stem Cell Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Osaka University	Tatsumi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Yamada Oka 1-7, Suita, Osaka 5650871, Japan.	tatsumi@cit.med.osaka-u.ac.jp			Ministry of Education, Science, Sports, Culture and Technology, Japan; Ministry of Health, Labour, and Welfare, Japan	Ministry of Education, Science, Sports, Culture and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour, and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science, Sports, Culture and Technology, Japan, and the Ministry of Health, Labour, and Welfare, Japan. We thank Yoko Esaki and Saki Nishioka of NPO Biotechnology Research and Development for technical assistance.	Alberta JA, 2003, BLOOD, V101, P2570, DOI 10.1182/blood-2002-06-1656; Alemdehy MF, 2012, CELL CYCLE, V11, P2799, DOI 10.4161/cc.21077; Algar EM, 1996, ONCOGENE, V12, P1005; Bao JQ, 2012, J BIOL CHEM, V287, P21686, DOI 10.1074/jbc.M111.328054; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Chau YY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002404; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; Dehbi M, 1996, ONCOGENE, V13, P447; Dehbi M, 1996, EMBO J, V15, P4297, DOI 10.1002/j.1460-2075.1996.tb00804.x; Discenza MT, 2004, FEBS LETT, V560, P183, DOI 10.1016/S0014-5793(04)00104-8; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Downing JR, 2003, CURR OPIN GENET DEV, V13, P48, DOI 10.1016/S0959-437X(02)00018-7; Funakoshi-Tago M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052844; Gao F, 2006, P NATL ACAD SCI USA, V103, P11987, DOI 10.1073/pnas.0600994103; Gao SM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-110; Gebeshuber CA, 2013, NAT MED, V19, P481, DOI 10.1038/nm.3142; Guo SQ, 2010, P NATL ACAD SCI USA, V107, P14229, DOI 10.1073/pnas.0913574107; Han YQ, 2004, ONCOGENE, V23, P6933, DOI 10.1038/sj.onc.1207609; Harada Y, 1999, MOL UROL, V3, P357; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hosen N, 2002, BRIT J HAEMATOL, V116, P409, DOI 10.1046/j.1365-2141.2002.03261.x; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; Ito K, 2006, ONCOGENE, V25, P4217, DOI 10.1038/sj.onc.1209455; Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349-7006.2006.00169.x; Kanato K, 2005, BIOCHEM BIOPH RES CO, V326, P836, DOI 10.1016/j.bbrc.2004.11.107; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Loeb DM, 2001, CANCER RES, V61, P921; Manikandan M, 2014, OMICS, V18, P142, DOI 10.1089/omi.2013.0098; Martinez-Estrada OM, 2010, NAT GENET, V42, P89, DOI 10.1038/ng.494; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Moore AW, 1999, DEVELOPMENT, V126, P1845; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; Nishida S, 2006, BLOOD, V107, P3303, DOI 10.1182/blood-2005-04-1656; Oji Y, 1999, JPN J CANCER RES, V90, P194, DOI 10.1111/j.1349-7006.1999.tb00733.x; Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476; Oji Y, 2004, CANCER SCI, V95, P822, DOI 10.1111/j.1349-7006.2004.tb02188.x; Oji Y, 2004, ANTICANCER RES, V24, P3103; Oji Y, 2004, CANCER SCI, V95, P583, DOI 10.1111/j.1349-7006.2004.tb02490.x; Oji Y, 2003, CANCER SCI, V94, P712, DOI 10.1111/j.1349-7006.2003.tb01507.x; Oji Y, 2003, CANCER SCI, V94, P606, DOI 10.1111/j.1349-7006.2003.tb01490.x; Oji Y, 2003, CANCER SCI, V94, P523, DOI 10.1111/j.1349-7006.2003.tb01477.x; Perez-Pomares JM, 2002, DEV BIOL, V247, P307, DOI 10.1006/dbio.2002.0706; Preskill Carina, 2013, Critical Reviews in Oncogenesis, V18, P327; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Sotobori T, 2006, CANCER-AM CANCER SOC, V106, P2233, DOI 10.1002/cncr.21861; Tatsumi N, 2008, INT J ONCOL, V32, P701; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Vidovic K, 2010, LEUKEMIA, V24, P992, DOI 10.1038/leu.2010.33; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34; Yamagami T, 1998, LEUKEMIA RES, V22, P383, DOI 10.1016/S0145-2126(97)00176-8; Zhang XH, 1997, J BIOL CHEM, V272, P29272, DOI 10.1074/jbc.272.46.29272; Zhao X, 2010, ARTHRITIS RHEUM-US, V62, P3425, DOI 10.1002/art.27632	59	12	13	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1003	1014		10.1038/onc.2015.154	http://dx.doi.org/10.1038/onc.2015.154			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961914				2022-12-28	WOS:000370823300006
J	Trono, P; Di Modugno, F; Circo, R; Spada, S; Di Benedetto, A; Melchionna, R; Palermo, B; Matteoni, S; Soddu, S; Mottolese, M; De Maria, R; Nistio, P				Trono, P.; Di Modugno, F.; Circo, R.; Spada, S.; Di Benedetto, A.; Melchionna, R.; Palermo, B.; Matteoni, S.; Soddu, S.; Mottolese, M.; De Maria, R.; Nistio, P.			hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells	ONCOGENE			English	Article							UP-REGULATION; TUMOR CELLS; MENA; GROWTH; PROTEIN; EXPRESSION; 3-KINASE; ACTIN; ENAH; BIM	Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 overexpression and an activated status of AKT and MAPK. The concomitant overexpression of hMENA and HER2 in breast cancer patients is indicative of a worse prognosis. hMENA is expressed along with alternatively expressed isoforms, hMENA(11a) and hMENA Delta v6 with opposite functions. A novel role for the epithelial-associated hMENA(11a) isoform in sustaining HER3 activation and pro-survival pathways in HER2-overexpressing breast cancer cells has been identified by reverse phase protein array and validated in vivo in a series of breast cancer tissues. As HER3 activation is crucial in mechanisms of cell resistance to PI3K inhibitors, we explored whether hMENA(11a) is involved in these resistance mechanisms. The specific hMENA(11a) depletion switched off the HER3r-elated pathway activated by PI3K inhibitors and impaired the nuclear accumulation of HER3 transcription factor FOXO3a induced by PI3K inhibitors, whereas PI3K inhibitors activated hMENA(11a) phosphorylation and affected its localization. At the functional level, we found that hMENA(11a) sustains cell proliferation and survival in response to PI3K inhibitor treatment, whereas hMENA(11a) silencing increases molecules involved in cancer cell apoptosis. As shown in three-dimensional cultures, hMENA(11a) contributes to resistance to PI3K inhibition because its depletion drastically reduced cell viability upon treatment with PI3K inhibitor BEZ235. Altogether, these results indicate that hMENA(11a) in HER2-overexpressing breast cancer cells sustains HER3/AKT axis activation and contributes to HER3-mediated resistance mechanisms to PI3K inhibitors. Thus, hMENA(11a) expression can be proposed as a marker of HER3 activation and resistance to PI3K inhibition therapies, to select patients who may benefit from these combined targeted treatments. hMENA(11a) activity could represent a new target for antiproliferative therapies in breast cancer.	[Trono, P.; Di Modugno, F.; Spada, S.; Melchionna, R.; Palermo, B.; Nistio, P.] Regina Elena Inst Canc Res, Lab Immunol, Expt Oncol, Rome, Italy; [Circo, R.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy; [Spada, S.; Palermo, B.] Univ Rome, Dept Mol Med, Rome, Italy; [Di Benedetto, A.; Mottolese, M.] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Matteoni, S.; Soddu, S.] Regina Elena Inst Canc Res, Expt Oncol, Rome, Italy; [De Maria, R.] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Nistio, P (corresponding author), Regina Elena Inst Canc Res, Immunol Lab, Via Elio Chianesi 53, I-00144 Rome, Italy.	nistico@ifo.it	Spada, Sheila/AAN-1520-2020; Nisticò, Paola/B-2862-2018; Matteoni, Silvia/U-7578-2017; Melchionna, Roberta/AAZ-4111-2021; De Maria, Ruggero/S-6385-2019; Di Modugno, Francesca/B-2865-2018; Di Modugno, Francesca/ABH-9406-2020; Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020	Nisticò, Paola/0000-0003-4409-2261; Matteoni, Silvia/0000-0001-6926-6593; Melchionna, Roberta/0000-0002-8410-9681; De Maria, Ruggero/0000-0003-2255-0583; Di Modugno, Francesca/0000-0003-1427-1883; Di Modugno, Francesca/0000-0003-1427-1883; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Palermo, Belinda/0000-0001-6293-0113; Trono, Paola/0000-0002-2053-6334; Di Benedetto, Anna/0000-0002-9853-8671	Associazione Italiana per la Ricerca sul Cancro (AIRC) [12182, 9979]; IG [11631]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); IG	We thank Dr C Rinaldo for her helpful suggestions, Dr M Panetta for her support, Dr I Terrenato for statistical analysis of data, Mrs G Falasca for technical support and Mrs MV Sarcone for secretarial assistance. This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) 5x1000 Grants 12182 and 9979 and IG 11631 (to PN).	Amin DN, 2012, BIOCHEM J, V447, P417, DOI 10.1042/BJ20120724; Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007; Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Andersen JN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001065; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Boudreau A, 2013, P NATL ACAD SCI USA, V110, pE3937, DOI 10.1073/pnas.1315022110; Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Desouza Melissa, 2012, Bioarchitecture, V2, P75; Di Modugno F, 2006, CLIN CANCER RES, V12, P1470, DOI 10.1158/1078-0432.CCR-05-2027; Di Modugno F, 2004, INT J CANCER, V109, P909, DOI 10.1002/ijc.20094; Di Modugno F, 2007, CANCER RES, V67, P2657, DOI 10.1158/0008-5472.CAN-06-1997; Di Modugno F, 2012, P NATL ACAD SCI USA, V109, P19280, DOI 10.1073/pnas.1214394109; Di Modugno F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015852; Dinkel H, 2012, NUCLEIC ACIDS RES, V40, pD242, DOI 10.1093/nar/gkr1064; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Federici G, 2013, MOL CANCER RES, V11, P676, DOI 10.1158/1541-7786.MCR-12-0690; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Goswami S, 2009, CLIN EXP METASTAS, V26, P153, DOI 10.1007/s10585-008-9225-8; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Howes AL, 2007, MOL CANCER THER, V6, P2505, DOI 10.1158/1535-7163.MCT-06-0698; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Knowlden JM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3018; Polo ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010786; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Morrison MM, 2013, J CLIN INVEST, V123, P4329, DOI 10.1172/JCI66764; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; NISTICO P, 1994, J CLIN INVEST, V94, P1426, DOI 10.1172/JCI117479; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Pinto Mauricio P, 2011, Front Endocrinol (Lausanne), V2, P15, DOI 10.3389/fendo.2011.00015; Rexer BN, 2013, CANCER RES, V73, P3817, DOI 10.1158/0008-5472.CAN-13-0687; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shapiro GI, 2014, CLIN CANCER RES, V20, P233, DOI 10.1158/1078-0432.CCR-13-1777; Singh A, 2010, MOL BIOL CELL, V21, P1140, DOI 10.1091/mbc.E09-09-0795; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; Urbanelli L, 2006, BBA-GENE STRUCT EXPR, V1759, P99, DOI 10.1016/j.bbaexp.2006.01.001; Vehlow A, 2013, EMBO J, V32, P2722, DOI 10.1038/emboj.2013.212; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weigelt B, 2014, ADV DRUG DELIVER REV, V69, P42, DOI 10.1016/j.addr.2014.01.001	50	8	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					887	896		10.1038/onc.2015.143	http://dx.doi.org/10.1038/onc.2015.143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961924	Green Published			2022-12-28	WOS:000370332200009
J	Finisguerra, V; Prenen, H; Mazzone, M				Finisguerra, V.; Prenen, H.; Mazzone, M.			Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; TIVANTINIB ARQ 197; ADVANCED SOLID TUMORS; FACTOR SCATTER FACTOR; RECEPTOR C-MET; RANDOMIZED PHASE-II; TOLEROGENIC DENDRITIC CELLS; PAPILLARY RENAL-CARCINOMAS; CHIMERIC ANTIGEN RECEPTORS; NEGATIVE BREAST-CANCER	A lot of attention has been dedicated to investigate the role of the tyrosine kinase receptor MET in tumors. The acquired notion that cancer cells from different histological origin strictly rely on the engagement of this specific oncogene for their growth and survival has certainly justified the development and the use of MET-targeted therapies in the clinic. However, the function and involvement of this pathway in the stroma (that often constitutes >50% of the global cellularity of the tumor) may offer the opportunity to conceive new patient stratification criteria, rational drug design and guided trials of new combination treatments. In this review, we will summarize and discuss the role of MET in cancer cells but especially in different stromal compartments, in light of the results showed by past and recent preclinical and clinical trials with anti-MET drugs.	[Finisguerra, V.] Ludwig Inst Canc Res, Brussels, Belgium; [Finisguerra, V.] Catholic Univ Louvain, de Duve Inst, Brussels, Belgium; [Prenen, H.] Univ Hosp Leuven, Digest Oncol, Leuven, Belgium; [Prenen, H.] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium; [Mazzone, M.] VIB, Lab Mol Oncol & Angiogenesis, Vesalius Res Ctr, Leuven, Belgium; [Mazzone, M.] Katholieke Univ Leuven, Dept Oncol, Vesalius Res Ctr, Lab Mol Oncol & Angiogenesis, Leuven, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; KU Leuven; University Hospital Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Mazzone, M (corresponding author), Katholieke Univ Leuven, VIB Vesalius Res Ctr, Herestr 49,Bus 912, B-3000 Leuven, Brabant, Belgium.	massimiliano.mazzone@vib-kuleuven.be	Finisguerra, Veronica/AGS-6956-2022	Prenen, Hans/0000-0001-8802-7352; Mazzone, Massimiliano/0000-0001-8824-4015	ERC Starting Grant (OxyMO); Televie F.R.S.-FNRS	ERC Starting Grant (OxyMO); Televie F.R.S.-FNRS(Fonds de la Recherche Scientifique - FNRS)	We thank Sandy Smets for administrative support. MM is holding an ERC Starting Grant (OxyMO). VF is supported by Televie F.R.S.-FNRS.	Abken H, 2015, IMMUNOTHERAPY-UK, V7, P535, DOI [10.2217/IMT.15.15, 10.2217/imt.15.15]; Abounader R, 2001, J NEUROCHEM, V76, P1497, DOI 10.1046/j.1471-4159.2001.00158.x; ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; Aftimos PG, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2580; Aguilar-Valenzuela R, 2014, J GASTROEN HEPATOL, V29, P878, DOI 10.1111/jgh.12456; Baek JH, 2012, J IMMUNOL, V189, P1699, DOI 10.4049/jimmunol.1200729; Bang YJ, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2520; Beilmann M, 2000, BLOOD, V95, P3964; Beilmann M, 1997, BLOOD, V90, P4450; Bendell JC, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.663; Benkhoucha M, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-154; Benkhoucha M, 2010, P NATL ACAD SCI USA, V107, P6424, DOI 10.1073/pnas.0912437107; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borset M, 1996, J BIOL CHEM, V271, P24655, DOI 10.1074/jbc.271.40.24655; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Camussi G, 1997, J IMMUNOL, V158, P1302; Castoldi R, 2013, ONCOGENE, V32, P5593, DOI 10.1038/onc.2013.245; CHANG H, 1994, NEPHRON, V67, P497, DOI 10.1159/000188032; Chen CT, 2012, MOL CANCER THER, V11, P660, DOI 10.1158/1535-7163.MCT-11-0754; Chen PM, 2014, J LEUKOCYTE BIOL, V96, P295, DOI 10.1189/jlb.3A0513-242R; Chen QY, 1996, CELL GROWTH DIFFER, V7, P821; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Choueiri TK, 2013, J CLIN ONCOL, V31, P181, DOI 10.1200/JCO.2012.43.3383; Cloughesy TF, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2015; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Corso S, 2013, CANCER DISCOV, V3, P978, DOI 10.1158/2159-8290.CD-13-0040; Cortner J, 1995, EXS, V74, P89; Coudriet GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015384; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Dieras V, 2015, ANN ONCOL, V26, P1904, DOI 10.1093/annonc/mdv263; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Falchook GS, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2591; Falenta K, 2013, J MICROSC-OXFORD, V250, P200, DOI 10.1111/jmi.12035; Feldman DR, 2013, INVEST NEW DRUG, V31, P1016, DOI 10.1007/s10637-013-9934-y; Feldman SA, 2015, SEMIN ONCOL, V42, P626, DOI 10.1053/j.seminoncol.2015.05.005; Finisguerra V, 2015, NATURE, V522, P349, DOI 10.1038/nature14407; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Futamatsu H, 2005, CIRC RES, V96, P823, DOI 10.1161/01.RES.0000163016.52653.2e; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gallo S, 2015, CLIN SCI, V129, P1173, DOI 10.1042/CS20150502; Gan HK, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.11111; Garber K, 2014, NAT REV DRUG DISCOV, V13, P563, DOI 10.1038/nrd4406; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Goldman JW, 2012, CANCER-AM CANCER SOC, V118, P5903, DOI 10.1002/cncr.27575; Gong RJ, 2006, J AM SOC NEPHROL, V17, P2464, DOI 10.1681/ASN.2006020185; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026; Harrison P, 2000, BIOCHEM BIOPH RES CO, V271, P203, DOI 10.1006/bbrc.2000.2612; Hirashima T, 2014, J CLIN ONCOL; Hong DS, 2015, ONCOTARGET, V6, P18693, DOI 10.18632/oncotarget.4472; Hong DS, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2508; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Hwang CI, 2011, P NATL ACAD SCI USA, V108, P14240, DOI 10.1073/pnas.1017536108; Ito W, 2005, AM J RESP CELL MOL, V32, P268, DOI 10.1165/rcmb.2004-0058OC; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Iveson T, 2014, LANCET ONCOL, V15, P1007, DOI 10.1016/S1470-2045(14)70023-3; Jensen MC, 2015, CURR OPIN IMMUNOL, V33, P9, DOI 10.1016/j.coi.2015.01.002; JIANG W, 1992, IMMUNOLOGY, V77, P147; Kang YK, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.167; Kang YK, 2014, INVEST NEW DRUG, V32, P355, DOI 10.1007/s10637-013-0057-2; Kentsis A, 2012, NAT MED, V18, P1118, DOI 10.1038/nm.2819; Kobayashi H, 2006, BLOOD, V108, P1260, DOI 10.1182/blood-2005-09-012807; Koeppen H, 2014, CLIN CANCER RES, V20, P4488, DOI 10.1158/1078-0432.CCR-13-1836; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Komarowska I, 2015, IMMUNITY, V42, P1087, DOI 10.1016/j.immuni.2015.05.014; Kontermann RE, 2015, DRUG DISCOV TODAY, V20, P838, DOI 10.1016/j.drudis.2015.02.008; Koochekpour S, 1997, CANCER RES, V57, P5391; Kumai T, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.976077; Kuroiwa T, 2001, J CLIN INVEST, V107, P1365, DOI 10.1172/JCI11808; Kurz SM, 2002, EUR J IMMUNOL, V32, P1832, DOI 10.1002/1521-4141(200207)32:7<1832::AID-IMMU1832>3.0.CO;2-2; Kwak EL, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps3087; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Liu Y, 2007, J PATHOL, V212, P12, DOI 10.1002/path.2155; Liu YH, 2004, AM J PHYSIOL-RENAL, V287, pF7, DOI 10.1152/ajprenal.00451.2003; Lolkema MP, 2015, CLIN CANCER RES, V21, P2297, DOI 10.1158/1078-0432.CCR-14-3258; LYON M, 1994, J BIOL CHEM, V269, P11216; Ma JH, 2009, J CLIN INVEST, V119, P478, DOI 10.1172/JCI36640; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; MARS WM, 1993, AM J PATHOL, V143, P949; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; Matsumoto K, 2005, BIOCHEM BIOPH RES CO, V333, P316, DOI 10.1016/j.bbrc.2005.05.131; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Matsumoto K, 2008, FRONT BIOSCI-LANDMRK, V13, P1943, DOI 10.2741/2813; McCoach CE, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2587; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Migliore C, 2012, CLIN CANCER RES, V18, P737, DOI 10.1158/1078-0432.CCR-11-1699; Mine S, 1998, LAB INVEST, V78, P1395; Misra S, 2011, FEBS J, V278, P1429, DOI 10.1111/j.1742-4658.2011.08071.x; Mizuno S, 2005, FASEB J, V19, P580, DOI 10.1096/fj.04-1535fje; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; Monk P, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.7_suppl.146; Moransard M, 2010, GLIA, V58, P559, DOI 10.1002/glia.20945; Mungunsukh O, 2013, MOL BIOL CELL, V24, P2088, DOI 10.1091/mbc.E13-01-0017; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Oh K, 2005, AM J PHYSIOL-GASTR L, V288, pG729, DOI 10.1152/ajpgi.00438.2004; Okunishi K, 2005, J IMMUNOL, V175, P4745, DOI 10.4049/jimmunol.175.7.4745; Okunishi K, 2007, J IMMUNOL, V179, P5504, DOI 10.4049/jimmunol.179.8.5504; Ovali E, 2000, HAEMATOLOGICA, V85, P464; Pant S, 2014, ANN ONCOL, V25, P1416, DOI 10.1093/annonc/mdu157; Pant S, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4065; Parikh RA, 2014, ONCOTARGETS THER, V7, P969, DOI 10.2147/OTT.S40241; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Patnaik A, 2014, BRIT J CANCER, V111, P272, DOI 10.1038/bjc.2014.290; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Rosen LS, 2011, CLIN CANCER RES, V17, P7754, DOI 10.1158/1078-0432.CCR-11-1002; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Rutella S, 2006, BLOOD, V108, P1435, DOI 10.1182/blood-2006-03-006403; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Salgia R, 2014, CLIN CANCER RES, V20, P1666, DOI 10.1158/1078-0432.CCR-13-2070; Santoro A, 2013, LANCET ONCOL, V14, P55, DOI 10.1016/S1470-2045(12)70490-4; Scagliotti GV, 2015, ANN ONCOL, V26, P2007, DOI 10.1093/annonc/mdv334; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Seidel C, 1998, MED ONCOL, V15, P145, DOI 10.1007/BF02821933; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570; Shah MA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4012; Shah MA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.2; SHIOTA G, 1995, HEPATOLOGY, V21, P106, DOI 10.1002/hep.1840210119; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; Skibinski G, 2001, IMMUNOLOGY, V102, P506, DOI 10.1046/j.1365-2567.2001.01186.x; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; Spigel DR, 2014, ASCO M, V32, P8000, DOI DOI 10.1200/jco.2014.32.15_suppl.8000; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Strickler JH, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2507; Tabernero J, 2014, CLIN CANCER RES, V20, P2793, DOI 10.1158/1078-0432.CCR-13-1837; Takada S, 1996, TRANSPLANT INT, V9, P151, DOI 10.1007/BF00336393; Tamura S, 1998, SCAND J IMMUNOL, V47, P296; Tesio M, 2011, BLOOD, V117, P419, DOI 10.1182/blood-2009-06-230359; Tolaney SM, 2015, INVEST NEW DRUG, V33, P1108, DOI 10.1007/s10637-015-0269-8; TOMIYA T, 1992, GASTROENTEROLOGY, V103, P1621, DOI 10.1016/0016-5085(92)91186-8; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tuck AB, 1996, AM J PATHOL, V148, P225; Twardowski P, 2015, J CLIN ONCOL, V33; Ueda H, 2001, CARDIOVASC RES, V51, P41, DOI 10.1016/S0008-6363(01)00272-3; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ueno M, 2013, DEV CELL, V27, P373, DOI 10.1016/j.devcel.2013.10.019; Valente G, 2009, CELL ONCOL, V31, P423, DOI 10.3233/CLO-2009-0504; vanderVoort R, 1997, J EXP MED, V185, P2121, DOI 10.1084/jem.185.12.2121; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Vokes EE, 2015, J CLIN ONCOL, V33; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wojta J, 1999, LAB INVEST, V79, P427; WU YL, 2014, J CLIN ONCOL, V32; Yamaura K, 2004, CIRCULATION, V110, P1650, DOI 10.1161/01.CIR.0000143052.45956.71; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yap TA, 2011, J CLIN ONCOL, V29, P1271, DOI 10.1200/JCO.2010.31.0367; Yen BLJ, 2013, STEM CELL REP, V1, P139, DOI 10.1016/j.stemcr.2013.06.006; Yoshioka H, 2015, ANN ONCOL, V26, P2066, DOI 10.1093/annonc/mdv288; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhao L, 2015, J PATHOL, V237, P319, DOI 10.1002/path.4578; Zhu XP, 2000, UROLOGY, V56, P1071, DOI 10.1016/S0090-4295(00)00795-0; Zucali PA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2549	166	22	22	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5457	5467		10.1038/onc.2016.36	http://dx.doi.org/10.1038/onc.2016.36			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	26996670				2022-12-28	WOS:000386998200001
J	Rice, MA; Ishteiwy, RA; Magani, F; Udayakumar, T; Reiner, T; Yates, TJ; Miller, P; Perez-Stable, C; Rai, P; Verdun, R; Dykxhoorn, DM; Burnstein, KL				Rice, M. A.; Ishteiwy, R. A.; Magani, F.; Udayakumar, T.; Reiner, T.; Yates, T. J.; Miller, P.; Perez-Stable, C.; Rai, P.; Verdun, R.; Dykxhoorn, D. M.; Burnstein, K. L.			The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related	ONCOGENE			English	Article							MICRORNA EXPRESSION; MOLECULAR PATHWAYS; HIP1R; FAMILY; GROWTH; MODEL	Deregulation of microRNAs (miRs) contributes to progression and metastasis of prostate and other cancers. miR-23b and -27b, encoded in the same miR cluster (miR-23b/-27b), are downregulated in human metastatic prostate cancer compared with primary tumors and benign tissue. Expression of miR-23b/-27b decreases prostate cancer cell migration, invasion and results in anoikis resistance. Conversely, antagomiR-mediated miR-23b and -27b silencing produces the opposite result in a more indolent prostate cancer cell line. However, neither miR-23b/-27b expression or inhibition impacts prostate cancer cell proliferation suggesting that miR-23b/-27b selectively suppresses metastasis. To examine the effects of miR-23b/-27b on prostate cancer metastasis in vivo, orthotopic prostate xenografts were established using aggressive prostate cancer cells transduced with miR-23b/-27b or non-targeting control miRNA. Although primary tumor formation was similar between miR-23b/-27b-transduced cells and controls, miR-23b/-27b expression in prostate cancer cells decreased seminal vesicle invasion and distant metastases. Gene-expression profiling identified the endocytic adaptor, Huntingtin-interacting protein 1-related (HIP1R) as being downregulated by miR-23b/-27b. Increased HIP1R expression in prostate cancer cells inversely phenocopied the effects of miR-23b/-27b overexpression on migration, invasion and anchorage-independent growth. HIP1R rescued miR-23b/-27b-mediated repression of migration in prostate cancer cells. HIP1R mRNA levels were decreased in seminal vesicle tissue from mice bearing miR-23b/-27b-transduced prostate cancer cell xenografts compared with scrambled controls, suggesting HIP1R is a key functional target of miR-23b/-27b. In addition, depletion of HIP1R led to a more rounded, less mesenchymal-like cell morphology, consistent with decreased metastatic properties. Together, these data demonstrate that the miR-23b/-27b cluster functions as a metastasis-suppressor by decreasing HIP1R levels in pre-clinical models of prostate cancer.	[Rice, M. A.; Magani, F.; Yates, T. J.] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Ishteiwy, R. A.; Burnstein, K. L.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,RMSB 6155,R-189, Miami, FL 33136 USA; [Udayakumar, T.] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA; [Reiner, T.; Perez-Stable, C.; Verdun, R.] Univ Miami, Miller Sch Med, Div Geriatr, Dept Med, Miami, FL 33136 USA; [Miller, P.; Perez-Stable, C.; Rai, P.; Verdun, R.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Dykxhoorn, D. M.] Univ Miami, Miller Sch Med, Dept Human Genet, John T Macdonald Fdn, Miami, FL 33136 USA; [Dykxhoorn, D. M.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Dykxhoorn, D. M.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; University of Miami	Burnstein, KL (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,RMSB 6155,R-189, Miami, FL 33136 USA.	KBurnstein@med.miami.edu	Rice, Meghan/AAH-3098-2019	Rai, Priyamvada/0000-0001-7822-7553; Rice, Meghan/0000-0003-4578-0461	DOD [W81XWH-11-1-0314]; NIH [R01CA132200]; Women's Cancer Association of the University of Miami; NATIONAL CANCER INSTITUTE [R01CA132200] Funding Source: NIH RePORTER	DOD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Women's Cancer Association of the University of Miami; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding provided by DOD pre-doctoral fellowship W81XWH-11-1-0314 (RAI/MAR), NIH R01CA132200 and Women's Cancer Association of the University of Miami (KLB). We thank UM investigators Drs Cale Fahrenholtz, Stephanie Peacock and Ning Zhao, as well as Annie Greene and Govindi Samaranayake for helpful technical assistance and guidance. Dr Michael Henry at the University of Iowa and Dr David Drubin at University of California at Berkeley generously provided the PQCXIN-luciferase and HIP1R-6myc constructs respectively.	Altuvia Y, 2005, NUCLEIC ACIDS RES, V33, P2697, DOI 10.1093/nar/gki567; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; Boettner DR, 2012, NAT CELL BIOL, V14, P2, DOI 10.1038/ncb2403; Brett TJ, 2006, NAT STRUCT MOL BIOL, V13, P121, DOI 10.1038/nsmb1043; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; D'Ambrosio J, 2009, CLIN EXP METASTAS, V26, P955, DOI 10.1007/s10585-009-9286-3; Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911; DAMICO AV, 1995, J UROLOGY, V154, P131, DOI 10.1016/S0022-5347(01)67248-3; Dykxhoorn DM, 2010, CANCER RES, V70, P6401, DOI 10.1158/0008-5472.CAN-10-1346; Engqvist-Goldstein AEY, 2004, MOL BIOL CELL, V15, P1666, DOI 10.1091/mbc.E03-09-0639; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Fuse M, 2012, J HUM GENET, V57, P691, DOI 10.1038/jhg.2012.95; Gandellini P, 2009, TRENDS MOL MED, V15, P381, DOI 10.1016/j.molmed.2009.07.004; Gottfried I, 2010, BIOCHEM SOC T, V38, P187, DOI 10.1042/BST0380187; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Hyun TS, 2004, MOL CELL BIOL, V24, P4329, DOI 10.1128/MCB.24.10.4329-4340.2004; Hyun TS, 2004, J BIOL CHEM, V279, P14294, DOI 10.1074/jbc.M312645200; Ishteiwy RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052106; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Liu W, 2014, CANCER MICROENVIRON, V7, P117, DOI 10.1007/s12307-014-0148-4; LOOP SM, 1993, PROSTATE, V22, P93, DOI 10.1002/pros.2990220202; Lyons LS, 2008, MOL ENDOCRINOL, V22, P597, DOI 10.1210/me.2007-0158; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Peacock SO, 2012, MOL ENDOCRINOL, V26, P1967, DOI 10.1210/me.2012-1165; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rao DS, 2002, J CLIN INVEST, V110, P351, DOI 10.1172/JCI200215529; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; Shi XB, 2008, J CELL MOL MED, V12, P1456, DOI 10.1111/j.1582-4934.2008.00420.x; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Sun T, 2012, PROSTATE, V72, P1093, DOI 10.1002/pros.22456; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Thomson DW, 2011, NUCLEIC ACIDS RES, V39, P6845, DOI 10.1093/nar/gkr330; Wang JH, 2008, NEOPLASIA, V10, P847, DOI 10.1593/neo.08450; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Wang YL, 2015, CLIN GENITOURIN CANC, V13, P261, DOI 10.1016/j.clgc.2015.01.003; Yates TJ, 2015, JNCI-J NATL CANCER I, V107, P7; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	45	34	38	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4752	4761		10.1038/onc.2016.6	http://dx.doi.org/10.1038/onc.2016.6			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26898757	Green Accepted			2022-12-28	WOS:000383324700008
J	Bognar, MK; Vincendeau, M; Erdmann, T; Seeholzer, T; Grau, M; Linnemann, JR; Ruland, J; Scheel, CH; Lenz, P; Ott, G; Lenz, G; Hauck, SM; Krappmann, D				Bognar, M. K.; Vincendeau, M.; Erdmann, T.; Seeholzer, T.; Grau, M.; Linnemann, J. R.; Ruland, J.; Scheel, C. H.; Lenz, P.; Ott, G.; Lenz, G.; Hauck, S. M.; Krappmann, D.			Oncogenic CARMA1 couples NF-kappa B and beta-catenin signaling in diffuse large B-cell lymphomas	ONCOGENE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; RNA INTERFERENCE; INTESTINAL TUMORIGENESIS; CARD11 MUTATIONS; ABC-DLBCL; ACTIVATION; INHIBITION; EXPRESSION; IMMUNITY; CANCER	Constitutive activation of the antiapoptotic nuclear factor-kappa B (NF-kappa B) signaling pathway is a hallmark of the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphomas (DLBCL). Recurrent oncogenic mutations are found in the scaffold protein CARMA1 (CARD11) that connects B-cell receptor (BCR) signaling to the canonical NF-kappa B pathway. We asked how far additional downstream processes are activated and contribute to the oncogenic potential of DLBCL-derived CARMA1 mutants. To this end, we expressed oncogenic CARMA1 in the NF-kappa B negative DLBCL lymphoma cell line BJAB. By a proteomic approach we identified recruitment of beta-catenin and its destruction complex consisting of APC, AXIN1, CK1a and GSK3 beta to oncogenic CARMA1. Recruitment of the beta-catenin destruction complex was independent of CARMA1-BCL10-MALT1 complex formation or constitutive NF-kappa B activation and promoted the stabilization of beta-catenin. The beta-catenin destruction complex was also recruited to CARMA1 in ABC DLBCL cell lines, which coincided with elevated beta-catenin expression. In line, beta-catenin was frequently detected in non-GCB DLBCL biopsies that rely on chronic BCR signaling. Increased beta-catenin amounts alone were not sufficient to induce classical WNT target gene signatures, but could augment TCF/LEF-dependent transcriptional activation in response to WNT signaling. In conjunction with NF-kappa B, beta-catenin enhanced expression of immunosuppressive interleukin-10 and suppressed antitumoral CCL3, indicating that beta-catenin can induce a favorable tumor microenvironment. Thus, parallel activation of NF-kappa B and beta-catenin signaling by gain-of-function mutations in CARMA1 augments WNT stimulation and is required for regulating the expression of distinct NF-kappa B target genes to trigger cell-intrinsic and extrinsic processes that promote DLBCL lymphomagenesis.	[Bognar, M. K.; Vincendeau, M.; Seeholzer, T.; Krappmann, D.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Mol Toxicol & Pharmacol, Res Unit Cellular Signal Integrat, Ingolstaedter Landstr 1, D-85764 Neuherberg, Bayern, Germany; [Erdmann, T.; Grau, M.; Lenz, G.] Univ Hosp Munster, Dept Med A, Translat Oncol, Albert Schweitzer Campus 1, Munster, Germany; [Erdmann, T.; Lenz, G.] Cluster Excellence EXC 1003, Cells Mot, Munster, Germany; [Grau, M.; Lenz, P.] Univ Marburg, Dept Phys, Marburg, Germany; [Linnemann, J. R.; Scheel, C. H.] Helmholtz Zentrum Munchen, Inst Stem Cell Res, German Res Ctr Environm Hlth, Neuherberg, Germany; [Ruland, J.] Tech Univ Munich, Klinikum Rechts Isar, Inst Klin Chem & Pathobiochem, Munich, Germany; [Ruland, J.] German Canc Consortium DKTK, Heidelberg, Germany; [Ruland, J.] German Ctr Infect Res DZIF, Partner Site Munich, Munich, Germany; [Ott, G.] Robert Bosch Krankenhaus, Dr Margarete Fischer Bosch Inst Clin Pharmacol, Dept Clin Pathol, Stuttgart, Germany; [Hauck, S. M.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Prot Sci, Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munster; Philipps University Marburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); German Center for Infection Research; Bosch; Robert Bosch Krankenhaus; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Krappmann, D (corresponding author), Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Mol Toxicol & Pharmacol, Res Unit Cellular Signal Integrat, Ingolstaedter Landstr 1, D-85764 Neuherberg, Bayern, Germany.	daniel.krappmann@helmholtz-muenchen.de	Krappmann, Daniel/ABF-4038-2021; Vincendeau, Michelle/AAD-4320-2022; Krappmann, Daniel/AAT-4354-2021; Hauck, Stefanie/B-3300-2013; Ruland, Jürgen/Q-6680-2018	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234; Hauck, Stefanie/0000-0002-1630-6827; Ruland, Jürgen/0000-0002-8381-3597; Lenz, Peter/0000-0001-7705-3950; Seeholzer, Thomas/0000-0002-1115-3358; Grau, Michael/0000-0003-1909-0133	Deutsche Krebshilfe; Else Krner-Fresenius-Stiftung; Swiss National Science Foundation (Sinergia grant); Deutsche Forschungsgemeinschaft (DFG) [EXC 1003]; Philipps-University Marburg (Doctoral Scholarship); Deutsche Krebshilfe [109434]	Deutsche Krebshilfe(Deutsche Krebshilfe); Else Krner-Fresenius-Stiftung; Swiss National Science Foundation (Sinergia grant)(Swiss National Science Foundation (SNSF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Philipps-University Marburg (Doctoral Scholarship); Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Bernhard Kloo for support. The following material was kindly provided by: pMD2.G (Addgene # 12259), psPAX2 (Addgene # 12260), pLVTHM (Addgene # 12247) and pLV-tTRKRAB-red (Addgene # 12250) from Didier Trono; TCF/LEF luciferase reporter from Roel Nusse (Addgene # 24307). Support: Deutsche Krebshilfe, Else Krner-Fresenius-Stiftung, Swiss National Science Foundation (Sinergia grant), Deutsche Forschungsgemeinschaft (DFG EXC 1003) to GL; Philipps-University Marburg (Doctoral Scholarship) to MG; Deutsche Krebshilfe (# 109434) to DK.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bidere N, 2009, NATURE, V458, P92, DOI 10.1038/nature07613; Chin M, 2009, ONCOGENE, V28, P2100, DOI 10.1038/onc.2009.74; Christian SL, 2002, J IMMUNOL, V169, P758, DOI 10.4049/jimmunol.169.2.758; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Eitelhuber AC, 2011, EMBO J, V30, P594, DOI 10.1038/emboj.2010.331; Etet PFS, 2013, BBA-REV CANCER, V1835, P1, DOI 10.1016/j.bbcan.2012.08.002; Fu CM, 2015, P NATL ACAD SCI USA, V112, P2823, DOI 10.1073/pnas.1414167112; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Ge XL, 2012, MOL MED REP, V5, P1433, DOI 10.3892/mmr.2012.835; Gloeckner CJ, 2007, PROTEOMICS, V7, P4228, DOI 10.1002/pmic.200700038; Hadian K, 2011, J BIOL CHEM, V286, P26107, DOI 10.1074/jbc.M111.233163; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Harlin H, 2009, CANCER RES, V69, P3077, DOI 10.1158/0008-5472.CAN-08-2281; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Jeelall YS, 2012, J EXP MED, V209, P1907, DOI 10.1084/jem.20112744; Koch R, 2014, BLOOD, V123, P2189, DOI 10.1182/blood-2013-08-523886; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lamason RL, 2010, BIOCHEMISTRY-US, V49, P8240, DOI 10.1021/bi101052d; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042775; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Lovatt M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012794; Nagel D, 2014, ONCOGENE, V33, P5655, DOI 10.1038/onc.2013.565; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Nakashima E, 1996, PHARMACEUT RES, V13, P1896, DOI 10.1023/A:1016057830271; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nogai H, 2013, BLOOD, V122, P2242, DOI 10.1182/blood-2013-06-508028; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008; Ramakrishna E, 2009, CANCER RES, V69, P1448, DOI 10.1158/0008-5472.CAN-08-1160; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Scharschmidt E, 2004, MOL CELL BIOL, V24, P3860, DOI 10.1128/MCB.24.9.3860-3873.2004; Schimmack G, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0049-7; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Tandon B, 2011, MODERN PATHOL, V24, P1433, DOI 10.1038/modpathol.2011.103; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Wilson WH, 2015, NAT MED, V21, P922, DOI 10.1038/nm.3884; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yaguchi T, 2012, J IMMUNOL, V189, P2110, DOI 10.4049/jimmunol.1102282; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024	54	31	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4269	4281		10.1038/onc.2015.493	http://dx.doi.org/10.1038/onc.2015.493			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26776161	Green Published, hybrid			2022-12-28	WOS:000382149800011
J	Antonczak, AK; Mullee, LI; Wang, Y; Comartin, D; Inoue, T; Pelletier, L; Morrison, CG				Antonczak, A. K.; Mullee, L. I.; Wang, Y.; Comartin, D.; Inoue, T.; Pelletier, L.; Morrison, C. G.			Opposing effects of pericentrin and microcephalin on the pericentriolar material regulate CHK1 activation in the DNA damage response	ONCOGENE			English	Article							CENTROSOME AMPLIFICATION; MITOTIC ENTRY; CHECKPOINT; SPINDLE; PHOSPHORYLATION; ORGANIZATION; SURVIVAL; DEFECTS; CELLS	Genotoxic stresses lead to centrosome amplification, a frequently-observed feature in cancer that may contribute to genome instability and to tumour cell invasion. Here we have explored how the centrosome controls DNA damage responses. For most of the cell cycle, centrosomes consist of two centrioles embedded in the proteinaceous pericentriolar material (PCM). Recent data indicate that the PCM is not an amorphous assembly of proteins, but actually a highly organised scaffold around the centrioles. The large coiled-coil protein, pericentrin, participates in PCM assembly and has been implicated in the control of DNA damage responses (DDRs) through its interactions with checkpoint kinase 1 (CHK1) and microcephalin (MCPH1). CHK1 is required for DNA damage-induced centrosome amplification, whereas MCPH1 deficiency greatly increases the amplification seen after DNA damage. We found that the PCM showed a marked expansion in volume and a noticeable change in higher-order organisation after ionising radiation treatment. PCM expansion was dependent on CHK1 kinase activity and was potentiated by MCPH1 deficiency. Furthermore, pericentrin deficiency or mutation of a separase cleavage site blocked DNA damage-induced PCM expansion. The extent of nuclear CHK1 activation after DNA damage reflected the level of PCM expansion, with a reduction in pericentrin-deficient or separase cleavage site mutant-expressing cells, and an increase in MCPH1-deficient cells that was suppressed by the loss of pericentrin. Deletion of the nuclear export signal of CHK1 led to its hyperphosphorylation after irradiation and reduced centrosome amplification. Deletion of the nuclear localisation signal led to low CHK1 activation and low centrosome amplification. From these data, we propose a feedback loop from the PCM to the nuclear DDR in which CHK1 regulates pericentrin-dependent PCM expansion to control its own activation.	[Antonczak, A. K.; Mullee, L. I.; Wang, Y.; Morrison, C. G.] Natl Univ Ireland Galway, Sch Nat Sci, Ctr Chromosome Biol, Galway, Ireland; [Comartin, D.; Pelletier, L.] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Inoue, T.] Johns Hopkins Univ, Dept Cell Biol, Baltimore, MD USA	Ollscoil na Gaillimhe-University of Galway; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Johns Hopkins University	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Ctr Chromosome Biol, Biosci Bldg, Galway, Ireland.	Ciaran.Morrison@nuigalway.ie	Pelletier, Laurence/F-8858-2013; Morrison, Ciaran/AAH-2034-2019; Morrison, Ciaran/B-6568-2008	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029	EMBO Long-term Postdoctoral Fellowship; Journal of Cell Science; National University of Ireland; Science Foundation Ireland [08/IN.1/B1029, 10/IN.1/B2972]	EMBO Long-term Postdoctoral Fellowship(European Molecular Biology Organization (EMBO)); Journal of Cell Science; National University of Ireland; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We are grateful to Alex Bird, David Drechsel, Fanni Gergely, Andreas Merdes and Eric Tippmann for reagents and to Brian McStay and Noel Lowndes for critically reading the manuscript. AKA received an EMBO Long-term Postdoctoral Fellowship and a Travelling Fellowship from the Journal of Cell Science. LIM received a Travelling Studentship from the National University of Ireland. This work was supported by Science Foundation Ireland Principal Investigator awards 08/IN.1/B1029 and 10/IN.1/B2972.	Agircan FG, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004672; Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Anderhub SJ, 2012, CANCER LETT, V322, P8, DOI 10.1016/j.canlet.2012.02.006; Barr AR, 2010, J CELL BIOL, V189, P23, DOI 10.1083/jcb.200912163; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Bird AW, 2008, J CELL BIOL, V182, P289, DOI 10.1083/jcb.200802005; Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962; Brown JAL, 2010, ONCOGENE, V29, P5537, DOI 10.1038/onc.2010.302; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Fu JY, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120104; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Griffith E, 2008, NAT GENET, V40, P232, DOI 10.1038/ng.2007.80; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kushner EJ, 2014, J CELL BIOL, V206, P257, DOI 10.1083/jcb.201311013; Lawo S, 2012, NAT CELL BIOL, V14, P1148, DOI 10.1038/ncb2591; Lee K, 2012, CELL CYCLE, V11, P2476, DOI 10.4161/cc.20878; Lee K, 2011, J CELL BIOL, V195, P1093, DOI 10.1083/jcb.201106093; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Loffler H, 2013, ONCOGENE, V32, P2963, DOI 10.1038/onc.2012.310; Loffler H, 2007, CELL CYCLE, V6, P2541; Loncarek J, 2008, NAT CELL BIOL, V10, P322, DOI 10.1038/ncb1694; Matsuo K, 2012, CURR BIOL, V22, P915, DOI 10.1016/j.cub.2012.03.048; Matsuyama M, 2011, J CELL SCI, V124, P2113, DOI 10.1242/jcs.086488; Mennella V, 2012, NAT CELL BIOL, V14, P1159, DOI 10.1038/ncb2597; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Palazzo RE, 2000, CURR TOP DEV BIOL, V49, P449; Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172; Pihan GA, 2001, CANCER RES, V61, P2212; Prosser SL, 2012, J CELL SCI, V125, P5353, DOI 10.1242/jcs.106096; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Robinson HMR, 2007, CELL CYCLE, V6, P982, DOI 10.4161/cc.6.8.4111; Sonnen KF, 2012, BIOL OPEN, V1, P965, DOI 10.1242/bio.20122337; Stephan AK, 2011, MOL CELL BIOL, V31, P1369, DOI 10.1128/MCB.00786-10; Tibelius A, 2009, J CELL BIOL, V185, P1149, DOI 10.1083/jcb.200810159; Wang Y- D, 2006, REV PROTOCOLS DT40 R, P439; Wang YF, 2013, CELL CYCLE, V12, P635, DOI 10.4161/cc.23516; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003	47	18	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					2003	2010		10.1038/onc.2015.257	http://dx.doi.org/10.1038/onc.2015.257			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26165835				2022-12-28	WOS:000374010300013
J	Mir, R; Pradhan, SJ; Patil, P; Mulherkar, R; Galande, S				Mir, R.; Pradhan, S. J.; Patil, P.; Mulherkar, R.; Galande, S.			Wnt/beta-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression	ONCOGENE			English	Article							CHROMATIN ORGANIZER SATB1; TUMOR PROGRESSION; GENE-EXPRESSION; GASTRIC-CANCER; UP-REGULATION; IN-VITRO; METASTASIS; GROWTH; CARCINOMA; GENOME	The chromatin organizer SATB1 has been implicated in the development and progression of multiple cancers including breast and colorectal cancers. However, the regulation and role of SATB1 in colorectal cancers is poorly understood. Here, we demonstrate that expression of SATB1 is induced upon hyperactivation of Wnt/beta-catenin signaling and repressed upon depletion of TCF7L2 (TCF4) and beta-catenin. Using several colorectal cancer cell line models and the APC min mutant zebrafish in vivo model, we established that SATB1 is a novel target of Wnt/beta-catenin signaling. We show that direct binding of TCF7L2/beta-catenin complex on Satb1 promoter is required for the regulation of SATB1. Moreover, SATB1 is sufficient to regulate the expression of beta-catenin, members of TCF family, multiple downstream effectors and mediators of Wnt pathway. SATB1 potentiates the cellular changes and expression of key cancer-associated genes in non-aggressive colorectal cells, promotes their aggressive phenotype and tumorigenesis in vivo. Conversely, depletion of SATB1 from aggressive cells reprograms the expression of cancer-associated genes, reverses their cancer phenotype and reduces the potential of these cells to develop tumors in vivo. We also show that SATB1 and beta-catenin bind to the promoters of TCF7L2 and the downstream targets of Wnt signaling and regulate their expression. Our findings suggest that SATB1 shares a feedback regulatory network with TCF7L2/beta-catenin signaling and is required for Wnt signaling-dependent regulation of beta-catenin. Collectively, these results provide unequivocal evidence to establish that SATB1 reprograms the expression of tumor growth-and metastasis-associated genes to promote tumorigenesis and functionally overlaps with Wnt signaling critical for colorectal cancer tumorigenesis.	[Mir, R.; Pradhan, S. J.; Galande, S.] Indian Inst Sci Educ & Res, Pune, Maharashtra, India; [Patil, P.] Tata Mem Hosp, Mumbai 400012, Maharashtra, India; [Mulherkar, R.] Adv Ctr Treatment Res & Educ Canc, Kharghar, Navi Mumbai, India; [Galande, S.] Natl Ctr Cell Sci, Pune, Maharashtra, India	Indian Institute of Science Education & Research (IISER) Pune; Tata Memorial Centre (TMC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Galande, S (corresponding author), Indian Inst Sci Educ & Res, Ctr Excellence Epigenet, Dr Homi Bhabha Rd, Pune 411008, Maharashtra, India.	sanjeev@iiserpune.ac.in		Patil, Prachi/0000-0002-5809-6282	Centre of Excellence in Epigenetics program of the Department of Biotechnology; Department of Science and Technology, Government of India; University Grants Commission, India	Centre of Excellence in Epigenetics program of the Department of Biotechnology; Department of Science and Technology, Government of India(Department of Science & Technology (India)); University Grants Commission, India(University Grants Commission, India)	We thank the staff of the experimental animal facility and in vivo imaging facility of NCCS. Work was supported by grants from the Centre of Excellence in Epigenetics program of the Department of Biotechnology and the Swarnajayanti Fellowship from the Department of Science and Technology, Government of India to SG. RM is supported by fellowship from the University Grants Commission, India. We thank Mahendra Sonawane for providing RNA and whole cell lysates from APC min mutant Zebrafish.	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cheng C, 2010, APMIS, V118, P855, DOI 10.1111/j.1600-0463.2010.02673.x; Chu SH, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-149; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Frietze S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r52; Fromberg A, 2014, INT J CANCER, V135, P2537, DOI 10.1002/ijc.28895; Galande S, 2007, CURR OPIN GENET DEV, V17, P408, DOI 10.1016/j.gde.2007.08.003; Galande S, 2002, CURR CANCER DRUG TAR, V2, P157, DOI 10.2174/1568009023333917; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-424; Kohwi-Shigematsu T, 2013, SEMIN CANCER BIOL, V23, P72, DOI 10.1016/j.semcancer.2012.06.009; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lu XM, 2010, ONCOL REP, V24, P981, DOI 10.3892/or_00000945; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; McInnes N, 2012, ONCOGENE, V31, P1045, DOI 10.1038/onc.2011.293; Meng WJ, 2012, INT J COLORECTAL DIS, V27, P143, DOI 10.1007/s00384-011-1302-9; Meng WJ, 2011, MED HYPOTHESES, V76, P277, DOI 10.1016/j.mehy.2010.10.022; Mir R, 2012, CURR DRUG TARGETS, V13, P1603, DOI 10.2174/138945012803530008; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Nodin B, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-115; Notani D, 2011, J BIOSCIENCES, V36, P461, DOI 10.1007/s12038-011-9091-4; Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296; Ordinario E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051786; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; Tu W, 2012, LIVER INT, V32, P1064, DOI 10.1111/j.1478-3231.2012.02815.x; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wagner RT, 2010, STEM CELLS, V28, P1794, DOI 10.1002/stem.502; Wang S, 2009, J PATHOL, V219, P114, DOI 10.1002/path.2575; Xiang JD, 2012, ONCOL LETT, V3, P865, DOI 10.3892/ol.2012.571; Zhang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0047902; Zhang LZ, 2004, MOL CELL BIOL, V24, P2169, DOI 10.1128/MCB.24.5.2169-2180.2004; Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100413; Zhao F, 2005, NUCLEIC ACIDS RES, V33, pD103, DOI 10.1093/nar/gki004	40	62	66	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1679	1691		10.1038/onc.2015.232	http://dx.doi.org/10.1038/onc.2015.232			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26165840				2022-12-28	WOS:000373064200007
J	Hein, SM; Haricharan, S; Johnston, AN; Toneff, MJ; Reddy, JP; Dong, J; Bu, W; Li, Y				Hein, S. M.; Haricharan, S.; Johnston, A. N.; Toneff, M. J.; Reddy, J. P.; Dong, J.; Bu, W.; Li, Y.			Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; MIDDLE T-ANTIGEN; STEM-CELLS; MOUSE MODEL; IDENTIFICATION; PROGENITORS; EXPRESSION; LINEAGE; TRANSFORMATION; TUMORIGENESIS	In the normal mammary gland, the basal epithelium is known to be bipotent and can generate either basal or luminal cells, whereas the luminal epithelium has not been demonstrated to contribute to the basal compartment in an intact and normally developed mammary gland. It is not clear whether cellular heterogeneity within a breast tumor results from transformation of bipotent basal cells or from transformation and subsequent basal conversion of the more differentiated luminal cells. Here we used a retroviral vector to express an oncogene specifically in a small number of the mammary luminal epithelial cells and tested their potential to produce basal cells during tumorigenesis. This in-vivo lineage-tracing work demonstrates that luminal cells are capable of producing basal cells on activation of either polyoma middle T antigen or ErbB2 signaling. These findings reveal the plasticity of the luminal compartment during tumorigenesis and provide an explanation for cellular heterogeneity within a cancer.	[Hein, S. M.; Toneff, M. J.; Reddy, J. P.; Dong, J.; Bu, W.; Li, Y.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza MS600, Houston, TX 77030 USA; [Hein, S. M.; Haricharan, S.; Johnston, A. N.; Dong, J.; Bu, W.; Li, Y.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Reddy, J. P.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Li, Y (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza MS600, Houston, TX 77030 USA.	liyi@bcm.edu	; Li, Yi/A-7635-2009	Reddy, Jay Paul/0000-0001-9378-4585; Li, Yi/0000-0002-9976-518X	NIH [CA124820, U54CA149196, T32AG000183, T32GM088129, P30 AI036211, P30 CA125123, S10 RR024574]; DOD [BC085050, BC112704, BC073703]; Nancy Owens Memorial Foundation; CPRIT Training Program [RP101499]; Cytometry and Cell Sorting Core at Baylor College of Medicine; Dan L. Duncan Cancer Center [P30CA125123]; Lester & Sue Smith Breast Center [P50CA058183, P50-CA186784]; NATIONAL CANCER INSTITUTE [U54CA149196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM088129] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Nancy Owens Memorial Foundation; CPRIT Training Program; Cytometry and Cell Sorting Core at Baylor College of Medicine; Dan L. Duncan Cancer Center; Lester & Sue Smith Breast Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Jeffrey Rosen for critical reading of this manuscript. This work was supported in part by funds from NIH CA124820 (to YL) and U54CA149196 (to YL; PI: Stephan Wong); from DOD CDMRP BC085050 (to YL), BC112704 (to YL) and BC073703 (YL); and from the Nancy Owens Memorial Foundation (to YL); as well as by the resources from the Dan L. Duncan Cancer Center (P30CA125123) and the Lester & Sue Smith Breast Center (P50CA058183 & P50-CA186784). SMH was supported by the CPRIT Training Program (RP101499) and by NIH training award T32AG000183. ANJ was supported by NIH training award T32GM088129. This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 AI036211, P30 CA125123 and S10 RR024574) and the expert assistance of Joel M. Sederstrom.	Chang THT, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3593; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Gastaldi S, 2013, ONCOGENE, V32, P1428, DOI 10.1038/onc.2012.154; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Haricharan S, 2014, ONCOGENE, V33, P5729, DOI 10.1038/onc.2013.521; Haricharan S, 2013, ELIFE, V2, DOI 10.7554/eLife.00996; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Ling H, 2013, ONCOGENE, V32, P3410, DOI 10.1038/onc.2012.341; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Reddy JP, 2010, P NATL ACAD SCI USA, V107, P3728, DOI 10.1073/pnas.0910665107; Reddy JP, 2009, J MAMMARY GLAND BIOL, V14, P405, DOI 10.1007/s10911-009-9157-1; Reis JS, 2006, HISTOPATHOLOGY, V49, P10, DOI 10.1111/j.1365-2559.2006.02467.x; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	44	25	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1461	1467		10.1038/onc.2015.206	http://dx.doi.org/10.1038/onc.2015.206			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26096929	Green Accepted			2022-12-28	WOS:000372196400012
J	Pazarentzos, E; Giannikopoulos, P; Hrustanovic, G; St John, J; Olivas, VR; Gubens, MA; Balassanian, R; Weissman, J; Polkinghorn, W; Bivona, TG				Pazarentzos, E.; Giannikopoulos, P.; Hrustanovic, G.; St John, J.; Olivas, V. R.; Gubens, M. A.; Balassanian, R.; Weissman, J.; Polkinghorn, W.; Bivona, T. G.			Oncogenic activation of the PI3-kinase p110 beta isoform via the tumor-derived PIK3C beta(D1067V) kinase domain mutation	ONCOGENE			English	Article							LUNG-CANCER; ERLOTINIB RESISTANCE; PIK3CA MUTATIONS; PI3 KINASE; PTEN LOSS; GROWTH; INHIBITORS; PATHWAY; BRAF	Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs widely in human cancers. Although somatic mutations in the PI3K pathway genes PIK3CA and PTEN are known to drive PI3K pathway activation and cancer growth, the significance of somatic mutations in other PI3K pathway genes is less clear. Here, we establish the signaling and oncogenic properties of a recurrent somatic mutation in the PI3K p110 beta isoform that resides within its kinase domain (PIK3C beta(D1067V)). We initially observed PIK3C beta(D1067V) by exome sequencing analysis of an EGFR-mutant non-small cell lung cancer (NSCLC) tumor biopsy from a patient with acquired erlotinib resistance. On the basis of this finding, we hypothesized that PIK3C beta(D1067V) might function as a novel tumor-promoting genetic alteration, and potentially an oncogene, in certain cancers. Consistent with this hypothesis, analysis of additional tumor exome data sets revealed the presence of PIK3C beta(D1067V) at low frequency in other patient tumor samples (including renal cell carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, melanoma, thyroid carcinoma and endometrial carcinoma). Functional studies revealed that PIK3C beta(D1067V) promoted PI3K pathway signaling, enhanced cell growth in vitro, and was sufficient for tumor formation in vivo. Pharmacologic inhibition of PIK3C beta with TGX-221 (isoform-selective p110 beta inhibitor) specifically suppressed growth in patient-derived renal-cell carcinoma cells with endogenous PIK3C beta(D1067V) and in NIH-3T3 and human EGFR-mutant lung adenocarcinoma cells engineered to express this mutant PI3K. In the EGFR-mutant lung adenocarcinoma cells, expression of PIK3C beta(D1067V) also promoted erlotinib resistance. Our data establish a novel oncogenic form of PI3K, revealing the signaling and oncogenic properties of PIK3C beta(D1067V) and its potential therapeutic relevance in cancer. Our findings provide new insight into the genetic mechanisms underlying PI3K pathway activation in human tumors and indicate that PIK3C beta(D1067V) is a rational therapeutic target in certain cancers.	[Pazarentzos, E.; Hrustanovic, G.; Olivas, V. R.; Gubens, M. A.; Bivona, T. G.] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA; [Pazarentzos, E.; Hrustanovic, G.; Olivas, V. R.; Gubens, M. A.; Bivona, T. G.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Giannikopoulos, P.; St John, J.; Polkinghorn, W.] Driver Grp, San Francisco, CA USA; [Balassanian, R.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Weissman, J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; [Weissman, J.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Bivona, TG (corresponding author), Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA.	trever.bivona@ucsf.edu		Weissman, Jonathan/0000-0003-2445-670X; Pazarentzos, Evangelos/0000-0002-5453-1646	NIH; Howard Hughes Medical Institute; Doris Duke Charitable Foundation; American Lung Association; National Lung Cancer Partnership; Sidney Kimmel Foundation for Cancer Research; Searle Scholars Program	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); American Lung Association; National Lung Cancer Partnership; Sidney Kimmel Foundation for Cancer Research; Searle Scholars Program	We acknowledge funding support (to TGB) from the following sources: NIH Director's New Innovator Award, Howard Hughes Medical Institute, Doris Duke Charitable Foundation, American Lung Association, National Lung Cancer Partnership, Sidney Kimmel Foundation for Cancer Research and Searle Scholars Program.	Bauer TM, 2015, PHARMACOL THERAPEUT, V146, P53, DOI 10.1016/j.pharmthera.2014.09.006; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Burger MT, 2011, ACS MED CHEM LETT, V2, P774, DOI 10.1021/ml200156t; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Charles RP, 2014, MOL CANCER RES, V12, P979, DOI 10.1158/1541-7786.MCR-14-0158-T; Dbouk HA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063833; Deuker MM, 2015, CANCER DISCOV, V5, P143, DOI 10.1158/2159-8290.CD-14-0856; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Janku F, 2011, MOL CANCER THER, V10, P558, DOI 10.1158/1535-7163.MCT-10-0994; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kosaka T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/165214; Lammers PE, 2014, J NATL COMPR CANC NE, V12, P6, DOI 10.6004/jnccn.2014.0002; Lin LP, 2014, P NATL ACAD SCI USA, V111, pE748, DOI 10.1073/pnas.1320956111; Ling YH, 2008, MOL PHARMACOL, V74, P793, DOI 10.1124/mol.107.044396; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schroeder MP, 2013, GENOME MED, V5, DOI 10.1186/gm413; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Tang J, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00015; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Wu JY, 2011, CLIN CANCER RES, V17, P3812, DOI 10.1158/1078-0432.CCR-10-3408	27	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1198	1205		10.1038/onc.2015.173	http://dx.doi.org/10.1038/onc.2015.173			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982275	Bronze			2022-12-28	WOS:000371351700014
J	Scala, F; Brighenti, E; Govoni, M; Imbrogno, E; Fornari, F; Trere, D; Montanaro, L; Derenzini, M				Scala, F.; Brighenti, E.; Govoni, M.; Imbrogno, E.; Fornari, F.; Trere, D.; Montanaro, L.; Derenzini, M.			Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate	ONCOGENE			English	Article							POLYMERASE I; PROTEIN L11; DNA-DAMAGE; ACTIVATION; APOPTOSIS; CANCER; MDM2; PATHWAY; VIVO; 5-FLUOROURACIL	Many drugs currently used in chemotherapy work by hindering the process of ribosome biogenesis. In tumors with functional p53, the inhibition of ribosome biogenesis may contribute to the efficacy of this treatment by inducing p53 stabilization. As the level of stabilized p53 is critical for the induction of cytotoxic effects, it seems useful to highlight those cancer cell characteristics that can predict the degree of p53 stabilization following the treatment with inhibitors of ribosome biogenesis. In the present study we exposed a series of p53 wild-type human cancer cell lines to drugs such as actinomycin D (ActD), doxorubicin, 5-fluorouracil and CX-5461, which hinder ribosomal RNA (rRNA) synthesis. We found that the amount of stabilized p53 was directly related to the level of ribosome biogenesis in cells before the drug treatment. This was due to different levels of inactivation of the ribosomal proteins-MDM2 pathway of p53 digestion. Inhibition of rRNA synthesis always caused cell cycle arrest, independent of the ribosome biogenesis rate of the cells, whereas apoptosis occurred only in cells with a high rDNA transcription rate. The level of p53 stabilization induced by drugs acting in different ways from the inhibition of ribosome biogenesis, such as hydroxyurea (HU) and nutlin-3, was independent of the level of ribosome biogenesis in cells and always lower than that occurring after the inhibition of rRNA synthesis. Interestingly, in cells with a low ribosome biogenesis rate, the combined treatment with ActD and HU exerted an additive effect on p53 stabilization. These results indicated that (i) drugs inhibiting ribosome biogenesis may be highly effective in p53 wild-type cancers with a high ribosome biogenesis rate, as they induce apoptotic cell death, and (ii) the combination of drugs capable of stabilizing p53 through different mechanisms may be useful for treating cancers with a low ribosome biogenesis rate.	[Scala, F.; Brighenti, E.; Govoni, M.; Imbrogno, E.; Trere, D.; Montanaro, L.; Derenzini, M.] Univ Bologna, Dept Expt Diagnost & Specialty Med, Via Massarenti 9, I-40138 Bologna, Italy; [Fornari, F.] Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Biomed & Appl Res Ctr, Bologna, Italy	University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Derenzini, M (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med, Via Massarenti 9, I-40138 Bologna, Italy.	massimo.derenzini@unibo.it	imbrogno, enrica/AAL-2342-2020; Montanaro, Lorenzo/I-4236-2019; Trere', Davide/AAC-4725-2021; Fornari, Francesca/K-6748-2016	Montanaro, Lorenzo/0000-0001-9776-9518; Trere', Davide/0000-0003-1127-1052; Fornari, Francesca/0000-0002-4302-4411; govoni, marzia/0000-0003-1673-0107; IMBROGNO, ENRICA/0000-0002-6375-9343	Roberto and Cornelia Pallotti's Legacy for Cancer Research; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG13480]	Roberto and Cornelia Pallotti's Legacy for Cancer Research; Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Roberto and Cornelia Pallotti's Legacy for Cancer Research and Associazione Italiana per la Ricerca sul Cancro (AIRC, grant number IG13480).	Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bland JM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3985; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Derenzini M, 2005, J CELL PHYSIOL, V202, P483, DOI 10.1002/jcp.20144; Derenzini M, 2000, MICRON, V31, P117, DOI 10.1016/S0968-4328(99)00067-0; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hu Wenwei, 2012, Genes Cancer, V3, P199, DOI 10.1177/1947601912454734; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Maggi LB, 2005, CANCER INVEST, V23, P599, DOI 10.1080/07357900500283085; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Oskarsson T, 2005, NAT CELL BIOL, V7, P215, DOI 10.1038/ncb0305-215; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Poortinga G, 2015, ONCOGENE, V34, P403, DOI 10.1038/onc.2014.13; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sax Joanna K, 2003, Methods Mol Biol, V234, P65; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	55	34	36	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					977	989		10.1038/onc.2015.147	http://dx.doi.org/10.1038/onc.2015.147			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961931				2022-12-28	WOS:000370823300004
J	Ahronian, LG; Zhu, LJ; Chen, YW; Chu, HC; Klimstra, DS; Lewis, BC				Ahronian, L. G.; Zhu, L. J.; Chen, Y-W; Chu, H-C; Klimstra, D. S.; Lewis, B. C.			A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination	ONCOGENE			English	Article							PROSTATE-CANCER PROGRESSION; NUCLEOTIDE EXCHANGE FACTOR; TUMOR-SUPPRESSOR GENE; RECURRENT MUTATIONS; DOWN-REGULATION; MOUSE MODEL; METASTASIS; EXPRESSION; RECEPTOR; P53	The presence of invasion into the extra-hepatic portion of the portal vein or the development of distant metastases renders hepatocellular carcinoma (HCC) patients ineligible for the only potential curative options for this malignancy-tumor resection or organ transplantation. Gene expression profiling of murine HCC cell lines identified KLF6 as a potential regulator of HCC cell migration. KLF6 knockdown increases cell migration, consistent with the correlation between decreased KLF6 mRNA levels and the presence of vascular invasion in human HCC. Concordantly, single-copy deletion of Klf6 in a HCC mouse model results in increased tumor formation, increased metastasis to the lungs and decreased survival, indicating that KLF6 suppresses both HCC development and metastasis. By combining gene expression profiling and chromatin immunoprecipitation coupled to deep sequencing, we identified novel transcriptional targets of KLF6 in HCC cells including VAV3, a known activator of the RAC1 small GTPase. Indeed, RAC1 activity is increased in KLF6-knockdown cells in a VAV3-dependent manner, and knockdown of either RAC1 or VAV3 impairs HCC cell migration. Together, our data demonstrate a novel function for KLF6 in constraining HCC dissemination through the regulation of a VAV3-RAC1 signaling axis.	[Ahronian, L. G.; Zhu, L. J.; Lewis, B. C.] Univ Massachusetts, Dept Mol Cell & Canc Biol, Sch Med, 364 Plantat St,LRB 521, Worcester, MA 01605 USA; [Zhu, L. J.; Lewis, B. C.] Univ Massachusetts, Program Mol Med, Sch Med, Worcester, MA 01605 USA; [Zhu, L. J.] Univ Massachusetts, Program Bioinformat & Integrat Biol, Sch Med, Worcester, MA 01605 USA; [Chen, Y-W; Chu, H-C] Natl Hlth Res Inst, Natl Inst Canc Res, Maioli, Taiwan; [Klimstra, D. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Lewis, B. C.] Univ Massachusetts, Canc Ctr, Sch Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Health Research Institutes - Taiwan; Memorial Sloan Kettering Cancer Center; University of Massachusetts System; University of Massachusetts Worcester	Lewis, BC (corresponding author), Univ Massachusetts, Dept Mol Cell & Canc Biol, Sch Med, 364 Plantat St,LRB 521, Worcester, MA 01605 USA.	Brian.Lewis@umassmed.edu		Zhu, Lihua/0000-0001-7416-0590	NIH grant [R01 CA121171]; NATIONAL CANCER INSTITUTE [R01CA121171, P30CA008748] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Genentech for sharing Klf6<SUP>flox</SUP> mice; Scott Friedman for providing the Klf6<SUP>flox</SUP> mice and sharing data before publication. We thank JiuFeng Cai and Victor Adelanwa for technical assistance; Dr Kerry Burnstein for providing the VAV3 expression constructs; Karl Simin, Leslie Shaw, Scot Wolfe and members of the Lewis lab for helpful discussions and critical review of the manuscript. The assistance of the Memorial Sloan-Kettering Cancer Center Genomics Core and the University of Massachusetts Medical School Genomics and Deep Sequencing core facilities is gratefully acknowledged. This study was supported by NIH grant R01 CA121171 to BCL. The funders played no role in the design, execution or interpretation of the study.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Chen YW, 2007, CANCER RES, V67, P7589, DOI 10.1158/0008-5472.CAN-07-0381; Chen YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069389; Chen YW, 2009, NEOPLASIA, V11, P835, DOI 10.1593/neo.09476; Das A, 2006, J BIOL CHEM, V281, P39105, DOI 10.1074/jbc.M607720200; Difeo A, 2006, ONCOGENE, V25, P6026, DOI 10.1038/sj.onc.1209611; Ding J, 2010, NAT CELL BIOL, V12, P390, DOI 10.1038/ncb2039; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Gehrau RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008929; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hatami R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004688; Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Iizuka N, 2004, ANTICANCER RES, V24, P4085; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; IZUMI R, 1992, J SURG ONCOL, V49, P151, DOI 10.1002/jso.2930490305; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236; Katyal S, 2000, RADIOLOGY, V216, P698, DOI 10.1148/radiology.216.3.r00se24698; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Kremer-Tal S, 2007, J HEPATOL, V46, P645, DOI 10.1016/j.jhep.2006.10.012; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Leow CC, 2009, J BIOL CHEM, V284, P21057, DOI 10.1074/jbc.M109.001776; Lewis BC, 2005, MOL CELL BIOL, V25, P1228, DOI 10.1128/MCB.25.4.1228-1237.2005; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; Lin KT, 2012, CANCER RES, V72, P3000, DOI 10.1158/0008-5472.CAN-11-2502; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Narla G, 2008, J CLIN INVEST, V118, P2711, DOI 10.1172/JCI34780; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Tan BB, 2014, TUMOR BIOL, V35, P1481, DOI 10.1007/s13277-013-1204-2; Tarocchi M, 2011, HEPATOLOGY, V54, P522, DOI 10.1002/hep.24413; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vetter D, 2012, HEPATOLOGY, V56, P1361, DOI 10.1002/hep.25810; Villanueva A, 2011, J HEPATOL, V55, P724, DOI 10.1016/j.jhep.2011.03.018; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zheng Q, 2008, NUCLEIC ACIDS RES, V36, pW358, DOI 10.1093/nar/gkn276; Zhou X, 2008, INT J ONCOL, V32, P1285; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237	52	21	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4653	4662		10.1038/onc.2016.2	http://dx.doi.org/10.1038/onc.2016.2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26876204	Green Accepted			2022-12-28	WOS:000382336300011
J	Yan, H; Tang, G; Wang, H; Hao, L; He, T; Sun, X; Ting, AH; Deng, A; Sun, S				Yan, H.; Tang, G.; Wang, H.; Hao, L.; He, T.; Sun, X.; Ting, A. H.; Deng, A.; Sun, S.			DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment	ONCOGENE			English	Article							MUCINOUS HISTOLOGY PREDICTS; METASTATIC COLON-CANCER; GAMMA-AMINOBUTYRIC-ACID; COLORECTAL-CANCER; GENE-EXPRESSION; AIRWAY EPITHELIUM; INDUCED APOPTOSIS; BINDING REGIONS; PROTEINS; SURVIVAL	Levels of gamma-aminobutyric acid (GABA) and glutamic acid decarboxylase 1 (GAD1), the enzyme that synthesizes GABA, are significantly increased in neoplastic tissues. However, the mechanism underlying this increase remains elusive. Instead of silencing gene transcription, we showed that the GAD1 promoter was hypermethylated in both colon and liver cancer cells, leading to the production of high levels of GAD1. GAD1 is a target gene that is silenced by H3K27me3. The key locus responsible for GAD1 reactivation was mapped to a DNA methylation-sensitive CTCF-binding site (CTCF-BS3) within the third intron of GAD1. Chromosome configuration capture (3C) analysis indicated that an intrachromosomal loop was formed by CTCF self-dimerisation in normal cells (CTCF binds to both unmethylated CTCF-BS3 and CTCF-BS2). The CTCF dimer then interacted with suppressor of zeste 12 homologue (SUZ12), which is a domain of Polycomb repressive complex 2 (PRC2), promoting the methylation of H3K27 and the silencing of GAD1 expression. This silencing was shown to be inhibited by DNA methylation in cancer cells. These findings strongly suggest that GAD1 is reactivated by DNA methylation, which provided a model for DNA methylation and the active orchestration of oncogenic gene expression by CTCF in cancer cells.	[Yan, H.; Sun, X.; Deng, A.] Second Mil Med Univ, Changhai Hosp, Dept Lab Med, 168 Changhai Rd, Shanghai 200433, Peoples R China; [Tang, G.; Sun, S.] Second Mil Med Univ, Inst Genet, Shanghai, Peoples R China; [Wang, H.; Hao, L.] Second Mil Med Univ, Changhai Hosp, Dept Colorectal Surg, Shanghai, Peoples R China; [He, T.] Second Mil Med Univ, Changhai Hosp, Div Hepatopancreatobiliary Surg, Shanghai, Peoples R China; [Ting, A. H.] Cleveland Clin Fdn, Genom Med Inst, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA	Naval Medical University; Naval Medical University; Naval Medical University; Naval Medical University; Cleveland Clinic Foundation	Yan, H; Deng, A; Sun, S (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Lab Med, 168 Changhai Rd, Shanghai 200433, Peoples R China.	hongliyan@smmu.edu.cn; amdeng70@163.com; shsun@vip.sina.com			National Natural Science Foundation of China Shanghai Pujiang Outstanding Young Scientist Project [81071680, 81272280, 81172307]	National Natural Science Foundation of China Shanghai Pujiang Outstanding Young Scientist Project	This work was supported by grants from the National Natural Science Foundation of China (grants no. 81071680, 81272280, 81172307) Shanghai Pujiang Outstanding Young Scientist Project.	Andang M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488; Azuma H, 2003, CANCER RES, V63, P8090; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Catalano V, 2009, BRIT J CANCER, V100, P881, DOI 10.1038/sj.bjc.6604955; Cotter PD, 2001, MOL MICROBIOL, V40, P465, DOI 10.1046/j.1365-2958.2001.02398.x; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Du WB, 2004, DIS COLON RECTUM, V47, P78, DOI 10.1007/s10350-003-0014-9; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Euskirchen GM, 2007, GENOME RES, V17, P898, DOI 10.1101/gr.5583007; Fu XW, 2011, AM J RESP CELL MOL, V44, P222, DOI 10.1165/rcmb.2010-0109OC; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Ha M, 2011, GENOME RES, V21, P590, DOI 10.1101/gr.116467.110; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hernandez A, 2012, CURR PHARM DESIGN, V18, P1317, DOI 10.2174/138161212799504894; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Huang HS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000809; Huerta S, 2003, INT J ONCOL, V22, P663; Jaraj SJ, 2011, SCAND J UROL NEPHROL, V45, P39, DOI 10.3109/00365599.2010.521189; JOH TH, 1985, FED PROC, V44, P2773; Jorissen RN, 2008, CLIN CANCER RES, V14, P8061, DOI 10.1158/1078-0432.CCR-08-1431; Kim BN, 2005, INT J ONCOL, V26, P1217; Kimura R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-555; Kobayashi T, 2003, BBA-GENE STRUCT EXPR, V1628, P156, DOI 10.1016/S0167-4781(03)00138-6; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204; Leopoldo S, 2008, ANN SURG ONCOL, V15, P1429, DOI 10.1245/s10434-007-9757-1; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08; Maemura K, 2003, J GASTROEN HEPATOL, V18, P1089, DOI 10.1046/j.1440-1746.2003.03131.x; Maisano R, 2012, J CHEMOTHERAPY, V24, P212, DOI 10.1179/1973947812Y.0000000013; Matuszek M, 2001, Med Sci Monit, V7, P377; Negri FV, 2005, ANN ONCOL, V16, P1305, DOI 10.1093/annonc/mdi244; Nozoe T, 2000, J SURG ONCOL, V75, P103, DOI 10.1002/1096-9098(200010)75:2<103::AID-JSO6>3.3.CO;2-3; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Ren LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031416; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125; Rodriguez C, 2010, BIOCHEM BIOPH RES CO, V392, P129, DOI 10.1016/j.bbrc.2009.12.159; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Stuhmer T, 2002, CEREB CORTEX, V12, P75, DOI 10.1093/cercor/12.1.75; Wang ZH, 2009, METHODS MOL BIOL, V567, P87, DOI 10.1007/978-1-60327-414-2_6; West AG, 2004, MOL CELL, V16, P453, DOI 10.1016/j.molcel.2004.10.005; Xiang YY, 2007, NAT MED, V13, P862, DOI 10.1038/nm1604; Xu YM, 2012, GENOME RES, V22, P283, DOI 10.1101/gr.122788.111; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Zhang JW, 2016, GUT, V65, P1482, DOI 10.1136/gutjnl-2014-308614	50	20	20	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3995	4008		10.1038/onc.2015.423	http://dx.doi.org/10.1038/onc.2015.423			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26549033				2022-12-28	WOS:000381013100011
J	Saran, S; Tran, DDH; Ewald, F; Koch, A; Hoffmann, A; Koch, M; Nashan, B; Tamura, T				Saran, S.; Tran, D. D. H.; Ewald, F.; Koch, A.; Hoffmann, A.; Koch, M.; Nashan, B.; Tamura, T.			Depletion of three combined THOC5 mRNA export protein target genes synergistically induces human hepatocellular carcinoma cell death	ONCOGENE			English	Article							INTERACTING PROTEIN; TREX COMPLEX; FMIP; TRANSCRIPTION; CONTRIBUTES; KINASES; MEMBER	Hepatocellular carcinoma (HCC) is a frequent form of cancer with a poor prognosis and with limited possibilities of medical intervention. It has been shown that over 100 putative driver genes are associated with multiple recurrently altered pathways in HCC, suggesting that multiple pathways will need to be inhibited for any therapeutic method. mRNA processing is regulated by a complex RNA-protein network that is essential for the maintenance of homeostasis. THOC5, a member of mRNA export complex, has a role in less than 1% of mRNA processing, and is required for cell growth and differentiation, but not for cell survival in normal fibroblasts, hepatocytes and macrophages. In this report, we show that 50% depletion of THOC5 in human HCC cell lines Huh7 and HepG2 induced apoptosis. Transcriptome analysis using THOC5-depleted cells revealed that 396 genes, such as transmembrane BAX inhibitor motif containing 4 (TMBIM4), transmembrane emp24-like trafficking protein 10 (Tmed10) and D-tyrosyl-tRNA deacylase 2 (Dtd2) genes were downregulated in both cell lines. The depletion of one of these THOC5 target genes in Huh7 or HepG2 did not significantly induce cell death, suggesting that these may be fine tuners for HCC cell survival. However, the depletion of a combination of these genes synergistically increased the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling)-positive HCC. It must be noted that the depletion of these genes did not induce cell death in the hepatocyte cell line, THLE-2 cells. THOC5 expression was enhanced in 78% of cytological differentiation grading G2 and G3 tumor in primary HCC. Furthermore, the expression of a putative glycoprotein, Tmed10, is correlated to THOC5 expression level in primary HCCs, suggesting that this protein may be a novel biomarker for HCC. These data imply that the suppression of the multiple THOC5 target genes may represent a novel strategy for HCC therapy.	[Saran, S.; Tran, D. D. H.; Koch, A.; Tamura, T.] Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany; [Ewald, F.; Koch, M.; Nashan, B.] Univ Med Ctr Eppendorf, Dept Hepatobiliary & Transplant Surg, Hamburg, Germany; [Hoffmann, A.] Hannover Med Sch, Klin Orthopadie, OE8893, Hannover, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	Tamura.Teruko@MH-Hannover.de	Tran, Doan Duy Hai/AGU-7573-2022; Hoffmann, Andrea/AAG-4488-2020; Koch, Martina/AAJ-6611-2020; Nashan, Björn/H-9087-2019	Tran, Doan Duy Hai/0000-0003-2392-0259; Hoffmann, Andrea/0000-0003-2318-8985; Nashan, Björn/0000-0001-7587-9935	Deutsche Krebshilfe [111153]; DFG [Ta-111/13-1]; PhD program Molecular Medicine; Leistungsorientierte Mittelvergabe	Deutsche Krebshilfe(Deutsche Krebshilfe); DFG(German Research Foundation (DFG)); PhD program Molecular Medicine; Leistungsorientierte Mittelvergabe	We thank C Bruce Boschek for critically reading the manuscript and Iris Albers and Annika Hamm for technical assistance. SS and DDHT contributed equally to this work. This research was supported by Deutsche Krebshilfe (111153), DFG Ta-111/13-1, and PhD program Molecular Medicine and Leistungsorientierte Mittelvergabe with Frauenfaktor from MHH.	Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Corkery DP, 2015, NUCLEUS-PHILA, V6, P279, DOI 10.1080/19491034.2015.1062194; Tran DDH, 2014, NUCLEIC ACIDS RES, V42, P12249, DOI 10.1093/nar/gku911; Ferrin G, 2015, HEPATIC MED-EVID RES, V7, P1, DOI 10.2147/HMER.S50161; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Griaud F, 2013, LEUKEMIA, V27, P932, DOI 10.1038/leu.2012.283; Gubser C, 2007, PLOS PATHOG, V3, P246, DOI 10.1371/journal.ppat.0030017; Guria A, 2011, RNA, V17, P1048, DOI 10.1261/rna.2607011; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Jimeno Sonia, 2010, Journal of Biology (London), V8, P6, DOI 10.1186/jbiol217; Koch A, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0073-7; Maguire SL, 2015, J PATHOL, V235, P571, DOI 10.1002/path.4483; Mancini A, 2007, ONCOGENE, V26, P1020, DOI 10.1038/sj.onc.1209853; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; Mancini A, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-1; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Panagopoulos I, 2014, INT J ONCOL, V45, P1829, DOI 10.3892/ijo.2014.2605; Pierce A, 2008, BRIT J HAEMATOL, V141, P641, DOI 10.1111/j.1365-2141.2008.07090.x; Rehwinkel J, 2004, NAT STRUCT MOL BIOL, V11, P558, DOI 10.1038/nsmb759; Saran S, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-51; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Tran DDH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.409; Tran DDH, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-3; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236	27	13	14	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3872	3879		10.1038/onc.2015.433	http://dx.doi.org/10.1038/onc.2015.433			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26549021				2022-12-28	WOS:000380753200012
J	Manda, KR; Tripathi, P; Hsi, AC; Ning, J; Ruzinova, MB; Liapis, H; Bailey, M; Zhang, H; Maher, CA; Humphrey, PA; Andriole, GL; Ding, L; You, Z; Chen, F				Manda, K. R.; Tripathi, P.; Hsi, A. C.; Ning, J.; Ruzinova, M. B.; Liapis, H.; Bailey, M.; Zhang, H.; Maher, C. A.; Humphrey, P. A.; Andriole, G. L.; Ding, L.; You, Z.; Chen, F.			NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence	ONCOGENE			English	Article							CELL-PROLIFERATION; CANCER PROGRESSION; C-MYC; ACTIVATION; EXPRESSION; INVASION; STAT3; OSTEOCLASTOGENESIS; INTERLEUKIN-6; INFLAMMATION	Despite recent insights into prostate cancer (PCa)-associated genetic changes, full understanding of prostate tumorigenesis remains elusive owing to complexity of interactions among various cell types and soluble factors present in prostate tissue. We found the upregulation of nuclear factor of activated T cells c1 (NFATc1) in human PCa and cultured PCa cells, but not in normal prostates and non-tumorigenic prostate cells. To understand the role of NFATc1 in prostate tumorigenesis in situ, we temporally and spatially controlled the activation of NFATc1 in mouse prostate and showed that such activation resulted in prostatic adenocarcinoma with features similar to those seen in human PCa. Our results indicate that the activation of a single transcription factor, NFATc1 in prostatic luminal epithelium to PCa can affect expression of diverse factors in both cells harboring the genetic changes and in neighboring cells through microenvironmental alterations. In addition to the activation of oncogenes c-MYC and STAT3 in tumor cells, a number of cytokines and growth factors, such as IL1 beta, IL6 and SPP1 ( osteopontin, a key biomarker for PCa), were upregulated in NFATc1-induced PCa, establishing a tumorigenic microenvironment involving both NFATc1 positive and negative cells for prostate tumorigenesis. To further characterize interactions between genes involved in prostate tumorigenesis, we generated mice with both NFATc1 activation and Pten inactivation in prostate. We showed that NFATc1 activation led to acceleration of Pten null-driven prostate tumorigenesis by overcoming the PTEN loss-induced cellular senescence through inhibition of p21 activation. This study provides direct in vivo evidence of an oncogenic role of NFATc1 in prostate tumorigenesis and reveals multiple functions of NFATc1 in activating oncogenes, in inducing proinflammatory cytokines, in oncogene addiction, and in overcoming cellular senescence, which suggests calcineurin-NFAT signaling as a potential target in preventing PCa.	[Manda, K. R.; Ning, J.; Maher, C. A.; Ding, L.; Chen, F.] Washington Univ, Sch Med, Dept Med, Campus Box 8126,660 S Euclid Ave, St Louis, MO 63110 USA; [Tripathi, P.; Ruzinova, M. B.; Liapis, H.] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA; [Hsi, A. C.; Ning, J.; Bailey, M.; Maher, C. A.; Ding, L.] Washington Univ, Genome Inst, St Louis, MO USA; [Zhang, H.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA; [Maher, C. A.; Andriole, G. L.; Ding, L.; Chen, F.] Washington Univ, Siteman Canc Ctr, St Louis, MO USA; [Humphrey, P. A.] Yale Univ, Dept Pathol, New Haven, CT USA; [Andriole, G. L.] Washington Univ, Dept Surg, St Louis, MO USA; [You, Z.] Tulane Univ, Dept Struct & Cellular Biol, New Orleans, LA 70118 USA; [Chen, F.] Washington Univ, Dept Cell Biol & Physiol, St Louis, MO USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Massachusetts System; University of Massachusetts Worcester; Siteman Cancer Center; Washington University (WUSTL); Yale University; Washington University (WUSTL); Tulane University; Washington University (WUSTL)	Chen, F (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8126,660 S Euclid Ave, St Louis, MO 63110 USA.	fchen@dom.wustl.edu		Bailey, Matthew H./0000-0003-4526-9727	DoD [PC130118]; NIH [DK087960, R01CA174714, R01CA180006, R01CA178383, U01HG006517]; NATIONAL CANCER INSTITUTE [R01CA178383, R01CA174714, R01CA180006] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG006517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087960] Funding Source: NIH RePORTER	DoD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Gerald Crabtree and Minggui Pan for providing the TetO-NFATc1<SUP>Nuc</SUP> mice. FC is supported in part by grants from DoD (PC130118) and NIH (DK087960). ZY is supported in part by NIH R01CA174714. LD is supported in part by grants from NIH (R01CA180006, R01CA178383 and U01HG006517).	Alberti C, 2008, EUR REV MED PHARMACO, V12, P167; Arredouani MS, 2009, CLIN CANCER RES, V15, P5794, DOI 10.1158/1078-0432.CCR-09-0911; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Carnero A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00252; Culig Z, 2014, AM J CLIN EXP UROL, V2, P231; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Foldynova-Trantirkova S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2581; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Huang HH, 2012, BIOCHEM BIOPH RES CO, V418, P186, DOI 10.1016/j.bbrc.2012.01.004; JANIK P, 1975, CANCER RES, V35, P3698; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang JF, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1015; Karlou M, 2010, NAT REV UROL, V7, P494, DOI 10.1038/nrurol.2010.134; Kavitha CV, 2014, MOL CARCINOGEN, V53, P169, DOI 10.1002/mc.21959; Kawahara T, 2015, PROSTATE, V75, P573, DOI 10.1002/pros.22937; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Lagunas L, 2009, J CELL BIOCHEM, V108, P237, DOI 10.1002/jcb.22245; Lee SJ, 2003, J MOL BIOL, V330, P749, DOI 10.1016/S0022-2836(03)00640-5; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; McCormick F, 2011, J SURG ONCOL, V103, P464, DOI 10.1002/jso.21749; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Nguyen DP, 2014, BJU INT, V113, P986, DOI 10.1111/bju.12452; Nilsson-Berglund LM, 2010, ARTERIOSCL THROM VAS, V30, P218, DOI 10.1161/ATVBAHA.109.199299; Ortega-Molina A, 2013, TRENDS ENDOCRIN MET, V24, P184, DOI 10.1016/j.tem.2012.11.002; Pan MG, 2013, CURR MOL MED, V13, P543; Pan MG, 2007, J IMMUNOL, V178, P4315, DOI 10.4049/jimmunol.178.7.4315; Phin S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00240; Rafiei S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-605; Robbs BK, 2008, MOL CELL BIOL, V28, P7168, DOI 10.1128/MCB.00256-08; Suzman DL, 2014, THER ADV MED ONCOL, V6, P167, DOI 10.1177/1758834014529176; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Tripathi P, 2014, ONCOGENE, V33, P1840, DOI 10.1038/onc.2013.132; Vincent AJ, 2012, FEBS LETT, V586, P3429, DOI 10.1016/j.febslet.2012.07.063; Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253; Wei Z, 2013, CELL SIGNAL, V25, P931, DOI 10.1016/j.cellsig.2013.01.011; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yiu GK, 2011, BIOCHEM J, V440, P157, DOI 10.1042/BJ20110530; Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhang H, 2008, J CELL PHYSIOL, V215, P613, DOI 10.1002/jcp.21337; Zhao D, 2014, ONCOGENE, V34, P107	46	28	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3282	3292		10.1038/onc.2015.389	http://dx.doi.org/10.1038/onc.2015.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477312	Green Accepted			2022-12-28	WOS:000378306400007
J	Su, Y; Li, J; Shi, C; Hruban, RH; Radice, GL				Su, Y.; Li, J.; Shi, C.; Hruban, R. H.; Radice, G. L.			N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN	ONCOGENE			English	Article							CONTACT INHIBITION; MESENCHYMAL TRANSITION; PANCREATIC-CANCER; SIGNALING-PATHWAY; PROLIFERATION; EXPRESSION; KI-RAS(G12V); INSTABILITY; SURVIVAL	Cadherin subtype switching from E-cadherin to N-cadherin is associated with the epithelial-to-mesenchymal transition (EMT), a process required for invasion and dissemination of carcinoma cells. We found that N-cadherin is expressed in human and mouse pancreatic intraepithelial neoplasia (PanIN), suggesting that N-cadherin may also have a role in early-stage pancreatic cancer. To investigate the role of N-cadherin in mouse PanIN (mPanIN), we simultaneously activated oncogenic K-ras(G12D) and deleted the N-cadherin (Cdh2) gene in the murine pancreas. Genetic ablation of N-cadherin (N-cad KO) caused hyperproliferation, accelerated mPanIN progression, and early tumor development in K-ras(G12D) mice. Decreased E-cadherin and redistribution of beta-catenin accompanied the loss of N-cadherin in pancreatic ductal epithelial cells (PDEC). Nuclear accumulation of beta-catenin and its transcription co-activator Tcf4 led to activation of Wnt/beta-catenin target genes. Unexpectedly, loss of N-cadherin in the K-rasG12D model resulted in increased mPanIN progression and tumor incidence. These in vivo results demonstrate for the first time that N-cadherin functions as a growth suppressor in the context of oncogenic K-ras.	[Su, Y.; Li, J.; Radice, G. L.] Thomas Jefferson Univ, Ctr Translat Med, Dept Med, Suite 543E Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA; [Shi, C.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Shi, C.; Hruban, R. H.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD USA; [Shi, C.; Hruban, R. H.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD USA; [Su, Y.] Fox Chase Canc Ctr, Breast Canc Res Lab, 7701 Burholme Ave, Philadelphia, PA 19111 USA	Jefferson University; Vanderbilt University; Johns Hopkins University; Johns Hopkins University; Fox Chase Cancer Center	Radice, GL (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Med Coll, Ctr Translat Med, Dept Med, Suite 543E Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	glenn.radice@jefferson.edu			NCI Cancer Center [P30 CA56036]; NIH [R21 CA176097]; SPORE grant [CA62924]; NATIONAL CANCER INSTITUTE [P30CA056036, P50CA062924, R21CA176097] Funding Source: NIH RePORTER	NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SPORE grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Frans van Roy, Anil Rustgi and Jennifer Wilson for comments. We thank David Tuveson for the LSL-K-ras<SUP>G12D</SUP> mice, Andrew Lowy for the Pdx1/Cre mice and Michael Goggins for the PanIN microarrays. We are grateful to Mathew Thakur for assistance with PET imaging, and Han Du, Craig Riley and David Kurz for technical assistance. Research in this study includes work carried out by the Jefferson Kimmel Cancer Center Small Animal Imaging Facility, which is supported in part by NCI Cancer Center Support Grant P30 CA56036. This work was supported by NIH R21 CA176097 (GR). This study was also supported by the SPORE grant CA62924 (RH).	Agbunag C, 2004, CANCER RES, V64, P5659, DOI 10.1158/0008-5472.CAN-04-0807; Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Deramaudt TB, 2006, MOL CELL BIOL, V26, P4185, DOI 10.1128/MCB.01055-05; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Gavard J, 2004, J BIOL CHEM, V279, P36795, DOI 10.1074/jbc.M401705200; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Johansson JK, 2010, GENESIS, V48, P374, DOI 10.1002/dvg.20628; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Kostetskii I, 2005, CIRC RES, V96, P346, DOI 10.1161/01.RES.0000156274.72390.2c; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Li JF, 2015, CIRC RES, V116, P70, DOI 10.1161/CIRCRESAHA.116.304472; Luo Y, 2005, DEV DYNAM, V232, P336, DOI 10.1002/dvdy.20241; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; McClatchey AI, 2012, CURR OPIN CELL BIOL, V24, P685, DOI 10.1016/j.ceb.2012.06.009; Mui KL, 2015, CELL REP, V10, P1477, DOI 10.1016/j.celrep.2015.02.023; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Qian X, 2014, ONCOGENE, V33, P3411, DOI 10.1038/onc.2013.310; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Shintani Y, 2006, CANCER RES, V66, P11745, DOI 10.1158/0008-5472.CAN-06-2322; Su Y, 2012, ONCOGENE, V31, P4484, DOI 10.1038/onc.2011.574; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Zhang YQ, 2013, CANCER RES, V73, P4909, DOI 10.1158/0008-5472.CAN-12-4384	33	18	18	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3335	3341		10.1038/onc.2015.382	http://dx.doi.org/10.1038/onc.2015.382			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477318	Green Accepted			2022-12-28	WOS:000378306400012
J	Taki, K; Ohmuraya, M; Tanji, E; Komatsu, H; Hashimoto, D; Semba, K; Araki, K; Kawaguchi, Y; Baba, H; Furukawa, T				Taki, K.; Ohmuraya, M.; Tanji, E.; Komatsu, H.; Hashimoto, D.; Semba, K.; Araki, K.; Kawaguchi, Y.; Baba, H.; Furukawa, T.			GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm	ONCOGENE			English	Article							FREQUENT GNAS MUTATIONS; STIMULATORY G-PROTEIN; ACTIVATING MUTATIONS; ADENOMA; ALPHA; GSP	Intraductal papillary mucinous neoplasm (IPMN), the most common pancreatic cystic neoplasm, is known to progress to invasive ductal adenocarcinoma. IPMNs commonly harbor activating somatic mutations in GNAS and KRAS, primarily GNAS(R201H) and KRAS(G12D). GNAS encodes the stimulatory G-protein alpha subunit (Gs alpha) that mediates a stimulatory signal to adenylyl cyclase to produce cyclic adenosine monophosphate (cAMP), subsequently activating cAMP-dependent protein kinase A. The GNAS(R201H) mutation results in constitutive activation of Gs alpha. To study the potential role of GNAS in pancreatic tumorigenesis in vivo, we generated lines of transgenic mice in which the transgene consisted of Lox-STOP-Lox (LSL)-GNAS(R201H) under the control of the CAG promoter (Tg(CAG-LSL-GNAS)). These mice were crossed with pancreatic transcription factor 1a (Ptf1a)-Cre mice (Ptf1a(Cre/+)), generating Tg(CAG-LSL-GNAS); Ptf1a(Cre/+) mice. This mouse line showed elevated cAMP levels, small dilated tubular complex formation, loss of acinar cells and fibrosis in the pancreas; however, no macroscopic tumorigenesis was apparent by 2 months of age. We then crossed Tg(CAG-LSL-GNAS); Ptf1a(Cre/+) mice with LSL-Kras(G12D) mice, generating Tg(CAG-LSL-GNAS); LSL-Kras(G12D); Ptf1a(Cre/+) mice. We used these mice to investigate a possible cooperative effect of GNAS(R201H) and Kras(G12D) in pancreatic tumorigenesis. Within 5 weeks, Tg(CAG-LSL-GNAS); LSL-Kras(G12D); Ptf1a(Cre/+) mice developed a cystic tumor consisting of marked dilated ducts lined with papillary dysplastic epithelia in the pancreas, which closely mimicked the human IPMN. Our data strongly suggest that activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis, which recapitulates IPMN. Our mouse model may serve as a unique in vivo platform to find biomarkers and effective drugs for diseases associated with GNAS mutations.	[Taki, K.; Ohmuraya, M.; Semba, K.; Araki, K.] Kumamoto Univ, Inst Resource Dev & Anal, Kumamoto, Japan; [Taki, K.; Hashimoto, D.; Baba, H.] Kumamoto Univ, Dept Gastroenterol Surg, Kumamoto, Japan; [Tanji, E.; Komatsu, H.; Furukawa, T.] Tokyo Womens Med Univ, Inst Integrated Med Sci, Tokyo 1628666, Japan; [Kawaguchi, Y.] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto, Japan	Kumamoto University; Kumamoto University; Tokyo Women's Medical University; Kyoto University	Furukawa, T (corresponding author), Tokyo Womens Med Univ, Inst Integrated Med Sci, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.	furukawa.toru@twmu.ac.jp	Furukawa, Toru/AAF-5596-2021; Hashimoto, Daisuke/AAE-7134-2020	Furukawa, Toru/0000-0002-1083-2324; 	Ministry of Education, Culture, Sports, Science and Technology [26110003]; Japan Society for the Promotion of Science [24659167]; Grants-in-Aid for Scientific Research [25640052] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr David A Tuveson (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) for providing LSL-Kras<SUP>G12D</SUP> mouse, Dr Takeshi Tanaka and Dr Emiko Hayama (Department of Pediatric Cardiology, Tokyo Women's Medical University) for their work preparing the anti-Gs alpha antibody and Ms Yuko Fukuchi and Ms Michiyo Nakata (Institute of Resource Development and Analysis, Kumamoto University) for their technical assistance. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas, Ministry of Education, Culture, Sports, Science and Technology (26110003) to MO and a Grant-in-Aid for Challenging Exploratory Research, Japan Society for the Promotion of Science (24659167) to TF.	Adsay NV., 2010, PATHOLOGY GENETICS T, P304; Delaney D, 2009, MODERN PATHOL, V22, P718, DOI 10.1038/modpathol.2009.32; Dhanasekaran Danny N, 2006, Sci STKE, V2006, ppe31, DOI 10.1126/stke.3472006pe31; Fragoso MCBV, 1998, J CLIN ENDOCR METAB, V83, P2074, DOI 10.1210/jc.83.6.2074; Furukawa T, 2011, SCI REP-UK, V1, DOI 10.1038/srep00161; Furukawa T, 2011, GUT, V60, P509, DOI 10.1136/gut.2010.210567; Hata T, 2013, PANCREATOLOGY, V13, P615, DOI 10.1016/j.pan.2013.09.003; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Kalfa N, 2006, J UROLOGY, V176, P891, DOI 10.1016/j.juro.2006.04.023; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Komatsu H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087875; Kuboki Y, 2015, PANCREAS, V44, P227, DOI 10.1097/MPA.0000000000000253; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Matsubara A, 2013, J PATHOL, V229, P579, DOI 10.1002/path.4153; Matthaei H, 2014, AM J SURG PATHOL, V38, P360, DOI 10.1097/PAS.0000000000000117; Nishikawa G, 2013, BRIT J CANCER, V108, P951, DOI 10.1038/bjc.2013.47; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; Semba K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003204; Taniwaki T, 2005, DEV GROWTH DIFFER, V47, P163; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Yamada M, 2012, J PATHOL, V228, P113, DOI 10.1002/path.4012	22	52	54	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2407	2412		10.1038/onc.2015.294	http://dx.doi.org/10.1038/onc.2015.294			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26257060				2022-12-28	WOS:000376165000013
J	Xue, X; Yang, YA; Zhang, A; Fong, KW; Kim, J; Song, B; Li, S; Zhao, JC; Yu, J				Xue, X.; Yang, Y. A.; Zhang, A.; Fong, K-W; Kim, J.; Song, B.; Li, S.; Zhao, J. C.; Yu, J.			LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer	ONCOGENE			English	Article							LONG NONCODING RNAS; HUMAN PROSTATE-CANCER; ANDROGEN RECEPTOR; PROGNOSTIC MARKER; GENE-EXPRESSION; ESTROGEN; PROGRESSION; METASTASIS; BINDING; CELLS	Tamoxifen, an estrogen receptor (ER) antagonist, is the mainstay treatment of breast cancer and the development of resistance represents a major obstacle for a cure. Although long non-coding RNAs such as HOTAIR have been implicated in breast tumorigenesis, their roles in chemotherapy resistance remain largely unknown. In this study, we report that HOTAIR (HOX antisense intergenic RNA) is upregulated in tamoxifen-resistant breast cancer tissues compared to their primary counterparts. Mechanistically, HOTAIR is a direct target of ER-mediated transcriptional repression and is thus restored upon the blockade of ER signaling, either by hormone deprivation or by tamoxifen treatment. Interestingly, this elevated HOTAIR increases ER protein level and thus enhances ER occupancy on the chromatin and potentiates its downstream gene regulation. HOTAIR overexpression is sufficient to activate the ER transcriptional program even under hormone-deprived conditions. Functionally, we found that HOTAIR overexpression increases breast cancer cell proliferation, whereas its depletion significantly impairs cell survival and abolishes tamoxifen-resistant cell growth. In conclusion, the long non-coding RNA HOTAIR is directly repressed by ER and its upregulation promotes ligand-independent ER activities and contributes to tamoxifen resistance.	[Xue, X.] Guangzhou Med Univ, Ctr Canc, Div Thorac Surg, Guangzhou, Guangdong, Peoples R China; [Xue, X.; Yang, Y. A.; Zhang, A.; Fong, K-W; Kim, J.; Song, B.; Li, S.; Zhao, J. C.; Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA; [Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Guangzhou Medical University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	li, shangze/AAW-6317-2021; Kim, Jung/Q-7801-2016	Fong, Ka-wing/0000-0001-6995-0264; Yang, Angela/0000-0002-9868-7431; Kim, Jung/0000-0001-6274-2841	Office of the Provost; Northwestern University Information Technology; US Department of Defense [W81XWH-13-1-0319]; Research Scholar Award from the American Cancer Society [RSG-12-085-01]; National Institutes of Health Training Program in Oncogenesis and Developmental Biology [T32 CA080621]; National Institutes of Health/National Cancer Institute training grant [T32 CA009560]; NATIONAL CANCER INSTITUTE [T32CA080621, T32CA009560] Funding Source: NIH RePORTER	Office of the Provost; Northwestern University Information Technology; US Department of Defense(United States Department of Defense); Research Scholar Award from the American Cancer Society(American Cancer Society); National Institutes of Health Training Program in Oncogenesis and Developmental Biology; National Institutes of Health/National Cancer Institute training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Bioinformatic analysis was supported by the computational resources and staff contributions provided for the Quest high-performance computing facility at Northwestern University, which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. This work was supported by the the US Department of Defense W81XWH-13-1-0319 (to JY) and the Research Scholar Award RSG-12-085-01 (to JY) from the American Cancer Society. JK was supported in part by the National Institutes of Health Training Program in Oncogenesis and Developmental Biology (T32 CA080621), and YAY was supported in part by the National Institutes of Health/National Cancer Institute training grant T32 CA009560.	Bussemakers MJG, 1999, CANCER RES, V59, P5975; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Chisholm KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047998; Clarke R, 2001, PHARMACOL REV, V53, P25; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Lee GL, 2011, NAT REV UROL, V8, P123, DOI 10.1038/nrurol.2011.10; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sorensen KP, 2013, BREAST CANCER RES TR, V142, P529, DOI 10.1007/s10549-013-2776-7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Wu L, 2014, ONCOGENE, V33, P504, DOI 10.1038/onc.2012.602; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200	36	299	320	1	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2746	2755		10.1038/onc.2015.340	http://dx.doi.org/10.1038/onc.2015.340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364613	Green Accepted			2022-12-28	WOS:000377472700008
J	Goswami, MT; Reka, AK; Kurapati, H; Kaza, V; Chen, J; Standiford, TJ; Keshamouni, VG				Goswami, M. T.; Reka, A. K.; Kurapati, H.; Kaza, V.; Chen, J.; Standiford, T. J.; Keshamouni, V. G.			Regulation of complement-dependent cytotoxicity by TGF-beta-induced epithelial-mesenchymal transition	ONCOGENE			English	Article							TUMOR-CELLS; CANCER; EXPRESSION; PROTEINS; CD59; NEUTRALIZATION; MODULATION; RESISTANCE; PREDICTS; SURVIVAL	The process of epithelial-mesenchymal transition (EMT), in addition to being an initiating event for tumor metastasis, is implicated in conferring several clinically relevant properties to disseminating cancer cells. These include stem cell-like properties, resistance to targeted therapies and ability to evade immune surveillance. Enrichment analysis of gene expression changes during transforming growth factor-beta (TGF-beta)-induced EMT in lung cancer cells identified complement cascade as one of the significantly enriched pathway. Further analysis of the genes in the complement pathway revealed an increase in the expression of complement inhibitors and a decrease in the expression of proteins essential for complement activity. In this study, we tested whether EMT confers resistance to complement-dependent cytotoxicity (CDC) in lung cancer cells and promotes tumor progression. CD59 is a potent inhibitor of membrane attack complex that mediates complement-dependent cell lysis. We observed a significant increase in the CD59 expression on the surface of cells after TGF-beta-induced EMT. Furthermore, CD59 knockdown restored susceptibility of cells undergoing EMT to cetuximab-mediated CDC. TGF-beta-induced CD59 expression during EMT is dependent on Smad3 but not on Smad2. Chromatin immunoprecipitation analysis confirmed that Smad3 directly binds to the CD59 promoter. Stable knockdown of CD59 in A549 cells inhibited experimental metastasis. These results demonstrate that TGF-beta-induced EMT and CD59 expression confers an immune-evasive mechanism to disseminating tumor cells facilitating tumor progression. Together, our data demonstrates that CD59 inhibition may serve as an adjuvant to enhance the efficacy of antibody-mediated therapies, as well as to inhibit metastasis in lung cancer.	[Goswami, M. T.; Reka, A. K.; Kurapati, H.; Kaza, V.; Chen, J.; Standiford, T. J.; Keshamouni, V. G.] Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, 4062 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Keshamouni, VG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, 4062 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	vkeshamo@med.umich.edu		Keshamouni, Venkateshwar/0000-0003-1947-791X	NIH/NCI [CA132571-01]; Elizabeth A Crary Fund; NIH/NHLBI [HL097564]; NATIONAL CANCER INSTITUTE [R01CA132571] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123515, R01HL097564] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Elizabeth A Crary Fund; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research is funded by an NIH/NCI (CA132571-01) grant and the Elizabeth A Crary Fund to VGK and NIH/NHLBI HL097564 to TJS.	Corrales L, 2012, J IMMUNOL, V189, P4674, DOI 10.4049/jimmunol.1201654; Cragg MS, 2000, CELL DEATH DIFFER, V7, P48, DOI 10.1038/sj.cdd.4400627; Donin N, 2003, CLIN EXP IMMUNOL, V131, P254, DOI 10.1046/j.1365-2249.2003.02066.x; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; Ge XW, 2011, CLIN CANCER RES, V17, P6702, DOI 10.1158/1078-0432.CCR-11-0647; Hsu YF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-139; Hu WG, 2011, CANCER RES, V71, P2298, DOI 10.1158/0008-5472.CAN-10-3016; Jurianz K, 1999, IMMUNOPHARMACOLOGY, V42, P209, DOI 10.1016/S0162-3109(99)00006-5; Jurianz K, 1999, MOL IMMUNOL, V36, P929, DOI 10.1016/S0161-5890(99)00115-7; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Keshamouni VG, 2009, J PROTEOME RES, V8, P35, DOI 10.1021/pr8006478; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014; Kim WS, 1999, ANTICANCER RES, V19, P301; Kohler BA, 2011, JNCI-J NATL CANCER I, V103, P714, DOI 10.1093/jnci/djr077; Kong FM, 1999, CANCER-AM CANCER SOC, V86, P1712, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1712::AID-CNCR12>3.0.CO;2-V; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655; Markiewski MM, 2009, TRENDS IMMUNOL, V30, P286, DOI 10.1016/j.it.2009.04.002; Masszi A, 2004, AM J PATHOL, V165, P1955, DOI 10.1016/S0002-9440(10)63247-6; NISHIOKA K, 1976, ANN NY ACAD SCI, V276, P303, DOI 10.1111/j.1749-6632.1976.tb41656.x; Pasch MC, 1999, EUR J IMMUNOL, V29, P100, DOI 10.1002/(SICI)1521-4141(199901)29:01<100::AID-IMMU100>3.3.CO;2-I; Reka AK, 2014, CARCINOGENESIS, V35, P1292, DOI 10.1093/carcin/bgu041; Reka AK, 2011, J THORAC ONCOL, V6, P1784, DOI 10.1097/JTO.0b013e31822adfb0; Reka AK, 2010, MOL CANCER THER, V9, P3221, DOI 10.1158/1535-7163.MCT-10-0570; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Varsano S, 1998, CLIN EXP IMMUNOL, V113, P173; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Watson NFS, 2006, CANCER IMMUNOL IMMUN, V55, P973, DOI 10.1007/s00262-005-0055-0; Xu CL, 2005, PROSTATE, V62, P224, DOI 10.1002/pros.20134; Yan J, 2008, ADV EXP MED BIOL, V632, P159, DOI 10.1007/978-0-387-78952-1_12; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zavadil J, 2008, CANCER RES, V68, P9574, DOI 10.1158/0008-5472.CAN-08-2316; Zhao WP, 2009, ONCOL REP, V21, P1405, DOI 10.3892/or_00000368	38	37	39	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1888	1898		10.1038/onc.2015.258	http://dx.doi.org/10.1038/onc.2015.258			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148233	Green Accepted			2022-12-28	WOS:000374010300002
J	Khongkow, P; Gomes, AR; Gong, C; Man, EPS; Tsang, JWH; Zhao, F; Monteiro, LJ; Coombes, RC; Medema, RH; Khoo, US; Lam, EWF				Khongkow, P.; Gomes, A. R.; Gong, C.; Man, E. P. S.; Tsang, J. W-H; Zhao, F.; Monteiro, L. J.; Coombes, R. C.; Medema, R. H.; Khoo, U. S.; Lam, E. W-F			Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance	ONCOGENE			English	Article							EPIRUBICIN RESISTANCE; MICROTUBULE MOTORS; KINESIN; PROTEINS; CYTOKINESIS; EXPRESSION; FOXO3A; CELLS; INHIBITION; MECHANISMS	FOXM1 has been implicated in taxane resistance, but the molecular mechanism involved remains elusive. In here, we show that FOXM1 depletion can sensitize breast cancer cells and mouse embryonic fibroblasts into entering paclitaxel-induced senescence, with the loss of clonogenic ability, and the induction of senescence-associated beta-galactosidase activity and flat cell morphology. We also demonstrate that FOXM1 regulates the expression of the microtubulin-associated kinesin KIF20A at the transcriptional level directly through a Forkhead response element (FHRE) in its promoter. Similar to FOXM1, KIF20A expression is downregulated by paclitaxel in the sensitive MCF-7 breast cancer cells and deregulated in the paclitaxel-resistant MCF-7Tax(R) cells. KIF20A depletion also renders MCF-7 and MCF-7Tax(R) cells more sensitive to paclitaxel-induced cellular senescence. Crucially, resembling paclitaxel treatment, silencing of FOXM1 and KIF20A similarly promotes abnormal mitotic spindle morphology and chromosome alignment, which have been shown to induce mitotic catastrophe-dependent senescence. The physiological relevance of the regulation of KIF20A by FOXM1 is further highlighted by the strong and significant correlations between FOXM1 and KIF20A expression in breast cancer patient samples. Statistical analysis reveals that both FOXM1 and KIF20A protein and mRNA expression significantly associates with poor survival, consistent with a role of FOXM1 and KIF20A in paclitaxel action and resistance. Collectively, our findings suggest that paclitaxel targets the FOXM1-KIF20A axis to drive abnormal mitotic spindle formation and mitotic catastrophe and that deregulated FOXM1 and KIF20A expression may confer paclitaxel resistance. These findings provide insights into the underlying mechanisms of paclitaxel resistance and have implications for the development of predictive biomarkers and novel chemotherapeutic strategies for paclitaxel resistance.	[Khongkow, P.; Gomes, A. R.; Gong, C.; Zhao, F.; Monteiro, L. J.; Coombes, R. C.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England; [Gong, C.; Man, E. P. S.; Zhao, F.; Khoo, U. S.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Tsang, J. W-H] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	Imperial College London; University of Hong Kong; University of Hong Kong; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Khoo, Ui Soon/C-1345-2014; Khoo, Ui Soon/K-2041-2019; Khoo, Ui Soon/C-4293-2009; Lam, Eric W-F/AAW-8566-2020; Monteiro, Lara J/AAU-8518-2020	Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; Khongkow, Pasarat/0000-0003-3068-2412; Coombes, Raoul Charles/0000-0002-4811-1100; Medema, Rene/0000-0002-6754-0381	Cancer Research UK; Breast Cancer Campaign; Royal Thai Government Scholarships; Committee on Research and Conference Grants from the University of Hong Kong (CRCG) [201007176118]; MRC [MR/N012097/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish; Breast Cancer Campaign [2012MayPR070, 2012NovPhD016] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Royal Thai Government Scholarships; Committee on Research and Conference Grants from the University of Hong Kong (CRCG); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Breast Cancer Campaign	EW-F Lam, AR Gomes and RC Coombes were supported by grants from Cancer Research UK; EW-F Lam by grants from Breast Cancer Campaign; P Khongkow, from the Royal Thai Government Scholarships. US Khoo received funding from Committee on Research and Conference Grants from the University of Hong Kong (CRCG) (201007176118). We also thank Muhammad Zaini, Marios Poullas and Laura Bella for help with this work.	Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293; Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Cortes J, 2007, ONCOLOGIST, V12, P271, DOI 10.1634/theoncologist.12-3-271; Dean-Colomb W, 2008, SEMIN ONCOL, V35, pS31, DOI 10.1053/j.seminoncol.2008.02.008; Exertier P, 2013, ONCOTARGET, V4, P2302, DOI 10.18632/oncotarget.1490; Francis RE, 2009, INT J ONCOL, V35, P57, DOI 10.3892/ijo_00000313; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Kitagawa M, 2014, CELL REP, V7, P166, DOI 10.1016/j.celrep.2014.02.034; Kline-Smith SL, 2004, MOL CELL, V15, P317, DOI 10.1016/j.molcel.2004.07.012; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu J, 2013, REPROD BIOL ENDOCRIN, V11, DOI 10.1186/1477-7827-11-117; Misiukiewicz K, 2014, ANTI-CANCER DRUG, V25, P561, DOI 10.1097/CAD.0000000000000086; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Myatt SS, 2014, ONCOGENE, V33, P4316, DOI 10.1038/onc.2013.546; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Neef R, 2005, METHOD ENZYMOL, V403, P618, DOI 10.1016/S0076-6879(05)03054-5; Nguyen PA, 2014, SCIENCE, V346, P244, DOI 10.1126/science.1256773; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Okuyama R, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27010; Rohena CC, 2014, NAT PROD REP, V31, P335, DOI 10.1039/c3np70092e; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tcherniuk S, 2010, ANGEW CHEM INT EDIT, V49, P8228, DOI 10.1002/anie.201003254; Verhey KJ, 2009, NAT REV MOL CELL BIO, V10, P765, DOI 10.1038/nrm2782; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059	41	138	143	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					990	1002		10.1038/onc.2015.152	http://dx.doi.org/10.1038/onc.2015.152			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961928	Green Published, hybrid, Green Accepted, Green Submitted			2022-12-28	WOS:000370823300005
J	Balmus, G; Lim, PX; Oswald, A; Hume, KR; Cassano, A; Pierre, J; Hill, A; Huang, W; August, A; Stokol, T; Southard, T; Weiss, RS				Balmus, G.; Lim, P. X.; Oswald, A.; Hume, K. R.; Cassano, A.; Pierre, J.; Hill, A.; Huang, W.; August, A.; Stokol, T.; Southard, T.; Weiss, R. S.			HUS1 regulates in vivo responses to genotoxic chemotherapies	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-CYCLE CHECKPOINT; LUNG-CARCINOMA CELLS; STRAND BREAK REPAIR; ATAXIA-TELANGIECTASIA; GENOMIC INSTABILITY; MOUSE HUS1; CHROMOSOMAL FRAGMENTATION; TRANSLESION SYNTHESIS; SYNTHETIC LETHALITY	Cells are under constant attack from genotoxins and rely on a multifaceted DNA damage response (DDR) network to maintain genomic integrity. Central to the DDR are the ATM and ATR kinases, which respond primarily to double-strand DNA breaks (DSBs) and replication stress, respectively. Optimal ATR signaling requires the RAD9A-RAD1-HUS1 (9-1-1) complex, a toroidal clamp that is loaded at damage sites and scaffolds signaling and repair factors. Whereas complete ATR pathway inactivation causes embryonic lethality, partial Hus1 impairment has been accomplished in adult mice using hypomorphic (Hus1(neo)) and null (Hus1(Delta 1)) Hus1 alleles, and here we use this system to define the tissue- and cell type-specific actions of the HUS1-mediated DDR in vivo. Hus1(neo/Delta 1) mice showed hypersensitivity to agents that cause replication stress, including the crosslinking agent mitomycin C (MMC) and the replication inhibitor hydroxyurea, but not the DSB inducer ionizing radiation. Analysis of tissue morphology, genomic instability, cell proliferation and apoptosis revealed that MMC treatment caused severe damage in highly replicating tissues of mice with partial Hus1 inactivation. The role of the 9-1-1 complex in responding to MMC was partially ATR-independent, as a HUS1 mutant that was proficient for ATR-induced checkpoint kinase 1 phosphorylation nevertheless conferred MMC hypersensitivity. To assess the interplay between the ATM and ATR pathways in responding to replication stress in vivo, we used Hus1/Atm double mutant mice. Whereas Hus1(neo/neo) and Atm(-/-) single mutant mice survived low-dose MMC similar to wild-type controls, Hus1(neo/neo) Atm(-/-) double mutants showed striking MMC hypersensitivity, consistent with a model in which MMC exposure in the context of Hus1 dysfunction results in DSBs to which the ATM pathway normally responds. This improved understanding of the inter-dependency between two major DDR mechanisms during the response to a conventional chemotherapeutic illustrates how inhibition of checkpoint factors such as HUS1 may be effective for the treatment of ATM-deficient and other cancers.	[Balmus, G.; Lim, P. X.; Oswald, A.; Hume, K. R.; Cassano, A.; Pierre, J.; Hill, A.; Southard, T.; Weiss, R. S.] Cornell Univ, Dept Biomed Sci, T2-006C Vet Res Tower, Ithaca, NY 14853 USA; [Hume, K. R.] Cornell Univ, Dept Clin Sci, T2-006C Vet Res Tower, Ithaca, NY 14853 USA; [Huang, W.; August, A.] Cornell Univ, Dept Microbiol & Immunol, T2-006C Vet Res Tower, Ithaca, NY 14853 USA; [Stokol, T.] Cornell Univ, Dept Populat Med & Diagnost Sci, T2-006C Vet Res Tower, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University; Cornell University	Weiss, RS (corresponding author), Cornell Univ, Dept Biomed Sci, T2-006C Vet Res Tower, Ithaca, NY 14853 USA.	rsw26@cornell.edu	Huang, Weishan/J-3127-2014; Balmus, Gabriel/GZM-2145-2022; Balmus, Gabriel/G-3497-2017	Huang, Weishan/0000-0002-1330-1131; Balmus, Gabriel/0000-0003-2872-4468; Balmus, Gabriel/0000-0003-2872-4468; Lim, Pei Xin/0000-0001-5742-3539	National Institutes of Health [R01 CA108773]; Cornell University College of Veterinary Medicine Graduate Research Assistantship; Cornell University College of Veterinary Medicine Clinical Fellowship; National Center for Research Resources grant [S10RR023781]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cornell University College of Veterinary Medicine Graduate Research Assistantship; Cornell University College of Veterinary Medicine Clinical Fellowship; National Center for Research Resources grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Amy Lyndaker, Steve Jackson and Yaron Galanti for helpful discussions and comments on the manuscript; Natasha Karp for help with statistical analysis and the staff of the Cornell Lab Animal Services and CARE programs for excellent animal care. This work was supported by a National Institutes of Health grant R01 CA108773 to RSW; a Cornell University College of Veterinary Medicine Graduate Research Assistantship to GB; a Cornell University College of Veterinary Medicine Clinical Fellowship to KRH; and a National Center for Research Resources grant (S10RR023781) for instrumentation.	Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Bai HB, 2010, DNA REPAIR, V9, P478, DOI 10.1016/j.dnarep.2010.01.011; Balmus G, 2012, HUM MOL GENET, V21, P3408, DOI 10.1093/hmg/dds173; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartek J, 2012, NAT STRUCT MOL BIOL, V19, P5, DOI 10.1038/nsmb.2220; Brooks K, 2013, ONCOGENE, V32, P788, DOI 10.1038/onc.2012.72; Broustas CG, 2014, RADIAT RES, V181, P111, DOI 10.1667/RR13515.1; Broustas CG, 2012, J BIOL CHEM, V287, P41324, DOI 10.1074/jbc.M112.402784; Brown EJ, 2000, GENE DEV, V14, P397; Church D, 2014, NAT REV CANCER, V14, P440, DOI 10.1038/nrc3729; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cotta-Ramusino C, 2011, SCIENCE, V332, P1313, DOI 10.1126/science.1203430; De la Torre J, 2008, INT J GYNECOL PATHOL, V27, P24, DOI 10.1097/pgp.0b013e31812dfaef; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Ellisen LW, 2011, CANCER CELL, V19, P165, DOI 10.1016/j.ccr.2011.01.047; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Fokas E, 2014, CANCER TREAT REV, V40, P109, DOI 10.1016/j.ctrv.2013.03.002; Friedrich-Heineken F, 2005, J MOL BIOL, V353, P980, DOI 10.1016/j.jmb.2005.09.018; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Goodship J, 2000, AM J HUM GENET, V67, P498, DOI 10.1086/303023; Hall AB, 2014, ONCOTARGET, V5, P5674, DOI 10.18632/oncotarget.2158; Han L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-67; Helt CE, 2005, CELL CYCLE, V4, P529, DOI 10.4161/cc.4.4.1598; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jansen JG, 2007, MOL CELL, V28, P522, DOI 10.1016/j.molcel.2007.11.005; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeon Y, 2011, J BIOL CHEM, V286, P5414, DOI 10.1074/jbc.M110.189704; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kass EM, 2013, P NATL ACAD SCI USA, V110, P5564, DOI 10.1073/pnas.1216824110; Kawasumi M, 2011, P NATL ACAD SCI USA, V108, P13716, DOI 10.1073/pnas.1111378108; Kinzel B, 2005, CANCER, V94, P1808; Kottemann MC, 2013, NATURE, V493, P356, DOI 10.1038/nature11863; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levitt PS, 2007, MOL CELL BIOL, V27, P2189, DOI 10.1128/MCB.01763-06; Levitt PS, 2005, GENOMICS, V86, P212, DOI 10.1016/j.ygeno.2005.04.007; Liu QH, 2000, GENE DEV, V14, P1448; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Lyndaker AM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003320; Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765; Maniwa Y, 2005, CANCER-AM CANCER SOC, V103, P126, DOI 10.1002/cncr.20740; Marechal A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012716; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McKinnon PJ, 2007, ANNU REV GENOM HUM G, V8, P37, DOI 10.1146/annurev.genom.7.080505.115648; McKinnon PJ, 2012, ANNU REV PATHOL-MECH, V7, P303, DOI 10.1146/annurev-pathol-011811-132509; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; O'Driscoll M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012773; Origanti S, 2013, ONCOGENE, V32, P577, DOI 10.1038/onc.2012.84; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Schoppy DW, 2012, J CLIN INVEST, V122, P241, DOI 10.1172/JCI58928; Shiotani B, 2009, J CELL SCI, V122, P301, DOI 10.1242/jcs.035105; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Tang Y, 2012, CANCER BIOL THER, V13, P379, DOI 10.4161/cbt.19240; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang WS, 2006, J BIOL CHEM, V281, P20865, DOI 10.1074/jbc.M602289200; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Xu XJ, 2013, NUCLEIC ACIDS RES, V41, P10020, DOI 10.1093/nar/gkt810; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yazinski SA, 2009, P NATL ACAD SCI USA, V106, P21282, DOI 10.1073/pnas.0904965106; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zhu A, 2008, CANCER RES, V68, P1267, DOI 10.1158/0008-5472.CAN-07-2304	68	8	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					662	669		10.1038/onc.2015.118	http://dx.doi.org/10.1038/onc.2015.118			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915840				2022-12-28	WOS:000369548800013
J	Riley, MF; You, MJ; Multani, AS; Lozano, G				Riley, M. F.; You, M. J.; Multani, A. S.; Lozano, G.			Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma	ONCOGENE			English	Article							GENE-EXPRESSION; P53; MICE; TAP73; BCL-2; INACTIVATION; DELTA-NP73; LEUKEMIA; PATHWAY; ABSENCE	Many human tumors express high levels of the p53 inhibitor Mdm2, resulting from amplification of the Mdm2 locus or aberrant post-translational regulation of the Mdm2 protein. While the importance of Mdm2 in regulating p53 is clear, Mdm2 also has p53-independent roles. For example, overexpression of Mdm2 results in genomic instability in a p53-independent manner. In addition, Mdm2 has many additional binding partners, some of which, such as the tumor suppressor p73, have also been implicated in genomic instability. In this study, cells and tumors with Mdm2 overexpression and p73 loss exhibit increased genomic instability as compared with either alteration alone and cooperate in development of B-cell lymphomagenesis. Cytogenetic analysis of mouse embryonic fibroblasts and pre-malignant B cells demonstrates that loss of p73 exacerbates the chromosome breaks and fusions observed in Mdm2(Tg) cells. B-cell lymphomas from Mdm2(Tg);p73(+/-) mice retain the remaining p73 allele, exhibit elevated levels of the antiapoptotic protein Bcl2 and thus dampen apoptosis. In summary, Mdm2 overexpression and p73 loss cooperate in genomic instability and tumor development, indicating that the oncogenic function of Mdm2 is a combined effect of inhibiting p53 and p73 functions. Given that p73 is lost or silenced in human B-cell lymphomas, the Mdm2(Tg);p73(+/-) mouse serves as a model for human disease and may provide additional insight into the pathways that contribute to B-cell lymphomagenesis.	[Riley, M. F.; Multani, A. S.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd,Unit 1010, Houston, TX 77030 USA; [You, M. J.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd,Unit 1010, Houston, TX 77030 USA.	gglozano@mdanderson.org			National Institutes of Health [CA47296]; T32 Training Grant [CA009299]; American Cancer Society; NIH/NCI [R01 CA164346]; Center for Genetics and Genomics; Sister Institution Network fund of MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA164346, R29CA047296, R01CA047296, T32CA009299] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); T32 Training Grant; American Cancer Society(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Genetics and Genomics; Sister Institution Network fund of MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Elsa Flores for the p73<SUP>+/-</SUP> mice, Stephen Jones for the Mdm2<SUP>Tg</SUP> mice, and Frederick W Alt for the J<INF>H</INF> plasmid. This work was supported by a National Institutes of Health grant (CA47296 to GL), and a T32 Training Grant (CA009299) and an American Cancer Society postdoctoral fellowships to MFR. MJY is supported in part by NIH/NCI R01 CA164346, and the Center for Genetics and Genomics and the Sister Institution Network fund of MD Anderson Cancer Center.	Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Corn PG, 1999, CANCER RES, V59, P3352; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Du WJ, 2013, NAT CELL BIOL, V15, P991, DOI 10.1038/ncb2789; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gostissa M, 2013, P NATL ACAD SCI USA, V110, P2934, DOI 10.1073/pnas.1222570110; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kawano S, 1999, BLOOD, V94, P1113; Levrero M, 2000, J CELL SCI, V113, P1661; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Lushnikova T, 2011, ONCOGENE, V30, P4622, DOI 10.1038/onc.2011.172; Martinez-Delgado B, 2002, INT J CANCER, V102, P15, DOI 10.1002/ijc.10618; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moller MB, 1999, MODERN PATHOL, V12, P1010; Pluta A, 2006, LEUKEMIA, V20, P757, DOI 10.1038/sj.leu.2404166; Riley Maurisa F, 2012, Genes Cancer, V3, P226, DOI 10.1177/1947601912455322; Talos F, 2007, MOL CELL, V27, P647, DOI 10.1016/j.molcel.2007.06.036; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; Wang TTY, 1997, CANCER LETT, V116, P61, DOI 10.1016/S0304-3835(97)00175-4; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zdzalik M, 2010, CELL CYCLE, V9, P4584, DOI 10.4161/cc.9.22.13871; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	36	12	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					358	365		10.1038/onc.2015.88	http://dx.doi.org/10.1038/onc.2015.88			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25915849	Green Accepted			2022-12-28	WOS:000369055300009
J	Najumudeen, AK; Jaiswal, A; Lectez, B; Oetken-Lindholm, C; Guzman, C; Siljamaki, E; Posada, IMD; Lacey, E; Aittokallio, T; Abankwa, D				Najumudeen, A. K.; Jaiswal, A.; Lectez, B.; Oetken-Lindholm, C.; Guzman, C.; Siljamaki, E.; Posada, I. M. D.; Lacey, E.; Aittokallio, T.; Abankwa, D.			Cancer stem cell drugs target K-ras signaling in a stemness context	ONCOGENE			English	Article							GENE-EXPRESSION; MEMBRANE ORIENTATION; PLASMA-MEMBRANE; SALINOMYCIN; CAVEOLIN-1; IDENTIFICATION; NANOCLUSTERS; RESISTANCE; CALMODULIN; PROTEINS	Cancer stem cells (CSCs) are considered to be responsible for treatment relapse and have therefore become a major target in cancer research. Salinomycin is the most established CSC inhibitor. However, its primary mechanistic target is still unclear, impeding the discovery of compounds with similar anti-CSC activity. Here, we show that salinomycin very specifically interferes with the activity of K-ras4B, but not H-ras, by disrupting its nanoscale membrane organization. We found that caveolae negatively regulate the sensitivity to this drug. On the basis of this novel mechanistic insight, we defined a K-ras-associated and stem cell-derived gene expression signature that predicts the drug response of cancer cells to salinomycin. Consistent with therapy resistance of CSC, 8% of tumor samples in the TCGA-database displayed our signature and were associated with a significantly higher mortality. Using our K-ras-specific screening platform, we identified several new candidate CSC drugs. Two of these, ophiobolin A and conglobatin A, possessed a similar or higher potency than salinomycin. Finally, we established that the most potent compound, ophiobolin A, exerts its K-ras4B-specific activity through inactivation of calmodulin. Our data suggest that specific interference with the K-ras4B/calmodulin interaction selectively inhibits CSC.	[Najumudeen, A. K.; Lectez, B.; Oetken-Lindholm, C.; Guzman, C.; Siljamaki, E.; Posada, I. M. D.; Abankwa, D.] Abo Akad Univ, Turku Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland; [Jaiswal, A.; Aittokallio, T.] Univ Helsinki, FIMM, Inst Mol Med Finland, Helsinki, Finland; [Lacey, E.] Microbial Screening Technol Pty Ltd, Bldg C, Smithfield, NSW, Australia	Abo Akademi University; University of Helsinki	Abankwa, D (corresponding author), Abo Akad Univ, Turku Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	daniel.abankwa@btk.fi	Najumudeen, Arafath/AAH-2250-2020; Aittokallio, Tero/B-6583-2009	Najumudeen, Arafath/0000-0002-3764-5721; Aittokallio, Tero/0000-0002-0886-9769; Jaiswal, Alok/0000-0002-1910-4681; Abankwa, Daniel/0000-0003-2769-0745; Siljamaki, Elina/0000-0003-1709-8633; Lectez, Benoit/0000-0001-9796-1606	Academy of Finland fellowship grant; Sigrid Juselius Foundation; Cancer Society of Finland; Marie-Curie Reintegration Grant; Jane and Aatos Erkko Foundation; Academy of Finland [272437, 269862, 279163]; ISB graduate school; Integrative Life Science Doctoral Program (ILS); Cancer Foundation Finland sr [150062] Funding Source: researchfish	Academy of Finland fellowship grant; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Society of Finland; Marie-Curie Reintegration Grant(European Commission); Jane and Aatos Erkko Foundation; Academy of Finland(Academy of Finland); ISB graduate school; Integrative Life Science Doctoral Program (ILS); Cancer Foundation Finland sr	Plasmids encoding tagged LactC2 and MDCK cells stably expressing either mGFP-K- or H-rasG12V were kindly provided by Prof John Hancock. Plasmids encoding PTRF and Cav-1 were kindly provided by Prof Rob Parton. We thank Lingjia Kong for help with the ESTOOLS database. We thank Jasmin Varjonen for experimental support. This work was supported by the Academy of Finland fellowship grant, the Sigrid Juselius Foundation, the Cancer Society of Finland, the Marie-Curie Reintegration Grant and the Jane and Aatos Erkko Foundation grants to DA, as well as Academy of Finland (grants 272437, 269862, 279163) and the Cancer Society of Finland grants to TA. AKN was supported by the ISB graduate school and AJ by the Integrative Life Science Doctoral Program (ILS).	Abankwa D, 2007, SEMIN CELL DEV BIOL, V18, P599, DOI 10.1016/j.semcdb.2007.08.003; Abankwa D, 2008, EMBO J, V27, P727, DOI 10.1038/emboj.2008.10; Abankwa D, 2007, J CELL SCI, V120, P2953, DOI 10.1242/jcs.001404; Abankwa D, 2010, P NATL ACAD SCI USA, V107, P1130, DOI 10.1073/pnas.0903907107; Ansieau S, 2013, CANCER LETT, V338, P63, DOI 10.1016/j.canlet.2012.05.014; Ariotti N, 2014, J CELL BIOL, V204, P777, DOI 10.1083/jcb.201307055; Au TK, 1998, PLANT PHYSIOL, V118, P965, DOI 10.1104/pp.118.3.965; Baker N, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt276; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bastiani M, 2009, J CELL BIOL, V185, P1259, DOI 10.1083/jcb.200903053; Blair K, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002019; Boehmerle W, 2014, J MOL MED, V92, P889, DOI 10.1007/s00109-014-1155-0; Buganim Y, 2013, NAT REV GENET, V14, P427, DOI 10.1038/nrg3473; Cho KJ, 2012, J BIOL CHEM, V287, P43573, DOI 10.1074/jbc.M112.424457; Collins BM, 2012, DEV CELL, V23, P11, DOI 10.1016/j.devcel.2012.06.012; Coxon FP, 2014, EUR J MED CHEM, V84, P77, DOI 10.1016/j.ejmech.2014.06.062; Crouthamel M, 2010, MOL PHARMACOL, V78, P767, DOI 10.1124/mol.110.066340; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Fairn GD, 2011, J CELL BIOL, V194, P257, DOI 10.1083/jcb.201012028; Fuchs D, 2009, BIOCHEM BIOPH RES CO, V390, P743, DOI 10.1016/j.bbrc.2009.10.042; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Guzman C, 2016, JALA-J LAB AUTOM, V21, P238, DOI 10.1177/2211068215606048; Guzman C, 2014, J BIOL CHEM, V289, P9519, DOI 10.1074/jbc.M113.537001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Huczynski A, 2012, BIOORG MED CHEM LETT, V22, P7002, DOI 10.1016/j.bmcl.2012.09.046; Kirkham M, 2008, J CELL SCI, V121, P2075, DOI 10.1242/jcs.024588; Kohnke M, 2012, CHEM BIOL, V19, P866, DOI 10.1016/j.chembiol.2012.05.019; Kong LJ, 2013, NAT METHODS, V10, P814, DOI 10.1038/nmeth.2576; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lemieux E, 2015, ONCOGENE, V34, P4914, DOI 10.1038/onc.2014.416; Li Q, 2013, NATURE, V504, P143, DOI 10.1038/nature12830; Lu DS, 2011, P NATL ACAD SCI USA, V108, P13253, DOI 10.1073/pnas.1110431108; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Meissner P, 2001, BIOTECHNOL BIOENG, V75, P197, DOI 10.1002/bit.1179; Najumudeen AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066425; Najurnudeen AK, 2015, BIOCHEMISTRY-US, V54, P7212, DOI 10.1021/acs.biochem.5b00724; Nassar ZD, 2013, NAT REV UROL, V10, P529, DOI 10.1038/nrurol.2013.168; Naujokat C, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/950658; Nussinov R, 2016, CANCER RES, V76, P18, DOI 10.1158/0008-5472.CAN-15-1536; Nussinov R, 2015, MOL CANCER RES, V13, P1265, DOI 10.1158/1541-7786.MCR-15-0165; Quinlan MP, 2008, MOL CELL BIOL, V28, P2659, DOI 10.1128/MCB.01661-07; Riccioni R, 2010, BLOOD CELL MOL DIS, V45, P86, DOI 10.1016/j.bcmd.2010.03.008; Rotblat B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011991; Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sinha B, 2011, CELL, V144, P402, DOI 10.1016/j.cell.2010.12.031; Solman M, 2015, ELIFE, V4, DOI 10.7554/eLife.08905; Sotgia F, 2005, CELL CYCLE, V4, P1808, DOI 10.4161/cc.4.12.2198; Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560; Sykes AM, 2012, J BIOL CHEM, V287, P43810, DOI 10.1074/jbc.M112.382903; Tian TH, 2007, NAT CELL BIOL, V9, P905, DOI 10.1038/ncb1615; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; Wang MT, 2015, CELL, V163, P1237, DOI 10.1016/j.cell.2015.10.041; Witkiewicz AK, 2009, AM J PATHOL, V174, P2023, DOI 10.2353/ajpath.2009.080873; Zhou S, 2013, CURR MED CHEM, V20, P4095; Zhou Y, 2015, BBA-MOL CELL RES, V1853, P841, DOI 10.1016/j.bbamcr.2014.09.008; Zhou Y, 2014, MOL CELL BIOL, V34, P862, DOI 10.1128/MCB.01227-13; Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956	68	59	60	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5248	5262		10.1038/onc.2016.59	http://dx.doi.org/10.1038/onc.2016.59			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26973241	hybrid, Green Published			2022-12-28	WOS:000386053000004
J	Dong, J; Zhao, W; Shi, A; Toneff, M; Lydon, J; So, D; Li, Y				Dong, J.; Zhao, W.; Shi, A.; Toneff, M.; Lydon, J.; So, D.; Li, Y.			The PR status of the originating cell of ER/PR-negative mouse mammary tumors	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; IN-VIVO; EXPRESSION; GLAND; MODEL; IMMUNOHISTOCHEMISTRY; PROLIFERATION; TUMORIGENESIS; ONCOPROTEIN	Progesterone receptor (PR) is usually co-localized with estrogen receptor (ER) in normal mammary cells. It is not known whether ER/PR-negative human breast cancer arises from an ER/PR-negative cell or from an ER/PR-positive cell that later lost ER/PR. Using intraductal injection of a lentivirus to deliver both an oncogene (ErbB2) and a floxed green fluorescent protein (GFP) in PRCre/+ mice, whose Cre gene is under the control of the PR promoter, we were able to trace the PR status of the infected cells as they progressed to cancer. We found that the resulting early lesions stained negative for PR in most of the cells and usually retained GFP. The resulting tumors lacked ER and PR, and 75% (15/20) of them retained the GFP signal in all tumor cells, suggesting PR was never expressed throughout the evolution of a majority of these tumors. In conclusion, our data demonstrate that ErbB2-initiated ER/PR-negative mammary tumors primarily originate from the subset of the mammary epithelium that is negative for PR and probably ER as well. These findings also provide an explanation for why antihormonal therapy fails to prevent ER-negative breast cancers.	[Dong, J.; Zhao, W.; Shi, A.; Toneff, M.; So, D.; Li, Y.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Dong, J.; Toneff, M.; Lydon, J.; Li, Y.] Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA; [Shi, A.] Jilin Univ, Hosp 1, Dept Breast Surg, Changchun, Peoples R China; [Li, Y.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Jilin University; Baylor College of Medicine	Li, Y (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza MS600, Houston, TX 77030 USA.	liyi@bcm.edu	; Li, Yi/A-7635-2009	shi, aiping/0000-0002-7272-453X; Li, Yi/0000-0002-9976-518X	NIH [CA124820, U54CA149196]; CDMRP [BC060332, BC085050, BC073703]; Mary Kay Foundation [TMKF042-14]; Dan L. Duncan Cancer Center [P30CA125123]; BCM SPORE career development award [P50-CA058183]; NATIONAL CANCER INSTITUTE [R01CA124820, P50CA186784, U54CA149196] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CDMRP(United States Department of Defense); Mary Kay Foundation; Dan L. Duncan Cancer Center; BCM SPORE career development award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Vidya Sinha and Sarah Hein for stimulating discussion. This work was supported in part by funds from NIH CA124820 (to YL) and U54CA149196 (to YL; PI: Stephan Wong); from CDMRP BC060332 (to YL), BC085050 (to YL) and BC073703 (to YL) and from Mary Kay Foundation (TMKF042-14 (to YL) as well as by the resources from the Lester & Sue Smith Breast Center (P50 CA186784), the Dan L. Duncan Cancer Center (P30CA125123). JD was supported by BCM SPORE career development award (P50-CA058183).	Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047; Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938; Aubele M, 2002, ANAL CELL PATHOL, V24, P69, DOI 10.1155/2002/371680; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Bu W, 2009, J MAMMARY GLAND BIOL, V14, P401, DOI 10.1007/s10911-009-9154-4; Clarke RB, 1997, CANCER RES, V57, P4987; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Du ZJ, 2007, CELL CYCLE, V6, P823, DOI 10.4161/cc.6.7.4074; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Edorh A, 1999, CELL MOL BIOL, V45, P831; Fendrick JL, 1998, J MAMMARY GLAND BIOL, V3, P7, DOI 10.1023/A:1018766000275; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; Haricharan S, 2014, ONCOGENE, V33, P5729, DOI 10.1038/onc.2013.521; Haricharan S, 2013, ELIFE, V2, DOI 10.7554/eLife.00996; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Heffelfinger SC, 2000, PATHOBIOLOGY, V68, P129, DOI 10.1159/000055913; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mukherjee A, 2006, GENESIS, V44, P601, DOI 10.1002/dvg.20257; Reddy JP, 2010, P NATL ACAD SCI USA, V107, P3728, DOI 10.1073/pnas.0910665107; Reddy JP, 2009, J MAMMARY GLAND BIOL, V14, P405, DOI 10.1007/s10911-009-9157-1; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Siwko SK, 2008, NEOPLASIA, V10, P653, DOI 10.1593/neo.08266; Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x	27	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4149	4154		10.1038/onc.2015.465	http://dx.doi.org/10.1038/onc.2015.465			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26640140	Green Accepted			2022-12-28	WOS:000381020900013
J	Gupta, SC; Singh, R; Asters, M; Liu, J; Zhang, X; Pabbidi, MR; Watabe, K; Mo, YY				Gupta, S. C.; Singh, R.; Asters, M.; Liu, J.; Zhang, X.; Pabbidi, M. R.; Watabe, K.; Mo, Y-Y			Regulation of breast tumorigenesis through acid sensors	ONCOGENE			English	Article							SENSING ION CHANNELS; NADPH-OXIDASE; CANCER GENOMICS; CALCIUM; CA2+; ACTIVATION; PH; METASTASIS; CELLS; ROS	The low extracellular pH in the microenvironment has been shown to promote tumor growth and metastasis; however, the underlying mechanism is poorly understood. Particularly, little is known how the tumor cell senses the acidic signal to activate the acidosis-mediated signaling. In this study, we show that breast cancer cells express acid-sensing ion channel 1 (ASIC1), a proton-gated cation channel primarily expressed in the nervous system. RNA interference, knockout and rescue experiments demonstrate a critical role for ASIC1 in acidosis-induced reactive oxidative species and NF-kappa B activation, two key events for tumorigenesis. Mechanistically, ASIC1 is required for acidosis-mediated signaling through calcium influx. We show that as a cytoplasmic membrane protein, ASIC1 is also associated with mitochondria, suggesting that ASIC1 may regulate mitochondrial calcium influx. Importantly, interrogation of the Cancer Genome Atlas breast invasive carcinoma data set indicates that alterations of ASIC1 alone or combined with other 4 ASIC genes are significantly correlated with poor patient survival. Furthermore, ASIC1 inhibitors cause a significant reduction of tumor growth and tumor load. Together, these results suggest that ASIC1 contributes to breast cancer pathogenesis in response to acidic tumor microenvironments, and ASIC1 may serve as a prognostic marker and a therapeutic target for breast cancer.	[Gupta, S. C.; Singh, R.; Asters, M.; Liu, J.; Mo, Y-Y] Univ Mississippi, Med Ctr, Inst Canc, 2500 N State St,Room G651, Jackson, MS 39216 USA; [Gupta, S. C.; Singh, R.] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; [Zhang, X.] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA; [Pabbidi, M. R.; Mo, Y-Y] Univ Mississippi, Med Ctr, Dept Pharmacol & Toxicol, Jackson, MS 39216 USA; [Watabe, K.] Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27109 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; Wake Forest University	Mo, YY (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 N State St,Room G651, Jackson, MS 39216 USA.	ymo@umc.edu	Mo, Yin-Yuan/R-8255-2019; Gupta, Subash/AAF-2563-2019; Singh, Ramesh/S-4568-2017	Gupta, Subash/0000-0002-0418-1940; Singh, Ramesh/0000-0001-5052-7925	National Institutes of Health [R01 CA154989]; UMMC's Intramural Research Support Program; COBRE grant [GM103328]; NATIONAL CANCER INSTITUTE [R01CA154989] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UMMC's Intramural Research Support Program; COBRE grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Parminder J.S. Vig at UMMC for providing mouse brain tissues. This work is supported in part by a grant from the National Institutes of Health R01 CA154989 (YM) and a grant from UMMC's Intramural Research Support Program (SCG). Imaging Core of Center for Psychiatric Neuroscience at UMMC is supported by COBRE grant GM103328.	Abbey CK, 2004, P NATL ACAD SCI USA, V101, P11438, DOI 10.1073/pnas.0404396101; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Benarroch EE, 2014, NEUROLOGY, V82, P628, DOI 10.1212/WNL.0000000000000134; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen XM, 2005, J GEN PHYSIOL, V126, P71, DOI 10.1085/jgp.200509303; Chu XP, 2012, CURR DRUG TARGETS, V13, P263, DOI 10.2174/138945012799201685; Damaghi M, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00370; Drago I, 2011, EMBO J, V30, P4119, DOI 10.1038/emboj.2011.337; El Jamali A, 2008, FREE RADICAL BIO MED, V44, P868, DOI 10.1016/j.freeradbiomed.2007.11.020; Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796; Feissner RF, 2009, FRONT BIOSCI-LANDMRK, V14, P1197, DOI 10.2741/3303; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Giorgio V, 2010, BBA-BIOENERGETICS, V1797, P1113, DOI 10.1016/j.bbabio.2009.12.006; Granfeldt D, 2002, J LEUKOCYTE BIOL, V71, P611; Gupta SC, 2014, ONCOTARGET, V5, P12070, DOI 10.18632/oncotarget.2514; Gupta SC, 2013, J BIOL CHEM, V288, P32343, DOI 10.1074/jbc.M113.455188; Hashim AI, 2011, NMR BIOMED, V24, P582, DOI 10.1002/nbm.1644; Ho TT, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1198; Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541; Jagnandan D, 2007, J BIOL CHEM, V282, P6494, DOI 10.1074/jbc.M608966200; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Pandey D, 2011, MOL PHARMACOL, V80, P407, DOI 10.1124/mol.110.070193; Peppicelli S, 2013, CLIN EXP METASTAS, V30, P957, DOI 10.1007/s10585-013-9595-4; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Robey IF, 2009, CANCER RES, V69, P2260, DOI 10.1158/0008-5472.CAN-07-5575; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Schaefer L, 2000, FEBS LETT, V471, P205, DOI 10.1016/S0014-5793(00)01403-4; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Viola HM, 2007, CIRC RES, V100, P1036, DOI 10.1161/01.RES.0000263010.19273.48; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wang G, 2006, HYPERTENSION, V48, P482, DOI 10.1161/01.HYP.0000236647.55200.07; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2013, NAT REV NEUROSCI, V14, P461, DOI 10.1038/nrn3529; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xu L, 2000, CANCER RES, V60, P4610; Ye JH, 2007, BIOCHEM BIOPH RES CO, V355, P986, DOI 10.1016/j.bbrc.2007.02.061; Zha XM, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-1; Zhang A, 2013, CELL RES, V23, P340, DOI 10.1038/cr.2012.164	52	50	50	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4102	4111		10.1038/onc.2015.477	http://dx.doi.org/10.1038/onc.2015.477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686084	Green Accepted			2022-12-28	WOS:000381020900008
J	Park, UH; Kang, MR; Kim, EJ; Kwon, YS; Hur, W; Yoon, SK; Song, BJ; Park, JH; Hwang, JT; Jeong, JC; Um, SJ				Park, U-H; Kang, M-R; Kim, E-J; Kwon, Y-S; Hur, W.; Yoon, S. K.; Song, B-J; Park, J. H.; Hwang, J-T; Jeong, J-C; Um, S-J			ASXL2 promotes proliferation of breast cancer cells by linking ER alpha to histone methylation	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; H3K27 DEMETHYLASES; HISTOLOGIC GRADE; LSD1; TRANSCRIPTION; COACTIVATOR; MECHANISMS; CARCINOGENESIS; EPIGENETICS	Estrogen receptor alpha (ER alpha) has a pivotal role in breast carcinogenesis by associating with various cellular factors. Selective expression of additional sex comb-like 2 (ASXL2) in ER alpha-positive breast cancer cells prompted us to investigate its role in chromatin modification required for ERa activation and breast carcinogenesis. Here, we observed that ASXL2 interacts with ligand E2-bound ERa and mediates ERa activation. Chromatin immunoprecipitation-sequencing analysis supports a positive role of ASXL2 at ERa target gene promoters. ASXL2 forms a complex with histone methylation modifiers including LSD1, UTX and MLL2, which all are recruited to the E2-responsive genes via ASXL2 and regulate methylations at histone H3 lysine 4, 9 and 27. The preferential binding of the PHD finger of ASXL2 to the dimethylated H3 lysine 4 may account for its requirement for ERa activation. On ASXL2 depletion, the proliferative potential of MCF7 cells and tumor size of xenograft mice decreased. Together with our finding on the higher ASXL2 expression in ERa-positive patients, we propose that ASXL2 could be a novel prognostic marker in breast cancer.	[Park, U-H; Kwon, Y-S; Um, S-J] Sejong Univ, Dept Biosci & Biotechnol, 98 Kunja Dong,Cuungmuguan 614, Seoul 143747, South Korea; [Kang, M-R] Korea Res Inst Biosci & Biotechnol, Bioevaluat Ctr, Ochang, Cheongwon, South Korea; [Kim, E-J] Dankook Univ, Dept Mol Biol, Gyeonggi Do, South Korea; [Hur, W.; Yoon, S. K.] Catholic Univ, Liver Res Ctr, Seoul, South Korea; [Hur, W.; Yoon, S. K.] Catholic Univ, Coll Med, WHO Collaborating Ctr Viral Hepatitis, Seoul, South Korea; [Song, B-J] Catholic Univ, Coll Med, Seoul St Marys Hosp, Breast Ctr,Dept Surg, Seoul, South Korea; [Park, J. H.; Hwang, J-T] Korea Food Res Inst, Songnam, Gyeonggi Do, South Korea; [Jeong, J-C] Dongguk Univ, Coll Oriental Med, Dept Biochem Mol Biol & Internal Med, Kyungpook, South Korea	Sejong University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Dankook University; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Korea Food Research Institute (KFRI); Dongguk University	Um, SJ (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, 98 Kunja Dong,Cuungmuguan 614, Seoul 143747, South Korea.	umsj@sejong.ac.kr			National R&D program for Cancer Control [1120210]; Korea Food Research Institute; Basic Science Research Program through NRF grant, Republic of Korea [2014R1A2A1A11052685]	National R&D program for Cancer Control(Ministry of Health & Welfare (MOHW), Republic of Korea); Korea Food Research Institute; Basic Science Research Program through NRF grant, Republic of Korea	This study was supported in part by a grant of the National R&D program for Cancer Control (1120210), a grant from the Korea Food Research Institute, and a grant of the Basic Science Research Program through NRF grant (2014R1A2A1A11052685), Republic of Korea.	Akhavantabasi S, 2010, MAMM GENOME, V21, P388, DOI 10.1007/s00335-010-9268-4; Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426; Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aravind L, 2012, CELL CYCLE, V11, P119, DOI 10.4161/cc.11.1.18475; Arteaga MF, 2013, CANCER CELL, V23, P376, DOI 10.1016/j.ccr.2013.02.014; Cho YS, 2006, J BIOL CHEM, V281, P17588, DOI 10.1074/jbc.M512616200; Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3; Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229; Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z; Farber CR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002038; Gage M, 2012, J SURG ONCOL, V105, P444, DOI 10.1002/jso.21856; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Glinsky GV, 2004, CLIN CANCER RES, V10, P2272, DOI 10.1158/1078-0432.CCR-03-0522; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Gozgit JM, 2007, BRIT J CANCER, V97, P809, DOI 10.1038/sj.bjc.6603926; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790; Horton JR, 2010, NAT STRUCT MOL BIOL, V17, P38, DOI 10.1038/nsmb.1753; Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Katoh M, 2013, BRIT J CANCER, V109, P299, DOI 10.1038/bjc.2013.281; Kawazu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017830; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Lai HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073983; Lai HL, 2012, J MOL CELL CARDIOL, V53, P734, DOI 10.1016/j.yjmcc.2012.08.014; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Park UH, 2011, J BIOL CHEM, V286, P1354, DOI 10.1074/jbc.M110.177816; Pollock JA, 2012, ACS CHEM BIOL, V7, P1221, DOI 10.1021/cb300108c; Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13; Shen YQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-470; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Stratmann A, 2012, MOL CELL ENDOCRINOL, V348, P12, DOI 10.1016/j.mce.2011.09.028; Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	52	28	29	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3742	3752		10.1038/onc.2015.443	http://dx.doi.org/10.1038/onc.2015.443			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26640146				2022-12-28	WOS:000379622800012
J	Trikha, P; Sharma, N; Pena, C; Reyes, A; Pecot, T; Khurshid, S; Rawahneh, M; Moffitt, J; Stephens, JA; Fernandez, SA; Ostrowski, MC; Leone, G				Trikha, P.; Sharma, N.; Pena, C.; Reyes, A.; Pecot, T.; Khurshid, S.; Rawahneh, M.; Moffitt, J.; Stephens, J. A.; Fernandez, S. A.; Ostrowski, M. C.; Leone, G.			E2f3 in tumor macrophages promotes lung metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; CELL MIGRATION; BREAST-CANCER; LIN-35 RB; FACTOR-I; EXPRESSION; ANGIOGENESIS; INVASION; MICROENVIRONMENT; INFILTRATION	The Rb-E2F axis is an important pathway involved in cell-cycle control that is deregulated in a number of cancers. E2f transcription factors have distinct roles in the control of cell proliferation, cell survival and differentiation in a variety of tissues. We have previously shown that E2fs are important downstream targets of a CSF-1 signaling cascade involved in myeloid development. In cancer, tumor-associated macrophages (TAMs) are recruited to the tumor stroma in response to cytokines secreted by tumor cells, and are believed to facilitate tumor cell invasion and metastasis. Using the MMTV-Polyoma Middle T antigen (PyMT) mouse model of human ductal carcinoma, we show that the specific ablation of E2f3 in TAMs, but not in tumor epithelial cells, attenuates lung metastasis without affecting primary tumor growth. Histological analysis and gene expression profiling suggest that E2f3 does not impact the proliferation or survival of TAMs, but rather controls a novel gene expression signature associated with cytoskeleton rearrangements, cell migration and adhesion. This E2f3 TAM gene expression signature was sufficient to predict cancer recurrence and overall survival of estrogen receptor (ER)-positive breast cancer patients. Interestingly, we find that E2f3b but not E2f3a levels are elevated in TAMs from PyMT mammary glands relative to controls, suggesting a differential role for these isoforms in metastasis. In summary, these findings identify E2f3 as a key transcription factor in TAMs, which influences the tumor microenvironment and tumor cell metastasis.	[Trikha, P.; Sharma, N.; Pena, C.; Reyes, A.; Pecot, T.; Khurshid, S.; Rawahneh, M.; Moffitt, J.; Ostrowski, M. C.; Leone, G.] Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA; [Trikha, P.; Sharma, N.; Pena, C.; Reyes, A.; Pecot, T.; Khurshid, S.; Rawahneh, M.; Moffitt, J.; Ostrowski, M. C.; Leone, G.] Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Trikha, P.; Sharma, N.; Pena, C.; Reyes, A.; Pecot, T.; Khurshid, S.; Rawahneh, M.; Moffitt, J.; Ostrowski, M. C.; Leone, G.] Ohio State Univ, Coll Biol Sci, Dept Mol Genet, Columbus, OH 43210 USA; [Stephens, J. A.; Fernandez, S. A.] Ohio State Univ, Coll Med, Ctr Biostat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Leone, G (corresponding author), Ohio State Univ, Dept Mol Virol, Human Canc Genet Program, Ctr Comprehens Canc, 460W 12th Ave, Columbus, OH 43210 USA.	Gustavo.Leone@osumc.edu	; Ostrowski, Michael/H-3108-2011	Khurshid, Safiya/0000-0003-1620-3091; Ostrowski, Michael/0000-0003-2948-6297; Pecot, Thierry/0000-0003-0772-9753	NIH [R01CA121275, R01CA098956, P01CA097189]; T32 fellowship [CA 106196-06]; NATIONAL CANCER INSTITUTE [T32CA106196, R01CA121275, R01CA098956, P01CA097189] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); T32 fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bryan Mcelwain for technical assistance with flow cytometry. This work was funded by NIH grants R01CA121275, R01CA098956 and P01CA097189 MC and GL to GL. PT and NS are recipients of the T32 fellowship (CA 106196-06).	Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; De Meyer T, 2009, J PATHOL, V217, P14, DOI 10.1002/path.2452; DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0; Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097-0142(20000615)88:12+<3080::AID-CNCR27>3.0.CO;2-W; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017; Hurley PJ, 2012, P NATL ACAD SCI USA, V109, P14977, DOI 10.1073/pnas.1203525109; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Leek RD, 1996, CANCER RES, V56, P4625; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609; Myers TR, 2005, DEV CELL, V8, P117, DOI 10.1016/j.devcel.2004.11.015; Nasser MW, 2012, CANCER RES, V72, P604, DOI 10.1158/0008-5472.CAN-11-0669; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; O'Shaughnessy J, 2005, ONCOLOGIST, V10, P20, DOI 10.1634/theoncologist.10-90003-20; Olsson AY, 2007, ONCOGENE, V26, P1028, DOI 10.1038/sj.onc.1209854; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Reynolds LE, 2010, NATURE, V465, P813, DOI 10.1038/nature09106; Sangaletti S, 2003, J EXP MED, V198, P1475, DOI 10.1084/jem.20030202; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Talmadge JE, 2007, CANCER METAST REV, V26, P373, DOI 10.1007/s10555-007-9072-0; Trikha P, 2011, J BIOL CHEM, V286, P4783, DOI 10.1074/jbc.M110.182733; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Van Nguyen A, 2002, DEV BIOL, V247, P11, DOI 10.1006/dbio.2002.0669; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wu L, 2013, ONCOGENE; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Yue W, 2009, CANCER RES, V69, P6339, DOI 10.1158/0008-5472.CAN-09-0398; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	50	36	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3636	3646		10.1038/onc.2015.429	http://dx.doi.org/10.1038/onc.2015.429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26549026	Green Accepted			2022-12-28	WOS:000379622800003
J	Yang, H; Liu, P; Zhang, J; Peng, X; Lu, Z; Yu, S; Meng, Y; Tong, WM; Chen, J				Yang, H.; Liu, P.; Zhang, J.; Peng, X.; Lu, Z.; Yu, S.; Meng, Y.; Tong, W-M; Chen, J.			Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negatively regulated by miR-193b	ONCOGENE			English	Article							EXPRESSION; MICRORNAS; PROLIFERATION; PROGRESSION; LOC554202; MIGRATION; PROMOTES; TARGETS; SITES	Long noncoding RNAs (lncRNAs) play important regulatory roles in a variety of diseases, including many tumors. However, the functional roles of these transcripts and mechanisms responsible for their deregulation in pancreatic ductal adenocarcinoma (PDAC) are not thoroughly understood. In this study, we discovered that lncRNA MIR31HG is markedly upregulated in PDAC. Knockdown of MIR31HG significantly suppressed PDAC cell growth, induced apoptosis and G1/S arrest, and inhibited invasion, whereas enhanced expression of MIR31HG had the opposite effects. Online database analysis tools showed that miR-193b could target MIR31HG and we found an inverse correlation between MIR31HG and miR-193b in PDAC specimens. Inhibition of miR-193b expression significantly upregulated the MIR31HG level, while overexpression of miR-193b suppressed MIR31HG's expression and function, suggesting that MIR31HG is negatively regulated by miR-193b. Moreover, using luciferase reporter and RIP assays, we provide evidence that miR-193b directly targeted MIR31HG by binding to two microRNA binding sites in the MIR31HG sequence. On the other hand, MIR31HG may act as an endogenous 'sponge' by competing for miR-193b binding to regulate the miRNA targets. Collectively, these results demonstrate that MIR31HG functions as an oncogenic lncRNA that promotes tumor progression, and miR-193b targets not only protein-coding genes but also the lncRNA, MIR31HG.	[Yang, H.; Liu, P.; Lu, Z.; Yu, S.; Meng, Y.; Chen, J.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China; [Yang, H.; Liu, P.; Zhang, J.; Peng, X.; Lu, Z.; Yu, S.; Meng, Y.; Tong, W-M; Chen, J.] Peking Union Med Coll, Beijing 100730, Peoples R China; [Zhang, J.; Peng, X.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Beijing, Peoples R China; [Zhang, J.; Peng, X.; Tong, W-M] Chinese Acad Med Sci, Sch Basic Med, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China; [Tong, W-M] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS	Chen, J (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China.; Chen, J (corresponding author), Peking Union Med Coll, Beijing 100730, Peoples R China.; Tong, WM (corresponding author), Chinese Acad Med Sci, Sch Basic Med, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.; Tong, WM (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.; Tong, WM (corresponding author), Peking Union Med Coll, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	wmtong@ibms.pumc.edu.cn; xhblk@163.com			National Nature Science Foundations of China [81472326, 81172334, 31021091]; China 973 [2011CBA01104]	National Nature Science Foundations of China(National Natural Science Foundation of China (NSFC)); China 973(National Basic Research Program of China)	We sincerely thank Dr Yamei Niu for technical support and critical comments on the manuscript, Weilong Zhang for detailed bioinformatics analysis of MIR31HG, and Yongsong Yue for technical support of ISH. This work was supported by the National Nature Science Foundations of China (81472326 and 81172334 to JC, 31021091 to W-MT) and the China 973 (2011CBA01104 to W-MT).	Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; Brummer A, 2014, BIOESSAYS, V36, P617, DOI 10.1002/bies.201300104; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233; Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010; Chen X, 2013, BIOINFORMATICS, V29, P2617, DOI 10.1093/bioinformatics/btt426; Da Sacco L, 2013, INT J MOL SCI, V14, P480, DOI 10.3390/ijms14010480; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gastaldi C, 2014, CARCINOGENESIS, V35, P1110, DOI 10.1093/carcin/bgt490; Guo G, 2015, ONCOGENE, V34, P1768, DOI 10.1038/onc.2014.131; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Harries LW, 2012, BIOCHEM SOC T, V40, P902, DOI 10.1042/BST20120020; Ikeda Y, 2012, MOL CANCER RES, V10, P259, DOI 10.1158/1541-7786.MCR-11-0035; Izaurralde E, 2012, EMBO REP, V13, P662, DOI 10.1038/embor.2012.91; Jeggari A, 2012, BIOINFORMATICS, V28, P2062, DOI 10.1093/bioinformatics/bts344; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leucci E, 2013, SCI REP-UK, V3, DOI 10.1038/srep02535; Lin ST, 2013, P NATL ACAD SCI USA, V110, P17468, DOI 10.1073/pnas.1317182110; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967; Muers M, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3088; Novikova IV, 2013, J MOL BIOL, V425, P3731, DOI 10.1016/j.jmb.2013.02.030; Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pD239, DOI 10.1093/nar/gks1246; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shi YG, 2014, BIOCHEM BIOPH RES CO, V446, P448, DOI 10.1016/j.bbrc.2014.02.144; Siegel R, 2013, CA-CANCER J CLIN, V2013, P63; Tahira AC, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-141; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Yang F, 2013, J CANCER RES CLIN, V139, P437, DOI 10.1007/s00432-012-1324-x; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang X, 2014, GUT, V63, P881, DOI 10.1136/gutjnl-2013-305266; Zhang G, 2012, J CONTROL SCI ENG, V2012, P7, DOI DOI 10.1371/J0URNAL.P0NE.0044568	45	106	112	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3647	3657		10.1038/onc.2015.430	http://dx.doi.org/10.1038/onc.2015.430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26549028	hybrid, Green Published			2022-12-28	WOS:000379622800004
J	Garibaldi, F; Falcone, E; Trisciuoglio, D; Colombo, T; Lisek, K; Walerych, D; Del Sal, G; Paci, P; Bossi, G; Piaggio, G; Gurtner, A				Garibaldi, F.; Falcone, E.; Trisciuoglio, D.; Colombo, T.; Lisek, K.; Walerych, D.; Del Sal, G.; Paci, P.; Bossi, G.; Piaggio, G.; Gurtner, A.			Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex	ONCOGENE			English	Article							MICRORNA BIOGENESIS; CELL-PROLIFERATION; CANCER; GAIN; EXPRESSION; PROTEINS; RNA; SUPPRESSES; MECHANISMS; MIGRATION	Downregulation of microRNAs (miRNAs) is commonly observed in cancers and promotes tumorigenesis suggesting that miRNAs may function as tumor suppressors. However, the mechanism through which miRNAs are regulated in cancer, and the connection between oncogenes and miRNA biogenesis remain poorly understood. The TP53 tumor-suppressor gene is mutated in half of human cancers resulting in an oncogene with gain-of-function activities. Here we demonstrate that mutant p53 (mutp53) oncoproteins modulate the biogenesis of a subset of miRNAs in cancer cells inhibiting their post-transcriptional maturation. Interestingly, among these miRNAs several are also downregulated in human tumors. By confocal, co-immunoprecipitation and RNA-chromatin immunoprecipitation experiments, we show that endogenous mutp53 binds and sequesters RNA helicases p72/82 from the microprocessor complex, interfering with Drosha-pri-miRNAs association. In agreement with this, the overexpression of p72 leads to an increase of mature miRNAs levels. Moreover, functional experiments demonstrate the oncosuppressive role of mutp53-dependent miRNAs (miR-517a, -519a, -218, -105). Our study highlights a previously undescribed mechanism by which mutp53 interferes with Drosha-p72/82 association leading, at least in part, to miRNA deregulation observed in cancer.	[Garibaldi, F.; Falcone, E.; Trisciuoglio, D.; Bossi, G.; Piaggio, G.; Gurtner, A.] Regina Elena Inst Canc Res, Translat Res Area, Dept Res Adv Diagnost & Technol Innovat, Rome, Italy; [Colombo, T.; Paci, P.] CNR, Inst Syst Anal & Comp Sci Antonio Ruberti, Rome, Italy; [Colombo, T.; Paci, P.] SysBio Ctr Syst Biol, Rome, Italy; [Lisek, K.; Walerych, D.; Del Sal, G.] Area Sci Pk Padriciano, Lab Nazl CIB, Trieste, Italy; [Lisek, K.; Del Sal, G.] Univ Trieste, Dipartimento Sci Vita, Trieste, Italy; [Bossi, G.] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Dept Res Adv Diagnost & Technol Innovat, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Analisi dei Sistemi ed Informatica "Antonio Ruberti" (IASI-CNR); University of Trieste; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Bossi, G; Piaggio, G; Gurtner, A (corresponding author), Regina Elena Inst Canc Res, Translat Res Area, Via Elio Chianesi 53, I-00144 Rome, Italy.	bossi@ifo.it; piaggio@ifo.it; gurtner@ifo.it	Piaggio, Giulia/AAD-7336-2022; Piaggio, Giulia/J-7214-2018; Bossi, Gianluca/B-9394-2017; gurtner, aymone/AAB-8843-2020; Bossi, Gianluca/ABH-6846-2020; trisciuoglio, daniela/AAL-4002-2021; Lisek, Kamil/J-5785-2016; Gurtner, Aymone/J-7217-2018; Colombo, Teresa/P-2959-2018; Trisciuoglio, Daniela/H-2131-2016	Piaggio, Giulia/0000-0003-2114-1892; Bossi, Gianluca/0000-0002-2947-1063; gurtner, aymone/0000-0002-7661-9059; Bossi, Gianluca/0000-0002-2947-1063; Lisek, Kamil/0000-0002-2406-8830; Gurtner, Aymone/0000-0002-7661-9059; Colombo, Teresa/0000-0003-2415-7507; Walerych, Dawid/0000-0002-8440-1375; Trisciuoglio, Daniela/0000-0002-7007-7914; DEL SAL, GIANNINO/0000-0003-2185-6003	Fondazione Umberto Veronesi Fellowship; FEBS postdoctoral fellowship; AIRC [MFAG 11752, IG 13234, 10016]; Italian Ministry of Health	Fondazione Umberto Veronesi Fellowship(Fondazione Umberto Veronesi); FEBS postdoctoral fellowship; AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy)	We thank Dr Vittorio Sartorelli for the p72 expression vector, Dr Silvia Bacchetti and Silvia Soddu for interesting discussions on the manuscript, Maria Pia Gentileschi for technical advice, Daniela Bona for secretary assistance. Aymone Gurtner and Gianluca Bossi were supported by a Fondazione Umberto Veronesi Fellowship; Dawid Walerych was a recipient of the FEBS postdoctoral fellowship. This work has been supported by grant from AIRC to AG (MFAG 11752); from AIRC to GP (IG 13234); from AIRC (Special Program Molecular Clinical Oncology '5 per mille') (grant no. 10016) to GDS and from Italian Ministry of Health to GDS.	Abdelmohsen K, 2010, CELL CYCLE, V9, P1354, DOI 10.4161/cc.9.7.11164; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Borralho PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023787; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Bossi G, 2008, CELL CYCLE, V7, P1870, DOI 10.4161/cc.7.12.6161; Braicu C, 2013, MOL CELL BIOCHEM, V381, P61, DOI 10.1007/s11010-013-1688-5; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Carleton M, 2007, CELL CYCLE, V6, P2127, DOI 10.4161/cc.6.17.4641; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Donzelli S, 2012, CELL DEATH DIFFER, V19, P1038, DOI 10.1038/cdd.2011.190; Fabbri M, 2007, EXPERT OPIN BIOL TH, V7, P1009, DOI 10.1517/14712598.7.7.1009; Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Fuller-Pace FV, 2013, BBA-GENE REGUL MECH, V1829, P756, DOI 10.1016/j.bbagrm.2013.03.004; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Garufi A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.163; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Gostissa M, 2004, J BIOL CHEM, V279, P48013, DOI 10.1074/jbc.M310801200; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Gurtner A, 2010, J BIOL CHEM, V285, P14160, DOI 10.1074/jbc.M109.094813; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Kawai S, 2012, J CELL BIOL, V197, P201, DOI 10.1083/jcb.201110008; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Liu RF, 2013, CANCER LETT, V329, P164, DOI 10.1016/j.canlet.2012.10.027; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Marasa BS, 2010, AGING-US, V2, P333, DOI 10.18632/aging.100159; Masciarelli S, 2014, ONCOGENE, V33, P1601, DOI 10.1038/onc.2013.106; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2014, J BIOL CHEM, V289, P122, DOI 10.1074/jbc.M113.502138; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; Nohata N, 2012, ONCOTARGET, V3, P9; Pinho FG, 2013, CANCER RES, V73, P5936, DOI 10.1158/0008-5472.CAN-13-0158; Subramanian M, 2015, ONCOGENE, V34, P1094, DOI 10.1038/onc.2014.46; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Trisciuoglio D, 2012, CLIN CANCER RES, V18, P475, DOI 10.1158/1078-0432.CCR-11-0579; Tu YY, 2013, CANCER RES, V73, P6046, DOI 10.1158/0008-5472.CAN-13-0358; Ubertini V, 2015, ONCOGENE, V34, P2493, DOI 10.1038/onc.2014.191; Uhlmann-Schiffler H, 2002, J BIOL CHEM, V277, P1066, DOI 10.1074/jbc.M107535200; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Wang W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.97; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wu LF, 2011, FEBS LETT, V585, P1322, DOI 10.1016/j.febslet.2011.03.067; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yoshitomi T, 2011, ONCOL REP, V25, P1661, DOI 10.3892/or.2011.1253; Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28; Zhang MX, 2012, FEBS LETT, V586, P3508, DOI 10.1016/j.febslet.2012.08.007	60	31	32	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3760	3770		10.1038/onc.2016.51	http://dx.doi.org/10.1038/onc.2016.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26996669				2022-12-28	WOS:000380753200002
J	Zhou, L; Lyons-Rimmer, J; Ammoun, S; Muller, J; Lasonder, E; Sharma, V; Ercolano, E; Hilton, D; Taiwo, I; Barczyk, M; Hanemann, CO				Zhou, L.; Lyons-Rimmer, J.; Ammoun, S.; Mueller, J.; Lasonder, E.; Sharma, V.; Ercolano, E.; Hilton, D.; Taiwo, I.; Barczyk, M.; Hanemann, C. O.			The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors	ONCOGENE			English	Article							KINASE SUPPRESSOR; HUMAN SCHWANNOMA; MAPK SCAFFOLD; GENE ENCODES; RAS; ACTIVATION; ERK; PROLIFERATION; TUMORIGENESIS; INHIBITION	Merlin has broad tumor-suppressor functions as its mutations have been identified in multiple benign tumors and malignant cancers. In all schwannomas, the majority of meningiomas and 1/3 of ependymomas Merlin loss is causative. In neurofibromatosis type 2, a dominantly inherited tumor disease because of the loss of Merlin, patients suffer from multiple nervous system tumors and die on average around age 40. Chemotherapy is not effective and tumor localization and multiplicity make surgery and radiosurgery challenging and morbidity is often considerable. Thus, a new therapeutic approach is needed for these tumors. Using a primary human in vitro model for Merlin-deficient tumors, we report that the Ras/Raf/mitogen-activated protein, extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) scaffold, kinase suppressor of Ras 1 (KSR1), has a vital role in promoting schwannomas development. We show that KSR1 overexpression is involved in many pathological phenotypes caused by Merlin loss, namely multipolar morphology, enhanced cell-matrix adhesion, focal adhesion and, most importantly, increased proliferation and survival. Our data demonstrate that KSR1 has a wider role than MEK1/2 in the development of schwannomas because adhesion is more dependent on KSR1 than MEK1/2. Immunoprecipitation analysis reveals that KSR1 is a novel binding partner of Merlin, which suppresses KSR1's function by inhibiting the binding between KSR1 and c-Raf. Our proteomic analysis also demonstrates that KSR1 interacts with several Merlin downstream effectors, including E3 ubiquitin ligase CRL4(DCAF1). Further functional studies suggests that KSR1 and DCAF1 may co-operate to regulate schwannomas formation. Taken together, these findings suggest that KSR1 serves as a potential therapeutic target for Merlin-deficient tumors.	[Zhou, L.; Lyons-Rimmer, J.; Ammoun, S.; Ercolano, E.; Taiwo, I.; Hanemann, C. O.] Univ Plymouth, Peninsula Sch Med & Dent, Inst Translat & Stratified Med, John Bull Bldg,Plymouth Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England; [Mueller, J.] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England; [Mueller, J.] Aston Univ, Aston Med Sch, Aston Med Res Inst, Birmingham, W Midlands, England; [Lasonder, E.; Sharma, V.] Univ Plymouth, Peninsula Sch Med & Dent, Sch Biomed & Healthcare Sci, Plymouth, Devon, England; [Hilton, D.] Derriford Hosp, Dept Neuropathol, Plymouth, Devon, England; [Barczyk, M.] MRC Lab Mol Biol, Cell Biol, Cambridge, England	University of Plymouth; University of Warwick; Aston University; University of Plymouth; Derriford Hospital; MRC Laboratory Molecular Biology	Zhou, L (corresponding author), Univ Plymouth, Peninsula Sch Med & Dent, Inst Translat & Stratified Med, John Bull Bldg,Plymouth Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England.	lu.zhou@plymouth.ac.uk	Hanemann, C Oliver/AAV-6257-2020	Hanemann, C Oliver/0000-0002-1951-1025; Lasonder, Edwin/0000-0003-2582-3444	Children's Tumor Foundation young investigator award; Brain Tumor Research Charity PhD studentship; Medical Research Council [G0600790] Funding Source: researchfish; MRC [G0600790] Funding Source: UKRI	Children's Tumor Foundation young investigator award; Brain Tumor Research Charity PhD studentship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	LZ is supported by a Children's Tumor Foundation young investigator award. JL-R is supported by Brain Tumor Research Charity PhD studentship.	Ammoun S, 2015, MOL ONCOL, V9, P236, DOI 10.1016/j.molonc.2014.08.005; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2012, GLIA, V60, P1721, DOI 10.1002/glia.22391; Ammoun S, 2010, NEUROBIOL DIS, V37, P141, DOI 10.1016/j.nbd.2009.09.017; Brennan JA, 2002, J BIOL CHEM, V277, P5369, DOI 10.1074/jbc.M109875200; Canal F, 2011, FASEB J, V25, P2362, DOI 10.1096/fj.10-173153; Dougherty MK, 2009, MOL CELL, V34, P652, DOI 10.1016/j.molcel.2009.06.001; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; Evans DGR, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-16; Flaiz C, 2007, J NEUROPATH EXP NEUR, V66, P608, DOI 10.1097/nen.0b013e318093e555; Hanemann CO, 2008, BRAIN, V131, P606, DOI 10.1093/brain/awm249; Hanemann CO, 2006, NEUROPATH APPL NEURO, V32, P605, DOI 10.1111/j.1365-2990.2006.00769.x; Hilton DA, 2009, HISTOPATHOLOGY, V55, P744, DOI 10.1111/j.1365-2559.2009.03440.x; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Li B, 2013, NEOPLASMA, V60, P406, DOI 10.4149/neo_2013_052; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Llobet D, 2011, AM J PATHOL, V178, P1529, DOI 10.1016/j.ajpath.2010.12.041; Lozano J, 2003, CANCER RES, V63, P4232; McKay MM, 2010, METHODS MOL BIOL, V661, P323, DOI 10.1007/978-1-60761-795-2_19; McKay MM, 2009, P NATL ACAD SCI USA, V106, P11022, DOI 10.1073/pnas.0901590106; Morrison DK, 2001, J CELL SCI, V114, P1609; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Stebbing J, 2015, ONCOGENE, V34, P2103, DOI 10.1038/onc.2014.129; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Szatmari E, 2007, J NEUROSCI, V27, P11389, DOI 10.1523/JNEUROSCI.3473-07.2007; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Utermark T, 2003, BRAIN PATHOL, V13, P352; Zhang H, 2013, BRIT J CANCER, V109, P2675, DOI 10.1038/bjc.2013.628; Zhou L, 2012, FEBS LETT, V586, P1403, DOI 10.1016/j.febslet.2012.03.016; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	36	10	10	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3443	3453		10.1038/onc.2015.404	http://dx.doi.org/10.1038/onc.2015.404			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26549023	Green Accepted, Green Submitted			2022-12-28	WOS:000379270100009
J	Nowicka, AM; Hauselmann, I; Borsig, L; Bolduan, S; Schindler, M; Schraml, P; Heikenwalder, M; Moch, H				Nowicka, A. M.; Hauselmann, I.; Borsig, L.; Bolduan, S.; Schindler, M.; Schraml, P.; Heikenwalder, M.; Moch, H.			A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization	ONCOGENE			English	Article							NF-KAPPA-B; CELL-CARCINOMA; IKK COMPLEX; REGULATORY SUBUNIT; PROGNOSTIC VALUE; C-MYC; EXPRESSION; GAMMA; VHL; PHOSPHORYLATION	Activation of hypoxia-inducible factor (HIF) is due to loss of von Hippel-Lindau protein (pVHL) function in most clear cell renal cell carcinomas (ccRCCs). Here we describe a novel pVHL-independent mechanism of HIF regulation and identify nuclear factor (NF)-kappa B essential modulator (NEMO) as a hitherto unknown oncogenic factor influencing human ccRCC progression. Over 60% of human ccRCCs (n = 157) have negative or weak NEMO protein expression by immunohistochemistry. Moderate/strong NEMO protein expression is more frequent in VHL wild-type ccRCCs. We show that NEMO stabilizes HIFa via direct interaction and independently of NF-kappa B signaling in vitro. NEMO prolongs tumor cell survival via regulation of apoptosis and activation of epithelial-to-mesenchymal transition, facilitating tumor metastasis. Our findings suggest that NEMO-driven HIF activation is involved in progression of ccRCC. Therefore, NEMO may represent a clinically relevant link between NF-kappa B and the VHL/HIF pathways. Targeting NEMO with specific inhibitors in patients with metastatic ccRCC could be a novel treatment approach in patients with ccRCC expressing functional pVHL.	[Nowicka, A. M.; Schraml, P.; Heikenwalder, M.; Moch, H.] Univ Zurich Hosp, Inst Surg Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland; [Hauselmann, I.; Borsig, L.] Univ Zurich, Inst Physiol, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Bolduan, S.; Schindler, M.; Heikenwalder, M.] Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, Schneckenburgerstr 8, D-81675 Munich, Germany; [Heikenwalder, M.] German Canc Res Ctr DKFZ Heidelberg, Div Chron Inflammat & Canc, Heidelberg, Germany	University of Zurich; University Zurich Hospital; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Moch, H (corresponding author), Univ Zurich Hosp, Inst Surg Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.; Heikenwalder, M (corresponding author), Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, Schneckenburgerstr 8, D-81675 Munich, Germany.	heikenwaelder@helmholtz-muenchen.de; holger.moch@usz.ch	Schindler, Michael/C-1647-2015; Heikenwalder, Mathias/AAA-2269-2020	Schindler, Michael/0000-0001-8989-5813; Borsig, Lubor/0000-0003-2263-9545	Swiss National Science Foundation [3238BO-103145]; European Research Council (ERC) starting grant; Stiftung fur experimentelle Biomedizin (Peter-Hans Hofschneider foundation); pre-clinical comprehensive center (PCCC); Else Kroner-Fresenius Foundation; NCCR-Kidney.ch;  [SFB-TR36]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Research Council (ERC) starting grant(European Research Council (ERC)); Stiftung fur experimentelle Biomedizin (Peter-Hans Hofschneider foundation); pre-clinical comprehensive center (PCCC); Else Kroner-Fresenius Foundation; NCCR-Kidney.ch; 	We thank M Bieri from University Hospital Zurich for preparing the script and establishing a novel formula for TMA staining intensity measurement, M Storz and S Dettwiler from the tissue biobank, A Fitsche, O Buchi and C Mittmann from the University Hospital Zurich for the excellent technical support, Professor I Frew from the University of Zurich and Dr T O'Connor from the Technical University of Munich for their critical input and reading the manuscript. This work was supported by the Swiss National Science Foundation Grants (3238BO-103145 and Sinergia) to HM; European Research Council (ERC) starting grant, a grant by the Stiftung fur experimentelle Biomedizin (Peter-Hans Hofschneider foundation), the pre-clinical comprehensive center (PCCC), the SFB-TR36 and the Else Kroner-Fresenius Foundation to MH. AMN was supported by the NCCR-Kidney.ch.	Aigelsreiter A, 2012, HUM PATHOL, V43, P1012, DOI 10.1016/j.humpath.2011.08.009; An JB, 2005, MOL CELL BIOL, V25, P7546, DOI 10.1128/MCB.25.17.7546-7556.2005; [Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Banning C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009344; Beleut M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-310; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Bist P, 2011, ONCOGENE, V30, P3174, DOI 10.1038/onc.2011.28; Bracken CP, 2005, J BIOL CHEM, V280, P14240, DOI 10.1074/jbc.M409987200; Carvalho G, 2007, ONCOGENE, V26, P2299, DOI 10.1038/sj.onc.1210043; Dahinden C, 2010, CLIN CANCER RES, V16, P88, DOI 10.1158/1078-0432.CCR-09-0260; Fisher R, 2013, SEMIN CANCER BIOL, V23, P38, DOI 10.1016/j.semcancer.2012.06.004; Frew IJ, 2008, EMBO J, V27, P1747, DOI 10.1038/emboj.2008.96; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Gassenmaier M, 2013, STEM CELLS, V31, P1467, DOI 10.1002/stem.1407; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haybaeck J, 2009, CANCER CELL, V16, P295, DOI 10.1016/j.ccr.2009.08.021; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Irrinki KM, 2011, MOL CELL BIOL, V31, P3745, DOI 10.1128/MCB.05303-11; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim BY, 2010, FEBS LETT, V584, P4524, DOI 10.1016/j.febslet.2010.10.031; Konda R, 2008, J UROLOGY, V180, P481, DOI 10.1016/j.juro.2008.04.006; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Legarda-Addison D, 2009, CELL DEATH DIFFER, V16, P1279, DOI 10.1038/cdd.2009.41; Li GR, 2013, HISTOL HISTOPATHOL, V28, P1217, DOI 10.14670/HH-28.1217; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Luu VD, 2009, CLIN CANCER RES, V15, P3297, DOI 10.1158/1078-0432.CCR-08-2779; Maher ER, 2013, SEMIN CANCER BIOL, V23, P10, DOI 10.1016/j.semcancer.2012.06.003; Maier HJ, 2013, ONCOGENE, V32, P2690, DOI 10.1038/onc.2012.272; Meteoglu I, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-53; Morais C, 2010, APOPTOSIS, V15, P412, DOI 10.1007/s10495-009-0414-y; Oya M, 2003, CARCINOGENESIS, V24, P377, DOI 10.1093/carcin/24.3.377; Palkowitsch L, 2008, J BIOL CHEM, V283, P76, DOI 10.1074/jbc.M708856200; Pawlowski R, 2013, INT J CANCER, V132, pE11, DOI 10.1002/ijc.27822; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Qi H, 2003, CANCER RES, V63, P7076; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Rechsteiner MP, 2011, CANCER RES, V71, P5500, DOI 10.1158/0008-5472.CAN-11-0757; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakamoto K, 2013, ONCOGENE, V32, P1854, DOI 10.1038/onc.2012.192; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Schlesinger-Raab A, 2008, EUR J CANCER, V44, P2485, DOI 10.1016/j.ejca.2008.07.039; Schraml P, 2002, J PATHOL, V196, P186, DOI 10.1002/path.1034; Schultz L, 2011, AM J SURG PATHOL, V35, P1549, DOI 10.1097/PAS.0b013e31822895e5; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tang SW, 2009, CANCER LETT, V273, P35, DOI 10.1016/j.canlet.2008.07.038; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Vogetseder A, 2013, INT J CANCER, V133, P2362, DOI 10.1002/ijc.28267; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wyler L, 2014, BRIT J CANCER, V110, P686, DOI 10.1038/bjc.2013.755; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Young AC, 2009, CLIN CANCER RES, V15, P7582, DOI 10.1158/1078-0432.CCR-09-2131	58	9	9	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3125	3138		10.1038/onc.2015.400	http://dx.doi.org/10.1038/onc.2015.400			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26500060				2022-12-28	WOS:000378092700005
J	Xing, R; Li, L; Chen, L; Gao, Z; Wang, H; Li, W; Cui, J; Tian, G; Liang, Q; Yu, J; Sung, JJ; Luo, G; Gao, H; Xu, X; Yang, H; Wang, J; Zhang, X; Wang, JM; Huang, J; Yu, Y; Wang, J; Lu, Y				Xing, R.; Li, L.; Chen, L.; Gao, Z.; Wang, H.; Li, W.; Cui, J.; Tian, G.; Liang, Q.; Yu, J.; Sung, J. J.; Luo, G.; Gao, H.; Xu, X.; Yang, H.; Wang, J.; Zhang, X.; Wang, J. M.; Huang, J.; Yu, Y.; Wang, J.; Lu, Y.			Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells	ONCOGENE			English	Article							LUNG-CANCER; RECEPTORS NKP30; THERAPY; NKP44; GENE	Nude mice are important in vivo model for characterization of cell malignancy behavior; however, many cancer cells fail to form tumors in it. Understanding this defective mechanism may provide novel insights into tumorigenesis and how tumor cells escape innate immunity. Whole-genome sequencing was conducted on two gastric cancer (GC) cells, BGC823 and AGS, which do and do not form tumors in nude mice, to identify their genomic differences relevant to natural killer (NK) cells. We found that the tumorigenic capacity of human GC cell lines was dependent on the recruitment and activation of NK cells in xenograft tumors. We used whole-genome sequence (WGS) on GC cell lines to identify potential genes controlling susceptibility to NK-mediated killing. The tumorigenic cell line BGC823 expressed high levels of HLA-I because of copy gain and was resistant to NK cell killing. In contrast, another cell line AGS expressing low levels of HLA-I with activated NKp30/MAPK/IL-12 (interleukin-12) or IL-2 (interleukin-2) pathway was susceptible to NK lysis. Treatment of tumor bearing mice with systemic administration of IL-12 in combination with intratumor injection of anti-HLA-I antibody significantly increased NK cell recruitment into xenograft tumors, which became sensitive to NK killing, resulting in reduced tumor progression. In human GC specimens, decreased HLA-I expression and increased NK cells surrounding tumor cells were correlated with decreased metastasis potential and better prognosis of patients. Our results provide a mechanistic basis for GC cells to escape NK lysis and a promising prospect of NK immunotherapy for GC cells.	[Xing, R.; Wang, H.; Li, W.; Cui, J.; Lu, Y.] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Lab Mol Oncol,Minist Educ, Fu Cheng Rd 52, Beijing 100142, Peoples R China; [Li, L.; Chen, L.; Gao, Z.; Tian, G.; Xu, X.; Yang, H.; Wang, J.; Zhang, X.; Wang, J.] Beijing Genom Inst Shenzhen, Shenzhen 518083, Peoples R China; [Liang, Q.; Yu, J.; Sung, J. J.] Chinese Univ Hong Kong, Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Liang, Q.; Yu, J.; Sung, J. J.] Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Luo, G.] Case Western Reserve Univ, Sch Med, Dept Genet & Genome Sci, Cleveland, OH USA; [Luo, G.] Beijing Univ Chinese Med, Beijing, Peoples R China; [Gao, H.] Shanghai Engn Ctr Mol Med, Shanghai, Peoples R China; [Wang, J. M.; Huang, J.] NCI, Mol Immunoregulat Lab, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21701 USA; [Yu, Y.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200030, Peoples R China; [Yu, Y.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Surg, Shanghai 200030, Peoples R China	Peking University; Beijing Genomics Institute (BGI); Chinese University of Hong Kong; Chinese University of Hong Kong; Case Western Reserve University; Beijing University of Chinese Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Shanghai Jiao Tong University; Shanghai Jiao Tong University	Lu, Y (corresponding author), Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Lab Mol Oncol,Minist Educ, Fu Cheng Rd 52, Beijing 100142, Peoples R China.; Wang, J (corresponding author), Beijing Genom Inst Shenzhen, Shenzhen 518083, Peoples R China.	wangj@genomics.org.cn; youyonglu@bjmu.edu.cn	Wang, Huanting/G-8399-2011; Yu, Jun/D-8569-2015; Xu, Xun/AAI-6763-2020; Huang, Jiaqiang/C-2375-2011; Sung, Joseph J. Y./R-3203-2018; Liang, Qiaoyi Jessie/G-9612-2019	Wang, Huanting/0000-0002-9887-5555; Yu, Jun/0000-0001-5008-2153; Xu, Xun/0000-0002-5338-5173; Huang, Jiaqiang/0000-0002-6610-8159; Sung, Joseph J. Y./0000-0003-3125-5199; Liang, Qiaoyi Jessie/0000-0001-8496-3442	Ministry of Science and Technology of China (863 program) [2012AA02A203, 2012AA02A504]; Beijing Nova program [XXJH2015037, Z151100000315069]; NATIONAL CANCER INSTITUTE [ZIABC010725, ZIABC010015] Funding Source: NIH RePORTER	Ministry of Science and Technology of China (863 program)(Ministry of Science and Technology, ChinaNational High Technology Research and Development Program of China); Beijing Nova program(Beijing Municipal Science & Technology Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Richard Ascione (Department of Biochemistry and Molecular Biology, Medical School of Georgetown University USA) and Dr Laurie Goodman for critical reviewing and editing of the manuscript. This work was supported by the Ministry of Science and Technology of China (863 program, grants 2012AA02A203, 2012AA02A504) and Beijing Nova program (XXJH2015037, No.Z151100000315069).	Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cheng M, 2013, CELL MOL IMMUNOL, V10, P230, DOI 10.1038/cmi.2013.10; Farhan S, 2012, IMMUNOTHERAPY-UK, V4, P305, DOI [10.2217/IMT.11.174, 10.2217/imt.11.174]; Haraksingh RR, 2013, J MOL BIOL, V425, P3970, DOI 10.1016/j.jmb.2013.07.015; Hecht ML, 2009, J PROTEOME RES, V8, P712, DOI 10.1021/pr800747c; Hsieh CL, 2006, EUR J IMMUNOL, V36, P2170, DOI 10.1002/eji.200635982; Iliopoulou EG, 2010, CANCER IMMUNOL IMMUN, V59, P1781, DOI 10.1007/s00262-010-0904-3; Imai C, 2005, BLOOD, V106, P376, DOI 10.1182/blood-2004-12-4797; Langers I, 2012, BIOL-TARGETS THER, V6, P73, DOI 10.2147/BTT.S23976; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Miller CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016327; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Ni XH, 2013, P NATL ACAD SCI USA, V110, P21083, DOI 10.1073/pnas.1320659110; Ponnampalam AP, 2008, EUR J IMMUNOL, V38, P216, DOI 10.1002/eji.200636429; Santos GC, 2007, J CLIN PATHOL, V60, P1, DOI 10.1136/jcp.2005.034389; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Srivastava BIS, 2006, LEUKEMIA RES, V30, P37, DOI 10.1016/j.leukres.2005.06.020; Sun JC, 2011, NAT REV IMMUNOL, V11, P645, DOI 10.1038/nri3044; Xing R, 2012, GUT, V61, P43, DOI 10.1136/gut.2010.230623	19	7	7	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2584	2591		10.1038/onc.2015.324	http://dx.doi.org/10.1038/onc.2015.324			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364607	Green Accepted			2022-12-28	WOS:000376165700005
J	Koufaris, C; Valbuena, GN; Pomyen, Y; Tredwell, GD; Nevedomskaya, E; Lau, CHE; Yang, T; Benito, A; Ellis, JK; Keun, HC				Koufaris, C.; Valbuena, G. N.; Pomyen, Y.; Tredwell, G. D.; Nevedomskaya, E.; Lau, C-H E.; Yang, T.; Benito, A.; Ellis, J. K.; Keun, H. C.			Systematic integration of molecular profiles identifies miR-22 as a regulator of lipid and folate metabolism in breast cancer cells	ONCOGENE			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; ATP-CITRATE LYASE; TUMOR-SUPPRESSOR; BIOCONDUCTOR PACKAGE; MICRORNA-22; CONTRIBUTES; MODEL; PROLIFERATION; TRANSCRIPTION; SIGNATURE	Dysregulated microRNA (miRNA) mediate malignant phenotypes, including metabolic reprogramming. By performing an integrative analysis of miRNA and metabolome data for the NCI-60 cell line panel, we identified an miRNA cluster strongly associated with both c-Myc expression and global metabolic variation. Within this cluster the cancer-associated and cardioprotective miR-22 was shown to repress fatty acid synthesis and elongation in tumour cells by targeting ATP citrate lyase and fatty acid elongase 6, as well as impairing mitochondrial one-carbon metabolism by suppression of methylene tetrahydrofolate dehydrogenase/cyclohydrolase. Across several data sets, expression of these target genes were associated with poorer outcomes in breast cancer patients. Importantly, a beneficial effect of miR-22 on clinical outcomes in breast cancer was shown to depend on the expression levels of the identified target genes, demonstrating the relevance of miRNA/mRNA interactions to disease progression in vivo. Our systematic analysis establishes miR-22 as a novel regulator of tumour cell metabolism, a function that could contribute to the role of this miRNA in cellular differentiation and cancer development. Moreover, we provide a paradigmatic example of effect modification in outcome analysis as a consequence of miRNA-directed gene targeting, a phenomenon that could be exploited to improve patient prognosis and treatment.	[Koufaris, C.; Valbuena, G. N.; Pomyen, Y.; Tredwell, G. D.; Lau, C-H E.; Yang, T.; Benito, A.; Ellis, J. K.; Keun, H. C.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England; [Koufaris, C.] Cyprus Inst Neurol & Genet, Dept Cytogenet & Genom, Nicosia, Cyprus; [Pomyen, Y.] Chulabhorn Res Inst, Translat Res Unit, Bangkok, Thailand; [Nevedomskaya, E.] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Leiden, Netherlands; [Keun, H. C.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Syst Oncol & Canc Innovat, London, England	Imperial College London; Chulabhorn Research Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Imperial College London	Keun, HC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Div Canc, Inst Reprod & Dev Biol,Hammersmith Hosp, London W12 0NN, England.	h.keun@imperial.ac.uk	Koufaris, Costas/ABW-5036-2022; Tredwell, Greg/L-2294-2015; Lau, ChungHo/K-3557-2019	Koufaris, Costas/0000-0002-1222-5130; Tredwell, Greg/0000-0002-0020-5626; Lau, ChungHo/0000-0002-3602-8326; Benito, Adrian/0000-0002-8088-9537; Valbuena, Gabriel/0000-0001-6825-7214; Pomyen, Yotsawat/0000-0002-1070-3047	European Community's Seventh Framework Programme-Health project DETECTIVE [266838]; Cancer Research UK programme grant [A15115]; EC project Euro-MOTOR [259867]; UK Biotechnology and Biological Sciences Research Council (BBSRC) PhD studentship [BB/F529270/1]; Royal Thai Government Scholarship; UK MRC PhD studentship (Imperial College London Faculty of Medicine Doctoral Training Award); EC project HeCaTos [602156]; Medical Research Council [1416153] Funding Source: researchfish	European Community's Seventh Framework Programme-Health project DETECTIVE; Cancer Research UK programme grant(Cancer Research UK); EC project Euro-MOTOR; UK Biotechnology and Biological Sciences Research Council (BBSRC) PhD studentship; Royal Thai Government Scholarship; UK MRC PhD studentship (Imperial College London Faculty of Medicine Doctoral Training Award); EC project HeCaTos; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	HK, CK, GT and JE acknowledge support by the European Community's Seventh Framework Programme-Health (FP7/2007-2013) project DETECTIVE (grant agreement number 266838). HK and JE are also supported by Cancer Research UK programme grant A15115. HK and GV are supported by the EC FP7/2007-2013 project Euro-MOTOR (grant agreement number 259867). CHL is supported by a UK Biotechnology and Biological Sciences Research Council (BBSRC) PhD studentship (grant number BB/F529270/1 for the Institute of Chemical Biology (Imperial College London) Doctoral Training Centre). YP is supported by a Royal Thai Government Scholarship. TY is supported by a UK MRC PhD studentship (Imperial College London Faculty of Medicine Doctoral Training Award). AB is supported by the EC FP7/20132018 project HeCaTos (grant agreement number 602156). We also acknowledge valuable discussions with Dr Charlotte Bevan, Professor Charles Coombes, Dr Jake Bundy, Professor Nigel Gooderham and Dr Tim Ebbels.	Alvarez-Diaz S, 2012, HUM MOL GENET, V21, P2157, DOI 10.1093/hmg/dds031; Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Behrends V, 2011, ANAL BIOCHEM, V415, P206, DOI 10.1016/j.ab.2011.04.009; Bylesjo M, 2007, PLANT J, V52, P1181, DOI 10.1111/j.1365-313X.2007.03293.x; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; Doria ML, 2014, FASEB J, V28, P4247, DOI 10.1096/fj.14-249672; Duarte NC, 2007, P NATL ACAD SCI USA, V104, P1777, DOI 10.1073/pnas.0610772104; Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Guillou H, 2010, PROG LIPID RES, V49, P186, DOI 10.1016/j.plipres.2009.12.002; Gurha P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075882; Gurha P, 2012, CIRCULATION, V125, P2751, DOI 10.1161/CIRCULATIONAHA.111.044354; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Helton JC, 2006, RELIAB ENG SYST SAFE, V91, P1175, DOI 10.1016/j.ress.2005.11.017; Huang ZP, 2013, CIRC RES, V112, P1234, DOI 10.1161/CIRCRESAHA.112.300682; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; Kirwan GM, 2012, ANAL CHEM, V84, P7064, DOI 10.1021/ac301269r; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kong LM, 2014, CANCER RES, V74, P3764, DOI 10.1158/0008-5472.CAN-13-3555; Kuchen S, 2010, IMMUNITY, V32, P828, DOI 10.1016/j.immuni.2010.05.009; Lehtinen L, 2013, ONCOTARGET, V4, P48, DOI 10.18632/oncotarget.756; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; LligonaTrulla L, 1997, J LIPID RES, V38, P1454; Lu TP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042390; Marzi MJ, 2012, J CELL BIOL, V199, P77, DOI 10.1083/jcb.201206033; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Meiri E, 2010, NUCLEIC ACIDS RES, V38, P6234, DOI 10.1093/nar/gkq376; Migita T, 2014, INT J CANCER, V135, P37, DOI 10.1002/ijc.28652; Millard P, 2012, BIOINFORMATICS, V28, P1294, DOI 10.1093/bioinformatics/bts127; Muir K, 2013, CANCER RES, V73, P4722, DOI 10.1158/0008-5472.CAN-12-3797; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; National Cancer Institute, MOL TARG DAT NCI NIH; Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Pike ST, 2010, J BIOL CHEM, V285, P4612, DOI 10.1074/jbc.M109.079855; Polioudakis D, 2013, NUCLEIC ACIDS RES, V41, P2239, DOI 10.1093/nar/gks1452; Rantalainen M, 2006, J PROTEOME RES, V5, P2642, DOI 10.1021/pr060124w; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shin M, 2014, J BIOL CHEM, V289, P15507, DOI 10.1074/jbc.M114.555573; Sokilde R, 2011, MOL CANCER THER, V10, P375, DOI 10.1158/1535-7163.MCT-10-0605; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003; Stein SE, 1999, J AM SOC MASS SPECTR, V10, P770, DOI 10.1016/S1044-0305(99)00047-1; Tedeschi PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.393; Therneau T. M, 2015, SURVIVAL SURVIVAL AN; Trygg J, 2002, J CHEMOMETR, V16, P283, DOI 10.1002/cem.724; Trygg J, 2003, J CHEMOMETR, V17, P53, DOI 10.1002/cem.775; Tsuchiya N, 2011, CANCER RES, V71, P4628, DOI 10.1158/0008-5472.CAN-10-2475; Vecchione A, 2013, P NATL ACAD SCI USA, V110, P9845, DOI 10.1073/pnas.1305472110; Volinia S, 2013, P NATL ACAD SCI USA, V110, P7413, DOI 10.1073/pnas.1304977110; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605; Xiong J, 2010, ONCOGENE, V29, P4980, DOI 10.1038/onc.2010.241; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Xu XD, 2012, J CELL PHYSIOL, V227, P1391, DOI 10.1002/jcp.22852; Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	74	48	51	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2766	2776		10.1038/onc.2015.333	http://dx.doi.org/10.1038/onc.2015.333			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26477310	Green Submitted			2022-12-28	WOS:000377472700010
J	Prudnikova, TY; Villamar-Cruz, O; Rawat, SJ; Cai, KQ; Chernoff, J				Prudnikova, T. Y.; Villamar-Cruz, O.; Rawat, S. J.; Cai, K. Q.; Chernoff, J.			Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells	ONCOGENE			English	Article							BETA-CATENIN; SIGNALING PATHWAY; TUMOR-FORMATION; WILD-TYPE; PAK1; TRANSFORMATION; ACTIVATION; BLOCKS; GROWTH; AMPLIFICATION	p21-activated kinases (Paks) are Cdc42/Rac-activated serine-threonine protein kinases that regulate several key cancer-relevant signaling pathways, such as the Mek/Erk, PI3K/Akt and Wnt/b-catenin signaling pathways. Pak1 is frequently overexpressed and/or hyperactivated in different human cancers, including human breast, ovary, prostate and brain cancer, due to amplification of the PAK1 gene in an 11q13 amplicon. Genetic or pharmacological inactivation of Pak1 has been shown to reduce proliferation of different cancer cells in vitro and reduce tumor progression in vivo. In this work, we examined the roles of Pak1 in cellular and animal models of PAK1-amplified ovarian cancer. We found that inhibition of Pak1 leads to decreased proliferation and migration in PAK1-amplified/overexpressed ovarian cancer cells, and has no effect in cell that lack such amplification/overexpression. Further, we observed that loss of Pak1 function causes 11q13-amplified ovarian cancer cells to arrest in the G2/M phase of the cell cycle. This arrest correlates with activation of p53 and p21(Cip) and decreased expression of cyclin B1. These findings suggest that small-molecule inhibitors of Pak1 may have a therapeutic role in the similar to 25% of ovarian cancers characterized by PAK1 gene amplification.	[Prudnikova, T. Y.; Villamar-Cruz, O.; Rawat, S. J.; Chernoff, J.] Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave, Philadelphia, PA 19111 USA; [Cai, K. Q.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Jonathan.Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836; Villamar-Cruz, Olga/0000-0003-4265-9367	National Institutes of Health [R01-CA142928, R01-CA148805]; Ovarian SPORE [P50 CA083638]; Fox Chase Cancer Center [P30-CA006927]; State of Pennsylvania; NATIONAL CANCER INSTITUTE [R01CA148805, P50CA083638, R01CA142928, P30CA006927] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fox Chase Cancer Center; State of Pennsylvania; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M. Einarson (Fox Chase Cancer Center, High Throughput and Translational Core Facility) for assistance with cell cycle analysis and the Cell Culture Facility. We thank D. Connolly (FCCC), N. Tonks (CSHL) and G. Mills (MD Anderson) for ovarian cancer cell lines and for insightful comments on the manuscript. This work was supported by grants from the National Institutes of Health to JC (R01-CA142928 and R01-CA148805), Ovarian SPORE P50 CA083638 (Pilot Award to JC), Fox Chase Cancer Center (P30-CA006927), as well as by an appropriation from the State of Pennsylvania.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Choi JH, 2009, CANCER RES, V69, P1407, DOI 10.1158/0008-5472.CAN-08-3602; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Chow HY, 2015, ONCOTARGET, V6, P1981, DOI 10.18632/oncotarget.2810; Dadke D, 2003, CANCER RES, V63, P8837; Davidson B, 2008, HUM PATHOL, V39, P1630, DOI 10.1016/j.humpath.2008.03.009; de Feraudy S, 2010, P NATL ACAD SCI USA, V107, P6870, DOI 10.1073/pnas.1002175107; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Guan YQ, 2012, BIOMATERIALS, V33, P6162, DOI 10.1016/j.biomaterials.2012.05.037; Hashimoto H, 2009, DRUG DISCOV THER, V3, P243; Hashimoto H, 2010, DRUG DISCOV THER, V4, P1; He H, 2008, BBA-MOL CELL RES, V1783, P1943, DOI 10.1016/j.bbamcr.2008.04.016; He H, 2012, CANCER LETT, V317, P65, DOI 10.1016/j.canlet.2011.11.014; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Holm K, 2012, BREAST CANCER RES TR, V133, P583, DOI 10.1007/s10549-011-1817-3; Huynh N, 2010, BBA-MOL CELL RES, V1803, P1106, DOI 10.1016/j.bbamcr.2010.05.007; Lambros MBK, 2005, J PATHOL, V205, P29, DOI 10.1002/path.1681; Limame R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046536; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Lundgren K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2150; Merabet A, 2010, BIOCHEM J, V427, P225, DOI 10.1042/BJ20091888; Motwani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066585; Murray BW, 2010, P NATL ACAD SCI USA, V107, P9446, DOI 10.1073/pnas.0911863107; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Prudnikova TY, 2015, CLIN CANCER RES, V21, P24, DOI 10.1158/1078-0432.CCR-14-0827; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shrestha Y, 2012, ONCOGENE, V31, P3397, DOI 10.1038/onc.2011.515; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wang ZP, 2013, J BIOL CHEM, V288, P20093, DOI 10.1074/jbc.M112.426023; Wu JY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0014-8; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yi CL, 2008, CANCER RES, V68, P7932, DOI 10.1158/0008-5472.CAN-08-0866	43	19	20	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2178	2185		10.1038/onc.2015.278	http://dx.doi.org/10.1038/onc.2015.278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26257058	Green Accepted			2022-12-28	WOS:000374986000004
J	Howley, BV; Hussey, GS; Link, LA; Howe, PH				Howley, B. V.; Hussey, G. S.; Link, L. A.; Howe, P. H.			Translational regulation of inhibin beta A by TGF beta via the RNA-binding protein hnRNP E1 enhances the invasiveness of epithelial-to-mesenchymal transitioned cells	ONCOGENE			English	Article							ACTIVIN-A; STEM-CELLS; BREAST; CANCER; EXPRESSION; ACTIVATION; PATHWAY; STATES; INHBA	The epithelial-to-mesenchymal transition (EMT) is a cellular process that functions during embryonic development and tissue regeneration, thought to be aberrantly activated in epithelial-derived cancer and has an important role in the process of metastasis. The transforming growth factor (TGF)-beta signaling pathway is a key inducer of EMT and we have elucidated a posttranscriptional mechanism by which TGF beta modulates expression of select transcripts via the RNA-binding protein hnRNP E1 during EMT. One such transcript inhibin beta A is a member of the TGF beta superfamily. Here, we show by polysome profiling that inhibin beta A is translationally regulated by TGF beta via hnRNP E1. TGF beta treatment or knockdown of hnRNP E1 relieves silencing of the inhibin beta A transcript, resulting in increased protein expression and secreted levels of the inhibin beta A homodimer, activin A. Our data indicate that the translational upregulation of inhibin beta A enhances the migration and invasion of cells that have undergone an EMT and promotes cancer progression in vivo.	[Howley, B. V.; Hussey, G. S.; Link, L. A.; Howe, P. H.] Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,MSC 509,Room 501, Charleston, SC 29425 USA; [Howley, B. V.; Hussey, G. S.; Link, L. A.; Howe, P. H.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Link, L. A.] Kent State Univ, Dept Biomed Sci, Kent, OH 44242 USA	Medical University of South Carolina; Medical University of South Carolina; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Howe, PH (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,MSC 509,Room 501, Charleston, SC 29425 USA.	howep@musc.edu			National Cancer Institute [CA055536, CA154663]; Abney Foundation; American Heart Association Pre-doctoral Fellowship [10PRE3870024]; National Institute of General Medicine [P30GM103331, P30GM103342, P30CA138313]; Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC; Gene Targeting and Knockout Shared Resource at MUSC; NATIONAL CANCER INSTITUTE [R01CA154663, R01CA055536] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Abney Foundation; American Heart Association Pre-doctoral Fellowship(American Heart Association); National Institute of General Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC; Gene Targeting and Knockout Shared Resource at MUSC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA055536 and CA154663 from the National Cancer Institute. BVH was supported by funding from the Abney Foundation. GSH was supported by an American Heart Association Pre-doctoral Fellowship 10PRE3870024. This study used the services of the MUSC Center for Oral Health Research (COHR), which is partially supported by the National Institute of General Medicine grant P30GM103331, the MUSC Flow Cytometry Facility which is supported by P30GM103342, the Cell & Molecular Imaging Shared Resource of MUSC supported by P30CA138313, the Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC and the Gene Targeting and Knockout Shared Resource at MUSC. We would like to thank Maya El Sabban for assisting us with xenograft experiments.	Antenos M, 2007, MOL ENDOCRINOL, V21, P1670, DOI 10.1210/me.2007-0050; Arai KY, 2011, ENDOCRINOLOGY, V152, P3779, DOI 10.1210/en.2011-0255; Burdette JE, 2005, CANCER RES, V65, P7968, DOI 10.1158/0008-5472.CAN-04-3553; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Hussey GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052624; Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003; Kang HY, 2009, J BONE MINER RES, V24, P1180, DOI [10.1359/JBMR.090219, 10.1359/jbmr.090219]; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim H, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-51; Le Bras GF, 2014, LAB INVEST, V94, P1134, DOI 10.1038/labinvest.2014.97; Lee KL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002130; Leto G, 2006, CLIN EXP METASTAS, V23, P117, DOI 10.1007/s10585-006-9010-5; LI RH, 1995, ENDOCRINOLOGY, V136, P849, DOI 10.1210/en.136.3.849; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; OGAWA Y, 1992, J BIOL CHEM, V267, P14233; Pearson S, 2008, DEVELOPMENT, V135, P1525, DOI 10.1242/dev.011767; Piek E, 1999, J CELL SCI, V112, P4557; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Reis FM, 2002, J CLIN ENDOCR METAB, V87, P2277, DOI 10.1210/jc.87.5.2277; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Seder CW, 2009, NEOPLASIA, V11, P388, DOI 10.1593/neo.81582; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Walia V, 2010, STEM CELLS DEV, V19, P1175, DOI 10.1089/scd.2009.0430; Wamsley JJ, 2015, CANCER RES, V75, P426, DOI 10.1158/0008-5472.CAN-13-2702; Wang Q, 2012, MED ONCOL, V29, P77, DOI 10.1007/s12032-010-9766-y; Wildi S, 2001, GUT, V49, P409, DOI 10.1136/gut.49.3.409	32	25	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1725	1735		10.1038/onc.2015.238	http://dx.doi.org/10.1038/onc.2015.238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096938	Green Accepted			2022-12-28	WOS:000373064200011
J	Cisowski, J; Sayin, VI; Liu, M; Karlsson, C; Bergo, MO				Cisowski, J.; Sayin, V. I.; Liu, M.; Karlsson, C.; Bergo, M. O.			Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF	ONCOGENE			English	Article							HUMAN-MELANOMA; RAS ONCOGENES; LUNG-CANCER; K-RAS; MUTATIONS; PATHWAY; BRAF(V600E); PROGRESSION; NRAS(Q61R); ACTIVATION	KRAS and BRAF are among the most commonly mutated oncogenes in human cancer that contribute to tumorigenesis in both distinct and overlapping tissues. However, KRAS and BRAF mutations are mutually exclusive; they never occur in the same tumor cell. The reason for the mutual exclusivity is unknown, but there are several possibilities. The two mutations could be functionally redundant and not create a selective advantage to tumor cells. Alternatively, they could be deleterious for the tumor cell and induce apoptosis or senescence. To distinguish between these possibilities, we activated the expression of BRAF(V600E) and KRAS(G12D) from their endogenous promoters in mouse lungs. Although the tumor-forming ability of BRAF(V600E) was higher than KRAS(G12D), KRAS(G12D) tumors were larger and more advanced. Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone. Moreover, several tumors expressed only one oncogene, suggesting negative selection against expression of both. Similarly, expression of both oncogenes in mouse embryonic fibroblasts essentially stopped proliferation. The expression of both oncogenes hyperactivated the MEK-ERK-cyclin D pathway but reduced proliferation by increasing the production of p15, p16 and p19 proteins encoded by the Ink4/Arf locus and thereby increased senescence-associated beta-galactosidase-positive cells. The data suggest that coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene-induced senescence.	[Cisowski, J.; Sayin, V. I.; Karlsson, C.; Bergo, M. O.] Univ Gothenburg, Inst Med, Sahlgrenska Canc Ctr, Dept Mol & Clin Med, Med Gatan 1G,POB 425, S-41390 Gothenburg, Sweden; [Sayin, V. I.] Univ Gothenburg, Inst Med, Wallenberg Lab, Dept Mol & Clin Med, S-41390 Gothenburg, Sweden; [Liu, M.] Univ Gothenburg, Inst Biomed, Dept Clin Chem & Transfus Med, S-41390 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Bergo, MO (corresponding author), Univ Gothenburg, Inst Med, Sahlgrenska Canc Ctr, Dept Mol & Clin Med, Med Gatan 1G,POB 425, S-41390 Gothenburg, Sweden.	martin.bergo@gu.se		Liu, Viktor/0000-0003-2865-034X	Swedish Cancer Society; Swedish Research Council; Goran Gustafsson Foundation; Swedish Children's Cancer Fund; BioCARE-a strategic research program at the University of Gothenburg; Ingabritt and Arne Lundberg's Research Foundation; Assar Gabrielsson Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Goran Gustafsson Foundation; Swedish Children's Cancer Fund; BioCARE-a strategic research program at the University of Gothenburg; Ingabritt and Arne Lundberg's Research Foundation; Assar Gabrielsson Foundation	We thank R Ister for technical assistance. This study was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Goran Gustafsson Foundation, the Swedish Children's Cancer Fund, BioCARE-a strategic research program at the University of Gothenburg, and Ingabritt and Arne Lundberg's Research Foundation (to MOB); and the Assar Gabrielsson Foundation (to VIS).	Alsina J, 2003, CLIN CANCER RES, V9, P6419; Andreadi C, 2012, GENE DEV, V26, P1945, DOI 10.1101/gad.193458.112; Borras E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-406; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goydos JS, 2005, J AM COLL SURGEONS, V200, P362, DOI 10.1016/j.jamcollsurg.2004.10.032; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Karreth FA, 2009, MOL CELL, V36, P477, DOI 10.1016/j.molcel.2009.10.017; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Maitra A, 2006, BEST PRACT RES CL GA, V20, P211, DOI 10.1016/j.bpg.2005.10.002; Matallanas D, 2011, MOL CELL, V44, P893, DOI 10.1016/j.molcel.2011.10.016; Monticone M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-92; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Petti C, 2006, CANCER RES, V66, P6503, DOI 10.1158/0008-5472.CAN-05-4671; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Sayin VI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055720; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Seth R, 2009, GUT, V58, P1234, DOI 10.1136/gut.2008.159137; Trejo CL, 2012, CANCER RES, V72, P3048, DOI 10.1158/0008-5472.CAN-11-3649; Vandal G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084745; Yeang CH, 2008, FASEB J, V22, P2605, DOI 10.1096/fj.08-108985	26	51	51	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1328	1333		10.1038/onc.2015.186	http://dx.doi.org/10.1038/onc.2015.186			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028035				2022-12-28	WOS:000371763100013
J	Paranjape, AN; Soundararajan, R; Werden, SJ; Joseph, R; Taube, JH; Liu, H; Rodriguez-Canales, J; Sphyris, N; Wistuba, I; Miura, N; Dhillon, J; Mahajan, N; Mahajan, K; Chang, JT; Ittmann, M; Maity, SN; Logothetis, C; Tang, DG; Mani, SA				Paranjape, A. N.; Soundararajan, R.; Werden, S. J.; Joseph, R.; Taube, J. H.; Liu, H.; Rodriguez-Canales, J.; Sphyris, N.; Wistuba, I.; Miura, N.; Dhillon, J.; Mahajan, N.; Mahajan, K.; Chang, J. T.; Ittmann, M.; Maity, S. N.; Logothetis, C.; Tang, D. G.; Mani, S. A.			Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; BREAST-CANCER; NEUROENDOCRINE DIFFERENTIATION; AGGRESSIVE PHENOTYPE; KINASE INHIBITORS; RESISTANCE; METASTASIS; ACTIVATION; P38	Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are difficult to treat, and account for up to 30% of prostate cancer-related deaths every year. While existing therapies for prostate cancer such as androgen deprivation therapy (ADT), destroy the bulk of the AR-positive cells within the tumor, eradicating this population eventually leads to castration-resistance, owing to the continued survival of AR-/lo stem-like cells. In this study, we identified a critical nexus between p38MAPK signaling, and the transcription factor Forkhead Box Protein C2 (FOXC2) known to promote cancer stem-cells and metastasis. We demonstrate that prostate cancer cells that are insensitive to ADT, as well as high-grade/NE prostate tumors, are characterized by elevated FOXC2, and that targeting FOXC2 using a well-tolerated p38 inhibitor restores epithelial attributes and ADT-sensitivity, and reduces the shedding of circulating tumor cells in vivo with significant shrinkage in the tumor mass. This study thus specifies a tangible mechanism to target the AR-/lo population of prostate cancer cells with stem-cell properties.	[Paranjape, A. N.; Soundararajan, R.; Werden, S. J.; Joseph, R.; Taube, J. H.; Liu, H.; Rodriguez-Canales, J.; Sphyris, N.; Wistuba, I.; Mani, S. A.] UT MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd,LSP9-2001, Houston, TX USA; [Miura, N.] Hamamatsu Univ, Sch Med, Dept Biochem, Hamamatsu, Shizuoka, Japan; [Dhillon, J.; Mahajan, N.; Mahajan, K.] Univ S Florida, Dept Oncol Sci, Moffitt Canc Ctr, Tampa, FL USA; [Chang, J. T.] UT Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Sch Med, Sch Biomed Informat, Houston, TX USA; [Ittmann, M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Maity, S. N.; Logothetis, C.] UT MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA; [Tang, D. G.] UT MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Sci Pk, Smithville, TX USA; [Mani, S. A.] UT MD Anderson Canc Ctr, Metastasis Res Ctr, Houston, TX USA; [Mani, S. A.] UT MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; Hamamatsu University School of Medicine; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mani, SA (corresponding author), UT MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd,LSP9-2001, Houston, TX USA.	mani@mdanderson.org	Tang, Dean/AAI-3457-2020; Paranjape, Anurag N./P-1255-2018; SPHYRIS, NATHALIE/GQY-6349-2022; Liu, Hui/AAJ-4339-2020; Mani, Sendurai A./A-7244-2009	Tang, Dean/0000-0001-5029-1174; Paranjape, Anurag N./0000-0001-6119-0766; Liu, Hui/0000-0002-7669-9386; Mani, Sendurai A./0000-0002-5918-4276; Sphyris, Nathalie/0000-0003-1860-1958; Taube, Joseph/0000-0002-3636-5189; Joseph, Robiya/0000-0003-3214-890X; Mahajan, Kiran/0000-0001-7192-396X; Maity, Sankar/0000-0002-2387-6545	American Cancer Society M Patricia Alexander Research Scholar award; MDACC Prostate-SPORE [NIH R01 CA155243]; NATIONAL CANCER INSTITUTE [R01CA155243, P30CA016672] Funding Source: NIH RePORTER	American Cancer Society M Patricia Alexander Research Scholar award; MDACC Prostate-SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Neeraja Bhangre for technical assistance and Dr Sue-Hwa Lin for helpful discussions. This research was supported by grants from MDACC Prostate-SPORE, NIH R01 CA155243 and the American Cancer Society M Patricia Alexander Research Scholar award.	Aggarwal R, 2014, J NATL COMPR CANC NE, V12, P719, DOI 10.6004/jnccn.2014.0073; Aparicio A, 2011, PROSTATE, V71, P846, DOI 10.1002/pros.21301; Balbas MD, 2013, ELIFE, V2, DOI 10.7554/eLife.00499; Castillo V, 2014, INT J ONCOL, V45, P985, DOI 10.3892/ijo.2014.2529; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Cheriyan J, 2011, CIRCULATION, V123, P515, DOI 10.1161/CIRCULATIONAHA.110.971986; Cohen S, 2010, CURR OPIN RHEUMATOL, V22, P330, DOI 10.1097/BOR.0b013e3283378e6f; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Friedlander TW, 2014, INT J CANCER, V134, P2284, DOI 10.1002/ijc.28561; Gan L, 2011, PROSTATE, V71, P1158, DOI 10.1002/pros.21331; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242; Izumi K, 2013, EMBO MOL MED, V5, P1383, DOI 10.1002/emmm.201202367; Khandrika L, 2009, ONCOGENE, V28, P1248, DOI 10.1038/onc.2008.476; Koul Hari K, 2013, Genes Cancer, V4, P342, DOI 10.1177/1947601913507951; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Li P, 2014, EXP BIOL MED, V239, P813, DOI 10.1177/1535370214538727; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Ma B, 2014, J BIOL CHEM, V289, P11153, DOI 10.1074/jbc.M113.540237; MacNee W, 2013, THORAX, V68, P738, DOI 10.1136/thoraxjnl-2012-202744; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Marin-Aguilera M, 2014, MOL CANCER THER, V13, P1270, DOI 10.1158/1535-7163.MCT-13-0775; McKeithen D, 2010, PROSTATE, V70, P982, DOI 10.1002/pros.21132; Milone MR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.165; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Nouri M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00370; Paranjape AN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-785; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Ricote M, 2006, APOPTOSIS, V11, P1969, DOI 10.1007/s10495-006-0086-9; Santoni M, 2014, BBA-REV CANCER, V1846, P630, DOI 10.1016/j.bbcan.2014.10.008; Sarkar TR, 2015, ONCOGENE, V34, P2958, DOI 10.1038/onc.2014.245; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shida Y, 2007, BIOCHEM BIOPH RES CO, V353, P744, DOI 10.1016/j.bbrc.2006.12.077; Shiota M, 2012, CANCER RES, V72, P5261, DOI 10.1158/0008-5472.CAN-12-0254; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tamaki H, 2014, ONCOTARGET, V5, P11399, DOI 10.18632/oncotarget.2550; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tzelepi V, 2012, CLIN CANCER RES, V18, P666, DOI 10.1158/1078-0432.CCR-11-1867; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Zhu ML, 2010, FASEB J, V24, P769, DOI 10.1096/fj.09-136994	47	51	53	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5963	5976		10.1038/onc.2015.498	http://dx.doi.org/10.1038/onc.2015.498			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	26804168	hybrid, Green Published			2022-12-28	WOS:000388509400004
J	Liu, W; Li, H; Hong, SH; Piszczek, GP; Chen, W; Rodgers, GP				Liu, W.; Li, H.; Hong, S-H; Piszczek, G. P.; Chen, W.; Rodgers, G. P.			Olfactomedin 4 deletion induces colon adenocarcinoma in ApcMin/+ mice	ONCOGENE			English	Article							NF-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; BETA-CATENIN EXPRESSION; STAPHYLOCOCCUS-AUREUS; COLORECTAL-CANCER; HGC-1; ACTIVATION; OLFM4; DIFFERENTIATION; SUSCEPTIBILITY	Colon carcinogenesis is a multiple-step process involving the accumulation of a series of genetic and epigenetic alterations. The most commonly initiating event of intestinal carcinogenesis is mutation of the adenomatous polyposis coli (APC) gene, which leads to activation of the Wnt/beta-catenin pathway. Olfactomedin 4 (OLFM4) has emerged as an intestinal stem-cell marker, but its biological function in the intestine remains to be determined. Here we show that Olfm4 deletion induced colon adenocarcinoma in the distal colon of Apc(Min/+) mice. Mechanistically, we found that OLFM4 is a target gene of the Wnt/beta-catenin pathway and can downregulate beta-catenin signaling by competing with Wnt ligands for binding to Frizzled receptors, as well as by inhibition of the Akt-GSK-3 beta (Akt-glycogen synthase kinase-3 beta) pathway. We have shown that both Wnt and nuclear factor-kappa B (NF-kappa B) signaling were boosted in tumor tissues of Apc Olfm4 double-mutant mice. These data establish OLFM4 as a critical negative regulator of the Wnt/beta-catenin and NF-kappa B pathways that inhibits colon-cancer development initiated by APC mutation. In addition, Olfm4 deletion significantly enhanced intestinal-crypt proliferation and inflammation induced by azoxymethane/dextran sodium sulfate. Thus, OLFM4 has an important role in the regulation of intestinal inflammation and tumorigenesis, and could be a potential therapeutic target for intestinal malignant tumors. Unlike the human colonic epithelium, the mouse colonic epithelium does not express OLFM4, but nevertheless, systemic OLFM4 deletion promotes colon tumorigenesis and that loss from mucosal neutrophils may have a role to play.	[Liu, W.; Li, H.; Hong, S-H; Rodgers, G. P.] NHLBI, Mol & Clin Hematol Branch, NIH, Bldg 10,Room 9N119,9000 Rockville Pike, Bethesda, MD 20892 USA; [Hong, S-H] Natl Canc Ctr, Canc Genom Branch, Goyang Si, Gyeonggi Do, South Korea; [Piszczek, G. P.] NHLBI, Biochem & Biophys Ctr, Bldg 10, Bethesda, MD 20892 USA; [Chen, W.] NIDDK, Genom Core Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Cancer Center - Korea (NCC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rodgers, GP (corresponding author), NHLBI, Mol & Clin Hematol Branch, NIH, Bldg 10,Room 9N119,9000 Rockville Pike, Bethesda, MD 20892 USA.	gr5n@nih.gov	Piszczek, Grzegorz/GYU-2029-2022		intramural research fund of the National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZICHL000338, ZIGHL006020, ZIAHL006004] Funding Source: NIH RePORTER	intramural research fund of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Michael A Eckhaus, National Institutes of Health, for the pathology assistance and Dr Ivan Ding, National Institutes of Health, for helpful suggestions and review of our manuscript. This study was supported by the intramural research fund of the National Institutes of Health.	Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Besson D, 2011, MOL CELL PROTEOMICS, V10, DOI [10.1074/mcp.M111.009712-1, 10.1074/mcp.M111.009712]; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Chin KL, 2008, BRIT J HAEMATOL, V143, P421, DOI 10.1111/j.1365-2141.2008.07368.x; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Gersemann M, 2012, J CROHNS COLITIS, V6, P425, DOI 10.1016/j.crohns.2011.09.013; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inomata M, 1996, CANCER RES, V56, P2213; Kaler P, 2009, CANCER MICROENVIRON, V2, P69, DOI 10.1007/s12307-009-0030-y; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kavandi L, 2012, J CELL BIOCHEM, V113, P3143, DOI 10.1002/jcb.24191; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kwon HS, 2009, MOL CELL BIOL, V29, P2139, DOI 10.1128/MCB.01274-08; Liu WL, 2008, CLIN CANCER RES, V14, P1041, DOI 10.1158/1078-0432.CCR-07-4125; Liu WL, 2006, EXP CELL RES, V312, P1785, DOI 10.1016/j.yexcr.2006.02.011; Liu WL, 2013, J CLIN INVEST, V123, P3751, DOI 10.1172/JCI68453; Liu WL, 2012, J IMMUNOL, V189, P2460, DOI 10.4049/jimmunol.1103179; Liu WL, 2010, BLOOD, V116, P4938, DOI 10.1182/blood-2009-10-246439; Liu WL, 2010, P NATL ACAD SCI USA, V107, P11056, DOI 10.1073/pnas.1001269107; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakaya N, 2008, J NEUROSCI, V28, P7900, DOI 10.1523/JNEUROSCI.0617-08.2008; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Rosenbauer F, 2004, BLOOD, V103, P4294, DOI 10.1182/blood-2003-08-2688; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Seko N, 2010, EXP THER MED, V1, P73, DOI 10.3892/etm_00000013; Shinozaki S, 2001, GUT, V48, P623, DOI 10.1136/gut.48.5.623; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; VanDussen KL, 2012, DEVELOPMENT, V139, P488, DOI 10.1242/dev.070763; Vlantis K, 2011, J CLIN INVEST, V121, P2781, DOI 10.1172/JCI45349; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6	42	48	48	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5237	5247		10.1038/onc.2016.58	http://dx.doi.org/10.1038/onc.2016.58			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26973250	Green Published, hybrid			2022-12-28	WOS:000386053000003
J	Kumar, A; Singhal, M; Chopra, C; Srinivasan, S; Surabhi, RP; Kanumuri, R; Tentu, S; Jagadeeshan, S; Sundaram, S; Ramanathan, K; Pitani, RS; Muthuswamy, B; Abhijit, S; Nair, AS; Venkatraman, G; Rayala, SK				Kumar, A.; Singhal, M.; Chopra, C.; Srinivasan, S.; Surabhi, R. P.; Kanumuri, R.; Tentu, S.; Jagadeeshan, S.; Sundaram, S.; Ramanathan, K.; Pitani, R. Shankar; Muthuswamy, B.; Abhijit, S.; Nair, A. S.; Venkatraman, G.; Rayala, S. K.			Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; PROMOTER HYPERMETHYLATION; PROTEIN MISLOCALIZATION; GASTRIC-CANCER; EXPRESSION; FAMILY	P21 Activated Kinase 1 (Pak1), an oncogenic serine/threonine kinase, is known to have a significant role in the regulation of cytoskeleton and cellular morphology. Runx3 was initially known for its role in tumor suppressor function, but recent studies have reported the oncogenic role of Runx3 in various cancers. However, the mechanism that controls the paradoxical functions of Runx3 still remains unclear. In this study, we show that Runx3 is a physiologically interacting substrate of Pak1. We identified the site of phosphorylation in Runx3 as Threonine 209 by mass spectrometry analysis and site-directed mutagenesis, and further confirmed the same with a site-specific antibody. Results from our functional studies showed that Threonine 209 phosphorylation in Runx3 alters its subcellular localization by protein mislocalization from the nucleus to the cytoplasm and subsequently converses its biological functions. This was further supported by in vivo tumor xenograft studies in nude mouse models which clearly demonstrated that PANC-28 cells transfected with the Runx3-T209E clone showed high tumorigenic potential as compared with other clones. Our results from clinical samples also suggest that Threonine 209 phosphorylation by Pak1 could be a potential therapeutic target and of great clinical relevance with implications for Runx3 inactivation in cancer cells where Runx3 is known to be oncogenic. The findings presented in this study provide evidence of Runx3-Threonine 209 phosphorylation as a molecular switch in dictating the tissue-specific dualistic functions of Runx3 for the first time.	[Kumar, A.; Singhal, M.; Chopra, C.; Srinivasan, S.; Surabhi, R. P.; Kanumuri, R.; Tentu, S.; Jagadeeshan, S.; Rayala, S. K.] IITM, Dept Biotechnol, Madras 600036, Tamil Nadu, India; [Sundaram, S.; Ramanathan, K.] Sri Ramachandra Univ, Dept Pathol, Madras, Tamil Nadu, India; [Pitani, R. Shankar] Sri Ramachandra Univ, Dept Community Med, Madras, Tamil Nadu, India; [Muthuswamy, B.; Abhijit, S.] MDRF, Madras, Tamil Nadu, India; [Nair, A. S.] RGCB, Thiruvananthapuram, Kerala, India; [Venkatraman, G.] Sri Ramachandra Univ, Dept Human Genet, Madras, Tamil Nadu, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); Sri Ramachandra Institute of Higher Education & Research	Rayala, SK (corresponding author), IITM, Dept Biotechnol, Madras 600036, Tamil Nadu, India.; Venkatraman, G (corresponding author), Sri Ramachandra Univ, Dept Human Genet, Madras, Tamil Nadu, India.	ganeshv@sriramachandra.edu.in; rayala@iitm.ac.in	Venkatraman, Ganesh/AAB-1467-2020; Singhal, Mahak/V-4017-2019; CHELLUBOYINA, ARUNA KUMAR/GZL-7536-2022; GAMPALA, SILPA/A-1541-2019; Gampala, Silpa/AAL-7982-2020; CHELLUBOYINA, ARUNA KUMAR/GXG-8165-2022; JAGADEESHAN, SANKAR/S-8384-2019; Kanumuri, Rahul Sankrityayan/AGF-8012-2022	Venkatraman, Ganesh/0000-0003-0179-9785; Singhal, Mahak/0000-0002-7303-9585; CHELLUBOYINA, ARUNA KUMAR/0000-0001-7201-3810; Gampala, Silpa/0000-0001-9928-3941; CHELLUBOYINA, ARUNA KUMAR/0000-0001-7201-3810; JAGADEESHAN, SANKAR/0000-0002-3778-8757; Kanumuri, Rahul Sankrityayan/0000-0001-6039-461X; Chopra, Chirag/0000-0002-7239-709X; Rayala, Suresh/0000-0003-4394-4450	DAE-BRNS Government of India [35/14/41/2014-BRNS-RTAC]; DBT Government of India [BT/PR14340/NNT/28/860/2015]	DAE-BRNS Government of India(Department of Atomic Energy (DAE)Board of Research in Nuclear Sciences (BRNS)); DBT Government of India(Department of Biotechnology (DBT) India)	We thank Prof Yoshiaki Ito, Cancer Science Institute of Singapore, Singapore, for providing us the Runx3 constructs. We profusely thank Prof Susanne M Gollin, University of Pittsburgh, for providing us with SCC-131 cells. We thank Dr Marsha Fraizer (University of Texas, M. D. Anderson Cancer Center, USA); for providing MDA Panc 28 cells. We thank Dr Rajeshwari, Bioklone, Chennai, for generating polyclonal Runx3-Threonine 209 phospho antibody. We thank DAE-BRNS (Grant # 35/14/41/2014-BRNS-RTAC), DBT (BT/PR14340/NNT/28/860/2015) Government of India for financial support to SKR and the Department of Biotechnology, Indian Institute of Technology Madras (IITM) for infrastructural facilities. We thank Mr Balabhaskara Rao and Ms Lakshmi Arivazhagan for the initial help with protein expression studies and Runx3 clones. We thank Professor SP Thyagarajan, Dean Research and Management of SRU for Support and encouragement.	Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Baross JA, 2015, CELL, V162, P13, DOI 10.1016/j.cell.2015.06.038; Chauang LS, 2013, INT J CANCER, V15, P1260; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Chuang LSH, 2013, INT J CANCER, V132, P1260, DOI 10.1002/ijc.27964; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Kudo Y, 2011, J CELL BIOCHEM, V112, P387, DOI 10.1002/jcb.22967; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee CWL, 2011, GYNECOL ONCOL, V122, P410, DOI 10.1016/j.ygyno.2011.04.044; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Tsang YHN, 2013, ONCOGENE, V32, P1488, DOI 10.1038/onc.2012.178; Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892; Yanagawa N, 2003, CANCER SCI, V94, P589, DOI 10.1111/j.1349-7006.2003.tb01487.x	19	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4857	4865		10.1038/onc.2016.18	http://dx.doi.org/10.1038/onc.2016.18			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26898755				2022-12-28	WOS:000383330700004
J	Park, CS; Kim, TK; Kim, HG; Kim, YJ; Jeoung, MH; Lee, WR; Go, NK; Heo, K; Lee, S				Park, C. S.; Kim, T-K; Kim, H. G.; Kim, Y-J; Jeoung, M. H.; Lee, W. R.; Go, N. K.; Heo, K.; Lee, S.			Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis	ONCOGENE			English	Article							COLORECTAL-CANCER; BREAST-CANCER; TUMOR-GROWTH; CO-029; ANTIBODY; DOMAIN; BEVACIZUMAB; MECHANISMS; CD151; CELLS	Epithelial ovarian cancer (EOC) invasion and metastasis are complex phenomena that result from the coordinated action of many metastatic regulators and must be overcome to improve clinical outcomes for patients with these cancers. The identification of novel therapeutic targets is critical because of the limited success of current treatment regimens, particularly in advanced-stage ovarian cancers. In this study, we found that tetraspanin 8 (TSPAN8) is overexpressed in about 52% (14/27) of EOC tissues and correlates with poor survival. Using small interfering RNA-mediated TSPAN8 knockdown and a competition assay with purified TSPAN8 large extracellular loop (TSPAN8-LEL) protein, we identified TSPAN8-LEL as a key regulator of EOC cell invasion. Furthermore, monotherapy with TSPAN8-blocking antibody we developed shows that antibody-based modulation of TSPAN8-LEL can significantly reduce the incidence of EOC metastasis without severe toxicity in vivo. Finally, we demonstrated that the TSPAN8-blocking antibody promotes the internalization and concomitant downregulation of cell surface TSPAN8. Collectively, our data suggest TSPAN8 as a potential novel therapeutic target in EOCs and antibody targeting of TSPAN8 as an effective strategy for inhibiting invasion and metastasis of TSPAN8-expressing EOCs.	[Park, C. S.; Kim, T-K; Jeoung, M. H.; Lee, W. R.; Go, N. K.; Lee, S.] Scripps Korea Antibody Inst, Lab Mol Canc Therapeut, Hyoja 2 Dong, Chuncheon Si 200701, Gangwon Do, South Korea; [Kim, H. G.; Heo, K.] Natl Canc Ctr, Res Inst, New Expt Therapeut Branch, 323 Ilsan Ro, Goyang Si 410769, South Korea; [Kim, Y-J] Natl Canc Ctr, Res Inst, Specif Organs Canc Branch, Goyang Si, South Korea; [Park, C. S.] Korea Inst Ceram Engn & Technol, Eco & Bio Convergence Team, 101 Soho Ro, Jinju Si 661031, Gyeongsangnam D, South Korea	National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); Korea Institute of Ceramic Engineering & Technology	Lee, S (corresponding author), Scripps Korea Antibody Inst, Lab Mol Canc Therapeut, Hyoja 2 Dong, Chuncheon Si 200701, Gangwon Do, South Korea.; Heo, K (corresponding author), Natl Canc Ctr, Res Inst, New Expt Therapeut Branch, 323 Ilsan Ro, Goyang Si 410769, South Korea.	hk@ncc.re.kr; lees@skai.or.kr			Scripps Korea Antibody Institute [10TS03]	Scripps Korea Antibody Institute	This work was supported by a research grant (10TS03) from the Scripps Korea Antibody Institute.	Ailane N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00364; Albanell J, 1999, J MAMMARY GLAND BIOL, V4, P337, DOI 10.1023/A:1018762216147; [Anonymous], 2011, J Natl Cancer Inst, V103, P1287, DOI 10.1093/jnci/djr342; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Huynh H, 2007, MOL CANCER THER, V6, P2959, DOI 10.1158/1535-7163.MCT-07-0237; Kanetaka K, 2003, J GASTROEN HEPATOL, V18, P1309, DOI 10.1046/j.1440-1746.2003.03182.x; Kanetaka K, 2001, J HEPATOL, V35, P637, DOI 10.1016/S0168-8278(01)00183-0; Keating GM, 2014, DRUGS, V74, P1891, DOI 10.1007/s40265-014-0302-9; Ki MK, 2013, ONCOGENE, V32, P5449, DOI 10.1038/onc.2013.156; Kim A, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-14; Kudo-Saito C, 2014, CANCER RES, V74, P1361, DOI 10.1158/0008-5472.CAN-13-1349; Kuhn S, 2007, MOL CANCER RES, V5, P553, DOI 10.1158/1541-7786.MCR-06-0384; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lee S, 2012, J IMMUNOL, V189, P4592, DOI 10.4049/jimmunol.1103803; Lennon S, 2009, J CLIN ONCOL, V27, P1685, DOI 10.1200/JCO.2008.16.8351; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Novoa-Vargas Arturo, 2014, Ginecol Obstet Mex, V82, P613; Okada Y, 2014, DIGESTION, V89, P18, DOI 10.1159/000356202; Payne SJL, 2008, HISTOPATHOLOGY, V52, P82, DOI 10.1111/j.1365-2559.2007.02897.x; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; Teo MCC, 2014, CURR OPIN OBSTET GYN, V26, P3, DOI 10.1097/GCO.0000000000000034; Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2; Xu Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-16; Yue SJ, 2013, EUR J CANCER, V49, P2934, DOI 10.1016/j.ejca.2013.03.032; Zhou Z, 2008, CLIN EXP METASTAS, V25, P537, DOI 10.1007/s10585-008-9168-0; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	28	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4540	4548		10.1038/onc.2015.520	http://dx.doi.org/10.1038/onc.2015.520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804173				2022-12-28	WOS:000382153100011
J	Ventura, S; Aryee, DNT; Felicetti, F; De Feo, A; Mancarella, C; Manara, MC; Picci, P; Colombo, MP; Kovar, H; Care, A; Scotlandi, K				Ventura, S.; Aryee, D. N. T.; Felicetti, F.; De Feo, A.; Mancarella, C.; Manara, M. C.; Picci, P.; Colombo, M. P.; Kovar, H.; Care, A.; Scotlandi, K.			CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-kappa B signaling	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; PANCREATIC-CANCER CELLS; OSTEOGENIC DIFFERENTIATION; GENOMIC LANDSCAPE; DOWN-REGULATION; FAMILY TUMORS; GROWTH-FACTOR; IN-VITRO; EXPRESSION; PATHWAY	Sarcomas are mesenchymal tumors characterized by blocked differentiation process. In Ewing sarcoma (EWS) both CD99 and EWS-FLI1 concur to oncogenesis and inhibition of differentiation. Here, we demonstrate that uncoupling CD99 from EWS-FLI1 by silencing the former, nuclear factor-kappa B (NF-kappa B) signaling is inhibited and the neural differentiation program is re-established. NF-kappa B inhibition passes through miR-34a-mediated repression of Notch pathway. CD99 counteracts EWS-FLI1 in controlling NF-kappa B signaling through the miR-34a, which is increased and secreted into exosomes released by CD99-silenced EWS cells. Delivery of exosomes from CD99-silenced cells was sufficient to induce neural differentiation in recipient EWS cells through miR-34a inhibition of Notch-NF-kappa B signaling. Notably, even the partial delivery of CD99 small interfering RNA may have a broad effect on the entire tumor cell population owing to the spread operated by their miR-34a-enriched exosomes, a feature opening to a new therapeutic option.	[Ventura, S.; Mancarella, C.; Manara, M. C.; Picci, P.; Scotlandi, K.] Ist Ortoped Rizzoli, Expt Oncol Lab, CRS Dev Biomol Therapies, Via Barbiano 1-10, I-40136 Bologna, Italy; [Aryee, D. N. T.; Kovar, H.] St Anna Kinderkrebsforsch, Childrens Canc Res Inst, Vienna, Austria; [Aryee, D. N. T.; Kovar, H.] Med Univ, Dept Pediat, Vienna, Austria; [Felicetti, F.; De Feo, A.; Care, A.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy; [Colombo, M. P.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Immunol Unit, Milan, Italy	IRCCS Istituto Ortopedico Rizzoli; Saint Anna Children's Hospital; Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, Expt Oncol Lab, CRS Dev Biomol Therapies, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Scotlandi, Katia/J-9009-2016; Mancarella, Caterina/C-7463-2019; Manara, Maria Cristina/K-3366-2018; Colombo, Mario P./V-7166-2017; De Feo, Alessandra/ABI-1458-2020; Felicetti, Federica/N-7077-2017; De Feo, Alessandra/C-7030-2019; Care, Alessandra/H-5090-2016	Scotlandi, Katia/0000-0001-6114-9499; Mancarella, Caterina/0000-0002-5778-4251; Manara, Maria Cristina/0000-0001-5686-720X; Colombo, Mario P./0000-0003-0042-7955; De Feo, Alessandra/0000-0002-9805-1361; Felicetti, Federica/0000-0003-4628-0696; De Feo, Alessandra/0000-0002-9805-1361; Kovar, Heinrich/0000-0001-6873-9109; Care, Alessandra/0000-0003-4106-3342	Italian Association for Cancer Research (AIRC project) [IG2013_14049, IG2012_13247]; Ministry of Education, Research and Universities (FIRB project) [RBAP11884 M_005]; Ministry of Health (PROVABES project) [PER-2011-2353839]; Austrian Science Fund [P24708-B21]; Austrian Science Fund (PROVABES project) [I-1225-B19]; fellowship 'Guglielmina Lucatello e Gino Mazzega' - Fondazione Italiana per la Ricerca sul Cancro (FIRC project) [13811]; Austrian Science Fund (FWF) [P 24708] Funding Source: researchfish	Italian Association for Cancer Research (AIRC project)(Fondazione AIRC per la ricerca sul cancro); Ministry of Education, Research and Universities (FIRB project); Ministry of Health (PROVABES project); Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Science Fund (PROVABES project)(Austrian Science Fund (FWF)); fellowship 'Guglielmina Lucatello e Gino Mazzega' - Fondazione Italiana per la Ricerca sul Cancro (FIRC project); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We are indebted to Cristina Ghinelli for editing the manuscript. We wish to thank Dr Gianfranco Mattia for the assessment of immunofluorescence analysis on the exosome fusion. We are also grateful to Prof. Alain Israel and Dr Johannes Schmid for sharing NF-kappa B reporter and plasmids. This work was supported by grants from the Italian Association for Cancer Research (AIRC project: IG2013_14049 to KS; IG2012_13247 to AC), Ministry of Education, Research and Universities (FIRB project: RBAP11884 M_005 to KS), Ministry of Health (PROVABES project: PER-2011-2353839 to PP and KS), Austrian Science Fund (project: P24708-B21 and PROVABES project: I-1225-B19 to HK). Selena Ventura is in receipt of the fellowship 'Guglielmina Lucatello e Gino Mazzega' granted by Fondazione Italiana per la Ricerca sul Cancro (FIRC project code: 13811).	Ahmed AA, 2012, HUM PATHOL, V43, P1077, DOI 10.1016/j.humpath.2011.09.001; Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; Armengol G, 1997, BRIT J CANCER, V75, P1403, DOI 10.1038/bjc.1997.242; Baliko F, 2007, AM J PATHOL, V170, P1686, DOI 10.2353/ajpath.2007.060971; Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; Bennani-Baiti IM, 2011, J PATHOL, V225, P353, DOI 10.1002/path.2966; Bernard G, 1997, J IMMUNOL, V158, P2543; Braicu C, 2015, CELL DEATH DIFFER, V22, P34, DOI 10.1038/cdd.2014.130; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; Carrillo J, 2007, CLIN CANCER RES, V13, P2429, DOI 10.1158/1078-0432.CCR-06-1762; Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015; Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; De Molfetta GA, 2010, DIFFERENTIATION, V80, P195, DOI 10.1016/j.diff.2010.07.004; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Di Martino MT, 2012, CLIN CANCER RES, V18, P6260, DOI 10.1158/1078-0432.CCR-12-1708; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403; Garofalo C, 2012, MOL ENDOCRINOL, V26, P1603, DOI 10.1210/me.2012-1142; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; Ginsberg JP, 2010, JNCI-J NATL CANCER I, V102, P1272, DOI 10.1093/jnci/djq278; Gonzalez I, 2007, J MOL MED, V85, P1015, DOI 10.1007/s00109-007-0202-5; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004; Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huang HY, 2005, J CLIN ONCOL, V23, P548, DOI 10.1200/JCO.2005.02.081; Javelaud D, 2002, INT J CANCER, V98, P193, DOI 10.1002/ijc.10192; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Kok MGM, 2015, FASEB J, V29, P3853, DOI 10.1096/fj.15-271312; Lagirand-Cantaloube J, 2010, BIOCHEM BIOPH RES CO, V399, P705, DOI 10.1016/j.bbrc.2010.08.004; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Lessnick SL, 2012, ANNU REV PATHOL-MECH, V7, P145, DOI 10.1146/annurev-pathol-011110-130237; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Guerrero JA, 2001, LAB INVEST, V81, P803, DOI 10.1038/labinvest.3780290; Magnan H, 2015, PEDIATR BLOOD CANCER, V62, P594, DOI 10.1002/pbc.25373; Maksimenko A, 2005, EXPERT OPIN THER TAR, V9, P825, DOI 10.1517/14728222.9.4.825; Marino MT, 2014, ANN ONCOL, V25, P2080, DOI 10.1093/annonc/mdu249; McDermott AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083718; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Nakatani F, 2012, J PATHOL, V226, P796, DOI 10.1002/path.3007; Nogueira L, 2011, ONCOGENE, V30, P3537, DOI 10.1038/onc.2011.74; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Ozeki A, 2012, NEUROREPORT, V23, P290, DOI 10.1097/WNR.0b013e3283509a79; Pang RTK, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-25; Pata Supansa, 2011, BMC Res Notes, V4, P293, DOI 10.1186/1756-0500-4-293; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Sabolek M, 2006, NEUROREPORT, V17, P1719, DOI 10.1097/01.wnr.0000236862.08834.50; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Sonnemann J, 2007, J CANCER RES CLIN, V133, P847, DOI 10.1007/s00432-007-0227-8; Sonnemann J, 2011, EUR J CANCER, V47, P1432, DOI 10.1016/j.ejca.2011.01.015; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Teitell MA, 1999, LAB INVEST, V79, P1535; Amaral AT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085814; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Wang ZW, 2006, INT J CANCER, V118, P1930, DOI 10.1002/ijc.21589; Widera D, 2006, INT J DEV NEUROSCI, V24, P91, DOI 10.1016/j.ijdevneu.2005.11.017; Womer RB, 2012, J CLIN ONCOL, V30, P4148, DOI 10.1200/JCO.2011.41.5703; Yang CB, 2010, STEM CELLS, V28, P1970, DOI 10.1002/stem.528	72	34	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3944	3954		10.1038/onc.2015.463	http://dx.doi.org/10.1038/onc.2015.463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616853	Green Accepted			2022-12-28	WOS:000381013100006
J	Kitadate, A; Ikeda, S; Teshima, K; Ito, M; Toyota, I; Hasunuma, N; Takahashi, N; Miyagaki, T; Sugaya, M; Tagawa, H				Kitadate, A.; Ikeda, S.; Teshima, K.; Ito, M.; Toyota, I.; Hasunuma, N.; Takahashi, N.; Miyagaki, T.; Sugaya, M.; Tagawa, H.			MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; ONCOGENE-INDUCED SENESCENCE; TUMOR-SUPPRESSOR GENES; MYCOSIS-FUNGOIDES; MANTLE CELL; CANCER; P53; EXPRESSION; SAHA; VORINOSTAT	Multiple sequential genetic and epigenetic alterations underlie cancer development and progression. Overcoming cellular senescence is an early step in cancer pathogenesis. Here, we demonstrate that a noncoding regulatory RNA, microRNA-16 (miR-16), has the potential to induce cellular senescence. First, we examined the expression of miR-16 in primary cutaneous T-cell lymphoma (CTCL) and other non-Hodgkin T/natural killer (NK)-cell lymphomas and found that miR-16 was downregulated than that in the corresponding normal cells. Notably, miR-16 expression was reduced as the primary CTCL progressed from the early stage to the advanced stage. Next, we transduced CTCL cells with miR-16 to examine whether this miRNA exhibited tumor-suppressive effects in CTCL cells. In CTCL cells expressing wild-type p53, forced expression of miR-16 enhanced p21 expression via downregulation of the polycomb group protein Bmi1, thereby inducing cellular senescence. Alternatively, in CTCL cells lacking functional p53, miR-16 induced compensatory apoptosis. The miR-16 transfection significantly decreased senescent cells and increased apoptotic cells in p21-knockdown CTCL cells expressing wild-type p53, suggesting that the presence or absence of p21 may be the most important condition in the senescence-apoptosis switch in CTCL lymphomagenesis. Furthermore, we found that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) restored the expression of miR-16 and its essential targets, induced senescence in CTCL cells expressing wild-type p53 and promoted apoptosis in cells with nonfunctional p53. Moreover, we found that other T/NK-cell lymphoma cell lines showed similar tumor-suppressive effects in response to miR-16 and SAHA and that these effects were dependent on p53 status. These results suggested that epigenetic silencing of miR-16 may be a key step during lymphoma development. Elucidation of the essential targets of miR-16 and SAHA provides a basis for the clinical application of SAHA in the treatment of CTCL and other non-Hodgkin T/NK-cell lymphomas.	[Kitadate, A.; Ikeda, S.; Teshima, K.; Ito, M.; Toyota, I.; Takahashi, N.; Tagawa, H.] Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, 1-1-1 Hondo, Akita 0108543, Japan; [Hasunuma, N.] Akita Univ, Dept Dermatol, Akita, Japan; [Miyagaki, T.; Sugaya, M.] Univ Tokyo, Dept Dermatol, Tokyo, Japan	Akita University; Akita University; University of Tokyo	Tagawa, H (corresponding author), Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, 1-1-1 Hondo, Akita 0108543, Japan.	htagawa0279jp@yahoo.co.jp	菅谷, 誠/GWC-3786-2022; Miyagaki, Tomomitsu/AFP-0003-2022; Kitadate, Akihiro/AAD-7306-2020	Kitadate, Akihiro/0000-0003-3218-2446	JSPS KAKENHI [25461405]; Uehara Memorial Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Uehara Memorial Foundation(Uehara Memorial Foundation)	We wish to express our appreciation to Mr J Yamashita for his outstanding technical assistance. This work was supported by JSPS KAKENHI Grant Number 25461405 (Grant-in-Aid for Scientific Research (to HT)) and a Grant from the Uehara Memorial Foundation.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Al-Yacoub N, 2012, J INVEST DERMATOL, V132, P2263, DOI 10.1038/jid.2012.125; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cui YX, 2009, BLOOD, V113, P5217, DOI 10.1182/blood-2008-06-160168; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Gallardo F, 2004, HAEMATOLOGICA, V89, P1401; Heider U, 2009, EUR J HAEMATOL, V82, P440, DOI 10.1111/j.1600-0609.2009.01239.x; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Ito M, 2014, BLOOD, V123, P1499, DOI 10.1182/blood-2013-09-527739; Janicke RU, 2007, CELL CYCLE, V6, P407; Jaffe ES, 2008, WORLD HLTH ORG CLASS, P269; Johmura Y, 2014, MOL CELL, V55, P73, DOI 10.1016/j.molcel.2014.05.003; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Krenning L, 2014, MOL CELL, V55, P59, DOI 10.1016/j.molcel.2014.05.007; Laharanne E, 2010, MODERN PATHOL, V23, P547, DOI 10.1038/modpathol.2009.196; Ling X, 2014, CANCER RES, V74, P7487, DOI 10.1158/0008-5472.CAN-14-0683; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Litvinov IV, 2014, CLIN CANCER RES, V20, P3799, DOI 10.1158/1078-0432.CCR-14-0307; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Manfe V, 2012, J INVEST DERMATOL, V132, P1487, DOI 10.1038/jid.2012.10; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; McGregor JM, 1999, J INVEST DERMATOL, V112, P317, DOI 10.1046/j.1523-1747.1999.00507.x; Miyagaki T, 2011, CLIN CANCER RES, V17, P7529, DOI 10.1158/1078-0432.CCR-11-1192; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109; Ralfkiaer E, 2008, WHO CLASSIFICATION T, P296; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sampath D, 2012, BLOOD, V119, P1162, DOI 10.1182/blood-2011-05-351510; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041; Teshima K, 2014, ONCOGENE, V33, P2191, DOI 10.1038/onc.2013.177; TOSCA A, 1991, ANTICANCER RES, V11, P1433; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; van Doorn R, 2005, J CLIN ONCOL, V23, P3886, DOI 10.1200/JCO.2005.11.353; Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81; Weinberg RA, 2007, BIOL CANC; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Zhang CL, 2007, HUM PATHOL, V38, P995, DOI 10.1016/j.humpath.2006.10.021; Zhang CL, 2005, J INVEST DERMATOL, V125, P1045, DOI 10.1111/j.0022-202X.2005.23925.x; Zhang X, 2012, ONCOGENE, V31, P3002, DOI 10.1038/onc.2011.470	50	37	39	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3692	3704		10.1038/onc.2015.435	http://dx.doi.org/10.1038/onc.2015.435			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26640145				2022-12-28	WOS:000379622800008
J	Mizutani, A; Koinuma, D; Seimiya, H; Miyazono, K				Mizutani, A.; Koinuma, D.; Seimiya, H.; Miyazono, K.			The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma	ONCOGENE			English	Article							TARGETED UBIQUITIN LIGASE; TGF-BETA; MESENCHYMAL TRANSITION; MESSENGER-RNA; EXPRESSION; COMPLEX; DEGRADATION; METASTASIS; PROTEINS; ESRP1	Tumor-specific alternative splicing is implicated in the progression of cancer, including clear-cell renal cell carcinoma (ccRCC). Using ccRCC RNA sequencing data from The Cancer Genome Atlas, we found that epithelial splicing regulatory protein 2 (ESRP2), one of the key regulators of alternative splicing in epithelial cells, is expressed in ccRCC. ESRP2 mRNA expression did not correlate with the overall survival rate of ccRCC patients, but the expression of some ESRP-target exons correlated with the good prognosis and with the expression of Arkadia ( also known as RNF111) in ccRCC. Arkadia physically interacted with ESRP2, induced polyubiquitination and modulated its splicing function. Arkadia and ESRP2 suppressed ccRCC tumor growth in a coordinated manner. Lower expression of Arkadia correlated with advanced tumor stages and poor outcomes in ccRCC patients. This study thus reveals a novel tumor-suppressive role of the Arkadia-ESRP2 axis in ccRCC.	[Mizutani, A.; Koinuma, D.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; [Mizutani, A.; Seimiya, H.] Japanese Fdn Canc Res, Div Mol Biotherapy, Ctr Canc Chemotherapy, Koto Ku, Tokyo, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Koinuma, Daizo/Y-8716-2018	Koinuma, Daizo/0000-0001-5611-2122; Seimiya, Hiroyuki/0000-0003-3314-9736	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [22112002, 24700968, 26830066, 24501311]; Grants-in-Aid for Scientific Research [26830066, 22112002] Funding Source: KAKEN	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr Hiroshi I Suzuki (The University of Tokyo) for discussion and advice. We also thank Keiko Yuki for technical assistance, as well as the members of the Miyazono laboratory for discussion and advice. This research was supported by KAKENHI grants-in-aid for scientific research on Innovative Area (Integrative Research on Cancer Microenvironment Network; 22112002, to KM), Young Scientists (B) (24700968 and 26830066, to AM) and Scientific Research (C) (24501311, to DK), from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). This study was performed, in part, as a research program for the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), MEXT.	Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Biamonti G, 2014, SEMIN CELL DEV BIOL, V32, P30, DOI 10.1016/j.semcdb.2014.03.016; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Briones-Orta MA, 2013, CANCER RES, V73, P1800, DOI 10.1158/0008-5472.CAN-12-1916; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; Cybulsky AV, 2009, AM J PHYSIOL-RENAL, V297, pF971, DOI 10.1152/ajprenal.00294.2009; Di Modugno F, 2007, CANCER RES, V67, P2657, DOI 10.1158/0008-5472.CAN-06-1997; Erker Y, 2013, MOL CELL BIOL, V33, P2163, DOI 10.1128/MCB.01019-12; Gamazon ER, 2014, HUM GENET, V133, P679, DOI 10.1007/s00439-013-1411-3; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Horvath A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02256; Hsu RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047649; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432; Isogaya K, 2014, CELL RES, V24, P994, DOI 10.1038/cr.2014.97; Kalsotra A, 2011, NAT REV GENET, V12, P715, DOI 10.1038/nrg3052; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Kulathu Y, 2012, NAT REV MOL CELL BIO, V13, P508, DOI 10.1038/nrm3394; Le Scolan E, 2008, CANCER RES, V68, P3277, DOI 10.1158/0008-5472.CAN-07-6793; Levy L, 2007, MOL CELL BIOL, V27, P6068, DOI 10.1128/MCB.00664-07; Miyazono K, 2011, J BIOCHEM, V149, P1, DOI 10.1093/jb/mvq133; Mizutani A, 2011, J BIOL CHEM, V286, P29848, DOI 10.1074/jbc.M110.217745; Mizutani A, 2010, J BIOCHEM, V148, P733, DOI 10.1093/jb/mvq127; Nagano Y, 2007, J BIOL CHEM, V282, P20492, DOI 10.1074/jbc.M701294200; Park JH, 2011, J BIOL CHEM, V286, P10911, DOI 10.1074/jbc.C110.210211; Peng DJ, 2011, J IMMUNOL, V186, P5638, DOI 10.4049/jimmunol.1003801; Poulsen SL, 2013, J CELL BIOL, V201, P797, DOI 10.1083/jcb.201212075; Ray KC, 2014, ONCOGENE, V33, P823, DOI 10.1038/onc.2013.3; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Sharma V, 2011, CANCER RES, V71, P6438, DOI 10.1158/0008-5472.CAN-11-1645; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Ueda J, 2014, ONCOGENE, V33, P4485, DOI 10.1038/onc.2013.392; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Wild JRL, 2012, INT J EXP PATHOL, V93, P81, DOI 10.1111/j.1365-2613.2012.00810.x; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yuzawa H, 2009, BONE, V44, P53, DOI 10.1016/j.bone.2008.09.013; Zhao Q, 2013, CLIN CANCER RES, V19, P2460, DOI 10.1158/1078-0432.CCR-12-3708; Zhou ZN, 2014, ONCOGENE, V33, P3784, DOI 10.1038/onc.2013.363	46	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3514	3523		10.1038/onc.2015.412	http://dx.doi.org/10.1038/onc.2015.412			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522722	hybrid, Green Published			2022-12-28	WOS:000379621500004
J	Arts, FA; Chand, D; Pecquet, C; Velghe, AI; Constantinescu, S; Hallberg, B; Demoulin, JB				Arts, F. A.; Chand, D.; Pecquet, C.; Velghe, A. I.; Constantinescu, S.; Hallberg, B.; Demoulin, J-B			PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib	ONCOGENE			English	Article							GASTROINTESTINAL STROMAL TUMORS; BASAL GANGLIA CALCIFICATION; RECEPTOR TYROSINE KINASES; CELL-TRANSFORMATION; ACTIVATING MUTATION; OF-FUNCTION; GROWTH; GENE; GAIN; DISORDERS	Recently, germline and somatic heterozygous mutations in the platelet-derived growth factor receptor beta (PDGFRB) have been associated with familial infantile myofibromatosis (IM), which is characterized by soft tissue tumors, and overgrowth syndrome, a disease that predisposes to cancer. These mutations have not been functionally characterized. In the present study, the activity of three PDGFRB mutants associated with familial IM (R561C, P660T and N666K) and one PDGFRB mutant found in patients with overgrowth syndrome (P584R) was tested in various models. The P660T mutant showed no difference with the wild-type receptor, suggesting that it might represent a polymorphic variant unrelated to the disease. By contrast, the three other mutants were constitutively active and able to transform NIH3T3 and Ba/F3 cells to different extents. In particular, the germline mutant identified in overgrowth syndrome, P584R, was a stronger oncogene than the germline R561C mutant associated with myofibromatosis. The distinct phenotypes associated with these two mutations could be related to this difference of potency. Importantly, all activated mutants were sensitive to tyrosine kinase inhibitors such as imatinib, nilotinib and ponatinib. In conclusion, the PDGFRB mutations previously identified in familial IM and overgrowth syndrome activate the receptor in the absence of ligand, supporting the hypothesis that these mutations cause the diseases. Moreover, imatinib seems to be a promising treatment for patients carrying these mutations. To our knowledge, these are the first confirmed gain-of-function point mutations of PDGFRB in human cancer.	[Arts, F. A.; Pecquet, C.; Velghe, A. I.; Constantinescu, S.; Demoulin, J-B] Catholic Univ Louvain, Duve Inst, Ave Hippocrate 75,Box B1-74-05, B-1200 Brussels, Belgium; [Chand, D.; Hallberg, B.] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Med Biochem & Cell Biol, Gothenburg, Sweden; [Chand, D.] Umea Univ, Dept Mol Biol, Umea, Sweden; [Pecquet, C.; Constantinescu, S.] Ludwig Inst Canc Res, Brussels, Belgium	Universite Catholique Louvain; University of Gothenburg; Umea University; Ludwig Institute for Cancer Research	Demoulin, JB (corresponding author), Catholic Univ Louvain, Duve Inst, Ave Hippocrate 75,Box B1-74-05, B-1200 Brussels, Belgium.	jb.demoulin@uclouvain.be		Demoulin, Jean-Baptiste/0000-0002-8016-6689; Christian, Pecquet/0000-0002-8623-3483; Constantinescu, Stefan N./0000-0002-8599-2699	FRS-FNRS - Televie [7.4501.13 F]	FRS-FNRS - Televie(Fonds de la Recherche Scientifique - FNRS)	We would like to thank Nicolas Dauguet for cell sorting, and Anabelle Decottignies, Guy Warnier and Laure Dumoutier for generous donation of reagents. We are grateful to Ahmed Essaghir for statistical analysis. FAA is the recipient of a fellowship from FRS-FNRS - Televie (grant number 7.4501.13 F).	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Ang P, 2004, CUTIS, V73, P229; Arts FA, 2015, J CELL MOL MED, V19, P239, DOI 10.1111/jcmm.12443; Barker KT, 2003, EUR J HUM GENET, V11, P665, DOI 10.1038/sj.ejhg.5201026; BRACKO M, 1992, CANCER-AM CANCER SOC, V69, P1294; Cheung YH, 2013, AM J HUM GENET, V92, P996, DOI 10.1016/j.ajhg.2013.04.026; Chiara F, 2004, J BIOL CHEM, V279, P42516, DOI 10.1074/jbc.M406051200; CHUNG EB, 1981, CANCER, V48, P1807, DOI 10.1002/1097-0142(19811015)48:8<1807::AID-CNCR2820480818>3.0.CO;2-G; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; David M, 2007, BLOOD, V109, P61, DOI 10.1182/blood-2006-05-024828; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 2003, ONCOGENE, V22, P1763, DOI 10.1038/sj.onc.1206253; Demoulin JB, 2014, CYTOKINE GROWTH F R, V25, P273, DOI 10.1016/j.cytogfr.2014.03.003; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; KEATING MT, 1989, J BIOL CHEM, V264, P9129; Lacerda LD, 2014, RADIOL RES PRACT, V2014, DOI 10.1155/2014/947451; Li-Wan-Po A, 2010, EUR J CLIN PHARMACOL, V66, P369, DOI 10.1007/s00228-009-0779-4; Lindhurst MJ, 2011, NEW ENGL J MED, V365, P611, DOI 10.1056/NEJMoa1104017; Linhares ND, 2014, GENET MOL RES, V13, P6287, DOI 10.4238/2014.August.15.11; Looman C, 2007, INT J DEV BIOL, V51, P361, DOI 10.1387/ijdb.072301cl; Martignetti JA, 2013, AM J HUM GENET, V92, P1001, DOI 10.1016/j.ajhg.2013.04.024; Mashiah J, 2014, J AM ACAD DERMATOL, V71, P264, DOI 10.1016/j.jaad.2014.03.035; Medves S, 2010, LEUKEMIA, V24, P1052, DOI 10.1038/leu.2010.13; Medves S, 2011, HAEMATOL-HEMATOL J, V96, P1406, DOI 10.3324/haematol.2011.040147; Miklossy J, 2005, ACTA NEUROPATHOL, V109, P643, DOI 10.1007/s00401-005-1007-7; Millot F, 2014, EUR J CANCER, V50, P3206, DOI 10.1016/j.ejca.2014.10.007; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nicolas G, 2013, BRAIN, V136, P3395, DOI 10.1093/brain/awt255; Nicolas G, 2013, NEUROLOGY, V80, P181, DOI 10.1212/WNL.0b013e31827ccf34; Noel LA, 2014, MOL ONCOL, V8, P728, DOI 10.1016/j.molonc.2014.02.003; Schonherr C, 2011, BIOCHEM J, V440, P405, DOI 10.1042/BJ20101796; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Velghe AI, 2014, ONCOGENE, V33, P2568, DOI 10.1038/onc.2013.218; Verstraete K, 2012, NAT REV CANCER, V12, P753, DOI 10.1038/nrc3371; WISWELL TE, 1985, PEDIATRICS, V76, P981; Zand DJ, 2004, AM J MED GENET A, V126A, P261, DOI 10.1002/ajmg.a.20598	40	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3239	3248		10.1038/onc.2015.383	http://dx.doi.org/10.1038/onc.2015.383			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26455322				2022-12-28	WOS:000378306400003
J	Tigan, AS; Bellutti, F; Kollmann, K; Tebb, G; Sexl, V				Tigan, A-S; Bellutti, F.; Kollmann, K.; Tebb, G.; Sexl, V.			CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation	ONCOGENE			English	Review							NF-KAPPA-B; DEPENDENT KINASE 6; HEMATOPOIETIC STEM-CELLS; ARF TUMOR-SUPPRESSOR; DNA-DAMAGE RESPONSE; THERAPEUTIC CDK4/6 INHIBITION; MEDIATED DOWN-REGULATION; GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE	The G1 cell-cycle kinase CDK6 has long been thought of as a redundant homolog of CDK4. Although the two kinases have very similar roles in cell-cycle progression, it has recently become apparent that they differ in tissue-specific functions and contribute differently to tumor development. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. These functions point to a role of CDK6 in tissue homeostasis and differentiation that is partially independent of CDK6's kinase activity and is not shared with CDK4. We review the literature on the contribution of CDK6 to transcription in an attempt to link the new findings on CDK6's transcriptional activity to cell-cycle progression. Finally, we note that anticancer therapies based on the inhibition of CDK6 kinase activity fail to take into account its kinase-independent role in tumor development.	[Tigan, A-S; Bellutti, F.; Kollmann, K.; Sexl, V.] Univ Vet Med, Inst Pharmacol & Toxicol, Vet Pl 1, A-1210 Vienna, Austria; [Kollmann, K.] Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust MRC Stem Cell Inst, Cambridge, England; [Kollmann, K.] Univ Cambridge, Dept Haematol, Cambridge, England; [Tebb, G.] Univ Vet Med, Vienna, Austria	University of Veterinary Medicine Vienna; University of Cambridge; University of Cambridge; University of Veterinary Medicine Vienna	Sexl, V (corresponding author), Univ Vet Med, Inst Pharmacol & Toxicol, Vet Pl 1, A-1210 Vienna, Austria.	veronika.sexl@vetmeduni.ac.at	; Sexl, Veronika/B-8657-2016	Kollmann, Karoline/0000-0002-7937-4245; Tebb, Graham/0000-0002-1294-2025; Bellutti, Florian/0000-0003-2095-4971; Sexl, Veronika/0000-0001-9363-0412	Austrian Science Foundation (FWF) [SFB F47, P24297-B23]; Austrian Science Fund (FWF) [P 24297] Funding Source: researchfish	Austrian Science Foundation (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We are grateful to Peter Alexander Martinek for technical help in the generation of figures. This work was supported by the Austrian Science Foundation (FWF) via grants to VS (SFB F47 and P24297-B23).	AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Aleem E, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00016; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Antony-Debre I, 2014, BLOOD, V124, P5, DOI 10.1182/blood-2014-05-572917; Baker GL, 2005, CELL CYCLE, V4, P330; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; BATES S, 1994, ONCOGENE, V9, P71; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bienvenu F, 2005, MOL BIOL CELL, V16, P1850, DOI 10.1091/mbc.e04-08-0654; Bienvenu F, 2010, NATURE, V463, P374, DOI 10.1038/nature08684; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bourgo RJ, 2011, MOL CELL, V43, P663, DOI 10.1016/j.molcel.2011.06.029; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brito-Babapulle V, 2002, HAEMATOLOGICA, V87, P357; Brower V, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju221; Burke JR, 2014, J MOL BIOL, V426, P245, DOI 10.1016/j.jmb.2013.09.031; Burke JR, 2010, J BIOL CHEM, V285, P16286, DOI 10.1074/jbc.M110.108167; Buss H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051847; Casimiro MC, 2015, AGING-US, V7, P455, DOI 10.18632/aging.100773; Casimiro MC, 2015, ONCOTARGET, V6, P8525, DOI 10.18632/oncotarget.3267; Casimiro MC, 2012, ONCOTARGET, V3, P224; Cerqueira A, 2014, MOL CELL BIOL, V34, P1452, DOI 10.1128/MCB.01163-13; Chavey C., 2013, PHYSL PHYSIOPATHOLOG, P17; Chen D, 2009, AM J SURG PATHOL, V33, P720, DOI 10.1097/PAS.0b013e3181934244; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chilosi M, 1998, AM J PATHOL, V152, P209; Choe KS, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.077727; Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137; Choi YJ, 2013, ONCOTARGET, V4, P176, DOI 10.18632/oncotarget.912; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ecker A, 2009, FRONT BIOSCI-LANDMRK, V14, P2944, DOI 10.2741/3425; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200; Fujimoto T, 2007, EMBO J, V26, P2361, DOI 10.1038/sj.emboj.7601675; Gallagher SJ, 2006, INT J BIOCHEM CELL B, V38, P1637, DOI 10.1016/j.biocel.2006.02.008; Gordon GM, 2011, PROTEIN CELL, V2, P864, DOI 10.1007/s13238-011-1117-z; Guzman ML, 2015, BLOOD, V125, P7, DOI 10.1182/blood-2014-11-609230; Handschick K, 2014, MOL CELL, V53, P193, DOI 10.1016/j.molcel.2013.12.002; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hayette S, 2003, BLOOD, V102, P1549, DOI 10.1182/blood-2003-04-1220; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hu MG, 2011, BLOOD, V117, P6120, DOI 10.1182/blood-2010-08-300517; Hu MG, 2009, CANCER RES, V69, P810, DOI 10.1158/0008-5472.CAN-08-2473; Huberts DHEW, 2010, BBA-MOL CELL RES, V1803, P520, DOI 10.1016/j.bbamcr.2010.01.022; Hussain MS, 2013, HUM MOL GENET, V22, P5199, DOI 10.1093/hmg/ddt374; Inoue K, 2007, ONCOGENE, V26, P4329, DOI 10.1038/sj.onc.1210226; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Jares P, 2007, NAT REV CANCER, V7, P750, DOI 10.1038/nrc2230; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Jing H, 2011, GENE DEV, V25, P2137, DOI 10.1101/gad.17620611; Jirawatnotai S, 2012, CANCER RES, V72, P4289, DOI 10.1158/0008-5472.CAN-11-3549; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen KE, 1999, CANCER RES, V59, P2297; Kohrt D, 2014, CELL CYCLE, V13, P62, DOI 10.4161/cc.26755; Kollmann K, 2013, ONCOTARGET, V4, P1858, DOI 10.18632/oncotarget.1541; Kollmann K, 2013, CANCER CELL, V24, P167, DOI 10.1016/j.ccr.2013.07.012; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Laurenti E, 2015, CELL STEM CELL, V16, P302, DOI 10.1016/j.stem.2015.01.017; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee YJ, 2014, NATURE, V510, P547, DOI 10.1038/nature13267; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Li ZP, 2010, CANCER RES, V70, P8802, DOI 10.1158/0008-5472.CAN-10-0312; Lien HC, 2000, LAB INVEST, V80, P893, DOI 10.1038/labinvest.3780093; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Malinkova V, 2015, EXPERT OPIN THER PAT, P1; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Matushansky I, 2003, ONCOGENE, V22, P4143, DOI 10.1038/sj.onc.1206484; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Min IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nagel S, 2008, LEUKEMIA, V22, P387, DOI 10.1038/sj.leu.2405028; Nakajima K, 2011, DEVELOPMENT, V138, P1771, DOI 10.1242/dev.059295; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560-6568.2004; Ogasawara T, 2004, J BONE MINER RES, V19, P1128, DOI 10.1359/jbmr.2004.19.7.1128; Parry D, 1999, MOL CELL BIOL, V19, P1775; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pauls E, 2014, J IMMUNOL, V193, P1988, DOI 10.4049/jimmunol.1400873; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Pestell RG, 2013, AM J PATHOL, V183, P3, DOI 10.1016/j.ajpath.2013.03.001; Placke T, 2014, BLOOD, V124, P13, DOI 10.1182/blood-2014-02-558114; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Resemann HK, 2014, MOL CELL ENDOCRINOL, V382, P603, DOI 10.1016/j.mce.2013.06.029; Ressler S, 2006, AGING CELL, V5, P379, DOI 10.1111/j.1474-9726.2006.00231.x; Rodriguez-Diez E, 2014, BLOOD, V124, P2380, DOI 10.1182/blood-2014-02-555292; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Rubio MF, 2012, BBA-MOL CELL RES, V1823, P1119, DOI 10.1016/j.bbamcr.2012.01.009; Ruiz A, 2015, CELL CYCLE, V14, P1657, DOI 10.1080/15384101.2015.1030558; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sanchez-Martinez C, 2015, BIOORG MED CHEM LETT, V25, P3420, DOI 10.1016/j.bmcl.2015.05.100; Saporita AJ, 2007, CURR MED CHEM, V14, P1815; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; Scheicher R, 2015, BLOOD, V125, P90, DOI 10.1182/blood-2014-06-584417; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Schwartz R, 2006, P NATL ACAD SCI USA, V103, P9976, DOI 10.1073/pnas.0603728103; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shen R, 2006, J BIOL CHEM, V281, P16347, DOI 10.1074/jbc.M603439200; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh AM, 2013, STEM CELL REP, V1, P532, DOI 10.1016/j.stemcr.2013.10.009; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Talluri S, 2012, CELL CYCLE, V11, P3189, DOI 10.4161/cc.21263; TAM SW, 1994, CANCER RES, V54, P5816; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; van der Linden MH, 2014, CELL CYCLE, V13, P834, DOI 10.4161/cc.27757; van der Velden PA, 2001, CANCER RES, V61, P5303; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vanden Bush T.J., 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019468; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wierstra I, 2013, ADV CANCER RES, V118, P97, DOI 10.1016/B978-0-12-407173-5.00004-2; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zacharek SJ, 2005, CANCER RES, V65, P11354, DOI 10.1158/0008-5472.CAN-05-2236; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang LS, 2008, BLOOD, V111, P1193, DOI 10.1182/blood-2007-08-109702; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	174	95	96	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3083	3091		10.1038/onc.2015.407	http://dx.doi.org/10.1038/onc.2015.407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26500059				2022-12-28	WOS:000378092700001
J	Nagaoka, K; Fujii, K; Zhang, H; Usuda, K; Watanabe, G; Ivshina, M; Richter, JD				Nagaoka, K.; Fujii, K.; Zhang, H.; Usuda, K.; Watanabe, G.; Ivshina, M.; Richter, J. D.			CPEB1 mediates epithelial-to-mesenchyme transition and breast cancer metastasis	ONCOGENE			English	Article							MESSENGER-RNA TRANSLATION; CYTOPLASMIC POLYADENYLATION; CELLULAR SENESCENCE; SYNAPTIC PLASTICITY; KNOCKOUT MICE; IN-VIVO; GROWTH; DIFFERENTIATION; MORPHOGENESIS; LOCALIZATION	In mouse mammary epithelial cells, cytoplasmic polyadenylation element binding protein 1 (CPEB1) mediates the apical localization of ZO-1 mRNA, which encodes a critical tight junction component. In mice lacking CPEB1 and in cultured cells from which CPEB has been depleted, randomly distributed ZO-1 mRNA leads to the loss of cell polarity. We have investigated whether this diminution of polarity results in an epithelial-to-mesenchyme (EMT) transition and possible increased metastatic potential. Here, we show that CPEB1-depleted mammary epithelial cells alter their gene expression profile in a manner consistent with an EMT and also become motile, which are made particularly robust when cells are treated with transforming growth factor-beta, an enhancer of EMT. CPEB1-depleted mammary cells become metastatic to the lung following injection into mouse fat pads while ectopically expressed CPEB1 prevents metastasis. Surprisingly, CPEB1 depletion causes some EMT/metastasis-related mRNAs to have shorter poly(A) tails while other mRNAs to have longer poly(A) tails. Matrix metalloproteinase 9 (MMP9) mRNA, which encodes a metastasis-promoting factor, undergoes poly(A) lengthening and enhanced translation upon CPEB reduction. Moreover, in human breast cancer cells that become progressively more metastatic, CPEB1 is reduced while MMP9 becomes more abundant. These data suggest that at least in part, CPEB1 regulation of MMP9 mRNA expression mediates metastasis of breast cancer cells.	[Nagaoka, K.; Fujii, K.; Zhang, H.; Usuda, K.; Watanabe, G.] Tokyo Univ Agr & Technol, Dept Vet Med, Lab Vet Physiol, Tokyo, Japan; [Ivshina, M.; Richter, J. D.] Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA	Tokyo University of Agriculture & Technology; University of Massachusetts System; University of Massachusetts Worcester	Nagaoka, K; Richter, JD (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	nagaokak@cc.tuat.ac.jp; joel.richter@umassmed.edu	Watanabe/G-1134-2013; Nagaoka, Kentaro/C-2019-2013	Watanabe/0000-0001-7611-4678; Nagaoka, Kentaro/0000-0003-1038-1380; Ivshina, Maria/0000-0002-0999-3470	NIH [GM46779]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046779] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grant GM46779 (to JDR).	Alarcon JM, 2004, LEARN MEMORY, V11, P318, DOI 10.1101/lm.72704; Alexandrov IM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002457; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; Berger-Sweeney J, 2006, LEARN MEMORY, V13, P4, DOI 10.1101/lm.73706; Bestman JE, 2008, P NATL ACAD SCI USA, V105, P20494, DOI 10.1073/pnas.0806296105; Burns DM, 2011, NATURE, V473, P105, DOI 10.1038/nature09908; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; D'Ambrogio A, 2013, NAT REV CANCER, V13, P283, DOI 10.1038/nrc3485; D'Ambrogio A, 2012, CELL REP, V2, P1537, DOI 10.1016/j.celrep.2012.10.023; Du L, 2005, RNA, V11, P1340, DOI 10.1261/rna.2870505; Eliscovich C, 2008, NAT CELL BIOL, V10, P858, DOI 10.1038/ncb1746; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Groisman I, 2006, GENE DEV, V20, P2701, DOI 10.1101/gad.1438906; Groppo R, 2011, MOL CELL BIOL, V31, P2707, DOI 10.1128/MCB.05133-11; Grudzien-Nogalska E, 2014, J CELL SCI, V127, P2326, DOI 10.1242/jcs.144956; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Huang YS, 2003, GENE DEV, V17, P638, DOI 10.1101/gad.1053003; Ivshina M, 2014, ANNU REV CELL DEV BI, V30, P393, DOI 10.1146/annurev-cellbio-101011-155831; Janusz A, 2013, J NEUROSCI, V33, P18234, DOI 10.1523/JNEUROSCI.2207-13.2013; Kim JH, 2006, MOL CELL, V24, P173, DOI 10.1016/j.molcel.2006.08.016; Knights Alexander J, 2012, Trends Cancer Res, V8, P61; Kochanek DM, 2013, MOL CANCER RES, V11, P149, DOI 10.1158/1541-7786.MCR-12-0498; Licatalosi DD, 2008, NATURE, V456, P464, DOI 10.1038/nature07488; Lin CL, 2010, RNA, V16, P338, DOI 10.1261/rna.1779810; Mailleux AA, 2008, CELL CYCLE, V7, P57, DOI 10.4161/cc.7.1.5150; Nagaoka K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1678; Nairismagi ML, 2012, ONCOGENE, V31, P4960, DOI 10.1038/onc.2011.650; Racki WJ, 2006, DEVELOPMENT, V133, P4527, DOI 10.1242/dev.02651; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Shen WH, 2014, CELL REP, V6, P737, DOI 10.1016/j.celrep.2014.01.024; Tay J, 2001, DEV CELL, V1, P201, DOI 10.1016/S1534-5807(01)00025-9; Udagawa T, 2013, NAT MED, V19, P1473, DOI 10.1038/nm.3353; Udagawa T, 2012, MOL CELL, V47, P253, DOI 10.1016/j.molcel.2012.05.016; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304	40	52	53	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2893	2901		10.1038/onc.2015.350	http://dx.doi.org/10.1038/onc.2015.350			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26411364	Green Accepted			2022-12-28	WOS:000377473700009
J	Sayadi, A; Jeyakani, J; Seet, SH; Wei, CL; Bourque, G; Bard, FA; Jenkins, NA; Copeland, NG; Bard-Chapeau, EA				Sayadi, A.; Jeyakani, J.; Seet, S. H.; Wei, C-L; Bourque, G.; Bard, F. A.; Jenkins, N. A.; Copeland, N. G.; Bard-Chapeau, E. A.			Functional features of EVI1 and EVI1 Delta 324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; MEIOTIC RECOMBINATION; MYELOID-LEUKEMIA; INTEGRATION SITE; BINDING-SITES; STEM-CELLS; OVARIAN; EXPRESSION; CHROMATIN; MOUSE	The MDS1 and ecotropic viral integration site 1 (EVI1) complex locus (MECOM) gene encodes several transcription factor variants including MDS1-EVI1, EVI1 and EVI1 Delta 324. Although MDS1-EVI1 has been associated with tumor-suppressing activity, EVI1 is a known oncogene in various cancers, whose expression is associated with poor patient survival. Although EVI1 Delta 324 is co-transcribed with EVI1, its activity in cancer cells is not fully understood. Previous reports described that unlike EVI1, EVI1 Delta 324 protein cannot transform fibroblasts because of its disrupted N-terminal zinc finger (ZNF) domain. To better understand EVI1 Delta 324 biology and function, we obtained genome-wide binding occupancies and expression data in ovarian cancer cells. We characterized its DNA-binding sites, binding motif and target genes. Comparative analyses with previous study show that EVI1 and EVI1 Delta 324 share similar transcriptional activities linked to their common C-terminus ZNF domain. They bind to an E-twenty-six family (ETS)-like motif, target to a large extent the same genes and cooperate with AP1 transcription factor. EVI1 Delta 324-occupied genes were 70.7% similar to EVI1-bound genes. More strikingly, EVI1 and EVI1 Delta 324 differentially expressed genes were 99.87% identical, indicating comparable transcriptional regulatory functions. Consistently with gene ontologies linked to these target genes, EVI1 Delta 324 expression in HeLa cells could enhance anchorage-independent growth, such as EVI1, showing that EVI1 Delta 324 expression also lead to pro-oncogenic effects. The main specific feature of EVI1 variant is its N-terminus ZNF domain that binds DNA through GATA-like motif. We found that most GATA-like EVI1 chromatin immunoprecipitation sequencing peaks are far from genes and are not involved in transcriptional regulation. These genomic regions were enriched in simple sequence repeats and displayed high meiotic recombination rates. Overall, our genomics analyses uncovered common and specific features of two major MECOM isoforms. Their influence on transcription and downstream cell proliferation was comparable. However, EVI1-specific GATA-like binding sites, from its N-terminus ZNF domain, associated with high recombination rates, suggesting possible additional oncogenic potential for EVI1 in modulating genomic stability.	[Sayadi, A.; Seet, S. H.; Bard, F. A.; Jenkins, N. A.; Copeland, N. G.; Bard-Chapeau, E. A.] Natl Univ Singapore, Inst Mol & Cell Biol, 10 Kent Ridge Crescent, Singapore 117548, Singapore; [Jeyakani, J.; Wei, C-L; Bourque, G.] Genome Inst Singapore, Singapore, Singapore; [Bard-Chapeau, E. A.] Novartis Inst Biomed Res, WKL 125-1-05A, CH-4002 Basel, Switzerland; [Jenkins, N. A.; Copeland, N. G.] Methodist Hosp Res Inst, Houston, TX USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Novartis; The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital Research Institute	Bard-Chapeau, EA (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 10 Kent Ridge Crescent, Singapore 117548, Singapore.; Bard-Chapeau, EA (corresponding author), Novartis Inst Biomed Res, WKL 125-1-05A, CH-4002 Basel, Switzerland.	emilie.chapeau@novartis.com	Bourque, Guillaume/AFR-2927-2022; Bard, Frederic Andre Jean/G-9914-2011	Bourque, Guillaume/0000-0002-3933-9656; Bard, Frederic Andre Jean/0000-0002-3783-4805	Agency for Science, Technology and Research (Singapore)	Agency for Science, Technology and Research (Singapore)(Agency for Science Technology & Research (A*STAR))	This work was supported by the Agency for Science, Technology and Research (Singapore). We thank Archibald Perkins, University of Rochester, for sharing his mouse Evi1 antibodies.	Aytekin M, 2005, GENE, V356, P160, DOI 10.1016/j.gene.2005.04.032; Bard-Chapeau EA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089397; Bard-Chapeau EA, 2013, P NATL ACAD SCI USA, V110, pE2885, DOI 10.1073/pnas.1309310110; Bard-Chapeau EA, 2012, P NATL ACAD SCI USA, V109, P2168, DOI 10.1073/pnas.1119229109; BARTHOLOMEW C, 1994, ONCOGENE, V9, P939; Baudat F, 2010, SCIENCE, V327, P836, DOI 10.1126/science.1183439; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; BORDEREAUX D, 1990, ONCOGENE, V5, P925; BORUM K, 1961, EXP CELL RES, V24, P495, DOI 10.1016/0014-4827(61)90449-9; Bouma GJ, 2007, GENE EXPR PATTERNS, V7, P113, DOI 10.1016/j.modgep.2006.05.011; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dutta P, 2013, MOL ONCOL, V7, P647, DOI 10.1016/j.molonc.2013.02.008; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Fog CK, 2012, BIOESSAYS, V34, P50, DOI 10.1002/bies.201100107; Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001; Goyama S, 2008, CELL STEM CELL, V3, P207, DOI 10.1016/j.stem.2008.06.002; Goyama S, 2010, INT J HEMATOL, V91, P753, DOI 10.1007/s12185-010-0618-5; Goyama S, 2009, CANCER SCI, V100, P990, DOI 10.1111/j.1349-7006.2009.01152.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heyer WD, 2010, ANNU REV GENET, V44, P113, DOI 10.1146/annurev-genet-051710-150955; Hirai H, 2001, CANCER CHEMOTH PHARM, V48, pS35, DOI 10.1007/s002800100303; Hohenauer T, 2012, DEVELOPMENT, V139, P2267, DOI 10.1242/dev.070110; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Jazaeri AA, 2010, GYNECOL ONCOL, V118, P189, DOI 10.1016/j.ygyno.2010.04.007; Ji HK, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl803; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karakaya K, 2012, CELL CYCLE, V11, P3492, DOI 10.4161/cc.21801; Kilbey A, 1998, ONCOGENE, V16, P2287, DOI 10.1038/sj.onc.1201732; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; Medina-Rivera A, 2011, NUCLEIC ACIDS RES, V39, P808, DOI 10.1093/nar/gkq710; Metais JY, 2008, MOL THER, V16, P439, DOI 10.1038/sj.mt.6300372; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Mok SC, 2009, CANCER CELL, V16, P521, DOI 10.1016/j.ccr.2009.10.018; MORISHITA K, 1990, ONCOGENE, V5, P963; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Namekawa SH, 2006, CURR BIOL, V16, P660, DOI 10.1016/j.cub.2006.01.066; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Nicolas A, 1998, P NATL ACAD SCI USA, V95, P87, DOI 10.1073/pnas.95.1.87; Nucifora G, 2006, GENE, V368, P1, DOI 10.1016/j.gene.2005.09.020; Ogawa S, 1996, LEUKEMIA, V10, P788; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Parvanov ED, 2010, SCIENCE, V327, P835, DOI 10.1126/science.1181495; Pavesi G, 2006, NUCLEIC ACIDS RES, V34, pW566, DOI 10.1093/nar/gkl285; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Segurel L, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001211; SPEED RM, 1982, CHROMOSOMA, V85, P427, DOI 10.1007/BF00330366; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Sunde JS, 2006, CANCER RES, V66, P8404, DOI 10.1158/0008-5472.CAN-06-0683; Tan FJ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002633; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Turatsinze JV, 2008, NAT PROTOC, V3, P1578, DOI 10.1038/nprot.2008.97; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu S, 2007, NAT STRUCT MOL BIOL, V14, P1165, DOI 10.1038/nsmb1332; Xia WL, 2007, J ENDOCRINOL, V192, P563, DOI 10.1677/JOE-06-0158; Yanowitz J, 2010, CURR OPIN CELL BIOL, V22, P744, DOI 10.1016/j.ceb.2010.08.016; Yatsula B, 2005, J BIOL CHEM, V280, P30712, DOI 10.1074/jbc.M504293200; Yoshimi A, 2011, ONCOTARGET, V2, P575, DOI 10.18632/oncotarget.304; Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679; Zaprazna K, 2012, MOL CELL BIOL, V32, P1542, DOI 10.1128/MCB.05989-11; Zhang Y, 2011, BLOOD, V118, P3853, DOI 10.1182/blood-2011-02-334680; Zhou LY, 2014, EXP THER MED, V8, P85, DOI 10.3892/etm.2014.1716	71	15	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2311	2321		10.1038/onc.2015.286	http://dx.doi.org/10.1038/onc.2015.286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26234679	Bronze			2022-12-28	WOS:000376165000004
J	Sun, F; Qu, Z; Xiao, Y; Zhou, J; Burns, TF; Stabile, LP; Siegfried, JM; Xiao, G				Sun, F.; Qu, Z.; Xiao, Y.; Zhou, J.; Burns, T. F.; Stabile, L. P.; Siegfried, J. M.; Xiao, G.			NF-kappa B1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-kappa B function	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-2; MOUSE MODEL; CANCER; PDLIM2; INFLAMMATION; ACTIVATION; DIFFERENTIATION; REQUIREMENT; REPRESSION; STABILITY	Nuclear factor-kappa B (NF-kappa B) is generally believed to be pro-tumorigenic. Here we report a tumor-suppressive function for NF-kappa B1, the prototypical member of NF-kappa B. While NF-kappa B1 downregulation is associated with high lung cancer risk in humans and poor patient survival, NF-kappa B1-deficient mice are more vulnerable to lung tumorigenesis induced by the smoke carcinogen, urethane. Notably, the tumor-suppressive function of NF-kappa B1 is independent of its classical role as an NF-kappa B factor, but instead through stabilization of the Tpl2 kinase. NF-kappa B1-deficient tumors exhibit 'normal' NF-kappa B activity, but a decreased protein level of Tpl2. Reconstitution of Tpl2 or the NF-kappa B1 p105, but not p50 (the processed product of p105), inhibits the tumorigenicity of NF-kappa B1-deficient lung tumor cells. Remarkably, Tpl2-knockout mice resemble NF-kappa B1 knockouts in urethane-induced lung tumorigenesis. Mechanistic studies indicate that p105/Tpl2 signaling is required for suppressing urethane-induced lung damage and inflammation, and activating mutations of the K-Ras oncogene. These studies reveal an unexpected, NF-kappa B-independent but Tpl2-depenednt role of NF-kappa B1 in lung tumor suppression. These studies also reveal a previously unexplored role of p105/Tpl2 signaling in lung homeostasis.	[Sun, F.; Qu, Z.; Xiao, Y.; Zhou, J.; Burns, T. F.; Stabile, L. P.; Siegfried, J. M.; Xiao, G.] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA 15213 USA; [Sun, F.; Qu, Z.; Zhou, J.; Xiao, G.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Hillman Canc Ctr Res Pavil,5117 Ctr Ave,Room 1-19, Pittsburgh, PA 15213 USA; [Xiao, Y.] La Roche Coll, Program Biol Sci, Pittsburgh, PA USA; [Stabile, L. P.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Qu, Z; Xiao, G (corresponding author), Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Hillman Canc Ctr Res Pavil,5117 Ctr Ave,Room 1-19, Pittsburgh, PA 15213 USA.	quz@upmc.edu; xiaog2@upmc.edu	SUN, FAN/K-8683-2017; Stabile, Laura/AAE-9235-2020; SUN, FAN/GWA-1524-2022	SUN, FAN/0000-0002-3538-9701	National Institute of Health (NIH)/National Cancer Institute (NCI) [R01 CA172090, R21 CA175252, R21 CA189703, P30 CA047904, P50 CA090440]; American Lung Association (ALA) Lung Cancer Discovery Award; American Cancer Society (ACS) Fellowship [PF-12-081-01-TBG]; NATIONAL CANCER INSTITUTE [P50CA090440, R01CA172090, R21CA189703, R21CA175252, P30CA047904] Funding Source: NIH RePORTER	National Institute of Health (NIH)/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Lung Association (ALA) Lung Cancer Discovery Award; American Cancer Society (ACS) Fellowship(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Philip N Tsichlis for providing us the Tpl2<SUP>Delta/Delta</SUP> mice. This study was supported in part by the National Institute of Health (NIH)/National Cancer Institute (NCI) grants R01 CA172090, R21 CA175252, R21 CA189703, P30 CA047904 and P50 CA090440-Lung Cancer Developmental Research Award, as well as the American Lung Association (ALA) Lung Cancer Discovery Award and American Cancer Society (ACS) Fellowship PF-12-081-01-TBG.	AOKI M, 1991, ONCOGENE, V6, P1515; Basseres Daniela S, 2014, Genes Cancer, V5, P41; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Cai Zhenjian, 2011, Cancers (Basel), V3, P4258, DOI 10.3390/cancers3044258; Mulero MC, 2013, CANCER CELL, V24, P151, DOI 10.1016/j.ccr.2013.06.003; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Chen WS, 2011, FRONT BIOSCI-LANDMRK, V16, P1172, DOI 10.2741/3782; Dougan M, 2011, J CLIN INVEST, V121, P2436, DOI 10.1172/JCI44796; Fu J, 2010, ONCOGENE, V29, P6499, DOI 10.1038/onc.2010.374; Fu J, 2011, BLOOD, V117, P1652, DOI 10.1182/blood-2010-08-303073; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; Ichikawa T, 1996, CANCER LETT, V107, P165, DOI 10.1016/0304-3835(96)04351-0; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Qing GL, 2005, J BIOL CHEM, V280, P40578, DOI 10.1074/jbc.M508776200; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Qu Z, 2015, CANC RES; Qu ZX, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-23; Qu ZX, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-18; Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263; Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Schramek D, 2011, NAT GENET, V43, P212, DOI 10.1038/ng.767; Serebrennikova OB, 2012, P NATL ACAD SCI USA, V109, pE1082, DOI 10.1073/pnas.1115098109; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Stabile LP, 2011, CLIN CANCER RES, V17, P154, DOI 10.1158/1078-0432.CCR-10-0992; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Sun F, 2015, J BIOL CHEM, V290, P7362, DOI 10.1074/jbc.C115.637918; Tsatsanis C, 2008, P NATL ACAD SCI USA, V105, P2987, DOI 10.1073/pnas.0708381104; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Wen Jing, 2011, Chin J Cancer, V30, P551, DOI 10.5732/cjc.011.10059; Wong KK, 2010, CANCER PREV RES, V3, P403, DOI 10.1158/1940-6207.CAPR-10-0042; Xiao GT, 2006, CYTOKINE GROWTH F R, V17, P281, DOI 10.1016/j.cytogfr.2006.04.005; Xiao GT, 2011, AM J CANCER RES, V1, P192; Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660; Zhang DL, 2007, ANN SURG ONCOL, V14, P3581, DOI 10.1245/s10434-007-9560-z; Zhou J, 2015, ONCOGENE, V34, P3804, DOI 10.1038/onc.2014.318	45	19	19	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2299	2310		10.1038/onc.2015.299	http://dx.doi.org/10.1038/onc.2015.299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26300007	Green Accepted			2022-12-28	WOS:000376165000003
J	Seoane, S; Montero, JC; Ocana, A; Pandiella, A				Seoane, S.; Montero, J. C.; Ocana, A.; Pandiella, A.			Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node	ONCOGENE			English	Article							ADJUVANT TRASTUZUMAB; BINDING-SITES; EXPRESSION; METASTASIS; RECEPTORS; HEREGULIN; CELL; DIFFERENTIATION; TUMORIGENICITY; ACTIVATION	Advances in the treatment of breast cancer have resulted in increased survival. However, in the metastatic setting, the disease remains incurable. Therefore, understanding of the mechanisms that promote dissemination of breast cancer cells may favor the development of novel therapeutic strategies to fight those tumors. Here, we show that the ErbB ligands, Neuregulins (NRGs), promote metastatic dissemination of breast cancer cells by switching on a kinase-metalloproteinase network. Clinicopathological analyses demonstrated that NRG expression in breast tumors associated to lymph node invasion and poor patient outcome. Preclinical in vivo analyses showed that NRG expression favored in situ tumor growth, local spreading and metastatic dissemination. Genomic, biochemical and functional studies identified matrix metalloproteinases, particularly stromelysin 2 and collagenase 3, as key mediators of the NRG-induced dissemination properties of breast cancer cells. Mechanistic analyses demonstrated that NRG augmented metalloproteinase expression through a route controlled by ERK1/2 kinases. ERK1/2 increased collagenase 3 expression by controlling the activity of an SBF1-related transcription factor. In conclusion, we describe a pathway linked to breast cancer dissemination. The clinical availability of agents that target some of the components of this signalling pathway suggests that patients with tumors fed by NRGs or other factors able to activate the ERK-Collagenase 3 route may benefit from agents that act on that signalling axis.	[Seoane, S.; Montero, J. C.; Pandiella, A.] Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, CIC Campus Miguel de Unamuno,Ave Univ Coimbra, Salamanca 37007, Spain; [Ocana, A.] Complejo Hosp Univ Albacete, Med Oncol Serv, Albcete, Spain; AECC Unit, Albcete, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Pandiella, A (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, CIC Campus Miguel de Unamuno,Ave Univ Coimbra, Salamanca 37007, Spain.	atanasio@usal.es	Seoane, Samuel/H-6299-2015; Montero, Juan Carlos/AAO-1780-2020; Pandiella, Atanasio/O-5180-2014	Seoane, Samuel/0000-0002-9178-0887; Montero, Juan Carlos/0000-0003-4773-053X; Pandiella, Atanasio/0000-0002-4704-8971; Ocana, Alberto/0000-0002-1067-9630	Instituto de Salud Carlos III through Spanish Cancer Centers Network Program [RD06/0020/0041, RD12/0036/0003]; Juan de la Cierva contract; Miguel Servet fellowship program	Instituto de Salud Carlos III through Spanish Cancer Centers Network Program; Juan de la Cierva contract; Miguel Servet fellowship program	Ministry of Economy and Competitiveness of Spain (BFU2009-07728 and BFU2012-39151), the Instituto de Salud Carlos III through the Spanish Cancer Centers Network Program (RD06/0020/0041 and RD12/0036/0003) and the Scientific Foundation of the Spanish Association Against Cancer (AECC). SSR was supported by a Juan de la Cierva contract. JCM is a recipient of a Miguel Servet fellowship program.	Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Atlas E, 2003, MOL CANCER RES, V1, P165; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Dawson SJ, 2013, EMBO J, V32, P617, DOI 10.1038/emboj.2013.19; de Alava E, 2007, J CLIN ONCOL, V25, P2656, DOI 10.1200/JCO.2006.08.6850; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kiran U, 2012, BIOINFORMATION, V8, P886, DOI 10.6026/97320630008886; Krane IM, 1996, ONCOGENE, V12, P1781; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; LAWTON MA, 1991, PLANT MOL BIOL, V16, P235, DOI 10.1007/BF00020555; Lee CYF, 2014, CANCER RES, V74, P341, DOI 10.1158/0008-5472.CAN-13-1055; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Montero JC, 2014, ONCOGENE, V33, P148, DOI 10.1038/onc.2012.572; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Montero JC, 2007, MOL BIOL CELL, V18, P380, DOI 10.1091/mbc.E06-06-0511; Montero JC, 2008, CLIN CANCER RES, V14, P3237, DOI 10.1158/1078-0432.CCR-07-5133; Morrison C, 2011, J BIOL CHEM, V286, P34271, DOI 10.1074/jbc.M111.222513; Ocana A, 2013, CURR PHARM DESIGN, V19, P808, DOI 10.2174/138161213804547303; Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440; Perez EA, 2010, J CLIN ONCOL, V28, P4307, DOI 10.1200/JCO.2009.26.2154; Phillips GDL, 2014, CLIN CANCER RES, V20, P456, DOI 10.1158/1078-0432.CCR-13-0358; Pivetta E, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3047; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Seoane S, 2010, JNCI-J NATL CANCER I, V102, P1432, DOI 10.1093/jnci/djq315; Shah M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029615; Shames DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056765; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Yuste L, 2005, CANCER RES, V65, P6801, DOI 10.1158/0008-5472.CAN-04-4023; Zhang B, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-83; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	41	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2756	2765		10.1038/onc.2015.337	http://dx.doi.org/10.1038/onc.2015.337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364598				2022-12-28	WOS:000377472700009
J	Yen, SY; Chen, SR; Hsieh, J; Li, YS; Chuang, SE; Chuang, HM; Huang, MH; Lin, SZ; Harn, HJ; Chiou, TW				Yen, S-Y; Chen, S-R; Hsieh, J.; Li, Y-S; Chuang, S-E; Chuang, H-M; Huang, M-H; Lin, S-Z; Harn, H-J; Chiou, T-W			Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; BREAST-CANCER METASTASIS; GLIOBLASTOMA-MULTIFORME; ANGELICA-SINENSIS; HUMAN GLIOMAS; IN-VITRO; BUTYLIDENEPHTHALIDE; GROWTH; CELLS; CHEMOTHERAPY	Glioblastoma multiforme (GBM) is the most common and aggressive brain tumour. The neoplasms are difficult to resect entirely because of their highly infiltration property and leading to the tumour edge is unclear. Gliadel wafer has been used as an intracerebral drug delivery system to eliminate the residual tumour. However, because of its local low concentration and short diffusion distance, patient survival improves non-significantly. Ax1 is an essential regulator in cancer metastasis and patient survival. In this study, we developed a controlled-release polyanhydride polymer loading a novel small molecule, n-butylidenephthalide (BP), which is not only increasing local drug concentration and extending its diffusion distance but also reducing tumour invasion, mediated by reducing Axl expression. First, we determined that BP inhibited the expression of Axl in a dose-and time-dependent manner and reduced the migratory and invasive capabilities of GBM cells. In addition, BP downregulated matrix metalloproteinase activity, which is involved in cancer cell invasion. Furthermore, we demonstrated that BP regulated Axl via the extracellular signal-regulated kinases pathway. Epithelial-to-mesenchymal transition (EMT) is related to epithelial cells in the invasive migratory mesenchymal cells that underlie cancer progression; we demonstrated that BP reduced the expression of EMT-related genes. Furthermore, we used the overexpression of Ax1 in GBM cells to prove that Axl is a crucial target in the inhibition of GBM EMT, migration and invasion. In an in vivo study, we demonstrated that BP inhibited tumour growth and suppressed Axl expression in a dose-dependent manner according to a subcutaneous tumour model. Most importantly, in an intracranial tumour model with BP wafer in situ treatment, we demonstrated that the BP wafer not only significantly increased the survival rate but also decreased Axl expression, and inhibited tumour invasion. These results contribute to the development of a BP wafer for a novel therapeutic strategy for treating GBM invasion and increasing survival in clinical subjects.	[Yen, S-Y; Chen, S-R; Li, Y-S; Chiou, T-W] Natl Dong Hwa Univ, Dept Life Sci, Grad Inst Biotechnol, 1,Sec 2,Da Hsueh Rd, Hualien 97401, Taiwan; [Hsieh, J.] Natl Taiwan Univ, Mol Med Program, Taipei 10764, Taiwan; [Chuang, S-E] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Chuang, H-M; Huang, M-H] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Lin, S-Z] China Med Univ, Grad Inst Immunol, Taichung, Taiwan; [Lin, S-Z] China Med Univ Hosp, Ctr Neuropsychiat, Taichung, Taiwan; [Lin, S-Z] China Med Univ, Beigang Hosp, Dept Neurosurg, Yunlin, Taiwan; [Harn, H-J] China Med Univ Hosp, Dept Pathol, 2 Yude Rd, Taichung 40447, Taiwan; [Chiou, T-W] China Med Univ, Dept Med, Taichung, Taiwan	National Dong Hwa University; National Taiwan University; National Health Research Institutes - Taiwan; National Chung Hsing University; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan	Chiou, TW (corresponding author), Natl Dong Hwa Univ, Dept Life Sci, Grad Inst Biotechnol, 1,Sec 2,Da Hsueh Rd, Hualien 97401, Taiwan.; Harn, HJ (corresponding author), China Med Univ Hosp, Dept Pathol, 2 Yude Rd, Taichung 40447, Taiwan.	duke_harn@yahoo.com.tw; twchiou@mail.ndhu.edu.tw	Lin, Shinn-Zong/AAX-2379-2020		Ministry of Science and Technology, Taiwan [MOST 103-2320-B-039-021-MY3, MOST 103-2221-E-259-035]; Ministry of Economic Affairs [102-EC-17-A-19-I1-0051]; Health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (Taiwan) [MOHW104-TDU-B-212-124-002]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]; CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Economic Affairs; Health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (Taiwan); Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence; CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan	We are grateful to Shuang-En Chuang for sharing the plasmid of pcDNA3.0-Axl. This study was funded by the Ministry of Science and Technology, Taiwan (MOST 103-2320-B-039-021-MY3, MOST 103-2221-E-259-035), Ministry of Economic Affairs (102-EC-17-A-19-I1-0051), Health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (MOHW104-TDU-B-212-124-002, Taiwan), Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002) and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan.	Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Bezbradica JS, 2009, NAT IMMUNOL, V10, P333, DOI 10.1038/ni.1713; BLACKLOCK JB, 1986, J NEUROSURG, V64, P284, DOI 10.3171/jns.1986.64.2.0284; DOMB AJ, 1987, J POLYM SCI POL CHEM, V25, P3373, DOI 10.1002/pola.1987.080251217; Elliott PJ, 1996, EXP NEUROL, V141, P214, DOI 10.1006/exnr.1996.0156; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Harn HJ CS, 2013, J PHARM PHARMACOL, V1, P36; Harn HJ, 2011, NEURO-ONCOLOGY, V13, P635, DOI 10.1093/neuonc/nor021; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Huang MH, 2014, TUMOR BIOL, V35, P4875, DOI 10.1007/s13277-014-1639-0; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; JELSMAN R, 1967, J NEUROSURG, V27, P388, DOI 10.3171/jns.1967.27.5.0388; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Lin PC, 2008, J NEUROCHEM, V106, P1017, DOI 10.1111/j.1471-4159.2008.05432.x; Lin PC, 2011, ANN SURG ONCOL, V18, P3514, DOI 10.1245/s10434-011-1644-0; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Pierce AM, 2014, BRAIN RES, V1542, P206, DOI 10.1016/j.brainres.2013.10.049; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Rajput S, 2013, MOL CANCER THER, V12, P1676, DOI 10.1158/1535-7163.MCT-12-1019; SHAPIRO WR, 1987, J NEUROSURG, V66, P313; Tsai NM, 2005, CLIN CANCER RES, V11, P3475, DOI 10.1158/1078-0432.CCR-04-1827; Tsai NM, 2006, J NEUROCHEM, V99, P1251, DOI 10.1111/j.1471-4159.2006.04151.x; Tsitlakidis A, 2010, J NEUROSURG, V112, P1020, DOI 10.3171/2009.7.JNS09758; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Volk-Draper L, 2014, CANCER RES, V74, P5421, DOI 10.1158/0008-5472.CAN-14-0067; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0	30	27	27	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2156	2165		10.1038/onc.2015.277	http://dx.doi.org/10.1038/onc.2015.277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26257061	hybrid, Green Published			2022-12-28	WOS:000374986000002
J	Zhu, G; Li, X; Guo, B; Ke, Q; Dong, M; Li, F				Zhu, G.; Li, X.; Guo, B.; Ke, Q.; Dong, M.; Li, F.			PAK5-mediated E47 phosphorylation promotes epithelial-mesenchymal transition and metastasis of colon cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; E-CADHERIN; TRANSCRIPTION FACTORS; GASTRIC-CANCER; DOWN-REGULATION; CELL-ADHESION; E2A PROTEINS; KINASE; MIGRATION; INVASION	The p21-activated kinase 5 (PAK5) is overexpressed in advanced cancer and the transcription factor E47 is a direct repressor of E-cadherin and inducer of epithelial-mesenchymal transition (EMT). However, the relationship between PAK5 and E47 has not been explored. In this study, we found that PAK5-mediated E47 phosphorylation promoted EMT in advanced colon cancer. PAK5 interacted with E47 and phosphorylated E47 on Ser39 under hepatocyte growth factor (HGF) stimulation, which decreased cell-cell cohesion, increased cell migration and invasion in vitro and promoted metastasis in a xenograft model. Furthermore, phosphorylation of E47 facilitated its accumulating in nucleus in an importin a-dependent manner, and enhanced E47 binding to E-cadherin promoter directly, leading to inhibition of E-cadherin transcription. In contrast, PAK5-knockdown resulted in blockage of HGF-induced E47 phosphorylation, attenuated association of E47 with importin a and decreased E47 binding to E-cadherin promoter. In addition, we demonstrated a close correlation between PAK5 and phospho-Ser39 E47 expression in colon cancer specimens. More importantly, high expression of phospho-E47 was associated with an aggressive phenotype of colon cancer and nuclear phospho-E47 staining was found in certain cases of colon cancer with metastasis. Collectively, E47 is a novel substrate of PAK5, and PAK5-mediated phosphorylation of E47 promotes EMT and metastasis of colon cancer, suggesting that phosphorylated E47 on Ser39 may be a potential therapeutic target in progressive colon cancer.	China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth, Shenyang 110122, Peoples R China; China Med Univ, Key Lab Med Cell Biol, Minist Educ, Shenyang 110122, Peoples R China; Hangzhou Normal Univ, Sch Med, Dept Diagnost, Hangzhou, Zhejiang, Peoples R China; China Med Univ, Hosp 1, Gastrointestinal Surg, Dept Gen Surg, Shenyang 110122, Peoples R China	China Medical University; China Medical University; Hangzhou Normal University; China Medical University	Li, F (corresponding author), China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth,Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Peoples R China.; Li, F (corresponding author), China Med Univ, Key Lab Med Cell Biol, Minist Educ, 77 Puhe Rd, Shenyang 110122, Peoples R China.	fli@mail.cmu.edu.cn		Li, Feng/0000-0001-5868-7456	National Natural Science Foundation of China [90813038, 31371424, 31171360, 31000627, 81201659, 81230077]; Ministry of Education of China [20102104110016, IRT 13101]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China)	We are grateful to Drs Stephen J Brandt and Akira Kato for providing essential expression vectors. We also thank Dr Funan Liu for technical assistance. This work was supported by grants from the National Natural Science Foundation of China (Nos 90813038, 31371424, 31171360, 31000627, 81201659 and 81230077), Doctoral fund of Ministry of Education of China (No. 20102104110016) and Ministry of Education of China (IRT 13101).	BERCHUCK A, 1989, CANCER RES, V49, P2091; Chen XS, 2012, J NEUROSCI RES, V90, P925, DOI 10.1002/jnr.22826; Chiaro C, 2012, BIOCHEM BIOPH RES CO, V428, P121, DOI 10.1016/j.bbrc.2012.10.018; Cochrane SW, 2009, BLOOD, V113, P1016, DOI 10.1182/blood-2008-06-164996; Coma S, 2010, CANCER RES, V70, P3823, DOI 10.1158/0008-5472.CAN-09-3048; Fang ZP, 2014, ACTA PHARMACOL SIN, V35, P82, DOI 10.1038/aps.2013.31; Fawdar S, 2013, P NATL ACAD SCI USA, V110, P12426, DOI 10.1073/pnas.1305207110; Giroux V, 2009, PANCREATOLOGY, V9, P738, DOI 10.1159/000199435; Gong W, 2009, INT J CANCER, V125, P548, DOI 10.1002/ijc.24428; Gu J, 2013, FEBS J, V280, P46, DOI 10.1111/febs.12048; Guo Q, 2014, ONCOGENE, V33, P3277, DOI 10.1038/onc.2013.296; He H, 2013, BBA-MOL CELL RES, V1833, P33, DOI 10.1016/j.bbamcr.2012.10.015; Hwang-Verslues WW, 2011, ONCOGENE, V30, P2463, DOI 10.1038/onc.2010.618; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Lee SH, 2011, MOL CANCER RES, V9, P782, DOI 10.1158/1541-7786.MCR-10-0535; Li XD, 2010, EXPERT OPIN THER TAR, V14, P419, DOI 10.1517/14728221003642019; Li XD, 2010, INT J BIOCHEM CELL B, V42, P70, DOI 10.1016/j.biocel.2009.09.008; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Mehmood R, 2011, MOL BIOL CELL, V22, P3715, DOI 10.1091/mbc.E10-10-0809; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OGO A, 1995, J BIOL CHEM, V270, P25340, DOI 10.1074/jbc.270.43.25340; Patel D, 2012, BIOCHEM BIOPH RES CO, V422, P146, DOI 10.1016/j.bbrc.2012.04.126; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Shao YG, 2010, NUCLEIC ACIDS RES, V38, P2813, DOI 10.1093/nar/gkq006; Shapira S, 2014, CURR MED CHEM, V21, P2410, DOI 10.2174/0929867321666140205134616; Slattery C, 2008, INT J BIOCHEM CELL B, V40, P1431, DOI 10.1016/j.biocel.2007.05.014; Slattery C, 2006, FEBS LETT, V580, P4021, DOI 10.1016/j.febslet.2006.06.039; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; Spender LC, 2014, CANCER MANAG RES, V6, P27, DOI 10.2147/CMAR.S37745; Teachenor R, 2012, MOL CELL BIOL, V32, P1671, DOI 10.1128/MCB.06452-11; Teng Y, 2014, CLIN EXP METASTAS, V31, P367, DOI 10.1007/s10585-013-9621-6; Tijchon E, 2013, LEUKEMIA, V27, P541, DOI 10.1038/leu.2012.293; Wang X, 2010, TUMOR BIOL, V31, P575, DOI 10.1007/s13277-010-0071-3; Wang XX, 2013, TUMOR BIOL, V34, P2721, DOI 10.1007/s13277-013-0824-x; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080; Whale A, 2011, FRONT BIOSCI-LANDMRK, V16, P849, DOI 10.2741/3724; Zhao HC, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-317	45	31	33	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1943	1954		10.1038/onc.2015.259	http://dx.doi.org/10.1038/onc.2015.259			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26212009				2022-12-28	WOS:000374010300007
J	Macari, F; El-houfi, Y; Boldina, G; Xu, H; Khoury-Hanna, S; Ollier, J; Yazdani, L; Zheng, G; Bieche, I; Legrand, N; Paulet, D; Durrieu, S; Bystrom, A; Delbecq, S; Lapeyre, B; Bauchet, L; Pannequin, J; Hollande, F; Pan, T; Teichmann, M; Vagner, S; David, A; Choquet, A; Joubert, D				Macari, F.; El-houfi, Y.; Boldina, G.; Xu, H.; Khoury-Hanna, S.; Ollier, J.; Yazdani, L.; Zheng, G.; Bieche, I.; Legrand, N.; Paulet, D.; Durrieu, S.; Bystrom, A.; Delbecq, S.; Lapeyre, B.; Bauchet, L.; Pannequin, J.; Hollande, F.; Pan, T.; Teichmann, M.; Vagner, S.; David, A.; Choquet, A.; Joubert, D.			TRM6/61 connects PKC alpha with translational control through tRNA(i)(Met) stabilization: impact on tumorigenesis	ONCOGENE			English	Article							PROTEIN-KINASE-C; MULTIDRUG-RESISTANCE; INITIATOR TRNA(MET); GENE-EXPRESSION; CELL-LINES; CANCER; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION; ACTIVATION	Accumulating evidence suggests that changes of the protein synthesis machinery alter translation of specific mRNAs and participate in malignant transformation. Here we show that protein kinase C alpha (PKC alpha) interacts with TRM61, the catalytic subunit of the TRM6/61 tRNA methyltransferase. The TRM6/61 complex is known to methylate the adenosine 58 of the initiator methionine tRNA (tRNA(i)(Met)), a nuclear post-transcriptional modification associated with the stabilization of this crucial component of the translation-initiation process. Depletion of TRM6/61 reduced proliferation and increased death of C6 glioma cells, effects that can be partially rescued by overexpression of tRNA(i)(Met). In contrast, elevated TRM6/61 expression regulated the translation of a subset of mRNAs encoding proteins involved in the tumorigenic process and increased the ability of C6 cells to form colonies in soft agar or spheres when grown in suspension. In TRM6/61/tRNA(i)(Met)-overexpressing cells, PKC alpha overexpression decreased tRNA(i)(Met) expression and both colony-and sphere-forming potentials. A concomitant increase in TRM6/TRM61 mRNA and tRNA(i)(Met) expression with decreased expression of PKC alpha mRNA was detected in highly aggressive glioblastoma multiforme as compared with Grade II/III glioblastomas, highlighting the clinical relevance of our findings. Altogether, we suggest that PKC alpha tightly controls TRM6/61 activity to prevent translation deregulation that would favor neoplastic development.	[Macari, F.; El-houfi, Y.; Khoury-Hanna, S.; Ollier, J.; Yazdani, L.; Legrand, N.; Pannequin, J.; Hollande, F.; David, A.; Choquet, A.; Joubert, D.] CNRS, UMR 5203, Dept Oncol, Inst Genom Fonct, 141 Rue Cardonille, F-34094 Montpellier, France; [Macari, F.; El-houfi, Y.; Khoury-Hanna, S.; Ollier, J.; Yazdani, L.; Legrand, N.; Pannequin, J.; Hollande, F.; David, A.; Choquet, A.; Joubert, D.] INSERM, U1191, Montpellier, France; [Macari, F.; El-houfi, Y.; Khoury-Hanna, S.; Ollier, J.; Yazdani, L.; Legrand, N.; Pannequin, J.; Hollande, F.; David, A.; Choquet, A.; Joubert, D.] Univ Montpellier, Montpellier, France; [Boldina, G.; Vagner, S.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Boldina, G.; Vagner, S.] CNRS, UMR3348, F-91405 Orsay, France; [Boldina, G.; Vagner, S.] Univ Paris 11, Orsay, France; [Boldina, G.; Vagner, S.] PSL Res Univ, Paris, France; [Xu, H.; Bystrom, A.] Umea Univ, Dept Mol Biol, Umea, Sweden; [Zheng, G.; Pan, T.] Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA; [Bieche, I.] Hop Rene Huguenin, Inst Curie, Lab Oncogenet, St Cloud, France; [Paulet, D.] Lab Informat Robot & Microelect Montpellier, Montpellier, France; [Durrieu, S.; Teichmann, M.] Univ Bordeaux, Inst Europeen Chim & Biol, ARNA Lab, Pessac, France; [Delbecq, S.] Univ Montpellier I, Lab Biol Cellulaire & Mol, Montpellier, France; [Lapeyre, B.] CNRS UPHE UPVD, CRIOBE, USR 3278, Moorea, France; [Lapeyre, B.] CNRS, UMR5237, Ctr Rech Biochim Macromol, F-34094 Montpellier, France; [Bauchet, L.] Hop Gui de Chauliac, Dept Neurosurg, Montpellier, France; [Hollande, F.] Univ Melbourne, Dept Pathol, Mol Mech Tumor Progress Lab, Melbourne, Vic, Australia	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Umea University; University of Chicago; Rene Huguenin Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Montpellier; UDICE-French Research Universities; Universite de Bordeaux; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; University of Melbourne	David, A; Choquet, A (corresponding author), CNRS, UMR 5203, Dept Oncol, Inst Genom Fonct, 141 Rue Cardonille, F-34094 Montpellier, France.	alexandre.david@igf.cnrs.fr; armelle.choquet@igf.cnrs.fr	Wegglin, Reto/AAV-4341-2021; macari, francoise/E-9941-2014; David, Alexandre/B-2447-2013; Hollande, Frederic/GLS-4120-2022; Vagner, Stephan/G-3664-2013; David, Alexandre/AAL-2758-2021; Bièche, Ivan/O-7399-2017; Teichmann, Martin/M-7407-2014	macari, francoise/0000-0001-8942-1845; David, Alexandre/0000-0003-3365-1339; Hollande, Frederic/0000-0002-7046-8392; David, Alexandre/0000-0003-3365-1339; Bièche, Ivan/0000-0002-2430-5429; Delbecq, Stephane/0000-0002-2813-1219; Teichmann, Martin/0000-0002-5257-0510; Choquet, armelle/0000-0002-6959-9387; Bystrom, Anders/0000-0003-1281-3888; vagner, stephan/0000-0003-1452-7164; pannequin, julie/0000-0002-9956-373X	Swedish Cancer Foundation [13 0301]; Swedish Research Council [621-2012-3576]; Karin and Harald Silvanders Foundation [223-2808-12]; Institut National du Cancer (INCa); Fondation ARC	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Karin and Harald Silvanders Foundation; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation ARC	This work was generously supported by the Institut National du Cancer (INCa) and the Fondation ARC. We thank Martial Seveno, Serge Urbach and Edith Demettre from the 'Plate-forme de Proteomique Fonctionnelle' (FPP) for their work on proteomic analysis of cell samples. We thank the Gustave Roussy Genomic Core Facility (Noemie Pata-Merci) and the Gustave Roussy Bioinformatic Core Facility (Guillaume Meurice). ASB is supported by grants from the Swedish Cancer Foundation (13 0301), Swedish Research Council (621-2012-3576) and Karin and Harald Silvanders Foundation (223-2808-12).	AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Andaya A, 2011, J PROTEOME RES, V10, P4613, DOI 10.1021/pr200429y; Anderson J, 2000, P NATL ACAD SCI USA, V97, P5173, DOI 10.1073/pnas.090102597; Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; BENZIL DL, 1992, CANCER RES, V52, P2951; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572; Budworth J, 1997, BRIT J CANCER, V75, P1330, DOI 10.1038/bjc.1997.225; Cameron AJ, 2008, INT J CANCER, V123, P769, DOI 10.1002/ijc.23560; Chen CC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002258; Collazos A, 2006, MOL CELL BIOL, V26, P2247, DOI 10.1128/MCB.26.6.2247-2261.2006; David A, 2012, J CELL BIOL, V197, P45, DOI 10.1083/jcb.201112145; David A, 2011, J BIOL CHEM, V286, P20688, DOI 10.1074/jbc.M110.209452; Diouf B, 2009, J BIOL CHEM, V284, P18808, DOI 10.1074/jbc.M109.004614; Torres AG, 2014, TRENDS MOL MED, V20, P306, DOI 10.1016/j.molmed.2014.01.008; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V48, P375, DOI 10.1016/0006-2952(94)90110-4; GRUBER JR, 1995, EXP CELL RES, V221, P377, DOI 10.1006/excr.1995.1388; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Hou JQ, 2012, ONCOTARGET, V3, P118; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; Koromilas A.-E., 2014, BIOCH BIOPHYS ACTA B, V1849, P871, DOI DOI 10.1016/J.BBAGRM.2014.12.007; Lee SK, 2012, MOL CELLS, V34, P61, DOI 10.1007/s10059-012-0087-1; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Mandil R, 2001, CANCER RES, V61, P4612; Marques JM, 2013, J NEUROSCI, V33, P18298, DOI 10.1523/JNEUROSCI.3136-13.2013; MISRAPRESS A, 1992, GLIA, V6, P188, DOI 10.1002/glia.440060306; Ozanick S, 2005, RNA, V11, P1281, DOI 10.1261/rna.5040605; Ozanick SG, 2009, NUCLEIC ACIDS RES, V37, P298, DOI 10.1093/nar/gkn925; Pavon-Eternod M, 2013, RNA, V19, P461, DOI 10.1261/rna.037507.112; Pavon-Eternod M, 2009, NUCLEIC ACIDS RES, V37, P7268, DOI 10.1093/nar/gkp787; Quittau-Prevostel C, 2004, J CELL SCI, V117, P63, DOI 10.1242/jcs.00832; Reme T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066574; Ron D, 2007, ELF2ALPHA PHOSPHORYL; Roovers M, 2004, NUCLEIC ACIDS RES, V32, P465, DOI 10.1093/nar/gkh191; Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847; Saikia M, 2010, RNA, V16, P1317, DOI 10.1261/rna.2057810; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Thakor N, 2012, NUCLEIC ACIDS RES, V40, P541, DOI 10.1093/nar/gkr701; Towns WL, 2012, DNA CELL BIOL, V31, P434, DOI 10.1089/dna.2011.1437; WELSH GI, 1994, BIOCHEM BIOPH RES CO, V201, P1279, DOI 10.1006/bbrc.1994.1843; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831; XIAO HG, 1994, J NEUROSURG, V81, P734, DOI 10.3171/jns.1994.81.5.0734; Zellner A, 1998, CLIN CANCER RES, V4, P1797; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420	49	30	31	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1785	1796		10.1038/onc.2015.244	http://dx.doi.org/10.1038/onc.2015.244			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26234676				2022-12-28	WOS:000373610400005
J	Zhu, S; Chen, Z; Katsha, A; Hong, J; Belkhiri, A; El-Rifai, W				Zhu, S.; Chen, Z.; Katsha, A.; Hong, J.; Belkhiri, A.; El-Rifai, W.			Regulation of CD44E by DARPP-32-dependent activation of SRp20 splicing factor in gastric tumorigenesis	ONCOGENE			English	Article							DIFFERENTIAL EXPRESSION; CANCER; DARPP-32; OVEREXPRESSION; RESISTANCE; CD44V8-10; VARIANTS; RECEPTOR; ISOFORM; MARKER	CD44E is a frequently overexpressed variant of CD44 in gastric cancer. Mechanisms that regulate CD44 splicing and expression in gastric cancer remain unknown. Herein, we investigated the role of DARPP-32 (dopamine and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 32000) in promoting tumor growth through regulation of CD44 splicing. Using western blot and quantitative real-time PCR analysis, our results indicated that knockdown of endogenous DARPP-32 markedly reduces the expression of CD44 V8-V10 (CD44E). Using a quantitative splicing luciferase reporter system, we detected a significant increase in the reporter activity following DARPP-32 overexpression (P < 0.001). Conversely, knocking down endogenous DARPP-32 significantly attenuated the splicing activity (P < 0.001). Further experiments showed that DARPP-32 regulates the expression of SRp20 splicing factor and co-exists with it in the same protein complex. Inhibition of alternative splicing with digitoxin followed by immunoprecipitation and immunoblotting indicated that DARPP-32 has an important role in regulating SRp20 protein stability. The knockdown of endogenous DARPP-32 confirmed that DARPP-32 regulates the SRp20-dependent CD44E splicing. Using tumor xenograft mouse model, knocking down endogenous DARPP-32 markedly reduced SRp20 and CD44E protein levels with a decreased tumor growth. The reconstitution of SRp20 expression in these cells rescued tumor growth. In addition, we also demonstrated frequent co-overexpression and positive correlation of DARPP-32, SRp20 and CD44E expression levels in human gastric primary tumors. Our novel findings establish for the first time the role of DARPP-32 in regulating splicing factors in gastric cancer cells. The DARPP-32-SRp20 axis has a key role in regulating the CD44E splice variant that promotes gastric tumorigenesis.	[Zhu, S.; Chen, Z.; Katsha, A.; Hong, J.; Belkhiri, A.; El-Rifai, W.] Vanderbilt Univ, Med Ctr, Dept Surg, 2220 Pierce Ave,760 Preston Res Bldg, Nashville, TN 37232 USA; [El-Rifai, W.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [El-Rifai, W.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	El-Rifai, W (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 2220 Pierce Ave,760 Preston Res Bldg, Nashville, TN 37232 USA.	wael.el-rifai@vanderbilt.edu			National Institutes of Health [R01CA93999]; Vanderbilt SPORE in Gastrointestinal Cancer [P50 CA95103]; Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA093999, P50CA095103, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; Veterans Affairs [IK6BX003787] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt SPORE in Gastrointestinal Cancer; Vanderbilt Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by grants from the National Institutes of Health (R01CA93999); Vanderbilt SPORE in Gastrointestinal Cancer (P50 CA95103); Vanderbilt Ingram Cancer Center (P30 CA68485); the Vanderbilt Digestive Disease Research Center (DK058404), and the Department of Veterans Affairs. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, Department of Veterans Affairs or Vanderbilt University.	Anderson ES, 2012, RNA, V18, P1041, DOI 10.1261/rna.032912.112; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Belkhiri A, 2008, CLIN CANCER RES, V14, P4564, DOI 10.1158/1078-0432.CCR-08-0121; Biamonti G, 1998, CLIN EXP RHEUMATOL, V16, P317; Bourguignon Lilly Y. W., 1998, Frontiers in Bioscience, V3, pD637; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Cohen-Eliav M, 2013, J PATHOL, V229, P630, DOI 10.1002/path.4129; da Cunha CB, 2010, LAB INVEST, V90, P1604, DOI 10.1038/labinvest.2010.155; El-Rifai W, 2002, CANCER RES, V62, P4061; Erkelenz S, 2013, RNA, V19, P96, DOI 10.1261/rna.037044.112; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Hamel S, 2010, BREAST CANCER RES TR, V120, P47, DOI 10.1007/s10549-009-0364-7; HEIDER KH, 1993, CANCER RES, V53, P4197; Hiraga T, 2013, CANCER RES, V73, P4112, DOI 10.1158/0008-5472.CAN-12-3801; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia R, 2010, INT J BIOL SCI, V6, P806; Jia R, 2009, J VIROL, V83, P167, DOI 10.1128/JVI.01719-08; Klingbeil P, 2010, BREAST CANCER RES TR, V120, P95, DOI 10.1007/s10549-009-0380-7; Lau WM, 2014, CANCER RES, V74, P2630, DOI 10.1158/0008-5472.CAN-13-2309; Long JC, 2009, BIOCHEM J, V417, P15, DOI 10.1042/BJ20081501; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Miwa T, 1996, CANCER, V77, P25, DOI 10.1002/(SICI)1097-0142(19960101)77:1<25::AID-CNCR6>3.0.CO;2-M; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Muramaki M, 2004, J UROLOGY, V171, P426, DOI 10.1097/01.ju.0000093446.54115.b6; Omara-Opyene AL, 2004, LAB INVEST, V84, P894, DOI 10.1038/labinvest.3700112; Pall T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029305; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prochazka L, 2014, CELL SIGNAL, V26, P2234, DOI 10.1016/j.cellsig.2014.07.011; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; TAKEUCHI K, 1995, JPN J CANCER RES, V86, P292, DOI 10.1111/j.1349-7006.1995.tb03053.x; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang MSJ, 2005, INT J CLIN PRACT, V59, P58, DOI 10.1111/j.1742-1241.2004.00305.x; Xi LQ, 2008, NUCLEIC ACIDS RES, V36, P6535, DOI 10.1093/nar/gkn697; Younis I, 2010, MOL CELL BIOL, V30, P1718, DOI 10.1128/MCB.01301-09; Zhu SM, 2013, MOL CANCER RES, V11, P86, DOI 10.1158/1541-7786.MCR-12-0243-T; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	39	18	19	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1847	1856		10.1038/onc.2015.250	http://dx.doi.org/10.1038/onc.2015.250			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119931	Green Accepted			2022-12-28	WOS:000373610400010
J	Busacca, S; Law, EWP; Powley, IR; Proia, DA; Sequeira, M; Le Quesne, J; Klabatsa, A; Edwards, JM; Matchett, KB; Luo, JL; Pringle, JH; El-Tanani, M; MacFarlane, M; Fennell, DA				Busacca, S.; Law, E. W. P.; Powley, I. R.; Proia, D. A.; Sequeira, M.; Le Quesne, J.; Klabatsa, A.; Edwards, J. M.; Matchett, K. B.; Luo, J. L.; Pringle, J. H.; El-Tanani, M.; MacFarlane, M.; Fennell, D. A.			Resistance to HSP90 inhibition involving loss of MCL1 addiction	ONCOGENE			English	Article							CANCER-CELLS; STRUCTURAL BASIS; APOPTOSIS; SENSITIVITY; EML4-ALK; BCL-2; IDENTIFICATION; EXPRESSION; DEATH; GENE	Inhibition of the chaperone heat-shock protein 90 (HSP90) induces apoptosis, and it is a promising anti-cancer strategy. The mechanisms underpinning apoptosis activation following HSP90 inhibition and how they are modified during acquired drug resistance are unknown. We show for the first time that, to induce apoptosis, HSP90 inhibition requires the cooperation of multi BH3-only proteins (BID, BIK, PUMA) and the reciprocal suppression of the pro-survival BCL-2 family member MCL1, which occurs via inhibition of STAT5A. A subset of tumour cell lines exhibit dependence on MCL1 expression for survival and this dependence is also associated with tumour response to HSP90 inhibition. In the acquired resistance setting, MCL1 suppression in response to HSP90 inhibitors is maintained; however, a switch in MCL1 dependence occurs. This can be exploited by the BH3 peptidomimetic ABT737, through non-BCL-2-dependent synthetic lethality.	[Busacca, S.; Law, E. W. P.; Le Quesne, J.; Luo, J. L.; Pringle, J. H.; Fennell, D. A.] Univ Leicester, Dept Canc Studies, Canc Res UK Leicester Ctr, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England; [Powley, I. R.; Le Quesne, J.; Edwards, J. M.; MacFarlane, M.] MRC Toxicol Unit, Leicester, Leics, England; [Proia, D. A.; Sequeira, M.] Synta Pharmaceut Corp, Lexington, MA USA; [Klabatsa, A.] Kings Coll London, Div Canc Studies, London WC2R 2LS, England; [Matchett, K. B.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [El-Tanani, M.] Univ Bradford, Sch Life Sci, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England	Cancer Research UK; University of Leicester; University of London; King's College London; Queens University Belfast; University of Bradford	Fennell, DA (corresponding author), Univ Leicester, Dept Canc Studies, Canc Res UK Leicester Ctr, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	df132@leicester.ac.uk	Klampatsa, Astero/AAK-4419-2020	Klampatsa, Astero/0000-0003-0572-502X; Le Quesne, John/0000-0003-3552-7446; Luo, Jinli/0000-0002-9241-5283; Matchett, Kyle/0000-0001-6148-6022; El-Tanani, Mohamed/0000-0002-4735-5445; Law, Edward/0000-0001-5089-6341	University of Leicester; Medical Research Council (MRC); British Lung Foundation (BLF); MRC [MC_PC_14117, MC_PC_15045, MC_U132685863, MC_UP_1203/1] Funding Source: UKRI; Medical Research Council [MC_U132685863, MC_PC_15045, MC_UP_1203/1, MC_PC_14117] Funding Source: researchfish	University of Leicester; Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Lung Foundation (BLF); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Dr Meike Vogler (University of Leicester) for critically revising the manuscript. DAF and SB are supported by the University of Leicester. MMF and IRP are funded by Medical Research Council (MRC) and British Lung Foundation (BLF).	Acquaviva J, 2014, MOL CANCER RES, V12, P1042, DOI 10.1158/1541-7786.MCR-14-0004; Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Altieri DC, 2012, BBA-MOL CELL RES, V1823, P767, DOI 10.1016/j.bbamcr.2011.08.007; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Busacca S, 2012, J PATHOL, V227, P200, DOI 10.1002/path.3979; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fritsch RM, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702673200; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Geserick P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.379; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heuckmann JM, 2012, CLIN CANCER RES, V18, P4682, DOI 10.1158/1078-0432.CCR-11-3260; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kotha A, 2006, MOL CANCER THER, V5, P621, DOI 10.1158/1535-7163.MCT-05-0268; Landmann H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.378; McCollum AK, 2006, CANCER RES, V66, P10967, DOI 10.1158/0008-5472.CAN-06-1629; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Moulick K, 2011, NAT CHEM BIOL, V7, P818, DOI 10.1038/nchembio.670; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nam S, 2007, MOL CANCER THER, V6, P1400, DOI 10.1158/1535-7163.MCT-06-0446; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paraiso KHT, 2012, CLIN CANCER RES, V18, P2502, DOI 10.1158/1078-0432.CCR-11-2612; Paul I, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.186; Paul I, 2011, J PATHOL, V224, P564, DOI 10.1002/path.2925; Pillai RN, 2014, CURR OPIN ONCOL, V26, P159, DOI 10.1097/CCO.0000000000000047; Powers MV, 2013, ONCOTARGET, V4, P1963, DOI 10.18632/oncotarget.1419; Prodromou C, 2009, ACS CHEM BIOL, V4, P289, DOI 10.1021/cb9000316; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Richards MW, 2014, P NATL ACAD SCI USA, V111, P5195, DOI 10.1073/pnas.1322892111; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Samant RS, 2014, P NATL ACAD SCI USA, V111, P6834, DOI 10.1073/pnas.1322412111; Sathe P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5539; Shah OJ, 2010, P NATL ACAD SCI USA, V107, P12634, DOI 10.1073/pnas.0913615107; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Travers J, 2012, DRUG DISCOV TODAY, V17, P242, DOI 10.1016/j.drudis.2011.12.021; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Twiddy D, 2010, BREAST CANCER RES, P58; Upton JP, 2008, MOL CELL BIOL, V28, P3943, DOI 10.1128/MCB.00013-08; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Workman P, 2013, NAT REV DRUG DISCOV, V12, P889, DOI 10.1038/nrd4184; Workman P, 2013, CURR OPIN PHARMACOL, V13, P486, DOI 10.1016/j.coph.2013.06.004	51	19	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1483	1492		10.1038/onc.2015.213	http://dx.doi.org/10.1038/onc.2015.213			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26096930	Green Published, hybrid			2022-12-28	WOS:000373063600002
J	Goodman, CR; Sato, T; Peck, AR; Girondo, MA; Yang, N; Liu, C; Yanac, AF; Kovatich, AJ; Hooke, JA; Shriver, CD; Mitchell, EP; Hyslop, T; Rui, H				Goodman, C. R.; Sato, T.; Peck, A. R.; Girondo, M. A.; Yang, N.; Liu, C.; Yanac, A. F.; Kovatich, A. J.; Hooke, J. A.; Shriver, C. D.; Mitchell, E. P.; Hyslop, T.; Rui, H.			Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism	ONCOGENE			English	Article							MEDROXYPROGESTERONE ACETATE; SIGNAL TRANSDUCER; BCL6 EXPRESSION; PROLACTIN; STAT5; DIFFERENTIATION; INHIBITION; PROGESTERONE; ACTIVATOR; SURVIVAL	Therapy resistance remains a major problem in estrogen receptor-alpha (ER alpha)-positive breast cancer. A subgroup of ER alpha-positive breast cancer is characterized by mosaic presence of a minor population of ER alpha-negative cancer cells expressing the basal cytokeratin-5 (CK5). These CK5-positive cells are therapy resistant and have increased tumor-initiating potential. Although a series of reports document induction of the CK5-positive cells by progestins, it is unknown if other 3-ketosteroids share this ability. We now report that glucocorticoids and mineralocorticoids effectively expand the CK5-positive cell population. CK5-positive cells induced by 3-ketosteroids lacked ER alpha and progesterone receptors, expressed stem cell marker, CD44, and displayed increased clonogenicity in soft agar and broad drug-resistance in vitro and in vivo. Upregulation of CK5-positive cells by 3-ketosteroids required induction of the transcriptional repressor BCL6 based on suppression of BCL6 by two independent BCL6 small hairpin RNAs or by prolactin. Prolactin also suppressed 3-ketosteroid induction of CK5+ cells in T47D xenografts in vivo. Survival analysis with recursive partitioning in node-negative ER alpha-positive breast cancer using quantitative CK5 and BCL6 mRNA or protein expression data identified patients at high or low risk for tumor recurrence in two independent patient cohorts. The data provide a mechanism by which common pathophysiological or pharmacologic elevations in glucocorticoids or other 3-ketosteroids may adversely affect patients with mixed ER alpha+/CK5+ breast cancer. The observations further suggest a cooperative diagnostic utility of CK5 and BCL6 expression levels and justify exploring efficacy of inhibitors of BCL6 and 3-ketosteroid receptors for a subset of ER alpha-positive breast cancers.	[Goodman, C. R.; Sato, T.; Peck, A. R.; Girondo, M. A.; Yang, N.; Liu, C.; Yanac, A. F.; Rui, H.] Thomas Jefferson Univ, Dept Canc Biol, 233 S 10th St,BLSB 330, Philadelphia, PA 19107 USA; [Kovatich, A. J.; Hooke, J. A.; Shriver, C. D.] Walter Reed Natl Mil Med Ctr, John P Murtha Canc Ctr, Bethesda, MD USA; [Mitchell, E. P.; Rui, H.] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA; [Hyslop, T.] Duke Univ, Duke Canc Inst, Dept Biostat & Bioinformat, Durham, NC USA; [Rui, H.] Thomas Jefferson Univ, Dept Pathol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Walter Reed National Military Medical Center; Jefferson University; Duke University; Jefferson University	Rui, H (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, 233 S 10th St,BLSB 330, Philadelphia, PA 19107 USA.	hallgeir.rui@jefferson.edu		Kovatich, Albert/0000-0002-5169-4087; Rui, Hallgeir/0000-0002-8778-261X; Goodman, Chelain/0000-0001-9083-3652	Susan G Komen [KG091116]; Ladies of Port Richmond; NCI [CA185918, CA188575, 1P30CA56036]; Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA188575, P30CA056036, R21CA185918] Funding Source: NIH RePORTER	Susan G Komen(Susan G. Komen Breast Cancer Foundation); Ladies of Port Richmond; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from Susan G Komen (KG091116), Ladies of Port Richmond and NCI (CA185918, CA188575; Support Grant 1P30CA56036), and in part, under a Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. We thank Colleen Lord for expert editorial assistance.	Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Axlund SD, 2013, HORM CANCER-US, V4, P36, DOI 10.1007/s12672-012-0127-5; Bentel JM, 1999, MOL CELL ENDOCRINOL, V154, P11, DOI 10.1016/S0303-7207(99)00109-4; Byrne MJ, 1997, J CLIN ONCOL, V15, P3141, DOI 10.1200/JCO.1997.15.9.3141; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134; Cittelly DM, 2013, ONCOGENE, V32, P2555, DOI 10.1038/onc.2012.275; Conde I, 2008, HISTOL HISTOPATHOL, V23, P77, DOI 10.14670/HH-23.77; Costanzo ES, 2011, IMMUNOL ALLERGY CLIN, V31, P109, DOI 10.1016/j.iac.2010.09.001; Duy C, 2011, NATURE, V473, P384, DOI 10.1038/nature09883; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933; Joensuu K, 2013, BREAST CANCER-BASIC, V7, P23, DOI 10.4137/BCBCR.S10701; Johnson KJ, 2010, AM J PATHOL, V177, P2971, DOI 10.2353/ajpath.2010.090399; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Knox AJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0418-6; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Palesh O, 2007, J PSYCHOSOM RES, V63, P233, DOI 10.1016/j.jpsychores.2007.05.012; Pang D, 2006, CANCER BIOL THER, V5, P933, DOI 10.4161/cbt.5.8.2875; Paredes J, 2007, VIRCHOWS ARCH, V450, P73, DOI 10.1007/s00428-006-0334-y; Peck AR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3328; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Plotnikov A, 2009, CANCER RES, V69, P3165, DOI 10.1158/0008-5472.CAN-08-4033; Rakha EA, 2007, HISTOPATHOLOGY, V50, P434, DOI 10.1111/j.1365-2559.2007.02638.x; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Sasano H, 1997, ANTICANCER RES, V17, P2001; Sato T, 2014, ONCOGENE, V33, P2215, DOI 10.1038/onc.2013.172; Sato T, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-59; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Tran TH, 2010, CANCER RES, V70, P1711, DOI 10.1158/0008-5472.CAN-09-2314; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Volden PA, 2013, BRAIN BEHAV IMMUN, V30, pS26, DOI 10.1016/j.bbi.2012.10.022; Wagner SD, 2011, BRIT J HAEMATOL, V152, P3, DOI 10.1111/j.1365-2141.2010.08420.x; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Wan YH, 2002, MOL ENDOCRINOL, V16, P1204, DOI 10.1210/me.16.6.1204; Wu Q, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-418; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Yamashita H, 2006, ENDOCR-RELAT CANCER, V13, P885, DOI 10.1677/erc.1.01095; Yang N, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3467; Yin P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029021; Yoo BH, 2012, J BIOMOL SCREEN, V17, P1211, DOI 10.1177/1087057112452138; Zhang C, 2007, CANCER BIOL THER, V6, P278, DOI 10.4161/cbt.6.2.3652	56	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1373	1385		10.1038/onc.2015.193	http://dx.doi.org/10.1038/onc.2015.193			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26096934	hybrid, Green Published			2022-12-28	WOS:000372196400004
J	Peyser, ND; Freilino, M; Wang, L; Zeng, Y; Li, H; Johnson, DE; Grandis, JR				Peyser, N. D.; Freilino, M.; Wang, L.; Zeng, Y.; Li, H.; Johnson, D. E.; Grandis, J. R.			Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer	ONCOGENE			English	Article							TARGETING STAT3	Signal transducer and activator of transcription 3 (STAT3) overactivation is a common event in many cancers, including head and neck squamous cell carcinoma (HNSCC), where STAT3 represents a promising therapeutic target. HNSCC is not characterized by frequent kinase mutations, in contrast to some malignancies where mutational activation of kinases upstream of STAT3 is common. Instead, STAT3 may be activated by loss-of-function of negative regulators of STAT3, including by promoter hypermethylation of PTPRT. Here we first analyzed The Cancer Genome Atlas data and determined that the PTPRT promoter is frequently hypermethylated in several cancers, including HNSCC (60.1% of tumors analyzed) in association with downregulation of PTPRT mRNA expression and upregulation of pSTAT3 expression. These findings were confirmed in an independent cohort of HNSCC tumors by methylation-specific PCR and immunohistochemistry. We demonstrate that PTPRT promoter methylation and gene silencing is reversible in HNSCC cells, leading to PTPRT-specific downregulation of pSTAT3 expression. We further show that PTPRT promoter methylation is significantly associated with sensitivity to STAT3 inhibition in HNSCC cells, suggesting that PTPRT promoter methylation may serve as a predictive biomarker for responsiveness to STAT3 inhibitors in clinical development.	[Peyser, N. D.; Johnson, D. E.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Peyser, N. D.; Freilino, M.; Wang, L.; Zeng, Y.; Li, H.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; [Johnson, D. E.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Grandis, J. R.] Univ Calif San Francisco, Dept Otolaryngol, 550 16th St,6th Floor, San Francisco, CA 94143 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco	Grandis, JR (corresponding author), Univ Calif San Francisco, Otolaryngol, 550 16th St,6th Floor, San Francisco, CA 94143 USA.	Jennifer.Grandis@ucsf.edu		Peyser, Noah/0000-0003-4529-8325	National Cancer Institute at the National Institutes of Health [P50 CA097190, R01 CA077308]; National Institute for Dental and Craniofacial Research at the National Institutes of Health [F31 DE024007]; NATIONAL CANCER INSTITUTE [R01CA077308, P50CA097190] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [F31DE024007] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute for Dental and Craniofacial Research at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers P50 CA097190 and R01 CA077308 to JRG); and by the National Institute for Dental and Craniofacial Research at the National Institutes of Health (grant number F31 DE024007 to NDP). The authors wish to thank Mark H Gage for technical assistance.	Benson E, 2014, ORAL ONCOL, V50, P565, DOI 10.1016/j.oraloncology.2013.09.008; Gao W, 2008, CARCINOGENESIS, V29, P1901, DOI 10.1093/carcin/bgn170; Ji T, 2013, CANCER LETT, V341, P231, DOI 10.1016/j.canlet.2013.08.022; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Laczmanska I, 2013, J HUM GENET, V58, P11, DOI 10.1038/jhg.2012.119; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Licitra L, 2011, ANN ONCOL, V22, P1078, DOI 10.1093/annonc/mdq588; Lui VWY, 2014, P NATL ACAD SCI USA, V111, P1114, DOI 10.1073/pnas.1319551111; Peyser ND, 2013, ONCOTARGETS THER, V6, P999, DOI 10.2147/OTT.S47903; Sen M, 2012, CLIN CANCER RES, V18, P4986, DOI 10.1158/1078-0432.CCR-12-0792; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104	13	30	31	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1163	1169		10.1038/onc.2015.171	http://dx.doi.org/10.1038/onc.2015.171			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982282	Green Accepted, Green Submitted			2022-12-28	WOS:000371351700010
J	Williamson, M; de Winter, P; Masters, JR				Williamson, M.; de Winter, P.; Masters, J. R.			Plexin-B1 signalling promotes androgen receptor translocation to the nucleus	ONCOGENE			English	Article							SERINE 81 PHOSPHORYLATION; PROSTATE-CANCER CELLS; THERAPEUTIC TARGETS; R-RAS; BINDING; GROWTH; SEMAPHORINS; ACTIVATION; EXPRESSION; MECHANISMS	Semaphorins and their receptors plexins have diverse roles in many cancers affecting tumour growth, metastasis and angiogenesis. Plexin-B1, the receptor for semaphorin4D (Sema4D), has been implicated in prostate cancer where mutation of the gene and overexpression of the protein occur. It is not clear, however, as to which of the several Sema4D-activated signalling pathways downstream of plexin-B1 function in prostate cancer progression. We show here that Sema4D/plexin-B1 increases the expression of androgen-responsive genes and activates the transcriptional activity of the androgen receptor (AR). Activation of plexin-B1 results in phosphorylation of AR at Serine 81, a site that is phosphorylated by nuclear kinases. Cell fractionation and immunocytochemistry studies demonstrated that the proportion of cells with AR in the nucleus increases significantly upon Sema4D treatment. The N-terminal (AF-1) domain of AR, which contains binding sites for transcription regulators, is not required for this response. Depletion of AR suppressed Sema4D-induced anchorage-independent growth of LNCaP and LNCaP-LN3 cells, demonstrating the functional significance of these findings. These results show that Sema4D/plexin-B1 signalling promotes the translocation of AR to the nucleus and thereby enhances AR transcriptional activity. Plexin-B1 is therefore a promising target for cancer therapy, especially in low androgen situations such as those imposed by androgen deprivation therapy.	[Williamson, M.] Kings Coll London, Fac Life Sci & Med, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [de Winter, P.] UCL, Div Surg & Intervent Sci, Translat Urooncol Grp, London, England; [Masters, J. R.] UCL, Prostate Canc Res Ctr, London, England	University of London; King's College London; University of London; University College London; University of London; University College London	Williamson, M (corresponding author), Kings Coll London, Fac Life Sci & Med, Randall Div Cell & Mol Biophys, London SE1 1UL, England.	magali.williamson@ucl.ac.uk		Williamson, Magali/0000-0002-7183-7495	Prostate Cancer Research Centre; Smith's Charity; Rosetrees Trust; Barcapel Foundation; McAlpine Foundation; Orchid Appeal	Prostate Cancer Research Centre; Smith's Charity; Rosetrees Trust(Rosetrees Trust); Barcapel Foundation; McAlpine Foundation; Orchid Appeal	We thank the Prostate Cancer Research Centre, Smith's Charity, the Rosetrees Trust, the Barcapel Foundation, the McAlpine Foundation and the Orchid Appeal for funding.	Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Chen SY, 2012, J BIOL CHEM, V287, P8571, DOI 10.1074/jbc.M111.325290; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Damola A, 2013, PROSTATE, V73, P1326, DOI 10.1002/pros.22678; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238; Gravina GL, 2004, INT J ONCOL, V25, P97; Gregory CW, 1999, ENDOCRINOLOGY, V140, P2372, DOI 10.1210/en.140.5.2372; Gross M, 2007, CLIN CANCER RES, V13, P1979, DOI 10.1158/1078-0432.CCR-06-1156; Hota PK, 2012, CELL MOL LIFE SCI, V69, P3765, DOI 10.1007/s00018-012-1019-0; Ito Y, 2006, EMBO REP, V7, P704, DOI 10.1038/sj.embor.7400737; Kesler CT, 2007, MOL ENDOCRINOL, V21, P2071, DOI 10.1210/me.2007-0240; Laht P, 2014, EXP CELL RES, V326, P174, DOI 10.1016/j.yexcr.2014.06.005; Mann F, 2007, J NEUROCHEM, V102, P316, DOI 10.1111/j.1471-4159.2007.04578.x; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Minner S, 2010, CLIN CANCER RES, V16, P1553, DOI 10.1158/1078-0432.CCR-09-2546; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Okada T, 2015, NAT CELL BIOL, V17, P81, DOI 10.1038/ncb3082; Rody A, 2009, EUR J CANCER, V45, P405, DOI 10.1016/j.ejca.2008.10.016; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; Soong J, 2013, J CELL SCI, V126, P688, DOI 10.1242/jcs.119487; Stevens L, 2010, J INVEST DERMATOL, V130, P1636, DOI 10.1038/jid.2010.13; Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2012, CANCER CELL, V22, P145, DOI 10.1016/j.ccr.2012.06.031; Thadani-Mulero M, 2012, CANCER RES, V72, P4611, DOI 10.1158/0008-5472.CAN-12-0783; Togashi H, 2006, J NEUROSCI, V26, P4961, DOI 10.1523/JNEUROSCI.0704-06.2006; Tong Y, 2007, J BIOL CHEM, V282, P37215, DOI 10.1074/jbc.M703800200; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Wang LG, 2001, CANCER RES, V61, P7544; Wang YX, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002636; Worzfeld T, 2014, NAT REV DRUG DISCOV, V13, P603, DOI 10.1038/nrd4337; Worzfeld T, 2012, J CLIN INVEST, V122, P1296, DOI 10.1172/JCI60568; Ye SM, 2010, BMC CANCER, V105, DOI 10.1186/1471-2407-10-611; Yoshizawa A, 2006, ENDOCR J, V53, P811, DOI 10.1507/endocrj.K06-017; Zhou C, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-11	41	25	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1066	1072		10.1038/onc.2015.160	http://dx.doi.org/10.1038/onc.2015.160			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25982277	Green Submitted			2022-12-28	WOS:000370823300012
J	Huang, W; Dong, Z; Chen, Y; Wang, F; Wang, CJ; Peng, H; He, Y; Hangoc, G; Pollok, K; Sandusky, G; Fu, XY; Broxmeyer, HE; Zhang, ZY; Liu, JY; Zhang, JT				Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, K.; Sandusky, G.; Fu, X-Y; Broxmeyer, H. E.; Zhang, Z-Y; Liu, J-Y; Zhang, J-T			Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo	ONCOGENE			English	Article							SIGNAL TRANSDUCER; CANCER; TRANSCRIPTION; ACTIVATOR; PHOSPHORYLATION; IL-6	Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness. Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clinical trials. Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its 'undruggable' nature and potentially limited selectivity. In a previous study, we reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-molecule STAT3 inhibitor (inS3-54). Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1. In this study, we describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compound (inS3-54A18) with increased specificity and pharmacological properties. InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes. InS3-54A18 is completely soluble in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals. Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be 'undruggable' as previously thought.	[Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; Pollok, K.; Liu, J-Y; Zhang, J-T] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [He, Y.; Zhang, Z-Y] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Hangoc, G.; Fu, X-Y; Broxmeyer, H. E.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Pollok, K.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Pollok, K.; Sandusky, G.; Fu, X-Y; Broxmeyer, H. E.; Zhang, Z-Y; Zhang, J-T] Indiana Univ Sch Med, IU Simon Canc Ctr, 980W Walnut St, Indianapolis, IN 46202 USA; [Sandusky, G.] Indiana Univ Sch Med, Dept Pathol & Mol Med, Indianapolis, IN 46202 USA; [Liu, J-Y] Indiana Univ Purdue Univ, Dept Comp & Informat Sci, Indianapolis, IN 46202 USA; [Huang, W.] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100871, Peoples R China	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Peking University	Zhang, JT (corresponding author), Indiana Univ Sch Med, IU Simon Canc Ctr, 980W Walnut St, Indianapolis, IN 46202 USA.; Liu, JY (corresponding author), IUPUI, Dept Comp & Informat Sci, 635 Barnhill Dr,MS550, Indianapolis, IN 46202 USA.	jliu2@iu.edu; jianzhan@iu.edu	Zhang, Jian-Ting/L-8334-2015	Wang, Chao/0000-0001-8951-5657; Zhang, Jian-Ting/0000-0002-2803-9914	Lung Cancer Working Group at IUSCC	Lung Cancer Working Group at IUSCC	We thank Anthony Sinn in the In Vivo Therapeutics Core and Sheng Zhang in the Chemical Genomics Core for their technical assistance for in vivo studies and chemical synthesis, respectively. Jiayuh Lin at Ohio State University provided MDA-MB-231-STAT3 cells with the STAT3-dependent luciferase reporter while George R Stark at Cleveland Clinic provided STAT1 cDNA. This work was supported in part by the Lung Cancer Working Group at IUSCC.	Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Caboni L, 2013, MED RES REV, V33, P1081, DOI 10.1002/med.21275; Chen Z, 2008, MED RES REV, V28, P185, DOI 10.1002/med.20101; Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Choi CH, 2010, J OBSTET GYNAECOL RE, V36, P304, DOI 10.1111/j.1447-0756.2009.01131.x; Debnath B, 2012, J MED CHEM, V55, P6645, DOI 10.1021/jm300207s; Deng JX, 2007, CURR CANCER DRUG TAR, V7, P91, DOI 10.2174/156800907780006922; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Fletcher S, 2009, CHEMBIOCHEM, V10, P1959, DOI 10.1002/cbic.200900172; Hao WS, 2008, BIOORG MED CHEM LETT, V18, P4988, DOI 10.1016/j.bmcl.2008.08.032; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Huang W, 2014, ACS CHEM BIOL, V9, P1188, DOI 10.1021/cb500071v; Lee H, 2011, CURR TOP MICROBIOL, V344, P41, DOI 10.1007/82_2010_51; Leung CH, 2013, MED RES REV, V33, P823, DOI 10.1002/med.21266; Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468; Lin L, 2010, NEOPLASIA, V12, P39, DOI 10.1593/neo.91196; Mantel C, 2012, BLOOD, V120, P2589, DOI 10.1182/blood-2012-01-404004; Nkansah E, 2013, FEBS LETT, V587, P833, DOI 10.1016/j.febslet.2013.01.065; Ren ZY, 2003, BIOORG MED CHEM LETT, V13, P633, DOI 10.1016/S0960-894X(02)01050-8; Schust J, 2004, ANAL BIOCHEM, V330, P114, DOI 10.1016/j.ab.2004.03.024; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Siddiquee KAZ, 2007, ACS CHEM BIOL, V2, P787, DOI 10.1021/cb7001973; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Timofeeva OA, 2012, J BIOL CHEM, V287, P14192, DOI 10.1074/jbc.M111.323899; Turkson J, 2004, MOL CANCER THER, V3, P261; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yang Youyun, 2011, Int J Biochem Mol Biol, V2, P89; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI 10.1517/13543780802565791 	35	62	67	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					783	792		10.1038/onc.2015.215	http://dx.doi.org/10.1038/onc.2015.215			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	26073084				2022-12-28	WOS:000370331300011
J	Raggi, C; Mousa, HS; Corrent, M; Sica, A; Invernizzi, P				Raggi, C.; Mousa, H. S.; Corrent, M.; Sica, A.; Invernizzi, P.			Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; BONE-MARROW MICROENVIRONMENT; BREAST-CANCER; FACTOR RECEPTOR; SELF-RENEWAL; MYELOGENOUS LEUKEMIA; SIGNALING PATHWAY; CYTOKINE NETWORKS	The idea that tumor initiation and progression are driven by a subset of cells endowed with stem-like properties was first described by Rudolf Virchow in 1855. 'Cancer stem cells', as they were termed more than a century later, represent a subset of tumor cells that are able to generate all tumorigenic and nontumorigenic cell types within the malignancy. Although their existence was hypothesized > 150 years ago, it was only recently that stem-like cells started to be isolated from different neoplastic malignancies. Interestingly, Virchow, in suggesting a correlation between cancer and the inflammatory microenvironment, also paved the way for the 'Seed and Soil' theory proposed by Paget a few years later. Despite the time that has passed since these two important concepts were suggested, the relationships between Virchow's 'stem-like cells' and Paget's 'soil' are far from being fully understood. One emerging topic is the importance of a stem-like niche in modulating the biological properties of stem-like cancer cells and thus in affecting the response of the tumor to drugs. This review aims to summarize the recent molecular data concerning the multilayered relationship between cancer stem cells and tumor-associated macrophages that form a key component of the tumor microenvironment. We also discuss the therapeutic implications of targeting this synergistic interplay.	[Raggi, C.; Mousa, H. S.; Corrent, M.; Invernizzi, P.] Humanitas Clin & Res Ctr, Liver Unit, Via Manzoni 56, I-20089 Milan, Italy; [Raggi, C.; Mousa, H. S.; Corrent, M.; Invernizzi, P.] Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Via Manzoni 56, I-20089 Milan, Italy; [Sica, A.] Humanitas Clin & Res Ctr, Lab Mol Immunol, Milan, Italy; [Sica, A.] Univ Piemonte Orientale Amedeo Avogadro, Dept Pharmaceut Sci, Novara, Italy	University of Eastern Piedmont Amedeo Avogadro	Raggi, C (corresponding author), Humanitas Clin & Res Ctr, Liver Unit, Via Manzoni 56, I-20089 Milan, Italy.; Raggi, C (corresponding author), Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Via Manzoni 56, I-20089 Milan, Italy.	Chiara.raggi@humanitasresearch.it	Invernizzi, Pietro/AAB-8367-2022; RAGGI, Chiara/U-3081-2017; Sica, Antonio/AAB-9546-2020	Invernizzi, Pietro/0000-0003-3262-1998; RAGGI, Chiara/0000-0003-2473-3535; Mousa, Hani S./0000-0002-8327-7114	Italian Foundation of Cancer Research (AIRC); Fondazione U Veronesi	Italian Foundation of Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione U Veronesi(Fondazione Umberto Veronesi)	CR, HSM, MC, AS and PI were supported by the Italian Foundation of Cancer Research (AIRC) and Fondazione U Veronesi.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Abel EV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091983; Ahmed N, 2006, AM J PHYSIOL-CELL PH, V290, pC1532, DOI 10.1152/ajpcell.00478.2005; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Arasada RR, 2014, CANCER RES, V74, P5572, DOI 10.1158/0008-5472.CAN-13-3724; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Asimakopoulos F, 2013, LEUKEMIA LYMPHOMA, V54, P2112, DOI 10.3109/10428194.2013.778409; Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BHATIA R, 1995, BLOOD, V85, P3636, DOI 10.1182/blood.V85.12.3636.bloodjournal85123636; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Biswas SK, 2013, SEMIN IMMUNOPATHOL, V35, P585, DOI 10.1007/s00281-013-0367-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Brissette MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036368; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; BUITING AMJ, 1994, J DRUG TARGET, V2, P357, DOI 10.3109/10611869408996810; Carpentino JE, 2009, CANCER RES, V69, P8208, DOI 10.1158/0008-5472.CAN-09-1132; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaturvedi P, 2014, P NATL ACAD SCI USA, V111, pE2120, DOI 10.1073/pnas.1406655111; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chow A, 2013, NAT MED, V19, P429, DOI 10.1038/nm.3057; Chow A, 2011, J EXP MED, V208, P261, DOI 10.1084/jem.20101688; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cook AM, 2014, BLOOD, V123, P2826, DOI 10.1182/blood-2013-05-505735; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Eljaszewicz A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/831387; Esch JSA, 2005, STEM CELLS, V23, P463, DOI 10.1634/stemcells.2004-0283; Ezekowitz RA, 2002, NAT IMMUNOL, V3, P510, DOI 10.1038/ni0602-510; Fan QM, 2014, CANCER LETT, V352, P160, DOI 10.1016/j.canlet.2014.05.008; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003; Gao L, 2014, CELL BIOCHEM BIOPHYS, V70, P273, DOI 10.1007/s12013-014-9900-0; Gao X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030676; Germano G, 2010, CANCER RES, V70, P2235, DOI 10.1158/0008-5472.CAN-09-2335; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gyorki DE, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2353; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hassan KA, 2013, CLIN CANCER RES, V19, P1972, DOI 10.1158/1078-0432.CCR-12-0370; He KF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/838632; HEPPNER GH, 1983, CANCER METAST REV, V2, P5, DOI 10.1007/BF00046903; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jan M, 2011, P NATL ACAD SCI USA, V108, P5009, DOI 10.1073/pnas.1100551108; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kaur S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01673; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Korkaya H, 2011, CELL CYCLE, V10, P2623, DOI 10.4161/cc.10.16.16414; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kusmartsev S, 2005, J IMMUNOL, V175, P4583, DOI 10.4049/jimmunol.175.7.4583; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; LaBarge MA, 2010, CLIN CANCER RES, V16, P3121, DOI 10.1158/1078-0432.CCR-09-2933; Laoui D, 2014, CANCER RES, V74, P24, DOI 10.1158/0008-5472.CAN-13-1196; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li L, 2014, CELL DEATH DIFFER; Li SH, 2013, MOL CELL BIOCHEM, V373, P217, DOI 10.1007/s11010-012-1493-6; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209; Liu DQ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003291; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Locati M, 2013, ADV IMMUNOL, V120, P163, DOI 10.1016/B978-0-12-417028-5.00006-5; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Ludin A, 2012, NAT IMMUNOL, V13, P1072, DOI 10.1038/ni.2408; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mantovani A, 2009, CANCER CELL, V16, P173, DOI 10.1016/j.ccr.2009.08.014; Margol AS, 2015, CLIN CANCER RES, V21, P1457, DOI 10.1158/1078-0432.CCR-14-1144; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Marquardt JU, 2011, HEPATOLOGY, V54, P1031, DOI 10.1002/hep.24454; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Ngiow SF, 2011, CANCER RES, V71, P3540, DOI 10.1158/0008-5472.CAN-11-0096; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Ninov N, 2012, DEVELOPMENT, V139, P1557, DOI 10.1242/dev.076000; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; OSULLIVAN C, 1993, LANCET, V342, P148, DOI 10.1016/0140-6736(93)91348-P; Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Porta C, 2009, IMMUNOBIOLOGY, V214, P761, DOI 10.1016/j.imbio.2009.06.014; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Raggi C, 2015, J HEPATOL, V62, P198, DOI 10.1016/j.jhep.2014.09.007; Raggi C, 2014, HEPATOLOGY, V59, P2251, DOI 10.1002/hep.27026; Rais Y, 2013, NATURE, V502, P65, DOI 10.1038/nature12587; Richards DM, 2013, CANCER MICROENVIRON, V6, P179, DOI 10.1007/s12307-012-0123-x; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Riether C, 2015, CELL DEATH DIFFER, V22, P187, DOI 10.1038/cdd.2014.89; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; Samanani S, 2013, CNS NEUROL DISORD-DR, V12, P741, DOI 10.2174/18715273113126660177; Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525-1373.1999.d01-1.x; Sarkar S, 2014, NAT NEUROSCI, V17, P46, DOI 10.1038/nn.3597; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Shang YJ, 2013, ONCOL LETT, V6, P490, DOI 10.3892/ol.2013.1410; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Shigdar S, 2012, THER DELIV, V3, P227, DOI 10.4155/TDE.11.148; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sikora A, 2007, J PHYSIOL PHARMACOL, V58, P43; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011; Smith RE, 2003, BLOOD, V102, P2532, DOI 10.1182/blood-2002-11-3596; Song Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017687; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Takagi S, 2012, BLOOD, V119, P2768, DOI 10.1182/blood-2011-05-353201; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Theocharides APA, 2012, J EXP MED, V209, P1883, DOI 10.1084/jem.20120502; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; van Beek EM, 2005, J IMMUNOL, V175, P7781, DOI 10.4049/jimmunol.175.12.7781; Virchow R, 1881, Br Med J, V2, P198; Wan SS, 2014, GASTROENTEROLOGY, V147, P1393, DOI 10.1053/j.gastro.2014.08.039; Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wilson E, 2014, J CELL SCI, V127, P3039, DOI 10.1242/jcs.140434; Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood-2009-11-253534; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu J, 2013, DNA CELL BIOL, V32, P648, DOI 10.1089/dna.2013.2116; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yamashina T, 2014, CANCER RES, V74, P2698, DOI 10.1158/0008-5472.CAN-13-2169; Yang J, 2013, STEM CELLS, V31, P248, DOI 10.1002/stem.1281; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019664; Zhang Y, 2013, EUR J CANCER, V49, P3320, DOI 10.1016/j.ejca.2013.06.005; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhao XW, 2011, P NATL ACAD SCI USA, V108, P18342, DOI 10.1073/pnas.1106550108; Zhou B, 2014, J CLIN INVEST, V124, P553, DOI 10.1172/JCI69804; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	181	89	94	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					671	682		10.1038/onc.2015.132	http://dx.doi.org/10.1038/onc.2015.132			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961921				2022-12-28	WOS:000370331300001
J	Lee, I; Maniar, K; Lydon, JP; Kim, JJ				Lee, Il; Maniar, K.; Lydon, J. P.; Kim, J. J.			Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MEDROXYPROGESTERONE ACETATE; GLUCOCORTICOID-RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION; STROMAL CELLS; YOUNG-WOMEN; CARCINOMA; 14-3-3-SIGMA; 14-3-3-PROTEINS	Progestins have long been used clinically for the treatment of endometrial cancers; however, the response rates to progestin therapy vary and the molecular mechanisms behind progestin insensitivity are poorly understood. We hypothesized that in PTEN-mutated endometrial cancers, hyperactive Akt signaling downregulates progesterone receptor B (PRB) transcriptional activity, leading to overall impaired progestin responses. We report that inhibition of Akt with the Akt inhibitor, MK-2206 (MK), in conjunction with progestin (R5020) treatment, is sufficient to upregulate a subset of PRB target genes in Ishikawa cells stably expressing PRB (PRB-Ishikawa). Through gene ontology analysis of Akt-regulated PRB target genes, angiogenesis was found to be the principle process regulated by Akt-PRB. To further interrogate the mechanism by which Akt modulates PRB transcriptional activity, ChIP-Mass spectrometry was performed to identify potential cofactors that differentially interact with PRB in the presence of R5020 and MK+R5020. 14-3-3 sigma was identified as a protein enriched in the MK+R5020 data set, and it was demonstrated that 14-3-3 sigma is required for the upregulation in PRB target gene expression following inhibition of Akt. To determine the ramifications of MK+R5020 treatment on angiogenesis, in vitro assays were performed and combinatorial MK+R5020 treatment significantly decreased endothelial cell invasion and tube formation more than MK or R5020 treatment alone. Furthermore, we found that combinatorial MK-2206+progesterone treatments decreased angiogenesis and proliferation in the Pten(d/d) conditional mouse model of endometrial cancer. Taken together, these findings suggest that a combinatorial therapeutic approach utilizing Akt inhibitors with progestins may improve the efficacy of progestin therapy for the treatment of endometrial cancer.	[Lee, Il; Kim, J. J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Reprod Sci Med,Dept Obstet & Gynecol, Chicago, IL 60611 USA; [Maniar, K.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Lydon, J. P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Baylor College of Medicine	Kim, JJ (corresponding author), Northwestern Univ, OB GYN, 303 E Super St Lurie 4-117, Chicago, IL 60611 USA.	j-kim4@northwestern.edu		Lee, Irene/0000-0002-5749-9389; Kim, J Julie/0000-0001-9834-8213	Robert H. Lurie Comprehensive Cancer Center of Northwestern University; NIH/NICHD [R01HD042311]; NIH/NCI [T32CA09560, R01CA155513]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042311] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA155513, P30CA060553, T32CA009560] Funding Source: NIH RePORTER	Robert H. Lurie Comprehensive Cancer Center of Northwestern University; NIH/NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to acknowledge the Northwestern Genomics Core Facility, the Northwestern Proteomics Core Facility, and the Northwestern Next Generation Sequencing Core Facility. We would also like to thank members of the Kim laboratory for technical assistance and insightful discussion and review of the manuscript. This work is supported by NIH/NCI training grant T32CA09560 (IIL), Malkin Scholars Program from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (IIL), NIH/NICHD grant R01HD042311 (JPL) and NIH/NCI grant R01CA155513 (JJK).	Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Bansal N, 2009, CANCER CONTROL, V16, P8, DOI 10.1177/107327480901600102; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Clarke CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035859; Dai D, 2002, CANCER RES, V62, P881; Dai DH, 2001, AM J OBSTET GYNECOL, V184, P790, DOI 10.1067/mob.2001.113844; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Erkanli S, 2010, INT J GYNECOL CANCER, V20, P1170, DOI 10.1111/IGC.0b013e3181e94f5a; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gibson DA, 2015, HUM REPROD, V30, P1290, DOI 10.1093/humrep/dev067; Goddard LM, 2014, CELL, V156, P549, DOI 10.1016/j.cell.2013.12.025; Goto T, 2008, ONCOGENE, V27, P9, DOI 10.1038/sj.onc.1210626; Gu CO, 2011, CANCER SCI, V102, P557, DOI 10.1111/j.1349-7006.2010.01829.x; Hsu SP, 2008, CELL MOL LIFE SCI, V65, P3839, DOI 10.1007/s00018-008-8441-3; Lebovic DI, 2000, HUM REPROD, V15, P67, DOI 10.1093/humrep/15.suppl_3.67; De Vries-van Leeuwen IJ, 2013, P NATL ACAD SCI USA, V110, P8894, DOI 10.1073/pnas.1220809110; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lodygin D, 2004, ONCOGENE, V23, P9034, DOI 10.1038/sj.onc.1208004; Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Nakayama H, 2005, PATHOL INT, V55, P707, DOI 10.1111/j.1440-1827.2005.01900.x; National Cancer Institute, 2015, SEER STAT FACT SHEET, V2015; Okada H, 2011, FERTIL STERIL, V96, P786, DOI 10.1016/j.fertnstert.2011.06.048; Pant A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041593; Park JY, 2015, ONCOLOGIST, V20, P270, DOI 10.1634/theoncologist.2013-0445; Quayle SN, 2007, CANCER LETT, V254, P137, DOI 10.1016/j.canlet.2007.03.003; Ramirez PT, 2004, GYNECOL ONCOL, V95, P133, DOI 10.1016/j.ygyno.2004.06.045; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Rubel CA, 2012, MOL ENDOCRINOL, V26, P1428, DOI 10.1210/me.2011-1355; Sefton EC, 2013, ENDOCRINOLOGY, V154, P4046, DOI 10.1210/en.2013-1389; Shifren JL, 1996, J CLIN ENDOCR METAB, V81, P3112, DOI 10.1210/jc.81.8.3112; Smid-Koopman E, 2003, J SOC GYNECOL INVEST, V10, P49, DOI 10.1016/S1071-5576(02)00217-4; Takano M, 2007, MOL ENDOCRINOL, V21, P2334, DOI 10.1210/me.2007-0058; Thigpen JT, 1999, J CLIN ONCOL, V17, P1736, DOI 10.1200/JCO.1999.17.6.1736; Titus MA, 2009, CLIN CANCER RES, V15, P7571, DOI 10.1158/1078-0432.CCR-08-1976; Ushijima K, 2007, J CLIN ONCOL, V25, P2798, DOI 10.1200/JCO.2006.08.8344; Vasquez YM, 2015, MOL ENDOCRINOL, V29, P421, DOI 10.1210/me.2014-1292; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Winter S, 2008, EMBO J, V27, P88, DOI 10.1038/sj.emboj.7601954; Yang S, 2011, TRENDS ENDOCRIN MET, V22, P145, DOI 10.1016/j.tem.2011.01.005; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/mend.15.4.0624	41	25	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5191	5201		10.1038/onc.2016.56	http://dx.doi.org/10.1038/onc.2016.56			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26996671	Green Accepted			2022-12-28	WOS:000384433000010
J	Bernaudo, S; Salem, M; Qi, X; Zhou, W; Zhang, C; Yang, W; Rosman, D; Deng, Z; Ye, G; Yang, BB; Vanderhyden, B; Wu, Z; Peng, C				Bernaudo, S.; Salem, M.; Qi, X.; Zhou, W.; Zhang, C.; Yang, W.; Rosman, D.; Deng, Z.; Ye, G.; Yang, B. B.; Vanderhyden, B.; Wu, Z.; Peng, C.			Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/beta-catenin signaling	ONCOGENE			English	Article							OVARIAN-CANCER; EXPRESSION; TRANSCRIPTION; CARCINOMA; MECHANISM; INVASION; CELLS; TRANSFORMATION; ACTIVATION; PATHWAY	Epithelial ovarian cancer (EOC) has the highest mortality rate among gynecological malignancies owing to poor screening methods, non-specific symptoms and limited knowledge of the cellular targets that contribute to the disease. Cyclin G2 is an unconventional cyclin that acts to oppose cell cycle progression. Dysregulation of the cyclin G2 gene (CCNG2) in a variety of human cancers has been reported; however, the role of cyclin G2 in tumorigenesis remains unclear. In this study, we investigated the function of cyclin G2 in EOC. In vitro and in vivo studies using several EOC-derived tumor cell lines revealed that cyclin G2 inhibited cell proliferation, migration, invasion and spheroid formation, as well as tumor formation and invasion. By interrogating cDNA microarray data sets, we found that CCGN2 mRNA is reduced in several large cohorts of human ovarian carcinoma when compared with normal ovarian surface epithelium or borderline tumors of the ovary. Mechanistically, cyclin G2 was found to suppress epithelial-to-mesenchymal transition (EMT), as demonstrated by the differential regulation of various EMT genes, such as Snail, Slug, vimentin and E-cadherin. Moreover, cyclin G2 potently suppressed the Wnt/beta-catenin signaling pathway by downregulating key Wnt components, namely LRP6, DVL2 and beta-catenin, which could be linked to inhibition of EMT. Taken together, our novel findings demonstrate that cyclin G2 has potent tumor-suppressive effects in EOCs by inhibiting EMT through attenuating Wnt/beta-catenin signaling.	[Bernaudo, S.; Salem, M.; Qi, X.; Zhou, W.; Zhang, C.; Yang, W.; Rosman, D.; Ye, G.; Wu, Z.; Peng, C.] York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada; [Deng, Z.; Yang, B. B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Vanderhyden, B.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Wu, Z.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; [Deng, Z.] Jiangsu Univ, Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China	York University - Canada; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Hong Kong University of Science & Technology; Jiangsu University	Peng, C (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	cpeng@yorku.ca			Canadian Institutes of Health Research (CIHR) [MOP-89931]; Natural Science and Engineering Foundation (NSERC) [203081-2009, 227937-2012]; NSERC; OGS; York University; Ovarian Cancer Canada	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Science and Engineering Foundation (NSERC); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); OGS(Ontario Graduate Scholarship); York University; Ovarian Cancer Canada	This study was supported by grants from Canadian Institutes of Health Research (CIHR) to CP (MOP-89931) and from Natural Science and Engineering Foundation (NSERC) to CP (203081-2009) and to BY (227937-2012). SB was a recipient of graduate scholarships from NSERC, OGS and York University. We thank Dr Mien-Chie Hung for SKOV3.ip1 cells and the tumor bank at Ottawa Hospital Research Institute for providing the ovarian cancer samples. The Ottawa Ovarian Cancer Tissue Bank is supported in part by Ovarian Cancer Canada.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Aguilar V, 2010, ENDOCRINOLOGY, V151, P5247, DOI 10.1210/en.2010-0461; Anglesio MS, 2008, MOL CANCER RES, V6, P1678, DOI 10.1158/1541-7786.MCR-08-0193; Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Burleson KM, 2004, CLIN EXP METASTAS, V21, P685, DOI 10.1007/s10585-004-5768-5; Chiu WT, 2015, ONCOTARGET, V6, P2349, DOI 10.18632/oncotarget.2957; Choi MG, 2009, J SURG RES, V157, P168, DOI 10.1016/j.jss.2008.06.020; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Davidowitz RA, 2014, J CLIN INVEST, V124, P2611, DOI 10.1172/JCI69815; Ford CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054362; Fu G, 2011, ONCOGENE, V30, P3953, DOI 10.1038/onc.2011.127; Gajate C, 2002, J BIOL CHEM, V277, P41580, DOI 10.1074/jbc.M204644200; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Ito Y, 2003, ANTICANCER RES, V23, P2335; Jia Jin-Song, 2005, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V13, P254; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kasukabe T, 2005, BREAST CANCER RES, V7, pR1097, DOI 10.1186/bcr1344; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lau MT, 2011, ONCOGENE, V30, P2753, DOI 10.1038/onc.2011.6; Lili LN, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-49; Liu J, 2004, WORLD J GASTROENTERO, V10, P1357; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mourgues L, 2015, LEUKEMIA, V29, P1993, DOI 10.1038/leu.2015.112; Nadeem L, 2011, AM J PATHOL, V178, P1177, DOI 10.1016/j.ajpath.2010.11.066; Pease JC, 2012, BIOL OPEN, V1, P622, DOI 10.1242/bio.2012653; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; Siragam V, 2012, ONCOTARGET, V3, P1370, DOI 10.18632/oncotarget.717; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; ten Berge D, 2008, CELL STEM CELL, V3, P508, DOI 10.1016/j.stem.2008.09.013; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Xu GX, 2008, MOL BIOL CELL, V19, P4968, DOI 10.1091/mbc.E08-03-0259; Ye G, 2012, ADV OVARIAN CANC MAN, P6; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yoshihara K, 2009, CANCER SCI, V100, P1421, DOI 10.1111/j.1349-7006.2009.01204.x; Yuan H, 2013, CANCER RES, V73, P1581, DOI 10.1158/0008-5472.CAN-12-2377; Zhu LY, 2015, CANCER LETT, V363, P71, DOI 10.1016/j.canlet.2015.04.002	51	49	54	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4816	4827		10.1038/onc.2016.15	http://dx.doi.org/10.1038/onc.2016.15			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876206	hybrid, Green Published			2022-12-28	WOS:000383324700014
J	Pinto, A; Mace, Y; Drouet, F; Bony, E; Boidot, R; Draoui, N; Lobysheva, I; Corbet, C; Polet, F; Martherus, R; Deraedt, Q; Rodriguez, J; Lamy, C; Schicke, O; Delvaux, D; Louis, C; Kiss, R; Kriegsheim, AV; Dessy, C; Elias, B; Quetin-Leclercq, J; Riant, O; Feron, O				Pinto, A.; Mace, Y.; Drouet, F.; Bony, E.; Boidot, R.; Draoui, N.; Lobysheva, I.; Corbet, C.; Polet, F.; Martherus, R.; Deraedt, Q.; Rodriguez, J.; Lamy, C.; Schicke, O.; Delvaux, D.; Louis, C.; Kiss, R.; Kriegsheim, A. V.; Dessy, C.; Elias, B.; Quetin-Leclercq, J.; Riant, O.; Feron, O.			A new ER-specific photosensitizer unravels O-1(2)-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; PHOTODYNAMIC THERAPY; MAMMALIAN TARGET; HYPOXIA; MTOR; PHOTOEXCITATION; MULTIMERIZATION; SENSITIZERS	Photosensitizers (PS) are ideally devoid of any activity in the absence of photoactivation, and rely on molecular oxygen for the formation of singlet oxygen (O-1(2)) to produce cellular damage. Off-targets and tumor hypoxia therefore represent obstacles for the use of PS for cancer photodynamic therapy. Herein, we describe the characterization of OR141, a benzophenazine compound identified through a phenotypic screening for its capacity to be strictly activated by light and to kill a large variety of tumor cells under both normoxia and hypoxia. This new class of PS unraveled an unsuspected common mechanism of action for PS that involves the combined inhibition of the mammalian target of rapamycin (mTOR) signaling pathway and proteasomal deubiquitinases (DUBs) USP14 and UCH37. Oxidation of mTOR and other endoplasmic reticulum (ER)-associated proteins drives the early formation of high molecular weight (MW) complexes of multimeric proteins, the concomitant blockade of DUBs preventing their degradation and precipitating cell death. Furthermore, we validated the antitumor effects of OR141 in vivo and documented its highly selective accumulation in the ER, further increasing the ER stress resulting from O-1(2) generation upon light activation.	[Pinto, A.; Draoui, N.; Lobysheva, I.; Corbet, C.; Polet, F.; Martherus, R.; Delvaux, D.; Louis, C.; Dessy, C.; Feron, O.] Catholic Univ Louvain, IREC, Pole Pharmacol & Therapeut FATH, Brussels, Belgium; [Mace, Y.; Drouet, F.; Boidot, R.; Deraedt, Q.; Lamy, C.; Schicke, O.; Elias, B.; Riant, O.] Catholic Univ Louvain, Inst Condensed Matter & Nanosci Mol Solids & Reac, 1 Pl Louis Pasteur,Bte 3, B-1348 Louvain La Neuve, Belgium; [Bony, E.; Quetin-Leclercq, J.] Catholic Univ Louvain, LDRI, Pharmacognosy Res Grp GNOS, Louvain La Neuve, Belgium; [Rodriguez, J.; Kriegsheim, A. V.] Conway Inst, Syst Biol Ireland, Dublin 4, Ireland; [Kiss, R.] Univ Libre Bruxelles, Fac Pharm, Lab Cancerol & Toxicol Expt, Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Universite Libre de Bruxelles	Riant, O (corresponding author), Catholic Univ Louvain, Inst Condensed Matter & Nanosci Mol Solids & Reac, 1 Pl Louis Pasteur,Bte 3, B-1348 Louvain La Neuve, Belgium.; Feron, O (corresponding author), UCLouvain, IREC, Pole Pharmacol & Therapeut FATH, 53 Ave E Mounier,B1-53-09, B-1200 Brussels, Belgium.	olivier.riant@uclouvain.be; olivier.feron@uclouvain.be	von Kriegsheim, Alex/C-2371-2016; FERON, Olivier/AAM-6395-2020; rodriguez, javier/AAB-1131-2019; riant, olivier/AAU-3567-2021	von Kriegsheim, Alex/0000-0002-4952-8573; FERON, Olivier/0000-0001-5360-0286; rodriguez, javier/0000-0001-7467-8533; Deraedt, Quentin/0000-0001-9226-2777; riant, olivier/0000-0003-4852-6469; Leclercq, Joelle/0000-0002-2278-6206	Region Bruxelles Capitale (Innoviris); Fonds national de la Recherche Scientifique (FRS-FNRS); Belgian Foundation against cancer; J Maisin Foundation; Belgian Science Policy Office (Belspo) [UP7-03]; Action de Recherche Concertee [ARC 14/19]	Region Bruxelles Capitale (Innoviris)(Innoviris); Fonds national de la Recherche Scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); Belgian Foundation against cancer; J Maisin Foundation; Belgian Science Policy Office (Belspo)(Belgian Federal Science Policy Office); Action de Recherche Concertee	This work was supported by grants from the Region Bruxelles Capitale (Innoviris), the Fonds national de la Recherche Scientifique (FRS-FNRS), the Belgian Foundation against cancer, the J Maisin Foundation, the interuniversity attraction pole (IUAP) research program #UP7-03 from the Belgian Science Policy Office (Belspo) and an Action de Recherche Concertee (ARC 14/19).	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Altun M, 2011, CHEM BIOL, V18, P1401, DOI 10.1016/j.chembiol.2011.08.018; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brodsky JL, 2012, CELL, V151, P1163, DOI 10.1016/j.cell.2012.11.012; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cao YT, 2005, CANCER RES, V65, P5498, DOI 10.1158/0008-5472.CAN-04-4553; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; Davies MJ, 2005, BBA-PROTEINS PROTEOM, V1703, P93, DOI 10.1016/j.bbapap.2004.08.007; Diao YR, 2010, P NATL ACAD SCI USA, V107, P20974, DOI 10.1073/pnas.1007225107; Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915; Draoui N, 2014, MOL CANCER THER, V13, P1410, DOI 10.1158/1535-7163.MCT-13-0653; Hiraoka W, 2006, ULTRASON SONOCHEM, V13, P535, DOI 10.1016/j.ultsonch.2005.10.001; Hwang JY, 2012, J CONTROL RELEASE, V163, P368, DOI 10.1016/j.jconrel.2012.09.015; Jain A, 2014, P NATL ACAD SCI USA, V111, P17833, DOI 10.1073/pnas.1419425111; Li WM, 2007, CIRC RES, V100, P79, DOI 10.1161/01.RES.0000253094.03023.3f; Liu XY, 2007, MOL BIOL CELL, V18, P1073, DOI 10.1091/mbc.E06-05-0406; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516; Nadeau PJ, 2007, MOL BIOL CELL, V18, P3903, DOI 10.1091/mbc.E07-05-0491; Nakatsukasa K, 2008, TRAFFIC, V9, P861, DOI 10.1111/j.1600-0854.2008.00729.x; Nau W., 2011, CHEMPHYSCHEM, V12, P2496; Ng WY, 2007, J CELL SCI, V120, P682, DOI 10.1242/jcs.03351; Ormond AB, 2013, MATERIALS, V6, P817, DOI 10.3390/ma6030817; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Seront E, 2013, BRIT J CANCER, V109, P1586, DOI 10.1038/bjc.2013.505; Sueishi Y, 2014, J CLIN BIOCHEM NUTR, V54, P67, DOI 10.3164/jcbn.13-53; Takahara T, 2006, J BIOL CHEM, V281, P28605, DOI 10.1074/jbc.M606087200; Udeshi ND, 2013, NAT PROTOC, V8, P1950, DOI 10.1038/nprot.2013.120; van der Wijk T, 2004, J BIOL CHEM, V279, P44355, DOI 10.1074/jbc.M407483200; Wilson BC, 2008, PHYS MED BIOL, V53, pR61, DOI 10.1088/0031-9155/53/9/R01; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Yoshii H, 2012, BIOCHEM BIOPH RES CO, V417, P640, DOI 10.1016/j.bbrc.2011.12.024	37	22	22	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3976	3985		10.1038/onc.2015.474	http://dx.doi.org/10.1038/onc.2015.474			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26686091				2022-12-28	WOS:000381013100009
J	Goto, K; Ishikawa, S; Honma, R; Tanimoto, K; Sakamoto, N; Sentani, K; Oue, N; Teishima, J; Matsubara, A; Yasui, W				Goto, K.; Ishikawa, S.; Honma, R.; Tanimoto, K.; Sakamoto, N.; Sentani, K.; Oue, N.; Teishima, J.; Matsubara, A.; Yasui, W.			The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation	ONCOGENE			English	Article							GENE-EXPRESSION; NONCODING RNAS; DOWN-REGULATION; NEUROBLASTOMA; CARCINOMA; INVASION; DIFFERENTIATION; CONTRIBUTES; PROGRESSION; METASTASIS	The transcribed-ultraconserved regions (T-UCRs) are a novel class of non-coding RNAs, which are absolutely conserved (100%) between the orthologous regions of the human, rat and mouse genomes. Previous studies have described that several T-UCRs show differential expressions in cancers and might be involved in cancer development. We investigated the transcriptional levels of representative 26 T-UCRs and determined the regions that were differently expressed in prostate cancer (PCa) and gastric cancer (GC). A quantitative reverse transcription-polymerase chain reaction analysis revealed the downregulation of Uc. 158+A expression by a DNA methylation-associated mechanism, which was restored by 5-Aza-dC (5-aza-2'-deoxycytidine) treatment. Bisulfite genomic sequencing using cell lines and tissue samples demonstrated cancer-specific CpG hypermethylation in both GC and PCa. However, Uc. 416+A was only overexpressed in GC and we identified an miR-153 binding site in the possible regulatory region of Uc. 416+A using online databases. Along with a forced expression or knockdown of miR-153 in MKN-74 GC cells, the transcriptional levels of Uc. 416+A were significantly disturbed. A luciferase reporter gene assay supported the direct regulation of Uc. 416+A expression by miR-153. Furthermore, Uc. 416+A was associated with cell growth through the regulation of IGFBP6 (insulin-like growth factor-binding protein 6) in GC. These findings suggest an oncogenic role of Uc. 416+A in GC, which suggests that our approach would provide new insights into functional studies of T-UCRs in cancer biology.	[Goto, K.; Sakamoto, N.; Sentani, K.; Oue, N.; Yasui, W.] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan; [Goto, K.; Teishima, J.; Matsubara, A.] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Urol, Hiroshima, Japan; [Ishikawa, S.; Honma, R.] Hiroshima Univ, Sch Med, Hiroshima, Japan; [Tanimoto, K.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Med, Hiroshima, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University	Yasui, W (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Keiji, Tanimoto/U-1839-2019	Keiji, Tanimoto/0000-0003-4912-4197; Goto, Keisuke/0000-0002-3580-1401	Ministry of Education, Culture, Science, Sports and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; National Institute of Biomedical Innovation (Program for Promotion of Fundamental Studies in Health Sciences); National Cancer Center Research and Development Fund	Ministry of Education, Culture, Science, Sports and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); National Institute of Biomedical Innovation (Program for Promotion of Fundamental Studies in Health Sciences); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	We thank Mr Shinichi Norimura for his excellent technical assistance. This work was carried out with the kind cooperation of the Research Center for Molecular Medicine of the Faculty of Medicine of Hiroshima University. We also thank the Analysis Center of Life Science of Hiroshima University for the use of their facilities. This work was supported, in part, by grants-in-aid for Cancer Research from the Ministry of Education, Culture, Science, Sports and Technology of Japan, and, in part, by a grant-in-aid for the Third Comprehensive. 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan, by the National Institute of Biomedical Innovation (Program for Promotion of Fundamental Studies in Health Sciences), and by the National Cancer Center Research and Development Fund.	Bach LA, 2005, GROWTH HORM IGF RES, V15, P185, DOI 10.1016/j.ghir.2005.04.001; Bach LA, 2013, CLIN SCI, V124, P215, DOI 10.1042/CS20120343; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Braconi C, 2011, P NATL ACAD SCI USA, V108, P786, DOI 10.1073/pnas.1011098108; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Fischbach NA, 2005, BLOOD, V105, P1456, DOI 10.1182/blood-2004-04-1583; Fu M, 2003, DEV DYNAM, V228, P1, DOI 10.1002/dvdy.10350; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; Goto K, 2013, MOL CLIN ONCOL, V1, P235, DOI 10.3892/mco.2012.46; Hudson RS, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-13; Hur H, 2014, MOL BIOTECHNOL, V56, P64, DOI 10.1007/s12033-013-9682-4; Kim TH, 2010, HISTOPATHOLOGY, V57, P734, DOI 10.1111/j.1365-2559.2010.03686.x; Liz J, 2014, MOL CELL, V55, P138, DOI 10.1016/j.molcel.2014.05.005; Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361; Luo JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040127; Matsumura S, 2007, INT J CANCER, V120, P1689, DOI 10.1002/ijc.22433; Mestdagh P, 2010, ONCOGENE, V29, P3583, DOI 10.1038/onc.2010.106; Morgan R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-89; Naito Y, 2015, PATHOBIOLOGY, V82, P68, DOI 10.1159/000398809; Naito Y, 2014, ONCOL REP, V32, P1720, DOI 10.3892/or.2014.3333; Naito Y, 2014, CANCER SCI, V105, P228, DOI 10.1111/cas.12329; Oue N, 2003, CANCER SCI, V94, P901, DOI 10.1111/j.1349-7006.2003.tb01373.x; Oue N, 2014, ONCOGENE, V33, P3918, DOI 10.1038/onc.2013.364; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Oue N, 2015, CANCER SCI, V106, P951, DOI 10.1111/cas.12706; Oue N, 2014, INT J CANCER, V134, P1926, DOI 10.1002/ijc.28522; Sakamoto N, 2014, CANCER SCI, V105, P236, DOI 10.1111/cas.12330; Scaruffi P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-441; Volpe MV, 2003, BIRTH DEFECTS RES A, V67, P550, DOI 10.1002/bdra.10086; Watters KM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-184; Wu ZQ, 2013, PROSTATE, V73, P596, DOI 10.1002/pros.22600; Xu JZ, 2011, INT J CANCER, V129, P2527, DOI 10.1002/ijc.25917; Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374; Yuan Y, 2015, INT J CANCER, V136, P1333, DOI 10.1002/ijc.29103; Zhang L, 2013, CANCER RES, V73, P6435, DOI 10.1158/0008-5472.CAN-12-3308; Zhang ZL, 2015, ONCOTARGETS THER, V8, P357, DOI 10.2147/OTT.S78236	40	28	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3598	3606		10.1038/onc.2015.445	http://dx.doi.org/10.1038/onc.2015.445			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26640143	Green Submitted			2022-12-28	WOS:000379621500012
J	Lu, MH; Tang, B; Zeng, S; Hu, CJ; Xie, R; Wu, YY; Wang, SM; He, FT; Yang, SM				Lu, M-H; Tang, B.; Zeng, S.; Hu, C-J; Xie, R.; Wu, Y-Y; Wang, S-M; He, F-T; Yang, S-M			Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer	ONCOGENE			English	Article							TELOMERASE ACTIVITY; CATALYTIC SUBUNIT; GENE-EXPRESSION; CELLS; MICRORNAS; DIFFERENTIATION; EVOLUTION; INVASION; GROWTH	Long noncoding RNAs (lncRNAs) are emerging as new players in gene regulation and are associated with the development of cancers. To investigate the important role and mechanism of lncRNAs in the progression of gastric cancer, we screened lncRNAs in gastric cancer tissues and corresponding adjacent tissues, and assessed the effects on gastric cancer. Here, we report that BC032469, a novel lncRNA, expressed highly in gastric cancer tissues, and the upregulation was clinically associated with larger tumor size, poor differentiation and shorter survival of gastric cancer patients. Downregulation of BC032469 resulted in a significant inhibition of proliferation in vitro and in vivo. Mechanistically, BC032469 could directly bind to miR-1207-5p and effectively functioned as a sponge for miR-1207-5p to modulate the derepression of hTERT. Thus, BC032469 may function as a ceRNA to impair miR-1207-5p-dependent hTERT downregulation, suggesting that it may be clinically valuable as a poor prognostic biomarker of gastric cancer.	[Lu, M-H; Tang, B.; Zeng, S.; Hu, C-J; Xie, R.; Wu, Y-Y; Wang, S-M; Yang, S-M] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Xinqiao St, Chongqing 400037, Peoples R China; [Lu, M-H] Luzhou Med Coll, Affiliated Hosp, Dept Gastroenterol, Luzhou, Peoples R China; [He, F-T] Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Chongqing, Peoples R China	Army Medical University; Southwest Medical University; Army Medical University	Yang, SM (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Xinqiao St, Chongqing 400037, Peoples R China.	shimingyang@yahoo.com	He, Feng/HHS-6457-2022	He, Feng/0000-0002-1996-0744	National Natural Science Foundation of China [81201950]; Luzhou Medical University [2014ZD-001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Luzhou Medical University	This study was supported by the National Natural Science Foundation of China (No. 81201950) and Luzhou Medical University Funding (No. 2014ZD-001). We thank Professor Xia Zhang for suggestions on the manuscript.	Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Berghoff EG, 2013, DEVELOPMENT, V140, P4407, DOI 10.1242/dev.099390; Boreiri M, 2013, ARCH IRAN MED, V16, P343, DOI 013166/AIM.007; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Cazalla D, 2010, SCIENCE, V328, P1563, DOI 10.1126/science.1187197; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.553; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Franco-Zorrilla JM, 2007, NAT GENET, V39, P1033, DOI 10.1038/ng2079; Hammell M, 2010, SEMIN CELL DEV BIOL, V21, P738, DOI 10.1016/j.semcdb.2010.01.004; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Lee DY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013599; Lu MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068972; Lu MH, 2012, EXP THER MED, V3, P728, DOI 10.3892/etm.2012.471; Lu SF, 2009, NUCLEIC ACIDS RES, V37, P1878, DOI 10.1093/nar/gkp031; Ma HR, 2014, INT J MOL MED, V33, P1627, DOI 10.3892/ijmm.2014.1722; Padberg I, 2013, INT J MED MICROBIOL, V303, P463, DOI 10.1016/j.ijmm.2013.06.001; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Ramachandran V, 2008, SCIENCE, V321, P1490, DOI 10.1126/science.1163728; Saldanha SN, 2003, ANAL BIOCHEM, V315, P1, DOI 10.1016/S0003-2697(02)00663-2; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Seitz H, 2009, CURR BIOL, V19, P870, DOI 10.1016/j.cub.2009.03.059; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Yadetie F, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-12; Yamaguchi A, 2012, J PLANT RES, V125, P693, DOI 10.1007/s10265-012-0513-7; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yang G, 2007, CARCINOGENESIS, V28, P174, DOI 10.1093/carcin/bgl115; Yu ST, 2012, CANCER-AM CANCER SOC, V118, P1884, DOI 10.1002/cncr.26476; Yu ST, 2009, INT J ONCOL, V35, P329, DOI 10.3892/ijo_00000344; Zhang S, 2013, BIOTECH HISTOCHEM, V88, P281, DOI 10.3109/10520295.2013.769633; Zhang Z, 2013, CELL DEATH DIFFER, V20, P1558, DOI 10.1038/cdd.2013.110	38	144	149	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3524	3534		10.1038/onc.2015.413	http://dx.doi.org/10.1038/onc.2015.413			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26549025				2022-12-28	WOS:000379621500005
J	Barbachano, A; Fernandez-Barral, A; Pereira, F; Segura, MF; Ordonez-Moran, P; Pau, ECD; Gonzalez-Sancho, JM; Hanniford, D; Martinez, N; Costales-Carrera, A; Real, FX; Palmer, HG; Rojas, JM; Hernando, E; Munoz, A				Barbachano, A.; Fernandez-Barral, A.; Pereira, F.; Segura, M. F.; Ordonez-Moran, P.; Carrillo-de Santa Pau, E.; Gonzalez-Sancho, J. M.; Hanniford, D.; Martinez, N.; Costales-Carrera, A.; Real, F. X.; Palmer, H. G.; Rojas, J. M.; Hernando, E.; Munoz, A.			SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; MESENCHYMAL TRANSITION; DOWN-REGULATION; CANCER-CELLS; MIR-200 FAMILY; BETA-CATENIN; EPIGENETIC INACTIVATION; TRANSCRIPTION FACTOR; COLORECTAL-CANCER; GENE-EXPRESSION	SPROUTY-2 (SPRY2) is a modulator of tyrosine kinase receptor signaling with receptor-and cell type-dependent inhibitory or enhancing effects. Studies on the action of SPRY2 in major cancers are conflicting and its role remains unclear. Here we have dissected SPRY2 action in human colon cancer. Global transcriptomic analyses show that SPRY2 downregulates genes encoding tight junction proteins such as claudin-7 and occludin and other cell-to-cell and cell-to-matrix adhesion molecules in human SW480-ADH colon carcinoma cells. Moreover, SPRY2 represses LLGL2/HUGL2, PATJ1/INADL and ST14, main regulators of the polarized epithelial phenotype, and ESRP1, an epithelial-to-mesenchymal transition (EMT) inhibitor. A key action of SPRY2 is the upregulation of the major EMT inducer ZEB1, as these effects are reversed by ZEB1 knock-down by means of RNA interference. Consistently, we found an inverse correlation between the expression level of claudin-7 and those of SPRY2 and ZEB1 in human colon tumors. Mechanistically, ZEB1 upregulation by SPRY2 results from the combined induction of ETS1 transcription factor and the repression of microRNAs (miR-200 family, miR-150) that target ZEB1 RNA. Moreover, SPRY2 increased AKT activation by epidermal growth factor, whereas AKT and also Src inhibition reduced the induction of ZEB1. Altogether, these data suggest that AKT and Src are implicated in SPRY2 action. Collectively, these results show a tumorigenic role of SPRY2 in colon cancer that is based on the dysregulation of tight junction and epithelial polarity master genes via upregulation of ZEB1. The dissection of the mechanism of action of SPRY2 in colon cancer cells is important to understand the upregulation of this gene in a subset of patients with this neoplasia that have poor prognosis.	[Barbachano, A.; Fernandez-Barral, A.; Pereira, F.; Ordonez-Moran, P.; Gonzalez-Sancho, J. M.; Costales-Carrera, A.; Munoz, A.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Madrid, Spain; [Segura, M. F.; Hanniford, D.; Hernando, E.] NYU, Sch Med, Dept Pathol, New York, NY USA; [Carrillo-de Santa Pau, E.; Real, F. X.] CSIC, Epithelial Carcinogenesis Grp, Madrid, Spain; [Martinez, N.] Inst Salud Carlos III, Unidad Func Invest Enfermedades Cron, Unidad Biol Celular, Madrid, Spain; [Real, F. X.] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain; [Palmer, H. G.] Vall dHebron Inst Oncol, Stem Cells & Canc Grp, Barcelona, Spain; [Segura, M. F.] Vall dHebron Inst Recerca VHIR, E-08035 Barcelona, Spain; [Ordonez-Moran, P.] Ecole Polytech Fed Lausanne, Canc Stem Cell Lab, CH-1015 Lausanne, Switzerland	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); New York University; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III; Unidad Funcional de Investigacion de Enfermedades Cronicas (UFIEC); Pompeu Fabra University; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Munoz, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain.	amunoz@iib.uam.es	Barbachano, Antonio/O-7731-2015; Arribas, Francisco X Real/H-5275-2015; Gonzalez-Sancho, Jose/AAA-6010-2019; Miquel, Josep Maria/AAG-3508-2019; Rojas, José M/D-3718-2018; Hanniford, Douglas/AAS-1480-2020; Rojas, José M./AAA-3354-2021; Munoz, Alberto/O-6393-2014; Fernández-Barral, Asunión/O-8133-2015; Costales, ALba/F-2773-2017; Segura, Miguel F/J-4749-2013; de Santa Pau, Enrique Carrillo/AAV-7544-2021; Palmer, Héctor G./AAG-8332-2019; Ordonez-Moran, Paloma/B-6371-2016; Hanniford, Doug/M-8251-2014	Barbachano, Antonio/0000-0002-1248-5143; Arribas, Francisco X Real/0000-0001-9501-498X; Gonzalez-Sancho, Jose/0000-0001-5875-1964; Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; Munoz, Alberto/0000-0003-3890-4251; Fernández-Barral, Asunión/0000-0002-1278-4645; Costales, ALba/0000-0002-9075-1646; Segura, Miguel F/0000-0003-0916-3618; de Santa Pau, Enrique Carrillo/0000-0002-2310-2267; Palmer, Hector/0000-0002-9823-5638; Ordonez-Moran, Paloma/0000-0001-7688-1252; Hanniford, Doug/0000-0001-6790-8441; Hernando, Eva/0000-0003-1023-0312; Pires Pereira, Fabio/0000-0002-9991-2805	FEDER-Instituto de Salud Carlos III [RD12/0036/0021, RD12/0036/0034, RD12/0036/0016, RD12/0036/0012, RD06/0020/0003, PS09/00562, PI13/00703]; Comunidad de Madrid [S2010/BMD-2344 Colomics2]; Fundacion Cientifica de la Asociacion Espanola contra el Cancer; US Department of Defense [CA093471, CA110602]; National Institutes of Health/National Cancer Institute [1R01CA155234-01]; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [1R21AR062239-01]; Melanoma Research Alliance; Ministerio de Economia y Competitividad of Spain; Fondo Europeo de Desarrollo Regional (FEDER) [SAF2013-43468-R, SAF2011-29530]; NATIONAL CANCER INSTITUTE [R01CA155234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR062239] Funding Source: NIH RePORTER	FEDER-Instituto de Salud Carlos III(Instituto de Salud Carlos III); Comunidad de Madrid(Comunidad de Madrid); Fundacion Cientifica de la Asociacion Espanola contra el Cancer; US Department of Defense(United States Department of Defense); National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Melanoma Research Alliance; Ministerio de Economia y Competitividad of Spain(Spanish Government); Fondo Europeo de Desarrollo Regional (FEDER)(European CommissionSpanish Government); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Drs G Goodall, T Brabletz and A Garcia de Herreros for kindly providing us reagents, T Martinez and X Langa for technical assistance and Robin Rycroft for help with the English manuscript. This study was supported by the Ministerio de Economia y Competitividad of Spain and Fondo Europeo de Desarrollo Regional (FEDER) (grant SAF2013-43468-R to AM, SAF2011-29530 to FXR); FEDER-Instituto de Salud Carlos III (RD12/0036/0021 to AM and JMR, RD12/0036/0034 to FXR, RD12/0036/0016 to MS, RD12/0036/0012 to HGP, RD06/0020/0003, PS09/00562 and PI13/00703 to JMR); Comunidad de Madrid (S2010/BMD-2344 Colomics2 to AM); Fundacion Cientifica de la Asociacion Espanola contra el Cancer (to JMR); US Department of Defense (CA093471 and CA110602 to EH); National Institutes of Health/National Cancer Institute (1R01CA155234-01 to EH); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R21AR062239-01 to EH); and the Melanoma Research Alliance (to EH).	Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; [Anonymous], 2010, R LANG ENV STAT COMP; Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Bornholdt J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-65; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Buzza MS, 2010, P NATL ACAD SCI USA, V107, P4200, DOI 10.1073/pnas.0903923107; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Dave N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168625; de Alvaro C, 2005, MOL BIOL CELL, V16, P4454, DOI 10.1091/mbc.E05-05-0419; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Edwin F, 2010, J BIOL CHEM, V285, P255, DOI 10.1074/jbc.M109.030882; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Faratian D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023772; Feng YH, 2011, CANCER BIOL THER, V11, P111, DOI 10.4161/cbt.11.1.13965; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Frank MJ, 2009, BLOOD, V113, P2478, DOI 10.1182/blood-2008-05-156943; Gemmill RM, 2011, CANCER LETT, V300, P66, DOI 10.1016/j.canlet.2010.09.007; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; Holgren C, 2010, ONCOGENE, V29, P5241, DOI 10.1038/onc.2010.264; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kohno Y, 2006, J BIOL CHEM, V281, P38941, DOI 10.1074/jbc.M608389200; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lei ZL, 2012, DEV BIOL, V371, P136, DOI 10.1016/j.ydbio.2012.07.005; Li X, 2004, J CELL SCI, V117, P6007, DOI 10.1242/jcs.01519; List K, 2009, AM J PATHOL, V175, P1453, DOI 10.2353/ajpath.2009.090240; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Masoumi-Moghaddam S, 2014, CANCER METAST REV, V33, P695, DOI 10.1007/s10555-014-9497-1; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Merikallio H, 2011, J CLIN PATHOL, V64, P136, DOI 10.1136/jcp.2010.086678; Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978; Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646; Ordonez-Moran P, 2014, ONCOGENE, V33, P1975, DOI 10.1038/onc.2013.140; Ozaki K, 2005, J CELL SCI, V118, P5861, DOI 10.1242/jcs.02711; Punzon I, 2004, BLOOD, V103, P580, DOI 10.1182/blood-2003-07-2298; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Risueno A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-221; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sanchez A, 2008, ONCOGENE, V27, P4969, DOI 10.1038/onc.2008.129; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swat A, 2009, MOL CELL BIOL, V29, P3332, DOI 10.1128/MCB.01955-08; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; van der Gun BTF, 2013, BRIT J CANCER, V108, P881, DOI 10.1038/bjc.2013.45; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Watanabe T, 2011, EUR J CANCER, V47, P1946, DOI 10.1016/j.ejca.2011.03.029; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wu CJ, 2013, J BIOL CHEM, V288, P12253, DOI 10.1074/jbc.M113.457499	61	31	34	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2991	3003		10.1038/onc.2015.366	http://dx.doi.org/10.1038/onc.2015.366			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26455323	Green Accepted, Green Submitted			2022-12-28	WOS:000377474500005
J	Lucchesi, C; Sheikh, MS; Huang, Y				Lucchesi, C.; Sheikh, M. S.; Huang, Y.			Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2	ONCOGENE			English	Article							MESSENGER-RNA; DOWN-REGULATION; CANCER; INHIBITOR; TARGET; GENE; XIAP	Esophageal cancer-related gene 2 (ECRG2) is a newer tumor suppressor whose function in the regulation of cell growth and apoptosis remains to be elucidated. Here we show that ECRG2 expression was upregulated in response to DNA damage, and increased ECRG2 expression induced growth suppression in cancer cells but not in non-cancerous epithelial cells. ECRG2-mediated growth suppression was associated with activation of caspases and marked reduction in the levels of apoptosis inhibitor, X chromosome-linked inhibitor of apoptosis protein (XIAP). ECRG2, via RNA-binding protein human antigen R (HuR), regulated XIAP mRNA stability and expression. Furthermore, ECRG2 increased HuR ubiquitination and degradation but was unable to modulate the non-ubiquitinable mutant form of HuR. We also identified missense and frame-shift ECRG2 mutations in various human malignancies and noted that, unlike wild-type ECRG2, one cancer-derived ECRG2 mutant harboring glutamic acid instead of valine at position 30 (V30E) failed to induce cell death and activation of caspases. This naturally occurring V30E mutant also did not suppress XIAP and HuR. Importantly, the V30E mutant overexpressing cancer cells acquired resistance against multiple anticancer drugs, thus suggesting that ECRG2 mutations appear to have an important role in the acquisition of anticancer drug resistance in a subset of human malignancies.	[Lucchesi, C.; Sheikh, M. S.; Huang, Y.] SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			Carol M Baldwin Breast Cancer Research Fund	Carol M Baldwin Breast Cancer Research Fund	We thank Dr Myriam Gorospe (NIH/NIA) for kindly providing the pTAP-HuR and pTAP-HuR-K182R as well as Ad-GFP and Ad-HuR expression vectors and Dr Bert Vogelstein's laboratory (Johns Hopkins University School of Medicine, Baltimore, MD, USA) for kindly providing the RKO p53<SUP>-/-</SUP> cell line. These studies are supported in part by the Carol M Baldwin Breast Cancer Research Fund to Dr Ying Huang.	Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299; Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Abdelmohsen K, 2009, EMBO J, V28, P1271, DOI 10.1038/emboj.2009.67; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Berthelet Jean, 2013, Cells, V2, P163, DOI 10.3390/cells2010163; Cheng XL, 2008, J BIOL CHEM, V283, P5888, DOI 10.1074/jbc.M708145200; Chu PC, 2012, J BIOL CHEM, V287, P43639, DOI 10.1074/jbc.M112.393678; Cui YP, 2010, INT J ONCOL, V37, P1521, DOI 10.3892/ijo_00000805; Cui YP, 2003, BIOCHEM BIOPH RES CO, V302, P904, DOI 10.1016/S0006-291X(03)00122-0; Danson S, 2007, CURR CANCER DRUG TAR, V7, P785, DOI 10.2174/156800907783220471; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Geng Y, 2008, ARCH BIOCHEM BIOPHYS, V479, P153, DOI 10.1016/j.abb.2008.08.023; Huang G, 2007, CARCINOGENESIS, V28, P2274, DOI 10.1093/carcin/bgm140; Kakuguchi W, 2010, MOL CANCER RES, V8, P520, DOI 10.1158/1541-7786.MCR-09-0367; Kim HH, 2008, GENE DEV, V22, P1804, DOI 10.1101/gad.1645808; Kotta-Loizou I, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0161-y; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Lui KMJ, 2011, J CELL BIOL, V126, P2436; Meisner NC, 2007, NAT CHEM BIOL, V3, P508, DOI 10.1038/nchembio.2007.14; Obexer P, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00197; Owens T.W., 2013, J CARCINOG MUTAG S14; Rong R, 2005, ONCOGENE, V24, P4867, DOI 10.1038/sj.onc.1208660; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Song H, 2012, CANCER GENE THER, V19, P875, DOI 10.1038/cgt.2012.77; Srikantan S, 2012, CURR PROTEIN PEPT SC, V13, P372, DOI 10.2174/138920312801619394; Su Tao, 1998, Zhonghua Zhongliu Zazhi, V20, P254; Sun H, 2013, ONCOGENE, V32, P234, DOI 10.1038/onc.2012.34; Wang J, 2013, INT J MOL SCI, V14, P10015, DOI 10.3390/ijms140510015; Yi J, 2010, NUCLEIC ACIDS RES, V38, P1547, DOI 10.1093/nar/gkp1114; Zhang X, 2009, NUCLEIC ACIDS RES, V37, P7623, DOI 10.1093/nar/gkp755	32	23	23	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2565	2573		10.1038/onc.2015.339	http://dx.doi.org/10.1038/onc.2015.339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26434587				2022-12-28	WOS:000376165700003
J	Workenhe, ST; Ketela, T; Moffat, J; Cuddington, BP; Mossman, KL				Workenhe, S. T.; Ketela, T.; Moffat, J.; Cuddington, B. P.; Mossman, K. L.			Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells	ONCOGENE			English	Article							HERPES-SIMPLEX-VIRUS; ANTITUMOR EFFICACY; THERAPEUTIC-EFFICACY; TOPOISOMERASE-I; SR PROTEINS; PHOSPHORYLATION; SPLICEOSOME; APOPTOSIS; GENES; HSV-1	Oncolytic human herpes simplex virus type 1 (HSV-1) shows promising treatment efficacy in late-stage clinical trials. The anticancer activity of oncolytic viruses relies on deregulated pathways in cancer cells, which make them permissive to oncolysis. To identify pathways that restrict HSV-1 KM100-mediated oncolysis, this study used a pooled genome-wide short hairpin RNA library and found that depletion of the splicing factor arginine-rich splicing factor 2 (SRSF2) leads to enhanced cytotoxicity of breast cancer cells by KM100. Serine/arginine-rich (SR) proteins are a family of RNA-binding phosphoproteins that control both constitutive and alternative pre-mRNA splicing. Further characterization showed that KM100 infection of HS578T cells under conditions of low SRSF2 leads to pronounced apoptosis without a corresponding increase in virus replication. As DNA topoisomerase I inhibitors can limit the phosphorylation of SRSF2, we combined a topoisomerase I inhibitor chemotherapeutic with KM100 and observed synergistic anticancer effect in vitro and prolonged survival of tumor-bearing mice in vivo.	[Workenhe, S. T.; Cuddington, B. P.; Mossman, K. L.] McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, 1280 Main St West,MDCL 5026, Hamilton, ON L8S 4K1, Canada; [Ketela, T.; Moffat, J.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	McMaster University; University of Toronto	Workenhe, ST; Mossman, KL (corresponding author), McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, 1280 Main St West,MDCL 5026, Hamilton, ON L8S 4K1, Canada.	samuelworkenhe@gmail.com; mossk@mcmaster.ca	Moffat, Jason/AAC-1110-2020	Moffat, Jason/0000-0002-5663-8586	Cancer Research Society; Canadian Cancer Society Research Institute	Cancer Research Society; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	These studies were supported by operating grants to KLM from the Cancer Research Society and the Canadian Cancer Society Research Institute.	Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Bolyard C, 2014, CLIN CANCER RES, V20, P6479, DOI 10.1158/1078-0432.CCR-14-0463; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Cheema TA, 2011, CLIN CANCER RES, V17, P7383, DOI 10.1158/1078-0432.CCR-11-1762; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Ciomei M, 2006, CLIN CANCER RES, V12, P2856, DOI 10.1158/1078-0432.CCR-05-1859; Diallo JS, 2010, MOL THER, V18, P1123, DOI 10.1038/mt.2010.67; Edmond V, 2013, CELL CYCLE, V12, P1267, DOI 10.4161/cc.24363; Edmond V, 2011, EMBO J, V30, P510, DOI 10.1038/emboj.2010.333; Hummel JL, 2005, MOL THER, V12, P1101, DOI 10.1016/j.ymthe.2005.07.533; Ilkow CS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003836; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Ketela T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-213; Kumler I, 2013, BREAST CANCER RES TR, V138, P347, DOI 10.1007/s10549-013-2476-3; Mahoney DJ, 2010, CYTOKINE GROWTH F R, V21, P161, DOI 10.1016/j.cytogfr.2010.02.013; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moorman NJ, 2010, J VIROL, V84, P5260, DOI 10.1128/JVI.02733-09; Mossman KL, 1999, J VIROL, V73, P9726, DOI 10.1128/JVI.73.12.9726-9733.1999; Pilch B, 2001, CANCER RES, V61, P6876; Quidville V, 2013, CANCER RES, V73, P2247, DOI 10.1158/0008-5472.CAN-12-2501; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Sobol PT, 2011, MOL THER, V19, P335, DOI 10.1038/mt.2010.264; Solier S, 2010, CANCER RES, V70, P8055, DOI 10.1158/0008-5472.CAN-10-2491; Soret J, 2003, CANCER RES, V63, P8203; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Tahara M, 2013, BIOCHEM BIOPH RES CO, V434, P753, DOI 10.1016/j.bbrc.2013.03.128; Twyffels L, 2011, FEBS J, V278, P3246, DOI 10.1111/j.1742-4658.2011.08274.x; Ueno M, 2002, EUR UROL, V42, P390, DOI 10.1016/S0302-2838(02)00321-4; Vanderbeeken MC, 2013, CURR BREAST CANCER R, V5, P31, DOI 10.1007/s12609-012-0098-0; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655; Workenhe ST, 2013, CANCER IMMUNOL RES, V1, P309, DOI 10.1158/2326-6066.CIR-13-0059-T; Workenhe ST, 2014, MOL THER, V22, P123, DOI 10.1038/mt.2013.238; Workenhe ST, 2009, MOL IMMUNOL, V46, P2955, DOI 10.1016/j.molimm.2009.06.015; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253	38	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2465	2474		10.1038/onc.2015.303	http://dx.doi.org/10.1038/onc.2015.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26257065				2022-12-28	WOS:000376165500005
J	Horikoshi, N; Hunt, CR; Pandita, TK				Horikoshi, N.; Hunt, C. R.; Pandita, T. K.			More complex transcriptional regulation and stress response by MOF	ONCOGENE			English	Editorial Material							H4 LYSINE 16; MALES ABSENT; MSL COMPLEX; DROSOPHILA; DELETION; MICE	MOF (males absent on the first) was initially discovered as a dosage compensation factor that regulates the epigenetic acetylation of histone H4 lysine 16. In this issue, Sheikh et al. demonstrate that MOF expression is not required for normal kidney tissue function but is required for maintaining transcriptional regulation under conditions of stress. This work along with results from previous investigators highlights the importance of the cell lineage-chromatin modification interaction in determining transcriptional programs and physiological outcomes under normal and stress conditions.	[Horikoshi, N.; Hunt, C. R.; Pandita, T. K.] Houston Methodist Res Inst, Dept Radiat Oncol, 6550 Fannin St, Houston, TX 77030 USA	The Methodist Hospital System; The Methodist Hospital - Houston	Pandita, TK (corresponding author), Houston Methodist Res Inst, Dept Radiat Oncol, 6550 Fannin St, Houston, TX 77030 USA.	tpandita@houstonmethodist.org	Pandita, Tej K/AAM-9188-2020; Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NATIONAL CANCER INSTITUTE [R01CA154320, R01CA129537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM109768] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA129537, R01 CA154320] Funding Source: Medline; NIGMS NIH HHS [R01 GM109768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhadra MP, 2012, CHROMOSOMA, V121, P79, DOI 10.1007/s00412-011-0344-7; Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981; Chelmicki T, 2014, ELIFE, V3, DOI 10.7554/eLife.02024; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07; Gupta A, 2013, MUTAGENESIS, V28, P263, DOI 10.1093/mutage/ges080; Horikoshi Nobuo, 2013, Genome Integr, V4, P3, DOI 10.1186/2041-9414-4-3; Hunt CR, 2013, RADIAT RES, V179, P383, DOI 10.1667/RR3308.2; Kumar R, 2011, P NATL ACAD SCI USA, V108, P3636, DOI 10.1073/pnas.1016524108; Laverty C, 2010, CURR OPIN GENET DEV, V20, P171, DOI 10.1016/j.gde.2010.01.007; Li XZ, 2012, CELL STEM CELL, V11, P163, DOI 10.1016/j.stem.2012.04.023; Lucchesi J. C., 2015, COLD SPRING HARB PER, V7; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Pandita TK, 2013, PROTEOMICS, V13, P1546, DOI 10.1002/pmic.201300145; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Raja SJ, 2010, MOL CELL, V38, P827, DOI 10.1016/j.molcel.2010.05.021; Ravens S, 2014, ELIFE, V3, DOI 10.7554/eLife.02104; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Sheikh BN, 2016, ONCOGENE, V35, P2698, DOI 10.1038/onc.2015.335; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Taylor GCA, 2013, GENOME RES, V23, P2053, DOI 10.1101/gr.155028.113	21	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2681	2683		10.1038/onc.2015.373	http://dx.doi.org/10.1038/onc.2015.373			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26434593				2022-12-28	WOS:000377472700001
J	Hua, G; Lv, X; He, C; Remmenga, SW; Rodabough, KJ; Dong, J; Yang, L; Lele, SM; Yang, P; Zhou, J; Karst, A; Drapkin, RI; Davis, JS; Wang, C				Hua, G.; Lv, X.; He, C.; Remmenga, S. W.; Rodabough, K. J.; Dong, J.; Yang, L.; Lele, S. M.; Yang, P.; Zhou, J.; Karst, A.; Drapkin, R. I.; Davis, J. S.; Wang, C.			YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; HIPPO SIGNALING PATHWAY; OVARIAN-CANCER CELLS; TRANSCRIPTIONAL COACTIVATOR; EXPRESSION; PROLIFERATION; TRANSFORMATION; DROSOPHILA; PATHOGENESIS; SUPPRESSES	Accumulating evidence indicates that ovarian high-grade serous carcinoma (HGSC) originates from fallopian tube secretory epithelial cells (FTSECs). However, the molecular mechanisms underlying the initiation and progression of HGSC derived from FTSECs remains unclear. In this study, we found that the Hippo/Yes-associated protein (YAP) signaling pathway has a critical role in the initiation and progression of fallopian tube and ovarian HGSC. Importantly, YAP was overexpressed in inflammatory and cancerous fallopian tube tissues. Further, overexpression of wild-type YAP, or constitutively active YAP in immortalized FTSECs, induced cell proliferation, migration, colony formation and tumorigenesis. Moreover, the Hippo/YAP and the fibroblast growth factor (FGF) signaling pathways formed an autocrine/paracrine-positive feedback loop to drive the progression of the FTSEC-derived HGSC. Evidence in this study strongly suggests that combined therapy with inhibitors of YAP (such as verteporfin) and FGF receptors (such as BGJ398) can provide a novel therapeutic strategy to treat fallopian tube and ovarian HGSC.	[Hua, G.; Lv, X.; He, C.; Remmenga, S. W.; Rodabough, K. J.; Davis, J. S.; Wang, C.] Univ Nebraska Med Ctr, Dept Obstet Gynecol, Olson Ctr Womens Hlth, Omaha, NE USA; [Hua, G.; He, C.; Yang, L.] Huazhong Agr Univ, Coll Anim Sci & Technol, Key Lab Agr Anim Genet Breeding & Reprod, Minist Educ, Wuhan, Peoples R China; [Dong, J.; Davis, J. S.; Wang, C.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA; [Lele, S. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Yang, P.] Univ Maryland, Sch Med, Dept Obstet Gynecol & Reprod Sci, Baltimore, MD 21201 USA; [Zhou, J.] Urumuqi Gen Hosp Lanzhou Mil Reg, Dept Obstet & Gynecol, Urumqi, Peoples R China; [Karst, A.; Drapkin, R. I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA; [Davis, J. S.] Omaha Vet Affairs Med Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; Huazhong Agricultural University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Wang, C (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Dept Obstet Gynecol, Olson Ctr Womens Hlth, 985860 Nebraska Med Ctr, Omaha, NE 68198 USA.	chengwang@unmc.edu	Lv, Xiangmin/I-7106-2019; Davis, John S/C-3234-2014; Drapkin, Ronny/E-9944-2016	Lv, Xiangmin/0000-0001-8338-6014; Drapkin, Ronny/0000-0002-6912-6977; Davis, John/0000-0003-3468-4079	Eunice Kennedy Shriver National Institute of Child Health and Human Development [5R00HD059985, 5P01AG029531]; Olson Center for Women's Health; Fred and Pamela Buffett Cancer Center [LB595]; Colleen's Dream Foundation; Omaha Veterans Administration Medical Center [5I01BX000512]; National Institute of Food and Agriculture [2011-67015-20076]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R00HD059985] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K99HD059985] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA197976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG029531] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000512] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Olson Center for Women's Health; Fred and Pamela Buffett Cancer Center; Colleen's Dream Foundation; Omaha Veterans Administration Medical Center; National Institute of Food and Agriculture(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Adam Karpf (The Pamela and Fred Cancer Center, University of Nebraska Medical Center) for providing ovarian HGSC cell lines. We acknowledge the cBioPortal for Cancer Genomics (http://cbioportal.org) for providing data sets and online analyzing tools. We also acknowledge the TCGA research Network (http://cancergenome.nih.gov) for providing data sets. This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (5R00HD059985, 5P01AG029531); the Olson Center for Women's Health (no number); the Fred and Pamela Buffett Cancer Center (LB595), the Colleen's Dream Foundation (no number), the Omaha Veterans Administration Medical Center (5I01BX000512) and the National Institute of Food and Agriculture (2011-67015-20076). We thank Melody Montgomery at the University of Nebraska Medical Center (UNMC) Research Editorial Office for the professional editing of the manuscript.	Al-Hussaini M, 2004, HISTOPATHOLOGY, V44, P109, DOI 10.1111/j.1365-2559.2004.01787.x; Ando H, 2000, HUM REPROD, V15, P1597, DOI 10.1093/humrep/15.7.1597; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Barakat RR, 2000, CANCER, V89, P383, DOI 10.1002/1097-0142(20000715)89:2<383::AID-CNCR25>3.0.CO;2-T; Beaufort CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103988; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Berek JS, 2012, INT J GYNECOL OBSTET, V119, pS118, DOI 10.1016/S0020-7292(12)60025-3; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Casey MJ, 2000, GYNECOL ONCOL, V78, P278, DOI 10.1006/gyno.2000.5861; Cathro HP, 2002, AM J CLIN PATHOL, V117, P944, DOI 10.1309/2T1Y-7BB7-DAPE-PQ6L; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Crum CP, 2007, CURR OPIN OBSTET GYN, V19, P3, DOI 10.1097/GCO.0b013e328011a21f; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; De Cecco L, 2004, ONCOGENE, V23, P8171, DOI 10.1038/sj.onc.1207979; DIBLASIO AM, 1993, AM J OBSTET GYNECOL, V169, P1517, DOI 10.1016/0002-9378(93)90428-L; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dubeau L, 2013, ANN ONCOL, V24, P28, DOI 10.1093/annonc/mdt308; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fearon AE, 2013, INT J BIOCHEM CELL B, V45, P2832, DOI 10.1016/j.biocel.2013.09.017; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Fu D, 2014, ENDOCR-RELAT CANCER, V21, P297, DOI 10.1530/ERC-13-0339; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Goodman MT, 2009, CANCER EPIDEM BIOMAR, V18, P132, DOI 10.1158/1055-9965.EPI-08-0771; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; He C, 2015, ONCOGENE, V34, P6040, DOI 10.1038/onc.2015.52; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Hwang H, 2004, APPL IMMUNOHISTO M M, V12, P122; Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Kendall SD, 2005, CANCER RES, V65, P9824, DOI 10.1158/0008-5472.CAN-05-1543; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krejci P, 2007, PEDIATR RES, V61, P267, DOI 10.1203/pdr.0b013e318030d157; Kuhn E, 2010, AM J SURG PATHOL, V34, P829, DOI 10.1097/PAS.0b013e3181dcede7; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Li T, 2010, PHARM BIOL, V48, P161, DOI 10.3109/13880200903062630; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Madore J, 2010, J PATHOL, V220, P392, DOI 10.1002/path.2659; MEYER GE, 1995, CANCER, V76, P2304, DOI 10.1002/1097-0142(19951201)76:11<2304::AID-CNCR2820761119>3.0.CO;2-N; Ono I, 2002, J DERMATOL SCI, V29, P104, DOI 10.1016/S0923-1811(02)00019-1; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Seidman JD, 2004, INT J GYNECOL PATHOL, V23, P41, DOI 10.1097/01.pgp.0000101080.35393.16; Selvaggi, 2000, Arch Pathol Lab Med, V124, P477; Shan WW, 2012, CELL CYCLE, V11, P2107, DOI 10.4161/cc.20544; Sherman-Baust CA, 2014, J PATHOL, V233, P228, DOI 10.1002/path.4353; Siffroi-Fernandez S, 2005, ARCH OPHTHALMOL-CHIC, V123, P368, DOI 10.1001/archopht.123.3.368; Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6; Stewart SL, 2007, GYNECOL ONCOL, V107, P392, DOI 10.1016/j.ygyno.2007.09.018; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tung CS, 2009, MODERN PATHOL, V22, P1243, DOI 10.1038/modpathol.2009.92; Wang C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.397; Wang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048299; Wang C, 2010, ENDOCRINOLOGY, V151, P2319, DOI 10.1210/en.2009-1489; Yang SP, 2013, CANCER RES, V73, P6722, DOI 10.1158/0008-5472.CAN-13-2049; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8	75	54	55	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2247	2265		10.1038/onc.2015.288	http://dx.doi.org/10.1038/onc.2015.288			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26364602	Green Submitted, Green Accepted			2022-12-28	WOS:000374986000010
J	Chen, X; Gohain, N; Zhan, C; Lu, WY; Pazgier, M; Lu, W				Chen, X.; Gohain, N.; Zhan, C.; Lu, W-Y; Pazgier, M.; Lu, W.			Structural basis of how stress-induced MDMX phosphorylation activates p53	ONCOGENE			English	Article							SITE-SPECIFIC INCORPORATION; EXPRESSED PROTEIN LIGATION; NATIVE CHEMICAL LIGATION; DNA-DAMAGE; TYROSINE PHOSPHORYLATION; EMBRYONIC LETHALITY; GENERAL-METHOD; ATM; DOMAIN; DEGRADATION	The tumor-suppressor protein p53 is tightly controlled in normal cells by its two negative regulators-the E3 ubiquitin ligase MDM2 and its homolog MDMX. Under stressed conditions such as DNA damage, p53 escapes MDM2- and MDMX-mediated functional inhibition and degradation, acting to prevent damaged cells from proliferating through induction of cell cycle arrest, DNA repair, senescence or apoptosis. Ample evidence suggests that stress signals induce phosphorylation of MDM2 and MDMX, leading to p53 activation. However, the structural basis of stress-induced p53 activation remains poorly understood because of the paucity of technical means to produce site-specifically phosphorylated MDM2 and MDMX proteins for biochemical and biophysical studies. Herein, we report total chemical synthesis, via native chemical ligation, and functional characterization of (24-108) MDMX and its Tyr99-phosphorylated analog with respect to their ability to interact with a panel of p53-derived peptide ligands and PMI, a p53-mimicking but more potent peptide antagonist of MDMX, using FP and surface plasmon resonance techniques. Phosphorylation of MDMX at Tyr99 weakens peptide binding by approximately two orders of magnitude. Comparative X-ray crystallographic analyses of MDMX and of pTyr99 MDMX in complex with PMI as well as modeling studies reveal that the phosphate group of pTyr99 imposes extensive steric clashes with the C-terminus of PMI or p53 peptide and induces a significant lateral shift of the peptide ligand, contributing to the dramatic decrease in the binding affinity of MDMX for p53. Because DNA damage activates c-Abl tyrosine kinase that phosphorylates MDMX at Tyr99, our findings afford a rare glimpse at the structural level of how stress-induced MDMX phosphorylation dislodges p53 from the inhibitory complex and activates it in response to DNA damage.	[Chen, X.; Gohain, N.; Zhan, C.; Pazgier, M.; Lu, W.] Univ Maryland, Sch Med, Inst Human Virol, 725 West Lombard St, Baltimore, MD 21201 USA; [Chen, X.; Gohain, N.; Zhan, C.; Pazgier, M.; Lu, W.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Chen, X.; Lu, W-Y] Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery MOE, Shanghai 200433, Peoples R China; [Chen, X.; Lu, W-Y] Fudan Univ, Sch Pharm, PLA, Shanghai 200433, Peoples R China; [Lu, W.] Xi An Jiao Tong Univ, Ctr Translat Med, Sch Life Sci & Technol, Xian, Shaanxi, Peoples R China	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Fudan University; Fudan University; Xi'an Jiaotong University	Pazgier, M; Lu, W (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, 725 West Lombard St, Baltimore, MD 21201 USA.	mpazgier@ihv.umaryland.edu; wlu@ihv.umaryland.edu	Lu, Wuyuan/B-2268-2010; Lu, Wuyuan/J-8452-2017; Gohain, Neelakshi/P-7493-2015; Lu, Weiyue/E-7938-2010	Lu, Wuyuan/0000-0003-1318-9968; Gohain, Neelakshi/0000-0003-1370-312X	US National Institutes of Health [CA167296]; National Natural Science Foundation of China [81128015]; National Basic Research Program of China (973 Program) [2013CB932500]; China Scholarship Council; DOE Office of Biological and Environmental Research; National Institutes of Health, National Center for Research Resources, Biomedical Technology Program [P41RR001209]; National Institute of General Medical Sciences; NATIONAL CANCER INSTITUTE [R21CA167296] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); China Scholarship Council(China Scholarship Council); DOE Office of Biological and Environmental Research(United States Department of Energy (DOE)); National Institutes of Health, National Center for Research Resources, Biomedical Technology Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was partially supported by the US National Institutes of Health grant CA167296 and the Overseas Scholars Collaborative Research grant 81128015 from the National Natural Science Foundation of China (WL), and by the National Basic Research Program of China (973 Program, 2013CB932500) (W-YL). XC was the recipient of a scholarship from the China Scholarship Council. Portions of this research were carried out at the University of Maryland X-ray Crystallography Shared Service and the Stanford Synchrotron Radiation Lightsource, a Directorate of SLAC National Accelerator Laboratory and an Office of Science User Facility operated for the U.S. Department of Energy Office of Science by Stanford University. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by the National Institutes of Health, National Center for Research Resources, Biomedical Technology Program (P41RR001209), and the National Institute of General Medical Sciences.	Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kallen J, 2009, J BIOL CHEM, V284, P8803, DOI 10.1074/jbc.M809096200; Kent SBH, 2009, CHEM SOC REV, V38, P338, DOI 10.1039/b700141j; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li C, 2010, 2010 INTERNATIONAL FORUM ON BIOMEDICAL TEXTILE MATERIALS, PROCEEDINGS, P398; Lu W, 2003, BIOCHEMISTRY-US, V42, P5461, DOI 10.1021/bi0340144; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; LUNA RMD, 1995, NATURE, V378, P203; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; McCoy MA, 2003, P NATL ACAD SCI USA, V100, P1645, DOI 10.1073/pnas.0334477100; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pazgiera M, 2009, P NATL ACAD SCI USA, V106, P4665, DOI 10.1073/pnas.0900947106; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Popowicz GM, 2008, CELL CYCLE, V7, P2441, DOI 10.4161/cc.6365; Popowicz GM, 2011, ANGEW CHEM INT EDIT, V50, P2680, DOI 10.1002/anie.201003863; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schwarzer D, 2005, CURR OPIN CHEM BIOL, V9, P561, DOI 10.1016/j.cbpa.2005.09.018; Showalter SA, 2008, J AM CHEM SOC, V130, P6472, DOI 10.1021/ja800201j; Tarrant MK, 2009, ANNU REV BIOCHEM, V78, P797, DOI 10.1146/annurev.biochem.78.070907.103047; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Waning DL, 2011, J BIOL CHEM, V286, P216, DOI 10.1074/jbc.M110.183012; Worralll EG, 2010, J MOL BIOL, V398, P414, DOI 10.1016/j.jmb.2010.03.023; Zhan CY, 2012, J MED CHEM, V55, P6237, DOI 10.1021/jm3005465; Zhan CY, 2012, J AM CHEM SOC, V134, P6855, DOI 10.1021/ja301255n; Zuckerman V, 2009, J BIOL CHEM, V284, P4031, DOI 10.1074/jbc.M809211200	44	14	15	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1919	1925		10.1038/onc.2015.255	http://dx.doi.org/10.1038/onc.2015.255			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148237	Green Accepted			2022-12-28	WOS:000374010300005
J	Chen, CC; Kim, KH; Lau, LF				Chen, C-C; Kim, K-H; Lau, L. F.			The matricellular protein CCN1 suppresses hepato-carcinogenesis by inhibiting compensatory proliferation	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; LIVER FIBROSIS; MOUSE MODELS; IN-VIVO; CYR61; CANCER; P53; HEPATOCARCINOGENESIS; APOPTOSIS	Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and is on the rise in the United States. Previous studies showed that the matricellular protein CCN1 (CYR61) is induced during hepatic injuries and functions to restrict and resolve liver fibrosis. Here, we show that CCN1 suppresses hepatocarcinogenesis by inhibiting carcinogen-induced compensatory hepatocyte proliferation, thus limiting the expansion of damaged and potentially oncogenic hepatocytes. Consistent with tumor suppression, CCN1 expression is downregulated in human HCC. Ccn1(Delta Hep) mice with hepatocyte-specific deletion of Ccn1 suffer increased HCC tumor multiplicity induced by the hepatocarcinogen diethylnitrosamine (DEN). Knockin mice (Ccn1(dm/dm)) that express an integrin alpha(6)beta(1)-binding defective CCN1 phenocopied Ccn1(Delta Hep) mice, indicating that CCN1 acts through its alpha(6)beta(1) binding sites in this context. CCN1 effectively inhibits epidermal growth factor receptor (EGFR)-dependent hepatocyte proliferation through integrin alpha(6)-mediated accumulation of reactive oxygen species (ROS), thereby triggering p53 activation and cell cycle block. Consequently, Ccn1(dm/dm) mice exhibit diminished p53 activation and elevated compensatory hepatocyte proliferation, resulting in increased HCC. Furthermore, we show that a single dose of the EGFR inhibitor erlotinib delivered prior to DEN-induced injury was sufficient to block compensatory proliferation and annihilate development of HCC nodules observed 8 months later, suggesting potential chemoprevention by targeting CCN1-inhibitable EGFR-dependent hepatocyte proliferation. Together, these results show that CCN1 is an injury response protein that functions not only to restrict fibrosis in the liver, but also to suppress hepatocarcinogenesis by inhibiting EGFR-dependent hepatocyte compensatory proliferation.	[Chen, C-C; Kim, K-H; Lau, L. F.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Coll Med, 900 S Ashland Ave, Chicago, IL 60607 USA.	LFLau@uic.edu		Kim, Ki-Hyun/0000-0001-8265-6609; Lau, Lester/0000-0002-4364-2914	NIH [R01GM78492]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR061791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078492] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Seungwon Shin and Guoqiang Yan for technical assistance. This work was supported by a grant from the NIH (R01GM78492) to LFL.	Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Baffy G, 2012, J HEPATOL, V56, P1384, DOI 10.1016/j.jhep.2011.10.027; Bakiri L, 2013, MOL ONCOL, V7, P206, DOI 10.1016/j.molonc.2013.01.005; Chen CC, 2007, EMBO J, V26, P1257, DOI 10.1038/sj.emboj.7601596; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chien WW, 2004, J BIOL CHEM, V279, P53087, DOI 10.1074/jbc.M410254200; Choi JS, 2015, MUCOSAL IMMUNOL, V8, P1285, DOI 10.1038/mi.2015.19; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Feng P, 2008, INT J BIOCHEM CELL B, V40, P98, DOI 10.1016/j.biocel.2007.06.020; Fuchs BC, 2014, HEPATOLOGY, V59, P1577, DOI 10.1002/hep.26898; Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Haque I, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-8; Hiotis SP, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-64; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070; Juric V, 2009, MOL CELL BIOL, V29, P3266, DOI 10.1128/MCB.00064-09; Kang JS, 2007, CANCER RES, V67, P11141, DOI 10.1158/0008-5472.CAN-07-1369; Kardeh S, 2014, EUR J PHARMACOL, V735, P150, DOI 10.1016/j.ejphar.2014.04.023; Kim KH, 2015, J CLIN INVEST, V125, P1886, DOI 10.1172/JCI79327; Kim KH, 2013, MOL CELL BIOL, V33, P2078, DOI 10.1128/MCB.00049-13; Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Li WC, 2010, METHODS MOL BIOL, V633, P185, DOI 10.1007/978-1-59745-019-5_13; Li ZY, 2012, COMPUT ENG APPL, V2012, P1, DOI DOI 10.1371/J0URNAL.P0NE.0040132; Liebermann DA, 2007, CELL CYCLE, V6, P166, DOI 10.4161/cc.6.2.3789; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mas VR, 2009, MOL MED, V15, P85, DOI 10.2119/molmed.2008.00110; Mellert H, 2013, CELL REP, V3, P1335, DOI 10.1016/j.celrep.2013.05.011; Mo FE, 2006, CIRC RES, V99, P961, DOI 10.1161/01.RES.0000248426.35019.89; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; O'Connor S., 2010, Morbidity and Mortality Weekly Report, V59, P517; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sakurai T, 2013, CANCER RES, V73, P215, DOI 10.1158/0008-5472.CAN-12-1602; Schiffer E, 2005, HEPATOLOGY, V41, P307, DOI 10.1002/hep.20538; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Smith NF, 2008, BRIT J CANCER, V98, P1630, DOI 10.1038/sj.bjc.6604353; Stepniak E, 2006, GENE DEV, V20, P2306, DOI 10.1101/gad.390506; Sun BC, 2013, FRONT MED-PRC, V7, P242, DOI 10.1007/s11684-013-0256-4; Teoh N, 2010, GASTROENTEROLOGY, V138, P1155, DOI 10.1053/j.gastro.2009.11.008; Thomas MB, 2007, CANCER-AM CANCER SOC, V110, P1059, DOI 10.1002/cncr.22886; Todorovic V, 2005, J CELL BIOL, V171, P559, DOI 10.1083/jcb.200504015; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Yan HX, 2013, ONCOGENE, V32, P4565, DOI 10.1038/onc.2012.451; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100	55	34	36	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1314	1323		10.1038/onc.2015.190	http://dx.doi.org/10.1038/onc.2015.190			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028023	Green Accepted			2022-12-28	WOS:000371763100011
J	Zhang, K; Zhao, H; Ji, Z; Zhang, C; Zhou, P; Wang, L; Chen, Q; Wang, J; Zhang, P; Chen, Z; Zhu, HH; Gao, WQ				Zhang, K.; Zhao, H.; Ji, Z.; Zhang, C.; Zhou, P.; Wang, L.; Chen, Q.; Wang, J.; Zhang, P.; Chen, Z.; Zhu, H. H.; Gao, W-Q			Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition	ONCOGENE			English	Article							HEMATOPOIETIC STEM; TUMOR-SUPPRESSOR; NOONAN-SYNDROME; PHOSPHATASE; KINASE; GAB1; TUMORIGENESIS; PROGRESSION; ACTIVATION; MECHANISMS	Epithelial-to-mesenchymal transition (EMT), marked by the dissolution of cell-cell junctions, loss of cell polarity and increased cell motility, is one of the essential steps for prostate cancer metastasis. However, the underlying mechanism has not been fully explored. We report in this study that Shp2 is upregulated in prostate cancers and is associated with a poor disease outcome, namely tumor metastasis and shortened patient survival. Overexpression of wild-type Shp2 or an oncogenic Shp2 mutant leads to increased prostate cancer cell proliferation, colony and sphere formation, and in vivo tumor formation. Opposite effects are seen in Shp2-knockdown cells. Moreover, Shp2 promotes in vitro migration and in vivo metastasis of prostatic tumor cells. Mechanistically, Shp2 interacts with PAR3 (partitioning-defective 3) via its Src homology-2 domain. Ectopic expression of Shp2 attenuates the phosphorylation of PAR3 and the formation of the PAR3/PAR6/atypical protein kinase C polarity protein complex, resulting in disrupted cell polarity, dysregulated cell-cell junctions and increased EMT. These findings provide a novel mechanism by which oncogenic signal-transduction molecules regulate cell polarity and induction of EMT.	[Zhang, K.; Zhao, H.; Ji, Z.; Zhang, C.; Zhou, P.; Wang, L.; Chen, Q.; Wang, J.; Zhu, H. H.; Gao, W-Q] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji MedX Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Biomed Engn, 160 Pujian Rd, Shanghai 200127, Peoples R China; [Zhang, P.] Chinese Acad Sci, Key Lab Syst Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Chen, Z.] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; ShanghaiTech University	Zhu, HH; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji MedX Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Biomed Engn, 160 Pujian Rd, Shanghai 200127, Peoples R China.	zhuhecrane@shsmu.edu.cn; gao.weiqiang@sjtu.edu.cn	Gao, Wei/GXH-0380-2022	Wang, Jia/0000-0002-2343-4755	Chinese Ministry of Science and Technology [2012CB966800, 2013CB945600]; National Natural Science Foundation of China (NSFC) [81130038, 81372189]; Shanghai Health Bureau Key Discipline and Specialty Foundation; Shanghai Education Committee Key Discipline and Specialty Foundation [J50208]; KC Wong foundation; NSFC [81270627]; Science and Technology Commission of Shanghai Municipality (Pujiang program) [12PJ1406100]; Shanghai Education Committee [12CG16, 13YZ030]; Shanghai Institutions of Higher Learning	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Health Bureau Key Discipline and Specialty Foundation; Shanghai Education Committee Key Discipline and Specialty Foundation; KC Wong foundation; NSFC(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality (Pujiang program); Shanghai Education Committee; Shanghai Institutions of Higher Learning	The study is supported by funds to W-Q Gao from the Chinese Ministry of Science and Technology (2012CB966800 and 2013CB945600), the National Natural Science Foundation of China (NSFC, 81130038 and 81372189), the Science and Technology Commission of Shanghai Municipality (Pujiang program), the Shanghai Health Bureau Key Discipline and Specialty Foundation, the Shanghai Education Committee Key Discipline and Specialty Foundation (J50208) and the KC Wong foundation, and by funds to HH Zhu from the NSFC (81270627), the Science and Technology Commission of Shanghai Municipality (Pujiang program 12PJ1406100) and the Shanghai Education Committee (Chenguang program12CG16, 13YZ030 and young investigator program) and Shanghai Institutions of Higher Learning (The Program for Professor of Special Appointment (Young Eastern Scholar)).	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Bard-Chapeau EA, 2006, MOL CELL BIOL, V26, P4664, DOI 10.1128/MCB.02253-05; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chan RJ, 2007, BLOOD, V109, P862, DOI 10.1182/blood-2006-07-028829; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hartman ZR, 2013, MOL CANCER RES, V11, P651, DOI 10.1158/1541-7786.MCR-12-0578; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lu Y, 2011, P NATL ACAD SCI USA, V108, P2957, DOI 10.1073/pnas.1009395108; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Mali RS, 2012, BLOOD, V120, P2669, DOI 10.1182/blood-2011-08-375873; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; Saadat I, 2007, NATURE, V447, P330, DOI 10.1038/nature05765; Sausgruber N, 2015, ONCOGENE, V34, P2272, DOI 10.1038/onc.2014.170; Schneeberger VE, 2014, CARCINOGENESIS, V35, P1717, DOI 10.1093/carcin/bgu025; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Takahashi A, 2011, MOL CELL, V43, P45, DOI 10.1016/j.molcel.2011.05.014; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; Wang JJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4415; Wang YG, 2006, EMBO J, V25, P5058, DOI 10.1038/sj.emboj.7601384; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Yang XQ, 2010, MOL CELL BIOL, V30, P5306, DOI 10.1128/MCB.00326-10; Yang ZQ, 2012, MOL CELL, V47, P469, DOI 10.1016/j.molcel.2012.06.037; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54; Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021; Zhu HH, 2011, CELL CYCLE, V10, P2241, DOI 10.4161/cc.10.14.15861; Zhu HH, 2011, BLOOD, V117, P5350, DOI 10.1182/blood-2011-01-333476	44	44	46	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1271	1282		10.1038/onc.2015.184	http://dx.doi.org/10.1038/onc.2015.184			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26050620				2022-12-28	WOS:000371763100007
J	Kharat, SS; Tripathi, V; Damodaran, AP; Priyadarshini, R; Chandra, S; Tikoo, S; Nandhakumar, R; Srivastava, V; Priya, S; Hussain, M; Kaur, S; Fishman, JB; Sengupta, S				Kharat, S. S.; Tripathi, V.; Damodaran, A. P.; Priyadarshini, R.; Chandra, S.; Tikoo, S.; Nandhakumar, R.; Srivastava, V.; Priya, S.; Hussain, M.; Kaur, S.; Fishman, J. B.; Sengupta, S.			Mitotic phosphorylation of Bloom helicase at Thr182 is required for its proteasomal degradation and maintenance of chromosomal stability	ONCOGENE			English	Article							BLM HELICASE; CELL-CYCLE; HOMOLOGOUS RECOMBINATION; REPLICATION STRESS; UBIQUITIN LIGASE; RECQ HELICASES; DNA-DAMAGE; MULTISITE PHOSPHORYLATION; SYNDROME PROTEIN; F-BOX	Mutations in Bloom helicase (BLM) lead to Bloom Syndrome (BS). BS is characterized by multiple clinical manifestations including predisposition to a wide spectrum of cancers. Studies have revealed the mechanism of BLM recruitment after stalled replication and its role during the repair of DNA damage. We now provide evidence that BLM undergoes K48-linked ubiquitylation and subsequent degradation during mitosis due to the E3 ligase, Fbw7 alpha. Fbw7 alpha carries out its function after GSK3 beta- and CDK2/cyclin A2-dependent phosphorylation events on Thr171 and Ser175 of BLM which lies within a well-defined phosphodegron, a sequence which is conserved in all primates. Phosphorylation on BLM Thr171 and Ser175 depends on prior phosphorylation at Thr182 by Chk1/Chk2. Thr182 phosphorylation not only controls BLM ubiquitylation and degradation during mitosis but is also a determinant for its localization on the ultrafine bridges. Consequently lack of Thr182 phosphorylation leads to multiple manifestations of chromosomal instability including increased levels of DNA damage, lagging chromatin, micronuclei formation, breaks and quadriradials. Hence Thr182 phosphorylation on BLM has two functions-it regulates BLM turnover during mitosis and also helps to maintain the chromosomal stability.	[Kharat, S. S.; Tripathi, V.; Damodaran, A. P.; Priyadarshini, R.; Chandra, S.; Tikoo, S.; Nandhakumar, R.; Srivastava, V.; Priya, S.; Hussain, M.; Kaur, S.; Sengupta, S.] Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India; [Fishman, J. B.] 21st Century Biochem, 260 Cedar Hill St, Marlborough, MA USA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Sengupta, S (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	sagar@nii.ac.in	Tripathi, Vivek/O-9164-2018; Tikoo, Shweta/AAX-1902-2021; Sengupta, Sagar/AGR-1063-2022; Kharat, Suhas/V-2129-2019; Hussain, Mansoor/GQI-2915-2022	Tripathi, Vivek/0000-0002-4453-0105; Tikoo, Shweta/0000-0001-5850-8075; Sengupta, Sagar/0000-0002-6365-1770; Kharat, Suhas/0000-0003-2283-7429; Hussain, Mansoor/0000-0003-4260-2256	National Institute of Immunology core funds, Department of Biotechnology (DBT), India [BT/PR3148/AGR/36/706/2011]; Science and Engineering Research Board, India [SR/SO/BB-0124/2013]; Indo-French Centre for the Promotion of Advanced Research (IFCPAR) [IFC/4603-A/2011/1250]; Council of Scientific and Industrial Research (CSIR), India [37(1541)/12/EMR-II]	National Institute of Immunology core funds, Department of Biotechnology (DBT), India; Science and Engineering Research Board, India; Indo-French Centre for the Promotion of Advanced Research (IFCPAR)(Indo-French Centre for the Promotion of Advanced Research (IFCPAR/CEFIPRA)); Council of Scientific and Industrial Research (CSIR), India(Council of Scientific & Industrial Research (CSIR) - India)	We acknowledge Bruce Clurman, Markus Welcker, Jonathan Grim, Ian Hickson, Stephen Elledge, Thanos Halazonetis, Jerry Shay, Nathan Ellis, Bert Vogelstein for plasmids and cells, Simon Gemble for help with SCEs and UFB staining, Priyanka Modi for transfection experiments, Jyoti Kumari for lentivirus-mediated stable line generation and Richa Mudgal for bioinformatic analysis. SS acknowledges National Institute of Immunology core funds, Department of Biotechnology (DBT), India (BT/PR3148/AGR/36/706/2011); Science and Engineering Research Board, India (SR/SO/BB-0124/2013); Indo-French Centre for the Promotion of Advanced Research (IFCPAR) (IFC/4603-A/2011/1250) and Council of Scientific and Industrial Research (CSIR), India [37(1541)/12/EMR-II] for financial assistance.	Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Aguilera A, 2013, ANNU REV GENET, V47, P1, DOI 10.1146/annurev-genet-111212-133232; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bayart E, 2006, CELL CYCLE, V5, P1681, DOI 10.4161/cc.5.15.3122; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Bendris N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022879; Bohm S, 2014, DNA REPAIR, V22, P123, DOI 10.1016/j.dnarep.2014.07.007; Bugreev DV, 2007, GENE DEV, V21, P3085, DOI 10.1101/gad.1609007; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chan KL, 2007, EMBO J, V26, P3397, DOI 10.1038/sj.emboj.7601777; Chandra S, 2013, J CELL SCI, V126, P3782, DOI 10.1242/jcs.124719; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dai XP, 2014, ONCOTARGET, V5, P3307, DOI 10.18632/oncotarget.1939; Davies SL, 2007, NAT STRUCT MOL BIOL, V14, P677, DOI 10.1038/nsmb1267; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; De Boer L, 2008, ONCOGENE, V27, P4261, DOI 10.1038/onc.2008.74; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Kaur S, 2010, MOL CANCER RES, V8, P1234, DOI 10.1158/1541-7786.MCR-10-0233; Ke YW, 2011, EMBO J, V30, P3309, DOI 10.1038/emboj.2011.226; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; Leng M, 2006, P NATL ACAD SCI USA, V103, P11485, DOI 10.1073/pnas.0601828103; Melixetian M, 2009, NAT CELL BIOL, V11, P1247, DOI 10.1038/ncb1969; Naim V, 2009, NAT CELL BIOL, V11, P761, DOI 10.1038/ncb1883; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nimonkar AV, 2008, P NATL ACAD SCI USA, V105, P16906, DOI 10.1073/pnas.0809380105; Nimonkar AV, 2011, GENE DEV, V25, P350, DOI 10.1101/gad.2003811; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Perez-Benavente B, 2013, ONCOGENE, V32, P2189, DOI 10.1038/onc.2012.235; Petsalaki E, 2014, J CELL SCI, V127, P3902, DOI 10.1242/jcs.155176; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; ROSIN MP, 1985, HUM GENET, V71, P187, DOI 10.1007/BF00284570; Rouzeau S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033905; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Spruck CH, 2002, CANCER RES, V62, P4535; Srivastava V, 2009, J CELL SCI, V122, P3093, DOI 10.1242/jcs.051813; Suhasini AN, 2011, EMBO J, V30, P692, DOI 10.1038/emboj.2010.362; Swaney DL, 2013, NAT METHODS, V10, P676, DOI [10.1038/NMETH.2519, 10.1038/nmeth.2519]; Takeishi S, 2013, CANCER CELL, V23, P347, DOI 10.1016/j.ccr.2013.01.026; Tan MJ, 2011, DEV CELL, V21, P1062, DOI 10.1016/j.devcel.2011.09.014; Tikoo S, 2013, EMBO J, V32, P1778, DOI 10.1038/emboj.2013.117; Tikoo Shweta, 2010, Genome Integr, V1, P14, DOI 10.1186/2041-9414-1-14; Tripathi V, 2008, CARCINOGENESIS, V29, P52, DOI 10.1093/carcin/bgm238; Tripathi V, 2007, J CELL BIOL, V178, P9, DOI 10.1083/jcb.200610051; Wang JD, 2013, MOL CELL, V52, P667, DOI 10.1016/j.molcel.2013.10.012; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290	57	11	12	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1025	1038		10.1038/onc.2015.157	http://dx.doi.org/10.1038/onc.2015.157			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	26028025				2022-12-28	WOS:000370823300008
J	D'Brot, A; Kurtz, P; Regan, E; Jakubowski, B; Abrams, JM				D'Brot, A.; Kurtz, P.; Regan, E.; Jakubowski, B.; Abrams, J. M.			A platform for interrogating cancer-associated p53 alleles This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue	ONCOGENE			English	Article							MUTANT P53; DROSOPHILA-MELANOGASTER; NUCLEAR-BODIES; MOUSE MODELS; CELL-DEATH; GAIN; PROTEIN; ACTIVATION; APOPTOSIS; NETWORK	p53 is the most frequently mutated gene in human cancer. Compelling evidence argues that full transformation involves loss of growth suppression encoded by wild-type p53 together with poorly understood oncogenic activity encoded by missense mutations. Furthermore, distinguishing disease alleles from natural polymorphisms is an important clinical challenge. To interrogate the genetic activity of human p53 variants, we leveraged the Drosophila model as an in vivo platform. We engineered strains that replace the fly p53 gene with human alleles, producing a collection of stocks that are, in effect, 'humanized' for p53 variants. Like the fly counterpart, human p53 transcriptionally activated a biosensor and induced apoptosis after DNA damage. However, all humanized strains representing common alleles found in cancer patients failed to complement in these assays. Surprisingly, stimulus-dependent activation of hp53 occurred without stabilization, demonstrating that these two processes can be uncoupled. Like its fly counterpart, hp53 formed prominent nuclear foci in germline cells but cancer-associated p53 variants did not. Moreover, these same mutant alleles disrupted hp53 foci and inhibited biosensor activity, suggesting that these properties are functionally linked. Together these findings establish a functional platform for interrogating human p53 alleles and suggest that simple phenotypes could be used to stratify disease variants.	[D'Brot, A.; Kurtz, P.; Abrams, J. M.] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA; [Regan, E.] Univ Texas Southwestern Med Ctr Dallas, Dept Phys Therapy, Dallas, TX 75390 USA; [Jakubowski, B.] Univ Texas Southwestern Med Ctr Dallas, Southwestern Med Sch, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Abrams, JM (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	john.abrams@utsouthwestern.edu		D'Brot, Alejandro/0000-0002-9885-0702	NIH [GM072124, GM115682, S10 RR029731-01]; Welch Foundation [1-1865]; Ellison Medical Foundation; CPRIT [RP110076]; NRSA [F31 GM108472-03]; NATIONAL CANCER INSTITUTE [P30CA142543] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR029731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM108472, R01GM072124, R56GM072124, R01GM115682] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); Ellison Medical Foundation(Lawrence Ellison Foundation); CPRIT; NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge Melissa O'neal for help cloning constructs for humanized lines and Akash Patel for help with crosses to make humanized lines. We are grateful to Anne Dejean for the dSmt3/dSUMO antibody and to Michael Buszczak for the coilin and Ism11 antibodies. We thank Kate Luby-Phelps, Abhijit Bugde and the Live Cell Imaging Facility at UT Southwestern for help with confocal imaging, deconvolution and Imaris. We also thank Po Chen, Nichole Link, Annika Wylie, Gianella Garcia-Hughes, Mike Buszczak, Robin Hiesinger and Helmut Kramer for discussion, advice and comments. This work was supported by the NIH (GM072124) and (GM115682), the Welch Foundation (1-1865), the Ellison Medical Foundation and CPRIT (RP110076) as well as NRSA (F31 GM108472-03) to Paula Kurtz and NIH (S10 RR029731-01) to Kate Luby-Phelps.	ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Akdemir F, 2007, ONCOGENE, V26, P5184, DOI 10.1038/sj.onc.1210328; Attrill H, 2016, NUCLEIC ACIDS RES, V44, pD786, DOI 10.1093/nar/gkv1046; Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brooks CL, 2010, CELL RES, V20, P614, DOI 10.1038/cr.2010.53; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Godfrey AC, 2009, RNA, V15, P1661, DOI 10.1261/rna.1518009; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Liu JL, 2009, MOL BIOL CELL, V20, P1661, DOI 10.1091/mbc.E08-05-0525; Lu WJ, 2010, SCIENCE, V328, P1278, DOI 10.1126/science.1185640; Lu WJ, 2009, NAT REV CANCER, V9, P758, DOI 10.1038/nrc2732; Lubin R, 1995, CLIN CANCER RES, V1, P1463; Mauri F, 2008, J BIOL CHEM, V283, P20848, DOI 10.1074/jbc.M710186200; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Monk AC, 2012, CELL TISSUE RES, V350, P385, DOI 10.1007/s00441-012-1479-4; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Schoborg T, 2013, J CELL BIOL, V202, P261, DOI 10.1083/jcb.201304181; Schumacher B, 2005, CELL, V120, P357, DOI 10.1016/j.cell.2004.12.009; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tritarelli A, 2004, MOL BIOL CELL, V15, P3751, DOI 10.1091/mbc.E03-12-0900; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Venken KJT, 2009, NAT METHODS, V6, P431, DOI [10.1038/NMETH.1331, 10.1038/nmeth.1331]; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wei QX, 2012, NAT PROTOC, V7, P1145, DOI 10.1038/nprot.2012.042; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wylie A, 2014, ELIFE, V3, DOI 10.7554/eLife.01530; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113	42	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					286	291		10.1038/onc.2016.48	http://dx.doi.org/10.1038/onc.2016.48			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	26996664	Green Accepted			2022-12-28	WOS:000393938100013
J	Cai, J; Zuo, Y; Wang, T; Cao, Y; Cai, R; Chen, FL; Cheng, J; Mu, J				Cai, J.; Zuo, Y.; Wang, T.; Cao, Y.; Cai, R.; Chen, F-L; Cheng, J.; Mu, J.			A crucial role of SUMOylation in modulating Sirt6 deacetylation of H3 at lysine 56 and its tumor suppressive activity	ONCOGENE			English	Article							CANCER METABOLISM; LIFE-SPAN; DRIVERS SEAT; DNA-REPAIR; CHROMATIN; SIRTUINS; PROTEIN; IDENTIFICATION; STABILIZATION; LOCALIZATION	Sirt6 is a histone deacetylase with NAD(+)-dependent activity. Sirt6 has been shown as a tumor suppressor partially via inhibiting the expression of c-Myc target genes and ribosome biogenesis. However, how to regulate Sirt6 activity is largely unknown. In this study, we identify that Sirt6 can be modified by small ubiquitin-like modifier. Sirt6 SUMOylation deficiency specifically decreases its deacetylation of H3K56 but not H3K9 in vivo. Mechanistically, we find that SUMOylation deficiency decreases Sirt6 binding with c-Myc, decreasing Sirt6 occupancy on the locus of c-Myc target genes. Therefore, Sirt6 SUMOylation deficiency reduces its deacetylation of H3k56 and its repression of c-Myc target genes. Moreover, Sirt6 SUMOylation deficiency reduces its suppression of cell proliferation and tumorigenesis. Thus, these results reveal that SUMOylation has an important role in regulation of Sirt6 deacetylation on H3K56, as well as its tumor suppressive activity.	[Cai, J.; Zuo, Y.; Wang, T.; Cao, Y.; Cai, R.; Cheng, J.] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, 280 Chongqing S Rd,Bldg 7 Rm 405, Shanghai 200025, Peoples R China; [Chen, F-L] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 3, Shanghai, Peoples R China; [Mu, J.] Chinese Acad Med Sci, Canc Hosp, Dept Thorac Surg, Beijing 100021, Peoples R China; [Mu, J.] Peking Union Med Coll, Beijing 100021, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Cheng, J (corresponding author), Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, 280 Chongqing S Rd,Bldg 7 Rm 405, Shanghai 200025, Peoples R China.; Mu, J (corresponding author), Chinese Acad Med Sci, Canc Hosp, Dept Thorac Surg, Beijing 100021, Peoples R China.; Mu, J (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	jkcheng@shsmu.edu.cn; mujuwei@cicams.ac.cn			National Basic Research Program of China (973 Program) [2013CB910902]; National Natural Science Foundation of China [91229202, 81430069]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Chuxia Deng (NIH, Bethesda, MD, USA) for kindly providing for Sirt6-/- MEF cells. This work was supported by National Basic Research Program of China (973 Program; no. 2013CB910902 to JC), National Natural Science Foundation of China (91229202 and 81430069 to JC).	Ardestani PM, 2012, NUCLEUS-PHILA, V3, P442, DOI 10.4161/nucl.21134; Baur JA, 2012, NAT REV DRUG DISCOV, V11, P443, DOI 10.1038/nrd3738; Bosch-Presegue Laia, 2011, Genes Cancer, V2, P648, DOI 10.1177/1947601911417862; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Davalos A, 2011, P NATL ACAD SCI USA, V108, P9232, DOI 10.1073/pnas.1102281108; Dominy JE, 2012, MOL CELL, V48, P900, DOI 10.1016/j.molcel.2012.09.030; Dutnall RN, 2001, CELL, V105, P161, DOI 10.1016/S0092-8674(01)00305-1; Escobar-Cabrera E, 2011, J BIOL CHEM, V286, P19816, DOI 10.1074/jbc.M111.231647; Etchegaray JP, 2013, CURR TOP MED CHEM, V13, P2991, DOI 10.2174/15680266113136660213; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gertler AA, 2013, BIOGERONTOLOGY, V14, P629, DOI 10.1007/s10522-013-9478-8; Jiang H, 2013, NATURE, V496, P110, DOI 10.1038/nature12038; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Kang XL, 2010, MOL CELL, V38, P191, DOI 10.1016/j.molcel.2010.03.005; Kawahara TLA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002153; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; Kolesar P, 2012, NUCLEIC ACIDS RES, V40, P7831, DOI 10.1093/nar/gks484; Kugel S, 2014, TRENDS BIOCHEM SCI, V39, P72, DOI 10.1016/j.tibs.2013.12.002; Lefort K, 2013, EMBO J, V32, P2248, DOI 10.1038/emboj.2013.156; Lin ZH, 2013, CELL REP, V5, P1639, DOI 10.1016/j.celrep.2013.11.029; Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365-2796.2007.01902.x; Lyssiotis CA, 2012, CELL, V151, P1155, DOI 10.1016/j.cell.2012.11.020; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Sharma A, 2013, J BIOL CHEM, V288, P18439, DOI 10.1074/jbc.M112.405928; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sundaresan NR, 2012, NAT MED, V18, P1643, DOI 10.1038/nm.2961; Takasaka N, 2014, J IMMUNOL, V192, P958, DOI 10.4049/jimmunol.1302341; Tasselli L, 2012, NATURE, V492, P362, DOI 10.1038/492362a; Tennen RI, 2010, MECH AGEING DEV, V131, P185, DOI 10.1016/j.mad.2010.01.006; Toiber D, 2013, MOL CELL, V51, P454, DOI 10.1016/j.molcel.2013.06.018; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Zhang ZG, 2014, MOL MED REP, V9, P882, DOI 10.3892/mmr.2013.1879; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	40	19	20	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4949	4956		10.1038/onc.2016.24	http://dx.doi.org/10.1038/onc.2016.24			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26898756				2022-12-28	WOS:000383330700012
J	Lei, Y; Kansy, BA; Li, J; Cong, L; Liu, Y; Trivedi, S; Wen, H; Ting, JPY; Ouyang, H; Ferris, RL				Lei, Y.; Kansy, B. A.; Li, J.; Cong, L.; Liu, Y.; Trivedi, S.; Wen, H.; Ting, J. P-Y; Ouyang, H.; Ferris, R. L.			EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex	ONCOGENE			English	Article							NF-KAPPA-B; CANCER-CELLS; TUMOR PROGRESSION; NATURAL-KILLER; I INTERFERON; CETUXIMAB; RECEPTOR; GROWTH; P62/SQSTM1; CARFILZOMIB	Epidermal growth factor receptor (EGFR)-targeted therapy in head and neck squamous cell carcinoma (HNSCC) patients frequently results in tumor resistance to treatment. Autophagy is an emerging underlying resistance mechanism, however, the molecular autophagy machinery in HNSCC cells and potential biomarkers of patient response to EGFR-targeted therapy remain insufficiently characterized. Here we show that the EGFR blocking with cetuximab leads to varied autophagic responses, which modulate cancer cell susceptibility to EGFR inhibition. Inhibition of autophagy sensitizes HNSCC cells to EGFR blockade. Importantly, we identify a novel signaling hub centering on the NLRX1 (nucleotide-binding, lots of leucine-rich repeats-containing protein member X1)-TUFM (Tu translation elongation factor mitochondrial) protein complex, promoting autophagic flux. Defects in the expression of either NLRX1 or TUFM result in compromised autophagy when treated with EGFR inhibitors. As a previously undefined autophagy-promoting mechanism, we found that TUFM serves as a novel anchorage site, recruiting Beclin-1 to mitochondria, promoting its polyubiquitination, and interfering with its interaction with Rubicon. This protein complex is also essential for endoplasmic reticulum stress signaling induction, possibly as an additional mechanism to promote autophagy. Utilizing tumor specimens from a novel neoadjuvant clinical trial, we show that increased expression of the autophagy adaptor protein, SQSTM1/p62, is associated with poor response to cetuximab therapy. These findings expand our understanding of the components involved in HNSCC autophagy machinery that responds to EGFR inhibitors, and suggest potential combinatorial approaches to enhance its therapeutic efficacy.	[Lei, Y.; Kansy, B. A.; Li, J.; Cong, L.; Liu, Y.; Trivedi, S.; Ferris, R. L.] Univ Pittsburgh, Dept Otolaryngol, Sch Med, Inst Canc, 5117 Ctr Ave,Suite 2-26, Pittsburgh, PA 15260 USA; [Wen, H.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Surg, Chapel Hill, NC 27599 USA; [Ting, J. P-Y] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Ouyang, H.] Univ Pittsburgh, Sch Dent Med, Dept Restorat Dent & Comprehens Care, Pittsburgh, PA USA; [Ferris, R. L.] Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA USA; [Lei, Y.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med,UM Comprehens Canc Ctr, Translat Oncol Program & Distributed Hlth Technol, Ann Arbor, MI 48109 USA; [Lei, Y.] Univ Michigan, UM Comprehens Canc Ctr, Dept Otolaryngol Head & Neck Surg, Sch Med,Translat Oncol Program & Distributed Hlth, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ferris, RL (corresponding author), Univ Pittsburgh, Dept Otolaryngol, Sch Med, Inst Canc, 5117 Ctr Ave,Suite 2-26, Pittsburgh, PA 15260 USA.	ferrisrl@upmc.edu	Wen, Haitao/AAJ-7621-2020	Li, Jing/0000-0002-9285-9423; Lei, Y Leo/0000-0002-9868-9824	NIH [K99 DE024173, T32 CA060397, R01 DE019727, P50 CA097190, R01 CA182418, R21 CA161150];  [P30 CA047904]; NATIONAL CANCER INSTITUTE [P30CA047904, P30CA016086, P50CA097190, R01CA182418, R21CA161150, T32CA060397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019727, K99DE024173, R00DE024173] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work is supported by NIH grants K99 DE024173 (YL), T32 CA060397 (RLF), R01 DE019727 (RLF), P50 CA097190 (RLF), R01 CA182418 (HO) and R21 CA161150 (HO). The UPCI core facilities are supported in part by P30 CA047904. We thank Dr Barton Branstetter for the interpretation of the radiographic findings of the enrolled patients.	Allen IC, 2011, IMMUNITY, V34, P854, DOI 10.1016/j.immuni.2011.03.026; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Argiris A, 2011, CLIN CANCER RES, V17, P5755, DOI 10.1158/1078-0432.CCR-11-0861; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Colosetti P, 2009, AUTOPHAGY, V5, P1092, DOI 10.4161/auto.5.8.9889; Davis BK, 2011, ANN REV IMMUNOL; Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509; Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Jie HB, 2015, CANCER RES, V75, P2200, DOI 10.1158/0008-5472.CAN-14-2788; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lei Y, 2013, AUTOPHAGY, V9, P432, DOI 10.4161/auto.23026; Lei Y, 2012, IMMUNITY, V36, P933, DOI 10.1016/j.immuni.2012.03.025; Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157; Liang XH, 2001, CANCER RES, V61, P3443; Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Lopez-Albaitero A, 2009, CANCER IMMUNOL IMMUN, V58, P1855, DOI 10.1007/s00262-009-0697-4; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Moore CB, 2008, NATURE, V451, P573, DOI 10.1038/nature06501; Moore CB, 2010, METHODS MOL BIOL, V629, P139, DOI 10.1007/978-1-60761-657-3_10; Reeves TD, 2011, OTOLARYNG HEAD NECK, V144, P676, DOI 10.1177/0194599811399559; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Sharafinski ME, 2010, HEAD NECK-J SCI SPEC, V32, P1412, DOI 10.1002/hed.21365; Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751; Srivastava RM, 2013, CLIN CANCER RES, V19, P1858, DOI 10.1158/1078-0432.CCR-12-2426; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006; Tattoli I, 2008, EMBO REP, V9, P293, DOI 10.1038/sj.embor.7401161; Ting JPY, 2008, NAT REV IMMUNOL, V8, P372, DOI 10.1038/nri2296; Ting JPY, 2010, SCIENCE, V327, P286, DOI 10.1126/science.1184004; Toepfer N, 2011, CANCER BIOL THER, V12, P691, DOI 10.4161/cbt.12.8.15978; Wei HJ, 2014, GENE DEV, V28, P1204, DOI 10.1101/gad.237354.113; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Xia MH, 2014, INT J ONCOL, V45, P2341, DOI 10.3892/ijo.2014.2669; Xia XJ, 2011, IMMUNITY, V34, P843, DOI 10.1016/j.immuni.2011.02.022; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Zang Y, 2012, AUTOPHAGY, V8, P1873, DOI 10.4161/auto.22185; Zang Y, 2012, CLIN CANCER RES, V18, P5639, DOI 10.1158/1078-0432.CCR-12-1213	46	42	46	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4698	4707		10.1038/onc.2016.11	http://dx.doi.org/10.1038/onc.2016.11			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876213	Green Submitted, Green Accepted			2022-12-28	WOS:000383324700003
J	Du, L; Chen, X; Cao, Y; Lu, L; Zhang, F; Bornstein, S; Li, Y; Owens, P; Malkoski, S; Said, S; Jin, F; Kulesz-Martin, M; Gross, N; Wang, XJ; Lu, SL				Du, L.; Chen, X.; Cao, Y.; Lu, L.; Zhang, F.; Bornstein, S.; Li, Y.; Owens, P.; Malkoski, S.; Said, S.; Jin, F.; Kulesz-Martin, M.; Gross, N.; Wang, X-J; Lu, S-L			Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF beta signaling	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; SQUAMOUS-CELL-CARCINOMA; AKT ACTIVATION; CHEMICAL CARCINOGENESIS; 3-KINASE PATHWAY; PI3K PATHWAY; MOUSE MODELS; CANCER; MUTATION; GROWTH	Head and neck squamous cell carcinoma (HNSCC) patients have a poor prognosis, with invasion and metastasis as major causes of mortality. The phosphatidylinositol 3-kinase (PI3K) pathway regulates a wide range of cellular processes crucial for tumorigenesis, and PIK3CA amplification and mutation are among the most common genetic alterations in human HNSCC. Compared with the well-documented roles of the PI3K pathway in cell growth and survival, the roles of the PI3K pathway in tumor invasion and metastasis have not been well delineated. We generated a PIK3CA genetically engineered mouse model (PIK3CA-GEMM) in which wild-type PIK3CA is overexpressed in head and neck epithelium. Although PIK3CA overexpression alone was not sufficient to initiate HNSCC formation, it significantly increased tumor susceptibility in an oral carcinogenesis mouse model. PIK3CA overexpression in mouse oral epithelium increased tumor invasiveness and metastasis by increasing epithelial-mesenchymal transition and by enriching a cancer stem cell phenotype in tumor epithelial cells. In addition to these epithelial alterations, we also observed marked inflammation in tumor stroma. AKT is a central signaling mediator of the PI3K pathway. However, molecular analysis suggested that progression of PIK3CA-driven HNSCC is facilitated by 3-phosphoinositide-dependent protein kinase (PDK1) and enhanced transforming growth factor beta (TGF beta) signaling rather than by AKT. Examination of human HNSCC clinical samples revealed that both PIK3CA and PDK1 protein levels correlated with tumor progression, highlighting the significance of this pathway. In summary, our results offer significant insight into how PIK3CA overexpression drives HNSCC invasion and metastasis, providing a rationale for targeting PI3K/PDK1 and TGF beta signaling in advanced HNSCC patients with PIK3CA amplification.	[Du, L.; Chen, X.; Cao, Y.; Lu, L.; Zhang, F.; Lu, S-L] Univ Colorado, Dept Otolaryngol, Anschutz Med Campus, 12700 E 19th Ave,Mail Stop 8606, Aurora, CO 80045 USA; [Du, L.] China Med Univ, Univ Hosp 4, Dept Otolaryngol, Shenyang, Peoples R China; [Cao, Y.; Jin, F.] China Med Univ, Univ Hosp 1, Dept Surg Oncol, Shenyang, Liaoning, Peoples R China; [Bornstein, S.; Li, Y.; Owens, P.; Gross, N.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA; [Malkoski, S.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA; [Said, S.; Wang, X-J; Lu, S-L] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO USA; [Kulesz-Martin, M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Lu, S-L] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; China Medical University; China Medical University; Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus	Lu, SL (corresponding author), Univ Colorado, Dept Otolaryngol, Anschutz Med Campus, 12700 E 19th Ave,Mail Stop 8606, Aurora, CO 80045 USA.	shi-long.lu@ucdenver.edu			National Institutes of Health [R01DE021788, R01DE015953]; University of Colorado Academic Enrichment Fund; American Cancer Society; University of Colorado Cancer Center; Cancer League of Colorado; NATIONAL CANCER INSTITUTE [P30CA046934, R21CA194662, K08CA131483, T32CA106195, R01CA192405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE021788] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Colorado Academic Enrichment Fund; American Cancer Society(American Cancer Society); University of Colorado Cancer Center; Cancer League of Colorado; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work is supported by National Institutes of Health grant R01DE021788 (to S-L Lu), R01DE015953 (to X-J Wang). University of Colorado Academic Enrichment Fund (to S-L Lu), American Cancer Society (to S-L Lu), University of Colorado Cancer Center (to S-L Lu), and Cancer League of Colorado (to S-L Lu). S-L Lu is an investigator of THANC foundation. We thank the Transgenic Core of Oregon Health and Science University for generating founders of the mouse model, and the University of Colorado Skin Disease Research Center Morphology Phenotyping Core (P30 AR057212) for assisting with histological work.	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Bhola NE, 2012, MOL CANCER THER, V11, P1236, DOI 10.1158/1535-7163.MCT-11-0936; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Curry NL, 2013, CANCER DISCOV, V3, P908, DOI 10.1158/2159-8290.CD-12-0507; Du L, 2012, J ONCOL, V2012, DOI 10.1155/2012/450179; Du Y, 2014, PHARMACOL THERAPEUT, V142, P88, DOI 10.1016/j.pharmthera.2013.11.007; Durban VM, 2013, J CLIN INVEST, V123, P5104, DOI 10.1172/JCI69619; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023; Estilo CL, 2003, CLIN CANCER RES, V9, P2300; Fan QW, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000014; Feng QT, 2010, MOL CELL BIOL, V30, P3711, DOI 10.1128/MCB.00420-10; Fenic I, 2007, ONCOL REP, V18, P253; Finlay DK, 2009, J EXP MED, V206, P2441, DOI 10.1084/jem.20090219; Garcia-Carracedo D, 2013, CLIN CANCER RES, V19, P6830, DOI 10.1158/1078-0432.CCR-13-0624; Han G, 2005, J CLIN INVEST, V115, P1714, DOI 10.1172/JCI24399; Hare LM, 2014, BIOCHEM J, V458, P251, DOI 10.1042/BJ20131412; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Iglesias-Bartolome R, 2013, CANCER DISCOV, V3, P722, DOI 10.1158/2159-8290.CD-13-0239; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kinross KM, 2012, J CLIN INVEST, V122, P553, DOI 10.1172/JCI59309; Klarenbeek S, 2013, MOL ONCOL, V7, P146, DOI 10.1016/j.molonc.2013.02.003; Kozaki KI, 2006, CANCER SCI, V97, P1351, DOI 10.1111/j.1349-7006.2006.00343.x; Lauring J, 2010, ONCOGENE, V29, P2337, DOI 10.1038/onc.2009.516; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Morri LGT, 2011, P NATL ACAD SCI USA, V108, P19024, DOI 10.1073/pnas.1111963108; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Raimondi C, 2012, J CELL SCI, V125, P3153, DOI 10.1242/jcs.100511; Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Signore M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.188; Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vitale-Cross L, 2009, CANCER PREV RES, V2, P419, DOI 10.1158/1940-6207.CAPR-09-0058; Vogt PK, 2009, CURR OPIN GENET DEV, V19, P12, DOI 10.1016/j.gde.2008.11.011; Wallin JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036402; Weber SM, 2011, INT J ONCOL, V39, P1193, DOI 10.3892/ijo.2011.1149; Woenckhaus J, 2002, J PATHOL, V198, P335, DOI 10.1002/path.1207; Wong KK, 2009, CANCER PREV RES, V2, P10, DOI 10.1158/1940-6207.CAPR-08-0234; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Zhang L, 2013, TRENDS BIOCHEM SCI, V38, P612, DOI 10.1016/j.tibs.2013.10.001	54	41	42	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4641	4652		10.1038/onc.2016.1	http://dx.doi.org/10.1038/onc.2016.1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26876212	Green Accepted			2022-12-28	WOS:000382336300010
J	Taylor, MA; Wappett, M; Delpuech, O; Brown, H; Chresta, CM				Taylor, M. A.; Wappett, M.; Delpuech, O.; Brown, H.; Chresta, C. M.			Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; CANCER; METHYLATION; GEFITINIB; SURVIVAL; PATHWAY; TARGET; PD-1; OVEREXPRESSION	Non-small-cell lung cancer is the leading cause of cancer death worldwide and is comprised of several histological subtypes, the two most common being adenocarcinoma (AC) and squamous cell carcinoma (SCC). Targeted therapies have successfully improved response rates in patients with AC tumors. However, the majority of SCC tumors lack specific targetable mutations, making development of new treatment paradigms for this disease challenging. In the present study, we used iterative non-negative matrix factorization, an unbiased clustering method, on mRNA expression data from the cancer genome atlas (TCGA) and a panel of 24 SCC cell lines to classify three disease segments within SCC. Analysis of gene set enrichment and drug sensitivity identified an immune-evasion subtype that showed increased sensitivity to nuclear factor-kappa B and mitogen-activated protein kinase (MAPK) inhibition, a replication-stress associated subtype that showed increased sensitivity to ataxia telangiectasia inhibition, and a neuroendocrine-associated subtype that showed increased sensitivity to phosphoinositide 3-kinase and fibroblast growth factor receptor inhibition. Additionally, each of these subtypes exhibited a unique microRNA expression profile. Focusing on the immuneevasion subtype, bioinformatic analysis of microRNA promoters revealed enrichment for binding sites for the MAPK-driven ETS1 transcription factor. Indeed, we found that knockdown of ETS1 led to upregulation of eight microRNAs and downregulation of miR-29b in the immune-evasion subtype. Mechanistically, we found that miR-29b targets the DNA-demethylating enzyme, TET1, for downregulation resulting in decreased 5-hmC epigenetic modifications. Moreover, inhibition of MAPK signaling by gefitinib led to decreased ETS1 and miR-29b expression with a corresponding increase in TET1 expression and increase in 5-hmC. Collectively, our work identifies three subtypes of lung SCC that differ in drug sensitivity and shows a novel mechanism of miR-29b regulation by MAPK-driven ETS1 expression which leads to downstream changes in TET1-mediated epigenetic modifications.	[Taylor, M. A.; Wappett, M.; Delpuech, O.; Chresta, C. M.] AstraZeneca, R&D Oncol iMed, Room 33F83-7 Mereside,Alderley Pk, Macclesfield SK10 4TG, Cheshire, England; [Brown, H.] AstraZeneca, Personalised Healthcare & Biomarkers, Alderley Pk, Macclesfield, Cheshire, England	AstraZeneca; AstraZeneca	Taylor, MA (corresponding author), AstraZeneca, R&D Oncol iMed, Room 33F83-7 Mereside,Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	molly.taylor@astrazeneca.com		Taylor, Molly/0000-0002-7885-8395	AstraZeneca Postdoc Programme	AstraZeneca Postdoc Programme(AstraZeneca)	We thank the Targets Biology group at AstraZeneca for critical comments of the manuscript, and Henry Brown and Hayley Campbell for their scientific expertise on fluidigm experiments. Funding was provided by the AstraZeneca Postdoc Programme.	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; D'Incecco A, 2015, BRIT J CANCER, V112, P95, DOI 10.1038/bjc.2014.555; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Del Prete A, 2011, BIOCHEM MEDICA, V21, P264; Devarajan K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000029; Dhillon T, 2010, J THORAC ONCOL, V5, P314, DOI 10.1097/JTO.0b013e3181ce6604; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Ficz G, 2014, GENOMICS, V104, P352, DOI 10.1016/j.ygeno.2014.08.017; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hayes DN, 2006, J CLIN ONCOL, V24, P5079, DOI 10.1200/JCO.2005.05.1748; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hsu SD, 2014, NUCLEIC ACIDS RES, V42, pD78, DOI 10.1093/nar/gkt1266; Huang Y, 2014, TRENDS GENET, V30, P464, DOI 10.1016/j.tig.2014.07.005; Jacobsen A, 2013, NAT STRUCT MOL BIOL, V20, P1325, DOI 10.1038/nsmb.2678; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jin CL, 2014, NUCLEIC ACIDS RES, V42, P6956, DOI 10.1093/nar/gku372; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Lan MS, 2009, FASEB J, V23, P2024, DOI 10.1096/fj.08-125971; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Li XY, 2013, ONCOL REP, V29, P1975, DOI 10.3892/or.2013.2298; Liao RG, 2012, LUNG CANCER MANAG, V1, P293, DOI 10.2217/LMT.12.40; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lin YC, 2015, CLIN CANCER RES, V21, P428, DOI 10.1158/1078-0432.CCR-14-1150; Liu AH, 2009, INT J CLIN EXP PATHO, V2, P519; Liu SY, 2005, CELL PHYSIOL BIOCHEM, V16, P207, DOI 10.1159/000089846; Lopez-Romero P, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-64; Lou YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097719; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marinov M, 2009, CLIN CANCER RES, V15, P1277, DOI 10.1158/1078-0432.CCR-08-2166; Nana-Sinkam SP, 2013, CHEST S, V143, pe30S; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramirez-Valle F, 2008, J CELL BIOL, V181, P293, DOI 10.1083/jcb.200710215; Sajadian SO, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0133-x; Senbabaoglu Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06207; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor Molly A, 2014, Mol Cell Ther, V2, P1, DOI 10.1186/2052-8426-2-30; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215; Weber A. M., 2014, PHARMACOL THERAPEUT, V149, P124; Wilkerson MD, 2010, CLIN CANCER RES, V16, P4864, DOI 10.1158/1078-0432.CCR-10-0199; Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066; Wojtalla A, 2013, CLIN CANCER RES, V19, P96, DOI 10.1158/1078-0432.CCR-12-1138; Wu BK, 2014, CELL REP, V9, P1827, DOI 10.1016/j.celrep.2014.10.063; Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	49	26	30	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4345	4357		10.1038/onc.2015.499	http://dx.doi.org/10.1038/onc.2015.499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26776158	hybrid, Green Published			2022-12-28	WOS:000382152100006
J	Ksionda, O; Melton, AA; Bache, J; Tenhagen, M; Bakker, J; Harvey, R; Winter, SS; Rubio, I; Roose, JP				Ksionda, O.; Melton, A. A.; Bache, J.; Tenhagen, M.; Bakker, J.; Harvey, R.; Winter, S. S.; Rubio, I.; Roose, J. P.			RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEINS; POSITIVE SELECTION; NEUROFIBROMIN 1; P120 RASGAP; LEUKEMIA; PROLIFERATION; STIMULATION; PROCEEDS; REQUIRES; GROWTH	Ras GTPases are activated by RasGEFs and inactivated by RasGAPs, which stimulate the hydrolysis of RasGTP to inactive RasGDP. GTPase-impairing somatic mutations in RAS genes, such as KRAS(G12D), are among the most common oncogenic events in metastatic cancer. A different type of cancer Ras signal, driven by overexpression of the RasGEF RasGRP1 (Ras guanine nucleotide-releasing protein 1), was recently implicated in pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients and murine models, in which RasGRP1 T-ALLs expand in response to treatment with interleukins (ILs) 2, 7 and 9. Here, we demonstrate that IL-2/7/9 stimulation activates Erk and Akt pathways downstream of Ras in RasGRP1 T-ALL but not in normal thymocytes. In normal lymphocytes, RasGRP1 is recruited to the membrane by diacylglycerol (DAG) in a phospholipase C-gamma (PLC gamma)-dependent manner. Surprisingly, we find that leukemic RasGRP1-triggered Ras-Akt signals do not depend on acute activation of PLC gamma to generate DAG but rely on baseline DAG levels instead. In agreement, using three distinct assays that measure different aspects of the RasGTP/GDP cycle, we established that overexpression of RasGRP1 in T-ALLs results in a constitutively high GTP-loading rate of Ras, which is constantly counterbalanced by hydrolysis of RasGTP. KRAS(G12D) T-ALLs do not show constitutive GTP loading of Ras. Thus, we reveal an entirely novel type of leukemogenic Ras signals that is based on a RasGRP1-driven increased in flux through the RasGTP/GDP cycle, which is mechanistically very different from KRAS(G12D) signals. Our studies highlight the dynamic balance between RasGEF and RasGAP in these T-ALLs and put forth a new model in which IL-2/7/9 decrease RasGAP activity.	[Ksionda, O.; Melton, A. A.; Tenhagen, M.; Bakker, J.; Roose, J. P.] Roose Univ Calif, Dept Anat, 513 Parnassus,HSW 1326, San Francisco, CA 94143 USA; [Melton, A. A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Bache, J.; Rubio, I.] Univ Jena, Univ Hosp, Ctr Mol Biomed, Inst Mol Cell Biol, Jena, Germany; [Harvey, R.; Winter, S. S.] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA; [Rubio, I.] Jena Univ Hosp, CSCC, Integrated Res & Treatment Ctr, Jena, Germany	University of California System; University of California San Francisco; Friedrich Schiller University of Jena; University of New Mexico; Friedrich Schiller University of Jena	Ksionda, O; Roose, JP (corresponding author), Roose Univ Calif, Dept Anat, 513 Parnassus,HSW 1326, San Francisco, CA 94143 USA.	olga.ksionda@ucsf.edu; jeroen.roose@ucsf.edu		Roose, Jeroen/0000-0003-4746-2811	NIH-NCI Physical Science Oncology Center Grant [U54CA143874]; NIH-NIAID Grant (P01 Program) [AI091580]; Gabrielle's Angel Foundation; NIH-NCI Grant [R01-CA187318]; NIH T32 training grant [5T32CA128583-05]; KWF (Dutch Cancer Society); NCI [U10 CA98543, CA180886, U10 CA98413, CA180899, U24 CA114766]; NATIONAL CANCER INSTITUTE [T32CA128583, P30CA118100, U10CA180899, U54CA143874, R01CA187318] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000041, UL1TR001449] Funding Source: NIH RePORTER	NIH-NCI Physical Science Oncology Center Grant; NIH-NIAID Grant (P01 Program); Gabrielle's Angel Foundation; NIH-NCI Grant; NIH T32 training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KWF (Dutch Cancer Society)(KWF Kankerbestrijding); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank the Roose lab members for helpful comments and Anna Hupalowska for the graphics in Figure 4. Our research was supported by an NIH-NCI Physical Science Oncology Center Grant U54CA143874, an NIH-NIAID Grant (P01 Program Project-AI091580), a Gabrielle's Angel Foundation Grant and NIH-NCI Grant (R01-CA187318) (all to JPR), as well as by an NIH T32 training grant (5T32CA128583-05) and the KWF (Dutch Cancer Society) (MT and JB). This work was also supported by grants from the NCI to the Children's Oncology Group including U10 CA98543 and CA180886 (COG Chair's Grant), U10 CA98413 and CA180899 (COG Statistical Center) and U24 CA114766 (COG Specimen Banking).	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Balgobind BV, 2008, BLOOD, V111, P4322, DOI 10.1182/blood-2007-06-095075; Barata JT, 2004, HAEMATOLOGICA, V89, P1459; Barata JT, 2004, J EXP MED, V200, P659, DOI 10.1084/jem.20040789; Cichowski K, 2003, GENE DEV, V17, P449, DOI 10.1101/gad.1054703; Daley SR, 2013, ELIFE, V2, DOI 10.7554/eLife.01020; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward Julian, 2003, Biochem J, V376, pe9, DOI 10.1042/BJ20031745; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233; Gorentla BK, 2011, BLOOD, V117, P4022, DOI 10.1182/blood-2010-08-300731; Hartzell C, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003848; Hennig A, 2015, BIOL CHEM, V396, P831, DOI 10.1515/hsz-2014-0257; Iwig JS, 2013, ELIFE, V2, DOI 10.7554/eLife.00813; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; King PD, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003669; Klinger MB, 2005, ONCOGENE, V24, P2695, DOI 10.1038/sj.onc.1208334; Krutzik PO, 2006, NAT METHODS, V3, P361, DOI 10.1038/NMETH872; Ksionda Olga, 2013, Front Biol (Beijing), V8, P508; Lapinski PE, 2011, J IMMUNOL, V187, P151, DOI 10.4049/jimmunol.1100178; Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773; Lubeck BA, 2015, J IMMUNOL, V195, P31, DOI 10.4049/jimmunol.1402639; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Neumann M, 2013, BLOOD, V121, P4749, DOI 10.1182/blood-2012-11-465138; Oki T, 2011, LEUKEMIA, V26, P1038; Oliver JA, 2013, MOL IMMUNOL, V55, P292, DOI 10.1016/j.molimm.2013.03.005; Roose JP, 2005, MOL CELL BIOL, V25, P4426, DOI 10.1128/MCB.25.11.4426-4441.2005; Rubio I, 2000, CURR BIOL, V10, P1225, DOI 10.1016/S0960-9822(00)00731-4; Rubio I, 2003, BIOCHEM J, V376, P571, DOI 10.1042/BJ20031410; Rubio I, 2006, BIOCHEM J, V398, P243, DOI 10.1042/BJ20060160; Rubio I, 2010, J IMMUNOL, V185, P3536, DOI 10.4049/jimmunol.1000334; Silva A, 2011, CANCER RES, V71, P4780, DOI 10.1158/0008-5472.CAN-10-3606; Stites EC, 2015, CELL REP, V10, P307, DOI 10.1016/j.celrep.2014.12.035; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	38	27	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3658	3668		10.1038/onc.2015.431	http://dx.doi.org/10.1038/onc.2015.431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26549032	Green Accepted			2022-12-28	WOS:000379622800005
J	Adrados, I; Larrasa-Alonso, J; Galarreta, A; Lopez-Antona, I; Menendez, C; Abad, M; Gil, J; Moreno-Bueno, G; Palmero, I				Adrados, I.; Larrasa-Alonso, J.; Galarreta, A.; Lopez-Antona, I.; Menendez, C.; Abad, M.; Gil, J.; Moreno-Bueno, G.; Palmero, I.			The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REGULATION; REPRESSIVE COMPLEXES; EPIGENETIC CONTROL; STEM-CELLS; 6 FAMILY; EXPRESSION; CONTRIBUTES; P53	Cellular senescence is an antiproliferative response with essential functions in tumor suppression and tissue homeostasis. Here we show that SIX1, a member of the SIX family of homeobox transcriptional factors, is a novel repressor of senescence. Our data show that SIX1 is specifically downregulated in fibroblasts upon oncogenic stress and other pro-senescence stimuli, as well as in senescent skin premalignant lesions. Silencing of SIX1 in human fibroblasts suffices to trigger senescence, which is mediated by p16INK4A and lacks a canonical senescence-associated secretory phenotype. Interestingly, SIX1-associated senescence is further characterized by the expression of a set of development and differentiation-related genes that significantly overlap with genes associated with SIX1 in organogenesis or human tumors, and show coincident regulation in oncogene-induced senescence. Mechanistically, we show that gene regulation by SIX1 during senescence is mediated, at least in part, by cooperation with Polycomb repressive complexes. In summary, our results identify SIX1, a key development regulator altered in human tumors, as a critical repressor of cellular senescence, providing a novel connection between senescence, differentiation and tumorigenesis.	[Adrados, I.; Larrasa-Alonso, J.; Galarreta, A.; Lopez-Antona, I.; Menendez, C.; Abad, M.; Moreno-Bueno, G.; Palmero, I.] UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain; [Gil, J.] Imperial Coll London, MRC Clin Sci Ctr, Cell Proliferat Grp, Hammersmith Campus, London, England; [Moreno-Bueno, G.] UAM, IdiPAZ Inst Invest Sanitaria La Paz, Dept Bioquim, Madrid, Spain; [Moreno-Bueno, G.] Fdn MD Anderson Int, Madrid, Spain; [Adrados, I.] Scripps Res Inst, 130 Scripps Way, Jupiter, FL 33458 USA; [Larrasa-Alonso, J.] CNIC, Madrid 28029, Spain; [Menendez, C.; Abad, M.] CNIO, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Imperial College London; Autonomous University of Madrid; University of Texas System; UTMD Anderson Cancer Center; Scripps Research Institute; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Centro Nacional de Investigaciones Oncologicas (CNIO)	Palmero, I (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	ipalmero@iib.uam.es	Abad, Maria/AAI-2366-2019; Adrados Moran, Isabel/B-2411-2018; Moreno-Bueno, Gema/K-9354-2016; Gil, Jesus/C-7739-2012; Vivancos, Ana/AAG-8331-2019	Abad, Maria/0000-0002-1462-2498; Moreno-Bueno, Gema/0000-0002-5030-6687; Gil, Jesus/0000-0002-4303-6260; Menendez, Maria del Camino/0000-0002-3535-2490; Vivancos, Ana/0000-0003-2888-6512; Adrados, Isabel/0000-0003-3337-6883; Galarreta, Antonio/0000-0003-2358-7927; Lopez-Antona, Irene/0000-0002-5393-6924	Spanish Government [SAF2012-32117]; Instituto de Salud Carlos III [PI13/00132, RETIC-RD12/0036/0007]; Regional Government of Madrid [S2010/BMD-2303]; Spanish Government FPI program; MRC [MC_U120085810] Funding Source: UKRI; Medical Research Council [MC_U120085810] Funding Source: researchfish	Spanish Government(Spanish GovernmentEuropean Commission); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Regional Government of Madrid; Spanish Government FPI program; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Manuel Serrano, Daniel Peeper and Rene Bernards for cells and reagents, and Masashi Narita for reagents and sharing unpublished data. This work was supported by grants from the Spanish Government (SAF2012-32117) to IP, Instituto de Salud Carlos III (PI13/00132 and RETIC-RD12/0036/0007) and Regional Government of Madrid (S2010/BMD-2303) to GM-B. IA is the recipient of a fellowship from the Spanish Government FPI program.	Abad M, 2011, AGING CELL, V10, P158, DOI 10.1111/j.1474-9726.2010.00651.x; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Auvergne RM, 2013, CELL REP, V3, P2127, DOI 10.1016/j.celrep.2013.04.035; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Buckingham M, 2014, DEV CELL, V28, P225, DOI 10.1016/j.devcel.2013.12.020; Chandra T, 2012, MOL CELL, V47, P203, DOI 10.1016/j.molcel.2012.06.010; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3; Coletta RD, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-4; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Delgado-Olguin P, 2012, NAT GENET, V44, P343, DOI 10.1038/ng.1068; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eid JE, 2015, SEMIN CANCER BIOL, V32, P18, DOI 10.1016/j.semcancer.2014.05.005; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gomez-Cabello D, 2013, AGING CELL, V12, P923, DOI 10.1111/acel.12117; Gomez-Cabello D, 2010, CANCER RES, V70, P1866, DOI 10.1158/0008-5472.CAN-09-2088; Imai Y, 2014, CELL REP, V7, P194, DOI 10.1016/j.celrep.2014.03.006; Irelan JT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005067; Iwanaga R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3219; Kirschner K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005053; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kumar JP, 2009, CELL MOL LIFE SCI, V66, P565, DOI 10.1007/s00018-008-8335-4; Laclef C, 2003, MECH DEVELOP, V120, P669, DOI 10.1016/S0925-4773(03)00065-0; Lanigan F, 2011, ONCOGENE, V30, P2901, DOI 10.1038/onc.2011.34; Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006; Le Grand F, 2012, J CELL BIOL, V198, P815, DOI 10.1083/jcb.201201050; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liu Y, 2013, ADV MATH PHYS, V2013, DOI 10.1155/2013/787891; Martin N, 2013, EMBO J, V32, P982, DOI 10.1038/emboj.2013.37; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Menendez C, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12241; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Orten DJ, 2008, HUM MUTAT, V29, P537, DOI 10.1002/humu.20691; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Patrick AN, 2013, NAT STRUCT MOL BIOL, V20, P447, DOI 10.1038/nsmb.2505; Pemberton H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r23; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Sehic D, 2012, PEDIATR BLOOD CANCER, V59, P62, DOI 10.1002/pbc.24025; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sousa-Victor P, 2014, NATURE, V506, P316, DOI 10.1038/nature13013; Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041; Tadjuidje E, 2013, CELL MOL LIFE SCI, V70, P1897, DOI 10.1007/s00018-012-1144-9; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Wong EYM, 2013, HEARING RES, V297, P13, DOI 10.1016/j.heares.2012.09.009; Xia Y, 2013, NAT CELL BIOL, V15, P1507, DOI 10.1038/ncb2872; Xu PX, 2013, PEDIATR NEPHROL, V28, P843, DOI 10.1007/s00467-012-2246-1; Xu PX, 2003, DEVELOPMENT, V130, P3085, DOI 10.1242/dev.00536; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360	65	10	10	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3485	3494		10.1038/onc.2015.408	http://dx.doi.org/10.1038/onc.2015.408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26500063	Green Accepted, Green Submitted			2022-12-28	WOS:000379621500001
J	Berscheminski, J; Brun, J; Speiseder, T; Wimmer, P; Ip, WH; Terzic, M; Dobner, T; Schreiner, S				Berscheminski, J.; Brun, J.; Speiseder, T.; Wimmer, P.; Ip, W. H.; Terzic, M.; Dobner, T.; Schreiner, S.			Sp100A is a tumor suppressor that activates p53-dependent transcription and counteracts E1A/E1B-55K-mediated transformation	ONCOGENE			English	Article							EARLY REGION 4; CELL-TRANSFORMATION; 55-KILODALTON PROTEIN; SUMO-1 MODIFICATION; NUCLEAR EXPORT; REPRESSES P53; ADENOVIRUS; ONCOPROTEIN; LOCALIZATION; EXPRESSION	Human adenoviruses (HAdV) are used as a model system to investigate tumorigenic processes in mammalian cells where the viral oncoproteins E1A and E1B-55K are absolutely required for oncogenic transformation, because they simultaneously accelerate cell cycle progression and inhibit tumor suppressor proteins such as p53, although the underlying mechanism is still not understood in detail. In our present study, we provide evidence that E1B-55K binding to the PML-NB component Sp100A apparently has an essential role in regulating adenovirus-mediated transformation processes. Specifically, when this E1B-55K/Sp100A complex recruits p53, Sp100A-induced activation of p53 transcriptional activity is effectively abolished. Hence, Sp100A exhibits tumor-suppressive activity, not only by stabilizing p53 transactivation but also by depressing E1A/E1B-55K-mediated transformation. E1B-55K counteracts this suppressive activity, inducing Sp100A SUMOylation and sequestering the modified cellular factor into the insoluble matrix of the nucleus or into cytoplasmic inclusions. These observations provide novel insights into how E1B-55K modulates cellular determinants to maintain growth-promoting activity during oncogenic processes and lytic infection.	[Berscheminski, J.; Brun, J.; Speiseder, T.; Wimmer, P.; Ip, W. H.; Dobner, T.; Schreiner, S.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Viral Transformat, D-20251 Hamburg, Germany; [Terzic, M.; Schreiner, S.] Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, D-80290 Munich, Germany	Heinrich Pette Institute; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Dobner, T (corresponding author), Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Viral Transformat, D-20251 Hamburg, Germany.; Schreiner, S (corresponding author), Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, D-80290 Munich, Germany.	thomas.dobner@hpi.uni-hamburg.de; sabrina.schreiner@tum.de		Brun, Juliane/0000-0002-0964-3681; Schreiner, Sabrina/0000-0002-5744-7159; Ip, Wing Hang/0000-0002-5367-1401	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit (BMG); Deutsche Forschungsgemeinschaft (DFG) [DO 343/7-1]; Drager Stiftung; DFG; Wilhelm Sander-Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Krebshilfe e. V.; B. Braun Stiftung; Fonds der Chemischen Industrie	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit (BMG); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Drager Stiftung; DFG(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Krebshilfe e. V.(Deutsche Krebshilfe); B. Braun Stiftung; Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission)	We thank Ron Hay, Ellis Jaffray, Roger Everett, Hans Will, Thomas Sternsdorf and Nicole Fischer for providing reagents and scientific discussion. The Heinrich Pette Institute, Leibniz Institute for Experimental Virology is supported by the Freie und Hansestadt Hamburg and the Bundesministerium fur Gesundheit (BMG). JB was supported by grant from the Deutsche Forschungsgemeinschaft (DFG) to TD (DO 343/7-1). MT was supported by the Drager Stiftung. TD is supported by the DFG and the Wilhelm Sander-Stiftung. SS was supported by the Else Kroner-Fresenius-Stiftung and the Deutsche Krebshilfe e. V. Part of this work was supported by the B. Braun Stiftung and the Fonds der Chemischen Industrie.	Adler M, 2011, J GEN VIROL, V92, P1532, DOI 10.1099/vir.0.030981-0; Berscheminski J, 2014, J VIROL, V88, P6076, DOI 10.1128/JVI.00469-14; Berscheminski J, 2013, J VIROL, V87, P965, DOI 10.1128/JVI.02023-12; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; Gunther T, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004274; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Guldner HH, 1999, J CELL SCI, V112, P733; Hartl B, 2008, ONCOGENE, V27, P3673, DOI 10.1038/sj.onc.1211039; Kim YE, 2011, J VIROL, V85, P11928, DOI 10.1128/JVI.00758-11; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; Li W, 2010, MED SCI MONITOR, V16, pBR174; Ling PD, 2005, EMBO J, V24, P3565, DOI 10.1038/sj.emboj.7600820; Logan J, 1984, CANCER CELL, V2, P527; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; Mitsudomi T, 1992, Nihon Geka Gakkai Zasshi, V93, P944; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Muller D, 2012, J VIROL, V86, P8296, DOI 10.1128/JVI.00222-12; Muller S, 2008, CELL CYCLE, V7, P754, DOI 10.4161/cc.7.6.5495; Negorev D, 2001, J CELL SCI, V114, P59; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 2006, ADENOVIRUS METHODS P, P187; Newhart A, 2013, MOL BIOL CELL, V24, P1454, DOI 10.1091/mbc.E12-09-0669; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Pennella MA, 2010, J VIROL, V84, P12210, DOI 10.1128/JVI.01442-10; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Schreiner S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002549; Schreiner S, 2011, J VIROL, V85, P8752, DOI 10.1128/JVI.00440-11; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Stepp WH, 2013, MBIO, V4, DOI 10.1128/mBio.00845-13; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Tatham MH, 2009, NAT PROTOC, V4, P1363, DOI 10.1038/nprot.2009.128; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Wimmer P, 2013, ONCOGENE, V32, P1626, DOI 10.1038/onc.2012.187; Wimmer P, 2010, ONCOGENE, V29, P5511, DOI 10.1038/onc.2010.284; Wimmer P, 2015, ONCOGENE, P53; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	46	14	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3178	3189		10.1038/onc.2015.378	http://dx.doi.org/10.1038/onc.2015.378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26477309				2022-12-28	WOS:000378092700009
J	Guo, ST; Chi, MN; Yang, RH; Guo, XY; Zan, LK; Wang, CY; Xi, YF; Jin, L; Croft, A; Tseng, HY; Yan, XG; Farrelly, M; Wang, FH; Lai, F; Wang, JF; Li, YP; Ackland, S; Scott, R; Agoulnik, IU; Hondermarck, H; Thorne, RF; Liu, T; Zhang, XD; Jiang, CC				Guo, S. T.; Chi, M. N.; Yang, R. H.; Guo, X. Y.; Zan, L. K.; Wang, C. Y.; Xi, Y. F.; Jin, L.; Croft, A.; Tseng, H-Y; Yan, X. G.; Farrelly, M.; Wang, F. H.; Lai, F.; Wang, J. F.; Li, Y. P.; Ackland, S.; Scott, R.; Agoulnik, I. U.; Hondermarck, H.; Thorne, R. F.; Liu, T.; Zhang, X. D.; Jiang, C. C.			INPP4B is an oncogenic regulator in human colon cancer	ONCOGENE			English	Article							LASER CAPTURE MICRODISSECTION; TUMOR-SUPPRESSOR; HUMAN-MELANOMA; BREAST-CANCER; PHOSPHORYLATION; PROTEIN; ACTIVATION; EXPRESSION; PATHWAY; ETS-1	Inositol polyphosphate 4-phosphatase type II (INPP4B) negatively regulates phosphatidylinositol 3-kinase signaling and is a tumor suppressor in some types of cancers. However, we have found that it is frequently upregulated in human colon cancer cells. Here we show that silencing of INPP4B blocks activation of Akt and serum-and glucocorticoid-regulated kinase 3 (SGK3), inhibits colon cancer cell proliferation and retards colon cancer xenograft growth. Conversely, overexpression of INPP4B increases proliferation and triggers anchorage-independent growth of normal colon epithelial cells. Moreover, we demonstrate that the effect of INPP4B on Akt and SGK3 is associated with inactivation of phosphate and tensin homolog through its protein phosphatase activity and that the increase in INPP4B is due to Ets-1-mediated transcriptional upregulation in colon cancer cells. Collectively, these results suggest that INPP4B may function as an oncogenic driver in colon cancer, with potential implications for targeting INPP4B as a novel approach to treat this disease.	[Guo, S. T.; Yang, R. H.; Guo, X. Y.; Wang, C. Y.; Wang, F. H.] Shanxi Med Univ, Affiliated Hosp, Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan, Shanxi, Peoples R China; [Chi, M. N.; Jin, L.; Yan, X. G.; Lai, F.; Jiang, C. C.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2308, Australia; [Zan, L. K.; Xi, Y. F.; Wang, J. F.] Shanxi Canc Hosp & Inst, Dept Pathol, Taiyuan, Shanxi, Peoples R China; [Croft, A.; Ackland, S.] Calvary Mater Newcastle Hosp, Dept Med Oncol, Newcastle, NSW, Australia; [Tseng, H-Y; Farrelly, M.; Scott, R.; Hondermarck, H.; Zhang, X. D.] Univ Newcastle, Sch Biomed Sci & Pharm, Newcastle, NSW 2300, Australia; [Li, Y. P.] Shanxi Canc Hosp & Inst, Dept Colorectal Surg, Taiyuan, Shanxi, Peoples R China; [Agoulnik, I. U.] Herbert Wertheim Coll Med, Dept Cellular Biol & Pharmacol, Miami, FL USA; [Thorne, R. F.] Univ Newcastle, Sch Environm & Life Sci, Callaghan, NSW 2308, Australia; [Liu, T.] Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia	Shanxi Medical University; University of Newcastle; Calvary Mater Newcastle Hospital; University of Newcastle; University of Newcastle; Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney	Zhang, XD; Jiang, CC (corresponding author), Univ Newcastle, Prior Res Ctr Canc Res, Sch Med & Publ Hlth, LS3-49,Life Sci Bldg, Callaghan, NSW 2308, Australia.	Xu.Zhang@newcastle.edu.au; Chenchen.Jiang@newcastle.edu.au	Jin, Lei/K-2315-2019; Jin, Lei/J-1896-2019; Tseng, Cindy Hsin-Yi/AAB-8958-2022; Zhang, xiaoyu/GXA-3206-2022; Liu, Tao/A-3922-2015; zhang, xu/GYE-3558-2022; zhang, xian/GYA-0290-2022; Agoulnik, Irina/AAD-4687-2020; zhang, xu/GRX-9733-2022; Ackland, Stephen P./G-7460-2013; Scott, Rodney/B-2827-2013	Jin, Lei/0000-0001-7187-9671; Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; Agoulnik, Irina/0000-0003-4889-0324; Ackland, Stephen P./0000-0001-5303-0017; Liu, Tao/0000-0001-6244-7316; Zhang, Xu Dong/0000-0001-9457-8003; Scott, Rodney/0000-0001-7724-3404	National Health and Medical Research Council (NHMRC) [APP1026458]; Cancer Council NSW, Australia [RG13-04, RG 13-15]; Shanxi Scholarship Council [2013-133]; Shanxi Natural Science Foundation, China [2013011043-3]; National Natural Science Foundation of China [81472837]; NATIONAL CANCER INSTITUTE [R15CA179287] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW, Australia(Cancer Council New South Wales); Shanxi Scholarship Council; Shanxi Natural Science Foundation, China(Natural Science Foundation of Shanxi Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Health and Medical Research Council (NHMRC) (APP1026458), the Cancer Council NSW (RG13-04 and RG 13-15), Australia, the Shanxi Scholarship Council (2013-133), Shanxi Natural Science Foundation (2013011043-3), China and National Natural Science Foundation of China (81472837). We thank Professor James R Woodgett (Samuel Lunenfeld Research Institute, Canada) for providing the Flag-myristoylated SGK3-CMV construct.	Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616; Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488; Colakoglu T, 2008, AM J SURG, V195, P719, DOI 10.1016/j.amjsurg.2007.05.061; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dzneladze I, 2015, LEUKEMIA, V29, P1485, DOI 10.1038/leu.2015.51; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Ferte C, 2010, NAT REV CLIN ONCOL, V7, P367, DOI 10.1038/nrclinonc.2010.84; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214; Hodgson MC, 2011, CANCER RES, V71, P572, DOI 10.1158/0008-5472.CAN-10-2314; Hopkins BD, 2014, TRENDS BIOCHEM SCI, V39, P183, DOI 10.1016/j.tibs.2014.02.006; Ito Y, 2002, ANTICANCER RES, V22, P1581; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Kisseleva MV, 2002, J BIOL CHEM, V277, P6266, DOI 10.1074/jbc.M105969200; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lopez SM, 2013, BIOCHEM BIOPH RES CO, V440, P277, DOI 10.1016/j.bbrc.2013.09.077; Ma K, 2008, CELL SIGNAL, V20, P684, DOI 10.1016/j.cellsig.2007.12.004; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Moniz Larissa S, 2013, Biochem J, V452, pe11, DOI 10.1042/BJ20130617; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Nystrom A, 2009, BLOOD, V114, P4897, DOI 10.1182/blood-2009-02-207134; Ooms LM, 2006, MOL BIOL CELL, V17, P607, DOI 10.1091/mbc.E05-05-0469; Papakonstanti EA, 2008, J CELL SCI, V121, P4124, DOI 10.1242/jcs.032763; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Rijal S, 2015, BLOOD, V125, P2815, DOI 10.1182/blood-2014-09-603555; Satoh-Nagasawa N, 2006, NATURE, V441, P227, DOI 10.1038/nature04725; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Scortegagna M, 2015, CANCER RES, V75, P1399, DOI 10.1158/0008-5472.CAN-14-2785; Struglics A, 2000, FEBS LETT, V475, P213, DOI 10.1016/S0014-5793(00)01680-X; Switzer CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3319; Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489	38	38	43	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3049	3061		10.1038/onc.2015.361	http://dx.doi.org/10.1038/onc.2015.361			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26411369	hybrid, Green Published			2022-12-28	WOS:000377474500010
J	Schneider, MR; Yarden, Y				Schneider, M. R.; Yarden, Y.			The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors	ONCOGENE			English	Review							EPIDERMAL-GROWTH-FACTOR; FACTOR-RECEPTOR MUTATIONS; KINASE DOMAIN MUTATIONS; BREAST-CANCER; EGF RECEPTOR; LUNG-CANCER; MICE LACKING; QUANTITATIVE-ANALYSIS; HUMAN GLIOBLASTOMAS; CARDIAC DEVELOPMENT	The epidermal growth factor receptor (EGFR) and a coreceptor denoted HER2/ERBB2 are frequently overexpressed or mutated in solid tumors, such as carcinomas and gliomas. In line with driver roles, cancer drugs intercepting EGFR or HER2 currently outnumber therapies targeting other hubs of signal transduction. To explain the roles for EGFR and HER2 as prime drivers and targets, we take lessons from invertebrates and refer to homeostatic regulation of several mammalian tissues. The model we infer ascribes to the EGFR-HER2 module pivotal functions in rapid clonal expansion of progenitors called transient amplifying cells (TACs). Accordingly, TACs of tumors suffer from replication stress, and hence accumulate mutations. In addition, several lines of evidence propose that in response to EGF and related mitogens, TACs might undergo dedifferentiation into tissue stem cells, which might enable entry of oncogenic mutations into the stem cell compartment. According to this view, antibodies or kinase inhibitors targeting EGFR-HER2 effectively retard some solid tumors because they arrest mutation- enriched TACs and possibly inhibit their dedifferentiation. Deeper understanding of the EGFR-HER2 module and relations between cancer stem cells and TACs will enhance our ability to control a broad spectrum of human malignancies.	[Schneider, M. R.] Ludwig Maximilians Univ Munchen, Gene Ctr, Inst Mol Anim Breeding & Biotechnol, Feodor Lynen Str 25, D-81377 Munich, Germany; [Yarden, Y.] Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel	University of Munich; Weizmann Institute of Science	Schneider, MR (corresponding author), Ludwig Maximilians Univ Munchen, Gene Ctr, Inst Mol Anim Breeding & Biotechnol, Feodor Lynen Str 25, D-81377 Munich, Germany.; Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel.	Marlon.schneider@lmu.de; Yosef.yarden@weizmann.ac.il		Schneider, Marlon/0000-0002-9570-3491	German Research Foundation (DFG); Else-Kroner-Fresenius Stiftung; Fritz Thyssen Foundation; Wilhelm Sander-Stiftung; European Research Council; Dr Miriam and Sheldon G Adelson Medical Research Foundation; family of Mr Marvin Tanner	German Research Foundation (DFG)(German Research Foundation (DFG)); Else-Kroner-Fresenius Stiftung; Fritz Thyssen Foundation; Wilhelm Sander-Stiftung; European Research Council(European Research Council (ERC)European Commission); Dr Miriam and Sheldon G Adelson Medical Research Foundation; family of Mr Marvin Tanner	We thank Lilach Gilboa and Maik Dahlhoff for insightful discussions. MRS is supported by the German Research Foundation (DFG), the Else-Kroner-Fresenius Stiftung, the Fritz Thyssen Foundation and the Wilhelm Sander-Stiftung. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. Currently, he is Research Professor of the Israel Cancer Research Fund. We would like to acknowledge financial support from the European Research Council, the Dr Miriam and Sheldon G Adelson Medical Research Foundation and the family of Mr Marvin Tanner.	Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Aguirre A, 2010, NATURE, V467, P323, DOI 10.1038/nature09347; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bashir O, 2003, CLIN SCI, V105, P323, DOI 10.1042/CS20030023; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Berasain C, 2014, SEMIN CELL DEV BIOL, V28, P31, DOI 10.1016/j.semcdb.2014.01.005; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Chaffer CL, 2015, CANCER DISCOV, V5, P22, DOI 10.1158/2159-8290.CD-14-0788; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Clevers H, 2013, CELL, V152, P1198, DOI 10.1016/j.cell.2013.02.030; D'Uva G, 2015, NAT CELL BIOL, V17, P627, DOI 10.1038/ncb3149; Dahlhoff M, 2008, FEBS LETT, V582, P2911, DOI 10.1016/j.febslet.2008.07.026; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Doan PL, 2013, NAT MED, V19, P295, DOI 10.1038/nm.3070; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Doupe DP, 2013, BIOESSAYS, V35, P443, DOI 10.1002/bies.201200166; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Erickson SL, 1997, DEVELOPMENT, V124, P4999; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Frederick L, 2000, CANCER RES, V60, P1383; Fuentealba LC, 2012, CELL STEM CELL, V10, P698, DOI 10.1016/j.stem.2012.05.012; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galvez-Contreras AY, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00258; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Genetos DC, 2010, CELL TISSUE RES, V340, P81, DOI 10.1007/s00441-010-0929-0; Goh LK, 2010, J CELL BIOL, V189, P871, DOI 10.1083/jcb.201001008; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gomez-Gaviro MV, 2012, P NATL ACAD SCI USA, V109, P1317, DOI 10.1073/pnas.1016199109; Gonzalez-Perez O, 2011, BRAIN RES REV, V67, P147, DOI 10.1016/j.brainresrev.2011.01.001; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Grompe M, 2014, CELL STEM CELL, V15, P257, DOI 10.1016/j.stem.2014.08.004; Gupta Bhagwati P, 2012, WormBook, P1, DOI 10.1895/wormbook.1.152.1; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hechtman JF, 2012, ARCH PATHOL LAB MED, V136, P691, DOI 10.5858/arpa.2011-0168-RS; Heinmoller P, 2003, CLIN CANCER RES, V9, P5238; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hsu D, 2010, LAB INVEST, V90, P1295, DOI 10.1038/labinvest.2010.100; Hsu YC, 2014, NAT MED, V20, P847, DOI 10.1038/nm.3643; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Iyer R, 2004, RADIOTHER ONCOL, V72, P283, DOI 10.1016/j.radonc.2004.07.012; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Jeong EG, 2006, INT J CANCER, V119, P2986, DOI 10.1002/ijc.22257; Jeuken J, 2009, BRAIN PATHOL, V19, P661, DOI 10.1111/j.1750-3639.2009.00320.x; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Kalman B, 2013, NEUROMOL MED, V15, P420, DOI 10.1007/s12017-013-8229-y; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kitade M, 2013, GENE DEV, V27, P1706, DOI 10.1101/gad.214601.113; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kovacs E, 2015, ANNU REV BIOCHEM, V84, P739, DOI 10.1146/annurev-biochem-060614-034402; Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood-2004-09-3645; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Kurppa K, 2009, PIGM CELL MELANOMA R, V22, P708, DOI 10.1111/j.1755-148X.2009.00635.x; Kwak EL, 2006, CLIN CANCER RES, V12, P4283, DOI 10.1158/1078-0432.CCR-06-0189; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Lagadec C, 2012, STEM CELLS, V30, P833, DOI 10.1002/stem.1058; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; LIBERMANN TA, 1985, J CELL SCI, P161; LIM RW, 1984, J CELL BIOL, V98, P739, DOI 10.1083/jcb.98.2.739; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARCHBANK T, 1995, CLIN SCI, V89, P117, DOI 10.1042/cs0890117; Mazouzi A, 2014, EXP CELL RES, V329, P85, DOI 10.1016/j.yexcr.2014.09.030; Mazzoleni S, 2010, CANCER RES, V70, P7500, DOI 10.1158/0008-5472.CAN-10-2353; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Morante J, 2008, CURR BIOL, V18, P553, DOI 10.1016/j.cub.2008.02.075; Nagane M, 1996, CANCER RES, V56, P5079; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; Ninomiya M, 2006, NEUROSCI LETT, V403, P63, DOI 10.1016/j.neulet.2006.04.039; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Panupinthu N, 2014, ONCOGENE, V33, P2846, DOI 10.1038/onc.2013.259; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pastrana E, 2009, P NATL ACAD SCI USA, V106, P6387, DOI 10.1073/pnas.0810407106; Pellettieri J, 2007, ANNU REV GENET, V41, P83, DOI 10.1146/annurev.genet.41.110306.130244; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Pines G, 2010, ONCOGENE, V29, P5850, DOI 10.1038/onc.2010.313; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Pinto AC, 2013, BREAST, V22, pS152, DOI 10.1016/j.breast.2013.07.029; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Ponti G, 2013, P NATL ACAD SCI USA, V110, pE1045, DOI 10.1073/pnas.1219563110; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005; Schneider MR, 2008, AM J PATHOL, V173, P14, DOI 10.2353/ajpath.2008.070942; Schneider MR, 2014, SEMIN CELL DEV BIOL, V28, P1, DOI 10.1016/j.semcdb.2014.02.003; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; Sun Y, 2005, NEURON, V45, P873, DOI 10.1016/j.neuron.2005.01.045; Tamama K, 2006, STEM CELLS, V24, P686, DOI 10.1634/stemcells.2005-0176; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; Teng YHF, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2857; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Tong CK, 2014, NEURON, V81, pe221; Troyer KL, 2001, GASTROENTEROLOGY, V121, P68, DOI 10.1053/gast.2001.25478; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Yan M, 2015, CANCER METAST REV, V34, P157, DOI 10.1007/s10555-015-9552-6; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Yasugi T, 2010, DEVELOPMENT, V137, P3193, DOI 10.1242/dev.048058; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zeineldin R, 2010, J HISTOCHEM CYTOCHEM, V58, P529, DOI 10.1369/jhc.2010.955104; Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094; Zwang Yaara, 2009, Traffic, V10, P349, DOI 10.1111/j.1600-0854.2008.00870.x	167	50	51	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2949	2960		10.1038/onc.2015.372	http://dx.doi.org/10.1038/onc.2015.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434585	Green Accepted			2022-12-28	WOS:000377474500001
J	Treps, L; Edmond, S; Harford-Wright, E; Galan-Moya, EM; Schmitt, A; Azzi, S; Citerne, A; Bidere, N; Ricard, D; Gavard, J				Treps, L.; Edmond, S.; Harford-Wright, E.; Galan-Moya, E. M.; Schmitt, A.; Azzi, S.; Citerne, A.; Bidere, N.; Ricard, D.; Gavard, J.			Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma	ONCOGENE			English	Article							NEWLY-DIAGNOSED GLIOBLASTOMA; ENDOTHELIAL-CELL PERMEABILITY; BEVACIZUMAB PLUS IRINOTECAN; STEM-CELLS; RECURRENT GLIOBLASTOMA; TUMOR-GROWTH; VE-CADHERIN; ANTI-VEGF; PHASE-II; THERAPY	Glioblastoma are malignant highly vascularized brain tumours, which feature large oedema resulting from tumour-promoted vascular leakage. The pro-permeability factor Semaphorin3A (Sema3A) produced within glioblastoma has been linked to the loss of endothelial barrier integrity. Here, we report that extracellular vesicles (EVs) released by patient-derived glioblastoma cells disrupt the endothelial barrier. EVs expressed Sema3A at their surface, which accounted for in vitro elevation of brain endothelial permeability and in vivo vascular permeability, in both skin and brain vasculature. Blocking Sema3A or its receptor Neuropilin1 (NRP1) hampered EV-mediated permeability. In vivo models using ectopically and orthotopically xenografted mice revealed that Sema3A-containing EVs were efficiently detected in the blood stream. In keeping with this idea, sera from glioblastoma multiforme (GBM) patients also contain high levels of Sema3A carried in the EV fraction that enhanced vascular permeability, in a Sema3A/NRP1-dependent manner. Our results suggest that EV-delivered Sema3A orchestrates loss of barrier integrity in glioblastoma and may be of interest for prognostic purposes.	[Treps, L.; Harford-Wright, E.; Galan-Moya, E. M.; Schmitt, A.; Azzi, S.; Citerne, A.; Bidere, N.; Gavard, J.] CNRS, UMR8104, Paris, France; [Treps, L.; Harford-Wright, E.; Galan-Moya, E. M.; Schmitt, A.; Azzi, S.; Citerne, A.; Bidere, N.; Gavard, J.] INSERM, U1016, Paris, France; [Treps, L.; Harford-Wright, E.; Galan-Moya, E. M.; Schmitt, A.; Azzi, S.; Citerne, A.; Bidere, N.; Gavard, J.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Edmond, S.; Ricard, D.] Hop Instruct Armees Val de Grace, Serv Neurol, Paris, France; [Harford-Wright, E.; Bidere, N.; Gavard, J.] INSERM, U892, Nantes, France; [Harford-Wright, E.; Bidere, N.; Gavard, J.] CNRS, UMR6299, Nantes, France; [Harford-Wright, E.; Bidere, N.; Gavard, J.] Univ Nantes, Nantes, France; [Ricard, D.] CNRS, COGNAC G UMR8257, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Val-de-Grace Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Nantes Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Gavard, J (corresponding author), CRCNA, INSERM U892, CNRS UMR6299, 8 Quai Moncousu, F-44000 Nantes, France.	julie.gavard@inserm.fr	Treps, Lucas/AAF-2499-2020; Gavard, Julie/I-5487-2012; Bidère, Nicolas/K-8887-2015; Galan-Moya, Eva M/I-2912-2015; Gavard, Julie/I-5487-2012	Treps, Lucas/0000-0003-0735-9000; Gavard, Julie/0000-0002-7985-9007; Bidère, Nicolas/0000-0001-9177-0008; Galan-Moya, Eva M/0000-0001-5758-7592; Citerne, Antoine/0000-0002-9746-931X; Gavard, Julie/0000-0003-3107-2026	Universite Paris Descartes; Ligue nationale contre le cancer, Canceropole Ile-de-France; Fondation ARC Association pour la Recherche sur le Cancer; Fondation pour la Recherche Medicale; Institut National du Cancer [INCA_6508]; Ligue nationale contre le cancer comite de Paris; Region Pays-de-la-Loire; Nantes Metropole	Universite Paris Descartes; Ligue nationale contre le cancer, Canceropole Ile-de-France; Fondation ARC Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue nationale contre le cancer comite de Paris; Region Pays-de-la-Loire(Region Pays de la Loire); Nantes Metropole(Region Pays de la Loire)	We are thankful to present and past members of the team, especially to Heloise Leclair and Armelle Le Guelte. We are grateful to Robin Lombard (Myltenyi Biotech, Paris, France) for technical assistance with the MacsQuant cytometer. We are also grateful to PO Couraud and F Niedergang's team (Institut Cochin, Paris, France) for helpful discussion and reagents. This research was funded by: Fondation pour la Recherche Medicale, Institut National du Cancer INCA_6508, Ligue nationale contre le cancer comite de Paris, Region Pays-de-la-Loire, Nantes Metropole. LT is supported by doctoral fellowship from Universite Paris Descartes. EMGM, EHW and SA are supported by post-doctoral fellowships from Ligue nationale contre le cancer, Canceropole Ile-de-France and Fondation ARC Association pour la Recherche sur le Cancer, respectively.	Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Casazza A, 2011, ARTERIOSCL THROM VAS, V31, P741, DOI 10.1161/ATVBAHA.110.211920; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Dwyer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045562; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Galan-Moya EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093505; Galan-Moya EM, 2011, EMBO REP, V12, P470, DOI 10.1038/embor.2011.39; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lai A, 2011, J CLIN ONCOL, V29, P142, DOI 10.1200/JCO.2010.30.2729; Le Guelte A, 2012, J CELL SCI, V125, P4137, DOI 10.1242/jcs.108282; Le Guelte A, 2011, BIOL CELL, V103, P593, DOI 10.1042/BC20110069; Maione F, 2012, J CLIN INVEST, V122, P1832, DOI 10.1172/JCI58976; Maione F, 2009, J CLIN INVEST, V119, P3356, DOI 10.1172/JCI36308; Narayana A, 2012, J NEUROSURG, V116, P341, DOI 10.3171/2011.9.JNS11656; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Piao YJ, 2012, NEURO-ONCOLOGY, V14, P1379, DOI 10.1093/neuonc/nos158; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Thirant C, 2012, STEM CELLS, V30, P845, DOI 10.1002/stem.1062; Vader P, 2014, TRENDS MOL MED, V20, P385, DOI 10.1016/j.molmed.2014.03.002; Vredenburgh JJ, 2007, J CLIN ONCOL, V25, P4722, DOI 10.1200/JCO.2007.12.2440; Yan K, 2013, CURR OPIN NEUROL, V26, P701, DOI 10.1097/WCO.0000000000000032; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311	34	74	75	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2615	2623		10.1038/onc.2015.317	http://dx.doi.org/10.1038/onc.2015.317			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364614				2022-12-28	WOS:000376165700008
J	Pinato, DJ; Chowdhury, S; Stebbing, J				Pinato, D. J.; Chowdhury, S.; Stebbing, J.			TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition	ONCOGENE			English	Editorial Material							RECEPTOR TYROSINE KINASES; CELL LUNG-CANCER; MYELOID-LEUKEMIA; HETEROGENEITY; ACTIVATION; CARCINOMA; THERAPY; TARGETS; TUMORS	TAM (Tyro3-Axl-Mer) receptor tyrosine kinases and Met are implicated in several hallmarks of cancer progression including sustained angiogenesis, enhanced motility, tissue invasion and acquisition of metastatic potential through the upregulation of epithelial-to-mesenchymal transition. Increasing evidence has confirmed Axl and Met as emerging central drivers of adaptive resistance to targeted therapies across a wide variety of cancers. In this issue of Oncogene, Zhou et al. describe the mechanisms linking Axl and Met activation to acquired resistance to sunitinib in renal cell carcinoma (RCC), providing a pre-clinical rationale for the development of Axl and Met inhibitors including cabozantinib in anti-angiogenic resistant RCC.	[Pinato, D. J.; Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0HS, England; [Chowdhury, S.] Guys & St Thomas NHS Fdn Trust, Guys Hosp, Dept Med Oncol, London, England	Imperial College London; Guy's & St Thomas' NHS Foundation Trust	Pinato, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0HS, England.	david.pinato@imperial.ac.uk	Pinato, David James/ABB-3719-2020	Stebbing, Justin/0000-0002-1117-6947; Pinato, David James/0000-0002-3529-0103	Medical Research Council [MR/L000172/1] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline; MRC [MR/L000172/1] Funding Source: UKRI; Academy of Medical Sciences (AMS) [AMS-SGCL13-Pinato] Funding Source: researchfish; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053, CL-2015-21-010] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))		Brand TM, 2014, CANCER RES, V74, P5152, DOI 10.1158/0008-5472.CAN-14-0294; Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; Choueiri TK, 2014, ANN ONCOL, V25, P1603, DOI 10.1093/annonc/mdu184; Ciccarese C, 2015, CANCER TREAT REV, V41, P614, DOI 10.1016/j.ctrv.2015.05.006; Dufies M, 2011, ONCOTARGET, V2, P874, DOI 10.18632/oncotarget.360; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847; Grunwald V, 2013, EUR J CANCER, V49, P2504, DOI 10.1016/j.ejca.2013.03.022; Kim MS, 2014, MOL CELL PROTEOMICS, V13, P2803, DOI 10.1074/mcp.M114.038547; Kirane A, 2015, CANC RES; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Park IK, 2015, LEUKEMIA, V29, P2382, DOI 10.1038/leu.2015.147; Rankin EB, 2014, P NATL ACAD SCI USA, V111, P13373, DOI 10.1073/pnas.1404848111; Santoro A, 2013, LANCET ONCOL, V14, P55, DOI 10.1016/S1470-2045(12)70490-4; Scagliotti GV, 2013, CANCER TREAT REV, V39, P793, DOI 10.1016/j.ctrv.2013.02.001; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Watermann I, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0362-5; Yoshida T, 2014, CLIN CANCER RES, V20, P4059, DOI 10.1158/1078-0432.CCR-13-1559	24	14	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2684	2686		10.1038/onc.2015.374	http://dx.doi.org/10.1038/onc.2015.374			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26434595				2022-12-28	WOS:000377472700002
J	Kruiswijk, F; Hasenfuss, SC; Sivapatham, R; Baar, MP; Putavet, D; Naipal, KAT; van den Broek, NJF; Kruit, W; van der Spek, PJ; van Gent, DC; Brenkman, AB; Campisi, J; Burgering, BMT; Hoeijmakers, JHJ; de Keizer, PLJ				Kruiswijk, F.; Hasenfuss, S. C.; Sivapatham, R.; Baar, M. P.; Putavet, D.; Naipal, K. A. T.; van den Broek, N. J. F.; Kruit, W.; van der Spek, P. J.; van Gent, D. C.; Brenkman, A. B.; Campisi, J.; Burgering, B. M. T.; Hoeijmakers, J. H. J.; de Keizer, P. L. J.			Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling	ONCOGENE			English	Article							MEK INHIBITION; TRANSCRIPTION FACTORS; IMPROVED SURVIVAL; MITOTIC PROGRAM; BRAF; FOXM1; EXPRESSION; GENE; RESISTANCE; PHOSPHORYLATION	Melanoma is the most lethal form of skin cancer and successful treatment of metastatic melanoma remains challenging. BRAF/MEK inhibitors only show a temporary benefit due to rapid occurrence of resistance, whereas immunotherapy is mainly effective in selected subsets of patients. Thus, there is a need to identify new targets to improve treatment of metastatic melanoma. To this extent, we searched for markers that are elevated in melanoma and are under regulation of potentially druggable enzymes. Here, we show that the pro-proliferative transcription factor FOXM1 is elevated and activated in malignant melanoma. FOXM1 activity correlated with expression of the enzyme Pin1, which we found to be indicative of a poor prognosis. In functional experiments, Pin1 proved to be a main regulator of FOXM1 activity through MEK-dependent physical regulation during the cell cycle. The Pin1-FOXM1 interaction was enhanced by BRAF(V600E), the driver oncogene in the majority of melanomas, and in extrapolation of the correlation data, interference with\Pin1 in BRAF(V600E)-driven metastatic melanoma cells impaired both FOXM1 activity and cell survival. Importantly, cell-permeable Pin1-FOXM1-blocking peptides repressed the proliferation of melanoma cells in freshly isolated human metastatic melanoma ex vivo and in three-dimensional-cultured patient-derived melanoids. When combined with the BRAF(V600) Einhibitor PLX4032 a robust repression in melanoid viability was obtained, establishing preclinical value of patient-derived melanoids for prognostic use of drug sensitivity and further underscoring the beneficial effect of Pin1-FOXM1 inhibitory peptides as anti-melanoma drugs. These proof-of-concept results provide a starting point for development of therapeutic Pin1-FOXM1 inhibitors to target metastatic melanoma.	[Kruiswijk, F.; Hasenfuss, S. C.; van den Broek, N. J. F.; Brenkman, A. B.; Burgering, B. M. T.; de Keizer, P. L. J.] Univ Med Ctr, Ctr Mol Med, Mol Canc Res, Utrecht, Netherlands; [Sivapatham, R.; Campisi, J.; de Keizer, P. L. J.] Buck Inst Res Aging, Novato, CA USA; [Baar, M. P.; Putavet, D.; Naipal, K. A. T.; van Gent, D. C.; Hoeijmakers, J. H. J.; de Keizer, P. L. J.] Erasmus MC, Dept Genet, Wytemaweg 80,POB 2040, NL-3000 CA Rotterdam, Netherlands; [Kruit, W.] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands; [van der Spek, P. J.] Erasmus MC, Dept Bioinformat, Rotterdam, Netherlands; [Brenkman, A. B.] Univ Med Ctr, Dept Metab & Endocrine Dis, Utrecht, Netherlands; [Campisi, J.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	Utrecht University; Utrecht University Medical Center; Buck Institute for Research on Aging; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	de Keizer, PLJ (corresponding author), Erasmus MC, Dept Genet, Wytemaweg 80,POB 2040, NL-3000 CA Rotterdam, Netherlands.	p.dekeizer@erasmusmc.nl	de+Keizer, Peter/AAD-5320-2020; Sivapatham, Renuka/AAS-3650-2020; Hoeijmakers, Jan/AAX-6972-2021	de+Keizer, Peter/0000-0002-6948-925X; Sivapatham, Renuka/0000-0003-0309-3671; van Gent, Dik C./0000-0003-1473-8148; Naipal, Kishan/0000-0001-8267-8218	NIH [R37-AG009909]; NIH/NIA [AG-17242-02]; KNAW; ERC; FP7 framework [HEALTH-F2-2010-259893]; Dutch Cancer Society [Buit-4649]; EMCR [2014-7141]; Erasmus Medical Center Rotterdam: EMC fellowship; CGC; NATIONAL INSTITUTE ON AGING [R37AG009909, P01AG017242] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); KNAW; ERC(European Research Council (ERC)European Commission); FP7 framework; Dutch Cancer Society(KWF Kankerbestrijding); EMCR; Erasmus Medical Center Rotterdam: EMC fellowship; CGC; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We would like to gratefully acknowledge Dr Richard Marais for material from BRAF<SUP>V600E-</SUP>inducible mice, Dr Hugo Snippert and Dr Rene Overmeer for advice on organoid culture and Dr Jamila Laoukili and Dr Rene Medema for general advice on FOXM1 signaling. This work has been supported by grants from the NIH: R37-AG009909 (JC), CGC (BB), NIH/NIA: AG-17242-02 (JC/JH), KNAW (JH), ERC (JH), FP7 framework HEALTH-F2-2010-259893 (JH), the Dutch Cancer Society: Buit-4649 (PDK), EMCR 2014-7141 (PDK) and the Erasmus Medical Center Rotterdam: 2013 EMC fellowship (PDK).	Alcala AM, 2012, CLIN CANCER RES, V18, P33, DOI 10.1158/1078-0432.CCR-11-0997; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brenkman AB, 2008, CANCER RES, V68, P7597, DOI 10.1158/0008-5472.CAN-08-1059; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Damsky WE, 2014, ONCOGENE, V33, P2413, DOI 10.1038/onc.2013.194; Damsky WE, 2010, PIGM CELL MELANOMA R, V23, P853, DOI 10.1111/j.1755-148X.2010.00777.x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Keizer PLJ, 2010, CANCER RES, V70, P8526, DOI 10.1158/0008-5472.CAN-10-1563; Dhomen N, 2009, HEMATOL ONCOL CLIN N, V23, P529, DOI 10.1016/j.hoc.2009.04.001; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Down CF, 2012, BBA-GENE REGUL MECH, V1819, P855, DOI 10.1016/j.bbagrm.2012.03.008; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Halasi M, 2009, CELL CYCLE, V8, P1966, DOI 10.4161/cc.8.12.8708; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li XX, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-204; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Naipal KAT, 2014, CLIN CANCER RES, V20, P4816, DOI 10.1158/1078-0432.CCR-14-0571; Nakamura A, 2013, CANCER RES, V73, P7043, DOI 10.1158/0008-5472.CAN-13-1825; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; REED JA, 1995, CANCER RES, V55, P2713; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Smith AP, 2005, CANCER BIOL THER, V4, P1018, DOI 10.4161/cbt.4.9.2165; Solit D, 2010, NATURE, V468, P902, DOI 10.1038/468902a; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Walker GJ, 2011, PIGM CELL MELANOMA R, V24, P1158, DOI 10.1111/j.1755-148X.2011.00923.x; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344; Zhang N, 2012, CLIN CANCER RES, V18, P5961, DOI 10.1158/1078-0432.CCR-12-0039	47	36	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2166	2177		10.1038/onc.2015.282	http://dx.doi.org/10.1038/onc.2015.282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26279295	Green Published, hybrid, Green Accepted, Green Submitted			2022-12-28	WOS:000374986000003
J	Madan, B; Ke, Z; Harmston, N; Ho, SY; Frois, AO; Alam, J; Jeyaraj, DA; Pendharkar, V; Ghosh, K; Virshup, IH; Manoharan, V; Ong, EHQ; Sangthongpitag, K; Hill, J; Petretto, E; Keller, TH; Lee, MA; Matter, A; Virshup, DM				Madan, B.; Ke, Z.; Harmston, N.; Ho, S. Y.; Frois, A. O.; Alam, J.; Jeyaraj, D. A.; Pendharkar, V.; Ghosh, K.; Virshup, I. H.; Manoharan, V.; Ong, E. H. Q.; Sangthongpitag, K.; Hill, J.; Petretto, E.; Keller, T. H.; Lee, M. A.; Matter, A.; Virshup, D. M.			Wnt addiction of genetically defined cancers reversed by PORCN inhibition	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; COLON-CANCER; STEM-CELLS; EXPRESSION; PORCUPINE; PATHWAY; GROWTH; RNF43; TRANSCRIPTION; GENE	Enhanced sensitivity to Wnts is an emerging hallmark of a subset of cancers, defined in part by mutations regulating the abundance of their receptors. Whether these mutations identify a clinical opportunity is an important question. Inhibition of Wnt secretion by blocking an essential post-translational modification, palmitoleation, provides a useful therapeutic intervention. We developed a novel potent, orally available PORCN inhibitor, ETC-1922159 (henceforth called ETC-159) that blocks the secretion and activity of all Wnts. ETC-159 is remarkably effective in treating RSPO-translocation bearing colorectal cancer (CRC) patient-derived xenografts. This is the first example of effective targeted therapy for this subset of CRC. Consistent with a central role of Wnt signaling in regulation of gene expression, inhibition of PORCN in RSPO3-translocated cancers causes a marked remodeling of the transcriptome, with loss of cell cycle, stem cell and proliferation genes, and an increase in differentiation markers. Inhibition of Wnt signaling by PORCN inhibition holds promise as differentiation therapy in genetically defined human cancers.	[Madan, B.; Frois, A. O.; Ghosh, K.; Virshup, I. H.; Virshup, D. M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Ke, Z.; Ho, S. Y.; Alam, J.; Jeyaraj, D. A.; Pendharkar, V.; Manoharan, V.; Ong, E. H. Q.; Sangthongpitag, K.; Hill, J.; Keller, T. H.; Lee, M. A.; Matter, A.] ASTAR, Ctr Expt Therapeut, Biopolis, Singapore, Singapore; [Harmston, N.; Petretto, E.] Duke NUS Grad Med Sch, Program Cardiovasc & Metab Dis, Singapore, Singapore; [Virshup, D. M.] Duke Univ, Dept Pediat, Durham, NC 27706 USA	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Experimental Drug Development Centre (EDDC); Experimental Therapeutics Centre; National University of Singapore; Duke University	Madan, B; Virshup, DM (corresponding author), Duke NUS, Grad Sch Med, Program Canc & Stem Cell Biol, 07-20,8 Coll Rd, Singapore 169857, Singapore.	Babita.Madan@duke-nus.edu.sg; David.Virshup@duke-nus.edu.sg	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Ho, Soo Yei/0000-0001-8535-389X; Petretto, Enrico/0000-0003-2163-5921; HARMSTON, NATHAN/0000-0002-8589-2938; Madan, Babita/0000-0003-1065-8589; Keller, Thomas/0000-0002-7553-6235	National Research Foundation Singapore; Agency for Science, Technology and Research (A*STAR), Singapore; MRC Clinical Sciences Centre, Imperial College, London; MRC [MC_U120097112] Funding Source: UKRI; Medical Research Council [MC_U120097112] Funding Source: researchfish	National Research Foundation Singapore(National Research Foundation, Singapore); Agency for Science, Technology and Research (A*STAR), Singapore(Agency for Science Technology & Research (A*STAR)); MRC Clinical Sciences Centre, Imperial College, London(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We acknowledge the assistance of members of the Virshup lab including Jamal Aliyev, Naushad Moti and Edison and members of Experimental Therapeutics Centre including Shermaine Q Y Lim, Sifang Wang, Yu Wang, Vivien Wei Wen Cheong, and Grace Ruiting Lin. We acknowledge Ivana Mihalek for help with the alignment of PORCN sequences and Ralph Bunte, DVM, for his expert advice with histological analysis. We also acknowledge the assistance of the vivarium staff including Hock Lee. This research is supported in part by the National Research Foundation Singapore and administered by the Singapore Ministry of Health's National Medical Research Council under the STAR Award Program to DMV. The research in Experimental Therapeutics Centre is supported by the Agency for Science, Technology and Research (A*STAR), Singapore. EP and NH acknowledge the support of the MRC Clinical Sciences Centre, Imperial College, London.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Cardona GM, 2014, P 105 ANN M AM ASS C; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Conway T, 2012, BIOINFORMATICS, V28, pI172, DOI 10.1093/bioinformatics/bts236; Coombs GS, 2012, ONCOGENE, V31, P213, DOI 10.1038/onc.2011.228; Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Fu J, 2009, P NATL ACAD SCI USA, V106, P18598, DOI 10.1073/pnas.0904894106; Gao XX, 2011, FEBS LETT, V585, P2501, DOI 10.1016/j.febslet.2011.06.033; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Gibaldi M., 1982, PHARMACOKINETICS, V2nd ed., P409; Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109; Gurtner A, 2010, CANCER RES, V70, P9711, DOI 10.1158/0008-5472.CAN-10-0721; Hannoush RN, 2009, ACS CHEM BIOL, V4, P581, DOI 10.1021/cb900085z; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lee SB, 2013, BIOCHEM BIOPH RES CO, V431, P746, DOI 10.1016/j.bbrc.2013.01.038; Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Lum L, 2012, SCIENCE, V337, P922, DOI 10.1126/science.1228179; Madan B, 2015, MOL CANCER THER, V14, P1087, DOI 10.1158/1535-7163.MCT-14-1038; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273; Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970; Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008-5472.CAN-12-2258; Rios-Esteves J, 2013, CELL REP, V4, P1072, DOI 10.1016/j.celrep.2013.08.027; Ryland GL, 2013, J PATHOL, V229, P469, DOI 10.1002/path.4134; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shinmura K, 2014, MOL BIOL REP, V41, P5375, DOI 10.1007/s11033-014-3409-x; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wang XL, 2013, J MED CHEM, V56, P2700, DOI 10.1021/jm400159c; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Yu J, 2014, BIOSCIENCE REP, V34, P593, DOI 10.1042/BSR20140119	49	185	197	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2197	2207		10.1038/onc.2015.280	http://dx.doi.org/10.1038/onc.2015.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26257057	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000374986000006
J	Hessmann, E; Schneider, G; Ellenrieder, V; Siveke, JT				Hessmann, E.; Schneider, G.; Ellenrieder, V.; Siveke, J. T.			MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies	ONCOGENE			English	Review							BET BROMODOMAIN INHIBITION; SMALL-MOLECULE INHIBITORS; C-MYC; GENE-EXPRESSION; DUCTAL ADENOCARCINOMA; N-MYC; TRANSCRIPTIONAL ACTIVATION; POTENTIAL TARGET; TRANSGENIC MICE; TUMOR	Owing to its aggressiveness, late detection and marginal therapeutic accessibility, pancreatic ductal adenocarcinoma (PDAC) remains a most challenging malignant disease. Despite scientific progress in the understanding of the mechanisms that underly PDAC initiation and progression, the successful translation of experimental findings into effective new therapeutic strategies remains a largely unmet need. The oncogene MYC is activated in many PDAC cases and is a master regulator of vital cellular processes. Excellent recent studies have shed new light on the tremendous functions of MYC in cancer and identified inhibition of MYC as a likewise beneficial and demanding effort. This review will focus on mechanisms that contribute to deregulation of MYC expression in pancreatic carcinogenesis and progression and will summarize novel biological findings from recent in vivo models. Finally, we provide a perspective, how regulation of MYC in PDAC may contribute to the development of new therapeutic approaches.	[Hessmann, E.; Ellenrieder, V.] Univ Med Ctr Goettingen, Clin Gastroenterol & Gastrointestinal Oncol, Gottingen, Germany; [Schneider, G.; Siveke, J. T.] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, Med Klin, D-80290 Munich, Germany; [Siveke, J. T.] German Canc Consortium DKTK, Heidelberg, Germany; [Siveke, J. T.] German Canc Res Ctr, Heidelberg, Germany	University of Gottingen; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Siveke, JT (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin, Dept Internal Med 2, Ismaninger St 22, D-81675 Munich, Germany.	jens.siveke@lrz.tum.de	Siveke, Jens/AAQ-6170-2021	Siveke, Jens/0000-0002-8772-4778				Aichler M, 2012, J PATHOL, V226, P723, DOI 10.1002/path.3017; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Bachireddy P, 2012, CLIN EXP IMMUNOL, V167, P188, DOI 10.1111/j.1365-2249.2011.04514.x; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870; Bisgrovet DA, 2007, P NATL ACAD SCI USA, V104, P13690, DOI 10.1073/pnas.0705053104; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bonal C, 2009, GASTROENTEROLOGY, V136, P309, DOI 10.1053/j.gastro.2008.10.015; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Cattoretti G, 2013, J PATHOL, V229, P430, DOI 10.1002/path.4141; Cermelli S., 2014, COLD SPRING HARB PER, V4; Chang DK, 2014, CURR OPIN GENET DEV, V24, P74, DOI 10.1016/j.gde.2013.12.001; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Cheng CY, 2014, CELL REP, V6, P1000, DOI 10.1016/j.celrep.2014.02.023; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Conacci-Sorrell Maralice, 2014, Cold Spring Harb Perspect Med, V4, pa014357, DOI 10.1101/cshperspect.a014357; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Elkon R, 2004, NUCLEIC ACIDS RES, V32, P4955, DOI 10.1093/nar/gkh816; Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802; Feldmann G, 2011, CANCER BIOL THER, V12, P598, DOI 10.4161/cbt.12.7.16475; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fukushima N, 2004, ONCOGENE, V23, P9042, DOI 10.1038/sj.onc.1208117; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gamberi G, 1998, J ORTHOP RES, V16, P1, DOI 10.1002/jor.1100160102; Gao YY, 2014, FEBS LETT, V588, P878, DOI 10.1016/j.febslet.2014.02.016; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Grippo PJ, 2012, INT J CANCER, V131, P1243, DOI 10.1002/ijc.27322; Groisman I, 2006, GENE DEV, V20, P2701, DOI 10.1101/gad.1438906; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Gurda GT, 2010, GASTROENTEROLOGY, V139, P609, DOI 10.1053/j.gastro.2010.04.050; Gustafson WC, 2014, CANCER CELL, V26, P414, DOI 10.1016/j.ccr.2014.07.015; Hamacher R, 2007, ONCOL REP, V18, P695; He WL, 2014, J GASTROEN HEPATOL, V29, P1427, DOI 10.1111/jgh.12558; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hodges LC, 2003, MOL CANCER RES, V1, P300; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Ischenko I, 2014, P NATL ACAD SCI USA, V111, P3466, DOI 10.1073/pnas.1319911111; Jackstadt R, 2015, BBA-GENE REGUL MECH, V1849, P544, DOI 10.1016/j.bbagrm.2014.04.003; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koenig A, 2010, GASTROENTEROLOGY, V138, P1189, DOI 10.1053/j.gastro.2009.10.045; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Lee H, 1995, Curr Top Microbiol Immunol, V194, P247; Lin WC, 2013, CANCER RES, V73, P1821, DOI 10.1158/0008-5472.CAN-12-2067; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107; McKeown MR, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014266; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Melisi D, 2008, MOL CANCER THER, V7, P829, DOI 10.1158/1535-7163.MCT-07-0337; Menssen A, 2012, ONCOTARGET, V3, P112, DOI 10.18632/oncotarget.440; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Murtaugh LC, 2005, DEVELOPMENT, V132, P4663, DOI 10.1242/dev.02063; Nakhai H, 2008, DEVELOPMENT, V135, P3191, DOI 10.1242/dev.017137; Nam S, 2013, MOL ONCOL, V7, P369, DOI 10.1016/j.molonc.2012.10.013; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ogami K, 2014, ONCOGENE, V33, P55, DOI 10.1038/onc.2012.548; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Ortiz-Zapater E, 2012, NAT MED, V18, P83, DOI 10.1038/nm.2540; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Palanichamy JK, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00054; Peter S, 2014, EMBO MOL MED, V6, P1525, DOI 10.15252/emmm.201403927; Politi K, 2004, ONCOGENE, V23, P1558, DOI 10.1038/sj.onc.1207275; Puri S, 2015, CELL STEM CELL, V16, P18, DOI 10.1016/j.stem.2014.11.001; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rojanala S, 2004, MOL CANCER THER, V3, P451; Rooman I, 2012, GUT, V61, P449, DOI 10.1136/gut.2010.235804; Roussel MF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014308; Sabo A, 2014, COLD SPRING HARB PER, V4; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Sahai V, 2014, MOL CANCER THER, V13, P1907, DOI 10.1158/1535-7163.MCT-13-0925; Sancho R, 2014, CELL STEM CELL, V15, P139, DOI 10.1016/j.stem.2014.06.019; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Schmitz R, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014282; Schneider Gunter, 2011, J Gastrointest Cancer, V42, P85, DOI 10.1007/s12029-011-9257-1; Schneider Gunter, 2003, Mol Cancer, V2, P15, DOI 10.1186/1476-4598-2-15; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Singh G, 2010, J BIOL CHEM, V285, P27241, DOI 10.1074/jbc.M110.100438; Singh SK, 2011, J BIOL CHEM, V286, P28761, DOI 10.1074/jbc.M110.197533; Skoudy Anouchka, 2011, J Gastrointest Cancer, V42, P76, DOI 10.1007/s12029-011-9258-0; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stellas D, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju320; Tazawa H, 2011, EXPERT OPIN BIOL TH, V11, P145, DOI 10.1517/14712598.2011.542749; Ullius A, 2014, NUCLEIC ACIDS RES, V42, P6901, DOI 10.1093/nar/gku312; van Riggelen J, 2010, GENE DEV, V24, P1281, DOI 10.1101/gad.585710; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang B, 2014, ONCOL REP, V31, P2279, DOI 10.3892/or.2014.3072; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wells JM, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-4; Wiese KE, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014290; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Xu DP, 2013, CANCER BIOL THER, V14, P492, DOI 10.4161/cbt.24343; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yang D, 2010, P NATL ACAD SCI USA, V107, P13836, DOI 10.1073/pnas.1008366107; Yang SB, 2010, EXP MOL MED, V42, P759, DOI 10.3858/emm.2010.42.11.077; Yochum GS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018966; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zadran S, 2013, P NATL ACAD SCI USA, V110, P19160, DOI 10.1073/pnas.1316991110; Zhang JS, 2011, ONCOGENE, V30, P3705, DOI 10.1038/onc.2011.90; Zheng YJ, 2005, J AM CHEM SOC, V127, P17182, DOI 10.1021/ja0558544; Zhou Q, 2007, DEV CELL, V13, P103, DOI 10.1016/j.devcel.2007.06.001; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	139	79	80	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1609	1618		10.1038/onc.2015.216	http://dx.doi.org/10.1038/onc.2015.216			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26119937				2022-12-28	WOS:000373064200001
J	Koppens, M; van Lohuizen, M				Koppens, M.; van Lohuizen, M.			Context-dependent actions of Polycomb repressors in cancer	ONCOGENE			English	Review							H3 LYSINE 27; HISTONE METHYLTRANSFERASE EZH2; EPITHELIAL-MESENCHYMAL TRANSITION; REGULATES CELL-PROLIFERATION; EMBRYONIC STEM-CELLS; BMI-1 MESSENGER-RNA; GENE-EXPRESSION; BREAST-CANCER; TUMOR-SUPPRESSOR; H2A UBIQUITYLATION	Polycomb Group (PcG) proteins form Polycomb Repressive Complexes (PRCs) that function as epigenetic repressors of gene expression. The large variety of PcG proteins, in addition to the high number of paralogs, allows for the formation of diverse PRCs with different properties, providing fine-tuned control over cell specification. Initially identified as being oncogenes, a small number of PcG genes are involved in tumor development in part through the repression of the CDKN2A locus. Therefore, enhanced PcG-mediated repression has long been assumed to be cancer promoting. However, recent data have revealed that for some cancers, PcG proteins act as tumor suppressors, indicating that this traditional view is oversimplified. In this review, we present an overview of the roles of PcG genes in oncogenesis and how the nature of their role is context dependent.	[Koppens, M.; van Lohuizen, M.] Netherlands Canc Inst, Div Mol Genet, H4012,Plesmanlaan 121,Postbus 90203, NL-1066 Amsterdam, Netherlands; [van Lohuizen, M.] Canc Genom Ctr Netherlands, Utrecht, Netherlands	Netherlands Cancer Institute	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Genet, H4012,Plesmanlaan 121,Postbus 90203, NL-1066 Amsterdam, Netherlands.	M.V.Lohuizen@NKI.NL						Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Aguilo F, 2011, CANCER RES, V71, P5365, DOI 10.1158/0008-5472.CAN-10-4379; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Akasaka T, 2001, DEVELOPMENT, V128, P1587; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Benard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108265; Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006; Bengani H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067217; Berezovska OP, 2006, CELL CYCLE, V5, P1886; Berg T, 2014, BLOOD, V123, P3914, DOI 10.1182/blood-2012-12-473439; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408; Brockdorff N, 2013, RNA, V19, P429, DOI 10.1261/rna.037598.112; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Caganova M, 2013, J CLIN INVEST, V123, P5009, DOI 10.1172/JCI70626; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113; Chen S, 2014, ONCOTARGET, V5, P10421, DOI 10.18632/oncotarget.2126; Chowdhury M, 2007, LEUKEMIA, V21, P1116, DOI 10.1038/sj.leu.2404623; Clermont PL, 2014, BRIT J CANCER, V111, P1663, DOI 10.1038/bjc.2014.474; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Cooper S, 2014, CELL REP, V7, P1456, DOI 10.1016/j.celrep.2014.04.012; Core N, 2004, ONCOGENE, V23, P7660, DOI 10.1038/sj.onc.1207998; Core N, 1997, DEVELOPMENT, V124, P721; Crea F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-265; Cuddapah S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036365; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; de Vries NA, 2015, CELL REP, V10, P383, DOI 10.1016/j.celrep.2014.12.028; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; Federico A, 2009, CANCER RES, V69, P7079, DOI 10.1158/0008-5472.CAN-09-1542; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620; Funato K, 2014, SCIENCE, V346, P1529, DOI 10.1126/science.1253799; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gilbertson RJ, 2011, CELL, V145, P25, DOI 10.1016/j.cell.2011.03.019; Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10; Grossmann V, 2011, LEUKEMIA, V25, P877, DOI 10.1038/leu.2011.10; Guglielmelli P, 2014, LEUKEMIA, V28, P1804, DOI 10.1038/leu.2014.76; Guglielmelli P, 2011, BLOOD, V118, P5227, DOI 10.1182/blood-2011-06-363424; Guo BH, 2010, ANN ONCOL, V21, P2361, DOI 10.1093/annonc/mdq241; Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10; Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Hashizume R, 2014, NAT MED, V20, P1394, DOI 10.1038/nm.3716; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hinz S, 2008, TUMOR BIOL, V29, P323, DOI 10.1159/000170879; Hosogane M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003698; Huang J, 2012, MED ONCOL, V29, P1606, DOI 10.1007/s12032-011-9998-5; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777; Jankowska AM, 2011, BLOOD, V118, P3932, DOI 10.1182/blood-2010-10-311019; Jermann P, 2014, P NATL ACAD SCI USA, V111, pE3415, DOI 10.1073/pnas.1400672111; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kajiume T, 2009, EXP HEMATOL, V37, P857, DOI 10.1016/j.exphem.2009.04.011; Kalb R, 2014, NAT STRUCT MOL BIOL, V21, P569, DOI 10.1038/nsmb.2833; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033; Karapetyan Armen R, 2013, Cancers (Basel), V5, P462, DOI 10.3390/cancers5020462; Katoh-Fukui Y, 1998, NATURE, V393, P688, DOI 10.1038/31482; Katoh-Fukui Y, 2005, BLOOD, V106, P1612, DOI 10.1182/blood-2004-08-3367; Katoh-Fukui Y, 2012, ENDOCRINOLOGY, V153, P913, DOI 10.1210/en.2011-1055; Kaustov L, 2011, J BIOL CHEM, V286, P521, DOI 10.1074/jbc.M110.191411; Khan SN, 2013, LEUKEMIA, V27, P1301, DOI 10.1038/leu.2013.80; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Lee SH, 2013, CANCER LETT, V335, P397, DOI 10.1016/j.canlet.2013.02.051; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Li G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080970; Li J, 2014, CANCER CELL, V25, P118, DOI 10.1016/j.ccr.2013.12.008; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Liu JH, 2008, J SURG ONCOL, V97, P267, DOI 10.1002/jso.20934; Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081484; Liu PW, 2014, J DIGEST DIS, V15, P166, DOI 10.1111/1751-2980.12129; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu YW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-143; Lynch MD, 2012, EMBO J, V31, P317, DOI 10.1038/emboj.2011.399; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Maethner E, 2013, CELL REP, V3, P1553, DOI 10.1016/j.celrep.2013.03.038; Makishima H, 2010, LEUKEMIA, V24, P1799, DOI 10.1038/leu.2010.167; Mansueto Gelsomina, 2010, Genes Cancer, V1, P210, DOI 10.1177/1947601910366860; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; Mendenhall EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001244; Mihara K, 2006, BLOOD, V107, P305, DOI 10.1182/blood-2005-06-2393; Miki J, 2007, GENES CELLS, V12, P1371, DOI 10.1111/j.1365-2443.2007.01135.x; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Mohty M, 2007, BLOOD, V110, P380, DOI 10.1182/blood-2006-12-065599; Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; Neff T, 2012, P NATL ACAD SCI USA, V109, P5028, DOI 10.1073/pnas.1202258109; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; O'Loghlen A, 2012, CELL STEM CELL, V10, P33, DOI 10.1016/j.stem.2011.12.004; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Oh EJ, 2014, HUM PATHOL, V45, P2043, DOI 10.1016/j.humpath.2014.07.002; Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Pallante P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098295; Pallante P, 2010, EUR J CANCER, V46, P2304, DOI 10.1016/j.ejca.2010.05.011; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Parris TZ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-324; Parris TZ, 2014, INT J CANCER, V134, P1617, DOI 10.1002/ijc.28497; Pemberton H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r23; Peschansky VJ, 2014, EPIGENETICS-US, V9, P3, DOI 10.4161/epi.27473; Proctor E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055820; Qian T, 2010, ONCOGENE, V29, P5818, DOI 10.1038/onc.2010.317; Riis Margit L H, 2012, ISRN Oncol, V2012, P450267, DOI 10.5402/2012/450267; Riising EM, 2014, MOL CELL, V55, P347, DOI 10.1016/j.molcel.2014.06.005; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Sahasrabuddhe AA, 2015, ONCOGENE, V34, P445, DOI 10.1038/onc.2013.571; Sashida G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5177; Scelfo A, 2015, FEBS J, V282, P1703, DOI 10.1111/febs.13112; Schwartz YB, 2014, CELL REP, V8, P321, DOI 10.1016/j.celrep.2014.07.001; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Score J, 2012, BLOOD, V119, P1208, DOI 10.1182/blood-2011-07-367243; Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104; Shinjo K, 2014, INT J CANCER, V135, P308, DOI 10.1002/ijc.28692; Silva J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1760; Simon C, 2012, GENE DEV, V26, P651, DOI 10.1101/gad.186411.111; Sing A, 2009, CELL, V138, P885, DOI 10.1016/j.cell.2009.08.020; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Song WJ, 2010, CANCER SCI, V101, P1754, DOI 10.1111/j.1349-7006.2010.01577.x; Stock K, 2012, NAT MED, V18, P1232, DOI 10.1038/nm.2827; Stojic L, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-16; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Suarez-Merino B, 2005, NEURO-ONCOLOGY, V7, P20; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Tanaka S, 2012, BLOOD, V120, P1107, DOI 10.1182/blood-2011-11-394932; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Tao J, 2014, TUMOR BIOL, V35, P9619, DOI 10.1007/s13277-014-2220-6; Tateishi K, 2006, CLIN CANCER RES, V12, P6960, DOI 10.1158/1078-0432.CCR-06-0449; Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029; Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5; Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; van Galen JC, 2007, J CLIN PATHOL, V60, P167, DOI 10.1136/jcp.2006.038752; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Vandamme J, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002642; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Vannucchi AM, 2013, LEUKEMIA, V27, P1861, DOI 10.1038/leu.2013.119; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149; Venneti S, 2013, BRAIN PATHOL, V23, P558, DOI 10.1111/bpa.12042; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Wan LY, 2013, CLIN TRANSL ONCOL, V15, P132, DOI 10.1007/s12094-012-0897-9; Wang BQ, 2013, ANN SURG ONCOL, V20, pS684, DOI 10.1245/s10434-013-3171-7; Wang CG, 2010, WORLD J GASTROENTERO, V16, P2421, DOI 10.3748/wjg.v16.i19.2421; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang W, 2014, ONCOTARGET, V5, P11604, DOI 10.18632/oncotarget.2598; Wang W, 2011, UROL ONCOL-SEMIN ORI, V29, P244, DOI 10.1016/j.urolonc.2009.02.004; Wang W, 2009, INT J CANCER, V125, P2836, DOI 10.1002/ijc.24721; Won HY, 2012, FASEB J, V26, P5002, DOI 10.1096/fj.12-209247; Woo CJ, 2010, CELL, V140, P99, DOI 10.1016/j.cell.2009.12.022; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Xu F, 2011, ANN HEMATOL, V90, P643, DOI 10.1007/s00277-010-1128-5; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang GF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-133; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Yuan W, 2012, SCIENCE, V337, P971, DOI 10.1126/science.1225237; Zhang F., 2008, Experimental Oncology, V30, P70; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	194	62	62	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1341	1352		10.1038/onc.2015.195	http://dx.doi.org/10.1038/onc.2015.195			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26050622				2022-12-28	WOS:000372196400001
J	Wang, Y; Deng, O; Feng, Z; Du, Z; Xiong, X; Lai, J; Yang, X; Xu, M; Wang, H; Taylor, D; Yan, C; Chen, C; Difeo, A; Ma, Z; Zhang, J				Wang, Y.; Deng, O.; Feng, Z.; Du, Z.; Xiong, X.; Lai, J.; Yang, X.; Xu, M.; Wang, H.; Taylor, D.; Yan, C.; Chen, C.; Difeo, A.; Ma, Z.; Zhang, J.			RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression	ONCOGENE			English	Article							SPORADIC BREAST-CANCER; NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE; OVARIAN-CANCER; DIFFERENTIAL REGULATION; REPLICATION ARREST; GENE-EXPRESSION; MESSENGER-RNA; FREQUENT LOSS; E2F1	RNF126 is an E3 ubiquitin ligase. The deletion of RNF126 gene was observed in a wide range of human cancers and is correlated with improved disease-free and overall survival. These data highlight the clinical relevance of RNF126 in tumorigenesis and cancer therapy. However, the specific functions of RNF126 remain largely unknown. Homologous recombination (HR)-mediated DNA double-strand break repair is important for tumor suppression and cancer therapy resistance. Here, we demonstrate that RNF126 facilitates HR by promoting the expression of BRCA1, in a manner independent of its E3 ligase activity but depending on E2F1, a well-known transcription factor of BRCA1 promoter. In support of this result, RNF126 promotes transactivation of BRCA1 promoter by directly binding to E2F1. Most importantly, an RNF126 mutant lacking 11 amino acids that is responsible for the interaction with E2F1 has a dominant-negative effect on BRCA1 expression and HR by suppressing E2F1-mediated transactivation of BRCA1 promoter and blocking the enrichment of E2F1 on BRCA1 promoter. Lastly, RNF126 depletion leads to the increased sensitivity to ionizing radiation and poly (ADP-ribose) polymerase inhibition. Collectively, our results suggest a novel role of RNF126 in promoting HR-mediated repair through positive regulation on BRCA1 expression by direct interaction with E2F1. This study not only offers novel insights into our current understanding of the biological functions of RNF126 but also provides a potential therapeutic target for cancer treatment.	[Wang, Y.; Deng, O.; Feng, Z.; Du, Z.; Xiong, X.; Lai, J.; Zhang, J.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, 10900 Euclid Ave,BRB 323, Cleveland, OH 44106 USA; [Deng, O.; Yang, X.; Ma, Z.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Lai, J.] Fujian Med Univ, Affiliated Hosp 2, Quanzhou, Fujian, Peoples R China; [Xu, M.; Taylor, D.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Wang, H.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Yan, C.] Georgia Regents Univ, GRU Canc Ctr, Augusta, GA USA; [Chen, C.] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China; [Difeo, A.] Case Western Reserve Univ, Gen Med Sci, Cleveland, OH 44106 USA	Case Western Reserve University; Sun Yat Sen University; Fujian Medical University; Case Western Reserve University; University System of Maryland; University of Maryland Baltimore; University System of Georgia; Augusta University; Chinese Academy of Sciences; Kunming Institute of Zoology; Case Western Reserve University	Zhang, J (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, 10900 Euclid Ave,BRB 323, Cleveland, OH 44106 USA.; Ma, Z (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	mazhefu@mail.sysu.edu.cn; Junran.zhang@case.edu	Du, Zhanwen/H-9903-2016	Deng, Ou/0000-0002-9933-1832; Yan, Chunhong/0000-0002-3974-7991; DiFeo, Analisa/0000-0001-8319-6763	National Cancer Institute [R01C A154625]; Department of Radiation Oncology, Case Western Reserve University School of Medicine; National Natural Science Foundation of China [31271503]; Guangdong Provincial Natural Science Foundation of China [S2012010008368]; Sun Yat-sen University; Radiation Resources Core Facility; Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center [P30 CA43703]; NATIONAL CANCER INSTITUTE [DP2CA186571, R01CA139107, R01CA154625, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM107058] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Radiation Oncology, Case Western Reserve University School of Medicine; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Sun Yat-sen University; Radiation Resources Core Facility; Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by a grant (R01C A154625) from the National Cancer Institute and a startup fund from the Department of Radiation Oncology, Case Western Reserve University School of Medicine to JZ; National Natural Science Foundation of China grant (31271503), Guangdong Provincial Natural Science Foundation of China grant (S2012010008368) and a startup fund from Sun Yat-sen University to ZM. This research was also supported by Radiation Resources Core Facility and Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center (P30 CA43703). We thank Daniel Li and Mehdi Haider for the technical support.	AMFO K, 1995, ONCOGENE, V11, P351; Andreassen PR, 2006, CARCINOGENESIS, V27, P883, DOI 10.1093/carcin/bgi319; Bindra RS, 2007, ONCOGENE, V26, P2048, DOI 10.1038/sj.onc.1210001; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Biswas AK, 2014, CANCER RES, V74, P3369, DOI 10.1158/0008-5472.CAN-13-3216; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen HH, 2011, RADIAT RES, V175, P214, DOI 10.1667/RR2323.1; Chen J, 2011, CELL CYCLE, V10, P1287, DOI 10.4161/cc.10.8.15341; De Siervi A, 2010, CANCER RES, V70, P532, DOI 10.1158/0008-5472.CAN-09-1477; Delker RK, 2013, P NATL ACAD SCI USA, V110, P1029, DOI 10.1073/pnas.1214538110; Evers B, 2006, ONCOGENE, V25, P5885, DOI 10.1038/sj.onc.1209871; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng ZH, 2012, NUCLEIC ACIDS RES, V40, P726, DOI 10.1093/nar/gkr748; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo RF, 2011, NUCLEIC ACIDS RES, V39, P1390, DOI 10.1093/nar/gkq983; Guo RF, 2010, J BIOL CHEM, V285, P19308, DOI 10.1074/jbc.M110.121939; Helleday T, 2010, CARCINOGENESIS, V31, P955, DOI 10.1093/carcin/bgq064; Iwanaga R, 2004, ONCOGENE, V23, P8581, DOI 10.1038/sj.onc.1207976; Johnson DG, 2006, CURR MOL MED, V6, P731; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Putzer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shi W, 2010, CARCINOGENESIS, V31, P994, DOI 10.1093/carcin/bgq035; Smith CJ, 2013, J CELL SCI, V126, P1366, DOI 10.1242/jcs.116129; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Yanaihara N, 2003, INT J ONCOL, V23, P567; Yang SZ, 2008, EMBO REP, V9, P907, DOI 10.1038/embor.2008.128; Yang TL, 2004, GENE CHROMOSOME CANC, V41, P250, DOI 10.1002/gcc.20080; Zhang JR, 2005, NAT STRUCT MOL BIOL, V12, P902, DOI 10.1038/nsmb991; Zhang JR, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-11; Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664; Zhi X, 2013, CANCER RES, V73, P385, DOI 10.1158/0008-5472.CAN-12-0562; Zhuang J, 2006, CANCER RES, V66, P1401, DOI 10.1158/0008-5472.CAN-05-3278	49	26	26	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1363	1372		10.1038/onc.2015.198	http://dx.doi.org/10.1038/onc.2015.198			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26234677	Green Accepted			2022-12-28	WOS:000372196400003
J	Prahallad, A; Bernards, R				Prahallad, A.; Bernards, R.			Opportunities and challenges provided by crosstalk between signalling pathways in cancer	ONCOGENE			English	Review							HISTONE DEACETYLASE INHIBITOR; SYNTHETIC LETHAL INTERACTION; KRAS-MUTANT LUNG; MEK INHIBITION; RAF INHIBITORS; COMBINED BRAF; BRAF(V600E) INHIBITION; TUMOR MICROENVIRONMENT; COLON-CANCER; RESISTANCE	During evolution, connections between the major signalling pathways were established to provide cells with an ability to deal with perturbations of homeostasis. However, these feedback and crosstalk mechanisms can become a liability in the treatment of cancer, as the inhibition of one cancer-relevant signalling pathway can lead to the activation of a secondary survival pathway that interferes with cancer drug efficacy. In this review, we discuss connections between signalling pathways in relation to cancer therapy and we evaluate the use of genetic approaches to identify pathway crosstalk. We also discuss how insight into connections between signalling pathways can be exploited to design powerful synthetic lethal drug combination therapies for the treatment of cancer.	[Prahallad, A.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherlands, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherlands, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl		Bernards, Rene/0000-0001-8677-3423	EU FP7 grant 'COLTHERES'; Cancer Genomics Netherlands consortium	EU FP7 grant 'COLTHERES'; Cancer Genomics Netherlands consortium	This work was funded by the EU FP7 grant 'COLTHERES' and by the Cancer Genomics Netherlands consortium.	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Alifrangis CC, 2014, MOL ONCOL, V8, P1112, DOI 10.1016/j.molonc.2014.05.014; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Azad NS, 2008, J CLIN ONCOL, V26, P3709, DOI 10.1200/JCO.2007.10.8332; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Bertino EM, 2011, EXPERT OPIN INV DRUG, V20, P1151, DOI 10.1517/13543784.2011.594437; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Dancey JE, 2006, NAT REV DRUG DISCOV, V5, P649, DOI 10.1038/nrd2089; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Garralda E, 2014, CLIN CANCER RES, V20, P2476, DOI 10.1158/1078-0432.CCR-13-3047; Geel R.V., 2014, J CLIN ONCOL, V32, P5; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Julien S, 2012, CLIN CANCER RES, V18, P5314, DOI 10.1158/1078-0432.CCR-12-0372; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kopetz S., 2010, J CLIN ONCOL, V28; Kuczynski EA, 2013, NAT REV CLIN ONCOL, V10, P571, DOI 10.1038/nrclinonc.2013.158; Kummar S, 2010, NAT REV DRUG DISCOV, V9, P843, DOI 10.1038/nrd3216; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Lee EQ, 2012, NEURO-ONCOLOGY, V14, P1511, DOI 10.1093/neuonc/nos264; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nebbioso A, 2012, MOL ONCOL, V6, P657, DOI 10.1016/j.molonc.2012.09.004; Packer LM, 2011, CANCER CELL, V20, P715, DOI 10.1016/j.ccr.2011.11.004; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sosman JA, 2008, EXPERT REV ANTICANC, V8, P481, DOI 10.1586/14737140.8.3.481; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI 10.2217/FON.11.2; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Valachis A, 2010, BREAST CANCER RES TR, V122, P1, DOI 10.1007/s10549-009-0727-0; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249	73	30	32	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1073	1079		10.1038/onc.2015.151	http://dx.doi.org/10.1038/onc.2015.151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982281				2022-12-28	WOS:000371351700001
J	Friedmann-Morvinski, D; Bhargava, V; Gupta, S; Verma, IM; Subramaniam, S				Friedmann-Morvinski, D.; Bhargava, V.; Gupta, S.; Verma, I. M.; Subramaniam, S.			Identification of therapeutic targets for glioblastoma by network analysis	ONCOGENE			English	Article							PLURIPOTENT STEM-CELLS; GENE-EXPRESSION; TUMOR-GROWTH; OSTEOPONTIN; CANCER; MICE; DEDIFFERENTIATION; PROGNOSIS; SURVIVAL; TISSUE	Glioblastoma can originate from terminally differentiated astrocytes and neurons, which can dedifferentiate to a stem cell-like state upon transformation. In this study, we confirmed that transformed dedifferentiated astrocytes and neurons acquired a stem/progenitor cell state, although they still retained gene expression memory from their parental cell. Transcriptional network analysis on these cells identified upregulated genes in three main pathways: Wnt signaling, cell cycle and focal adhesion with the gene Spp1, also known as osteopontin (OPN) serving as a key common node connecting these three pathways. Inhibition of OPN blocked the formation of neurospheres, affected the proliferative capacity of transformed neurons and reduced the expression levels of neural stem cell markers. Specific inhibition of OPN in both murine and human glioma tumors prolonged mice survival. We conclude that OPN is an important player in dedifferentiation of cells during tumor formation, hence its inhibition can be a therapeutic target for glioblastoma.	[Friedmann-Morvinski, D.; Verma, I. M.] Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Friedmann-Morvinski, D.] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem & Mol Biol, IL-69978 Tel Aviv, Israel; [Bhargava, V.; Subramaniam, S.] Univ Calif San Diego, Bioinformat & Syst Biol Grad Program, San Diego, CA 92103 USA; [Gupta, S.; Subramaniam, S.] Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA; [Subramaniam, S.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Subramaniam, S.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Salk Institute; Tel Aviv University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Verma, IM (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.; Subramaniam, S (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.; Subramaniam, S (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Dept Bioengn, La Jolla, CA 92093 USA.	verma@salk.edu; shankar@ucsd.edu			NIH [HL053670]; Cancer Center Core Grant [P30 CA014195-38]; H.N. and Frances C. Berger Foundation; Leona M. and Harry B. Helmsley Charitable Trust grant [2012-PG-MED002]; National Institutes of Health (NIH) National Heart, Lung and Blood Institute [HL087375, HL106579, HL108735]; National Science Foundation (NSF) [DBI-0835541, STC-0939370]; California Institute for Regenerative Medicine (CIRM) Graduate Fellowship [T1-00003, TG2-01154]; NATIONAL CANCER INSTITUTE [P30CA023100, P30CA014195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108735, R33HL087375, R01HL106579, R01HL053670] Funding Source: NIH RePORTER; Direct For Biological Sciences [0835541] Funding Source: National Science Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Core Grant; H.N. and Frances C. Berger Foundation; Leona M. and Harry B. Helmsley Charitable Trust grant; National Institutes of Health (NIH) National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Science Foundation (NSF)(National Science Foundation (NSF)); California Institute for Regenerative Medicine (CIRM) Graduate Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	We thank Gabriela Estepa for her technical help and Ruben Alvarez Rodriguez for designing the inducible miRNA lentivector. IMV is an American Cancer Society Professor of Molecular Biology, and holds the Irwin and Joan Jacobs Chair in Exemplary Life Science. This work was supported in part by grants from the NIH (HL053670) (to IM Verma and D Friedmann-Morvinski), Cancer Center Core Grant (P30 CA014195-38), the H.N. and Frances C. Berger Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust grant #2012-PG-MED002 (to IM Verma). S Subramaniam is supported by National Institutes of Health (NIH) National Heart, Lung and Blood Institute Grant HL087375, HL106579, HL108735, the National Science Foundation (NSF) grants DBI-0835541 and STC-0939370. V Bhargava was the recipient of a California Institute for Regenerative Medicine (CIRM) Graduate Fellowship (T1-00003 and TG2-01154, Interdisciplinary Stem Cell Training Program at UCSD). Accession Code. Gene Expression Omnibus: GSE64411 (sequencing read data).	Atai NA, 2011, IMMUNOLOGY, V132, P39, DOI 10.1111/j.1365-2567.2010.03335.x; Bache M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-132; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhargava V, 2014, SCI REP-UK, V4, DOI 10.1038/srep03678; Bhargava V, 2013, SCI REP-UK, V3, DOI 10.1038/srep01740; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chatr-aryamontri A, 2013, NUCLEIC ACIDS RES, V41, pD816, DOI 10.1093/nar/gks1158; Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Ghosh Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008975; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Ikawa M, 2003, MOL THER, V8, P666, DOI 10.1016/S1525-0016(03)00240-5; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Jain N, 2003, BIOINFORMATICS, V19, P1945, DOI 10.1093/bioinformatics/btg264; Jan HJ, 2010, NEURO-ONCOLOGY, V12, P58, DOI 10.1093/neuonc/nop013; Katagiri YU, 1999, CANCER RES, V59, P219; Lamour V, 2010, INT J CANCER, V126, P1797, DOI 10.1002/ijc.24751; Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Marchetto MCN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007076; Mason CK, 2008, MOL CANCER THER, V7, P548, DOI 10.1158/1535-7163.MCT-07-2251; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Ohi Y, 2011, NAT CELL BIOL, V13, P541, DOI 10.1038/ncb2239; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sreekanthreddy P, 2010, CANCER EPIDEM BIOMAR, V19, P1409, DOI 10.1158/1055-9965.EPI-09-1077; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yamaguchi Y, 2013, J BIOL CHEM, V288, P3097, DOI 10.1074/jbc.M112.362954; Zhao WX, 2012, MOLECULES, V17, P6196, DOI 10.3390/molecules17066196; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	48	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					608	620		10.1038/onc.2015.119	http://dx.doi.org/10.1038/onc.2015.119			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25961929	Green Accepted			2022-12-28	WOS:000369548800008
J	Roeser, JC; Leach, SD; McAllister, F				Roeser, J. C.; Leach, S. D.; McAllister, F.			Emerging strategies for cancer immunoprevention	ONCOGENE			English	Review							REGULATORY T-CELLS; ALPHA-GALACTOSYLCERAMIDE KRN7000; HEPATITIS-B VACCINATION; SMALL INTERFERING RNA; SUPPRESSOR-CELLS; BREAST-CANCER; MAST-CELLS; NATURAL-KILLER; TUMOR-GROWTH; TRANSCRIPTION FACTOR	The crucial role of the immune system in the formation and progression of tumors has been widely accepted. On one hand, the surveillance role of the immune system plays an important role in endogenous tumor prevention, but on the other hand, in some special circumstances such as in chronic inflammation, the immune system can actually contribute to the formation and progression of tumors. In recent years, there has been an explosion of novel targeted immunotherapies for advanced cancers. In the present manuscript, we explore known and potential various types of cancer prevention strategies and focus on nonvaccine-based cancer preventive strategies targeting the immune system at the early stages of tumorigenesis.	[Roeser, J. C.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA; [Leach, S. D.] Mem Sloan Kettering Canc Ctr, David M Rubenstein Ctr Pancreat Canc Res, New York, NY 10021 USA; [McAllister, F.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA	Johns Hopkins University; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McAllister, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe, Houston, TX 77030 USA.	fmcallister@mdanderson.org			Pancreatic Cancer Action Network-AACR Career Development Award [14-20-25-MCAL]; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA134292] Funding Source: NIH RePORTER	Pancreatic Cancer Action Network-AACR Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by 2014 Pancreatic Cancer Action Network-AACR Career Development Award, grant 14-20-25-MCAL.	Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Bar-Natan Michal, 2012, JAKSTAT, V1, P55, DOI 10.4161/jkst.20006; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Becker JC, 2013, CANCER IMMUNOL IMMUN, V62, P1137, DOI 10.1007/s00262-013-1434-6; Blank CU, 2015, INT IMMUNOL, V27, P3, DOI 10.1093/intimm/dxu076; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CDC, VACC INF STAT HPV HU; Chae WJ, 2010, P NATL ACAD SCI USA, V107, P5540, DOI 10.1073/pnas.0912675107; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chang YJ, 2007, P NATL ACAD SCI USA, V104, P10299, DOI 10.1073/pnas.0703824104; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Ciric B, 2009, J IMMUNOL, V182, P5296, DOI 10.4049/jimmunol.0900036; Cuff S, 2010, J IMMUNOL, V184, P607, DOI 10.4049/jimmunol.0804089; Darrasse-Jeze G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00292; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Do JS, 2010, J IMMUNOL, V184, P1675, DOI 10.4049/jimmunol.0903539; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Dwyer MP, 2006, J MED CHEM, V49, P7603, DOI 10.1021/jm0609622; Fagard Remi, 2013, JAKSTAT, V2, pe22882, DOI 10.4161/jkst.22882; Filipazzi P, 2012, CANCER IMMUNOL IMMUN, V61, P255, DOI 10.1007/s00262-011-1161-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017; Fuji N, 2000, CLIN CANCER RES, V6, P3380; FUJIMOTO S, 1975, IMMUNOL COMMUN, V4, P201, DOI 10.3109/08820137409055774; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Ghebeh H, 2006, NEOPLASIA, V8, P190, DOI 10.1593/neo.05733; Giaccone G, 2002, CLIN CANCER RES, V8, P3702; Gogas H, 2006, NEW ENGL J MED, V354, P709, DOI 10.1056/NEJMoa053007; Gonsiorek W, 2007, J PHARMACOL EXP THER, V322, P477, DOI 10.1124/jpet.106.118927; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; GRESSER I, 1990, J INVEST DERMATOL, V95, pS66, DOI 10.1111/1523-1747.ep12874776; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Greten TF, 2010, J IMMUNOTHER, V33, P211, DOI 10.1097/CJI.0b013e3181bb499f; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Gu FM, 2011, WORLD J GASTROENTERO, V17, P3922, DOI 10.3748/wjg.v17.i34.3922; Gu-Trantien C, 2013, J CLIN INVEST, V123, P2873, DOI 10.1172/JCI67428; Gwack J, 2011, ASIAN PAC J CANCER P, V12, P2205; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Harvey RD, 2014, CLIN PHARMACOL THER, V96, P214, DOI 10.1038/clpt.2014.74; Hegmans JPJJ, 2014, CURR OPIN PHARMACOL, V17, P17, DOI 10.1016/j.coph.2014.06.007; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hemdan NYA, 2013, IMMUNOL LETT, V149, P123, DOI 10.1016/j.imlet.2012.11.002; Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Huang C, 2011, WORLD J GASTROENTERO, V17, P2992, DOI 10.3748/wjg.v17.i25.2992; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Hyun YS, 2012, CARCINOGENESIS, V33, P931, DOI 10.1093/carcin/bgs106; Iwai Y, 2005, INT IMMUNOL, V17, P133, DOI 10.1093/intimm/dxh194; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Johansson A, 2010, AM J PATHOL, V177, P1031, DOI 10.2353/ajpath.2010.100070; Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Kilinc MO, 2009, J IMMUNOL, V182, P4217, DOI 10.4049/jimmunol.0802793; Kim YJ, 2010, CANCER PREV RES, V3, P1314, DOI 10.1158/1940-6207.CAPR-09-0272; Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010; Kurzrock R, 2013, CLIN CANCER RES, V19, P3659, DOI 10.1158/1078-0432.CCR-12-3349; Kusmartsev S, 2004, J IMMUNOL, V172, P989, DOI 10.4049/jimmunol.172.2.989; Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491; Lai GF, 2008, BIOORG MED CHEM LETT, V18, P1864, DOI 10.1016/j.bmcl.2008.02.010; Lazarevic V, 2013, NAT REV IMMUNOL, V13, P777, DOI 10.1038/nri3536; Lebwohl M, 2012, NEW ENGL J MED, V366, P1010, DOI 10.1056/NEJMoa1111170; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Lewis AM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-48; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Lust JA, 2009, MAYO CLIN PROC, V84, P114, DOI 10.4065/84.2.114; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Markowitz J, 2013, BREAST CANCER RES TR, V140, P13, DOI 10.1007/s10549-013-2618-7; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; McCleland BW, 2007, BIOORG MED CHEM LETT, V17, P1713, DOI 10.1016/j.bmcl.2006.12.067; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Mian BM, 2003, CLIN CANCER RES, V9, P3167; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Mitsunaga S, 2013, BRIT J CANCER, V108, P2063, DOI 10.1038/bjc.2013.174; Molling JW, 2007, J CLIN ONCOL, V25, P862, DOI 10.1200/JCO.2006.08.5787; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Mundy-Bosse BL, 2011, CANCER IMMUNOL IMMUN, V60, P1269, DOI 10.1007/s00262-011-1029-z; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Murdaca G, 2015, EXPERT OPIN DRUG SAF, V14, P571, DOI 10.1517/14740338.2015.1009036; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Murugaiyan G, 2009, J IMMUNOL, V183, P4169, DOI 10.4049/jimmunol.0901017; Najjar YG, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00049; Nakanishi Y, 2011, CARCINOGENESIS, V32, P1333, DOI 10.1093/carcin/bgr128; Nam JS, 2008, CANCER RES, V68, P3915, DOI 10.1158/0008-5472.CAN-08-0206; NANUS DM, 1990, CANCER RES, V50, P4190; Ning Y, 2012, MOL CANCER THER, V11, P1353, DOI 10.1158/1535-7163.MCT-11-0915; Nishimoto N, 2005, BLOOD, V106, P2627, DOI 10.1182/blood-2004-12-4602; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Nowell MA, 2009, J IMMUNOL, V182, P613, DOI 10.4049/jimmunol.182.1.613; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Oka T, 2012, LAB INVEST, V92, P1472, DOI 10.1038/labinvest.2012.116; Okazaki T, 2006, TRENDS IMMUNOL, V27, P195, DOI 10.1016/j.it.2006.02.001; Okudaira K, 2009, INT J ONCOL, V35, P741, DOI 10.3892/ijo_00000387; Olive KP, 2006, CLIN CANCER RES, V12, P5277, DOI 10.1158/1078-0432.CCR-06-0436; Onizuka S, 1999, CANCER RES, V59, P3128; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Pardoll DM, 2012, NAT IMMUNOL, V13, P1129, DOI 10.1038/ni.2392; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patterson SL, 2013, CLIN CHEM, V59, P94, DOI 10.1373/clinchem.2012.185389; Pentcheva-Hoang T, 2014, CANCER IMMUNOL RES, V2, P970, DOI 10.1158/2326-6066.CIR-14-0104; Phillips RKS, 2002, GUT, V50, P857, DOI 10.1136/gut.50.6.857; PORTIER M, 1993, BRIT J HAEMATOL, V85, P514; Rabenhorst A, 2012, BLOOD, V120, P2042, DOI 10.1182/blood-2012-03-415638; Rachitskaya AV, 2008, J IMMUNOL, V180, P5167, DOI 10.4049/jimmunol.180.8.5167; Ribas A, 2013, J CLIN ONCOL, V31, P616, DOI 10.1200/JCO.2012.44.6112; Rizza P, 2010, AUTOIMMUNITY, V43, P204, DOI 10.3109/08916930903510880; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schlessinger K, 2005, CANCER RES, V65, P5828, DOI 10.1158/0008-5472.CAN-05-0317; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma RK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073145; SHEIL AGR, 1986, WORLD J SURG, V10, P389; Shields JD, 2010, SCIENCE, V328, P749, DOI 10.1126/science.1185837; Shimizu J, 1999, J IMMUNOL, V163, P5211; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Solomon SD, 2006, CIRCULATION, V114, P1028, DOI 10.1161/CIRCULATIONAHA.106.636746; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; SPRATT JS, 1981, J SURG ONCOL, V18, P219, DOI 10.1002/jso.2930180302; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Steinberg G, 2000, J UROLOGY, V163, P761, DOI 10.1016/S0022-5347(05)67799-3; STUTMAN O, 1974, SCIENCE, V183, P534, DOI 10.1126/science.183.4124.534; Sun M, 2010, NAT REV UROL, V7, P327, DOI 10.1038/nrurol.2010.57; Sylvester RJ, 2011, INT J UROL, V18, P113, DOI 10.1111/j.1442-2042.2010.02678.x; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tachibana T, 2005, CLIN CANCER RES, V11, P7322, DOI 10.1158/1078-0432.CCR-05-0877; Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781; Vicari AP, 2002, SEMIN CANCER BIOL, V12, P33, DOI 10.1006/scbi.2001.0400; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wagsater D, 2006, ANTICANCER RES, V26, P4213; Walker LSK, 2011, NAT REV IMMUNOL, V11, P852, DOI 10.1038/nri3108; Walters I, 2008, BIOORG MED CHEM LETT, V18, P798, DOI 10.1016/j.bmcl.2007.11.039; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wasiuk A, 2012, CANCER IMMUNOL IMMUN, V61, P2273, DOI 10.1007/s00262-012-1276-7; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wilcox RA, 2012, EUR J HAEMATOL, V88, P465, DOI 10.1111/j.1600-0609.2012.01766.x; Winters MP, 2008, BIOORG MED CHEM LETT, V18, P1926, DOI 10.1016/j.bmcl.2008.01.127; Wojno EDT, 2012, CELL HOST MICROBE, V12, P445, DOI 10.1016/j.chom.2012.10.003; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Yang ZS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008922; Yao C, 2007, INT J CANCER, V121, P1949, DOI 10.1002/ijc.22930; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZEID NA, 1993, PATHOLOGY, V25, P338, DOI 10.3109/00313029309090853; Zhang YQ, 2013, CANCER RES, V73, P6359, DOI 10.1158/0008-5472.CAN-13-1558-T; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	189	27	28	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6029	6039		10.1038/onc.2015.98	http://dx.doi.org/10.1038/onc.2015.98			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	26364615				2022-12-28	WOS:000366113800001
J	Vervliet, T; Parys, JB; Bultynck, G				Vervliet, T.; Parys, J. B.; Bultynck, G.			Bcl-2 proteins and calcium signaling: complexity beneath the surface	ONCOGENE			English	Review							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; DEPENDENT ANION CHANNEL; SARCOPLASMIC/ENDOPLASMIC RETICULUM CA2+-ATPASE; FAMILY-MEMBER BOK; BCL-X(L)-INHIBITORY BH3 MIMETICS; CANCER-CELL-PROLIFERATION; APOPTOTIC CA2+ SIGNALS; ENDOPLASMIC-RETICULUM; MITOCHONDRIAL CA2+; PLASMA-MEMBRANE	Antiapoptotic Bcl-2-family members are well known for their 'mitochondrial' functions as critical neutralizers of proapoptotic Bcl-2-family members, including the executioner multidomain proteins Bax and Bak and the BH3-only proteins. It has been clear for more than 20 years that Bcl-2 proteins can impact intracellular Ca2+ homeostasis and dynamics. Moreover, altered Ca2+ signaling is increasingly linked to oncogenic behavior. Specifically targeting the Ca2+-signaling machinery may thus prove to be a valuable strategy for cancer treatment. Over 10 years ago a major controversy was recognized concerning whether or not Bcl-2 proteins exerted their antiapoptotic functions via Ca2+ signaling through lowering the filling state of the endoplasmic reticulum (ER) Ca2+ stores or by suppressing Ca2+ release from the ER without affecting the filling state of this Ca2+ store. Further research from different laboratories indicated a wide variety of mechanisms by which Bcl-2-family members can impact Ca2+ signaling. In this review, we propose that antiapoptotic Bcl-2-family members are multimodal regulators of intracellular Ca2+-signaling events in cell survival and cell death. We will discuss how different Bcl-2-family members impact cell survival and cell death by regulating Ca2+ transport systems at the ER, mitochondria and plasma membrane and by impacting the organization of organelles and how these insights can be exploited for causing cell death in cancer cells. Finally, we propose that the existing controversy reflects the diversity of links between Bcl-2 proteins and Ca2+ signaling, as certainly not all targets or mechanisms will be operative in every cell type and every condition.	[Bultynck, G.] Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Cellular & Mol Med, Campus Gasthuisberg O-N Bus 802,Herestr 49, BE-3000 Leuven, Belgium; [Bultynck, G.] LKI, Campus Gasthuisberg O-N Bus 802,Herestr 49, BE-3000 Leuven, Belgium	KU Leuven	Bultynck, G (corresponding author), Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Cellular & Mol Med, Campus Gasthuisberg O-N Bus 802,Herestr 49, BE-3000 Leuven, Belgium.; Bultynck, G (corresponding author), LKI, Campus Gasthuisberg O-N Bus 802,Herestr 49, BE-3000 Leuven, Belgium.	geert.bultynck@med.kuleuven.be		Vervliet, Tim/0000-0002-4030-5875; Bultynck, Geert/0000-0002-5968-4828; Parys, Jan/0000-0002-3591-4967	Research Foundation-Flanders (FWO) [6.057.12, G.0819.13, G.0C91.14, G.0A34.16]; Research Council of the KU Leuven [14/101, BOF PDM/15/188]; Interuniversity Attraction Poles Program (Belgian Science Policy) [IAP-P7/13]	Research Foundation-Flanders (FWO)(FWO); Research Council of the KU Leuven(KU Leuven); Interuniversity Attraction Poles Program (Belgian Science Policy)(Belgian Federal Science Policy Office)	Work performed in the authors' laboratory was supported by grants from the Research Foundation-Flanders (FWO grants 6.057.12, G.0819.13, G.0C91.14 and G.0A34.16), by the Research Council of the KU Leuven (OT grant 14/101) and by the Interuniversity Attraction Poles Program (Belgian Science Policy; IAP-P7/13). TV is a recipient of a post-doctoral fellowship of the Research Council of the KU Leuven (BOF PDM/15/188). We thank all lab members for fruitful discussions.	Abu-Hamad S, 2008, J BIOL CHEM, V283, P13482, DOI 10.1074/jbc.M708216200; Abu-Hamad S, 2009, J CELL SCI, V122, P1906, DOI 10.1242/jcs.040188; Ahmad S, 2009, AM J RESP CRIT CARE, V179, P816, DOI 10.1164/rccm.200807-1104OC; Ahn T, 2010, CELL CALCIUM, V47, P387, DOI 10.1016/j.ceca.2010.02.003; Akimzhanov AM, 2013, CELL CALCIUM, V53, P152, DOI 10.1016/j.ceca.2012.10.002; Akl H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.140; Akl H, 2015, INT J DEV BIOL, V59, P391, DOI 10.1387/ijdb.150213gb; Akl H, 2014, BBA-MOL CELL RES, V1843, P2240, DOI 10.1016/j.bbamcr.2014.04.017; Akl H, 2013, HAEMATOLOGICA, V98, pE49, DOI 10.3324/haematol.2012.080598; Akl H, 2013, BBA-REV CANCER, V1835, P180, DOI 10.1016/j.bbcan.2012.12.001; Alavian KN, 2011, NAT CELL BIOL, V13, P1224, DOI 10.1038/ncb2330; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Arbabian A, 2011, BIOFACTORS, V37, P139, DOI 10.1002/biof.142; Arbel N, 2012, J BIOL CHEM, V287, P23152, DOI 10.1074/jbc.M112.345918; Arbel N, 2010, J BIOL CHEM, V285, P6053, DOI 10.1074/jbc.M109.082990; Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; Autret A, 2009, MOL CELL, V36, P355, DOI 10.1016/j.molcel.2009.10.011; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Barclay LA, 2015, MOL CELL, V57, P873, DOI 10.1016/j.molcel.2015.01.014; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Berman SB, 2009, J CELL BIOL, V184, P707, DOI 10.1083/jcb.200809060; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Bittremieux M, 2016, BBA-MOL CELL RES, V1863, P1364, DOI 10.1016/j.bbamcr.2016.01.002; Bonneau B, 2013, BBA-MOL CELL RES, V1833, P1755, DOI 10.1016/j.bbamcr.2013.01.021; Bononi A, 2012, ADV EXP MED BIOL, V740, P411, DOI 10.1007/978-94-007-2888-2_17; Bonora M, 2015, PHARMACOL RES, V99, P82, DOI 10.1016/j.phrs.2015.05.008; Bonora M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00302; Bootman MD, 2001, J CELL SCI, V114, P2213; Brini M, 2013, FEBS J, V280, P5385, DOI 10.1111/febs.12193; Brooks C, 2007, P NATL ACAD SCI USA, V104, P11649, DOI 10.1073/pnas.0703976104; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Bultynck G, 2012, J BIOL CHEM, V287, P2544, DOI 10.1074/jbc.M111.275354; Burgoyne T, 2015, BBA-MOL CELL RES, V1853, P2012, DOI 10.1016/j.bbamcr.2015.01.022; Cao X, 2015, CELL CALCIUM, V58, P342, DOI 10.1016/j.ceca.2015.03.003; Cardenas C, 2012, CELL CALCIUM, V52, P44, DOI 10.1016/j.ceca.2012.03.001; Cardenas C, 2010, CELL, V142, P270, DOI 10.1016/j.cell.2010.06.007; Carpio MA, 2015, P NATL ACAD SCI USA, V112, P7201, DOI 10.1073/pnas.1421063112; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chan J, 2010, J BIOL CHEM, V285, P36092, DOI 10.1074/jbc.M110.140160; Chang MJ, 2014, P NATL ACAD SCI USA, V111, P1186, DOI 10.1073/pnas.1323098111; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Cleland MM, 2011, CELL DEATH DIFFER, V18, P235, DOI 10.1038/cdd.2010.89; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Csordas G, 2010, MOL CELL, V39, P121, DOI 10.1016/j.molcel.2010.06.029; Curry MC, 2011, BIOFACTORS, V37, P132, DOI 10.1002/biof.146; Dang D, 2016, BBA-MOL CELL RES, V1863, P1344, DOI 10.1016/j.bbamcr.2015.11.016; Davids MS, 2012, J CLIN ONCOL, V30, P3127, DOI 10.1200/JCO.2011.37.0981; de Mattia F, 2009, MOL BIOL CELL, V20, P3638, DOI 10.1091/mbc.E09-05-0385; De Stefani D, 2012, CELL DEATH DIFFER, V19, P267, DOI 10.1038/cdd.2011.92; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Decuypere JP, 2011, BBA-MOL CELL RES, V1813, P1003, DOI 10.1016/j.bbamcr.2010.11.023; Dellis O, 2006, SCIENCE, V313, P229, DOI 10.1126/science.1125203; Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05; Distelhorst CW, 2004, ONCOGENE, V23, P2875, DOI 10.1038/sj.onc.1207519; Dremina ES, 2012, BIOCHEM J, V444, P127, DOI 10.1042/BJ20111114; Dremina ES, 2006, BIOCHEMISTRY-US, V45, P175, DOI 10.1021/bi050800s; Dremina ES, 2004, BIOCHEM J, V383, P361, DOI 10.1042/BJ20040187; Dubois C, 2014, CANCER CELL, V26, P19, DOI 10.1016/j.ccr.2014.04.025; Echeverry N, 2013, CELL DEATH DIFFER, V20, P785, DOI 10.1038/cdd.2013.10; Eckenrode EF, 2010, J BIOL CHEM, V285, P13678, DOI 10.1074/jbc.M109.096040; Elkoreh G, 2012, J CELL BIOCHEM, V113, P2775, DOI 10.1002/jcb.24155; Ferdek PE, 2012, CURR BIOL, V22, P1241, DOI 10.1016/j.cub.2012.05.002; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Foskett JK, 2007, PHYSIOL REV, V87, P593, DOI 10.1152/physrev.00035.2006; Foskett JK, 2009, BIOPHYS J, V96, p391A, DOI 10.1016/j.bpj.2008.12.2917; Gandini MA, 2015, CURR TOP MED CHEM, V15, P604, DOI 10.2174/1568026615666150225112605; Gees M, 2012, COMPR PHYSIOL, V2, P563, DOI 10.1002/cphy.c110026; Giorgi C, 2015, ANTIOXID REDOX SIGN, V22, P995, DOI 10.1089/ars.2014.6223; Giorgi C, 2015, ONCOTARGET, V6, P1435, DOI 10.18632/oncotarget.2935; Giorgi C, 2012, CELL CALCIUM, V52, P36, DOI 10.1016/j.ceca.2012.02.008; Giorgi Carlotta, 2011, Commun Integr Biol, V4, P334, DOI 10.4161/cib.4.3.15021; Greenberg EF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.355; Greenberg EF, 2014, BBA-MOL CELL RES, V1843, P2205, DOI 10.1016/j.bbamcr.2014.03.008; Grimm S, 2012, BBA-MOL CELL RES, V1823, P327, DOI 10.1016/j.bbamcr.2011.11.018; Habermacher C, 2016, NEUROPHARMACOLOGY, V104, P18, DOI 10.1016/j.neuropharm.2015.07.032; Han BS, 2015, CANCER CELL, V27, P852, DOI 10.1016/j.ccell.2015.04.010; Hang LS, 2000, J NEUROCHEM, V75, P1852; Hanson CJ, 2008, CELL CALCIUM, V44, P324, DOI 10.1016/j.ceca.2008.01.003; Hanson CJ, 2008, CELL CALCIUM, V44, P243, DOI 10.1016/j.ceca.2007.11.014; Harr MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005579; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hedgepeth SC, 2015, J BIOL CHEM, V290, P7304, DOI 10.1074/jbc.M114.611186; Henke N, 2011, CELL CALCIUM, V50, P251, DOI 10.1016/j.ceca.2011.05.005; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Hoth M, 2016, BBA-MOL CELL RES, V1863, P1408, DOI 10.1016/j.bbamcr.2015.12.009; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Huang GJ, 2006, J CELL SCI, V119, P153, DOI 10.1242/jcs.02731; Huang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.419; Huang HY, 2013, J BIOL CHEM, V288, P19870, DOI 10.1074/jbc.M112.448290; Hwang MS, 2014, CELL DEATH DIFFER, V21, P1733, DOI 10.1038/cdd.2014.84; Ishikawa T, 2011, CELL DEATH DIFFER, V18, P1271, DOI 10.1038/cdd.2011.59; Ivanova H, 2014, BBA-MOL CELL RES, V1843, P2164, DOI 10.1016/j.bbamcr.2014.03.007; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Kanekura K, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0341; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kim HR, 2008, J BIOL CHEM, V283, P15946, DOI 10.1074/jbc.M800075200; Kiviluoto S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.103; Kiviluoto S, 2013, BBA-MOL CELL RES, V1833, P1612, DOI 10.1016/j.bbamcr.2013.01.026; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Kobrinsky EM, 2001, ONCOGENE, V20, P933, DOI 10.1038/sj.onc.1204153; Krebs J, 2015, BBA-MOL CELL RES, V1853, P2018, DOI 10.1016/j.bbamcr.2014.12.020; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Kvansakul M, 2008, CELL DEATH DIFFER, V15, P1564, DOI 10.1038/cdd.2008.83; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lanner JT, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003996; Lavik AR, 2015, ONCOTARGET, V6, P27388, DOI 10.18632/oncotarget.4489; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Li C, 2007, P NATL ACAD SCI USA, V104, P12565, DOI 10.1073/pnas.0702489104; Li H, 2008, P NATL ACAD SCI USA, V105, P2169, DOI 10.1073/pnas.0711647105; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lisak DA, 2015, BBA-MOL CELL RES, V1853, P2104, DOI 10.1016/j.bbamcr.2015.03.002; Liu Z, 2015, DRUG DISCOV TODAY S; Llambi F, 2011, CURR OPIN GENET DEV, V21, P12, DOI 10.1016/j.gde.2010.12.001; Lopreiato R, 2014, J BIOL CHEM, V289, P10261, DOI 10.1074/jbc.O114.555565; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Malia TJ, 2007, BIOCHEMISTRY-US, V46, P514, DOI 10.1021/bi061577h; Marchi S, 2014, BBA-BIOENERGETICS, V1837, P461, DOI 10.1016/j.bbabio.2013.10.015; McAndrew D, 2011, MOL CANCER THER, V10, P448, DOI 10.1158/1535-7163.MCT-10-0923; Mekahli D, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004317; Michels Judith, 2013, Int J Cell Biol, V2013, P705294, DOI 10.1155/2013/705294; Monaco G, 2012, CELL DEATH DIFFER, V19, P295, DOI 10.1038/cdd.2011.97; Monaco G, 2015, J BIOL CHEM, V290, P9150, DOI 10.1074/jbc.M114.622514; Monaco G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073386; Monaco G, 2013, CELL MOL LIFE SCI, V70, P1171, DOI 10.1007/s00018-012-1118-y; Monaco G, 2012, BIOCHEM BIOPH RES CO, V428, P31, DOI 10.1016/j.bbrc.2012.10.002; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Morciano G, 2016, MOL BIOL CELL, V27, P20, DOI 10.1091/mbc.E15-01-0028; Munoz-Pinedo C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.246; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Padanyi R, 2016, BBA-MOL CELL RES, V1863, P1351, DOI 10.1016/j.bbamcr.2015.12.011; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Palty R, 2012, J BIOL CHEM, V287, P31650, DOI 10.1074/jbc.R112.355867; Parys JB, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005093; Parys JB, 2012, ADV EXP MED BIOL, V740, P255, DOI 10.1007/978-94-007-2888-2_11; Pavlov E, 2005, BBA-BIOENERGETICS, V1710, P96, DOI 10.1016/j.bbabio.2005.09.006; Pernas L, 2016, ANNU REV PHYSIOL, V78, P505, DOI 10.1146/annurev-physiol-021115-105011; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Prins Daniel, 2011, Cold Spring Harb Perspect Biol, V3, DOI 10.1101/cshperspect.a004069; Rajan S, 2015, SCI REP-UK, V5, DOI 10.1038/srep10609; Raphael M, 2014, P NATL ACAD SCI USA, V111, pE3870, DOI 10.1073/pnas.1413409111; Raturi A, 2013, BBA-MOL CELL RES, V1833, P213, DOI 10.1016/j.bbamcr.2012.04.013; Raynal NJM, 2016, CANCER RES, V76, P1494, DOI 10.1158/0008-5472.CAN-14-2391; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Rojas-Rivera D, 2015, ONCOGENE, V34, P269, DOI 10.1038/onc.2014.6; Rojas-Rivera D, 2012, CELL DEATH DIFFER, V19, P1013, DOI 10.1038/cdd.2011.189; Rong YP, 2008, MOL CELL, V31, P255, DOI 10.1016/j.molcel.2008.06.014; Rong YP, 2009, P NATL ACAD SCI USA, V106, P14397, DOI 10.1073/pnas.0907555106; Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852; Roome CJ, 2013, ADV EXP MED BIOL, V961, P251, DOI 10.1007/978-1-4614-4756-6_21; Rooswinkel RW, 2014, BLOOD, V123, P2806, DOI 10.1182/blood-2013-08-519470; Sammels E, 2010, CELL CALCIUM, V47, P297, DOI 10.1016/j.ceca.2010.02.001; Saraiva N, 2013, J CELL BIOL, V202, P699, DOI 10.1083/jcb.201301016; Saraiva N, 2013, J BIOL CHEM, V288, P13057, DOI 10.1074/jbc.M112.414367; Schoenwaelder SM, 2012, BLOOD, V119, P1320, DOI 10.1182/blood-2011-10-387399; Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849; Schulman JJ, 2013, J BIOL CHEM, V288, P25340, DOI 10.1074/jbc.M113.496570; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shoshan-Barmatz V, 2008, J BIOENERG BIOMEMBR, V40, P183, DOI 10.1007/s10863-008-9147-9; Shoshan-Barmatz V, 2010, MOL ASPECTS MED, V31, P227, DOI 10.1016/j.mam.2010.03.002; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Sung PJ, 2013, P NATL ACAD SCI USA, V110, P20593, DOI 10.1073/pnas.1306431110; Szabadkai G, 2006, J CELL BIOL, V175, P901, DOI 10.1083/jcb.200608073; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Treves S, 2004, J CELL BIOL, V166, P537, DOI 10.1083/jcb.200404079; Treves S, 2010, J CELL SCI, V123, P4170, DOI 10.1242/jcs.068387; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Vandecaetsbeek Ilse, 2011, Cold Spring Harb Perspect Biol, V3, DOI 10.1101/cshperspect.a004184; Varadarajan S, 2012, CELL DEATH DIFFER, V19, P1896, DOI 10.1038/cdd.2012.108; Vashisht A, 2015, AM J PHYSIOL-CELL PH, V309, pC457, DOI 10.1152/ajpcell.00064.2015; Verbert L, 2008, BIOL CELL, V100, P39, DOI 10.1042/BC20070086; Vervliet T, 2015, BIOCHEM SOC T, V43, P396, DOI 10.1042/BST20140298; Vervliet T, 2015, SCI REP-UK, V5, DOI 10.1038/srep09641; Vervliet T, 2014, J CELL SCI, V127, P2782, DOI 10.1242/jcs.150011; Vervloessem T, 2015, AGING-US, V7, P748, DOI 10.18632/aging.100828; Vervloessem T, 2015, BBA-MOL CELL RES, V1853, P1992, DOI 10.1016/j.bbamcr.2014.12.006; Vogler M, 2011, BLOOD, V117, P7145, DOI 10.1182/blood-2011-03-344812; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang X, 2011, CELL DEATH DIFFER, V18, P38, DOI 10.1038/cdd.2010.68; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Wiel C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4792; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zhang LN, 2011, P NATL ACAD SCI USA, V108, P13653, DOI 10.1073/pnas.1103360108; Zhong F, 2006, J CELL BIOL, V172, P127, DOI 10.1083/jcb.200506189; Zhong F, 2011, BLOOD, V117, P2924, DOI 10.1182/blood-2010-09-307405; Zhu LP, 2001, J MOL CELL CARDIOL, V33, P2135, DOI 10.1006/jmcc.2001.1476; Zorzano A, 2010, SEMIN CELL DEV BIOL, V21, P566, DOI 10.1016/j.semcdb.2010.01.002	214	116	119	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5079	5092		10.1038/onc.2016.31	http://dx.doi.org/10.1038/onc.2016.31			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26973249	Green Published			2022-12-28	WOS:000384433000001
J	Roth, I; Campbell, H; Rubio, C; Vennin, C; Wilson, M; Wiles, A; Williams, G; Woolley, A; Timpson, P; Berridge, MV; Fleming, N; Baird, M; Braithwaite, AW				Roth, I.; Campbell, H.; Rubio, C.; Vennin, C.; Wilson, M.; Wiles, A.; Williams, G.; Woolley, A.; Timpson, P.; Berridge, M. V.; Fleming, N.; Baird, M.; Braithwaite, A. W.			The Delta 133p53 isoform and its mouse analogue Delta 122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; P53 ISOFORMS; ANGIOGENESIS; EXPRESSION; CANCER; INHIBITOR; MIGRATION; MOTILITY; MUTANT	A number of naturally occurring isoforms of the tumour suppressor protein p53 have been discovered, which appear to have differing roles in tumour prevention or promotion. We are investigating the tumour-promoting activities of the Delta 133p53 isoform using our mouse model of Delta 133p53 (Delta 122p53). Here, we report that tumours from Delta 122p53 homozygous mice show evidence of invasion and metastasis and that Delta 122p53 promotes migration though a 3-dimensional collagen matrix. We also show that Delta 122p53 and Delta 133p53 promote cell migration in scratch wound and Transwell assays, similar to the 'gain-of-function' phenotypes seen with mutant p53. Using the well-defined B16 mouse melanoma metastatic model, we show that Delta 122p53 leads to faster generation of lung metastases. The increased migratory phenotypes are dependent on secreted factors, including the cytokine interleukin-6 and the chemokine CCL2. We propose that Delta 122p53 (and Delta 133p53) acts in a similar manner to 'gain-of-function' mutant p53 proteins to promote migration, invasion and metastasis, which may contribute to poor survival in patients with Delta 133p53-expressing tumours.	[Roth, I.; Wilson, M.; Wiles, A.; Williams, G.; Woolley, A.; Fleming, N.; Baird, M.; Braithwaite, A. W.] Univ Otago, Dunedin Sch Med, Dept Pathol, 58 Hanover St, Dunedin, New Zealand; [Roth, I.; Baird, M.; Braithwaite, A. W.] Univ Auckland, Sch Biol Sci, Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand; [Campbell, H.; Rubio, C.; Braithwaite, A. W.] Univ Sydney, Childrens Med Res Inst, Sydney, NSW, Australia; [Vennin, C.; Timpson, P.] Garvan Inst Med Res, Sydney, NSW, Australia; [Berridge, M. V.] Malaghan Inst Med Res, Wellington, New Zealand	University of Otago; University of Auckland; Children's Medical Research Institute - Australia; University of Sydney; Garvan Institute of Medical Research; Malaghan Institute; Victoria University Wellington	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, 58 Hanover St, Dunedin, New Zealand.	antony.braithwaite@otago.ac.nz	Timpson, Paul/A-9429-2016	Berridge, Michael/0000-0003-2619-7473; Vennin, Claire/0000-0001-9088-4177; Timpson, Paul/0000-0002-5514-7080	Health Research Council of New Zealand; Marsden Fund; Maurice Wilkins Centre for Molecular Biodiscovery; Cancer Council NSW; National Health and Medical Research Council	Health Research Council of New Zealand(Health Research Council of New Zealand); Marsden Fund(Royal Society of New ZealandMarsden Fund (NZ)); Maurice Wilkins Centre for Molecular Biodiscovery; Cancer Council NSW(Cancer Council New South Wales); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the Health Research Council of New Zealand, Marsden Fund, Maurice Wilkins Centre for Molecular Biodiscovery, Cancer Council NSW and National Health and Medical Research Council.	Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Anensen N, 2006, CLIN CANCER RES, V12, P3985, DOI 10.1158/1078-0432.CCR-05-1970; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Bernard H, 2013, ONCOGENE, V32, P2150, DOI 10.1038/onc.2012.242; BLAY JY, 1992, CANCER RES, V52, P3317; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bystry RS, 2001, NAT IMMUNOL, V2, P1126, DOI 10.1038/ni735; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Gudkov Andrei V, 2011, Genes Cancer, V2, P503, DOI 10.1177/1947601911409747; Guo FK, 2004, ONCOGENE, V23, P5577, DOI 10.1038/sj.onc.1207752; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hafsi H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-134; Hofstetter G, 2010, ONCOGENE, V29, P1997, DOI 10.1038/onc.2009.482; JOHNSON RK, 1979, INT J RADIAT ONCOL, V5, P1605, DOI 10.1016/0360-3016(79)90782-X; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nutthasirikul N, 2013, INT J ONCOL, V42, P1181, DOI 10.3892/ijo.2013.1818; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; Ravi R, 2000, GENE DEV, V14, P34; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Slatter TL, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.149; Slatter TL, 2011, BLOOD, V117, P5166, DOI 10.1182/blood-2010-11-321851; Song W, 2009, CHINESE MED J-PEKING, V122, P921, DOI 10.3760/cma.j.issn.0366-6999.2009.08.008; Timpson P, 2011, JOVE-J VIS EXP, DOI 10.3791/3089	33	23	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					4981	4989		10.1038/onc.2016.45	http://dx.doi.org/10.1038/onc.2016.45			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26996665				2022-12-28	WOS:000383965300003
J	Marjon, KD; Termini, CM; Karlen, KL; Saito-Reis, C; Soria, CE; Lidke, KA; Gillette, JM				Marjon, K. D.; Termini, C. M.; Karlen, K. L.; Saito-Reis, C.; Soria, C. E.; Lidke, K. A.; Gillette, J. M.			Tetraspanin CD82 regulates bone marrow homing of acute myeloid leukemia by modulating the molecular organization of N-cadherin	ONCOGENE			English	Article							CANCER-CELL-LINES; HEMATOPOIETIC STEM; PROGENITOR CELLS; PROTEIN; METASTASIS; MEMBRANE; ADHESION; PALMITOYLATION; EXPRESSION; INTEGRIN	Communication between acute myeloid leukemia (AML) and the bone marrow microenvironment is known to control disease progression. Therefore, regulation of AML cell trafficking and adhesion to the bone marrow is of significant interest. In this study, we demonstrate that differential expression of the membrane scaffold CD82 modulates the bone marrow homing of AML cells. By combining mutational analysis and super-resolution imaging, we identify membrane protein clustering by CD82 as a regulator of AML cell adhesion and bone marrow homing. Cluster analysis of super-resolution data indicates that N-linked glycosylation and palmitoylation of CD82 are both critical modifications that control the microdomain organization of CD82 as well as the nanoscale clustering of associated adhesion protein, N-cadherin. We demonstrate that the inhibition of CD82 glycosylation increases the molecular packing of N-cadherin and promotes the bone marrow homing of AML cells. In contrast, we find that the inhibition of CD82 palmitoylation disrupts the formation and organization of N-cadherin clusters and significantly diminishes bone marrow trafficking of AML. Taken together, these data establish a mechanism where the membrane organization of CD82, through specific posttranslational modifications, regulates N-cadherin clustering and membrane density, which impacts the in vivo trafficking of AML cells. As such, these observations provide an alternative model for targeting AML where modulation of protein organization within the membrane may be an effective treatment therapy to disrupt the bone marrow homing potential of AML cells.	[Marjon, K. D.; Termini, C. M.; Karlen, K. L.; Saito-Reis, C.; Soria, C. E.; Gillette, J. M.] Univ New Mexico, Dept Pathol, Hlth Sci Ctr, MSC 08-4640, Albuquerque, NM 87131 USA; [Lidke, K. A.] Univ New Mexico, Dept Phys & Astron, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico	Gillette, JM (corresponding author), Univ New Mexico, Dept Pathol, Hlth Sci Ctr, MSC 08-4640, Albuquerque, NM 87131 USA.	JGillette@salud.unm.edu	Termini, Christina/AAC-7667-2019	Termini, Christina/0000-0002-1831-1347; Saito Reis, Chelsea/0000-0002-6431-4602; Volcko, Karin Linnea/0000-0002-4234-0703	NIH [R01 HL122483-01A1]; New Mexico INBRE grant [NIH P20 GM103451]; University of New Mexico Cancer Center [NIH P30CA118100]; American Cancer Society Institutional Research Grant; NM Spatiotemporal Modeling Center [NIH T32 HL007736, NIH P50 GM085273, NIH F31 HL124977]; University of New Mexico Department of Pathology; NATIONAL CANCER INSTITUTE [P30CA118100] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007736, R01HL122483, F31HL124977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM085273, P20GM103451] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Mexico INBRE grant; University of New Mexico Cancer Center; American Cancer Society Institutional Research Grant(American Cancer Society); NM Spatiotemporal Modeling Center; University of New Mexico Department of Pathology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to acknowledge all of the funding sources that made this work possible. This includes funding from an NIH R01 HL122483-01A1 to JMG, a New Mexico INBRE grant subaward to JMG (NIH P20 GM103451), pilot funding from the University of New Mexico Cancer Center (NIH P30CA118100), an American Cancer Society Institutional Research Grant, a Post-Doctoral Training Fellowship to KDM (NIH T32 HL007736), Graduate Student Training Fellowships to CMT from the NM Spatiotemporal Modeling Center (NIH P50 GM085273) and (NIH F31 HL124977), and a Graduate Student Training Fellowship to CSR (NIH T32 HL007736). We also thank the NM Spatiotemporal Modeling Center for supporting the Super-Resolution Imaging Core Facility (NIH P50 GM085273) and the University of New Mexico Cancer Center (NIH P30CA118100) for use of the Keck-UNM Small Animal Models and Imaging Shared Resource. This work was also supported through faculty start-up funds to JMG from the University of New Mexico Department of Pathology. Finally, we would like to acknowledge the technical assistance of Rebecca J. Dodd and Dr I-Ming Chen, University of New Mexico Health Sciences Center. In addition, we would like to acknowledge the assistance of Dr Ravi Majeti, Division of Hematology, Institute for Stem Cell Biology and Regenerative Medicine, and Cancer Institute, Stanford University and the Stanford University Division of Hematology Tissue Bank for samples. (http://www.nature.com/onc)	Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Bassani S, 2012, INT J BIOCHEM CELL B, V44, P703, DOI 10.1016/j.biocel.2012.01.020; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Bonardi F, 2013, MOL CELL PROTEOMICS, V12, P626, DOI 10.1074/mcp.M112.021931; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; Bromberg O, 2012, BLOOD, V120, P303, DOI 10.1182/blood-2011-09-377853; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DWIVEDI C, 1988, CANCER DETECT PREV, V11, P191; Ester M., 1996, P KDD 96, P1; Gibson LF, 2002, LEUKEMIA LYMPHOMA, V43, P19, DOI 10.1080/10428190210188; GIL ML, 1992, J IMMUNOL, V148, P2826; Greenbaum AM, 2012, BLOOD, V120, P295, DOI 10.1182/blood-2011-09-377457; Guzman ML, 2014, STEM CELLS, V32, P844, DOI 10.1002/stem.1597; Heilemann M, 2008, ANGEW CHEM INT EDIT, V47, P6172, DOI 10.1002/anie.200802376; Hemler ME, 2008, NAT REV DRUG DISCOV, V7, P747, DOI 10.1038/nrd2659; Hong S, 2013, J CELL BIOL, V201, P131, DOI 10.1083/jcb.201211054; Huang F, 2011, BIOMED OPT EXPRESS, V2, P1377, DOI 10.1364/BOE.2.001377; IMAI T, 1992, J IMMUNOL, V149, P2879; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Larochelle A, 2012, BLOOD, V119, P1848, DOI 10.1182/blood-2011-08-371583; LEBELBINAY S, 1994, CELL IMMUNOL, V154, P468, DOI 10.1006/cimm.1994.1092; Machida U, 1999, NEW ENGL J MED, V340, P810; Malik FA, 2009, HISTOL HISTOPATHOL, V24, P519, DOI 10.14670/HH-24.519; Mattila PK, 2013, IMMUNITY, V38, P461, DOI 10.1016/j.immuni.2012.11.019; Mazurov D, 2007, J BIOL CHEM, V282, P3896, DOI 10.1074/jbc.M607322200; Miranti CK, 2009, CELL SIGNAL, V21, P196, DOI 10.1016/j.cellsig.2008.08.023; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nishioka C, 2013, INT J CANCER, V132, P2006, DOI 10.1002/ijc.27904; Qiu SW, 2014, LEUKEMIA RES, V38, P632, DOI 10.1016/j.leukres.2014.03.007; Seales EC, 2003, ONCOGENE, V22, P7137, DOI 10.1038/sj.onc.1206834; Swindall AF, 2013, CANCER RES, V73, P2368, DOI 10.1158/0008-5472.CAN-12-3424; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Termini CM, 2014, MOL BIOL CELL, V25, P1560, DOI 10.1091/mbc.E13-11-0660; Wang H, 2012, J PROTEOMICS, V75, P1375, DOI 10.1016/j.jprot.2011.11.013; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Xu Y, 2014, INT J CLIN EXP PATHO, V7, P5569; Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100; Yoshida T, 2008, TRAFFIC, V9, P540, DOI [10.1111/j.1600-0854.2007.00700.x, 10.1111/j.1600-0854.2008.00700.x]; Zaitseva L, 2014, ONCOTARGET, V5, P9930, DOI 10.18632/oncotarget.2479; Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood-2012-02-412890; Zhang J, 2006, MICRON, V37, P14, DOI 10.1016/j.micron.2005.03.014; Zhi L, 2010, CANCER LETT, V296, P65, DOI 10.1016/j.canlet.2010.03.021; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574	48	29	30	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4132	4140		10.1038/onc.2015.449	http://dx.doi.org/10.1038/onc.2015.449			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26592446	Green Accepted, Bronze			2022-12-28	WOS:000381020900011
J	Heuser, S; Hufbauer, M; Steiger, J; Marshall, J; Sterner-Kock, A; Mauch, C; Zigrino, P; Akgul, B				Heuser, S.; Hufbauer, M.; Steiger, J.; Marshall, J.; Sterner-Kock, A.; Mauch, C.; Zigrino, P.; Akguel, B.			The fibronectin/alpha 3 beta 1 integrin axis serves as molecular basis for keratinocyte invasion induced by beta HPV	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN-PAPILLOMAVIRUS TYPE-8; SQUAMOUS-CELL CARCINOMA; SKIN TUMOR-FORMATION; TRANSGENIC MICE; E-CADHERIN; UP-REGULATION; STEM-CELLS; ORGANOTYPIC CULTURES; EARLY GENES	Organ-transplant-recipients exhibit cancerization of the skin from which multiple human papillomavirus (HPV)-positive squamous cell carcinomas (SCCs) arise. However, the molecular basis for HPV-induced invasion of skin keratinocytes is not known. We generated a transgenic mouse model expressing the E7 oncoprotein of HPV8 in the murine epidermis under the control of the keratin-14 promoter and showed that E7 is carcinogenic in mice. We further showed that both, the E7-expressing keratinocyte and mesenchymal components of the extracellular matrix as critical in eliciting the invasive behavior. E7 expression in basal keratinocytes, grown on fibronectin, led to epithelial-mesenchymal transition mediated by a cadherin switch. E7-positive keratinocytes displayed enhanced EDA-fibronectin expression and secretion and stimulated dermal fibroblasts to express EDA-fibronectin. Deposition of fibronectin was also detected in the peritumoral stroma of HPV8-positive skin SCC. When grown on fibronectin, E7-positive keratinocytes, in particular stem cell-like cells, exhibited increased cell surface levels of the alpha 3-integrin chain. Functional blocking confirmed alpha 3 as a critical molecule sufficient to induce E7-mediated invasion. This mechanistic link is further supported by expression of an E7-mutant, impaired in targeting alpha 3 to the cell surface. These findings highlight the importance of epithelial-extracellular matrix interaction required for keratinocyte invasion and provide further mechanistic evidence for a role of HPV in skin carcinogenesis.	[Heuser, S.; Hufbauer, M.; Akguel, B.] Univ Cologne, Inst Virol, Furst Puckler Str 56, D-50935 Cologne, Germany; [Steiger, J.; Mauch, C.; Zigrino, P.] Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany; [Marshall, J.] Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol, John Vane Sci Ctr, London, England; [Sterner-Kock, A.] Univ Cologne, Univ Hosp, Ctr Med Expt, Cologne, Germany	University of Cologne; University of Cologne; University of London; Queen Mary University London; University of Cologne	Akgul, B (corresponding author), Univ Cologne, Inst Virol, Furst Puckler Str 56, D-50935 Cologne, Germany.	baki.akguel@uk-koeln.de	Akgül, Baki/H-5629-2019; Hufbauer, Martin/AAZ-5473-2020	Akgül, Baki/0000-0002-6564-9412; Zigrino, Paola/0000-0002-7470-0064	Wilhelm-Sander-Stiftung, Germany [2012.105.1, 2012.105.2]; Deutsche Forschungsgemeinschaft [SFB 829]; Deutsche Krebshilfe [111087]	Wilhelm-Sander-Stiftung, Germany; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Herbert Pfister for helpful discussions, Esther Mahabir-Brenner (Animal Facility, Centre of Molecular Medicine Cologne (CMMC)) for generation of the K14-HPV8-E7 mice, John Doorbar for providing HPV8-E4 antibodies and Manuel Koch for collagen IV antibodies. This study was supported by the Wilhelm-Sander-Stiftung, Germany (grant no. 2012.105.1; 2012.105.2) to BA and by the Deutsche Forschungsgemeinschaft through SFB 829 (B4) to CM. MH was supported by the Deutsche Krebshilfe (no. 111087), which was granted to BA.	Aggarwal A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-459; Akgul B, 2007, EXP DERMATOL, V16, P590, DOI 10.1111/j.1600-0625.2007.00569.x; Akgul B, 2011, J GEN VIROL, V92, P395, DOI 10.1099/vir.0.025064-0; Akgul B, 2006, J PATHOL, V208, P165, DOI 10.1002/path.1893; Akgul B, 2005, CANCER RES, V65, P2216, DOI 10.1158/0008-5472.CAN-04-1952; Benton G, 2011, INT J CANCER, V128, P1751, DOI 10.1002/ijc.25781; Boxman ILA, 2001, J INVEST DERMATOL, V117, P1397, DOI 10.1046/j.0022-202x.2001.01602.x; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chen SH, 2010, ANTICANCER RES, V30, P4177; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Euvrard S, 2012, NEW ENGL J MED, V367, P329, DOI 10.1056/NEJMoa1204166; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Hellner K, 2009, VIROLOGY, V391, P57, DOI 10.1016/j.virol.2009.05.036; Howley PM, 2015, VIROLOGY, V479, P290, DOI 10.1016/j.virol.2015.02.004; Hufbauer M, 2010, VIROLOGY, V403, P128, DOI 10.1016/j.virol.2010.04.013; Hufbauer M, 2013, J VIROL, V87, P12158, DOI 10.1128/JVI.01510-13; Hufbauer M, 2011, J DERMATOL SCI, V64, P7, DOI 10.1016/j.jdermsci.2011.06.008; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Jones SM, 2006, NAT REV CANCER, V6, P175, DOI 10.1038/nrc1817; Kurtz KA, 2006, OTOLARYNG HEAD NECK, V134, P142, DOI 10.1016/j.otohns.2005.08.026; Lazic D, 2011, J DERMATOL SCI, V62, P84, DOI 10.1016/j.jdermsci.2011.02.006; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Leverrier S, 2007, APOPTOSIS, V12, P549, DOI 10.1007/s10495-006-0004-1; Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcuzzi GP, 2014, MED MICROBIOL IMMUN, V203, P155, DOI 10.1007/s00430-014-0327-4; Marcuzzi GP, 2009, J GEN VIROL, V90, P2855, DOI 10.1099/vir.0.012872-0; Margadant C, 2010, FASEB J, V24, P4133, DOI 10.1096/fj.09-151449; Margulis A, 2006, INT J CANCER, V118, P821, DOI 10.1002/ijc.21409; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Missan DS, 2014, J INVEST DERMATOL, V134, P2418, DOI 10.1038/jid.2014.166; Missan DS, 2012, CRIT REV EUKAR GENE, V22, P309, DOI 10.1615/CritRevEukarGeneExpr.v22.i4.50; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; O'Shaughnessy RFL, 2007, CANCER RES, V67, P8207, DOI 10.1158/0008-5472.CAN-07-0755; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Peh WL, 2005, METH MOLEC MED, V119, P49; Pfefferle R, 2008, J INVEST DERMATOL, V128, P2310, DOI 10.1038/jid.2008.73; Quint KD, 2015, J PATHOL, V235, P342, DOI 10.1002/path.4425; Sachs N, 2012, P NATL ACAD SCI USA, V109, P21468, DOI 10.1073/pnas.1204614110; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schmidt DS, 2004, EXP CELL RES, V297, P329, DOI 10.1016/j.yexcr.2004.02.023; Sun XJ, 2014, CARCINOGENESIS, V35, P184, DOI 10.1093/carcin/bgt276; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Vinzon SE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003924; Westphal K, 2009, CELL ONCOL, V31, P213, DOI 10.3233/CLO-2009-0476; Zhang WT, 2006, J CELL SCI, V119, P283, DOI 10.1242/jcs.02738	49	24	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4529	4539		10.1038/onc.2015.512	http://dx.doi.org/10.1038/onc.2015.512			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804167				2022-12-28	WOS:000382153100010
J	Nitzki, F; Cuvelier, N; Drager, J; Schneider, A; Braun, T; Hahn, H				Nitzki, F.; Cuvelier, N.; Draeger, J.; Schneider, A.; Braun, T.; Hahn, H.			Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing mesodermal cells	ONCOGENE			English	Article							WNT INHIBITORY FACTOR-1; EMBRYONAL RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; SKELETAL MYOGENESIS; MOUSE MODEL; GENE; EXPRESSION; PATHWAY; GLI; PROTEINS	Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. In children, the 2 major RMS subtypes are alveolar and embryonal RMS. Aberrant Hedgehog/Patched1 (Hh/Ptch) signaling is a hallmark of embryonal RMS. We demonstrate that mice carrying a Ptch mutation in mesodermal Delta1-expressing cells develop embryonal-like RMS at a similar rate as mice harboring a Ptch mutation in the germline or the brachury-expressing mesoderm. The tumor incidence decreases dramatically when Ptch is mutated in Myf5- or Pax3-expressing cells. No RMS develop from Myogenin/Mef2c-expressing cells. This suggests that Hh/Ptch-associated RMS are derived from Delta1-positive, Myf5-negative, Myogenin-negative and Pax3-negative mesodermal progenitors that can undergo myogenic differentiation but lack stable lineage commitment. Additional preliminary genetic data and data on mesodermal progenitors further imply an interplay of Hh/Ptch and Delta/Notch signaling activity during RMS initiation. In contrast, Wnt signals supposedly suppress RMS formation because RMS multiplicity decreases after inactivation of the Wnt-inhibitor Wif1. Finally, our results strongly suggest that the tumor-initiating event determines the lineage of RMS origin.	[Nitzki, F.; Cuvelier, N.; Draeger, J.; Hahn, H.] Univ Med Ctr Goettingen, Dept Human Genet, Heinrich Dueker Weg 12, D-37073 Gottingen, Germany; [Schneider, A.; Braun, T.] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodelling, Bad Nauheim, Germany	University of Gottingen; Max Planck Society	Hahn, H (corresponding author), Univ Med Ctr Goettingen, Dept Human Genet, Heinrich Dueker Weg 12, D-37073 Gottingen, Germany.	hhahn@gwdg.de	Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	DFG [HA2197/7-1]	DFG(German Research Foundation (DFG))	We thank Lars Wittler and Ludger Hartmann for Wnt<SUP>vt/vt</SUP> mice, Walter Birchmeier and Felix Brembeck for beta-cat<SUP>flox/flox</SUP> mice and Christoph Englert and David Thomas for Wif1<SUP>-/-</SUP> mice. We are grateful to Susan Peter and Stefan Wolf for excellent animal care. We thank Anke Frommhold, Ina Hess and Tobias Goldak for technical assistance and Walter Schulz-Schaeffer (Institute of Neuropathology, University Medical Center Gottingen) and Ilona Skerjanc for useful advice. This work was supported by the DFG Grant HA2197/7-1 to HH.	Abraham J, 2014, GENE DEV, V28, P1578, DOI 10.1101/gad.238733.114; Beckers J, 2000, MECH DEVELOP, V95, P23, DOI 10.1016/S0925-4773(00)00322-1; Belyea Brian, 2012, Sarcoma, V2012, P406239, DOI 10.1155/2012/406239; Benito-Gonzalez A, 2014, J NEUROSCI, V34, P12865, DOI 10.1523/JNEUROSCI.1494-14.2014; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; Dequeant ML, 2008, NAT REV GENET, V9, P370, DOI 10.1038/nrg2320; Diaconescu S, 2013, ROM J MORPHOL EMBRYO, V54, P531; Ecke I, 2008, MOL CARCINOGEN, V47, P361, DOI 10.1002/mc.20394; Engleka KA, 2005, DEV BIOL, V280, P396, DOI 10.1016/j.ydbio.2005.02.002; Feller J, 2008, GENE DEV, V22, P2166, DOI 10.1101/gad.480408; Gianakopoulos PJ, 2011, J BIOL CHEM, V286, P2517, DOI 10.1074/jbc.M110.163709; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; Gurney JG, 1999, CANC INCIDENCE SURVI, P111; Hahn H, 2004, GENOMICS, V84, P853, DOI 10.1016/j.ygeno.2004.07.002; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Ji SJ, 2006, DEV BIOL, V297, P249, DOI 10.1016/j.ydbio.2006.05.015; Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Nitzki F, 2011, ONCOGENE, V30, P4428, DOI 10.1038/onc.2011.157; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Petropoulos H, 2004, J BIOL CHEM, V279, P23874, DOI 10.1074/jbc.M312612200; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Pressey JG, 2011, PEDIATR BLOOD CANCER, V57, P930, DOI 10.1002/pbc.23174; Rajurkar M, 2014, ONCOGENE, V33, P5370, DOI 10.1038/onc.2013.480; Roma J, 2011, CLIN CANCER RES, V17, P505, DOI 10.1158/1078-0432.CCR-10-0166; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Sanchez-Gurmaches J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5099; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sebire NJ, 2003, J CLIN PATHOL, V56, P412, DOI 10.1136/jcp.56.6.412; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sprinzak D, 2010, NATURE, V465, P86, DOI 10.1038/nature08959; Stock M, 2013, ARTHRITIS RHEUM-US, V65, P2310, DOI 10.1002/art.38054; Surmann-Schmitt C, 2009, J CELL SCI, V122, P3627, DOI 10.1242/jcs.048926; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tamplin OJ, 2011, DEV BIOL, V360, P415, DOI 10.1016/j.ydbio.2011.10.002; Tews D, 2011, HORM RES PAEDIAT, V75, P231, DOI 10.1159/000324806; Uhmann A, 2007, BLOOD, V110, P1814, DOI 10.1182/blood-2007-02-075648; von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368; Zibat A, 2009, CARCINOGENESIS, V30, P918, DOI 10.1093/carcin/bgp068	57	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2923	2931		10.1038/onc.2015.346	http://dx.doi.org/10.1038/onc.2015.346			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387541				2022-12-28	WOS:000377473700012
J	Wei, Q; Chen, ZH; Wang, L; Zhang, T; Duan, L; Behrens, C; Wistuba, II; Minna, JD; Gao, B; Luo, JH; Liu, ZP				Wei, Q.; Chen, Z-H; Wang, L.; Zhang, T.; Duan, L.; Behrens, C.; Wistuba, I. I.; Minna, J. D.; Gao, B.; Luo, J-H; Liu, Z. P.			LZTFL1 suppresses lung tumorigenesis by maintaining differentiation of lung epithelial cells	ONCOGENE			English	Article							CANCER; MAINTENANCE; MIGRATION	Lung cancer is the leading cause of cancer-related death in the United States, and metastatic behavior is largely responsible for this mortality. Mutations in multiple 'driver' oncogenes and tumor suppressors are known to contribute to the lung tumorigenesis and in some cases represent therapeutic targets. Leucine Zipper Transcription Factor-like 1 (LZTFL1) is located in the chromosome region 3p21.3 where allelic loss and genetic alterations occur early and frequently in lung cancers. Previously, we found that LZTFL1 is downregulated in epithelial tumors, including lung cancer, and functions as a tumor suppressor in gastric cancers. However, the functional role of LZTFL1 in lung oncogenesis is undefined. We show here that downregulation of LZTFL1 expression in non-small cell lung cancer is associated with recurrence and poor survival, whereas re-expression of LZTFL1 in lung tumor cells inhibited extravasation/colonization of circulating tumor cells to the lung and inhibited tumor growth in vivo. Mechanistically, we found that LZTFL1 is expressed in ciliated human bronchial epithelial cells (HBECs) and its expression correlates with HBEC differentiation. LZTFL1 inhibits transforming growth factor beta-activated mitogen-activated protein kinase and hedgehog signaling. Alteration of intracellular levels of LZTFL1 resulted in changes of expression of genes associated with epithelial-to-mesenchymal transition (EMT). We conclude that LZTFL1 inhibits lung tumorigenesis, possibly by maintaining epithelial cell differentiation and/or inhibition of signalings that lead to EMT and suggest that reactivation of LZTFL1 expression in tumor cells may be a novel lung cancer therapeutic approach.	[Wei, Q.; Chen, Z-H; Wang, L.; Zhang, T.; Duan, L.; Minna, J. D.; Liu, Z. P.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, 6000 Harry Hines Blvd, Dallas, TX 75235 USA; [Wei, Q.] Zhejiang Univ, Sir Run Run Shaw Hosp Coll Med, Dept Surg Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Wei, Q.] Zhejiang Univ, Sir Run Run Shaw Hosp Coll Med, Inst Clin Med, Hangzhou 310003, Zhejiang, Peoples R China; [Chen, Z-H; Luo, J-H] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou 510275, Guangdong, Peoples R China; [Behrens, C.; Wistuba, I. I.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Behrens, C.; Wistuba, I. I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Minna, J. D.; Gao, B.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; [Minna, J. D.; Gao, B.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75235 USA; [Liu, Z. P.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Zhejiang University; Zhejiang University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Liu, ZP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Internal Med, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.; Luo, JH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou 510275, Guangdong, Peoples R China.; Liu, ZP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.	luojunh@mail.sysu.edu.cn; Zhi-Ping.Liu@UTsouthwestern.edu			NIHRO1; CPRIT-MIRA [RP120717-P1]; National Natural Science Foundation of China [81101581]; National Cancer Institute Specialized Program of Research Excellence in Lung Cancer Grant [P50CA70907]; Cancer Center Support Grant by National Cancer Institute of the National Institutes of Health [5P30CA142543]; NATIONAL CANCER INSTITUTE [P50CA070907, P30CA142543] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109471] Funding Source: NIH RePORTER	NIHRO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT-MIRA; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Cancer Institute Specialized Program of Research Excellence in Lung Cancer Grant; Cancer Center Support Grant by National Cancer Institute of the National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work is supported by NIHRO1 and CPRIT-MIRA RP120717-P1 (to ZPL), National Natural Science Foundation of China No. 81101581 (to QW), National Cancer Institute Specialized Program of Research Excellence in Lung Cancer Grant P50CA70907 (to JDM) and Cancer Center Support Grant by the National Cancer Institute of the National Institutes of Health under award number 5P30CA142543.	Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509; Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920; Gao X, 2013, P NATL ACAD SCI USA, V110, P9356, DOI 10.1073/pnas.1307589110; Gomperts BN, 2013, CANCER PREV RES, V6, P4, DOI 10.1158/1940-6207.CAPR-12-0470; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Huang YJ, 2009, CANCER RES, V69, P7529, DOI 10.1158/0008-5472.CAN-08-4382; Jia YF, 2015, ARCH TOXICOL, V89, P179, DOI 10.1007/s00204-014-1433-1; Kenny PM, 2008, J CLIN ONCOL, V26, P233, DOI 10.1200/JCO.2006.07.7230; Kiss H, 2001, GENOMICS, V73, P10, DOI 10.1006/geno.2000.6498; Kugler MC, 2015, AM J RESP CELL MOL, V52, P1, DOI 10.1165/rcmb.2014-0132TR; Look DC, 2001, AM J PATHOL, V159, P2055, DOI 10.1016/S0002-9440(10)63057-X; Maitah MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016068; Mendoza A, 2010, J CLIN INVEST, V120, P2979, DOI 10.1172/JCI40252; Minna JD, 2002, CANCER J, V8, pS41; Nanjundan M, 2010, J THORAC ONCOL, V5, P1894, DOI 10.1097/JTO.0b013e3181f2a266; Pacheco-Pinedo EC, 2011, J CLIN INVEST, V121, P1935, DOI 10.1172/JCI44871; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Rock JR, 2011, ANNU REV CELL DEV BI, V27, P493, DOI 10.1146/annurev-cellbio-100109-104040; Sato M, 2012, RESPIROLOGY, V17, P1048, DOI 10.1111/j.1440-1843.2012.02173.x; Seo S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002358; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Uttamsingh S, 2008, ONCOGENE, V27, P2626, DOI 10.1038/sj.onc.1210915; Wang LB, 2014, J CANCER RES CLIN, V140, P1997, DOI 10.1007/s00432-014-1753-9; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Wei Q, 2010, CANCER RES, V70, P2942, DOI 10.1158/0008-5472.CAN-09-3826; Xiao Dakai, 2010, J Thorac Dis, V2, P154, DOI 10.3978/j.issn.2072-1439.2010.02.03.7; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	31	27	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2655	2663		10.1038/onc.2015.328	http://dx.doi.org/10.1038/onc.2015.328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364604	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000376165700012
J	Zhang, S; Chung, WC; Xu, K				Zhang, S.; Chung, W-C; Xu, K.			Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; DUCTAL ADENOCARCINOMA; PROGENITOR CELLS; NOTCH; EXPRESSION; PROGRESSION; PATHWAY; NEOPLASIA; PROSTATE	Notch controls pancreatic differentiation during development and is reactivated in pancreatic cancer. In recent years, the importance of Notch signaling in pancreatic tumorigenesis has become increasingly evident; however, it remains unclear how Notch activities are regulated in this context. Here we report differential regulation of Notch receptors by Lunatic Fringe (Lfng), which encodes an O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase known to modify epidermal growth factor repeats in the Notch extracellular domain, during pathogenesis of Kras-induced pancreatic ductal adenocarcinoma (PDAC). We show that Lfng is uniquely expressed in a subset of acinar cells in the adult pancreas. Deletion of Lfng in the Kras(LSL-G12D/+); Pdx1-Cre mouse model caused increased activation of Notch3 throughout PDAC initiation and progression, and Notch1 after the onset of disease, associated with marked upregulation of Notch target gene Hes1. Deletion of Lfng also resulted in accumulation of Aldh1-positive cell population. We found that loss of Lfng significantly accelerated Kras-initiated PDAC development and shortened survival of the PDAC mice. Interestingly, Lfng-deficient tumors showed a propensity for a poorly differentiated state with features of epithelial-tomesenchymal transition. Likewise, knockdown of LFNG in human PDAC cell lines caused elevated Notch activation, associated with either accelerated cell proliferation or expanded Aldh1-positive cell population. Deletion of Lfng resulted in downregulation of Tgfb1, Tgfb2 and Tgfbr2 expression in the wild-type pancreas at all ages examined, and in the Kras(LSL-G12D/+); Pdx1-Cre pancreas after PDAC onset, as well as reduced phospho-Smad2 levels in pancreatic tumors. We provide evidence that Lfng regulates transforming growth factor (TGF)-beta-signaling through Notch-mediated transcriptional repression of TGF-beta pathway genes. Taken together, our results reveal a potent tumor-suppressive function for Lfng and crosstalk between Notch and TGF-beta pathways in the pancreas, which provides new insight into initiation of PDAC and signals involved in disease progression.	[Zhang, S.; Chung, W-C; Xu, K.] Univ Mississippi, Med Ctr, Inst Canc, 2500 North State St, Jackson, MS 39216 USA; [Zhang, S.] Cent S Univ, State Key Lab Med Genet, Changsha, Hunan, Peoples R China; [Zhang, S.] Cent S Univ, Sch Life Sci, Changsha, Hunan, Peoples R China; [Xu, K.] Univ Mississippi, Med Ctr, Dept Neurobiol & Anat Sci, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; Central South University; Central South University; University of Mississippi; University of Mississippi Medical Center	Xu, K (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 North State St, Jackson, MS 39216 USA.	kxu@umc.edu			NIH [R21CA175136]; UMMC Cancer Institute; NATIONAL CANCER INSTITUTE [R21CA175136] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UMMC Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors are thankful to Sean Egan and Tom Gridley for providing mouse strains. We also thank Sean Egan for critical reading of the manuscript. This work was supported in part by NIH grant R21CA175136 and by start-up funds from UMMC Cancer Institute to KX.	Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Avila JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052133; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Baumgart A, 2014, ONCOGENE, V34, P578; Court H, 2013, J CLIN INVEST, V123, P4681, DOI 10.1172/JCI65764; De Waele E, 2014, PANCREAS, V43, P1083, DOI 10.1097/MPA.0000000000000154; Doucas H, 2008, J SURG ONCOL, V97, P63, DOI 10.1002/jso.20894; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Han LF, 2014, CANCER RES, V74, P6509, DOI 10.1158/0008-5472.CAN-14-0816; Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645; Hezel AF, 2012, CANCER RES, V72, P4840, DOI 10.1158/0008-5472.CAN-12-0634; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Ischenko I, 2014, P NATL ACAD SCI USA, V111, P3466, DOI 10.1073/pnas.1319911111; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jean-Paul D, 2008, P NATL ACAD SCI USA, V105, P18907, DOI 10.1073/pnas.0810111105; Kopinke D, 2012, DEV BIOL, V362, P57, DOI 10.1016/j.ydbio.2011.11.010; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Leung L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084366; Liu H, 2009, CIRC RES, V104, P466, DOI 10.1161/CIRCRESAHA.108.184846; Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797; Mann CD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051119; Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107; Misra K, 2014, DEVELOPMENT, V141, P187, DOI 10.1242/dev.092536; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Ohnuki H, 2014, CANCER RES, V74, P2038, DOI 10.1158/0008-5472.CAN-13-3118; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Rovira M, 2010, P NATL ACAD SCI USA, V107, P75, DOI 10.1073/pnas.0912589107; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schiavone M, 2014, DIS MODEL MECH, V7, P883, DOI 10.1242/dmm.014969; Shih HP, 2012, DEVELOPMENT, V139, P2488, DOI 10.1242/dev.078634; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Svensson P, 2009, MOL CELL BIOL, V29, P2129, DOI 10.1128/MCB.01644-08; Ungefroren H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-67; Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003; Vo K, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-138; Xie MJ, 2002, PANCREAS, V25, P234, DOI 10.1097/00006676-200210000-00004; Xu KL, 2012, CANCER CELL, V21, P626, DOI 10.1016/j.ccr.2012.03.041; Xu KL, 2010, AM J PHYSIOL-LUNG C, V298, pL45, DOI 10.1152/ajplung.90550.2008; Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078-0432.CCR-14-2808; Yu XB, 2006, STEM CELLS, V24, P876, DOI 10.1634/stemcells.2005-0598; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625; Zhang SB, 2014, NEOPLASIA, V16, P158, DOI 10.1593/neo.131870	46	25	25	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2485	2495		10.1038/onc.2015.306	http://dx.doi.org/10.1038/onc.2015.306			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279302				2022-12-28	WOS:000376165500007
J	Wang, H; Liang, L; Fang, JY; Xu, J				Wang, H.; Liang, L.; Fang, J-Y; Xu, J.			Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers	ONCOGENE			English	Review							LONG NONCODING RNA; LYMPH-NODE METASTASIS; CELL LUNG-CANCER; POOR-PROGNOSIS; MITOCHONDRIAL-DNA; COLON-CANCER; MUTUAL EXCLUSIVITY; CHROMOSOME 20Q; PROTEIN EXPRESSION; MULTIPLE PATHWAYS	Colorectal cancer (CRC) results from the accumulation of genetic alterations, and somatic copy number alterations (CNAs) are crucial for the development of CRC. Genome-wide survey of CNAs provides opportunities for identifying cancer driver genes in an unbiased manner. The detection of aberrant CNAs may provide novel markers for the early diagnosis and personalized treatment of CRC. A major challenge in array-based profiling of CNAs is to distinguish the alterations that play causative roles from the random alterations that accumulate during colorectal carcinogenesis. In this view, we systematically discuss the frequent CNAs in CRC, focusing on functional genes that have potential diagnostic, prognostic and therapeutic significance.	[Xu, J.] Minist Hlth, Key Lab Gastroenterol & Hepatol, State Key Lab Oncogenes & Related Genes, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Xu, J.] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Gastroenterol & Hepatol, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Xu, J.] Shanghai Inst Digest Dis, Shanghai Canc Inst, Mid Shandong Rd 145, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xu, J (corresponding author), Minist Hlth, Key Lab Gastroenterol & Hepatol, State Key Lab Oncogenes & Related Genes, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Xu, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Gastroenterol & Hepatol, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Xu, J (corresponding author), Shanghai Inst Digest Dis, Shanghai Canc Inst, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.	xujieletter@gmail.com	Xu, Jie/C-4283-2016; Xu, Jie/K-3712-2019	Xu, Jie/0000-0001-9163-3898; Xu, Jie/0000-0001-9163-3898	National Natural Science Foundation of China [30971330, 31371420, 81320108024, 81000861, 81322036, 81272383]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81421001]; Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project [2013XJ]; Shanghai Science and Technology Commission 'Pujiang Project' [13PJ1405900]; Shanghai Natural Science Foundation [12ZR1417900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project; Shanghai Science and Technology Commission 'Pujiang Project'; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai)	This project was supported by grants from the National Natural Science Foundation of China (30971330, 31371420, 81320108024, 81000861, 81322036 and 81272383); Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81421001), the Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project (2013XJ); Shanghai Science and Technology Commission 'Pujiang Project' (13PJ1405900); and Shanghai Natural Science Foundation (12ZR1417900). The sponsors of this study had no role in the analysis and interpretation of the literatures, the decision to submit the manuscript for publication or the writing of the manuscript.	Ali RH, 2014, INT J MOL SCI, V15, P17344, DOI 10.3390/ijms151017344; ALIHASSAN NZ, 2014, PLOS ONE, V0009; Amgalan B, 2015, BIOINFORMATICS, V31, P2452, DOI 10.1093/bioinformatics/btv175; Andersen CL, 2011, INT J CANCER, V129, P1848, DOI 10.1002/ijc.25841; Aytekin T, 2010, CANCER GENET CYTOGEN, V201, P32, DOI 10.1016/j.cancergencyto.2010.05.005; Bacolod MD, 2010, J MOL DIAGN, V12, P552, DOI 10.2353/jmoldx.2010.100098; Bavi P, 2013, BRIT J CANCER, V109, P2735, DOI 10.1038/bjc.2013.641; Benedettini E, 2010, AM J PATHOL, V177, P415, DOI 10.2353/ajpath.2010.090863; Berg M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-100; Berteaux N, 2008, MOL CELL BIOL, V28, P6731, DOI 10.1128/MCB.02103-07; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bouteille N, 2009, ONCOGENE, V28, P2569, DOI 10.1038/onc.2009.120; Brosens RPM, 2010, ANAL CELL PATHOL, V33, P95, DOI [10.1155/2010/161608, 10.3233/ACP-CLO-2010-0531]; Cancer Genome Atlas N., 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065; Chen HY, 2014, MOL ONCOL, V8, P1393, DOI 10.1016/j.molonc.2014.05.010; Chen T, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-8; Chen WX, 2013, GENOMICS, V102, P27, DOI 10.1016/j.ygeno.2013.02.003; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Choi J, 2012, ANTICANCER RES, V32, P559; Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111; Cowling VH, 2010, BIOCHEM J, V425, P295, DOI 10.1042/BJ20091352; Cui HH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-110; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Darsigny M, 2010, CANCER RES, V70, P9423, DOI 10.1158/0008-5472.CAN-10-1697; Deng QW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103022; Diep CB, 2006, GENE CHROMOSOME CANC, V45, P31, DOI 10.1002/gcc.20261; Eldai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076251; Fang ZY, 2010, ONCOL LETT, V1, P925, DOI 10.3892/ol_00000163; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Feng S, 2011, ONCOL LETT, V2, P899, DOI 10.3892/ol.2011.322; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fernandez-Sanchez ME, 2009, MOL CELL BIOL, V29, P6182, DOI 10.1128/MCB.00973-09; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Flora M, 2012, CANCER GENET-NY, V205, P630, DOI 10.1016/j.cancergen.2012.10.005; Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208; Gonzalez-Gonzalez M, 2014, CANCER-AM CANCER SOC, V120, P1948, DOI 10.1002/cncr.28681; Gonzalez-Perez A, 2013, NAT METHODS, V10, P723, DOI 10.1038/nmeth.2562; Gonzalez-Perez A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks743; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Gruber SB, 2002, SCIENCE, V297, P2013, DOI 10.1126/science.1074399; Guilmeau S, 2008, GASTROENTEROLOGY, V135, P849, DOI 10.1053/j.gastro.2008.05.050; Han CB, 2012, CANCER LETT, V314, P63, DOI 10.1016/j.canlet.2011.09.012; Han D, 2015, CANCER LETT, V361, P13, DOI 10.1016/j.canlet.2015.03.002; Han SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064271; Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593; Henningham A, 2014, J BIOL CHEM, V289, P32303, DOI 10.1074/jbc.M114.602847; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hoang Don, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2013-008684; Honma K, 2008, NAT MED, V14, P939, DOI 10.1038/nm.1858; Hornstein Max, 2008, Cancer Genomics & Proteomics, V5, P123; Horvath HC, 2010, J HISTOCHEM CYTOCHEM, V58, P277, DOI 10.1369/jhc.2009.954339; Hossini AM, 2008, BIOCHEM PHARMACOL, V76, P1612, DOI 10.1016/j.bcp.2008.08.013; Hou JP, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0056-8; Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686; Hu Y, 2014, ONCOTARGET, V5, P2230, DOI 10.18632/oncotarget.1895; Iguchi T, 2015, ANTICANCER RES, V35, P1385; Issa JP, 2008, CLIN CANCER RES, V14, P5939, DOI 10.1158/1078-0432.CCR-08-1596; Iwatsuki M, 2010, INT J CANCER, V126, P1828, DOI 10.1002/ijc.24879; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Kazuo M, 2008, ANN SURG ONCOL, V15, P1530, DOI 10.1245/s10434-007-9746-4; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; King AN, 2010, ANTI-CANCER AGENT ME, V10, P213; Knosel T, 2004, NEOPLASIA, V6, P23, DOI 10.1016/s1476-5586(04)80050-2; Kruszewski W, 2004, FOLIA HISTOCHEM CYTO, V42, P173; Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848; Kurashina K, 2008, CANCER SCI, V99, P1835, DOI 10.1111/j.1349-7006.2008.00881.x; Lam AKY, 2011, MOL ONCOL, V5, P475, DOI 10.1016/j.molonc.2011.06.003; Larsson A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-282; Liang L, 2016, ONCOGENE, V35, P1475, DOI 10.1038/onc.2015.209; Liang LX, 2015, SCI REP-UK, V5, DOI 10.1038/srep11763; Liang WC, 2015, ONCOTARGET; Lin CH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-36; Little SE, 2012, CANCER RES, V72, P1614, DOI 10.1158/0008-5472.CAN-11-4069; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Liu J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-261; Liu XP, 2007, ONCOL REP, V17, P261; Liu ZH, 2005, MOL CANCER RES, V3, P21; Loo LWM, 2013, GENE CHROMOSOME CANC, V52, P450, DOI 10.1002/gcc.22043; Lu YM, 2012, CANCER BIOMARK, V11, P219, DOI 10.3233/CBM-2012-00282; Ma YL, 2014, CHINESE J CANCER RES, V26, P525, DOI 10.3978/j.issn.1000-9604.2014.09.02; Maffei M, 2014, CYTOGENET GENOME RES, V144, P9, DOI 10.1159/000367909; Mekenkamp LJM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-292; Meng XB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018715; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Mitra AK, 2011, ONCOGENE, V30, P1566, DOI 10.1038/onc.2010.532; Miyabe I, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002407; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Moniz S, 2010, CELL MOL LIFE SCI, V67, P1265, DOI 10.1007/s00018-010-0261-6; MUSCATELLI F, 1995, P NATL ACAD SCI USA, V92, P4987, DOI 10.1073/pnas.92.11.4987; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Nehls O, 2007, BRIT J CANCER, V96, P1409, DOI 10.1038/sj.bjc.6603728; Ogunbiyi OA, 1997, GASTROENTEROLOGY, V113, P761, DOI 10.1016/S0016-5085(97)70169-0; Orsetti B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-121; Park DY, 2007, AM J PATHOL, V171, P1509, DOI 10.2353/ajpath.2007.070331; Park SY, 2009, MITOCHONDRION, V9, P318, DOI 10.1016/j.mito.2009.04.006; Pillaire MJ, 2010, ONCOGENE, V29, P876, DOI 10.1038/onc.2009.378; Postma C, 2007, CELL ONCOL, V29, P73; Postma C, 2009, ANN ONCOL, V20, P1048, DOI 10.1093/annonc/mdn738; Poulogiannis G, 2010, J PATHOL, V220, P338, DOI 10.1002/path.2640; Price TJ, 2013, CANCER MED-US, V2, P277, DOI 10.1002/cam4.75; Quinlan KGR, 2007, BBA-REV CANCER, V1775, P333, DOI 10.1016/j.bbcan.2007.05.001; Ramirez-Ramirez R, 2015, GENET MOL RES, V14, P362, DOI 10.4238/2015.January.23.9; Rand V, 2008, BRIT J CANCER, V99, P1136, DOI 10.1038/sj.bjc.6604651; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Reimand J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.68; Sabbah M, 2011, MOL CELL BIOL, V31, P1459, DOI 10.1128/MCB.01316-10; Sapkota Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053850; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schunke D, 2007, CANCER RES, V67, P10694, DOI 10.1158/0008-5472.CAN-07-1621; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106; Shi DB, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0031-7; Sillars-Hardebol AH, 2012, GUT, V61, P1568, DOI 10.1136/gutjnl-2011-301153; Sillars-Hardebol AH, 2012, J PATHOL, V226, P442, DOI 10.1002/path.2983; Silva FP, 2005, NEOPLASIA, V7, P348, DOI 10.1593/neo.04544; Singhal SS, 2007, CANCER RES, V67, P4382, DOI 10.1158/0008-5472.CAN-06-4124; Sokolenko AP, 2012, INT J CANCER, V130, P2867, DOI 10.1002/ijc.26342; Stahl M, 2008, J BIOL CHEM, V283, P13638, DOI 10.1074/jbc.M802027200; Stawski R, 2013, BRAIN TUMOR PATHOL, V30, P160, DOI 10.1007/s10014-012-0117-x; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Storojeva I, 2005, ONCOLOGY-BASEL, V68, P246, DOI 10.1159/000086781; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Tamborero D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055489; Thean LF, 2010, GENE CHROMOSOME CANC, V49, P99, DOI 10.1002/gcc.20724; Thomas SM, 2003, CANCER RES, V63, P5629; Ungerback J, 2012, CARCINOGENESIS, V33, P2126, DOI 10.1093/carcin/bgs256; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wells A, 2003, CLIN EXP METASTAS, V20, P285, DOI 10.1023/A:1024088922957; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Wierzbicki PM, 2009, J PHYSIOL PHARMACOL, V60, P63; Wu CL, 2001, CANCER RES, V61, P7325; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xie T, 2014, GENOMICS, V104, P234, DOI 10.1016/j.ygeno.2014.07.012; Xie T, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042001, 10.1371/journal.pone.0047577]; Xue Y, 2015, MUTAGENESIS, V30, P303, DOI 10.1093/mutage/geu076; Yamada S, 2006, EJSO-EUR J SURG ONC, V32, P303, DOI 10.1016/j.ejso.2006.01.002; Yang RX, 2014, CARCINOGENESIS, V35, P315, DOI 10.1093/carcin/bgt344; Yao D, 2011, BLOOD, V117, P5652, DOI 10.1182/blood-2010-12-326074; Yoshida T, 2010, CANCER INFORM, V9, P147; Yue SQ, 2003, WORLD J GASTROENTERO, V9, P2863; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhang CW, 2011, MOL GENET METAB, V103, P104, DOI 10.1016/j.ymgme.2011.02.005; Zhang Zi-Chao, 2015, Asian Pac J Cancer Prev, V16, P2459; Zhao D, 2011, HUM PATHOL, V42, P1514, DOI 10.1016/j.humpath.2010.03.012; Zhu J, 2015, BIOINFORMATICS, V31, P1436, DOI 10.1093/bioinformatics/btu834; Zuern C, 2010, ONCOL REP, V23, P183, DOI 10.3892/or_00000621	154	63	64	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2011	2019		10.1038/onc.2015.304	http://dx.doi.org/10.1038/onc.2015.304			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26257062				2022-12-28	WOS:000374505600001
J	Carvalho, S; Catarino, TA; Dias, AM; Kato, M; Almeida, A; Hessling, B; Figueiredo, J; Gartner, F; Sanches, JM; Ruppert, T; Miyoshi, E; Pierce, M; Carneiro, F; Kolarich, D; Seruca, R; Yamaguchi, Y; Taniguchi, N; Reis, CA; Pinho, SS				Carvalho, S.; Catarino, T. A.; Dias, A. M.; Kato, M.; Almeida, A.; Hessling, B.; Figueiredo, J.; Gaertner, F.; Sanches, J. M.; Ruppert, T.; Miyoshi, E.; Pierce, M.; Carneiro, F.; Kolarich, D.; Seruca, R.; Yamaguchi, Y.; Taniguchi, N.; Reis, C. A.; Pinho, S. S.			Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer	ONCOGENE			English	Article							CELL-CELL ADHESION; GLYCOMICS EXPERIMENT; ORAL-CANCER; IN-SITU; TOOL; GLYCOPROTEINS; ORGANIZATION; ANNOTATION; PROTEINS; FEATURES	E-cadherin is a central molecule in the process of gastric carcinogenesis and its posttranslational modifications by N-glycosylation have been described to induce a deleterious effect on cell adhesion associated with tumor cell invasion. However, the role that site-specific glycosylation of E-cadherin has in its defective function in gastric cancer cells needs to be determined. Using transgenic mice models and human clinical samples, we demonstrated that N-acetylglucosaminyltransferase V (GnT-V)-mediated glycosylation causes an abnormal pattern of E-cadherin expression in the gastric mucosa. In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with beta 1,6 GlcNAc-branched N-glycans catalyzed by GnT-V. This aberrant glycan modification on this specific asparagine site of E-cadherin was demonstrated to affect its critical functions in gastric cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular assembly and stability of the adherens junctions and cell-cell aggregation, which was further observed in human gastric carcinomas. Interestingly, manipulating this site-specific glycosylation, by preventing Asn-554 from receiving the deleterious branched structures, either by a mutation or by silencing GnT-V, resulted in a protective effect on E-cadherin, precluding its functional dysregulation and contributing to tumor suppression.	[Carvalho, S.; Catarino, T. A.; Dias, A. M.; Figueiredo, J.; Gaertner, F.; Carneiro, F.; Seruca, R.; Reis, C. A.; Pinho, S. S.] Univ Porto, Inst Res & Innovat Hlth, Rua Campo Alegre 823, P-4100 Oporto, Portugal; [Carvalho, S.; Catarino, T. A.; Dias, A. M.; Figueiredo, J.; Gaertner, F.; Carneiro, F.; Seruca, R.; Reis, C. A.; Pinho, S. S.] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Oporto, Portugal; [Carvalho, S.; Dias, A. M.; Gaertner, F.; Reis, C. A.; Pinho, S. S.] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Rua Campo Alegre 823, P-4100 Oporto, Portugal; [Kato, M.; Yamaguchi, Y.; Taniguchi, N.] RIKEN Global Res Cluster, Syst Glycobiol Res Grp, RIKEN Max Planck Joint Res Ctr, Wako, Saitama, Japan; [Almeida, A.; Kolarich, D.] Max Planck Inst Colloids & Interfaces, Dept Biomol Syst, Potsdam, Germany; [Almeida, A.] Free Univ Berlin, Inst Chem & Biochem, Berlin, Germany; [Hessling, B.; Ruppert, T.] Heidelberg Univ, Ctr Mol Biol, Heidelberg, Germany; [Sanches, J. M.] Univ Lisbon, Inst Super Tecn, LARSyS, Inst Syst & Robot ISR IST, P-1699 Lisbon, Portugal; [Miyoshi, E.] Osaka Univ, Mol Biochem & Clin Invest, Grad Sch Med, Osaka, Japan; [Pierce, M.] Univ Georgia, Complex Carbohydrate Res Ctr, Dept Biochem & Mol Biol, 220 Riverbend Rd, Athens, GA 30602 USA; [Carneiro, F.; Seruca, R.; Reis, C. A.] Univ Porto, Med Fac, Rua Campo Alegre 823, P-4100 Oporto, Portugal; [Carneiro, F.] Hosp Sao Joao, Dept Pathol, Oporto, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; RIKEN; Max Planck Society; Free University of Berlin; Ruprecht Karls University Heidelberg; Universidade de Lisboa; Instituto Superior Tecnico; Osaka University; University System of Georgia; University of Georgia; Universidade do Porto; Sao Joao Hospital	Pinho, SS (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, Glycobiol Canc Grp, Rua Doutor Roberto Frias, P-4200465 Oporto, Portugal.	salomep@ipatimup.pt	REIS, Celso A/B-9969-2008; Carvalho, Sandra S/K-1724-2016; Carneiro, Fatima/AAV-8677-2021; Kolarich, Daniel/B-6893-2012; Carvalho, Sandra/ABA-8715-2020; Figueiredo, Joana/J-7305-2013; Kolarich, Daniel/AAJ-3550-2020; Yamaguchi, Yoshiki/N-5246-2015; Taniguchi, Naoyuki/I-4182-2014; Sanches, Joao/ABG-2684-2021; Carneiro, Fatima/J-6432-2013; Sanches, Joao Miguel/C-1947-2013; Ruppert, Thomas/AAC-2467-2021; Dias, Ana/AAE-8828-2020; Taniguchi, Naoyuki/A-7086-2016; Gartner, Maria de Fatima/A-3530-2010; Pinho, Salome/F-1764-2011; Araujo Catarino, Telmo/L-2012-2013	REIS, Celso A/0000-0002-0286-6639; Carvalho, Sandra S/0000-0003-3647-3582; Carneiro, Fatima/0000-0002-1964-1006; Kolarich, Daniel/0000-0002-8452-1350; Carvalho, Sandra/0000-0003-3647-3582; Figueiredo, Joana/0000-0002-1590-1974; Kolarich, Daniel/0000-0002-8452-1350; Yamaguchi, Yoshiki/0000-0003-0100-5439; Taniguchi, Naoyuki/0000-0001-5889-5968; Sanches, Joao/0000-0001-9089-2740; Carneiro, Fatima/0000-0002-1964-1006; Sanches, Joao Miguel/0000-0001-9089-2740; Ruppert, Thomas/0000-0001-9152-2266; Gartner, Maria de Fatima/0000-0002-5302-0086; Dias, Ana/0000-0003-0060-2872; Seruca, Raquel/0000-0002-8851-4166; Pinho, Salome/0000-0002-3484-5162; Araujo Catarino, Telmo/0000-0002-2498-9648	FCT, the Portuguese Foundation for Science and Technology; FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE-; National Funds through the FCT-Foundation for Science and Technology [PTDC/CVT/111358/2009, EXPL/BIM-MEC/0149/2012, PTDC/BBB-EBI/0786/2012]; FCT [SFRH/BD/77386/2011, SFRH/BI/52380/2013, SFRH/BPD/63094/2009]; Luso-American Foundation (FLAD) [SFRH/BD/77386/2011, SFRH/BI/52380/2013, SFRH/BPD/63094/2009]; Max Planck Society; European Union [PCIG09-GA-2011-293847, 316929]; NATIONAL CANCER INSTITUTE [U01CA128454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103490] Funding Source: NIH RePORTER; Fundação para a Ciência e a Tecnologia [PTDC/CVT/111358/2009, UID/EEA/50009/2013, PTDC/BBB-EBI/0786/2012, EXPL/BIM-MEC/0149/2012] Funding Source: FCT	FCT, the Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE-; National Funds through the FCT-Foundation for Science and Technology; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Luso-American Foundation (FLAD); Max Planck Society(Max Planck SocietyFoundation CELLEX); European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Fundação para a Ciência e a Tecnologia	IPATIMUP integrates the I3S Research Unit, which is partially supported by FCT, the Portuguese Foundation for Science and Technology. This work is funded by FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE- and National Funds through the FCT-Foundation for Science and Technology, under the projects: PTDC/CVT/111358/2009; EXPL/BIM-MEC/0149/2012; and PTDC/BBB-EBI/0786/2012. SC (SFRH/BD/77386/2011), AMD (SFRH/BI/52380/2013) BiotechHealth Doctoral Programme, and SSP (SFRH/BPD/63094/2009) thank FCT and the Luso-American Foundation (FLAD) for funding. JMS acknowledges FCT (UID/EEA/50009/2013). DK acknowledges support by the Max Planck Society and European Union (Seventh Framework Programme 'Glycoproteomics', grant number PCIG09-GA-2011-293847. CAR and DK acknowledge GastricGlycoExplorer project, grant number 316929). We thank Ola Soderberg and Gaelle Cane (Department of Genetics and Pathology, University of Uppsala, Uppsala, Sweden) for providing the Streptavidin PLA probe and to Marcia Pereira and Sara Campos for the support in PLA technique and statistical analyses.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Ceroni A, 2008, J PROTEOME RES, V7, P1650, DOI 10.1021/pr7008252; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; Cooper CA, 2001, PROTEOMICS, V1, P340, DOI 10.1002/1615-9861(200102)1:2<340::AID-PROT340>3.0.CO;2-B; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Deshpande N, 2010, J PROTEOME RES, V9, P1063, DOI 10.1021/pr900956x; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gu JG, 2012, GLYCOCONJUGATE J, V29, P599, DOI 10.1007/s10719-012-9386-1; Gu J, 2009, J PROTEOME RES, V8, P431, DOI 10.1021/pr800674g; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Guo HB, 2009, J BIOL CHEM, V284, P34986, DOI 10.1074/jbc.M109.060806; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Jensen PH, 2012, NAT PROTOC, V7, P1299, DOI 10.1038/nprot.2012.063; Jones J, 2005, BIOCHIM BIOPHYS ACTA, V1726, P121; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kitada T, 2001, J BIOL CHEM, V276, P475, DOI 10.1074/jbc.M006689200; Kolarich D, 2013, MOL CELL PROTEOMICS, V12, P991, DOI 10.1074/mcp.O112.026492; Langer MD, 2012, J CELL SCI, V125, P2478, DOI 10.1242/jcs.101147; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; LEWIS JE, 1994, J CELL SCI, V107, P3615; Liwosz A, 2006, J BIOL CHEM, V281, P23138, DOI 10.1074/jbc.M512621200; Lommel M, 2013, P NATL ACAD SCI USA, V110, P21024, DOI 10.1073/pnas.1316753110; de-Freitas JCM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081579; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nita-Lazar M, 2009, CANCER RES, V69, P5673, DOI 10.1158/0008-5472.CAN-08-4512; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Paredes J, 2012, BBA-REV CANCER, V1826, P297, DOI 10.1016/j.bbcan.2012.05.002; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Pinho SS, 2013, TRENDS MOL MED, V19, P664, DOI [10.1016/j.molmed.2013, 10.1016/j.molmed.2013.07.003]; Pinho SS, 2013, BBA-GEN SUBJECTS, V1830, P2690, DOI 10.1016/j.bbagen.2012.10.021; Pinho SS, 2011, CELL MOL LIFE SCI, V68, P1011, DOI 10.1007/s00018-010-0595-0; Pinho SS, 2009, HUM MOL GENET, V18, P2599, DOI 10.1093/hmg/ddp194; Pinho SS, 2009, BIOCHEM BIOPH RES CO, V379, P1091, DOI 10.1016/j.bbrc.2009.01.024; Pruitt KD, 2012, NUCLEIC ACIDS RES, V40, pD130, DOI 10.1093/nar/gkr1079; Przybylo Malgorzata, 2002, Cancer Cell Int, V2, P6, DOI 10.1186/1475-2867-2-6; Rose PW, 2013, NUCLEIC ACIDS RES, V41, pD475, DOI 10.1093/nar/gks1200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanches JM, 2015, EUR J HUM GENET, V23, P1072, DOI 10.1038/ejhg.2014.240; Sato Y, 2009, J BIOL CHEM, V284, P11873, DOI 10.1074/jbc.M807660200; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Thaysen-Andersen M, 2012, GLYCOBIOLOGY, V22, P1440, DOI 10.1093/glycob/cws110; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; Varelas X, 2014, GLYCOBIOLOGY, V24, P579, DOI 10.1093/glycob/cwu031; Vester-Christensen MB, 2013, P NATL ACAD SCI USA, V110, P21018, DOI 10.1073/pnas.1313446110; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; York WS, 2014, GLYCOBIOLOGY, V24, P402, DOI 10.1093/glycob/cwu018; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; Zhou F, 2008, GLYCOCONJUGATE J, V25, P727, DOI 10.1007/s10719-008-9133-9	51	73	73	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1619	1631		10.1038/onc.2015.225	http://dx.doi.org/10.1038/onc.2015.225			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26189796	Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000373064200002
J	Zhu, Z; Zhao, X; Zhao, L; Yang, H; Liu, L; Li, J; Wu, J; Yang, F; Huang, G; Liu, J				Zhu, Z.; Zhao, X.; Zhao, L.; Yang, H.; Liu, L.; Li, J.; Wu, J.; Yang, F.; Huang, G.; Liu, J.			p54(nrb)/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A	ONCOGENE			English	Article							FATTY-ACID SYNTHASE; ELEMENT-BINDING PROTEIN-1; DE-NOVO LIPOGENESIS; PROSTATE-CANCER; ACTIVATION; EXPRESSION; ANDROGEN; PATHWAY; CELLS; TRANSCRIPTION	Dysregulation of lipid metabolism is common in breast cancer. However, the underlying mechanisms remain elusive and the contribution of aberrant lipid metabolism to the malignant phenotypes of breast cancer is poorly understood. Here, we show that the nuclear protein p54(nrb)/Nono is highly expressed in breast cancer tissues as compared with the adjacent normal tissues in human patients. To determine the functions of p54(nrb) in breast cancer, we performed a biochemical screen and identified SREBP-1a, a master activator for genes involved in lipid biosynthesis, as a novel interacting protein of p54(nrb). In human breast cancer tissues, the levels of p54(nrb) and SREBP-1a proteins were positively correlated with each other. Our biochemical analyses showed that the conserved Y267 residue of p54(nrb) was required for its binding to the nuclear form of SREBP-1a. Interestingly, p54(nrb) binding to nuclear SREBP-1a caused an increase of nuclear SREBP-1a protein stability. As a result, p54(nrb) stimulates SREBP-1-meidated transcription of lipogenic genes and lipid production in breast cancer cells. Moreover, both p54(nrb) and SREBP-1a were required for breast cancer cell growth in vitro, and p54(nrb) binding to nuclear SREBP-1a was also critical for breast tumor development in vivo. Together, we conclude that p54(nrb) is a novel regulator of SREBP-1a in the nucleus, and our data suggest that p54(nrb) regulation of SREBP-1a supports the increased cellular demand of lipids for breast cancer growth. Thus, the SREBP pathway may represent a novel target for treating breast cancer.	[Zhu, Z.; Zhao, X.; Zhao, L.; Liu, L.; Li, J.; Wu, J.; Huang, G.; Liu, J.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai 200127, Peoples R China; [Yang, H.; Huang, G.] Shanghai Jiao Tong Univ, Sch Med, Chinese Acad Sci, Shanghai Inst Biol Sci,Inst Hlth Sci, Shanghai 200030, Peoples R China; [Yang, F.] Albert Einstein Coll Med, Dept Med, New York, NY USA; [Yang, F.] Albert Einstein Coll Med, Dept Dev & Mol Biol, New York, NY USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Yeshiva University; Yeshiva University	Huang, G; Liu, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nucl Med, Shanghai 200127, Peoples R China.	huang2802@163.com; nuclearj@163.com			'973' Project [2012CB932604]; New Drug Discovery Project [2012ZX09506-001-005]; Shanghai First-class Discipline (Medical technology); National Natural Science Foundation of China [81372195, 81471685, 81471687]; Shanghai Pujiang Program [13PJ1406000]; Science and Technology Commission of Shanghai Municipality [134119a5600]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [1410000157]; Shanghai Municipal Commission of Health and Family Planning [XYQ2013109]; NIH [R01 (DK093623)]	'973' Project(National Basic Research Program of China); New Drug Discovery Project; Shanghai First-class Discipline (Medical technology); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Pujiang Program(Shanghai Pujiang Program); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Municipal Commission of Health and Family Planning; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The study was supported by research grants from '973' Project (No. 2012CB932604), New Drug Discovery Project (No. 2012ZX09506-001-005), Shanghai First-class Discipline (Medical technology), National Natural Science Foundation of China (No. 81372195, 81471685 and 81471687), Shanghai Pujiang Program (No. 13PJ1406000), Science and Technology Commission of Shanghai Municipality (No. 134119a5600), Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 1410000157) and Shanghai Municipal Commission of Health and Family Planning (XYQ2013109). FY was supported by NIH R01 (DK093623).	Amelio AL, 2007, P NATL ACAD SCI USA, V104, P20314, DOI 10.1073/pnas.0707999105; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hata K, 2008, J CLIN INVEST, V118, P3098, DOI 10.1172/JCI31373; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ishiguro H, 2003, INT J CANCER, V105, P26, DOI 10.1002/ijc.11021; Ishitani K, 2003, BIOCHEM BIOPH RES CO, V306, P660, DOI 10.1016/S0006-291X(03)01021-0; Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673; Kuhnert A, 2012, J CELL BIOCHEM, V113, P1744, DOI 10.1002/jcb.24045; Kuwahara S, 2006, BIOL REPROD, V75, P352, DOI 10.1095/biolreprod.106.051136; Li JN, 2000, EXP CELL RES, V261, P159, DOI 10.1006/excr.2000.5054; Li WH, 2012, CELL CYCLE, V11, P2348, DOI 10.4161/cc.20811; Liu PY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju113; Lu SY, 2010, INT J CANCER, V126, P416, DOI 10.1002/ijc.24761; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Nieva C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046456; Park J, 2014, NAT REV ENDOCRINOL, V10, P455, DOI 10.1038/nrendo.2014.94; Passon DM, 2012, P NATL ACAD SCI USA, V109, P4846, DOI 10.1073/pnas.1120792109; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Rysman E, 2010, CANCER RES, V70, P8117, DOI 10.1158/0008-5472.CAN-09-3871; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Williams KJ, 2013, CANCER RES, V73, P2850, DOI 10.1158/0008-5472.CAN-13-0382-T; Yamashita T, 2009, J HEPATOL, V50, P100, DOI 10.1016/j.jhep.2008.07.036; Yang YA, 2003, EXP CELL RES, V282, P132, DOI 10.1016/S0014-4827(02)00023-X; Yecies JL, 2011, CELL METAB, V14, P21, DOI 10.1016/j.cmet.2011.06.002; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhao XP, 2014, DIABETES, V63, P2464, DOI 10.2337/db13-0835; Zhao XP, 2012, J CLIN INVEST, V122, P2417, DOI 10.1172/JCI61462	47	47	51	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1399	1410		10.1038/onc.2015.197	http://dx.doi.org/10.1038/onc.2015.197			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26148231				2022-12-28	WOS:000372196400006
J	Ricoult, SJH; Yecies, JL; Ben-Sahra, I; Manning, BD				Ricoult, S. J. H.; Yecies, J. L.; Ben-Sahra, I.; Manning, B. D.			Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP	ONCOGENE			English	Article							STEAROYL-COA DESATURASE; ELEMENT-BINDING PROTEINS; UNSATURATED FATTY-ACIDS; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; CELL-GROWTH; COMPLEX 1; CANCER PATHOGENESIS; TSC1-TSC2 COMPLEX; SIGNALING AXIS	An enhanced capacity for de novo lipid synthesis is a metabolic feature of most cancer cells that distinguishes them from their cells of origin. However, the mechanisms through which oncogenes alter lipid metabolism are poorly understood. We find that expression of oncogenic PI3K (H1047R) or K-Ras (G12V) in breast epithelial cells is sufficient to induce de novo lipogenesis, and this occurs through the convergent activation of the mechanistic target of rapamycin complex 1 (mTORC1) downstream of these common oncogenes. Oncogenic stimulation of mTORC1 signaling in this isogenic setting or a panel of eight breast cancer cell lines leads to activation of the sterol regulatory element-binding proteins (SREBP1 and SREBP2) that are required for oncogene-induced lipid synthesis. The SREBPs are also required for the growth factor-independent growth and proliferation of oncogene-expressing cells. Finally, we find that elevated mTORC1 signaling is associated with increased mRNA and protein levels of canonical SREBP targets in primary human breast cancer samples. These data suggest that the mTORC1/SREBP pathway is a major mechanism through which common oncogenic signaling events induce de novo lipid synthesis to promote aberrant growth and proliferation of cancer cells.	[Ricoult, S. J. H.; Yecies, J. L.; Ben-Sahra, I.; Manning, B. D.] Harvard Univ, Dept Genet & Complex Dis, TH Chan Sch Publ Hlth, 665 Huntington Ave,SPH2-117, Boston, MA 02115 USA; [Yecies, J. L.] Genentech Inc, San Francisco, CA 94080 USA	Harvard University; Harvard T.H. Chan School of Public Health; Roche Holding; Genentech	Manning, BD (corresponding author), Harvard Univ, Dept Genet & Complex Dis, TH Chan Sch Publ Hlth, 665 Huntington Ave,SPH2-117, Boston, MA 02115 USA.	bmanning@hsph.harvard.edu	Manning, Brendan/ABD-6528-2021	Manning, Brendan/0000-0003-3895-5956	NSF [DGE-1144152]; LAM Foundation; Sanofi Innovation Award; NIH [R01-CA181390, P01-CA120964]; NATIONAL CANCER INSTITUTE [R01CA181390, R35CA197459, P01CA120964] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); LAM Foundation; Sanofi Innovation Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NSF predoctoral fellowship DGE-1144152 (to SJHR), a postdoctoral fellowship from the LAM Foundation (to IB-S), a Sanofi Innovation Award (to BDM) and NIH Grants R01-CA181390 and P01-CA120964 (to BDM).	Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakrabarti P, 2010, DIABETES, V59, P775, DOI 10.2337/db09-1602; Clendening JW, 2012, ONCOGENE, V31, P4967, DOI 10.1038/onc.2012.6; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Howell JJ, 2013, BIOCHEM SOC T, V41, P906, DOI 10.1042/BST20130041; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jeon TI, 2012, TRENDS ENDOCRIN MET, V23, P65, DOI 10.1016/j.tem.2011.10.004; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kasiske BL, 2008, AM J TRANSPLANT, V8, P1384, DOI 10.1111/j.1600-6143.2008.02272.x; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krycer JR, 2012, BIOCHEM J, V446, P191, DOI 10.1042/BJ20120545; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; Li SJ, 2010, P NATL ACAD SCI USA, V107, P3441, DOI 10.1073/pnas.0914798107; Li SY, 2011, BIOCHEM BIOPH RES CO, V412, P197, DOI 10.1016/j.bbrc.2011.07.038; Liu XL, 2012, BBA-MOL BASIS DIS, V1822, P1716, DOI 10.1016/j.bbadis.2012.07.008; Luyimbazi D, 2010, MOL CANCER THER, V9, P2770, DOI 10.1158/1535-7163.MCT-09-0980; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Minville-Walz M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014363; Morrisett JD, 2002, J LIPID RES, V43, P1170, DOI 10.1194/jlr.M100392-JLR200; NAKANISHI S, 1970, EUR J BIOCHEM, V16, P161, DOI 10.1111/j.1432-1033.1970.tb01068.x; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Owen JL, 2012, P NATL ACAD SCI USA, V109, P16184, DOI 10.1073/pnas.1213343109; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Ricoult SJH, 2013, EMBO REP, V14, P242, DOI 10.1038/embor.2013.5; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Soliman GA, 2010, LIPIDS, V45, P1089, DOI 10.1007/s11745-010-3488-y; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; TWETO J, 1971, J BIOL CHEM, V246, P2468; Wang BT, 2011, P NATL ACAD SCI USA, V108, P15201, DOI 10.1073/pnas.1103746108; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Williams KJ, 2013, CANCER RES, V73, P2850, DOI 10.1158/0008-5472.CAN-13-0382-T; Yecies JL, 2011, CELL METAB, V14, P21, DOI 10.1016/j.cmet.2011.06.002; Young RM, 2013, GENE DEV, V27, P1115, DOI 10.1101/gad.198630.112; Zhang CB, 2009, AM J PHYSIOL-ENDOC M, V296, pE862, DOI 10.1152/ajpendo.90651.2008; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	65	133	136	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1250	1260		10.1038/onc.2015.179	http://dx.doi.org/10.1038/onc.2015.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028026	Green Accepted			2022-12-28	WOS:000371763100005
J	Ho, JCS; Nadeem, A; Rydstrom, A; Puthia, M; Svanborg, C				Ho, J. C. S.; Nadeem, A.; Rydstrom, A.; Puthia, M.; Svanborg, C.			Targeting of nucleotide-binding proteins by HAMLET-a conserved tumor cell death mechanism	ONCOGENE			English	Article							HUMAN ALPHA-LACTALBUMIN; TYROSINE KINASES; INHIBITION; CANCER; IDENTIFICATION; FEATURES; LETHAL	HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) kills tumor cells broadly suggesting that conserved survival pathways are perturbed. We now identify nucleotide-binding proteins as HAMLET binding partners, accounting for about 35% of all HAMLET targets in a protein microarray comprising 8000 human proteins. Target kinases were present in all branches of the Kinome tree, including 26 tyrosine kinases, 10 tyrosine kinase-like kinases, 13 homologs of yeast sterile kinases, 4 casein kinase 1 kinases, 15 containing PKA, PKG, PKC family kinases, 15 calcium/calmodulin-dependent protein kinase kinases and 13 kinases from CDK, MAPK, GSK3, CLK families. HAMLET acted as a broad kinase inhibitor in vitro, as defined in a screen of 347 wild-type, 93 mutant, 19 atypical and 17 lipid kinases. Inhibition of phosphorylation was also detected in extracts from HAMLET-treated lung carcinoma cells. In addition, HAMLET recognized 24 Ras family proteins and bound to Ras, RasL11B and Rap1B on the cytoplasmic face of the plasma membrane. Direct cellular interactions between HAMLET and activated Ras family members including Braf were confirmed by co-immunoprecipitation. As a consequence, oncogenic Ras and Braf activity was inhibited and HAMLET and Braf inhibitors synergistically increased tumor cell death in response to HAMLET. Unlike most small molecule kinase inhibitors, HAMLET showed selectivity for tumor cells in vitro and in vivo. The results identify nucleotide-binding proteins as HAMLET targets and suggest that dysregulation of the ATPase/kinase/GTPase machinery contributes to cell death, following the initial, selective recognition of HAMLET by tumor cells. The findings thus provide a molecular basis for the conserved tumoricidal effect of HAMLET, through dysregulation of kinases and oncogenic GTPases, to which tumor cells are addicted.	[Ho, J. C. S.; Nadeem, A.; Rydstrom, A.; Puthia, M.; Svanborg, C.] Lund Univ, Inst Lab Med, Dept Microbiol Immunol & Glycobiol MIG, Solvegatan 23, S-22362 Lund, Sweden	Lund University	Svanborg, C (corresponding author), Lund Univ, Inst Lab Med, Dept Microbiol Immunol & Glycobiol MIG, Solvegatan 23, S-22362 Lund, Sweden.	catharina.svanborg@med.lu.se	Ho, James CS/AAF-8197-2022; Ho, James CS/ADQ-2735-2022; Nadeem, Aftab/GRJ-0009-2022	Ho, James CS/0000-0002-6131-1297; Ho, James CS/0000-0002-6131-1297; Nadeem, Aftab/0000-0002-1439-6216; Rydstrom, Anna/0000-0002-3404-7195; Puthia, Manoj/0000-0001-6048-7234	Sharon D Lund foundation grant; Swedish Cancer Society; Medical Faculty (Lund University); Soderberg Foundation; Segerfalk Foundation; Maggie Stephens Foundation; Gunnar Nilsson Cancer Foundation; Inga-Britt and Arne Lundberg Foundation; HJ Forssman Foundation for Medical Research; Royal Physiographic Society	Sharon D Lund foundation grant; Swedish Cancer Society(Swedish Cancer Society); Medical Faculty (Lund University); Soderberg Foundation; Segerfalk Foundation; Maggie Stephens Foundation; Gunnar Nilsson Cancer Foundation; Inga-Britt and Arne Lundberg Foundation; HJ Forssman Foundation for Medical Research; Royal Physiographic Society	This study was supported by the Sharon D Lund foundation grant, the Swedish Cancer Society, the Medical Faculty (Lund University), the Soderberg Foundation, the Segerfalk Foundation, the Maggie Stephens Foundation, the Gunnar Nilsson Cancer Foundation, the Inga-Britt and Arne Lundberg Foundation, the HJ Forssman Foundation for Medical Research and the Royal Physiographic Society. We thank Petter Storm for conducting the Biacore and Braf activity experiments.	Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chene P, 2002, NAT REV DRUG DISCOV, V1, P665, DOI 10.1038/nrd894; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Duringer C, 2003, J BIOL CHEM, V278, P42131, DOI 10.1074/jbc.M306462200; Egorov VV, 2007, DOKL BIOCHEM BIOPHYS, V414, P152, DOI 10.1134/S1607672907030167; Fischer W, 2004, CANCER RES, V64, P2105, DOI 10.1158/0008-5472.CAN-03-2661; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Garuti L, 2010, CURR MED CHEM, V17, P2804, DOI 10.2174/092986710791859333; Gustafsson L, 2004, NEW ENGL J MED, V350, P2663, DOI 10.1056/NEJMoa032454; Gustafsson L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005229; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; Ho J, 2015, J MOL BIOL, V427, P1866, DOI 10.1016/j.jmb.2015.01.024; Hojjat-Farsangi M, 2014, INT J MOL SCI, V15, P13768, DOI 10.3390/ijms150813768; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; KIRSTEN WH, 1970, BIBL HAEMATOL, V1969, P246; MacBeath G, 2000, SCIENCE, V289, P1760; Manning Brendan D, 2002, Sci STKE, V2002, ppe49, DOI 10.1126/stke.2002.162.pe49; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Mossberg AK, 2007, INT J CANCER, V121, P1352, DOI 10.1002/ijc.22810; Mossberg AK, 2010, J UROLOGY, V183, P1590, DOI 10.1016/j.juro.2009.12.008; Nakano H, 2009, J ANTIBIOT, V62, P17, DOI 10.1038/ja.2008.4; Newman RH, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.12; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Puthia M, 2014, GUT, V63, P131, DOI 10.1136/gutjnl-2012-303715; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Satoh J, 2006, J NEUROSCI METH, V152, P278, DOI 10.1016/j.jneumeth.2005.09.015; Sekiguchi T, 2004, J BIOL CHEM, V279, P8343, DOI 10.1074/jbc.M305935200; Spang A, 2010, FEBS LETT, V584, P2646, DOI 10.1016/j.febslet.2010.04.005; Stolle K, 2007, BBA-GENE STRUCT EXPR, V1769, P514, DOI 10.1016/j.bbaexp.2007.05.005; Storm P, 2011, ONCOGENE, V30, P4765, DOI 10.1038/onc.2011.196; Storm P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058578; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tee AR, 2005, FEBS LETT, V579, P4763, DOI 10.1016/j.febslet.2005.07.054; Trulsson M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017179; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Yan JL, 2008, MOL CELL BIOL, V28, P5803, DOI 10.1128/MCB.00393-08; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	49	14	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					897	907		10.1038/onc.2015.144	http://dx.doi.org/10.1038/onc.2015.144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	26028028				2022-12-28	WOS:000370332200010
J	Chen, X; Bosques, L; Sung, P; Kupfer, GM				Chen, X.; Bosques, L.; Sung, P.; Kupfer, G. M.			A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage	ONCOGENE			English	Article							FANCONI-ANEMIA PATHWAY; CROSS-LINK REPAIR; HOMOLOGOUS RECOMBINATION; REPLICATION FORK; TRANSLESION SYNTHESIS; PHYSICAL INTERACTION; POLYMERASE SWITCH; PCNA; ACTIVATION; MUTAGENESIS	Fanconi anemia (FA) is a genetic disease of bone marrow failure, cancer susceptibility, and sensitivity to DNA crosslinking agents. FANCD2, the central protein of the FA pathway, is monoubiquitinated upon DNA damage, such as crosslinkers and replication blockers such as hydroxyurea (HU). Even though FA cells demonstrate unequivocal sensitivity to crosslinkers, such as mitomycin C (MMC), we find that they are largely resistant to HU, except for cells absent for expression of FANCD2. FANCD2, RAD51 and RAD18 form a complex, which is enhanced upon HU exposure. Surprisingly, although FANCD2 is required for this enhanced interaction, its monoubiquitination is not. Similarly, non-ubiquitinated FANCD2 can still support proliferation cell nuclear antigen (PCNA) monoubiquitination. RAD51, but not BRCA2, is also required for PCNA monoubiquitination in response to HU, suggesting that this function is independent of homologous recombination (HR). We further show that translesion (TLS) polymerase PolH chromatin localization is decreased in FANCD2 deficient cells, FANCD2 siRNA knockdown cells and RAD51 siRNA knockdown cells, and PolH knockdown results in HU sensitivity only. Our data suggest that FANCD2 and RAD51 have an important role in PCNA monoubiquitination and TLS in a FANCD2 monoubiquitination and HR-independent manner in response to HU. This effect is not observed with MMC treatment, suggesting a non-canonical function for the FA pathway in response to different types of DNA damage.	[Chen, X.; Bosques, L.; Kupfer, G. M.] Yale Univ, Sch Med, Yale Canc Ctr, Dept Pediat,Sect Hematol Oncol, New Haven, CT 06520 USA; [Chen, X.; Bosques, L.; Kupfer, G. M.] Yale Univ, Sch Med, Yale Canc Ctr, Dept Pathol,Sect Hematol Oncol, New Haven, CT 06520 USA; [Sung, P.] Yale Univ, Sch Med, Yale Canc Ctr, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Kupfer, GM (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, Dept Pediat,Sect Hematol Oncol, LMP2073,333 Cedar St, New Haven, CT 06520 USA.	gary.kupfer@yale.edu			NATIONAL CANCER INSTITUTE [R01CA168635] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA168635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpi AF, 2009, DNA REPAIR, V8, P430, DOI 10.1016/j.dnarep.2009.01.019; Bagby GC, 2006, SEMIN HEMATOL, V43, P147, DOI 10.1053/j.seminhematol.2006.04.005; Bindra RS, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt255; Brown S, 2009, CELL CYCLE, V8, P689, DOI 10.4161/cc.8.5.7707; Chang DJ, 2009, NAT CHEM BIOL, V5, P82, DOI 10.1038/nchembio.139; Chaudhury I, 2013, NUCLEIC ACIDS RES, V41, P6444, DOI 10.1093/nar/gkt348; Chen JJ, 2011, CELL BIOCHEM BIOPHYS, V60, P47, DOI 10.1007/s12013-011-9187-3; Dunn J, 2006, CANCER RES, V66, P11140, DOI 10.1158/0008-5472.CAN-06-0563; Fu DC, 2013, CELL CYCLE, V12, P803, DOI 10.4161/cc.23755; Garaycoechea JI, 2014, BLOOD, V123, P26, DOI 10.1182/blood-2013-09-427740; Green AM, 2009, HEMATOL ONCOL CLIN N, V23, P193, DOI 10.1016/j.hoc.2009.01.008; Hirano S, 2005, EMBO J, V24, P418, DOI 10.1038/sj.emboj.7600534; Ho V, 2010, ENVIRON MOL MUTAGEN, V51, P552, DOI 10.1002/em.20573; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Holloman WK, 2011, NAT STRUCT MOL BIOL, V18, P748, DOI 10.1038/nsmb.2096; Howlett NG, 2005, HUM MOL GENET, V14, P693, DOI 10.1093/hmg/ddi065; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Howlett NG, 2009, J BIOL CHEM, V284, P28935, DOI 10.1074/jbc.M109.016352; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Johnstone P, 1997, SOMAT CELL MOLEC GEN, V23, P371, DOI 10.1007/BF02673747; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kim H, 2012, GENE DEV, V26, P1393, DOI 10.1101/gad.195248.112; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Koc A, 2004, J BIOL CHEM, V279, P223, DOI 10.1074/jbc.M303952200; Lehmann AR, 2007, DNA REPAIR, V6, P891, DOI 10.1016/j.dnarep.2007.02.003; Lin JR, 2011, MOL CELL, V42, P237, DOI 10.1016/j.molcel.2011.02.026; Lossaint G, 2013, MOL CELL, V51, P678, DOI 10.1016/j.molcel.2013.07.023; MAURERSCHULTZE B, 1988, EXP CELL RES, V174, P230, DOI 10.1016/0014-4827(88)90157-7; McCabe KM, 2008, MOL GENET METAB, V95, P66, DOI 10.1016/j.ymgme.2008.06.009; Mirchandani KD, 2008, DNA REPAIR, V7, P902, DOI 10.1016/j.dnarep.2008.03.001; Miyase S, 2005, J BIOL CHEM, V280, P515, DOI 10.1074/jbc.M409219200; Moldovan GL, 2012, MOL CELL, V45, P75, DOI 10.1016/j.molcel.2011.11.010; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Palle K, 2011, CELL CYCLE, V10, P1625, DOI 10.4161/cc.10.10.15617; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pickering A, 2013, CANCER BIOL THER, V14, P1089, DOI 10.4161/cbt.26380; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Reliene R, 2010, CANCER RES, V70, P9703, DOI 10.1158/0008-5472.CAN-09-1022; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Suhasini AN, 2011, EMBO J, V30, P692, DOI 10.1038/emboj.2010.362; Tanaka T, 2007, CYTOM PART A, V71A, P648, DOI 10.1002/cyto.a.20426; Terai K, 2010, MOL CELL, V37, P143, DOI 10.1016/j.molcel.2009.12.018; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Williams SA, 2011, HUM MOL GENET, V20, P4395, DOI 10.1093/hmg/ddr366; Williams SA, 2011, BLOOD, V117, P5078, DOI 10.1182/blood-2010-10-311761; Zeman MK, 2014, J CELL BIOL, V206, P183, DOI 10.1083/jcb.201311063	50	33	33	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					22	34		10.1038/onc.2015.68	http://dx.doi.org/10.1038/onc.2015.68			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25893307	Green Accepted			2022-12-28	WOS:000367812400003
J	Laugier, F; Delyon, J; Andre, J; Bensussan, A; Dumaz, N				Laugier, F.; Delyon, J.; Andre, J.; Bensussan, A.; Dumaz, N.			Hypoxia and MITF regulate KIT oncogenic properties in melanocytes	ONCOGENE			English	Article							STEM-CELL FACTOR; HUMAN-MELANOMA CELLS; METASTATIC MELANOMA; SIGNAL-TRANSDUCTION; OXYGEN; SKIN; ACTIVATION; EXPRESSION; SURVIVAL; IMATINIB	KIT mutations are frequent in acral, mucosal and chronic sun-damage (CSD) melanoma, but little is known about the mechanisms driving the transformation of KIT-mutated melanocytes into melanoma cells. We showed that exposition of melanocytes harboring the L576PKIT mutation to a hypoxic environment induced their transformation into malignant cells. Transformed L576PKIT melanocytes showed downregulation of MITF expression characteristic of melanoma initiating cells (MICs). In agreement, these cells were able to form spheres in neural crest cell medium and low-adherence conditions, also a characteristic of MICs. Downregulation of MITF by RNA interference induced transformation of KIT-mutated melanocytes in normoxia and acquisition of a MIC phenotype by these cells. Hence, low level of MITF cooperates with oncogenic KIT to transform melanocytes. Activation of the cAMP pathway in transformed L576PKIT melanocytes stimulated MITF expression, and reduced cellular proliferation and sphere formation. These findings highlight the essential role of MITF in revealing the oncogenic activity of KIT in melanocytes and suggest that the cAMP pathway is a therapeutic target in KIT-mutated melanoma.	[Laugier, F.; Delyon, J.; Andre, J.; Bensussan, A.; Dumaz, N.] Hop St Louis, Ctr Rech Peau, INSERM, U976, Paris, France; [Laugier, F.; Delyon, J.; Andre, J.; Bensussan, A.; Dumaz, N.] Univ Paris Diderot, Sorbonne Paris Cite, UMRS976, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Dumaz, N (corresponding author), Hop St Louis, U976, INSERM, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	nicolas.dumaz@inserm.fr	Bensussan, Armand/E-5434-2017; Delyon, Julie/O-5147-2019; Dumaz, Nicolas/B-5907-2008	Delyon, Julie/0000-0002-4557-3377; Dumaz, Nicolas/0000-0003-3511-2160; Bensussan, Armand/0000-0002-0409-2497	L'Oreal Research Innovation; INSERM; Universite Paris Diderot; Fondation ARC pour la Recherche sur le Cancer	L'Oreal Research Innovation; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris Diderot; Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer)	We thank Pr Antoni Ribas for the M230 melanoma cell line. This work was funded by L'Oreal Research & Innovation, INSERM, Universite Paris Diderot and Fondation ARC pour la Recherche sur le Cancer. FL was supported by L'Oreal Research & Innovation.	Bastian BC, 2013, J CLIN ONCOL, V31, P3288, DOI 10.1200/JCO.2013.50.3227; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bedogni B, 2009, PIGM CELL MELANOMA R, V22, P166, DOI 10.1111/j.1755-148X.2009.00553.x; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bourillon A, 2013, PIGM CELL MELANOMA R, V26, P88, DOI 10.1111/pcmr.12032; Carvajal RD, 2011, JAMA-J AM MED ASSOC, V305, P2327, DOI 10.1001/jama.2011.746; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dumaz N, 2015, MELANOMA RES, V25, P88, DOI 10.1097/CMR.0000000000000116; Evans SM, 2006, J INVEST DERMATOL, V126, P2596, DOI 10.1038/sj.jid.5700451; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Feige E, 2011, P NATL ACAD SCI USA, V108, pE924, DOI 10.1073/pnas.1106351108; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garrido MC, 2010, J INVEST DERMATOL, V130, P20, DOI 10.1038/jid.2009.334; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; Hamai A, 2006, ONCOGENE, V25, P7618, DOI 10.1038/sj.onc.1209738; Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; HORIKOSHI T, 1991, J INVEST DERMATOL, V96, P841, DOI 10.1111/1523-1747.ep12474550; Huang SY, 1996, ONCOGENE, V13, P2339; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; LASSAM N, 1992, ONCOGENE, V7, P51; Liang RX, 2011, PIGM CELL MELANOMA R, V24, P714, DOI 10.1111/j.1755-148X.2011.00870.x; Liu HL, 2007, EMBO J, V26, P891, DOI 10.1038/sj.emboj.7601545; Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Park E, 2012, AM J DERMATOPATH, V34, P41, DOI 10.1097/DAD.0b013e31821ec0ef; Ramgolam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018784; Rezvani HR, 2011, J INVEST DERMATOL, V131, P1793, DOI 10.1038/jid.2011.141; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Todd JR, 2014, ONCOGENE, V33, P236, DOI 10.1038/onc.2012.562; von Euw E, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-22; Young SM, 2007, CELL SIGNAL, V19, P2572, DOI 10.1016/j.cellsig.2007.08.004	39	6	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5070	5077		10.1038/onc.2016.39	http://dx.doi.org/10.1038/onc.2016.39			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26973244				2022-12-28	WOS:000383965300010
J	El Ghamrasni, S; Cardoso, R; Li, L; Guturi, KKN; Bjerregaard, VA; Liu, Y; Venkatesan, S; Hande, MP; Henderson, JT; Sanchez, O; Hickson, ID; Hakem, A; Hakem, R				El Ghamrasni, S.; Cardoso, R.; Li, L.; Guturi, K. K. N.; Bjerregaard, V. A.; Liu, Y.; Venkatesan, S.; Hande, M. P.; Henderson, J. T.; Sanchez, O.; Hickson, I. D.; Hakem, A.; Hakem, R.			Rad54 and Mus81 cooperation promotes DNA damage repair and restrains chromosome missegregation	ONCOGENE			English	Article							LARGE T-ANTIGEN; DOWN-REGULATION; RECOMBINATION; PROTEIN; INSTABILITY; DISRUPTION; INTEGRITY; CELLS; GENE	Rad54 and Mus81 mammalian proteins physically interact and are important for the homologous recombination DNA repair pathway; however, their functional interactions in vivo are poorly defined. Here, we show that combinatorial loss of Rad54 and Mus81 results in hypersensitivity to DNA-damaging agents, defects on both the homologous recombination and non-homologous DNA end joining repair pathways and reduced fertility. We also observed that while Mus81 deficiency diminished the cleavage of common fragile sites, very strikingly, Rad54 loss impaired this cleavage to even a greater extent. The inefficient repair of DNA double-strand breaks (DSBs) in Rad54(-/-) Mus81(-/-) cells was accompanied by elevated levels of chromosome missegregation and cell death. Perhaps as a consequence, tumor incidence in Rad54(-/-) Mus81(-/-) mice remained comparable to that in Mus81(-/-) mice. Our study highlights the importance of the cooperation between Rad54 and Mus81 for mediating DNA DSB repair and restraining chromosome missegregation.	[El Ghamrasni, S.; Cardoso, R.; Li, L.; Guturi, K. K. N.; Hakem, A.; Hakem, R.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; [El Ghamrasni, S.; Cardoso, R.; Li, L.; Guturi, K. K. N.; Hakem, A.; Hakem, R.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada; [Bjerregaard, V. A.; Liu, Y.; Hickson, I. D.] Univ Copenhagen, Panum Inst, Ctr Chromosome Stabil, Dept Cellular & Mol Med, Copenhagen, Denmark; [Bjerregaard, V. A.; Liu, Y.; Hickson, I. D.] Univ Copenhagen, Panum Inst, Ctr Hlth Ageing, Copenhagen, Denmark; [Venkatesan, S.; Hande, M. P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Venkatesan, S.; Hande, M. P.] Natl Univ Singapore, Tembusu Coll, Singapore, Singapore; [Henderson, J. T.] Univ Toronto, Leslie Dan Fac Pharm, Div Biomol Sci, Dept Pharmaceut Sci, Toronto, ON, Canada; [Sanchez, O.] Univ Ontario, Inst Technol, Dept Pathol, Oshawa, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Copenhagen; University of Copenhagen; National University of Singapore; National University of Singapore; University of Toronto; Ontario Tech University	Hakem, R (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.; Hakem, R (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada.	rhakem@uhnres.utoronto.ca	El Ghamrasni, Samah/AAA-1350-2022; Venkatesan, Shriram/AAY-9319-2021; Hande, M. Prakash/B-1645-2008; Hickson, Ian/AAJ-7548-2020; Venkatesan, Shriram/AFL-5405-2022	El Ghamrasni, Samah/0000-0003-4346-1360; Venkatesan, Shriram/0000-0003-0778-2474; Hande, M. Prakash/0000-0002-4511-6256; Venkatesan, Shriram/0000-0003-0778-2474; Hakem, Razqallah/0000-0001-5948-7931; Hickson, Ian/0000-0002-0583-566X	Canadian Institute of Health Research	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by the Canadian Institute of Health Research (RH). We thank P McPherson and members of the RH laboratory for helpful discussions and critical reading of the manuscript. In addition, we thank S Hakem for editing the manuscript and R Kanaar for providing Rad54<SUP>-/-</SUP> mice.	Agarwal S, 2011, J CELL BIOL, V192, P735, DOI 10.1083/jcb.201011025; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Ceballos SJ, 2011, BBA-GENE REGUL MECH, V1809, P509, DOI 10.1016/j.bbagrm.2011.06.006; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dendouga N, 2005, MOL CELL BIOL, V25, P7569, DOI 10.1128/MCB.25.17.7569-7579.2005; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; El Ghamrasni S, 2015, ONCOGENE, V34, P1780, DOI 10.1038/onc.2014.121; El Ghamrasni S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001385; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Garner E, 2013, CELL REP, V5, P207, DOI 10.1016/j.celrep.2013.08.041; Hakem R, 2008, EMBO J, V27, P589, DOI 10.1038/emboj.2008.15; Hanada K, 2006, EMBO J, V25, P4921, DOI 10.1038/sj.emboj.7601344; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Hiyama T, 2006, NUCLEIC ACIDS RES, V34, P880, DOI 10.1093/nar/gkj495; Hussain Syed A, 2004, Expert Rev Anticancer Ther, V4, P1179, DOI 10.1586/14737140.4.6.1179; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Mazin AV, 2010, DNA REPAIR, V9, P286, DOI 10.1016/j.dnarep.2009.12.006; Mazina OM, 2008, P NATL ACAD SCI USA, V105, P18249, DOI 10.1073/pnas.0807016105; McManus KJ, 2009, P NATL ACAD SCI USA, V106, P3276, DOI 10.1073/pnas.0813414106; McPherson JP, 2004, SCIENCE, V304, P1822, DOI 10.1126/science.1094557; McPherson JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371; Munoz-Galvan S, 2012, MOL CELL BIOL, V32, P1592, DOI 10.1128/MCB.00111-12; Naim V, 2013, NAT CELL BIOL, V15, P1008, DOI 10.1038/ncb2793; Ozeri-Galai E, 2012, TRENDS GENET, V28, P295, DOI 10.1016/j.tig.2012.02.006; Pamidi A, 2007, CANCER RES, V67, P8527, DOI 10.1158/0008-5472.CAN-07-1161; Pepe A, 2014, CELL REP, V7, P1048, DOI 10.1016/j.celrep.2014.04.007; Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600; Sarbajna S, 2014, TRENDS BIOCHEM SCI, V39, P409, DOI 10.1016/j.tibs.2014.07.003; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Wechsler T, 2011, NATURE, V471, P642, DOI 10.1038/nature09790; Wesoly J, 2006, MOL CELL BIOL, V26, P976, DOI 10.1128/MCB.26.3.976-989.2006; Wu F, 2008, CANCER-AM CANCER SOC, V112, P2002, DOI 10.1002/cncr.23396; Wu F, 2011, CANCER SCI, V102, P472, DOI 10.1111/j.1349-7006.2010.01790.x; Wu F, 2010, ANTICANCER RES, V30, P5011; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	44	10	10	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4836	4845		10.1038/onc.2016.16	http://dx.doi.org/10.1038/onc.2016.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876210				2022-12-28	WOS:000383330700002
J	Fabris, L; Berton, S; Citron, F; D'Andrea, S; Segatto, I; Nicoloso, MS; Massarut, S; Armenia, J; Zafarana, G; Rossi, S; Ivan, C; Perin, T; Vaidya, JS; Avanzo, M; Roncadin, M; Schiappacassi, M; Bristow, RG; Calin, G; Baldassarre, G; Belletti, B				Fabris, L.; Berton, S.; Citron, F.; D'Andrea, S.; Segatto, I.; Nicoloso, M. S.; Massarut, S.; Armenia, J.; Zafarana, G.; Rossi, S.; Ivan, C.; Perin, T.; Vaidya, J. S.; Avanzo, M.; Roncadin, M.; Schiappacassi, M.; Bristow, R. G.; Calin, G.; Baldassarre, G.; Belletti, B.			Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway	ONCOGENE			English	Article							GROWTH-FACTOR LEVELS; INTRAOPERATIVE RADIOTHERAPY; CELL-PROLIFERATION; ERBB RECEPTORS; RADIATION; SURGERY; MORPHOGENESIS; INHIBITION; SURVIVAL; INVASION	In breast cancer (BC) patients, local recurrences often arise in proximity of the surgical scar, suggesting that response to surgery may have a causative role. Radiotherapy (RT) after lumpectomy significantly reduces the risk of recurrence. We investigated the direct effects of surgery and of RT delivered intraoperatively (IORT), by collecting irradiated and non-irradiated breast tissues from BC patients, after tumor removal. These breast tissue specimens have been profiled for their microRNA (miR) expression, in search of differentially expressed miR among patients treated or not with IORT. Our results demonstrate that IORT elicits effects that go beyond the direct killing of residual tumor cells. IORT altered the wound response, inducing the expression of miR-223 in the peritumoral breast tissue. miR-223 downregulated the local expression of epidermal growth factor (EGF), leading to decreased activation of EGF receptor (EGFR) on target cells and, eventually, dampening a positive EGF-EGFR autocrine/paracrine stimulation loop induced by the post-surgical wound-healing response. Accordingly, both RT-induced miR-223 and peri-operative inhibition of EGFR efficiently prevented BC cell growth and reduced recurrence formation in mouse models of BC. Our study uncovers unknown effects of RT delivered on a wounded tissue and prompts to the use of anti-EGFR treatments, in a peri-operative treatment schedule, aimed to timely treat BC patients and restrain recurrence formation.	[Fabris, L.; Berton, S.; Citron, F.; D'Andrea, S.; Segatto, I.; Nicoloso, M. S.; Armenia, J.; Schiappacassi, M.; Baldassarre, G.; Belletti, B.] Natl Canc Inst, CRO Aviano, Dept Translat Res, Div Expt Oncol 2, Via Gallini 2, I-33081 Aviano, Italy; [Berton, S.; Zafarana, G.; Bristow, R. G.] Univ Toronto, Dept Radiat Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Berton, S.; Zafarana, G.; Bristow, R. G.] Univ Toronto, Dept Med Biophys, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Nicoloso, M. S.; Rossi, S.; Ivan, C.; Calin, G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Massarut, S.] Natl Canc Inst, CRO Aviano, Dept Oncol & Surg, Breast Surg Unit, Aviano, Italy; [Perin, T.] Natl Canc Inst, CRO Aviano, Dept Translat Res, Pathol Unit, Aviano, Italy; [Vaidya, J. S.] UCL, Div Surg & Intervent Sci, London, England; [Avanzo, M.] Natl Canc Inst, CRO Aviano, Dept Radiotherapy & Oncol, Med Phys Unit, Aviano, Italy; [Roncadin, M.] Natl Canc Inst, CRO Aviano, Dept Radiotherapy & Oncol, Radiotherapy Unit, Aviano, Italy; [Rossi, S.] Swiss Inst Bioinformat, Batiment Genopode, CH-1015 Lausanne, Switzerland	IRCCS Aviano (CRO); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Texas System; UTMD Anderson Cancer Center; IRCCS Aviano (CRO); IRCCS Aviano (CRO); University of London; University College London; IRCCS Aviano (CRO); IRCCS Aviano (CRO); Swiss Institute of Bioinformatics	Baldassarre, G; Belletti, B (corresponding author), Natl Canc Inst, CRO Aviano, Dept Translat Res, Div Expt Oncol 2, Via Gallini 2, I-33081 Aviano, Italy.	gbaldassarre@cro.it; bbelletti@cro.it	Baldassarre, Gustavo/K-1350-2016; Nicoloso, Milena S/K-6411-2012; Vaidya, Jayant S/F-7717-2010; Schiappacassi, Monica/AAX-5505-2020; Perin, Tiziana/AAC-2403-2020; Avanzo, Michele/C-8529-2009; Belletti, Barbara/J-2028-2018; Citron, Francesca/AAC-2249-2020; Calin, George/E-9390-2011; D'Andrea, Sara/AAC-2148-2020; Massarut, Samuele/J-2995-2018; Segatto, Ilenia/AAX-5513-2020; Vaidya, Jayant S/A-7218-2008	Baldassarre, Gustavo/0000-0002-9750-8825; Nicoloso, Milena S/0000-0003-4231-9303; Vaidya, Jayant S/0000-0003-1760-1278; Schiappacassi, Monica/0000-0003-4804-4291; Perin, Tiziana/0000-0002-9823-0167; Avanzo, Michele/0000-0003-1711-4242; Belletti, Barbara/0000-0003-2249-0285; Citron, Francesca/0000-0002-5896-3008; D'Andrea, Sara/0000-0001-5736-6431; Massarut, Samuele/0000-0003-4717-0544; Segatto, Ilenia/0000-0001-5282-1028; Vaidya, Jayant S/0000-0003-1760-1278; Bristow, Robert/0000-0002-8553-9544; Ivan, Cristina/0000-0002-4848-0168; Calin, George/0000-0002-7427-0578; Calin, George/0000-0001-6704-5615	Associazione Italiana Ricerca sul Cancro (AIRC) [IG 15902, IG 12854]; CRO Intramural Research Grant; Friuli Exchange Program; AIRC-Marie Curie Outgoing International Fellowship; AIRC fellowship [16620]; NATIONAL CANCER INSTITUTE [R01CA182905] Funding Source: NIH RePORTER; National Institute for Health Research [10/104/07, 07/60/49] Funding Source: researchfish	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); CRO Intramural Research Grant; Friuli Exchange Program; AIRC-Marie Curie Outgoing International Fellowship(Fondazione AIRC per la ricerca sul cancro); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute for Health Research(National Institute for Health Research (NIHR))	This work is dedicated to the memory of Dr Mauro Gaetano Trovo, who strongly supported this research. We are grateful to the patients who participated to this study. We thank Dr Debora Martinuzzo for her valuable contribution, Sara Benevol for expert technical assistance, Maria Giulia Baldassarre for her useful observations and all members of the SCICC lab for supportive scientific discussions. We thank Dr Qiao Li (University of Michigan Medical Center, USA) for providing EO771E2 cell line and Dr Roberta Maestro (CRO Aviano, Aviano, Italy) for providing HMEC hTERT cells. This work was supported by research funding from Associazione Italiana Ricerca sul Cancro (AIRC) to BB (IG 15902) and to GB (IG 12854); from CRO Intramural Research Grant to GB and SM; from Friuli Exchange Program to SB. SB was a recipient of AIRC-Marie Curie Outgoing International Fellowship. IS was a recipient of AIRC fellowship (ref. 16620).	Armenia J, 2014, ONCOTARGET, V5, P1185, DOI 10.18632/oncotarget.1803; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Baum M, 2005, EUR J CANCER, V41, P508, DOI 10.1016/j.ejca.2004.09.031; Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007; Belletti B, 2008, CLIN CANCER RES, V14, P1325, DOI 10.1158/1078-0432.CCR-07-4453; Christensen ME, 1996, ACTA OTO-LARYNGOL, V116, P137, DOI 10.3109/00016489609137727; de Gonzalez AB, 2013, INT J RADIAT ONCOL, V86, P224, DOI 10.1016/j.ijrobp.2012.09.001; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Demicheli R, 2008, ANN ONCOL, V19, P1821, DOI 10.1093/annonc/mdn386; Demicheli R, 2001, BRIT J CANCER, V85, P490, DOI 10.1054/bjoc.2001.1969; Demicheli R, 2007, NAT CLIN PRACT ONCOL, V4, P699, DOI 10.1038/ncponc0999; Doan PL, 2013, NAT MED, V19, P295, DOI 10.1038/nm.3070; Dumbrigue HB, 2000, ORAL SURG ORAL MED O, V89, P710, DOI 10.1067/moe.2000.106343; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Epstein JB, 2000, CANCER-AM CANCER SOC, V89, P2258, DOI 10.1002/1097-0142(20001201)89:11<2258::AID-CNCR14>3.0.CO;2-Z; Halvorsen AR, 2014, INT J CANCER, V135, P2085, DOI 10.1002/ijc.28862; Haraguchi T, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp040; Helland A, 2006, RADIOTHER ONCOL, V80, P230, DOI 10.1016/j.radonc.2006.07.007; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Inui M, 2012, CURR OPIN CELL BIOL, V24, P194, DOI 10.1016/j.ceb.2011.11.013; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kuonen F, 2012, CLIN CANCER RES, V18, P5196, DOI 10.1158/1078-0432.CCR-11-1758; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002; Pinatel EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084859; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Redis RS, 2012, PHARMACOL THERAPEUT, V136, P169, DOI 10.1016/j.pharmthera.2012.08.003; Schmitz KH, 2012, CANCER-AM CANCER SOC, V118, P2270, DOI 10.1002/cncr.27462; Segatto I, 2014, ONCOTARGET, V5, P6267, DOI 10.18632/oncotarget.2195; Segatto I, 2014, MOL ONCOL, V8, P766, DOI 10.1016/j.molonc.2014.02.006; Segatto I, 2013, J MOL CELL BIOL, V5, P428, DOI 10.1093/jmcb/mjt027; Shao H, 2003, CANCER RES, V63, P3923; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Vaidya JS, 2014, LANCET, V383, P603, DOI 10.1016/S0140-6736(13)61950-9; Vaidya JS, 2010, LANCET, V376, P91, DOI 10.1016/S0140-6736(10)60837-9; Wang SH, 2014, INT J BIOL SCI, V10, P25, DOI 10.7150/ijbs.6309; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006	41	43	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4914	4926		10.1038/onc.2016.23	http://dx.doi.org/10.1038/onc.2016.23			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876200	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000383330700009
J	Li, X; Roife, D; Kang, Y; Dai, B; Pratt, M; Fleming, JB				Li, X.; Roife, D.; Kang, Y.; Dai, B.; Pratt, M.; Fleming, J. B.			Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; STELLATE CELLS; PHASE-III; CANCER; LOCALIZATION; GEMCITABINE; EXPRESSION; RESISTANCE; CARCINOMA; TARGET	Lumican, an extracellular matrix proteoglycan overexpressed by pancreatic stellate cells (PSCs) and pancreatic ductal adenocarcinoma cells (PDACs), drives the formation of a tumor-specific microenvironment. We recently showed that extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Here we investigated the role of extracellular lumican in chemotherapy-mediated cancer therapy. Lumican secretion was increased by chemotherapeutic agents in PDAC, and especially in PSCs, and appeared to be linked to the extent of cells' response to chemotherapy-induced growth inhibition. In multiple PDAC models, including cell lines, patient-derived xenografts and lumican knockout mice, lumican significantly increased antitumor effect of chemotherapy. This effect was associated with DNA damage, apoptosis and inhibition of cell viability, glucose consumption, lactate production and vascular endothelial growth factor secretion. In PDAC cells, chemotherapeutic agents triggered autophagosome formation and increased LC3 expression through the reactive oxygen species-mediated AMP-activated kinase (AMPK) signaling pathway. Inhibition of gemcitabine-induced autophagy in cancer cells by treatment with AMPK inhibitor compound C, lysosomal inhibitor chloroquine or autophagy inhibitor 3MA enhanced gemcitabine-induced apoptosis, suggesting that autophagy is a protective cellular response to gemcitabine treatment. Importantly, lumican dramatically decreased AMPK activity, inhibiting chemotherapy-induced autophagy in both in vitro and in vivo PDAC models. Co-treatment of PDAC cells with lumican and gemcitabine increased mitochondrial damage, reactive oxygen species (ROS) production and cytochrome c release, indicating that lumican-induced disruption of mitochondrial function may be the mechanism of sensitization to gemcitabine. Together, our findings demonstrate that extracellular lumican augments cytotoxicity of chemotherapy in PDAC cells through inhibition of chemotherapeutic agent-induced autophagy.	[Li, X.; Roife, D.; Kang, Y.; Dai, B.; Pratt, M.; Fleming, J. B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,FCT17-5048, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fleming, JB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,FCT17-5048, Houston, TX 77030 USA.	jbflemin@mdanderson.org		Roife, David/0000-0001-9052-2248	Viragh Family Foundation; W. Smith Foundation; National Institutes of Health (NIH) [T32CA009599]	Viragh Family Foundation; W. Smith Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the Viragh Family Foundation (to JF), the W. Smith Foundation (to JF) and National Institutes of Health (NIH) grant T32CA009599 (to DR).	Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Baba H, 2001, JPN CIRC J, V65, P445, DOI 10.1253/jcj.65.445; Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149; Bin-Umer MA, 2014, P NATL ACAD SCI USA, V111, P11798, DOI 10.1073/pnas.1403145111; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Coulson-Thomas VJ, 2013, EXP CELL RES, V319, P967, DOI 10.1016/j.yexcr.2013.01.023; Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031; Erkan M, 2012, GUT, V61, P172, DOI 10.1136/gutjnl-2011-301220; Hamada S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00331; Hardie DG, 2015, CURR OPIN CELL BIOL, V33, P1, DOI 10.1016/j.ceb.2014.09.004; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Ishiwata T, 2007, ONCOL REP, V18, P537; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim MP, 2012, ANN SURG ONCOL, V19, pS395, DOI 10.1245/s10434-011-1839-4; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156; Li XQ, 2015, ONCOTARGET, V6, P11507, DOI 10.18632/oncotarget.3432; Li XQ, 2014, CLIN CANCER RES, V20, P6529, DOI 10.1158/1078-0432.CCR-14-0970; Masamune A, 2013, PANCREATOLOGY, V13, P102, DOI 10.1016/j.pan.2012.12.058; Masamune A, 2009, J GASTROENTEROL, V44, P249, DOI 10.1007/s00535-009-0013-2; Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627; Nikitovic D, 2008, IUBMB LIFE, V60, P818, DOI 10.1002/iub.131; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Rehman G, 2014, ARCH PHARM, V347, P457, DOI 10.1002/ardp.201300402; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Vonlaufen A, 2008, CANCER RES, V68, P2085, DOI 10.1158/0008-5472.CAN-07-2477; Zhu H, 2013, J BIOL CHEM, V288, P16495, DOI 10.1074/jbc.M112.443580	34	36	36	0	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4881	4890		10.1038/onc.2016.20	http://dx.doi.org/10.1038/onc.2016.20			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876211				2022-12-28	WOS:000383330700006
J	Musa, J; Orth, MF; Dallmayer, M; Baldauf, M; Pardo, C; Rotblat, B; Kirchner, T; Leprivier, G; Grunewald, TGP				Musa, J.; Orth, M. F.; Dallmayer, M.; Baldauf, M.; Pardo, C.; Rotblat, B.; Kirchner, T.; Leprivier, G.; Gruenewald, T. G. P.			Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis	ONCOGENE			English	Review							RAPAMYCIN SIGNALING PATHWAY; CAP-BINDING PROTEIN; INTERNAL RIBOSOMAL ENTRY; CELL-CYCLE PROGRESSION; RAT EMBRYO FIBROBLASTS; FACTOR 4E; MAMMALIAN TARGET; BREAST-CANCER; MTOR PATHWAY; POOR-PROGNOSIS	Protein synthesis activity is abnormally enhanced in cancer cells to support their uncontrolled growth. However, this process needs to be tightly restricted under metabolic stress - a condition often found within the tumor microenvironment - to preserve cell viability. mTORC1 is critical to link protein synthesis activity to nutrient and oxygen levels, in part by controlling the 4E-BP1-eIF4E axis. Whereas mTORC1 and eIF4E are known pro-tumorigenic factors, whose expression or activity is increased in numerous cancers, the role of 4E-BP1 in cancer is not yet definitive. On the one hand, 4E-BP1 has tumor suppressor activity by inhibiting eIF4E and, thus, blocking mRNA translation and proliferation. This is corroborated by elevated levels of phosphorylated and hence inactive 4E-BP1, which are detected in various cancers. On the other hand, 4E-BP1 has pro-tumorigenic functions as it promotes tumor adaptation to metabolic and genotoxic stress by selectively enhancing or preventing the translation of specific transcripts. Here we describe the molecular and cellular functions of 4E-BP1 and highlight the distinct roles of 4E-BP1 in cancer depending on the microenvironmental context of the tumor.	[Musa, J.; Orth, M. F.; Dallmayer, M.; Baldauf, M.; Gruenewald, T. G. P.] Ludwig Maximilians Univ Munchen, Inst Pathol, Lab Pediat Sarcoma Biol, Thalkirchner Str 36, D-80337 Munich, Germany; [Pardo, C.; Rotblat, B.; Leprivier, G.] Ben Gurion Univ Negev, Dept Life Sci, Beer Sheva, Israel; [Kirchner, T.] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany; [Kirchner, T.] German Canc Consortium DKTK, Heidelberg, Germany; [Kirchner, T.] German Canc Res Ctr, Heidelberg, Germany; [Leprivier, G.] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, Beer Sheva, Israel	University of Munich; Ben Gurion University; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ben Gurion University	Grunewald, TGP (corresponding author), Ludwig Maximilians Univ Munchen, Inst Pathol, Lab Pediat Sarcoma Biol, Thalkirchner Str 36, D-80337 Munich, Germany.	thomas.gruenewald@med.uni-muenchen.de	Grünewald, Thomas G. P./O-2317-2013; Rotblat, Barak/H-5970-2019	Grünewald, Thomas G. P./0000-0003-0920-7377; Rotblat, Barak/0000-0003-2985-7115; Musa, Julian/0000-0002-9138-1819; Orth, Martin/0000-0002-1789-6427; Dallmayer, Marlene/0000-0002-6877-7268	Bundesministerium fur Bildung und Forschung (BMBF); LMU Munich; Deutsche Stiftung fur Junge Erwachsene mit Krebs; Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed); Daimler and Benz Foundation; Reinhard Frank Foundation; LMU Munich's Institutional Strategy LMUexcellent within German Excellence Initiative; Mehr LEBEN fur krebskranke Kinder - Bettina-Brau-Stiftung; Fritz-Thyssen Foundation [FTF-40.15.0.030MN]; Deutsche Forschungsgemeinschaft [DFG GR3728/2-1]; German Cancer Aid [DKH-111886]	Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); LMU Munich; Deutsche Stiftung fur Junge Erwachsene mit Krebs; Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed); Daimler and Benz Foundation; Reinhard Frank Foundation; LMU Munich's Institutional Strategy LMUexcellent within German Excellence Initiative; Mehr LEBEN fur krebskranke Kinder - Bettina-Brau-Stiftung; Fritz-Thyssen Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe)	JM is supported by a scholarship in frame of the 'Deutschlandstipendium' program of the Bundesministerium fur Bildung und Forschung (BMBF) and the LMU Munich. MD is supported by a grant of the 'Deutsche Stiftung fur Junge Erwachsene mit Krebs'. TGPG is supported by a grant from the 'Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed)', the Daimler and Benz Foundation in cooperation with the Reinhard Frank Foundation, by LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative, the 'Mehr LEBEN fur krebskranke Kinder - Bettina-Brau-Stiftung', the Fritz-Thyssen Foundation (FTF-40.15.0.030MN), the Deutsche Forschungsgemeinschaft (DFG GR3728/2-1) and by the German Cancer Aid (DKH-111886).	Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Bidinosti M, 2010, J BIOL CHEM, V285, P19402, DOI 10.1074/jbc.M110.120774; Bidinosti M, 2010, MOL CELL, V37, P797, DOI 10.1016/j.molcel.2010.02.022; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cai WJ, 2014, ONCOTARGET, V5, P6015, DOI 10.18632/oncotarget.2109; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Cen L, 2007, MODERN PATHOL, V20, P936, DOI 10.1038/modpathol.3800834; Chao MW, 2015, ONCOTARGET, V6, P24092, DOI 10.18632/oncotarget.4483; Chaux A, 2013, HUM PATHOL, V44, P2323, DOI 10.1016/j.humpath.2013.05.014; Chaux A, 2013, UROLOGY, V81, P116, DOI 10.1016/j.urology.2012.09.007; Chen CN, 2004, J SURG ONCOL, V86, P22, DOI 10.1002/jso.20037; Chen J, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-30; Chen S, 2009, BRIT J DERMATOL, V161, P357, DOI 10.1111/j.1365-2133.2009.09179.x; Chen SJ, 2009, BRIT J DERMATOL, V160, P442, DOI 10.1111/j.1365-2133.2008.08903.x; Chen WN, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-292; Clark C, 2010, LARYNGOSCOPE, V120, P1159, DOI 10.1002/lary.20917; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Dai B, 2009, BJU INT, V104, P1009, DOI 10.1111/j.1464-410X.2009.08538.x; Dai N, 2011, GENE DEV, V25, P1159, DOI 10.1101/gad.2042311; Darb-Esfahani S, 2009, J CANCER RES CLIN, V135, P933, DOI 10.1007/s00432-008-0529-5; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Martino MC, 2014, ENDOCR-RELAT CANCER, V21, P601, DOI 10.1530/ERC-13-0112; Demicco EG, 2012, MODERN PATHOL, V25, P212, DOI 10.1038/modpathol.2011.148; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Dubois L, 2009, INT J RADIAT ONCOL, V73, P1219, DOI 10.1016/j.ijrobp.2008.12.003; Efeyan A, 2013, NATURE, V493, P679, DOI 10.1038/nature11745; Eguchi S, 2006, GENES CELLS, V11, P757, DOI 10.1111/j.1365-2443.2006.00977.x; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fonseca BD, 2015, J BIOL CHEM, V290, P15996, DOI 10.1074/jbc.M114.621730; Fonseca BD, 2014, SEMIN CELL DEV BIOL, V36, P102, DOI 10.1016/j.semcdb.2014.09.014; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Grunewald TGP, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-79; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haddad AQ, 2015, CANCER-AM CANCER SOC, V121, P43, DOI 10.1002/cncr.28976; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Italiano A, 2012, CANCER-AM CANCER SOC, V118, P5878, DOI 10.1002/cncr.27614; Izycka-Swieszewska E, 2010, POL J PATHOL, V61, P192; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jiang H, 2008, ONCOGENE, V27, P5729, DOI 10.1038/onc.2008.180; Jiao XD, 2013, HEPATO-GASTROENTEROL, V60, P921, DOI 10.5754/hge12865; Karlsson E, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3557; Karlsson E, 2011, GENE CHROMOSOME CANC, V50, P775, DOI 10.1002/gcc.20900; Kasajima A, 2011, ENDOCR-RELAT CANCER, V18, P181, DOI 10.1677/ERC-10-0126; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Korkolopoulou P, 2012, HISTOPATHOLOGY, V61, P293, DOI 10.1111/j.1365-2559.2012.04236.x; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Kouvaraki MA, 2011, SURGERY, V150, P1258, DOI 10.1016/j.surg.2011.09.022; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kremer CL, 2006, PROSTATE, V66, P1203, DOI 10.1002/pros.20410; Kuang XH, 2009, BIOCHEM BIOPH RES CO, V383, P368, DOI 10.1016/j.bbrc.2009.04.019; Lahat G, 2010, ANN SURG, V251, P1098, DOI 10.1097/SLA.0b013e3181dbb75a; Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laplante M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011593; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Lee HW, 2015, INT J CLIN EXP PATHO, V8, P3955; Lee VHY, 2008, FEBS J, V275, P2185, DOI 10.1111/j.1742-4658.2008.06372.x; Leprivier G, 2015, BBA-GENE REGUL MECH, V1849, P845, DOI 10.1016/j.bbagrm.2014.11.002; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li N, 2012, INT J CLIN EXP PATHO, V5, P660; Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Milella M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00024; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; Mueller S, 2012, NEURO-ONCOLOGY, V14, P1146, DOI 10.1093/neuonc/nos140; Nemes K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059335; Nishikawa M, 2015, UROL ONCOL, V33; No JH, 2011, GYNECOL ONCOL, V121, P8, DOI 10.1016/j.ygyno.2010.12.364; O'Reilly KE, 2009, CLIN CANCER RES, V15, P2872, DOI 10.1158/1078-0432.CCR-08-2336; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; Peng JZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107362; Perrone F, 2010, EUR J CANCER, V46, P2837, DOI 10.1016/j.ejca.2010.06.130; Petricoin EF, 2007, CANCER RES, V67, P3431, DOI 10.1158/0008-5472.CAN-06-1344; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rice LW, 2006, AM J OBSTET GYNECOL, V194, P1119, DOI 10.1016/j.ajog.2005.12.020; Righi L, 2010, ENDOCR-RELAT CANCER, V17, P977, DOI 10.1677/ERC-10-0157; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; Roh MS, 2015, VIRCHOWS ARCH, V467, P667, DOI 10.1007/s00428-015-1860-2; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruys AT, 2014, ANN SURG ONCOL, V21, P487, DOI 10.1245/s10434-013-3286-x; Salehi Z, 2006, CLIN BIOCHEM, V39, P404, DOI 10.1016/j.clinbiochem.2005.11.007; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schultz L, 2011, AM J SURG PATHOL, V35, P1549, DOI 10.1097/PAS.0b013e31822895e5; Schultz L, 2010, CANCER-AM CANCER SOC, V116, P5517, DOI 10.1002/cncr.25502; Shantz LM, 1996, CANCER RES, V56, P3265; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Siddiqui N, 2012, J MOL BIOL, V415, P781, DOI 10.1016/j.jmb.2011.12.002; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sunavala-Dossabhoy G, 2011, LARYNGOSCOPE, V121, P2136, DOI 10.1002/lary.22144; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tejada S, 2009, J HISTOCHEM CYTOCHEM, V57, P503, DOI 10.1369/jhc.2009.952929; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Thumma SC, 2007, CANCER LETT, V258, P1, DOI 10.1016/j.canlet.2007.08.022; Topisirovic I, 2015, BBA-GENE REGUL MECH, V1849, P751, DOI 10.1016/j.bbagrm.2015.05.004; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Truitt ML, 2015, CELL, V162, P59, DOI 10.1016/j.cell.2015.05.049; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; Wang WY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106098; Wang Z, 2012, NEOPLASMA, V59, P137, DOI 10.4149/neo_2012_018; Yamada Y, 2014, CANCER-AM CANCER SOC, V120, P864, DOI 10.1002/cncr.28506; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112; Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056	178	77	78	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4675	4688		10.1038/onc.2015.515	http://dx.doi.org/10.1038/onc.2015.515			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26829052				2022-12-28	WOS:000383324700001
J	Wunsch, D; Hahlbrock, A; Jung, S; Schirmeister, T; van den Boom, J; Schilling, O; Knauer, SK; Stauber, RH				Wuensch, D.; Hahlbrock, A.; Jung, S.; Schirmeister, T.; van den Boom, J.; Schilling, O.; Knauer, S. K.; Stauber, R. H.			Taspase1: a 'misunderstood' protease with translational cancer relevance	ONCOGENE			English	Review							NECK-CANCER; MLL TRANSLOCATIONS; MOLECULAR-BASIS; HEAD; MATRIX; BREAST; PROTEINS; INHIBITORS; EXPRESSION; CELLS	Proteolysis is not only a critical requirement for life, but the executing enzymes also play important roles in numerous pathological conditions, including cancer. Therefore, targeting proteases is clearly relevant for improving cancer patient care. However, to effectively control proteases, a profound knowledge of their mechanistic function as well as their regulation and downstream signalling in health and disease is required. The highly conserved protease Threonine Aspartase1 (Taspase1) is overexpressed in numerous liquid and solid malignancies and was characterized as a 'non-oncogene addiction' protease. Although Taspase1 was shown to cleave various regulatory proteins in humans as well as leukaemia provoking mixed lineage leukaemia fusions, our knowledge on its detailed functions and the underlying mechanisms contributing to cancer is still incomplete. Despite superficial similarity to type 2 asparaginases as well as Ntn proteases, such as the proteasome, Taspase1-related research so far gives us the picture of a unique protease exhibiting special features. Moreover, neither effective genetic nor chemical inhibitors for this enzyme are available so far, thus hampering not only to further dissect Taspase1's pathobiological functions but also precluding the assessment of its clinical impact. Based on recent insights, we here critically review the current knowledge of Taspase1's structurefunction relationship and its mechanistic relevance for tumorigenesis obtained from in vitro and in vivo cancer models. We provide a comprehensive overview of tumour entities for which Taspase1 might be of predictive and therapeutic value, and present the respective experimental evidence. To stimulate progress in the field, a comprehensive overview of Taspase1 targeting approaches is presented, including coverage of Taspase1-related patents. We conclude by discussing future inhibition strategies and relevant challenges, which need to be resolved by the field.	[Wuensch, D.; Hahlbrock, A.; Stauber, R. H.] ENT Univ Med Ctr Mainz, Mol & Cellular Oncol, Langenbeckstr 1, D-55101 Mainz, Germany; [Jung, S.; Schirmeister, T.] Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, Mainz, Germany; [van den Boom, J.] Univ Duisburg Essen, Ctr Med Biotechnol ZMB, Struct Biochem, Essen, Germany; [Schilling, O.] Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; [Knauer, S. K.] Univ Duisburg Essen, Ctr Med Biotechnol ZMB, Inst Mol Biol, Essen, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Duisburg Essen; University of Freiburg; University of Duisburg Essen	Wunsch, D (corresponding author), ENT Univ Med Ctr Mainz, Mol & Cellular Oncol, Langenbeckstr 1, D-55101 Mainz, Germany.	wuensch@uni-mainz.de	Gül, Désirée/AAB-5965-2022; Schilling, O/AAC-8302-2019; Schirmeister, Tanja/N-6886-2016; Knauer, Shirley K/E-7931-2012	Schirmeister, Tanja/0000-0002-4587-5076; Knauer, Shirley K/0000-0003-4321-0924; Schilling, Oliver/0000-0001-7678-7653; Guel, Desiree/0000-0002-2446-5756	IFF Mainz Intramural Research Funding; Zeiss foundation ChemBioMed	IFF Mainz Intramural Research Funding; Zeiss foundation ChemBioMed	Grant support: IFF Mainz Intramural Research Funding, Zeiss foundation ChemBioMed.	Aklilu M, 2011, NAT REV CLIN ONCOL, V8, P649, DOI 10.1038/nrclinonc.2011.118; Arkin MR, 2009, CURR OPIN CHEM BIOL, V13, P284, DOI 10.1016/j.cbpa.2009.05.125; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Benedikt A, 2011, LEUKEMIA, V25, P135, DOI 10.1038/leu.2010.249; Bier C, 2012, FASEB J, V26, P3421, DOI 10.1096/fj.11-202432; Bier C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034142; Bier C, 2011, TRAFFIC, V12, P703, DOI 10.1111/j.1600-0854.2011.01191.x; Bier C, 2011, J BIOL CHEM, V286, P3007, DOI 10.1074/jbc.M110.161646; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Bursen A, 2010, BLOOD, V115, P3570, DOI 10.1182/blood-2009-06-229542; Chan N, 2015, SCI REP-UK, V5, DOI 10.1038/srep11777; Chen DY, 2012, CANCER RES, V72, P2913, DOI 10.1158/0008-5472.CAN-12-1074; Chen DY, 2012, CANCER RES, V72, P736, DOI 10.1158/0008-5472.CAN-11-2584; Chen DY, 2010, CANCER RES, V70, P5358, DOI 10.1158/0008-5472.CAN-10-0027; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Dehart MP, 2007, J PHARM SCI-US, V96, P2667, DOI 10.1002/jps.20905; Demircan K, 2009, HEAD NECK-J SCI SPEC, V31, P793, DOI 10.1002/hed.21045; Docter D, 2015, NANOMEDICINE-UK, V10, P503, DOI 10.2217/nnm.14.184; Dong YY, 2014, CELL RES, V24, P1354, DOI 10.1038/cr.2014.129; Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053; Dufour A, 2013, TRENDS PHARMACOL SCI, V34, P233, DOI 10.1016/j.tips.2013.02.004; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Falini B, 2009, LEUKEMIA, V23, P1731, DOI 10.1038/leu.2009.124; Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gibellini L, 2014, FASEB J, V28, P5122, DOI 10.1096/fj.14-255869; Hadler-Olsen E, 2013, TUMOR BIOL, V34, P2041, DOI 10.1007/s13277-013-0842-8; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoffmann M, 2013, ONCOL REP, V29, P1962, DOI 10.3892/or.2013.2327; Hsieh JJ, 2011, Pat.No.US 7 964,700 B2, Patent No. 7694700; Hsieh JJ, 2013, Pat.No.US 8,501,811 B2, Patent No. 8501811; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Huber EM, 2015, STRUCTURE, V23, P407, DOI 10.1016/j.str.2014.11.019; Huber EM, 2012, ANGEW CHEM INT EDIT, V51, P8708, DOI 10.1002/anie.201201616; Hutchinson L, 2010, NAT REV CLIN ONCOL, V7, P669, DOI 10.1038/nrclinonc.2010.192; Kar G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000601; Khan JA, 2005, STRUCTURE, V13, P1443, DOI 10.1016/j.str.2005.07.006; Knauer SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018253; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Kornfeld JW, 2011, BRIT J CANCER, V104, P138, DOI 10.1038/sj.bjc.6606017; Kramer OH, 2013, LEUKEMIA, V27, P792, DOI 10.1038/leu.2012.284; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Lagadec C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-152; Lee JT, 2009, BIOORG MED CHEM LETT, V19, P5086, DOI 10.1016/j.bmcl.2009.07.045; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Michalska K, 2006, ACTA BIOCHIM POL, V53, P627, DOI 10.18388/abp.2006_3291; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; National Comprehensive Cancer Network, 2008, J Natl Compr Canc Netw, V6, P646; Niehof M, 2008, GASTROENTEROLOGY, V134, P1191, DOI 10.1053/j.gastro.2008.01.027; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ordonez Gonzalo R., 2009, V539, P33, DOI 10.1007/978-1-60327-003-8_2; Ottmann C, 2009, J MOL BIOL, V386, P913, DOI 10.1016/j.jmb.2009.01.005; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Oyama T, 2013, DEV CELL, V27, P188, DOI 10.1016/j.devcel.2013.09.025; Pal A, 2014, CANCER RES, V74, P4955, DOI 10.1158/0008-5472.CAN-14-1211; Pless B, 2011, LEUKEMIA, V25, P663, DOI 10.1038/leu.2010.308; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; Rao VH, 2012, ONCOGENE, V31, P2888, DOI 10.1038/onc.2011.460; Rawlings ND, 2011, J BIOL CHEM, V286, P38321, DOI 10.1074/jbc.M111.260026; Romero-Garcia S, 2011, CANCER BIOL THER, V12, P939, DOI 10.4161/cbt.12.11.18140; Rose R, 2010, ANGEW CHEM INT EDIT, V49, P4129, DOI 10.1002/anie.200907203; Rosenthal EL, 2006, HEAD NECK-J SCI SPEC, V28, P639, DOI 10.1002/hed.20365; Sabiani S, 2015, EBIOMEDICINE, V2, P386, DOI 10.1016/j.ebiom.2015.04.009; Saunders LP, 2008, MOL CANCER THER, V7, P3352, DOI 10.1158/1535-7163.MCT-08-0463; Scarbaci K, 2014, CHEMMEDCHEM, V9, P1801, DOI 10.1002/cmdc.201402075; Singh JC, 2014, BRIT J CANCER, V111, P1888, DOI 10.1038/bjc.2014.388; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494; Stauber RH, 2012, ONCOTARGET, V3, P31; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406; Thiel P, 2012, ANGEW CHEM INT EDIT, V51, P2012, DOI 10.1002/anie.201107616; Tomasetti C, 2015, P NATL ACAD SCI USA, V112, P118, DOI 10.1073/pnas.1421839112; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; van den Boom J, 2014, CHEMBIOCHEM, V15, P2233, DOI 10.1002/cbic.201402108; Vandenbroucke RE, 2014, NAT REV DRUG DISCOV, V13, P904, DOI 10.1038/nrd4390; Witt S, 2006, STRUCTURE, V14, P1179, DOI 10.1016/j.str.2006.05.019; Wunsch D, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.22; Wunsch D, 2015, FASEB J, V29, P1973, DOI 10.1096/fj.14-262451; Wunsch D, 2015, BIOL CHEM, V396, P367, DOI 10.1515/hsz-2014-0318; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5; Zhou HQ, 2006, MOL CELL BIOL, V26, P2728, DOI 10.1128/MCB.26.7.2728-2735.2006; Zudaire E, 2011, Pat.No.EP2461806, Patent No. 2461806	96	16	16	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3351	3364		10.1038/onc.2015.436	http://dx.doi.org/10.1038/onc.2015.436			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26657154				2022-12-28	WOS:000379270100001
J	Schulze, M; Fedorchenko, O; Zink, TG; Knobbe-Thomsen, CB; Kraus, S; Schwinn, S; Beilhack, A; Reifenberger, G; Monoranu, CM; Siren, AL; Jeanclos, E; Gohla, A				Schulze, M.; Fedorchenko, O.; Zink, T. G.; Knobbe-Thomsen, C. B.; Kraus, S.; Schwinn, S.; Beilhack, A.; Reifenberger, G.; Monoranu, C. M.; Siren, A-L; Jeanclos, E.; Gohla, A.			Chronophin is a glial tumor modifier involved in the regulation of glioblastoma growth and invasiveness	ONCOGENE			English	Article							MALIGNANT GLIOMA; CELL-LINE; COFILIN; INVASION; BRAIN; ADF/COFILIN; INHIBITION; LANDSCAPE; DELETION; MOTILITY	Glioblastoma is the most aggressive primary brain tumor in adults. Although the rapid recurrence of glioblastomas after treatment is a major clinical challenge, the relationships between tumor growth and intracerebral spread remain poorly understood. We have identified the cofilin phosphatase chronophin (gene name: pyridoxal phosphatase, PDXP) as a glial tumor modifier. Monoallelic PDXP loss was frequent in four independent human astrocytic tumor cohorts and increased with tumor grade. We found that aberrant PDXP promoter methylation can be a mechanism leading to further chronophin downregulation in glioblastomas, which correlated with shorter glioblastoma patient survival. Moreover, we observed an inverse association between chronophin protein expression and cofilin phosphorylation levels in glioma tissue samples. Chronophin-deficient glioblastoma cells showed elevated cofilin phosphorylation, an increase in polymerized actin, a higher directionality of cell migration, and elevated in vitro invasiveness. Tumor growth of chronophin-depleted glioblastoma cells xenografted into the immunodeficient mouse brain was strongly impaired. Our study suggests a mechanism whereby the genetic and epigenetic alterations of PDXP resulting in altered chronophin expression may regulate the interplay between glioma cell proliferation and invasion.	[Schulze, M.; Zink, T. G.; Jeanclos, E.; Gohla, A.] Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Bavaria, Germany; [Schulze, M.; Jeanclos, E.; Gohla, A.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Bavaria, Germany; [Fedorchenko, O.] Univ Dusseldorf, Inst Biochem & Mol Biol 2, Dusseldorf, Germany; [Knobbe-Thomsen, C. B.; Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany; [Knobbe-Thomsen, C. B.; Reifenberger, G.] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Kraus, S.; Schwinn, S.; Beilhack, A.] Univ Wurzburg, Dept Internal Med 2, D-97078 Wurzburg, Bavaria, Germany; [Kraus, S.; Schwinn, S.; Beilhack, A.] Univ Wurzburg, Ctr Interdisciplinary Clin Res, D-97078 Wurzburg, Bavaria, Germany; [Monoranu, C. M.] Univ Wurzburg, Inst Pathol, Dept Neuropathol, D-97078 Wurzburg, Bavaria, Germany; [Monoranu, C. M.] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, D-97078 Wurzburg, Bavaria, Germany; [Siren, A-L] Univ Wurzburg, Dept Neurosurg, D-97078 Wurzburg, Bavaria, Germany; [Schulze, M.] Univ Regensburg, Dept Neuropathol, D-93053 Regensburg, Germany; [Fedorchenko, O.] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany	University of Wurzburg; University of Wurzburg; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Helmholtz Association; German Cancer Research Center (DKFZ); University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Regensburg; University of Cologne	Gohla, A (corresponding author), Univ Wurzburg, Dept Pharmacol, Versbacher Str 9, D-97078 Wurzburg, Germany.	antje.gohla@uni-wuerzburg.de	Knobbe-Thomsen, Christiane B/D-3116-2019; Sirén, Anna-Leena/AAE-1374-2019; Fedorchenko, Oleg/AAA-6533-2021; Reifenberger, Guido/AAE-3599-2019	Sirén, Anna-Leena/0000-0002-2217-0081; Gohla, Antje/0000-0002-7442-1487; Knobbe-Thomsen, Christiane/0000-0003-1231-0076; Jeanclos, Elisabeth/0000-0001-5934-5490	Deutsche Forschungsgemeinschaft [SFB728, SFB688, FZ82, TR17]; Forschungskommission of the Medical Faculty of Heinrich Heine University Dusseldorf; IZKF Wurzburg research grant; Medical Faculty of the University of Wurzburg (Graduate School of Life Sciences); Else Kroner-Fresenius-Stiftung; Max Eder Program of the German Cancer Aid (Deutsche Krebshilfe)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Forschungskommission of the Medical Faculty of Heinrich Heine University Dusseldorf; IZKF Wurzburg research grant; Medical Faculty of the University of Wurzburg (Graduate School of Life Sciences); Else Kroner-Fresenius-Stiftung; Max Eder Program of the German Cancer Aid (Deutsche Krebshilfe)	We thank Andrea Odersky and Beate Vogt for excellent technical assistance and Miriam Ritz, Carolin Graf, Thorsten Winter and Katja Ottmuller for help with bioluminescence imaging. We also thank Stephan Kissler for the gift of viral vectors, Christian Linden for FACS sorting and Michael Krause and Lukas Rycak, Marburg University, for microarray analysis. This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB728 to AG and GR; SFB688 and FZ82 to AG), the Forschungskommission of the Medical Faculty of Heinrich Heine University Dusseldorf (to AG) and by an IZKF Wurzburg research grant (to AB). TGZ was supported by a predoctoral fellowship from the Medical Faculty of the University of Wurzburg (Graduate School of Life Sciences) and by the Deutsche Forschungsgemeinschaft TR17. SK was supported by a fellowship of the Else Kroner-Fresenius-Stiftung, and CBKT is supported by the Max Eder Program of the German Cancer Aid (Deutsche Krebshilfe).	Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bernstein BW, 2006, AM J PHYSIOL-CELL PH, V291, pC828, DOI 10.1152/ajpcell.00066.2006; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Binda E, 2012, CANCER CELL, V22, P765, DOI 10.1016/j.ccr.2012.11.005; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bugyi B, 2010, ANNU REV BIOPHYS, V39, P449, DOI 10.1146/annurev-biophys-051309-103849; Carlsson SK, 2014, EMBO MOL MED, V6, P1359, DOI 10.15252/emmm.201302627; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chopra M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081320; Clark MJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000832; Collazo J, 2014, CANCER RES, V74, P2362, DOI 10.1158/0008-5472.CAN-13-3058; de Stahl TD, 2005, GENE CHROMOSOME CANC, V44, P161, DOI 10.1002/gcc.20226; Di Tomaso E, 2000, NEUROPATH APPL NEURO, V26, P22, DOI 10.1046/j.1365-2990.2000.00214.x; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Floyd D, 2014, NEURO-ONCOLOGY, V16, P622, DOI 10.1093/neuonc/nou049; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Galluzzi L, 2012, CELL REP, V2, P257, DOI 10.1016/j.celrep.2012.06.017; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartmann C, 2004, INT J CANCER, V108, P839, DOI 10.1002/ijc.11638; Horing E, 2012, ACTA NEUROPATHOL, V124, P83, DOI 10.1007/s00401-011-0940-x; Huang TY, 2008, DEV CELL, V15, P691, DOI 10.1016/j.devcel.2008.09.017; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Ino Y, 1999, J NEUROPATH EXP NEUR, V58, P881, DOI 10.1097/00005072-199908000-00010; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; KRUSE CA, 1992, IN VITRO CELL DEV-AN, V28A, P609; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mizuno K, 2013, CELL SIGNAL, V25, P457, DOI 10.1016/j.cellsig.2012.11.001; Muhammad A K, 1997, Neurol Med Chir (Tokyo), V37, P606, DOI 10.2176/nmc.37.606; Muhammad AK, 1997, NEUROL MEDICOCHIRURG, V37, P611; Nagai Shoichi, 2011, Genes Cancer, V2, P859, DOI 10.1177/1947601911431839; Oskam NT, 2000, INT J CANCER, V85, P336, DOI 10.1002/(SICI)1097-0215(20000201)85:3<336::AID-IJC7>3.0.CO;2-9; Park JY, 2014, J KOREAN RELIG, V5, P5, DOI 10.1353/jkr.2014.0003; Poincloux R, 2011, P NATL ACAD SCI USA, V108, P1943, DOI 10.1073/pnas.1010396108; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ren S, 2012, CANCER CHEMOTH PHARM, V70, P415, DOI 10.1007/s00280-012-1921-z; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Sauzeau V, 2010, ONCOGENE, V29, P3781, DOI 10.1038/onc.2010.134; Seifried A, 2014, J BIOL CHEM, V289, P3416, DOI 10.1074/jbc.M113.503359; Seifried A, 2013, FEBS J, V280, P549, DOI 10.1111/j.1742-4658.2012.08633.x; Seng TJ, 2005, GENE CHROMOSOME CANC, V43, P181, DOI 10.1002/gcc.20181; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Wiggan O, 2012, DEV CELL, V22, P530, DOI 10.1016/j.devcel.2011.12.026; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100	53	8	8	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3163	3177		10.1038/onc.2015.376	http://dx.doi.org/10.1038/onc.2015.376			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26549022				2022-12-28	WOS:000378092700008
J	Joly, AL; Deepti, A; Seignez, A; Goloudina, A; Hebrard, S; Schmitt, E; Richaud, S; Fourmaux, E; Hammann, A; Collura, A; Svrcek, M; Jego, G; Robinet, E; Solary, E; Demidov, O; Kohli, E; Garrido, C				Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Collura, A.; Svrcek, M.; Jego, G.; Robinet, E.; Solary, E.; Demidov, O.; Kohli, E.; Garrido, C.			The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development	ONCOGENE			English	Article							NEURAL PROGENITOR CELLS; ER STRESS; T-CELLS; SENSITIVITY; MOLECULES; THERAPY; TARGET; HSP70; RISK	Graft versus host disease (GvHD), which is the primary complication of allogeneic bone marrow transplantation, can alter the intestinal barrier targeted by activated donor T-cells. Chemical inhibition of the stress protein HSP90 was demonstrated in vitro to inhibit T-cell activation and to modulate endoplasmic reticulum (ER) stress to which intestinal cells are highly susceptible. Since the HSP90 inhibitor 17-allylamino-demethoxygeldanamycin (17AAG) is developed in clinics, we explored here its ability to control intestinal acute GvHD in vivo in two mouse GvHD models (C57BL/6 -> BALB/c and FVB/N -> Lgr5-eGFP), ex vivo in intestine organoids and in vitro in intestinal epithelial cultures. We show that 17AAG decreases GvHD-associated mortality without impairing graft versus leukemia effect. While 17AAG effect in T-cell activation is just moderate at the dose used in vivo, we observe a striking intestinal integrity protection. At the intestine level, the drug promotes the splicing of the transcription factor X-box binding protein 1 (XBP1), which is a key component of the ER stress. This effect is associated with a decrease in intestinal damage and an increase in Lgr5(+) stem cells, Paneth cells and defensins production. The importance of XBP1 splicing control is further confirmed in cultured cells and organoids of primary intestinal epithelium where XBP1 is either shRNA depleted or inhibited with toyocamycin. In conclusion, 17AAG has a protective effect on the epithelial intestinal barrier in mouse models of acute GvHD. This compound deserves to be tested in the therapeutic control of acute GvHD.	[Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Jego, G.; Demidov, O.; Kohli, E.; Garrido, C.] INSERM, UMR 866, Equipe Labellisee Ligue Natl Canc, F-21079 Dijon, France; [Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Jego, G.; Demidov, O.; Kohli, E.; Garrido, C.] Lab Excellence LipSTIC, Dijon, France; [Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Jego, G.; Demidov, O.; Kohli, E.; Garrido, C.] Univ Bourgogne, Dijon, France; [Seignez, A.] CHU, Dijon, France; [Collura, A.; Svrcek, M.] INSERM, UMR S938, Ctr Rech St Antoine, Paris, France; [Robinet, E.] INSERM, U748, Inst Virol, Strasbourg, France; [Robinet, E.] Inst Hosp Univ Strasbourg, Strasbourg, France; [Solary, E.] Inst Gustave Roussy, INSERM, UMR1009, F-94805 Villejuif, France; [Solary, E.] Univ Paris 11, Villejuif, France; [Garrido, C.] Anticanc Ctr George Francois Leclerc, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; CHU Dijon Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Garrido, C (corresponding author), INSERM, Fac Med & Pharm, UMR866, 7 Blvd Jeanne dArc, F-21079 Dijon, France.	cgarrido@u-bourgogne.fr	Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018; Demidov, Oleg/AAC-4462-2021; Demidov, Oleg/U-2050-2017; Goloudina, Anastasia/T-4989-2019; jego, gaetan/N-7226-2018	Garrido, carmen/0000-0003-1368-1493; Demidov, Oleg/0000-0003-4323-7174; Demidov, Oleg/0000-0003-4323-7174; jego, gaetan/0000-0003-0376-9299; Solary, Eric/0000-0002-8629-1341; deepti, ayswaria/0000-0001-7159-6911	Institut National du Cancer; Agence Nationale de la Recherche; Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer; FEDER; La Ligue Nationale Contre le Cancer; Conseil Regional de Bourgogne	Institut National du Cancer(Institut National du Cancer (INCA) France); Agence Nationale de la Recherche(French National Research Agency (ANR)); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); FEDER(European Commission); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte)	We thank J Haiech (University of Strasbourg), P Saas and B Gaugler (INSERM U1098, Besancon, France), for helpful discussions. We thank P Saas, H Clevers (Hubrecht Institute, The Netherlands) and A Jevnikar (Ontario, CA) for providing A20-luc cells, Lgr5-eGFP mice and IEC 4-1, respectively, and A Bouchot and JF Merlin (INSERM U866, Dijon, France) for excellent technical assistance. This work was supported by grants from the Institut National du Cancer, Agence Nationale de la Recherche, Ligue Nationale Contre le Cancer ('Labeled teams' to CG and ES), the Association pour la Recherche sur le Cancer (labeled team to CG and OD), and FEDER. CG team belongs to the LabEx LipSTIC and GR-Ex. ALJ has a doctoral fellowship from La Ligue Nationale Contre le Cancer and AD by the 'Conseil Regional de Bourgogne'.	Aucagne R, 2011, J CLIN INVEST, V121, P2361, DOI 10.1172/JCI45213; Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476; Biamonte MA, 2010, J MED CHEM, V53, P3, DOI 10.1021/jm9004708; Bradley E, 2014, J CELL COMMUN SIGNAL, V8, P353, DOI 10.1007/s12079-014-0247-5; Cawley K, 2011, METHOD ENZYMOL, V490, P31, DOI 10.1016/B978-0-12-385114-7.00002-7; Choi SW, 2014, NAT REV CLIN ONCOL, V11, P536, DOI 10.1038/nrclinonc.2014.102; Collins CB, 2013, MUCOSAL IMMUNOL, V6, P960, DOI 10.1038/mi.2012.134; Contassot E, 1998, TRANSPLANTATION, V65, P1365, DOI 10.1097/00007890-199805270-00014; Cooke KR, 1998, J CLIN INVEST, V102, P1882, DOI 10.1172/JCI4285; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Couturier M, 2013, LEUKEMIA, V27, P1527, DOI 10.1038/leu.2013.39; Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728; Didelot C, 2008, CELL DEATH DIFFER, V15, P859, DOI 10.1038/sj.cdd.4402320; Elo MA, 2005, BBA-MOL CELL RES, V1743, P115, DOI 10.1016/j.bbamcr.2004.09.004; Eriguchi Y, 2012, BLOOD, V120, P223, DOI 10.1182/blood-2011-12-401166; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Hanash AM, 2012, IMMUNITY, V37, P339, DOI 10.1016/j.immuni.2012.05.028; Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Kabiri Z, 2014, DEVELOPMENT, V141, P2206, DOI 10.1242/dev.104976; Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021; Kaser A, 2010, CURR OPIN GASTROEN, V26, P318, DOI 10.1097/MOG.0b013e32833a9ff1; Levine JE, 2013, BLOOD, V122, P1505, DOI 10.1182/blood-2013-02-485813; Li XC, 1997, CELL IMMUNOL, V175, P58, DOI 10.1006/cimm.1996.1050; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Mimura N, 2012, BLOOD, V119, P5772, DOI 10.1182/blood-2011-07-366633; Mjahed H, 2012, EXP CELL RES, V318, P1946, DOI 10.1016/j.yexcr.2012.05.012; Moser C, 2009, ANTICANCER RES, V29, P2031; Murphy S, 2011, LEUKEMIA LYMPHOMA, V52, P1844, DOI 10.3109/10428194.2011.580476; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Pelicano H, 2006, LEUKEMIA, V20, P610, DOI 10.1038/sj.leu.2404140; Penack O, 2010, BLOOD, V115, P1865, DOI 10.1182/blood-2009-09-242784; Rerole AL, 2011, CANCER RES, V71, P484, DOI 10.1158/0008-5472.CAN-10-1443; Ri M, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.26; Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Stuehler C, 2009, BLOOD, V114, P2829, DOI 10.1182/blood-2009-06-224600; Takashima S, 2011, J EXP MED, V208, P285, DOI 10.1084/jem.20101559; Tirosh B, 2006, J BIOL CHEM, V281, P5852, DOI 10.1074/jbc.M509061200; Wang GH, 2011, J NEUROCHEM, V117, P703, DOI 10.1111/j.1471-4159.2011.07239.x; Werner T, 2011, GUT, V60, P325, DOI 10.1136/gut.2010.216929	43	16	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2842	2851		10.1038/onc.2015.242	http://dx.doi.org/10.1038/onc.2015.242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26364610				2022-12-28	WOS:000377473700004
J	Zhou, L; Liu, XD; Sun, M; Zhang, X; German, P; Bai, S; Ding, Z; Tannir, N; Wood, CG; Matin, SF; Karam, JA; Tamboli, P; Sircar, K; Rao, P; Rankin, EB; Laird, DA; Hoang, AG; Walker, CL; Giaccia, AJ; Jonasch, E				Zhou, L.; Liu, X-D; Sun, M.; Zhang, X.; German, P.; Bai, S.; Ding, Z.; Tannir, N.; Wood, C. G.; Matin, S. F.; Karam, J. A.; Tamboli, P.; Sircar, K.; Rao, P.; Rankin, E. B.; Laird, D. A.; Hoang, A. G.; Walker, C. L.; Giaccia, A. J.; Jonasch, E.			Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; CABOZANTINIB XL184; C-MET; GROWTH; EXPRESSION; CANCER; ANGIOGENESIS; PROGRESSION; METASTASIS; ACTIVATION	Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance to sunitinib, an antiangiogenic small molecule, and to exploit this mechanism therapeutically. We hypothesized that sunitinib-induced upregulation of the prometastatic MET and AXL receptors is associated with resistance to sunitinib and with more aggressive tumor behavior. In the present study, tissue microarrays containing sunitinib-treated and untreated RCC tissues were stained with MET and AXL antibodies. The low malignant RCC cell line 786-O was chronically treated with sunitinib and assayed for AXL, MET, epithelial-mesenchymal transition (EMT) protein expression and activation. Co-culture experiments were used to examine the effect of sunitinib pretreatment on endothelial cell growth. The effects of AXL and MET were evaluated in various cell-based models by short hairpin RNA or inhibition by cabozantinib, the multi-tyrosine kinases inhibitor that targets vascular endothelial growth factor receptor, MET and AXL. Xenograft mouse models tested the ability of cabozantinib to rescue sunitinib resistance. We demonstrated that increased AXL and MET expression was associated with inferior clinical outcome in patients. Chronic sunitinib treatment of RCC cell lines activated both AXL and MET, induced EMT-associated gene expression changes, including upregulation of Snail and beta-catenin, and increased cell migration and invasion. Pretreatment with sunitinib enhanced angiogenesis in 786-0/human umbilical vein endothelial cell co-culture models. The suppression of AXL or MET expression and the inhibition of AXL and MET activation using cabozantinib both impaired chronic sunitinib treatment-induced prometastatic behavior in cell culture and rescued acquired resistance to sunitinib in xenograft models. In summary, chronic sunitinib treatment induces the activation of AXL and MET signaling and promotes prometastatic behavior and angiogenesis. The inhibition of AXL and MET activity may overcome resistance induced by prolonged sunitinib therapy in metastatic RCC.	[Zhou, L.; Liu, X-D; Sun, M.; Zhang, X.; German, P.; Bai, S.; Ding, Z.; Tannir, N.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1155 Hermann Pressler Dr, Houston, TX 77030 USA; [Wood, C. G.; Matin, S. F.; Karam, J. A.] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Urol, Houston, TX 77030 USA; [Tamboli, P.; Sircar, K.; Rao, P.; Hoang, A. G.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Rankin, E. B.; Giaccia, A. J.] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; [Laird, D. A.] Exelixis Inc, San Francisco, CA USA; [Walker, C. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Stanford University; Exelixis, Inc.; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1155 Hermann Pressler Dr, Houston, TX 77030 USA.	ejonasch@mdanderson.org		Liu, xiande/0000-0002-9639-0458	Exelixis; Renee Kaye Cure Fur Cancer Foundation; Monteleone Family Foundation; UT MD Anderson Cancer Center P30 Cancer Center Support Grant; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA067166, R01CA143811, R01CA198291] Funding Source: NIH RePORTER	Exelixis; Renee Kaye Cure Fur Cancer Foundation; Monteleone Family Foundation; UT MD Anderson Cancer Center P30 Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Exelixis, Renee Kaye Cure Fur Cancer Foundation, the Monteleone Family Foundation and the UT MD Anderson Cancer Center P30 Cancer Center Support Grant.	Bentzien F, 2013, THYROID, V23, P1569, DOI 10.1089/thy.2013.0137; Betsunoh H, 2007, CANCER SCI, V98, P491, DOI 10.1111/j.1349-7006.2007.00412.x; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Chinchar E, 2014, VASC CELL, V6, DOI 10.1186/2045-824X-6-12; Choueiri TK, 2014, ANN ONCOL, V25, P1603, DOI 10.1093/annonc/mdu184; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; Domblides C, 2013, EXPERT OPIN EMERG DR, V18, P495, DOI 10.1517/14728214.2013.858697; Ellison AR, 2003, J STEROID BIOCHEM, V86, P15, DOI 10.1016/S0960-0760(03)00257-7; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gibney GT, 2013, ANN ONCOL, V24, P343, DOI 10.1093/annonc/mds463; Griffioen AW, 2012, CLIN CANCER RES, V18, P3961, DOI 10.1158/1078-0432.CCR-12-0002; Gujral TS, 2013, ONCOGENE, V32, P3470, DOI 10.1038/onc.2012.378; Gustafsson A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007575; Gustafsson A, 2009, CLIN CANCER RES, V15, P4742, DOI 10.1158/1078-0432.CCR-08-2514; Harshman LC, 2013, CANCER J, V19, P316, DOI 10.1097/PPO.0b013e31829e3c9a; Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Horie S, 1999, J UROLOGY, V161, P990, DOI 10.1016/S0022-5347(01)61834-2; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Jonasch E, 2010, CANCER-AM CANCER SOC, V116, P57, DOI 10.1002/cncr.24685; Jonasch E, 2009, J CLIN ONCOL, V27, P4076, DOI 10.1200/JCO.2008.21.3660; Kanesvaran Ravindran, 2014, J Carcinog, V13, P3, DOI 10.4103/1477-3163.127638; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Kumar R, 2009, BRIT J CANCER, V101, P1717, DOI 10.1038/sj.bjc.6605366; Leconet W, 2014, ONCOGENE, V33, P5405, DOI 10.1038/onc.2013.487; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078-0432.CCR-06-0362; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pao-Chun L, 2009, J BIOL CHEM, V284, P34954, DOI 10.1074/jbc.M109.072660; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Plimack ER, 2009, CANCER-AM CANCER SOC, V115, P1859, DOI 10.1002/cncr.24211; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rankin EB, 2014, P NATL ACAD SCI USA, V111, P13373, DOI 10.1073/pnas.1404848111; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Ruan GX, 2012, EMBO J, V31, P1692, DOI 10.1038/emboj.2012.21; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Singhal E, 2011, INT J BIOCHEM CELL B, V43, P1134, DOI 10.1016/j.biocel.2011.04.006; Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Tsavachidou-Fenner D, 2010, ANN ONCOL, V21, P1599, DOI 10.1093/annonc/mdp600; WEIDNER N, 1995, AM J PATHOL, V147, P9; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang Y, 2010, IDRUGS, V13, P112; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	47	253	260	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2687	2697		10.1038/onc.2015.343	http://dx.doi.org/10.1038/onc.2015.343			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364599	Green Accepted			2022-12-28	WOS:000377472700003
J	Kuo, TL; Weng, CC; Kuo, KK; Chen, CY; Wu, DC; Hung, WC; Cheng, KH				Kuo, T-L; Weng, C-C; Kuo, K-K; Chen, C-Y; wu, D-C; Hung, W-C; Cheng, K-H			APC haploinsufficiency coupled with p53 loss sufficiently induces mucinous cystic neoplasms and invasive pancreatic carcinoma in mice	ONCOGENE			English	Article							SOLID-PSEUDOPAPILLARY TUMORS; POLYPOSIS-COLI PROTEIN; SOMATIC MUTATIONS; SIGNALING PATHWAY; WNT/BETA-CATENIN; MOUSE MODEL; CANCER; PROGRESSION; EXPRESSION; GENE	Adenomatous polyposis coli (APC), a tumor-suppressor gene critically involved in familial adenomatous polyposis, is integral in Wnt/beta-catenin signaling and is implicated in the development of sporadic tumors of the distal gastrointestinal tract including pancreatic cancer (PC). Here we report for the first time that functional APC is required for the growth and maintenance of pancreatic islets and maturation. Subsequently, a non-Kras mutation-induced premalignancy mouse model was developed; in this model, APC haploinsufficiency coupled with p53 deletion resulted in the development of a distinct type of pancreatic premalignant precursors, mucinous cystic neoplasms (MCNs), exhibiting pathomechanisms identical to those observed in human MCNs, including accumulation of cystic fluid secreted by neoplastic and ovarian-like stromal cells, with 100% penetrance and the presence of hepatic and gastric metastases in >30% of the mice. The major clinical implications of this study suggest targeting the Wnt signaling pathway as a novel strategy for managing MCN.	[Kuo, T-L; Weng, C-C; Cheng, K-H] Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan; [Kuo, K-K] Kaohsiung Med Univ Hosp, Div Hepatobiliopancreat Surg, Dept Surg, Kaohsiung, Taiwan; [Kuo, K-K; Chen, C-Y; wu, D-C; Cheng, K-H] Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung, Taiwan; [Chen, C-Y] Kaohsiung Med Univ Hosp, Dept Med Imaging, Kaohsiung, Taiwan; [wu, D-C] Kaohsiung Med Univ Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung, Taiwan; [wu, D-C] Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Div Internal Med, Kaohsiung, Taiwan; [Hung, W-C] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Cheng, K-H] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan	National Sun Yat Sen University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; National Health Research Institutes - Taiwan; Kaohsiung Medical University	Cheng, KH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan.	khcheng@faculty.nsysu.edu.tw			National Science Council, Taiwan ROC [NSC 101-2314-B-110-001-MY2, 101-2628-B-110-001-MY2, MOST 103-2314-B-037-062]; Kaohsiung Medical University, Kaohsiung, Taiwan [KMU-TP103G00, KMU-TP103G01]	National Science Council, Taiwan ROC(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University, Kaohsiung, Taiwan	We gratefully thank Dr Sheau-Fang Yang, at Kaohsiung Medical University for helping us to confirm the histologic features and pathology of MCN mice. This work was supported by grants NSC 101-2314-B-110-001-MY2, 101-2628-B-110-001-MY2 (to KH Cheng) and MOST 103-2314-B-037-062 (to DC Wu and KH Cheng) from the National Science Council, Taiwan ROC, and grants KMU-TP103G00 and KMU-TP103G01 (to DC Wu and KH Cheng) from Kaohsiung Medical University, Kaohsiung, Taiwan.	Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; Abraham SC, 2001, AM J PATHOL, V159, P1619, DOI 10.1016/S0002-9440(10)63008-8; Al-Haddad M, 2011, CLIN GASTROENTEROL H, V9, P635, DOI 10.1016/j.cgh.2011.03.005; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P121, DOI 10.1093/nar/24.1.121; Bonk T, 2002, CLIN BIOCHEM, V35, P87, DOI 10.1016/S0009-9120(02)00279-5; Chiu CY, 2012, MOL CANCER RES, V10, P415, DOI 10.1158/1541-7786.MCR-11-0293; Dessimoz J, 2006, CELL CYCLE, V5, P7, DOI 10.4161/cc.5.1.2293; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Emmrich S, 2014, GENE DEV, V28, P858, DOI 10.1101/gad.233791.113; Farrell JJ, 2013, GASTROENTEROLOGY, V144, P1303, DOI 10.1053/j.gastro.2013.01.073; Fazeli A, 1997, P NATL ACAD SCI USA, V94, P10199, DOI 10.1073/pnas.94.19.10199; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Guo MZ, 2014, DISCOV MED, V17, P67; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; HORII A, 1992, CANCER RES, V52, P6696; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Jiang H, 2014, AM J PATHOL, V184, P1355, DOI 10.1016/j.ajpath.2014.01.037; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kuijper S, 2005, DEVELOPMENT, V132, P1601, DOI 10.1242/dev.01735; Kuraguchi M, 2006, PLOS GENET, V2, P1362, DOI 10.1371/journal.pgen.0020146; Lang J, 2013, J NEUROSCI, V33, P3113, DOI 10.1523/JNEUROSCI.3467-12.2013; Le Borgne J, 1997, Chirurgie, V122, P31; Li AH, 2011, AM J PATHOL, V178, P1340, DOI 10.1016/j.ajpath.2010.11.058; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Maitra A, 2005, ADV ANAT PATHOL, V12, P81, DOI 10.1097/01.pap.0000155055.14238.25; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mavila N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050401; Milde-Langosch K, 2014, BREAST CANCER RES TR, V145, P295, DOI 10.1007/s10549-014-2949-z; Mimeault M, 2008, GUT, V57, P1456, DOI 10.1136/gut.2008.150052; Monti P, 2003, CANCER RES, V63, P7451; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Murakami Y, 2006, SURGERY, V140, P448, DOI 10.1016/j.surg.2006.03.017; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Niu JG, 2007, J BIOL CHEM, V282, P6001, DOI 10.1074/jbc.M606878200; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Pujal J, 2006, BBA-MOL BASIS DIS, V1762, P73, DOI 10.1016/j.bbadis.2005.08.002; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Reilein A, 2005, NAT CELL BIOL, V7, P463, DOI 10.1038/ncb1248; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sano M, 2014, GASTROENTEROLOGY, V146, P257, DOI 10.1053/j.gastro.2013.09.044; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Sekine H, 2012, BIOCHEM BIOPH RES CO, V429, P214, DOI 10.1016/j.bbrc.2012.10.048; Shimada M, 2002, J IMMUNOL, V168, P861, DOI 10.4049/jimmunol.168.2.861; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Strom A, 2007, DEVELOPMENT, V134, P2719, DOI 10.1242/dev.02875; Su HT, 2013, MOL CANCER RES, V11, P768, DOI 10.1158/1541-7786.MCR-12-0511; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tang LH, 2005, AM J SURG PATHOL, V29, P512, DOI 10.1097/01.pas.0000155159.28530.88; Toivonen S, 2013, EXP CELL RES, V319, P2535, DOI 10.1016/j.yexcr.2013.07.007; Tsukamoto N, 2013, PANCREAS, V42, P1027, DOI 10.1097/MPA.0b013e31828804e7; Ueno K, 2011, INT J CANCER, V129, P2360, DOI 10.1002/ijc.25899; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Zhu M, 2013, J CELL BIOL, V200, P773, DOI 10.1083/jcb.201207050; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	67	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2223	2234		10.1038/onc.2015.284	http://dx.doi.org/10.1038/onc.2015.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26411367				2022-12-28	WOS:000374986000008
J	Venturutti, L; Romero, LV; Urtreger, AJ; Chervo, MF; Russo, RIC; Mercogliano, MF; Inurrigarro, G; Pereyra, MG; Proietti, CJ; Izzo, F; Flaque, MCD; Sundblad, V; Roa, JC; Guzman, P; Joffe, EDBD; Charreau, EH; Schillaci, R; Elizalde, PV				Venturutti, L.; Romero, L. V.; Urtreger, A. J.; Chervo, M. F.; Cordo Russo, R. I.; Mercogliano, M. F.; Inurrigarro, G.; Pereyra, M. G.; Proietti, C. J.; Izzo, F.; Diaz Flaque, M. C.; Sundblad, V.; Roa, J. C.; Guzman, P.; Bal de Kier Joffe, E. D.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.			Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis	ONCOGENE			English	Article							PROGESTERONE-RECEPTOR; MICRORNA EXPRESSION; SIGNAL TRANSDUCER; TRANSGENIC MICE; MAMMARY-TUMORS; UP-REGULATION; TRANSCRIPTIONAL COMPLEX; TISSUE INHIBITOR; ACTIVATION; GROWTH	Membrane overexpression of the receptor tyrosine kinase ErbB-2 (MErbB-2) accounts for a clinically aggressive breast cancer (BC) subtype (ErbB-2-positive) with increased incidence of metastases. We and others demonstrated that nuclear ErbB-2 (NErbB-2) also plays a key role in BC and is a poor prognostic factor in ErbB-2-positive tumors. The signal transducer and activator of transcription 3 (Stat3), another player in BC, has been recognized as a downstream mediator of MErbB-2 action in BC metastasis. Here, we revealed an unanticipated novel direction of the ErbB-2 and Stat3 interaction underlying BC metastasis. We found that Stat3 binds to its response elements (GAS) at the ErbB-2 promoter to upregulate ErbB-2 transcription in metastatic, ErbB-2-positive BC. We validated these results in several BC subtypes displaying metastatic and non-metastatic ability, highlighting Stat3 general role as upstream regulator of ErbB-2 expression in BC. Moreover, we showed that Stat3 co-opts NErbB-2 function by recruiting ErbB-2 as its coactivator at the GAS sites in the promoter of microRNA-21 (miR-21), a metastasis-promoting microRNA (miRNA). Using an ErbB-2 nuclear localization domain mutant and a constitutively activated ErbB-2 variant, we found that NErbB-2 role as a Stat3 coactivator and also its direct role as transcription factor upregulate miR-21 in BC. This reveals a novel function of NErbB-2 as a regulator of miRNAs expression. Increased levels of miR-21, in turn, downregulate the expression of the metastasis-suppressor protein programmed cell death 4 (PDCD4), a validated miR-21 target. Using an in vivo model of metastatic ErbB-2-postive BC, in which we silenced Stat3 and reconstituted ErbB-2 or miR-21 expression, we showed that both are downstream mediators of Stat3-driven metastasis. Supporting the clinical relevance of our results, we found an inverse correlation between ErbB-2/Stat3 nuclear co-expression and PDCD4 expression in ErbB-2-positive primary invasive BCs. Our findings identify Stat3 and NErbB-2 as novel therapeutic targets to inhibit ErbB-2-positive BC metastasis.	[Venturutti, L.; Romero, L. V.; Chervo, M. F.; Cordo Russo, R. I.; Mercogliano, M. F.; Pereyra, M. G.; Proietti, C. J.; Izzo, F.; Diaz Flaque, M. C.; Sundblad, V.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Mol Mech Carcinogenesis, RA-1033 Buenos Aires, DF, Argentina; [Urtreger, A. J.; Bal de Kier Joffe, E. D.] Univ Buenos Aires, Inst Oncol Angel H Roffo, Res Area, Buenos Aires, DF, Argentina; [Inurrigarro, G.] Sanatorio Mater Dei, Serv Patol, Buenos Aires, DF, Argentina; [Roa, J. C.; Guzman, P.] Univ La Frontera, Dept Anat Patol BIOREN, Temuco, Chile; [Roa, J. C.] Pontificia Univ Catolica Chile, Escuela Med, Dept Anat Patol, Santiago, Chile; [Roa, J. C.] Pontificia Univ Catolica Chile, Adv Ctr Chron Dis ACCDIS, Santiago, Chile	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires; Universidad de La Frontera; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Schillaci, R; Elizalde, PV (corresponding author), Inst Biol & Med Expt IBYME, Lab Mol Mech Carcinogenesis, Vuelta de Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	rschillaci@ibyme.conicet.gov.ar; patriciaelizalde@ibyme.conicet.gov.ar	Roa, Juan C./K-4749-2014; Russo, Rosalia Cordo/O-9149-2017	Roa, Juan C./0000-0001-8313-8774; Russo, Rosalia Cordo/0000-0002-5984-9717; Mercogliano, Maria Florencia/0000-0003-1094-9247; Chervo, Maria Florencia/0000-0001-8878-5591; BAL de KIER JOFFE, ELISA DORA/0000-0001-6952-0029; Elizalde, Patricia V./0000-0002-5923-9898; Diaz Flaque, Maria Celeste/0000-0003-4167-6149	Susan G Komen for the Cure [KG090250]; National Agency of Scientific Promotion of Argentina [IDB/PICT 2012-668, PID 2012-066, IDB/PICT 2012-0382]; Oncomed-Reno CONICET from Henry Moore Institute of Argentina [1819/03]	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); National Agency of Scientific Promotion of Argentina(ANPCyT); Oncomed-Reno CONICET from Henry Moore Institute of Argentina	We thank MC Hung (MD Anderson Cancer Center, Houston, TX, USA) for his generous gift of the hErbB-2.NLS, which indeed made this work possible, AA Molinolo (NIH, Bethesda, MD, USA) for his constant help and support and V Chiauzzi for her technical assistance. This work was supported by the Susan G Komen for the Cure KG090250 investigator-initiated research Grant, and IDB/PICT 2012-668 and PID 2012-066 from the National Agency of Scientific Promotion of Argentina, all of them awarded to PVE, IDB/PICT 2012-0382 (awarded to RS) and Oncomed-Reno CONICET 1819/03, from the Henry Moore Institute of Argentina (awarded to PVE and RS).	AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Alonso DF, 1999, BREAST CANCER RES TR, V57, P271, DOI 10.1023/A:1006291607871; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Barbieri I, 2010, CANCER RES, V70, P2558, DOI 10.1158/0008-5472.CAN-09-2840; Barbieri I, 2010, MOL CARCINOGEN, V49, P114, DOI 10.1002/mc.20605; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; Beguelin W, 2010, MOL CELL BIOL, V30, P5456, DOI 10.1128/MCB.00012-10; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Carnevale RP, 2007, MOL ENDOCRINOL, V21, P1335, DOI 10.1210/me.2006-0304; Chen J, 2014, CLIN TRANSL ONCOL, V16, P225, DOI 10.1007/s12094-013-1132-z; Russo RIC, 2015, ONCOGENE, V34, P3413, DOI 10.1038/onc.2014.272; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Flaque MCD, 2013, STEROIDS, V78, P559, DOI 10.1016/j.steroids.2012.11.003; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Freudenberg JA, 2009, EXP MOL PATHOL, V87, P1, DOI 10.1016/j.yexmp.2009.05.001; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gomez-Martin C, 2014, CANCER LETT, V351, P30, DOI 10.1016/j.canlet.2014.05.019; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Han ML, 2012, MOL CELL BIOCHEM, V363, P427, DOI 10.1007/s11010-011-1195-5; Henderson IC, 1998, BREAST CANCER RES TR, V52, P261, DOI 10.1023/A:1006141703224; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Izzo F, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0491-x; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Kang HJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07201; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Landgraf R, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1633; Li CH, 2014, EUR J CANCER, V50, P2560, DOI 10.1016/j.ejca.2014.07.008; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Marino ALF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-739; Meric-Bernstam F, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3343; Mitsui K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-863; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; Niu JX, 2012, J BIOL CHEM, V287, P21783, DOI 10.1074/jbc.M112.355495; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Ou HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109929; Peters MG, 2003, BREAST CANCER RES TR, V80, P221, DOI 10.1023/A:1024549729256; Petrovic N, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0867-x; Proietti C, 2005, MOL CELL BIOL, V25, P4826, DOI 10.1128/MCB.25.12.4826-4840.2005; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; Qian L, 2006, BIOCHEM BIOPH RES CO, V345, P660, DOI 10.1016/j.bbrc.2006.04.153; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Schillaci R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-74; Shishodia G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-996; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; Tetzlaff MT, 2007, ENDOCR PATHOL, V18, P163, DOI 10.1007/s12022-007-0023-7; Tran N, 2007, BIOCHEM BIOPH RES CO, V358, P12, DOI 10.1016/j.bbrc.2007.03.201; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Urtreger AJ, 1997, INT J ONCOL, V11, P489; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367; Wen YH, 2007, ONCOL REP, V18, P1387; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yan M, 2014, CANCER TREAT REV, V40, P770, DOI 10.1016/j.ctrv.2014.02.008; Yang CH, 2011, J BIOL CHEM, V286, P39172, DOI 10.1074/jbc.M111.285098; Yang CH, 2010, CANCER RES, V70, P8108, DOI 10.1158/0008-5472.CAN-10-2579; Zhang J, 2012, BRIT J CANCER, V107, P352, DOI 10.1038/bjc.2012.251; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zhou X, 2014, ONCOL REP, V31, P2173, DOI 10.3892/or.2014.3114; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	79	45	47	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2208	2222		10.1038/onc.2015.281	http://dx.doi.org/10.1038/onc.2015.281			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26212010	Green Published			2022-12-28	WOS:000374986000007
J	Su, CM; Wang, MY; Hong, CC; Chen, HA; Su, YH; Wu, CH; Huang, MT; Chang, YW; Jiang, SS; Sung, SY; Chang, JY; Chen, LT; Chen, PS; Su, JL				Su, C-M; Wang, M-Y; Hong, C-C; Chen, H-A; Su, Y-H; Wu, C-H; Huang, M-T; Chang, Y-W; Jiang, S-S; Sung, S-Y; Chang, J-Y; Chen, L-T; Chen, P-S; Su, J-L			miR-520h is crucial for DAPK2 regulation and breast cancer progression	ONCOGENE			English	Article							DRUG-RESISTANCE; TARGETING BCL2; PROTEIN-KINASE; FOLLOW-UP; MICRORNA; CELLS; SURVIVAL; DEATH; CHEMOTHERAPY; METASTASIS	MicroRNAs (miRNAs) are small RNAs that suppress gene expression by their interaction with 3'untranslated region of specific target mRNAs. Although the dysregulation of miRNAs has been identified in human cancer, only a few of these miRNAs have been functionally documented in breast cancer. Thus, defining the important miRNA and functional target involved in chemoresistance is an urgent need for human breast cancer treatment. In this study, we, for the first time, identified a key role of miRNA 520h (miR-520h) in drug resistance. Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells. Bioinformatics prediction, compensatory mutation and functional validation further confirmed the essential role of miR-520h-suppressed Death-associated protein kinase 2 (DAPK2) expression, as restoring DAPK2 abolished miR-520h-promoted drug resistance, and knockdown of DAPK2 mitigated cell death caused by the depletion of miR-520h. Furthermore, we observed that higher level of miR-520h is associated with poor prognosis and lymph node metastasis in human breast cancer patients. These results show that miR-520h is not only an independent prognostic factor, but is also a potential functional target for future applications in cancer therapeutics.	[Su, C-M; Chen, H-A; Wu, C-H] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Su, C-M; Chen, H-A; Su, Y-H; Wu, C-H; Huang, M-T] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Wang, M-Y] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Hong, C-C; Chang, Y-W; Jiang, S-S; Chang, J-Y; Chen, L-T; Su, J-L] Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan 35053, Miaoli, Taiwan; [Sung, S-Y] Taipei Med Univ, Coll Med Sci & Technol, Program Translat Med, Taipei, Taiwan; [Chen, P-S] Natl Cheng Kung Univ, Inst Basic Med Sci, 1 Univ Rd, Tainan 70101, Taiwan; [Chen, P-S] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, 1 Univ Rd, Tainan 70101, Taiwan; [Su, J-L] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Su, J-L] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Su, J-L] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan	Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan; Taipei Medical University; National Cheng Kung University; National Cheng Kung University; China Medical University Taiwan; Asia University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Su, JL (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan 35053, Miaoli, Taiwan.; Chen, PS (corresponding author), Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, 1 Univ Rd, Tainan 70101, Taiwan.	bio.benson@gmail.com; jlsu@nhri.org.tw	Jiang, Shih Sheng/J-9671-2019; Chen, Pai-Sheng/G-2130-2012	Jiang, Shih Sheng/0000-0003-1909-437X; Chen, Pai-Sheng/0000-0003-0513-1467	National Science Council grant from Taiwan [NSC 101-2320-B-400-016-MY3, NSC 102-2314-B-038-028-MY3, NSC 103-2314-B-038-059, NSC 101-2320-B-006-045-MY2, MOST 103-2628-B-006-003-MY3]; National Health Research Institutes grant from Taiwan [CA-102-PP-41, CA-104-SP-01, CA-104-PP-12, MOHW104-TDU-B-212-124-008]; Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan [103TMU-SHH-26]; Ministry of Education, Taiwan, R.O.C.	National Science Council grant from Taiwan; National Health Research Institutes grant from Taiwan; Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan; Ministry of Education, Taiwan, R.O.C.(Ministry of Education, Taiwan)	This work was supported by the National Science Council grant from Taiwan (NSC 101-2320-B-400-016-MY3, NSC 102-2314-B-038-028-MY3, NSC 103-2314-B-038-059, NSC 101-2320-B-006-045-MY2, MOST 103-2628-B-006-003-MY3); National Health Research Institutes grant from Taiwan (CA-102-PP-41, CA-104-SP-01, CA-104-PP-12, MOHW104-TDU-B-212-124-008); Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan (103TMU-SHH-26). We thank National RNAi Core Facility (Academia Sinica, Taiwan) for providing specific shRNAs. We thank Ms Fang-Yu Tsai and Dr I-Shou Chang of Taiwan Bioinformatics Institute Core Facility for assistances on using Oncomine (National Core Facility Program for Biotechnology, NSC-100-2319-B-400-001). This research was, in part, supported by the Ministry of Education, Taiwan, R.O.C. The Aim for the Top University Project to the National Cheng Kung University (NCKU).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Barthel FMS, 2006, STAT MED, V25, P2521, DOI 10.1002/sim.2517; Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12; Chen PS, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-90; Chen PS, 2011, J CLIN INVEST, V121, P3442, DOI 10.1172/JCI45390; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Giordano SH, 2004, CANCER, V100, P44, DOI 10.1002/cncr.11859; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Gordon V, 2013, CLIN CANCER RES, V19, P3738, DOI 10.1158/1078-0432.CCR-12-0274; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI 10.1007/s13148-011-0040-8; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Ogawa T, 2012, CELL CYCLE, V11, P1656, DOI 10.4161/cc.20120; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Su JL, 2010, CANCER RES, V70, P5096, DOI 10.1158/0008-5472.CAN-09-4148; Tanaka T, 2012, ONCOL REP, V28, P330, DOI 10.3892/or.2012.1774; To KKW, 2009, MOL CANCER THER, V8, P2959, DOI 10.1158/1535-7163.MCT-09-0292; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74; Zhang XT, 2010, ANTICANCER RES, V30, P915; Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782	28	38	38	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1134	1142		10.1038/onc.2015.168	http://dx.doi.org/10.1038/onc.2015.168			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982274				2022-12-28	WOS:000371351700007
J	Garcia, PL; Miller, AL; Kreitzburg, KM; Council, LN; Gamblin, TL; Christein, JD; Heslin, MJ; Arnoletti, JP; Richardson, JH; Chen, D; Hanna, CA; Cramer, SL; Yang, ES; Qi, J; Bradner, JE; Yoon, KJ				Garcia, P. L.; Miller, A. L.; Kreitzburg, K. M.; Council, L. N.; Gamblin, T. L.; Christein, J. D.; Heslin, M. J.; Arnoletti, J. P.; Richardson, J. H.; Chen, D.; Hanna, C. A.; Cramer, S. L.; Yang, E. S.; Qi, J.; Bradner, J. E.; Yoon, K. J.			The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models	ONCOGENE			English	Article							SALMONELLA-TYPHIMURIUM A1-R; C-MYC; CELL-CYCLE; SELECTIVE-INHIBITION; CLINICAL BENEFIT; GENE-EXPRESSION; CANCER-CELLS; THERAPY; CDC25B; TARGET	The primary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (tumorgraft) models. A secondary aim of the study was to evaluate whether JQ1 decreases expression of the oncogene c-Myc in PDAC tumors, as has been reported for other tumor types. We used five PDAC tumorgraft models that retain specific characteristics of tumors of origin to evaluate the antitumor efficacy of JQ1. Tumor-bearing mice were treated with JQ1 (50 mg/kg daily for 21 or 28 days). Expression analyses were performed with tumors harvested from host mice after treatment with JQ1 or vehicle control. An nCounter PanCancer Pathways Panel (NanoString Technologies) of 230 cancer-related genes was used to identify gene products affected by JQ1. Quantitative RT-PCR, immunohistochemistry and immunoblots were carried out to confirm that changes in RNA expression reflected changes in protein expression. JQ1 inhibited the growth of all five tumorgraft models (P < 0.05), each of which harbors a KRAS mutation; but induced no consistent change in expression of c-Myc protein. Expression profiling identified CDC25B, a regulator of cell cycle progression, as one of the three RNA species (TIMP3, LMO2 and CDC25B) downregulated by JQ1 (P < 0.05). Inhibition of tumor progression was more closely related to decreased expression of nuclear CDC25B than to changes in c-Myc expression. JQ1 and other agents that inhibit the function of proteins with bromodomains merit further investigation for treating PDAC tumors. Work is ongoing in our laboratory to identify effective drug combinations that include JQ1.	[Garcia, P. L.; Miller, A. L.; Kreitzburg, K. M.; Gamblin, T. L.; Yoon, K. J.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; [Hanna, C. A.] Univ Alabama Birmingham, Div Anat Pathol, Dept Pathol, Birmingham, AL USA; [Christein, J. D.; Heslin, M. J.; Arnoletti, J. P.; Richardson, J. H.] Univ Alabama Birmingham, Div Gen Surg Gastrointestinal Surg Surg Oncol, Dept Surg, Birmingham, AL USA; [Chen, D.] Univ Alabama Birmingham, Div Prevent Med, Dept Med, Birmingham, AL USA; [Cramer, S. L.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA; [Yang, E. S.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA; [Qi, J.; Bradner, J. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Dana-Farber Cancer Institute	Yoon, KJ (corresponding author), Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.	kyoon@uab.edu			UAB/UMN SPORE in pancreatic cancer [P50 CA101955]; NATIONAL CANCER INSTITUTE [P30CA013148, P50CA101955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER	UAB/UMN SPORE in pancreatic cancer(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Donald J Buchsbaum, William E Grizzle, Mary-Ann Bjornsti and Christopher Klug for their insightful guidance and helpful discussions. This research was supported in part by UAB/UMN SPORE in pancreatic cancer (P50 CA101955).	American Cancer Society, 2014, CANC FACTS FIG 2014; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Briasoulis E, 1998, ANTICANCER RES, V18, P1907; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Burris H, 1997, EUR J CANCER, V33, pS18, DOI 10.1016/S0959-8049(96)00324-3; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chandra S, 2013, J CELL SCI, V126, P3782, DOI 10.1242/jcs.124719; Chen YH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-246; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Da Costa D, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.24; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fowler T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087003; FU XY, 1992, P NATL ACAD SCI USA, V89, P5645, DOI 10.1073/pnas.89.12.5645; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Garcia PL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078183; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; GERDES J, 1984, J IMMUNOL, V133, P1710; Gillen S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000267; Guerra L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008924; Guo JC, 2004, ONCOGENE, V23, P71, DOI 10.1038/sj.onc.1206926; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hiroshima Y, 2014, ONCOTARGET, V5, P12346, DOI 10.18632/oncotarget.2641; Hiroshima Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114310; Hiroshima Y, 2014, J CELL BIOCHEM, V115, P1254, DOI 10.1002/jcb.24769; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Kulkarni MV, 2011, MOL ONCOL, V5, P24, DOI 10.1016/j.molonc.2010.10.004; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin WC, 2013, CANCER RES, V73, P1821, DOI 10.1158/0008-5472.CAN-12-2067; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Loosveld M, 2014, ONCOTARGET, V5, P3168, DOI 10.18632/oncotarget.1873; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Roderick JE, 2014, BLOOD, V123, P1040, DOI 10.1182/blood-2013-08-522698; Rozenblum E, 1997, CANCER RES, V57, P1731; Sahai V, 2014, MOL CANCER THER, V13, P1907, DOI 10.1158/1535-7163.MCT-13-0925; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Sibani S, 2005, J CELL SCI, V118, P3247, DOI 10.1242/jcs.02427; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Suetsugu A, 2012, ANTICANCER RES, V32, P3063; Suetsugu A, 2012, J CELL BIOCHEM, V113, P2290, DOI 10.1002/jcb.24099; Suetsugu A, 2012, ANTICANCER RES, V32, P1175; Trabucco SE, 2015, CLIN CANCER RES, V21, P113, DOI 10.1158/1078-0432.CCR-13-3346; Wang WJ, 2013, CANCER RES, V73, P1219, DOI 10.1158/0008-5472.CAN-12-1408; Yu XY, 2012, ASIAN PAC J CANCER P, V13, P931, DOI 10.7314/APJCP.2012.13.3.931	69	100	102	1	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					833	845		10.1038/onc.2015.126	http://dx.doi.org/10.1038/onc.2015.126			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961927	Green Accepted			2022-12-28	WOS:000370332200004
J	Pan, D; Jiang, C; Ma, Z; Blonska, M; You, MJ; Lin, X				Pan, D.; Jiang, C.; Ma, Z.; Blonska, M.; You, M. J.; Lin, X.			MALT1 is required for EGFR-induced NF-kappa B activation and contributes to EGFR-driven lung cancer progression	ONCOGENE			English	Article							T-CELL-ACTIVATION; LYMPHOID-TISSUE; SIGNALING PATHWAYS; ABC-DLBCL; IN-VIVO; K-RAS; ADENOCARCINOMAS; PHOSPHORYLATION; LYMPHOCYTES; PARACASPASE	The transcription factor nuclear factor kappa B (NF-kappa B) has been implicated in having a crucial role in the tumorigenesis of many types of human cancers. Although epidermal growth factor receptor (EGFR) can directly activate NF-kappa B, the mechanism by which EGFR induces NF-kappa B activation and the role of NF-kappa B in EGFR-associated tumor progression is still not fully defined. Herein, we found that mucosa-associated lymphoid tissue 1 (MALT1) is involved in EGFR-induced NF-kappa B activation in cancer cells, and that MALT1 deficiency impaired EGFR-induced NF-kappa B activation. MALT1 mainly functions as a scaffold protein by recruiting E3 ligase TRAF6 to IKK complex to activate NF-kappa B in response to EGF stimulation. Functionally, MALT1 inhibition shows significant defects in EGFR-associated tumor malignancy, including cell migration, metastasis and anchorageindependent growth. To further access a physiological role of MALT1-dependent NF-kappa B activation in EGFR-driven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Malt1(-/-)), in which mutant EGFR-driven lung cancer was developed in the absence of MALT1 expression. MALT1-deficient mice show significantly less lung tumor burden when compared with its heterozygous controls, suggesting that MALT1 is required for the progression of EGFR-induced lung cancer. Mechanistically, MALT1 deficiency abolished both NF-kappa B and STAT3 activation in vivo, which is a result of a defect of interleukin-6 production. In comparison, MALT1 deficiency does not affect tumor progression in a mouse model (LSL-K-ras(G12D); CCSP-Cre; Malt1(-/-)) in which lung cancer is induced by expressing a K-ras mutant. Thus, our study has provided the cellular and genetic evidence that suggests MALT1-dependent NF-kappa B activation is important in EGFR-associated solid-tumor progression.	[Pan, D.; Jiang, C.; Ma, Z.; Blonska, M.; Lin, X.] Univ Texas MD Anderson Canc Ctr, Ctr Inflammat & Canc, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Pan, D.; You, M. J.; Lin, X.] Univ Texas Houston, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX USA; [You, M. J.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Lin, X (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr Inflammat & Canc, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xllin@mdanderson.org	Jiang, Changying/AAL-3711-2020; Ma, Zhongliang/D-9490-2015; Blonska, Marzenna/U-7751-2019	Ma, Zhongliang/0000-0002-4429-5213; Pan, Deng/0000-0002-6475-0463; Jiang, Changying/0000-0003-3778-4438; Blonska, Marzenna/0000-0001-5237-8732	Cancer Prevention Research Institute of Texas (CPRIT) [RP120316]; National Institutes of Health (NIH) [GM079451, GM065899]; NCI/NIH [R01 CA164346]; Developmental Research Awards in Leukemia SPORE [CA100632]; Center for Inflammation and Cancer; Center for Genetics and Genomics; IRG; Sister Institution Network fund of UT MD Anderson Cancer Center; Cancer Prevention Research Institute of Texas; NATIONAL CANCER INSTITUTE [R01CA164346, P50CA100632, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065899, R56GM065899, R01GM079451] Funding Source: NIH RePORTER	Cancer Prevention Research Institute of Texas (CPRIT); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental Research Awards in Leukemia SPORE; Center for Inflammation and Cancer; Center for Genetics and Genomics; IRG; Sister Institution Network fund of UT MD Anderson Cancer Center; Cancer Prevention Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Vishva Dixit (Genentech Corporation) for providing Malt1-deficient mice and Dr Francesco J DeMayo (Baylor College of Medicine) for providing CCSP-Cre mice and Dr Jeffrey Whitsett (Cincinnati Children's Hospital Medical Center) for providing CCSP-tTA mice. This work is partially supported by grants, RP120316 from Cancer Prevention Research Institute of Texas (CPRIT) to XL, GM079451 and GM065899 from National Institutes of Health (NIH) to XL and R01 CA164346 (NCI/NIH), Developmental Research Awards in Leukemia SPORE CA100632 to MJY, and Center for Inflammation and Cancer, Center for Genetics and Genomics, IRG, Sister Institution Network fund of UT MD Anderson Cancer Center, and Cancer Prevention Research Institute of Texas to MJY.	Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Blonska M, 2011, CELL RES, V21, P55, DOI 10.1038/cr.2010.182; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Fan Q. W., 2009, SCI SIGNAL, V2, pra4, DOI DOI 10.1126/SCISIGNAL.2000014; Ferch U, 2009, J EXP MED, V206, P2313, DOI 10.1084/jem.20091167; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hailfinger S, 2009, P NATL ACAD SCI USA, V106, P19946, DOI 10.1073/pnas.0907511106; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141; Li HG, 2008, GENESIS, V46, P300, DOI 10.1002/dvg.20396; Marion S, 2012, DEV CELL, V23, P954, DOI 10.1016/j.devcel.2012.09.021; Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Morgan JA, 1999, CANCER RES, V59, P6205; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Pan D, 2013, CANCER J, V19, P461, DOI 10.1097/PPO.0000000000000001; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Songur N, 2004, TUMORI J, V90, P196, DOI 10.1177/030089160409000207; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Stewart JR, 2005, MOL CANCER THER, V4, P726, DOI 10.1158/1535-7163.MCT-05-0013; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thome M, 2008, NAT REV IMMUNOL, V8, P495, DOI 10.1038/nri2338; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028	43	36	40	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					919	928		10.1038/onc.2015.146	http://dx.doi.org/10.1038/onc.2015.146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25982276	Green Accepted			2022-12-28	WOS:000370332200012
J	Zhang, L; Ma, T; Brozick, J; Babalola, K; Budiu, R; Tseng, G; Vlad, AM				Zhang, L.; Ma, T.; Brozick, J.; Babalola, K.; Budiu, R.; Tseng, G.; Vlad, A. M.			Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer	ONCOGENE			English	Article							K-RAS; DISTANT METASTASES; MOUSE MODEL; CELL-LINES; EXPRESSION; CARCINOMA; IMMUNOBIOLOGY; INHIBITION; MUTATIONS; ONCOGENE	Mucin1 (MUC1) is an epithelial glycoprotein overexpressed in ovarian cancer and actively involved in tumor cell migration and metastasis. Using novel in vitro and in vivo MUC1-expressing conditional (Cre-loxP) ovarian tumor models, we focus here on MUC1 biology and the roles of Kras activation and Pten deletion during cell transformation and epithelial-to-mesenchymal transition (EMT). We generated several novel murine ovarian cancer cell lines derived from the ovarian surface epithelia (OSE) of mice with conditional mutations in Kras, Pten or both. In addition, we also generated several tumor-derived new cell lines that reproduce the original tumor phenotype in vivo and mirror late stage metastatic disease. Our results demonstrate that de novo activation of oncogenic Kras does not trigger increased proliferation, cellular transformation or EMT, and prevents MUC1 upregulation. In contrast, Pten deletion accelerates cell proliferation, triggers cellular transformation in vitro and in vivo, and stimulates MUC1 expression. Ovarian tumor-derived cell lines MKP-Liver and MKP-Lung cells reproduce in vivo EMT and represent the first immune competent mouse model for distant hematogenous spread. Whole genome microarray expression analysis using tumor and OSE-derived cell lines reveal a 121 gene signature associated with EMT and metastasis. When applied to n = 542 cases from The Cancer Genome Atlas (TCGA) ovarian cancer dataset, the gene signature identifies a patient subset with decreased survival (P = 0.04). Using an extensive collection of novel murine cell lines we have identified distinct roles for Kras and Pten on MUC1 and EMT in vivo and in vitro. The data has implications for future design of combination therapies targeting Kras mutations, Pten deletions and MUC1 vaccines.	[Zhang, L.; Babalola, K.; Budiu, R.; Vlad, A. M.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, B403,204 Craft Ave, Pittsburgh, PA 15213 USA; [Zhang, L.; Brozick, J.; Budiu, R.; Vlad, A. M.] Magee Womens Res Inst, B403,204 Craft Ave, Pittsburgh, PA 15213 USA; [Ma, T.; Tseng, G.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Vlad, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, B403,204 Craft Ave, Pittsburgh, PA 15213 USA.; Vlad, AM (corresponding author), Magee Womens Res Inst, B403,204 Craft Ave, Pittsburgh, PA 15213 USA.	vladam@upmc.edu	Brozick, Joan/AAA-5785-2019; Ma, Tianzhou/AAC-8221-2021	Ma, Tianzhou/0000-0003-3605-0811	Department of Defense (DOD) Ovarian Cancer Academy Award [W81XWH-10-1-0525]; NIH/NCI [R01 CA163462]; NIH; NATIONAL CANCER INSTITUTE [R01CA163462] Funding Source: NIH RePORTER	Department of Defense (DOD) Ovarian Cancer Academy Award; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was partly supported by the Department of Defense (DOD) Ovarian Cancer Academy Award W81XWH-10-1-0525 and NIH/NCI R01 CA163462 (to AMV). Dr Vlad's work has been funded by the NIH.	Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Budiu RA, 2013, ONCOGENE, V32, P3664, DOI 10.1038/onc.2012.397; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Cormio G, 2003, INT J GYNECOL CANCER, V13, P125, DOI 10.1046/j.1525-1438.2003.13054.x; DAUPLAT J, 1987, CANCER-AM CANCER SOC, V60, P1561, DOI 10.1002/1097-0142(19871001)60:7<1561::AID-CNCR2820600725>3.0.CO;2-V; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; Deng JL, 2013, CANCER METAST REV, V32, P535, DOI 10.1007/s10555-013-9423-y; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dong Y, 1997, J PATHOL, V183, P311, DOI 10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Hasan N, 2015, TRANSL CANCER RES, V4, P14, DOI 10.3978/j.issn.2218-676X.2015.01.02; Horlings HM, 2015, J PATHOL, V236, P397, DOI 10.1002/path.4542; Horlings HM, 2015, JAMA ONCOL, V1, P275, DOI 10.1001/jamaoncol.2015.35; Huang J, 2011, GENE CHROMOSOME CANC, V50, P606, DOI 10.1002/gcc.20883; Ince TA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8419; Iwanaga K, 2008, CANCER RES, V68, P1119, DOI 10.1158/0008-5472.CAN-07-3117; Jain N, 2014, CLIN CANCER RES, V20, P490, DOI 10.1158/1078-0432.CCR-13-1311; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kandil E, 2013, J SURG RES, V184, P898, DOI 10.1016/j.jss.2013.03.052; KERR VE, 1985, CANCER, V56, P1209, DOI 10.1002/1097-0142(19850901)56:5<1209::AID-CNCR2820560542>3.0.CO;2-Y; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Maione P, 2013, REV RECENT CLIN TRIA, V8, P93, DOI 10.2174/15748871113089990047; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; MIZUUCHI H, 1995, CANCER, V76, P86, DOI 10.1002/1097-0142(19950701)76:1<86::AID-CNCR2820760112>3.0.CO;2-L; Nick AM, 2015, NAT REV CLIN ONCOL, V12, P239, DOI 10.1038/nrclinonc.2015.26; Obata K, 1998, CANCER RES, V58, P2095; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Vlad AM, 2004, ADV IMMUNOL, V82, P249, DOI 10.1016/S0065-2776(04)82006-6; Wang L, 2007, GYNECOL ONCOL, V105, P695, DOI 10.1016/j.ygyno.2007.02.004; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zhang LX, 2013, CANCER IMMUNOL IMMUN, V62, P423, DOI 10.1007/s00262-012-1325-2	45	15	15	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5010	5020		10.1038/onc.2016.53	http://dx.doi.org/10.1038/onc.2016.53			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26973247	Green Accepted			2022-12-28	WOS:000383965300005
J	Podmirseg, SR; Jakel, H; Ranches, GD; Kullmann, MK; Sohm, B; Villunger, A; Lindner, H; Hengst, L				Podmirseg, S. R.; Jaekel, H.; Ranches, G. D.; Kullmann, M. K.; Sohm, B.; Villunger, A.; Lindner, H.; Hengst, L.			Caspases uncouple p27(Kip1) from cell cycle regulated degradation and abolish its ability to stimulate cell migration and invasion	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; CDK-INHIBITORS; NEURONAL DIFFERENTIATION; MOLECULAR-MECHANISMS; UP-REGULATION; IN-VITRO; APOPTOSIS; PHOSPHORYLATION; P27	In addition to their role in programmed cell death, caspases exert non-lethal functions in diverse developmental processes including cell differentiation or tissue remodeling. Terminal cell cycle exit and differentiation can be promoted by increased level of the CDK inhibitor p27(Kip1). Activated caspases cause proteolytic processing of p27, and we identified a novel caspase cleavage site in human p27 that removes a C-terminal fragment of 22 amino acids from the CDK inhibitor, including a phosphodegron. Thereby, caspases protect the inhibitor from SCF-Skp2-mediated degradation in S, G2 and M phases of the cell cycle. As a consequence, p27 becomes stabilized and remains an efficient nuclear inhibitor of cell cycle progression. Besides controlling cyclin/CDK kinase activity, p27 also regulates cytoskeletal dynamics, cell motility and cell invasion. Following processing by caspases, p27 fails to bind to RhoA and to inhibit its activation, and thereby abolishes the ability of p27 to stimulate cell migration and invasion. We propose that the stabilization of the CDK inhibitor and elimination of RhoA-induced cytoskeletal remodeling upon caspase processing could contribute to cell cycle exit and cytoskeletal remodeling during non-lethal caspase controlled differentiation processes.	[Podmirseg, S. R.; Jaekel, H.; Ranches, G. D.; Kullmann, M. K.; Hengst, L.] Med Univ Innsbruck, Bioctr, Div Med Biochem, Innsbruck, Austria; [Sohm, B.] Univ Lorraine, LIEC, UMR 7360, Metz, France; [Sohm, B.] CNRS, LIEC, UMR 7360, Metz, France; [Villunger, A.] Med Univ Innsbruck, Bioctr, Div Dev Immunol, Innsbruck, Austria; [Villunger, A.] Tyrolean Canc Res Inst, Innsbruck, Austria; [Lindner, H.] Med Univ Innsbruck, Bioctr, Div Clin Biochem, Innsbruck, Austria	Medical University of Innsbruck; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Lorraine; Medical University of Innsbruck; Medical University of Innsbruck	Hengst, L (corresponding author), Bioctr, Div Med Biochem, Innrain 80-82, A-6020 Innsbruck, Austria.	ludger.hengst@i-med.ac.at	Kullmann, Michael Keith/AGY-4711-2022	Hengst, Ludger/0000-0002-0605-0223; Ranches, Glory/0000-0002-3623-1746; Kullmann, Michael Keith/0000-0003-3567-3806; SOHM, Benedicte/0000-0002-7204-5414	FWF [P24031, P26856]; Tiroler Krebshilfe; Austrian Science Fund (FWF) [P 24031] Funding Source: researchfish	FWF(Austrian Science Fund (FWF)); Tiroler Krebshilfe; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We acknowledge Stephan Geley for providing plasmids and cell lines, Jan Wiegers for useful advice with mouse experiments and all members of the Hengst lab for their help and stimulating discussions. Work was funded by the FWF-grant P24031 to Ludger Hengst, the FWF-grant P26856 to Andreas Villunger and the Tiroler Krebshilfe.	Ashkenazi A, 2014, ANNU REV CELL DEV BI, V30, P337, DOI 10.1146/annurev-cellbio-100913-013226; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bryja V, 2004, CELL MOL LIFE SCI, V61, P1384, DOI 10.1007/s00018-004-4081-4; Chen P, 1999, DEVELOPMENT, V126, P1581; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Crawford ED, 2013, MOL CELL PROTEOMICS, V12, P813, DOI 10.1074/mcp.O112.024372; Cremisi F, 2003, CURR OPIN NEUROBIOL, V13, P26, DOI 10.1016/S0959-4388(03)00005-9; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; De Vita F, 2012, CELL CYCLE, V11, P1583, DOI 10.4161/cc.20003; Dehay C, 2007, NAT REV NEUROSCI, V8, P438, DOI 10.1038/nrn2097; Dix MM, 2012, CELL, V150, P426, DOI 10.1016/j.cell.2012.05.040; Doetsch F, 2002, J NEUROSCI, V22, P2255, DOI 10.1523/JNEUROSCI.22-06-02255.2002; Durand B, 2000, BIOESSAYS, V22, P64; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fan XM, 2004, J GASTROEN HEPATOL, V19, P31, DOI 10.1111/j.1440-1746.2004.03194.x; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Godin JD, 2012, DEV CELL, V23, P729, DOI 10.1016/j.devcel.2012.08.006; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Hyman BT, 2012, NAT REV NEUROSCI, V13, P395, DOI 10.1038/nrn3228; Jakel H, 2011, ONCOGENE, V30, P3502, DOI 10.1038/onc.2011.68; Jakel H, 2012, CELL CYCLE, V11, P1910, DOI 10.4161/cc.19957; Janzen V, 2008, CELL STEM CELL, V2, P584, DOI 10.1016/j.stem.2008.03.012; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Katayose Y, 1997, CANCER RES, V57, P5441; Kossatz U, 2006, EMBO J, V25, P5159, DOI 10.1038/sj.emboj.7601388; Kullmann MK, 2013, CELL CYCLE, V12, P2625, DOI 10.4161/cc.25622; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; Kurokawa M, 2009, CELL, V138, P838, DOI 10.1016/j.cell.2009.08.021; Lacy ER, 2004, NAT STRUCT MOL BIOL, V11, P358, DOI 10.1038/nsmb746; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Medina-Palazon C, 2004, EUR J BIOCHEM, V271, P2716, DOI 10.1111/j.1432-1033.2004.04200.x; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nguyen L, 2006, CELL CYCLE, V5, P2314, DOI 10.4161/cc.5.20.3381; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; PERANDONES CE, 1993, J IMMUNOL, V151, P3521; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Rots NY, 1999, BLOOD, V93, P2721, DOI 10.1182/blood.V93.8.2721.408k28_2721_2729; Schiappacassi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017673; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; See WL, 2010, CELL CYCLE, V9, P1562, DOI 10.4161/cc.9.8.11259; Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Tambyrajah WS, 2007, ARCH BIOCHEM BIOPHYS, V466, P186, DOI 10.1016/j.abb.2007.07.019; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tozser J, 2003, BIOCHEM J, V372, P137, DOI 10.1042/BJ20021901; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vosper J, 2015, ONCOTARGET, V6, P2889, DOI 10.18632/oncotarget.3068; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhang R, 2008, CANCER CHEMOTH PHARM, V62, P407, DOI 10.1007/s00280-007-0619-0; Zhao D, 2015, ONCOGENE, V34, P5447, DOI 10.1038/onc.2014.473; Zou P, 2011, CELL STEM CELL, V9, P247, DOI 10.1016/j.stem.2011.07.003	82	19	19	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4580	4590		10.1038/onc.2015.524	http://dx.doi.org/10.1038/onc.2015.524			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26829051	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000382336300004
J	Paauwe, M; Heijkants, RC; Oudt, CH; van Pelt, GW; Cui, C; Theuer, CP; Hardwick, JCH; Sier, CFM; Hawinkels, LJAC				Paauwe, M.; Heijkants, R. C.; Oudt, C. H.; van Pelt, G. W.; Cui, C.; Theuer, C. P.; Hardwick, J. C. H.; Sier, C. F. M.; Hawinkels, L. J. A. C.			Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer	ONCOGENE			English	Article							TGF-BETA-RECEPTOR; MAMMARY-CARCINOMA; ENDOTHELIAL-CELLS; SOLID TUMORS; EXPRESSION; ANTIBODY; TRC105; BEVACIZUMAB; PROTEIN; NORMALIZATION	Endoglin, a transforming growth factor-beta co-receptor, is highly expressed on angiogenic endothelial cells in solid tumors. Therefore, targeting endoglin is currently being explored in clinical trials for anti-angiogenic therapy. In this project, the redundancy between endoglin and vascular endothelial growth factor (VEGF) signaling in angiogenesis and the effects of targeting both pathways on breast cancer metastasis were explored. In patient samples, increased endoglin signaling after VEGF inhibition was observed. In vitro TRC105, an endoglin-neutralizing antibody, increased VEGF signaling in endothelial cells. Moreover, combined targeting of the endoglin and VEGF pathway, with the VEGF receptor kinase inhibitor SU5416, increased antiangiogenic effects in vitro and in a zebrafish angiogenesis model. Next, in a mouse model for invasive lobular breast cancer, the effects of TRC105 and SU5416 on tumor growth and metastasis were explored. Although TRC105 and SU5416 decreased tumor vascular density, tumor volume was unaffected. Strikingly, in mice treated with TRC105, or TRC105 and SU5416 combined, a strong inhibition in the number of metastases was seen. Moreover, upon resection of the primary tumor, strong inhibition of metastatic spread by TRC105 was observed in an adjuvant setting. To confirm these data, we assessed the effects of endoglin-Fc (an endoglin ligand trap) on metastasis formation. Similar to treatment with TRC105 in the resection model, endoglin-Fc-expressing tumors showed strong inhibition of distant metastases. These results show, for the first time, that targeting endoglin, either with neutralizing antibodies or a ligand trap, strongly inhibits metastatic spread of breast cancer in vivo.	[Paauwe, M.; Heijkants, R. C.; Oudt, C. H.; Cui, C.; Hawinkels, L. J. A. C.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands; [Paauwe, M.; Hardwick, J. C. H.; Sier, C. F. M.; Hawinkels, L. J. A. C.] Leiden Univ, Med Ctr, Dept Gastroenterol Hepatol, Leiden, Netherlands; [van Pelt, G. W.; Sier, C. F. M.] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands; [Theuer, C. P.] Tracon Pharmaceut, San Diego, CA USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Hawinkels, LJAC (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol & Gastroenterol Hepatol, Bldg 1,C4-P,POB 9600, NL-2300 RC Leiden, Netherlands.	L.J.A.C.Hawinkels@LUMC.nl	Hawinkels, Lukas/Q-5098-2019; Sier, Cornelis/A-7664-2008; Paauwe, Madelon/C-8244-2018; Hardwick, James/J-4862-2013	Hawinkels, Lukas/0000-0002-2274-9325; Sier, Cornelis/0000-0002-4337-2758; Hardwick, James/0000-0002-9575-5099	Alpe d'huZes/Bas Mulder award [UL2011-5051]; Tracon Pharmaceuticals	Alpe d'huZes/Bas Mulder award; Tracon Pharmaceuticals	We thank Jos Jonkers (Netherlands Cancer Institute, Amsterdam) for providing the KEP1-11 mouse breast cancer cells, Midory Thorikay for generating Fc and endoglin-Fc lentiviral expression constructs, Henry Cheung and Gabri van der Pluijm for practical help in establishing the in vivo model and Peter ten Dijke, Hans van Dam and Marie-Jose Goumans (Leiden University Medical Center) for valuable discussions. This work was supported by the Alpe d'huZes/Bas Mulder award 2011 (UL2011-5051) to LJACH and MP and by a sponsored research grant from Tracon Pharmaceuticals.	Anderberg C, 2013, J EXP MED, V210, P563, DOI 10.1084/jem.20120662; Aristorena M, 2014, J CELL SCI, V127, P2723, DOI 10.1242/jcs.143644; Arjaans M, 2013, CANCER RES, V73, P3347, DOI 10.1158/0008-5472.CAN-12-3518; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Buijs JT, 2015, J PATHOL, V235, P745, DOI 10.1002/path.4488; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Charpin-Taranger C, 2003, B ACAD NAT MED PARIS, V187, P1129, DOI 10.1016/S0001-4079(19)33943-3; de Kruijf EM, 2013, ANN ONCOL, V24, P384, DOI 10.1093/annonc/mds333; Dekker TJA, 2013, BREAST CANCER RES TR, V139, P371, DOI 10.1007/s10549-013-2571-5; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1966, ANN SURG, V164, P491, DOI 10.1097/00000658-196609000-00012; Fonsatti E, 2000, CLIN CANCER RES, V6, P2037; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Gordon MS, 2014, CLIN CANCER RES, V20, P5918, DOI 10.1158/1078-0432.CCR-14-1143; Hawinkels L. J., 2015, CLIN CANC RES; Hawinkels LJAC, 2007, BRIT J CANCER, V97, P398, DOI 10.1038/sj.bjc.6603877; Hawinkels LJAC, 2014, ONCOGENE, V33, P97, DOI 10.1038/onc.2012.536; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Henry LA, 2011, ONCOGENE, V30, P1046, DOI 10.1038/onc.2010.488; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Jerkic M, 2015, FASEB J, V29, P3678, DOI 10.1096/fj.14-269258; Karzai FH, 2015, BJU INT, V116, P546, DOI 10.1111/bju.12986; Khamis ZI, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/574025; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YM, 2014, INVEST NEW DRUG, V32, P851, DOI 10.1007/s10637-014-0129-y; Liu YM, 2014, CANCER MED-US, V3, P580, DOI 10.1002/cam4.207; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; Nolan-Stevaux O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050920; Paauwe M, 2013, EXPERT OPIN THER TAR, V17, P421, DOI 10.1517/14728222.2013.758716; Pan CC, 2014, J BIOL CHEM, V289, P25486, DOI 10.1074/jbc.M114.578609; Perez-Gomez E, 2010, THESCIENTIFICWORLDJO, V10, P2367, DOI 10.1100/tsw.2010.230; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Romero D, 2011, CANCER RES, V71, P3482, DOI 10.1158/0008-5472.CAN-10-2665; Rosen LS, 2012, CLIN CANCER RES, V18, P4820, DOI 10.1158/1078-0432.CCR-12-0098; Seon BK, 2011, CURR DRUG DELIV, V8, P135; Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008-5472.CAN-11-3406; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsujie M, 2008, INT J CANCER, V122, P2266, DOI 10.1002/ijc.23314; van Baardewijk LJ, 2013, INT ORTHOP, V37, P523, DOI 10.1007/s00264-012-1750-z; Zijlmans HJ, 2009, BRIT J CANCER, V100, P1617, DOI 10.1038/sj.bjc.6605009	48	44	48	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4069	4079		10.1038/onc.2015.509	http://dx.doi.org/10.1038/onc.2015.509			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26804178	Green Published			2022-12-28	WOS:000381020900005
J	Bailey, JM; Hendley, AM; Lafaro, KJ; Pruski, MA; Jones, NC; Alsina, J; Younes, M; Maitra, A; McAllister, F; Iacobuzio-Donahue, CA; Leach, SD				Bailey, J. M.; Hendley, A. M.; Lafaro, K. J.; Pruski, M. A.; Jones, N. C.; Alsina, J.; Younes, M.; Maitra, A.; McAllister, F.; Iacobuzio-Donahue, C. A.; Leach, S. D.			p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells	ONCOGENE			English	Article							ADULT MICE; CANCER; METASTASIS; ACTIVATION; INDUCTION	Pancreatic cancer is one of the most lethal malignancies, with virtually all patients eventually succumbing to their disease. Mutations in p53 have been documented in >50% of pancreatic cancers. Owing to the high incidence of p53 mutations in PanIN 3 lesions and pancreatic tumors, we interrogated the comparative ability of adult pancreatic acinar and ductal cells to respond to oncogenic Kras and mutant Tp53(R172H) using Hnf1b:CreER(T2) and Mist1:CreER(T2) mice. These studies involved co-activation of a membrane-tethered GFP lineage label, allowing for direct visualization and isolation of cells undergoing Kras and mutant p53 activation. Kras activation in Mist1(+) adult acinar cells resulted in brisk PanIN formation, whereas no evidence of pancreatic neoplasia was observed for up to 6 months following Kras activation in Hnf1beta(+) adult ductal cells. In contrast to the lack of response to oncogenic Kras alone, simultaneous activation of Kras and mutant p53 in adult ductal epithelium generated invasive PDAC in 75% of mice as early as 2.5 months after tamoxifen administration. These data demonstrate that pancreatic ductal cells, whereas exhibiting relative resistance to oncogenic Kras alone, can serve as an effective cell of origin for pancreatic ductal adenocarcinoma in the setting of gain-of-function mutations in p53.	[Bailey, J. M.; Hendley, A. M.; Pruski, M. A.; Jones, N. C.] Univ Texas Hlth Sci Ctr Houston, Div Gastroenterol Hepatol & Nutr, Dept Internal Med, 6431A Fannin St MSB 1-162, Houston, TX 77030 USA; [Lafaro, K. J.; Iacobuzio-Donahue, C. A.; Leach, S. D.] Mem Sloan Kettering Canc Ctr, David Rubenstein Pancreat Canc Res Ctr, 1275 York Ave, New York, NY 10021 USA; [Alsina, J.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Younes, M.] Univ Texas Hlth Sci Ctr Houston, Dept Pathol & Lab Med, Houston, TX 77030 USA; [Maitra, A.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Maitra, A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [McAllister, F.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [McAllister, F.] Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bailey, JM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Div Gastroenterol Hepatol & Nutr, Dept Internal Med, 6431A Fannin St MSB 1-162, Houston, TX 77030 USA.	Jennifer.M.Bailey@uth.tmc.edu	Alsina, Janivette/AAE-9043-2020; Iacobuzio-Donahue, Christine/ABF-1295-2020	Iacobuzio-Donahue, Christine/0000-0002-4672-3023; Hendley, Audrey/0000-0003-0289-2092; Younes, Mamoun/0000-0001-9618-3451; Bailey-Lundberg, Jennifer/0000-0002-4750-106X	NIH [P01 CA134292, R21 CA158898, F32CA157044, T35 DK007676-22]; AACR/Pancreatic Cancer Action Network Pathway to Leadership Award; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR/Pancreatic Cancer Action Network Pathway to Leadership Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge Anzer Habibulla, Danielle Blake, Mara Swaim, Jeffery Roeser and Qingfeng Zhu for their help in maintaining mouse colonies and genotyping. We thank Jorge Ferrer for providing the Hnf1b mice. This work was supported by NIH P01 CA134292 and R21 CA158898 (to SDL). JMB was supported by an NIH F32CA157044 and an AACR/Pancreatic Cancer Action Network Pathway to Leadership Award. NCJ was supported by an NIH T35 DK007676-22.	Bailey JM, 2014, GASTROENTEROLOGY, V146, P245, DOI 10.1053/j.gastro.2013.09.050; Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Huang H, 2014, ONCOGENE, V33, P532, DOI 10.1038/onc.2012.619; Ji B, 2009, GASTROENTEROLOGY, V137; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Logsdon CD, 2009, CLIN GASTROENTEROL H, V7, pS40, DOI 10.1016/j.cgh.2009.07.040; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Sivere JT, 2008, GASTROENTEROLOGY, V134, P544, DOI 10.1053/j.gastro.2007.11.003; Solar M, 2009, DEV CELL, V17, P849, DOI 10.1016/j.devcel.2009.11.003; Strobel O, 2007, GASTROENTEROLOGY, V133, P1999, DOI 10.1053/j.gastro.2007.09.009; von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066	17	78	80	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4282	4288		10.1038/onc.2015.441	http://dx.doi.org/10.1038/onc.2015.441			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26592447				2022-12-28	WOS:000382149800012
J	Kumar, R; Li, DQ; Muller, S; Knapp, S				Kumar, R.; Li, D-Q; Mueller, S.; Knapp, S.			Epigenomic regulation of oncogenesis by chromatin remodeling	ONCOGENE			English	Review							METASTASIS-ASSOCIATED PROTEIN-1; I HISTONE DEACETYLASES; TUMOR-SUPPRESSOR GENE; SMALL-CELL CARCINOMA; FREQUENT INACTIVATING MUTATIONS; RECURRENT SOMATIC MUTATIONS; MALIGNANT RHABDOID TUMORS; HUMAN PROSTATE-CANCER; DNA-DAMAGE RESPONSE; MTA1 MESSENGER-RNA	Disruption of the intricate gene expression program represents one of major driving factors for the development, progression and maintenance of human cancer, and is often associated with acquired therapeutic resistance. At the molecular level, cancerous phenotypes are the outcome of cellular functions of critical genes, regulatory interactions of histones and chromatin remodeling complexes in response to dynamic and persistent upstream signals. A large body of genetic and biochemical evidence suggests that the chromatin remodelers integrate the extracellular and cytoplasmic signals to control gene activity. Consequently, widespread dysregulation of chromatin remodelers and the resulting inappropriate expression of regulatory genes, together, lead to oncogenesis. We summarize the recent developments and current state of the dysregulation of the chromatin remodeling components as the driving mechanism underlying the growth and progression of human tumors. Because chromatin remodelers, modifying enzymes and protein-protein interactions participate in interpreting the epigenetic code, selective chromatin remodelers and bromodomains have emerged as new frontiers for pharmacological intervention to develop future anti-cancer strategies to be used either as single-agent or in combination therapies with chemotherapeutics or radiotherapy.	[Kumar, R.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA; [Kumar, R.] Rajiv Gandhi Ctr Biotechnol, Canc Biol Program, Thiruvananthapuram, Kerala, India; [Li, D-Q] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Li, D-Q] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Li, D-Q] Fudan Univ, Shanghai Med Coll, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China; [Li, D-Q] Fudan Univ, Shanghai Med Coll, Key Lab Epigenet Shanghai, Shanghai, Peoples R China; [Mueller, S.; Knapp, S.] Univ Oxford, Nuffield Dept Clin Med, Old Rd Campus, Oxford OX3 7LD, England; [Mueller, S.; Knapp, S.] Dept Pharmaceut Chem, Riedberg Campus, Frankfurt, Germany; [Mueller, S.; Knapp, S.] Buchmann Inst Life Sci, Riedberg Campus, Frankfurt, Germany	George Washington University; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); Fudan University; Fudan University; Fudan University; Fudan University; University of Oxford	Kumar, R (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA.; Knapp, S (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Old Rd Campus, Oxford OX3 7LD, England.	bcmrxk@gwu.edu; knapp@pharmchem.uni-frankfurt.de	Kumar, Rakesh/ABD-1065-2020; Knapp, Stefan/AAG-2347-2019	Kumar, Rakesh/0000-0001-7664-0803; Knapp, Stefan/0000-0001-5995-6494; Muller-Knapp, Susanne/0000-0003-2402-4157	National Institutes of Health grants [CA98823, CA090970]; National Natural Science Foundation of China [81372847, 81572584]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [2013-06]; Innovation Program of Shanghai Municipal Education Commission [2015ZZ007]; Structural Genomic Consortium [1097737]; AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada; Innovative Medicines Initiative (EU/EFPIA); Janssen; Merck Co.; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Welcome Trust	National Institutes of Health grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Structural Genomic Consortium; AbbVie(AbbVie); Bayer Pharma AG; Boehringer Ingelheim(Boehringer Ingelheim); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genome Canada(Genome Canada); Innovative Medicines Initiative (EU/EFPIA); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck Co.(Merck & Company); Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer(Pfizer); Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Welcome Trust(Wellcome Trust)	We are in debt to our colleagues in this field whose original work may have not been cited here due to space limitations. The chromatin remodeling and signaling work in Kumar laboratory is being supported by grants from the National Institutes of Health grants CA98823 and CA090970. The Li laboratory is funded by the National Natural Science Foundation of China (Number 81372847 and 81572584), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (Number 2013-06) and the Innovation Program of Shanghai Municipal Education Commission (Number 2015ZZ007). The Knapp laboratory is supported by the Structural Genomic Consortium, a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, the Eshelman Institute for Innovation, the Genome Canada, the Innovative Medicines Initiative (EU/EFPIA), Janssen, Merck & Co., Novartis Pharma AG, the Ontario Ministry of Economic Development and Innovation, Pfizer, the Sao Paulo Research Foundation-FAPESP, Takeda, and the Welcome Trust.	Adams H, 2010, EXPERT OPIN THER TAR, V14, P577, DOI 10.1517/14728221003796609; Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alqarni SSM, 2014, J BIOL CHEM, V289, P21844, DOI 10.1074/jbc.M114.558940; Andersen CL, 2009, BRIT J CANCER, V100, P511, DOI 10.1038/sj.bjc.6604884; Aydin OZ, 2014, CELL CYCLE, V13, P3016, DOI 10.4161/15384101.2014.956551; Balasenthil S, 2006, HUM PATHOL, V37, P656, DOI 10.1016/j.humpath.2006.01.024; Balasubramaniam S, 2013, CLIN CANCER RES, V19, P2657, DOI 10.1158/1078-0432.CCR-12-3049; Bamborough P, 2015, J MED CHEM, V58, P6151, DOI 10.1021/acs.jmedchem.5b00773; Bao Yunhe, 2007, Cell, V129, P632, DOI 10.1016/j.cell.2007.04.018; Bao YH, 2011, CELL, V144, P158, DOI 10.1016/j.cell.2010.12.024; Barak O, 2003, EMBO J, V22, P6089, DOI 10.1093/emboj/cdg582; Basheer F, 2015, EXP HEMATOL, V43, P718, DOI 10.1016/j.exphem.2015.06.004; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Biegel JA, 1999, CANCER RES, V59, P74; Bisson N, 2012, CELL CYCLE, V11, P1316, DOI 10.4161/cc.19685; Brown PJ, 2015, FUTURE MED CHEM, V7, P1901, DOI 10.4155/fmc.15.127; Burrows AE, 2010, P NATL ACAD SCI USA, V107, P14280, DOI 10.1073/pnas.1009559107; Buurman R, 2012, GASTROENTEROLOGY, V143, P811, DOI 10.1053/j.gastro.2012.05.033; Cajuso T, 2014, INT J CANCER, V135, P611, DOI 10.1002/ijc.28705; Campos B, 2011, CANCER SCI, V102, P387, DOI 10.1111/j.1349-7006.2010.01792.x; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Caramel J, 2008, CANCER RES, V68, P6154, DOI 10.1158/0008-5472.CAN-08-0115; Caron C, 2010, ONCOGENE, V29, P5171, DOI 10.1038/onc.2010.259; Chen P., 2015, J MED CHEM; Chen TJ, 2011, APMIS, V119, P808, DOI 10.1111/j.1600-0463.2011.02808.x; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cho H, 2013, HUM PATHOL, V44, P1365, DOI 10.1016/j.humpath.2012.11.007; Choi J, 2009, NUCLEIC ACIDS RES, V37, P5993, DOI 10.1093/nar/gkp660; Choi JH, 2009, CANCER RES, V69, P1407, DOI 10.1158/0008-5472.CAN-08-3602; Chu HY, 2014, TUMOR BIOL, V35, P3487, DOI 10.1007/s13277-013-1460-1; Ciro M, 2009, CANCER RES, V69, P8491, DOI 10.1158/0008-5472.CAN-09-2131; Clapier CR, 2012, NATURE, V492, P280, DOI 10.1038/nature11625; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Clark PGK, 2015, ANGEW CHEM INT EDIT, V54, P6217, DOI 10.1002/anie.201501394; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Corona DFV, 2000, EMBO J, V19, P3049, DOI 10.1093/emboj/19.12.3049; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Covington KR, 2013, BREAST CANCER RES TR, V141, P375, DOI 10.1007/s10549-013-2709-5; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Dannenmann C, 2008, CANCER BIOL THER, V7, P1462, DOI 10.4161/cbt.7.9.6427; Dar AA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv034; Darr J, 2014, ONCOGENE, V33, P3024, DOI 10.1038/onc.2013.261; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Drouin L, 2015, J MED CHEM, V58, P2553, DOI 10.1021/jm501963e; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; Euskirchen G, 2012, J BIOL CHEM, V287, P30897, DOI 10.1074/jbc.R111.309302; Fang FM, 2011, AM J PATHOL, V178, P2407, DOI 10.1016/j.ajpath.2011.01.043; Fedorov O, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500723; Feng XH, 2014, MOL CELLS, V37, P699, DOI 10.14348/molcells.2014.0029; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2012, FEBS LETT, V586, P2692, DOI 10.1016/j.febslet.2012.04.045; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Flynn EM, 2015, STRUCTURE, V23, P1801, DOI 10.1016/j.str.2015.08.004; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Garcia-Pedrero JM, 2006, J BIOL CHEM, V281, P22656, DOI 10.1074/jbc.M602561200; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Giaginis C, 2014, TUMOR BIOL, V35, P61, DOI 10.1007/s13277-013-1007-5; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80; Grand F, 1999, CANCER RES, V59, P3870; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/nchembio.1859, 10.1038/NCHEMBIO.1859]; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Guillemette S, 2015, GENE DEV, V29, P489, DOI 10.1101/gad.256214.114; Gunduz E, 2005, INT J ONCOL, V26, P201; Hah N, 2010, CANCER RES, V70, P4402, DOI 10.1158/0008-5472.CAN-09-2767; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Heeboll S, 2008, HISTOL HISTOPATHOL, V23, P1069, DOI 10.14670/HH-23.1069; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Higashijima J, 2011, ONCOL REP, V26, P343, DOI 10.3892/or.2011.1312; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hofer MD, 2004, CANCER RES, V64, P825, DOI 10.1158/0008-5472.CAN-03-2755; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Hohmann AF, 2014, TRENDS GENET, V30, P356, DOI 10.1016/j.tig.2014.05.001; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Huether R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4630; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; Hwang WL, 2014, NATURE, V512, P213, DOI 10.1038/nature13380; Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442; Iguchi H, 2000, INT J ONCOL, V16, P1211; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Iwagami Y, 2013, BRIT J CANCER, V109, P502, DOI 10.1038/bjc.2013.320; Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251; James LI, 2013, J MED CHEM, V56, P7358, DOI 10.1021/jm400919p; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Jelinic P, 2014, NAT GENET, V46, P424, DOI 10.1038/ng.2922; Jiao YC, 2013, NAT GENET, V45, P1470, DOI 10.1038/ng.2813; Jin JY, 2005, J BIOL CHEM, V280, P41207, DOI 10.1074/jbc.M509128200; Jin QX, 2015, TUMOR BIOL, V36, P1895, DOI 10.1007/s13277-014-2791-2; Johnson DG, 2013, CELL, V152, P685, DOI 10.1016/j.cell.2013.01.017; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Jones S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6006; Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Jordan NV, 2013, MOL CELL BIOL, V33, P3011, DOI 10.1128/MCB.01443-12; Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kahali B, 2014, ONCOGENE, V33, P653, DOI 10.1038/onc.2012.613; Kahali B, 2014, ONCOTARGET, V5, P3316, DOI 10.18632/oncotarget.1945; Kapoor P, 2015, GENE DEV, V29, P591, DOI 10.1101/gad.257626.114; Kapur P, 2013, LANCET ONCOL, V14, P159, DOI 10.1016/S1470-2045(12)70584-3; Kasten MM, 2011, CELL, V144, DOI 10.1016/j.cell.2011.01.007; Khursheed M, 2013, BRIT J CANCER, V108, P2056, DOI 10.1038/bjc.2013.200; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Kim MS, 2011, HISTOPATHOLOGY, V58, P660, DOI 10.1111/j.1365-2559.2011.03819.x; Knapp S, 2013, CHEMMEDCHEM, V8, P1885, DOI 10.1002/cmdc.201300344; Kothandapani A, 2012, EXP CELL RES, V318, P1973, DOI 10.1016/j.yexcr.2012.06.011; Kuwahara Y, 2013, MOL CANCER RES, V11, P251, DOI 10.1158/1541-7786.MCR-12-0390; Kwon SJ, 2015, MOL CANCER THER, V14, P597, DOI 10.1158/1535-7163.MCT-14-0372; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Lee H, 2009, J GASTROEN HEPATOL, V24, P1445, DOI 10.1111/j.1440-1746.2009.05965.x; Lee SH, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.116; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; Li DQ, 2015, ADV CANCER RES, V127, P1, DOI 10.1016/bs.acr.2015.04.005; Li DQ, 2014, CANCER METAST REV, V33, P993, DOI 10.1007/s10555-014-9524-2; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066679; Li H, 2014, TUMOR BIOL, V35, P5771, DOI 10.1007/s13277-014-1766-7; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Li WF, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-78; Liang PI, 2012, J CLIN PATHOL, V65, P802, DOI 10.1136/jclinpath-2012-200897; Lichner Z, 2013, AM J PATHOL, V182, P1163, DOI 10.1016/j.ajpath.2013.01.007; Lin CY, 2012, J CLIN PATHOL, V65, P687, DOI 10.1136/jclinpath-2012-200786; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Lin H, 2009, CLIN CANCER RES, V15, P6404, DOI 10.1158/1078-0432.CCR-09-1135; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Link KA, 2008, CANCER RES, V68, P4551, DOI 10.1158/0008-5472.CAN-07-6392; Liu J, 2015, MOL ONCOL, V9, P218, DOI 10.1016/j.molonc.2014.08.007; Liu SL, 2012, TUMOR BIOL, V33, P1485, DOI 10.1007/s13277-012-0399-y; Liu TB, 2013, HUM PATHOL, V44, P2275, DOI 10.1016/j.humpath.2013.05.009; Liu Xi-bo, 2010, Chinese Journal of Pathology, V39, P591, DOI 10.3760/cma.j.issn.0529-5807.2010.09.004; Liu XR, 2014, EUR J CANCER, V50, P2251, DOI 10.1016/j.ejca.2014.05.017; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Loyola A, 2003, MOL CELL BIOL, V23, P6759, DOI 10.1128/MCB.23.19.6759-6768.2003; Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001; Lu P, 2013, NUCLEUS-AUSTIN, V4, P374, DOI 10.4161/nucl.26654; Ludwigsen J, 2013, EMBO REP, V14, P1092, DOI 10.1038/embor.2013.160; Luk E, 2010, CELL, V143, P725, DOI 10.1016/j.cell.2010.10.019; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maitra A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3873; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Marquard L, 2008, HISTOPATHOLOGY, V53, P267, DOI [10.1111/j.1365-2559.2008.03109.x, 10.1111/j.0309-0167.2008.03109.x]; Marquard L, 2009, HISTOPATHOLOGY, V54, P688, DOI 10.1111/j.1365-2559.2009.03290.x; Marquez SB, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00372; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Mayer C, 2008, EMBO REP, V9, P774, DOI 10.1038/embor.2008.109; Min JN, 2013, CELL RES, V23, P1396, DOI 10.1038/cr.2013.113; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Modena P, 2005, CANCER RES, V65, P4012, DOI 10.1158/0008-5472.CAN-04-3050; Moon WS, 2004, HUM PATHOL, V35, P424, DOI 10.1016/j.humpath.2003.11.007; Mora-Blanco EL, 2014, ONCOGENE, V33, P933, DOI 10.1038/onc.2013.37; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Morrison AJ, 2009, NAT REV MOL CELL BIO, V10, P373, DOI 10.1038/nrm2693; Mueller AC, 2013, ONCOGENE, V32, P1164, DOI 10.1038/onc.2012.131; Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992; Murzina NV, 2008, STRUCTURE, V16, P1077, DOI 10.1016/j.str.2008.05.006; Musselman CA, 2012, P NATL ACAD SCI USA, V109, P787, DOI 10.1073/pnas.1113655109; Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Nair SS, 2013, MOL CELL, V49, P704, DOI 10.1016/j.molcel.2012.12.016; Oike T, 2013, CANCER RES, V73, P5508, DOI 10.1158/0008-5472.CAN-12-4593; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Orvis T, 2014, CANCER RES, V74, P6486, DOI 10.1158/0008-5472.CAN-14-0061; Pan MR, 2012, J BIOL CHEM, V287, P6764, DOI 10.1074/jbc.M111.287037; Papadakis AI, 2015, CELL RES, V25, P445, DOI 10.1038/cr.2015.16; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Park JO, 2011, EUR ARCH OTO-RHINO-L, V268, P1329, DOI 10.1007/s00405-010-1478-6; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Petty E, 2013, TRENDS GENET, V29, P621, DOI 10.1016/j.tig.2013.06.006; Picaud S, 2015, CANCER RES, V75, P5106, DOI 10.1158/0008-5472.CAN-15-0236; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Ramos P, 2014, NAT GENET, V46, P427, DOI 10.1038/ng.2928; Reddy SDN, 2012, J BIOL CHEM, V287, P27843, DOI 10.1074/jbc.M112.348474; Revenko AS, 2010, MOL CELL BIOL, V30, P5260, DOI 10.1128/MCB.00484-10; Reynolds N, 2012, EMBO J, V31, P593, DOI 10.1038/emboj.2011.431; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rousseau-Merck MF, 1999, CANCER RES, V59, P3152; Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053; Ryme J, 2009, J CELL BIOCHEM, V108, P565, DOI 10.1002/jcb.22288; Sakamaki A, 2015, CARCINOGENESIS, V36, P622, DOI 10.1093/carcin/bgv044; Saladi SV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-280; Santiago C, 2011, J COMPUT AID MOL DES, V25, P1171, DOI 10.1007/s10822-011-9505-2; Sasaki H, 2002, LUNG CANCER-J IASLC, V35, P149, DOI 10.1016/S0169-5002(01)00329-4; Sausen M, 2013, NAT GENET, V45, P12, DOI 10.1038/ng.2493; Schneppenheim R, 2010, AM J HUM GENET, V86, P279, DOI 10.1016/j.ajhg.2010.01.013; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Shen JJC, 2008, CANCER RES, V68, P4050, DOI 10.1158/0008-5472.CAN-07-3240; Shen J, 2015, CANCER RES, V75, P754, DOI 10.1158/0008-5472.CAN-14-1301; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Sheu JJC, 2013, J PATHOL, V229, P559, DOI 10.1002/path.4147; Sheu JJC, 2010, J BIOL CHEM, V285, P38260, DOI 10.1074/jbc.M110.138735; Shih LM, 2005, P NATL ACAD SCI USA, V102, P14004, DOI 10.1073/pnas.0504195102; Smith MJ, 2014, J PATHOL, V234, P436, DOI 10.1002/path.4427; Smith MJ, 2013, NAT GENET, V45, P295, DOI 10.1038/ng.2552; Smith-Roe SL, 2015, ONCOTARGET, V6, P732, DOI 10.18632/oncotarget.2715; Song SJ, 2014, MOL CANCER RES, V12, P560, DOI 10.1158/1541-7786.MCR-13-0427; Sperlazza J, 2015, BLOOD, V126, P1462, DOI 10.1182/blood-2015-03-631606; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Strohner R, 2001, EMBO J, V20, P4892, DOI 10.1093/emboj/20.17.4892; Sullivan LM, 2013, MODERN PATHOL, V26, P385, DOI 10.1038/modpathol.2012.175; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Tae S, 2011, NUCLEIC ACIDS RES, V39, P5424, DOI 10.1093/nar/gkr170; Tai HC, 2012, J CLIN PATHOL, V65, P248, DOI 10.1136/jclinpath-2011-200413; Taulli R, 2014, ONCOGENE, V33, P2354, DOI 10.1038/onc.2013.188; Theodoulou N. H., 2015, J MED CHEM; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; Toiber D, 2013, MOL CELL, V51, P454, DOI 10.1016/j.molcel.2013.06.018; Tolstorukov MY, 2013, P NATL ACAD SCI USA, V110, P10165, DOI 10.1073/pnas.1302209110; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Torchy MP, 2015, CELL MOL LIFE SCI, V72, P2491, DOI 10.1007/s00018-015-1880-8; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2007, EMBO J, V26, P4113, DOI 10.1038/sj.emboj.7601835; van de Wijngaart DJ, 2009, MOL ENDOCRINOL, V23, P1776, DOI 10.1210/me.2008-0280; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vidi PA, 2014, NUCLEIC ACIDS RES, V42, P6365, DOI 10.1093/nar/gku296; Vidler LR, 2012, J MED CHEM, V55, P7346, DOI 10.1021/jm300346w; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang DH, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039920, 10.1371/journal.pone.0040364]; Wang G, 2016, CANCER DISCOV, V1, P1; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang L, 2014, CELL STEM CELL, V14, P575, DOI 10.1016/j.stem.2014.02.013; Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104; Watanabe R, 2014, CANCER RES, V74, P2465, DOI 10.1158/0008-5472.CAN-13-3608; Watanabe S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8108; Wei Wang, 2014, Advances in Materials Science and Engineering, DOI 10.1155/2014/494851; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Weichert W, 2008, NEOPLASIA, V10, P1021, DOI 10.1593/neo.08474; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wijdeven RH, 2015, CANCER RES, V75, P4176, DOI 10.1158/0008-5472.CAN-15-0380; Wilson BG, 2014, MOL CELL BIOL, V34, P1136, DOI 10.1128/MCB.01372-13; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Wong AKC, 2000, CANCER RES, V60, P6171; Wu M, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-1; Wu Q, 2015, J CELL PHYSIOL, V230, P2683, DOI 10.1002/jcp.24991; Xia W, 2008, CANCER RES, V68, P1667, DOI 10.1158/0008-5472.CAN-07-5276; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Xie CY, 2014, TUMOR BIOL, V35, P7595, DOI 10.1007/s13277-014-2008-8; Xu Y, 2010, ONCOGENE, V29, P4090, DOI 10.1038/onc.2010.159; Xu YC, 2012, EXP CELL RES, V318, P177, DOI 10.1016/j.yexcr.2011.11.010; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yadon AN, 2011, CELL, V144, P454, DOI 10.1016/j.cell.2011.01.019; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yan HB, 2014, CARCINOGENESIS, V35, P867, DOI 10.1093/carcin/bgt398; Yang YI, 2014, CANCER RES, V74, P2258, DOI 10.1158/0008-5472.CAN-13-2459; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601; Ye JQ, 2014, HUM PATHOL, V45, P2430, DOI 10.1016/j.humpath.2014.08.007; Ye Y, 2009, MOL CANCER RES, V7, P1984, DOI 10.1158/1541-7786.MCR-09-0119; Yu L, 2013, FEBS LETT, V587, P2542, DOI 10.1016/j.febslet.2013.06.029; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zhao H, 2011, ONCOTARGET, V2, P886; Zhao SM, 2013, P NATL ACAD SCI USA, V110, P2916, DOI 10.1073/pnas.1222577110; Zhou YG, 2005, CURR BIOL, V15, P1434, DOI 10.1016/j.cub.2005.06.057; Zou JX, 2007, P NATL ACAD SCI USA, V104, P18067, DOI 10.1073/pnas.0705814104	298	61	62	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4423	4436		10.1038/onc.2015.513	http://dx.doi.org/10.1038/onc.2015.513			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804164				2022-12-28	WOS:000382153100001
J	Park, YH; Kim, SU; Kwon, TH; Kim, JM; Song, IS; Shin, HJ; Lee, BK; Bang, DH; Lee, SJ; Lee, DS; Chang, KT; Kim, BY; Yu, DY				Park, Y-H; Kim, S-U; Kwon, T-H; Kim, J-M; Song, I-S; Shin, H-J; Lee, B-K; Bang, D-H; Lee, S-J; Lee, D-S; Chang, K-T; Kim, B-Y; Yu, D-Y			Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway	ONCOGENE			English	Article							H-RAS12V TRANSGENIC MICE; CANCER STEM-CELLS; HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; POOR-PROGNOSIS; TRANSCRIPTION FACTOR; FOXM1; EXPRESSION; ACTIVATION; HEPATOCARCINOGENESIS	The current study was carried out to define the involvement of Peroxiredoxin (Prx) II in progression of hepatocellular carcinoma (HCC) and the underlying molecular mechanism(s). Expression and function of Prx II in HCC was determined using H-ras(G12V)-transformed HCC cells (H-ras(G12V)-HCC cells) and the tumor livers from H-ras(G12V)-transgenic (Tg) mice and HCC patients. Prx II was upregulated in H-ras(G12V)-HCC cells and H-ras(G12V)-Tg mouse tumor livers, the expression pattern of which highly similar to that of forkhead Box M1 (FoxM1). Moreover, either knockdown of FoxM1 or site-directed mutagenesis of FoxM1-binding site of Prx II promoter significantly reduced Prx II levels in H-ras(G12V)-HCC cells, indicating FoxM1 as a direct transcription factor of Prx II in HCC. Interestingly, the null mutation of Prx II markedly decreased the number and size of tumors in H-ras(G12V)-Tg livers. Consistent with this, knockdown of Prx II in H-ras(G12V)-HCC cells reduced the expression of cyclin D1, cell proliferation, anchorage-independent growth and tumor formation in athymic nude mice, whereas overexpression of Prx II increased or aggravated the tumor phenotypes. Importantly, the expression of Prx II was correlated with that of FoxM1 in HCC patients. The activation of extracellular signal-related kinase (ERK) pathway and the expression of FoxM1 and cyclin D1 were highly dependent on Prx II in H-ras(G12V)-HCC cells and H-ras(G12V)-Tg livers. Prx II is FoxM1-dependently- expressed antioxidant in HCC and function as an enhancer of Ras(G12V) oncogenic potential in hepatic tumorigenesis through activation of ERK/FoxM1/cyclin D1 cascade.	[Park, Y-H; Kim, S-U; Kwon, T-H; Shin, H-J; Lee, B-K; Yu, D-Y] Korea Res Inst Biosci & Biotechnol, Aging Intervent Res Ctr, 125 Gwahak Ro, Daejeon 305806, South Korea; [Park, Y-H; Kim, S-U; Chang, K-T] Korea Res Inst Biosci & Biotechnol, Natl Primate Res Ctr, Daejeon, South Korea; [Park, Y-H; Kim, S-U; Yu, D-Y] Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea; [Kim, J-M] Chungnam Natl Univ, Sch Med, Daejeon, South Korea; [Song, I-S] Inje Univ, Cardiovasc & Metab Dis Ctr, Busan, South Korea; [Bang, D-H] Wonkwang Univ, Sch Med, Iksan, South Korea; [Lee, S-J] Hanyang Univ, Res Inst Nat Sci, Seoul, South Korea; [Lee, D-S] Kyungpook Natl Univ, Coll Nat Sci, Daegu, South Korea; [Kim, B-Y] Korea Res Inst Biosci & Biotechnol, World Class Inst, Ochang, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST); Chungnam National University; Inje University; Wonkwang University; Hanyang University; Kyungpook National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Yu, DY (corresponding author), Korea Res Inst Biosci & Biotechnol, Aging Intervent Res Ctr, 125 Gwahak Ro, Daejeon 305806, South Korea.	dyyu10@kribb.re.kr		KIM, JIN MAN/0000-0003-0905-9730; Lee, Dong Seok/0000-0001-6348-8937	Mid-career Researcher Program through NFR grant - MSIP [OGM0021312]; World Class Institute (WCI) Program of the NRF - MSIP NRF [WCI 2009-002]; National Research Foundation of Korea - Korean government [2010-0020877]; KRIBB Research Initiative Program of Korea [KGM3141312]; Next-Generation BioGreen 21 Program - Rural Development Administration of Korea [PJ0099592015]	Mid-career Researcher Program through NFR grant - MSIP; World Class Institute (WCI) Program of the NRF - MSIP NRF; National Research Foundation of Korea - Korean government(National Research Foundation of KoreaKorean Government); KRIBB Research Initiative Program of Korea; Next-Generation BioGreen 21 Program - Rural Development Administration of Korea	This work was supported by Mid-career Researcher Program through NFR grant funded by the MSIP (OGM0021312), by the World Class Institute (WCI) Program of the NRF, funded by the MSIP NRF (WCI 2009-002), by the National Research Foundation of Korea (2010-0020877), funded by Korean government, by the KRIBB Research Initiative Program (KGM3141312) of Korea, and by the Next-Generation BioGreen 21 Program (PJ0099592015), funded by Rural Development Administration of Korea. We thank Dr Pradip Raychaudhuri (University of Illinois at Chicago) who provided us with pCMV-T7-FoxM1 expression vectors.	Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Calvisi DF, 2009, GUT, V58, P679, DOI 10.1136/gut.2008.152652; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Choi AR, 2012, BIOCHEM BIOPH RES CO, V425, P436, DOI 10.1016/j.bbrc.2012.07.120; Diao S, 2010, PROTEOMICS, V10, P3723, DOI 10.1002/pmic.201000050; Han YH, 2005, FEBS LETT, V579, P4897, DOI 10.1016/j.febslet.2005.07.049; Han YH, 2012, BIOCHEM BIOPH RES CO, V426, P427, DOI 10.1016/j.bbrc.2012.08.113; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jungst C, 2004, HEPATOLOGY, V39, P1663, DOI 10.1002/hep.20241; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kang DH, 2011, MOL CELL, V44, P545, DOI 10.1016/j.molcel.2011.08.040; KIARIS H, 1995, INT J ONCOL, V7, P413; Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559; Kim SU, 2011, NEUROBIOL AGING, V32, P1054, DOI 10.1016/j.neurobiolaging.2009.05.017; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Kwon J, 2003, FREE RADICAL BIO MED, V35, P406, DOI 10.1016/S0891-5849(03)00318-6; Lee KW, 2011, J BIOL CHEM, V286, P8394, DOI 10.1074/jbc.M110.179416; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Li W, 2010, J CLIN INVEST, V120, P3996, DOI 10.1172/JCI42823; Li Y, 2008, PROTEOMICS, V8, P1490, DOI 10.1002/pmic.200700229; Lu Y, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-115; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Park HJ, 2009, EMBO J, V28, P2908, DOI 10.1038/emboj.2009.239; Park JG, 2011, CIRC RES, V109, P739, DOI 10.1161/CIRCRESAHA.111.245530; Park YH, 2013, ANTIOXID REDOX SIGN, V19, P482, DOI 10.1089/ars.2011.4421; Perkins A, 2015, TRENDS BIOCHEM SCI, V40, P435, DOI 10.1016/j.tibs.2015.05.001; Petrovic V, 2008, J BIOL CHEM, V283, P453, DOI 10.1074/jbc.M705792200; Saha B, 2009, HEPATOLOGY, V50, P1547, DOI 10.1002/hep.23180; Shi XK, 2012, ANTIOXID REDOX SIGN, V16, P1215, DOI 10.1089/ars.2012.4529; Sun HC, 2011, ONCOL REP, V25, P1533, DOI 10.3892/or.2011.1230; Sun HN, 2010, J NEUROCHEM, V114, P39, DOI 10.1111/j.1471-4159.2010.06691.x; Tai P, 2011, MOL ENDOCRINOL, V25, P885, DOI 10.1210/me.2010-0489; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wang AG, 2005, J HEPATOL, V43, P836, DOI 10.1016/j.jhep.2005.04.012; Wang AG, 2011, BIOCHEM BIOPH RES CO, V409, P532, DOI 10.1016/j.bbrc.2011.05.039; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Xia LM, 2012, J HEPATOL, V57, P600, DOI 10.1016/j.jhep.2012.04.020; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Zhang B, 2009, CANCER LETT, V286, P154, DOI 10.1016/j.canlet.2009.04.043	44	18	20	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3503	3513		10.1038/onc.2015.411	http://dx.doi.org/10.1038/onc.2015.411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26500057				2022-12-28	WOS:000379621500003
J	Shigeta, S; Toyoshima, M; Kitatani, K; Ishibashi, M; Usui, T; Yaegashi, N				Shigeta, S.; Toyoshima, M.; Kitatani, K.; Ishibashi, M.; Usui, T.; Yaegashi, N.			Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer	ONCOGENE			English	Article							FALLOPIAN-TUBE EPITHELIUM; HUMAN FOLLICULAR-FLUID; CANDIDATE PRECURSOR; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; DAMAGE RESPONSE; IRON; INFLAMMATION; WOMEN; MODEL	Fallopian tubal epithelium is a candidate for the origin of high-grade serous ovarian cancer. Transferrin-containing follicular fluid and/or retrograde menstrual blood are possible risk factors for carcinogenesis. Accumulation of DNA double-strand breaks (DNA-DSBs) in the fallopian tubal epithelium is considered to play an important role in the development of cancer. However, the mechanisms by which DNA-DSBs accumulate have not yet been fully elucidated. The hydroxyl radical, which is produced in a Fenton reaction catalyzed by an iron ion, serves as a potent DNA-DSB-inducing molecule, raising the potential of an iron ion transporter of transferrin in the formation of DNA-DSBs. We studied the potential involvement of transferrin in DNA damage and the development of ovarian cancer. Treatment with transferrin facilitated the formation of histone 2AX phosphorylated at Serine 139 (gamma H2AX), which is known as a DNA-DSB marker, in human fallopian tube secretory epithelial cells and A2780 ovarian cancer cells. Knockdown of transferrin receptor 1 (TfR1), but not transferrin receptor 2, suppressed the transferrin uptake and consequent formation of gamma H2AX. As hydroxyl radicals in reactive oxygen species (ROS) are involved in DNA-DSBs, the formation of ROS was determined. Treatment with TfR1-specific small interference RNAs significantly diminished transferrin-induced formation of ROS. Moreover, TfR1-dependent uptake of transferrin was revealed to augment the formation of DNA-DSBs in the presence of hydrogen peroxide, which served as a substrate for the Fenton reaction. An ex vivo study with murine fallopian tubes further demonstrated that transferrin treatment introduced DNA-DSBs in the fallopian tubal epithelium. Collectively, these data suggested that the transferrin-TfR1 axis accounts for the induction of DNA-DSBs that potentially lead to DNA damage/genome instability. These findings also suggested that exposure to transferrin initiates and promotes the development of ovarian cancer by aiding the accumulation of DNA-DSBs in the fallopian tubal epithelium.	[Shigeta, S.; Toyoshima, M.; Kitatani, K.; Ishibashi, M.; Yaegashi, N.] Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi, Japan; [Toyoshima, M.] Sendai Med Ctr, Dept Obstet & Gynecol, Sendai, Miyagi, Japan; [Kitatani, K.; Usui, T.] Tohoku Univ, Tohoku Med Megabank Org, Sendai, Miyagi, Japan	Tohoku University; Tohoku University	Toyoshima, M (corresponding author), Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.; Kitatani, K (corresponding author), Tohoku Univ, Tohoku Med Megabank Org, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9800873, Japan.	m-toyo@med.tohoku.ac.jp; kitatani@med.tohoku.ac.jp	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; xing zhi, shi zhi/0000-0003-3289-5681	JSPS KAKENHI [23791801, 26462509, 23790366, 26861304, 40539235, 24390375, 26670710]; Health Labor Sciences Research Grant [201221019A]; Kurokawa Cancer Research Foundation; Japan Society of Gynecologic Oncology; Foundation for Promotion of Cancer Research; Tohoku University Graduate School of Medicine United Center for Advanced Research and Translational Medicine; Grants-in-Aid for Scientific Research [26462509, 26670710] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Health Labor Sciences Research Grant; Kurokawa Cancer Research Foundation(Kurokawa Cancer Research Foundation); Japan Society of Gynecologic Oncology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Foundation for Promotion of Cancer Research; Tohoku University Graduate School of Medicine United Center for Advanced Research and Translational Medicine; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs Ronny Drapkin and Alison M Karst for kindly providing FTSECs established in their laboratory. This study was supported in part by the JSPS KAKENHI Grants (23791801 and 26462509 to MT, 23790366, 26861304 and 40539235 to KK, 24390375 and 26670710 to NY), a Health Labor Sciences Research Grant (201221019A to NY), the Kurokawa Cancer Research Foundation (MT), the Japan Society of Gynecologic Oncology (MT), the Foundation for Promotion of Cancer Research (MT) and Tohoku University Graduate School of Medicine United Center for Advanced Research and Translational Medicine (MT).	Bahar-Shany K, 2014, GYNECOL ONCOL, V132, P322, DOI 10.1016/j.ygyno.2013.12.015; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bowtell DDL, 2010, NAT REV CANCER, V10, P803, DOI 10.1038/nrc2946; Briggs DA, 1999, MOL HUM REPROD, V5, P1107, DOI 10.1093/molehr/5.12.1107; Calzolari A, 2007, BLOOD CELL MOL DIS, V39, P82, DOI 10.1016/j.bcmd.2007.02.003; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; Carbone MC, 2003, MOL HUM REPROD, V9, P639, DOI 10.1093/molehr/gag090; CASAGRANDE JT, 1979, LANCET, V2, P170; Chen EY, 2010, J PATHOL, V222, P110, DOI 10.1002/path.2739; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Elizur SE, 2014, GYNECOL ENDOCRINOL, V30, P705, DOI 10.3109/09513590.2014.924100; ENTMAN SS, 1987, J IN VITRO FERTIL EM, V4, P98, DOI 10.1007/BF01555447; Falconer H, 2015, J NATL CANC IN PRESS, V107; FATHALLA MF, 1971, LANCET, V2, P163; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Folkins AK, 2008, GYNECOL ONCOL, V109, P168, DOI 10.1016/j.ygyno.2008.01.012; Fridlich R, 2015, DNA REPAIR, V30, P11, DOI 10.1016/j.dnarep.2015.03.002; Garcia-Canton C, 2012, TOXICOL IN VITRO, V26, P1075, DOI 10.1016/j.tiv.2012.06.006; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gupta S, 2011, REPROD FERT DEVELOP, V23, P673, DOI 10.1071/RD10270; Havrilesky LJ, 2013, OBSTET GYNECOL, V122, P139, DOI 10.1097/AOG.0b013e318291c235; Hennet ML, 2013, J ASSIST REPROD GEN, V30, P333, DOI 10.1007/s10815-012-9925-5; Herbison CE, 2009, AM J PHYSIOL-CELL PH, V297, pC1567, DOI 10.1152/ajpcell.00649.2008; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kumari A, 2004, ONCOGENE, V23, P2324, DOI 10.1038/sj.onc.1207379; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Lau A, 2014, EXP BIOL MED, V239, P24, DOI 10.1177/1535370213508216; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Madsen C, 2015, ACTA OBSTET GYN SCAN, V94, P86, DOI 10.1111/aogs.12516; Mashiko S, 2015, CANCER BIOL THER, V16, P253, DOI 10.1080/15384047.2014.1001271; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Modugno F, 2012, INT J GYNECOL CANCER, V22, pS45, DOI 10.1097/IGC.0b013e31826bd1f2; Narod SA, 2001, LANCET, V357, P1467, DOI 10.1016/S0140-6736(00)04642-0; NASCIMENTO ALTO, 1995, CARCINOGENESIS, V16, P1335, DOI 10.1093/carcin/16.6.1335; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Oyawoye O, 2003, HUM REPROD, V18, P2270, DOI 10.1093/humrep/deg450; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Pra D, 2012, MUTAT RES-FUND MOL M, V733, P92, DOI 10.1016/j.mrfmmm.2012.02.001; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sabatini L, 1999, FERTIL STERIL, V72, P1027, DOI 10.1016/S0015-0282(99)00411-2; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shaw PA, 2009, MODERN PATHOL, V22, P1133, DOI 10.1038/modpathol.2009.89; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Squires S, 2004, CELL CYCLE, V3, P1543, DOI 10.4161/cc.3.12.1272; Takabayashi H, 2013, HUM PATHOL, V44, P1038, DOI 10.1016/j.humpath.2012.09.006; Vercellini P, 2011, HUM REPROD, V26, P2262, DOI 10.1093/humrep/der211; West AP, 2000, J BIOL CHEM, V275, P38135, DOI 10.1074/jbc.C000664200	53	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3577	3586		10.1038/onc.2015.425	http://dx.doi.org/10.1038/onc.2015.425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26549031				2022-12-28	WOS:000379621500010
J	Morioka, S; Sai, K; Omori, E; Ikeda, Y; Matsumoto, K; Ninomiya-Tsuji, J				Morioka, S.; Sai, K.; Omori, E.; Ikeda, Y.; Matsumoto, K.; Ninomiya-Tsuji, J.			TAK1 regulates hepatic lipid homeostasis through SREBP	ONCOGENE			English	Article							ELEMENT-BINDING PROTEINS; IL-1 SIGNALING PATHWAY; MTOR COMPLEX 1; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; DEPENDENT DEGRADATION; TRANSCRIPTION FACTORS; INSULIN-RESISTANCE; CANCER DEVELOPMENT; ADIPOSE-TISSUE	Sterol-regulatory element-binding proteins (SREBPs) are key transcription factors regulating cholesterol and fatty acid biosynthesis. SREBP activity is tightly regulated to maintain lipid homeostasis, and is modulated upon extracellular stimuli such as growth factors. While the homeostatic SREBP regulation is well studied, stimuli-dependent regulatory mechanisms are still elusive. Here we demonstrate that SREBPs are regulated by a previously uncharacterized mechanism through transforming growth factor-beta activated kinase 1 (TAK1), a signaling molecule of inflammation. We found that TAK1 binds to and inhibits mature forms of SREBPs. In an in vivo setting, hepatocyte-specific Tak1 deletion upregulates liver lipid deposition and lipogenic enzymes in the mouse model. Furthermore, hepatic Tak1 deficiency causes steatosis pathologies including elevated blood triglyceride and cholesterol levels, which are established risk factors for the development of hepatocellular carcinoma (HCC) and are indeed correlated with Tak1-deficiency-induced HCC development. Pharmacological inhibition of SREBPs alleviated the steatosis and reduced the expression level of the HCC marker gene in the Tak1-deficient liver. Thus, TAK1 regulation of SREBP critically contributes to the maintenance of liver homeostasis to prevent steatosis, which is a potentially important mechanism to prevent HCC development.	[Morioka, S.; Sai, K.; Omori, E.; Ikeda, Y.; Ninomiya-Tsuji, J.] North Carolina State Univ, Dept Biol Sci, Campus Box 7633,850 Main Campus Dr, Raleigh, NC 27695 USA; [Sai, K.; Matsumoto, K.] Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi, Japan; [Morioka, S.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA	University of North Carolina; North Carolina State University; Nagoya University; University of Virginia	Morioka, S; Ninomiya-Tsuji, J (corresponding author), North Carolina State Univ, Dept Biol Sci, Campus Box 7633,850 Main Campus Dr, Raleigh, NC 27695 USA.; Morioka, S (corresponding author), Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.	sm9ss@virginia.edu; Jun_Tsuji@ncsu.edu	Morioka, Sho/I-2074-2019	Morioka, Sho/0000-0002-1153-4919; Ninomiya-Tsuji, Jun/0000-0002-5584-0176; Ikeda-Iwabu, Yuka/0000-0003-3550-7891	National Institutes of Health [GM068812]; Grants-in-Aid for Scientific Research [26112706] Funding Source: KAKEN; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM112986, R01GM068812] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank NC State biological animal facility for technical support, Dr Akira for Tak1-loxed mice and Simmons, A. for critical reading. This work was supported by National Institutes of Health Grant GM068812 (to JNT).	Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Braeuning A, 2006, TOXICOLOGY, V227, P127, DOI 10.1016/j.tox.2006.07.024; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102; Cohen JC, 2011, SCIENCE, V332, P1519, DOI 10.1126/science.1204265; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Glass CK, 2012, CELL METAB, V15, P635, DOI 10.1016/j.cmet.2012.04.001; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Heindryckx F, 2009, INT J EXP PATHOL, V90, P367, DOI 10.1111/j.1365-2613.2009.00656.x; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ikeda Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088037; Inokuchi S, 2010, P NATL ACAD SCI USA, V107, P844, DOI 10.1073/pnas.0909781107; Inokuchi-Shimizu S, 2014, J CLIN INVEST, V124, P3566, DOI 10.1172/JCI74068; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Kajino T, 2007, J BIOL CHEM, V282, P9475, DOI 10.1074/jbc.M700875200; Kajino T, 2006, J BIOL CHEM, V281, P39891, DOI 10.1074/jbc.M608155200; Kajino-Sakamoto R, 2008, J IMMUNOL, V181, P1143, DOI 10.4049/jimmunol.181.2.1143; Kamisuki S, 2009, CHEM BIOL, V16, P882, DOI 10.1016/j.chembiol.2009.07.007; Kammoun HL, 2009, J CLIN INVEST, V119, P1201, DOI 10.1172/JCI37007; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kwak JH, 2008, J BIOL CHEM, V283, P19816, DOI 10.1074/jbc.M802285200; Laplante M, 2010, P NATL ACAD SCI USA, V107, P3281, DOI 10.1073/pnas.1000323107; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Morioka S, 2009, ONCOGENE, V28, P2257, DOI 10.1038/onc.2009.110; Morioka S, 2014, J CELL BIOL, V204, P607, DOI 10.1083/jcb.201305070; Morioka S, 2012, BLOOD, V120, P3846, DOI 10.1182/blood-2012-03-416198; Nakayama H, 2007, METABOLISM, V56, P470, DOI 10.1016/j.metabol.2006.11.004; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Ringseis R, 2013, MOL ENDOCRINOL, V27, P781, DOI 10.1210/me.2012-1269; Ron D, 2004, J CELL BIOL, V167, P23, DOI 10.1083/jcb.200408117; Sabio G, 2009, CELL METAB, V10, P491, DOI 10.1016/j.cmet.2009.09.007; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Scholz R, 2010, J BIOL CHEM, V285, P25753, DOI 10.1074/jbc.M109.093468; Schuck S, 2009, J CELL BIOL, V187, P525, DOI 10.1083/jcb.200907074; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; SMITH JR, 1990, J BIOL CHEM, V265, P2306; Sohda T, 1998, J HUM GENET, V43, P49, DOI 10.1007/s100380050036; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Sundqvist A, 2003, P NATL ACAD SCI USA, V100, P13833, DOI 10.1073/pnas.2335135100; Tacer KF, 2007, PHYSIOL GENOMICS, V31, P216, DOI 10.1152/physiolgenomics.00264.2006; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; Uemura N, 2006, J BIOL CHEM, V281, P7863, DOI 10.1074/jbc.M509834200; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Yang L, 2013, GASTROENTEROLOGY, V144, P1042, DOI 10.1053/j.gastro.2013.01.056; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yecies JL, 2011, CELL METAB, V14, P21, DOI 10.1016/j.cmet.2011.06.002; Zhang HH, 2002, DIABETES, V51, P2929, DOI 10.2337/diabetes.51.10.2929; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381	70	19	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3829	3838		10.1038/onc.2015.453	http://dx.doi.org/10.1038/onc.2015.453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26973245	Green Accepted			2022-12-28	WOS:000380753200008
J	Yu, EJ; Kim, SH; Kim, HJ; Heo, K; Ou, CY; Stallcup, MR; Kim, JH				Yu, E. J.; Kim, S-H; Kim, H. J.; Heo, K.; Ou, C-Y; Stallcup, M. R.; Kim, J. H.			Positive regulation of beta-catenin-PROX1 signaling axis by DBC1 in colon cancer progression	ONCOGENE			English	Article							BETA-CATENIN; WNT/BETA-CATENIN; COLORECTAL TUMORIGENESIS; ANDROGEN RECEPTOR; GENE ACTIVATION; GROWTH; P53; PROX1; CELLS; SIRT1	Aberrant activation of Wnt/beta-catenin pathway contributes to colorectal cancer (CRC) progression. However, little is known about regulatory mechanisms of the beta-catenin activity in cancer progression. Here we investigated the role of DBC1, which was recently reported as a negative regulator of SIRT1 and a transcriptional coactivator, in the regulation of Wnt/beta-catenin signaling. We identified the genome-wide targets of DBC1 and found that loss of DBC1 inhibits the expression of beta-catenin target genes including PROX1, a transcription factor linked to CRC progression. Mechanistically, DBC1 stabilizes LEF1-beta-catenin interaction by inhibiting SIRT1-mediated beta-catenin deacetylation, thereby enhancing LEF1-beta-catenin complex formation and long-range chromatin looping at the PROX1 locus. Furthermore, DBC1 is also required for the transcriptional activity of PROX1, suggesting that DBC1 has a dual function in regulating beta-catenin-PROX1 signaling axis: as a coactivator for both beta-catenin and PROX1. Importantly, loss of DBC1 inhibited growth and tumorigenic potential of colon cancer cells, and DBC1 expression correlated with shorter relapse-free survival in patients with advanced CRC. Our results firmly establish DBC1 as a critical positive regulator of beta-catenin-PROX1 signaling axis and a key factor in beta-catenin-PROX1-mediated CRC progression.	[Yu, E. J.; Kim, S-H; Kim, H. J.; Kim, J. H.] Sungkyunkwan Univ, Samsung Canc Ctr, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea; [Yu, E. J.; Kim, H. J.; Kim, J. H.] Samsung Med Ctr, Samsung Biomed Res Inst, Dept Biomed Sci, Seoul, South Korea; [Kim, S-H] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Heo, K.] Dongnam Inst Radiol & Med Sci, Dept Clin Res, Busan, South Korea; [Ou, C-Y; Stallcup, M. R.] Univ Southern Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Korea Institute of Radiological & Medical Sciences; University of Southern California	Kim, JH (corresponding author), Sungkyunkwan Univ, Samsung Canc Ctr, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea.; Kim, JH (corresponding author), Samsung Med Ctr, Samsung Biomed Res Inst, Dept Biomed Sci, Seoul, South Korea.; Stallcup, MR (corresponding author), Univ Southern Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.	stallcup@usc.edu; jeongkim@skku.edu	Ou, Chenyin/AAM-7473-2020	Ou, Chenyin/0000-0002-8036-7317; Heo, Kyu/0000-0001-8833-4731	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning (MISP) [NRF-2013R1A1A2059697]; National R&D Program through the Dongnam Institute of Radiological and Medical Sciences (DIRAMS) - MISP [50590-2015]; National Institutes of Health [DK043093]; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning (MISP); National R&D Program through the Dongnam Institute of Radiological and Medical Sciences (DIRAMS) - MISP; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Woo-Young Seo (Sungkyunkwan University) for expert technical assistance and Dr Yong-Kwon Hong (University of Southern California) for providing PROX1 expression and reporter constructs. This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MISP) (NRF-2013R1A1A2059697 to JHK), National R&D Program through the Dongnam Institute of Radiological and Medical Sciences (DIRAMS) funded by MISP (50590-2015), and the National Institutes of Health (DK043093 to MRS).	BAKER SJ, 1990, CANCER RES, V50, P7717; Chini EN, 2013, BIOSCIENCE REP, V33, P637, DOI 10.1042/BSR20130062; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363; Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212; Kim HJ, 2015, ONCOGENE, V34, P4500, DOI 10.1038/onc.2014.381; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kim SH, 2012, HISTOL HISTOPATHOL, V27, P49, DOI 10.14670/HH-27.49; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Neumann H, 2009, MOL CELL, V36, P153, DOI 10.1016/j.molcel.2009.07.027; Ou CY, 2009, J BIOL CHEM, V284, P20629, DOI 10.1074/jbc.M109.014332; Pangon L, 2015, INT J CANCER, V136, P55, DOI 10.1002/ijc.28967; Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020; Qin B, 2015, CELL REP, V10, P1324, DOI 10.1016/j.celrep.2015.01.066; Ragusa S, 2014, CELL REP, V8, P1957, DOI 10.1016/j.celrep.2014.08.041; Sebio A, 2014, EXPERT OPIN THER TAR, V18, P611, DOI 10.1517/14728222.2014.906580; Seo WY, 2013, NUCLEIC ACIDS RES, V41, P8526, DOI 10.1093/nar/gkt644; SINICROPE FA, 1995, CANCER RES, V55, P237; Skog M, 2011, BRIT J CANCER, V105, P1346, DOI 10.1038/bjc.2011.297; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Tutter AV, 2001, GENE DEV, V15, P3342, DOI 10.1101/gad.946501; Wiener Z, 2014, CELL REP, V8, P1943, DOI 10.1016/j.celrep.2014.08.034; Xu WQ, 2007, J CELL SCI, V120, P3337, DOI 10.1242/jcs.013771; Yang CK, 2006, J BIOL CHEM, V281, P3389, DOI 10.1074/jbc.M510403200; Yu EJ, 2013, ONCOGENE, V32, P4160, DOI 10.1038/onc.2012.420; Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347; Zhang YG, 2014, INT J CLIN ONCOL, V19, P106, DOI 10.1007/s10147-012-0506-5	31	20	21	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3410	3418		10.1038/onc.2015.401	http://dx.doi.org/10.1038/onc.2015.401			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26477307	Green Accepted			2022-12-28	WOS:000379270100006
J	Greil, C; Krohs, J; Schnerch, D; Follo, M; Felthaus, J; Engelhardt, M; Wasch, R				Greil, C.; Krohs, J.; Schnerch, D.; Follo, M.; Felthaus, J.; Engelhardt, M.; Waesch, R.			The role of APC/C-Cdh1 in replication stress and origin of genomic instability	ONCOGENE			English	Article							ANAPHASE-PROMOTING COMPLEX; MCM4,6,7 HELICASE ACTIVITY; E3 UBIQUITIN LIGASES; CELL-CYCLE; S-PHASE; TUMOR SUPPRESSION; DNA-REPLICATION; CHROMOSOMAL INSTABILITY; DEPENDENT PROTEOLYSIS; MAMMALIAN-CELLS	It has been proposed that the APC/C-Cdh1 functions as a tumor suppressor by maintaining genomic stability. However, the exact nature of genomic instability following loss of Cdh1 is unclear. Using biochemistry and live cell imaging of single cells we found that Cdh1 knockdown (kd) leads to strong nuclear stabilization of the substrates cyclin A and B and deregulated kinetics of DNA replication. Restoration of the Cdh1-dependent G2 DNA damage checkpoint did not result in G2 arrest but blocked cells in prometaphase, suggesting that these cells enter mitosis despite incomplete replication. This results in DNA double-strand breaks, anaphase bridges, cytokinesis defects and tetraploidization. Tetraploid cells are the source of supernumerary centrosomes following Cdh1-kd, leading to multipolar mitosis or centrosome clustering, in turn resulting in merotelic attachment and lagging chromosomes. Whereas some of these events cause apoptosis during mitosis, surviving cells may accumulate chromosomal aberrations.	[Greil, C.; Krohs, J.; Schnerch, D.; Follo, M.; Felthaus, J.; Engelhardt, M.; Waesch, R.] Univ Med Ctr, Dept Hematol Oncol & Stem Cell Transplanta, Hugstetter Str 55, D-79106 Freiburg, Germany; [Krohs, J.] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany; [Schnerch, D.] Univ Basel, Biozentrum, Basel, Switzerland	University of Freiburg; University of Freiburg; University of Basel	Wasch, R (corresponding author), Univ Med Ctr, Dept Hematol Oncol & Stem Cell Transplanta, Hugstetter Str 55, D-79106 Freiburg, Germany.	ralph.waesch@uniklinik-freiburg.de	Waesch, Ralph/F-6282-2019	Follo, Marie/0000-0002-3090-7442	Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work is supported by Deutsche Forschungsgemeinschaft. We thank G Ihorst for statistical advice.	Alver RC, 2014, DNA REPAIR, V19, P182, DOI 10.1016/j.dnarep.2014.03.012; Ayuda-Duran P, 2014, NUCLEIC ACIDS RES, V42, P7057, DOI 10.1093/nar/gku313; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Clijsters L, 2013, J CELL BIOL, V201, P1013, DOI 10.1083/jcb.201211019; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Drosopoulos K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4686; Eguren M, 2014, CELL REP, V6, P670, DOI 10.1016/j.celrep.2014.01.017; Eguren M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3880; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; Floyd S, 2008, CURR BIOL, V18, P1649, DOI 10.1016/j.cub.2008.09.058; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Held M, 2010, NAT METHODS, V7, P747, DOI 10.1038/nmeth.1486; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Johansson P, 2014, J BIOL CHEM, V289, P18514, DOI 10.1074/jbc.M114.559930; Kawabata T, 2011, MOL CELL, V41, P543, DOI 10.1016/j.molcel.2011.02.006; Komamura-Kohno Y, 2006, FEBS J, V273, P1224, DOI 10.1111/j.1742-4658.2006.05146.x; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Neelsen KJ, 2013, J CELL BIOL, V200, P699, DOI 10.1083/jcb.201212058; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pines J, 2011, NAT REV MOL CELL BIO, V12, P427, DOI 10.1038/nrm3132; Qiao XX, 2010, CELL CYCLE, V9, P3904, DOI 10.4161/cc.9.19.13585; Schnerch D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074379; Schnerch D, 2012, CELL CYCLE, V11, P310, DOI 10.4161/cc.11.2.18737; Sigl R, 2009, J CELL SCI, V122, P4208, DOI 10.1242/jcs.054197; Skaar JR, 2008, NAT CELL BIOL, V10, P755, DOI 10.1038/ncb0708-755; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; Torres-Rosell J, 2007, SCIENCE, V315, P1411, DOI 10.1126/science.1134025; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wheeler LW, 2008, CELL CYCLE, V7, P2179, DOI 10.4161/cc.7.14.6270; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108; Yuan X, 2014, MOL BIOL CELL, V25, P441, DOI 10.1091/mbc.E13-08-0480; Zhang JF, 2014, BBA-REV CANCER, V1845, P277, DOI 10.1016/j.bbcan.2014.02.001	50	24	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3062	3070		10.1038/onc.2015.367	http://dx.doi.org/10.1038/onc.2015.367			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26455319				2022-12-28	WOS:000377474500011
J	Liu, XS; Liu, Z; Gerarduzzi, C; Choi, DE; Ganapathy, S; Pandolfi, PP; Yuan, ZM				Liu, X-S; Liu, Z.; Gerarduzzi, C.; Choi, D. E.; Ganapathy, S.; Pandolfi, P. P.; Yuan, Z-M			Somatic human ZBTB7A zinc finger mutations promote cancer progression	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSOR; POZ DOMAIN; GENE; PROTEINS; LRF	We recently reported that ZBTB7A is a bona fide transcription repressor of key glycolytic genes and its downregulation in human cancer contributes to tumor metabolism. As reduced expression of ZBTB7A is found only in a subset of human cancers, we explored alternative mechanisms of its inactivation by mining human cancer genome databases. We discovered recurrent somatic mutations of ZBTB7A in multiple types of human cancers with a marked enrichment of mutations within the zinc finger domain. Functional characterization of the mutants demonstrated that mutations within the zinc finger region of ZBTB7A invariably resulted in loss of function. As a consequence, the glycolytic genes were markedly upregulated in cancer cells harboring ZBTB7A zinc finger mutation, leading to increased glycolysis and proliferation. Our study uncovers the loss-of-function mutation in ZBTB7A as a novel mechanism causing elevated glycolysis in human cancer, which carries important therapeutic implication.	[Liu, X-S; Gerarduzzi, C.; Choi, D. E.; Ganapathy, S.; Yuan, Z-M] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA; [Liu, X-S] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China; [Liu, Z.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Pandolfi, P. P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Canc Genet Program,Beth Israel Deaconess Canc Ctr, Boston, MA 02215 USA; [Pandolfi, P. P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Pathol, Canc Genet Program,Beth Israel Deaconess Canc Ctr, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; ShanghaiTech University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Liu, Xue-Song/ADF-2183-2022	Liu, Xue-Song/0000-0002-7736-0077; Pandolfi, Pier Paolo/0000-0002-5352-5295; Gerarduzzi, Casimiro/0000-0001-7098-1455; Liu, Zhonghua/0000-0003-3048-9823	Morningside Foundation; NIH/NCI [R01CA085679, RO1CA167814, RO1CA125144]; NATIONAL CANCER INSTITUTE [R01CA183074, R01CA167814, R01CA085679, R01CA125144] Funding Source: NIH RePORTER	Morningside Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to current and former members of the Yuan lab for experimental support, advice and helpful discussions. This work was supported in part by the Morningside Foundation and grants from NIH/NCI (R01CA085679, RO1CA167814 and RO1CA125144).	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Costoya Jose A., 2007, Briefings in Functional Genomics & Proteomics, V6, P8, DOI 10.1093/bfgp/elm002; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee SU, 2012, IMMUNOL REV, V247, P107, DOI 10.1111/j.1600-065X.2012.01116.x; Liu CJ, 2004, J BIOL CHEM, V279, P47081, DOI 10.1074/jbc.M405288200; Liu XS, 2014, GENE DEV, V28, P1917, DOI 10.1101/gad.245910.114; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Maeda T, 2007, SCIENCE, V316, P860, DOI 10.1126/science.1140881; Maeda T, 2009, DEV CELL, V17, P527, DOI 10.1016/j.devcel.2009.09.005; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Sakurai N, 2011, J CLIN INVEST, V121, P2583, DOI 10.1172/JCI45682; Stogios PJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r82; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	24	23	24	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3071	3078		10.1038/onc.2015.371	http://dx.doi.org/10.1038/onc.2015.371			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26455326	Green Accepted			2022-12-28	WOS:000377474500012
J	Pangon, L; Ng, I; Giry-Laterriere, M; Currey, N; Morgan, A; Benthani, F; Tran, PN; Al-Sohaily, S; Segelov, E; Parker, BL; Cowley, MJ; Wright, DC; St Heaps, L; Carey, L; Rooman, I; Kohonen-Corish, MRJ				Pangon, L.; Ng, I.; Giry-Laterriere, M.; Currey, N.; Morgan, A.; Benthani, F.; Tran, P. N.; Al-Sohaily, S.; Segelov, E.; Parker, B. L.; Cowley, M. J.; Wright, D. C.; St Heaps, L.; Carey, L.; Rooman, I.; Kohonen-Corish, M. R. J.			JRK is a positive regulator of beta-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer	ONCOGENE			English	Article							INHIBITION; JERKY; BCL9	The loss of beta-catenin inhibitory components is a well-established mechanism of carcinogenesis but beta-catenin hyperactivity can also be enhanced through its coactivators. Here we first interrogated a highly validated genomic screen and the largest repository of cancer genomics data and identified JRK as a potential new oncogene and therapeutic target of the beta-catenin pathway. We proceeded to validate the oncogenic role of JRK in colon cancer cells and primary tumors. Consistent with a beta-catenin activator function, depletion of JRK in several cancer cell lines repressed beta-catenin transcriptional activity and reduced cell proliferation. Importantly, JRK expression was aberrantly elevated in 21% of colorectal cancers, 15% of breast and ovarian cancers and was associated with increased expression of beta-catenin target genes and increased cell proliferation. This study shows that JRK is required for beta-catenin hyperactivity regardless of the adenomatous polyposis coli/beta-catenin mutation status and targeting JRK presents new opportunities for therapeutic intervention in cancer.	[Pangon, L.; Ng, I.; Giry-Laterriere, M.; Currey, N.; Morgan, A.; Benthani, F.; Tran, P. N.; Al-Sohaily, S.; Cowley, M. J.; Rooman, I.; Kohonen-Corish, M. R. J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW 2010, Australia; [Pangon, L.; Benthani, F.; Segelov, E.; Cowley, M. J.; Rooman, I.; Kohonen-Corish, M. R. J.] UNSW Australia, UNSW Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Parker, B. L.] Garvan Inst Med Res, Biol Mass Spectrometry Unit, Sydney, NSW 2010, Australia; [Parker, B. L.] Univ Sydney, Sch Mol Biosci, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Cowley, M. J.] Garvan Inst Med Res, Kinghorn Ctr Clin Genom, Sydney, NSW 2010, Australia; [Wright, D. C.; St Heaps, L.; Carey, L.] Childrens Hosp Westmead, Cytogenet, Westmead, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; Garvan Institute of Medical Research; University of Sydney; Garvan Institute of Medical Research; University of Sydney	Pangon, L (corresponding author), Garvan Inst Med Res, Canc Div, 384 Victoria St, Sydney, NSW 2010, Australia.	l.pangon@garvan.org.au	Segelov, Eva/Q-7611-2019; Kohonen-Corish, Maija/Q-9763-2019; Cowley, Mark/K-8731-2019; Parker, Beth L/E-6013-2019	Segelov, Eva/0000-0002-4410-6144; Kohonen-Corish, Maija/0000-0002-4073-1479; Cowley, Mark/0000-0002-9519-5714; Parker, Beth L/0000-0002-5513-7333; Rooman, Ilse/0000-0001-7264-2246; Dyson, Nicola/0000-0002-4173-1913; Benthani, Fahad/0000-0002-3283-307X	National Health and Medical Research Council of Australia [GNT1020406]; Cure Cancer Australia/Cancer Australia [1049846]; Cancer Institute NSW [13ECF1-46, 10CDF232]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cure Cancer Australia/Cancer Australia; Cancer Institute NSW	We thank the South Western Sydney Colorectal Tissue Bank for the colorectal cancer patient specimens and Dr Christopher Henderson (Liverpool Hospital, Sydney, Australia) for helping with immunohistochemistry scoring. beta-Catenin constructs were a gift from A/Prof Beric Henderson (Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, Australia). JRK-FLAG and TCf7L2 constructs were a gift from Dr Benchabane (Department of Genetics and the Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH, USA). The M50 Super 8x TOPFlash and M51 Super 8x FOPFlash reporter constructs were obtained from Addgene and originally provided by Prof Randall Moon (University of Washington, Seattle, Washington). This work was supported by grants from the National Health and Medical Research Council of Australia (GNT1020406), Cure Cancer Australia/Cancer Australia (1049846), Cancer Institute NSW (13ECF1-46) and Cancer Institute NSW (10CDF232). The contents of the published material are solely the responsibility of the administering institution, participating institutions or individual authors and do not reflect the views of NHMRC.	Al-Sohaily S, 2014, HISTOPATHOLOGY, V65, P155, DOI 10.1111/his.12295; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Benchabane H, 2011, EMBO J, V30, P1444, DOI 10.1038/emboj.2011.67; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; de la Roche M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1680; de la Roche M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-199; Donovan GP, 1997, J NEUROSCI, V17, P4562; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07; Kawamoto SA, 2012, J MED CHEM, V55, P1137, DOI 10.1021/jm201125d; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037; Mani M, 2009, CANCER RES, V69, P7577, DOI 10.1158/0008-5472.CAN-09-0773; Moore T, 2001, EPILEPSY RES, V46, P157, DOI 10.1016/S0920-1211(01)00275-3; Morris JR, 2006, HUM MOL GENET, V15, P599, DOI 10.1093/hmg/ddi476; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Pangon L, 2015, INT J CANCER, V136, P55, DOI 10.1002/ijc.28967; Pangon L, 2012, BBA-MOL CELL RES, V1823, P1058, DOI 10.1016/j.bbamcr.2012.03.011; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2012, EMBO J, V31, P2737, DOI 10.1038/emboj.2012.126; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Trosset JY, 2006, PROTEINS, V64, P60, DOI 10.1002/prot.20955; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Waldron R, 2004, BIOCHEM SOC T, V32, P920, DOI 10.1042/BST0320920	28	14	14	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2834	2841		10.1038/onc.2015.347	http://dx.doi.org/10.1038/onc.2015.347			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26455321				2022-12-28	WOS:000377473700003
J	Schumacher, Y; Aparicio, T; Ourabah, S; Baraille, F; Martin, A; Wind, P; Dentin, R; Postic, C; Guilmeau, S				Schumacher, Y.; Aparicio, T.; Ourabah, S.; Baraille, F.; Martin, A.; Wind, P.; Dentin, R.; Postic, C.; Guilmeau, S.			Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth	ONCOGENE			English	Article							COACTIVATOR CRTC1; GENE-EXPRESSION; COLORECTAL-CANCER; BINDING PROTEIN; TRANSCRIPTIONAL COACTIVATOR; MODULATES GLUCONEOGENESIS; CREB ACTIVATION; IL-10; FUSION; CELLS	First identified as a dedicated CREB (cAMP response element-binding protein) co-activator, CRTC1 (CREB-regulated transcription coactivator 1) has been widely implicated in various neuronal functions because of its predominant expression in the brain. However, recent evidences converge to indicate that CRTC1 is aberrantly activated in an expanding number of adult malignancies. In this study, we provide strong evidences of enhanced CRTC1 protein content and transcriptional activity in mouse models of sporadic (APC(min/+) mice) or colitis-associated colon cancer azoxymethane/dextran sulfate sodium (AOM/DSS-treated mice), and in human colorectal tumors specimens compared with adjacent normal mucosa. Among signals that could trigger CRTC1 activation during colonic carcinogenesis, we demonstrate that treatment with cyclooxygenase 2 (COX2) inhibitors reduced nuclear CRTC1 active form levels in colonic tumors of APC(min/+) or AOM/DSS mice. In accordance, prostaglandins E2 (PGE2) exposure to human colon cancer cell lines promoted CRTC1 dephosphorylation and parallel nuclear translocation, resulting in enhanced CRTC1 transcriptional activity, through EP1 and EP2 receptors signaling and consecutive calcineurin and protein kinase A activation. In vitro CRTC1 loss of function in colon cancer cell lines was associated with reduced viability and cell division rate as well as enhanced chemotherapy-induced apoptosis on PGE2 treatment. Conversely, CRTC1 stable overexpression significantly increased colonic xenografts tumor growth, therefore demonstrating the role of CRTC1 signaling in colon cancer progression. Identification of the transcriptional program triggered by enhanced CRTC1 expression during colonic carcinogenesis, revealed some notable pro-tumorigenic CRTC1 target genes including NR4A2, COX2, amphiregulin (AREG) and IL-6. Finally, we demonstrate that COX2, AREG and IL-6 promoter activities triggered by CRTC1 are dependent on functional AP1 and CREB transcriptional partners. Overall, our study establishes CRTC1 as new mediator of PGE2 signaling, unravels the importance of its dysregulation in colon cancer and strengthens its use as a bona fide cancer marker.	[Schumacher, Y.; Ourabah, S.; Baraille, F.; Dentin, R.; Postic, C.; Guilmeau, S.] INSERM, Inst Cochin, U1016, Paris, France; [Schumacher, Y.; Ourabah, S.; Baraille, F.; Dentin, R.; Postic, C.; Guilmeau, S.] CNRS, UMR 8104, Paris, France; [Schumacher, Y.; Ourabah, S.; Baraille, F.; Dentin, R.; Postic, C.; Guilmeau, S.] Univ Paris 05, Paris, France; [Schumacher, Y.] Univ Paris Diderot, Paris, France; [Aparicio, T.] Univ Paris 13, Avicenne Hosp, AP HP, Gastroenterol & Digest Oncol Unit,HUPSSD, Bobigny, France; [Martin, A.] Univ Paris 13, Avicenne Hosp, AP HP, Pathol Unit,HUPSSD, Bobigny, France; [Wind, P.] Univ Paris 13, Avicenne Hosp, AP HP, Digest Surg Unit,HUPSSD, Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Guilmeau, S (corresponding author), Univ Paris 05, Endocrinol Metab & Canc INSERM U1016, 24 Rue Fbg St Jacques, F-75014 Paris, France.	sandra.guilmeau@inserm.fr	Dentin, Renaud/AAV-5818-2020; dentin, Renaud/P-4939-2017; Postic, Catherine/P-2271-2017; Guilmeau, Sandra/P-2318-2017	Dentin, Renaud/0000-0003-0988-4458; dentin, Renaud/0000-0003-0988-4458; Postic, Catherine/0000-0002-1875-6960; Guilmeau, Sandra/0000-0002-8260-1218; Martin, Alberto/0000-0002-0795-0418	Paris Descartes University; INSERM; ARC research foundation against cancer	Paris Descartes University; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ARC research foundation against cancer(Australian Research Council)	We gratefully acknowledge the Canceropole IdF funding source that made Yoann Schumacher PhD work possible. Otherwise, the studies were supported by grants from the Paris Descartes University, INSERM and the ARC research foundation against cancer. The authors are indebted to the Cochin Institute Transcriptomic Facility for technical help. The authors also thank (i) J Mathieu (Institut Cochin, Inserm U1016, Paris, France) for providing mouse BM-derived macrophage-conditioned media, (ii) Y Attie and D Vignjevic for providing human cancer associated fibroblasts conditioned media (Institut Curie, UMR144, Paris, France) and (ii) Ono Pharmaceutical Co. Ltd (Osaka, Japan) for providing PGE2 receptor subtype agonists. The authors are grateful to AF. Burnol (Institut Cochin, Inserm U1016, Paris, France), J Lebihan and M Legall (Centre de Recherche sur l'Inflammation Paris Montmartre, Inserm UMRS 1149, Paris, France), M Moldes (INSERM UMRS 938, Paris, France) and S Thenet (Centre de Recherche des Cordeliers, UMRS 1138, Paris, France) for critical reading of the manuscript.	Altarejos JY, 2008, NAT MED, V14, P1112, DOI 10.1038/nm.1866; Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072; Alvarez Y, 2009, J IMMUNOL, V183, P1471, DOI 10.4049/jimmunol.0900312; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Breuillaud L, 2012, BIOL PSYCHIAT, V72, P528, DOI 10.1016/j.biopsych.2012.04.011; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; Cao Chunxia, 2015, J Natl Cancer Inst, V107, P358, DOI 10.1093/jnci/dju358; Ch'ng TH, 2012, CELL, V150, P207, DOI 10.1016/j.cell.2012.05.027; Chell S, 2006, BBA-REV CANCER, V1766, P104, DOI 10.1016/j.bbcan.2006.05.002; Chen QH, 2013, ADV MECH ENG, DOI 10.1155/2013/589156; Choong E, 2013, JAMA PSYCHIAT, V70, P1011, DOI 10.1001/jamapsychiatry.2013.187; Clark K, 2012, P NATL ACAD SCI USA, V109, P16986, DOI 10.1073/pnas.1215450109; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; de Leng WWJ, 2003, CLIN CANCER RES, V9, P3065; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Eberhard CE, 2013, ENDOCRINOLOGY, V154, P2308, DOI 10.1210/en.2012-2088; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; Feng Y, 2012, CANCER RES, V72, P6502, DOI 10.1158/0008-5472.CAN-12-1909; Finsterwald C, 2011, EUR J NEUROSCI, V34, P1053, DOI 10.1111/j.1460-9568.2011.07839.x; Galizia G, 2002, CLIN IMMUNOL, V102, P169, DOI 10.1006/clim.2001.5163; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Gunderson LL, 2010, J CLIN ONCOL, V28, P264, DOI 10.1200/JCO.2009.24.0952; Guzman Michael J, 2013, J Gastrointest Cancer, V44, P211, DOI 10.1007/s12029-012-9474-2; Holla VR, 2011, J BIOL CHEM, V286, P30003, DOI 10.1074/jbc.M110.184697; Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Kim SJ, 2008, MOL CELL BIOL, V28, P1644, DOI 10.1128/MCB.00325-07; Komiya T, 2010, ONCOGENE, V29, P1672, DOI 10.1038/onc.2009.453; Konstantinopoulos PA, 2007, CELL ONCOL, V29, P477; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; Kucharzik T, 1997, CLIN EXP IMMUNOL, V110, P296; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Li B, 2014, MUCOSAL IMMUNOL, V7, P869, DOI 10.1038/mi.2013.103; Liu Y, 2008, NATURE, V456, P269, DOI 10.1038/nature07349; MacKenzie KF, 2013, J IMMUNOL, V190, P565, DOI 10.4049/jimmunol.1202462; Mocellin S, 2005, J LEUKOCYTE BIOL, V78, P1043, DOI 10.1189/jlb.0705358; Muraoka M, 2009, AM J PHYSIOL-ENDOC M, V296, pE1430, DOI 10.1152/ajpendo.00024.2009; Nagasaki T, 2014, BRIT J CANCER, V110, P469, DOI 10.1038/bjc.2013.748; Park SW, 2011, J PHARMACOL EXP THER, V336, P516, DOI 10.1124/jpet.110.173278; Rasmuson A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029331; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; Sakamoto K, 2013, J NEUROSCI, V33, P9021, DOI 10.1523/JNEUROSCI.4202-12.2013; Samarajeewa NU, 2013, HORM CANCER-US, V4, P233, DOI 10.1007/s12672-013-0142-1; Sekeres MJ, 2012, J NEUROSCI, V32, P17857, DOI 10.1523/JNEUROSCI.1419-12.2012; Shouval DS, 2014, ADV IMMUNOL, V122, P177, DOI 10.1016/B978-0-12-800267-4.00005-5; Sinicrope FA, 1999, GASTROENTEROLOGY, V117, P350, DOI 10.1053/gast.1999.0029900350; Siu YT, 2008, MOL BIOL CELL, V19, P4750, DOI 10.1091/mbc.E08-04-0369; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Takeda H, 2004, BRIT J CANCER, V90, P701, DOI 10.1038/sj.bjc.6601584; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103; Yamada Y, 2007, CANCER SCI, V98, P6, DOI 10.1111/j.1349-7006.2006.00348.x; Zagani R, 2009, GASTROENTEROLOGY, V137, P1358, DOI 10.1053/j.gastro.2009.06.039	59	27	28	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2602	2614		10.1038/onc.2015.283	http://dx.doi.org/10.1038/onc.2015.283			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26300003				2022-12-28	WOS:000376165700007
J	Gkouskou, KK; Ioannou, M; Pavlopoulos, GA; Georgila, K; Siganou, A; Nikolaidis, G; Kanellis, DC; Moore, S; Papadakis, KA; Kardassis, D; Iliopoulos, I; McDyer, FA; Drakos, E; Eliopoulos, AG				Gkouskou, K. K.; Ioannou, M.; Pavlopoulos, G. A.; Georgila, K.; Siganou, A.; Nikolaidis, G.; Kanellis, D. C.; Moore, S.; Papadakis, K. A.; Kardassis, D.; Iliopoulos, I.; McDyer, F. A.; Drakos, E.; Eliopoulos, A. G.			Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis	ONCOGENE			English	Article							INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; TUMOR-DEVELOPMENT; MIMETIC PEPTIDES; MOUSE MODELS; COLON-CANCER; PROGRESSION; MICE; IL-6; EXPRESSION	In both humans with long-standing ulcerative colitis and mouse models of colitis-associated carcinogenesis (CAC), tumors develop predominantly in the distal part of the large intestine but the biological basis of this intriguing pathology remains unknown. Herein we report intrinsic differences in gene expression between proximal and distal colon in the mouse, which are augmented during dextran sodium sulfate (DSS)/azoxymethane (AOM)-induced CAC. Functional enrichment of differentially expressed genes identified discrete biological pathways operating in proximal vs distal intestine and revealed a cluster of genes involved in lipid metabolism to be associated with the disease-resistant proximal colon. Guided by this finding, we have further interrogated the expression and function of one of these genes, apolipoprotein A-I (ApoA-I), a major component of high-density lipoprotein. We show that ApoA-I is expressed at higher levels in the proximal compared with the distal part of the colon and its ablation in mice results in exaggerated DSS-induced colitis and disruption of epithelial architecture in larger areas of the large intestine. Conversely, treatment with an ApoA-I mimetic peptide ameliorated the phenotypic, histopathological and inflammatory manifestations of the disease. Genetic interference with ApoA-I levels in vivo impacted on the number, size and distribution of AOM/DSS-induced colon tumors. Mechanistically, ApoA-I was found to modulate signal transducer and activator of transcription 3 (STAT3) and nuclear factor-kappa B activation in response to the bacterial product lipopolysaccharide with concomitant impairment in the production of the pathogenic cytokine interleukin-6. Collectively, these data demonstrate a novel protective role for ApoA-I in colitis and CAC and unravel an unprecedented link between lipid metabolic processes and intestinal pathologies.	[Gkouskou, K. K.; Georgila, K.; Siganou, A.; Nikolaidis, G.; Kanellis, D. C.; Eliopoulos, A. G.] Univ Crete, Sch Med, Mol & Cellular Biol Lab, Div Basic Sci, Iraklion 71003, Crete, Greece; [Ioannou, M.; Kardassis, D.; Eliopoulos, A. G.] Fdn Res & Technol Hellas FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece; [Pavlopoulos, G. A.; Iliopoulos, I.] Univ Crete, Sch Med, Div Basic Sci, Bioinformat & Computat Biol Lab, Iraklion 71003, Crete, Greece; [Moore, S.; McDyer, F. A.] Almac Diagnost, Craigavon, North Ireland; [Papadakis, K. A.] Univ Crete, Sch Med, Dept Gastroenterol, Iraklion 71003, Crete, Greece; [Papadakis, K. A.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Kardassis, D.] Univ Crete, Sch Med, Div Basic Sci, Lab Biochem, Iraklion 71003, Crete, Greece; [Drakos, E.] Univ Crete, Sch Med, Dept Pathol, Iraklion 71003, Crete, Greece	University of Crete; University of Crete; University of Crete; Mayo Clinic; University of Crete; University of Crete	Eliopoulos, AG (corresponding author), Univ Crete, Sch Med, Mol & Cellular Biol Lab, Div Basic Sci, Iraklion 71003, Crete, Greece.	eliopag@med.uoc.gr	Gkouskou, Kalliopi/AAY-4666-2021; Kanellis, Dimitrios/AHB-0318-2022; Pavlopoulos, Georgios A./L-7544-2017; ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	Kanellis, Dimitrios/0000-0001-8690-2010; Pavlopoulos, Georgios A./0000-0002-4577-8276; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761	European Commission (EC) [223151]; Almac Diagnostics; EC [285948]	European Commission (EC)(European CommissionEuropean Commission Joint Research Centre); Almac Diagnostics; EC(European CommissionEuropean Commission Joint Research Centre)	We thank Dimitra Vyrla (University of Crete Medical School), Triantafyllos Liloglou (University of Liverpool) and Maria Denis (Biomedcode Hellas SA) for helpful discussions. This work was supported by the European Commission (EC) research program Inflammation and Cancer Research in Europe (INFLA-CARE; EC contract number 223151) to AGE and Almac Diagnostics and the EC REGPOT support program Translational Potential (TransPOT; EC contract number 285948) to AGE, KP, II and DK.	Basque JR, 1998, J CELL BIOCHEM, V70, P354, DOI 10.1002/(SICI)1097-4644(19980901)70:3<354::AID-JCB9>3.3.CO;2-8; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Bersudsky M, 2014, GUT, V63, P598, DOI 10.1136/gutjnl-2012-303329; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bonn V, 2002, ATHEROSCLEROSIS, V163, P59; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; CHOI PM, 1993, GASTROENTEROLOGY, V104, P666, DOI 10.1016/0016-5085(93)90455-L; COOPER HS, 1993, LAB INVEST, V69, P238; Cooper HS, 2000, CARCINOGENESIS, V21, P757, DOI 10.1093/carcin/21.4.757; Danese S, 2010, ONCOGENE, V29, P3313, DOI 10.1038/onc.2010.109; Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385; Do RQ, 2014, EMBO MOL MED, V6, P1215, DOI 10.15252/emmm.201404000; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Eyking A, 2011, GASTROENTEROLOGY, V141, P2154, DOI 10.1053/j.gastro.2011.08.043; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Gkouskou KK, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00028; Goldstone R, 2012, INFLAMM BOWEL DIS, V18, P832, DOI 10.1002/ibd.21809; Goldstone R, 2011, GASTROINTEST ENDOSC, V74, P1087, DOI 10.1016/j.gie.2011.06.028; Greenhill CJ, 2011, J IMMUNOL, V186, P1199, DOI 10.4049/jimmunol.1002971; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Gupta H, 2005, CIRC RES, V97, P236, DOI 10.1161/01.RES.0000176530.66400.48; Gupta J, 2014, CANCER CELL, V25, P484, DOI 10.1016/j.ccr.2014.02.019; Haberman Y, 2014, J CLIN INVEST, V124, P3617, DOI 10.1172/JCI75436; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Kanagarajan N, 2008, INFLAMM RES, V57, P34, DOI 10.1007/s00011-007-6177-4; Laroui H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032084; Ma J, 2004, ACTA BIOCH BIOPH SIN, V36, P419, DOI 10.1093/abbs/36.6.419; Mahler M, 1998, AM J PHYSIOL-GASTR L, V274, pG544, DOI 10.1152/ajpgi.1998.274.3.G544; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; MILLER JCE, 1983, P NATL ACAD SCI-BIOL, V80, P1511, DOI 10.1073/pnas.80.6.1511; Mudter J, 2007, INFLAMM BOWEL DIS, V13, P1016, DOI 10.1002/ibd.20148; Navab M, 2005, CIRC RES, V97, P1085, DOI 10.1161/01.RES.0000194558.86099.ba; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1426, DOI 10.1161/01.ATV.0000167412.98221.1a; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; Navab M, 2006, NAT CLIN PRACT CARD, V3, P540, DOI 10.1038/ncpcardio0661; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Ou JS, 2005, CIRC RES, V97, P1190, DOI 10.1161/01.RES.0000190634.60042.cb; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Ramasamy I, 2014, CLIN CHEM LAB MED, V52, P1695, DOI 10.1515/cclm-2013-0358; Rubin DC, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00107; Smythies LE, 2010, AM J PHYSIOL-CELL PH, V298, pC1538, DOI 10.1152/ajpcell.00467.2009; Su F, 2012, MOL CANCER THER, V11, P1311, DOI 10.1158/1535-7163.MCT-11-0905; Su F, 2010, P NATL ACAD SCI USA, V107, P19997, DOI 10.1073/pnas.1009010107; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; van Duijnhoven FJB, 2011, GUT, V60, P1094, DOI 10.1136/gut.2010.225011; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; WU AL, 1979, J BIOL CHEM, V254, P7316; Yan YT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006073	53	31	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2496	2505		10.1038/onc.2015.307	http://dx.doi.org/10.1038/onc.2015.307			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279300	Bronze			2022-12-28	WOS:000376165500008
J	Sveen, A; Kilpinen, S; Ruusulehto, A; Lothe, RA; Skotheim, RI				Sveen, A.; Kilpinen, S.; Ruusulehto, A.; Lothe, R. A.; Skotheim, R. I.			Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; TYROSINE KINASE INHIBITORS; MESSENGER-RNA; SOMATIC MUTATIONS; RECURRENT MUTATIONS; HUMAN TRANSCRIPTOME; ANTITUMOR-ACTIVITY; TUMOR-SUPPRESSOR; HUMAN TISSUES	Alternative splicing is a widespread process contributing to structural transcript variation and proteome diversity. In cancer, the splicing process is commonly disrupted, resulting in both functional and non-functional end-products. Cancer-specific splicing events are known to contribute to disease progression; however, the dysregulated splicing patterns found on a genome-wide scale have until recently been less well-studied. In this review, we provide an overview of aberrant RNA splicing and its regulation in cancer. We then focus on the executors of the splicing process. Based on a comprehensive catalog of splicing factor encoding genes and analyses of available gene expression and somatic mutation data, we identify cancer-associated patterns of dysregulation. Splicing factor genes are shown to be significantly differentially expressed between cancer and corresponding normal samples, and to have reduced inter-individual expression variation in cancer. Furthermore, we identify enrichment of predicted cancer-critical genes among the splicing factors. In addition to previously described oncogenic splicing factor genes, we propose 24 novel cancer-critical splicing factors predicted from somatic mutations.	[Sveen, A.; Lothe, R. A.; Skotheim, R. I.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Mol Oncol, POB 4953, NO-0424 Oslo, Norway; [Sveen, A.; Lothe, R. A.; Skotheim, R. I.] Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, NO-0424 Oslo, Norway; [Sveen, A.; Lothe, R. A.; Skotheim, R. I.] Univ Oslo, Fac Med, Ctr Canc Biomed, Oslo, Norway; [Kilpinen, S.; Ruusulehto, A.] MediSapiens Ltd, Helsinki, Finland	University of Oslo; University of Oslo; University of Oslo	Skotheim, RI (corresponding author), Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Mol Oncol, POB 4953, NO-0424 Oslo, Norway.	rolf.i.skotheim@rr-research.no	Skotheim, Rolf I./H-6192-2017	Skotheim, Rolf I./0000-0002-5609-4048; Lothe, Ragnhild A./0000-0002-1693-1032; Sveen, Anita/0000-0001-8219-6251	Southern and Eastern Norway Regional Health Authority (Research Grant 'Genome Medicine of Colorectal Cancer') [2011024]; Norwegian Cancer Society [PR-2007-0166, PR-2006-0442]; KG Jebsen foundation; Research Council of Norway [179571]	Southern and Eastern Norway Regional Health Authority (Research Grant 'Genome Medicine of Colorectal Cancer'); Norwegian Cancer Society(Norwegian Cancer Society); KG Jebsen foundation; Research Council of Norway(Research Council of Norway)	This study was supported by the Southern and Eastern Norway Regional Health Authority (Research Grant 'Genome Medicine of Colorectal Cancer', project number 2011024), the Norwegian Cancer Society (PR-2007-0166 and PR-2006-0442), the KG Jebsen foundation and the Research Council of Norway through its Centres of Excellence funding scheme (project number 179571).	Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306; Adler AS, 2014, GENE DEV, V28, P1068, DOI 10.1101/gad.237206.113; Agrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Albert FW, 2015, NAT REV GENET, V16, P197, DOI 10.1038/nrg3891; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Astrof S, 2009, ANGIOGENESIS, V12, P165, DOI 10.1007/s10456-009-9136-6; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489; Barash Y, 2010, NATURE, V465, P53, DOI 10.1038/nature09000; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223; Bauman J, 2009, OLIGONUCLEOTIDES, V19, P1, DOI 10.1089/oli.2008.0161; Bauman John A, 2011, Bioeng Bugs, V2, P125; Bauman JA, 2010, NUCLEIC ACIDS RES, V38, P8348, DOI 10.1093/nar/gkq731; Bemmo A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-529; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Birzele F, 2015, CLIN CANCER RES, V21, P2753, DOI 10.1158/1078-0432.CCR-14-2141; Bland CS, 2010, NUCLEIC ACIDS RES, V38, P7651, DOI 10.1093/nar/gkq614; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Blencowe BJ, 2000, RNA, V6, P111, DOI 10.1017/S1355838200991982; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boutz PL, 2007, GENE DEV, V21, P71, DOI 10.1101/gad.1500707; Braeutigam C, 2014, ONCOGENE, V33, P1082, DOI 10.1038/onc.2013.50; Bria E, 2014, ONCOTARGET, V5, P11054, DOI 10.18632/oncotarget.2609; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; Brock A, 2009, NAT REV GENET, V10, P336, DOI 10.1038/nrg2556; Brooks AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087361; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carter H, 2009, CANCER RES, V69, P6660, DOI 10.1158/0008-5472.CAN-09-1133; Chen HH, 2006, MOL CELL BIOL, V26, P2736, DOI 10.1128/MCB.26.7.2736-2745.2006; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; Chen L, 2011, HUM MOL GENET, V20, P4422, DOI 10.1093/hmg/ddr370; Choi JW, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001351; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Clark TA, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r64; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Cohen-Eliav M, 2013, J PATHOL, V229, P630, DOI 10.1002/path.4129; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dales JP, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-44; Dao T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005661; Dardenne E, 2012, NAT STRUCT MOL BIOL, V19, P1139, DOI 10.1038/nsmb.2390; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DeBoever C, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004105; Dees ND, 2012, GENOME RES, V22, P1589, DOI 10.1101/gr.134635.111; Dehm SM, 2013, CANCER RES, V73, P5309, DOI 10.1158/0008-5472.CAN-13-0444; Ding L, 2010, HUM MOL GENET, V19, pR188, DOI 10.1093/hmg/ddq391; Dixon RJ, 2007, BIOINFORMATICS, V23, P150, DOI 10.1093/bioinformatics/btl575; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Dorman SN, 2014, SCI REP-UK, V4, DOI 10.1038/srep07063; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9; Ecker S, 2015, GENOME MED, V7, DOI 10.1186/s13073-014-0125-z; Elliott DJ, 2006, REPRODUCTION, V132, P811, DOI 10.1530/REP-06-0147; Engstrom PG, 2013, NAT METHODS, V10, P1185, DOI [10.1038/NMETH.2722, 10.1038/nmeth.2722]; Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689; Fackenthal JD, 2008, DIS MODEL MECH, V1, P37, DOI 10.1242/dmm.000331; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Feltes CM, 2002, CANCER RES, V62, P6688; Femel J, 2014, ONCOTARGET, V5, P12418, DOI 10.18632/oncotarget.2628; Feng SJ, 1997, CANCER RES, V57, P5369; Ferrarese R, 2014, J CLIN INVEST, V124, P2861, DOI 10.1172/JCI68836; Ferreira PG, 2014, GENOME RES, V24, P212, DOI 10.1101/gr.152132.112; Finta C, 2000, GENOMICS, V63, P433, DOI 10.1006/geno.1999.6063; Flouriot G, 2002, J BIOL CHEM, V277, P26244, DOI 10.1074/jbc.M203513200; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; French PJ, 2007, CANCER RES, V67, P5635, DOI 10.1158/0008-5472.CAN-06-2869; Fu XD, 2014, NAT REV GENET, V15, P689, DOI 10.1038/nrg3778; Furney SJ, 2013, CANCER DISCOV, V3, P1122, DOI 10.1158/2159-8290.CD-13-0330; Fushimi K, 2008, P NATL ACAD SCI USA, V105, P15708, DOI 10.1073/pnas.0805569105; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gaffney DJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003501; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; Gardina PJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-325; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Gonsalvez GB, 2007, J CELL BIOL, V178, P733, DOI 10.1083/jcb.200702147; Gonzalez-Perez A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks743; Gonzalez-Porta M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r70; Goransson M, 2009, ONCOGENE, V28, P270, DOI 10.1038/onc.2008.378; Goswami S, 2009, CLIN EXP METASTAS, V26, P153, DOI 10.1007/s10585-008-9225-8; Graubert TA, 2012, NAT GENET, V44, P53, DOI 10.1038/ng.1031; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Grosso AR, 2008, NUCLEIC ACIDS RES, V36, P4823, DOI 10.1093/nar/gkn463; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Guo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062729; Hahn CN, 2015, IMMUNOL REV, V263, P257, DOI 10.1111/imr.12241; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hartel M, 2008, EUR J CANCER, V44, P1895, DOI 10.1016/j.ejca.2008.06.030; Hatami R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004688; He CJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004732; Himeji D, 2002, BLOOD, V99, P4070, DOI 10.1182/blood.V99.11.4070; Hirschi B, 2013, INT J CANCER, V133, P590, DOI 10.1002/ijc.28061; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hong J, 2014, CANCER RES, V74, P1845, DOI 10.1158/0008-5472.CAN-13-2104; Hooper JE, 2014, HUM GENOMICS, V8, DOI 10.1186/1479-7364-8-3; Horowitz DS, 2002, EMBO J, V21, P470, DOI 10.1093/emboj/21.3.470; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Huelga SC, 2012, CELL REP, V1, P167, DOI 10.1016/j.celrep.2012.02.001; Iacobucci I, 2008, BLOOD, V112, P3847, DOI 10.1182/blood-2007-09-112631; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Ji HB, 2006, P NATL ACAD SCI USA, V103, P7817, DOI 10.1073/pnas.0510284103; Jia PL, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0489-9; Jiang SW, 2013, INT J MOL SCI, V14, P22655, DOI 10.3390/ijms141122655; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Johnston JJ, 2010, AM J HUM GENET, V86, P743, DOI 10.1016/j.ajhg.2010.04.007; Kalyana-Sundaram S, 2012, NEOPLASIA, V14, P702, DOI 10.1593/neo.12914; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kato M, 2012, CANCER SCI, V103, P1363, DOI 10.1111/j.1349-7006.2012.02298.x; Kelemen O, 2013, GENE, V514, P1, DOI 10.1016/j.gene.2012.07.083; Kikuta K, 2012, J PROTEOMICS, V75, P1089, DOI 10.1016/j.jprot.2011.10.005; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kim Yun-Ji, 2012, Genomics & Informatics, V10, P74, DOI 10.5808/GI.2012.10.2.74; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Konno R, 2000, CLIN CANCER RES, V6, P3576; Koscielny G, 2009, GENOMICS, V93, P213, DOI 10.1016/j.ygeno.2008.11.003; Koslowski M, 2002, CANCER RES, V62, P6750; Krawczak M, 2007, HUM MUTAT, V28, P150, DOI 10.1002/humu.20400; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Ladomery Michael, 2013, Int J Cell Biol, V2013, P463786, DOI 10.1155/2013/463786; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531; Lapuk A, 2010, MOL CANCER RES, V8, P961, DOI 10.1158/1541-7786.MCR-09-0528; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee JH, 2003, CANCER RES, V63, P7247; Lee TK, 2011, J CLIN INVEST, V121, P880, DOI 10.1172/JCI40433; LeFave CV, 2011, EMBO J, V30, P4084, DOI 10.1038/emboj.2011.259; Lenos K, 2012, CANCER RES, V72, P4074, DOI 10.1158/0008-5472.CAN-12-0215; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Li H, 2008, SCIENCE, V321, P1357, DOI 10.1126/science.1156725; Li ZM, 2013, CANCER LETT, V328, P278, DOI 10.1016/j.canlet.2012.09.026; Lin KT, 2014, ONCOGENE, V33, P4786, DOI 10.1038/onc.2013.424; Listerman I, 2013, CANCER RES, V73, P2817, DOI 10.1158/0008-5472.CAN-12-3082; Liu JF, 2012, GENOME RES, V22, P2315, DOI 10.1101/gr.140988.112; Lokody I, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3753; Lovf M, 2014, INT J CANCER, V135, P2077, DOI 10.1002/ijc.28855; Lovf M, 2011, GENE CHROMOSOME CANC, V50, P348, DOI 10.1002/gcc.20860; Lu J, 2015, NAT REV UROL, V12, P137, DOI 10.1038/nrurol.2015.13; Lu XW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3124; Lukas J, 2001, CANCER RES, V61, P3212; Ma YL, 2005, STRUCTURE, V13, P883, DOI 10.1016/j.str.2005.03.014; Marcel V, 2014, CELL DEATH DIFFER, V21, P1377, DOI 10.1038/cdd.2014.73; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Matos P, 2008, MOL CANCER RES, V6, P1178, DOI 10.1158/1541-7786.MCR-08-0008; Matsuda Y, 2012, MOL CANCER THER, V11, P2010, DOI 10.1158/1535-7163.MCT-12-0243; Mazin P, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.67; McGlincy NJ, 2008, TRENDS BIOCHEM SCI, V33, P385, DOI 10.1016/j.tibs.2008.06.001; Melamud E, 2009, NUCLEIC ACIDS RES, V37, P4873, DOI 10.1093/nar/gkp471; Mele M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355; Miura K, 2012, CARCINOGENESIS, V33, P2311, DOI 10.1093/carcin/bgs347; Moscatello DK, 1996, ONCOGENE, V13, P85; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nacu S, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-11; Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638; Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Oscier DG, 2013, BLOOD, V121, P468, DOI 10.1182/blood-2012-05-429282; Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3; Palve V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111927; Pan DS, 2012, BIOCHEM BIOPH RES CO, V422, P727, DOI 10.1016/j.bbrc.2012.05.070; Pan Q, 2004, MOL CELL, V16, P929, DOI 10.1016/j.molcel.2004.12.004; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Parada GE, 2014, NUCLEIC ACIDS RES, V42, P10564, DOI 10.1093/nar/gku744; Park SJ, 2001, BIOCHEM BIOPH RES CO, V289, P1205, DOI 10.1006/bbrc.2001.6086; Pickrell JK, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001236; Pieter A, 2012, CANCER BIOL THER, V13, P1185, DOI 10.4161/cbt.21348; Planque C, 2010, CLIN CHEM, V56, P987, DOI 10.1373/clinchem.2009.138917; Plowman SJ, 2006, J EXP CLIN CANC RES, V25, P259; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Pruitt KD, 2009, GENOME RES, V19, P1316, DOI 10.1101/gr.080531.108; Przychodzen B, 2013, BLOOD, V122, P999, DOI 10.1182/blood-2013-01-480970; Qian J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045760; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ramalingam Satish, 2012, Immunogastroenterology, V1, P27; Reimand J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.68; Renkonen E, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.017269; Revenkova E, 2009, HUM MOL GENET, V18, P418, DOI 10.1093/hmg/ddn369; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rossi D, 2011, BLOOD, V118, P6904, DOI 10.1182/blood-2011-08-373159; Rouas-Freiss N, 2005, INT J CANCER, V117, P114, DOI 10.1002/ijc.21151; Rubio-Perez C, 2015, CANCER CELL, V27, P382, DOI 10.1016/j.ccell.2015.02.007; Ryan MC, 2012, BIOINFORMATICS, V28, P2385, DOI 10.1093/bioinformatics/bts452; Safa Ahmad R, 2011, Cancers (Basel), V3, P1639, DOI 10.3390/cancers3021639; Sahin U, 2008, CLIN CANCER RES, V14, P7624, DOI 10.1158/1078-0432.CCR-08-1547; Saltzman AL, 2011, GENE DEV, V25, P373, DOI 10.1101/gad.2004811; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Samatov TR, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-107; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schubert EL, 1997, HUM GENET, V100, P557, DOI 10.1007/s004390050551; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Scott LM, 2013, JNCI-J NATL CANCER I, V105, P1540, DOI 10.1093/jnci/djt257; Sebestyen E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392; Shao CW, 2014, NAT STRUCT MOL BIOL, V21, P997, DOI 10.1038/nsmb.2906; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shehadeh LA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009104; Shieh JJ, 2009, J INVEST DERMATOL, V129, P2497, DOI 10.1038/jid.2009.83; Shirai CL, 2015, CANCER CELL, V27, P631, DOI 10.1016/j.ccell.2015.04.008; Shitashige M, 2007, GASTROENTEROLOGY, V132, P1039, DOI 10.1053/j.gastro.2007.01.007; Silipo M, 2015, J MOL CELL BIOL; Singh R, 2005, NAT STRUCT MOL BIOL, V12, P645, DOI 10.1038/nsmb961; Singh RK, 2012, TRENDS MOL MED, V18, P472, DOI 10.1016/j.molmed.2012.06.006; Skotheim RI, 2007, INT J BIOCHEM CELL B, V39, P1432, DOI 10.1016/j.biocel.2007.02.016; Stark M, 2009, BLOOD, V113, P4362, DOI 10.1182/blood-2008-08-173799; Sterne-Weiler T, 2014, GENOME BIOL, V15, DOI 10.1186/gb4150; Sugiura T, 2007, CANCER BIOL THER, V6, P957, DOI 10.4161/cbt.6.6.4192; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Surget S, 2014, ONCOTARGETS THER, V7, P57, DOI 10.2147/OTT.S53876; Sveen A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-672; Sveen A, 2012, INT J CANCER, V131, P1479, DOI 10.1002/ijc.27399; Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248; Talwar S, 2013, RNA BIOL, V10, P277, DOI 10.4161/rna.23315; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Tamborero D, 2013, BIOINFORMATICS, V29, P2238, DOI 10.1093/bioinformatics/btt395; Tanackovic G, 2005, MOL BIOL CELL, V16, P1366, DOI 10.1091/mbc.E04-11-1034; Thomas M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1500-x; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Thorsen K, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002998; Tilgner H, 2015, NAT BIOTECHNOL, V33, P736, DOI 10.1038/nbt.3242; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Tomsic J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10566; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Uckun FM, 2015, INTEGR BIOL-UK, V7, P237, DOI 10.1039/c4ib00221k; Ullrich N, 2015, CANCER RES, V75, P1897, DOI 10.1158/0008-5472.CAN-14-1752; Valles I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042086; van Doorn R, 2002, CANCER RES, V62, P5389; Vauchy C, 2015, INT J CANCER, V137, P116, DOI 10.1002/ijc.29366; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Venables JP, 2013, MOL CELL BIOL, V33, P396, DOI 10.1128/MCB.01174-12; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Vivas-Mejia PE, 2011, CLIN CANCER RES, V17, P3716, DOI 10.1158/1078-0432.CCR-11-0233; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Vudattu NK, 2009, GENES IMMUN, V10, P132, DOI 10.1038/gene.2008.90; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Waks Z, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.32; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Wang H, 2011, NEOPLASIA, V13, P461, DOI 10.1593/neo.101744; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Wang XQ, 2005, CLIN CANCER RES, V11, P483; Wang Y, 2014, CANCER CELL, V26, P374, DOI 10.1016/j.ccr.2014.07.010; Wang YB, 2013, EMBO MOL MED, V5, P1431, DOI 10.1002/emmm.201302663; Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Wegran F, 2006, CLIN CANCER RES, V12, P5794, DOI 10.1158/1078-0432.CCR-06-0725; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Weischenfeldt J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-5-r35; Wheeler DA, 2013, GENOME RES, V23, P1054, DOI 10.1101/gr.157602.113; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Wong MS, 2014, TRENDS GENET, V30, P430, DOI 10.1016/j.tig.2014.07.006; Wong MS, 2013, CELL REP, V3, P1028, DOI 10.1016/j.celrep.2013.03.011; Xi LQ, 2008, NUCLEIC ACIDS RES, V36, P6535, DOI 10.1093/nar/gkn697; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Xu WH, 2011, P NATL ACAD SCI USA, V108, P3707, DOI 10.1073/pnas.1019753108; Yadav SP, 2014, HUM MOL GENET, V23, P2132, DOI 10.1093/hmg/ddt609; Yan Y, 2015, STEM CELLS TRANSL ME; Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800; Yeo G, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r74; Yi YJ, 2009, MOL CYTOGENET, V2, DOI 10.1186/1755-8166-2-18; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Zammarchi F, 2011, P NATL ACAD SCI USA, V108, P17779, DOI 10.1073/pnas.1108482108; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhao Q, 2013, CLIN CANCER RES, V19, P2460, DOI 10.1158/1078-0432.CCR-12-3708; Zhao S, 2014, TRANSL ONCOL, V7, P429, DOI 10.1016/j.tranon.2014.04.001; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99	287	298	306	2	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2413	2427		10.1038/onc.2015.318	http://dx.doi.org/10.1038/onc.2015.318			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26300000				2022-12-28	WOS:000376165500001
J	Meads, MB; Fang, B; Mathews, L; Gemmer, J; Nong, L; Rosado-Lopez, I; Nguyen, T; Ring, JE; Matsui, W; MacLeod, AR; Pachter, JA; Hazlehurst, LA; Koomen, JM; Shain, KH				Meads, M. B.; Fang, B.; Mathews, L.; Gemmer, J.; Nong, L.; Rosado-Lopez, I.; Nguyen, T.; Ring, J. E.; Matsui, W.; MacLeod, A. R.; Pachter, J. A.; Hazlehurst, L. A.; Koomen, J. M.; Shain, K. H.			Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma	ONCOGENE			English	Article							BONE-MARROW MICROENVIRONMENT; NOVO DRUG-RESISTANCE; TYROSINE KINASE PYK2; KAPPA-B; GROWTH-FACTOR; CANCER-CELLS; LUNG-CANCER; ACTIVATION; THERAPY; INHIBITION	Multiple myeloma (MM) remains an incurable malignancy due, in part, to the influence of the bone marrow microenvironment on survival and drug response. Identification of microenvironment-specific survival signaling determinants is critical for the rational design of therapy and elimination of MM. Previously, we have shown that collaborative signaling between beta(1) integrin-mediated adhesion to fibronectin and interleukin-6 confers a more malignant phenotype via amplification of signal transducer and activator of transcription 3 (STAT3) activation. Further characterization of the events modulated under these conditions with quantitative phosphotyrosine profiling identified 193 differentially phosphorylated peptides. Seventy-seven phosphorylations were upregulated upon adhesion, including PYK2/FAK2, Paxillin, CASL and p130CAS consistent with focal adhesion (FA) formation. We hypothesized that the collaborative signaling between beta(1) integrin and gp130 (IL-6 beta receptor, IL-6 signal transducer) was mediated by FA formation and proline-rich tyrosine kinase 2 (PYK2) activity. Both pharmacological and molecular targeting of PYK2 attenuated the amplification of STAT3 phosphorylation under co-stimulatory conditions. Co-culture of MM cells with patient bone marrow stromal cells (BMSC) showed similar beta(1) integrin-specific enhancement of PYK2 and STAT3 signaling. Molecular and pharmacological targeting of PYK2 specifically induced cell death and reduced clonogenic growth in BMSC-adherent myeloma cell lines, aldehyde dehydrogenase-positive MM cancer stem cells and patient specimens. Finally, PYK2 inhibition similarly attenuated MM progression in vivo. These data identify a novel PYK2-mediated survival pathway in MM cells and MM cancer stem cells within the context of microenvironmental cues, providing preclinical support for the use of the clinical stage FAK/PYK2 inhibitors for treatment of MM, especially in a minimal residual disease setting.	[Meads, M. B.; Mathews, L.; Gemmer, J.; Nong, L.; Rosado-Lopez, I.; Nguyen, T.; Shain, K. H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Chem Biol & Mol Med Program, Tampa, FL 33612 USA; [Meads, M. B.; Mathews, L.; Gemmer, J.; Nong, L.; Rosado-Lopez, I.; Nguyen, T.; Shain, K. H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, 12902 Magnolia Dr SRB2, Tampa, FL 33612 USA; [Fang, B.; Koomen, J. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Prote Core Facil, Tampa, FL 33612 USA; [Ring, J. E.; Pachter, J. A.] Verastem Inc, Needham, MA USA; [Matsui, W.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [MacLeod, A. R.] ISIS Pharmaceut, Carlsbad, CA USA; [Hazlehurst, L. A.; Koomen, J. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; Isis Pharmaceuticals Inc; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Shain, KH (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, 12902 Magnolia Dr SRB2, Tampa, FL 33612 USA.	ken.shain@moffitt.org			Florida Department of Health Bankhead-Coley Team Science Program grant [2BT03]; US Army Medical Research and Materiel Command for a National Functional Genomics Center [W81XWH-08-2-0101]; National Cancer Institute as a Cancer Center Support Grant [P30-CA076292]; Moffitt Foundation; NATIONAL CANCER INSTITUTE [P30CA076292, K24CA198315, R01CA174951, P30CA006973, R01CA193887] Funding Source: NIH RePORTER	Florida Department of Health Bankhead-Coley Team Science Program grant; US Army Medical Research and Materiel Command for a National Functional Genomics Center; National Cancer Institute as a Cancer Center Support Grant; Moffitt Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jianguo Tao and William S Dalton for helpful discussions and critical reading of the manuscript. This work was supported by Florida Department of Health Bankhead-Coley Team Science Program grant 2BT03 (to KSH and LHA). The Moffitt Proteomics Facility is supported by the US Army Medical Research and Materiel Command under Award W81XWH-08-2-0101 for a National Functional Genomics Center, the National Cancer Institute under Award P30-CA076292 as a Cancer Center Support Grant and the Moffitt Foundation. Patient specimens were obtained from the Total Cancer Care program at Moffitt Cancer Center. Patient specimen collection, phosphoproteome mapping and flow cytometry were performed by the Translational Research, Proteomics and Flow Cytometry Core facilities at Moffitt Cancer Center. Antisense oligonucleotides were provided by Isis Pharmaceuticals (Carlsbad, CA, USA). The focal adhesion kinase inhibitors VS-6062, VS-6063 (defactinib), and VS-4718 were provided by Verastem, Inc. (Needham, MA, USA).	[Anonymous], 2012, AUTHENTICATION HUMAN; Ara T, 2013, CANCER RES, V73, P3852, DOI 10.1158/0008-5472.CAN-12-2353; Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood-2008-10-186668; Benbernou N, 2000, J BIOL CHEM, V275, P7060, DOI 10.1074/jbc.275.10.7060; Boucher K, 2012, CLIN CANCER RES, V18, P6155, DOI 10.1158/1078-0432.CCR-12-0531; Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104; Burel SA, 2013, NUCLEIC ACID THER, V23, P213, DOI 10.1089/nat.2013.0422; Butler B, 2005, J BIOL CHEM, V280, P14556, DOI 10.1074/jbc.M411765200; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Codony-Servat J, 2013, PROSTATE, V73, P512, DOI 10.1002/pros.22591; Fuhler GM, 2012, MOL MED, V18, P65, DOI 10.2119/molmed.2011.00178; Golubovskaya V, 2010, ANTI-CANCER AGENT ME, V10, P713, DOI 10.2174/187152010794728693; Guessous F, 2012, MOL CANCER THER, V11, P288, DOI 10.1158/1535-7163.MCT-11-0490; Hazlehurst LA, 2009, CANCER CONTROL, V16, P100, DOI 10.1177/107327480901600202; Kerr WG, 2011, ANN NY ACAD SCI, V1217, P1, DOI 10.1111/j.1749-6632.2010.05869.x; Kesanakurti D, 2013, ONCOGENE, V32, P327, DOI 10.1038/onc.2012.52; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Kingsley LA, 2007, P NATL ACAD SCI USA, V104, P10753, DOI 10.1073/pnas.0704357104; Kirshner J, 2008, BLOOD, V112, P2935, DOI 10.1182/blood-2008-02-142430; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]; Lin HY, 2012, J AGR FOOD CHEM, V60, P2480, DOI 10.1021/jf204362n; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Meads MB, 2010, J IMMUNOL, V185, P1606, DOI 10.4049/jimmunol.0902026; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Meyer AN, 2004, J BIOL CHEM, V279, P28450, DOI 10.1074/jbc.M403335200; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood-2003-07-2340; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259; Rajkumar SV, 2013, AM J HEMATOL, V88, P225, DOI 10.1002/ajh.23390; Rajkumar SV, 2011, AM J HEMATOL, V86, P57, DOI 10.1002/ajh.21913; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Shain KH, 2009, EXPERT REV HEMATOL, V2, P649, DOI [10.1586/ehm.09.55, 10.1586/EHM.09.55]; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Shi CS, 2004, J BIOL CHEM, V279, P17224, DOI 10.1074/jbc.M311875200; Shi Z, 2012, BREAST CANCER RES TR, V135, P737, DOI 10.1007/s10549-012-2196-0; St-Germain JR, 2009, P NATL ACAD SCI USA, V106, P20127, DOI 10.1073/pnas.0910957106; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Voorhees PM, 2009, BRIT J HAEMATOL, V145, P481, DOI 10.1111/j.1365-2141.2009.07647.x; Wang L, 2008, NAT IMMUNOL, V9, P186, DOI 10.1038/ni1548; Yang Y, 2015, CANCER RES, V75, P594, DOI 10.1158/0008-5472.CAN-14-2362; Yarde DN, 2009, CANCER RES, V69, P9367, DOI 10.1158/0008-5472.CAN-09-2616; Zhang GL, 2011, J PROTEOME RES, V10, P305, DOI 10.1021/pr1006203; Zhang Y, 2014, BLOOD, V124, P2675, DOI 10.1182/blood-2014-03-563981	51	25	26	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2723	2734		10.1038/onc.2015.334	http://dx.doi.org/10.1038/onc.2015.334			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26387544	Green Accepted			2022-12-28	WOS:000377472700006
J	Tie, SR; McCarthy, DJ; Kendrick, TS; Louw, A; Le, C; Satiaputra, J; Kucera, N; Phillips, M; Ingley, E				Tie, S. R.; McCarthy, D. J.; Kendrick, T. S.; Louw, A.; Le, C.; Satiaputra, J.; Kucera, N.; Phillips, M.; Ingley, E.			Regulation of sarcoma cell migration, invasion and invadopodia formation by AFAP1L1 through a phosphotyrosine-dependent pathway	ONCOGENE			English	Article							ERYTHROPOIETIN-INDUCED DIFFERENTIATION; PODOSOME FORMATION; ERYTHROID-CELLS; TYROSINE KINASE; ADAPTER PROTEIN; ACTIN DYNAMICS; SRC SUBSTRATE; TUMOR-CELLS; N-WASP; CORTACTIN	Invasion and metastasis are controlled by the invadopodia, which delivers matrix-degrading enzymes to the invasion interface permitting cancer cell penetration and spread into healthy tissue. We have identified a novel pathway that directs Lyn/Src family tyrosine kinase signals to the invadopodia to regulate sarcoma cell invasion via the molecule AFAP-1-like-1 (AFAP1L1), a new member of the AFAP (actin filament-associated protein) family. We show that AFAP1L1 can transform cells, promote migration and co-expression with active Lyn profoundly influences cell morphology and movement. AFAP1L1 intersects several invadopodia pathway components through its multiple domains and motifs, including the following (i) pleckstrin homology domains that bind phospholipids generated at the plasma membrane by phosphoinositide 3-kinase, (ii) a direct filamentous-actin binding domain and (iii) phospho-tyrosine motifs (pY136 and pY566) that specifically bind Vav2 and Nck2 SH2 domains, respectively. These phosphotyrosine motifs are essential for AFAP1L1-mediated cytoskeleton regulation. Through its interaction with Vav2, AFAP1L1 regulates Rac activity and downstream control of PAK1/2/3 (p21-activated kinases) phosphorylation of myosin light chain (MLC) kinase and MLC2. AFAP1L1 interaction with Nck2 recruits actin-nucleating complexes. Significantly, in osteosarcoma cell lines, knockdown of AFAP1L1 inhibits phosphorylated MLC2 recruitment to filamentous-actin structures, disrupts invadopodia formation, cell attachment, migration and invasion. These data define a novel pathway that directs Lyn/Src family tyrosine kinase signals to sarcoma cell invadopodia through specific recruitment of Vav2 and Nck2 to phosphorylated AFAP1L1, to control cell migration and invasion.	[Tie, S. R.; McCarthy, D. J.; Kendrick, T. S.; Louw, A.; Le, C.; Satiaputra, J.; Kucera, N.; Ingley, E.] Univ Western Australia, Harry Perkins Inst Med Res, Cell Signalling Grp, Nedlands, WA 6009, Australia; [Tie, S. R.; McCarthy, D. J.; Kendrick, T. S.; Louw, A.; Le, C.; Satiaputra, J.; Kucera, N.; Ingley, E.] Univ Western Australia, Med Res Ctr, Nedlands, WA 6009, Australia; [Louw, A.] Royal Perth Hosp, Med Res Fdn, Perth, WA 6001, Australia; [Phillips, M.] Univ Western Australia, Harry Perkins Inst Med Res, Perth, WA 6009, Australia; [Phillips, M.] Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; Royal Perth Hospital; Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia	Ingley, E (corresponding author), Univ Western Australia, Harry Perkins Inst Med Res, Cell Signalling Grp, QEII Med Ctr, Level 7,QQ Block,6 Verdun St, Nedlands, WA 6009, Australia.; Ingley, E (corresponding author), Univ Western Australia, Med Res Ctr, QEII Med Ctr, Level 7,QQ Block,6 Verdun St, Nedlands, WA 6009, Australia.	evan.ingley@uwa.edu.au	Ingley, Evan/C-2401-2013	Ingley, Evan/0000-0002-8112-9134; Phillips, Michael/0000-0002-0252-9085	National Health and Medical Research Council [513714, 634352]; Medical Research Foundation of Royal Perth Hospital; Cancer Council of Western Australia; Harry Perkins Institute of Medical Research; Sock-it-to-Sarcoma; Hollywood Private Hospital Research Foundation	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Foundation of Royal Perth Hospital; Cancer Council of Western Australia(Cancer Council Western Australia); Harry Perkins Institute of Medical Research; Sock-it-to-Sarcoma; Hollywood Private Hospital Research Foundation	We thank Janice Lam, Matt Lee, Rebecca Shapiro, Morgane Davies, Irma Larma and Kevin Li for technical assistance. This work was supported by grants from the National Health and Medical Research Council (513714 and 634352), the Medical Research Foundation of Royal Perth Hospital and the Cancer Council of Western Australia. EI received support from the Cancer Council of Western Australia, The Harry Perkins Institute of Medical Research, Sock-it-to-Sarcoma and the Hollywood Private Hospital Research Foundation.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06-01-0088; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014; Crimaldi L, 2009, EXP CELL RES, V315, P2581, DOI 10.1016/j.yexcr.2009.06.012; Dang I, 2013, NATURE, V503, P281, DOI 10.1038/nature12611; Delorme-Walker VD, 2011, J CELL BIOL, V193, P1289, DOI 10.1083/jcb.201010059; DesMarais V, 2009, CELL MOTIL CYTOSKEL, V66, P303, DOI 10.1002/cm.20361; Dorfleutner A, 2008, J CELL SCI, V121, P2394, DOI 10.1242/jcs.026187; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Furu M, 2011, ONCOGENE, V30, P4015, DOI 10.1038/onc.2011.108; Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578-7597.2004; Heo J, 2005, BIOCHEMISTRY-US, V44, P6573, DOI 10.1021/bi047443q; Huang CH, 2013, NAT CELL BIOL, V15, P1307, DOI 10.1038/ncb2859; Ingley E, 1999, FEBS LETT, V459, P69, DOI 10.1016/S0014-5793(99)01188-6; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Kaipparettu BA, 2008, BIOTECHNIQUES, V45, P165, DOI 10.2144/000112883; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Li A, 2010, CURR BIOL, V20, P339, DOI 10.1016/j.cub.2009.12.035; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Lodyga M, 2010, J CELL SCI, V123, P4156, DOI 10.1242/jcs.071050; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Moshfegh Y, 2014, NAT CELL BIOL, V16, P571, DOI 10.1038/ncb2972; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nakahara H, 2003, GENES CELLS, V8, P1019, DOI 10.1111/j.1365-2443.2003.00695.x; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Rivera GM, 2006, P NATL ACAD SCI USA, V103, P9536, DOI 10.1073/pnas.0603786103; Samuels AL, 2009, BLOOD, V113, P3845, DOI 10.1182/blood-2008-04-153452; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Snyder BN, 2011, EUR J CELL BIOL, V90, P376, DOI 10.1016/j.ejcb.2010.11.016; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Stylli SS, 2009, J CELL SCI, V122, P2727, DOI 10.1242/jcs.046680; Takahashi R, 2014, CANCER MED-US, V3, P759, DOI 10.1002/cam4.237; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Wells CM, 2005, EXP CELL RES, V310, P303, DOI 10.1016/j.yexcr.2005.07.015; Xu J, 2007, J BIOL CHEM, V282, P16401, DOI 10.1074/jbc.M701684200; Yamaguchi H, 2011, J CELL BIOL, V193, P1275, DOI 10.1083/jcb.201009126	57	4	4	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2098	2111		10.1038/onc.2015.272	http://dx.doi.org/10.1038/onc.2015.272			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26212012	Green Submitted			2022-12-28	WOS:000374505600009
J	Lee, CK; Yang, Y; Chen, C; Liu, J				Lee, C. K.; Yang, Y.; Chen, C.; Liu, J.			Syk-mediated tyrosine phosphorylation of mule promotes TNF-induced JNK activation and cell death	ONCOGENE			English	Article							NF-KAPPA-B; ARF TUMOR-SUPPRESSOR; E3 UBIQUITIN LIGASE; RECEPTOR GAMMA-CHAIN; DNA-DAMAGE; PROTEIN-KINASE; JUN KINASES; APOPTOSIS; MIZ1; P53	The transcription factor Miz1 negatively regulates TNF-induced JNK activation and cell death by suppressing TRAF2 K63-polyubiquitination; upon TNF stimulation, the suppression is relieved by Mule/ARF-BP1-mediated Miz1 ubiquitination and subsequent degradation. It is not known how Mule is activated by TNF. Here we report that TNF activates Mule by inducing the dissociation of Mule from its inhibitor ARF. ARF binds to and thereby inhibits the E3 ligase activity of Mule in the steady state. TNF induces tyrosine phosphorylation of Mule, which subsequently dissociates from ARF and becomes activated. Inhibition of Mule phosphorylation by silencing of the Spleen Tyrosine Kinase (Syk) prevents its dissociation from ARF, thereby inhibiting Mule E3 ligase activity and TNF-induced JNK activation and cell death. Our data provides a missing link in TNF signaling pathway that leads to JNK activation and cell death.	[Lee, C. K.; Chen, C.; Liu, J.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, McGaw Pavil Suite M-300,240 E Huron, Chicago, IL 60611 USA; [Yang, Y.] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China	Northwestern University; Feinberg School of Medicine; Fudan University	Liu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, McGaw Pavil Suite M-300,240 E Huron, Chicago, IL 60611 USA.	jing@northwestern.edu			National Institutes of Health [GM081603-03, HL114763-01A1]; Lung Science Training Program [2T32HL076139-11A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL114763, T32HL076139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081603] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lung Science Training Program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Anning Lin (University of Chicago) for valuable reagents that made this work possible. We thank Jie Yan (University of Chicago), Hong Kuang (Northwestern University) and Chi Do (Northwestern University) for excellent technical assistance. This work was partially supported by National Institutes of Health (GM081603-03, HL114763-01A1) (JL), and the Lung Science Training Program (2T32HL076139-11A1) (CL).	Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069; Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Do-Umehara HC, 2013, NAT IMMUNOL, V14, P461, DOI 10.1038/ni.2566; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; GU J, 1995, ONCOGENE, V11, P2175; Hall JR, 2007, MOL BIOL CELL, V18, P3340, DOI 10.1091/mbc.E07-02-0173; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Kosan C, 2010, IMMUNITY, V33, P917, DOI 10.1016/j.immuni.2010.11.028; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020; Liu J, 2012, P NATL ACAD SCI USA, V109, P191, DOI 10.1073/pnas.1105176108; Liu J, 2009, P NATL ACAD SCI USA, V106, P18279, DOI 10.1073/pnas.0906328106; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Liu ZQ, 2005, MOL CELL BIOL, V25, P2819, DOI 10.1128/MCB.25.7.2819-2831.2005; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Mocsai A, 2006, NAT IMMUNOL, V7, P1326, DOI 10.1038/ni1407; Noy T, 2012, BIOCHEM BIOPH RES CO, V418, P408, DOI 10.1016/j.bbrc.2012.01.045; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Parsons JL, 2009, EMBO J, V28, P3207, DOI 10.1038/emboj.2009.243; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Vines CM, 2001, IMMUNITY, V15, P507, DOI 10.1016/S1074-7613(01)00221-7; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Yang Y, 2010, P NATL ACAD SCI USA, V107, P13444, DOI 10.1073/pnas.0913690107; Yeh KW, 1997, PLANT MOL BIOL, V33, P565, DOI 10.1023/A:1005764702510; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	54	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1988	1995		10.1038/onc.2015.275	http://dx.doi.org/10.1038/onc.2015.275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26212014	Green Accepted			2022-12-28	WOS:000374010300011
J	Bjork, JK; Akerfelt, M; Joutsen, J; Puustinen, MC; Cheng, F; Sistonen, L; Nees, M				Bjork, J. K.; Akerfelt, M.; Joutsen, J.; Puustinen, M. C.; Cheng, F.; Sistonen, L.; Nees, M.			Heat-shock factor 2 is a suppressor of prostate cancer invasion	ONCOGENE			English	Article							GENE-EXPRESSION PROFILES; METASTASIS SUPPRESSOR; CELL-CULTURE; IN-VITRO; STRESS; TRANSCRIPTION; PROGRESSION; HSF1; DIFFERENTIATION; CARCINOMAS	Heat-shock factors (HSFs) are key transcriptional regulators in cell survival. Although HSF1 has been identified as a driver of carcinogenesis, HSF2 has not been explored in malignancies. Here, we report that HSF2 suppresses tumor invasion of prostate cancer (PrCa). In three-dimensional organotypic cultures and the in vivo xenograft chorioallantoic membrane model HSF2 knockdown perturbs organoid differentiation and promotes invasiveness. Gene expression profiling together with functional studies demonstrated that the molecular mechanism underlying the effect on tumor progression originates from HSF2 steering the switch between acinar morphogenesis and invasion. This is achieved by the regulation of genes connected to, for example, GTPase activity, cell adhesion, extracellular matrix and actin cytoskeleton dynamics. Importantly, low HSF2 expression correlates with high Gleason score, metastasis and poor survival of PrCa patients, highlighting the clinical relevance of our findings. Finally, the study was expanded beyond PrCa, revealing that the expression of HSF2 is decreased in a wide range of cancer types. This study provides the first evidence for HSF2 acting as a suppressor of invasion in human malignancies.	[Bjork, J. K.; Akerfelt, M.; Joutsen, J.; Puustinen, M. C.; Cheng, F.; Sistonen, L.; Nees, M.] Univ Turku, Ctr Biotechnol, Tykistokatu 6, FIN-20520 Turku, Finland; [Bjork, J. K.; Akerfelt, M.; Joutsen, J.; Puustinen, M. C.; Cheng, F.; Sistonen, L.; Nees, M.] Abo Akad Univ, Tykistokatu 6, FIN-20520 Turku, Finland; [Bjork, J. K.; Akerfelt, M.] VTT Tech Res Ctr Finland, Med Biotechnol, Turku, Finland; [Joutsen, J.; Puustinen, M. C.; Cheng, F.; Sistonen, L.] Abo Akad Univ, Dept Biosci, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; VTT Technical Research Center Finland; Abo Akademi University	Sistonen, L; Nees, M (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6, FIN-20520 Turku, Finland.; Sistonen, L; Nees, M (corresponding author), Abo Akad Univ, Tykistokatu 6, FIN-20520 Turku, Finland.	lea.sistonen@abo.fi; matthias.nees@btk.fi	Nees, Matthias/W-6596-2018; Nees, Matthias/AAT-5577-2020	Nees, Matthias/0000-0002-9034-301X; Sistonen, Lea/0000-0003-1341-2867; Joutsen, Jenny/0000-0002-7868-556X; Akerfelt, Malin/0000-0003-4810-7862	Academy of Finland; IMI PREDECT consortium; Sigrid Juselius Foundation; Finnish Cancer Organizations; Abo Akademi University; Abo Akademi University Endowment Research Institute; Tor, Joe and Pentti Borg Foundation	Academy of Finland(Academy of Finland); IMI PREDECT consortium; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Organizations; Abo Akademi University; Abo Akademi University Endowment Research Institute; Tor, Joe and Pentti Borg Foundation	We thank the members of our laboratories for invaluable comments. Vidal Fey, Samu V Himanen, Heidi Lustig, Satu Orasniemi, Pauliina Toivonen, and Johannes Virtanen are acknowledged for technical assistance and other contributions. The work was supported by The Academy of Finland (FC, JKB, LS, MN, MA), IMI PREDECT consortium (MN, MA), The Sigrid Juselius Foundation (LS), The Finnish Cancer Organizations (LS), Abo Akademi University (JKB, LS), Abo Akademi University Endowment Research Institute, and Tor, Joe and Pentti Borg Foundation (JKB).	Acloque H, 2008, EMBO REP, V9, P322, DOI 10.1038/embor.2008.30; Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Ahlskog JK, 2010, MOL CELL BIOL, V30, P5608, DOI 10.1128/MCB.01506-09; Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bjork JK, 2010, FEBS J, V277, P4126, DOI 10.1111/j.1742-4658.2010.07828.x; Bjork JK, 2010, DEVELOPMENT, V137, P3177, DOI 10.1242/dev.050955; Burns-Cox N, 2001, J UROLOGY, V166, P1698, DOI 10.1016/S0022-5347(05)65656-X; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi YL, 2007, ONCOGENE, V26, P1245, DOI 10.1038/sj.onc.1209898; DAGG CP, 1956, CANCER RES, V16, P589; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Durig J, 2007, LEUKEMIA, V21, P2153, DOI 10.1038/sj.leu.2404877; El Fatimy R, 2014, EMBO MOL MED, V6, P1043, DOI 10.15252/emmm.201303311; Elsing AN, 2014, J CELL BIOL, V206, P735, DOI 10.1083/jcb.201402002; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Estilo CL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-11; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gutmann DH, 2002, CANCER RES, V62, P2085; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harma V, 2012, ONCOGENE, V31, P2075, DOI 10.1038/onc.2011.396; Harma V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096426; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Haslinger C, 2004, J CLIN ONCOL, V22, P3937, DOI 10.1200/JCO.2004.12.133; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Jin XJ, 2011, CELL METAB, V14, P91, DOI 10.1016/j.cmet.2011.03.025; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kimchi ET, 2005, CANCER RES, V65, P3146, DOI 10.1158/0008-5472.CAN-04-2490; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kogan I, 2006, CANCER RES, V66, P3531, DOI 10.1158/0008-5472.CAN-05-2183; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Kunzi-Rapp K, 2001, J UROLOGY, V166, P1502, DOI 10.1016/S0022-5347(05)65820-X; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Loison F, 2006, BIOCHEM J, V395, P223, DOI 10.1042/BJ20051190; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Massard C, 2011, CLIN CANCER RES, V17, P3876, DOI 10.1158/1078-0432.CCR-10-2815; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morin P, 2011, EUR J CELL BIOL, V90, P13, DOI 10.1016/j.ejcb.2010.09.009; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Ostling P, 2007, J BIOL CHEM, V282, P7077, DOI 10.1074/jbc.M607556200; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rossi A, 2014, J BIOL CHEM, V289, P12705, DOI 10.1074/jbc.M113.513242; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sandqvist A, 2009, MOL BIOL CELL, V20, P1340, DOI 10.1091/mbc.E08-08-0864; Santagata S, 2013, SCIENCE, V341, P250, DOI 10.1126/science.1238303; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; Scherz-Shouval R, 2014, CELL, V158, P564, DOI 10.1016/j.cell.2014.05.045; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Sinha S, 2008, CELL SIGNAL, V20, P1927, DOI 10.1016/j.cellsig.2008.05.002; Skotheim RI, 2005, CANCER RES, V65, P5588, DOI 10.1158/0008-5472.CAN-05-0153; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vihervaara A, 2013, P NATL ACAD SCI USA, V110, pE3388, DOI 10.1073/pnas.1305275110; Wang X, 2009, J ANDROL, V30, P259, DOI 10.2164/jandrol.108.006494; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152	75	36	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1770	1784		10.1038/onc.2015.241	http://dx.doi.org/10.1038/onc.2015.241			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119944	hybrid, Green Published			2022-12-28	WOS:000373610400004
J	Wu, DW; Chen, CY; Chu, CL; Lee, H				Wu, D-W; Chen, C-Y; Chu, C-L; Lee, H.			Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability	ONCOGENE			English	Article							PHOSPHORYLATION; EXPRESSION; SURVIVAL; MUTATION; CELLS; DEGRADATION; PROMOTES; PATHWAY	Tyrosine kinase inhibitors (TKIs) have been documented to have substantial clinical benefits to non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation. TKI resistance occurs in nearly all patients who receive TKI-targeting therapy, resulting in a modest overall survival benefit. Therefore, establishing a biomarker for early prediction and exploring the mechanism of primary TKI resistance is essential for improving the therapeutic efficacy in non-small cell lung cancer patients. In this study, we provide evidence indicating that paxillin (PXN) overexpression may confer TKI resistance in EGFR-mutant lung cancer cells. Mechanistically, PXN-mediated extracellular signal-regulated kinases (ERK) activation is responsible for TKI resistance via decreased Bcl2-interacting mediator of cell death (BIM) and increased Mcl-1 expression due to modulating their protein stabilities by phosphorylation of BIM at serine 69 and Mcl-1 at threonine 163. The mechanistic action in the cell model was further confirmed by the observation of xenograft tumors in nude mice, revealing that the PXN-mediated TKI resistance was conquered by ERK inhibitor (AZD6244) and Bcl-2 family inhibitor (obatoclax), but the TKI resistance overcome by AZD6244 is more effective than that of obatoclax. Therefore, we suggest that PXN expression may be useful in predicting primary TKI resistance, and combining TKI with ERK inhibitors may clinically benefit EGFR-mutant non-small cell lung cancer patients whose tumors exhibit high PXN expression.	[Wu, D-W; Lee, H.] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Chen, C-Y; Chu, C-L] China Med Univ Hosp, Ctr Canc, Taichung, Taiwan; [Chen, C-Y] Chung Shan Med Univ Hosp, Dept Surg, Taichung 40201, Taiwan	Taipei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Room 5,12F,3 Pk St, Taipei 115, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI-EX103-10328BI]; National Science Council of Taiwan, ROC [NSC100-2314-B-038-043-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI-EX103-10328BI) and the National Science Council (NSC100-2314-B-038-043-MY3) of Taiwan, ROC.	Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Costa DB, 2007, LUNG CANCER, V58, P95, DOI 10.1016/j.lungcan.2007.05.017; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Huang MH, 2013, MOL ONCOL, V7, P112, DOI 10.1016/j.molonc.2012.09.002; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Kim HR, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-50; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Liao MM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-44; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Ochi N, 2014, EXP CELL RES, V322, P168, DOI 10.1016/j.yexcr.2014.01.007; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Song JY, 2013, INVEST NEW DRUG, V31, P1458, DOI 10.1007/s10637-013-0030-0; Vela L, 2013, J BIOL CHEM, V288, P4935, DOI 10.1074/jbc.M112.422204; Wang J, 2011, J BIOL CHEM, V286, P22384, DOI 10.1074/jbc.M111.239566; Wu DW, 2014, ONCOGENE, V33, P4385, DOI 10.1038/onc.2013.389; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032; Zhao JF, 2009, MOL CANCER RES, V7, P1954, DOI 10.1158/1541-7786.MCR-09-0304	28	28	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					621	630		10.1038/onc.2015.120	http://dx.doi.org/10.1038/onc.2015.120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915848				2022-12-28	WOS:000369548800009
J	Lin, EW; Karakasheva, TA; Hicks, PD; Bass, AJ; Rustgi, AK				Lin, E. W.; Karakasheva, T. A.; Hicks, P. D.; Bass, A. J.; Rustgi, A. K.			The tumor microenvironment in esophageal cancer	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; REGULATORY T-CELLS; GROWTH-FACTOR-BETA; OXIDATIVE DNA-DAMAGE; DYSPLASIA-ADENOCARCINOMA SEQUENCE; UPPER GASTROINTESTINAL-TRACT; TRANSFORMED BARRETTS CELLS; SUPPRESSOR-CELLS; SIGNALING PATHWAY	Esophageal cancer is a deadly disease, ranking sixth among all cancers in mortality. Despite incremental advances in diagnostics and therapeutics, esophageal cancer still carries a poor prognosis, and thus, there remains a need to elucidate the molecular mechanisms underlying this disease. There is accumulating evidence that a comprehensive understanding of the molecular composition of esophageal cancer requires attention to not only tumor cells but also the tumor microenvironment (TME), which contains diverse cell populations, signaling factors and structural molecules that interact with tumor cells and support all stages of tumorigenesis. In esophageal cancer, environmental exposures can trigger chronic inflammation, which leads to constitutive activation of pro-inflammatory signaling pathways that promote survival and proliferation. Antitumor immunity is attenuated by cell populations such as myeloid-derived suppressor cells and regulatory T cells, as well as immune checkpoints like programmed death-1. Other immune cells such as tumor-associated macrophages can have other pro-tumorigenic functions, including the induction of angiogenesis and tumor cell invasion. Cancer-associated fibroblasts secrete growth factors and alter the extracellular matrix to create a tumor niche and enhance tumor cell migration and metastasis. Further study of how these TME components relate to the different stages of tumor progression in each esophageal cancer subtype will lead to development of novel and specific TME-targeting therapeutic strategies, which offer considerable potential especially in the setting of combination therapy.	[Lin, E. W.; Karakasheva, T. A.; Hicks, P. D.; Rustgi, A. K.] Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, 951 BRB 421 Curie Blvd, Philadelphia, PA 19104 USA; [Lin, E. W.; Karakasheva, T. A.; Hicks, P. D.; Rustgi, A. K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Bass, A. J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Rustgi, A. K.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, 951 BRB 421 Curie Blvd, Philadelphia, PA 19104 USA.	anil2@mail.med.upenn.edu	Karakasheva, Tatiana/F-4246-2018	Karakasheva, Tatiana/0000-0001-9070-2804; Hicks, Philip/0000-0002-1574-5692; Lin, Eric/0000-0002-1064-2010	NCI NIH HHS [P01 CA098101] Funding Source: Medline; NIDDK NIH HHS [P30 DK050306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdel-Latif MMM, 2004, ANN SURG, V239, P491, DOI 10.1097/01.sla.0000118751.95179.c6; Abdel-Latif MMM, 2009, CURR OPIN PHARMACOL, V9, P396, DOI 10.1016/j.coph.2009.06.010; Akutsu Y, 2011, ANN SURG ONCOL, V18, P2946, DOI 10.1245/s10434-011-1645-z; Anderson MR, 2006, CLIN CANCER RES, V12, P5936, DOI 10.1158/1078-0432.CCR-06-1208; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bailey SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00276; Bao CH, 2015, BIOCHEM BIOPH RES CO, V458, P441, DOI 10.1016/j.bbrc.2015.02.001; Bardou M, 2004, CLIN GASTROENTEROL H, V2, P880, DOI 10.1016/S1542-3565(04)00389-1; Bertos NR, 2011, J CLIN INVEST, V121, P3789, DOI 10.1172/JCI57100; Bianchini F, 2002, LANCET ONCOL, V3, P565, DOI 10.1016/S1470-2045(02)00849-5; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Chalmin F, 2012, IMMUNITY, V36, P362, DOI 10.1016/j.immuni.2011.12.019; Chen DY, 2012, CELL IMMUNOL, V272, P166, DOI 10.1016/j.cellimm.2011.10.015; Chen LY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05911; Chen LJ, 2014, INT J CLIN EXP PATHO, V7, P6015; Chen ML, 2012, CANCER EPIDEM BIOMAR, V21, P1126, DOI 10.1158/1055-9965.EPI-12-0020; Chen MF, 2014, ONCOTARGET, V5, P8716, DOI 10.18632/oncotarget.2368; Chen MF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-26; Chen YS, 2014, TUMOR BIOL, V35, P7275, DOI 10.1007/s13277-014-1987-9; Chung Y, 2007, ANN SURG ONCOL, V14, P3260, DOI 10.1245/s10434-007-9511-8; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Couvelard A, 2000, J PATHOL, V192, P14; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Derks S, 2015, CANCER IMMUNOL RES, V3, P1123, DOI 10.1158/2326-6066.CIR-15-0046; Dreikhausen L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1120-5; Duggan C, 2013, CLIN GASTROENTEROL H, V11, P934, DOI 10.1016/j.cgh.2013.02.017; Dvorak K, 2007, CLIN CANCER RES, V13, P5305, DOI 10.1158/1078-0432.CCR-07-0483; Dvorak K, 2007, GUT, V56, P763, DOI 10.1136/gut.2006.103697; Dvorak K, 2013, WORLD J GASTROENTERO, V19, P2307, DOI 10.3748/wjg.v19.i15.2307; Dvorakova K, 2004, CLIN CANCER RES, V10, P2020, DOI 10.1158/1078-0432.CCR-0437-03; Eder K, 2009, INFLAMM RES, V58, P727, DOI 10.1007/s00011-009-0060-4; Ekman S, 2007, ONCOLOGIST, V12, P1165, DOI 10.1634/theoncologist.12-10-1165; Farhadi A, 2002, AM J GASTROENTEROL, V97, P22; Fitzgerald RC, 2002, GUT, V51, P316, DOI 10.1136/gut.51.3.316; Fong SFT, 2007, GENE CHROMOSOME CANC, V46, P644, DOI 10.1002/gcc.20444; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fukai Y, 2003, INT J CANCER, V104, P161, DOI 10.1002/ijc.10929; Fukuchi M, 2002, CANCER, V95, P737, DOI 10.1002/cncr.10727; Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104453; GILLISON EW, 1972, SURG GYNECOL OBSTETR, V134, P419; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goldman L, 2015, GOLDMAN CECIL MED EX; Gomez-Rodriguez J, 2014, J EXP MED, V211, P529, DOI 10.1084/jem.20131459; Gong JJ, 2014, CLIN CANCER RES, V20, P1259, DOI 10.1158/1078-0432.CCR-13-1664; Grimm M, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-99; Groblewska M, 2012, CLIN CHIM ACTA, V413, P1583, DOI 10.1016/j.cca.2012.05.009; Gros SJ, 2012, IN VIVO, V26, P711; Grugan KD, 2010, P NATL ACAD SCI USA, V107, P11026, DOI 10.1073/pnas.0914295107; Gu ZD, 2005, AM J GASTROENTEROL, V100, P1835, DOI 10.1111/j.1572-0241.2005.50018.x; Ha SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099955; Ha Tai-You, 2009, Immune Netw, V9, P209, DOI 10.4110/in.2009.9.6.209; Hardikar S, 2014, CANCER EPIDEM BIOMAR, V23, P2393, DOI 10.1158/1055-9965.EPI-14-0384; Hatata T, 2012, DIS ESOPHAGUS, V25, P716, DOI 10.1111/j.1442-2050.2011.01308.x; Hayden AL, 2012, GUT, V61, pA52, DOI 10.1136/gutjnl-2012-302514a.121; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; Hou J, 2013, CANCER PREV RES, V6, P791, DOI 10.1158/1940-6207.CAPR-12-0352; Howard JM, 2010, BRIT J SURG, V97, P1020, DOI 10.1002/bjs.7072; Huang JX, 2013, ONCOL LETT, V6, P13, DOI 10.3892/ol.2013.1348; Ichihara F, 2003, CLIN CANCER RES, V9, P4404; Ito TK, 2007, ONCOGENE, V26, P7194, DOI 10.1038/sj.onc.1210535; Izzo JG, 2007, CANCER EPIDEM BIOMAR, V16, P1200, DOI 10.1158/1055-9965.EPI-06-1083; Izzo JG, 2006, MOL CANCER THER, V5, P2844, DOI 10.1158/1535-7163.MCT-06-0351; Jayaraman P, 2012, J IMMUNOL, V188, P5365, DOI 10.4049/jimmunol.1103553; Jenkins GJS, 2004, CARCINOGENESIS, V25, P317, DOI 10.1093/carcin/bgh032; Jiao ZJ, 2012, WORLD J GASTROENTERO, V18, P5454, DOI 10.3748/wjg.v18.i38.5454; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kant P, 2011, NAT REV GASTRO HEPAT, V8, P224, DOI 10.1038/nrgastro.2011.23; Karakasheva TA, 2015, CANCER RES, V75, P4074, DOI 10.1158/0008-5472.CAN-14-3639; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KAUER WKH, 1995, ANN SURG, V222, P525; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim AH, 2003, INT J ONCOL, V23, P1593; Kitadai Y, 2004, ONCOL REP, V11, P315; Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453; Koide N, 2004, AM J GASTROENTEROL, V99, P1667, DOI 10.1111/j.1572-0241.2004.30733.x; Kono K, 2006, CANCER IMMUNOL IMMUN, V55, P1064, DOI 10.1007/s00262-005-0092-8; Kubo N, 2014, DIS ESOPHAGUS, V27, P285, DOI 10.1111/dote.12107; Lebman DA, 2002, INT J ONCOL, V20, P1241; Lee JS, 2001, MUTAT RES-FUND MOL M, V480, P189, DOI 10.1016/S0027-5107(01)00199-3; Leu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084; Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152; Li HY, 2014, INT J CLIN EXP PATHO, V7, P7989; Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87; Lin CY, 2013, CANCER RES, V73, P3638, DOI 10.1158/0008-5472.CAN-12-4028; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; Lord RVN, 2003, J THORAC CARDIOV SUR, V125, P246, DOI 10.1067/mtc.2003.203; Lukaszewicz-Zajac M, 2012, DIS ESOPHAGUS, V25, P242, DOI 10.1111/j.1442-2050.2011.01242.x; Macfarlane S, 2007, CLIN INFECT DIS, V45, P29, DOI 10.1086/518578; Makuuchi Y, 2013, CANCER SCI, V104, P1045, DOI 10.1111/cas.12187; Malhotra U, 2005, CANCER RES, V65, P548; Martin RCG, 2007, CLIN CANCER RES, V13, P5176, DOI 10.1158/1078-0432.CCR-07-1152; Mazzoni A, 2002, J IMMUNOL, V168, P689, DOI 10.4049/jimmunol.168.2.689; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Miyashita T, 2014, ANN SURG ONCOL, V21, P2012, DOI 10.1245/s10434-014-3537-5; Mobius C, 2007, WORLD J SURG, V31, P1768, DOI 10.1007/s00268-006-0373-1; Morris CD, 2001, AM J GASTROENTEROL, V96, P990; Nabeki B, 2015, ANTICANCER RES, V35, P2941; Nguyen DM, 2004, J THORAC CARDIOV SUR, V127, P365, DOI 10.1016/j.jtcvs.2003.09.033; Noma K, 2008, GASTROENTEROLOGY, V134, P1981, DOI 10.1053/j.gastro.2008.02.061; O'Riordan JM, 2005, AM J GASTROENTEROL, V100, P1257, DOI 10.1111/j.1572-0241.2005.41338.x; Ogunwobi O, 2006, ENDOCRINOLOGY, V147, P4505, DOI 10.1210/en.2006-0224; Ogura M, 2013, SURGERY, V154, P512, DOI 10.1016/j.surg.2013.06.013; Oh DS, 2007, ARCH SURG-CHICAGO, V142, P554, DOI 10.1001/archsurg.142.6.554; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Oka M, 1996, J INTERF CYTOK RES, V16, P1001, DOI 10.1089/jir.1996.16.1001; Okawa T, 2007, GENE DEV, V21, P2788, DOI 10.1101/gad.1544507; Onwuegbusi BA, 2006, GUT, V55, P764, DOI 10.1136/gut.2005.076430; Osaki T, 2009, DIS ESOPHAGUS, V22, P49, DOI 10.1111/j.1442-2050.2008.00855.x; Oshima H, 2012, J GASTROENTEROL, V47, P97, DOI 10.1007/s00535-011-0523-6; Ostrand-Rosenberg S, 2014, J IMMUNOL, V193, P3835, DOI 10.4049/jimmunol.1401572; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007; Patel ZS, 2012, RADIAT RES, V177, P200, DOI 10.1667/RR2790.1; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; Prins MJD, 2012, J GASTROINTEST SURG, V16, P956, DOI 10.1007/s11605-011-1814-1; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Quante M, 2012, CANCER CELL, V21, P36, DOI 10.1016/j.ccr.2011.12.004; Radojicic J, 2012, INT J BIOL MARKER, V27, P1, DOI 10.5301/JBM.2011.8737; Rafiee P, 2009, AM J PHYSIOL-GASTR L, V296, pG388, DOI 10.1152/ajpgi.90428.2008; Ren Y, 2005, CLIN CANCER RES, V11, P6190, DOI 10.1158/1078-0432.CCR-04-2553; Rubenstein JH, 2009, GUT, V58, P1583, DOI 10.1136/gut.2008.171553; Rubenstein JH, 2014, CLIN GASTROENTEROL H, V12, P239, DOI 10.1016/j.cgh.2013.08.029; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Salmela MT, 2001, BRIT J CANCER, V85, P383, DOI 10.1054/bjoc.2001.1929; Sasaki K, 2009, ONCOL REP, V21, P65, DOI 10.3892/or_00000190; Seo BR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010467; Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621; Shigeoka M, 2013, CANCER SCI, V104, P1112, DOI 10.1111/cas.12188; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Shivappa N, 2015, CANCER CAUSE CONTROL, V105, P9250; Sihvo EIT, 2002, INT J CANCER, V102, P551, DOI 10.1002/ijc.10755; Song S, 2007, GUT, V56, P1512, DOI 10.1136/gut.2007.121244; Song SM, 2013, CANCER RES, V73, P2159, DOI 10.1158/0008-5472.CAN-12-1962; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Souza RF, 2000, CANCER RES, V60, P5767; Srivastava MK, 2010, CANCER RES, V70, P68, DOI 10.1158/0008-5472.CAN-09-2587; Stachler MD, 2015, NAT GENET, V47, P1047, DOI 10.1038/ng.3343; Stairs DB, 2011, CANCER CELL, V19, P470, DOI 10.1016/j.ccr.2011.02.007; Suchi K, 2011, ANTICANCER RES, V31, P67; Sun NX, 2014, TUMOR BIOL, V35, P11359, DOI 10.1007/s13277-014-2434-7; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Sunpaweravong P, 2005, J CANCER RES CLIN, V131, P111, DOI 10.1007/s00432-004-0610-7; Taccioli C, 2012, ONCOGENE, V31, P4550, DOI 10.1038/onc.2011.592; Tachezy M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-238; TAKADA N, 1995, CANCER LETT, V97, P145, DOI 10.1016/0304-3835(95)03967-2; Tanaka K, 2015, CARCINOGENESIS, V36, P894, DOI 10.1093/carcin/bgv067; Thelin MA, 2012, CANCER RES, V72, P1943, DOI 10.1158/0008-5472.CAN-11-1351; Tian F, 2006, ACTA BIOCH BIOPH SIN, V38, P318, DOI 10.1111/j.1745-7270.2006.00166.x; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tselepis C, 2002, ONCOGENE, V21, P6071, DOI 10.1038/sj.onc.1205731; Tuynman JB, 2008, BRIT J CANCER, V98, P1102, DOI 10.1038/sj.bjc.6604251; Twarock S, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-30; Underwood TJ, 2015, J PATHOL, V235, P466, DOI 10.1002/path.4467; Vacchelli E, 2015, ONCOTARGET, V6, P20840, DOI 10.18632/oncotarget.4428; von Boehmer H, 2013, NAT REV DRUG DISCOV, V12, P51, DOI 10.1038/nrd3683; von Rahden BHA, 2006, MOL CARCINOGEN, V45, P786, DOI 10.1002/mc.20259; Waldron TJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24117; Walker MM, 2014, ALIMENT PHARM THER, V39, P767, DOI 10.1111/apt.12666; Wang C, 1996, AM J PATHOL, V148, P1861; Wang Dao-Feng, 2009, Ai Zheng, V28, P154; Wang DH, 2010, GASTROENTEROLOGY, V138, P1810, DOI 10.1053/j.gastro.2010.01.048; Wang T, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-104; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei XL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1379-6; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wong GS, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.17; Wu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095509; Xia M, 2013, J INT MED RES, V41, P1002, DOI 10.1177/0300060513488504; Xu TY, 2011, CELL BIOCHEM BIOPHYS, V61, P389, DOI 10.1007/s12013-011-9197-1; [Xu Weiguo 徐卫国], 2004, Chinese Journal of Cancer Research, V16, P85, DOI 10.1007/s11670-004-0002-1; Xu ZB, 2013, ONCOL LETT, V6, P401, DOI 10.3892/ol.2013.1409; Yan S, 2008, CANCER LETT, V271, P85, DOI 10.1016/j.canlet.2008.05.035; Yang LY, 2012, CLIN CANCER RES, V18, P2138, DOI 10.1158/1078-0432.CCR-11-0934; Yang LY, 2009, GASTROENTEROLOGY, V137, P588, DOI 10.1053/j.gastro.2009.04.046; Yoneda M, 2013, ANTICANCER RES, V33, P2699; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Yu CH, 2012, AM J PHYSIOL-GASTR L, V303, pG561, DOI 10.1152/ajpgi.00033.2012; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang CY, 2009, CLIN CANCER RES, V15, P4017, DOI 10.1158/1078-0432.CCR-08-2824; Zhang H, 2007, CANC BIOL MED, V4, P83; Zhang HY, 2011, AM J PHYSIOL-GASTR L, V300, pG454, DOI 10.1152/ajpgi.00458.2010; Zhang J, 2005, J PATHOL, V207, P402, DOI 10.1002/path.1846; Zhang Q, 2015, TUMOR BIOL, V36, P2135, DOI 10.1007/s13277-014-2823-y; Zhang YL, 2014, ONCOL REP, V31, P2298, DOI 10.3892/or.2014.3095; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569; Zhi HY, 2006, CARCINOGENESIS, V27, P1214, DOI 10.1093/carcin/bgi304; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742	208	193	204	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5337	5349		10.1038/onc.2016.34	http://dx.doi.org/10.1038/onc.2016.34			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	26923327	Green Accepted			2022-12-28	WOS:000386677800001
J	Jiang, YY; Shang, L; Shi, ZZ; Zhang, TT; Ma, S; Lu, CC; Zhang, Y; Hao, JJ; Shi, C; Shi, F; Xu, X; Cai, Y; Jia, XM; Zhan, QM; Wang, MR				Jiang, Y-Y; Shang, L.; Shi, Z-Z; Zhang, T-T; Ma, S.; Lu, C-C; Zhang, Y.; Hao, J-J; Shi, C.; Shi, F.; Xu, X.; Cai, Y.; Jia, X-M; Zhan, Q-M; Wang, M-R			Microtubule-associated protein 4 is an important regulator of cell invasion/migration and a potential therapeutic target in esophageal squamous cell carcinoma	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CANCER CELLS; BREAST-CANCER; TUMOR-GROWTH; FACTOR VEGF; P38 MAPK; ANGIOGENESIS; INVASION; PATHWAY; METASTASIS	Cell invasion and migration significantly contribute to tumor metastasis. Microtubule-associated protein 4 (MAP4) protein is one member of microtubule-associate proteins family. It is responsible for stabilization of microtubules by modulation of microtubule dynamics. However, there is little information about the involvement of MAP4 in human cancer. Here we show that MAP4 serves as a regulator of invasion and migration in esophageal squamous cancer cells. By activating the ERK-c-Jun-vascular endothelial growth factor A signaling pathway, MAP4 promotes cell invasion and migration in vitro, tumor growth and metastasis in mouse models. Immunohistochemical staining of operative tissues indicated that MAP4 expression was associated with tumor stage, lymph node metastasis and shorter survival of the patients with esophageal squamous cell carcinoma (ESCC). Multivariate Cox regression analysis showed that MAP4 is an independent prognostic indicator. In the serial sections of ESCC tissues, there was a positive correlation between MAP4 and vascular endothelial growth factor A expression. Notably, an intratumoral injection of MAP4-small interfering RNA (siRNA) remarkably inhibited the growth of the tumors that formed by the MAP4-expressing ESCC cells in nude mice, and a combination of MAP4-siRNA and Bevacizumab significantly enhanced the inhibition effect. Our data suggest that MAP4 is probably a useful prognostic biomarker and a potential therapeutic target for the disease.	[Jiang, Y-Y; Shang, L.; Shi, Z-Z; Zhang, T-T; Ma, S.; Zhang, Y.; Hao, J-J; Shi, C.; Shi, F.; Xu, X.; Cai, Y.; Zhan, Q-M; Wang, M-R] Peking Union Med Coll, Canc Inst Hosp, State Key Lab Mol Oncol, Panjiayuan South 17, Beijing 100021, Peoples R China; [Jiang, Y-Y; Shang, L.; Shi, Z-Z; Zhang, T-T; Ma, S.; Zhang, Y.; Hao, J-J; Shi, C.; Shi, F.; Xu, X.; Cai, Y.; Zhan, Q-M; Wang, M-R] Chinese Acad Med Sci, Panjiayuan South 17, Beijing 100021, Peoples R China; [Lu, C-C; Jia, X-M] Anhui Med Univ, Dept Histol & Embryol, Hefei, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Anhui Medical University	Wang, MR (corresponding author), Peking Union Med Coll, Canc Inst Hosp, State Key Lab Mol Oncol, Panjiayuan South 17, Beijing 100021, Peoples R China.; Wang, MR (corresponding author), Chinese Acad Med Sci, Panjiayuan South 17, Beijing 100021, Peoples R China.	wangmr2015@126.com		WANG, Ming-Rong/0000-0002-8767-9356	National Natural Science Foundation of China [81330052, 81321091]; National High-Tech R&D Program of China [2012AA02A503, 2012AA020206]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High-Tech R&D Program of China(National High Technology Research and Development Program of China)	This work was supported by National Natural Science Foundation of China (81330052 and 81321091) and National High-Tech R&D Program of China (2012AA02A503 and 2012AA020206).	Brock A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007048; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang W, 2001, J CELL SCI, V114, P2879; Chen HX, 2001, ONCOLOGY-NY, V15, P1017; Darrington E, 2012, ASIAN J ANDROL, V14, P745, DOI 10.1038/aja.2011.197; Deng ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036739; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Feng YB, 2009, INT J CANCER, V124, P578, DOI 10.1002/ijc.23990; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fruchon S, 2012, LEUKEMIA, V26, P795, DOI 10.1038/leu.2011.248; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; He Yu-Tong, 2005, Asian Pac J Cancer Prev, V6, P510; Honma N, 2006, LAB INVEST, V86, P687, DOI 10.1038/labinvest.3700427; Hu JY, 2010, CELL MOL LIFE SCI, V67, P321, DOI 10.1007/s00018-009-0187-z; Huang S, 2000, CANCER RES, V60, P5334; Jiang GZ, 2010, GUT, V59, P1535, DOI 10.1136/gut.2009.200105; Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114; Kremer BE, 2005, MOL BIOL CELL, V16, P4648, DOI 10.1091/mbc.E05-03-0267; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Lee WJ, 2008, TOXICOL APPL PHARM, V226, P178, DOI 10.1016/j.taap.2007.09.013; Luo ML, 2006, CANCER RES, V66, P11690, DOI 10.1158/0008-5472.CAN-06-1484; Monami G, 2006, CANCER RES, V66, P7103, DOI 10.1158/0008-5472.CAN-06-0633; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; Ou Y, 2014, UROL ONCOL, V32, pe21, DOI DOI 10.1016/J.UR0L0NC.2013.06.017; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; Patel V, 2011, CANCER RES, V71, P7103, DOI 10.1158/0008-5472.CAN-10-3192; Permana S, 2005, CELL STRUCT FUNCT, V29, P147, DOI 10.1247/csf.29.147; Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469; Tekedereli I, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.45; Weigand Melanie, 2005, Angiogenesis, V8, P197, DOI 10.1007/s10456-005-9010-0; Xu YB, 2013, EUR REV MED PHARMACO, V17, P2486; Zhang Y, 2008, INT J CANCER, V122, P260, DOI 10.1002/ijc.23104; Zhu B, 2012, HEPATO-GASTROENTEROL, V59, P785, DOI 10.5754/hge11427	40	24	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4846	4856		10.1038/onc.2016.17	http://dx.doi.org/10.1038/onc.2016.17			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876215				2022-12-28	WOS:000383330700003
J	Zhang, ZM; Wu, JF; Luo, QC; Liu, QF; Wu, QW; Ye, GD; She, HQ; Li, BA				Zhang, Z-M; Wu, J-F; Luo, Q-C; Liu, Q-F; Wu, Q-W; Ye, G-D; She, H-Q; Li, B-A			Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/beta-catenin pathway	ONCOGENE			English	Article							WNT SIGNALING PATHWAY; BETA-CATENIN; GENE-EXPRESSION; CELLS; NEUROBLASTOMA; COMPLEX; TRANSACTIVATION; TRANSCRIPTION; METHYLATION; MECHANISMS	The Wnt/beta-catenin pathway has important roles in chemoresistance and multidrug resistance 1 (MDR1) expression in some cancers, but its involvement in breast cancer and the underlying molecular mechanism are undefined. In this study, we demonstrated that the Wnt/beta-catenin pathway is activated in chemoresistant breast cancer cells. Using a Wnt pathway-specific PCR array screening assay, we detected that Pygo2, a newly identified Wnt/beta-catenin pathway component, was the most upregulated gene in the resistant cells. Additional experiments indicated that Pygo2 activated MDR1 expression in the resistant cells via the Wnt/beta-catenin pathway. Moreover, the inhibition of Pygo2 expression restored the chemotherapeutic drug sensitivity of the resistant cells and reduced the breast cancer stem cell population in these cells in response to chemotherapy. Importantly, these activities induced by Pygo2 were mediated by MDR1. We also determined the effect of Pygo2 on the sensitivity of breast tumors resistant to doxorubicin in a mouse model. Finally, RNA samples from 64 paired patient tumors (before and after chemotherapy) highly and significantly overexpressed Pygo2 and/or MDR1 after treatment, thus underlining a pivotal role for the Pygo2-mediated Wnt/beta-catenin pathway in the clinical chemoresistance of breast cancer. Our data represent the first implication of the Wnt/beta-catenin pathway in breast cancer chemoresistance and identify potential new targets to treat the recurrence of breast cancer.	[Zhang, Z-M; Luo, Q-C; Wu, Q-W; She, H-Q] Xiamen Univ, Affiliated Hosp 1, Dept Breast Surg, 55 Zhenhai Rd, Xiamen 361003, Fujian, Peoples R China; [Zhang, Z-M; Wu, J-F; Liu, Q-F; Ye, G-D; Li, B-A] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [Wu, J-F] Henan Univ Sci & Technol, Dept Bioengn, Coll Food & Bioengn, Luoyang, Peoples R China; [Liu, Q-F; Ye, G-D; Li, B-A] Xiamen Univ, Sch Life Sci, Engn Res Ctr Mol Diagnost, Minist Educ, Xiamen, Fujian, Peoples R China	Xiamen University; Xiamen University; Henan University of Science & Technology; Xiamen University	She, HQ (corresponding author), Xiamen Univ, Affiliated Hosp 1, Dept Breast Surg, 55 Zhenhai Rd, Xiamen 361003, Fujian, Peoples R China.; Li, BA (corresponding author), Xiamen Univ, Dept Biomed Sci, Sch Life Sci, D212 Huang Chaoyang Hall,Xiangan Campus, Xiamen 361100, Fujian, Peoples R China.	hongqiangshe68@163.com; bali@xmu.edu.cn	LUO, QI/GQH-7209-2022		'973' Project of the Ministry of Science and Technology [2013CB530600]; National Natural Science Foundation of China [U1205023, 81472457, 81201616, 81201617, 81272384]; Health-Education Joint Research Project of Fujian Province [WKJ-FJ-23]; Major Project of Science and Technology from the Department of Education [313051]; Natural Science Foundation of Fujian Province [2011D017]; Science and Technology Program of Xiamen [3502Z20114003]; 'Project 111' - State Bureau of Foreign Experts and Ministry of Education [B06016]	'973' Project of the Ministry of Science and Technology(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Health-Education Joint Research Project of Fujian Province; Major Project of Science and Technology from the Department of Education; Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Science and Technology Program of Xiamen; 'Project 111' - State Bureau of Foreign Experts and Ministry of Education	This work was supported by grants from the '973' Project of the Ministry of Science and Technology (grant numbers 2013CB530600 to B-AL); the National Natural Science Foundation of China (grant numbers U1205023, 81472457, 81201616, 81201617 and 81272384 to B-AL, Q-CL and Q-FL); the Health-Education Joint Research Project of Fujian Province (grant numbers WKJ-FJ-23 to B-AL and Z-MZ); the Major Project of Science and Technology from the Department of Education (grant number 313051 to B-AL); the Natural Science Foundation of Fujian Province (grant numbers 2011D017 to Z-MZ); the Science and Technology Program of Xiamen (grant numbers 3502Z20114003 to H-QS) and 'Project 111' sponsored by the State Bureau of Foreign Experts and Ministry of Education (grant number B06016).	Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; Andrews PGP, 2007, INT J ONCOL, V30, P357; Andrews PGP, 2009, BIOCHEM J, V422, P493, DOI 10.1042/BJ20090134; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5; Cai WY, 2013, J CELL SCI, V126, P2877, DOI 10.1242/jcs.123810; Cantu C, 2013, DEVELOPMENT, V140, P2377, DOI 10.1242/dev.093591; Carrera I, 2008, P NATL ACAD SCI USA, V105, P6644, DOI 10.1073/pnas.0709749105; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Flahaut M, 2009, ONCOGENE, V28, P2245, DOI 10.1038/onc.2009.80; Gu BN, 2013, CELL STEM CELL, V13, P48, DOI 10.1016/j.stem.2013.04.012; Gu BN, 2009, J CELL BIOL, V185, P811, DOI 10.1083/jcb.200810133; Haber M, 1997, EUR J CANCER, V33, P2031, DOI 10.1016/S0959-8049(97)00229-3; Han CY, 2008, CARCINOGENESIS, V29, P1837, DOI 10.1093/carcin/bgn092; Huang Chenghui, 2009, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V34, P369; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Li B, 2007, GENESIS, V45, P318, DOI 10.1002/dvg.20299; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-346; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Milovanovic T, 2004, INT J ONCOL, V25, P1337; Moghbeli M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0516-9; Munoz M, 2007, IUBMB LIFE, V59, P752, DOI 10.1080/15216540701736285; Nagahata T, 2003, CANCER SCI, V94, P515, DOI 10.1111/j.1349-7006.2003.tb01475.x; Polakis P, 2000, GENE DEV, V14, P1837; Popadiuk CM, 2006, CLIN CANCER RES, V12, P2216, DOI 10.1158/1078-0432.CCR-05-2433; Sun P, 2014, P NATL ACAD SCI USA, V111, P10215, DOI 10.1073/pnas.1311395111; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Townsley FM, 2004, NAT CELL BIOL, V6, P626, DOI 10.1038/ncb1141; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Wang ZX, 2010, J NEURO-ONCOL, V100, P31, DOI 10.1007/s11060-010-0144-6; Watanabe K, 2014, ONCOGENE, V33, P632, DOI 10.1038/onc.2012.620; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wright KJ, 2009, P NATL ACAD SCI USA, V106, P55, DOI 10.1073/pnas.0811914106; Yamada T, 2000, CANCER RES, V60, P4761; Zardawi SJ, 2009, HISTOL HISTOPATHOL, V24, P385, DOI 10.14670/HH-24.385	38	55	60	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4787	4797		10.1038/onc.2016.10	http://dx.doi.org/10.1038/onc.2016.10			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876203				2022-12-28	WOS:000383324700011
J	Wells, JE; Howlett, M; Halse, HM; Heng, J; Ford, J; Cheung, LC; Samuels, AL; Crook, M; Charles, AK; Cole, CH; Kees, UR				Wells, J. E.; Howlett, M.; Halse, H. M.; Heng, J.; Ford, J.; Cheung, L. C.; Samuels, A. L.; Crook, M.; Charles, A. K.; Cole, C. H.; Kees, U. R.			High expression of connective tissue growth factor accelerates dissemination of leukaemia	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; MARROW STROMAL CELLS; HUMAN-BONE-MARROW; EXTRACELLULAR-MATRIX; TUMOR-GROWTH; CLINICAL-SIGNIFICANCE; MOUSE MODEL; FACTOR CTGF; IN-VITRO	To improve treatment of acute lymphoblastic leukaemia (ALL), a better understanding of disease development is needed to tailor new therapies. Connective tissue growth factor (CTGF/CCN2) is highly expressed in leukaemia cells from the majority of paediatric patients with B-lineage ALL (pre-B ALL). CTGF is a matricellular protein and plays a role in aggressive cancers. Here we have genetically engineered leukaemia cells to modulate CTGF expression levels. Elevated CTGF levels accelerated disease dissemination and reduced survival in NOD/SCID mice. In vitro studies showed that CTGF protein induces stromal cell proliferation, promotes adhesion of leukaemia cells to stromal cells and leads to overexpression of genes associated with cell cycle and synthesis of extracellular matrix (ECM). Corresponding data from our leukaemia xenograft models demonstrated that CTGF leads to increased proliferation of non-leukaemia cells and deposition of ECM in the bone marrow. We document for the first time a functional role of CTGF in altering disease progression in a lymphoid malignancy. The findings provide support for targeting the bone marrow microenvironment in aggressive forms of leukaemia.	[Wells, J. E.; Howlett, M.; Halse, H. M.; Heng, J.; Ford, J.; Cheung, L. C.; Samuels, A. L.; Kees, U. R.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Wells, J. E.; Cole, C. H.; Kees, U. R.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia; [Crook, M.; Charles, A. K.; Cole, C. H.] Princess Margaret Hosp Children, Perth, WA, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Kees, UR (corresponding author), Telethon Kids Inst, Head Childrens Leukaemia & Canc Div, POB 855,West Perth, Perth, WA 6872, Australia.	ursula.kees@telethonkids.org.au	Cheung, Laurence/R-9932-2017; Cheung, Laurence/HGU-5859-2022	Cheung, Laurence/0000-0001-6298-5288; Cheung, Laurence/0000-0001-6298-5288; Howlett, Meegan/0000-0003-4332-6572				Aikawa T, 2006, MOL CANCER THER, V5, P1108, DOI 10.1158/1535-7163.MCT-05-0516; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; BENTLEY SA, 1981, BRIT J HAEMATOL, V48, P287, DOI 10.1111/j.1365-2141.1981.tb08462.x; Biondi A, 2012, LANCET ONCOL, V13, P936, DOI 10.1016/S1470-2045(12)70377-7; Boag JM, 2006, LEUKEMIA, V20, P1731, DOI 10.1038/sj.leu.2404365; Boag JM, 2007, BRIT J HAEMATOL, V138, P740, DOI 10.1111/j.1365-2141.2007.06739.x; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Boyerinas B, 2013, BLOOD, V121, P4821, DOI 10.1182/blood-2012-12-475483; Capparelli C, 2012, CELL CYCLE, V11, P2272, DOI 10.4161/cc.20717; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Cheung LC, 2014, HAEMATOLOGICA, V99, P1149, DOI 10.3324/haematol.2013.102327; Cichon MA, 2014, CELL ADHES MIGR, V8, P588, DOI 10.4161/19336918.2014.972788; Conter V, 2010, BLOOD, V115, P3206, DOI 10.1182/blood-2009-10-248146; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Duan CW, 2014, CANCER CELL, V25, P778, DOI 10.1016/j.ccr.2014.04.015; Dworzak MN, 2002, BLOOD, V99, P1952, DOI 10.1182/blood.V99.6.1952; Finger EC, 2014, ONCOGENE, V33, P1093, DOI 10.1038/onc.2013.47; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Fujii M, 2012, CELL CYCLE, V11, P3373, DOI 10.4161/cc.21397; GORDON MY, 1988, BRIT J HAEMATOL, V70, P1, DOI 10.1111/j.1365-2141.1988.tb02425.x; Ijichi H, 2011, J CLIN INVEST, V121, P4106, DOI 10.1172/JCI42754; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kang HN, 2010, BLOOD, V115, P1394, DOI 10.1182/blood-2009-05-218560; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; Khan RB, 2014, J CANCER SURVIV, V8, P688, DOI 10.1007/s11764-014-0375-1; Kim SK, 2014, MOL ONCOL, V8, P1653, DOI 10.1016/j.molonc.2014.06.016; Kuter DJ, 2007, BRIT J HAEMATOL, V139, P351, DOI 10.1111/j.1365-2141.2007.06807.x; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lu HB, 2014, ANN HEMATOL, V93, P485, DOI 10.1007/s00277-013-1939-2; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; MANABE A, 1994, BLOOD, V83, P758; Mayorca-Guiliani A, 2013, ONCOTARGETS THER, V6, P1729, DOI 10.2147/OTT.S38110; Neesse A, 2013, P NATL ACAD SCI USA, V110, P12325, DOI 10.1073/pnas.1300415110; Nishida T, 2000, J CELL PHYSIOL, V184, P197, DOI 10.1002/1097-4652(200008)184:2<197::AID-JCP7>3.0.CO;2-R; Noren-Nystrom U, 2008, LEUKEMIA, V22, P504, DOI 10.1038/sj.leu.2405072; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Pui CH, 2014, LEUKEMIA, V28, P2336, DOI 10.1038/leu.2014.142; Safadi FF, 2003, J CELL PHYSIOL, V196, P51, DOI 10.1002/jcp.10319; Sala-Torra O, 2007, BLOOD, V109, P3080, DOI 10.1182/blood-2006-06-031096; SANERKIN NG, 1964, J CLIN PATHOL, V17, P541, DOI 10.1136/jcp.17.5.541; Schultz KR, 2009, J CLIN ONCOL, V27, P5175, DOI 10.1200/JCO.2008.21.2514; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; Sison EAR, 2011, EXPERT REV HEMATOL, V4, P271, DOI [10.1586/ehm.11.30, 10.1586/EHM.11.30]; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Stow P, 2010, BLOOD, V115, P4657, DOI 10.1182/blood-2009-11-253435; Tesfai Y, 2012, LEUKEMIA RES, V36, P299, DOI 10.1016/j.leukres.2011.08.001; Vorwerk P, 2000, BRIT J CANCER, V83, P756, DOI 10.1054/bjoc.2000.1364; Welch MD, 2013, BRIT J HAEMATOL, V162, P537, DOI 10.1111/bjh.12417; Wells JE, 2015, INT J CANCER, V137, P504, DOI 10.1002/ijc.28972; WICKRAMASINGHE SN, 1991, CLIN LAB HAEMATOL, V13, P263; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zombori L, 2013, PEDIATR RHEUMATOL, V11, DOI 10.1186/1546-0096-11-20	55	5	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4591	4600		10.1038/onc.2015.525	http://dx.doi.org/10.1038/onc.2015.525			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26804166				2022-12-28	WOS:000382336300005
J	Kim, JE; Roh, E; Lee, MH; Yu, DH; Kim, DJ; Lim, TG; Jung, SK; Peng, C; Cho, YY; Dickinson, S; Alberts, D; Bowden, GT; Einspahr, J; Stratton, SP; Curiel-Lewandrowski, C; Bode, AM; Lee, KW; Dong, Z				Kim, J-E; Roh, E.; Lee, M. H.; Yu, D. H.; Kim, D. J.; Lim, T-G; Jung, S. K.; Peng, C.; Cho, Y-Y; Dickinson, S.; Alberts, D.; Bowden, G. T.; Einspahr, J.; Stratton, S. P.; Curiel-Lewandrowski, C.; Bode, A. M.; Lee, K. W.; Dong, Z.			Fyn is a redox sensor involved in solar ultraviolet light-induced signal transduction in skin carcinogenesis	ONCOGENE			English	Article							SRC-FAMILY KINASES; TYROSINE PHOSPHORYLATION; PKC-DELTA; C-DELTA; APOPTOSIS; CANCER; ACTIVATION; RADIATION; STRESS; TARGET	Solar ultraviolet (UV) light is a major etiological factor in skin carcinogenesis, with solar UV-stimulated signal transduction inducing pathological changes and skin damage. The primary sensor of solar UV-induced cellular signaling has not been identified. We use an experimental system of solar simulated light (SSL) to mimic solar UV and we demonstrate that Fyn is a primary redox sensor involved in SSL-induced signal transduction. Reactive oxygen species (ROS) generated by SSL exposure directly oxidize Cys488 of Fyn, resulting in increased Fyn kinase activity. Fyn oxidation was increased in mouse skin after SSL exposure and Fyn-knockout mice formed larger and more tumors compared with Fyn wild-type mice when exposed to SSL for an extended period of time. Murine embryonic fibroblasts (MEFs) lacking Fyn and cells in which Fyn expression was knocked down were resistant to SSL-induced apoptosis. Furthermore, cells expressing mutant Fyn (C448A) were resistant to SSL-induced apoptosis. These findings suggest that Fyn acts as a regulatory nexus between solar UV, ROS and signal transduction during skin carcinogenesis.	[Kim, J-E; Roh, E.; Lee, M. H.; Yu, D. H.; Kim, D. J.; Lim, T-G; Jung, S. K.; Peng, C.; Cho, Y-Y; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Kim, J-E; Lim, T-G; Jung, S. K.; Lee, K. W.] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea; [Kim, J-E; Lim, T-G; Lee, K. W.] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon, Gyeonggi Do, South Korea; [Lee, M. H.] China US Hormel Canc Inst, Zhenzhou, Henan, Peoples R China; [Lim, T-G; Jung, S. K.] Korea Food Res Inst, Div Strateg Food Res, Songnam, Gyeonggi Do, South Korea; [Cho, Y-Y] Catholic Univ Korea, Coll Pharm, Bucheon Si, Gyeonggi Do, South Korea; [Dickinson, S.; Alberts, D.; Bowden, G. T.; Einspahr, J.; Stratton, S. P.; Curiel-Lewandrowski, C.] Univ Arizona, Ctr Canc, Tucson, AZ USA	University of Minnesota System; Seoul National University (SNU); Seoul National University (SNU); Korea Food Research Institute (KFRI); Catholic University of Korea; University of Arizona	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Lee, KW (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea.	kiwon@snu.ac.kr; zgdong@hi.umn.edu	Lee, Ki Won/M-4114-2018; kim, jong-eun/B-3550-2017; Lim, Tae-Gyu/AAO-8475-2020; Cho, Yong-Yeon/AAD-4263-2020	kim, jong-eun/0000-0002-5030-6126; Lim, Tae-Gyu/0000-0001-6930-9565; Cho, Yong-Yeon/0000-0003-1107-2651	National Institutes of Health [CA077646, CA027502, CA166011, CA172457, R37CA081064]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [F00044]; Leap Research Program through the National Research Foundation, Ministry of Science, ICT and Future Planning, Republic of Korea [2015R1A2A1A10053567]; Hormel Foundation; NATIONAL CANCER INSTITUTE [P01CA027502, R37CA081064, R01CA077646, R21CA172457, R01CA166011] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology; Leap Research Program through the National Research Foundation, Ministry of Science, ICT and Future Planning, Republic of Korea; Hormel Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Hormel Foundation and National Institutes of Health grants to ZD (CA077646, CA027502, CA166011, CA172457 and R37CA081064), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (F00044) and the Leap Research Program through the National Research Foundation, Ministry of Science, ICT and Future Planning, Republic of Korea (2015R1A2A1A10053567).	Abdel-Malek ZA, 2010, PIGM CELL MELANOMA R, V23, P171, DOI 10.1111/j.1755-148X.2010.00679.x; Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328; Basu A, 2010, THESCIENTIFICWORLDJO, V10, P2272, DOI 10.1100/tsw.2010.214; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Breitkreutz D, 2007, J CANCER RES CLIN, V133, P793, DOI 10.1007/s00432-007-0280-3; Byun S, 2013, CARCINOGENESIS, V34, P397, DOI 10.1093/carcin/bgs358; Byun S, 2010, CANCER RES, V70, P2415, DOI 10.1158/0008-5472.CAN-09-4093; Chan CB, 2010, DIABETES, V59, P883, DOI 10.2337/db09-1404; Chen ZY, 2011, CARCINOGENESIS, V32, P1419, DOI 10.1093/carcin/bgr088; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005; Giannoni E, 2010, FREE RADICAL BIO MED, V49, P516, DOI 10.1016/j.freeradbiomed.2010.04.025; Hanson KM, 2002, PHOTOCHEM PHOTOBIOL, V76, P57, DOI 10.1562/0031-8655(2002)076<0057:OAQOUI>2.0.CO;2; Humphries MJ, 2008, ONCOGENE, V27, P3045, DOI 10.1038/sj.onc.1210967; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Jung SK, 2008, CANCER RES, V68, P6021, DOI 10.1158/0008-5472.CAN-08-0899; Krutmann J, 2010, TXB AGING SKIN, P101; Kulms D, 2002, J INVEST DERM SYMP P, V7, P46, DOI 10.1046/j.1523-1747.2002.19638.x; Lee KM, 2010, BIOCHEM PHARMACOL, V80, P2042, DOI 10.1016/j.bcp.2010.06.042; Lee KM, 2010, CANCER PREV RES, V3, P454, DOI 10.1158/1940-6207.CAPR-09-0137; Li JX, 2012, CANCER RES, V72, P260, DOI 10.1158/0008-5472.CAN-11-2596; Li WJ, 2007, J BIOL CHEM, V282, P1161, DOI 10.1074/jbc.M606583200; Lippens S, 2009, APOPTOSIS, V14, P549, DOI 10.1007/s10495-009-0324-z; Liu KD, 2013, CANCER RES, V73, P2181, DOI 10.1158/0008-5472.CAN-12-3408; Loesch M, 2008, FRONT BIOSCI-LANDMRK, V13, P3581, DOI 10.2741/2951; Madan V, 2010, LANCET, V375, P673, DOI 10.1016/S0140-6736(09)61196-X; Narayanan DL, 2010, INT J DERMATOL, V49, P978, DOI 10.1111/j.1365-4632.2010.04474.x; Oi N, 2012, CANCER PREV RES, V5, P1103, DOI 10.1158/1940-6207.CAPR-11-0397; Parkin DM, 2011, BRIT J CANCER, V105, pS66, DOI 10.1038/bjc.2011.486; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Raj D, 2006, J INVEST DERMATOL, V126, P243, DOI 10.1038/sj.jid.5700008; Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879; Shim JH, 2010, CANCER PREV RES, V3, P670, DOI 10.1158/1940-6207.CAPR-09-0185; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019; Tang X, 2007, CELL DEATH DIFFER, V14, P368, DOI 10.1038/sj.cdd.4402011; Vasant C, 2003, FREE RADICAL BIO MED, V35, P1082, DOI 10.1016/S0891-5849(03)00471-4; Wagener FADTG, 2013, INT J MOL SCI, V14, P9126, DOI 10.3390/ijms14059126; Xu YR, 2005, J DERMATOL SCI, pS1, DOI 10.1016/j.descs.2005.06.002; Yoo SK, 2011, NATURE, V480, P109, DOI 10.1038/nature10632; Zhao L, 2009, CANCER RES, V69, P9439, DOI 10.1158/0008-5472.CAN-09-2976	42	21	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4091	4101		10.1038/onc.2015.471	http://dx.doi.org/10.1038/onc.2015.471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686094	Green Accepted			2022-12-28	WOS:000381020900007
J	Chen, Y; Guo, Y; Zhao, W; Ho, WTT; Fu, X; Zhao, ZJ				Chen, Y.; Guo, Y.; Zhao, W.; Ho, W-T Tina; Fu, X.; Zhao, Z. J.			Identification of an orally available compound with potent and broad FLT3 inhibition activity	ONCOGENE			English	Article							TYROSINE KINASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; EFFECTIVE PROTEIN SUBSTRATE; DRUG-RESISTANCE; MUTANT FLT3; AMG 925; MUTATIONS; EXPRESSION; GENERATION; CRENOLANIB	FLT3 internal tandem duplication (FLT3-ITD) is an activating mutation found in 20-30% of patients with acute myeloid leukemia (AML), which makes FLT3 an attractive target for the treatment of AML. Although FLT3-mutant patients respond to current FLT3 inhibitors, relapse usually happens because of the acquisition of resistant secondary mutations at the FLT3 catalytic domain, which is mainly on D835. In the search for compounds with broad FLT3 inhibition activities, we screened a kinase inhibitor library by using our unique FLT3 substrate and identified JAK3 inhibitor VI (designated JI6 hereafter) as a novel FLT3 inhibitor, which selectively targets FLT3 D835 mutants as well as FLT3-ITD. JI6 effectively inhibited FLT3-ITD-containing MV4-11 cells and HCD-57 cells transformed with FLT3-ITD and D835 mutants. Furthermore, administration of JI6 effectively targeted FLT3 signaling in vivo and suppressed the myeloproliferative phenotypes in FLT3-ITD knock-in mice, and significantly prolonged the survival of immunodeficient mice implanted with the transformed HCD-57 cells. Therefore, JI6 is a promising candidate for the development of next-generation anti-AML drugs.	[Chen, Y.; Zhao, W.; Ho, W-T Tina; Zhao, Z. J.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA; [Guo, Y.; Fu, X.; Zhao, Z. J.] Jilin Univ, Coll Life Sci, Edmond H Fischer Signal Transduct Lab, Changchun 130023, Peoples R China	University of Oklahoma System; University of Oklahoma Health Sciences Center; Jilin University	Zhao, ZJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	joe-zhao@ouhsc.edu			National Institutes of Health [HL079441]; Oklahoma Center for the Advancement of Science and Technology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079441] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Oklahoma Center for the Advancement of Science and Technology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Grant HL079441 from the National Institutes of Health and a grant from Oklahoma Center for the Advancement of Science and Technology.	Adams C, 2003, BIOORG MED CHEM LETT, V13, P3105, DOI 10.1016/S0960-894X(03)00657-7; Annesley CE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00263; Bramson HN, 2001, J MED CHEM, V44, P4339, DOI 10.1021/jm010117d; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Chen Y, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-39; Cools J, 2004, CANCER RES, V64, P6385, DOI 10.1158/0008-5472.CAN-04-2148; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Estey EH, 2014, AM J HEMATOL, V89, P1063, DOI 10.1002/ajh.23834; Farkas T, 2011, J BIOL CHEM, V286, P38904, DOI 10.1074/jbc.M111.269134; Gregory TK, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-23; Guo Y, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-72; Hofmann M, 2012, LEUKEMIA, V26, P1228, DOI 10.1038/leu.2011.372; Hsu FYY, 2006, CANCER RES, V66, P9002, DOI 10.1158/0008-5472.CAN-05-4101; Lee BH, 2007, CANCER CELL, V12, P367, DOI 10.1016/j.ccr.2007.08.031; Lee HK, 2014, BLOOD, V123, P2209, DOI 10.1182/blood-2013-04-493916; Leung AYH, 2013, LEUKEMIA, V27, P260, DOI 10.1038/leu.2012.195; Levis M, 2014, FUTURE ONCOL, V10, P1571, DOI [10.2217/FON.14.105, 10.2217/fon.14.105]; Li C, 2015, MOL CANCER THER, V14, P375, DOI 10.1158/1535-7163.MCT-14-0388; Li Z, 2007, EXP HEMATOL, V35, P1624, DOI 10.1016/j.exphem.2007.07.003; Li Z, 2007, J BIOL CHEM, V282, P3428, DOI 10.1074/jbc.C600277200; Li ZH, 2014, J MED CHEM, V57, P3430, DOI 10.1021/jm500118j; Lockman JW, 2011, BIOORG MED CHEM LETT, V21, P1724, DOI 10.1016/j.bmcl.2011.01.077; Ma HS, 2014, CANCER RES, V74, P5206, DOI 10.1158/0008-5472.CAN-14-1028; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Moreno-Miralles I, 2005, J BIOL CHEM, V280, P40097, DOI 10.1074/jbc.M506855200; Papaetis GS, 2009, BIODRUGS, V23, P377, DOI 10.2165/11318860-000000000-00000; Schlenk RF, 2014, BLOOD, V124, P3441, DOI 10.1182/blood-2014-05-578070; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Smith CC, 2012, NATURE, V485, P260, DOI 10.1038/nature11016; Smith CC, 2014, P NATL ACAD SCI USA, V111, P5319, DOI 10.1073/pnas.1320661111; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Swords R, 2012, LEUKEMIA, V26, P2176, DOI 10.1038/leu.2012.114; Takahashi S, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-36; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; WEN DY, 1994, J BIOL CHEM, V269, P22839; Williams AB, 2013, LEUKEMIA, V27, P48, DOI 10.1038/leu.2012.191; Wodicka LM, 2010, CHEM BIOL, V17, P1241, DOI 10.1016/j.chembiol.2010.09.010; Wood ER, 2004, BIOORG MED CHEM LETT, V14, P953, DOI 10.1016/j.bmcl.2003.12.002; Xing S, 2008, BLOOD, V111, P5109, DOI 10.1182/blood-2007-05-091579; Xu MJ, 2003, BLOOD, V102, P4354, DOI 10.1182/blood-2003-04-1308; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034; Zhang WG, 2008, JNCI-J NATL CANCER I, V100, P184, DOI 10.1093/jnci/djm328; Zhao W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099017; Zhao WK, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-15; Zimmerman EI, 2013, BLOOD, V122, P3607, DOI 10.1182/blood-2013-07-513044	46	8	8	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2971	2978		10.1038/onc.2015.362	http://dx.doi.org/10.1038/onc.2015.362			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26411368	Green Accepted			2022-12-28	WOS:000377474500003
J	Wilky, BA; Kim, C; McCarty, G; Montgomery, EA; Kammers, K; DeVine, LR; Cole, RN; Raman, V; Loeb, DM				Wilky, B. A.; Kim, C.; McCarty, G.; Montgomery, E. A.; Kammers, K.; DeVine, L. R.; Cole, R. N.; Raman, V.; Loeb, D. M.			RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma	ONCOGENE			English	Article							CELL-GROWTH; PROTEIN; TRANSLATION; TUMOR; RESISTANCE; STRATEGY; SURVIVAL; FUSION	RNA helicase DDX3 has oncogenic activity in breast and lung cancers and is required for translation of complex mRNA transcripts, including those encoding key cell-cycle regulatory proteins. We sought to determine the expression and function of DDX3 in sarcoma cells, and to investigate the antitumor activity of a novel small molecule DDX3 inhibitor, RK-33. Utilizing various sarcoma cell lines, xenografts and human tissue microarrays, we measured DDX3 expression at the mRNA and protein levels, and evaluated cytotoxicity of RK-33 in sarcoma cell lines. To study the role of DDX3 in Ewing sarcoma, we generated stable DDX3-knockdown Ewing sarcoma cell lines using DDX3-specific small hairpin RNA (shRNA), and assessed oncogenic activity. DDX3-knockdown and RK-33-treated Ewing sarcoma cells were compared with wild-type cells using an isobaric mass-tag quantitative proteomics approach to identify target proteins impacted by DDX3 inhibition. Overall, we found high expression of DDX3 in numerous human sarcoma subtypes compared with non-malignant mesenchymal cells, and knockdown of DDX3 by RNA interference inhibited oncogenic activity in Ewing sarcoma cells. Treatment with RK-33 was preferentially cytotoxic to sarcoma cells, including chemotherapy-resistant Ewing sarcoma stem cells, while sparing non-malignant cells. Sensitivity to RK-33 correlated with DDX3 protein expression. Growth of human Ewing sarcoma xenografts expressing high DDX3 was inhibited by RK-33 treatment in mice, without overt toxicity. DDX3 inhibition altered the Ewing sarcoma cellular proteome, especially proteins involved in DNA replication, mRNA translation and proteasome function. These data support further investigation of the role of DDX3 in sarcomas, advancement of RK-33 to Ewing sarcoma clinical trials and development of RNA helicase inhibition as a novel anti-neoplastic strategy.	[Wilky, B. A.; Kim, C.; McCarty, G.; Raman, V.; Loeb, D. M.] Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Montgomery, E. A.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Kammers, K.] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [DeVine, L. R.; Cole, R. N.] Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD USA; [Raman, V.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University	Wilky, BA (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, 1120 NW 14th St,Suite 610E, Miami, FL 33136 USA.	b.wilky@med.miami.edu		Wilky, Breelyn/0000-0001-5080-497X	NIH [R01 CA138212, T32 CA009071-31, P30 CA006973, HHSN268201000032C]; Alex's Lemonade Stand Foundation, LLC; Conquer Cancer Foundation/ASCO Young Investigator Award - WWWW Foundation, Inc. (QuadW); Giant Food Children's Cancer Research Fund; Heather Brooke Foundation; German Research Foundation [KA 3884/1-1]; Flight Attendant Medical Research Institute (FAMRI); Alpha Omega Alpha Postgraduate Award; NATIONAL CANCER INSTITUTE [R01CA138212, P30CA006973, T32CA009071] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alex's Lemonade Stand Foundation, LLC; Conquer Cancer Foundation/ASCO Young Investigator Award - WWWW Foundation, Inc. (QuadW); Giant Food Children's Cancer Research Fund; Heather Brooke Foundation; German Research Foundation(German Research Foundation (DFG)); Flight Attendant Medical Research Institute (FAMRI); Alpha Omega Alpha Postgraduate Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to thank Jeffrey Toretsky (Georgetown University), Jonathan Powell (JHU), Lee Helman (NIH), Chand Khanna (Pediatric Oncology Branch NCI) and Nita Ahuja (JHU) for providing cell lines and xenografts. They also credit Richard Jones, MD, Milada Vala and Gabriel Ghaiur, MD, PhD (JHU) for assistance with hematopoietic stem cells experiments; Hao Zhang, PhD (JHU) for assistance with flow cytometry; and Enrico Capobianco at the Center for Computational Analysis at the University of Miami for assistance with STRING networking. This work was supported by grants from the NIH (R01 CA138212 (DL),T32 CA009071-31 (BW), P30 CA006973 and HHSN268201000032C) (RC); a 2013 Reach Award from Alex's Lemonade Stand Foundation, LLC (DL); a Conquer Cancer Foundation/ASCO 2012 Young Investigator Award sponsored by WWWW Foundation, Inc. (QuadW) (BW); additional funding provided from the Giant Food Children's Cancer Research Fund (DL), the Heather Brooke Foundation (DL), German Research Foundation (KA 3884/1-1) (KK), Flight Attendant Medical Research Institute (FAMRI) (VR), and a 2012 Alpha Omega Alpha Postgraduate Award (BW).	Abdelhaleem M, 2004, BBA-REV CANCER, V1704, P37, DOI 10.1016/j.bbcan.2004.05.001; Awad O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013943; Bol GM, 2012, CANC RES CHICAGO IL; Bol GM, 2015, EMBO MOL MED, V7, P648, DOI 10.15252/emmm.201404368; Bol GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063548; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Fukumura J, 2003, J BIOCHEM, V134, P71, DOI 10.1093/jb/mvg126; Garbelli A, 2011, CURR MED CHEM, V18, P3015, DOI 10.2174/092986711796391688; Geissler R, 2012, NUCLEIC ACIDS RES, V40, P4998, DOI 10.1093/nar/gks070; Gonzalez-Nieto D, 2012, BLOOD, V119, P5144, DOI 10.1182/blood-2011-07-368506; HAZELTON BJ, 1987, CANCER RES, V47, P4501; Herbrich SM, 2013, J PROTEOME RES, V12, P594, DOI 10.1021/pr300624g; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Italiano A, 2011, CANCER-AM CANCER SOC, V117, P1049, DOI 10.1002/cncr.25538; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Kondaskar A, 2011, ACS MED CHEM LETT, V2, P252, DOI 10.1021/ml100281b; Lai MC, 2008, MOL BIOL CELL, V19, P3847, DOI 10.1091/mbc.E07-12-1264; Lai MC, 2010, MOL CELL BIOL, V30, P5444, DOI 10.1128/MCB.00560-10; Lee CS, 2008, NUCLEIC ACIDS RES, V36, P4708, DOI 10.1093/nar/gkn454; Miao XY, 2013, INT J CLIN EXP PATHO, V6, P179; NYGREN P, 1991, INT J CANCER, V48, P598, DOI 10.1002/ijc.2910480419; Pierce A, 2008, MOL CELL PROTEOMICS, V7, P853, DOI 10.1074/mcp.M700251-MCP200; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Shih JW, 2008, ONCOGENE, V27, P700, DOI 10.1038/sj.onc.1210687; Sison EAR, 2013, BRIT J HAEMATOL, V160, P785, DOI 10.1111/bjh.12205; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soto-Rifo R, 2012, EMBO J, V31, P3745, DOI 10.1038/emboj.2012.220; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Sun M, 2008, CELL DEATH DIFFER, V15, P1887, DOI 10.1038/cdd.2008.124; Sun MN, 2013, BBA-MOL CELL RES, V1833, P1489, DOI 10.1016/j.bbamcr.2013.02.026; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Velikodvorskaya T, 2010, CANCER RES, V70, P663; Wang YX, 2011, PROTEOMICS, V11, P2019, DOI 10.1002/pmic.201000722; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107	39	39	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2574	2583		10.1038/onc.2015.336	http://dx.doi.org/10.1038/onc.2015.336			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364611				2022-12-28	WOS:000376165700004
J	Li, X; Liang, Q; Liu, W; Zhang, N; Xu, L; Zhang, X; Zhang, J; Sung, JJY; Yu, J				Li, X.; Liang, Q.; Liu, W.; Zhang, N.; Xu, L.; Zhang, X.; Zhang, J.; Sung, J. J. Y.; Yu, J.			Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway	ONCOGENE			English	Article							FUNCTIONAL TUMOR-SUPPRESSOR; CELL-CYCLE PROGRESSION; C-JUN; EPIGENETIC INACTIVATION; TRANSCRIPTION; RASSF10; METHYLATION; PROTEIN; GENE; AP-1	The Ras association domain family (RASSF) encodes several members with tumor-suppressive potentials. We aimed to investigate the biological function and clinical implication of RASSF10 in gastric cancer (GC). We found that RASSF10 was silenced in six of seven GC cell lines and in primary GC tissues, but was highly expressed in normal gastric tissues. The silence of RASSAF10 was mediated by promoter methylation as evaluated by bisulfite genomic sequencing. RASSF10 expression could be restored by demethylation treatment. A negative correlation between methylation and mRNA expression of RASSF10 was observed in 223 gastric samples of The Cancer Genome Atlas study (P<0.0001). Re-expression of RASSF10 in GC cell lines (AGS and MKN45) significantly suppressed cell viability, colony formation, migration and invasion, reduced cells in S phase, accumulated cells in G2 phase and induced cell apoptosis in vitro, and inhibited tumorigenicity in nude mice. These were confirmed by decreased expression of proliferation markers (proliferating cell nuclear antigen, p-CDC2 and p-CDC25) and increased apoptotic cascades (cleaved caspases-9, -8, -3 and cleaved poly (ADP-ribose) polymerase). Conversely, RASSF10 knockdown in normal gastric cell line yielded an opposing effect. Co-immunoprecipitation combined with mass spectrometry analyses were performed to reveal the downstream effectors of RASSF10. The result revealed that glutathione S-transferase Pi 1 (GSTP1) was a direct cooperator of RASSF10. The tumor-suppressive effect of RASSF10 was partially mediated by cooperating with GSTP1 to deregulate Jun N-terminal kinase (JNK)/c-Jun/AP-1 pathway. Importantly, RASSF10 methylation was detected in 56.6% (98/173) of primary GCs and is an independent risk factor for poor survival of GC patients (P = 0.001). In conclusions, RASSF10 functions as a tumor suppressor by cooperating with GSTP1 to deregulate JNK/c-Jun/AP-1 pathway in GC. Promoter methylation of RASSF10 is associated with poor survival of GC patients.	[Li, X.; Liang, Q.; Xu, L.; Zhang, X.; Zhang, J.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Institute Digest Dis,Dept Med & Therapeut,State K, Shatin, Hong Kong, Peoples R China; [Li, X.] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Liu, W.] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China; [Zhang, N.; Xu, L.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China	Chinese University of Hong Kong; State Key Lab Oncology South China; Sun Yat Sen University; Zhejiang University; Sun Yat Sen University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Li, Xiao-xing/B-9114-2008; Liang, Qiaoyi Jessie/G-9612-2019; ZHANG, Xiang/N-7918-2015; Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015; ZHANG, Jingwan/AIC-2560-2022	Li, Xiao-xing/0000-0001-8791-7505; Liang, Qiaoyi Jessie/0000-0001-8496-3442; ZHANG, Xiang/0000-0002-3222-5824; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153; ZHANG, Jingwan/0000-0002-0344-3398	Natural Science Foundation of China (NSFC) [81201963, 81372600]; China 863 Program [2012AA02A504]; Shenzhen Municipal Science and Technology RD fund [JCYJ20130401151108652]; Pearl River SAMP;T Nova Program of Guangzhou [201506010050]; Shenzhen Virtual University Park Support Scheme; Natural Science Foundation of China (NSFC) [81201963, 81372600]; China 863 Program [2012AA02A504]; Shenzhen Municipal Science and Technology RD fund [JCYJ20130401151108652]; Pearl River SAMP;T Nova Program of Guangzhou [201506010050]; Shenzhen Virtual University Park Support Scheme	Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China 863 Program(National High Technology Research and Development Program of China); Shenzhen Municipal Science and Technology RD fund; Pearl River SAMP;T Nova Program of Guangzhou; Shenzhen Virtual University Park Support Scheme; Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China 863 Program(National High Technology Research and Development Program of China); Shenzhen Municipal Science and Technology RD fund; Pearl River SAMP;T Nova Program of Guangzhou; Shenzhen Virtual University Park Support Scheme	This project was supported by research funds of Natural Science Foundation of China (NSFC) (81201963 and 81372600), a China 863 Program (2012AA02A504), Shenzhen Municipal Science and Technology R&D fund (JCYJ20130401151108652), Pearl River S&T Nova Program of Guangzhou (201506010050) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. The results shown here are in part based on data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CELIS JE, 1988, ARCH BIOL MED EXP, V21, P417; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Lee JG, 2013, FOOD CHEM TOXICOL, V55, P214, DOI 10.1016/j.fct.2012.12.026; Li X, 2012, ONCOGENE, V31, P3419, DOI 10.1038/onc.2011.511; Li X, 2014, CANCER LETT, V348, P146, DOI 10.1016/j.canlet.2014.03.017; Li ZH, 2014, ONCOL REP, V31, P1661, DOI 10.3892/or.2014.3039; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Otani K, 2013, EXPERT REV MOL DIAGN, V13, P445, DOI [10.1586/ERM.13.32, 10.1586/erm.13.32]; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Richter AM, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.18; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Takai Daiya, 2003, In Silico Biology, V3, P235; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tomita H, 2011, GASTROENTEROLOGY, V140, P879, DOI 10.1053/j.gastro.2010.11.037; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Wei ZR, 2013, BIOCHEM BIOPH RES CO, V432, P632, DOI 10.1016/j.bbrc.2013.02.033; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xu LX, 2012, GUT, V61, P977, DOI 10.1136/gutjnl-2011-300411; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zhang Y, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-145	35	22	22	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2453	2464		10.1038/onc.2015.300	http://dx.doi.org/10.1038/onc.2015.300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279301				2022-12-28	WOS:000376165500004
J	Calabretta, S; Bielli, P; Passacantilli, I; Pilozzi, E; Fendrich, V; Capurso, G; Delle Fave, G; Sette, C				Calabretta, S.; Bielli, P.; Passacantilli, I.; Pilozzi, E.; Fendrich, V.; Capurso, G.; Delle Fave, G.; Sette, C.			Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells	ONCOGENE			English	Article							PYRUVATE-KINASE; EMERGING ROLE; RNA; APOPTOSIS; M2; TRANSCRIPTION; ACTIVATION; PATHWAYS; REVEALS; ISOFORM	Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first-line chemotherapeutic approach. Thus, there is a strong need for novel therapies, targeting more directly the molecular aberrations of this disease. We found that chronic exposure of PDAC cells to gemcitabine selected a subpopulation of cells that are drug-resistant (DR-PDAC cells). Importantly, alternative splicing (AS) of the pyruvate kinase gene (PKM) was differentially modulated in DR-PDAC cells, resulting in promotion of the cancer-related PKM2 isoform, whose high expression also correlated with shorter recurrence-free survival in PDAC patients. Switching PKM splicing by antisense oligonucleotides to favor the alternative PKM1 variant rescued sensitivity of DR-PDAC cells to gemcitabine and cisplatin, suggesting that PKM2 expression is required to withstand drug-induced genotoxic stress. Mechanistically, upregulation of the polypyrimidine-tract binding protein (PTBP1), a key modulator of PKM splicing, correlated with PKM2 expression in DR-PDAC cell lines. PTBP1 was recruited more efficiently to PKM pre-mRNA in DR-than in parental PDAC cells. Accordingly, knockdown of PTBP1 in DR-PDAC cells reduced its recruitment to the PKM pre-mRNA, promoted splicing of the PKM1 variant and abolished drug resistance. Thus, chronic exposure to gemcitabine leads to upregulation of PTBP1 and modulation of PKM AS in PDAC cells, conferring resistance to the drug. These findings point to PKM2 and PTBP1 as new potential therapeutic targets to improve response of PDAC to chemotherapy.	[Calabretta, S.; Passacantilli, I.; Sette, C.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy; [Calabretta, S.; Passacantilli, I.; Capurso, G.; Delle Fave, G.] Univ Roma La Sapienza, Dept Sci Med Chirurg & Translat Med, Via Grottarossa, I-00189 Rome, Italy; [Bielli, P.; Sette, C.] Fdn Santa Lucia, Lab Neuroembryol, Rome, Italy; [Pilozzi, E.] Univ Roma La Sapienza, Dept Clin & Mol Med, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Fendrich, V.] Univ Marburg, Dept Surg, Marburg, Germany	University of Rome Tor Vergata; Sapienza University Rome; IRCCS Santa Lucia; Sapienza University Rome; Philipps University Marburg	Sette, C (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.; Delle Fave, G (corresponding author), Univ Roma La Sapienza, Dept Sci Med Chirurg & Translat Med, Via Grottarossa, I-00189 Rome, Italy.	gianfranco.dellefave@uniroma1.it; claudio.sette@uniroma2.it	PILOZZI, Emanuela/AAC-1854-2022; Sette, Claudio/S-4307-2019; Capurso, Gabriele/AAB-1389-2019; Bielli, Pamela/K-1208-2018	PILOZZI, Emanuela/0000-0002-7110-9172; Sette, Claudio/0000-0003-2864-8266; Capurso, Gabriele/0000-0002-0019-8753; Bielli, Pamela/0000-0003-3347-8345	Association for International Cancer Research (AICR) [12-0150]; Associazione Italiana Ricerca sul Cancro (AIRC) [14581]; Fondazione Santa Lucia Ricerca Corrente; Worldwide Cancer Research [12-0150] Funding Source: researchfish	Association for International Cancer Research (AICR); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Santa Lucia Ricerca Corrente; Worldwide Cancer Research	We thank Andrea D'Ascenzo and Enrico Duranti for help with immunohistochemistry; Dr Chiara Naro for helpful suggestions throughout the study; and Dr Vittoria Pagliarini for critical reading of the manuscript. This work was supported by Association for International Cancer Research (AICR) (grant 12-0150), Associazione Italiana Ricerca sul Cancro (AIRC) (grant 14581) and Fondazione Santa Lucia Ricerca Corrente.	Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306; Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Bielli P, 2014, NUCLEIC ACIDS RES, V42, P12070, DOI 10.1093/nar/gku922; Bielli P, 2014, EMBO REP, V15, P419, DOI 10.1002/embr.201338241; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Bonomi Serena, 2013, Int J Cell Biol, V2013, P962038, DOI 10.1155/2013/962038; Braunschweig U, 2013, CELL, V152, P1252, DOI 10.1016/j.cell.2013.02.034; Busa R, 2010, NUCLEIC ACIDS RES, V38, P3005, DOI 10.1093/nar/gkq004; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Cerwenka H, 1999, ANTICANCER RES, V19, P849; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011; Costello BA, 2014, INVEST NEW DRUG, V32, P710, DOI 10.1007/s10637-014-0096-3; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Dutertre M, 2011, RNA BIOL, V8, P740, DOI 10.4161/rna.8.5.16016; Goldberg MS, 2012, J EXP MED, V209, P217, DOI 10.1084/jem.20111487; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Hayes GM, 2007, CANCER RES, V67, P2072, DOI 10.1158/0008-5472.CAN-06-2969; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kole R, 2012, NAT REV DRUG DISCOV, V11, P125, DOI 10.1038/nrd3625; Llorian M, 2010, NAT STRUCT MOL BIOL, V17, P1114, DOI 10.1038/nsmb.1881; Maimon A, 2014, CELL REP, V7, P501, DOI 10.1016/j.celrep.2014.03.041; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Michl P, 2013, GUT, V62, P317, DOI 10.1136/gutjnl-2012-303588; Nakajima S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084899; Naro Chiara, 2013, Int J Cell Biol, V2013, P151839, DOI 10.1155/2013/151839; Omenn GS, 2010, DIS MARKERS, V28, P241, DOI [10.1155/2010/705847, 10.3233/DMA-2010-0702]; Paronetto MP, 2011, MOL CELL, V43, P353, DOI 10.1016/j.molcel.2011.05.035; Paronetto MP, 2007, J CELL BIOL, V176, P929, DOI 10.1083/jcb.200701005; Paronetto MP, 2010, CANCER RES, V70, P229, DOI 10.1158/0008-5472.CAN-09-2788; Proussakova OV, 2003, J BIOL CHEM, V278, P36236, DOI 10.1074/jbc.M305896200; Sawa H, 1998, ONCOGENE, V16, P1701, DOI 10.1038/sj.onc.1201691; Sette Claudio, 2013, Int J Cell Biol, V2013, P421606, DOI 10.1155/2013/421606; Shi HS, 2010, CANCER SCI, V101, P1447, DOI 10.1111/j.1349-7006.2010.01562.x; Shultz JC, 2011, MOL CANCER RES, V9, P889, DOI 10.1158/1541-7786.MCR-11-0061; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Tamada M, 2012, CLIN CANCER RES, V18, P5554, DOI 10.1158/1078-0432.CCR-12-0859; Tang SC, 2014, WORLD J GASTROENTERO, V20, P10825, DOI 10.3748/wjg.v20.i31.10825; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang ZX, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120133; Xue YC, 2009, MOL CELL, V36, P996, DOI 10.1016/j.molcel.2009.12.003; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581	50	134	135	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2031	2039		10.1038/onc.2015.270	http://dx.doi.org/10.1038/onc.2015.270			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26234680	Green Published, Green Accepted			2022-12-28	WOS:000374505600003
J	Shinderman-Maman, E; Cohen, K; Weingarten, C; Nabriski, D; Twito, O; Baraf, L; Hercbergs, A; Davis, PJ; Werner, H; Ellis, M; Ashur-Fabian, O				Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Nabriski, D.; Twito, O.; Baraf, L.; Hercbergs, A.; Davis, P. J.; Werner, H.; Ellis, M.; Ashur-Fabian, O.			The thyroid hormone-alpha v beta 3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; CELL-SURFACE RECEPTOR; ALPHA-V; ALPHA(V)BETA(3) INTEGRIN; GROWTH-FACTOR; TETRAIODOTHYROACETIC ACID; ALPHA-V-BETA-3 INTEGRIN; HORMONE STIMULATION; PLASMA-MEMBRANE; UP-REGULATION	Ovarian carcinoma is the fifth common cause of cancer death in women, despite advanced therapeutic approaches. alpha v beta 3 integrin, a plasma membrane receptor, binds thyroid hormones (L-thyroxine, T4; 3,5,3'-triiodo-L-thyronine, T3) and is overexpressed in ovarian cancer. We have demonstrated selective binding of fluorescently labeled hormones to alpha v beta 3-positive ovarian cancer cells but not to integrin-negative cells. Physiologically relevant T3 (1 nM) and T4 (100 nM) concentrations in OVCAR-3 (high alpha v beta 3) and A2780 (low alpha v beta 3) cells promoted alpha v and beta 3 transcription in association with basal integrin levels. This transcription was effectively blocked by RGD (Arg-Gly-Asp) peptide and neutralizing alpha v beta 3 antibodies, excluding T3-induced beta 3 messenger RNA, suggesting subspecialization of T3 and T4 binding to the integrin receptor pocket. We have provided support for extracellular regulated kinase (ERK)-mediated transcriptional regulation of the alpha v monomer by T3 and of beta 3 monomer by both hormones and documented a rapid (30-120 min) and dose-dependent (0.1-1000 nM) ERK activation. OVCAR-3 cells and alpha v beta 3-deficient HEK293 cells treated with alpha v beta 3 blockers confirmed the requirement for an intact thyroid hormone-integrin interaction in ERK activation. In addition, novel data indicated that T4, but not T3, controls integrin's outside-in signaling by phosphorylating tyrosine 759 in the beta 3 subunit. Both hormones induced cell proliferation (cell counts), survival (Annexin-PI), viability (WST-1) and significantly reduced the expression of genes that inhibit cell cycle (p21, p16), promote mitochondrial apoptosis (Nix, PUMA) and tumor suppression (GDF-15, IGFBP-6), particularly in cells with high integrin expression. At last, we have confirmed that hypothyroid environment attenuated ovarian cancer growth using a novel experimental platform that exploited paired euthyroid and severe hypothyroid serum samples from human subjects. To conclude, our data define a critical role for thyroid hormones as potent alpha v beta 3-ligands, driving ovarian cancer cell proliferation and suggest that disruption of this axis may present a novel treatment strategy in this aggressive disease.	[Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Ellis, M.; Ashur-Fabian, O.] Meir Med Ctr, Translat Hematooncol Lab, Inst Hematol, Tchernichovsky 59, IL-6997801 Kefar Sava, NA, Israel; [Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Ellis, M.; Ashur-Fabian, O.] Meir Med Ctr, Blood Bank, Tchernichovsky 59, IL-6997801 Kefar Sava, NA, Israel; [Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Werner, H.; Ashur-Fabian, O.] Tel Aviv Univ, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; [Shinderman-Maman, E.; Cohen, K.; Weingarten, C.; Nabriski, D.; Werner, H.; Ellis, M.; Ashur-Fabian, O.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Nabriski, D.; Twito, O.; Baraf, L.] Meir Med Ctr, Dept Endocrinol, IL-6997801 Kefar Sava, NA, Israel; [Hercbergs, A.] Cleveland Clin, Radiat Oncol, Cleveland, OH 44106 USA; [Davis, P. J.] Albany Med Coll, Dept Med, Albany, NY 12208 USA	Tel Aviv University; Tel Aviv University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Cleveland Clinic Foundation; Albany Medical College	Ashur-Fabian, O (corresponding author), Meir Med Ctr, Translat Hematooncol Lab, Inst Hematol, Tchernichovsky 59, IL-6997801 Kefar Sava, NA, Israel.; Ashur-Fabian, O (corresponding author), Meir Med Ctr, Blood Bank, Tchernichovsky 59, IL-6997801 Kefar Sava, NA, Israel.	osnataf@gmail.com	Ashur, Osnat/AAC-1417-2020	twito, orit/0000-0002-8865-3860; Ashur-Fabian, Osnat/0000-0001-8624-3182	Li Ka Shing Foundation (LKSF)	Li Ka Shing Foundation (LKSF)	The work of Elena Shinderman Maman and Keren Cohen was done in partial fulfillment of the requirements for a PhD degree and of Chen Weingarten MSc degree from the Sackler Faculty of Medicine, Tel Aviv University, Israel. This work was partially supported by the Li Ka Shing Foundation (LKSF). We are grateful to Professor Jean-Luc Col (Institut Albert Bonniot and Universite Joseph Fourier, France) for HEK293 beta 3 and beta 1 cells.	Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bach LA, 2015, J CELL COMMUN SIGNAL, V9, P189, DOI 10.1007/s12079-015-0288-4; Bassett JHD, 2003, MOL CELL ENDOCRINOL, V213, P1, DOI 10.1016/j.mce.2003.10.033; Beral V, 2007, LANCET, V369, P1703, DOI 10.1016/S0140-6736(07)60534-0; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Blystone SD, 2002, J BIOL CHEM, V277, P46886, DOI 10.1074/jbc.M209506200; Boger C, 2013, APPL IMMUNOHISTO M M, V21, P553, DOI 10.1097/PAI.0b013e318284a03a; Brinton LA, 2007, GYNECOL ONCOL, V107, P487, DOI 10.1016/j.ygyno.2007.08.002; Brix K, 2011, THYROID RES, V4, DOI 10.1186/1756-6614-4-S1-S9; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; Carduner L, 2014, CLIN EXP METASTAS, V31, P675, DOI 10.1007/s10585-014-9658-1; Chambery D, 2000, GROWTH HORM IGF RES, V10, P349, DOI 10.1054/ghir.2000.0179; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Cody V, 2007, STEROIDS, V72, P165, DOI 10.1016/j.steroids.2006.11.008; Cohen K, 2015, LEUKEMIA LYMPHOMA, V56, P1107, DOI 10.3109/10428194.2014.947612; Cohen K, 2014, ONCOTARGET, V5, P6312, DOI 10.18632/oncotarget.2205; Cohen K, 2011, MOL CANCER RES, V9, P1385, DOI 10.1158/1541-7786.MCR-11-0187; Colombo R, 2012, J MED CHEM, V55, P10460, DOI 10.1021/jm301058f; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Datta A, 2002, J BIOL CHEM, V277, P3943, DOI 10.1074/jbc.M109536200; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; Davis PJ, 2015, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00240; Davis PJ, 2014, ONCOTARGETS THER, V7, P1619, DOI 10.2147/OTT.S67393; Davis PJ, 2013, HORM CANCER-US, V4, P335, DOI 10.1007/s12672-013-0156-8; Davis PJ, 2011, ANNU REV PHARMACOL, V51, P99, DOI 10.1146/annurev-pharmtox-010510-100512; Davis PJ, 2000, J BIOL CHEM, V275, P38032, DOI 10.1074/jbc.M002560200; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dijkgraaf I, 2007, INT J CANCER, V120, P605, DOI 10.1002/ijc.22297; Dittrich R, 2011, J REPROD IMMUNOL, V90, P58, DOI 10.1016/j.jri.2011.02.009; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Edson MA, 2009, ENDOCR REV, V30, P624, DOI 10.1210/er.2009-0012; Freindorf M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/959057; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hall LC, 2008, J STEROID BIOCHEM, V109, P57, DOI 10.1016/j.jsbmb.2007.12.008; Hanna L, 2006, BEST PRACT RES CL OB, V20, P339, DOI 10.1016/j.bpobgyn.2005.10.016; Hapke S, 2003, BIOL CHEM, V384, P1073, DOI 10.1515/BC.2003.120; Hercbergs A, 2015, ONCOLOGIST, V20, P72, DOI 10.1634/theoncologist.2014-0308; Hercbergs AH, 2010, CURR OPIN ENDOCRINOL, V17, P432, DOI 10.1097/MED.0b013e32833d9710; Huang CY, 2011, J CELL PHYSIOL, V226, P1274, DOI 10.1002/jcp.22455; Huang YC, 2007, BIOCHEM PHARMACOL, V74, P1702, DOI 10.1016/j.bcp.2007.08.025; Illario M, 2005, J CLIN ENDOCR METAB, V90, P2865, DOI 10.1210/jc.2004-1520; Incerpi S, 1999, ENDOCRINOLOGY, V140, P683, DOI 10.1210/en.140.2.683; Incerpi S, 2005, ENDOCRINOLOGY, V146, P2861, DOI 10.1210/en.2005-0394; Janssen ML, 2002, CANCER RES, V62, P6146; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kang JH, 2013, OBSTET GYNECOL INT, V2013, DOI 10.1155/2013/743721; Krassas GE, 2010, ENDOCR REV, V31, P702, DOI 10.1210/er.2009-0041; Landen CN, 2008, NEOPLASIA, V10, P1259, DOI 10.1593/neo.08740; Liapis H, 1997, HUM PATHOL, V28, P443, DOI 10.1016/S0046-8177(97)90033-2; Lin HY, 2008, CARCINOGENESIS, V29, P62, DOI 10.1093/carcin/bgm239; Lin HY, 2007, STEROIDS, V72, P180, DOI 10.1016/j.steroids.2006.11.014; Lin HY, 2013, FASEB J, V27, P3209, DOI 10.1096/fj.12-227132; Lin HY, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001073; Lin HY, 2009, AM J PHYSIOL-CELL PH, V296, pC980, DOI 10.1152/ajpcell.00305.2008; Lin HY, 1998, J IMMUNOL, V161, P843; Liu J, 2014, CLIN CANCER RES, V20, P5150, DOI 10.1158/1078-0432.CCR-14-1312; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martinez MB, 2000, ANTICANCER RES, V20, P4141; Miller CR, 2014, GYNECOL ONCOL, V133, P128, DOI 10.1016/j.ygyno.2014.01.008; Moeller LC, 2011, THYROID RES, V4, DOI 10.1186/1756-6614-4-S1-S6; Moriggi G, 2011, ANTICANCER RES, V31, P89; Mousa SA, 2012, LUNG CANCER, V76, P39, DOI 10.1016/j.lungcan.2011.10.003; Ness RB, 2000, EPIDEMIOLOGY, V11, P111, DOI 10.1097/00001648-200003000-00006; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pascual A, 2013, BBA-GEN SUBJECTS, V1830, P3908, DOI 10.1016/j.bbagen.2012.03.012; Rae MT, 2007, J CLIN ENDOCR METAB, V92, P322, DOI 10.1210/jc.2006-1522; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Saegusa M, 2001, CANCER, V92, P1177, DOI 10.1002/1097-0142(20010901)92:5<1177::AID-CNCR1436>3.0.CO;2-5; Scanlan TS, 2004, NAT MED, V10, P638, DOI 10.1038/nm1051; Scarlett A, 2008, J ENDOCRINOL, V196, P509, DOI 10.1677/JOE-07-0344; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; Sterle HA, 2014, J ENDOCRINOL, V222, P243, DOI 10.1530/JOE-14-0159; Storey NM, 2006, P NATL ACAD SCI USA, V103, P5197, DOI 10.1073/pnas.0600089103; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Tang HY, 2004, ENDOCRINOLOGY, V145, P3265, DOI 10.1210/en.2004-0308; Theodossiou C, 1999, CANCER, V86, P1596, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1596::AID-CNCR30>3.0.CO;2-C; Verga Falzacappa C, 2006, J CELL PHYSIOL, V206, P309, DOI 10.1002/jcp.20460; Wang XY, 2013, BIOCHEM PHARMACOL, V85, P597, DOI 10.1016/j.bcp.2012.11.025; Wang YF, 2011, INT J MOL SCI, V12, P3409, DOI 10.3390/ijms12063409; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Wu W, 2013, J LIPID RES, V54, P936, DOI 10.1194/jlr.M031450; Xi XD, 2006, J BIOL CHEM, V281, P29426, DOI 10.1074/jbc.C600039200; Xiong SB, 1998, P NATL ACAD SCI USA, V95, P12260, DOI 10.1073/pnas.95.21.12260; Yalcin M, 2013, HORM CANCER-US, V4, P176, DOI 10.1007/s12672-013-0137-y; Yamauchi M, 2008, MOL ENDOCRINOL, V22, P893, DOI 10.1210/me.2007-0249; Yehuda-Shnaidman E, 2014, ENDOCR REV, V35, P35, DOI 10.1210/er.2013-1006; Yu YC, 2013, ONCOL RES, V21, P217, DOI 10.3727/096504014X13907540404879; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008-5472.CAN-06-4499	93	53	53	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1977	1987		10.1038/onc.2015.262	http://dx.doi.org/10.1038/onc.2015.262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26165836				2022-12-28	WOS:000374010300010
J	Zhang, J; Gao, Q; Zhou, Y; Dier, U; Hempel, N; Hochwald, SN				Zhang, J.; Gao, Q.; Zhou, Y.; Dier, U.; Hempel, N.; Hochwald, S. N.			Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis	ONCOGENE			English	Article							PANCREATIC-CANCER CELLS; GROWTH-FACTOR-I; FAK; PROLIFERATION; INHIBITION; ACTIVATION; MIGRATION; COMPLEX; IGF-1R	Cancer cells often gains a growth advantage by taking up glucose at a high rate and undergoing aerobic glycolysis through intrinsic cellular factors that reprogram glucose metabolism. Focal adhesion kinase (FAK), a key transmitter of growth factor and anchorage stimulation, is aberrantly overexpressed or activated in most solid tumors, including pancreatic ductal adenocarcinomas (PDACs). We determined whether FAK can act as an intrinsic driver to promote aerobic glycolysis and tumorigenesis. FAK inhibition decreases and overexpression increases intracellular glucose levels during unfavorable conditions, including growth factor deficiency and cell detachment. Amplex glucose assay, fluorescence and carbon-13 tracing studies demonstrate that FAK promotes glucose consumption and glucose-to-lactate conversion. Extracellular flux analysis indicates that FAK enhances glycolysis and decreases mitochondrial respiration. FAK increases key glycolytic proteins, including enolase, pyruvate kinase M2 (PKM2), lactate dehydrogenase and monocarboxylate transporter. Furthermore, active/tyrosine-phosphorylated FAK directly binds to PKM2 and promotes PKM2-mediated glycolysis. On the other hand, FAK-decreased levels of mitochondrial complex I can result in reduced oxidative phosphorylation (OXPHOS). Attenuation of FAK-enhanced glycolysis re-sensitizes cancer cells to growth factor withdrawal, decreases cell viability and reduces growth of tumor xenografts. These observations, for the first time, establish a vital role of FAK in cancer glucose metabolism through alterations in the OXPHOS-to-glycolysis balance. Broadly targeting the common phenotype of aerobic glycolysis and more specifically FAK-reprogrammed glucose metabolism will disrupt the bioenergetic and biosynthetic supply for uncontrolled growth of tumors, particularly glycolytic PDAC.	[Zhang, J.; Gao, Q.; Zhou, Y.; Hochwald, S. N.] Roswell Pk Canc Inst, Dept Surg Oncol, Elm & Carlton St, Buffalo, NY 14263 USA; [Dier, U.; Hempel, N.] SUNY Coll Nanoscale Sci & Engn, Nanobiosci Constellat, Albany, NY USA	Roswell Park Cancer Institute; SUNY Polytechnic Institute	Hochwald, SN (corresponding author), Roswell Pk Canc Inst, Dept Surg Oncol, Elm & Carlton St, Buffalo, NY 14263 USA.	steven.hochwald@roswellpark.org	Hempel, Nadine/F-1700-2014	Hempel, Nadine/0000-0002-5574-8783	NIH (National Institute of Mental Health) from the National Cancer Institute [R00CA143229]; NATIONAL CANCER INSTITUTE [R00CA143229, P30CA016056] Funding Source: NIH RePORTER	NIH (National Institute of Mental Health) from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	UD and NH are supported by an NIH (National Institute of Mental Health) grant R00CA143229 from the National Cancer Institute.	Andersson S, 2009, BIOCHEM BIOPH RES CO, V387, P36, DOI 10.1016/j.bbrc.2009.06.088; Arbet-Engels C, 1999, FEBS LETT, V454, P252, DOI 10.1016/S0014-5793(99)00815-7; Blum R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.38; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Cui JJ, 2014, CLIN CANCER RES, V20, P2595, DOI 10.1158/1078-0432.CCR-13-2407; Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Keshari KR, 2013, CANCER RES, V73, P529, DOI 10.1158/0008-5472.CAN-12-3461; Konstantinidou G, 2013, CANCER DISCOV, V3, P444, DOI 10.1158/2159-8290.CD-12-0388; Lee HZ, 2004, LIFE SCI, V74, P2085, DOI 10.1016/j.lfs.2003.06.046; Lee SH, 2011, J CELL PHYSIOL, V226, P1850, DOI 10.1002/jcp.22510; Lim SK, 2012, CLIN EXP METASTAS, V29, P901, DOI 10.1007/s10585-012-9479-z; Mikuriya K, 2007, INT J ONCOL, V30, P849; Muller G, 2001, BIOCHEMISTRY-US, V40, P14603, DOI 10.1021/bi0108352; Muller G, 2000, MOL CELL BIOL, V20, P4708, DOI 10.1128/MCB.20.13.4708-4723.2000; Peng X, 2006, J CLIN INVEST, V116, P217, DOI 10.1172/JCI24497; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; Schultze A, 2011, ANTI-CANCER AGENT ME, V11, P593, DOI 10.2174/187152011796817727; Serrels A, 2012, INT J CANCER, V131, P287, DOI 10.1002/ijc.26351; Shang YL, 2008, MOL CANCER THER, V7, P2599, DOI 10.1158/1535-7163.MCT-07-2401; Sudhakaran PR, 2009, GLYCOCONJUGATE J, V26, P697, DOI 10.1007/s10719-008-9188-7; Tomaino B, 2011, J PROTEOME RES, V10, P105, DOI 10.1021/pr100213b; Tornatore TF, 2011, AM J PHYSIOL-HEART C, V300, pH902, DOI 10.1152/ajpheart.00319.2010; Ucar DA, 2013, ANTI-CANCER AGENT ME, V13, P595; Walker-Samuel S, 2013, NAT MED, V19, P1067, DOI 10.1038/nm.3252; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; ZHANG C, 1994, J BIOL CHEM, V269, P25247; Zhang JL, 2014, CELL CYCLE, V13, P3143, DOI 10.4161/15384101.2014.949550; Zhang JL, 2014, PHARMACOL THERAPEUT, V142, P154, DOI 10.1016/j.pharmthera.2013.12.003; Zheng DH, 2010, MOL CARCINOGEN, V49, P200, DOI 10.1002/mc.20590; Zheng DH, 2009, BIOCHEM BIOPH RES CO, V388, P301, DOI 10.1016/j.bbrc.2009.07.156; Zhu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087904	37	31	31	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1926	1942		10.1038/onc.2015.256	http://dx.doi.org/10.1038/onc.2015.256			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26119934	Green Accepted			2022-12-28	WOS:000374010300006
J	Wethmar, K; Schulz, J; Muro, EM; Talyan, S; Andrade-Navarro, MA; Leutz, A				Wethmar, K.; Schulz, J.; Muro, E. M.; Talyan, S.; Andrade-Navarro, M. A.; Leutz, A.			Comprehensive translational control of tyrosine kinase expression by upstream open reading frames	ONCOGENE			English	Article							INITIATION; DATABASE; GENE; CENSUS	Post-transcriptional control has emerged as a major regulatory event in gene expression and often occurs at the level of translation initiation. Although overexpression or constitutive activation of tyrosine kinases (TKs) through gene amplification, translocation or mutation are well-characterized oncogenic events, current knowledge about translational mechanisms of TK activation is scarce. Here, we report the presence of translational cis-regulatory upstream open reading frames (uORFs) in the majority of transcript leader sequences of human TK mRNAs. Genetic ablation of uORF initiation codons in TK transcripts resulted in enhanced translation of the associated downstream main protein-coding sequences (CDSs) in all cases studied. Similarly, experimental removal of uORF start codons in additional non-TK proto-oncogenes, and naturally occurring loss-of-uORF alleles of the c-met proto-oncogene (MET) and the kinase insert domain receptor (KDR), was associated with increased CDS translation. Based on genome-wide sequence analyses we identified polymorphisms in 15.9% of all human genes affecting uORF initiation codons, associated Kozak consensus sequences or uORF-related termination codons. Together, these data suggest a comprehensive role of uORF-mediated translational control and delineate how aberrant induction of proto-oncogenes through loss-of-function mutations at uORF initiation codons may be involved in the etiology of cancer. We provide a detailed map of uORFs across the human genome to stimulate future research on the pathogenic role of uORFs.	[Wethmar, K.; Schulz, J.; Leutz, A.] Max Delbrueck Ctr Mol Med, Dept Cell Differentiat & Tumorigenesis, Berlin, Germany; [Wethmar, K.] Univ Hosp Muenster, Dept Hematol Oncol & Pneumol, Albert Schweitzer Campus 1, D-48149 Munster, Germany; [Muro, E. M.; Andrade-Navarro, M. A.] Max Delbrueck Ctr Mol Med, Dept Computat Biol & Data Min, Berlin, Germany; [Muro, E. M.; Talyan, S.; Andrade-Navarro, M. A.] Johannes Gutenberg Univ Mainz, Dept Biol, Inst Mol Biol, D-55122 Mainz, Germany; [Leutz, A.] Humboldt Univ, Dept Biol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Munster; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Institute of Molecular Biology (IMB); Johannes Gutenberg University of Mainz; Humboldt University of Berlin	Wethmar, K (corresponding author), Univ Hosp Muenster, Dept Hematol Oncol & Pneumol, Albert Schweitzer Campus 1, D-48149 Munster, Germany.	klaus.wethmar@ukmuenster.de	Wethmar, Klaus/AAQ-7085-2021; Leutz, Achim/K-9643-2013; Talyan, Sweta/AAR-1436-2021; Muro, Enrique M./AAX-3698-2021	Leutz, Achim/0000-0001-8259-927X; Talyan, Sweta/0000-0002-7160-6742; 	Deutsche Krebshilfe e.V., Bonn, Germany [110525]	Deutsche Krebshilfe e.V., Bonn, Germany(Deutsche Krebshilfe)	This work was supported by the Deutsche Krebshilfe e.V., Bonn, Germany (grant 110525 to KW and AL).	Barbosa C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003529; Calkhoven CF, 2000, GENE DEV, V14, P1920; Calvo SE, 2009, P NATL ACAD SCI USA, V106, P7507, DOI 10.1073/pnas.0810916106; Chen HY, 2012, J MOL NEUROSCI, V47, P448, DOI 10.1007/s12031-012-9705-9; Churbanov A, 2005, NUCLEIC ACIDS RES, V33, P5512, DOI 10.1093/nar/gki847; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Glubb DM, 2011, CLIN CANCER RES, V17, P5257, DOI 10.1158/1078-0432.CCR-11-0379; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hampf M, 2006, ANAL BIOCHEM, V356, P94, DOI 10.1016/j.ab.2006.04.046; Iacono M, 2005, GENE, V349, P97, DOI 10.1016/j.gene.2004.11.041; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Ivanov IP, 2010, P NATL ACAD SCI USA, V107, P18056, DOI 10.1073/pnas.1009269107; Jackson RJ, 2012, ADV PROTEIN CHEM STR, V86, P45, DOI [10.1016/B978-0-12-386497-0.00002-5, 10.1016/B978-0-12.386497.000002-5]; Jin XP, 2003, J BIOL CHEM, V278, P25716, DOI 10.1074/jbc.M300316200; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lee S, 2012, P NATL ACAD SCI USA, V109, pE2424, DOI 10.1073/pnas.1207846109; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Michel AM, 2014, NUCLEIC ACIDS RES, V42, pD859, DOI 10.1093/nar/gkt1035; Occhi G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003350; Pabst S, 2010, CHEST, V137, P156, DOI 10.1378/chest.09-1003; Pruitt KD, 2014, NUCLEIC ACIDS RES, V42, pD756, DOI 10.1093/nar/gkt1114; Rosenbloom KR, 2015, NUCLEIC ACIDS RES, V43, pD670, DOI 10.1093/nar/gku1177; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Somers J, 2013, INT J BIOCHEM CELL B, V45, P1690, DOI 10.1016/j.biocel.2013.04.020; Spevak CC, 2006, BIOCHEM BIOPH RES CO, V350, P834, DOI 10.1016/j.bbrc.2006.09.128; Uzunoglu FG, 2013, ANN ONCOL, V24, P1282, DOI 10.1093/annonc/mds634; Wethmar K, 2014, WIRES RNA, V5, P765, DOI 10.1002/wrna.1245; Wethmar K, 2014, NUCLEIC ACIDS RES, V42, pD60, DOI 10.1093/nar/gkt952; Wethmar K, 2010, BIOESSAYS, V32, P885, DOI 10.1002/bies.201000037	32	22	22	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1736	1742		10.1038/onc.2015.233	http://dx.doi.org/10.1038/onc.2015.233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096937	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000373064200012
J	Ahn, BY; Saldanha-Gama, RFG; Rahn, JJ; Hao, X; Zhang, J; Dang, NH; Alshehri, M; Robbins, SM; Senger, DL				Ahn, B. Y.; Saldanha-Gama, R. F. G.; Rahn, J. J.; Hao, X.; Zhang, J.; Dang, N-H; Alshehri, M.; Robbins, S. M.; Senger, D. L.			Glioma invasion mediated by the p75 neurotrophin receptor (p75(NTR)/CD271) requires regulated interaction with PDLIM1	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; LIM-DOMAIN PROTEIN; NF-KAPPA-B; PDZ-DOMAIN; GENE AMPLIFICATION; MALIGNANT GLIOMAS; ALPHA-ACTININ; CELL; BINDING; MELANOMA	The invasive nature of glioblastoma renders them incurable by current therapeutic interventions. Using a novel invasive human glioma model, we previously identified the neurotrophin receptor p75(NTR) (aka CD271) as a mediator of glioma invasion. Herein, we provide evidence that preventing phosphorylation of p75(NTR) on S303 by pharmacological inhibition of PKA, or by a mutational strategy (S303G), cripples p75(NTR)-mediated glioma invasion resulting in serine phosphorylation within the C-terminal PDZ-binding motif (SPV) of p75(NTR). Consistent with this, deletion (Delta SPV) or mutation (SPM) of the PDZ motif results in abrogation of p75(NTR)-mediated invasion. Using a peptide-based strategy, we identified PDLIM1 as a novel signaling adaptor for p75(NTR) and provide the first evidence for a regulated interaction via S425 phosphorylation. Importantly, PDLIM1 was shown to interact with p75(NTR) in highly invasive patient-derived glioma stem cells/tumor-initiating cells and shRNA knockdown of PDLIM1 in vitro and in vivo results in complete ablation of p75(NTR)-mediated invasion. Collectively, these data demonstrate a requirement for a regulated interaction of p75(NTR) with PDLIM1 and suggest that targeting either the PDZ domain interactions and/or the phosphorylation of p75(NTR) by PKA could provide therapeutic strategies for patients with glioblastoma.	[Ahn, B. Y.; Saldanha-Gama, R. F. G.; Rahn, J. J.; Hao, X.; Zhang, J.; Dang, N-H; Alshehri, M.; Robbins, S. M.; Senger, D. L.] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada; [Ahn, B. Y.; Rahn, J. J.; Hao, X.; Robbins, S. M.; Senger, D. L.] Univ Calgary, Hughes Childhood Canc Program, Calgary, AB, Canada; [Ahn, B. Y.; Saldanha-Gama, R. F. G.; Rahn, J. J.; Hao, X.; Dang, N-H; Alshehri, M.; Robbins, S. M.; Senger, D. L.] Univ Calgary, Dept Oncol, Room 362,Heritage Med Res Bldg,Hosp Dr NW, Calgary, AB T2N 4N1, Canada; [Saldanha-Gama, R. F. G.; Zhang, J.; Dang, N-H; Alshehri, M.; Robbins, S. M.; Senger, D. L.] Univ Calgary, Clark H Smith Brain Tumour Ctr, Calgary, AB, Canada; [Saldanha-Gama, R. F. G.] Univ Estado Rio de Janeiro, Dept Biol Celular, Rua Sao Francisco Xavier 524,PHLC Sala 500, BR-20550013 Rio De Janeiro, Brazil	University of Calgary; University of Calgary; University of Calgary; University of Calgary; Universidade do Estado do Rio de Janeiro	Senger, DL (corresponding author), Univ Calgary, Dept Oncol, Room 362,Heritage Med Res Bldg,Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	senger@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665; Alshehri, Mana/0000-0001-9587-2693; Senger, Donna/0000-0003-2403-3395	Hotchkiss Brain Institute; Alberta Cancer Foundation; Terry Fox Research Institute; Clark H. Smith Family; Southern Alberta Mass Spectrometry (SAMS) Centre; Alberta Children's Hospital Foundation; Alberta Innovates Health Solutions; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Ministerio da Educacao - Brasil; Alberta Innovates [201201242] Funding Source: researchfish	Hotchkiss Brain Institute; Alberta Cancer Foundation; Terry Fox Research Institute; Clark H. Smith Family; Southern Alberta Mass Spectrometry (SAMS) Centre; Alberta Children's Hospital Foundation; Alberta Innovates Health Solutions; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Ministerio da Educacao - Brasil; Alberta Innovates	We would like to thank the Brain Tumor Stem Cell Core supported by funds from the Hotchkiss Brain Institute, the Alberta Cancer Foundation and the Terry Fox Research Institute. We also thank the Calgary Brain Tumour and Tissue Bank generously supported by funds from the Clark H. Smith Family and the Southern Alberta Mass Spectrometry (SAMS) Centre. This work was supported by grants to SMR and DLS from the Alberta Children's Hospital Foundation, the Alberta Cancer Foundation and Alberta Innovates Health Solutions. RSG acknowledges fellowship support from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Ministerio da Educacao - Brasil.	ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Babault N, 2011, STRUCTURE, V19, P1518, DOI 10.1016/j.str.2011.07.007; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; Bashirova AA, 1998, GENE, V210, P239, DOI 10.1016/S0378-1119(98)00080-8; Bauer K, 2000, BLOOD, V96, P4236; Bentley CA, 2000, J NEUROSCI, V20, P7706; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Blazer LL, 2009, NEUROPSYCHOPHARMACOL, V34, P126, DOI 10.1038/npp.2008.151; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Chan JR, 2006, SCIENCE, V314, P832, DOI 10.1126/science.1134069; Collin GB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037925; Cragnolini AB, 2008, TRENDS NEUROSCI, V31, P99, DOI 10.1016/j.tins.2007.11.005; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Eli Lilly and Company, 2010, LILL HALTS DEV SEM A; Elkins JM, 2007, PROTEIN SCI, V16, P683, DOI 10.1110/ps.062657507; Ensign SPF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00241; Essmann CL, 2008, NAT NEUROSCI, V11, P1035, DOI 10.1038/nn.2171; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Fujitani M, 2005, J NEUROCHEM, V94, P15, DOI 10.1111/j.1471-4159.2005.03121.x; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gauthier LR, 2003, LIFE SCI, V74, P207, DOI 10.1016/j.lfs.2003.09.029; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gil C, 2007, FEBS LETT, V581, P1851, DOI 10.1016/j.febslet.2007.03.080; Gold MG, 2013, J CELL SCI, V126, P4537, DOI 10.1242/jcs.133751; Gritsenko PG, 2012, J PATHOL, V226, P185, DOI 10.1002/path.3031; Hasegawa T, 2010, NEUROSCI LETT, V476, P53, DOI 10.1016/j.neulet.2010.03.081; HERRMANN JL, 1993, MOL BIOL CELL, V4, P1205, DOI 10.1091/mbc.4.11.1205; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Hopkins CR, 2011, ACS CHEM NEUROSCI, V2, P279, DOI 10.1021/cn2000469; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Hupalowska A, 2012, TRAFFIC, V13, P9, DOI 10.1111/j.1600-0854.2011.01249.x; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; Ivarsson Y, 2012, FEBS LETT, V586, P2638, DOI 10.1016/j.febslet.2012.04.015; Johnston ALM, 2007, PLOS BIOL, V5, P1723, DOI 10.1371/journal.pbio.0050212; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; Kaplan DR, 2004, NATURE, V427, P798, DOI 10.1038/427798a; Kegelman TP, 2014, NEURO-ONCOLOGY, V16, P50, DOI 10.1093/neuonc/not157; Kelly JJP, 2009, STEM CELLS, V27, P1722, DOI 10.1002/stem.98; KERBEL RS, 1984, INVAS METAST, V4, P31; KERBEL RS, 1984, J NATL CANCER I, V72, P93, DOI 10.1093/jnci/72.1.93; Kikuchi S, 2008, CLIN CANCER RES, V14, P5348, DOI 10.1158/1078-0432.CCR-08-0075; Klaavuniemi T, 2006, EXP CELL RES, V312, P1299, DOI 10.1016/j.yexcr.2005.12.036; Kotaka M, 2000, J CELL BIOCHEM, V78, P558, DOI 10.1002/1097-4644(20000915)78:4<558::AID-JCB5>3.0.CO;2-I; Kotaka M, 1999, J CELL BIOCHEM, V72, P279, DOI 10.1002/(SICI)1097-4644(19990201)72:2<279::AID-JCB12>3.0.CO;2-7; Kraemer B R, 2014, Handb Exp Pharmacol, V220, P121, DOI 10.1007/978-3-642-45106-5_6; Kwiatkowska A, 2013, ADV EXP MED BIOL, V986, P121, DOI 10.1007/978-94-007-4719-7_7; Le Moan N, 2011, MOL CELL, V44, P476, DOI 10.1016/j.molcel.2011.08.033; Li A, 2009, CANCER RES, V69, P2091, DOI 10.1158/0008-5472.CAN-08-2100; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; LIU Z, 2014, ONCOGENE, V0034, P01300, DOI DOI 10.1038/ONC.2014.64; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Mariani L, 2001, CANCER RES, V61, P4190; MENTER DG, 1994, INVAS METAST, V14, P372; Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5; Nakagawa N, 2000, BIOCHEM BIOPH RES CO, V272, P505, DOI 10.1006/bbrc.2000.2787; Ohno K, 2009, J NEUROCHEM, V111, P790, DOI 10.1111/j.1471-4159.2009.06370.x; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Quick Q, 2010, EXP CELL RES, V316, P1137, DOI 10.1016/j.yexcr.2010.02.011; Redmer T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092596; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Robbins SM, 2013, NEUROMETHODS, P275; Sarkar S, 2015, NEUROONCOL; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Shonukan T, 2003, ONCOGENE, V22, P3616, DOI 10.1038/sj.onc.1206561; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Skeldal S, 2011, BIOESSAYS, V33, P614, DOI 10.1002/bies.201100036; Smith MA, 2014, TRENDS CELL BIOL, V24, P575, DOI [10.1016/J.tcb.2014.04.009, 10.1016/j.tcb.2014.04.009]; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Teodorczyk M, 2010, J CELL PHYSIOL, V222, P1, DOI 10.1002/jcp.21901; Teyra J, 2012, FEBS LETT, V586, P2631, DOI 10.1016/j.febslet.2012.05.043; Torrado M, 2004, INVEST OPHTH VIS SCI, V45, P3955, DOI 10.1167/iovs.04-0721; Underwood CK, 2008, MOL CELL NEUROSCI, V37, P346, DOI 10.1016/j.mcn.2007.10.005; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; Verbeke S, 2013, FEBS LETT, V587, P2591, DOI 10.1016/j.febslet.2013.06.039; Verbeke S, 2010, CELL SIGNAL, V22, P1864, DOI 10.1016/j.cellsig.2010.07.014; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; von Nandelstadh P, 2009, MOL CELL BIOL, V29, P822, DOI 10.1128/MCB.01454-08; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; Wang LM, 2008, PLOS BIOL, V6, P2496, DOI 10.1371/journal.pbio.0060289; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	98	30	31	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1411	1422		10.1038/onc.2015.199	http://dx.doi.org/10.1038/onc.2015.199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26119933	Green Published, hybrid			2022-12-28	WOS:000372196400007
J	Deguchi, A; Tomita, T; Ohto, U; Takemura, K; Kitao, A; Akashi-Takamura, S; Miyake, K; Maru, Y				Deguchi, A.; Tomita, T.; Ohto, U.; Takemura, K.; Kitao, A.; Akashi-Takamura, S.; Miyake, K.; Maru, Y.			Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment	ONCOGENE			English	Article							CALCIUM-BINDING PROTEINS; TOLL-LIKE RECEPTORS; NF-KAPPA-B; S100 PROTEINS; SIGNAL-TRANSDUCTION; SUPPRESSOR-CELLS; STRUCTURAL BASIS; MYELOID CELLS; TLR4; EXPRESSION	S100A8/A9 is a major component of the acute phase of inflammation, and appears to regulate cell proliferation, redox regulation and chemotaxis. We previously reported that S100A8/S100A9 are upregulated in the premetastatic lung. However, the detailed mechanisms by which S100A8 contributes to tumor progression have not been elucidated. In this study, we investigated the TLR4/MD-2 dependency by S100A8 on tumor progression. We found that S100A8 (2-89) peptide stimulated cell migration in a manner dependent on TLR4, MD-2 and MyD88. The S100A8 (2-89) peptide also activated p38 and NF-kappa B in TLR4-dependent manner. The peptide induced the upregulation of both IL-6 and Ccl2 in peritoneal macrophages obtained from wild-type mice, but not TLR4-deficient mice. We then investigated the responsible region of S100A8 for TLR4/MD-2 binding by a binding assay, and found that C-terminal region of S100A8 binds to TLR4/MD-2 complex. To further evaluate the TLR4 dependency on tumor microenvironment, Lewis lung carcinoma-bearing mice were treated with Eritoran, an antagonist of TLR4/MD-2 complex. We found that both tumor volume and pulmonary recruitment of myeloid-derived suppressor cells were reduced with the treatment of Eritoran for five consecutive days. Eritoran reduced the development of tumor vasculature, and increased tumor-infiltration of CD8(+) T-cells. Taken together, S100A8 appears to play a crucial role in the activation of the TLR4/MD-2 pathway and the promotion of a tumor growth-enhancing immune microenvironment.	[Deguchi, A.; Tomita, T.; Maru, Y.] Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan; [Ohto, U.] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan; [Takemura, K.; Kitao, A.] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan; [Akashi-Takamura, S.] Aichi Med Univ, Dept Microbiol & Immunol, Nagakute, Aichi 48011, Japan; [Miyake, K.] Univ Tokyo, Inst Med Sci, Div Infect Genet, Tokyo, Japan	Tokyo Women's Medical University; University of Tokyo; University of Tokyo; Aichi Medical University; University of Tokyo	Deguchi, A; Maru, Y (corresponding author), Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	deguchi@research.twmu.ac.jp; ymaru@research.twmu.ac.jp	Kitao, Akio/B-8371-2008	Kitao, Akio/0000-0002-5221-0806; Takemura, Kazuhiro/0000-0001-5946-4502; Tomita, Takeshi/0000-0001-6815-2244	Ministry of Education, Culture, Sports, Science and Technology of Japan [21117008, 24501321, 26440063]; Grants-in-Aid for Scientific Research [15H04357] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs Hiroyuki Aburatani and Akira Watanabe (Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo) for providing an expression system for mammalian cell-derived S100A8, and Dr Mihich (Roswell Park Cancer Institute, NY, USA) for providing E0771 cells. We thank Dr Tatsuya Shimizu (Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University) for cell sorting technology. We also thank Dr Sachie Hiratsuka for valuable discussion and Messr. Tsutomu Omori and Taishi Mishima for technical assistance. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to YM, 21117008) (to AD, 24501321) (to TT, 26440063).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Andreani V, 2007, CANCER RES, V67, P10519, DOI 10.1158/0008-5472.CAN-07-0079; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Bjork P, 2009, PLOS BIOL, V7, P800, DOI 10.1371/journal.pbio.1000097; Chen KQ, 2007, INT IMMUNOPHARMACOL, V7, P1271, DOI 10.1016/j.intimp.2007.05.016; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Deguchi A, 2013, J IMMUNOL, V191, P1856, DOI 10.4049/jimmunol.1201996; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Ewens A, 2005, ANTICANCER RES, V25, P3905; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397; Grimbaldeston MA, 2003, J INVEST DERMATOL, V121, P1168, DOI 10.1046/j.1523-1747.2003.12561.x; Healy AM, 2006, CIRCULATION, V113, P2278, DOI 10.1161/CIRCULATIONAHA.105.607333; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hiratsuka S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2856; Hsu K, 2005, J IMMUNOL, V174, P2318, DOI 10.4049/jimmunol.174.4.2318; Hsu RYC, 2011, CANCER RES, V71, P1989, DOI 10.1158/0008-5472.CAN-10-2833; Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109; Hunter MJ, 1998, J BIOL CHEM, V273, P12427, DOI 10.1074/jbc.273.20.12427; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kawasaki K, 2001, J ENDOTOXIN RES, V7, P232, DOI 10.1177/09680519010070030701; Kerkhoff C, 2005, FASEB J, V19, P467, DOI 10.1096/fj.04-2377fje; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Kitamura T, 2010, P NATL ACAD SCI USA, V107, P13063, DOI 10.1073/pnas.1002372107; Kumar A, 2003, INT ARCH ALLERGY IMM, V132, P40, DOI 10.1159/000073263; Kumar RK, 2001, J LEUKOCYTE BIOL, V70, P59; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; McCormick MM, 2005, J BIOL CHEM, V280, P41521, DOI 10.1074/jbc.M509442200; Merline R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001868; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohto U, 2012, P NATL ACAD SCI USA, V109, P7421, DOI 10.1073/pnas.1201193109; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Omori S, 2013, PROTEINS, V81, P1005, DOI 10.1002/prot.24252; Pal D, 2012, NAT MED, V18, P1279, DOI 10.1038/nm.2851; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Passey RJ, 1999, J IMMUNOL, V163, P2209; Pierce BG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024657; Propper C, 1999, J BIOL CHEM, V274, P183, DOI 10.1074/jbc.274.1.183; Qin H, 2014, NAT MED, V20, P676, DOI 10.1038/nm.3560; Rahimi F, 2005, FEBS J, V272, P2811, DOI 10.1111/j.1742-4658.2005.04703.x; Rajput S, 2013, MOL CANCER THER, V12, P1676, DOI 10.1158/1535-7163.MCT-12-1019; Rammes A, 1997, J BIOL CHEM, V272, P9496; Riva M, 2012, IMMUNOLOGY, V137, P172, DOI 10.1111/j.1365-2567.2012.03619.x; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Shi C, 2011, IMMUNITY, V34, P590, DOI 10.1016/j.immuni.2011.02.016; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Szajnik M, 2009, ONCOGENE, V28, P4353, DOI 10.1038/onc.2009.289; Szczepanski MJ, 2009, CANCER RES, V69, P3105, DOI 10.1158/0008-5472.CAN-08-3838; Tomita T, 2011, ONCOGENE, V30, P3429, DOI 10.1038/onc.2011.53; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Vogl T, 2006, BBA-MOL CELL RES, V1763, P1298, DOI 10.1016/j.bbamcr.2006.08.028; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Volk-Draper L, 2014, CANCER RES, V74, P5421, DOI 10.1158/0008-5472.CAN-14-0067; Xu K, 2001, J IMMUNOL, V166, P6358, DOI 10.4049/jimmunol.166.10.6358; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107; Yen T, 1997, BLOOD, V90, P4812, DOI 10.1182/blood.V90.12.4812.4812_4812_4821; Zreiqat H, 2007, J MOL HISTOL, V38, P381, DOI 10.1007/s10735-007-9117-2	73	40	43	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1445	1456		10.1038/onc.2015.211	http://dx.doi.org/10.1038/onc.2015.211			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26165843				2022-12-28	WOS:000372196400010
J	Duvall-Noelle, N; Karwandyar, A; Richmond, A; Raman, D				Duvall-Noelle, N.; Karwandyar, A.; Richmond, A.; Raman, D.			LASP-1: a nuclear hub for the UHRF1-DNMT1-G9a-Snail1 complex	ONCOGENE			English	Article							METASTATIC BREAST-CANCER; E-CADHERIN REPRESSION; CHEMOKINE RECEPTORS; TUMOR-GROWTH; CELLS; SNAIL; EXPRESSION; LOCALIZATION; CARCINOMA; CXCR4	Nuclear LASP-1 (LIM and SH3 protein-1) has a direct correlation with overall survival of breast cancer patients. In this study, immunohistochemical analysis of a human breast TMA showed that LASP-1 is absent in normal human breast epithelium but the expression increases with malignancy and is highly nuclear in aggressive breast cancer. We investigated whether the chemokines and growth factors present in the tumor microenvironment could trigger nuclear translocation of LASP-1. Treatment of human breast cancer cells with CXCL12, EGF and HRG, and HMEC-CXCR2 cells with CXCL8 facilitated nuclear shuttling of LASP-1. Data from the biochemical analysis of the nuclear and cytosolic fractions further confirmed the nuclear translocation of LASP-1 upon chemokine and growth factor treatment. CXCL12-dependent nuclear import of LASP-1 could be blocked by CXCR4 antagonist, AMD-3100. Knock down of LASP-1 resulted in alterations in gene expression leading to an increased level of cell-junction and extracellular matrix proteins and an altered cytokine secretory profile. Three-dimensional cultures of human breast cancer cells on Matrigel revealed an altered colony growth, morphology and arborization pattern in LASP-1 knockdown cells. Functional analysis of the LASP-1 knockdown cells revealed increased adhesion to collagen IV and decreased invasion through the Matrigel. Proteomic analysis of immunoprecipitates of LASP-1 and subsequent validation approaches revealed that LASP-1 associated with the epigenetic machinery especially UHRF1, DNMT1, G9a and the transcription factor Snail1. Interestingly, LASP-1 associated with UHRF1, G9a, Snail1 and di- and tri-methylated histoneH3 in a CXCL12-dependent manner based on immunoprecipitation and proximity ligation assays. LASP-1 also directly bound to Snail1 which may stabilize Snail1. Thus, nuclear LASP-1 appears to functionally serve as a hub for the epigenetic machinery.	[Duvall-Noelle, N.; Karwandyar, A.; Richmond, A.; Raman, D.] Vanderbilt Univ, Sch Med, Dept Canc Biol, 436 Preston Res Bldg,23rd Ave South Pierce, Nashville, TN 37232 USA; [Richmond, A.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Raman, D (corresponding author), Vanderbilt Univ, Med Ctr, Dept Canc Biol, 436 Preston Res Bldg,23rd Ave South Pierce, Nashville, TN 37232 USA.	dayanidhi.raman@vanderbilt.edu			Department of Defense, IDEA grant [W81XWH-11-1-0413]; VICTR award - Vanderbilt Clinical and Translational Science Award (CTSA) grant from NCRR/NIH [UL1 TR000445]; NIH [CA-34590]; VA Merit Award; Career Scientist Award from the Tennessee Valley Healthcare System; Department of Veterans Affairs; Ingram Professorship; NATIONAL CANCER INSTITUTE [R23CA034590, R01CA034590] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002301] Funding Source: NIH RePORTER	Department of Defense, IDEA grant(United States Department of Defense); VICTR award - Vanderbilt Clinical and Translational Science Award (CTSA) grant from NCRR/NIH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Award(US Department of Veterans Affairs); Career Scientist Award from the Tennessee Valley Healthcare System; Department of Veterans Affairs(US Department of Veterans Affairs); Ingram Professorship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Department of Defense, IDEA grant W81XWH-11-1-0413 (to DR), VICTR award, supported in part by Vanderbilt Clinical and Translational Science Award (CTSA) grant, UL1 TR000445 from NCRR/NIH (to DR), NIH grants CA-34590 (to AR), VA Merit Award (to AR), Career Scientist Award (to AR) from the Tennessee Valley Healthcare System and the Department of Veterans Affairs and Ingram Professorship (to AR).	Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Cipriano R, 2014, ONCOGENE, V33, P3298, DOI 10.1038/onc.2013.293; Cipriano R, 2013, ONCOTARGET, V4, P729, DOI 10.18632/oncotarget.1027; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Frietsch JJ, 2010, BRIT J CANCER, V102, P1645, DOI 10.1038/sj.bjc.6605685; Fulton AM, 2009, CURR ONCOL REP, V11, P125, DOI 10.1007/s11912-009-0019-1; Goldberg-Bittman L, 2004, IMMUNOL LETT, V92, P171, DOI 10.1016/j.imlet.2003.10.020; Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016; Grunewald TGP, 2007, BMC CANCER, V7, P1, DOI 10.1186/1471-2407-7-198; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Li HY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2680; Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Mihlan S, 2013, ONCOGENE, V32, P2107, DOI 10.1038/onc.2012.216; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Neel NF, 2008, THESIS; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318; Orth MF, 2015, ONCOTARGET, V6, P26, DOI 10.18632/oncotarget.3083; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Raman D, 2009, METHOD ENZYMOL, V460, P297; Raman D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010050; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Ueda Y, 2006, CANCER RES, V66, P5665, DOI 10.1158/0008-5472.CAN-05-3579; Walser TC, 2006, CANCER RES, V66, P7701, DOI 10.1158/0008-5472.CAN-06-0709; Wikman H, 2014, ONCOTARGET, V5, P3076, DOI 10.18632/oncotarget.1832; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128	39	29	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1122	1133		10.1038/onc.2015.166	http://dx.doi.org/10.1038/onc.2015.166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982273	Green Accepted			2022-12-28	WOS:000371351700006
J	Rodriguez, M; Siwko, S; Zeng, L; Li, J; Yi, Z; Liu, M				Rodriguez, M.; Siwko, S.; Zeng, L.; Li, J.; Yi, Z.; Liu, M.			Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression	ONCOGENE			English	Article							STROMAL ANDROGEN RECEPTOR; INTRAEPITHELIAL NEOPLASIA; TUMOR-SUPPRESSOR; EXPRESSION; PSGR; GENE; TISSUE; MICROENVIRONMENT; INACTIVATION; INFLAMMATION	Among frequent events in prostate cancer are loss of the tumor-suppressor phosphatase and tensin homologue (PTEN) and overexpression of prostate-specific G-protein-coupled receptor (PSGR), but the potential tumorigenic synergy between these lesions is unknown. Here, we report a new mouse model (PSGR-Pten(Delta/Delta)) combining prostate-specific loss of Pten with probasin promoter-driven PSGR overexpression. By 12 months PSGR-Pten(Delta/Delta) mice developed invasive prostate tumors featuring Akt activation and extensive inflammatory cell infiltration. PSGR-Pten(Delta/Delta) tumors exhibited E-cadherin loss and increased stromal androgen receptor (AR) expression. PSGR overexpression increased LNCaP proliferation, whereas PSGR short hairpin RNA knockdown inhibited proliferation and migration. In conclusion, we demonstrate that PSGR overexpression synergizes with loss of PTEN to accelerate prostate cancer development, and present a novel bigenic mouse model that mimics the human condition, where both PSGR overexpression and loss of PTEN occur concordantly in the majority of advanced prostate cancers, yielding an environment more relevant to studying human prostate cancer.	[Rodriguez, M.; Siwko, S.; Zeng, L.; Liu, M.] Texas A&M Univ, Hlth Sci Ctr, Ctr Canc & Stem Cell Biol, Inst Biosci & Technol,Dept Cellular & Mol Med, 2121 W Holcombe Blvd, Houston, TX 77030 USA; [Li, J.; Yi, Z.; Liu, M.] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China; [Li, J.; Yi, Z.; Liu, M.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; East China Normal University; East China Normal University	Liu, M (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Ctr Canc & Stem Cell Biol, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Siwko, Stefan/0000-0003-4260-2985	State Key Development Programs of China [2012CB910400]; DOD Prostate Cancer Research Program (PCRP) [W81XWH-10-1-0612, W81XWH-10-10147]; NIH [5R01CA134731]; NATIONAL CANCER INSTITUTE [R01CA134731] Funding Source: NIH RePORTER	State Key Development Programs of China; DOD Prostate Cancer Research Program (PCRP); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michael Ittmann (Baylor College of Medicine) for his insights and suggestions. We thank Dr Fen Wang (Texas A&M Health Science Center) for the gift of the PTEN<SUP>fl/fl</SUP> Cre mice and for valuable discussions and suggestions, and Dr Dekai Zhang (Texas A&M Health Science Center) for the gift of the RAW264.7 cells. This work was partially supported by grants from the State Key Development Programs of China (2012CB910400), DOD Prostate Cancer Research Program (PCRP, W81XWH-10-1-0612, W81XWH-10-10147) and NIH (5R01CA134731). This work was partially supported by grants from the State Key Development Programs of China (2012CB910400), DOD Prostate Cancer Research Program (PCRP, W81XWH-10-1-0612, W81XWH-10-10147) and NIH (5R01CA134731).	Cairns P, 1997, CANCER RES, V57, P4997; Cano P, 2007, CANCER RES, V67, P511, DOI 10.1158/0008-5472.CAN-06-1478; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Giles Graham G, 2003, Methods Mol Med, V81, P1; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gurel B, 2014, CANCER EPIDEM BIOMAR, V23, P847, DOI 10.1158/1055-9965.EPI-13-1126; Kwon OJ, 2014, P NATL ACAD SCI USA, V111, pE592, DOI 10.1073/pnas.1318157111; Lai KP, 2012, EMBO MOL MED, V4, P791, DOI 10.1002/emmm.201101140; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lee JT, 2008, CELL CYCLE, V7, P1745, DOI 10.4161/cc.7.12.6166; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; MacKenzie L, 2012, HUM PATHOL, V43, P1491, DOI 10.1016/j.humpath.2011.11.009; McCall P, 2012, BRIT J CANCER, V107, P1554, DOI 10.1038/bjc.2012.372; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rodriguez M, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.29; Roy AK, 1999, VITAM HORM, V55, P309; Russell Pamela J, 2003, Methods Mol Med, V81, P21; Sanz G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085110; Shen MM, 2007, CANCER RES, V67, P6535, DOI 10.1158/0008-5472.CAN-07-1271; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vanaja DK, 2003, CANCER RES, V63, P3877; Wang JH, 2006, PROSTATE, V66, P847, DOI 10.1002/pros.20389; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Weng JS, 2005, J CELL BIOCHEM, V96, P1034, DOI 10.1002/jcb.20600; Weng JS, 2005, INT J CANCER, V113, P811, DOI 10.1002/ijc.20635; Wikstrom P, 2009, PROSTATE, V69, P799, DOI 10.1002/pros.20927; Xia CZ, 2001, ONCOGENE, V20, P5903, DOI 10.1038/sj.onc.1204803; Xu LL, 2000, CANCER RES, V60, P6568; Xu LL, 2006, PROSTATE CANCER P D, V9, P56, DOI 10.1038/sj.pcan.4500836; Yoshimoto M, 2007, BRIT J CANCER, V97, P678, DOI 10.1038/sj.bjc.6603924; Yoshimoto M, 2008, MODERN PATHOL, V21, P1451, DOI 10.1038/modpathol.2008.96; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727; Zhou Y, 2015, J MOL ENDOCRINOL, V54, pR15, DOI 10.1530/JME-14-0203	40	24	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1153	1162		10.1038/onc.2015.170	http://dx.doi.org/10.1038/onc.2015.170			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26028029	Green Accepted			2022-12-28	WOS:000371351700009
J	Olcina, MM; Leszczynska, KB; Senra, JM; Isa, NF; Harada, H; Hammond, EM				Olcina, M. M.; Leszczynska, K. B.; Senra, J. M.; Isa, N. F.; Harada, H.; Hammond, E. M.			H3K9me3 facilitates hypoxia-induced p53-dependent apoptosis through repression of APAK	ONCOGENE			English	Article							CHROMATIN-STRUCTURE; ATM ACTIVATION; SOLID TUMORS; HUMAN GENOME; HISTONE H3; STRESS; P53; HETEROCHROMATIN; METHYLTRANSFERASE; REPLICATION	Regions of hypoxia occur in most solid tumors, and they are associated with a poor prognostic outcome. Despite the absence of detectable DNA damage, severe hypoxia (<0.1% O-2) induces a DNA damage response, including the activation of p53 and subsequent induction of p53-dependent apoptosis. Factors affecting hypoxia-induced p53-dependent apoptosis are unclear. Here we asked whether H3K9me3, through mediating gene repression, could regulate hypoxia-induced p53-dependent apoptosis. Under hypoxic conditions, increases in H3K9me3 occur in an oxygen-dependent but HIF-1-independent manner. We demonstrate that under hypoxic conditions, which induce p53 activity, the negative regulator of p53, APAK, is repressed by increases in H3K9me3 along the APAK loci. APAK repression in hypoxia is mediated by the methyltransferase SETDB1 but not Suv39h1 or G9a. Interestingly, increasing hypoxia-induced H3K9me3 through pharmacological inhibition of JMJD2 family members leads to an increase in apoptosis and decreased clonogenic survival and again correlates with APAK expression. The relevance of understanding the mechanisms of APAK expression regulation to human disease was suggested by analysis of patients with colorectal cancer, which demonstrates that high APAK expression correlates with poor prognosis. Together, these data demonstrate the functional importance of H3K9me3 in hypoxia, and they provide a novel mechanistic link between H3K9me3, p53 and apoptosis in physiologically relevant conditions of hypoxia.	[Olcina, M. M.; Leszczynska, K. B.; Senra, J. M.; Isa, N. F.; Hammond, E. M.] Univ Oxford, Dept Oncol, CR UK & MRC Oxford Inst Radiat Oncol, Oxford, England; [Harada, H.] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Applied Therapy, Kyoto, Japan	University of Oxford; Kyoto University	Hammond, EM (corresponding author), Univ Oxford, CR UK & MRC Oxford Inst Radiat Oncol, Dept Oncol, ORCRB, Off Roosevelt Dr, Oxford OX3 7DQ, England.	Ester.Hammond@oncology.ox.ac.uk	isa, nur firdaus/HGU-0902-2022; Leszczynska, Katarzyna/AAK-9655-2020; Isa, Nur Firdaus/AAV-2880-2021	Leszczynska, Katarzyna/0000-0002-3504-1553; Isa, Nur Firdaus/0000-0003-3476-6306; Hammond, Ester/0000-0002-2335-3146	Cancer Research UK grant; MRC; MRC Centenary award; Cancer Research UK [19276] Funding Source: researchfish; Medical Research Council [891635] Funding Source: researchfish	Cancer Research UK grant(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Centenary award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to Chunyan Tian for the APAK constructs and Amato Giaccia and Laura Castellini for helpful discussions. KBL, JMS and EMH are supported by a Cancer Research UK grant (awarded to EMH). MO is supported by the MRC with an additional MRC Centenary award (awarded to MMO).	Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bencokova Z, 2009, MOL CELL BIOL, V29, P526, DOI 10.1128/MCB.01301-08; Brown JM, 1998, CANCER RES, V58, P1408; Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Johnson AB, 2007, MUTAT RES-FUND MOL M, V618, P149, DOI 10.1016/j.mrfmmm.2006.10.007; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Loyola A, 2009, EMBO REP, V10, P769, DOI 10.1038/embor.2009.90; Lu YH, 2014, CELL REP, V8, P500, DOI 10.1016/j.celrep.2014.06.035; Lu YH, 2011, MOL CELL BIOL, V31, P3339, DOI 10.1128/MCB.01121-10; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Olcina MM, 2013, MOL CELL, V52, P758, DOI 10.1016/j.molcel.2013.10.019; Rai G, 2010, PROBE REPORTS NIH MO; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tian C, 2009, NAT CELL BIOL, V11, P580, DOI 10.1038/ncb1864; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Wang S, 2010, FEBS LETT, V584, P3909, DOI 10.1016/j.febslet.2010.08.015; Yuan L, 2012, EMBO REP, V13, P363, DOI 10.1038/embor.2012.10	29	41	45	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					793	799		10.1038/onc.2015.134	http://dx.doi.org/10.1038/onc.2015.134			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961932	Green Published, hybrid			2022-12-28	WOS:000370331300012
J	German, P; Bai, S; Liu, XD; Sun, M; Zhou, L; Kalra, S; Zhang, X; Minelli, R; Scott, KL; Mills, GB; Jonasch, E; Ding, Z				German, P.; Bai, S.; Liu, X-D; Sun, M.; Zhou, L.; Kalra, S.; Zhang, X.; Minelli, R.; Scott, K. L.; Mills, G. B.; Jonasch, E.; Ding, Z.			Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function	ONCOGENE			English	Article							PROTEIN-KINASE CK2; TUMOR-SUPPRESSOR PROTEIN; GENE ALTERATIONS; IN-VIVO; MUTATIONS; PRODUCT; COMPLEX; BINDING; HIF; IDENTIFICATION	Loss of von Hippel Lindau (VHL) protein function is a key driver of VHL diseases, including sporadic and inherited clear cell renal cell carcinoma. Modulation of the proteostasis of VHL, especially missense point-mutated VHL, is a promising approach to augmenting VHL levels and function. VHL proteostasis is regulated by multiple mechanisms including folding, chaperone binding, complex formation and phosphorylation. Nevertheless, many details underlying the regulations of VHL proteostasis are unknown. VHL is expressed as two variants, VHL30 and VHL19. Furthermore, the long-form variant of VHL was often detected as multiple bands by western blotting. However, how these multiple species of VHL are generated and whether the process regulates VHL proteostasis and function are unknown. We hypothesized that the two major species are generated by VHL protein cleavage, and the cleavage regulates VHL proteostasis and subsequent function. We characterized VHL species using genetical and pharmacological approaches and showed that VHL was first cleaved at the N-terminus by chymotrypsin C before being directed for proteasomal degradation. Casein kinase 2-mediated phosphorylation at VHL N-terminus was required for the cleavage. Furthermore, inhibition of cleavage stabilized VHL protein and thereby promoted HIF downregulation. Our study reveals a novel mechanism regulating VHL proteostasis and function, which is significant for identifying new drug targets and developing new therapeutic approaches targeting VHL deficiency in VHL diseases.	[German, P.; Bai, S.; Liu, X-D; Sun, M.; Zhou, L.; Kalra, S.; Zhang, X.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Minelli, R.; Scott, K. L.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Mills, G. B.; Ding, Z.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Ding, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Unit 950, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ejonasch@mdanderson.org; zding@mdanderson.org		Liu, xiande/0000-0002-9639-0458	University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; MD Anderson Cancer Center Institutional Research Grant; NIH grant [UO1CA168394, 5 PN2 EY016525-10]; NCI CCSG grant; NATIONAL CANCER INSTITUTE [P30CA016672, U01CA168394] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY016525] Funding Source: NIH RePORTER	University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; MD Anderson Cancer Center Institutional Research Grant; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI CCSG grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Dr Kimryn Rathmell for providing renal proximal tubule epithelial cells. This work was supported by a grant from The University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program (ZD), an MD Anderson Cancer Center Institutional Research Grant (ZD), the NIH grant UO1CA168394 (KLS and GBM), the NIH grant 5 PN2 EY016525-10 (EJ) and NCI CCSG grant to MD Anderson Cancer Center.	Ampofo E, 2010, INT J BIOCHEM CELL B, V42, P1729, DOI 10.1016/j.biocel.2010.07.008; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Ding ZY, 2014, CANCER RES, V74, P3127, DOI 10.1158/0008-5472.CAN-13-3213; Ding ZY, 2012, J BIOMOL SCREEN, V17, P572, DOI 10.1177/1087057112436557; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Feldman DE, 2003, MOL CELL, V12, P1213, DOI 10.1016/S1097-2765(03)00423-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Guerra B, 2015, CANCER LETT, V356, P751, DOI 10.1016/j.canlet.2014.10.026; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lee CM, 2009, ONCOGENE, V28, P1694, DOI 10.1038/onc.2009.12; Lolkema MP, 2005, J BIOL CHEM, V280, P22205, DOI 10.1074/jbc.M503220200; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Montenarh M, 2014, ADV CLIN EXP MED, V23, P153, DOI 10.17219/acem/37040; Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Pizzi M, 2015, ONCOTARGET, V6, P6544, DOI 10.18632/oncotarget.3446; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; Rechsteiner MP, 2011, CANCER RES, V71, P5500, DOI 10.1158/0008-5472.CAN-11-0757; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Yang CZ, 2013, CELL REP, V3, P52, DOI 10.1016/j.celrep.2012.12.007	33	7	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					4973	4980		10.1038/onc.2016.40	http://dx.doi.org/10.1038/onc.2016.40			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26973240	Green Accepted			2022-12-28	WOS:000383965300002
J	van Jaarsveld, MTM; Houthuijzen, JM; Voest, EE				van Jaarsveld, M. T. M.; Houthuijzen, J. M.; Voest, E. E.			Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer	ONCOGENE			English	Review							PROTEIN-COUPLED-RECEPTOR; LEUKOTRIENE B-4 RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; ACTIVATING-FACTOR RECEPTOR; THROMBOXANE A(2) RECEPTOR; SITE-DIRECTED MUTAGENESIS; CHAIN FATTY-ACIDS; EPITHELIAL-MESENCHYMAL TRANSITION; RETRACTED ARTICLE. SEE; GROWTH-FACTOR RECEPTOR	Over the past decade the importance of lipids for cancer cell metabolism and cancer-related processes such as proliferation, metastasis and chemotherapy resistance has become more apparent. The mechanisms by which lipid signals are transduced are poorly understood, but frequently involve G-protein Coupled Receptors (GPCRs), which can be explored as druggable targets. Here, we discuss how GPCRs recognize four classes of cancer-relevant lipids (lysophospholipids, phospholipids, fatty acids and eicosanoids). We compare the ligand-binding properties of >50 lipid receptors, we examine how their dysregulation contributes to tumorigenesis and how they may be therapeutically exploited.	[van Jaarsveld, M. T. M.; Houthuijzen, J. M.; Voest, E. E.] Netherlands Canc Inst, Dept Mol Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [van Jaarsveld, M. T. M.] Otto Warburg Lab, Max Planck Inst Mol Genet, Berlin, Germany	Netherlands Cancer Institute; Max Planck Society	Voest, EE (corresponding author), Netherlands Canc Inst, Dept Mol Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	e.voest@nki.nl		Houthuijzen, Julia/0000-0003-0404-1961	Dutch Cancer Society [UU2012-5712, UU2009-4534]	Dutch Cancer Society(KWF Kankerbestrijding)	We thank Dr Perrakis and Dr Moolenaar for helpful discussions. The study was funded by Dutch Cancer Society grants UU2012-5712 and UU2009-4534.	Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X; Ahn KH, 2009, MOL PHARMACOL, V76, P833, DOI 10.1124/mol.109.057356; Akiyama K, 2013, PATHOL INT, V63, P37, DOI 10.1111/pin.12031; Alaa M, 2009, INT J ONCOL, V34, P805, DOI 10.3892/ijo_00000206; Altman MK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-140; Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Ansell SM, 2012, BLOOD, V120, P3949, DOI 10.1182/blood-2011-11-389908; Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912; Audoly L, 1997, MOL PHARMACOL, V51, P61, DOI 10.1124/mol.51.1.61; Bae YS, 2003, MOL PHARMACOL, V64, P721, DOI 10.1124/mol.64.3.721; Bai XM, 2013, INT J ONCOL, V42, P1833, DOI 10.3892/ijo.2013.1859; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Baltoumas FA, 2013, J STRUCT BIOL, V182, P209, DOI 10.1016/j.jsb.2013.03.004; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Basu S, 2007, J BIOL CHEM, V282, P10005, DOI 10.1074/jbc.M609552200; Bena S, 2012, J BIOL CHEM, V287, P24690, DOI 10.1074/jbc.M112.377101; Benned-Jensen T, 2010, BRIT J PHARMACOL, V159, P1092, DOI 10.1111/j.1476-5381.2009.00633.x; Bermudez Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020487; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103; Brindley DN, 2013, BBA-MOL CELL BIOL L, V1831, P74, DOI 10.1016/j.bbalip.2012.08.015; Brink C, 2007, THESCIENTIFICWORLDJO, V7, P1285, DOI 10.1100/tsw.2007.163; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2005, DNA CELL BIOL, V24, P54, DOI 10.1089/dna.2005.24.54; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Brown SL, 2006, J IMMUNOL, V177, P3242, DOI 10.4049/jimmunol.177.5.3242; Caffarel MM, 2012, CANCER TREAT REV, V38, P911, DOI 10.1016/j.ctrv.2012.06.005; Carnini C, 2011, FASEB J, V25, P3519, DOI 10.1096/fj.10-177030; Cash JL, 2014, DRUG DISCOV TODAY, V19, P1186, DOI 10.1016/j.drudis.2014.06.023; Catalano RD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019209; Cattoretti G, 2009, CANCER RES, V69, P8686, DOI 10.1158/0008-5472.CAN-09-1110; Chakraborty R, 2013, MOL CELL BIOL, V33, P184, DOI 10.1128/MCB.00725-12; Chang J, 2015, ONCOTARGET, V6, P33500, DOI 10.18632/oncotarget.5589; Chen J, 2015, CANCER RES, V75, P4198, DOI 10.1158/0008-5472.CAN-15-1062; Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1927, DOI 10.1152/ajpcell.00400.2006; Chen YC, 2014, INT J CANCER, V135, P117, DOI 10.1002/ijc.28658; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; Chillar A, 2008, FEBS LETT, V582, P2863, DOI 10.1016/j.febslet.2008.07.018; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Chrencik JE, 2015, CELL, V161, P1633, DOI 10.1016/j.cell.2015.06.002; Chu ZL, 2007, ENDOCRINOLOGY, V148, P2601, DOI 10.1210/en.2006-1608; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Cork SM, 2011, J MOL MED, V89, P743, DOI 10.1007/s00109-011-0759-x; Czech MP, 2013, DIABETOLOGIA, V56, P949, DOI 10.1007/s00125-013-2869-1; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; Daniele S, 2010, CELL SIGNAL, V22, P697, DOI 10.1016/j.cellsig.2009.12.006; Dong XW, 2013, EUR J MED CHEM, V62, P754, DOI 10.1016/j.ejmech.2013.01.041; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Drost AC, 2012, LEUKEMIA LYMPHOMA, V53, P665, DOI 10.3109/10428194.2011.625578; E SY, 2009, J BIOL CHEM, V284, P14558, DOI 10.1074/jbc.M900185200; Eberini I, 2011, J COMPUT AID MOL DES, V25, P743, DOI 10.1007/s10822-011-9455-8; Elangovan S, 2014, CANCER RES, V74, P1166, DOI 10.1158/0008-5472.CAN-13-1451; Elbegdorj O, 2013, J MOL GRAPH MODEL, V39, P50, DOI 10.1016/j.jmgm.2012.10.005; Feng WK, 2003, BIOCHEM PHARMACOL, V65, P1077, DOI 10.1016/S0006-2952(03)00005-4; Frasch SC, 2008, J BIOL CHEM, V283, P33736, DOI 10.1074/jbc.M807047200; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Fujiwara Y, 2007, J BIOL CHEM, V282, P2374, DOI 10.1074/jbc.M609648200; Fukushima K, 2015, BIOCHEM BIOPH RES CO, V465, P512, DOI 10.1016/j.bbrc.2015.08.050; Fukushima Y, 1998, INT J ONCOL, V13, P967; Funke M, 2012, AM J RESP CELL MOL, V46, P355, DOI 10.1165/rcmb.2010-0155OC; Furui T, 1999, CLIN CANCER RES, V5, P4308; Gaetano CG, 2009, MOL CARCINOGEN, V48, P801, DOI 10.1002/mc.20524; Galamb O, 2009, CELL ONCOL, V31, P19, DOI 10.3233/CLO-2009-0458; Gaudreau R, 2004, J BIOL CHEM, V279, P10338, DOI 10.1074/jbc.M309207200; Gaudreau R, 2002, J BIOL CHEM, V277, P31567, DOI 10.1074/jbc.M202723200; Giaginis C, 2014, NEOPLASMA, V61, P309, DOI 10.4149/neo_2014_040; Glatt S, 2008, INT J CANCER, V122, P2008, DOI 10.1002/ijc.23349; Gotoh M, 2012, BIOCHEM SOC T, V40, P31, DOI 10.1042/BST20110608; Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Gugger M, 2008, DIS MARKERS, V24, P41, DOI 10.1155/2008/857474; Guo YD, 2011, J BIOL CHEM, V286, P33832, DOI 10.1074/jbc.M110.216564; Gustafsson A, 2007, ACTA ONCOL, V46, P1107, DOI 10.1080/02841860701403061; Gustafsson A, 2007, INT J CANCER, V121, P232, DOI 10.1002/ijc.22582; Halder S, 2013, EXPERT OPIN THER PAT, V23, P1581, DOI 10.1517/13543776.2013.842977; Han C, 2005, J BIOL CHEM, V280, P24053, DOI 10.1074/jbc.M500562200; Han C, 2006, J CELL PHYSIOL, V207, P261, DOI 10.1002/jcp.20560; Hanson MA, 2012, SCIENCE, V335, P851, DOI [10.1126/science.1244693, 10.1126/science.1215904]; Hata AN, 2005, J BIOL CHEM, V280, P32442, DOI 10.1074/jbc.M502563200; Hatanaka H, 2000, INT J MOL MED, V5, P181; Hayashi M, 2012, CANCER LETT, V316, P91, DOI 10.1016/j.canlet.2011.10.030; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA T, 1994, J CLIN INVEST, V94, P1662, DOI 10.1172/JCI117510; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Hong S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00013; Hosoi T, 2005, BIOCHEM BIOPH RES CO, V334, P987, DOI 10.1016/j.bbrc.2005.06.191; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Houthuijzen JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6275; Hsu A, 2012, INT J ONCOL, V40, P1619, DOI 10.3892/ijo.2012.1379; HUANG CF, 1995, BIOCHEM J, V307, P493, DOI 10.1042/bj3070493; Huang HFS, 2013, MOL CANCER RES, V11, P427, DOI 10.1158/1541-7786.MCR-12-0464; Huang RY, 2014, J CANCER RES CLIN, V140, P375, DOI 10.1007/s00432-013-1573-3; Hudson BD, 2014, J BIOL CHEM, V289, P20345, DOI 10.1074/jbc.M114.561449; Hurst DP, 2010, J BIOL CHEM, V285, P17954, DOI 10.1074/jbc.M109.041590; Iida Y, 2014, ANTICANCER RES, V34, P5465; Ikubo M, 2015, J MED CHEM, V58, P4204, DOI 10.1021/jm5020082; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Inada M, 2015, J BIOL CHEM, V2015; Inagaki Y, 2005, BIOCHEM J, V389, P187, DOI 10.1042/BJ20050046; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/nmeth.2172, 10.1038/NMETH.2172]; Ishdorj G, 2008, J BIOL CHEM, V283, P16818, DOI 10.1074/jbc.M710177200; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jabbour HN, 2004, TRENDS ENDOCRIN MET, V15, P398, DOI 10.1016/j.tem.2004.08.006; Jiang JX, 2013, J PHARMACOL EXP THER, V344, P360, DOI 10.1124/jpet.112.200444; Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; Jongsma M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029260; Justus CR, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00354; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187; Kargl J, 2016, BRIT J PHARMACOL, V173, P142, DOI 10.1111/bph.13345; Kastner S, 2012, MOL CANCER RES, V10, P1343, DOI 10.1158/1541-7786.MCR-12-0139; Katritch V, 2013, ANNU REV PHARMACOL, V53, P531, DOI 10.1146/annurev-pharmtox-032112-135923; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Kebede MA, 2009, DIABETES OBES METAB, V11, P10, DOI 10.1111/j.1463-1326.2009.01114.x; Kedzie KM, 1998, MOL PHARMACOL, V54, P584, DOI 10.1124/mol.54.3.584; Khasawneh FT, 2006, J BIOL CHEM, V281, P26951, DOI 10.1074/jbc.M507469200; Kim EY, 2010, ONCOGENE, V29, P1167, DOI 10.1038/onc.2009.412; Kim EY, 2010, FREE RADICAL BIO MED, V49, P1072, DOI 10.1016/j.freeradbiomed.2010.06.023; Kim H, 2013, BRIT J CANCER, V109, P351, DOI 10.1038/bjc.2013.333; Kim H, 2014, J BIOL CHEM, V289, P22151, DOI 10.1074/jbc.M114.556126; Kim KS, 2006, CANCER RES, V66, P7983, DOI 10.1158/0008-5472.CAN-05-4381; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Kiss GN, 2012, MOL PHARMACOL, V82, P1162, DOI 10.1124/mol.112.079699; Kitamura H, 2012, J BIOCHEM, V151, P511, DOI 10.1093/jb/mvs011; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; Kleivi K, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-2; Kobayashi T, 2000, J BIOL CHEM, V275, P24294, DOI 10.1074/jbc.M002437200; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; Kohno M, 2006, BIOCHEM BIOPH RES CO, V347, P827, DOI 10.1016/j.bbrc.2006.06.175; Koike D, 2006, J BIOCHEM, V139, P543, DOI 10.1093/jb/mvj060; Komachi M, 2012, CANCER SCI, V103, P1099, DOI 10.1111/j.1349-7006.2012.02246.x; Kotarsky K, 2003, BIOCHEM BIOPH RES CO, V301, P406, DOI 10.1016/S0006-291X(02)03064-4; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Kothapalli R, 2002, BBA-GENE STRUCT EXPR, V1579, P117, DOI 10.1016/S0167-4781(02)00529-8; Krishnamoorthy S, 2012, AM J PATHOL, V180, P2018, DOI 10.1016/j.ajpath.2012.01.028; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Kudo S, 2007, ONCOL REP, V18, P785; Kumar JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104877; Kuniyeda K, 2007, J BIOL CHEM, V282, P3998, DOI 10.1074/jbc.M610540200; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lee HJ, 2013, INT J BIOCHEM CELL B, V45, P2801, DOI 10.1016/j.biocel.2013.09.018; Lee JH, 2001, INT J ONCOL, V18, P355; Lee JW, 2013, J BIOL CHEM, V288, P30054, DOI 10.1074/jbc.M113.481283; Lee JW, 2012, BIOCHEM BIOPH RES CO, V420, P428, DOI 10.1016/j.bbrc.2012.03.012; Lee SC, 2015, MOL CANCER RES, V13, P174, DOI 10.1158/1541-7786.MCR-14-0263; Lee Z, 2008, MOL BIOL CELL, V19, P5435, DOI 10.1091/mbc.E08-03-0316; Li YY, 2007, J AM CHEM SOC, V129, P10720, DOI 10.1021/ja070865d; Liebscher I, 2011, J BIOL CHEM, V286, P2101, DOI 10.1074/jbc.M110.196659; Lim HS, 2004, BIOORG MED CHEM LETT, V14, P2499, DOI 10.1016/j.bmcl.2004.03.001; Lin DCH, 2012, MOL PHARMACOL, V82, P843, DOI 10.1124/mol.112.079640; Lin FT, 2007, J BIOL CHEM, V282, P37759, DOI 10.1074/jbc.M705025200; Lin SB, 2010, GASTROENTEROLOGY, V138, P649, DOI 10.1053/j.gastro.2009.09.055; Liu JF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-43; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Liu Z, 2015, J PHARMACOL EXP THER, V352, P380, DOI 10.1124/jpet.114.218974; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Maekawa A, 2009, P NATL ACAD SCI USA, V106, P11685, DOI 10.1073/pnas.0905364106; Magnusson C, 2011, INT J CANCER, V129, P9, DOI 10.1002/ijc.25648; Marcu J, 2013, J PHARMACOL EXP THER, V345, P189, DOI 10.1124/jpet.112.201046; Margan D, 2012, REV ROUM CHIM, V57, P39; Marshall JCA, 2012, JNCI-J NATL CANCER I, V104, P1306, DOI 10.1093/jnci/djs319; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matsuyama M, 2007, ONCOL REP, V18, P99; Matula K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1718-7; Meisen WH, 2015, MOL CANCER THER, V14, P307, DOI 10.1158/1535-7163.MCT-14-0659; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Melnikova VO, 2009, J BIOL CHEM, V284, P28845, DOI 10.1074/jbc.M109.042150; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; Mercier RW, 2010, CHEM BIOL, V17, P1132, DOI 10.1016/j.chembiol.2010.08.010; Milligan G, 2014, BRIT J PHARMACOL, V172, P3254; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Murakami M, 2008, BIOCHEM BIOPH RES CO, V371, P707, DOI 10.1016/j.bbrc.2008.04.145; Nam DH, 2004, ONCOL REP, V11, P863; Natarajan C, 2013, MOL PHARMACOL, V83, P206, DOI 10.1124/mol.112.080473; NEGISHI M, 1995, J BIOL CHEM, V270, P16122, DOI 10.1074/jbc.270.27.16122; Nehra D, 2014, J SURG RES, V188, P451, DOI 10.1016/j.jss.2014.01.037; Neuschafer-Rube F, 2003, BIOCHEM J, V371, P443, DOI 10.1042/BJ20021429; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Niedernberg A, 2003, CELL SIGNAL, V15, P435, DOI 10.1016/S0898-6568(02)00119-5; Nikaido Y, 2015, J BIOCHEM, V157, P311, DOI 10.1093/jb/mvu075; Nilsson NE, 2003, BIOCHEM BIOPH RES CO, V303, P1047, DOI 10.1016/S0006-291X(03)00488-1; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Nygaard R, 2009, TRENDS PHARMACOL SCI, V30, P249, DOI 10.1016/j.tips.2009.02.006; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Oka S, 2010, BIOCHEM BIOPH RES CO, V395, P232, DOI 10.1016/j.bbrc.2010.03.169; Oka S, 2009, J BIOCHEM, V145, P13, DOI 10.1093/jb/mvn136; Okabe K, 2013, MOL CARCINOGEN, V52, P247, DOI 10.1002/mc.21851; Okabe K, 2011, MOL CARCINOGEN, V50, P635, DOI 10.1002/mc.20750; Okazoe H, 2013, INT J MOL SCI, V14, P12367, DOI 10.3390/ijms140612367; Okumura S, 2004, CANCER SCI, V95, P131, DOI 10.1111/j.1349-7006.2004.tb03193.x; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329; Okuyama T, 2002, J LAB CLIN MED, V140, P92, DOI 10.1067/mlc.2002.125784; Onuchic AC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/175408; Parhamifar L, 2005, CARCINOGENESIS, V26, P1988, DOI 10.1093/carcin/bgi159; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; Parravicini C, 2010, BMC STRUCT BIOL, V10, DOI 10.1186/1472-6807-10-8; Parrill AL, 2013, BBA-MOL CELL BIOL L, V1831, P2, DOI 10.1016/j.bbalip.2012.09.002; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Patmanathan SN, 2015, J CELL MOL MED, V19, P2329, DOI 10.1111/jcmm.12635; Perez-Gomez E, 2013, ONCOGENE, V32, P2534, DOI 10.1038/onc.2012.278; Pettipher R, 2008, BRIT J PHARMACOL, V153, pS191, DOI 10.1038/sj.bjp.0707488; Pham TCT, 2008, J MOL GRAPH MODEL, V26, P1189, DOI 10.1016/j.jmgm.2007.11.001; Pierce KL, 1998, LIFE SCI, V62, P1479, DOI 10.1016/S0024-3205(98)00093-9; Pisanti S, 2013, TRENDS PHARMACOL SCI, V34, P273, DOI 10.1016/j.tips.2013.03.003; Poso A, 2008, BRIT J PHARMACOL, V153, P335, DOI 10.1038/sj.bjp.0707567; Pradhan MP, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-141; Pugliese AM, 2009, AM J PHYSIOL-CELL PH, V297, pC1028, DOI 10.1152/ajpcell.00658.2008; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Qin Y, 2011, PIGM CELL MELANOMA R, V24, P207, DOI 10.1111/j.1755-148X.2010.00781.x; Quint K, 2014, TUMOR BIOL, V35, P8979, DOI 10.1007/s13277-014-2172-x; Raitio KH, 2005, CURR MED CHEM, V12, P1217, DOI 10.2174/0929867053764617; Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004; Reggio PH, 2010, CURR MED CHEM, V17, P1468, DOI 10.2174/092986710790980005; Rehwald M, 1999, FEBS LETT, V443, P357, DOI 10.1016/S0014-5793(99)00007-1; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Resh MD, 2013, CURR BIOL, V23, pR431, DOI 10.1016/j.cub.2013.04.024; Rhee MH, 2000, J NEUROCHEM, V75, P2485, DOI 10.1046/j.1471-4159.2000.0752485.x; Rocconi RP, 2008, REPROD SCI, V15, P321, DOI 10.1177/1933719108316390; Romanuik TL, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-43; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Rundhaug JE, 2011, CANCER METAST REV, V30, P465, DOI 10.1007/s10555-011-9317-9; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Sabirsh A, 2006, BIOCHEMISTRY-US, V45, P5733, DOI 10.1021/bi060076t; Sales KJ, 2004, J CLIN ENDOCR METAB, V89, P986, DOI 10.1210/jc.2003-031434; Salim T, 2014, EXP CELL RES, V321, P255, DOI 10.1016/j.yexcr.2013.10.021; Samadi N, 2009, ONCOGENE, V28, P1028, DOI 10.1038/onc.2008.442; Samson MT, 2003, J IMMUNOL, V170, P4953, DOI 10.4049/jimmunol.170.10.4953; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Sawyer N, 2002, BRIT J PHARMACOL, V137, P1163, DOI 10.1038/sj.bjp.0704973; Sawzdargo M, 1997, BIOCHEM BIOPH RES CO, V239, P543, DOI 10.1006/bbrc.1997.7513; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Seo JM, 2012, J BIOL CHEM, V287, P13840, DOI 10.1074/jbc.M111.317131; Seo JM, 2011, EXP MOL MED, V43, P129, DOI 10.3858/emm.2011.43.3.014; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2011, CURR TOP MED CHEM, V11, P629; Shen M, 2011, LEUKEMIA RES, V35, P968, DOI 10.1016/j.leukres.2010.12.012; Shida D, 2008, CANCER RES, V68, P6569, DOI 10.1158/0008-5472.CAN-08-0411; Shim JY, 2010, CURR TOP MED CHEM, V10, P779, DOI 10.2174/156802610791164210; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Singh LS, 2007, JNCI-J NATL CANCER I, V99, P1313, DOI 10.1093/jnci/djm107; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; So SP, 2003, J BIOL CHEM, V278, P10922, DOI 10.1074/jbc.M209337200; Soga T, 2005, BIOCHEM BIOPH RES CO, V326, P744, DOI 10.1016/j.bbrc.2004.11.120; Song MY, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv007; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spisak S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046215; Srivastava A, 2014, NATURE, V513, P124, DOI 10.1038/nature13494; Stephenson JR, 2013, J BIOL CHEM, V288, P22248, DOI 10.1074/jbc.M113.489757; Stillman BA, 1998, EUR J PHARMACOL, V357, P73, DOI 10.1016/S0014-2999(98)00522-6; Stitham J, 2003, J BIOL CHEM, V278, P4250, DOI 10.1074/jbc.M207420200; Stoddart LA, 2008, J BIOL CHEM, V283, P32913, DOI 10.1074/jbc.M805601200; Sugino Y, 2007, ONCOGENE, V26, P7401, DOI 10.1038/sj.onc.1210550; Sugita K, 2013, BIOCHEM BIOPH RES CO, V430, P190, DOI 10.1016/j.bbrc.2012.11.046; Sugo T, 2006, BIOCHEM BIOPH RES CO, V341, P1078, DOI 10.1016/j.bbrc.2006.01.069; Sum CS, 2007, J BIOL CHEM, V282, P29248, DOI 10.1074/jbc.M705077200; Sum CS, 2009, J BIOL CHEM, V284, P3529, DOI 10.1074/jbc.M806987200; Sun L, 2015, INT J CLIN EXP PATHO, V8, P432; Sundaram S, 2006, BIOCHEM BIOPH RES CO, V339, P93, DOI 10.1016/j.bbrc.2005.10.189; Sung YM, 2006, ONCOGENE, V25, P5507, DOI 10.1038/sj.onc.1209538; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Suzuki M, 2013, J BIOL CHEM, V288, P10684, DOI 10.1074/jbc.M112.420042; Tabata KI, 2007, BIOCHEM BIOPH RES CO, V363, P861, DOI 10.1016/j.bbrc.2007.09.063; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; Taghavi P, 2008, ONCOGENE, V27, P6806, DOI 10.1038/onc.2008.294; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; Tan J, 2014, ADV IMMUNOL, V121, P91, DOI 10.1016/B978-0-12-800100-4.00003-9; Tang Y, 2011, INT J CANCER, V128, P847, DOI 10.1002/ijc.25638; Thangaraju M, 2009, CANCER RES, V69, P2826, DOI 10.1158/0008-5472.CAN-08-4466; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Tian DW, 2015, MOL MED REP, V12, P4522, DOI 10.3892/mmr.2015.3984; Tikhonova IG, 2015, BMC STRUCT BIOL, V15, DOI 10.1186/s12900-015-0044-2; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Ungrin MD, 2001, MOL PHARMACOL, V59, P1446, DOI 10.1124/mol.59.6.1446; Uwamizu A, 2015, J BIOCHEM, V157, P151, DOI 10.1093/jb/mvu060; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; van Loenen PB, 2011, EUR J PHARMACOL, V667, P105, DOI 10.1016/j.ejphar.2011.05.071; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Varsano T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049227; Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896; Wang DA, 2001, J BIOL CHEM, V276, P49213, DOI 10.1074/jbc.M107301200; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang JH, 2006, J BIOL CHEM, V281, P34457, DOI 10.1074/jbc.M608019200; Wang JH, 2006, J BIOL CHEM, V281, P22021, DOI 10.1074/jbc.M603503200; Watson C, 2010, AM J PATHOL, V177, P2205, DOI 10.2353/ajpath.2010.100220; Watson SJ, 2012, MOL PHARMACOL, V81, P631, DOI 10.1124/mol.111.077388; Williams JR, 2009, J BIOL CHEM, V284, P17304, DOI 10.1074/jbc.M109.003194; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Wu Q, 2013, ONCOGENE, V32, P5541, DOI 10.1038/onc.2013.264; Xin XP, 2012, LAB INVEST, V92, P1115, DOI 10.1038/labinvest.2012.90; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamada T, 2005, J BIOL CHEM, V280, P19358, DOI 10.1074/jbc.M414561200; Yan MX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061056; Yanagida K, 2013, BBA-MOL CELL BIOL L, V1831, P33, DOI 10.1016/j.bbalip.2012.08.003; Yanagida K, 2009, J BIOL CHEM, V284, P17731, DOI 10.1074/jbc.M808506200; Yang HL, 2010, J BIOL CHEM, V285, P32242, DOI 10.1074/jbc.M110.160820; Yang L, 2006, CANCER RES, V66, P9665, DOI 10.1158/0008-5472.CAN-06-1271; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yokomizo T, 2015, J BIOCHEM, V157, P65, DOI 10.1093/jb/mvu078; Yokota Y, 2012, BLOOD, V120, P3444, DOI 10.1182/blood-2011-10-383240; Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195; Yoshida Y, 1999, INT J ONCOL, V15, P1221; Yoshida Y, 2010, INT J CANCER, V126, P2341, DOI 10.1002/ijc.24933; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378; Yu WD, 2013, HISTOL HISTOPATHOL, V28, P1629, DOI 10.14670/HH-28.1629; Yu Y, 2014, BRIT J CANCER, V111, P515, DOI 10.1038/bjc.2014.323; Yun CC, 2005, AM J PHYSIOL-CELL PH, V289, pC2, DOI 10.1152/ajpcell.00610.2004; Zare Behnoush, 2011, Sci Pharm, V79, P793, DOI 10.3797/scipharm.1106-24; Zhang HC, 2007, J BIOL CHEM, V282, P15541, DOI 10.1074/jbc.M700702200; Zhang HC, 2007, CELL SIGNAL, V19, P261, DOI 10.1016/j.cellsig.2006.06.008; Zhang Lijun, 2010, Genomics Proteomics & Bioinformatics, V8, P1, DOI 10.1016/S1672-0229(10)60001-0; Zhang YH, 2009, CANCER RES, V69, P6049, DOI 10.1158/0008-5472.CAN-09-0621; Zhou HP, 1999, BIOCHEM BIOPH RES CO, V264, P171, DOI 10.1006/bbrc.1999.1508; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026	346	12	12	4	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4021	4035		10.1038/onc.2015.467	http://dx.doi.org/10.1038/onc.2015.467			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26640151				2022-12-28	WOS:000381020900001
J	Wang, Y; Xu, J; Gao, G; Li, J; Huang, H; Jin, H; Zhu, J; Che, X; Huang, C				Wang, Y.; Xu, J.; Gao, G.; Li, J.; Huang, H.; Jin, H.; Zhu, J.; Che, X.; Huang, C.			Tumor-suppressor NF kappa B2 p100 interacts with ERK2 and stabilizes PTEN mRNA via inhibition of miR-494	ONCOGENE			English	Article							KAPPA-B PATHWAY; MAP KINASE; CELL PROLIFERATION; SIGNALING PATHWAY; DOWN-REGULATION; PEA-15 REVEALS; PROTEIN; CANCER; EXPRESSION; APOPTOSIS	Emerging evidence from The Cancer Genome Atlas has revealed that nuclear factor kappa B2 (nf kappa b2) gene encoding p100 is genetically deleted or mutated in human cancers, implicating NF kappa B2 as a potential tumor suppressor. However, the molecular mechanism underlying the antitumorigenic action of p100 remains poorly understood. Here we report that p100 inhibits cancer cell anchorageindependent growth, a hallmark of cellular malignancy, by stabilizing the tumor-suppressor phosphatase and tensin homolog (PTEN) mRNA via a mechanism that is independent of p100' s inhibitory role in NF kappa B activation. We further demonstrate that the regulatory effect of p100 on PTEN expression is mediated by its downregulation of miR-494 as a result of the inactivation of extracellular signal-regulated kinase 2 (ERK2), in turn leading to inhibition of c-Jun/ activator protein-1-dependent transcriptional activity. Furthermore, we identify that p100 specifically interacts with non-phosphorylated ERK2 and prevents ERK2 phosphorylation and nuclear translocation. Moreover, the death domain at C-terminal of p100 is identified as being crucial and sufficient for its interaction with ERK2. Taken together, our findings provide novel mechanistic insights into the understanding of the tumor-suppressive role for NF kappa B2 p100.	[Wang, Y.; Xu, J.; Gao, G.; Li, J.; Huang, H.; Jin, H.; Zhu, J.; Che, X.; Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA	New York University	Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu.huang@nyumc.org		Huang, Chuanshu/0000-0003-4133-5096; Wang, Yulei/0000-0002-6495-3391	 [NIH/NCI CA165980];  [CA177665];  [CA112557];  [NIH/NIEHS ES000260]; NATIONAL CANCER INSTITUTE [P01CA165980, R01CA177665, R01CA112557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We greatly appreciate Dr Han-Fei Ding for his generous gifts about constructs expressing p100 and various deletion mutants of p100. We also appreciate Dr Shao-Cong Sun from the Department of Immunology, University of Texas MD Anderson Cancer Center for the gift of constructs expressing p100Ser866/870Ala or p100 Delta DD. This work was supported partially by grants from NIH/NCI CA165980, CA177665 and CA112557, as well as NIH/NIEHS ES000260.	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Arabi A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1975; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Dioletis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070095; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Fukushima H, 2012, CELL REP, V1, P434, DOI 10.1016/j.celrep.2012.04.002; Fusco AJ, 2008, J BIOL CHEM, V283, P12324, DOI 10.1074/jbc.M707898200; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kim WK, 2011, CLIN CANCER RES, V17, P7584, DOI 10.1158/1078-0432.CCR-11-0166; Li J, 1998, CANCER RES, V58, P5667; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Liu LH, 2010, LIFE SCI, V86, P192, DOI 10.1016/j.lfs.2009.12.002; Mace PD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2687; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Romagnoli M, 2012, CANCER RES, V72, P6268, DOI 10.1158/0008-5472.CAN-12-2270; Romano G, 2012, P NATL ACAD SCI USA, V109, P16570, DOI 10.1073/pnas.1207917109; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Shi YJ, 2012, J CELL SCI, V125, P4687, DOI 10.1242/jcs.093765; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Song L, 2007, MOL CELL BIOL, V27, P2713, DOI 10.1128/MCB.00657-06; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Wang Z, 2008, J BIOL CHEM, V283, P10698, DOI 10.1074/jbc.M800806200; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yilmaz ZB, 2014, CELL REP, V9, P1756, DOI 10.1016/j.celrep.2014.11.014; Yu HS, 2013, INT J MOL SCI, V14, P13329, DOI 10.3390/ijms140713329; Yu Y, 2014, ONCOGENE, V33, P996, DOI 10.1038/onc.2013.8; Zhang DY, 2014, J CELL SCI, V127, P2920, DOI 10.1242/jcs.148130; Zhang RW, 2014, J BIOL CHEM, V289, P6394, DOI 10.1074/jbc.M113.513960	50	24	25	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4080	4090		10.1038/onc.2015.470	http://dx.doi.org/10.1038/onc.2015.470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686085	Green Accepted			2022-12-28	WOS:000381020900006
J	Than, BLN; Linnekamp, JF; Starr, TK; Largaespada, DA; Rod, A; Zhang, Y; Bruner, V; Abrahante, J; Schumann, A; Luczak, T; Niemczyk, A; O'Sullivan, MG; Medema, JP; Fijneman, RJA; Meijer, GA; Van den Broek, E; Hodges, CA; Scott, PM; Vermeulen, L; Cormier, RT				Than, B. L. N.; Linnekamp, J. F.; Starr, T. K.; Largaespada, D. A.; Rod, A.; Zhang, Y.; Bruner, V.; Abrahante, J.; Schumann, A.; Luczak, T.; Niemczyk, A.; O'Sullivan, M. G.; Medema, J. P.; Fijneman, R. J. A.; Meijer, G. A.; Van den Broek, E.; Hodges, C. A.; Scott, P. M.; Vermeulen, L.; Cormier, R. T.			CFTR is a tumor suppressor gene in murine and human intestinal cancer	ONCOGENE			English	Article							CYSTIC-FIBROSIS; COLORECTAL-CANCER; IDENTIFIES GENES; MOUSE MODELS; HUMAN COLON; STEM-CELLS; RISK; EXPRESSION; REGULATOR; MICE	CFTR, the cystic fibrosis (CF) gene, encodes for the CFTR protein that plays an essential role in anion regulation and tissue homeostasis of various epithelia. In the gastrointestinal (GI) tract CFTR promotes chloride and bicarbonate secretion, playing an essential role in ion and acid-base homeostasis. Cftr has been identified as a candidate driver gene for colorectal cancer (CRC) in several Sleeping Beauty DNA transposon-based forward genetic screens in mice. Further, recent epidemiological and clinical studies indicate that CF patients are at high risk for developing tumors in the colon. To investigate the effects of CFTR dysregulation on GI cancer, we generated Apc(Min) mice that carried an intestinal-specific knockout of Cftr. Our results indicate that Cftr is a tumor suppressor gene in the intestinal tract as Cftr mutant mice developed significantly more tumors in the colon and the entire small intestine. In Apc(+/+) mice aged to similar to 1 year, Cftr deficiency alone caused the development of intestinal tumors in >60% of mice. Colon organoid formation was significantly increased in organoids created from Cftr mutant mice compared with wild-type controls, suggesting a potential role of Cftr in regulating the intestinal stem cell compartment. Microarray data from the Cftr-deficient colon and the small intestine identified dysregulated genes that belong to groups of immune response, ion channel, intestinal stem cell and other growth signaling regulators. These associated clusters of genes were confirmed by pathway analysis using Ingenuity Pathway Analysis and gene set enrichment analysis (GSEA). We also conducted RNA Seq analysis of tumors from Apc(+/+) Cftr knockout mice and identified sets of genes dysregulated in tumors including altered Wnt beta-catenin target genes. Finally we analyzed expression of CFTR in early stage human CRC patients stratified by risk of recurrence and found that loss of expression of CFTR was significantly associated with poor disease-free survival.	[Than, B. L. N.; Rod, A.; Bruner, V.; Schumann, A.; Luczak, T.; Niemczyk, A.; Scott, P. M.; Cormier, R. T.] Univ Minnesota, Sch Med, Dept Biomed Sci, 1035 Univ Dr,247 Med, Duluth, MN 55812 USA; [Linnekamp, J. F.; Medema, J. P.; Vermeulen, L.] Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol, Amsterdam, Netherlands; [Starr, T. K.; Abrahante, J.] Univ Minnesota, Sch Med, Masonic Canc Ctr, Dept Genet Cell Biol & Dev,Ctr Genome Engn, Minneapolis, MN 55455 USA; [Starr, T. K.] Univ Minnesota, Sch Med, Masonic Canc Ctr, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN 55455 USA; [Largaespada, D. A.] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; [Zhang, Y.] Univ Minnesota, Inst Supercomp, Minneapolis, MN 55455 USA; [O'Sullivan, M. G.] Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA; [Fijneman, R. J. A.; Meijer, G. A.; Van den Broek, E.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands; [Fijneman, R. J. A.; Meijer, G. A.] Netherlands Canc Inst, Amsterdam, Netherlands; [Hodges, C. A.] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; [Than, B. L. N.] Weill Cornell Med Coll, Div Gastroenterol & Hepatol, New York, NY USA	University of Minnesota System; University of Minnesota Duluth; University of Amsterdam; Academic Medical Center Amsterdam; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Case Western Reserve University; Cornell University	Scott, PM; Cormier, RT (corresponding author), Univ Minnesota, Sch Med, Dept Biomed Sci, 1035 Univ Dr,247 Med, Duluth, MN 55812 USA.; Vermeulen, L (corresponding author), Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol, Amsterdam, Netherlands.	pscott@d.umn.edu; l.vermeulen@amc.nl; rcormier@d.umn.edu	Fijneman, Remond/X-4199-2019; Starr, Tim/AAX-9342-2021; Vermeulen, Louis/B-7488-2008	Fijneman, Remond/0000-0003-2076-5521; Vermeulen, Louis/0000-0002-6066-789X; Starr, Timothy/0000-0002-6308-3451; Abrahante, Juan/0000-0002-9074-4307; Medema, Jan Paul/0000-0003-3045-2924; Meijer, Gerrit/0000-0003-0330-3130	National Cancer Institute (NCI) [NCI R01 CA134759-01A1, NCI P30-CA775598, NCI 5R00CA151672-04, P30-CA77598]; Mezin-Koats Colon Cancer Research fund; Whiteside Institute for Clinical Research; University of Minnesota Foundation; Essentia Health Systems; AICR [14-1164]; Dutch Cancer Society [UVA2011-4969, UVA2014-7245]; NWO gravitation grant; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA113636, P30CA077598, R01CA134759, R00CA151672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Mezin-Koats Colon Cancer Research fund; Whiteside Institute for Clinical Research; University of Minnesota Foundation(University of Minnesota System); Essentia Health Systems; AICR; Dutch Cancer Society(KWF Kankerbestrijding); NWO gravitation grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the grant from the National Cancer Institute (NCI) to RC and DL (NCI R01 CA134759-01A1); grant from the Mezin-Koats Colon Cancer Research fund to TS; grant from NCI to support the University of Minnesota Masonic Cancer Center (NCI P30-CA775598); grant from the Whiteside Institute for Clinical Research to RC and PS; grant from the University of Minnesota Foundation to RC, TS and DL; grant from Essentia Health Systems to RC; grant from the AICR (14-1164) to LV; grants from the Dutch Cancer Society (UVA2011-4969, UVA2014-7245) to LV; NWO gravitation grant to JL; grants from the National Cancer Institute to TS (NCI 5R00CA151672-04 and P30-CA77598). We also wish to thank Drs Mitchell Drumm and Craig Hodges of CWRU for providing the Cftr mutant mice.	Billings JL, 2014, J CLIN GASTROENTEROL, V48, pE85, DOI 10.1097/MCG.0000000000000034; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Burger-van Paassen N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038798; Chen J, 2012, J CELL PHYSIOL, V227, P2759, DOI 10.1002/jcp.23020; Clarke LL, 1996, LAB ANIM SCI, V46, P612; Clarke LL, 2004, AM J PHYSIOL-GASTR L, V286, pG1050, DOI 10.1152/ajpgi.00393.2003; Collawn JF, 2014, AM J PHYSIOL-LUNG C, V307, pL431, DOI 10.1152/ajplung.00177.2014; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; De Lisle RC, 2014, CELL TISSUE RES, V355, P131, DOI 10.1007/s00441-013-1734-3; De Lisle RC, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a009753; De Lisle RC, 2011, J PEDIATR GASTR NUTR, V53, P371, DOI 10.1097/MPG.0b013e318219c397; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008; DENAMUR E, 1995, DNA CELL BIOL, V14, P811, DOI 10.1089/dna.1995.14.811; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; Garcia MAS, 2009, J CLIN INVEST, V119, P2613, DOI 10.1172/JCI38662; Gelfond D, 2013, CLIN GASTROENTEROL H, V11, P333, DOI 10.1016/j.cgh.2012.11.006; Hodges CA, 2008, GENESIS, V46, P546, DOI 10.1002/dvg.20433; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Juric M, 2013, INFLAMM BOWEL DIS, V19, P904, DOI 10.1097/MIB.0b013e3182813322; Maisonneuve P, 2003, JNCI-J NATL CANCER I, V95, P381, DOI 10.1093/jnci/95.5.381; Maisonneuve P, 2013, JNCI-J NATL CANCER I, V105, P122, DOI 10.1093/jnci/djs481; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; McWilliams R, 2005, GUT, V54, P1661, DOI 10.1136/gut.2005.074534; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Munck A, 2014, INT J BIOCHEM CELL B, V52, P180, DOI 10.1016/j.biocel.2014.02.005; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; Norkina O, 2004, AM J PHYSIOL-GASTR L, V286, pG1032, DOI 10.1152/ajpgi.00473.2003; Oh SC, 2012, GUT, V61, P1291, DOI 10.1136/gutjnl-2011-300812; Pedersen SF, 2013, CANCER RES, V73, P1658, DOI 10.1158/0008-5472.CAN-12-4188; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roth EK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024445; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schutte A, 2014, P NATL ACAD SCI USA, V111, P12396, DOI 10.1073/pnas.1407597111; Shan MM, 2013, SCIENCE, V342, P447, DOI 10.1126/science.1237910; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Son JW, 2011, RESPIROLOGY, V16, P1203, DOI 10.1111/j.1440-1843.2011.01994.x; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun TT, 2014, BBA-MOL CELL RES, V1843, P618, DOI 10.1016/j.bbamcr.2013.12.013; Takeda H, 2015, NAT GENET, V47, P142, DOI 10.1038/ng.3175; Than BLN, 2014, ONCOGENE, V33, P3861, DOI 10.1038/onc.2013.350; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Vij N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004664; Wilke M, 2011, J CYST FIBROS, V10, pS152, DOI 10.1016/S1569-1993(11)60020-9; Xie C, 2013, ONCOGENE, V32, P2282, DOI 10.1038/onc.2012.251; Xu ZD, 1998, GENE, V211, P117, DOI 10.1016/S0378-1119(98)00090-0; Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598; Zhang JT, 2013, BBA-MOL CELL RES, V1833, P2961, DOI 10.1016/j.bbamcr.2013.07.021	53	101	104	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4191	4199		10.1038/onc.2015.483	http://dx.doi.org/10.1038/onc.2015.483			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26751771	Green Accepted			2022-12-28	WOS:000382149800004
J	Li, Z; Hao, Q; Luo, J; Xiong, J; Zhang, S; Wang, T; Bai, L; Wang, W; Chen, M; Wang, W; Gu, L; Lv, K; Chen, J				Li, Z.; Hao, Q.; Luo, J.; Xiong, J.; Zhang, S.; Wang, T.; Bai, L.; Wang, W.; Chen, M.; Wang, W.; Gu, L.; Lv, K.; Chen, J.			USP4 inhibits p53 and NF-kappa B through deubiquitinating and stabilizing HDAC2	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; HISTONE DEACETYLASES; GENE-EXPRESSION; DNA-BINDING; ACETYLATION; ACTIVATION; APOPTOSIS; PHOSPHORYLATION; RECEPTOR; TARGETS	Histone deacetylases (HDACs) are major epigenetic modulators involved in a broad spectrum of human diseases including cancers. As HDACs are promising targets of cancer therapy, it is important to understand the mechanisms of HDAC regulation. In this study, we show that ubiquitin-specific peptidase 4 (USP4) interacts directly with and deubiquitinates HDAC2, leading to the stabilization of HDAC2. Accumulation of HDAC2 in USP4-overexpression cells leads to compromised p53 acetylation as well as crippled p53 transcriptional activation, accumulation and apoptotic response upon DNA damage. Moreover, USP4 targets HDAC2 to downregulate tumor necrosis factor TNF alpha-induced nuclear factor (NF)-kappa B activation. Taken together, our study provides a novel insight into the ubiquitination and stability of HDAC2 and uncovers a previously unknown function of USP4 in cancers.	[Li, Z.; Hao, Q.; Xiong, J.; Wang, T.] Xiamen Univ, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Li, Z.; Hao, Q.; Xiong, J.; Wang, T.] Xiamen Univ, Sch Life Sci, Xiamen, Peoples R China; [Li, Z.; Hao, Q.; Xiong, J.; Wang, W.; Chen, M.; Wang, W.; Gu, L.; Chen, J.] State Ocean Adm, Inst Oceanog 3, Key Lab Breeding Base Marine Genet Resources, Xiamen 361005, Fujian, Peoples R China; [Luo, J.] Soochow Univ, Changzhou Tumor Hosp, Dept Radiotherapy, Changzhou, Peoples R China; [Zhang, S.] Soochow Univ, Sch Radiat Med & Protect, Suzhou, Peoples R China; [Zhang, S.] Soochow Univ, Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou, Peoples R China; [Bai, L.] Xiamen Univ, Zhongshan Hosp, Xiamen, Peoples R China; [Lv, K.] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; [Lv, K.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Xiamen University; Xiamen University; State Oceanic Administration; Soochow University - China; Soochow University - China; Soochow University - China; Xiamen University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Chen, J (corresponding author), State Ocean Adm, Inst Oceanog 3, Key Lab Breeding Base Marine Genet Resources, Xiamen 361005, Fujian, Peoples R China.	chenjianming@tio.org.cn		Hao, Qiongyu/0000-0002-4720-767X	Scientific Research Foundation of Third Institute of Oceanography, SOA [2015011, 2014007]; China Ocean Mineral Resources RD Association [DY125-15-T-03, DY-125-15-T-08]; National Natural Science Foundation of China [81402518, 41201531, 31272684]; China Postdoctoral Science Foundation [2013M541853, 2014T70606]; Marine Public Welfare Project [201005022]; National Science Foundation [31171366]; special financial fund of innovative development of marine economic demonstration project [GD2012-D01-001]	Scientific Research Foundation of Third Institute of Oceanography, SOA; China Ocean Mineral Resources RD Association; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Marine Public Welfare Project; National Science Foundation(National Science Foundation (NSF)); special financial fund of innovative development of marine economic demonstration project	We thank all the members of the Jianming Chen laboratory for their help and assistance. This work was supported by the Scientific Research Foundation of Third Institute of Oceanography, SOA (No. 2015011), DY125-15-T-03 from China Ocean Mineral Resources R&D Association, the National Natural Science Foundation of China (81402518), grants from China Postdoctoral Science Foundation (No. 2013M541853), China Postdoctoral Science Foundation (No. 2014T70606), Marine Public Welfare Project 201005022, the National Science Foundation grant 31171366, the Scientific Research Foundation of Third Institute of Oceanography, SOA (No. 2014007), the National Natural Science Foundation of China (41201531), China Ocean Mineral Resources R&D Association (DY-125-15-T-08), the National Natural Science Foundation of China (31272684), special financial fund of innovative development of marine economic demonstration project, GD2012-D01-001.	Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baek KH, 2006, CURR PROTEIN PEPT SC, V7, P171, DOI 10.2174/138920306776359740; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Chang AA, 2005, ADV OTO-RHINO-LARYNG, V62, P92; Chen Y, 2011, NAT NEUROSCI, V14, P437, DOI 10.1038/nn.2780; Chung CH, 2006, CANCER RES, V66, P8210, DOI 10.1158/0008-5472.CAN-06-1213; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fan YH, 2011, CELL DEATH DIFFER, V18, P1547, DOI 10.1038/cdd.2011.11; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gong FD, 2013, MUTAT RES-FUND MOL M, V750, P23, DOI 10.1016/j.mrfmmm.2013.07.002; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Heideman MR, 2013, BLOOD, V121, P2038, DOI 10.1182/blood-2012-08-450916; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LeBoeuf M, 2010, DEV CELL, V19, P807, DOI 10.1016/j.devcel.2010.10.015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730; Milojevic T, 2006, MOL PHARMACOL, V69, P1083, DOI 10.1124/mol.105.015818; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Ramakrishna S, 2011, CELL MOL LIFE SCI, V68, P15, DOI 10.1007/s00018-010-0504-6; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Segre CV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/690848; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wagner T, 2014, BBA-REV CANCER, V1846, P524, DOI 10.1016/j.bbcan.2014.07.010; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Xiao N, 2012, BIOCHEM J, V441, P979, DOI 10.1042/BJ20111358; Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599; Zhang J, 2011, GENE DEV, V25, P2610, DOI 10.1101/gad.170605.111; Zhang L, 2012, NAT CELL BIOL, V14, P717, DOI 10.1038/ncb2522; Zhang XN, 2011, EMBO J, V30, P2177, DOI 10.1038/emboj.2011.125; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou FF, 2012, J BIOL CHEM, V287, P11002, DOI 10.1074/jbc.M111.328187; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	52	49	51	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2902	2912		10.1038/onc.2015.349	http://dx.doi.org/10.1038/onc.2015.349			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26411366	Green Published, hybrid			2022-12-28	WOS:000377473700010
J	Perez, JG; Tran, NL; Rosenblum, MG; Schneider, CS; Connolly, NP; Kim, AJ; Woodworth, GF; Winkles, JA				Perez, J. G.; Tran, N. L.; Rosenblum, M. G.; Schneider, C. S.; Connolly, N. P.; Kim, A. J.; Woodworth, G. F.; Winkles, J. A.			The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics	ONCOGENE			English	Review							CONVECTION-ENHANCED DELIVERY; NF-KAPPA-B; BLOOD-BRAIN-BARRIER; FACTOR-INDUCIBLE 14; RANDOMIZED PHASE-III; MALIGNANT GLIOMAS; WEAK INDUCER; DRUG-DELIVERY; IN-VIVO; TUMOR-GROWTH	Fibroblast growth factor-inducible 14 (Fn14; TNFRSF12A) is the cell surface receptor for the tumor necrosis factor (TNF) family member TNF-like weak inducer of apoptosis (TWEAK). The Fn14 gene is normally expressed at low levels in healthy tissues but expression is significantly increased after tissue injury and in many solid tumor types, including glioblastoma (GB; formerly referred to as 'GB multiforme'). GB is the most common and aggressive primary malignant brain tumor and the current standard-of-care therapeutic regimen has a relatively small impact on patient survival, primarily because glioma cells have an inherent propensity to invade into normal brain parenchyma, which invariably leads to tumor recurrence and patient death. Despite major, concerted efforts to find new treatments, a new GB therapeutic that improves survival has not been introduced since 2005. In this review article, we summarize studies indicating that (i) Fn14 gene expression is low in normal brain tissue but is upregulated in advanced brain cancers and, in particular, in GB tumors exhibiting the mesenchymal molecular subtype; (ii) Fn14 expression can be detected in glioma cells residing in both the tumor core and invasive rim regions, with the maximal levels found in the invading glioma cells located within normal brain tissue; and (iii) TWEAK: Fn14 engagement as well as Fn14 overexpression can stimulate glioma cell migration, invasion and resistance to chemotherapeutic agents in vitro. We also discuss two new therapeutic platforms that are currently in development that leverage Fn14 overexpression in GB tumors as a way to deliver cytotoxic agents to the glioma cells remaining after surgical resection while sparing normal healthy brain cells.	[Perez, J. G.; Schneider, C. S.; Connolly, N. P.; Kim, A. J.; Woodworth, G. F.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Tran, N. L.] Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ USA; [Rosenblum, M. G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Kim, A. J.] Univ Maryland, Sch Med, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Kim, A. J.; Woodworth, G. F.; Winkles, J. A.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Winkles, J. A.] Univ Maryland, Sch Med, Dept Surg, UMB BioPk Bldg 1,Room 320,800 West Baltimore St, Baltimore, MD 21201 USA; [Winkles, J. A.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Translational Genomics Research Institute; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Winkles, JA (corresponding author), Univ Maryland, Sch Med, Dept Surg, UMB BioPk Bldg 1,Room 320,800 West Baltimore St, Baltimore, MD 21201 USA.	jwinkles@som.umaryland.edu	Kim, Anthony/A-1681-2012		NIH [R01 CA177796, T32 CA154274, K25 EB018370, K08 NS090430]; Ben & Catherine Ivy Foundation; Clayton Foundation for Research; DOD CDMRP Lung Cancer Research Program IDEA Award [W81XWH-14-1-0324]; NATIONAL CANCER INSTITUTE [T32CA154274, R01CA177796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [K25EB018370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS090430] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ben & Catherine Ivy Foundation; Clayton Foundation for Research; DOD CDMRP Lung Cancer Research Program IDEA Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs David Hersh and Rudi Castellani (University of Maryland School of Medicine) for the GB patient MRI images and Fn14 IHC data, respectively. Research in the authors' laboratories is supported, in part, by NIH R01 CA177796 and The Ben & Catherine Ivy Foundation (NLT), The Clayton Foundation for Research (MGR), NIH T32 CA154274 (NPC), NIH K25 EB018370 (AJK), NIH K08 NS090430 (GFW) and DOD CDMRP Lung Cancer Research Program IDEA Award W81XWH-14-1-0324 (JAW).	Agarwal S, 2013, DRUG METAB DISPOS, V41, P33, DOI 10.1124/dmd.112.048322; Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108; Akhtar MJ, 2014, CLIN CHIM ACTA, V436, P78, DOI 10.1016/j.cca.2014.05.004; Alewine C, 2015, ONCOLOGIST, V20, P176, DOI 10.1634/theoncologist.2014-0358; Allard E, 2009, BIOMATERIALS, V30, P2302, DOI 10.1016/j.biomaterials.2009.01.003; Allhenn D, 2012, INT J PHARMACEUT, V436, P299, DOI 10.1016/j.ijpharm.2012.06.025; Aryal M, 2014, ADV DRUG DELIVER REV, V72, P94, DOI 10.1016/j.addr.2014.01.008; Beers R, 2000, CLIN CANCER RES, V6, P2835; Sanz AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047440; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bernal GM, 2014, NANOMED-NANOTECHNOL, V10, P149, DOI 10.1016/j.nano.2013.07.003; Bertrand N, 2014, ADV DRUG DELIVER REV, V66, P2, DOI 10.1016/j.addr.2013.11.009; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Blanco-Colio LM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00003; BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown SAN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065248; Brown SAN, 2010, J BIOL CHEM, V285, P17432, DOI 10.1074/jbc.M110.131979; Burkly LC, 2014, SEMIN IMMUNOL, V26, P229, DOI 10.1016/j.smim.2014.02.006; Burkly LC, 2011, IMMUNOL REV, V244, P99, DOI 10.1111/j.1600-065X.2011.01054.x; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandramohan V, 2013, CLIN CANCER RES, V19, P4717, DOI 10.1158/1078-0432.CCR-12-3891; Chandramohan V, 2013, INT J CANCER, V132, P2339, DOI 10.1002/ijc.27919; Chandramohan V, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/480429; Chao DT, 2013, J CANCER RES CLIN, V139, P315, DOI 10.1007/s00432-012-1332-x; Chauhan VP, 2013, NAT MATER, V12, P958, DOI 10.1038/nmat3792; Chauhan VP, 2011, ANNU REV CHEM BIOMOL, V2, P281, DOI 10.1146/annurev-chembioeng-061010-114300; Chen Z, 2010, TRENDS MOL MED, V16, P594, DOI 10.1016/j.molmed.2010.08.001; Cheng E, 2015, MOL CANCER RES, V13, P575, DOI 10.1158/1541-7786.MCR-14-0411; Cheng E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00473; Cherry EM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0273-1; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; COOMBER BL, 1987, J NEURO-ONCOL, V5, P299, DOI 10.1007/BF00148386; Culp PA, 2010, CLIN CANCER RES, V16, P497, DOI 10.1158/1078-0432.CCR-09-1929; Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027; de Plater L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104227; Desplat-Jego S, 2005, CLIN IMMUNOL, V117, P15, DOI 10.1016/j.clim.2005.06.005; Dhruv H, 2013, J BIOL CHEM, V288, P32261, DOI 10.1074/jbc.M113.493536; Dhruv HD, 2014, CARCINOGENESIS, V35, P218, DOI 10.1093/carcin/bgt289; Dhruv HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072134; Diaz RJ, 2014, NANOMED-NANOTECHNOL, V10, P1075, DOI 10.1016/j.nano.2013.12.006; Dohi T, 2012, J LEUKOCYTE BIOL, V92, P265, DOI 10.1189/jlb.0112042; Ensign SPF, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M113.468686; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Fortin SP, 2009, MOL CANCER RES, V7, P1871, DOI 10.1158/1541-7786.MCR-09-0194; Fung LK, 1996, PHARM RES-DORDR, V13, P671, DOI 10.1023/A:1016083113123; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gilbert MR, 2013, J CLIN ONCOL, V31, P4085, DOI 10.1200/JCO.2013.49.6968; Gill BJ, 2014, P NATL ACAD SCI USA, V111, P12550, DOI 10.1073/pnas.1405839111; Girgenrath M, 2006, EMBO J, V25, P5826, DOI 10.1038/sj.emboj.7601441; Gladson CL, 2010, ANNU REV PATHOL-MECH, V5, P33, DOI 10.1146/annurev-pathol-121808-102109; Gu LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057436; Gurunathan S, 2014, J BIOL CHEM, V289, P12976, DOI 10.1074/jbc.M114.563478; Hadjipanayis CG, 2010, CANCER RES, V70, P6303, DOI 10.1158/0008-5472.CAN-10-1022; Halliday J, 2014, P NATL ACAD SCI USA, V111, P5248, DOI 10.1073/pnas.1321014111; Hambardzumyan D, 2009, TRANSL ONCOL, V2, P89, DOI 10.1593/tlo.09100; Hatzikirou H, 2012, MATH MED BIOL, V29, P49, DOI 10.1093/imammb/dqq011; Healy Andrew T, 2015, Surg Neurol Int, V6, pS59, DOI 10.4103/2152-7806.151337; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Ho DH, 2004, CANCER RES, V64, P8968, DOI 10.1158/0008-5472.CAN-04-1879; Hu CMJ, 2012, BIOCHEM PHARMACOL, V83, P1104, DOI 10.1016/j.bcp.2012.01.008; Huang MG, 2011, CARCINOGENESIS, V32, P1589, DOI 10.1093/carcin/bgr182; Huse JT, 2013, ANNU REV MED, V64, P59, DOI 10.1146/annurev-med-100711-143028; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139; Jarboe JS, 2007, CANCER RES, V67, P7983, DOI 10.1158/0008-5472.CAN-07-1493; Ji Y, 1996, J NEURO-ONCOL, V30, P189; Joo KM, 2013, CELL REP, V3, P260, DOI 10.1016/j.celrep.2012.12.013; Juratli TA, 2013, PHARMACOL THERAPEUT, V139, P341, DOI 10.1016/j.pharmthera.2013.05.003; Kawakita T, 2004, BIOCHEM BIOPH RES CO, V318, P726, DOI 10.1016/j.bbrc.2004.04.084; Kim SS, 2015, NANOMED-NANOTECHNOL, V11, P301, DOI 10.1016/j.nano.2014.09.005; Kioi M, 2008, MOL CANCER THER, V7, P1579, DOI 10.1158/1535-7163.MCT-07-2131; Kuan CT, 2011, INT J CANCER, V129, P111, DOI 10.1002/ijc.25645; Kunwar S, 2007, J CLIN ONCOL, V25, P837, DOI 10.1200/JCO.2006.08.1117; Kunwar S, 2010, NEURO-ONCOLOGY, V12, P871, DOI 10.1093/neuonc/nop054; Lassen UN, 2015, CLIN CANCER RES, V21, P258, DOI 10.1158/1078-0432.CCR-14-1334; Lewis GK, 2012, J NEUROSURG, V117, P1128, DOI 10.3171/2012.7.JNS11144; Li A, 2009, CANCER RES, V69, P2091, DOI 10.1158/0008-5472.CAN-08-2100; Li XP, 2014, ANTI-CANCER DRUG, V25, P1152, DOI 10.1097/CAD.0000000000000153; Li YM, 2013, J NEURO-ONCOL, V114, P155, DOI 10.1007/s11060-013-1157-8; Lin BR, 2012, ANN SURG ONCOL, V19, pS385, DOI 10.1245/s10434-011-1825-x; Lipsman N, 2014, NEUROTHERAPEUTICS, V11, P593, DOI 10.1007/s13311-014-0281-2; Liu TF, 2005, CLIN CANCER RES, V11, P329; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Madhankumar AB, 2009, MOL CANCER THER, V8, P648, DOI 10.1158/1535-7163.MCT-08-0853; Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002; Mangraviti Antonella, 2015, Surg Neurol Int, V6, pS78, DOI 10.4103/2152-7806.151345; Mariani L, 2001, J NEURO-ONCOL, V53, P161, DOI 10.1023/A:1012253317934; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Michaelson JS, 2011, MABS-AUSTIN, V3, P362, DOI 10.4161/mabs.3.4.16090; Mueller S, 2011, J NEURO-ONCOL, V101, P267, DOI 10.1007/s11060-010-0255-0; Murad GJA, 2006, CLIN CANCER RES, V12, P3145, DOI 10.1158/1078-0432.CCR-05-2583; Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5; Nance E, 2014, ACS NANO, V8, P10655, DOI 10.1021/nn504210g; Nance EA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003594; NICHOLSON C, 1993, BIOPHYS J, V65, P2277, DOI 10.1016/S0006-3495(93)81324-9; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Ostrom Q.T., 2014, NEUROONCOL S4, V16, piv1, DOI DOI 10.1093/NEU0NC/N0U223; Pang ZQ, 2011, BIOCONJUGATE CHEM, V22, P1171, DOI 10.1021/bc200062q; Pardridge William M, 2005, NeuroRx, V2, P3; Parker NR, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00055; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pelekanou V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083250; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Prabhakar U, 2013, CANCER RES, V73, P2412, DOI 10.1158/0008-5472.CAN-12-4561; Rand RW, 2000, CLIN CANCER RES, V6, P2157; Roos C, 2010, J IMMUNOL, V185, P1593, DOI 10.4049/jimmunol.0903555; Rustamzadeh E, 2006, INT J CANCER, V118, P2594, DOI 10.1002/ijc.21647; Rustamzadeh E, 2007, INT J CANCER, V120, P411, DOI 10.1002/ijc.22278; del Burgo LS, 2014, NANOMED-NANOTECHNOL, V10, P905, DOI 10.1016/j.nano.2013.10.001; Salzmann S, 2013, J BIOL CHEM, V288, P13455, DOI 10.1074/jbc.M112.435917; Sampson JH, 2008, NEURO-ONCOLOGY, V10, P320, DOI 10.1215/15228517-2008-012; Sampson JH, 2007, NEUROSURGERY, V60, P89, DOI 10.1227/01.NEU.0000249256.09289.5F; Sampson JH, 2011, NEUROSURGERY, V69, P668, DOI 10.1227/NEU.0b013e3182181ba8; Sampson JH, 2010, J NEUROSURG, V113, P301, DOI 10.3171/2009.11.JNS091052; Schneider CS, 2015, BIOMATERIALS, V42, P42, DOI 10.1016/j.biomaterials.2014.11.054; Shimada K, 2012, CLIN CANCER RES, V18, P5247, DOI 10.1158/1078-0432.CCR-12-0955; Shirahata M, 2007, CLIN CANCER RES, V13, P7341, DOI 10.1158/1078-0432.CCR-06-2789; Shirahata M, 2009, CANCER SCI, V100, P165, DOI 10.1111/j.1349-7006.2008.01002.x; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; Sullivan JP, 2014, CANCER DISCOV, V4, P1299, DOI 10.1158/2159-8290.CD-14-0471; Suzuki A, 2014, J NUCL MED, V55, P1323, DOI 10.2967/jnumed.114.138404; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; Tailor TD, 2010, MOL CANCER THER, V9, P1798, DOI 10.1158/1535-7163.MCT-09-0856; Tanner PG, 2007, NEUROSURGERY, V61, P880, DOI 10.1227/01.NEU.0000298922.77921.F2; Teesalu T, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00216; Thorne RG, 2006, P NATL ACAD SCI USA, V103, P5567, DOI 10.1073/pnas.0509425103; Torchilin VP, 2014, NAT REV DRUG DISCOV, V13, P813, DOI 10.1038/nrd4333; Tran NL, 2006, CANCER RES, V66, P9535, DOI 10.1158/0008-5472.CAN-06-0418; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Tran NL, 2003, AM J PATHOL, V162, P1313, DOI 10.1016/S0002-9440(10)63927-2; Tzeng SY, 2013, THER DELIV, V4, P687, DOI [10.4155/tde.13.38, 10.4155/TDE.13.38]; Vallera DA, 2002, J NATL CANCER I, V94, P597; van der Meel R, 2013, ADV DRUG DELIVER REV, V65, P1284, DOI 10.1016/j.addr.2013.08.012; van Tellingen O, 2015, DRUG RESIST UPDATE, V19, P1, DOI 10.1016/j.drup.2015.02.002; Varfolomeev E, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001878; Vargova L, 2003, GLIA, V42, P77, DOI 10.1002/glia.10204; Vehlow A, 2013, BBA-REV CANCER, V1836, P236, DOI 10.1016/j.bbcan.2013.07.001; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wait SD, 2015, NEURO-ONCOLOGY, V17, pII9, DOI 10.1093/neuonc/nou360; Wajant H, 2013, BRIT J PHARMACOL, V170, P748, DOI 10.1111/bph.12337; Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544; Watts GS, 2007, INT J CANCER, V121, P2132, DOI 10.1002/ijc.22898; Weaver M, 2003, J NEURO-ONCOL, V65, P3, DOI 10.1023/A:1026246500788; Weber F, 2003, J NEURO-ONCOL, V64, P125, DOI 10.1023/A:1024901501173; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Whitsett TG, 2014, CLIN EXP METASTAS, V31, P613, DOI 10.1007/s10585-014-9653-6; Whitsett TG, 2012, AM J PATHOL, V181, P111, DOI 10.1016/j.ajpath.2012.03.026; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Willis AL, 2008, MOL CANCER RES, V6, P725, DOI 10.1158/1541-7786.MCR-08-0005; Winkles JA, 2006, CANCER LETT, V235, P11, DOI 10.1016/j.canlet.2005.03.048; Winkles JA, 2008, NAT REV DRUG DISCOV, V7, P411, DOI 10.1038/nrd2488; Winkles JA, 2007, FRONT BIOSCI-LANDMRK, V12, P2761, DOI 10.2741/2270; Wisniacki N, 2013, CLIN THER, V35, P1137, DOI 10.1016/j.clinthera.2013.06.008; Wolburg H, 2012, MOL ASPECTS MED, V33, P579, DOI 10.1016/j.mam.2012.02.003; Woodworth GE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00126; Wykosky J, 2007, MOL CANCER THER, V6, P3208, DOI 10.1158/1535-7163.MCT-07-0200; Xi GF, 2014, NANOMED-NANOTECHNOL, V10, P381, DOI 10.1016/j.nano.2013.07.013; Xie Q, 2014, NEURO-ONCOLOGY, V16, P1575, DOI 10.1093/neuonc/nou147; Xu XY, 2015, TRENDS MOL MED, V21, P223, DOI 10.1016/j.molmed.2015.01.001; Yin JJ, 2014, CANCER RES, V74, P4306, DOI 10.1158/0008-5472.CAN-13-3233; Yin XF, 2013, CLIN CANCER RES, V19, P5686, DOI 10.1158/1078-0432.CCR-13-0405; Yoriki R, 2011, EXP THER MED, V2, P103, DOI 10.3892/etm.2010.181; Zhou H, 2014, MOL CANCER THER, V13, P2688, DOI 10.1158/1535-7163.MCT-14-0346; Zhou H, 2013, CANCER RES, V73, P4439, DOI 10.1158/0008-5472.CAN-13-0187; Zhou H, 2013, J INVEST DERMATOL, V133, P1052, DOI 10.1038/jid.2012.402; Zhou H, 2011, MOL CANCER THER, V10, P1276, DOI 10.1158/1535-7163.MCT-11-0161; Zhou JB, 2013, P NATL ACAD SCI USA, V110, P11751, DOI 10.1073/pnas.1304504110	180	45	46	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2145	2155		10.1038/onc.2015.310	http://dx.doi.org/10.1038/onc.2015.310			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26300004	Green Accepted			2022-12-28	WOS:000374986000001
J	Sotoca, AM; Prange, KHM; Reijnders, B; Mandoli, A; Nguyen, LN; Stunnenberg, HG; Martens, JHA				Sotoca, A. M.; Prange, K. H. M.; Reijnders, B.; Mandoli, A.; Nguyen, L. N.; Stunnenberg, H. G.; Martens, J. H. A.			The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; GENOME-WIDE ANALYSIS; PML-RAR-ALPHA; TRANSCRIPTION FACTOR; PROSTATE-CANCER; BINDING-SITES; HISTONE DEACETYLASE; RECEPTOR-ALPHA; CD38 ANTIGEN; SELF-RENEWAL	The ETS transcription factor ERG has been implicated as a major regulator of both normal and aberrant hematopoiesis. In acute myeloid leukemias harboring t(16; 21), ERG function is deregulated due to a fusion with FUS/TLS resulting in the expression of a FUS-ERG oncofusion protein. How this oncofusion protein deregulates the normal ERG transcription program is unclear. Here, we show that FUS-ERG acts in the context of a heptad of proteins (ERG, FLI1, GATA2, LYL1, LMO2, RUNX1 and TAL1) central to proper expression of genes involved in maintaining a stem cell hematopoietic phenotype. Moreover, in t(16; 21) FUS-ERG co-occupies genomic regions bound by the nuclear receptor heterodimer RXR:RARA inhibiting target gene expression and interfering with hematopoietic differentiation. All-trans retinoic acid treatment of t(16; 21) cells as well as FUS-ERG knockdown alleviate the myeloid-differentiation block. Together, the results suggest that FUS-ERG acts as a transcriptional repressor of the retinoic acid signaling pathway.	[Sotoca, A. M.; Prange, K. H. M.; Reijnders, B.; Mandoli, A.; Nguyen, L. N.; Stunnenberg, H. G.; Martens, J. H. A.] Radboud Univ Nijmegen, Dept Mol Biol, Fac Sci, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Martens, JHA (corresponding author), Radboud Univ Nijmegen, Dept Mol Biol, Fac Sci, Nijmegen Ctr Mol Life Sci,FNWI, Geert Grootepl 28, NL-6500 HB Nijmegen, Netherlands.	j.martens@ncmls.ru.nl	Stunnenberg, Hendrik G./D-6875-2012; Martens, Joost/D-4966-2012; Nguyen, Luan/GYA-2927-2022	Stunnenberg, Hendrik G./0000-0002-0066-1576; Martens, Joost/0000-0003-2008-6537; Prange, Koen/0000-0002-9835-1735	EU [BLUEPRINT-282510]; Dutch Cancer Foundation [KWF KUN 2009-4527, KUN 2011-4937]; Netherlands Organization for Scientific Research (NWO-VIDI)	EU(European Commission); Dutch Cancer Foundation(KWF Kankerbestrijding); Netherlands Organization for Scientific Research (NWO-VIDI)(Netherlands Organization for Scientific Research (NWO))	This work was supported by the EU (BLUEPRINT-282510), the Dutch Cancer Foundation (KWF KUN 2009-4527 and KUN 2011-4937) and the Netherlands Organization for Scientific Research (NWO-VIDI to JHAM). Database accession: All ChIP-seq and RNA-seq data can be downloaded from the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE60477.	Beck D, 2013, BLOOD, V122, pE12, DOI 10.1182/blood-2013-03-490425; Bock J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052872; Boersema PJ, 2009, NAT PROTOC, V4, P484, DOI 10.1038/nprot.2009.21; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; De Bellis F, 2014, CANCER RES, V74, P2328, DOI 10.1158/0008-5472.CAN-13-2568; Delva L, 2004, ONCOGENE, V23, P4389, DOI 10.1038/sj.onc.1207578; Denissov S, 2007, EMBO J, V26, P944, DOI 10.1038/sj.emboj.7601550; Diffner E, 2013, BLOOD, V121, P2289, DOI 10.1182/blood-2012-07-446120; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DRACH J, 1994, CANCER RES, V54, P1746; DUBOIS C, 1994, BLOOD, V83, P3264; Ebralidze AK, 2008, GENE DEV, V22, P2085, DOI 10.1101/gad.1654808; Goldberg L, 2013, BLOOD, V122, P2694, DOI 10.1182/blood-2013-01-477133; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Kong XT, 1997, BLOOD, V90, P1192; Kryndushkin D, 2011, PROTEIN CELL, V2, P223, DOI 10.1007/s13238-011-1525-0; Lacadie SA, 2011, GENE DEV, V25, P289, DOI 10.1101/gad.2031511; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu SJ, 2007, J PHARMACOL EXP THER, V321, P953, DOI 10.1124/jpet.106.118406; Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617; Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050; Martens JHA, 2010, CANCER CELL, V17, P173, DOI 10.1016/j.ccr.2009.12.042; Mills KI, 2000, BRIT J HAEMATOL, V108, P316; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Ng AP, 2011, BLOOD, V118, P2454, DOI 10.1182/blood-2011-03-344739; Pereira DS, 1998, P NATL ACAD SCI USA, V95, P8239, DOI 10.1073/pnas.95.14.8239; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rapin N, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.22; Saeed S, 2011, BRIT J CANCER, V104, P554, DOI 10.1038/sj.bjc.6606095; Saeed S, 2012, BLOOD, V120, P3058, DOI 10.1182/blood-2011-10-386086; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shikami M, 1999, BRIT J HAEMATOL, V105, P711, DOI 10.1046/j.1365-2141.1999.01384.x; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sugawara T, 2010, EXP HEMATOL, V38, P696, DOI 10.1016/j.exphem.2010.04.006; Sun ZH, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000614; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Walsby EJ, 2007, BRIT J HAEMATOL, V139, P94, DOI 10.1111/j.1365-2141.2007.06756.x; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Wilson NK, 2010, CELL STEM CELL, V7, P532, DOI 10.1016/j.stem.2010.07.016; Winnes M, 2007, ONCOL REP, V17, P1033; Yamamoto K, 1997, LEUKEMIA, V11, P599, DOI 10.1038/sj.leu.2400594; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854; Zinszner H, 1997, J CELL SCI, V110, P1741; Zou JH, 2005, MOL CELL BIOL, V25, P6235, DOI 10.1128/MCB.25.14.6235-6246.2005	54	27	30	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1965	1976		10.1038/onc.2015.261	http://dx.doi.org/10.1038/onc.2015.261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148230	Green Published, hybrid			2022-12-28	WOS:000374010300009
J	Dodd, RD; Sachdeva, M; Mito, JK; Eward, WC; Brigman, BE; Ma, Y; Dodd, L; Kim, Y; Lev, D; Kirsch, DG				Dodd, R. D.; Sachdeva, M.; Mito, J. K.; Eward, W. C.; Brigman, B. E.; Ma, Y.; Dodd, L.; Kim, Y.; Lev, D.; Kirsch, D. G.			Myogenic transcription factors regulate pro-metastatic miR-182	ONCOGENE			English	Article							MOUSE MODEL; SARCOMA; PAX7; NETWORKS; DISTINCT; GENES	Approximately 30% of patients with soft-tissue sarcoma die from pulmonary metastases. The mechanisms that drive sarcoma metastasis are not well understood. Recently, we identified miR-182 as a driver of sarcoma metastasis in a primary mouse model of soft-tissue sarcoma. We also observed elevated miR-182 in a subset of primary human sarcomas that metastasized to the lungs. Here, we show that myogenic differentiation factors regulate miR-182 levels to contribute to metastasis in mouse models. We find that MyoD directly binds the miR-182 promoter to increase miR-182 expression. Furthermore, mechanistic studies revealed that Pax7 can promote sarcoma metastasis in vivo through MyoD-dependent regulation of pro-metastatic miR-182. Taken together, these results suggest that sarcoma metastasis can be partially controlled through Pax7/MyoD-dependent activation of miR-182 and provide insight into the role that myogenic transcription factors have in sarcoma progression.	[Dodd, R. D.; Sachdeva, M.; Ma, Y.; Kirsch, D. G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Box 91006, Durham, NC 27708 USA; [Mito, J. K.; Kirsch, D. G.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Eward, W. C.; Brigman, B. E.] Duke Univ, Med Ctr, Dept Orthopaed Surg, Durham, NC 27708 USA; [Dodd, L.] Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; [Kim, Y.] Seoul Natl Univ, Coll Vet Med, Dept Clin Pathol, Seoul, South Korea; [Lev, D.] Univ Texas MD Anderson Canc Ctr, Sarcoma Res Ctr, Houston, TX 77030 USA	Duke University; Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Seoul National University (SNU); University of Texas System; UTMD Anderson Cancer Center	Kirsch, DG (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Box 91006, Durham, NC 27708 USA.	david.kirsch@duke.edu		Dodd, Rebecca/0000-0001-7295-1882	American Cancer Society/Canary Foundation; Children's Tumor Foundation; QuadW/AACR; SARC SPORE pilot project [5U54 CA 168512-02];  [RO1 CA 138265]; NATIONAL CANCER INSTITUTE [R01CA138265] Funding Source: NIH RePORTER	American Cancer Society/Canary Foundation(American Cancer Society); Children's Tumor Foundation; QuadW/AACR; SARC SPORE pilot project; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ron Dephino (MD Anderson) for providing the Ink4a/Arf flox mice, Tyler Jacks (MIT) for the LSL-Kras mice, and Anton Berns (Netherlands Cancer Institute) for the p53 flox mice. We thank Michael Rudnicki for the Pax7-FLAG tagged vectors. We thank Laura Jeffords, Rafaela Rodrigues, and Loretta Woodleif for assistance with mouse work. RDD is supported by postdoctoral fellowships from the American Cancer Society/Canary Foundation and the Children's Tumor Foundation. MS is supported by a postdoctoral fellowship from the QuadW/AACR. This work is supported by RO1 CA 138265 (DGK) and a SARC SPORE pilot project 5U54 CA 168512-02 (DKG and RDD).	Blum JM, 2013, CELL REP, V5, P933, DOI 10.1016/j.celrep.2013.10.020; Borden EC, 2003, CLIN CANCER RES, V9, P1941; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Buckingham M, 2014, DEV CELL, V28, P225, DOI 10.1016/j.devcel.2013.12.020; Canter RJ, 2007, CANCER, V110, P2050, DOI 10.1002/cncr.23023; Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834; Dodd RD, 2010, DIS MODEL MECH, V3, P557, DOI 10.1242/dmm.005223; Eisinger-Mathason TSK, 2013, CANCER DISCOV, V3, P1190, DOI 10.1158/2159-8290.CD-13-0118; Fletcher CDM, 2001, J CLIN ONCOL, V19, P3045, DOI 10.1200/JCO.2001.19.12.3045; Gibbons DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005401; Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm434; Hu P, 2008, DEV CELL, V15, P534, DOI 10.1016/j.devcel.2008.08.018; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671; Mito JK, 2013, J PATHOL, V229, P132, DOI 10.1002/path.4099; Mito JK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008075; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Sachdeva M, 2014, J CLIN INVEST, V124, P4305, DOI 10.1172/JCI77116; Salazar R, 2011, J CLIN ONCOL, V29, P17, DOI 10.1200/JCO.2010.30.1077; Soleimani VD, 2012, DEV CELL, V22, P1208, DOI 10.1016/j.devcel.2012.03.014; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	29	16	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1868	1875		10.1038/onc.2015.252	http://dx.doi.org/10.1038/onc.2015.252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26234681	Green Accepted, Green Submitted			2022-12-28	WOS:000373610400012
J	Ho, TH; Park, IY; Zhao, H; Tong, P; Champion, MD; Yan, H; Monzon, FA; Hoang, A; Tamboli, P; Parker, AS; Joseph, RW; Qiao, W; Dykema, K; Tannir, NM; Castle, EP; Nunez-Nateras, R; Teh, BT; Wang, J; Walker, CL; Hung, MC; Jonasch, E				Ho, T. H.; Park, I. Y.; Zhao, H.; Tong, P.; Champion, M. D.; Yan, H.; Monzon, F. A.; Hoang, A.; Tamboli, P.; Parker, A. S.; Joseph, R. W.; Qiao, W.; Dykema, K.; Tannir, N. M.; Castle, E. P.; Nunez-Nateras, R.; Teh, B. T.; Wang, J.; Walker, C. L.; Hung, M-C; Jonasch, E.			High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma	ONCOGENE			English	Article							ANTITUMOR-ACTIVITY; SNP MICROARRAYS; METHYLATION; TARGET; SETD2; HYPB/SETD2; MUTATIONS; EVOLUTION; CANCER; REPAIR	Mutations in SETD2, a histone H3 lysine trimethyltransferase, have been identified in clear cell renal cell carcinoma (ccRCC); however it is unclear if loss of SETD2 function alters the genomic distribution of histone 3 lysine 36 trimethylation (H3K36me3) in ccRCC. Furthermore, published epigenomic profiles are not specific to H3K36me3 or metastatic tumors. To determine if progressive SETD2 and H3K36me3 dysregulation occurs in metastatic tumors, H3K36me3, SETD2 copy number (CN) or SETD2 mRNA abundance was assessed in two independent cohorts: metastatic ccRCC (n = 71) and the Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma data set (n = 413). Although SETD2 CN loss occurs with high frequency (490%), H3K36me3 is not significantly impacted by monoallelic loss of SETD2. H3K36me3-positive nuclei were reduced an average of similar to 20% in primary ccRCC (90% positive nuclei in uninvolved vs 70% positive nuclei in ccRCC) and reduced by similar to 60% in metastases (90% positive in uninvolved kidney vs 30% positive in metastases) (P<0.001). To define a kidney-specific H3K36me3 profile, we generated genome-wide H3K36me3 profiles from four cytoreductive nephrectomies and SETD2 isogenic renal cell carcinoma (RCC) cell lines using chromatin immunoprecipitation coupled with high-throughput DNA sequencing and RNA sequencing. SETD2 loss of methyltransferase activity leads to regional alterations of H3K36me3 associated with aberrant RNA splicing in a SETD2 mutant RCC and SETD2 knockout cell line. These data suggest that during progression of ccRCC, a decline in H3K36me3 is observed in distant metastases, and regional H3K36me3 alterations influence alternative splicing in ccRCC.	[Ho, T. H.] Mayo Clin, Div Hematol & Med Oncol, Scottsdale, AZ USA; [Ho, T. H.; Champion, M. D.; Yan, H.] Mayo Clin, Ctr Individualized Med, Rochester, MN USA; [Park, I. Y.; Walker, C. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX USA; [Zhao, H.; Tong, P.; Wang, J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Champion, M. D.] Mayo Clin, Dept Biomed Stat & Informat, Scottsdale, AZ USA; [Yan, H.] Dept Biomed Stat & Informat, Rochester, MN USA; [Monzon, F. A.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Monzon, F. A.; Hoang, A.; Tannir, N. M.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Unit 1374, Houston, TX 77030 USA; [Tamboli, P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Parker, A. S.] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA; [Joseph, R. W.] Mayo Clin, Div Hematol & Med Oncol, Jacksonville, FL 32224 USA; [Qiao, W.] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Houston, TX 77030 USA; [Dykema, K.; Teh, B. T.] Van Andel Inst, Ctr Canc Genom & Computat Biol, Grand Rapids, MI USA; [Castle, E. P.; Nunez-Nateras, R.] Mayo Clin, Dept Urol, Scottsdale, AZ USA; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Monzon, F. A.] Invitae, San Francisco, CA USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Mayo Clinic Phoenix; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center; Van Andel Institute; Mayo Clinic; Mayo Clinic Phoenix; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Unit 1374, Houston, TX 77030 USA.	ejonasch@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Joseph, Richard/0000-0001-6102-4661	ASCO Young Investigator Award from the Kidney Cancer Association; Action to Cure Kidney Cancer Organization; MD Anderson Hematology-Oncology Fellowship; NIH grant [K12 CA90628]; Mayo Clinic CR5 grant; Mayo Clinic Center for Individualized Medicine Epigenomics Translational Program; Kathryn H and Roger Penske Career Development Award to Support Medical Research; Mayo Clinic Center for Individualized Medicine; NATIONAL CANCER INSTITUTE [R01CA143811, K12CA090628, R01CA134466, P30CA015083, P30CA016672] Funding Source: NIH RePORTER	ASCO Young Investigator Award from the Kidney Cancer Association; Action to Cure Kidney Cancer Organization; MD Anderson Hematology-Oncology Fellowship; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Clinic CR5 grant; Mayo Clinic Center for Individualized Medicine Epigenomics Translational Program; Kathryn H and Roger Penske Career Development Award to Support Medical Research; Mayo Clinic Center for Individualized Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ian Davis, W Kimryn Rathmell, Kathryn E Hacker and Jeremy M Simon for helpful discussions and assistance with the genotyping of tissue. THH is supported by funding from the ASCO Young Investigator Award from the Kidney Cancer Association, the Action to Cure Kidney Cancer Organization, the MD Anderson Hematology-Oncology Fellowship, NIH grant K12 CA90628, a Mayo Clinic CR5 grant, the Mayo Clinic Center for Individualized Medicine Epigenomics Translational Program and a Kathryn H and Roger Penske Career Development Award to Support Medical Research. MDC is supported by the Mayo Clinic Center for Individualized Medicine.	Alvarez K, 2010, DIAGN MOL PATHOL, V19, P127, DOI 10.1097/PDM.0b013e3181d527c5; Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Buck MJ, 2013, ONCOGENE; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Champion MD, 2014, CHIP RNA SEQPRO STRA; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967; Finley SD, 2012, AAPS J, V14, P500, DOI 10.1208/s12248-012-9363-4; Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300; Hu M, 2010, P NATL ACAD SCI USA, V107, P2956, DOI 10.1073/pnas.0915033107; James LI, 2013, NAT CHEM BIOL, V9, P184, DOI [10.1038/NCHEMBIO.1157, 10.1038/nchembio.1157]; Jonasch E, 2010, CANCER-AM CANCER SOC, V116, P57, DOI 10.1002/cncr.24685; Jonasch E, 2009, J CLIN ONCOL, V27, P4076, DOI 10.1200/JCO.2008.21.3660; Joseph CG, 2014, GENE CHROMOSOME CANC, V53, P15, DOI 10.1002/gcc.22114; Kim HJ, 2009, AM J SURG PATHOL, V33, P1276, DOI 10.1097/PAS.0b013e3181a2aa36; Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Mar BG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4469; Monzon FA, 2011, MODERN PATHOL, V24, P1470, DOI 10.1038/modpathol.2011.107; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Simon JM, 2014, GENOME RES, V24, P241, DOI 10.1101/gr.158253.113; Singh RK, 2012, TRENDS MOL MED, V18, P472, DOI 10.1016/j.molmed.2012.06.006; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Vivas-Mejia PE, 2011, CLIN CANCER RES, V17, P3716, DOI 10.1158/1078-0432.CCR-11-0233; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Xie P, 2008, CELL SIGNAL, V20, P1671, DOI 10.1016/j.cellsig.2008.05.012	42	47	49	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1565	1574		10.1038/onc.2015.221	http://dx.doi.org/10.1038/onc.2015.221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073078	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000373063600009
J	Saitoh, M; Endo, K; Furuya, S; Minami, M; Fukasawa, A; Imamura, T; Miyazawa, K				Saitoh, M.; Endo, K.; Furuya, S.; Minami, M.; Fukasawa, A.; Imamura, T.; Miyazawa, K.			STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SMAD TRANSCRIPTIONAL ACTIVITY; PROTEIN INHIBITOR; ACTIVATOR; PATHWAY; GROWTH; CELLS; IL-6; EMT; TRANSDUCER	The epithelial-mesenchymal transition (EMT) is a crucial morphological event that occurs during the progression of epithelial tumors. EMT can be induced by transforming growth factor beta (TGF-beta) in certain kinds of cancer cells through the induction of Snail, a key regulator of EMT. We have previously found that TGF-beta remarkably induces Snail expression in cooperation with Ras signals; however, the underlying mechanism of this synergism has not yet been determined. Here, we demonstrate that signal transducer and activator of transcription 3 (STAT3) acts as a mediator that synergizes TGF-beta and Ras signals. The overexpression of STAT3 enhanced Snail induction, whereas siRNA-mediated knockdown of STAT3 inhibited it. The STAT3-gamma F mutant, which has Tyr 705 substituted with Phe, did not enhance Snail induction. Several STAT3 mutants lacking transcriptional activity also failed to enhance it; however, the putative STAT3-binding elements in the Snail promoter regions were not required for STAT3-mediated Snail induction. Protein inhibitor of activated STAT3 (PIAS3) inhibited the enhanced Snail promoter activity induced by TGF-beta and Ras. The interaction between PIAS3 and STAT3 was reduced by TGF-beta in cells harboring oncogenic Ras, whereas TGF-beta promoted the binding of PIAS3 to Smad3, a crucial mediator of TGF-beta signaling. Therefore, these findings suggest that STAT3 enhances Snail induction when it is dissociated from PIAS3 by TGF-beta in cooperation with Ras signals.	[Saitoh, M.; Endo, K.; Furuya, S.; Minami, M.; Fukasawa, A.; Miyazawa, K.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Biochem, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan; [Furuya, S.; Minami, M.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Res Training Program Undergrad, Chuo, Yamanashi 4093898, Japan; [Imamura, T.] Ehime Univ, Grad Sch Med, Dept Mol Med Pathogenesis, Matsuyama, Ehime 790, Japan	University of Yamanashi; University of Yamanashi; Ehime University	Saitoh, M (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Biochem, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.	msaitoh-ind@umin.ac.jp			JSPS KAKENHI [24390419]; JSPS; Ministry of Education, Culture, Sports, Science and Technology of Japan; Astellas Foundation for Research on Metabolic Disorders; Fugaku Trust for Medicinal Research; Mitsubishi Foundation; Terumo Life Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Astellas Foundation for Research on Metabolic Disorders; Fugaku Trust for Medicinal Research; Mitsubishi Foundation; Terumo Life Science Foundation(Terumo Life Science Foundation)	We would like to thank M Myogahara for her excellent secretarial assistance. We also thank Dr T Shirakihara, Dr K Horiguchi, Dr D Koinuma, Dr S Ehata, Dr H Suzuki, and Dr K Miyazono for their helpful advice. This work was supported by JSPS KAKENHI Grant Number 24390419, the JSPS Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling', and a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also supported by Astellas Foundation for Research on Metabolic Disorders (to MS) and research grants from the Fugaku Trust for Medicinal Research, the Mitsubishi Foundation, and Terumo Life Science Foundation (to KM). This work was supported by JSPS KAKENHI Grant Number 24390419, the JSPS Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling', and a research program of the Project for the Development of Innovative Research on Cancer Therapeutics (P-Direct) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also supported by Astellas Foundation for Research on Metabolic Disorders (to MS) and research grants from the Fugaku Trust for Medicinal Research, the Mitsubishi Foundation and Terumo Life Science Foundation (to KM).	Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fu XT, 2015, INT J ONCOL, V46, P587, DOI 10.3892/ijo.2014.2761; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Huang C, 2011, NEOPLASMA, V58, P396, DOI 10.4149/neo_2011_05_396; Inman GJ, 2011, CURR OPIN GENET DEV, V21, P93, DOI 10.1016/j.gde.2010.12.004; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Kohsaka S, 2012, MOL CANCER THER, V11, P1289, DOI 10.1158/1535-7163.MCT-11-0801; Lee J, 2012, J BIOL CHEM, V287, P18182, DOI 10.1074/jbc.M111.328831; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Liu Y, 2013, J BIOL CHEM, V288, P30708, DOI 10.1074/jbc.M113.478685; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Ozawa Y, 2008, J BIOL CHEM, V283, P24561, DOI 10.1074/jbc.M802238200; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Saitoh M, 2012, J BIOCHEM, V151, P563, DOI 10.1093/jb/mvs040; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Subramaniam A, 2013, BBA-REV CANCER, V1835, P46, DOI 10.1016/j.bbcan.2012.10.002; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yagil Z, 2010, TRENDS IMMUNOL, V31, P199, DOI 10.1016/j.it.2010.01.005; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X; Zhang QF, 2013, J BIOL CHEM, V288, P31280, DOI 10.1074/jbc.M113.505057	35	72	73	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1049	1057		10.1038/onc.2015.161	http://dx.doi.org/10.1038/onc.2015.161			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961936				2022-12-28	WOS:000370823300010
J	Zhai, W; Sun, Y; Jiang, M; Wang, M; Gasiewicz, TA; Zheng, J; Chang, C				Zhai, W.; Sun, Y.; Jiang, M.; Wang, M.; Gasiewicz, T. A.; Zheng, J.; Chang, C.			Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2 alpha/C-MYC axis under hypoxia	ONCOGENE			English	Article							CLEAR-CELL; NONCODING RNAS; BINDING; GENE; HIF; CARCINOMA; CANCER; EPIDEMIOLOGY; SPECIFICITY; PROGRESSION	It is well established that hypoxia contributes to tumor progression in a hypoxia inducible factor-2 alpha (HIF-2 alpha)-dependent manner in renal cell carcinoma (RCC), yet the role of long noncoding RNAs (LncRNAs) involved in hypoxia-mediated RCC progression remains unclear. Here we demonstrate that LncRNA-SARCC (Suppressing Androgen Receptor in Renal Cell Carcinoma) is differentially regulated by hypoxia in a von Hippel-Lindau (VHL)-dependent manner both in RCC cell culture and clinical specimens. LncRNA-SARCC can suppress hypoxic cell cycle progression in the VHL-mutant RCC cells while derepress it in the VHL-restored RCC cells. Mechanism dissection reveals that LncRNA-SARCC can post-transcriptionally regulate androgen receptor (AR) by physically binding and destablizing AR protein to suppress AR/HIF-2 alpha/C-MYC signals. In return, HIF-2 alpha can transcriptionally regulate the LncRNA-SARCC expression via binding to hypoxia-responsive elements on the promoter of LncRNA-SARCC. The negative feedback modulation between LncRNA-SARCC/AR complex and HIF-2 alpha signaling may then lead to differentially modulated RCC progression in a VHL-dependent manner. Together, these results may provide us a new therapeutic approach via targeting this newly identified signal from LncRNA-SARCC to AR-mediated HIF-2 alpha/C-MYC signals against RCC progression.	[Zhai, W.; Zheng, J.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Urol, Shanghai, Peoples R China; [Zhai, W.; Sun, Y.; Wang, M.; Chang, C.] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Zhai, W.; Sun, Y.; Wang, M.; Chang, C.] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Zhai, W.; Sun, Y.; Wang, M.; Chang, C.] Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Zhai, W.; Sun, Y.; Wang, M.; Chang, C.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Jiang, M.] Nantong Univ, Sch Med, Lab Nucl Receptors & Canc Res, Nantong, Jiangsu, Peoples R China; [Gasiewicz, T. A.] Univ Rochester, Med Ctr, Dept Environm Med, Rochester, NY 14642 USA; [Chang, C.] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	Tongji University; University of Rochester; University of Rochester; University of Rochester; University of Rochester; Nantong University; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Zheng, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Zheng, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Zheng, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Zheng, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	zhengjh0471@sina.com.cn; chang@urmc.rochester.edu		Jiang, Ming/0000-0003-3361-9881	NIH [CA155477, CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence [DOH99-TD-B-111-004]; National Science Foundation of China [31570775]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial, Research Center of Excellence (DOH99-TD-B-111-004 to China Medical University, Taichung, Taiwan) and the National Science Foundation of China (31570775). We also gratefully acknowledged the help from Mr Jason Walrath of Department of Environmental Medicine of URMC for hypoxia experiments using In ViVo<INF>2</INF> hypoxic workstation. We thank Karen Wolf for help preparing the manuscript.	Cabianca DS, 2012, CELL, V149, DOI 10.1016/j.cell.2012.03.035; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Chen Y, 2015, ONCOTARGET, V6, P31203, DOI 10.18632/oncotarget.4522; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ding JH, 2012, P NATL ACAD SCI USA, V109, P2654, DOI 10.1073/pnas.1121374109; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harrison L, 2004, ONCOLOGIST, V9, P31, DOI 10.1634/theoncologist.9-90005-31; Harrison LRE, 2011, J CLIN INVEST, V121, P1075, DOI 10.1172/JCI43505; He DL, 2014, CANCER RES, V74, P4420, DOI 10.1158/0008-5472.CAN-13-2681; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Kuo HP, 2009, BIOCHEM BIOPH RES CO, V389, P640, DOI 10.1016/j.bbrc.2009.09.042; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Lipworth L, 2006, J UROLOGY, V176, P2353, DOI 10.1016/j.juro.2006.07.130; Lu W, 2015, MOL BIOL CELL, V26, P1296, DOI 10.1091/mbc.E14-10-1423; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mitani T, 2011, J STEROID BIOCHEM, V123, P58, DOI 10.1016/j.jsbmb.2010.10.009; Moon EJ, 2007, ANTIOXID REDOX SIGN, V9, P1237, DOI 10.1089/ars.2007.1623; Moreno-Manzano V, 2010, J BIOL CHEM, V285, P1333, DOI 10.1074/jbc.M109.008326; Muller H, 2007, BIOORGAN MED CHEM, V15, P7470, DOI 10.1016/j.bmc.2007.07.024; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Park SY, 2006, CANCER RES, V66, P5121, DOI 10.1158/0008-5472.CAN-05-1341; Parker AS, 2005, UROLOGY, V65, P1090, DOI 10.1016/j.urology.2004.12.040; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Stone Louise, 2015, Nat Rev Urol, V12, P125, DOI 10.1038/nrurol.2015.26; Takahashi K, 2014, J CELL SCI, V127, P1585, DOI 10.1242/jcs.141069; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; Wang J, 2014, MOL ENDOCRINOL, V28, P239, DOI 10.1210/me.2013-1258; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wennemers M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2934; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054; Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569; Yu G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042377	52	52	53	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4866	4880		10.1038/onc.2016.19	http://dx.doi.org/10.1038/onc.2016.19			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26973243				2022-12-28	WOS:000383330700005
J	Duckworth, C; Zhang, L; Carroll, SL; Ethier, SP; Cheung, HW				Duckworth, C.; Zhang, L.; Carroll, S. L.; Ethier, S. P.; Cheung, H. W.			Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression	ONCOGENE			English	Article							BREAST-CANCER; EPITHELIAL OVARIAN; TUMORIGENESIS; INHIBITION; PROLIFERATION; MALIGNANCIES; METASTASIS; ACTIVATION; RESISTANCE; BLOCKADE	We previously found that the scaffold adapter GRB2-associated binding protein 2 (GAB2) is amplified and overexpressed in a subset of primary high-grade serous ovarian cancers and cell lines. Ovarian cancer cells overexpressing GAB2 are dependent on GAB2 for activation of the phosphatidylinositol 3-kinase (PI3K) pathway and are sensitive to PI3K inhibition. In this study, we show an important role of GAB2 overexpression in promoting tumor angiogenesis by upregulating expression of multiple chemokines. Specifically, we found that suppression of GAB2 by inducible small hairpin RNA in ovarian cancer cells inhibited tumor cell proliferation, angiogenesis and peritoneal tumor growth in immunodeficient mice. Overexpression of GAB2 upregulated the secretion of several chemokines from ovarian cancer cells, including CXCL1, CXCL2 and CXCL8. The secreted chemokines not only signal through endothelial CXCR2 receptor in a paracrine manner to promote endothelial tube formation, but also act as autocrine growth factors for GAB2-induced transformation of fallopian tube secretory epithelial cells and clonogenic growth of ovarian cancer cells overexpressing GAB2. Pharmacological inhibition of inhibitor of nuclear factor kappa-B kinase subunit beta (IKK beta), but not PI3K, mechanistic target of rapamycin (mTOR) or mitogen-activated protein kinase (MEK), could effectively suppress GAB2-induced chemokine expression. Inhibition of IKK beta augmented the efficacy of PI3K/mTOR inhibition in suppressing clonogenic growth of ovarian cancer cells with GAB2 overexpression. Taken together, these findings suggest that overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating expression of CXCL1, CXCL2 and CXCL8 that is IKK beta-dependent. Co-targeting IKK beta and PI3K pathways downstream of GAB2 might be a promising therapeutic strategy for ovarian cancer that overexpresses GAB2.	[Duckworth, C.; Zhang, L.; Carroll, S. L.; Ethier, S. P.; Cheung, H. W.] Med Univ South Carolina, Dept Pathol & Lab Med, 68 President St,Room BE413,MSC 908, Charleston, SC 29425 USA; [Duckworth, C.; Zhang, L.; Carroll, S. L.; Ethier, S. P.; Cheung, H. W.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Duckworth, C.; Zhang, L.; Carroll, S. L.; Ethier, S. P.; Cheung, H. W.] Med Univ South Carolina, Ctr Genom Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Cheung, HW (corresponding author), Med Univ South Carolina, Dept Pathol & Lab Med, 68 President St,Room BE413,MSC 908, Charleston, SC 29425 USA.	cheungh@musc.edu	Duckworth, Carrie/AAC-8361-2020; Duckworth, Carrie A/K-7302-2014	Duckworth, Carrie/0000-0001-9992-7540; Duckworth, Carrie A/0000-0001-9992-7540	Ovarian Cancer Research Fund [292377]; V Foundation for Cancer Research; Marsha Rivkin Center for Ovarian Cancer Research; American Cancer Society Institutional Research Grant [IRG-97-219-14]; Colleen's Dream Foundation; Cancer Center Support Grant [P30 CA139313]; NATIONAL CANCER INSTITUTE [R03CA139313] Funding Source: NIH RePORTER	Ovarian Cancer Research Fund; V Foundation for Cancer Research; Marsha Rivkin Center for Ovarian Cancer Research; American Cancer Society Institutional Research Grant(American Cancer Society); Colleen's Dream Foundation; Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants from the Ovarian Cancer Research Fund (292377) (HWC); the V Foundation for Cancer Research (HWC); the Marsha Rivkin Center for Ovarian Cancer Research (HWC); the American Cancer Society Institutional Research Grant #IRG-97-219-14 (HWC); Colleen's Dream Foundation (HWC); Department start-up fund (HWC). This research utilized the Cell & Molecular Imaging, and Genomics Shared Resources which were supported, in part, by Cancer Center Support Grant P30 CA139313 to the Hollings Cancer Center, Medical University of South Carolina. We thank Alfred Moore for assistance with bioluminescent imaging. We thank Dennis Watson, Patricia Watson, Bart Smits and Qi Wang for stimulating discussion.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Adams SJ, 2012, MOL CANCER RES, V10, P1265, DOI 10.1158/1541-7786.MCR-12-0352; Allegretti M, 2012, IMMUNOL LETT, V145, P68, DOI 10.1016/j.imlet.2012.04.003; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Behbakht K, 2011, GYNECOL ONCOL, V123, P19, DOI 10.1016/j.ygyno.2011.06.022; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112; Charles KA, 2009, J CLIN INVEST, V119, P3011, DOI 10.1172/JCI39065; Cheung HW, 2011, CANCER DISCOV, V1, P608, DOI 10.1158/2159-8290.CD-11-0046; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Choi HJ, 2015, CANCER METAST REV, V34, P19, DOI 10.1007/s10555-014-9538-9; Davis SJ, 2015, MOL CANCER THER, V14, P1495, DOI 10.1158/1535-7163.MCT-15-0039; Dunn GP, 2014, P NATL ACAD SCI USA, V111, P1102, DOI 10.1073/pnas.1311909111; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Hernandez L, 2010, CANCER RES, V70, P4005, DOI 10.1158/0008-5472.CAN-09-3912; Huang J, 2011, GENE CHROMOSOME CANC, V50, P606, DOI 10.1002/gcc.20883; Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Schmitt J, 2012, CANCER TREAT REV, V38, P272, DOI 10.1016/j.ctrv.2011.06.004; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Wang Y, 2012, CYTOKINE, V59, P145, DOI 10.1016/j.cyto.2012.04.013; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Yang G, 2006, P NATL ACAD SCI USA, V103, P16472, DOI 10.1073/pnas.0605752103; Yang G, 2010, CLIN CANCER RES, V16, P3875, DOI 10.1158/1078-0432.CCR-10-0483; Yang Y, 2013, ONCOGENE, V32, P3627, DOI 10.1038/onc.2012.367; Yuan TL, 2008, P NATL ACAD SCI USA, V105, P9739, DOI 10.1073/pnas.0804123105	34	34	37	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4036	4047		10.1038/onc.2015.472	http://dx.doi.org/10.1038/onc.2015.472			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26657155	Green Published, hybrid			2022-12-28	WOS:000381020900002
J	Rupaimoole, R; Ivan, C; Yang, D; Gharpure, KM; Wu, SY; Pecot, CV; Previs, RA; Nagaraja, AS; Armaiz-Pena, GN; McGuire, M; Pradeep, S; Mangala, LS; Rodriguez-Aguayo, C; Huang, L; Bar-Eli, M; Zhang, W; Lopez-Berestein, G; Calin, GA; Sood, AK				Rupaimoole, R.; Ivan, C.; Yang, D.; Gharpure, K. M.; Wu, S. Y.; Pecot, C. V.; Previs, R. A.; Nagaraja, A. S.; Armaiz-Pena, G. N.; McGuire, M.; Pradeep, S.; Mangala, L. S.; Rodriguez-Aguayo, C.; Huang, L.; Bar-Eli, M.; Zhang, W.; Lopez-Berestein, G.; Calin, G. A.; Sood, A. K.			Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression	ONCOGENE			English	Article							DOWN-REGULATION; POOR-PROGNOSIS; LUNG-CANCER; EXPRESSION; DROSHA; METASTASIS; BIOGENESIS; MIR-210	MicroRNAs (miRNAs) are small RNA molecules that affect cellular processes by controlling gene expression. Recent studies have shown that hypoxia downregulates Drosha and Dicer, key enzymes in miRNA biogenesis, causing a decreased pool of miRNAs in cancer and resulting in increased tumor growth and metastasis. Here we demonstrate a previously unrecognized mechanism by which hypoxia downregulates Dicer. We found that miR-630, which is upregulated under hypoxic conditions, targets and downregulates Dicer expression. In an orthotopic mouse model of ovarian cancer, delivery of miR-630 using 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) nanoliposomes resulted in increased tumor growth and metastasis, and decreased Dicer expression. Treatment with the combination of anti-miR-630 and anti-vascular endothelial growth factor antibody in mice resulted in rescue of Dicer expression and significantly decreased tumor growth and metastasis. These results indicate that targeting miR-630 is a promising approach to overcome Dicer deregulation in cancer. As demonstrated in the study, use of DOPC nanoliposomes for anti-miR delivery serves as a better alternative approach to cell line-based overexpression of sense or antisense miRNAs, while avoiding potential in vitro selection effects. Findings from this study provide a new understanding of miRNA biogenesis downregulation observed under hypoxia and suggest therapeutic avenues to target this dysregulation in cancer.	[Rupaimoole, R.; Ivan, C.; Gharpure, K. M.; Wu, S. Y.; Previs, R. A.; Nagaraja, A. S.; Armaiz-Pena, G. N.; McGuire, M.; Pradeep, S.; Mangala, L. S.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Rupaimoole, R.; Gharpure, K. M.; Nagaraja, A. S.] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Ivan, C.; Mangala, L. S.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Calin, G. A.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA; [Yang, D.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA; [Pecot, C. V.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; [Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Huang, L.; Bar-Eli, M.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Canc Biol, Houston, TX 77030 USA; [Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Dept Gynecol Oncol & Reprod Med & Canc Biol, 1155 Hemann P Pressler,Unit 1362, Houston, TX 77030 USA.	asood@mdanderson.org	Nagaraja, Archana/AAE-8529-2021; Calin, George/E-9390-2011; Nagaraja, Archana Sidalaghatta/AAE-2205-2021; Sood, Anoop Kumar/A-7344-2013; Rupaimoole, Rajesha/K-3272-2016	Sood, Anoop Kumar/0000-0001-5702-4108; Ivan, Cristina/0000-0002-4848-0168; Gharpure, Kshipra/0000-0003-4954-5696; Armaiz-Pena, Guillermo N/0000-0002-9081-5339; Calin, George/0000-0001-6704-5615; Calin, George/0000-0002-7427-0578; McGuire, Michael/0000-0003-2699-8430; Previs, Rebecca/0000-0001-8087-9120; Rupaimoole, Rajesha/0000-0002-4795-7921; Nagaraja, Archana/0000-0002-2851-9272; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Yang, Da/0000-0002-8336-9457	National Institutes of Health [P30 CA016672, CA109298, UH2TR000943-01, P50 CA083639, P50 CA098258, CA128797, U54 CA151668, U24CA143835]; Cancer Prevention and Research Institute of Texas [RP110595]; Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; RGK Foundation; Gilder Foundation; Blanton-Davis Ovarian Cancer Research Program; Betty Anne Asche Murray Distinguished Professorship; Russell and Diana Hawkins Family Foundation Discovery Fellowship; Ovarian Cancer Research Fund, Inc.; Foundation for Women's Cancer; Cancer Prevention and Research Institute of Texas training grants [RP101502, RP101489]; NCI-DHHS-NIH T32 training grant [T32 CA101642]; NCI (T32 training grant) [CA009666]; Conquer Cancer Foundation ASCO Young Investigator Award; DoCM Advanced Scholar Program; Research Training Award from Cancer Prevention and Research Institute of Texas (CPRIT) [RP140106]; Altman Goldstein Discovery fellowship; NATIONAL CANCER INSTITUTE [P50CA098258, U54CA151668, R01CA109298, P50CA083639, R01CA128797, U24CA143835, T32CA009666, T32CA101642, R01CA182905, P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000943, UH2TR000943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [RC2GM092599] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; RGK Foundation; Gilder Foundation; Blanton-Davis Ovarian Cancer Research Program; Betty Anne Asche Murray Distinguished Professorship; Russell and Diana Hawkins Family Foundation Discovery Fellowship; Ovarian Cancer Research Fund, Inc.; Foundation for Women's Cancer; Cancer Prevention and Research Institute of Texas training grants; NCI-DHHS-NIH T32 training grant; NCI (T32 training grant); Conquer Cancer Foundation ASCO Young Investigator Award; DoCM Advanced Scholar Program; Research Training Award from Cancer Prevention and Research Institute of Texas (CPRIT); Altman Goldstein Discovery fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Portions of this work were supported by the National Institutes of Health (P30 CA016672, CA109298, UH2TR000943-01, P50 CA083639, P50 CA098258, CA128797, U54 CA151668 and U24CA143835); the Cancer Prevention and Research Institute of Texas (RP110595); the Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; the RGK Foundation; the Gilder Foundation; the Blanton-Davis Ovarian Cancer Research Program; and the Betty Anne Asche Murray Distinguished Professorship (AKS). RR is supported in part by the Russell and Diana Hawkins Family Foundation Discovery Fellowship. S.Y.W. is supported by the Ovarian Cancer Research Fund, Inc., Foundation for Women's Cancer and Cancer Prevention and Research Institute of Texas training grants (RP101502 and RP101489). RAP is supported by the NCI-DHHS-NIH T32 training grant (T32 CA101642). CVP is supported by a grant from the NCI (T32 training grant CA009666), the 2011 Conquer Cancer Foundation ASCO Young Investigator Award and the DoCM Advanced Scholar Program. ASN is supported by a Research Training Award from the Cancer Prevention and Research Institute of Texas (CPRIT RP140106). KMG is supported by Altman Goldstein Discovery fellowship. We thank Dr Xinna Zhang for assistance with the in situ hybridization analysis.	Allegra D, 2014, LEUKEMIA, V28, P98, DOI 10.1038/leu.2013.246; Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Dedes KJ, 2011, EUR J CANCER, V47, P138, DOI 10.1016/j.ejca.2010.08.007; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Kuo TC, 2013, J CLIN INVEST, V123, P1082, DOI 10.1172/JCI64044; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Mutharasan RK, 2011, AM J PHYSIOL-HEART C, V301, pH1519, DOI 10.1152/ajpheart.01080.2010; Nishimura M, 2013, CANCER DISCOV, V3, P1302, DOI 10.1158/2159-8290.CD-13-0159; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Tokumaru S, 2008, CARCINOGENESIS, V29, P2073, DOI 10.1093/carcin/bgn187; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wang XW, 2013, SCI REP-UK, V3, DOI 10.1038/srep01942; Wu SY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4459; Yamagishi N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-229	31	62	66	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4312	4320		10.1038/onc.2015.492	http://dx.doi.org/10.1038/onc.2015.492			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26725326	Green Accepted, Green Submitted			2022-12-28	WOS:000382152100003
J	Yagi, H; Asanoma, K; Ohgami, T; Ichinoe, A; Sonoda, K; Kato, K				Yagi, H.; Asanoma, K.; Ohgami, T.; Ichinoe, A.; Sonoda, K.; Kato, K.			GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; HIPPO SIGNALING PATHWAY; YES-ASSOCIATED PROTEIN; ALPHA-SUBUNIT; SIZE-CONTROL; G12 FAMILY; ORGAN SIZE; IDENTIFICATION; ESTABLISHMENT	G-protein-coupled receptors (GPCRs) and their ligands function in the progression of human malignancies. G alpha(12) and G alpha(13), encoded by GNA12 and GNA13, respectively, are referred to as the GEP oncogene and are implicated in tumor progression. However, the molecular mechanisms by which G alpha(12/13) activation promotes cancer progression are not fully elucidated. Here, we demonstrate elevated expression of G alpha 12/13 in human ovarian cancer tissues. G alpha(12/13) activation did not promote cellular migration in the ovarian cancer cell lines examined. Rather, G alpha(12/13) activation promoted cell growth. We used a synthetic biology approach using chimeric G proteins and GPCRs activated solely by artificial ligands to selectively trigger signaling pathways downstream of specific G proteins. We found that G alpha(12/13) promotes proliferation of ovarian cancer cells by activating the transcriptional coactivator YAP, a critical component of the Hippo signaling pathway. Furthermore, we reveal that inhibition of YAP by short hairpin RNA or a specific inhibitor prevented the growth of ovarian cancer cells. Therefore, YAP may be a suitable therapeutic target in ovarian cancer.	[Yagi, H.; Asanoma, K.; Ohgami, T.; Ichinoe, A.; Sonoda, K.; Kato, K.] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka, Japan	Kyushu University	Yagi, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yagih@med.kyushu-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24791709, 26861332]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We are grateful to Ms Emiko Hori, Ms Yoko Miyanari and Research Support Center, Graduate School of Medical Science, Kyushu University for technical supports. This study was supported in part by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#24791709 and #26861332).	Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/j.tips.2007.06.005; Gan CP, 2014, ONCOTARGET, V5, P9626, DOI 10.18632/oncotarget.2437; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Goldsmith Zachariah G, 2011, Genes Cancer, V2, P563, DOI 10.1177/1947601911419362; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; IMAI S, 1990, ONCOLOGY, V47, P177; Itamochi H, 2013, HUM CELL, V26, P121, DOI 10.1007/s13577-013-0062-y; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005; Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sudol M, 2012, SEMIN CELL DEV BIOL, V23, P827, DOI 10.1016/j.semcdb.2012.05.002; Tan WF, 2006, J BIOL CHEM, V281, P39542, DOI 10.1074/jbc.M609062200; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Worzfeld T, 2008, TRENDS PHARMACOL SCI, V29, P582, DOI 10.1016/j.tips.2008.08.002; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yang YM, 2015, ONCOGENE, V34, P2910, DOI 10.1038/onc.2014.218; Yotsumoto F, 2008, BIOCHEM BIOPH RES CO, V365, P555, DOI 10.1016/j.bbrc.2007.11.015; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210	45	28	29	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4471	4480		10.1038/onc.2015.505	http://dx.doi.org/10.1038/onc.2015.505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804165				2022-12-28	WOS:000382153100005
J	Schabath, MB; Welsh, EA; Fulp, WJ; Chen, L; Teer, JK; Thompson, ZJ; Engel, BE; Xie, M; Berglund, AE; Creelan, BC; Antonia, SJ; Gray, JE; Eschrich, SA; Chen, DT; Cress, WD; Haura, EB; Beg, AA				Schabath, M. B.; Welsh, E. A.; Fulp, W. J.; Chen, L.; Teer, J. K.; Thompson, Z. J.; Engel, B. E.; Xie, M.; Berglund, A. E.; Creelan, B. C.; Antonia, S. J.; Gray, J. E.; Eschrich, S. A.; Chen, D-T; Cress, W. D.; Haura, E. B.; Beg, A. A.			Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma	ONCOGENE			English	Article							NF-KAPPA-B; TUMOR MICROENVIRONMENT; CANCER-IMMUNOTHERAPY; SOMATIC MUTATIONS; T-CELLS; LKB1; SIGNATURE; METASTASIS; SURVIVAL; INNATE	While mutations in the KRAS oncogene are among the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also likely that heterogeneity in KRAS-mutant tumor biology significantly contributes to the response to therapy. We hypothesized that the presence of commonly co-occurring mutations in STK11 and TP53 tumor suppressors may represent a significant source of heterogeneity in KRAS-mutant tumors. To address this, we utilized a large cohort of resected tumors from 442 lung adenocarcinoma patients with data including annotation of prevalent driver mutations (KRAS and EGFR) and tumor suppressor mutations (STK11 and TP53), microarray-based gene expression and clinical covariates, including overall survival (OS). Specifically, we determined impact of STK11 and TP53 mutations on a new KRAS mutation-associated gene expression signature as well as previously defined signatures of tumor cell proliferation and immune surveillance responses. Interestingly, STK11, but not TP53 mutations, were associated with highly elevated expression of KRAS mutation-associated genes. Mutations in TP53 and STK11 also impacted tumor biology regardless of KRAS status, with TP53 strongly associated with enhanced proliferation and STK11 with suppression of immune surveillance. These findings illustrate the remarkably distinct ways through which tumor suppressor mutations may contribute to heterogeneity in KRAS-mutant tumor biology. In addition, these studies point to novel associations between gene mutations and immune surveillance that could impact the response to immunotherapy.	[Schabath, M. B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL 33612 USA; [Welsh, E. A.; Teer, J. K.; Berglund, A. E.; Eschrich, S. A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Bioinformat, Tampa, FL 33612 USA; [Fulp, W. J.; Chen, L.; Thompson, Z. J.; Chen, D-T] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat, Tampa, FL 33612 USA; [Engel, B. E.; Xie, M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Canc Biol Grad Program, Tampa, FL 33612 USA; [Creelan, B. C.; Antonia, S. J.; Gray, J. E.; Haura, E. B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL 33612 USA; [Cress, W. D.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Beg, A. A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Schabath, MB; Beg, AA (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.	matthew.schabath@moffitt.org; amer.beg@moffitt.org	Fulp, William/AAD-2369-2022; Schabath, Matthew B./J-3763-2016; Eschrich, Steven/K-6848-2013	Schabath, Matthew B./0000-0003-3241-3216; Eschrich, Steven/0000-0002-9833-2788; Creelan, Ben/0000-0002-2728-8070; Berglund, Anders/0000-0002-0393-3530; Fulp, William/0000-0001-6888-0794	National Institutes of Health SPORE Grant [P50 CA119997]; DeBartolo Family; Cancer Center Support Grant (CCSG grant) at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center [P30-CA76292]; NATIONAL CANCER INSTITUTE [P50CA070907, P30CA076292, P50CA119997, R25CA174664] Funding Source: NIH RePORTER	National Institutes of Health SPORE Grant; DeBartolo Family; Cancer Center Support Grant (CCSG grant) at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a National Institutes of Health SPORE Grant (P50 CA119997). We would also like to thank Mr Andrew 'Ross' Myers, Anastasia Belock, Mercedes Rodriguez, Edward T Chwieseni, Marek Wloch, Hiba Gohar, and Moffitt's Tissue Core facility, Moffitt's Cancer Registry (Director: Karen A Coyne), Research Information Technology (IT) group, and the Data Management and Integration Technology (DMIT) group. Total Cancer Care is enabled, in part, by the generous support of the DeBartolo Family, and we thank the many patients who provided data and tissue to the Total Cancer Care Consortium. Our study also received valuable assistance from the following Core Facilities at the Moffitt Cancer Center: Biostatistics and Cancer Informatics, Tissue, and Molecular Genomics. This work has been supported in part by a Cancer Center Support Grant (CCSG grant P30-CA76292) at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center.	Baker NM, 2014, CLIN CANCER RES, V20, P4740, DOI 10.1158/1078-0432.CCR-13-1727; Bang D, 2013, CANCER DISCOV, V3, P690, DOI 10.1158/2159-8290.CD-12-0541; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Chen DT, 2011, JNCI-J NATL CANCER I, V103, P1859, DOI 10.1093/jnci/djr420; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cox Adrienne D, 2010, Small GTPases, V1, P2; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316; Fuertes MB, 2013, TRENDS IMMUNOL, V34, P67, DOI 10.1016/j.it.2012.10.004; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gajewski TF, 2013, CURR OPIN IMMUNOL, V25, P259, DOI 10.1016/j.coi.2013.03.008; Gajewski TF, 2013, CURR OPIN IMMUNOL, V25, P268, DOI 10.1016/j.coi.2013.02.009; Gao YJ, 2011, PROTEIN CELL, V2, P99, DOI 10.1007/s13238-011-1021-6; Gao YJ, 2010, P NATL ACAD SCI USA, V107, P18892, DOI 10.1073/pnas.1004952107; Gibbons DL, 2014, MOL CANCER RES, V12, P3, DOI 10.1158/1541-7786.MCR-13-0539; Hopewell EL, 2013, J CLIN INVEST, V123, P2509, DOI 10.1172/JCI67250; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Ji RR, 2012, CANCER IMMUNOL IMMUN, V61, P1019, DOI 10.1007/s00262-011-1172-6; Kaufman JM, 2014, J THORAC ONCOL, V9, P794, DOI 10.1097/JTO.0000000000000173; Kim HS, 2013, CELL, V155, P552, DOI 10.1016/j.cell.2013.09.041; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Meng DQ, 2013, LUNG CANCER, V81, P1, DOI 10.1016/j.lungcan.2013.03.019; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2011, FAM CANCER, V10, P447, DOI 10.1007/s10689-011-9443-0; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shah U, 2008, CANCER RES, V68, P3562, DOI 10.1158/0008-5472.CAN-07-6620; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; Ulloa-Montoya F, 2013, J CLIN ONCOL, V31, P2388, DOI 10.1200/JCO.2012.44.3762; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	46	179	184	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3209	3216		10.1038/onc.2015.375	http://dx.doi.org/10.1038/onc.2015.375			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26477306	Green Accepted			2022-12-28	WOS:000378092700012
J	Wang, J; Cai, J; Huang, Y; Ke, Q; Wu, B; Wang, S; Han, X; Wang, T; Wang, Y; Li, W; Lao, C; Song, W; Xiang, AP				Wang, J.; Cai, J.; Huang, Y.; Ke, Q.; Wu, B.; Wang, S.; Han, X.; Wang, T.; Wang, Y.; Li, W.; Lao, C.; Song, W.; Xiang, A. P.			Nestin regulates proliferation and invasion of gastrointestinal stromal tumor cells by altering mitochondrial dynamics	ONCOGENE			English	Article							INTERMEDIATE-FILAMENT NESTIN; PLURIPOTENT STEM-CELLS; OXIDATIVE STRESS; TARGETING MITOCHONDRIA; CANCER-THERAPY; MORPHOLOGY; EXPRESSION; ROS; PHOSPHORYLATION; VIMENTIN	Nestin is widely expressed in numerous tumors and has become a diagnostic and prognostic indicator. However, the exact mechanism by which nestin contributes to tumor malignancy remains poorly understood. Here, we found marked upregulation of nestin expression in highly proliferative and invasive gastrointestinal stromal tumor (GIST) specimens. Nestin knockdown in GIST cells reduced the proliferative and invasive activity owing to a decrease of mitochondrial intracellular reactive oxygen species (ROS) generation. Furthermore, nestin was co-localized with mitochondria, and knockdown of nestin increased mitochondrial elongation and influenced the mitochondrial function, including oxygen consumption rates, ATP generation and mitochondrial membrane potential and so on. In exploring the underlying mechanism, we demonstrated nestin knockdown inhibited the mitochondrial recruitment of Dynamin-related protein1 and induced the change of mitochondrial dynamics. Thus, nestin may have an important role in GIST malignancy by regulating mitochondrial dynamics and altering intracellular ROS levels. The findings provide new clues to reveal mechanisms by which nestin mediates the proliferation and invasion of GISTs.	[Wang, J.; Cai, J.; Li, W.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Affiliated Guangzhou Women & Childrens Hosp, Program Stem Cells & Regenerat Med, Guangzhou 510275, Guangdong, Peoples R China; [Wang, J.; Cai, J.; Huang, Y.; Ke, Q.; Wang, T.; Wang, Y.; Li, W.; Lao, C.; Xiang, A. P.] Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, 74 Zhongshan 2nd Rd, Guangzhou 510275, Guangdong, Peoples R China; [Cai, J.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Ke, Q.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Cell Biol, Guangzhou 510275, Guangdong, Peoples R China; [Wu, B.] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Cardiol, Guangzhou 510275, Guangdong, Peoples R China; [Wang, S.; Song, W.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Pancreat Surg, Guangzhou 510275, Guangdong, Peoples R China; [Han, X.] Peking Union Med Coll, Fuwai Hosp, Dept Populat Genet & Prevent, Beijing 100021, Peoples R China; [Li, W.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Sun Yat Sen University	Xiang, AP (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, 74 Zhongshan 2nd Rd, Guangzhou 510275, Guangdong, Peoples R China.	xiangp@mail.sysu.edu.cn	Cai, Jianye/GOK-2676-2022	Huang, Yinong/0000-0002-7364-2894	National Basic Research Program of China [2012CBA01302]; National Natural Science Foundation of China [81425016, 81270646, 31171398]; Natural Science Foundation of Guangdong Province [S2013030013305, 2015A030312013]; Key Scientific and Technological Projects of Guangdong Province [2014B020226002, 2015B020226004, 2014B020228003, 2007A032100003]; Key Scientific and Technological Program of Guangzhou City [201400000003-3, 201508020262, 201300000089, 2010U1-E00551]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS)	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Key Scientific and Technological Projects of Guangdong Province; Key Scientific and Technological Program of Guangzhou City; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS)	This work was supported by the National Basic Research Program of China (2012CBA01302); the National Natural Science Foundation of China (81425016, 81270646, 31171398); the Natural Science Foundation of Guangdong Province (S2013030013305, 2015A030312013); the Key Scientific and Technological Projects of Guangdong Province (2014B020226002, 2015B020226004, 2014B020228003, 2007A032100003); Key Scientific and Technological Program of Guangzhou City (201400000003-3, 201508020262, 201300000089, 2010U1-E00551); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS, 2013).	Anesti V, 2006, BBA-BIOENERGETICS, V1757, P692, DOI 10.1016/j.bbabio.2006.04.013; Chan DC, 2012, ANNU REV GENET, V46, P265, DOI 10.1146/annurev-genet-110410-132529; Chappell NP, 2012, J PROTEOME RES, V11, P4605, DOI 10.1021/pr300403d; Chen ZG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085584; Cheng FY, 2012, BIOMATERIALS, V33, P3195, DOI 10.1016/j.biomaterials.2012.01.023; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Gilyarov A V, 2008, Neurosci Behav Physiol, V38, P165, DOI 10.1007/s11055-008-0025-z; Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801; Huang YL, 2009, J BIOCHEM, V146, P307, DOI 10.1093/jb/mvp070; Jiang MH, 2014, CELL RES, V24, P1466, DOI 10.1038/cr.2014.149; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Ke Q, 2013, HUM MOL GENET, V22, P2221, DOI 10.1093/hmg/ddt074; Kleeberger W, 2007, CANCER RES, V67, P9199, DOI 10.1158/0008-5472.CAN-07-0806; Koopman WJH, 2005, AM J PHYSIOL-CELL PH, V289, pC881, DOI 10.1152/ajpcell.00104.2005; Le Belle JE, 2011, CELL STEM CELL, V8, P59, DOI 10.1016/j.stem.2010.11.028; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li P, 2013, NAT NEUROSCI, V16, P1737, DOI 10.1038/nn.3553; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu J, 2014, STEM CELLS, V32, P1843, DOI 10.1002/stem.1682; Malhas AN, 2009, J CELL BIOL, V184, P45, DOI 10.1083/jcb.200804155; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsuda Y., 2014, CANCER BIOL THER, V11, P512; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; Ngan CY, 2007, BRIT J CANCER, V96, P986, DOI 10.1038/sj.bjc.6603651; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sahlgren CM, 2006, EMBO J, V25, P4808, DOI 10.1038/sj.emboj.7601366; Serasinghe Madhavika N, 2015, MOL CELL, V57, P521; StoneO MR, 2007, J CELL SCI, V120, P3999, DOI 10.1242/jcs.009241; Su HT, 2013, MOL CANCER RES, V11, P768, DOI 10.1158/1541-7786.MCR-12-0511; Tang HL, 2008, BIOCHEM J, V410, P141, DOI 10.1042/BJ20071072; Tao GZ, 2009, J CELL SCI, V122, P3851, DOI 10.1242/jcs.051862; Tao GZ, 2005, J BIOL CHEM, V280, P12162, DOI 10.1074/jbc.M412505200; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Toivola DM, 2005, TRENDS CELL BIOL, V15, P608, DOI 10.1016/j.tcb.2005.09.004; Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007; Tsujimura T, 2001, AM J PATHOL, V158, P817, DOI 10.1016/S0002-9440(10)64029-1; Vanderwinden JM, 2002, CELL TISSUE RES, V309, P261, DOI 10.1007/s00441-002-0590-3; Verstraeten VLRM, 2009, J CELL MOL MED, V13, P959, DOI 10.1111/j.1582-4934.2009.00690.x; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang YD, 1998, SCIENCE, V279, P537, DOI 10.1126/science.279.5350.537; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wikstrom JD, 2013, MOL ENDOCRINOL, V27, P1706, DOI 10.1210/me.2013-1109; Winter L, 2008, J CELL BIOL, V181, P903, DOI 10.1083/jcb.200710151; Yang XH, 2008, J CLIN PATHOL, V61, P467, DOI 10.1136/jcp.2007.047605; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	54	17	19	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3139	3150		10.1038/onc.2015.370	http://dx.doi.org/10.1038/onc.2015.370			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26434586				2022-12-28	WOS:000378092700006
J	Dai, B; Chen, AY; Corkum, CP; Peroutka, RJ; Landon, A; Houng, S; Muniandy, PA; Zhang, Y; Lehrmann, E; Mazan-Mamczarz, K; Steinhardt, J; Shlyak, M; Chen, QC; Becker, KG; Livak, F; Michalak, TI; Talwani, R; Gartenhaus, RB				Dai, B.; Chen, A. Y.; Corkum, C. P.; Peroutka, R. J.; Landon, A.; Houng, S.; Muniandy, P. A.; Zhang, Y.; Lehrmann, E.; Mazan-Mamczarz, K.; Steinhardt, J.; Shlyak, M.; Chen, Q. C.; Becker, K. G.; Livak, F.; Michalak, T. I.; Talwani, R.; Gartenhaus, R. B.			Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders	ONCOGENE			English	Article							BLOOD MONONUCLEAR-CELLS; IN-VIVO; DNA-REPAIR; IONIZING-RADIATION; OCCULT INFECTION; LOW-LEVEL; EXPRESSION; LYMPHOMA; CHK2; REPLICATION	B-cell receptor (BCR) signaling is essential for the development of B cells and has a critical role in B-cell neoplasia. Increasing evidence indicates an association between chronic hepatitis C virus (HCV) infection and B-cell lymphoma, however, the mechanisms by which HCV causes B-cell lymphoproliferative disorder are still unclear. Herein, we demonstrate the expression of HCV viral proteins in B cells of HCV-infected patients and show that HCV upregulates BCR signaling in human primary B cells. HCV nonstructural protein NS3/4A interacts with CHK2 and downregulates its activity, modulating HuR posttranscriptional regulation of a network of target mRNAs associated with B-cell lymphoproliferative disorders. Interestingly, the BCR signaling pathway was found to have the largest number of transcripts with increased association with HuR and was upregulated by NS3/4A. Our study reveals a previously unidentified role of NS3/4A in regulation of host BCR signaling during HCV infection, contributing to a better understanding of the molecular mechanisms underlying HCV-associated B-cell lymphoproliferative disorders.	[Dai, B.; Peroutka, R. J.; Landon, A.; Houng, S.; Muniandy, P. A.; Mazan-Mamczarz, K.; Steinhardt, J.; Livak, F.; Gartenhaus, R. B.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Dept Med, Baltimore, MD 21201 USA; [Chen, A. Y.; Corkum, C. P.; Michalak, T. I.] Mem Univ Newfoundland, Fac Med, Div Biomed Sci, Mol Virol & Hepatol Res Grp, St John, NF, Canada; [Zhang, Y.; Lehrmann, E.; Becker, K. G.] NIA, Gene Express & Genom Unit, Genet Lab, NIH, Baltimore, MD 21224 USA; [Shlyak, M.; Talwani, R.] Univ Maryland, Sch Med, Inst Human Virol, Dept Infect Dis, Baltimore, MD 21201 USA; [Chen, Q. C.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Gartenhaus, R. B.] Vet Adm Med Ctr, Baltimore, MD 21218 USA	University System of Maryland; University of Maryland Baltimore; Memorial University Newfoundland; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gartenhaus, RB (corresponding author), Univ Maryland, Med Ctr, Marlene & Stewart Greenebaum Canc Ctr, Dept Med, 655 West Baltimore St,BRB 9-011, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu	Talwani, Rohit/B-8234-2019	Lehrmann, Elin/0000-0002-9869-9475	Department of Veterans Affairs; National Institutes of Health [R01AA017972, R01CA164311]; Canadian Institutes of Health Research [MOP-126056]; Canada Research Chair Program in Viral Hepatitis/Immunology; Intramural Research Program of the NIH, National Institute on Aging; NATIONAL CANCER INSTITUTE [R01CA164311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017972] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002990, I01BX001219] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chair Program in Viral Hepatitis/Immunology; Intramural Research Program of the NIH, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Veterans Affairs(US Department of Veterans Affairs)	We are grateful to Dr El Mustapha Bahassi for the gift of CHK2 and its truncated constructs. We thank Dr Michael MC Lai from the Institute of Molecular Biology, Academia Sinica, Taiwan for generously sharing NS3/4A constructs. We are thankful to Dr Michael Gale Jr (University of Washington, WA, USA) for generously sharing a series of FLAG epitope-tagged NS3/4A truncation and deletion mutant plasmids. We are very grateful to Dr Eric Campeau for the use of pLenti-CMVTRE3G and pLenti-CMV-rtTA3-Blast plasmids. We thank Dr Shyamasundaran Kottilil and Dr Patricia M Mulrooney-Cousins for helpful discussions. Flow cytometry analyses were performed at the University of Maryland Marlene and Stewart Greenebaum Cancer Center Flow Cytometry Shared Service. This work was supported in part by a Merit Review Award from the Department of Veterans Affairs (RBG), R01AA017972 (RBG) and R01CA164311 (RBG) from the National Institutes of Health, as well as MOP-126056 (TIM) from the Canadian Institutes of Health Research and the Canada Research Chair Program in Viral Hepatitis/Immunology (TIM). This research was also supported in part by the Intramural Research Program of the NIH, National Institute on Aging (YZ, EL and KGB).	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Beran RKF, 2008, J BIOL CHEM, V283, P29929, DOI 10.1074/jbc.M804065200; Bleesing JJH, 2003, CYTOM PART B-CLIN CY, V51B, P1, DOI 10.1002/cyto.b.10007; Dai BJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1404; Dai BJ, 2009, CANCER RES, V69, P7835, DOI 10.1158/0008-5472.CAN-09-1606; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; De Sanjose S, 2008, CLIN GASTROENTEROL H, V6, P451, DOI 10.1016/j.cgh.2008.02.011; Durand T, 2010, GUT, V59, P934, DOI 10.1136/gut.2009.192088; Hermine O, 2002, NEW ENGL J MED, V347, P89, DOI 10.1056/NEJMoa013376; Inokuchi M, 2009, J MED VIROL, V81, P619, DOI 10.1002/jmv.21388; Ito M, 2010, CLIN IMMUNOL, V135, P459, DOI 10.1016/j.clim.2010.02.002; Januszkiewicz-Lewandowska D, 2007, JPN J INFECT DIS, V60, P29; Kasama Y, 2010, BLOOD, V116, P4926, DOI 10.1182/blood-2010-05-283358; Lai CK, 2008, VIROLOGY, V370, P295, DOI 10.1016/j.virol.2007.08.037; LANFORD RE, 1995, J VIROL, V69, P8079, DOI 10.1128/JVI.69.12.8079-8083.1995; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lin L, 2002, J VIROL METHODS, V100, P97, DOI 10.1016/S0166-0934(01)00399-8; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Machida K, 2010, J IMMUNOL, V185, P6985, DOI 10.4049/jimmunol.1000618; Masuda K, 2011, EMBO J, V30, P1040, DOI 10.1038/emboj.2011.24; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; Mazan-Mamczarz K, 2011, BLOOD, V117, P2441, DOI 10.1182/blood-2010-09-310987; Mellor J, 1998, J GEN VIROL, V79, P705, DOI 10.1099/0022-1317-79-4-705; Ng PP, 2014, BLOOD, V123, P1512, DOI 10.1182/blood-2013-10-532895; Okudela K, 2013, INT J CLIN EXP PATHO, V6, P1; Pal S, 2006, GASTROENTEROLOGY, V130, P1107, DOI 10.1053/j.gastro.2005.12.039; Pham TNQ, 2004, J VIROL, V78, P5867, DOI 10.1128/JVI.78.11.5867-5874.2004; Pham TNQ, 2005, J GEN VIROL, V86, P657, DOI 10.1099/vir.0.80624-0; Pham TNQ, 2008, GASTROENTEROLOGY, V134, P812, DOI 10.1053/j.gastro.2007.12.011; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Sarhan MA, 2012, J VIROL, V86, P3723, DOI 10.1128/JVI.06956-11; Sung VMH, 2003, J VIROL, V77, P2134, DOI 10.1128/JVI.77.3.2134-2146.2003; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Touma SE, 2009, BIOCHEM PHARMACOL, V78, P1127, DOI 10.1016/j.bcp.2009.06.022; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937	37	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2979	2990		10.1038/onc.2015.364	http://dx.doi.org/10.1038/onc.2015.364			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434584	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000377474500004
J	Salas, E; Roy, S; Marsh, T; Rubin, B; Debnath, J				Salas, E.; Roy, S.; Marsh, T.; Rubin, B.; Debnath, J.			Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death	ONCOGENE			English	Article							ADVANCED SOLID TUMORS; PHASE-I TRIAL; AUTOPHAGY INHIBITION; BREAST-CANCER; HYDROXYCHLOROQUINE; P53; TEMOZOLOMIDE; COMBINATION; HOMEOSTASIS; PROGRESSION	Despite immense interest in using antimalarials as autophagy inhibitors to treat cancer, it remains unclear whether these agents act predominantly via autophagy inhibition or whether other pathways direct their anti-cancer properties. By comparing the treatment effects of the antimalarials chloroquine (CQ) and quinacrine (Q) on KRAS mutant lung cancer cells, we demonstrate that inhibition of the oxidative arm of the pentose phosphate pathway (oxPPP) is required for antimalarial induced apoptosis. Despite inhibiting autophagy, neither CQ treatment nor RNAi against autophagy regulators (ATGs) promote cell death. In contrast, Q triggers high levels of apoptosis, both in vitro and in vivo, and this phenotype requires both autophagy inhibition and p53-dependent inhibition of the oxPPP. Simultaneous genetic targeting of the oxPPP and autophagy is sufficient to trigger apoptosis in lung cancer cells, including cells lacking p53. Thus, in addition to reduced autophagy, oxPPP inhibition serves as an important determinant of antimalarial cytotoxicity in cancer cells.	[Salas, E.; Roy, S.; Marsh, T.; Debnath, J.] Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA; [Salas, E.; Roy, S.; Marsh, T.; Debnath, J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA; [Rubin, B.] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA; [Rubin, B.] Cleveland Clin, Dept Mol Genet, Cleveland, OH 44106 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Debnath, J (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA.; Debnath, J (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA.	Jayanta.Debnath@ucsf.edu		Marsh, Timothy/0000-0002-8772-7645; Debnath, Jayanta/0000-0002-8745-4069	NIH [R01CA126792, R01CA188404]; California Tobacco Related Diseases Research Program [18XT-0106]; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA126792, R01CA188404] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Tobacco Related Diseases Research Program; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support to JD includes the NIH (R01CA126792 and R01CA188404), California Tobacco Related Diseases Research Program (18XT-0106) and Samuel Waxman Cancer Research Foundation.	Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barnard RA, 2014, AUTOPHAGY, V10, P1415, DOI 10.4161/auto.29165; Buchakjian MR, 2010, NAT REV MOL CELL BIO, V11, P715, DOI 10.1038/nrm2972; Ehsanian R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-13; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gallant JN, 2011, CANCER BIOL THER, V12, P239, DOI 10.4161/cbt.12.3.17034; Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231; Maycotte P, 2014, CANCER RES, V74, P2579, DOI 10.1158/0008-5472.CAN-13-3470; Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119; Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111	35	9	9	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2913	2922		10.1038/onc.2015.348	http://dx.doi.org/10.1038/onc.2015.348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26434592	Green Accepted, Green Submitted			2022-12-28	WOS:000377473700011
J	Sartorius, CA; Hanna, CT; Gril, B; Cruz, H; Serkova, NJ; Huber, KM; Kabos, P; Schedin, TB; Borges, VF; Steeg, PS; Cittelly, DM				Sartorius, C. A.; Hanna, C. T.; Gril, B.; Cruz, H.; Serkova, N. J.; Huber, K. M.; Kabos, P.; Schedin, T. B.; Borges, V. F.; Steeg, P. S.; Cittelly, D. M.			Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism	ONCOGENE			English	Article							RECEPTOR-ALPHA; AROMATASE EXPRESSION; PROGNOSTIC-FACTORS; TUMOR-GROWTH; SURVIVAL; S100A4; BETA; INVASION; ANGIOGENESIS; CARCINOMA	Brain metastases (BM) are a devastating consequence of breast cancer. BM occur more frequently in patients with estrogen receptor-negative (ER-) breast cancer subtypes; HER2 overexpressing (HER2+) tumors and triple-negative (TN) (ER-, progesterone receptor-negative (PR-) and normal HER2) tumors. Young age is an independent risk factor for the development of BM, thus we speculated that higher circulating estrogens in young, pre-menopausal women could exert paracrine effects through the highly estrogen-responsive brain microenvironment. Using a TN experimental metastases model, we demonstrate that ovariectomy decreased the frequency of magnetic resonance imaging-detectable lesions by 56% as compared with estrogen supplementation, and that the combination of ovariectomy and letrozole further reduced the frequency of large lesions to 14.4% of the estrogen control. Human BM expressed 4.2-48.4% ER+ stromal area, particularly ER+ astrocytes. In vitro, E2-treated astrocytes increased proliferation, migration and invasion of 231BR-EGFP cells in an ER-dependent manner. E2 upregulated epidermal growth factor receptor (EGFR) ligands Egf, Ereg and Tgfa mRNA and protein levels in astrocytes, and activated EGFR in brain metastatic cells. Co-culture of 231BR-EGFP cells with E2-treated astrocytes led to the upregulation of the metastatic mediator S100 Calcium-binding protein A4 (S100A4) (1.78-fold, P < 0.05). Exogenous EGF increased S100A4 mRNA levels in 231BR-EGFP cells (1.40 +/- 0.02-fold, P < 0.01 compared with vehicle control) and an EGFR/HER2 inhibitor blocked this effect, suggesting that S100A4 is a downstream effector of EGFR activation. Short hairpin RNA-mediated S100A4 silencing in 231BR-EGFP cells decreased their migration and invasion in response to E2-CM, abolished their increased proliferation in co-cultures with E2-treated astrocytes and decreased brain metastatic colonization. Thus, S100A4 is one effector of the paracrine action of E2 in brain metastatic cells. These studies provide a novel mechanism by which estrogens, acting through ER+ astrocytes in the brain microenvironment, can promote BM of TN breast cancers, and suggests existing endocrine agents may provide some clinical benefit towards reducing and managing BM.	[Sartorius, C. A.; Hanna, C. T.; Cruz, H.; Cittelly, D. M.] Univ Colorado Denver, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA; [Gril, B.; Steeg, P. S.] NCI, Womens Malignancies Branch, Bethesda, MD 20892 USA; [Serkova, N. J.; Huber, K. M.] Univ Colorado Denver, Dept Anesthesiol, Anschutz Med, Aurora, CO 80045 USA; [Kabos, P.; Schedin, T. B.; Borges, V. F.] Univ Colorado Denver, Div Med Oncol, Dept Med, Anschutz Med Campus, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Cittelly, DM (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,12801 E 17th Ave MS8104, Aurora, CO 80045 USA.	Diana.Cittelly@ucdenver.edu		Cittelly, Diana/0000-0002-8392-0800	NCI [P30CA046934, K22CA181250]; CTSA Center grant [UL1TR001082]; DOD BCRP [W81XWH-11-1-0101]; ACS IRG [57-001-53]; NIH [R01 CA140985]; NATIONAL CANCER INSTITUTE [K08CA164048, P30CA046934, K22CA181250, R01CA140985, ZIABC010538] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA Center grant; DOD BCRP(United States Department of Defense); ACS IRG(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the University of Colorado Cancer Center Animal Imaging Shared Resources, Tissue Culture Core, Cytometry and Cell Sorting Shared Resource and Functional Genomics Facility supported by NCI P30CA046934 and CTSA UL1TR001082 Center grants. Susan Edgerton provided de-identified tissue. This work was supported by DOD BCRP W81XWH-11-1-0101 (DMC), ACS IRG # 57-001-53 (DMC) and NCI K22CA181250 (DMC). CAS was supported by NIH R01 CA140985.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Arnold S, 2005, NEUROBIOL DIS, V20, P82, DOI 10.1016/j.nbd.2005.02.002; Arnold S, 2012, J STEROID BIOCHEM, V131, P2, DOI 10.1016/j.jsbmb.2012.01.012; Azcoitia I, 2010, EUR J NEUROSCI, V32, P1995, DOI 10.1111/j.1460-9568.2010.07516.x; Barouk S, 2011, ENDOCRINOLOGY, V152, P1745, DOI 10.1210/en.2010-1290; BOOGERD W, 1993, J NEURO-ONCOL, V15, P165, DOI 10.1007/BF01053937; Braccini AL, 2013, BREAST, V22, P993, DOI 10.1016/j.breast.2013.05.011; Brufsky AM, 2011, CLIN CANCER RES, V17, P4834, DOI 10.1158/1078-0432.CCR-10-2962; Cheng X, 2007, CANCER METAST REV, V26, P635, DOI 10.1007/s10555-007-9083-x; Dahlmann M, 2012, ONCOTARGET, V3, P783, DOI 10.18632/oncotarget.572; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Evans AJ, 2004, CLIN ONCOL-UK, V16, P345, DOI 10.1016/j.clon.2004.03.012; Fidler IJ, 2011, SEMIN CANCER BIOL, V21, P107, DOI 10.1016/j.semcancer.2010.12.009; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Frey L, 2014, NEUROL RES, V36, P26, DOI 10.1179/1743132813Y.0000000269; Garcia-Ovejero D, 2002, J COMP NEUROL, V450, P256, DOI 10.1002/cne.10325; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; GARCIASEGURA LM, 1989, DEV BRAIN RES, V47, P298, DOI 10.1016/0165-3806(89)90186-7; Gril B, 2008, JNCI-J NATL CANCER I, V100, P1092, DOI 10.1093/jnci/djn216; Gril B, 2013, AM J PATHOL, V182, P2368, DOI 10.1016/j.ajpath.2013.02.043; Hicks DG, 2006, AM J SURG PATHOL, V30, P1097; Hung MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089389; Iyer V, 2012, CANCER RES, V72, P2705, DOI 10.1158/0008-5472.CAN-11-3287; Jenkinson SR, 2004, BRIT J CANCER, V90, P253, DOI 10.1038/sj.bjc.6601483; Kaal EC, 2005, LANCET NEUROL, V4, P289, DOI 10.1016/S1474-4422(05)70072-7; Kim SJ, 2011, NEOPLASIA, V13, P286, DOI 10.1593/neo.11112; Kodack DP, 2015, CANCER CELL, V27, P163, DOI 10.1016/j.ccell.2015.01.001; Lee E, 2012, GLIA, V60, P1024, DOI 10.1002/glia.22329; Lee SS, 2008, BREAST CANCER RES TR, V111, P523, DOI 10.1007/s10549-007-9806-2; LEE YTNM, 1983, J SURG ONCOL, V23, P175, DOI 10.1002/jso.2930230311; Lin NU, 2012, CANCER-AM CANCER SOC, V118, P5463, DOI 10.1002/cncr.27581; Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175; MA YJ, 1994, J NEUROSCI, V14, P5644; Montelli S, 2012, BRAIN RES, V1475, P11, DOI 10.1016/j.brainres.2012.08.010; Morissette M, 2008, J STEROID BIOCHEM, V108, P327, DOI 10.1016/j.jsbmb.2007.09.011; Neman J, 2013, CLIN EXP METASTAS, V30, P753, DOI 10.1007/s10585-013-9576-7; OSBORNE CK, 1985, CANCER RES, V45, P584; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Pequeux C, 2012, CANCER RES, V72, P3010, DOI 10.1158/0008-5472.CAN-11-3768; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Razmara A, 2008, J PHARMACOL EXP THER, V325, P782, DOI 10.1124/jpet.107.134072; Saleem M, 2006, P NATL ACAD SCI USA, V103, P14825, DOI 10.1073/pnas.0606747103; Stanczyk FZ, 2015, STEROIDS, V99, P91, DOI 10.1016/j.steroids.2014.12.011; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Tham YL, 2006, CANCER, V107, P696, DOI 10.1002/cncr.22041; TSUKADA Y, 1983, CANCER-AM CANCER SOC, V52, P2349, DOI 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Wang L, 2012, ACTA BIOCHIM POL, V59, P593; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080933; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Yague JG, 2006, NEUROSCIENCE, V138, P389, DOI 10.1016/j.neuroscience.2005.11.054; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486	54	46	47	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2881	2892		10.1038/onc.2015.353	http://dx.doi.org/10.1038/onc.2015.353			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26411365	Green Accepted			2022-12-28	WOS:000377473700008
J	Pieraccioli, M; Nicolai, S; Antonov, A; Somers, J; Malewicz, M; Melino, G; Raschella, G				Pieraccioli, M.; Nicolai, S.; Antonov, A.; Somers, J.; Malewicz, M.; Melino, G.; Raschella, G.			ZNF281 contributes to the DNA damage response by controlling the expression of XRCC2 and XRCC4	ONCOGENE			English	Article							C-MYC; REVEALS; SURVIVAL; GENES; IDENTIFICATION; ACTIVATION; NUCLEOLIN; NETWORK; BINDING; TOOL	ZNF281 is a zinc-finger factor involved in the control of cellular stemness and epithelial-mesenchymal transition (EMT). Here, we report that ZNF281 expression increased after genotoxic stress caused by DNA-damaging drugs. Comet assays demonstrated that DNA repair was delayed in cells silenced for the expression of ZNF281 and treated with etoposide. Furthermore, the expression of 10 DNA damage response genes was downregulated in cells treated with etoposide and silenced for ZNF281. In line with this finding, XRCC2 and XRCC4, two genes that take part in homologous recombination and non-homologous end joining, respectively, were transcriptionally activated by ZNF281 through a DNA-binding-dependent mechanism, as demonstrated by luciferase assays and Chromatin crosslinking ImmunoPrecipitation experiments. c-Myc, which also binds to the promoters of XRCC2 and XRCC4, was unable to promote their transcription or to modify ZNF281 activity. Of interest, bioinformatic analysis of 1971 breast cancer patients disclosed a significant correlation between the expression of ZNF281 and that of XRCC2. In summary, our data highlight, for the first time, the involvement of ZNF281 in the cellular response to genotoxic stress through the control exercised on the expression of genes that act in different repair mechanisms.	[Pieraccioli, M.; Nicolai, S.; Melino, G.; Raschella, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Antonov, A.; Somers, J.; Malewicz, M.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Raschella, G.] Italian Natl Agcy New Technol Energy & Sustainabl, Res Ctr Casaccia, Radiat Biol & Human Hlth Unit, Via Anguillarese 301, I-00123 Rome, Lazio, Italy	University of Rome Tor Vergata; University of Leicester; Italian National Agency New Technical Energy & Sustainable Economics Development	Melino, G; Raschella, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.; Raschella, G (corresponding author), Italian Natl Agcy New Technol Energy & Sustainabl, Res Ctr Casaccia, Radiat Biol & Human Hlth Unit, Via Anguillarese 301, I-00123 Rome, Lazio, Italy.	melino@uniroma2.it; giuseppe.raschella@enea.it	Pieraccioli, Marco/K-4294-2018	Pieraccioli, Marco/0000-0003-3995-535X	AIRC IG Grant [2014-IG15653]; AIRC 5xmille Grant [9979]; Fondazione Roma NCDs grant awarded; AIRC 5xmille Grant; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_UP_A600_1109, MC_U132670600] Funding Source: researchfish	AIRC IG Grant(Fondazione AIRC per la ricerca sul cancro); AIRC 5xmille Grant(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma NCDs grant awarded; AIRC 5xmille Grant(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by AIRC IG Grant (2014-IG15653), AIRC 5xmille Grant (2010-MCO no. 9979) and Fondazione Roma NCDs grant awarded to GM. SN was sponsored by a postdoctoral fellowship from AIRC 5xmille Grant. We thank Dr Eugenia Cordelli for assistance in the execution of Comet assays.	Adhikari D, 2014, MOL CELL ENDOCRINOL, V382, P480, DOI 10.1016/j.mce.2013.07.027; Amelio I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.9; Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Antonov AV, 2014, ONCOGENE, V33, P1621, DOI 10.1038/onc.2013.119; Antonov AV, 2013, CELL DEATH DIFFER, V20, P367, DOI 10.1038/cdd.2012.137; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Calabretta B, 1997, ANTI-CANCER DRUG DES, V12, P373; Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635; Chun J, 2013, MOL CELL BIOL, V33, P387, DOI 10.1128/MCB.00465-12; Cordelli E, 2012, ENVIRON MOL MUTAGEN, V53, P429, DOI 10.1002/em.21703; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Durut N, 2015, GENE, V556, P7, DOI 10.1016/j.gene.2014.09.023; Fidalgo M, 2012, P NATL ACAD SCI USA, V109, P16202, DOI 10.1073/pnas.1208533109; Fidalgo M, 2011, STEM CELLS, V29, P1705, DOI 10.1002/stem.736; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; John S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034252; Kakarougkas A, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130685; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; Law DJ, 1999, BIOCHEM BIOPH RES CO, V262, P113, DOI 10.1006/bbrc.1999.1180; Li ZZ, 2012, NEOPLASIA, V14, P1190, DOI 10.1593/neo.121258; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Luoto KR, 2010, CANCER RES, V70, P8748, DOI 10.1158/0008-5472.CAN-10-0944; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Murfuni I, 2013, ONCOGENE, V32, P610, DOI 10.1038/onc.2012.80; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15; Pieraccioli M, 2013, CELL CYCLE, V12, P2309, DOI 10.4161/cc.25405; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Sabatel H, 2011, BIOCHEM PHARMACOL, V82, P1371, DOI 10.1016/j.bcp.2011.07.105; Sabo A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014191; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Soucek L, 2002, CANCER CELL, V1, P406, DOI 10.1016/S1535-6108(02)00077-6; Wang F, 2013, CELL MOL LIFE SCI, V70, P3989, DOI 10.1007/s00018-012-1254-4; Yano K, 2008, CELL CYCLE, V7, P1321, DOI 10.4161/cc.7.10.5898; Yin XY, 2001, CANCER RES, V61, P6487	44	28	29	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2592	2601		10.1038/onc.2015.320	http://dx.doi.org/10.1038/onc.2015.320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26300006				2022-12-28	WOS:000376165700006
J	Qiao, Y; Lin, SJ; Chen, Y; Voon, DCC; Zhu, F; Chuang, LSH; Wang, T; Tan, P; Lee, SC; Yeoh, KG; Sudol, M; Ito, Y				Qiao, Y.; Lin, S. J.; Chen, Y.; Voon, D. C-C; Zhu, F.; Chuang, L. S. H.; Wang, T.; Tan, P.; Lee, S. C.; Yeoh, K. G.; Sudol, M.; Ito, Y.			RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR RUNX3; HIPPO PATHWAY; WW DOMAIN; PROMOTES METASTASIS; SIGNALING PATHWAY; EPITHELIAL-CELLS; BREAST-CANCER; SIZE-CONTROL; PROTEIN; GROWTH	Runt-related transcription factor 3 (RUNX3) is a well-documented tumour suppressor that is frequently inactivated in gastric cancer. Here, we define a novel mechanism by which RUNX3 exerts its tumour suppressor activity involving the TEAD-YAP complex, a potent positive regulator of proliferative genes. We report that the TEAD-YAP complex is not only frequently hyperactivated in liver and breast cancer, but also confers a strong oncogenic activity in gastric epithelial cells. The increased expression of TEAD-YAP in tumour tissues significantly correlates with poorer overall survival of gastric cancer patients. Strikingly, RUNX3 physically interacts with the N-terminal region of TEAD through its Runt domain. This interaction markedly reduces the DNA-binding ability of TEAD that attenuates the downstream signalling of TEAD-YAP complex. Mutation of RUNX3 at Arginine 122 to Cysteine, which was previously identified in gastric cancer, impairs the interaction between RUNX3 and TEAD. Our data reveal that RUNX3 acts as a tumour suppressor by negatively regulating the TEAD-YAP oncogenic complex in gastric carcinogenesis.	[Qiao, Y.; Chen, Y.; Voon, D. C-C; Chuang, L. S. H.; Wang, T.; Tan, P.; Lee, S. C.; Ito, Y.] Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr,12-01 Ctr Translat Med,MD6, Singapore 117599, Singapore; [Lin, S. J.; Tan, P.] Genome Inst Singapore, Canc Therapeut & Stratified Oncol, Singapore, Singapore; [Zhu, F.; Lee, S. C.] Natl Univ Hlth Syst, Natl Univ Canc Inst, Dept Haematol & Oncol, Singapore, Singapore; [Tan, P.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore; [Tan, P.] Natl Canc Ctr, Cellular & Mol Res, Singapore, Singapore; [Yeoh, K. G.; Sudol, M.] Natl Univ Singapore, NUS Yong Loo Lin Sch Med, Singapore 117599, Singapore; [Sudol, M.] Mechanobiol Inst MBI, Singapore, Singapore; [Sudol, M.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; National University of Singapore; National Cancer Centre Singapore (NCCS); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Ito, Y (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr,12-01 Ctr Translat Med,MD6, Singapore 117599, Singapore.	csiitoy@nus.edu.sg	Lee, Soo Chin/S-9111-2016	Lee, Soo Chin/0000-0002-5835-6419; Voon, Dominic Chih-Cheng/0000-0002-2963-9305	Singapore National Research Foundation under its Translational and Clinical Research Flagship Programme; Singapore Ministry of Health's National Medical Research Council [NMRC/TCR/001/2007, NMRC/TCR/009-NUHS/2013]; NUS-Medical School, MBI; IMCB A*STAR; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centres of Excellence initiative	Singapore National Research Foundation under its Translational and Clinical Research Flagship Programme(National Research Foundation, Singapore); Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore); NUS-Medical School, MBI; IMCB A*STAR; National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centres of Excellence initiative(Ministry of Education, Singapore)	This research is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative. The study was also supported by the Singapore National Research Foundation under its Translational and Clinical Research Flagship Programme and administered by the Singapore Ministry of Health's National Medical Research Council (Grants NMRC/TCR/001/2007 and NMRC/TCR/009-NUHS/2013). M Sudol was supported by seed grants from The NUS-Medical School, MBI and IMCB A*STAR. We are grateful to Professor Stefano Piccolo for providing us the 8xGTIIC-luciferase plasmid via Addgene. We also thank Professor Kunliang Guan for providing us myc-TEAD1 plasmid via Addgene. We acknowledge valuable comments on the manuscript from Dr Megan Finch-Edmondson.	Anbanandam A, 2006, P NATL ACAD SCI USA, V103, P17225, DOI 10.1073/pnas.0607171103; Avruch J, 2012, CELL CYCLE, V11, P1090, DOI 10.4161/cc.11.6.19453; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brusgard JL, 2015, ONCOTARGET IN PRESS; Chakraborty PK, 2014, CANCER RES, V74, P3489, DOI 10.1158/0008-5472.CAN-13-2708; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Cinghu S, 2012, J CELL PHYSIOL, V227, P1071, DOI 10.1002/jcp.22820; Dembele D, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-14; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Fan XY, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-92; Fukumoto Y, 2011, J BIOL CHEM, V286, P43537, DOI 10.1074/jbc.M111.308858; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jiang CG, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-122; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Karagiannis GS, 2012, ONCOTARGET, V3, P267, DOI 10.18632/oncotarget.451; Koh CP, 2013, LEUKEMIA, V27, P1793, DOI 10.1038/leu.2013.200; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Li H, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0539-5; Li P, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-52; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Lin YT, 2012, EXP CELL RES, V318, P1877, DOI 10.1016/j.yexcr.2012.05.005; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lochhead P, 2008, BRIT MED BULL, V85, P87, DOI 10.1093/bmb/ldn007; Min B, 2012, J CELL PHYSIOL, V227, P839, DOI 10.1002/jcp.22887; Oh YS, 2013, CELL, V152, P831, DOI 10.1016/j.cell.2013.01.014; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Rho SB, 2008, CANCER LETT, V271, P306, DOI 10.1016/j.canlet.2008.06.020; Shah MA, 2010, JAMA-J AM MED ASSOC, V303, P1753, DOI 10.1001/jama.2010.553; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; SUDOL M, 1994, ONCOGENE, V9, P2145; Tsang YH, 2010, ONCOGENE, V29, P5643, DOI 10.1038/onc.2010.304; Tsutsumi R, 2013, DEV CELL, V26, P658, DOI 10.1016/j.devcel.2013.08.013; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Voon DCC, 2012, STEM CELLS, V30, P2088, DOI 10.1002/stem.1183; Wang CQ, 2014, CELL REP, V8, P767, DOI 10.1016/j.celrep.2014.06.046; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamada C, 2010, J BIOL CHEM, V285, P16693, DOI 10.1074/jbc.M109.055525; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210	59	57	58	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2664	2674		10.1038/onc.2015.338	http://dx.doi.org/10.1038/onc.2015.338			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364597				2022-12-28	WOS:000376165700013
J	Hsu, PY; Hsu, HK; Hsiao, TH; Ye, Z; Wang, E; Profit, AL; Jatoi, I; Chen, Y; Kirma, NB; Jin, VX; Sharp, ZD; Huang, THM				Hsu, P-Y; Hsu, H-K; Hsiao, T-H; Ye, Z.; Wang, E.; Profit, A. L.; Jatoi, I.; Chen, Y.; Kirma, N. B.; Jin, V. X.; Sharp, Z. D.; Huang, T. H-M			Spatiotemporal control of estrogen-responsive transcription in ER alpha-positive breast cancer cells	ONCOGENE			English	Article							GENE-EXPRESSION; RECEPTOR-ALPHA; CERVICAL-CANCER; CHROMATIN; HETEROCHROMATIN; FACTORIES; BINDING; GROWTH; MECHANISMS; EVOLUTION	Recruitment of transcription machinery to target promoters for aberrant gene expression has been well studied, but underlying control directed by distant-acting enhancers remains unclear in cancer development. Our previous study demonstrated that distant estrogen response elements (DEREs) located on chromosome 20q13 are frequently amplified and translocated to other chromosomes in ER alpha-positive breast cancer cells. In this study, we used three-dimensional interphase fluorescence in situ hybridization to decipher spatiotemporal gathering of multiple DEREs in the nucleus. Upon estrogen stimulation, scattered 20q13 DEREs were mobilized to form regulatory depots for synchronized gene expression of target loci. A chromosome conformation capture assay coupled with chromatin immunoprecipitation further uncovered that ER alpha-bound regulatory depots are tethered to heterochromatin protein 1 (HP1) for coordinated chromatin movement and histone modifications of target loci, resulting in transcription repression. Neutralizing HP1 function dysregulated the formation of DERE-involved regulatory depots and transcription inactivation of candidate tumor-suppressor genes. Deletion of amplified DEREs using the CRISPR/Cas9 genomic-editing system profoundly altered transcriptional profiles of proliferation-associated signaling networks, resulting in reduction of cancer cell growth. These findings reveal a formerly uncharacterized feature wherein multiple copies of the amplicon congregate as transcriptional units in the nucleus for synchronous regulation of function-related loci in tumorigenesis. Disruption of their assembly can be a new strategy for treating breast cancers and other malignancies.	[Hsu, P-Y; Hsu, H-K; Ye, Z.; Kirma, N. B.; Jin, V. X.; Sharp, Z. D.; Huang, T. H-M] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, STRF 300-31,8403 Floyd Curl Dr, San Antonio, TX 78229 USA; [Hsiao, T-H; Chen, Y.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Hsiao, T-H; Profit, A. L.; Jatoi, I.; Chen, Y.; Sharp, Z. D.; Huang, T. H-M] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA; [Hsiao, T-H] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan; [Wang, E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Profit, A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Jatoi, I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA; [Chen, Y.; Jin, V. X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; Taichung Veterans General Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Huang, THM (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, STRF 300-31,8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	huangt3@uthscsa.edu			National Institutes of Health (NIH) [R01 CA069065, R01 ES017594, U01 ES015986, U54 CA113001]; NCI CCSG [P30 CA054174]; University of Texas System STARS award; UTHSCSA; NIH-NCI [P30 CA54174]; NATIONAL CANCER INSTITUTE [R01CA069065, P30CA054174, U54CA113001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES015986, R01ES017594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM114142] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI CCSG; University of Texas System STARS award; UTHSCSA; NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank staff at the Optical Imaging Facility of the Cancer Therapy and Research Center (CTRC) for technical assistance of FISH analyses. This work was supported by National Institutes of Health (NIH) grants (R01 CA069065, R01 ES017594, U01 ES015986, U54 CA113001; Integrative Cancer Biology Program) and NCI CCSG (P30 CA054174) and the University of Texas System STARS award and by generous gifts from the CTRC Foundation and the Voelcker Fund. Confocal images were generated in the Optical Imaging Core Facility, which is supported by UTHSCSA and NIH-NCI grant (P30 CA54174).	Beisel C, 2011, NAT REV GENET, V12, P123, DOI 10.1038/nrg2932; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Deng BW, 2013, SEMIN CANCER BIOL, V23, P65, DOI 10.1016/j.semcancer.2012.01.003; Fahrner JA, 2003, GENE DEV, V17, P1805, DOI 10.1101/gad.1123303; Feng XS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-633; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gaszner M, 2006, NAT REV GENET, V7, P703, DOI 10.1038/nrg1925; Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339; Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980; Harmston N, 2013, NUCLEIC ACIDS RES, V41, P7185, DOI 10.1093/nar/gkt499; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Hsu PY, 2013, CANCER CELL, V24, P197, DOI 10.1016/j.ccr.2013.07.007; Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; Kim J, 2004, GENOMICS, V84, P47, DOI 10.1016/j.ygeno.2004.02.007; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Ma DD, 2013, GYNECOL ONCOL, V131, P445, DOI 10.1016/j.ygyno.2013.07.113; Michell JA, 2008, GENE DEV, V22, P20; Misteli T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000794; Ong CT, 2012, EMBO REP, V13, P423, DOI 10.1038/embor.2012.52; Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192; Papantonis A, 2013, CHEM REV, V113, P8683, DOI 10.1021/cr300513p; Papantonis A, 2012, EMBO J, V31, P4404, DOI 10.1038/emboj.2012.288; Protty MB, 2009, BIOCHEM J, V417, P391, DOI 10.1042/BJ20081126; Qi JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098052; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Sciacovelli M, 2013, CELL METAB, V17, P988, DOI 10.1016/j.cmet.2013.04.019; Sharma RP, 2012, PHARMACOGENOMICS J, V12, P361, DOI 10.1038/tpj.2011.64; Sleeman JE, 2014, CURR OPIN CELL BIOL, V28, P76, DOI 10.1016/j.ceb.2014.03.004; Springuel L, 2014, BLOOD, V124, P3924, DOI 10.1182/blood-2014-05-576652; Sutherland H, 2009, NAT REV GENET, V10, P457, DOI 10.1038/nrg2592; Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Ulbricht T, 2012, J CELL BIOL, V199, P49, DOI 10.1083/jcb.201112015; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589; Yamada T, 1999, J BIOCHEM, V125, P832, DOI 10.1093/oxfordjournals.jbchem.a022356; Zhang CZ, 2013, GENE DEV, V27, P2513, DOI 10.1101/gad.229559.113; Zhang XP, 2007, CANCER RES, V67, P9425, DOI 10.1158/0008-5472.CAN-07-1310; Zhen S, 2014, BIOCHEM BIOPH RES CO, V450, P1422, DOI 10.1016/j.bbrc.2014.07.014	47	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2379	2389		10.1038/onc.2015.298	http://dx.doi.org/10.1038/onc.2015.298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26300005	Green Published, hybrid			2022-12-28	WOS:000376165000010
J	Yang, WH; Su, YH; Hsu, WH; Wang, CC; Arbiser, JL; Yang, MH				Yang, W-H; Su, Y-H; Hsu, W-H; Wang, C-C; Arbiser, J. L.; Yang, M-H			Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation	ONCOGENE			English	Article							TREATMENT STRATEGIES; TRANSCRIPTION; ACTIVATION; TRANSITION; PLASTICITY; CELLS; MECHANISMS; METASTASES; CARCINOMA; SNAIL	The unique characteristic of head and neck squamous cell carcinoma (HNSCC) is that local invasion rather than distant metastasis is the major route for dissemination. Therefore, targeting the locally invasive cancer cells is more important than preventing systemic metastasis in HNSCC and other invasive-predominant cancers. We previously demonstrate a specific mechanism for HNSCC local invasion: the epithelial-mesenchymal transition (EMT) regulator Twist1 represses microRNA let-7i expression, leading to the activation of the small GTPase Rac1 and engendering the mesenchymal-mode movement in three-dimensional (3D) culture. However, targeting the EMT regulator is relatively difficult because of its transcription factor nature and the strategy for confining HNSCC invasion to facilitate local treatment is limited. Imipramine blue (IB) is a newly identified anti-invasive compound that effectively inhibits glioma invasion. Here we demonstrate that in HNSCC cells, a noncytotoxic dose of IB represses mesenchymal-mode migration in two-and-a-half-dimensional/3D culture system. IB suppresses EMT and stemness of HNSCC cells through inhibition of Twist1-mediated let-7i downregulation and Rac1 activation and the EMT signalling. Mechanistically, IB inhibits reactive oxygen species-induced nuclear factor-kappa B pathway activation. Importantly, IB promotes degradation of the EMT inducer Twist1 by enhancing F-box and leucine-rich repeat protein 14 (FBXL14)-mediated polyubiquitination of Twist1. Together, this study demonstrates the potent anti-invasion and EMT-inhibition effect of IB, suggesting the potential of IB in treating local invasion-predominant cancers.	[Yang, W-H; Su, Y-H; Hsu, W-H; Yang, M-H] Natl Yang Ming Univ, Inst Clin Med, 155,Sec 2,Li Nong St, Taipei 11221, Taiwan; [Wang, C-C] Taichung Vet Gen Hosp, Dept Otolaryngol Head & Neck Surg, Taichung, Taiwan; [Wang, C-C] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Wang, C-C] Chung Shan Med Univ, Sch Speech Language Pathol & Audiol, Taichung 40201, Taiwan; [Arbiser, J. L.] Emory Sch Med, Dept Dermatol, Atlanta, GA USA; [Arbiser, J. L.] Atlanta Vet Adm Med Ctr, Atlanta, GA USA; [Yang, M-H] Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; [Yang, M-H] Natl Yang Ming Univ, Genome Res Ctr, Taipei 112, Taiwan; [Yang, M-H] Taipei Vet Gen Hosp, Div Hematol Oncol, Dept Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; Chung Shan Medical University; Emory University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Yang, MH (corresponding author), Natl Yang Ming Univ, Inst Clin Med, 155,Sec 2,Li Nong St, Taipei 11221, Taiwan.; Arbiser, JL (corresponding author), Emory Sch Med, Dept Dermatol, Atlanta, GA USA.; Arbiser, JL (corresponding author), Atlanta Vet Adm Med Ctr, Atlanta, GA USA.; Arbiser, JL (corresponding author), Winship Canc Inst, Dept Dermatol, Atlanta, GA USA.; Arbiser, JL (corresponding author), Emory Univ, Sch Med, Atlanta Vet Adm Hosp, WMB 5309,1639 Pierce Dr, Atlanta, GA 30322 USA.	jarbise@emory.edu; mhyang2@vghtpe.gov.tw	Yang, Muh-Hwa/AAE-4691-2020	Hsu, Wen-Hao/0000-0001-9050-8227; Su, Yen-Hao/0000-0001-8288-3772	Ministry of Science and Technology [103-2321-B-010-019, 103-2314-B-010-034, 103-2633-H-010-001, 103-2314-B-010-035]; Taipei Veterans General Hospital [V104-E8-001]; Ministry of Education, Aim for the Top University Plan; Ministry of Health and Welfare, Center of Excellence for Cancer Research [MOHW104-TDU-B-211-124-001]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047901] Funding Source: NIH RePORTER	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taipei Veterans General Hospital(Taipei Veterans General Hospital); Ministry of Education, Aim for the Top University Plan(Ministry of Education, Taiwan); Ministry of Health and Welfare, Center of Excellence for Cancer Research; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Professor Victor M Diaz (Universitat Pompeu Fabra, Barcelona, Spain) for the generous gifts of pcDNA3-myc-FBXL14 and pcDNA3-FBXL14 Delta F plasmids. We thank Professor Kuo-Wei Chang (National Yang-Ming University, Taiwan) for providing OECM-1 cell line. This work was supported by Ministry of Science and Technology (103-2321-B-010-019, 103-2314-B-010-034, 103-2633-H-010-001, and 103-2314-B-010-035 to M-HY), Taipei Veterans General Hospital (V104-E8-001 to M-HY), a grant from Ministry of Education, Aim for the Top University Plan (to M-HY) and a grant from the Ministry of Health and Welfare, Center of Excellence for Cancer Research (MOHW104-TDU-B-211-124-001 to M-HY).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Carlsson SK, 2014, EMBO MOL MED, V6, P1359, DOI 10.15252/emmm.201302627; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Di CH, 2010, ANTI-CANCER AGENT ME, V10, P543, DOI 10.2174/187152010793498618; Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015; Forastiere AA, 2013, J CLIN ONCOL, V31, P845, DOI 10.1200/JCO.2012.43.6097; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Garavello W, 2006, ARCH OTOLARYNGOL, V132, P762, DOI 10.1001/archotol.132.7.762; Ho MS, 2006, J BIOMED SCI, V13, P181, DOI 10.1007/s11373-005-9058-2; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI 10.1016/S1470-2045(10)70279-5; Madsen CD, 2010, DEV CELL, V19, P13, DOI 10.1016/j.devcel.2010.06.013; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Michael J Morgan, 2011, Cell Research, V21, P103; Munson JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003016; NEWTON HB, 1992, CANCER, V69, P2149, DOI 10.1002/1097-0142(19920415)69:8<2149::AID-CNCR2820690822>3.0.CO;2-G; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Pentenero M, 2005, HEAD NECK-J SCI SPEC, V27, P1080, DOI 10.1002/hed.20275; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sanz-Moreno V, 2010, CURR OPIN CELL BIOL, V22, P690, DOI 10.1016/j.ceb.2010.08.020; Slorach EM, 2011, GENE DEV, V25, P471, DOI 10.1101/gad.1998111; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang WH, 2013, BIOCHEM BIOPH RES CO, V433, P24, DOI 10.1016/j.bbrc.2013.02.076; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zhong JT, 2013, DISCOV MED, V15, P7	35	36	36	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2287	2298		10.1038/onc.2015.291	http://dx.doi.org/10.1038/onc.2015.291			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26257063	Green Accepted			2022-12-28	WOS:000376165000002
J	Ahn, JS; Li, J; Chen, E; Kent, DG; Park, HJ; Green, AR				Ahn, J. S.; Li, J.; Chen, E.; Kent, D. G.; Park, H. J.; Green, A. R.			JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; FORKHEAD TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM-CELLS; ABL-EXPRESSING CELLS; MYELOPROLIFERATIVE DISORDERS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; GENE-EXPRESSION; CANCER-CELLS; JAK2	The JAK2V617F mutation is found in most patients with a myeloproliferative neoplasm (MPN). This gain-of-function mutation dysregulates cytokine signaling and is associated with increased accumulation of DNA damage, a process likely to drive disease evolution. JAK2V617F inhibits NHE-1 upregulation in response to DNA damage and consequently represses Bcl-xL deamidation and apoptosis, thus giving rise to inappropriate cell survival. However, the mechanism whereby NHE-1 expression is inhibited by JAK2V617F is unknown. In this study, we demonstrate that the accumulation of reactive oxygen species (ROS) in cells expressing JAK2V617F compromises the NHE-1/Bcl-xL deamidation pathway by repressing NHE-1 upregulation in response to DNA damage. In JAK2V617F-positive cells, increased ROS levels results from aberrant PI3K signaling, which decreases nuclear localization of FOXO3A and decreases catalase expression. Furthermore, when compared with autologous control erythroblasts, clonally derived JAK2V617F-positive erythroblasts from MPN patients displayed increased ROS levels and reduced nuclear FOXO3A. However, in hematopoietic stem cells (HSCs), FOXO3A is largely localized within the nuclei despite the presence of JAK2V617F mutation, suggesting that JAK2-FOXO signaling has a different effect on progenitors compared with stem cells. Inactivation of FOXO proteins and elevation of intracellular ROS are characteristics common to many cancers, and hence these findings are likely to be of relevance beyond the MPN field.	[Ahn, J. S.; Li, J.; Chen, E.; Kent, D. G.; Park, H. J.; Green, A. R.] Univ Cambridge, Cambridge Inst Med Res, Cambridge, England; [Ahn, J. S.; Li, J.; Chen, E.; Kent, D. G.; Park, H. J.; Green, A. R.] Univ Cambridge, Wellcome Trust MRC Stem Cell Inst, Cambridge, England; [Ahn, J. S.; Li, J.; Chen, E.; Kent, D. G.; Park, H. J.; Green, A. R.] Univ Cambridge, Dept Haematol, Cambridge, England; [Green, A. R.] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 2QQ, England	University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Green, AR (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge CB2 0XY, England.	arg1000@cam.ac.uk	Kent, David/AAZ-4916-2021	Kent, David/0000-0001-7871-8811; Green, Anthony/0000-0002-9795-0218	Leukemia and Lymphoma Research, Cancer Research UK; Kay Kendall Leukaemia Fund; NIHR Cambridge Biomedical Research Centre; Cambridge Experimental Cancer Medicine Centre; Leukemia & Lymphoma Society of America; Canadian Institutes of Health Research (Ottawa, ON); Lady Tata Memorial Trust International Award for Research in Leukaemia (London, UK); Human Frontier Science Program; Cancer Research UK [12765] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10079] Funding Source: researchfish	Leukemia and Lymphoma Research, Cancer Research UK; Kay Kendall Leukaemia Fund; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Cambridge Experimental Cancer Medicine Centre; Leukemia & Lymphoma Society of America(Leukemia and Lymphoma Society); Canadian Institutes of Health Research (Ottawa, ON)(Canadian Institutes of Health Research (CIHR)); Lady Tata Memorial Trust International Award for Research in Leukaemia (London, UK); Human Frontier Science Program(Human Frontier Science Program); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We thank patients and staff of the Addenbrookes MPN clinic who have contributed samples to this study; Yvonne Silber for technical assistance; Philip Beer, Anna Godfrey, Christina Ortmann and Joanna Baxter (Translational Research Laboratory, University of Cambridge) for help with acquiring clinical samples; Peter Campbell (Sanger Institute) for helpful discussions; and Michael Murphy (MRC MBU) for supplying MitoQ. Work in the Green lab is supported by Leukemia and Lymphoma Research, Cancer Research UK, the Kay Kendall Leukaemia Fund, the NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre and the Leukemia & Lymphoma Society of America. DGK was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research (Ottawa, ON), and a Lady Tata Memorial Trust International Award for Research in Leukaemia (London, UK). HJP was supported by a postdoctoral fellowship from the Human Frontier Science Program.	Akram S, 2006, CELL DEATH DIFFER, V13, P628, DOI 10.1038/sj.cdd.4401775; Bakker WJ, 2007, MOL CELL BIOL, V27, P3839, DOI 10.1128/MCB.01662-06; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Chan DW, 2008, CARCINOGENESIS, V29, P1742, DOI 10.1093/carcin/bgn167; Chen E, 2014, P NATL ACAD SCI USA, V111, P15190, DOI 10.1073/pnas.1401873111; Chomel JC, 2011, BLOOD, V118, P3657, DOI 10.1182/blood-2011-02-335497; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Fernandes MS, 2009, BLOOD, V114, P1813, DOI 10.1182/blood-2008-07-172148; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gaetani GF, 1996, BLOOD, V87, P1595, DOI 10.1182/blood.V87.4.1595.bloodjournal8741595; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Imai Y, 2014, CELL REP, V7, P194, DOI 10.1016/j.celrep.2014.03.006; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jhumka Z, 2009, INT J BIOCHEM CELL B, V41, P945, DOI 10.1016/j.biocel.2008.09.028; Kagoya Y, 2014, BLOOD, V124, P2996, DOI 10.1182/blood-2014-04-570572; Kent DG, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001576; Kent DG, 2009, BLOOD, V113, P6342, DOI 10.1182/blood-2008-12-192054; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kumar AP, 2007, CELL DEATH DIFFER, V14, P1733, DOI 10.1038/sj.cdd.4402176; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levine RL, 2006, BLOOD, V107, P4139, DOI 10.1182/blood-2005-09-3900; Li J, 2014, BLOOD, V123, P3139, DOI 10.1182/blood-2013-06-510222; Li JA, 2010, BLOOD, V116, P1528, DOI 10.1182/blood-2009-12-259747; Lin B, 2014, SCI REP-UK, V4, DOI 10.1038/srep07041; Marty C, 2013, LEUKEMIA, V27, P2187, DOI 10.1038/leu.2013.102; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Miyamoto K, 2008, BLOOD, V112, P4485, DOI 10.1182/blood-2008-05-159848; Mullally A, 2010, CANCER CELL, V17, P584, DOI 10.1016/j.ccr.2010.05.015; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Naughton R, 2009, LEUKEMIA, V23, P1432, DOI 10.1038/leu.2009.49; Pellicano F, 2014, STEM CELLS, V32, P2324, DOI 10.1002/stem.1748; Plo I, 2008, BLOOD, V112, P1402, DOI 10.1182/blood-2008-01-134114; Pourova J, ACTA PHYSL OXF, V198, P15; Quentmeier H, 2006, LEUKEMIA, V20, P471, DOI 10.1038/sj.leu.2404081; Rakshit S, 2009, APOPTOSIS, V14, P298, DOI 10.1007/s10495-008-0305-7; Sedelnikova OA, 2010, MUTAT RES-REV MUTAT, V704, P152, DOI 10.1016/j.mrrev.2009.12.005; Sikora MJ, 2008, CANCER BIOL THER, V7, P767, DOI 10.4161/cbt.7.5.5767; Swerdlow SH, 2008, WHO CLASSIFICATION T; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tsai SY, 2007, CANCER SCI, V98, P1206, DOI 10.1111/j.1349-7006.2007.00513.x; Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709; Vainchenker W, 2011, BLOOD, V118, P1723, DOI 10.1182/blood-2011-02-292102; Weinberg F, P NATL ACAD SCI US, V107, P8788; Yalcin S, 2008, J BIOL CHEM, V283, P25692, DOI 10.1074/jbc.M800517200; Yalcin S, 2010, EMBO J, V29, P4118, DOI 10.1038/emboj.2010.292; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Zhao R, 2007, PLOS BIOL, V5, P39, DOI 10.1371/journal.pbio.0050001; Zhao R, 2008, NEW ENGL J MED, V359, P2778, DOI 10.1056/NEJMoa0804953	58	19	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2235	2246		10.1038/onc.2015.285	http://dx.doi.org/10.1038/onc.2015.285			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26234675	Green Accepted			2022-12-28	WOS:000374986000009
J	Napolitano, A; Pellegrini, L; Dey, A; Larson, D; Tanji, M; Flores, EG; Kendrick, B; Lapid, D; Powers, A; Kanodia, S; Pastorino, S; Pass, HI; Dixit, V; Yang, H; Carbone, M				Napolitano, A.; Pellegrini, L.; Dey, A.; Larson, D.; Tanji, M.; Flores, E. G.; Kendrick, B.; Lapid, D.; Powers, A.; Kanodia, S.; Pastorino, S.; Pass, H. I.; Dixit, V.; Yang, H.; Carbone, M.			Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; CROCIDOLITE ASBESTOS; UBIQUITIN HYDROLASE; DEUBIQUITINASE BAP1; MUTATIONS; CELLS; POLARIZATION; MECHANISMS; SUPPRESSOR; REGULATOR	Germline BAP1 mutations predispose to several cancers, in particular malignant mesothelioma. Mesothelioma is an aggressive malignancy generally associated with professional exposure to asbestos. However, to date, we found that none of the mesothelioma patients carrying germline BAP1 mutations were professionally exposed to asbestos. We hypothesized that germline BAP1 mutations might influence the asbestos-induced inflammatory response that is linked to asbestos carcinogenesis, thereby increasing the risk of developing mesothelioma after minimal exposure. Using a BAP1(+/-) mouse model, we found that, compared with their wild-type littermates, BAP1(+/-) mice exposed to low-dose asbestos fibers showed significant alterations of the peritoneal inflammatory response, including significantly higher levels of pro-tumorigenic alternatively polarized M2 macrophages, and lower levels of several chemokines and cytokines. Consistent with these data, BAP1(+/-) mice had a significantly higher incidence of mesothelioma after exposure to very low doses of asbestos, doses that rarely induced mesothelioma in wild-type mice. Our findings suggest that minimal exposure to carcinogenic fibers may significantly increase the risk of malignant mesothelioma in genetically predisposed individuals carrying germline BAP1 mutations, possibly via alterations of the inflammatory response.	[Napolitano, A.; Pellegrini, L.; Larson, D.; Tanji, M.; Flores, E. G.; Kendrick, B.; Lapid, D.; Powers, A.; Pastorino, S.; Yang, H.; Carbone, M.] Univ Hawaii Manoa, Ctr Canc, Univ Hawaii, Honolulu, HI 96822 USA; [Napolitano, A.] Univ Hawaii Manoa, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA; [Dey, A.; Dixit, V.] Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA; [Kanodia, S.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Kanodia, S.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Pass, H. I.] NYU, Dept Cardiothorac Surg, New York, NY USA	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; Roche Holding; Genentech; Cedars Sinai Medical Center; Cedars Sinai Medical Center; New York University	Carbone, M (corresponding author), Univ Hawaii, Ctr Canc, Canc Biol, 701 Ilalo St, Honolulu, HI 96813 USA.	mcarbone@cc.hawaii.edu	Napolitano, Andrea/I-3146-2019; Pellegrini, Laura/K-7940-2016; dixit, vishva m/A-4496-2012	Napolitano, Andrea/0000-0002-7509-1555; Pellegrini, Laura/0000-0002-8833-2987; dixit, vishva m/0000-0001-6983-0326; Pass, Harvey/0000-0003-3222-3471	National Institute of Health [R01CA106567, P01CA114047, P30CA071789, R01CA160715-0A]; DoD CDMRP PRMRP Career Development Award; V Foundation; UHCC Pathology Shared Resource [P30 CA071789]; Mesothelioma Applied Research Foundation; United-4A Cure; Hawaii Community Foundation; University of Hawaii Foundation; Honeywell International Inc.; NATIONAL CANCER INSTITUTE [P01CA114047, R01CA198138, P30CA016087, R01CA160715, P30CA071789, R01CA106567] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD CDMRP PRMRP Career Development Award; V Foundation; UHCC Pathology Shared Resource; Mesothelioma Applied Research Foundation; United-4A Cure; Hawaii Community Foundation; University of Hawaii Foundation; Honeywell International Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institute of Health (grant numbers R01CA106567, P01CA114047, P30CA071789 to MC and R01CA160715-0A to HY); the DoD CDMRP PRMRP Career Development Award to HY, and the V Foundation to MC and HY, the P30 CA071789 (UHCC Pathology Shared Resource); the Mesothelioma Applied Research Foundation to HY, the United-4A Cure, the Hawaii Community Foundation to HY, and the University of Hawaii Foundation, which received donations to support mesothelioma research from Honeywell International Inc., to MC.	Altomare DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018828; Baumann F, 2015, J THORAC ONCOL, V10, P731, DOI 10.1097/JTO.0000000000000506; Baumann F, 2015, CARCINOGENESIS, V36, P76, DOI 10.1093/carcin/bgu227; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Burt BM, 2011, CANCER-AM CANCER SOC, V117, P5234, DOI 10.1002/cncr.26143; Carbone M, 2013, NAT REV CANCER, V13, P153, DOI 10.1038/nrc3459; Carbone M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-179; Carbone M, 2012, CLIN CANCER RES, V18, P598, DOI 10.1158/1078-0432.CCR-11-2259; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Comertpay S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0301-3; Cornelissen R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106742; Cybulski C, 2014, INT J CANCER, V135, P1756, DOI 10.1002/ijc.28988; DAVIS MR, 1992, INT J CANCER, V52, P881, DOI 10.1002/ijc.2910520609; de Reynies A, 2014, CLIN CANCER RES, V20, P1323, DOI 10.1158/1078-0432.CCR-13-2429; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Guo GW, 2015, CANCER RES, V75, P264, DOI 10.1158/0008-5472.CAN-14-1008; Henley SJ, 2013, INT J OCCUP ENV HEAL, V19, P1, DOI 10.1179/2049396712Y.0000000016; Ismail IH, 2014, CANCER RES, V74, P4282, DOI 10.1158/0008-5472.CAN-13-3109; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Kroczynska B, 2006, P NATL ACAD SCI USA, V103, P14128, DOI 10.1073/pnas.0604544103; Lee HS, 2014, NAT COMMUN, V5, P5128; Lo Iacono M, 2015, J THORAC ONCOL, V10, P492, DOI 10.1097/JTO.0000000000000436; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Marsella JM, 1997, ENVIRON HEALTH PERSP, V105, P1069, DOI 10.2307/3433511; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Nasu M, 2015, J THORAC ONCOL, V10, P565, DOI 10.1097/JTO.0000000000000471; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Occupational Safety & Health Administration, 2014, OSHA FACTSHEET ASB; Pantano F, 2013, J CELL MOL MED, V17, P1415, DOI 10.1111/jcmm.12109; Qi F, 2013, AM J PATHOL, V183, P1654, DOI 10.1016/j.ajpath.2013.07.029; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; SEBASTIEN P, 1982, SCIENCE, V216, P1410, DOI 10.1126/science.6283630; Simeonova PP, 1997, J IMMUNOL, V159, P3921; Tanaka S, 2000, EXP LUNG RES, V26, P241; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Xu JF, 2014, CANCER RES, V74, P4388, DOI 10.1158/0008-5472.CAN-14-1328; Yoshikawa Y, 2012, CANCER SCI, V103, P868, DOI 10.1111/j.1349-7006.2012.02223.x; Yu H, 2014, P NATL ACAD SCI USA, V111, P285, DOI 10.1073/pnas.1309085110; Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10; Zarrizi R, 2014, CANCER RES, V74, P6499, DOI 10.1158/0008-5472.CAN-14-0221; Zauderer MG, 2013, J THORAC ONCOL, V8, P1430, DOI 10.1097/JTO.0b013e31829e7ef9; Zhang MY, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-19	45	105	106	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1996	2002		10.1038/onc.2015.243	http://dx.doi.org/10.1038/onc.2015.243			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26119930	Green Accepted			2022-12-28	WOS:000374010300012
J	O'Leary, L; van der Sloot, AM; Reis, CR; Deegan, S; Ryan, AE; Dhami, SPS; Murillo, LS; Cool, RH; de Sampaio, PC; Thompson, K; Murphy, G; Quax, WJ; Serrano, L; Samali, A; Szegezdi, E				O'Leary, L.; van der Sloot, A. M.; Reis, C. R.; Deegan, S.; Ryan, A. E.; Dhami, S. P. S.; Murillo, L. S.; Cool, R. H.; de Sampaio, P. Correa; Thompson, K.; Murphy, G.; Quax, W. J.; Serrano, L.; Samali, A.; Szegezdi, E.			Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity	ONCOGENE			English	Article							INDUCED APOPTOSIS; DEATH; EXPRESSION; SIGNALS; FADD	Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a death ligand cytokine known for its cytotoxic activity against malignantly transformed cells. TRAIL induces cell death through binding to death receptors DR4 and DR5. The inhibitory decoy receptors (DcR1 and DcR2) co-expressed with death receptor 4 (DR4)/DR5 on the same cell can block the transmission of the apoptotic signal. Here, we show that DcRs also regulate TRAIL sensitivity at a supracellular level and thus represent a mechanism by which the microenvironment can diminish tumour TRAIL sensitivity. Mathematical modelling and layered or spheroid stroma-extracellular matrix-tumour cultures were used to model the tumour microenvironment. By engineering TRAIL to escape binding by DcRs, we found that DcRs do not only act in a cell-autonomous or cis-regulatory manner, but also exert trans-cellular regulation originating from stromal cells and affect tumour cells, highlighting the potent inhibitory effect of DcRs in the tumour tissue and the necessity of selective targeting of the two death-inducing TRAIL receptors to maximise efficacy.	[O'Leary, L.; Deegan, S.; Dhami, S. P. S.; Samali, A.; Szegezdi, E.] Natl Univ Ireland, Apoptosis Res Ctr, Galway, Ireland; [van der Sloot, A. M.; Serrano, L.] CRG, EMBL CRG Syst Biol Res Unit, Barcelona, Spain; [van der Sloot, A. M.] Univ Montreal, Inst Res Immunol & Canc, 2950 Chemin Polytech Pavillon Marcelle Coutu, Montreal, PQ, Canada; [Reis, C. R.; Cool, R. H.; Quax, W. J.] Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands; [Ryan, A. E.] Natl Univ Ireland, Sch Med, Discipline Pharmacol & Therapeut, Galway, Ireland; [Murillo, L. S.] Natl Univ Ireland, Natl Ctr Biomed Engn Sci, Galway, Ireland; [de Sampaio, P. Correa; Murphy, G.] Univ Cambridge, Canc Res UK Cambridge Res Inst, Dept Oncol, Li Ka Shing Ctr, Cambridge, England; [Thompson, K.] Natl Univ Ireland, Ctr Microscopy & Imaging, Galway, Ireland; [O'Leary, L.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England; [Reis, C. R.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [de Sampaio, P. Correa] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Metastasis Res Ctr, Houston, TX 77030 USA	Ollscoil na Gaillimhe-University of Galway; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Universite de Montreal; University of Groningen; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Ollscoil na Gaillimhe-University of Galway; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center	Samali, A; Szegezdi, E (corresponding author), Natl Univ Ireland, Apoptosis Res Ctr, Discipline Biochem, Univ Rd, Galway, Ireland.	afshin.samali@nuigalway.ie; eva.szegezdi@nuigalway.ie	Dhami, Sukhraj Pal Singh/AFP-2634-2022; Samali, Afshin/A-9571-2008; Szegezdi, Eva/B-7142-2008; Serrano, Luis/B-3355-2013; Quax, Wim/K-2802-2012; Ryan, Aideen/H-3909-2019; Deegan, Shane/P-4793-2017; Quax, Wim/O-2875-2019; van der Sloot, Almer/M-7083-2015	Dhami, Sukhraj Pal Singh/0000-0003-1326-9845; Samali, Afshin/0000-0002-8610-8375; Szegezdi, Eva/0000-0002-5708-3535; Serrano, Luis/0000-0002-5276-1392; Quax, Wim/0000-0002-5162-9947; Ryan, Aideen/0000-0002-5831-6783; Deegan, Shane/0000-0001-8824-9617; Quax, Wim/0000-0002-5162-9947; Correa de Sampaio, Pedro/0000-0001-5597-2825; Thompson, Kerry/0000-0003-2721-8977; van der Sloot, Almer/0000-0003-0049-2044; Cool, Robbert/0000-0002-9845-2202	Enterprise Ireland; National Development Plan of Ireland; Commercialisation Fund [CFTD/06/112]; SFI SIRG award [09/SIRG/B1575]; NUIG	Enterprise Ireland; National Development Plan of Ireland; Commercialisation Fund; SFI SIRG award; NUIG	Financial Support: The project was funded by Enterprise Ireland, National Development Plan of Ireland, Commercialisation Fund to AS and ES (CFTD/06/112), SFI SIRG award to ES (09/SIRG/B1575) and Millennium Grant to ES from the NUIG.	Allen JE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004828; Ander M., 2004, Systems Biology, V1, P129, DOI 10.1049/sb:20045017; Anees M, 2011, CANCER-AM CANCER SOC, V117, P1172, DOI 10.1002/cncr.25504; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boland K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.250; Chamuleau MED, 2011, LEUKEMIA RES, V35, P741, DOI 10.1016/j.leukres.2010.12.032; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Cullen SP, 2013, MOL CELL, V49, P1034, DOI 10.1016/j.molcel.2013.01.025; de Sampaio PC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030753; Dublanche Y, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100081; Dyer MJS, 2007, J CLIN ONCOL, V25, P4505, DOI 10.1200/JCO.2007.13.1011; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Finnberg N, 2008, J CLIN INVEST, V118, P111, DOI 10.1172/JCI29900; Furth PA, 1997, APOPTOSIS, V2, P19, DOI 10.1023/A:1026454207398; Ganten TM, 2009, J MOL MED, V87, P995, DOI 10.1007/s00109-009-0510-z; Ivanov VN, 2014, APOPTOSIS, V19, P399, DOI 10.1007/s10495-013-0925-4; Kim KL, 2005, AM J RESP CELL MOL, V33, P541, DOI 10.1165/rcmb.2004-0355OC; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Koksal IT, 2008, UROL ONCOL-SEMIN ORI, V26, P158, DOI 10.1016/j.urolonc.2007.01.022; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Luce A, 2009, CARCINOGENESIS, V30, P432, DOI 10.1093/carcin/bgp008; Mahalingam D, 2010, BRIT J CANCER, V102, P754, DOI 10.1038/sj.bjc.6605545; Mahalingam D, 2009, CANCER TREAT REV, V35, P280, DOI 10.1016/j.ctrv.2008.11.006; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Milo R, 2010, NUCLEIC ACIDS RES, V38, pD750, DOI 10.1093/nar/gkp889; Perez-Garijo A, 2013, ELIFE, V2, DOI 10.7554/eLife.01004; Reis CR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.61; Riccioni R, 2005, HAEMATOLOGICA, V90, P612; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Sanlioglu AD, 2007, INT J RADIAT ONCOL, V69, P716, DOI 10.1016/j.ijrobp.2007.03.057; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387; Shareef MM, 2007, CANCER RES, V67, P11811, DOI 10.1158/0008-5472.CAN-07-0722; Shirley S, 2011, RECENT PAT ANTI-CANC, V6, P311, DOI 10.2174/157489211796957757; Szegezdi E, 2012, MOL CELL PROTEOMICS, P11; Szegezdi E, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013730; Szegezdi E, 2011, J CELL MOL MED, V15, P2216, DOI 10.1111/j.1582-4934.2010.01211.x; Tur V, 2008, J BIOL CHEM, V283, P20560, DOI 10.1074/jbc.M800457200; Van der Sloot AM, 2006, P NATL ACAD SCI USA, V103, P8634, DOI 10.1073/pnas.0510187103; van Dijk M, 2013, CELL DEATH DIS, P4; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; Wilson NS, 2012, CANCER CELL, V22, P80, DOI 10.1016/j.ccr.2012.05.014; Wu GS, 1999, CANCER RES, V59, P2770; Zhang XD, 1999, CANCER RES, V59, P2747	46	46	48	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1261	1270		10.1038/onc.2015.180	http://dx.doi.org/10.1038/onc.2015.180			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26050621	Green Published			2022-12-28	WOS:000371763100006
J	Peng, C; Zeng, W; Su, J; Kuang, Y; He, Y; Zhao, S; Zhang, J; Ma, W; Bode, AM; Dong, Z; Chen, X				Peng, C.; Zeng, W.; Su, J.; Kuang, Y.; He, Y.; Zhao, S.; Zhang, J.; Ma, W.; Bode, A. M.; Dong, Z.; Chen, X.			Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway	ONCOGENE			English	Article							TERNARY COMPLEX FACTOR; C-FOS PROMOTER; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; PROSTATE-CANCER; FACTOR SAP-1A; INHIBITION; RB; DNA	Cyclin-dependent kinase 2 (CDK2) is a known regulator in the cell cycle control of the G1/S and S/G2 transitions. However, the role of CDK2 in tumorigenesis is controversial. Evidence from knockout mice as well as colon cancer cell lines indicated that CDK2 is dispensable for cell proliferation. In this study, we found that ectopic CDK2 enhances Ras (G12V)-induced foci formation and knocking down CDK2 expression markedly decreases epidermal growth factor (EGF)-induced cell transformation mediated through the downregulation of c-fos expression. Interestingly, CDK2 directly phosphorylates ELK4 at Thr194 and Ser387 and regulates the ELK4 transcriptional activity, which serves as a mechanism to regulate c-fos expression. In addition, ELK4 is overexpressed in melanoma and knocking down the ELK4 or CDK2 expression significantly attenuated the malignant phenotype of melanoma cells. Taken together, our study reveals a novel function of CDK2 in EGF-induced cell transformation and the associated signal transduction pathways. This indicates that CDK2 is a useful molecular target for the chemoprevention and therapy against skin cancer.	[Peng, C.; Ma, W.; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Peng, C.; Zeng, W.; Su, J.; Kuang, Y.; He, Y.; Zhao, S.; Zhang, J.; Chen, X.] Cent S Univ, Xiangya Hosp, Dept Dermatol, Xiangya Rd 87, Changsha 410008, Hunan, Peoples R China	University of Minnesota System; Central South University	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Chen, X (corresponding author), Cent S Univ, Xiangya Hosp, Dept Dermatol, Xiangya Rd 87, Changsha 410008, Hunan, Peoples R China.	zgdong@hi.umn.edu; chenxiangck@gmail.com		Zhao, Shuang/0000-0001-7081-6177; Jianglin, Zhang/0000-0003-0434-1729	Hormel Foundation; National Institutes of Health in China [CA172457, CA1669011, CA827502, R37, CA081064, 81225013, 81430075, 2015JJ2161]; NATIONAL CANCER INSTITUTE [R01CA166011, P01CA027502, R21CA172457, R37CA081064] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health in China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Hormel Foundation and National Institutes of Health grants ZD: CA172457, CA1669011, CA827502, R37, CA081064 and by grant no. 81225013, 81430075, 2015JJ2161 in China.	Akiyama T, 1997, CANCER RES, V57, P1495; Ayadi A, 2001, MECH DEVELOP, V102, P205, DOI 10.1016/S0925-4773(01)00289-1; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Calbo J, 2004, CELL DEATH DIFFER, V11, P1055, DOI 10.1038/sj.cdd.4401481; Cen L, 2012, NEURO-ONCOLOGY, V14, P870, DOI 10.1093/neuonc/nos114; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x; Gebhardt C, 2005, AM J PATHOL, V167, P243, DOI 10.1016/S0002-9440(10)62969-0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Guinea-Viniegra J, 2012, J CLIN INVEST, V122, P2898, DOI 10.1172/JCI63103; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hjortoe GM, 2005, DNA CELL BIOL, V24, P35, DOI 10.1089/dna.2005.24.35; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Kumar-Sinha C, 2012, CANCER DISCOV, V2, P582, DOI 10.1158/2159-8290.CD-12-0212; Li J, 2003, J BIOL CHEM, V278, P13183, DOI 10.1074/jbc.M300269200; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; Rickman DS, 2009, CANCER RES, V69, P2734, DOI 10.1158/0008-5472.CAN-08-4926; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SKOUV J, 1986, CARCINOGENESIS, V7, P331, DOI 10.1093/carcin/7.2.331; Takahashi S., 1994, Journal of Dermatological Science, V7, P54, DOI 10.1016/0923-1811(94)90022-1; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vanden Bush T.J., 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019468; Volm M, 1997, INT J CANCER, V74, P508, DOI 10.1002/(SICI)1097-0215(19971021)74:5<508::AID-IJC5>3.0.CO;2-7; Wallace M, 2004, MOL CELL BIOL, V24, P5606, DOI 10.1128/MCB.24.12.5606-5619.2004; WU WS, 1992, ONCOGENE, V7, P2287; Zheng D, 2008, CANCER RES, V68, P7650, DOI 10.1158/0008-5472.CAN-08-1137; Zhou Y, 1999, J BIOL REG HOMEOS AG, V13, P207	45	33	35	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1170	1179		10.1038/onc.2015.175	http://dx.doi.org/10.1038/onc.2015.175			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26028036	Green Accepted			2022-12-28	WOS:000371351700011
J	Tanas, MR; Ma, S; Jadaan, FO; Ng, CKY; Weigelt, B; Reis-Filho, JS; Rubin, BP				Tanas, M. R.; Ma, S.; Jadaan, F. O.; Ng, C. K. Y.; Weigelt, B.; Reis-Filho, J. S.; Rubin, B. P.			Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein	ONCOGENE			English	Article							PROMOTES APOPTOSIS; CELL-PROLIFERATION; HIPPO PATHWAY; CAMTA1; GROWTH; DROSOPHILA; TAZ; ENCODES; PROTEIN; KINASE	The WWTR1 (protein is known as TAZ)-CAMTA1 (WC) fusion gene defines epithelioid hemangioendothelioma, a malignant vascular cancer. TAZ (transcriptional coactivator with PDZ binding motif) is a transcriptional coactivator and end effector of the Hippo tumor suppressor pathway. It is inhibited by phosphorylation by the Hippo kinases LATS1 and LATS2. Such phosphorylation causes cytoplasmic localization, 14-3-3 protein binding and the phorphorylation of a terminal phosphodegron promotes ubiquitin-dependent degradation (the phosphorylation of the different motifs has several effects). CAMTA1 is a putative tumor suppressive transcription factor. Here we demonstrate that TAZ-CAMTA1 (TC) fusion results in its nuclear localization and constitutive activation. Consequently, cells expressing TC display a TAZ-like transcriptional program that causes resistance to anoikis and oncogenic transformation. Our findings elucidate the mechanistic basis of TC oncogenic properties, highlight that TC is an important model to understand how the Hippo pathway can be inhibited in cancer, and provide approaches for targeting this chimeric protein.	[Tanas, M. R.; Ma, S.; Jadaan, F. O.; Rubin, B. P.] Cleveland Clin, Lerner Res Inst, Dept Mol Genet, NE2,9500 Euclid Ave, Cleveland, OH 44195 USA; [Tanas, M. R.; Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Robert J Tomsich Pathol Inst, Lerner Res Inst, Cleveland, OH 44195 USA; [Ng, C. K. Y.; Weigelt, B.; Reis-Filho, J. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Memorial Sloan Kettering Cancer Center	Rubin, BP (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Mol Genet, NE2,9500 Euclid Ave, Cleveland, OH 44195 USA.	rubinb2@ccf.org	Ng, Charlotte K Y/AAY-3178-2021; Ng, Charlotte K Y/AAA-1670-2020	Ng, Charlotte K Y/0000-0002-6100-0026; Tanas, Munir/0000-0002-6779-2642	National Cancer Institute of the National Institutes of Health [U54CA168512]; Liddy Shriver Sarcoma Initiative; Center for Research and Analysis of Vascular Tumors (CRAVAT); Friends of EHE research; NATIONAL CANCER INSTITUTE [P30CA008748, U54CA168512] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Liddy Shriver Sarcoma Initiative; Center for Research and Analysis of Vascular Tumors (CRAVAT); Friends of EHE research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U54CA168512 to BR. This work was also supported by grants from the Liddy Shriver Sarcoma Initiative, the Center for Research and Analysis of Vascular Tumors (CRAVAT), and the Friends of EHE research to BR.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Finkler A, 2007, FEBS LETT, V581, P3893, DOI 10.1016/j.febslet.2007.07.051; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Henrich KO, 2012, CANCER RES, V72, P6079, DOI 10.1158/0008-5472.CAN-12-2230; Henrich KO, 2011, CANCER RES, V71, P3142, DOI 10.1158/0008-5472.CAN-10-3014; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036; Huentelman MJ, 2007, HUM MOL GENET, V16, P1469, DOI 10.1093/hmg/ddm097; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma S, 2014, LAB INVEST, V94, P430, DOI 10.1038/labinvest.2014.13; Mendlick MR, 2001, AM J SURG PATHOL, V25, P684, DOI 10.1097/00000478-200105000-00019; Miller LA, 2011, PSYCHOGERIATRICS, V11, P135, DOI 10.1111/j.1479-8301.2011.00357.x; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nguyen BA, 2009, BMC BIOINFORMATICS, V10, P202, DOI [10.1186/1471-2105-10-202, DOI 10.1186/1471-2105-10-202]; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Pandey N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-216; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Schraivogel D, 2011, EMBO J, V30, P4309, DOI 10.1038/emboj.2011.301; Song K, 2006, CELL, V125, P453, DOI 10.1016/j.cell.2006.02.048; Tanas MR, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002409; Taylor BS, 2011, NAT REV CANCER, V11, P541, DOI 10.1038/nrc3087; Thevenon J, 2012, J MED GENET, V49, P400, DOI 10.1136/jmedgenet-2012-100856; Tremblay AM, 2014, CANCER CELL, V26, P273, DOI 10.1016/j.ccr.2014.05.029; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111	46	56	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					929	938		10.1038/onc.2015.148	http://dx.doi.org/10.1038/onc.2015.148			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961935	Green Accepted			2022-12-28	WOS:000370332200013
J	Shvab, A; Haase, G; Ben-Shmuel, A; Gavert, N; Brabletz, T; Dedhar, S; Ben-Ze'ev, A				Shvab, A.; Haase, G.; Ben-Shmuel, A.; Gavert, N.; Brabletz, T.; Dedhar, S.; Ben-Ze'ev, A.			Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression	ONCOGENE			English	Article							INTEGRIN-LINKED KINASE; COLORECTAL-CANCER; EXPRESSION; METASTASIS; DISEASE; TARGET; L1; OVEREXPRESSION; TUMORIGENESIS; PROTEINS	Overactivation of Wnt-beta-catenin signaling, including beta-catenin-TCF target gene expression, is a hallmark of colorectal cancer (CRC) development. We identified the immunoglobulin family of cell-adhesion receptors member L1 as a beta-catenin-TCF target gene preferentially expressed at the invasive edge of human CRC tissue. L1 can confer enhanced motility and liver metastasis when expressed in CRC cells. This ability of L1-mediated metastasis is exerted by a mechanism involving ezrin and the activation of NF-kappa B target genes. In this study, we identified the secreted modular calcium-binding matricellular protein-2 (SMOC-2) as a gene activated by L1-ezrin-NF-kappa B signaling. SMOC-2 is also known as an intestinal stem cell signature gene in mice expressing Lgr5 in cells at the bottom of intestinal crypts. The induction of SMOC-2 expression in L1-expressing CRC cells was necessary for the increase in cell motility, proliferation under stress and liver metastasis conferred by L1. SMOC-2 expression induced a more mesenchymal like phenotype in CRC cells, a decrease in E-cadherin and an increase in Snail by signaling that involves integrin-linked kinase (ILK). SMOC-2 was localized at the bottom of normal human colonic crypts and at increased levels in CRC tissue with preferential expression in invasive areas of the tumor. We found an increase in Lgr5 levels in CRC cells overexpressing L1, p65 or SMOC-2, suggesting that L1-mediated CRC progression involves the acquisition of a stem cell-like phenotype, and that SMOC-2 elevation is necessary for L1-mediated induction of more aggressive/invasive CRC properties.	[Shvab, A.; Haase, G.; Ben-Shmuel, A.; Gavert, N.; Ben-Ze'ev, A.] Weizmann Inst Sci, Dept Mol & Cell Biol, 234 Hertzl St, IL-76100 Rehovot, Israel; [Brabletz, T.] Univ Erlangen Nuernberg, Dept Expt Med 1, Erlangen, Germany; [Dedhar, S.] British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada	Weizmann Institute of Science; University of Erlangen Nuremberg; British Columbia Cancer Agency	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol & Cell Biol, 234 Hertzl St, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		Gavert, Nancy/0000-0003-1639-4684; Dedhar, Shoukat/0000-0003-4355-1657; ben-ze'ev, avri/0000-0001-6113-3921	Israel Cancer Research Fund (ICRF); Israel Science Foundation (ISF)	Israel Cancer Research Fund (ICRF); Israel Science Foundation (ISF)(Israel Science Foundation)	We thank Drs C Vaziri, U Hartmann, B Lenarcic, S Milano, R Cerione and P McDonald for reagents. This study was supported by grants from the Israel Cancer Research Fund (ICRF) and from the Israel Science Foundation (ISF).	Ben-Shmuel A, 2013, ONCOGENE, V32, P3220, DOI 10.1038/onc.2012.340; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gavert N, 2013, CANCER RES, V73, P5754, DOI 10.1158/0008-5472.CAN-13-0576; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Gavert N, 2010, J CELL SCI, V123, P2134, DOI 10.1242/jcs.069542; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Liu PJ, 2008, MOL BIOL CELL, V19, P248, DOI 10.1091/mbc.E07-05-0510; Liu P, 2009, GENE, V433, P72, DOI 10.1016/j.gene.2008.12.010; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Milano SK, 2012, J BIOL CHEM, V287, P24955, DOI 10.1074/jbc.M111.306514; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Novinec M, 2008, PROTEIN EXPRES PURIF, V62, P75, DOI 10.1016/j.pep.2008.07.009; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Rocnik EF, 2006, J BIOL CHEM, V281, P22855, DOI 10.1074/jbc.M513463200; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Serrano I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3976; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Simons BD, 2011, EXP CELL RES, V317, P2719, DOI 10.1016/j.yexcr.2011.07.010; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x; Vannahme C, 2003, BIOCHEM J, V373, P805, DOI 10.1042/BJ20030532; Yan ZP, 2014, ACTA HISTOCHEM, V116, P527, DOI 10.1016/j.acthis.2013.11.001	30	38	39	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					549	557		10.1038/onc.2015.127	http://dx.doi.org/10.1038/onc.2015.127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915847				2022-12-28	WOS:000369548800002
J	Zhou, R; Curry, JM; Roy, LD; Grover, P; Haider, J; Moore, LJ; Wu, ST; Kamesh, A; Yazdanifar, M; Ahrens, WA; Leung, T; Mukherjee, P				Zhou, R.; Curry, J. M.; Roy, L. D.; Grover, P.; Haider, J.; Moore, L. J.; Wu, S-t; Kamesh, A.; Yazdanifar, M.; Ahrens, W. A.; Leung, T.; Mukherjee, P.			A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ADVANCED SOLID TUMORS; CANCER STEM-CELLS; TYROSINE KINASE; FACTOR RECEPTOR; IN-VITRO; EXPRESSION; PROGRESSION; MICE; TRANSDUCTION	We report that Mucin1 (MUC1), a transmembrane glycoprotein that is overexpressed in >80% of pancreatic ductal adenocarcinoma (PDA), induced a pro-angiogenic tumor microenvironment by increasing the levels of neuropilin-1 (NRP1, a co-receptor of vascular endothelial growth factor (VEGF)) and its ligand VEGF. Expression of tumor-associated MUC1 (tMUC1) positively correlated with NRP1 levels in human and mouse PDA. Further, tMUC1(hi) PDA cells secreted high levels of VEGF and expressed high levels of VEGF receptor 2 (VEGFR2) and its phosphorylated forms as compared with tMUC1(low/null) PDA. This enabled the tMUC1(hi)/NRP1(hi) PDA cells to (a) induce endothelial cell tube formation, (b) generate long ectopic blood vessels and (c) enhance distant metastasis in a zebrafish xenograft model. Concurrently, the proteins associated with epithelial-to-mesenchymal transition, N-cadherin and Vimentin, were highly induced in these tMUC1/NRP1(hi) PDA cells. Hence, blocking signaling via the NRP1-VEGF axis significantly reduced tube formation, new vessel generation and metastasis induced by tMUC1(hi) PDA cells. Finally, we show that blocking the interaction between VEGF(165) and NRP1 with a NRP1 antagonist significantly reduced VEGFR signaling and PDA tumor growth in vivo. Taken together, our data suggest a novel molecular mechanism by which tMUC1 may modulate NRP1-dependent VEGFR signaling in PDA cells.	[Zhou, R.; Curry, J. M.; Roy, L. D.; Grover, P.; Moore, L. J.; Wu, S-t; Kamesh, A.; Yazdanifar, M.; Mukherjee, P.] Univ N Carolina, Dept Biol Sci, 9201 Univ City Blvd, Charlotte, NC 28223 USA; [Haider, J.; Leung, T.] North Carolina Cent Univ, Julius L Chambers Biomed Biotechnol Res Inst, Kannapolis, NC USA; [Ahrens, W. A.] Carolinas Med Ctr, Dept Surg, Sect Hepatobiliary & Pancreas Surg, Charlotte, NC 28203 USA	University of North Carolina; University of North Carolina Charlotte; University of North Carolina; North Carolina Central University; Carolinas Medical Center	Mukherjee, P (corresponding author), Univ N Carolina, Dept Biol Sci, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	pmukherj@uncc.edu			NIH [CA118944-01A1, CA173668-01]; Office of the Assistant Secretary of Defense for Health Affairs through the Pancreatic Cancer Research Program [W81XWH-12-1-0220]; NATIONAL CANCER INSTITUTE [R15CA173668, R03CA110832, R01CA118944] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Assistant Secretary of Defense for Health Affairs through the Pancreatic Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH CA118944-01A1 and NIH CA173668-01. This work was also supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Pancreatic Cancer Research Program under Award No. W81XWH-12-1-0220. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. We thank Dr Tim D Eubank (Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA) for the valuable support with angiogenesis study. We thank Dr Lloye Dillon (OncoTAB, Inc., Charlotte, NC, USA) for the critical review of the manuscript. We thank all the technicians in the animal facility for their assistance in maintaining our colonies.	Adham SAI, 2014, J HISTOCHEM CYTOCHEM, V62, P619, DOI 10.1369/0022155414538821; Bagri A, 2009, CLIN CANCER RES, V15, P1860, DOI 10.1158/1078-0432.CCR-08-0563; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525; Bruder D, 2004, EUR J IMMUNOL, V34, P623, DOI 10.1002/eji.200324799; Chang BW, 2010, J PANCREAS, V11, P313; Curry JM, 2013, J SURG ONCOL, V107, P713, DOI 10.1002/jso.23316; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Guidolin D, 2004, MICROVASC RES, V67, P117, DOI 10.1016/j.mvr.2003.11.002; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hess-Stumpp H, 2005, CHEMBIOCHEM, V6, P550, DOI 10.1002/cbic.200400305; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; LAN MS, 1990, J BIOL CHEM, V265, P15294; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Moshal Karni S, 2011, Cancers (Basel), V3, P4102, DOI 10.3390/cancers3044102; Moshal KS, 2010, TRENDS CARDIOVAS MED, V20, P114, DOI 10.1016/j.tcm.2010.10.001; Nath S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.16; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560; PARK JE, 1994, J BIOL CHEM, V269, P25646; Patnaik A, 2014, CANCER CHEMOTH PHARM, V73, P951, DOI 10.1007/s00280-014-2426-8; Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639; Prud'homme GJ, 2012, ONCOTARGET, V3, P921, DOI 10.18632/oncotarget.626; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Robinson CJ, 2001, J CELL SCI, V114, P853; Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Sahraei M, 2012, ONCOGENE, V31, P4935, DOI 10.1038/onc.2011.651; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Solorzano CC, 2001, CANCER BIOTHER RADIO, V16, P359, DOI 10.1089/108497801753354267; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Starzec A, 2006, LIFE SCI, V79, P2370, DOI 10.1016/j.lfs.2006.08.005; Staton CA, 2007, J PATHOL, V212, P237, DOI 10.1002/path.2182; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weekes CD, 2014, INVEST NEW DRUG, V32, P653, DOI 10.1007/s10637-014-0071-z; Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016; Wild JRL, 2012, INT J EXP PATHOL, V93, P81, DOI 10.1111/j.1365-2613.2012.00810.x; Woo JK, 2012, ONCOGENE, V31, P2187, DOI 10.1038/onc.2011.410; Xin Y, 2012, CLIN CANCER RES, V18, P6040, DOI 10.1158/1078-0432.CCR-12-1652	53	41	44	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5608	5618		10.1038/onc.2015.516	http://dx.doi.org/10.1038/onc.2015.516			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	26804176	Green Accepted			2022-12-28	WOS:000386998300004
J	Johnson, J; Thijssen, B; McDermott, U; Garnett, M; Wessels, LFA; Bernards, R				Johnson, J.; Thijssen, B.; McDermott, U.; Garnett, M.; Wessels, L. F. A.; Bernards, R.			Targeting the RB-E2F pathway in breast cancer	ONCOGENE			English	Review							GENE-EXPRESSION SIGNATURE; RETINOBLASTOMA TUMOR-SUPPRESSOR; KINASE 4/6 INHIBITOR; TRANSCRIPTION FACTORS; CELL-CYCLE; METASTASIS; TAMOXIFEN; MYC; TUMORIGENESIS; INDUCTION	Mutations of the retinoblastoma tumor-suppressor gene (RB1) or components regulating the CDK-RB-E2F pathway have been identified in nearly every human malignancy. Re-establishing cell cycle control through cyclin-dependent kinase (CDK) inhibition has therefore emerged as an attractive option in the development of targeted cancer therapy. The most successful example of this today is the use of the CDK4/6 inhibitor palbociclib combined with aromatase inhibitors for the treatment of estrogen receptorpositive breast cancers. Multiple studies have demonstrated that the CDK-RB-E2F pathway is critical for the control of cell proliferation. More recently, studies have highlighted additional roles of this pathway, especially E2F transcription factors themselves, in tumor progression, angiogenesis and metastasis. Specific E2Fs also have prognostic value in breast cancer, independent of clinical parameters. We discuss here recent advances in understanding of the RB-E2F pathway in breast cancer. We also discuss the application of genome-wide genetic screening efforts to gain insight into synthetic lethal interactions of CDK4/6 inhibitors in breast cancer for the development of more effective combination therapies.	[Johnson, J.; Thijssen, B.; Wessels, L. F. A.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherland, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands; [McDermott, U.; Garnett, M.] Wellcome Trust Sanger Inst, Cambridge, England	Netherlands Cancer Institute; Wellcome Trust Sanger Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherland, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	; Ford, Caroline/A-7850-2010	McDermott, Ultan/0000-0001-9032-4700; Ford, Caroline/0000-0002-4438-2309; Bernards, Rene/0000-0001-8677-3423	Dutch Cancer Society; Cancer Genomics Netherlands consortium; Wellcome Trust [102696]; Dutch Cancer Society [H1/2014-6919]; Stand Up 2 Cancer; European Research Council	Dutch Cancer Society(KWF Kankerbestrijding); Cancer Genomics Netherlands consortium; Wellcome Trust(Wellcome TrustEuropean Commission); Dutch Cancer Society(KWF Kankerbestrijding); Stand Up 2 Cancer; European Research Council(European Research Council (ERC)European Commission)	The work of RB and LFAW is supported by grants of The Dutch Cancer Society and the and by the Cancer Genomics Netherlands consortium. MG's work is supported by the Wellcome Trust (102696), the Dutch Cancer Society (H1/2014-6919), Stand Up 2 Cancer and a European Research Council Synergy grant.	Andrechek ER, 2015, ONCOGENE, V34, P217, DOI 10.1038/onc.2013.540; Arima Y, 2012, J BIOL CHEM, V287, P7896, DOI 10.1074/jbc.M111.313759; Baker Stacey J, 2012, Genes Cancer, V3, P658, DOI 10.1177/1947601913478972; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bose P, 2013, EXPERT OPIN INV DRUG, V22, P723, DOI 10.1517/13543784.2013.789859; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Canduri F, 2008, MED CHEM, V4, P210, DOI 10.2174/157340608784325205; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Dickson MA, 2014, CLIN CANCER RES, V20, P3379, DOI 10.1158/1078-0432.CCR-13-1551; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Hollern DP, 2014, MOL CELL BIOL, V34, P3229, DOI 10.1128/MCB.00737-14; Huang L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022274; Johnson JL, 2012, CANCER RES, V72, P516, DOI 10.1158/0008-5472.CAN-11-2647; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khaleel SS, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0486-7; Lin X, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3588; Liu HY, 2015, NAT CELL BIOL, V17, P1036, DOI 10.1038/ncb3210; Loi S, 2007, CRIT REV ONCOL HEMAT, V61, P187, DOI 10.1016/j.critrevonc.2006.09.005; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Niida A, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-71; Niida A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-404; Opavsky R, 2007, P NATL ACAD SCI USA, V104, P15400, DOI 10.1073/pnas.0706307104; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pillai S, 2015, CANCER RES, V75, P1009, DOI 10.1158/0008-5472.CAN-14-0681; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Rakha EA, 2004, J PATHOL, V203, P754, DOI 10.1002/path.1573; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sage J, 2012, GENE DEV, V26, P1409, DOI 10.1101/gad.193730.112; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Singh S, 2010, BBA-GENE REGUL MECH, V1799, P788, DOI 10.1016/j.bbagrm.2010.07.004; Thomassen M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-394; Tian S, 2010, BIOMARK INSIGHTS, V5, P129, DOI 10.4137/BMI.S6184; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Trikha P, 2016, ONCOGENE, V35, P3636, DOI 10.1038/onc.2015.429; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vandenbosch R, 2007, CELL CYCLE, V6, P3065, DOI 10.4161/cc.6.24.5048; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Witkiewicz AK, 2014, ONCOGENE, V33, P3980, DOI 10.1038/onc.2013.367; Wu L, 2015, ONCOGENE, V34, P119, DOI 10.1038/onc.2013.511; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yoon SO, 2006, CANCER RES, V66, P6288, DOI 10.1158/0008-5472.CAN-06-0826; Yuwanita I, 2015, ONCOTARGET, V6, P38210, DOI 10.18632/oncotarget.5690; Zhu MZ, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-504	66	121	128	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4829	4835		10.1038/onc.2016.32	http://dx.doi.org/10.1038/onc.2016.32			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26923330	Green Accepted			2022-12-28	WOS:000383330700001
J	Cui, J; Xia, T; Xie, D; Gao, Y; Jia, Z; Wei, D; Wang, L; Huang, S; Quan, M; Xie, K				Cui, J.; Xia, T.; Xie, D.; Gao, Y.; Jia, Z.; Wei, D.; Wang, L.; Huang, S.; Quan, M.; Xie, K.			HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes	ONCOGENE			English	Article							C-MET; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PROMOTES; GROWTH; PROGRESSION; RECEPTOR; TARGET; INDUCTION; HGF/SF	Hepatocyte growth factor (HGF)/Met signaling has critical roles in pancreatic ductal adenocarcinoma (PDA) development and progression and is considered a potential therapeutic target for this disease. However, the mechanism of aberrant activation of HGF/Met signaling and resistance to Met inhibition in PDA remains unclear. The mechanistic role of cross talk between Forkhead box M1 (FOXM1) and HGF/Met signaling in promotion of PDA growth and resistance to Met inhibition was examined using cell culture, molecular biology and mouse models; and the relevance of our experimental and mechanistic findings were validated using human PDA tissues. Met was markedly overexpressed in both PDA cell lines and pancreatic tumor specimens, and the expression of Met correlated directly with that of FOXM1 in human tumor specimens. Mechanistically, FOXM1 bound to the promoter region of the Met gene and transcriptionally increased the expression of Met. Increased expression of FOXM1 enhanced the activation of HGF/Met signaling and its downstream pathways, including retrovirus-associated DNA sequences/extracellular signal-regulated kinase 1/2, phosphoinositide 3-kinase/AKT and signal transducer and activator of transcription 3. Furthermore, activation of HGF/Met signaling increased the expression and transcriptional activity of FOXM1, and the cross talk between FOXM1 and HGF/Met signaling promoted PDA growth and resistance to Met inhibition. Collectively, our findings identified a positive feedback loop formed by FOXM1 and HGF/Met and revealed that this loop is a potentially effective therapeutic target for PDA.	[Cui, J.; Jia, Z.; Wei, D.; Wang, L.; Quan, M.; Xie, K.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Xia, T.] Second Mil Med Univ, Shanghai Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Xie, D.; Gao, Y.; Quan, M.] Shanghai Tongji Univ, Dept Oncol, Affiliated East Hosp, Shanghai, Peoples R China; [Huang, S.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Naval Medical University; Tongji University; University of Texas System; UTMD Anderson Cancer Center	Quan, M (corresponding author), Shanghai Tongji Univ, Dept Oncol, Affiliated East Hosp, Shanghai, Peoples R China.; Xie, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Unit 1466, 1515 Holcombe Blvd, Houston, TX 77030 USA.	quanming2013@gmail.com; kepxie@mdanderson.org		Wang, Liang/0000-0001-5038-694X	National Cancer Institute, National Institutes of Health [R01-CA129956, R01-CA148954, R01CA152309, R01CA172233]; NATIONAL CANCER INSTITUTE [R01CA148954, R01CA198090, R01CA172233, R01CA195651, R01CA152309, R01CA129956] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Don Norwood for editorial assistance and Xuemei Wang, Associate Director of Quantitative Research at The University of Texas MD Anderson Cancer Center, for assistance with statistical analyses. This work was supported by grants R01-CA129956, R01-CA148954, R01CA152309, and R01CA172233 from the National Cancer Institute, National Institutes of Health (to K Xie).	Altomare DA, 2010, CLIN CANCER RES, V16, P486, DOI 10.1158/1078-0432.CCR-09-1026; Avan A, 2014, CURR MED CHEM, V21, P975, DOI 10.2174/09298673113209990231; Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Chiu WT, 2015, ONCOTARGET, V6, P2349, DOI 10.18632/oncotarget.2957; Christensen JG, 2003, CANCER RES, V63, P7345; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cui JJ, 2014, J MED CHEM, V57, P4427, DOI 10.1021/jm401427c; Cui JJ, 2014, CLIN CANCER RES, V20, P2595, DOI 10.1158/1078-0432.CCR-13-2407; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Huang C, 2014, BBA-REV CANCER, V1845, P104, DOI 10.1016/j.bbcan.2014.01.002; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Ketterer K, 2009, CANCER LETT, V277, P72, DOI 10.1016/j.canlet.2008.11.028; Kitajima Y, 2008, CANCER SCI, V99, P1341, DOI 10.1111/j.1349-7006.2008.00828.x; Lam AKY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00011; Li L, 2014, GASTROENTEROLOGY, V147, P485, DOI 10.1053/j.gastro.2014.04.048; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Logan-Collins J, 2010, CANCER RES, V70, P1130, DOI 10.1158/0008-5472.CAN-09-0761; Mencalha AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048160; Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092; Otte JM, 2000, SCAND J GASTROENTERO, V35, P90; Qi J, 2011, CANCER RES, V71, P1081, DOI 10.1158/0008-5472.CAN-10-1623; Sanders DA, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0696-z; Sen N, 2012, P NATL ACAD SCI USA, V109, P600, DOI 10.1073/pnas.1114232109; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sunaga N, 2013, ONCOGENE, V32, P4034, DOI 10.1038/onc.2012.402; Wang HX, 2010, CARCINOGENESIS, V31, P1132, DOI 10.1093/carcin/bgq058; Wang ZW, 2010, CANCER TREAT REV, V36, P151, DOI 10.1016/j.ctrv.2009.11.006; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wierstra I, 2006, BIOL CHEM, V387, P963, DOI 10.1515/BC.2006.120; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yeh CY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-139; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang YJ, 2008, CANCER RES, V68, P8733, DOI 10.1158/0008-5472.CAN-08-1968; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhao S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.36; Zhu GH, 2011, DIGEST DIS SCI, V56, P1090, DOI 10.1007/s10620-010-1416-x	41	29	30	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4708	4718		10.1038/onc.2016.14	http://dx.doi.org/10.1038/onc.2016.14			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876216	Green Accepted			2022-12-28	WOS:000383324700004
J	Muralidharan, SV; Bhadury, J; Nilsson, LM; Green, LC; McLure, KG; Nilsson, JA				Muralidharan, S. V.; Bhadury, J.; Nilsson, L. M.; Green, L. C.; McLure, K. G.; Nilsson, J. A.			BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells	ONCOGENE			English	Article							NF-KAPPA-B; RNA-POLYMERASE-II; C-MYC; PROTEIN BRD4; CANCER-CELLS; P-TEFB; KINASE; CHROMATIN; TRANSCRIPTION; ELONGATION	Inhibiting the bromodomain and extra-terminal (BET) domain family of epigenetic reader proteins has been shown to have potent anti-tumoral activity, which is commonly attributed to suppression of transcription. In this study, we show that two structurally distinct BET inhibitors (BETi) interfere with replication and cell cycle progression of murine Myc-induced lymphoma cells at sublethal concentrations when the transcriptome remains largely unaltered. This inhibition of replication coincides with a DNA-damage response and enhanced sensitivity to inhibitors of the upstream replication stress sensor ATR in vitro and in mouse models of B-cell lymphoma. Mechanistically, ATR and BETi combination therapy cause robust transcriptional changes of genes involved in cell death, senescence-associated secretory pathway, NFkB signaling and ER stress. Our data reveal that BETi can potentiate the cell stress and death caused by ATR inhibitors. This suggests that ATRi can be used in combination therapies of lymphomas without the use of genotoxic drugs.	[Muralidharan, S. V.; Bhadury, J.; Nilsson, L. M.; Green, L. C.; Nilsson, J. A.] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Surg,Sahlgrenska Canc Ctr, Medicinaregatan 1G,Plan 6, SE-40530 Gothenburg, Sweden; [McLure, K. G.] Zenith Epigenet Corp, Calgary, AB, Canada; [McLure, K. G.] Ermaris Bio Corp, Calgary, AB, Canada	University of Gothenburg	Nilsson, JA (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Surg,Sahlgrenska Canc Ctr, Medicinaregatan 1G,Plan 6, SE-40530 Gothenburg, Sweden.	jonas.a.nilsson@surgery.gu.se	Bhadury, Joydeep/GPX-3446-2022; Bhadury, Joydeep/ABB-9252-2021; Bhadury, Joydeep/I-5059-2014	Bhadury, Joydeep/0000-0002-4333-9974; Bhadury, Joydeep/0000-0002-4333-9974; Nilsson, Jonas/0000-0003-0346-6837	Swedish Cancer Society; Swedish Research Council; Region Vastra Gataland (Sahlgrenska University Hospital, Gothenburg); Knut and Alice Wallenberg Foundation; Sahlgrenska Academy; BioCARE-a National Strategic Cancer Research Program at University of Gothenburg; Assar Gabrielsson Foundation; W&M Lundgren Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Region Vastra Gataland (Sahlgrenska University Hospital, Gothenburg); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Sahlgrenska Academy; BioCARE-a National Strategic Cancer Research Program at University of Gothenburg; Assar Gabrielsson Foundation; W&M Lundgren Foundation	We thank Sofia Nordstrand for animal care, and Eric Campeau and Zenith Epigenetics for RVX2135 and helpful discussions. This work was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Region Vastra Gataland (Sahlgrenska University Hospital, Gothenburg), the Knut and Alice Wallenberg Foundation, the Sahlgrenska Academy and BioCARE-a National Strategic Cancer Research Program at University of Gothenburg (to JAN), and from the Assar Gabrielsson Foundation and the W&M Lundgren Foundation (to SVM, JB and LCG).	Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Bhadury J, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.8; Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111; Boi M, 2015, CLIN CANCER RES, V21, P1628, DOI 10.1158/1078-0432.CCR-14-1561; Bolden JE, 2014, CELL REP, V8, P1919, DOI 10.1016/j.celrep.2014.08.025; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Denis GV, 2006, J PROTEOME RES, V5, P502, DOI 10.1021/pr050430u; Denis GV, 2000, CELL GROWTH DIFFER, V11, P417; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Ember SWJ, 2014, ACS CHEM BIOL, V9, P1160, DOI 10.1021/cb500072z; Fang J, 2014, CELL REP, V8, P1328, DOI 10.1016/j.celrep.2014.07.062; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; Foote KM, 2013, J MED CHEM, V56, P2125, DOI 10.1021/jm301859s; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hoglund A, 2011, CLIN CANCER RES, V17, P7067, DOI 10.1158/1078-0432.CCR-11-1198; Hoglund A, 2011, CELL CYCLE, V10, P3598, DOI 10.4161/cc.10.20.17887; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jing H, 2011, GENE DEV, V25, P2137, DOI 10.1101/gad.17620611; Josse R, 2014, CANCER RES, V74, P6968, DOI 10.1158/0008-5472.CAN-13-3369; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Keller U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-348; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; Klapproth K, 2009, BLOOD, V114, P2448, DOI 10.1182/blood-2008-09-181008; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; Loosveld M, 2014, ONCOTARGET, V5, P3168, DOI 10.18632/oncotarget.1873; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Pastori C, 2014, EPIGENETICS-US, V9, P611, DOI 10.4161/epi.27906; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Shortt J, 2013, BLOOD, V121, P2964, DOI 10.1182/blood-2012-08-446096; Sinha A, 2005, BIOCHEM J, V387, P257, DOI 10.1042/BJ20041793; Stanlie A, 2014, MOL CELL, V55, P97, DOI 10.1016/j.molcel.2014.05.018; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Tang C, 2014, CANCER IMMUNOL RES, V2, P831, DOI 10.1158/2326-6066.CIR-14-0069; Tolani B, 2014, ONCOGENE, V33, P2928, DOI 10.1038/onc.2013.242; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Venkataraman S, 2014, ONCOTARGET, V5, P2355; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	57	38	40	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4689	4697		10.1038/onc.2015.521	http://dx.doi.org/10.1038/onc.2015.521			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26804177				2022-12-28	WOS:000383324700002
J	Choi, EB; Yang, AY; Kim, SC; Lee, J; Choi, JK; Choi, C; Kim, MY				Choi, E-B; Yang, A-Y; Kim, S. C.; Lee, J.; Choi, J. K.; Choi, C.; Kim, M-Y			PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair	ONCOGENE			English	Article							BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; E-CADHERIN EXPRESSION; GENE-EXPRESSION; POLY(ADP-RIBOSE) POLYMERASE; CHROMATIN-STRUCTURE; ANOIKIS RESISTANCE; TRANSCRIPTION; INHIBITION; INCREASES	The role of poly (ADP-ribose) polymerase 1 (PARP1) in cancer has been extensively studied in the context of DNA repair, leading to clinical trials of PARP1 inhibitors in cancers defective in homologous recombination. However, the DNA repair-independent roles of PARP1 in carcinogenesis and metastasis, particularly in lung cancer metastasis, remain largely uncharacterized. Here, we report that PARP1 promotes lung adenocarcinoma relapse to the brain and bones by regulating several steps of the metastatic process in a DNA repair-independent manner. We find that PARP1 expression is associated with overall and distant metastasis-free survival in lung adenocarcinoma patients. Consistent with this, genetic knockdown and pharmacological inhibition of PARP1 significantly attenuated the metastatic potential of lung adenocarcinoma cells. Further investigation revealed that PARP1 potentiates lung adenocarcinoma metastasis by promoting invasion, anoikis resistance, extravasation and self-renewal of lung adenocarcinoma cells and also by modifying the brain microenvironment. Finally, we identified S100A4 and CLDN7 as novel transcriptional targets and clinically relevant effectors of PARP1. Collectively, our study not only revealed previously unknown functions of PARP1 in lung adenocarcinoma metastasis but also delineated the molecular mechanisms underlying the pro-metastatic function of PARP1. Furthermore, these findings provide a foundation for the potential use of PARP1 inhibitors as a new treatment option for lung adenocarcinoma patients with elevated PARP1 expression.	[Choi, E-B; Yang, A-Y; Kim, M-Y] Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 305701, South Korea; [Kim, S. C.] KCDC, Natl Inst Hlth, Ctr Genome Sci, Dept Biomed Informat, Choongchung Buk Do, South Korea; [Lee, J.; Choi, J. K.; Choi, C.] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon, South Korea; [Choi, C.; Kim, M-Y] Korea Adv Inst Sci & Technol, Canc Metastasis Control Ctr, Inst BioCentury, Daejeon, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Genome Science; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Kim, MY (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 305701, South Korea.	miyoungkim@kaist.ac.kr	Kim, Sun Chang/C-2026-2011; Choi, Chulhee/C-1642-2011; Kim, Sun/GSN-4867-2022; Kim, Mi Young/C-1829-2011; Choi, Jung Kyoon/C-2070-2011	Choi, Chulhee/0000-0001-5542-9136; 	Converging Research Center Program [2014048778]; Intelligent Synthetic Biology Center of Global Frontier Project - Ministry of Science, ICT & Future Planning [2011-0031955]; Basic Science Research Program through the National Research Foundation of Korea [NRF-2011-0020334]	Converging Research Center Program; Intelligent Synthetic Biology Center of Global Frontier Project - Ministry of Science, ICT & Future Planning; Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea)	We thank for Drs Joan Massague, Incheol Shin, Michael Davidson and W Lee Kraus for providing NCI-H2030, PC9 and their metastatic derivatives; pBabe-S100A4; mEmerald-Claudin7-C-12 (CLDN7, Addgene plasmid #54041); and PARP1 shRNA constructs and antibody, respectively. We also thank Dr Sun Kyu Kim for help with bioinformatics analysis, Dr David M Helfman for helpful discussion. This research was supported by the Converging Research Center Program (2014048778), the Intelligent Synthetic Biology Center of Global Frontier Project (2011-0031955) funded by the Ministry of Science, ICT & Future Planning, and the Basic Science Research Program through the National Research Foundation of Korea (NRF-2011-0020334).	Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Botling J, 2013, CLIN CANCER RES, V19, P194, DOI 10.1158/1078-0432.CCR-12-1139; Brenner JC, 2012, CANCER RES, V72, P1608, DOI 10.1158/0008-5472.CAN-11-3648; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960; Chen N, 2014, BIOCHEM BIOPH RES CO, V447, P459, DOI 10.1016/j.bbrc.2014.04.025; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cheng HY, 2013, CARCINOGENESIS, V34, P739, DOI 10.1093/carcin/bgs393; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Chitale D, 2009, ONCOGENE, V28, P2773, DOI 10.1038/onc.2009.135; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dahiya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022119; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; Davies MPA, 1996, ONCOGENE, V13, P1631; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Doege CA, 2012, NATURE, V488, P652, DOI 10.1038/nature11333; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Elser M, 2008, MOL CANCER RES, V6, P282, DOI 10.1158/1541-7786.MCR-07-0377; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; Frizzell KM, 2009, J BIOL CHEM, V284, P33926, DOI 10.1074/jbc.M109.023879; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; Rodriguez MI, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003531; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kim SK, 2014, BIOINFORMATICS, V30, P3284, DOI 10.1093/bioinformatics/btu521; Kraus WL, 2013, MOL ASPECTS MED, V34, P1109, DOI 10.1016/j.mam.2013.01.005; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Lee MH, 2012, ONCOGENE, V31, P5099, DOI 10.1038/onc.2012.2; Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; MARTINI N, 1995, J THORAC CARDIOV SUR, V109, P120, DOI 10.1016/S0022-5223(95)70427-2; Matsubara D, 2005, CANCER SCI, V96, P844, DOI 10.1111/j.1349-7006.2005.00121.x; McPhee TR, 2008, DEV DYNAM, V237, P2737, DOI 10.1002/dvdy.21685; Michels J, 2015, ANN ONCOL, V26, P2470, DOI 10.1093/annonc/mdv393; Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000; Michels J, 2013, CELL CYCLE, V12, P877, DOI 10.4161/cc.24034; Minami D, 2013, MOL CANCER RES, V11, P140; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Nowsheen S, 2012, CANCER RES, V72, P4796, DOI 10.1158/0008-5472.CAN-12-1287; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; OGATA N, 1981, J BIOL CHEM, V256, P4135; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Piccolo SR, 2013, P NATL ACAD SCI USA, V110, P17778, DOI 10.1073/pnas.1305823110; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez MI, 2011, ONCOGENE, V30, P4365, DOI 10.1038/onc.2011.153; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Ryu KW, 2015, CHEM REV, V115, P2453, DOI 10.1021/cr5004248; Saleem M, 2006, P NATL ACAD SCI USA, V103, P14825, DOI 10.1073/pnas.0606747103; Senra JM, 2011, MOL CANCER THER, V10, P1949, DOI 10.1158/1535-7163.MCT-11-0278; Shan L, 2014, ONCOGENE, V33, P3205, DOI 10.1038/onc.2013.270; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Shen W, 2011, CANCER SCI, V102, P1014, DOI 10.1111/j.1349-7006.2011.01915.x; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tentori L, 2008, EUR J CANCER, V44, P1302, DOI 10.1016/j.ejca.2008.03.019; Tomida S, 2009, J CLIN ONCOL, V27, P2793, DOI 10.1200/JCO.2008.19.7053; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426	79	36	40	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4569	4579		10.1038/onc.2016.3	http://dx.doi.org/10.1038/onc.2016.3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26898760				2022-12-28	WOS:000382336300003
J	Li, Y; Lauriola, M; Kim, D; Francesconi, M; D'Uva, G; Shibata, D; Malafa, MP; Yeatman, TJ; Coppola, D; Solmi, R; Cheng, JQ				Li, Y.; Lauriola, M.; Kim, D.; Francesconi, M.; D'Uva, G.; Shibata, D.; Malafa, M. P.; Yeatman, T. J.; Coppola, D.; Solmi, R.; Cheng, J. Q.			Adenomatous polyposis coli (APC) regulates miR17-92 cluster through beta-catenin pathway in colorectal cancer	ONCOGENE			English	Article							MIR-17-92 CLUSTER; TCF/BETA-CATENIN; CELL-MIGRATION; BREAST-CANCER; CYCLIN D1; EXPRESSION; MICRORNAS; ANGIOGENESIS; CARCINOMA; INVASION	Adenomatous polyposis coli (APC) mutation is the most common genetic change in sporadic colorectal cancer (CRC). Although deregulations of miRNAs have been frequently reported in this malignancy, APC-regulated miRNAs have not been extensively documented. Here, by using an APC-inducible cell line and array analysis, we identified a total of 26 deregulated miRNAs. Among them, members of miR-17-92 cluster were dramatically inhibited by APC and induced by enforced expression of beta-catenin. Furthermore, we demonstrate that activated beta-catenin resulted from APC loss binds to and activates the miR-17-92 promoter. Notably, enforced expression of miR-19a overrides APC tumor suppressor activity, and knockdown of miR-19a in cancer cells with compromised APC function reduced their aggressive features in vitro. Finally, we observed that expression of miR-19a significantly correlates with beta-catenin levels in colorectal cancer specimens, and it is associated to the aggressive stage of tumor progression. Thus, our study reveals that miR-17-92 cluster is directly regulated by APC/beta-catenin pathway and could be a potential therapeutic target in colon cancers with aberrant APC/beta-catenin signaling.	[Li, Y.; Lauriola, M.; Kim, D.; Cheng, J. Q.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr,SRB-3, Tampa, FL 33612 USA; [Lauriola, M.; D'Uva, G.; Solmi, R.] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Via Massarenti 9, I-40138 Bologna, Italy; [Francesconi, M.] Ctr Genom Regulat CRG, EMBL CRG Syst Biol Unit, Barcelona, Spain; [Shibata, D.; Malafa, M. P.; Yeatman, T. J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA; [Coppola, D.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA; [Yeatman, T. J.] Gibbs Canc Ctr & Res Inst, Spartanburg, SC USA	H Lee Moffitt Cancer Center & Research Institute; University of Bologna; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Cheng, JQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr,SRB-3, Tampa, FL 33612 USA.; Solmi, R (corresponding author), Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Via Massarenti 9, I-40138 Bologna, Italy.; Coppola, D (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	domenico.coppola@moffitt.org; rossella.solmi@unibo.it; jin.cheng@moffitt.org	Kim, Donghwa/AAJ-8148-2021; francesconi, mirko/O-8080-2015; D'Uva, Gabriele/A-6252-2015	Kim, Donghwa/0000-0002-8994-8513; francesconi, mirko/0000-0002-8702-0877; D'Uva, Gabriele/0000-0001-9622-9288; lauriola, mattia/0000-0002-7966-0065	Moffitt Cancer Center Foundation; NCI Cancer Center Support Grant [P30 CA076292]; 'Fondazione del Monte di Bologna e di Ravenna' (Bologna, Italy);  [CA137041];  [CA160455]; NATIONAL CANCER INSTITUTE [P30CA076292, R01CA137041, R01CA160455] Funding Source: NIH RePORTER	Moffitt Cancer Center Foundation; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); 'Fondazione del Monte di Bologna e di Ravenna' (Bologna, Italy); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful for the Molecular Biology and Analytic Microscopy Core and Tissue Core facilities at H. Lee Moffitt Cancer Center. We also thank Dr Thomas Ried for providing NCI-H508 cell line. This work was supported in part by CA137041, CA160455 (JQC) and the Moffitt Cancer Center Foundation. The H. Lee Moffitt Cancer Center & Research Institute is supported in part by NCI Cancer Center Support Grant #P30 CA076292. ML was supported by 'Fondazione del Monte di Bologna e di Ravenna' (Bologna, Italy).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Barth AIM, 2008, SEMIN CELL DEV BIOL, V19, P245, DOI 10.1016/j.semcdb.2008.02.003; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; D'Uva G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080742; Diosdado B, 2009, BRIT J CANCER, V101, P707, DOI 10.1038/sj.bjc.6605037; Fish JE, 2009, SCI SIGNAL, V1, DOI 10.1126/scisignal.252pe1; Grillari J, 2010, BIOGERONTOLOGY, V11, P501, DOI 10.1007/s10522-010-9272-9; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Jiang H, 2014, AM J PATHOL, V184, P1355, DOI 10.1016/j.ajpath.2014.01.037; Koga Y, 2010, CANCER PREV RES, V3, P1435, DOI 10.1158/1940-6207.CAPR-10-0036; Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kudo Y, 2004, CLIN CANCER RES, V10, P5455, DOI 10.1158/1078-0432.CCR-04-0372; Lanza G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-54; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lindow M, 2012, J CELL BIOL, V199, P407, DOI 10.1083/jcb.201208082; Luo XY, 2011, CANCER EPIDEM BIOMAR, V20, P1272, DOI 10.1158/1055-9965.EPI-11-0035; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mimori-Kiyosue Y, 2007, GENES CELLS, V12, P219, DOI 10.1111/j.1365-2443.2007.01045.x; Miyazawa K, 2000, VIRCHOWS ARCH, V437, P508, DOI 10.1007/s004280000283; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Necela BM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018501; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Pendas-Franco N, 2008, ONCOGENE, V27, P4467, DOI 10.1038/onc.2008.88; Phelps RA, 2009, CELL CYCLE, V8, P2549, DOI 10.4161/cc.8.16.9278; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Solmi R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-227; Song S, 2011, CANCER RES, V71, P7628, DOI 10.1158/0008-5472.CAN-11-2745; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Takahashi-Yanaga F, 2009, J PHARMACOL SCI, V109, P179, DOI 10.1254/jphs.08R28FM; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tysnes BB, 2010, NEOPLASIA, V12, P506, DOI 10.1593/neo.10290; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; van Haaften G, 2010, GENE DEV, V24, P1, DOI 10.1101/gad.1887110; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yu G, 2012, J SURG ONCOL, V106, P232, DOI 10.1002/jso.22138; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200; Zhou Jiao-Jiao, 2014, World J Biol Chem, V5, P301, DOI 10.4331/wjbc.v5.i3.301	50	35	35	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4558	4568		10.1038/onc.2015.522	http://dx.doi.org/10.1038/onc.2015.522			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26804172	Green Accepted, Green Submitted			2022-12-28	WOS:000382336300002
J	Nie, D; Shan, X; Nie, L; Duan, Y; Chen, Z; Yang, Y; Li, Z; Tian, L; Gao, Q; Shan, Y; Tang, N				Nie, D.; Shan, X.; Nie, L.; Duan, Y.; Chen, Z.; Yang, Y.; Li, Z.; Tian, L.; Gao, Q.; Shan, Y.; Tang, N.			Hepatitis C virus core protein interacts with Snail and histone deacetylases to promote the metastasis of hepatocellular carcinoma	ONCOGENE			English	Article							E-CADHERIN EXPRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; B-VIRUS; REPRESSOR; PHOSPHORYLATION; REPLICATION; DIFFERENTIATION; AGGRESSIVENESS; HDAC2	Downregulation of E-cadherin by the transcriptional repressor Snail is associated with acquisition of metastatic potential. Although hepatitis C virus (HCV) core protein has been implicated in hepatocarcinogenesis, it is unclear whether Snail is involved in HCV core-induced dysregulation of E-cadherin. Herein, we investigated the mechanism by which HCV core induces E-cadherin repression and the role of Snail in HCV core-mediated invasiveness and metastasis. We found that HCV infection, especially HCV core expression, effectively induced the epithelial-mesenchymal transition (EMT) in hepatoma cells by repressing E-cadherin. HCV core interacted with Snail and enhanced its binding to the E-box in the promoter region of E-cadherin, leading to decreased E-cadherin promoter activity. We found that HCV core, Snail, and the histone deacetylases HDAC1/HDAC2 formed a co-repressor complex at the E-cadherin promoter. Moreover, HCV core was shown to stabilize Snail through activation of the PI3K/Akt/GSK3 beta pathway. Silencing Snail expression restored E-cadherin expression and inhibited HCV core-promoted tumor growth and distant lung metastasis in vivo. Collectively, these results demonstrated that HCV core induced EMT by interacting with the transcriptional repressor complex Snail/HDACs at the E-cadherin promoter, which led to E-cadherin repression and increased invasiveness of hepatoma cells. These findings increase understanding of factors regulating metastasis in hepatoma and may ultimately lead to the development of novel treatment strategies for HCV-associated hepatocellular carcinoma.	[Shan, Y.; Tang, N.] Chongqing Med Univ, Affiliated Hosp 2, Chongqing 400016, Peoples R China; Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Chinese Minist Educ, Chongqing 400016, Peoples R China	Chongqing Medical University; Chongqing Medical University	Shan, Y; Tang, N (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Chongqing 400016, Peoples R China.; Shan, Y; Tang, N (corresponding author), Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Chongqing 400016, Peoples R China.	shanyoulan11@163.com; nitang@cqmu.edu.cn	Tang, Ni/Z-5133-2019	Tang, Ni/0000-0001-5830-8786; Nie, Lizhu/0000-0001-6353-5211	Major National ST program [2013ZX10002002-005-003, 2012ZX10002005-003-002]; China National Natural Science Foundation [81572683, 81371827, 31171307, 81502062]; Innovation Fund Designated for Graduate Students of Chongqing Government [CYS14124]; Outstanding Young talent program of 2nd affiliated hospital of CQMU	Major National ST program; China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Innovation Fund Designated for Graduate Students of Chongqing Government; Outstanding Young talent program of 2nd affiliated hospital of CQMU	We would like to thank Dr T-C He (University of Chicago, USA) for the kind provision of adenoviruses AdGFP, AdRFP, and AdR-FLuc. We are also grateful to Dr Takaji Wakita (National Institute of Infectious Diseases, Tokyo) for providing an HCV JFH1 cDNA clone and to Dr Haizhen Zhu (Hunan University, China) for the HLCZ01 cells. This study was supported by research grants from Major National S&T program (2013ZX10002002-005-003, NT; 2012ZX10002005-003-002, NT), China National Natural Science Foundation (#81572683, #81371827, #31171307, NT; #81502062, DN), Innovation Fund Designated for Graduate Students of Chongqing Government (#CYS14124, LN) and the Outstanding Young talent program of 2nd affiliated hospital of CQMU (NT).	Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Akkari L, 2012, J HEPATOL, V57, P1021, DOI 10.1016/j.jhep.2012.06.027; Arzumanyan A, 2012, ONCOGENE, V31, P563, DOI 10.1038/onc.2011.255; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254; Bose SK, 2012, J VIROL, V86, P13621, DOI 10.1128/JVI.02016-12; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Garg Minal, 2013, World J Stem Cells, V5, P188, DOI 10.4252/wjsc.v5.i4.188; Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hashiguchi M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-572; Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Li TY, 2010, ANN SURG ONCOL, V17, P1937, DOI 10.1245/s10434-010-0925-3; Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077; Liu JX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023098; Mingot JM, 2009, J CELL SCI, V122, P1452, DOI 10.1242/jcs.041749; Noh JH, 2014, CANCER RES, V74, P1728, DOI 10.1158/0008-5472.CAN-13-2109; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Quan H, 2014, ONCOGENE, V33, P2826, DOI 10.1038/onc.2013.225; MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Rosen HR, 2011, NEW ENGL J MED, V364, P2429, DOI 10.1056/NEJMcp1006613; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sideridou M, 2011, J CELL BIOL, V195, P1123, DOI 10.1083/jcb.201108121; Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97; Tacke RS, 2011, J BIOL CHEM, V286, P10847, DOI 10.1074/jbc.M110.217653; Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582-4934.2008.00569.x; Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Xie Q, 2014, INT J CANCER, V135, P635, DOI 10.1002/ijc.28697; Yang DR, 2014, P NATL ACAD SCI USA, V111, pE1264, DOI 10.1073/pnas.1320071111; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	40	22	24	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3626	3635		10.1038/onc.2015.428	http://dx.doi.org/10.1038/onc.2015.428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26549030	Bronze			2022-12-28	WOS:000379622800002
J	Chakedis, J; French, R; Babicky, M; Jaquish, D; Howard, H; Mose, E; Lam, R; Holman, P; Miyamoto, J; Walterscheid, Z; Lowy, AM				Chakedis, J.; French, R.; Babicky, M.; Jaquish, D.; Howard, H.; Mose, E.; Lam, R.; Holman, P.; Miyamoto, J.; Walterscheid, Z.; Lowy, A. M.			A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells	ONCOGENE			English	Article							MACROPHAGE-STIMULATING PROTEIN; THERAPEUTIC TARGET; CANCER CELLS; TUMORIGENIC ACTIVITIES; PROGNOSTIC MARKER; SPLICING VARIANT; BREAST-CANCER; MET FAMILY; EXPRESSION; IDENTIFICATION	The MST1R gene is overexpressed in pancreatic cancer producing elevated levels of the RON tyrosine kinase receptor protein. While mutations in MST1R are rare, alternative splice variants have been previously reported in epithelial cancers. We report the discovery of a novel RON isoform discovered in human pancreatic cancer. Partial splicing of exons 5 and 6 (P5P6) produces a RON isoform that lacks the first extracellular immunoglobulin-plexin-transcription domain. The splice variant is detected in 73% of xenografts derived from pancreatic adenocarcinoma patients and 71% of pancreatic cancer cell lines. Peptides specific to RON P5P6 detected in human pancreatic cancer specimens by mass spectrometry confirm translation of the protein isoform. The P5P6 isoform is found to be constitutively phosphorylated, present in the cytoplasm, and it traffics to the plasma membrane. Expression of P5P6 in immortalized human pancreatic duct epithelial (HPDE) cells activates downstream AKT, and in human pancreatic epithelial nestin-expressing cells, activates both the AKT and MAPK pathways. Inhibiting RON P5P6 in HPDE cells using a small molecule inhibitor BMS-777607 blocked constitutive activation and decreased AKT signaling. P5P6 transforms NIH3T3 cells and induces tumorigenicity in HPDE cells. Resultant HPDE-P5P6 tumors develop a dense stromal compartment similar to that seen in pancreatic cancer. In summary, we have identified a novel and constitutively active isoform of the RON tyrosine kinase receptor that has transforming activity and is expressed in human pancreatic cancer. These findings provide additional insight into the biology of the RON receptor in pancreatic cancer and are clinically relevant to the study of RON as a potential therapeutic target.	[Chakedis, J.; French, R.; Babicky, M.; Jaquish, D.; Howard, H.; Mose, E.; Lam, R.; Holman, P.; Miyamoto, J.; Walterscheid, Z.; Lowy, A. M.] Univ Calif San Diego, Moores Canc Ctr, Div Surg Oncol, Dept Surg, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Lowy, AM (corresponding author), Univ Calif San Diego, Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	alowy@ucsd.edu			National Cancer Institute of the National Institutes of Health [R01 CA155620, T32 CA121938]; NCI Cancer Center Support Grant [2 P30 CA023100-23]; NATIONAL CANCER INSTITUTE [R01CA155620, T32CA121938, P30CA023100] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge the generosity of our patients who supported this work through both monetary contributions and/or by allowing tumor tissue to be used for research. Without their contributions, this work would not have been possible. We thank the Tsao and Klemke labs for providing HPDE and HPNE ells, respectively. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01 CA155620 (AML) and T32 CA121938 (JC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. DNA sequencing was performed by the DNA Sequencing Shared Resource, UCSD Moore's Cancer Center, which is funded in part by NCI Cancer Center Support Grant # 2 P30 CA023100-23.	Angeloni D, 2004, J BIOL CHEM, V279, P3726, DOI 10.1074/jbc.M309342200; Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Benight NM, 2012, EXPERT OPIN THER TAR, V16, P921, DOI 10.1517/14728222.2012.710200; Braga E., 2011, Experimental Oncology, V33, P33; Camp ER, 2007, CANCER-AM CANCER SOC, V109, P1030, DOI 10.1002/cncr.22490; Catenacci DVT, 2011, CANCER BIOL THER, V12, P9, DOI 10.4161/cbt.12.1.15747; Chao KLL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041912; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Eckerich C, 2009, J NEUROCHEM, V109, P969, DOI 10.1111/j.1471-4159.2009.06027.x; Eyob H, 2013, CANCER DISCOV, V3, P751, DOI 10.1158/2159-8290.CD-12-0480; Feres KJ, 2009, ONCOGENE, V28, P279, DOI 10.1038/onc.2008.383; Furukawa T, 1996, AM J PATHOL, V148, P1763; Gurusamy D, 2013, CANCER RES, V73, P1752, DOI 10.1158/0008-5472.CAN-12-2474; Guttman M, 2009, PROTEOMICS, V9, P5016, DOI 10.1002/pmic.200900457; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Kumanogoh A, 2013, NAT REV IMMUNOL, V13, P802, DOI 10.1038/nri3545; Liu Xuemei, 2011, Genes Cancer, V2, P753, DOI 10.1177/1947601911421924; Logan-Collins J, 2010, CANCER RES, V70, P1130, DOI 10.1158/0008-5472.CAN-09-0761; Ma Q, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-307; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Pfaffl M.W., 2004, A Z QUANT PCR, P87; RONSIN C, 1993, ONCOGENE, V8, P1195; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Schroeder GM, 2009, J MED CHEM, V52, P1251, DOI 10.1021/jm801586s; Tactacan CM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-395; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Thomas RM, 2010, PANCREAS, V39, P301, DOI 10.1097/MPA.0b013e3181bb9f73; Wang J, 2009, J BIOL CHEM, V284, P10912, DOI 10.1074/jbc.M809551200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang QR, 2013, CANCER LETT, V340, P43, DOI 10.1016/j.canlet.2013.06.022; Wang X, 2013, CRIT REV IMMUNOL, V33, P549; Xu XM, 2005, J BIOL CHEM, V280, P25087, DOI 10.1074/jbc.M414699200; Yao HP, 2013, CURR CANCER DRUG TAR, V13, P686, DOI 10.2174/15680096113139990038; Yao HP, 2013, NAT REV CANCER, V13, P466, DOI 10.1038/nrc3545; Zeng JY, 2014, MOL CANCER THER, V13, P37, DOI 10.1158/1535-7163.MCT-13-0242; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	42	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3249	3259		10.1038/onc.2015.384	http://dx.doi.org/10.1038/onc.2015.384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477314	Green Submitted, Green Accepted			2022-12-28	WOS:000378306400004
J	Felli, N; Errico, MC; Pedini, F; Petrini, M; Puglisi, R; Bellenghi, M; Boe, A; Felicetti, F; Mattia, G; De Feo, A; Bottero, L; Tripodo, C; Care, A				Felli, N.; Errico, M. C.; Pedini, F.; Petrini, M.; Puglisi, R.; Bellenghi, M.; Boe, A.; Felicetti, F.; Mattia, G.; De Feo, A.; Bottero, L.; Tripodo, C.; Care, A.			AP2 alpha controls the dynamic balance between miR-126&126*and miR-221&222 during melanoma progression	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; AP-2 TRANSCRIPTION FACTOR; CUTANEOUS MELANOMA; GROWTH-FACTOR; METASTATIC MELANOMA; TERMINAL FRAGMENT; CANCER-CELLS; TUMOR-GROWTH; MIR-126; METHYLATION	Accumulating evidences have shown the association between aberrantly expressed microRNAs (miRs) and cancer, where these small regulatory RNAs appear to dictate the cell fate by regulating all the main biological processes. We demonstrated the responsibility of the circuitry connecting the oncomiR-221&222 with the tumor suppressors miR-126&126* in melanoma development and progression. According to the inverse correlation between endogenous miR-221&222 and miR-126&126*, respectively increasing or decreasing with malignancy, their enforced expression or silencing was sufficient for a reciprocal regulation. In line with the opposite roles of these miRs, protein analyses confirmed the reverse expression pattern of miR-126&126*-targeted genes that were induced by miR-221&222. Looking for a central player in this complex network, we revealed the dual regulation of AP2 alpha, on one side directly targeted by miR-221&222 and on the other a transcriptional activator of miR-126&126*. We showed the chance of restoring miR-126&126* expression in metastatic melanoma to reduce the amount of mature intracellular heparin-binding EGF like growth factor, thus preventing promyelocytic leukemia zinc finger delocalization and maintaining its repression on miR-221&222 promoter. Thus, the low-residual quantity of these two miRs assures the release of AP2 alpha expression, which in turn binds to and induces miR-126&126* transcription. All together these results point to an unbalanced ratio functional to melanoma malignancy between these two couples of miRs. During progression this balance gradually moves from miR-126&126* toward miR-221&222. This circuitry, besides confirming the central role of AP2 alpha in orchestrating melanoma development and/or progression, further displays the significance of these miRs in cancer and the option of utilizing them for novel therapeutics.	[Felli, N.; Errico, M. C.; Pedini, F.; Petrini, M.; Puglisi, R.; Bellenghi, M.; Boe, A.; Felicetti, F.; Mattia, G.; Bottero, L.; Care, A.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy; [Tripodo, C.] Univ Palermo, Dept Hlth Sci, Palermo, Italy	Istituto Superiore di Sanita (ISS); University of Palermo	Care, A (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	alessandra.care@iss.it	De Feo, Alessandra/ABI-1458-2020; Puglisi, Rossella/M-7120-2017; Mattia, Gianfranco/K-5194-2016; Tripodo, Claudio/AAB-6004-2022; Tripodo, Claudio/O-4536-2016; Errico, Maria Cristina/K-3971-2016; Pedini, Francesca/N-5677-2017; Boe, Alessandra/AAA-2653-2019; Felicetti, Federica/N-7077-2017; Bellenghi, Maria/AHE-8886-2022; De Feo, Alessandra/C-7030-2019; Care, Alessandra/H-5090-2016; Felli, Nadia/G-2088-2012	De Feo, Alessandra/0000-0002-9805-1361; Puglisi, Rossella/0000-0003-1680-1032; Mattia, Gianfranco/0000-0001-7047-6360; Tripodo, Claudio/0000-0002-0821-6231; Tripodo, Claudio/0000-0002-0821-6231; Errico, Maria Cristina/0000-0003-3014-2643; Pedini, Francesca/0000-0002-3454-6162; Boe, Alessandra/0000-0002-8888-7501; Felicetti, Federica/0000-0003-4628-0696; De Feo, Alessandra/0000-0002-9805-1361; Care, Alessandra/0000-0003-4106-3342; petrini, marina/0000-0003-4891-3389; Felli, Nadia/0000-0001-6763-3361; Bellenghi, Maria/0000-0002-1156-5950	Italian Ministry of Health [RF-2010-2310494]; Italian Association for Cancer Research [AIRC IG13247]	Italian Ministry of Health(Ministry of Health, Italy); Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Italian Ministry of Health (RF-2010-2310494) and the Italian Association for Cancer Research (AIRC IG13247) to AC.	Aftab MN, 2014, ARCH BIOCHEM BIOPHYS, V563, P60, DOI 10.1016/j.abb.2014.07.022; Alcazar O, 2012, INT J CANCER, V131, P18, DOI 10.1002/ijc.26320; Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Braeuer RR, 2011, SEMIN CANCER BIOL, V21, P83, DOI 10.1016/j.semcancer.2010.12.007; Dai X, 2015, ADV DRUG DELIVER REV, V81, P184, DOI 10.1016/j.addr.2014.09.010; Das Thakur M, 2013, CANCER RES, V73, P6106, DOI 10.1158/0008-5472.CAN-13-1633; Du CL, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0259-1; Ebrahimi F, 2014, EXP MOL PATHOL, V96, P98, DOI 10.1016/j.yexmp.2013.12.004; Eggermont AMM, 2014, LANCET, V383, P816, DOI 10.1016/S0140-6736(13)60802-8; Errico MC, 2013, INT J CANCER, V133, P879, DOI 10.1002/ijc.28097; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Felli N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056824; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170; Hallberg AR, 2014, EPIGENETICS-US, V9, P1641, DOI 10.4161/15592294.2014.988062; Igoucheva O, 2009, BIOCHEM BIOPH RES CO, V379, P790, DOI 10.1016/j.bbrc.2008.12.152; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jonckheere N, 2009, BRIT J CANCER, V101, P637, DOI 10.1038/sj.bjc.6605190; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Kivisaari AK, 2010, BRIT J DERMATOL, V163, P726, DOI 10.1111/j.1365-2133.2010.09924.x; Kwong LN, 2014, ONCOGENE, V33, P1, DOI 10.1038/onc.2013.34; Le Bras A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012156; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Little EG, 2012, DERMATOL CLIN, V30, P355, DOI 10.1016/j.det.2012.04.001; Liu RH, 2015, CLIN CANCER RES, V21, P854, DOI 10.1158/1078-0432.CCR-14-1740; Mattia G, 2011, PIGM CELL MELANOMA R, V24, P953, DOI 10.1111/j.1755-148X.2011.00881.x; Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198; Melnikova VO, 2008, CANCER BIOL THER, V7, P997, DOI 10.4161/cbt.7.7.6535; Menzies AM, 2014, LANCET ONCOL, V15, pE371, DOI 10.1016/S1470-2045(14)70072-5; Mobley AK, 2012, CANCER METAST REV, V31, P621, DOI 10.1007/s10555-012-9358-8; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; Ozeki K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056770; Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098; Sun YQ, 2010, BIOCHEM BIOPH RES CO, V391, P1483, DOI 10.1016/j.bbrc.2009.12.098; Toki F, 2005, J CELL PHYSIOL, V202, P839, DOI 10.1002/jcp.20175; Wang J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003785; Xu M, 2013, AM J PATHOL, V182, P84, DOI 10.1016/j.ajpath.2012.09.018; Yang XL, 2014, MOL MED REP, V10, P125, DOI 10.3892/mmr.2014.2171; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690	41	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3016	3026		10.1038/onc.2015.357	http://dx.doi.org/10.1038/onc.2015.357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434590	Green Published, hybrid			2022-12-28	WOS:000377474500007
J	Weekes, D; Kashima, TG; Zandueta, C; Perurena, N; Thomas, DP; Sunters, A; Vuillier, C; Bozec, A; El-Emir, E; Miletich, I; Patino-Garcia, A; Lecanda, F; Grigoriadis, AE				Weekes, D.; Kashima, T. G.; Zandueta, C.; Perurena, N.; Thomas, D. P.; Sunters, A.; Vuillier, C.; Bozec, A.; El-Emir, E.; Miletich, I.; Patino-Garcia, A.; Lecanda, F.; Grigoriadis, A. E.			Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; C-FOS PROTOONCOGENE; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; TRANSGENIC MICE; BONE; DIFFERENTIATION; CANCER; OVEREXPRESSION; OSTEOBLASTS	Osteosarcoma is the most common primary malignancy of the skeleton and is prevalent in children and adolescents. Survival rates are poor and have remained stagnant owing to chemoresistance and the high propensity to form lung metastases. In this study, we used in vivo transgenic models of c-fos oncogene-induced osteosarcoma and chondrosarcoma in addition to c-Fos-inducible systems in vitro to investigate downstream signalling pathways that regulate osteosarcoma growth and metastasis. Fgfr1 (fibroblast growth factor receptor 1) was identified as a novel c-Fos/activator protein-1(AP-1)-regulated gene. Induction of c-Fos in vitro in osteoblasts and chondroblasts caused an increase in Fgfr1 RNA and FGFR1 protein expression levels that resulted in increased and sustained activation of mitogen-activated protein kinases (MAPKs), morphological transformation and increased anchorage-independent growth in response to FGF2 ligand treatment. High levels of FGFR1 protein and activated pFRS2 alpha signalling were observed in murine and human osteosarcomas. Pharmacological inhibition of FGFR1 signalling blocked MAPK activation and colony growth of osteosarcoma cells in vitro. Orthotopic injection in vivo of FGFR1-silenced osteosarcoma cells caused a marked twofold to fivefold decrease in spontaneous lung metastases. Similarly, inhibition of FGFR signalling in vivo with the small-molecule inhibitor AZD4547 markedly reduced the number and size of metastatic nodules. Thus deregulated FGFR signalling has an important role in osteoblast transformation and osteosarcoma formation and regulates the development of lung metastases. Our findings support the development of anti-FGFR inhibitors as potential antimetastatic therapy.	[Weekes, D.; Kashima, T. G.; Thomas, D. P.; Sunters, A.; Vuillier, C.; El-Emir, E.; Miletich, I.; Grigoriadis, A. E.] Kings Coll London, Dept Craniofacial Dev & Stem Cell Biol, London SE1 9RT, England; [Zandueta, C.; Perurena, N.; Lecanda, F.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, Adhes & Metastasis Lab, E-31080 Pamplona, Spain; [Bozec, A.] Univ Klinikum Erlangen, Dept Rheumatol & Immunol, Erlangen, Germany; [Patino-Garcia, A.] Univ Navarra, Ctr Appl Med Res CIMA, Lab Pediat, E-31080 Pamplona, Spain; [Patino-Garcia, A.; Lecanda, F.] Navarra Inst Hlth Res, IdiSNA, Pamplona, Spain; [Weekes, D.] Kings Coll London, Breakthrough Breast Canc Unit, London SE1 9RT, England; [Sunters, A.] Univ London Royal Vet Coll, London, England	University of London; King's College London; University of Navarra; University of Erlangen Nuremberg; University of Navarra; University of London; King's College London; University of London; University of London Royal Veterinary College	Grigoriadis, AE (corresponding author), Kings Coll London, Guys Hosp, Dept Craniofacial Dev & Stem Cell Biol, Tower Floor 27, London SE1 9RT, England.	agi.grigoriadis@kcl.ac.uk	Patiño-Garcia, Ana/I-4299-2012; Bozec, Aline/M-6942-2015	Patiño-Garcia, Ana/0000-0002-4066-8203; Bozec, Aline/0000-0001-8174-2118; Weekes, Daniel/0000-0001-8083-7617; Zandueta Pascual, Carolina/0000-0002-7931-8649; Miletich, Isabelle/0000-0003-2817-7492; Perurena, Naiara/0000-0003-0874-3389	Bone Cancer Research Trust, UK [BCRT04/07, BCRT09/08]; Wellcome Trust [059344]; Arthritis Research UK [G0538]; Medical Research Council [G78/4785]; 'UTE project FIMA' agreement; Cancer Research Thematic Network of the Health Institute Carlos III [RTICC RD06/0020/0066]; Spanish Ministry of Science and Innovation; European Regional Development Fund (ERDF); AECC grant	Bone Cancer Research Trust, UK; Wellcome Trust(Wellcome Trust); Arthritis Research UK(Versus Arthritis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); 'UTE project FIMA' agreement; Cancer Research Thematic Network of the Health Institute Carlos III; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Regional Development Fund (ERDF)(European Commission); AECC grant	This manuscript is dedicated to the memory of Dr Takeshi G Kashima, friend and colleague, without whom this work would not progress. We thank Dr M Albert Basson (KCL, London, UK), Dr Ozge Uluckan (CNIO, Madrid, Spain) and Dr Latifa Bakiri (CNIO, Madrid, Spain) for helpful comments and critical reading of the manuscript and Professor Larry J Suva (UAMS, Little Rock, AR, USA) for the microCT analysis. This work was supported in part by: Bone Cancer Research Trust, UK (BCRT04/07; BCRT09/08), Wellcome Trust (059344), Arthritis Research UK (G0538) and Medical Research Council (G78/4785) to AEG; 'UTE project FIMA' agreement, The Cancer Research Thematic Network of the Health Institute Carlos III (RTICC RD06/0020/0066), Spanish Ministry of Science and Innovation and European Regional Development Fund (ERDF) 'Una manera de hacer Europa' and AECC grant to FL. FL is an investigator from the I3 Program.	Amary MF, 2014, CANCER MED-US, V3, P980, DOI 10.1002/cam4.268; Ando Kosei, 2012, Sarcoma, V2012, P523432, DOI 10.1155/2012/523432; Behr B, 2010, BONE, V47, P281, DOI 10.1016/j.bone.2010.05.008; Bodo M, 2002, MOL MED, V8, P393, DOI 10.1007/BF03402020; Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111; Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Carter EP, 2015, TRENDS CELL BIOL, V25, P221, DOI 10.1016/j.tcb.2014.11.003; Chen Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098293; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; David JP, 2005, J CLIN INVEST, V115, P664, DOI 10.1172/JCI200522877; Durchdewald M, 2008, CANCER RES, V68, P6877, DOI 10.1158/0008-5472.CAN-08-0299; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FERRACINI R, 1995, ONCOGENE, V10, P739; Franchi A, 1998, VIRCHOWS ARCH, V432, P515, DOI 10.1007/s004280050199; Fujiwara M, 2011, TUMOR BIOL, V32, P611, DOI 10.1007/s13277-011-0160-y; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Greulich H, 2011, TRENDS MOL MED, V17, P283, DOI 10.1016/j.molmed.2011.01.012; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Grose R, 2007, EMBO J, V26, P1268, DOI 10.1038/sj.emboj.7601583; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Hajihosseini MK, 2004, DEVELOPMENT, V131, P325, DOI 10.1242/dev.00940; Jamil N, 2010, INT J EXP PATHOL, V91, P387, DOI 10.1111/j.1365-2613.2010.00749.x; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kashimaa TG, 2009, HUM PATHOL, V40, P226, DOI 10.1016/j.humpath.2008.07.008; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kunita A, 2011, AM J PATHOL, V179, P1041, DOI 10.1016/j.ajpath.2011.04.027; LADANYI M, 1993, DIAGN MOL PATHOL, V2, P163, DOI 10.1097/00019606-199303000-00024; Marie PJ, 2005, J CELL BIOCHEM, V96, P888, DOI 10.1002/jcb.20582; Marshall ME, 2011, CLIN CANCER RES, V17, P5016, DOI 10.1158/1078-0432.CCR-11-0050; Mills IG, 2012, SEMIN CELL DEV BIOL, V23, P165, DOI 10.1016/j.semcdb.2011.09.004; Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9; Ng AJM, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045-3329-2-19; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323; Sabbieti MG, 2005, CELL TISSUE RES, V319, P267, DOI 10.1007/s00441-004-0981-8; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Shimizu T, 2012, MOL CANCER RES, V10, P454, DOI 10.1158/1541-7786.MCR-11-0347; Sorensen V, 2006, BIOESSAYS, V28, P504, DOI 10.1002/bies.20405; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Thomas DP, 2000, J CELL SCI, V113, P439; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008-5472.CAN-07-6493; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; WU JX, 1990, ONCOGENE, V5, P989; Yaguchi Y, 2009, DEV DYNAM, V238, P2058, DOI 10.1002/dvdy.22013; Zenz R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2338	53	38	38	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2852	2861		10.1038/onc.2015.344	http://dx.doi.org/10.1038/onc.2015.344			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387545	Green Accepted			2022-12-28	WOS:000377473700005
J	Meng, X; Vander Ark, A; Lee, P; Hostetter, G; Bhowmick, NA; Matrisian, LM; Williams, BO; Miranti, CK; Li, X				Meng, X.; Vander Ark, A.; Lee, P.; Hostetter, G.; Bhowmick, N. A.; Matrisian, L. M.; Williams, B. O.; Miranti, C. K.; Li, X.			Myeloid-specific TGF-beta signaling in bone promotes basic-FGF and breast cancer bone metastasis	ONCOGENE			English	Article							TUMOR-METASTASIS; II RECEPTOR; GROWTH; CELLS; PROGRESSION; EXPRESSION	Breast cancer (BCa) bone metastases cause osteolytic bone lesions, which result from the interactions of metastatic BCa cells with osteoclasts and osteoblasts. Osteoclasts differentiate from myeloid lineage cells. To understand the cell-specific role of transforming growth factor beta (TGF-beta) in the myeloid lineage, in BCa bone metastases, MDA-MB-231 BCa cells were intra-tibially or intra-cardially injected into LysM(Cre)/Tgfbr2(floxE2/floxE2) knockout (LysM(Cre)/Tgfbr2 KO) or Tgfbr2(floxE2/floxE2) mice. Metastatic bone lesion development was compared by analysis of both lesion number and area. We found that LysM(Cre)/Tgfbr2 knockout significantly decreased MDA-MB-231 bone lesion development in both the cardiac and tibial injection models. LysM(Cre)/Tgfbr2 knockout inhibited the tumor cell proliferation, angiogenesis and osteoclastogenesis of the metastatic bones. Cytokine array analysis showed that basic fibroblast growth factor (bFGF) was downregulated in MDA-MB-231-injected tibiae from the LysM(Cre)/Tgfbr2 KO group, and intravenous injection of the recombinant bFGF to LysM(Cre)/Tgfbr2 KO mice rescued the inhibited metastatic bone lesion development. The mechanism by which bFGF rescued the bone lesion development was by promotion of tumor cell proliferation through the downstream mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK)-cFos pathway after binding to the FGF receptor 1 (FGFR1). Consistent with animal studies, we found that in human BCa bone metastatic tissues, TGF-beta type II receptor (T beta RII) and p-Smad2 were expressed in osteoclasts and tumor cells, and were correlated with the expression of FGFR1. Our studies suggest that myeloid-specific TGF-beta signaling-mediated bFGF in the bone promotes BCa bone metastasis.	[Meng, X.; Vander Ark, A.; Lee, P.; Williams, B. O.; Miranti, C. K.; Li, X.] Van Andel Res Inst, Ctr Canc & Cell Biol, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA; [Hostetter, G.] Van Andel Res Inst, Pathol & Biorepository Core, Grand Rapids, MI 49503 USA; [Bhowmick, N. A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Bhowmick, N. A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Matrisian, L. M.] Pancreat Canc Act Network, Washington, DC USA	Van Andel Institute; Van Andel Institute; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Li, X (corresponding author), Van Andel Res Inst, Ctr Canc & Cell Biol, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA.	xiaohong.li@vai.org	Miranti, Cindy/AAJ-3783-2020; Williams, Bart/A-3539-2013; Bhowmick, Neil/AAA-7302-2019	Williams, Bart/0000-0002-5261-5301; Bhowmick, Neil/0000-0001-8747-5989; Meng, Xiangqi/0000-0002-6407-6122; , Xiaohong/0000-0001-5074-193X	Van Andel Research Institute [53010A]	Van Andel Research Institute	We thank Dr Julie A Sterling from Vanderbilt University and Dr Yibin Kang from Princeton University for providing cell lines. The Van Andel Research Institute supported this research (VARI start-up to X Li, 53010A). We thank Lisa Turner of the Pathology and Biorepository Core for her pathology expertise, the Vivarium and Transgenics Core for animal technical assistance and Diana Lewis for administrative support. We thank Dr Travis Burgers for the construction of 3D micro-CT pictures. Special thanks to Dr Mary E Winn from the Bioinformatics and Biostatistics Core for her great help in answering statistical questions. Finally, we thank David Nadziejka for his technical editing of this manuscript. The content is solely the responsibility of the authors.	Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; BRUNNER G, 1993, BLOOD, V81, P631; Busch S, 2015, ONCOGENE, V34, P27, DOI 10.1038/onc.2013.527; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Cheng N, 2007, CANCER RES, V67, P4869, DOI 10.1158/0008-5472.CAN-06-3381; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Courjal F, 1997, CANCER RES, V57, P4360; Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Johnson RW, 2014, CLIN EXP METASTAS, V31, P945, DOI 10.1007/s10585-014-9682-1; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Li XH, 2012, MOL CANCER RES, V10, P494, DOI 10.1158/1541-7786.MCR-11-0506; Novitskiy SV, 2012, J LEUKOCYTE BIOL, V92, P641, DOI 10.1189/jlb.1211639; Pang YL, 2013, CANCER DISCOV, V3, P936, DOI 10.1158/2159-8290.CD-12-0527; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Reddi AH, 2003, J BONE MINER RES, V18, P190, DOI 10.1359/jbmr.2003.18.2.190; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332; Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109	23	33	34	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2370	2378		10.1038/onc.2015.297	http://dx.doi.org/10.1038/onc.2015.297			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26279296				2022-12-28	WOS:000376165000009
J	Golmard, L; Delnatte, C; Lauge, A; Moncoutier, V; Lefol, C; Abidallah, K; Tenreiro, H; Copigny, F; Giraudeau, M; Guy, C; Barbaroux, C; Amorim, G; Briaux, A; Guibert, V; Tarabeux, J; Caputo, S; Collet, A; Gesta, P; Ingster, O; Stern, MH; Rouleau, E; De Pauw, A; Gauthier-Villars, M; Buecher, B; Bezieau, S; Stoppa-Lyonnet, D; Houdayer, C				Golmard, L.; Delnatte, C.; Lauge, A.; Moncoutier, V.; Lefol, C.; Abidallah, K.; Tenreiro, H.; Copigny, F.; Giraudeau, M.; Guy, C.; Barbaroux, C.; Amorim, G.; Briaux, A.; Guibert, V.; Tarabeux, J.; Caputo, S.; Collet, A.; Gesta, P.; Ingster, O.; Stern, M-H; Rouleau, E.; De Pauw, A.; Gauthier-Villars, M.; Buecher, B.; Bezieau, S.; Stoppa-Lyonnet, D.; Houdayer, C.			Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations	ONCOGENE			English	Article							DE-NOVO MUTATIONS; ONSET BREAST; HEREDITARY BREAST; GENE BRCA1; PATIENT; WOMAN; SUSCEPTIBILITY; IDENTIFICATION; DIAGNOSTICS; PREVALENCE	BRCA1 and BRCA2 are the two major genes predisposing to breast and ovarian cancer. Whereas high de novo mutation rates have been demonstrated for several genes, only 11 cases of de novo BRCA1/2 mutations have been reported to date and the BRCA1/2 de novo mutation rate remains unknown. The present study was designed to fill this gap based on a series of 12 805 consecutive unrelated patients diagnosed with breast and/or ovarian cancer who met the inclusion criteria for BRCA1/2 gene analysis according to French guidelines. BRCA1/2 mutations were detected in 1527 (12%) patients, and three BRCA1 mutations and one BRCA2 mutation were de novo. The BRCA1/2 de novo mutation rate was estimated to be 0.3% (0.1%; 0.7%). Although rare, it may be useful to take the possibility of de novo BRCA1/2 mutation into account in genetic counseling of relatives and to improve the understanding of complex family histories of breast and ovarian cancers.	[Golmard, L.; Lauge, A.; Moncoutier, V.; Lefol, C.; Abidallah, K.; Tenreiro, H.; Copigny, F.; Giraudeau, M.; Guy, C.; Barbaroux, C.; Amorim, G.; Briaux, A.; Tarabeux, J.; Caputo, S.; Collet, A.; Stern, M-H; Rouleau, E.; De Pauw, A.; Gauthier-Villars, M.; Buecher, B.; Stoppa-Lyonnet, D.; Houdayer, C.] Inst Curie, Dept Biopathol, F-75005 Paris, France; [Golmard, L.; Tarabeux, J.; Stern, M-H; Stoppa-Lyonnet, D.; Houdayer, C.] Inst Curie, INSERM, U830, F-75005 Paris, France; [Delnatte, C.; Guibert, V.; Bezieau, S.] CHU Nantes, Serv Genet Med, F-44035 Nantes 01, France; [Gesta, P.] Oncogenet Poitou Charentes, Pole Oncol, Niort, France; [Ingster, O.] CHU Angers, Serv Genet Med, Angers, France; [Bezieau, S.] Univ Nantes, Fac Med Nantes, Nantes, France; [Stoppa-Lyonnet, D.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Houdayer, C.] Univ Paris 05, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Nantes Universite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Houdayer, C (corresponding author), Inst Curie, Lab Genet Constitut, 26 Rue Ulm, F-75005 Paris, France.	claude.houdayer@curie.fr	Bézieau, stéphane/G-5621-2015; Stern, Marc-Henri/A-2728-2011; De Pauw, Antoine/ABC-6019-2020; Caputo, Sandrine M/I-7460-2019; Lambert, Blandine S/O-6002-2016; Caputo, Sandrine M./C-3860-2018	Bézieau, stéphane/0000-0003-0095-1319; Stern, Marc-Henri/0000-0002-8100-2272; De Pauw, Antoine/0000-0003-3898-073X; Lambert, Blandine S/0000-0002-8429-2404; Caputo, Sandrine M./0000-0001-5338-9388				Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Biesecker LG, 2013, NAT REV GENET, V14, P307, DOI 10.1038/nrg3424; Bonaiti B, 2014, J MED GENET, V51, P114, DOI 10.1136/jmedgenet-2013-101674; Caputo S, 2012, NUCLEIC ACIDS RES, V40, pD992, DOI 10.1093/nar/gkr1160; Caux-Moncoutier V, 2011, HUM MUTAT, V32, P325, DOI 10.1002/humu.21414; De Leeneer K, 2012, BREAST CANCER RES TR, V132, P87, DOI 10.1007/s10549-011-1544-9; Delon I, 2013, CLIN GENET, V84, P297, DOI 10.1111/cge.12057; Diez O, 2010, BREAST CANCER RES TR, V121, P221, DOI 10.1007/s10549-009-0494-y; Edwards E, 2009, FAM CANCER, V8, P479, DOI 10.1007/s10689-009-9270-8; Friedman E, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1387; Garcia-Casado Z, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-134; Hansen TVO, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-58; Hodgkinson A, 2011, NAT REV GENET, V12, P756, DOI 10.1038/nrg3098; Houdayer C, 2012, RETINOBLASTOMA UPDAT, P55, DOI [10.5772/34069, DOI 10.5772/34069]; Kwong A, 2011, FAM CANCER, V10, P233, DOI 10.1007/s10689-011-9429-y; Marshall M, 2009, CLIN GENET, V76, P427, DOI 10.1111/j.1399-0004.2009.01246.x; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moslehi R, 2010, AM J HUM BIOL, V22, P201, DOI 10.1002/ajhb.20978; Pal T, 2010, FERTIL STERIL, V93, P1805, DOI 10.1016/j.fertnstert.2008.12.052; Ripa R, 2002, EUR J HUM GENET, V10, P631, DOI 10.1038/sj.ejhg.5200853; Robson M, 2002, J MED GENET, V39, P126, DOI 10.1136/jmg.39.2.126; Rouleau E, 2007, CLIN GENET, V72, P199, DOI 10.1111/j.1399-0004.2007.00849.x; Tarabeux J, 2014, EUR J HUM GENET, V22, P535, DOI 10.1038/ejhg.2013.181; Tesoriero A, 1999, AM J HUM GENET, V65, P567, DOI 10.1086/302503; van der Luijt RB, 2001, J MED GENET, V38, P102, DOI 10.1136/jmg.38.2.102; van Minkelen R, 2014, CLIN GENET, V85, P318, DOI 10.1111/cge.12187; Veltman JA, 2012, NAT REV GENET, V13, P565, DOI 10.1038/nrg3241; Walsh T, 2010, P NATL ACAD SCI USA, V107, P12629, DOI 10.1073/pnas.1007983107; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang L, 2011, CLIN GENET, V80, P97, DOI 10.1111/j.1399-0004.2011.01691.x	32	24	24	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1324	1327		10.1038/onc.2015.181	http://dx.doi.org/10.1038/onc.2015.181			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028024				2022-12-28	WOS:000371763100012
J	Hubackova, S; Kucerova, A; Michlits, G; Kyjacova, L; Reinis, M; Korolov, O; Bartek, J; Hodny, Z				Hubackova, S.; Kucerova, A.; Michlits, G.; Kyjacova, L.; Reinis, M.; Korolov, O.; Bartek, J.; Hodny, Z.			IFN gamma induces oxidative stress, DNA damage and tumor cell senescence via TGF beta/SMAD signaling-dependent induction of Nox4 and suppression of ANT2	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; ADENINE-NUCLEOTIDE TRANSLOCATOR-2; NADPH OXIDASE NOX4; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; MESENCHYMAL TRANSITION; SECRETORY PHENOTYPE; HUMAN FIBROBLASTS; GENE-EXPRESSION; UP-REGULATION	Cellular senescence provides a biological barrier against tumor progression, often associated with oncogene-induced replication and/or oxidative stress, cytokine production and DNA damage response (DDR), leading to persistent cell-cycle arrest. While cytokines such as tumor necrosis factor-alpha (TNF alpha) and interferon gamma (IFN gamma) are important components of senescence-associated secretome and induce senescence in, for example, mouse pancreatic beta-cancer cell model, their downstream signaling pathway(s) and links with oxidative stress and DDR are mechanistically unclear. Using human and mouse normal and cancer cell models, we now show that TNF alpha and IFN gamma induce NADPH oxidases Nox4 and Nox1, reactive oxygen species (ROS), DDR signaling and premature senescence. Unlike mouse tumor cells that required concomitant presence of IFN gamma and TNF alpha, short exposure to IFN gamma alone was sufficient to induce Nox4, Nox1 and DDR in human cells. siRNA-mediated knockdown of Nox4 but not Nox1 decreased IFN gamma-induced DDR. The expression of Nox4/Nox1 required Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling and the effect was mediated by downstream activation of transforming growth factor-beta (TGF beta) secretion and consequent autocrine/paracrine activation of the TGF beta/Smad pathway. Furthermore, the expression of adenine nucleotide translocase 2 (ANT2) was suppressed by IFN gamma contributing to elevation of ROS and DNA damage. In contrast to mouse B16 cells, inability of TC-1 cells to respond to IFN gamma/TNF alpha by DDR and senescence correlated with the lack of TGF beta and Nox4 response, supporting the role of ROS induced by NADPH oxidases in cytokine-induced senescence. Overall, our data reveal differences between cytokine effects in mouse and human cells, and mechanistically implicate the TGF beta/SMAD pathway, via induction of NADPH oxidases and suppression of ANT2, as key mediators of IFN gamma/TNF alpha-evoked genotoxicity and cellular senescence.	[Hubackova, S.; Kucerova, A.; Kyjacova, L.; Bartek, J.; Hodny, Z.] Acad Sci Czech Republ, Dept Genome Integr, Inst Mol Genet, Vvi, Videnska 1083, CZ-14220 Prague 4, Czech Republic; [Michlits, G.; Reinis, M.; Korolov, O.] Acad Sci Czech Republ, Dept Tumour Immunol, Inst Mol Genet, Vvi, CZ-14220 Prague 4, Czech Republic; [Bartek, J.] Danish Canc Soc, Res Ctr, Genome Integr Unit, Strandblvd 49, DK-2100 Copenhagen, Denmark; [Michlits, G.; Reinis, M.; Korolov, O.] Acad Sci Czech Republ, Immunol Lab, Czech Ctr Phenogen, Inst Mol Genet,Vvi, CZ-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Danish Cancer Society; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Bartek, J; Hodny, Z (corresponding author), Acad Sci Czech Republ, Dept Genome Integr, Inst Mol Genet, Vvi, Videnska 1083, CZ-14220 Prague 4, Czech Republic.; Bartek, J (corresponding author), Danish Canc Soc, Res Ctr, Genome Integr Unit, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk; hodny@img.cas.cz	Uvizl, Alena/AAL-8198-2021	Uvizl, Alena/0000-0002-5819-1482; Michlits, Georg/0000-0002-3337-8291; Stemberkova Hubackova, Sona/0000-0002-3454-6840	Grant Agency of the Czech Republic [13-17658S]; Grant Agency of the Ministry of Health of the Czech Republic [NT14461]; Academy of Sciences of the Czech Republic [L200521301]; Faculty of Science, Charles University, Prague;  [RVO 68378050]; Lundbeck Foundation [R93-2011-8990] Funding Source: researchfish; Novo Nordisk Fonden [NNF15OC0016584, NNF12OC0002290] Funding Source: researchfish; The Danish Cancer Society [R124-A7785] Funding Source: researchfish	Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Grant Agency of the Ministry of Health of the Czech Republic; Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Faculty of Science, Charles University, Prague; ; Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Fonden(Novo Nordisk Foundation); The Danish Cancer Society(Danish Cancer Society)	We thank Marketa Vancurova and Katerina Krejcikova for excellent technical assistance. This study was supported by the Grant Agency of the Czech Republic (Project 13-17658S), NT14461 grant from the Grant Agency of the Ministry of Health of the Czech Republic and Institutional Grant (Project RVO 68378050). SH was supported by Academy of Sciences of the Czech Republic (Project L200521301), LK was supported in part by the Faculty of Science, Charles University, Prague.	AARDEN LA, 1989, ANN NY ACAD SCI, V557, P192; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Adachi Y, 2008, ONCOGENE, V27, P4921, DOI 10.1038/onc.2008.133; Altenhofer S, 2012, CELL MOL LIFE SCI, V69, P2327, DOI 10.1007/s00018-012-1010-9; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Barath P, 1999, EXP CELL RES, V248, P583, DOI 10.1006/excr.1999.4432; Bartek J, 2008, NAT CELL BIOL, V10, P887, DOI 10.1038/ncb0808-887; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Besancenot R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000476; Boudreau HE, 2012, FREE RADICAL BIO MED, V53, P1489, DOI 10.1016/j.freeradbiomed.2012.06.016; Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Braumuller H, 2013, NATURE, V494, P361, DOI 10.1038/nature11824; Caja L, 2009, CANCER RES, V69, P7595, DOI 10.1158/0008-5472.CAN-09-1482; Carmona-Cuenca I, 2008, J HEPATOL, V49, P965, DOI 10.1016/j.jhep.2008.07.021; Chainiaux F, 2002, ANN NY ACAD SCI, V973, P44, DOI 10.1111/j.1749-6632.2002.tb04603.x; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chiantore MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036909; Chiera F, 2008, FREE RADICAL BIO MED, V44, P332, DOI 10.1016/j.freeradbiomed.2007.09.018; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009188; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di X, 2008, CANCER BIOL THER, V7, P864, DOI 10.4161/cbt.7.6.5861; Ding GH, 2001, EXP MOL PATHOL, V70, P43, DOI 10.1006/exmp.2000.2346; Evangelou K, 2013, CELL DEATH DIFFER, V20, P1485, DOI 10.1038/cdd.2013.76; Fazeli G, 2012, MUTAGENESIS, V27, P673, DOI 10.1093/mutage/ges033; Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200; Geiszt M, 2006, CARDIOVASC RES, V71, P289, DOI 10.1016/j.cardiores.2006.05.004; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harris JE, 2007, FASEB J, V21, P356, DOI 10.1096/fj.06-6925com; Hiraga R, 2013, ANTICANCER RES, V33, P4431; Hu TS, 2005, AM J PHYSIOL-RENAL, V289, pF816, DOI 10.1152/ajprenal.00024.2005; Hubackova S, 2012, AGING-US, V4, P932, DOI 10.18632/aging.100520; Hubackova S, 2012, J BIOL CHEM, V287, P26702, DOI 10.1074/jbc.M111.316869; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Katakura Y, 2003, BIOSCI BIOTECH BIOCH, V67, P815, DOI 10.1271/bbb.67.815; Kaynor C, 2002, J INTERF CYTOK RES, V22, P1089, DOI 10.1089/10799900260442511; Kim HS, 2012, FREE RADICAL RES, V46, P21, DOI 10.3109/10715762.2011.636042; Kim KS, 2009, MECH AGEING DEV, V130, P179, DOI 10.1016/j.mad.2008.11.004; Kodama R, 2013, GENES CELLS, V18, P32, DOI 10.1111/gtc.12015; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Koziel R, 2013, BIOCHEM J, V452, P231, DOI 10.1042/BJ20121778; Kretova M, 2014, CELL SIGNAL, V26, P2903, DOI 10.1016/j.cellsig.2014.08.029; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Laberge RM, 2012, CANCER MICROENVIRON, V5, P39, DOI 10.1007/s12307-011-0069-4; Lena A, 2010, FEBS J, V277, P2853, DOI 10.1111/j.1742-4658.2010.07702.x; Lener B, 2009, BIOCHEM J, V423, P363, DOI 10.1042/BJ20090666; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luciakova K, 2003, J BIOL CHEM, V278, P30624, DOI 10.1074/jbc.M303530200; Luciakova K, 2008, BIOCHEM J, V412, P123, DOI 10.1042/BJ20071440; Luciakova K, 2011, BIOCHEM BIOPH RES CO, V411, P648, DOI 10.1016/j.bbrc.2011.07.017; Maghzal GJ, 2012, FREE RADICAL BIO MED, V53, P1903, DOI 10.1016/j.freeradbiomed.2012.09.002; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Manea A, 2010, BIOCHEM BIOPH RES CO, V396, P901, DOI 10.1016/j.bbrc.2010.05.019; Manea A, 2010, ARTERIOSCL THROM VAS, V30, P105, DOI 10.1161/ATVBAHA.109.193896; Michaeloudes C, 2011, AM J PHYSIOL-LUNG C, V300, pL295, DOI 10.1152/ajplung.00134.2010; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Minamino T, 2003, CIRCULATION, V108, P2264, DOI 10.1161/01.CIR.0000093274.82929.22; Moiseeva O, 2006, MOL BIOL CELL, V17, P1583, DOI 10.1091/mbc.E05-09-0858; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839; Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x; Novakova Z, 2010, ONCOGENE, V29, P273, DOI 10.1038/onc.2009.318; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Panieri E, 2013, FREE RADICAL BIO MED, V57, P176, DOI 10.1016/j.freeradbiomed.2012.12.024; Rajagopalan S, 2012, P NATL ACAD SCI USA, V109, P20596, DOI 10.1073/pnas.1208248109; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sagiv A, 2013, ONCOGENE, V32, P1971, DOI 10.1038/onc.2012.206; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stadler M, 1995, ONCOGENE, V11, P2565; Sturrock A, 2006, AM J PHYSIOL-LUNG C, V290, pL661, DOI 10.1152/ajplung.00269.2005; Takacova S, 2012, CANCER CELL, V21, P517, DOI 10.1016/j.ccr.2012.01.021; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vlasakova J, 2007, BLOOD, V109, P1373, DOI 10.1182/blood-2006-02-003418; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wieder T, 2013, CELL CYCLE, V12, P3146, DOI 10.4161/cc.26060; Xu PL, 2012, FEBS LETT, V586, P1871, DOI 10.1016/j.febslet.2012.05.010; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang KE, 2011, MOL CELLS, V32, P99, DOI 10.1007/s10059-011-0064-0; Yoon G, 2002, BIOCHEM J, V366, P613, DOI 10.1042/BJ20011445; Yu Q, 2000, GENE DEV, V14, P163	97	57	58	3	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1236	1249		10.1038/onc.2015.162	http://dx.doi.org/10.1038/onc.2015.162			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	25982278				2022-12-28	WOS:000371763100004
J	Samanta, S; Sun, H; Goel, HL; Pursell, B; Chang, C; Khan, A; Greiner, DL; Cao, S; Lim, E; Shultz, LD; Mercurio, AM				Samanta, S.; Sun, H.; Goel, H. L.; Pursell, B.; Chang, C.; Khan, A.; Greiner, D. L.; Cao, S.; Lim, E.; Shultz, L. D.; Mercurio, A. M.			IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG	ONCOGENE			English	Article							REPRESSES E-CADHERIN; SELF-RENEWAL; CARCINOMA PHENOTYPE; TGF-BETA; CELLS; SOX2; EXPRESSION; IDENTIFICATION; TRANSITIONS; RESISTANCE	IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is an oncofetal protein whose expression is prognostic for poor outcome in several cancers. Although IMP3 is expressed preferentially in triple-negative breast cancer (TNBC), its function is poorly understood. We observed that IMP3 expression is significantly higher in tumor initiating than in non-tumor initiating breast cancer cells and we demonstrate that IMP3 contributes to self-renewal and tumor initiation, properties associated with cancer stem cells (CSCs). The mechanism by which IMP3 contributes to this phenotype involves its ability to induce the stem cell factor SOX2. IMP3 does not interact with SOX2 mRNA significantly or regulate SOX2 expression directly. We discovered that IMP3 binds avidly to SNAI2 (SLUG) mRNA and regulates its expression by binding to the 5' UTR. This finding is significant because SLUG has been implicated in breast CSCs and TNBC. Moreover, we show that SOX2 is a transcriptional target of SLUG. These data establish a novel mechanism of breast tumor initiation involving IMP3 and they provide a rationale for its association with aggressive disease and poor outcome.	[Samanta, S.; Sun, H.; Goel, H. L.; Pursell, B.; Chang, C.; Mercurio, A. M.] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA; [Khan, A.] Univ Massachusetts, Sch Med, Dept Pathol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA; [Greiner, D. L.] Univ Massachusetts, Sch Med, Program Mol Med, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA; [Cao, S.; Lim, E.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Shultz, L. D.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Dana-Farber Cancer Institute; Jackson Laboratory	Mercurio, AM (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	arthur.mercurio@umassmed.edu	Lim, Elgene/AAS-7280-2020	Lim, Elgene/0000-0001-8065-8838; Cao, Shiliang/0000-0003-4908-0091; /0000-0003-1726-3037	Megan Lally Memorial Fund; NIH [CA168464, CA034196, AI46629]; National Breast Cancer Foundation [PRAC-14-002] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA168464, P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046629] Funding Source: NIH RePORTER	Megan Lally Memorial Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Breast Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Chung-Cheng Hsieh (University of Massachusetts Medical School) for statistical analysis of our in vivo data. This work was supported by the Megan Lally Memorial Fund and NIH Grants CA168464, CA034196 and AI46629.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaudhary J, 1999, MOL ENDOCRINOL, V13, P774, DOI 10.1210/me.13.5.774; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goel HL, 2014, CELL REP, V7, P747, DOI 10.1016/j.celrep.2014.03.059; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Hajra KM, 2002, CANCER RES, V62, P1613; Idowu MO, 2012, HUM PATHOL, V43, P364, DOI 10.1016/j.humpath.2011.05.005; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; Jiang Z, 2006, LANCET ONCOL, V7, P556, DOI 10.1016/S1470-2045(06)70732-X; Jonson L, 2014, CELL REP, V7, P539, DOI 10.1016/j.celrep.2014.03.015; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kono K, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-141; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Mak P, 2006, NEOPLASIA, V8, P896, DOI 10.1593/neo.06538; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rodriguez-Pinilla SM, 2007, MODERN PATHOL, V20, P474, DOI 10.1038/modpathol.3800760; Rybak AP, 2013, CELL SIGNAL, V25, P2734, DOI 10.1016/j.cellsig.2013.08.041; Samanta S, 2012, ONCOGENE, V31, P4689, DOI 10.1038/onc.2011.620; Samanta S, 2013, J BIOL CHEM, V288, P12569, DOI 10.1074/jbc.C112.442319; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; Su P, 2014, INT J CLIN EXP PATHO, V7, P3008; Tada Y, 2015, ONCOGENE, V34, P752, DOI 10.1038/onc.2013.599; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Walter O, 2009, HUM PATHOL, V40, P1528, DOI 10.1016/j.humpath.2009.05.005; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhao XL, 2015, ONCOL REP, V33, P149, DOI 10.3892/or.2014.3562	50	42	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1111	1121		10.1038/onc.2015.164	http://dx.doi.org/10.1038/onc.2015.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982283	Green Accepted			2022-12-28	WOS:000371351700005
J	Zlatanou, A; Sabbioneda, S; Miller, ES; Greenwalt, A; Aggathanggelou, A; Maurice, MM; Lehmann, AR; Stankovic, T; Reverdy, C; Colland, F; Vaziri, C; Stewart, GS				Zlatanou, A.; Sabbioneda, S.; Miller, E. S.; Greenwalt, A.; Aggathanggelou, A.; Maurice, M. M.; Lehmann, A. R.; Stankovic, T.; Reverdy, C.; Colland, F.; Vaziri, C.; Stewart, G. S.			USP7 is essential for maintaining Rad18 stability and DNA damage tolerance	ONCOGENE			English	Article							UBIQUITIN-SPECIFIC PROTEASE; CELL NUCLEAR ANTIGEN; POLYMERASE-ETA; PCNA MONOUBIQUITINATION; TRANSLESION SYNTHESIS; MAMMALIAN-CELLS; BINDING MOTIF; POL-ETA; S-PHASE; REV1	Rad18 functions at the cross-roads of three different DNA damage response (DDR) pathways involved in protecting stressed replication forks: homologous recombination repair, DNA inter-strand cross-link repair and DNA damage tolerance. Although Rad18 serves to facilitate replication of damaged genomes by promoting translesion synthesis (TLS), this comes at a cost of potentially error-prone lesion bypass. In contrast, loss of Rad18-dependent TLS potentiates the collapse of stalled forks and leads to incomplete genome replication. Given the pivotal nature with which Rad18 governs the fine balance between replication fidelity and genome stability, Rad18 levels and activity have a major impact on genomic integrity. Here, we identify the de-ubiquitylating enzyme USP7 as a critical regulator of Rad18 protein levels. Loss of USP7 destabilizes Rad18 and compromises UV-induced PCNA mono-ubiquitylation and Pol eta recruitment to stalled replication forks. USP7-depleted cells also fail to elongate nascent daughter strand DNA following UV irradiation and show reduced DNA damage tolerance. We demonstrate that USP7 associates with Rad18 directly via a consensus USP7-binding motif and can disassemble Rad18-dependent poly-ubiquitin chains both in vitro and in vivo. Taken together, these observations identify USP7 as a novel component of the cellular DDR involved in preserving the genome stability.	[Zlatanou, A.; Miller, E. S.; Aggathanggelou, A.; Stankovic, T.; Stewart, G. S.] Univ Birmingham, Sch Canc Sci, Vincent Dr, Birmingham B15 2TT, W Midlands, England; [Sabbioneda, S.] CNR, Ist Genet Mol, I-27100 Pavia, Italy; [Greenwalt, A.; Vaziri, C.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Maurice, M. M.] UMCU, Heidelberglaan 100, Utrecht, Netherlands; [Lehmann, A. R.] Univ Sussex, MRC Genome Damage & Stabil Ctr, Brighton, E Sussex, England; [Reverdy, C.; Colland, F.] Hybrigen Pharma, Paris, France	University of Birmingham; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of North Carolina; University of North Carolina Chapel Hill; Unilever; Utrecht University; Utrecht University Medical Center; University of Sussex	Stewart, GS (corresponding author), Univ Birmingham, Sch Canc Sci, Vincent Dr, Birmingham B15 2TT, W Midlands, England.	g.s.stewart@bham.ac.uk	Sabbioneda, Simone/N-7017-2015	Sabbioneda, Simone/0000-0001-8551-5465; Maurice, Madelon/0000-0001-6885-5361; Stankovic, Tatjana/0000-0002-3780-274X; Stewart, Grant/0000-0002-0960-3241	Lister Institute Research Prize; WWCR [13-1012]; CR-UK Senior Research Fellowship [C17183/A13030]; LLR [11045]; AIRC [12710]; 7th Framework Program [CIG 303806]; NIEHS [R01ES009558]; NCI [F31 CA177179]; University of Birmingham; MRC [G0501450] Funding Source: UKRI; Medical Research Council [G0501450] Funding Source: researchfish; Worldwide Cancer Research [13-1012] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [F31CA177179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009558] Funding Source: NIH RePORTER	Lister Institute Research Prize; WWCR; CR-UK Senior Research Fellowship; LLR; AIRC(Fondazione AIRC per la ricerca sul cancro); 7th Framework Program(European Commission); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Birmingham; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Worldwide Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Drs Akira Yasui, Jun Huang, Justin Leung, Junjie Chen and Patricia Kannouche for the kind gift of various Rad18 expression plasmids. We thank Drs Jan van der Knaap, Chris Boutell and Roger Everett for providing recombinant purified WT and catalytically inactive USP7 and Dr Jakob Nilsson for providing the HeLa Flp-In/T-Rex cells. We also thank Dr Malcolm Taylor for critical reading of the manuscript. This work was funded by a Lister Institute Research Prize (AZ and GS), a WWCR project grant (AZ and GS; 13-1012), a CR-UK Senior Research Fellowship (GS and EM; C17183/A13030) and a LLR program grant (AA and TS; 11045), SS was supported by an AIRC Grant 12710 and a 7th Framework Program (CIG 303806). CV was supported by R01ES009558 from the NIEHS. AMG was funded by a pre-doctoral fellowship (F31 CA177179) from the NCI. Lastly, we thank the University of Birmingham for supporting this work.	Bekes M, 2013, CELL REP, V5, P826, DOI 10.1016/j.celrep.2013.10.008; Bergink S, 2009, NATURE, V458, P461, DOI 10.1038/nature07963; Bi XH, 2006, MOL CELL BIOL, V26, P3527, DOI 10.1128/MCB.26.9.3527-3540.2006; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Bienko M, 2010, MOL CELL, V37, P396, DOI 10.1016/j.molcel.2009.12.039; Bomar MG, 2010, MOL CELL, V37, P408, DOI 10.1016/j.molcel.2009.12.038; Canning M, 2004, J BIOL CHEM, V279, P38160, DOI 10.1074/jbc.M402885200; Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535-7163.MCT-09-0097; Day TA, 2010, J CELL BIOL, V191, P953, DOI 10.1083/jcb.201006043; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Felle M, 2011, NUCLEIC ACIDS RES, V39, P8355, DOI 10.1093/nar/gkr528; Gan GN, 2008, CELL RES, V18, P174, DOI 10.1038/cr.2007.117; Garg P, 2005, P NATL ACAD SCI USA, V102, P18361, DOI 10.1073/pnas.0505949102; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guo CX, 2006, MOL CELL BIOL, V26, P8892, DOI 10.1128/MCB.01118-06; Hashimoto K, 2012, J BIOL CHEM, V287, P9613, DOI 10.1074/jbc.M111.331728; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang J, 2009, NAT CELL BIOL, V11, P592, DOI 10.1038/ncb1865; Huether R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4630; Jacq X, 2013, CELL BIOCHEM BIOPHYS, V67, P25, DOI 10.1007/s12013-013-9635-3; Jansen JG, 2009, MOL CELL BIOL, V29, P3113, DOI 10.1128/MCB.00071-09; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kim H, 2012, NAT STRUCT MOL BIOL, V19, P164, DOI 10.1038/nsmb.2222; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE CW, 1976, GENETICS, V82, P207; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lin JR, 2011, MOL CELL, V42, P237, DOI 10.1016/j.molcel.2011.02.026; Masuda Y, 2012, NUCLEIC ACIDS RES, V40, P1065, DOI 10.1093/nar/gkr805; McNally K, 2008, DNA REPAIR, V7, P597, DOI 10.1016/j.dnarep.2007.12.013; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Miyase S, 2005, J BIOL CHEM, V280, P515, DOI 10.1074/jbc.M409219200; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Nicholson B, 2011, CELL BIOCHEM BIOPHYS, V60, P61, DOI 10.1007/s12013-011-9185-5; Oh YM, 2007, BIOCHEM BIOPH RES CO, V357, P615, DOI 10.1016/j.bbrc.2007.03.193; Palle K, 2011, CELL CYCLE, V10, P1625, DOI 10.4161/cc.10.10.15617; PARRIS CN, 1992, GENE, V117, P1, DOI 10.1016/0378-1119(92)90482-5; Qian J, 2015, ONCOGENE, V34, P4791, DOI 10.1038/onc.2014.394; Qing P, 2011, J CELL BIOCHEM, V112, P3856, DOI 10.1002/jcb.23317; Reverdy C, 2012, CHEM BIOL, V19, P467, DOI 10.1016/j.chembiol.2012.02.007; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Stary A, 2003, J BIOL CHEM, V278, P18767, DOI 10.1074/jbc.M211838200; Tateishi S, 2003, MOL CELL BIOL, V23, P474, DOI 10.1128/MCB.23.2.474-481.2003; Wagner JM, 2009, MOL PHARMACOL, V76, P208, DOI 10.1124/mol.109.055178; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Wood A, 2007, J BIOL CHEM, V282, P20256, DOI 10.1074/jbc.M702366200; Yoon JH, 2012, P NATL ACAD SCI USA, V109, P7799, DOI 10.1073/pnas.1204105109; Zeman MK, 2014, J CELL BIOL, V206, P183, DOI 10.1083/jcb.201311063; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zlatanou A, 2011, MOL CELL, V43, P649, DOI 10.1016/j.molcel.2011.06.023	53	47	48	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					965	976		10.1038/onc.2015.149	http://dx.doi.org/10.1038/onc.2015.149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961918	Green Submitted			2022-12-28	WOS:000370823300003
J	Franciosa, G; Diluvio, G; Del Gaudio, F; Giuli, MV; Palermo, R; Grazioli, P; Campese, AF; Talora, C; Bellavia, D; D'Amati, G; Besharat, ZM; Nicoletti, C; Siebel, CW; Choy, L; Rustighi, A; Del Sal, G; Screpanti, I; Checquolo, S				Franciosa, G.; Diluvio, G.; Del Gaudio, F.; Giuli, M. V.; Palermo, R.; Grazioli, P.; Campese, A. F.; Talora, C.; Bellavia, D.; D'Amati, G.; Besharat, Z. M.; Nicoletti, C.; Siebel, C. W.; Choy, L.; Rustighi, A.; Del Sal, G.; Screpanti, I.; Checquolo, S.			Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; FACTOR-KAPPA-B; CELL LEUKEMIA; BREAST-CANCER; DOWN-REGULATION; PRE-TCR; DRUG-SENSITIVITY; INVASION	Deregulated Notch signaling is associated with T-cell Acute Lymphoblastic Leukemia (T-ALL) development and progression. Increasing evidence reveals that Notch pathway has an important role in the invasion ability of tumor cells, including leukemia, although the underlying molecular mechanisms remain mostly unclear. Here, we show that Notch3 is a novel target protein of the prolyl-isomerase Pin1, which is able to regulate Notch3 protein processing and to stabilize the cleaved product, leading to the increased expression of the intracellular domain (N3(IC)), finally enhancing Notch3-dependent invasiveness properties. We demonstrate that the combined inhibition of Notch3 and Pin1 in the Notch3-overexpressing human leukemic TALL-1 cells reduces their high invasive potential, by decreasing the expression of the matrix metalloprotease MMP9. Consistently, Pin1 depletion in a mouse model of Notch3-induced T-ALL, by reducing N3(IC) expression and signaling, impairs the expansion/invasiveness of CD4(+)CD8(+) DP cells in peripheral lymphoid and non-lymphoid organs. Notably, in in silico gene expression analysis of human T-ALL samples we observed a significant correlation between Pin1 and Notch3 expression levels, which may further suggest a key role of the newly identified Notch3-Pin1 axis in T-ALL aggressiveness and progression. Thus, combined suppression of Pin1 and Notch3 proteins may be exploited as an additional target therapy for T-ALL.	[Franciosa, G.; Diluvio, G.; Del Gaudio, F.; Giuli, M. V.; Grazioli, P.; Campese, A. F.; Talora, C.; Bellavia, D.; Besharat, Z. M.; Screpanti, I.] Sapienza Univ, Dept Mol Med, Lab Mol Pathol, Rome, Italy; [Palermo, R.; Screpanti, I.] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy; [D'Amati, G.] Sapienza Univ, Dept Radiol Oncol & Pathol Sci, Rome, Italy; [Nicoletti, C.] Sapienza Univ, Dept Anat Histol Forens Med & Orthopaed, Unit Histol & Med Embryol, Rome, Italy; [Siebel, C. W.; Choy, L.] Genentech Inc, Dept Discovery Oncol, San Francisco, CA USA; [Rustighi, A.; Del Sal, G.] Univ Trieste, Lab Nazl CIB Area Sci Pk Trieste, Trieste, Italy; [Rustighi, A.; Del Sal, G.] Univ Trieste, Dept Life Sci, Trieste, Italy; [Screpanti, I.] Sapienza Univ, Inst Pasteur, Fdn Cenci Bolognetti, Rome, Italy; [Checquolo, S.] Sapienza Univ, Dept Med Surg Sci & Biotechnol, Corso Repubbl 69, I-04100 Latina, Italy	Sapienza University Rome; Istituto Italiano di Tecnologia - IIT; Sapienza University Rome; Sapienza University Rome; Roche Holding; Genentech; University of Trieste; University of Trieste; Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome	Checquolo, S (corresponding author), Sapienza Univ, Dept Med Surg Sci & Biotechnol, Corso Repubbl 69, I-04100 Latina, Italy.; Screpanti, I (corresponding author), Sapienza Univ, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it; saula.checquolo@uniroma1.it	Talora, Claduio/AIC-4932-2022; Del Gaudio, Francesca/AAD-3685-2022; Bellavia, Diana/AAO-6348-2021; Besharat, Zein Mersini/G-5413-2013; Franciosa, Giulia/AAV-1211-2021; d'Amati, Giulia/F-1251-2011; Palermo, Rocco/I-5140-2016	Talora, Claduio/0000-0002-6973-2184; Del Gaudio, Francesca/0000-0001-8342-1377; Besharat, Zein Mersini/0000-0003-0317-9854; Franciosa, Giulia/0000-0001-5309-5558; d'Amati, Giulia/0000-0002-6959-691X; Palermo, Rocco/0000-0003-0134-9370; CHECQUOLO, Saula/0000-0001-5109-8392; CAMPESE, Antonio Francesco/0000-0002-8535-6609; NICOLETTI, Carmine/0000-0001-5896-2040; DILUVIO, GIULIA/0000-0002-9541-848X	Italian Association for Cancer Research (AIRC) [13214]; Italian Ministry of University and Research (MIUR); FIRB Program [RBAP11WCRZ]; PRIN (MCLPLB) Program; AIRC Special Program Molecular Clinical Oncology '5 per mille'; Italian Ministry of Health Ricerca-Finalizzata	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); FIRB Program(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); PRIN (MCLPLB) Program(Ministry of Education, Universities and Research (MIUR)); AIRC Special Program Molecular Clinical Oncology '5 per mille'(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health Ricerca-Finalizzata(Ministry of Health, Italy)	This work was supported by the Italian Association for Cancer Research (AIRC) IG 13214, the Italian Ministry of University and Research (MIUR), FIRB (RBAP11WCRZ) and PRIN (2010 MCLPLB) Programs to IS, AIRC Special Program Molecular Clinical Oncology '5 per mille', and Italian Ministry of Health Ricerca-Finalizzata 2011 to GDS.	Agnusdei V, 2014, LEUKEMIA, V28, P278, DOI 10.1038/leu.2013.183; Aifantis L, 1998, IMMUNITY, V9, P649, DOI 10.1016/S1074-7613(00)80662-7; Arasada RR, 2014, CANCER RES, V74, P5572, DOI 10.1158/0008-5472.CAN-13-3724; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Atchison FW, 2003, DEVELOPMENT, V130, P3579, DOI 10.1242/dev.00584; Baik SH, 2015, ANN NEUROL, V77, P504, DOI 10.1002/ana.24347; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Buonamici S, 2009, NATURE, V459, P1000, DOI 10.1038/nature08020; Campese AF, 2009, INT IMMUNOL, V21, P727, DOI 10.1093/intimm/dxp042; Checquolo S, 2010, ONCOGENE, V29, P1463, DOI 10.1038/onc.2009.446; Cialfi S, 2013, LEUKEMIA, V27, P485, DOI 10.1038/leu.2012.192; Demarest RM, 2011, BLOOD, V117, P2901, DOI 10.1182/blood-2010-05-286351; Fan G, 2009, CANCER RES, V69, P4589, DOI 10.1158/0008-5472.CAN-08-4117; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Ghisi M, 2011, BLOOD, V117, P7053, DOI 10.1182/blood-2010-12-326629; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; HIRAKI S, 1978, GANN, V69, P115; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Kumar V, 2014, LEUKEMIA, V28, P2324, DOI 10.1038/leu.2014.133; Lee SY, 2005, LEUKEMIA, V19, P1841, DOI 10.1038/sj.leu.2403896; Lin LI, 2002, BRIT J HAEMATOL, V117, P835, DOI 10.1046/j.1365-2141.2002.03510.x; Liou YC, 2011, TRENDS BIOCHEM SCI, V36, P501, DOI 10.1016/j.tibs.2011.07.001; Lopez-Guerra M, 2015, LEUKEMIA, V29, P96, DOI 10.1038/leu.2014.143; Louvi A, 2012, SEMIN CELL DEV BIOL, V23, P473, DOI 10.1016/j.semcdb.2012.02.005; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Mansour MR, 2006, LEUKEMIA, V20, P537, DOI 10.1038/sj.leu.2404101; Martin-Blanco NM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.438; Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Palermo R, 2014, CURR MOL MED, V14, P34, DOI 10.2174/1566524013666131118105216; Palermo R, 2012, ONCOGENE, V31, P3807, DOI 10.1038/onc.2011.533; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pelullo M, 2014, NEOPLASIA, V16, P1007, DOI 10.1016/j.neo.2014.10.004; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Redondo-Munoz J, 2010, CANCER CELL, V17, P160, DOI 10.1016/j.ccr.2009.12.044; Rustighi A, 2014, EMBO MOL MED, V6, P99, DOI 10.1002/emmm.201302909; Rustighi A, 2009, NAT CELL BIOL, V11, P133, DOI 10.1038/ncb1822; Santarpia L, 2012, BREAST CANCER RES TR, V134, P333, DOI 10.1007/s10549-012-2035-3; Screpanti I, 2003, TRENDS MOL MED, V9, P30, DOI 10.1016/S1471-4914(02)00003-5; Sorrentino G, 2014, MITOCHONDRION, V19, P88, DOI 10.1016/j.mito.2014.08.003; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Vacca A, 2000, Dev Immunol, V7, P77, DOI 10.1155/2000/74372; Wang J, 2011, ONCOL REP, V26, P1295, DOI 10.3892/or.2011.1399; Wang XW, 2015, ONCOL REP, V33, P1402, DOI 10.3892/or.2015.3731; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Wei S, 2015, NAT MED, V21, P457, DOI 10.1038/nm.3839; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yin CC, 2015, EXP CELL RES, V332, P39, DOI 10.1016/j.yexcr.2015.01.008; Zampieri M, 2014, BBA-GENE REGUL MECH, V1839, P813, DOI 10.1016/j.bbagrm.2014.06.017; Zhang ZY, 2010, AM J PATHOL, V177, P1459, DOI 10.2353/ajpath.2010.090476; Zhou L, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057382, 10.1371/journal.pone.0073724]; Zou J, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-3	65	41	43	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4741	4751		10.1038/onc.2016.5	http://dx.doi.org/10.1038/onc.2016.5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876201	hybrid, Green Published			2022-12-28	WOS:000383324700007
J	Moles, A; Butterworth, JA; Sanchez, A; Hunter, JE; Leslie, J; Sellier, H; Tiniakos, D; Cockell, SJ; Mann, DA; Oakley, F; Perkins, ND				Moles, A.; Butterworth, J. A.; Sanchez, A.; Hunter, J. E.; Leslie, J.; Sellier, H.; Tiniakos, D.; Cockell, S. J.; Mann, D. A.; Oakley, F.; Perkins, N. D.			A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-kappa B-dependent liver regeneration and cancer	ONCOGENE			English	Article							ARF TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; CELL-FUNCTION; P65; PHOSPHORYLATION; TRANSACTIVATION; INFLAMMATION; REPRESSION; DISEASE	Post-translational modifications of nuclear factor (NF)-kappa B subunits provide a mechanism to differentially regulate their activity in response to the many stimuli that induce this pathway. However, the physiological significance of these modifications is largely unknown, and it remains unclear if these have a critical role in the normal and pathological functions of NF-kappa B in vivo. Among these, phosphorylation of the RelA(p65) Thr505 residue has been described as an important regulator of NF-kappa B activity in cell lines, but its physiological significance was not known. Therefore, to learn more about the role of this pathway in vivo, we generated a knockin mouse with a RelA T505A mutation. Unlike RelA knockout mice, the RelA T505A mice develop normally but exhibit aberrant hepatocyte proliferation following liver partial hepatectomy or damage resulting from carbon tetrachloride (CCl4) treatment. Consistent with these effects, RelA T505A mice exhibit earlier onset of cancer in the N-nitrosodiethylamine model of hepatocellular carcinoma. These data reveal a critical pathway controlling NF-kappa B function in the liver that acts to suppress the tumour-promoting activities of RelA.	[Moles, A.; Leslie, J.; Tiniakos, D.; Mann, D. A.; Oakley, F.] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Butterworth, J. A.; Sanchez, A.; Hunter, J. E.; Sellier, H.; Perkins, N. D.] Newcastle Univ, Fac Med Sci, Inst Cell & Mol Biosci ICaMB, Newcastle Upon Tyne, Tyne & Wear, England; [Cockell, S. J.] Newcastle Univ, Fac Med Sci, Bioinformat Support Unit, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Oakley, F; Perkins, ND (corresponding author), Newcastle Univ, Sch Med, Fac Med Sci, Inst Cell & Mol Biosci ICaMB, Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	fiona.oakley@ncl.ac.uk; neil.perkins@ncl.ac.uk	Moles, Ana/A-5889-2017; Tiniakos, Dina G/AAA-5708-2020; Sanchez, Ana M/K-4970-2016	Moles, Ana/0000-0002-3915-0060; Sanchez, Ana M/0000-0003-4293-4648; Mann, Derek/0000-0003-0950-243X; Oakley, Fiona/0000-0001-8692-1836; Cockell, Simon/0000-0002-6831-9806	Newcastle University; Wellcome Trust [094409]; Leukaemia Lymphoma Research Grant [11022]; Cancer Research UK Programme Grant [C1443/A12750]; Medical Research Council (MRC) [G0900535]; Welcome Trust Equipment Grant [087961]; MRC [G0900535, MR/K001949/1] Funding Source: UKRI; Cancer Research UK [22095, 12750] Funding Source: researchfish; Medical Research Council [MR/K001949/1, 1367534, G0900535] Funding Source: researchfish; National Centre for the Replacement [NC/K000748/1] Funding Source: researchfish	Newcastle University; Wellcome Trust(Wellcome TrustEuropean Commission); Leukaemia Lymphoma Research Grant; Cancer Research UK Programme Grant(Cancer Research UK); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Welcome Trust Equipment Grant; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Centre for the Replacement	We would like to thank Adam Moore for technical assistance. We are also grateful to Sonia Rocha, Kirsteen Campbell, Niall Kenneth and all members of the NDP laboratory for helpful advice. AM is a Newcastle University Fellow funded by Newcastle University. JB and HS are funded by the Wellcome Trust Grant 094409, JEH is funded by Leukaemia Lymphoma Research Grant 11022, AS was funded by Cancer Research UK Programme Grant C1443/A12750. FO receives funding from Medical Research Council (MRC) Grant G0900535. The IVIS Spectrum system was funded by Welcome Trust Equipment Grant 087961.	Alexander J, 2013, J GASTROEN HEPATOL, V28, P848, DOI 10.1111/jgh.12116; Algul H, 2007, J CLIN INVEST, V117, P1490, DOI 10.1172/JCI29882; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Dong J, 2008, GENE DEV, V22, P1159, DOI 10.1101/gad.1657408; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Ebrahimkhani MR, 2011, NAT MED, V17, P1668, DOI 10.1038/nm.2490; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Heindryckx F, 2009, INT J EXP PATHOL, V90, P367, DOI 10.1111/j.1365-2613.2009.00656.x; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; Hunter JE, 2015, ONCOGENE; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Mari M, 2008, GASTROENTEROLOGY, V134, P1507, DOI 10.1053/j.gastro.2008.01.073; Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093/nar/gkq439; Msaki A, 2011, MOL BIOL CELL, V22, P3032, DOI 10.1091/mbc.E11-04-0280; O'Shea JM, 2008, BIOCHEM SOC T, V36, P603, DOI 10.1042/BST0360603; O'Shea JM, 2010, BIOCHEM J, V426, P345, DOI 10.1042/BJ20091630; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2009, BIOL CHEM, V390, P965, DOI 10.1515/BC.2009.111; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Ringelhan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046469; Robinson SM, 2010, CLIN SCI, V118, P691, DOI 10.1042/CS20090549; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004; Stein SJ, 2013, BLOOD, V121, P5015, DOI 10.1182/blood-2013-02-486142; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wilson CL, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms7818, 10.1038/ncomms9901]; Wu ZH, 2008, EMBO J, V27, P1963, DOI 10.1038/emboj.2008.127	39	24	27	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4623	4632		10.1038/onc.2015.526	http://dx.doi.org/10.1038/onc.2015.526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26853469	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000382336300008
J	Kim, DY; Helfman, DM				Kim, D. Y.; Helfman, D. M.			Loss of MLCK leads to dleisruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling	ONCOGENE			English	Article							LIGHT-CHAIN KINASE; E-CADHERIN; CANCER-CELLS; SPHEROID FORMATION; DISTINCT ROLES; MIGRATION; PHOSPHORYLATION; PAXILLIN; RECEPTOR; GROWTH	Myosin light chain kinase (MLCK) expression is downregulated in breast cancer, including invasive ductal carcinoma compared with ductal breast carcinoma in situ and metastatic breast tumors. However, little is known about how loss of MLCK expression contributes to tumor progression. MLCK is a component of the actin cytoskeleton and its known role is the phosphorylation of the regulatory light chain of myosin II. To gain insights into the role of MLCK in breast cancer, we perturbed its function using small interfering RNA (siRNA) or pharmacological inhibition in untransformed breast epithelial cells (MCF10A). Loss of MLCK by siRNAs led to increased cell migration and invasion, disruption of cell-cell adhesions and enhanced formation of focal adhesions at the leading edge of migratory cells. In addition, downregulation of MLCK cooperated with HER2 in MCF10A cells to promote cell migration and invasion and low levels of MLCK is associated with a poor prognosis in HER2-positive breast cancer patients. Associated with these altered migratory behaviors were increased expression of epidermal growth factor receptor and activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase signaling pathways in MLCK downregulated MCF10A cells. By contrast, inhibition of the kinase function of MLCK using pharmacological agents inhibited cell migration and invasion, and did not affect cellular adhesions. Our results show that loss of MLCK contributes to the migratory properties of epithelial cells resulting from changes in cell-cell and cell-matrix adhesions, and increased epidermal growth factor receptor signaling. These findings suggest that decreased expression of MLCK may have a critical role during tumor progression by facilitating the metastatic potential of tumor cells.	[Kim, D. Y.; Helfman, D. M.] Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 34141, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Helfman, DM (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 34141, South Korea.	dhelfman@kaist.ac.kr			National Research Foundation of Korea - Ministry of Education Science and Technology [R1A2A2A01003372]	National Research Foundation of Korea - Ministry of Education Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea)	DMH is supported by the National Research Foundation of Korea funded by the Ministry of Education Science and Technology (#R1A2A2A01003372).	Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Chen C, 2014, J BIOL CHEM, V289, P28478, DOI 10.1074/jbc.M114.567446; Chen J, 2012, CANCER RES, V72, P4130, DOI 10.1158/0008-5472.CAN-12-0655; Choi C, 2014, ONCOGENE, V33, P3668, DOI 10.1038/onc.2013.341; Connell LE, 2006, J CELL SCI, V119, P2269, DOI 10.1242/jcs.02926; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Duan L, 2011, J BIOL CHEM, V286, P620, DOI 10.1074/jbc.M110.188086; Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0; Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876; Dulyaninova NG, 2004, J CELL SCI, V117, P1481, DOI 10.1242/jcs.00993; Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Glinsky VV, 2003, CANCER RES, V63, P3805; Gu LZ, 2006, EUR J CANCER, V42, P948, DOI 10.1016/j.ejca.2005.12.017; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ivascu A, 2007, INT J ONCOL, V31, P1403; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kimura K, 2008, INVEST OPHTH VIS SCI, V49, P125, DOI 10.1167/iovs.07-0725; Laprise P, 2004, J CELL PHYSIOL, V199, P32, DOI 10.1002/jcp.10432; Li QW, 2008, NEOPLASIA, V10, P1444, DOI 10.1593/neo.08968; Lin RZ, 2006, CELL TISSUE RES, V324, P411, DOI 10.1007/s00441-005-0148-2; Mukherjee M, 2012, EMBO J, V31, P1308, DOI 10.1038/emboj.2011.496; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Ren G, 2009, J BIOL CHEM, V284, P18913, DOI 10.1074/jbc.M109.000307; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Usatyuk PV, 2012, J BIOL CHEM, V287, P9360, DOI 10.1074/jbc.M111.294546; Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126; Wadgaonkar R, 2003, J CELL BIOCHEM, V88, P623, DOI 10.1002/jcb.10370; Wang HH, 2009, AM J PHYSIOL-HEART C, V296, pH1683, DOI 10.1152/ajpheart.00965.2008; WATTERSON DM, 1995, FEBS LETT, V373, P217; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wu Q, 2010, ONCOGENE, V29, P4183, DOI 10.1038/onc.2010.165; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yu HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079776; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	49	15	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4495	4508		10.1038/onc.2015.508	http://dx.doi.org/10.1038/onc.2015.508			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26876209				2022-12-28	WOS:000382153100007
J	Lee, JM; Lee, SH; Wang, JH; Oh, SJ; Kim, B; Jung, S; Shim, SH; Lin, PW; Lee, SB; Cho, MY; Koh, YJ; Kim, SY; Ahn, S; Lee, J; Kim, KM; Cheong, KH; Choi, J; Kim, KA				Lee, J. M.; Lee, S. H.; Wang, J-H; Oh, S. J.; Kim, B.; Jung, S.; Shim, S-h; Lin, P. W.; Lee, S. B.; Cho, M-Y; Koh, Y. J.; Kim, S. Y.; Ahn, S.; Lee, J.; Kim, K-m; Cheong, K. H.; Choi, J.; Kim, K-A			Novel strategy for a bispecific antibody: induction of dual target internalization and degradation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; C-MET ANTIBODY; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; RNA INTERFERENCE; IN-VIVO; THERAPY; MECHANISM; CETUXIMAB	Activation of the extensive cross-talk among the receptor tyrosine kinases (RTKs), particularly ErbB family-Met cross-talk, has emerged as a likely source of drug resistance. Notwithstanding brilliant successes were attained while using small-molecule inhibitors or antibody therapeutics against specific RTKs in multiple cancers over recent decades, a high recurrence rate remains unsolved in patients treated with these targeted inhibitors. It is well aligned with multifaceted properties of cancer and cross-talk and convergence of signaling pathways of RTKs. Thereby many therapeutic interventions have been actively developed to overcome inherent or acquired resistance. To date, no bispecific antibody (BsAb) showed complete depletion of dual RTKs from the plasma membrane and efficient dual degradation. In this manuscript, we report the first findings of a target-specific dual internalization and degradation of membrane RTKs induced by designed BsAbs based on the internalizing monoclonal antibodies and the therapeutic values of these BsAbs. Leveraging the anti-Met mAb able to internalize and degrade by a unique mechanism, we generated the BsAbs for Met/epidermal growth factor receptor (EGFR) and Met/HER2 to induce an efficient EGFR or HER2 internalization and degradation in the presence of Met that is frequently overexpressed in the invasive tumors and involved in the resistance against EGFR-or HER2-targeted therapies. We found that Met/EGFR BsAb ME22S induces dissociation of the Met-EGFR complex from Hsp90, followed by significant degradation of Met and EGFR. By employing patient-derived tumor models we demonstrate therapeutic potential of the BsAb-mediated dual degradation in various cancers.	[Lee, J. M.; Oh, S. J.; Kim, B.; Jung, S.; Kim, K-A] Samsung Bioepis Co Ltd, Open Innovat Team, 107 Chomdandaero, Inchon 406840, South Korea; [Lee, S. H.; Shim, S-h; Choi, J.] SAIT, Samsung Biomed Res Inst, Gyeonggi Do, South Korea; [Wang, J-H] Samsung Bioepis Co Ltd, Qual Evaluat Team, Bioassay Grp, Inchon, South Korea; [Lin, P. W.; Lee, S. B.] Samsung Bioepis Co Ltd, Cell Engn Team, Inchon, South Korea; [Cho, M-Y; Koh, Y. J.; Cheong, K. H.] SAIT, Gyeonggi Do, South Korea; [Kim, S. Y.; Lee, J.; Kim, K-m] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea; [Ahn, S.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, KA (corresponding author), Samsung Bioepis Co Ltd, Open Innovat Team, 107 Chomdandaero, Inchon 406840, South Korea.	ka10.kim@samsung.com	Lee, Jee Yun/C-9646-2011; Lee, Ji Min/ABE-7494-2021	Lee, Ji Min/0000-0003-2978-2440				Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Annamalai B, 2009, MOL CANCER RES, V7, P1021, DOI 10.1158/1541-7786.MCR-08-0582; Castoldi R, 2013, ONCOGENE, V32, P5593, DOI 10.1038/onc.2013.245; Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Doebele RC, 2010, LUNG CANCER, V69, P1, DOI 10.1016/j.lungcan.2009.12.009; Doody JF, 2007, MOL CANCER THER, V6, P2642, DOI 10.1158/1535-7163.MCT-06-0506; Duan Y, 2012, MOL IMMUNOL, V51, P188, DOI 10.1016/j.molimm.2012.03.015; Dulak AM, 2011, ONCOGENE, V30, P3625, DOI 10.1038/onc.2011.84; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Goffin JR, 2013, CLIN THER, V35, P1282, DOI 10.1016/j.clinthera.2013.08.007; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Gusenbauer S, 2013, ONCOGENE, V32, P3846, DOI 10.1038/onc.2012.396; Ha SY, 2015, INT J CANCER, V136, P1629, DOI 10.1002/ijc.29159; Jin HK, 2008, CANCER RES, V68, P4360, DOI 10.1158/0008-5472.CAN-07-5960; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karamouzis MV, 2009, LANCET ONCOL, V10, P709, DOI 10.1016/S1470-2045(09)70137-8; Kim B, 2015, ONCOGENE, V34, P1083, DOI 10.1038/onc.2014.51; Kim S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111693; Krishnamoorthy GP, 2013, J BIOL CHEM, V288, P17481, DOI 10.1074/jbc.M112.439422; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Lee JY, 2015, ONCOTARGET, V6, P25619, DOI 10.18632/oncotarget.4627; Lin L., 2012, CHEMOTHER RES PRACT, V2012, DOI DOI 10.1155/2012/817297; Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568; Mahalingam D, 2009, BRIT J CANCER, V100, P1523, DOI 10.1038/sj.bjc.6605066; Martens T, 2006, CLIN CANCER RES, V12, P6144, DOI 10.1158/1078-0432.CCR-05-1418; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Miyata Y, 2013, CURR PHARM DESIGN, V19, P347, DOI 10.2174/138161213804143725; Modjtahedi H, 1996, BRIT J CANCER, V73, P228, DOI 10.1038/bjc.1996.40; Oh YM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04980; Oh YM, 2012, MOL CELLS, V34, P523, DOI 10.1007/s10059-012-0194-z; Pai SI, 2006, GENE THER, V13, P464, DOI 10.1038/sj.gt.3302694; REITER Y, 1994, BIOCHEMISTRY-US, V33, P5451, DOI 10.1021/bi00184a014; Reungwetwattana Thanyanan, 2013, J Carcinog, V12, P22, DOI 10.4103/1477-3163.123972; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585; Sgambato A, 2012, CURR PHARM DESIGN, V18, P6155, DOI 10.2174/138161212803582478; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; Sliwkowski MX, 2013, SCIENCE, V341, P1192, DOI 10.1126/science.1241145; Spigel DR, 2013, J CLIN ONCOL, V31, P4105, DOI 10.1200/JCO.2012.47.4189; Stevenson M, 2004, NEW ENGL J MED, V351, P1772, DOI 10.1056/NEJMra045004; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423; Weatherill EE, 2012, PROTEIN ENG DES SEL, V25, P321, DOI 10.1093/protein/gzs021; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Yang HY, 2009, MOL CELLS, V27, P225, DOI 10.1007/s10059-009-0028-9; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	48	15	15	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4437	4446		10.1038/onc.2015.514	http://dx.doi.org/10.1038/onc.2015.514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26853467				2022-12-28	WOS:000382153100002
J	Ueda, T; Nakata, Y; Yamasaki, N; Oda, H; Sentani, K; Kanai, A; Onishi, N; Ikeda, K; Sera, Y; Honda, Z; Tanaka, K; Sata, M; Ogawa, S; Yasui, W; Saya, H; Takita, J; Honda, H				Ueda, T.; Nakata, Y.; Yamasaki, N.; Oda, H.; Sentani, K.; Kanai, A.; Onishi, N.; Ikeda, K.; Sera, Y.; Honda, Z-i; Tanaka, K.; Sata, M.; Ogawa, S.; Yasui, W.; Saya, H.; Takita, J.; Honda, H.			ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; ALK; GENE; LYMPHOMA; EXPRESSION; SPECTRUM; PROTEIN; TARGET; TUMORS	Overexpression of MYCN is a hallmark of neuroblastoma (NB). ALK(R1275Q), an activating mutation of ALK (anaplastic lymphoma kinase), has been found in sporadic and familial NB patients. In this report, we demonstrated that ALK(R1275Q) knock-in, MYCN transgenic compound mice developed NB with complete penetrance. Transcriptome analysis revealed that ALK(R1275Q) globally downregulated the expression of extracellular matrix (ECM)- and basement membrane (BM)-associated genes in both primary neuronal cells and NB tumors. Accordingly, ALK(R1275Q)/MYCN tumors exhibited reduced expression of ECM/BM-related proteins as compared with MYCN tumors. In addition, on MYCN transduction, ALK(R1275Q)-expressing neuronal cells exhibited increased migratory and invasive activities. Consistently, enhanced invasion and metastasis were demonstrated in ALK(R1275Q)/MYCN mice. These results collectively indicate that ALK(R1275Q) confers a malignant potential on neuronal cells that overexpress MYCN by impairing normal ECM/BM integrity and enhancing tumor growth and dissemination. Moreover, we found that crizotinib, an ALK inhibitor, almost completely inhibited the growth of ALK(R1275Q)/MYCN tumors in an allograft model. Our findings provided insights into the cooperative mechanism of the mutated ALK and overexpressed MYCN in the pathogenesis of NB and demonstrated the effectiveness of crizotinib on ALK(R1275Q)-positive tumors.	[Ueda, T.; Nakata, Y.; Yamasaki, N.; Ikeda, K.; Sera, Y.; Honda, H.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan; [Oda, H.] Tokyo Womens Med Univ, Dept Pathol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo, Japan; [Sentani, K.; Yasui, W.] Hiroshima Univ, Dept Mol Pathol, Inst Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima, Japan; [Kanai, A.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Oncol, Minami Ku, 1-2-3 Kasumi, Hiroshima, Japan; [Onishi, N.; Saya, H.] Keio Univ, Inst Adv Med Res, Div Gene Regulat, Sch Med, 35 Shinanomachi, Tokyo, Japan; [Honda, Z-i] Ochanomizu Univ, Inst Environm Sci Human Life, Hlth Care Ctr, Bunkyo Ku, 2-1-1 Otsuka, Tokyo, Japan; [Honda, Z-i] Ochanomizu Univ, Inst Environm Sci Human Life, Grad Sch Humanities & Sci, Bunkyo Ku, 2-1-1 Otsuka, Tokyo, Japan; [Tanaka, K.] Univ Tokyo, Div Hlth Serv Promot, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan; [Sata, M.] Univ Tokushima, Inst Hlth Biosci, Dept Cardiovasc Med, Grad Sch, Tokushima, Japan; [Ogawa, S.] Kyoto Univ, Grad Sch Med, Dept Pathol, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Japan; [Takita, J.] Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan	Hiroshima University; Tokyo Women's Medical University; Hiroshima University; Hiroshima University; Keio University; Ochanomizu University; Ochanomizu University; University of Tokyo; Tokushima University; Kyoto University; University of Tokyo	Honda, H (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp	Saya, Hideyuki/J-4325-2013	Saya, Hideyuki/0000-0001-6610-1902; Ueda, Takeshi/0000-0001-9823-6764	Grants-in-Aid for Scientific Research [26293227] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Cazes A, 2014, ONCOTARGET, V5, P2688, DOI 10.18632/oncotarget.1883; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Hasan MK, 2013, SCI REP-UK, V3, DOI 10.1038/srep03450; Heukamp LC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003967; Honda H, 2011, P NATL ACAD SCI USA, V108, P2468, DOI 10.1073/pnas.1003403108; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Nagamachi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087425; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Ribatti D, 2004, ANN NY ACAD SCI, V1028, P133, DOI 10.1196/annals.1322.014; Saito A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1971; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Schonerr C, 2012, ONCOGENE, V31, P5193, DOI 10.1038/onc.2012.12; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010	35	19	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4447	4458		10.1038/onc.2015.519	http://dx.doi.org/10.1038/onc.2015.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26829053				2022-12-28	WOS:000382153100003
J	Rey, C; Faustin, B; Mahouche, I; Ruggieri, R; Brulard, C; Ichas, F; Soubeyran, I; Lartigue, L; De Giorgi, F				Rey, C.; Faustin, B.; Mahouche, I.; Ruggieri, R.; Brulard, C.; Ichas, F.; Soubeyran, I.; Lartigue, L.; De Giorgi, F.			The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer	ONCOGENE			English	Article							MIXED-LINEAGE KINASE; PROTEIN TRIPLE KINASE; TUMOR-CELL INVASION; HYPERTROPHIC GROWTH; EXPRESSION PROFILES; ACTIVATION; PHOSPHORYLATION; GTPASE; RHOGDI; JNK	Often described as a mediator of cell cycle arrest or as a pro-apoptotic factor in stressful conditions, the MAP3K ZAK (Sterile alpha motif and leucine zipper-containing kinase) has also been proven to positively regulate epidermal growth factor receptor (EGFR) and WNT signaling pathways, cancer cell proliferation and cellular neoplastic transformation. Here, we show that both isoforms of ZAK, ZAK-alpha and ZAK-beta are key factors in cancer cell migration. While ZAK depletion reduced cell motility of HeLa and HCT116 cells, its overexpression triggered the activation of all three mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), c-JUN N-terminal kinase (JNK) and p38, as well as an increase in cell motion. On the contrary, the kinase-dead mutants, ZAK-alpha K45M and ZAK-beta K45M, were not able to provoke such events, and instead exerted a dominant-negative effect on MAPK activation and cell migration. Pharmacological inhibition of ZAK by nilotinib, preventing ZAK-autophosphorylation and thereby auto-activation, led to the same results. Activated by epidermal growth factor (EGF), we further showed that ZAK constitutes an essential element of the EGF/ERK-dependent cell migration pathway. Using public transcriptomic databases and tissue microarrays, we finally established that, as strong factors of the EGFR signaling pathway, ZAK-alpha and/or ZAK-beta transcripts and protein(s) are frequently upregulated in colorectal adenoma and carcinoma patients. Notably, gene set enrichment analysis disclosed a significant correlation between ZAK+ colorectal premalignant lesions and gene sets belonging to the MAPK/ERK and motility-related signaling pathways of the reactome database, strongly suggesting that ZAK induces such pro-tumoral reaction cascades in human cancers.	[Rey, C.; Mahouche, I.; Brulard, C.; Lartigue, L.] Univ Bordeaux 2, Inst Bergonie, Lab Validat & Identificat Nouvelles Cibles Oncol, INSERM U916, 229 Cours Argonne, F-33076 Bordeaux, France; [Faustin, B.] CNRS CIRID, Bordeaux, France; [Ruggieri, R.] Feinstein Inst Med Res, Lab Cell Signaling, Manhasset, NY USA; [Ichas, F.; De Giorgi, F.] Fluofarma, 2 Rue R Escarpit, Pessac, France; [Soubeyran, I.] Inst Bergonie, Dept Biopathol, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; Northwell Health; UNICANCER; Institut Bergonie	Lartigue, L (corresponding author), Univ Bordeaux 2, Inst Bergonie, Lab Validat & Identificat Nouvelles Cibles Oncol, INSERM U916, 229 Cours Argonne, F-33076 Bordeaux, France.	l.lartigue-faustin@bordeaux.unicancer.fr	Ichas, François/ABD-8277-2020	Ichas, François/0000-0001-8184-5248	French National Institute for Medical Research (INSERM); Aquitaine Region; French Ministry of Research; Institut Bergonie; Association for Cancer Research (ARC); Ligue Contre le Cancer; Canceropole Grand Sud-Ouest; 'Agir Cancer' Gironde; French National Research Agency (ANR)	French National Institute for Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Aquitaine Region(Region Nouvelle-Aquitaine); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Institut Bergonie; Association for Cancer Research (ARC); Ligue Contre le Cancer(Ligue nationale contre le cancer); Canceropole Grand Sud-Ouest; 'Agir Cancer' Gironde; French National Research Agency (ANR)(French National Research Agency (ANR))	This work was supported by the French National Institute for Medical Research (INSERM), Aquitaine Region, French Ministry of Research, Institut Bergonie, Association for Cancer Research (ARC), the Ligue Contre le Cancer, and Canceropole Grand Sud-Ouest, 'Agir Cancer' Gironde and The French National Research Agency (ANR). We thank Nicolas Faur, Raphael Moustie and Assia Chaibi for their technical help and Pippa McKelvie-Sebileau of Institut Bergonie for medical editorial assistance.	Adler AS, 2014, GENE DEV, V28, P1068, DOI 10.1101/gad.237206.113; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Bloem LJ, 2001, J MOL CELL CARDIOL, V33, P1739, DOI 10.1006/jmcc.2001.1437; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Choi HS, 2005, J BIOL CHEM, V280, P13545, DOI 10.1074/jbc.M410521200; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Griner EM, 2013, ONCOGENE, V32, P1010, DOI 10.1038/onc.2012.124; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang CY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-56; Huang CY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-11; Huang CY, 2004, BIOCHEM BIOPH RES CO, V324, P973, DOI 10.1016/j.bbrc.2004.09.156; Korkina O, 2013, J BIOL CHEM, V288, P5364, DOI 10.1074/jbc.M112.414060; Liu JF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4830; Liu TC, 2000, BIOCHEM BIOPH RES CO, V274, P811, DOI 10.1006/bbrc.2000.3236; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Manley PW, 2010, BBA-PROTEINS PROTEOM, V1804, P445, DOI 10.1016/j.bbapap.2009.11.008; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Ray RM, 2012, CELL SIGNAL, V24, P931, DOI 10.1016/j.cellsig.2011.12.016; Reiterer V, 2013, P NATL ACAD SCI USA, V110, pE2934, DOI 10.1073/pnas.1301985110; Rey C, 2013, CELL CYCLE, V12, P1879, DOI 10.4161/cc.24927; Rix U, 2010, LEUKEMIA, V24, P44, DOI 10.1038/leu.2009.228; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soubeyran I, 2011, AM J PATHOL, V178, P1986, DOI 10.1016/j.ajpath.2011.01.021; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi M, 2003, J BIOCHEM, V133, P181, DOI 10.1093/jb/mvg022; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Vinayagam A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001699; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang XS, 2005, J BIOL CHEM, V280, P19298, DOI 10.1074/jbc.M413059200; Yang JJ, 2010, CANCER SCI, V101, P1374, DOI 10.1111/j.1349-7006.2010.01537.x; Yang JJ, 2003, BIOCHEM BIOPH RES CO, V301, P71, DOI 10.1016/S0006-291X(02)02980-7; Yang JJ, 2002, BIOCHEM BIOPH RES CO, V297, P105, DOI 10.1016/S0006-291X(02)02123-X; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	45	27	27	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3190	3200		10.1038/onc.2015.379	http://dx.doi.org/10.1038/onc.2015.379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26522728				2022-12-28	WOS:000378092700010
J	Bousquet, E; Calvayrac, O; Mazieres, J; Lajoie-Mazenc, I; Boubekeur, N; Favre, G; Pradines, A				Bousquet, E.; Calvayrac, O.; Mazieres, J.; Lajoie-Mazenc, I.; Boubekeur, N.; Favre, G.; Pradines, A.			RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; TYROSINE PHOSPHORYLATION; INCREASED EXPRESSION; CANCER; AKT; CARCINOMA; SUBUNIT; GROWTH; SLUG; TRANSFORMATION	Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, which is mainly due to its high risk of metastatic dissemination. One critical point of this process is the ability of cancer cells to detach from the primary tumor and migrate through the extracellular matrix; however, the underlying molecular mechanisms are not yet fully understood. In the present study, we identified the small GTPase RhoB as a key regulator of bronchial cell morphology in a three-dimensional (3D) matrix. RhoB loss, which is frequently observed during lung cancer progression, induced an epithelial-mesenchymal transition (EMT) characterized by an increased proportion of invasive elongated cells in 3D. The process was mediated by Slug induction and E-cadherin repression. In addition, downregulation of RhoB induced Akt1 activation, which in turn activated Rac1 through the guanine-exchange factor Trio to control cell shape rearrangement. Further, we provide evidence that RhoB interacted with and positively regulates phosphatase PP2A through the recruitment of its regulatory subunit B55, which was found to be crucial for Akt dephosphorylation. B55 inhibition completely suppressed RhoB-mediated PP2A regulation. Finally, we show that PP2A inactivation, by targeting either its catalytic or its regulatory B55 subunit, completely reversed RhoB-dependent morphological changes and also fully prevented the ability of RhoB to decrease the invasiveness of bronchial cells. Altogether, these results highlight a novel signaling axis and describe new molecular mechanisms that could explain the tumor suppressor role of RhoB in lung cancer. Therefore, we propose that RhoB could be responsible for early metastatic prevention by inhibiting the EMT-derived invasiveness of lung cells through the control of PP2A activity.	[Bousquet, E.; Calvayrac, O.; Mazieres, J.; Lajoie-Mazenc, I.; Boubekeur, N.; Favre, G.; Pradines, A.] INSERM, UMR 1037, CRCT, Toulouse, France; [Bousquet, E.; Calvayrac, O.; Mazieres, J.; Lajoie-Mazenc, I.; Boubekeur, N.; Favre, G.; Pradines, A.] Univ Toulouse 3, F-31062 Toulouse, France; [Bousquet, E.; Calvayrac, O.; Lajoie-Mazenc, I.; Boubekeur, N.; Favre, G.; Pradines, A.] Inst Claudius Regaud, Dept Biol, Toulouse, France; [Mazieres, J.] CHU Toulouse, Dept Pneumol, Hop Larrey, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UNICANCER; Institut Claudius Regaud; CHU de Toulouse	Pradines, A (corresponding author), Inst Univ Canc Toulouse Oncopole, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France.	pradines.anne@iuct-oncopole.fr	Lajoie-Mazenc, Isabelle/M-4636-2014; FAVRE, Gilles/K-9189-2014; MAZIERES, JULIEN/M-3986-2014; Pradines, Anne/M-3935-2014; Calvayrac, Olivier/A-7145-2016	FAVRE, Gilles/0000-0002-2344-1883; Pradines, Anne/0000-0002-2449-678X; Calvayrac, Olivier/0000-0002-0908-8323; MAZIERES, JULIEN/0000-0002-5921-7613	INSERM (Institut National de la Sante et de la Recherche Medicale); Groupe de Recherche Institut Claudius Regaud; Foundation Recherche et Innovation Therapeutique en Cancerologie; INCa (Institut National du Cancer) France	INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Groupe de Recherche Institut Claudius Regaud; Foundation Recherche et Innovation Therapeutique en Cancerologie; INCa (Institut National du Cancer) France	We are grateful to Professor Alain Puisieux (CRCL, Lyon, France) for his helpful comments on the manuscript. We thank Remi Gence for helping with recombinant proteins. This work was supported by grants from INSERM (Institut National de la Sante et de la Recherche Medicale), Groupe de Recherche Institut Claudius Regaud, the Foundation Recherche et Innovation Therapeutique en Cancerologie and INCa (Institut National du Cancer) France.	Adnane J, 2002, CLIN CANCER RES, V8, P2225; Barber Mark A, 2006, Bull Cancer, V93, pE44; Bellovin DI, 2006, ONCOGENE, V25, P6959, DOI 10.1038/sj.onc.1209682; Benefield Janet, 1997, Invasion and Metastasis, V17, P210; Bousquet E, 2009, CANCER RES, V69, P6092, DOI 10.1158/0008-5472.CAN-08-4147; Bustelo XR, 2012, BIOESSAYS, V34, P748, DOI 10.1002/bies.201200041; Calvayrac O, 2014, CLIN CANCER RES, V20, P6541, DOI 10.1158/1078-0432.CCR-14-0506; Carpenter RL, 2014, ONCOGENE, V34, P546; CHEN J, 1994, J BIOL CHEM, V269, P7957; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cordonnier T, 2015, INT J CANCER, V136, pE496, DOI 10.1002/ijc.29122; DeGeer J, 2013, MOL CELL BIOL, V33, P739, DOI 10.1128/MCB.01264-12; Delord JP, 2010, BRIT J CANCER, V103, P61, DOI 10.1038/sj.bjc.6605699; Fenouille N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040378; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gerald D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3824; Grise F, 2012, HEPATOLOGY, V55, P1766, DOI 10.1002/hep.25568; Ho HH, 2013, TOXICOL APPL PHARM, V266, P76, DOI 10.1016/j.taap.2012.10.019; Jackson Jodi, 1997, Invasion and Metastasis, V17, P199; Kazerounian S, 2013, CANCER RES, V73, P50, DOI 10.1158/0008-5472.CAN-11-3055; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; Lee WJ, 2007, PROTEOMICS, V7, P206, DOI 10.1002/pmic.200600480; Li YY, 2014, IUBMB LIFE, V66, P507, DOI 10.1002/iub.1285; Li Yong, 2011, Genes Cancer, V2, P880, DOI 10.1177/1947601911433129; Liao Y, 2010, AM J TRANSL RES, V2, P19; Lin CH, 2014, MOL CELL BIOCHEM, V395, P135, DOI 10.1007/s11010-014-2119-y; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Mamouni K, 2014, MOL CELL BIOL, V34, P3144, DOI 10.1128/MCB.01525-13; Mao KP, 2014, SCI WORLD J, DOI 10.1155/2014/908326; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mazieres J, 2005, EXP CELL RES, V304, P354, DOI 10.1016/j.yexcr.2004.10.019; Merikallio H, 2014, INT J CLIN EXP PATHO, V7, P5846; Nakada N, 2005, CELL PHYSIOL BIOCHEM, V15, P19, DOI 10.1159/000083635; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rintoul RC, 2001, LANCET ONCOL, V2, P437, DOI 10.1016/S1470-2045(00)00421-6; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Ruvolo PP, 2011, LEUKEMIA, V25, P1711, DOI 10.1038/leu.2011.146; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sato N, 2007, INT J CANCER, V120, P543, DOI 10.1002/ijc.22328; Schmidt Susanne, 2014, Small GTPases, V5, pe29769, DOI 10.4161/sgtp.29769; Sents W, 2013, FEBS J, V280, P644, DOI 10.1111/j.1742-4658.2012.08579.x; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Shi-wen X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007438; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; van Rijssel J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029912; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vega FM, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0085-y; Wang SW, 2003, ONCOGENE, V22, P6204, DOI 10.1038/sj.onc.1206653; Wheeler AP, 2007, EXP CELL RES, V313, P3505, DOI 10.1016/j.yexcr.2007.07.014; Zhang DQ, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-241; Zhang YZ, 2011, MOL CELL BIOCHEM, V357, P363, DOI 10.1007/s11010-011-0907-1; Zhou JT, 2011, INT J CANCER, V128, P1057, DOI 10.1002/ijc.25445	58	48	48	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1760	1769		10.1038/onc.2015.240	http://dx.doi.org/10.1038/onc.2015.240			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26148238	Green Published			2022-12-28	WOS:000373610400003
J	Srinivasan, S; Guha, M; Dong, DW; Whelan, KA; Ruthel, G; Uchikado, Y; Natsugoe, S; Nakagawa, H; Avadhani, NG				Srinivasan, S.; Guha, M.; Dong, D. W.; Whelan, K. A.; Ruthel, G.; Uchikado, Y.; Natsugoe, S.; Nakagawa, H.; Avadhani, N. G.			Disruption of cytochrome c oxidase function induces the Warburg effect and metabolic reprogramming	ONCOGENE			English	Article							MITOCHONDRIAL RESPIRATORY STRESS; KAPPA-B-BETA; CANCER-CELLS; DNA MUTATIONS; ALTERED METABOLISM; COMPLEX-III; SUBUNIT-VB; FACTOR-I; ACTIVATION; HYPOXIA	Defects in mitochondrial oxidative phosphorylation complexes, altered bioenergetics and metabolic shift are often seen in cancers. Here we show a role for the dysfunction of the electron transport chain component cytochrome c oxidase (CcO) in cancer progression. We show that genetic silencing of the CcO complex by shRNA expression and loss of CcO activity in multiple cell types from the mouse and human sources resulted in metabolic shift to glycolysis, loss of anchorage-dependent growth and acquired invasive phenotypes. Disruption of the CcO complex caused loss of transmembrane potential and induction of Ca2+/Calcineurin-mediated retrograde signaling. Propagation of this signaling includes activation of PI3-kinase, IGF1R and Akt, Ca2(+)-sensitive transcription factors and also TGF beta 1, MMP16 and periostin, which are involved in oncogenic progression. Whole-genome expression analysis showed the upregulation of genes involved in cell signaling, extracellular matrix interactions, cell morphogenesis, cell motility and migration. The transcription profiles reveal extensive similarity to retrograde signaling initiated by partial mitochondrial DNA depletion, although distinct differences are observed in signaling induced by CcO dysfunction. The possible CcO dysfunction as a biomarker for cancer progression was supported by data showing that esophageal tumors from human patients show reduced CcO subunits IVi1 and Vb in regions that were previously shown to be the hypoxic core of the tumors. Our results show that mitochondrial electron transport chain defect initiates a retrograde signaling. These results suggest that a defect in the CcO complex can potentially induce tumor progression.	[Srinivasan, S.; Guha, M.; Dong, D. W.; Ruthel, G.; Avadhani, N. G.] Mari Lowe Ctr Comparat Oncol, Dept Biomed Sci, Sch Vet Med, Philadelphia, PA USA; [Whelan, K. A.; Nakagawa, H.] Univ Penn, Dept Med, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Uchikado, Y.; Natsugoe, S.] Kagoshima Univ, Dept Digest Surg Breast & Thyroid Surg, Grad Sch Med, Kagoshima 890, Japan	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Kagoshima University	Avadhani, NG (corresponding author), Univ Penn, Dept Biomed Sci, Sch Vet Med, 3800 Spruce St,Room 189E Vet, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Ruthel, Gordon/GYU-9133-2022		NIH [CA-22762, GM-34883]; Mitochondria research affinity group, Children's hospital of Philadelphia; Harriet Ellison Woodward Trust; NATIONAL CANCER INSTITUTE [R01CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mitochondria research affinity group, Children's hospital of Philadelphia; Harriet Ellison Woodward Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants CA-22762 and GM-34883, and an endowment from the Harriet Ellison Woodward Trust to NGA and a grant to SS from Mitochondria research affinity group, Children's hospital of Philadelphia. We also acknowledge the help of the Imaging Core facility at the School of Veterinary Medicine and the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30DK050306) and its Molecular Pathology and Imaging Core facilities at the Perelman School of Medicine.	Acin-Perez R, 2008, MOL CELL, V32, P529, DOI 10.1016/j.molcel.2008.10.021; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Bansal S, 2012, J BIOL CHEM, V287, P15284, DOI 10.1074/jbc.M111.314062; Bardella C, 2011, BBA-BIOENERGETICS, V1807, P1432, DOI 10.1016/j.bbabio.2011.07.003; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028; Biswas G, 2008, J BIOL CHEM, V283, P12586, DOI 10.1074/jbc.M710481200; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Chen ZX, 2010, CELL DEATH DIFFER, V17, P408, DOI 10.1038/cdd.2009.132; Dakubo GD, 2006, J CLIN PATHOL, V59, P10, DOI 10.1136/jcp.2005.027664; Dasgupta S, 2008, CANCER RES, V68, P700, DOI 10.1158/0008-5472.CAN-07-5532; Devin A, 2001, EUR J BIOCHEM, V268, P3943, DOI 10.1046/j.1432-1327.2001.02306.x; Fang HZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-421; Fang JK, 2007, FEBS LETT, V581, P1302, DOI 10.1016/j.febslet.2007.02.042; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Frezza C, 2014, INT J BIOCHEM CELL B, V48, P11, DOI 10.1016/j.biocel.2013.12.013; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Galati D, 2009, BIOCHEM J, V420, P439, DOI 10.1042/BJ20090214; Gallardo ME, 2006, HUM MUTAT, V27, P575, DOI 10.1002/humu.20338; Guha M, 2014, ONCOGENE, V33, P5238, DOI 10.1038/onc.2013.467; Guha M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M611693200; Guha M, 2013, MITOCHONDRION, V13, P577, DOI 10.1016/j.mito.2013.08.007; Guha M, 2010, MOL BIOL CELL, V21, P3578, DOI 10.1091/mbc.E10-03-0192; Guha M, 2009, MOL BIOL CELL, V20, P4107, DOI 10.1091/mbc.E09-04-0296; Guzy RD, 2006, EXP PHYSIOL, V91, P807, DOI 10.1113/expphysiol.2006.033506; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Krell D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019868; Li YF, 2006, J BIOENERG BIOMEMBR, V38, P283, DOI 10.1007/s10863-006-9052-z; Liu X, 2011, CELL DEATH DIFFER, V18, P1561, DOI 10.1038/cdd.2011.13; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miccoli L, 1996, BIOCHEM J, V313, P957, DOI 10.1042/bj3130957; Moro L, 2009, CELL DEATH DIFFER, V16, P571, DOI 10.1038/cdd.2008.178; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Natsuizaka M, 2012, FASEB J, V26, P2620, DOI 10.1096/fj.11-198598; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Picaud S, 2011, J INHERIT METAB DIS, V34, P671, DOI 10.1007/s10545-011-9294-8; Prabu SK, 2006, J BIOL CHEM, V281, P2061, DOI 10.1074/jbc.M507741200; Rainbolt TK, 2014, TRENDS ENDOCRIN MET, V25, P528, DOI 10.1016/j.tem.2014.06.007; Sayen MR, 2003, AM J PHYSIOL-CELL PH, V284, pC562, DOI 10.1152/ajpcell.00336.2002; Schafer E, 2006, J BIOL CHEM, V281, P15370, DOI 10.1074/jbc.M513525200; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sharma LK, 2011, HUM MOL GENET, V20, P4605, DOI 10.1093/hmg/ddr395; Srinivasan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077129; Srinivasan S, 2012, FREE RADICAL BIO MED, V53, P1252, DOI 10.1016/j.freeradbiomed.2012.07.021; Vannuvel K, 2013, J CELL PHYSIOL, V228, P1802, DOI 10.1002/jcp.24360; Vonck J, 2009, BBA-MOL CELL RES, V1793, P117, DOI 10.1016/j.bbamcr.2008.05.019; WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; WARBURG O, 1956, SCIENCE, V124, P269; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064	59	54	54	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1585	1595		10.1038/onc.2015.227	http://dx.doi.org/10.1038/onc.2015.227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26148236	Green Accepted			2022-12-28	WOS:000373063600011
J	Yang, E; Cisowski, J; Nguyen, N; O'Callaghan, K; Xu, J; Agarwal, A; Kuliopulos, A; Covic, L				Yang, E.; Cisowski, J.; Nguyen, N.; O'Callaghan, K.; Xu, J.; Agarwal, A.; Kuliopulos, A.; Covic, L.			Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2	ONCOGENE			English	Article							CELL-PENETRATING PEPDUCINS; THROMBIN-RECEPTOR; MESENCHYMAL TRANSITIONS; EXPRESSION; TRANSCRIPTION; INVASION; DIFFERENTIATION; INTERVENTION; PROGRESSION; COOPERATION	As the majority of patients with basal-like breast carcinoma present with invasive, metastatic disease that do not respond to available therapies, it is essential to identify new therapeutic targets that impact invasion and metastasis. Protease-activated receptor 1 (PAR1), a G-protein coupled receptor has been shown to act as an oncogene, but underlying mechanisms are not well understood. Here, we show that ectopic expression of functionally active PAR1 in MCF-7 cells induced a hormone-refractory, invasive phenotype representative of advanced basal-like breast carcinoma that readily formed metastatic lesions in lungs of mice. PAR1 was found to globally upregulate mesenchymal markers, including vimentin, a direct target of PAR1, and downregulate the epithelial markers including E-cadherin, as well as estrogen receptor. In contrast, non-signaling PAR1 mutant receptor did not lead to an invasive, hormone refractory phenotype. PAR1 expression increased spheroid formation and the level of stemness markers and self-renewal capacity in human breast cancer cells. We identified HMGA2 (high mobility group A2) as an important regulator of PAR1-mediated invasion. Inhibition of PAR1 signaling suppresses HMGA2-driven invasion in breast cancer cells. HMGA2 gene and protein are highly expressed in metastatic breast cancer cells. Overall, our results show that PAR1/HMGA2 pathway may present a novel therapeutic target.	[Yang, E.; Cisowski, J.; Nguyen, N.; O'Callaghan, K.; Xu, J.; Agarwal, A.; Kuliopulos, A.; Covic, L.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA; [Yang, E.; Kuliopulos, A.; Covic, L.] Dept Biochem, Boston, MA USA; [Yang, E.; Kuliopulos, A.; Covic, L.] Tufts Med Ctr, Boston, MA USA; [Kuliopulos, A.; Covic, L.] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA; [Kuliopulos, A.; Covic, L.] Tufts Med Ctr, Dept Med, Boston, MA USA	Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center	Covic, L (corresponding author), Tufts Med Ctr, Mol Oncol Res Inst, Div Hematol Oncol, Box 7510,750 Washington St, Boston, MA 02111 USA.	lcovic@tuftsmedicalcenter.org			NIH [CA104406, CA122992, HL64701]; Susan G. Komen [BCTR0706763]; Diane Connolly-Zaniboni Research Scholarship; NNDS [P30 NS047243]; Aid for Cancer Research, Boston, MA	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Diane Connolly-Zaniboni Research Scholarship; NNDS; Aid for Cancer Research, Boston, MA	We thank Vishal Trivedi, Chris Parkin, Akiko Hata, Larry Feig and Anna Wronski for their expert advice and Ryan Stevenson for critically reading the manuscript. The microarray analysis was carried out in the Genomics Core of the Tufts Center for Neuroscience Research, Tufts University School of Medicine (supported by NNDS - P30 NS047243). This work was supported by NIH grants CA104406 (LC), Susan G. Komen BCTR0706763, Diane Connolly-Zaniboni Research Scholarship (LC) and a fellowship from Aid for Cancer Research, Boston, MA (EY) by NIH CA122992, HL64701 (to AK).	Agarwal A, 2008, MOL CANCER THER, V7, P2746, DOI 10.1158/1535-7163.MCT-08-0177; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Becker RC, 2009, LANCET, V373, P919, DOI 10.1016/S0140-6736(09)60230-0; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen JQ, 2009, BBA-REV CANCER, V1796, P162, DOI 10.1016/j.bbcan.2009.06.003; Cisowski J, 2011, AM J PATHOL, V179, P513, DOI 10.1016/j.ajpath.2011.03.025; Cleynen I, 2007, MOL CANCER RES, V5, P363, DOI 10.1158/1541-7786.MCR-06-0331; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Hatziapostolou M, 2008, CANCER RES, V68, P1851, DOI 10.1158/0008-5472.CAN-07-5793; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; Kamath L, 2001, CANCER RES, V61, P5933; Korkola JE, 2003, CANCER RES, V63, P7167; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; Lahat G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010105; Li Y, 2014, CANCER LETT, V355, P130, DOI 10.1016/j.canlet.2014.09.007; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Medeiros F, 2007, GENE CHROMOSOME CANC, V46, P981, DOI 10.1002/gcc.20483; Morrow DA, 2012, NEW ENGL J MED, V366, P1404, DOI 10.1056/NEJMoa1200933; NELSON WJ, 1983, MOL CELL BIOL, V3, P1146, DOI 10.1128/MCB.3.6.1146; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; Pegoraro S, 2013, ONCOTARGET, V4, P1293, DOI 10.18632/oncotarget.1136; Peluso S, 2010, BREAST CARE, V5, P81, DOI 10.1159/000297717; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reeves R, 2010, BBA-GENE REGUL MECH, V1799, P3, DOI 10.1016/j.bbagrm.2009.09.001; Rudroff C, 2002, CLIN EXP METASTAS, V19, P181, DOI 10.1023/A:1014598904644; Salah Z, 2005, FASEB J, V19, P62, DOI 10.1096/fj.04-2386com; Salah Z, 2012, FASEB J, V26, P2031, DOI 10.1096/fj.11-194704; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Sgarra R, 2010, BBA-GENE REGUL MECH, V1799, P37, DOI 10.1016/j.bbagrm.2009.08.009; Sheen YS, 2015, J INVEST DERMATOL, V135, P1065, DOI 10.1038/jid.2014.480; Slofstra SH, 2007, BLOOD, V110, P3176, DOI 10.1182/blood-2007-02-075440; Sun JM, 2005, EXP CELL RES, V302, P96, DOI 10.1016/j.yexcr.2004.08.015; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Tallini G, 1997, AM J PATHOL, V151, P37; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Tricoci P, 2012, NEW ENGL J MED, V366, P20, DOI 10.1056/NEJMoa1109719; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Xi YN, 2014, ASIAN PAC J TROP MED, V7, P289, DOI 10.1016/S1995-7645(14)60040-7; Yang E, 2009, CANCER RES, V69, P6223, DOI 10.1158/0008-5472.CAN-09-0187; Zhang P, 2012, CIRCULATION, V126, P83, DOI 10.1161/CIRCULATIONAHA.112.091918	54	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1529	1540		10.1038/onc.2015.217	http://dx.doi.org/10.1038/onc.2015.217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26165842	Green Accepted			2022-12-28	WOS:000373063600006
J	Kurppa, KJ; Denessiouk, K; Johnson, MS; Elenius, K				Kurppa, K. J.; Denessiouk, K.; Johnson, M. S.; Elenius, K.			Activating ERBB4 mutations in non-small cell lung cancer	ONCOGENE			English	Article							KINASE DOMAIN; GROWTH; MECHANISM; CLEAVAGE; INHIBITION; RECEPTORS; SURVIVAL; ISOFORMS; LIGAND	Recent efforts to comprehensively characterize the mutational landscape of non-small cell lung cancer have identified frequent mutations in the receptor tyrosine kinase ERBB4. However, the significance of mutated ERBB4 in non-small cell lung cancer remains elusive. Here, we have functionally characterized nine ERBB4 mutations previously identified in lung adenocarcinoma. Four out of the nine mutations, Y285C, D595V, D931Y and K935I, were found to be activating, increasing both basal and ligand-induced ErbB4 phosphorylation. According to structural analysis, the four activating mutations were located at critical positions at the dimerization interfaces of the ErbB4 extracellular (Y285C and D595V) and kinase (D931Y and K935I) domains. Consistently, the mutations enhanced ErbB4 dimerization and increased the trans activation in ErbB4 homodimers and ErbB4-ErbB2 heterodimers. The expression of the activating ERBB4 mutants promoted survival of NIH 3T3 cells in the absence of serum. Interestingly, serum starvation of NIH 3T3 cells expressing the ERBB4 mutants only moderately increased the phosphorylation of canonical ErbB signaling pathway effectors Erk1/2 and Akt as compared with wild-type ERBB4. In contrast, the mutations clearly enhanced the proteolytic release of signaling-competent ErbB4 intracellular domain. These results suggest the presence of activating driver mutations of ERBB4 in non-small cell lung cancer.	[Kurppa, K. J.; Elenius, K.] Univ Turku, Dept Med Biochem & Genet, MediC Res Labs, FIN-20520 Turku, Finland; [Kurppa, K. J.] Turku Doctoral Programme Mol Med, Turku, Finland; [Denessiouk, K.; Johnson, M. S.] Abo Akad Univ, Fac Sci & Engn, Biochem, Struct Bioinformat Lab, Turku, Finland; [Elenius, K.] Turku Univ Hosp, Dept Oncol, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; University of Turku	Elenius, K (corresponding author), Univ Turku, Dept Med Biochem & Genet, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021	Elenius, Klaus/0000-0001-5700-0827	Academy of Finland, Finnish Cancer Organizations; Sigrid Juselius Foundation; Turku University Central Hospital; Abo Akademi Center fo Excellence in Cell Stress and Aging; Joe, Pentti and Tor Borg memorial fund; Cancer Foundation Finland sr [130077, 160067] Funding Source: researchfish	Academy of Finland, Finnish Cancer Organizations(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku University Central Hospital; Abo Akademi Center fo Excellence in Cell Stress and Aging; Joe, Pentti and Tor Borg memorial fund; Cancer Foundation Finland sr	We thank Maria Tuominen, Minna Santanen and Mika Savisalo for excellent technical assistance. This work was financially supported by the Academy of Finland, Finnish Cancer Organizations, the Sigrid Juselius Foundation, the Turku University Central Hospital, the Abo Akademi Center fo Excellence in Cell Stress and Aging and the Joe, Pentti and Tor Borg memorial fund. The use of computational infrastructures of Biocenter Finland (bioinformatics) and CSC IT Center for Science is gratefully acknowledged.	Aertgeerts K, 2011, J BIOL CHEM, V286, P18756, DOI 10.1074/jbc.M110.206193; Alvarado D, 2010, CELL, V142, P568, DOI 10.1016/j.cell.2010.07.015; Bouyain S, 2005, P NATL ACAD SCI USA, V102, P15024, DOI 10.1073/pnas.0507591102; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Greulich H, 2012, P NATL ACAD SCI USA, V109, P14476, DOI 10.1073/pnas.1203201109; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hegde GV, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004438; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kurppa K, 2009, PIGM CELL MELANOMA R, V22, P708, DOI 10.1111/j.1755-148X.2009.00635.x; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lehtonen JV, 2004, J COMPUT AID MOL DES, V18, P401, DOI 10.1007/s10822-004-3752-4; Liu P, 2012, P NATL ACAD SCI USA, V109, P10861, DOI 10.1073/pnas.1201114109; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Monsey J, 2010, J BIOL CHEM, V285, P7035, DOI 10.1074/jbc.M109.096032; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Qiu C, 2008, STRUCTURE, V16, P460, DOI 10.1016/j.str.2007.12.016; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Red Brewer M, 2013, P NATL ACAD SCI USA, V110, pE3595, DOI 10.1073/pnas.1220050110; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Settleman J, 2009, CANCER CELL, V16, P278, DOI 10.1016/j.ccr.2009.09.013; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sundvall M, 2010, MOL BIOL CELL, V21, P4275, DOI 10.1091/mbc.E10-04-0332; Takahashi Y, 2013, AM J HUM GENET, V93, P900, DOI 10.1016/j.ajhg.2013.09.008; Toivanen PI, 2009, J BIOL CHEM, V284, P16037, DOI 10.1074/jbc.M109.001123; Tvorogov D, 2009, J BIOL CHEM, V284, P5582, DOI 10.1074/jbc.M805438200; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	40	43	44	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1283	1291		10.1038/onc.2015.185	http://dx.doi.org/10.1038/onc.2015.185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26050618				2022-12-28	WOS:000371763100008
J	Collins, CT; Hess, JL				Collins, C. T.; Hess, J. L.			Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; LONG NONCODING RNA; HEMATOPOIETIC STEM-CELLS; BONE-MARROW-CELLS; ACUTE MYELOGENOUS LEUKEMIA; GENE-EXPRESSION PATTERN; MIXED-LINEAGE LEUKEMIA; HOMEOBOX-GENE; TRANSCRIPTION FACTORS; POOR-PROGNOSIS	HOXA9 is a homeodomain-containing transcription factor that has an important role in hematopoietic stem cell expansion and is commonly deregulated in acute leukemias. A variety of upstream genetic alterations in acute myeloid leukemia lead to overexpression of HOXA9, which is a strong predictor of poor prognosis. In many cases, HOXA9 has been shown to be necessary for maintaining leukemic transformation; however, the molecular mechanisms through which it promotes leukemogenesis remain elusive. Recent work has established that HOXA9 regulates downstream gene expression through binding at promoter distal enhancers along with a subset of cell-specific cofactor and collaborator proteins. Increasing efforts are being made to identify both the critical cofactors and target genes required for maintaining transformation in HOXA9-overexpressing leukemias. With continued advances in understanding HOXA9-mediated transformation, there is a wealth of opportunity for developing novel therapeutics that would be applicable for greater than 50% of AML with overexpression of HOXA9.	[Collins, C. T.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Hess, J. L.] Indiana Univ, Sch Med, Dept Pathol & Lab Med, 340 West 10th St, Indianapolis, IN 46202 USA; [Hess, J. L.] Indiana Univ, Sch Med, Dept Med, 340 West 10th St, Indianapolis, IN 46202 USA	University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Hess, JL (corresponding author), Indiana Univ, Sch Med, Univ Clin Affairs, 340 West 10th St, Indianapolis, IN 46202 USA.	jayhess@iu.edu			NATIONAL CANCER INSTITUTE [R01CA151425] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA151425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O, 2000, LEUKEMIA RES, V24, P849, DOI 10.1016/S0145-2126(00)00059-X; Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Andreeff M, 2008, LEUKEMIA, V22, P2041, DOI 10.1038/leu.2008.198; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Bandyopadhyay S, 2012, MOL CELL BIOL, V32, P1202, DOI 10.1128/MCB.05977-11; Bansal D, 2006, P NATL ACAD SCI USA, V103, P16924, DOI 10.1073/pnas.0604579103; Bantignies F, 2011, CELL, V144, P214, DOI 10.1016/j.cell.2010.12.026; Bei L, 2007, J BIOL CHEM, V282, P16846, DOI 10.1074/jbc.M609744200; Berger MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024; Bergiers I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080387; Bijl J, 2006, BLOOD, V108, P116, DOI 10.1182/blood-2005-06-2245; Bjornsson JM, 2003, MOL CELL BIOL, V23, P3872, DOI 10.1128/MCB.23.11.3872-3883.2003; Brayer KJ, 2011, P NATL ACAD SCI USA, V108, pE414, DOI 10.1073/pnas.1100990108; Breitinger C, 2013, LEUKEMIA, V27, P236, DOI 10.1038/leu.2012.166; Breitinger C, 2012, BLOOD, V120, P4018, DOI 10.1182/blood-2011-10-384685; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Brumatti G, 2013, ONCOTARGET, V4, P1933, DOI 10.18632/oncotarget.1306; Brun ACM, 2004, BLOOD, V103, P4126, DOI 10.1182/blood-2003-10-3557; Busser BW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069385; Calero-Nieto FJ, 2013, ONCOGENE, V32, P5471, DOI 10.1038/onc.2013.175; Chen FJ, 2013, MOL CARCINOGEN, V52, P908, DOI 10.1002/mc.21944; Choe SK, 2014, DEV CELL, V28, P203, DOI 10.1016/j.devcel.2013.12.011; Choo SW, 2011, ADV GENET, V76, P55, DOI 10.1016/B978-0-12-386481-9.00003-1; Choo SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014778; Collins C, 2014, P NATL ACAD SCI USA, V111, P9899, DOI 10.1073/pnas.1402238111; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; Cui Ling, 2013, Sichuan Da Xue Xue Bao Yi Xue Ban, V44, P57; Dasse E, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.20; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; Davidson AJ, 2006, DEV BIOL, V292, P506, DOI 10.1016/j.ydbio.2006.01.003; de Rooij JDE, 2013, LEUKEMIA, V27, P2280, DOI 10.1038/leu.2013.87; Dieppois G, 2010, J CELL SCI, V123, P1989, DOI 10.1242/jcs.053694; Dinger ME, 2008, GENOME RES, V18, P1433, DOI 10.1101/gr.078378.108; Dintilhac A, 2004, GENE EXPR PATTERNS, V4, P215, DOI 10.1016/j.modgep.2003.08.006; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eklund E. A., 2011, Critical Reviews in Oncogenesis, V16, P65; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; Falini B, 2009, LEUKEMIA, V23, P1731, DOI 10.1038/leu.2009.124; Falini B, 2009, CURR OPIN ONCOL, V21, P573, DOI 10.1097/CCO.0b013e3283313dfa; Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; Fung TK, 2012, CURR OPIN HEMATOL, V19, P280, DOI 10.1097/MOH.0b013e3283545615; Ge XS, 2013, CANCER SCI, V104, P1675, DOI 10.1111/cas.12296; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goodman FR, 2002, AM J MED GENET, V112, P256, DOI 10.1002/ajmg.10776; Gough SM, 2011, BLOOD, V118, P6247, DOI 10.1182/blood-2011-07-328880; Guerreiro I, 2012, DEVELOPMENT, V139, P2703, DOI 10.1242/dev.081448; Gurumurthy M, 2008, J MOL BIOL, V378, P302, DOI 10.1016/j.jmb.2008.02.055; Gwin K, 2010, J IMMUNOL, V185, P6572, DOI 10.4049/jimmunol.0904203; Hassawi M, 2014, DEV DYNAM, V243, P145, DOI 10.1002/dvdy.24056; He XY, 2014, INT J MOL MED, V33, P325, DOI 10.3892/ijmm.2013.1570; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Hoelz A, 2011, ANNU REV BIOCHEM, V80, P613, DOI 10.1146/annurev-biochem-060109-151030; Hollink IHIM, 2011, BLOOD, V118, P3645, DOI 10.1182/blood-2011-04-346643; Hu YL, 2007, BLOOD, V109, P4732, DOI 10.1182/blood-2006-08-043356; Huang YS, 2012, BLOOD, V119, P388, DOI 10.1182/blood-2011-03-341081; Inoue D, 2013, J CLIN INVEST, V123, P4627, DOI 10.1172/JCI70739; Izon DJ, 1998, BLOOD, V92, P383, DOI 10.1182/blood.V92.2.383.414k41_383_393; Jude CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019; Karakas T, 1998, ANN ONCOL, V9, P159, DOI 10.1023/A:1008255511404; Khan SN, 2013, LEUKEMIA, V27, P1301, DOI 10.1038/leu.2013.80; Ko KH, 2007, EXP HEMATOL, V35, P465, DOI 10.1016/j.exphem.2006.10.014; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Ladam F, 2014, DEV DYNAM, V243, P4, DOI 10.1002/dvdy.23997; Lambert B, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-29; Lawrence HJ, 2005, BLOOD, V106, P3988, DOI 10.1182/blood-2005-05-2003; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; Lehnertz B, 2014, GENE DEV, V28, P317, DOI 10.1101/gad.236794.113; Lelli KM, 2011, P NATL ACAD SCI USA, V108, P21122, DOI 10.1073/pnas.1114118109; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li ZJ, 2013, BLOOD, V121, P1422, DOI 10.1182/blood-2012-07-442004; Li ZJ, 2012, BLOOD, V119, P2314, DOI 10.1182/blood-2011-10-386235; Liu XH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-464; Longobardi E, 2014, DEV DYNAM, V243, P59, DOI 10.1002/dvdy.24016; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; Rivas ML, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003252; Mann RS, 2009, CURR TOP DEV BIOL, V88, P63, DOI 10.1016/S0070-2153(09)88003-4; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; McKinney-Freeman SL, 2008, BLOOD, V111, P4944, DOI 10.1182/blood-2007-11-124644; Merabet S, 2014, DEV DYNAM, V243, P16, DOI 10.1002/dvdy.24002; Meyer C, 2009, LEUKEMIA, V23, P1490, DOI 10.1038/leu.2009.33; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Min H, 2013, INT J BIOL SCI, V9, P960, DOI 10.7150/ijbs.6739; Misra M, 2012, DEV DYNAM, V241, P718, DOI 10.1002/dvdy.23763; Monroe SC, 2011, EXP HEMATOL, V39, P77, DOI 10.1016/j.exphem.2010.09.003; Morgan R, 2007, CANCER RES, V67, P5806, DOI 10.1158/0008-5472.CAN-06-4231; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Mullighan CG, 2007, LEUKEMIA, V21, P2000, DOI 10.1038/sj.leu.2404808; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakayama I, 2013, INT J ONCOL, V43, P63, DOI 10.3892/ijo.2013.1935; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; Ng RK, 2014, J PATHOL, V232, P65, DOI 10.1002/path.4279; Novak RL, 2012, EXP HEMATOL, V40, P1016, DOI 10.1016/j.exphem.2012.08.001; Noyes MB, 2008, CELL, V133, P1277, DOI 10.1016/j.cell.2008.05.023; Ohno Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053161; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Papadopoulos DK, 2012, DEV BIOL, V367, P78, DOI 10.1016/j.ydbio.2012.04.021; Penkov D, 2013, CELL REP, V3, P1321, DOI 10.1016/j.celrep.2013.03.029; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Polychronidou M, 2013, FLY, V7, DOI 10.4161/fly.22939; Pombo A, 2015, NAT REV MOL CELL BIO, V16, P245, DOI 10.1038/nrm3965; Radulovic V, 2013, LEUKEMIA, V27, P523, DOI 10.1038/leu.2012.368; Rawat VPS, 2012, BLOOD, V120, P519, DOI 10.1182/blood-2012-02-385898; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Rezsohazy R, 2014, DEV DYNAM, V243, P117, DOI 10.1002/dvdy.24060; Rozovskaia T, 2003, P NATL ACAD SCI USA, V100, P7853, DOI 10.1073/pnas.1132115100; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Sambrani N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003307; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Saw J, 2013, LEUKEMIA RES, V37, P1668, DOI 10.1016/j.leukres.2013.09.013; Schaefer LK, 2001, J BIOL CHEM, V276, P43074, DOI 10.1074/jbc.M102552200; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Serrano E, 2006, ACTA HAEMATOL-BASEL, V116, P77, DOI 10.1159/000093636; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Sheth R, 2014, DEV DYNAM, V243, P182, DOI 10.1002/dvdy.24019; Shi XM, 2001, J BIOL CHEM, V276, P850, DOI 10.1074/jbc.M005955200; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Shima H, 2014, INT J HEMATOL, V99, P21, DOI 10.1007/s12185-013-1466-x; Shimamoto T, 1999, J EXP ZOOL, V283, P186; Sitwala KV, 2008, INT J CLIN EXP PATHO, V1, P461; Slattery M, 2011, CELL, V147, P1270, DOI 10.1016/j.cell.2011.10.053; Slattery M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014686; Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004; So CW, 2004, BLOOD, V103, P3192, DOI 10.1182/blood-2003-10-3722; Sorensen KP, 2013, BREAST CANCER RES TR, V142, P529, DOI 10.1007/s10549-013-2776-7; Sorge S, 2012, EMBO J, V31, P3323, DOI 10.1038/emboj.2012.179; Speleman F, 2005, LEUKEMIA, V19, P358, DOI 10.1038/sj.leu.2403657; Steger J, 2015, LEUKEMIA, V29, P901, DOI 10.1038/leu.2014.287; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; Tholouli E, 2012, BIOCHEM BIOPH RES CO, V425, P333, DOI 10.1016/j.bbrc.2012.07.092; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Tolhuis B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001343; Topisirovic I, 2005, MOL CELL BIOL, V25, P1100, DOI 10.1128/MCB.25.3.1100-1112.2005; Vassiliou GS, 2011, NAT GENET, V43, P470, DOI 10.1038/ng.796; Vijapurkar U, 2004, MOL CELL BIOL, V24, P3827, DOI 10.1128/MCB.24.9.3827-3837.2004; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang Y, 2008, P NATL ACAD SCI USA, V105, P7756, DOI 10.1073/pnas.0708951105; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024; Whelan JT, 2008, LEUKEMIA, V22, P1161, DOI 10.1038/leu.2008.57; Williams RT, 2008, COLD SH Q B, V73, P461, DOI 10.1101/sqb.2008.73.039; Wolff L, 2013, BLOOD CELL MOL DIS, V50, P227, DOI 10.1016/j.bcmd.2013.01.006; Wu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029622; Yasunaga S, 2013, MOL CELL BIOL, V33, P644, DOI 10.1128/MCB.00974-12; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang JX, 2013, NEURO-ONCOLOGY, V15, P1595, DOI 10.1093/neuonc/not131; Zhang Y, 2003, EMBO J, V22, P6057, DOI 10.1093/emboj/cdg577; Zhou B, 2012, P NATL ACAD SCI USA, V109, P8931, DOI 10.1073/pnas.1200874109; Zhuang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-35	166	92	94	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1090	1098		10.1038/onc.2015.174	http://dx.doi.org/10.1038/onc.2015.174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26028034	Green Accepted			2022-12-28	WOS:000371351700003
J	Shi, Y; Yang, Y; Hoang, B; Bardeleben, C; Holmes, B; Gera, J; Lichtenstein, A				Shi, Y.; Yang, Y.; Hoang, B.; Bardeleben, C.; Holmes, B.; Gera, J.; Lichtenstein, A.			Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress	ONCOGENE			English	Article							RIBOSOME ENTRY SITE; UNFOLDED PROTEIN RESPONSE; RAPAMYCIN; KINASE; ACTIVATION; EXPRESSION; INITIATION; INDUCE; GENE	Protein translation is inhibited by the unfolded protein response (UPR)-induced eIF-2 alpha phosphorylation to protect against endoplasmic reticulum (ER) stress. In addition, we found additional inhibition of protein translation owing to diminished mTORC1 (mammalian target of rapamycin complex1) activity in ER-stressed multiple myeloma (MM) cells. However, c-myc protein levels and myc translation was maintained. To ascertain how c-myc was maintained, we studied myc IRES (internal ribosome entry site) function, which does not require mTORC1 activity. Myc IRES activity was upregulated in MM cells during ER stress induced by thapsigargin, tunicamycin or the myeloma therapeutic bortezomib. IRES activity was dependent on upstream MAPK (mitogen-activated protein kinase) and MNK1 (MAPK-interacting serine/threonine kinase 1) signaling. A screen identified hnRNP A1 (A1) and RPS25 as IRES-binding trans-acting factors required for ER stress-activated activity. A1 associated with RPS25 during ER stress and this was prevented by an MNK inhibitor. In a proof of principle, we identified a compound that prevented binding of A1 to the myc IRES and specifically inhibited myc IRES activity in MM cells. This compound, when used alone, was not cytotoxic nor did it inhibit myc translation or protein expression. However, when combined with ER stress inducers, especially bortezomib, a remarkable synergistic cytotoxicity ensued with associated inhibition of myc translation and expression. These results underscore the potential for targeting A1-mediated myc IRES activity in MM cells during ER stress.	VA West LA Hosp Hematol Oncol, West LA VA Hosp, UCLA Greater Los Angeles VA Healthcare Ctr, Div Hematol Oncol, W111H, Los Angeles, CA USA; VA West LA Hosp Hematol Oncol, West LA VA Hosp, Jonsson Comprehens Canc Ctr, W111H, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center	Lichtenstein, A (corresponding author), VA West LA Hosp Hematol Oncol, West LA VA Hosp, Div Hematol Oncol, UCLA Greater Los Angeles VA Healthcare Ctr, W111H,11301 Wilshire Blvd,Bldg 500,Room 4237, Los Angeles, CA 90073 USA.; Lichtenstein, A (corresponding author), VA West LA Hosp Hematol Oncol, West LA VA Hosp, Jonsson Comprehens Canc Ctr, W111H,11301 Wilshire Blvd,Bldg 500,Room 4237, Los Angeles, CA 90073 USA.	Alan.lichtenstein@med.va.gov		Holmes, Brent/0000-0002-2768-2991; Gera, Joseph/0000-0002-2908-6894	NIH [RO1CA168700, 2RO1CA111448, RO1CA132778, R21CA168491]; Veteran's Administration; Multiple Myeloma Research Foundation; NATIONAL CANCER INSTITUTE [R01CA168700, R01CA111448, R01CA132778, R21CA168491] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veteran's Administration(US Department of Veterans Affairs); Multiple Myeloma Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grants RO1CA168700, 2RO1CA111448, RO1CA132778 and R21CA168491 and research funds of the Veteran's Administration and Multiple Myeloma Research Foundation	Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bliskovsky V, 2003, P NATL ACAD SCI USA, V100, P14982, DOI 10.1073/pnas.2431627100; Bodescot M, 1996, GENE, V174, P115, DOI 10.1016/0378-1119(96)00464-7; Bommert KS, 2013, LEUKEMIA, V27, P441, DOI 10.1038/leu.2012.185; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015; Chaidos A, 2014, BLOOD, V123, P697, DOI 10.1182/blood-2013-01-478420; Damiano F, 2013, BIOCHEM J, V449, P543, DOI 10.1042/BJ20120906; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Denys A, 2004, FEBS LETT, V564, P177, DOI 10.1016/S0014-5793(04)00361-8; Dibrov SM, 2003, P NATL ACAD SCI USA, V100, P14982; Gera JF, 2002, METHOD ENZYMOL, V350, P499, DOI 10.1016/S0076-6879(02)50981-2; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; Kuehl WM, 2012, BLOOD, V120, P2351, DOI 10.1182/blood-2012-08-445262; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liang SH, 2006, BIOCHEM J, V393, P201, DOI 10.1042/BJ20050374; Lin JY, 2008, J GEN VIROL, V89, P2540, DOI 10.1099/vir.0.2008/003673-0; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Martin J, 2008, J BIOL CHEM, V283, P23274; Nakamura RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048194; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Paulin FEM, 1996, ONCOGENE, V13, P505; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi Y, 2013, ONCOGENE, V32, P190, DOI 10.1038/onc.2012.43; Shi YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094011; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Suzuki A, 2005, ONCOGENE, V24, P6936, DOI 10.1038/sj.onc.1208844	35	51	52	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1015	1024		10.1038/onc.2015.156	http://dx.doi.org/10.1038/onc.2015.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961916	Green Accepted			2022-12-28	WOS:000370823300007
J	Carvalho, S; Lindzen, M; Lauriola, M; Shirazi, N; Sinha, S; Abdul-Hai, A; Levanon, K; Korach, J; Barshack, I; Cohen, Y; Onn, A; Mills, G; Yarden, Y				Carvalho, S.; Lindzen, M.; Lauriola, M.; Shirazi, N.; Sinha, S.; Abdul-Hai, A.; Levanon, K.; Korach, J.; Barshack, I.; Cohen, Y.; Onn, A.; Mills, G.; Yarden, Y.			An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors	ONCOGENE			English	Article							FACTOR RECEPTOR; ERBB RECEPTORS; EGFR LIGANDS; CANCER; AUTOCRINE; EXPRESSION; COMBINATIONS; GEFITINIB; CARCINOMA; PARACRINE	Growth factors of the epidermal growth factor (EGF)/neuregulin family are involved in tumor progression and, accordingly, antibodies that intercept a cognate receptor, epidermal growth factor receptor ( EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy. Although they might improve safety and delay onset of chemoresistance, no anti-ligand antibodies have been clinically approved. To identify suitable ligands, we surveyed fluids from ovarian and lung cancer patients and found that amphiregulin (AREG) is the most abundant and generalized ligand secreted by advanced tumors. AREG is a low affinity EGFR ligand, which is upregulated following treatment with chemotherapeutic drugs. Because AREG depletion retarded growth of xenografted ovarian tumors in mice, we generated a neutralizing monoclonal anti-AREG antibody. The antibody inhibited growth of ovarian cancer xenografts and strongly enhanced chemotherapy efficacy. Taken together, these results raise the possibility that AREG and other low-or high-affinity binders of EGFR might serve as potential targets for cancer therapy.	[Carvalho, S.; Lindzen, M.; Lauriola, M.; Shirazi, N.; Sinha, S.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Abdul-Hai, A.] Kaplan Med Ctr, Rehovot, Israel; [Levanon, K.] Chaim Sheba Med Ctr, Dr Pinchas Borenstein Talpiot Med Leadership Prog, Ramat Gan, Israel; [Levanon, K.] Chaim Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel; [Korach, J.] Chaim Sheba Med Ctr, Dept Gynecol Oncol, Ramat Gan, Israel; [Barshack, I.] Sheba Med Ctr, Dept Pathol, Ramat Gan, Israel; [Cohen, Y.] Sheba Med Ctr, Inst Tissue Banks, Ramat Gan, Israel; [Onn, A.] Chaim Sheba Med Ctr, Inst Pulm Oncol, Ramat Gan, Israel; [Mills, G.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Lauriola, M.] Univ Bologna, Dept Expt Diagnost & Specialty Med, Unit Histol Embryol & Appl Biol, I-40126 Bologna, Italy	Weizmann Institute of Science; Hebrew University of Jerusalem; Kaplan Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Bologna	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	lauriola, mattia/N-6435-2014	Levanon, Keren/0000-0002-5122-064X; lauriola, mattia/0000-0002-7966-0065	Merck KGaA; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; MD Moross Institute for Cancer Research; Flight Attendants Medical Research Institute (FAMRI); NATIONAL CANCER INSTITUTE [P50CA098258] Funding Source: NIH RePORTER	Merck KGaA(Merck & Company); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; MD Moross Institute for Cancer Research; Flight Attendants Medical Research Institute (FAMRI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Julian Downward for lung cell lines. This work was performed at the Marvin Tanner Laboratory for Cancer Research and it was supported, in part, by Merck KGaA. The research in our laboratory is supported by the Israel Cancer Research Fund and the Dr Miriam and Sheldon G Adelson Medical Research Foundation and by the MD Moross Institute for Cancer Research. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. The Sheba Institutional Tissue Banks have received financial support from the Flight Attendants Medical Research Institute (FAMRI).	Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Baldys A, 2009, BIOCHEMISTRY-US, V48, P1462, DOI 10.1021/bi801771g; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Berasain C, 2014, SEMIN CELL DEV BIOL, V28, P31, DOI 10.1016/j.semcdb.2014.01.005; Blivet-Van Eggelpoel MJ, 2012, J HEPATOL, V57, P108, DOI 10.1016/j.jhep.2012.02.019; Brustmann H, 2008, INT J GYNECOL PATHOL, V27, P380, DOI 10.1097/PGP.0b013e31815d060d; Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844; Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104; DeWitt A, 2002, DEV BIOL, V250, P305, DOI 10.1006/dbio.2002.0807; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Eckstein N, 2008, J BIOL CHEM, V283, P739, DOI 10.1074/jbc.M706287200; Esposito CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024071; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Frosi Y, 2010, J CELL BIOL, V189, P557, DOI 10.1083/jcb.201002032; Gui T, 2012, CANCER EPIDEMIOL, V36, P490, DOI 10.1016/j.canep.2012.06.005; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Higginbotham JN, 2011, CURR BIOL, V21, P779, DOI 10.1016/j.cub.2011.03.043; Hsu D, 2010, LAB INVEST, V90, P1295, DOI 10.1038/labinvest.2010.100; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kochupurakkal BS, 2005, J BIOL CHEM, V280, P8503, DOI 10.1074/jbc.M413919200; Lassus H, 2006, J MOL MED-JMM, V84, P671, DOI 10.1007/s00109-006-0054-4; Lazzara MJ, 2009, EXP CELL RES, V315, P717, DOI 10.1016/j.yexcr.2008.10.033; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lindzen M, 2012, ONCOGENE, V31, P3505, DOI 10.1038/onc.2011.518; Lindzen M, 2010, P NATL ACAD SCI USA, V107, P12559, DOI 10.1073/pnas.1006218107; Lopez J, 2013, ANN ONCOL, V24, P69, DOI 10.1093/annonc/mdt475; Murphy M, 2011, DRUG RESIST UPDATE, V14, P177, DOI 10.1016/j.drup.2011.02.004; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; Panupinthu N, 2014, ONCOGENE, V33, P2846, DOI 10.1038/onc.2013.259; Pedersen MW, 2010, CANCER RES, V70, P588, DOI 10.1158/0008-5472.CAN-09-1417; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Sato S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051964; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; Siwak DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/568938; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Stern KA, 2008, BIOCHEM J, V410, P585, DOI 10.1042/BJ20071505; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Van Zoelen E J, 2000, Vitam Horm, V59, P99, DOI 10.1016/S0083-6729(00)59005-0; Willmarth NE, 2006, J BIOL CHEM, V281, P37728, DOI 10.1074/jbc.M606532200; Wilson KJ, 2012, GROWTH FACTORS, V30, P107, DOI 10.3109/08977194.2011.649918; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Zwang Yaara, 2009, Traffic, V10, P349, DOI 10.1111/j.1600-0854.2008.00870.x	52	23	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					438	447		10.1038/onc.2015.93	http://dx.doi.org/10.1038/onc.2015.93			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25915843				2022-12-28	WOS:000369056700004
